In	O
a	O
study	O
addressed	O
to	O
evaluate	O
the	O
variation	O
of	O
polyamines	B
in	O
the	O
pre	O
and	O
post-surgery	O
serum	O
of	O
BC	O
patients,	O
no	O
significant	O
difference	O
was	O
reported.	O

Levels	O
of	O
MMA,	O
SDMA,	O
ADMA,	B
methyl-Lys,	B
and	O
ArgMI	O
were	O
divided	O
into	O
quartiles	O
for	O
analyses.	O

In	O
accordance,	O
Troseid	O
et	O
al	O
.	O
reported	O
that	O
whereas	O
increased	O
LPS	B
levels	O
in	O
155	O
patients	O
with	O
chronic	O
heart	O
failure	O
did	O
not	O
associate	O
with	O
TMAO	B
or	O
choline	B
it	O
was	O
inversely	O
associated	O
with	O
betaine	B
levels.	O

The	O
Lactobacillus	B
diversity	O
was	O
higher	O
in	O
the	O
IBS	O
samples	O
than	O
in	O
the	O
nIBS	O
samples.	O

24,25(OH)_2	B
D_3	I
,	I
24,25-dihydroxyvitamin	I
D_3	I
;	I
25(OH)D_3	I
,	I
25-hydroxyvitamin	I
D_3	O
Pooling	O
data	O
from	O
MESA,	O
CHS,	O
and	O
SKS	O
in	O
a	O
multivariable	O
model,	O
lower	O
eGFR	O
was	O
associated	O
with	O
a	O
significantly	O
reduced	O
increment	O
in	O
24,25(OH)_2	B
D_3	O
concentration	O
per	O
given	O
increment	O
in	O
25(OH)D_3	O
concentration	O
(slope)	O
and	O
a	O
significantly	O
reduced	O
mean	O
24,25(OH)_2	B
D_3	O
concentration	O
at	O
a	O
25(OH)D_3	O
of	O
20	O
ng/mL,	O
adjusting	O
for	O
relevant	O
potential	O
confounding	O
clinical	O
characteristics.	O

Taken	O
together,	O
these	O
findings	O
suggest	O
an	O
acceleration	O
of	O
caffeine	B
metabolism	O
in	O
COPD	O
smokers,	O
especially	O
for	O
the	O
downstream	O
caffeine	B
metabolites	O
resulting	O
from	O
activated	B
CYP2A6.	O

Abbreviation:	O
T,	O
triplet	O
due	O
to	O
enrichment	O
in	O
carbons	O
2,	O
3	O
and	O
4	O
of	O
glutamate	B
or	O
glutamine.	B

The	O
mobile	O
phase	O
consisted	O
of	O
two	O
solutions	O
including	O
solvent	O
A	O
(0.1%	O
formic	B
acid	I
in	O
water)	O
and	O
solvent	O
B	O
(acetonitrile),	O
and	O
the	O
flow	O
rate	O
was	O
0.3	O
mL/min.	O

First,	O
triacylglycerol	B
and	O
glycerophospholipids	B
are	O
synthesized	O
from	O
phosphatidic	B
acid.	I

Trimethylamine-N	B
-oxide	I
(TMAO)	O
concentrations	O
in	O
human	O
cerebrospinal	O
fluid	O
(CSF).	O

In	O
our	O
series,	O
histidine	B
levels	O
were	O
lower	O
in	O
sepsis	O
than	O
in	O
controls.	O

A1,	O
B1,	O
C1,	O
and	O
D1	O
are	O
MS/MS	O
spectra	O
of	O
authentic	O
compounds	O
TCA,	O
3	O
sulfo-GCDCA,	B
LysoPC	O
16:0,	O
and	O
S-1-P,	O
respectively.	O

LysoPC	O
(16:0)	O
induced	O
higher	O
release	O
of	O
arachidonic	B
acid	I
mediated	O
via	O
cytosolic	O
PLA_2	O
from	O
human	O
coronary	O
artery	O
smooth	O
muscle	O
cells,	O
compared	O
to	O
that	O
for	O
treatment	O
with	O
lysoPC	O
(14:0)	O
or	O
unsaturated	O
lysoPC	O
.	O

propionate-2,2,3,3-d4	B
(TSP))	O
immediately	O
before	O
the	O
NMR	O
spectra	O
acquisition.	O

GDM,	O
gestational	O
diabetes	O
mellitus;	O
TMAO,	B
trimethylamine-N	B
-oxide.	I
_2	O
Tests	O
for	O
linear	O
trend	O
were	O
conducted	O
by	O
using	O
the	O
medium	O
value	O
for	O
each	O
quartile	O
and	O
treating	O
it	O
as	O
a	O
continuous	O
variable	O
in	O
the	O
conditional	O
logistic	O
regression.	O

It	O
is	O
also	O
notable	O
that	O
the	O
glutamyl	O
moiety	O
of	O
reduced	O
GSH	B
showed	O
the	O
same	O
splitting	O
pattern	O
as	O
free	O
glutamate,	B
implying	O
de	O
novo	O
biosynthesis	O
of	O
GSH	B
from	O
the	O
free	O
glutamate	B
pool.	O

This	O
sensitivity	O
to	O
gradient	O
imperfections	O
is	O
apparent	O
in	O
our	O
relatively	O
new	O
600	O
MHz	O
AVIII-HD,	O
as	O
shown	O
on	O
a	O
sample	O
of	O
glucose	B
in	O
water	O
(b).	O

It	O
seems	O
that	O
in	O
MS	O
there	O
is	O
an	O
increase	O
of	O
phospholipids	B
and	O
a	O
decrease	O
of	O
sphingolipids,	B
perhaps	O
reflecting	O
a	O
reduction	O
of	O
myelin-specific	B
lipid	O
content	O
or	O
production	O
in	O
the	O
CNS	O
associated	O
with	O
increased	O
cellularity	O
due	O
to	O
glial	O
scars.	O

The	O
glucose	B
level	O
was	O
measured	O
by	O
means	O
of	O
glucose	B
oxidase	O
method.	O

After	O
30 min,	O
ethanol	B
had	O
increased	O
to	O
2.5	O
and	O
0.055 mM,	O
respectively	O
(see	O
Fig. ).	O

For	O
this	O
study,	O
phenylalanine,	B
isoleucine,	B
glutamine,	B
leucine,	B
alanine,	B
tyrosine,	B
histidine	B
and	O
valine	B
were	O
measured	O
in	O
stored	O
plasma	O
samples	O
by	O
proton	O
NMR	O
metabolomics.	O

Threonine	B
is	O
also	O
a	O
fuel	O
substrate	O
that	O
can	O
be	O
converted	O
to	O
pyruvic	B
acid	I
and	O
become	O
part	O
of	O
the	O
tricarboxylic	B
acid	I
cycle	O
(TCA).	O

Lactate	B
metabolite	O
is	O
normally	O
found	O
in	O
elevated	O
levels	O
in	O
tumor	O
hypoxia,	O
a	O
condition	O
in	O
which	O
cells	O
acquire	O
energy	O
through	O
glycolysis	O
instead	O
of	O
oxidative	O
phosphorylation.	O

The	O
product	O
ion	O
corresponding	O
the	O
pyridinium	B
moiety	O
(m/z	O
93.1;	O
fragment	O
a,	O
)	O
was	O
observed	O
for	O
all	O
of	O
the	O
estrogen	B
NMPS-derivatives.	O

All	O
solvents	O
used	O
were	O
LC-MS	O
grade	O
from	O
EMD	O
Millipore	O
(Billerica,	O
Massachusetts)	O
and	O
Fisher	O
Scientific	O
(Hampton,	O
New	O
Hampshire).	O

However,	O
we	O
found	O
no	O
difference	O
in	O
the	O
use	O
of	O
dyslipidaemia	O
or	O
anti-hypertensive	O
medications	O
within	O
the	O
BCAA	O
factor	O
quartiles	O
outlined	O
in	O
(p	O
=0.33	O
for	O
medications	O
for	O
dyslipidaemia,	O
p	O
=0.37	O
for	O
statins,	B
p	O
=0.73	O
for	O
anti-hypertension	O
medications).	O

In	O
young	O
females,	O
levels	O
of	O
sphingolipids	B
and	O
cholesterol	B
are	O
increased	O
from	O
young	O
age	O
to	O
middle	O
age,	O
and	O
this	O
effect	O
is	O
elevated	O
when	O
contraceptives	O
are	O
used,	O
suggesting	O
a	O
strong	O
interplay	O
between	O
sex	O
hormones	O
and	O
lipid	O
levels.	O

These	O
results	O
may	O
indicate	O
different	O
excretion	O
mechanisms	O
for	O
creatinine,	B
cotinine	B
and	O
trans	B
-3′-hydroxycotinine,	I
consistent	O
with	O
the	O
arguments	O
provided	O
by	O
and	O
which	O
suggest	O
that	O
the	O
creatinine	B
adjustment	O
method	O
may	O
not	O
adequately	O
reduce	O
the	O
measurement	O
variability	O
due	O
to	O
urine	O
dilution	O
for	O
ETS	O
biomarkers.	O

Our	O
finding	O
that	O
both	O
tryptophan	B
and	O
kynurenine	B
were	O
reduced	O
in	O
the	O
plasma	O
of	O
breast	O
cancer	O
patients	O
versus	O
normal	O
controls	O
led	O
us	O
to	O
investigate	O
whether	O
there	O
were	O
differences	O
in	O
nicotinamide,	B
the	O
final	O
metabolite	O
in	O
the	O
kynurenine	B
pathway	O
of	O
tryptophan	B
catabolism,	O
between	O
breast	O
cancer	O
patient	O
and	O
normal	O
plasma.	O

Numbers	O
indicate	O
the	O
following	O
metabolites	O
(quantified	O
compounds):	O
1:	O
pyruvic	B
acid;	I
2:	O
L-lactic	B
acid;	I
3:	O
alpha-hydroxyisobutyric	B
acid;	I
4:	O
glycolic	B
acid;	I
5:	O
levulinic	B
acid;	I
6∶3-hydroxyisovaleric	O
acid;	O
7∶2-hydroxy-2-methylbutyric	O
acid;	O
8:	O
hydroxypropionic	B
acid;	I
9∶2-methyl-3-hydroxybutyric	O
acid;	O
10:	O
malonic	B
acid;	I
11∶3-hydroxyisovaleric	O
acid;	O
12:	O
methylmalonic	B
acid;	I
13∶2-ethylhydracrylic	O
acid;	O
14:	O
benzoic	B
acid;	I
15:	O
phosphoric	B
acid;	I
16:	O
ethylmalonic	B
acid;	I
17:	O
succinic	B
acid;	I
18:	O
methylsuccinic	B
acid;	I
19∶4-deoxythreonic	O
acid;	O
20∶5-hydroxyhexanoic	O
acid;	O
21:	O
citraconic	B
acid;	I
22:	O
glutaric	B
acid;	I
23:	O
m-chlorobenzoic	B
acid;	I
24;	B
3,4-dihydroxybutanoic	I
acid;	I
25∶3-methylglutaconic	O
acid;	O
26:	O
adipic	B
acid;	I
27:	O
pyroglutamic	B
acid;	I
28∶3-methyladipic	O
acid;	O
29:	O
sumiki’s	O
acid;	O
30:	O
o-hydroxyphenylacetic	B
acid;	I
31:	O
oxoglutaric	B
acid;	I
32:	O
pimelic	B
acid;	I
33∶3-hydroxymethylglutaric	O
acid;	O
34∶3-hydroxyphenylacetic	O
acid;	O
35∶4-hydroxybenzoic	O
acid;	O
36∶2-furoylglycine;	O
37:	O
suberic	B
acid;	I
38:	O
quinolinic	B
acid;	I
39:	O
Cis/Trans-aconitic	O
acid;	O
40:	O
homovanillic	B
acid;	I
41:	O
azelaic	B
acid;	I
42:	O
hippuric	B
acid;	I
43∶3,4-dihydroxybenzeneacetic	O
acid;	O
44∶3-(3-hydroxyphenyl)-3-hydroxypropanoic	O
acid	O
(HPHPA);	O
45:	O
vanillylmandelic	B
acid;	I
46∶4-hydroxyphenyllactic	O
acid;	O
47:	O
indoleacetic	B
acid;	I
48:	O
palmitic	B
acid;	I
49:	O
kynurenic	B
acid;	I
50∶3-hydroxyhippuric	O
acid;	O
51∶3-hydroxysebacic	O
acid;	O
52:	O
Trans-ferulic	B
acid;	I
53∶5-hydroxyindoleacetic	O
acid;	O
54:	O
stearic	B
acid.	I

Gradient	O
elution	O
was	O
performed	O
for	O
both	O
methods	O
with	O
(A)	O
0.01%	O
formic	B
acid	I
in	O
water	O
and	O
(B)	O
0.01%	O
formic	B
acid	I
in	O
acetonitrile:methanol	O
(50:50,	O
v/v)	O
at	O
a	O
flow	O
rate	O
of	O
0.5	O
ml/min.	O

For	O
_13	O
C_2	B
-oxalate,	I
this	O
was	O
from	O
6	O
to	O
10	O
h	O
after	O
start	O
of	O
the	O
infusion.	O

Male	O
combat-exposed	O
veterans	O
from	O
OEF/OIF	O
were	O
recruited	O
at	O
The	O
New	O
York	O
University	O
Langone	O
School	O
of	O
Medicine	O
and	O
Mt.	O
Sinai/James	O
J.	O
Peters	O
VA	B
Medical	O
Center	O
through	O
flyers,	O
presentations,	O
newspaper	O
and	O
television	O
advertisement,	O
internet	O
postings,	O
and	O
referral	O
from	O
clinicians.	O

Incretin	B
hormones,	O
glucagon-like	O
peptide-1	B
(GLP-1)	O
and	O
glucose-dependent	O
insulinotropic	O
polypeptide	O
(GIP)	O
were	O
measured	O
using	O
ELISA	O
methods	O
(Linco	O
Research,	O
Missouri,	O
MO,	O
US).	O

Given	O
the	O
known	O
limitations	O
of	O
serum	O
creatinine	B
and	O
widespread	O
use	O
of	O
GFR	O
estimation,	O
the	O
clinical	O
implications	O
that	O
a	O
panel	O
of	O
metabolites	O
can	O
provide	O
an	O
accurate	O
estimate	O
of	O
GFR	O
with	O
or	O
without	O
serum	O
creatinine	B
or	O
demographics	O
could	O
be	O
substantial	O
if	O
these	O
initial	O
results	O
can	O
be	O
taken	O
through	O
the	O
full	O
diagnostic	O
test	O
development	O
process.	O

The	O
diffusion	O
of	O
CO_2	O
into	O
cryo	O
vials	O
and	O
hydrogen	B
carbonate	I
formation	O
in	O
aqueous	O
solutions	O
with	O
concomitant	O
changes	O
in	O
pH	O
is	O
detected	O
in	O
NMR	O
analyses,	O
due	O
to	O
the	O
simple	O
sample	O
preparation	O
that	O
preserves	O
as	O
much	O
as	O
possible	O
of	O
the	O
original	O
properties	O
of	O
the	O
samples.	O

Calcium,	O
chloride,	B
potassium,	O
sodium,	O
phosphate,	B
and	O
also	O
iron	O
concentrations,	O
as	O
well	O
as	O
creatinine,	B
bilirubin,	B
LDL-,	O
HDL-,	O
and	O
total	O
cholesterol,	B
triglycerides,	B
glucose,	B
uric	B
acid,	I
urea,	B
free	O
T3	O
and	O
free	O
T4	B
thyroid	I
hormone	I
concentrations	O
were	O
determined	O
in	O
blood	O
serum.	O

We	O
also	O
measured	O
the	O
recoveries	O
of	O
4-OH-E_1	B
-1-N	I
3Ade	O
and	O
4-OH-E_1	B
-1-N	I
3(U-_15	O
N)Ade	O
from	O
extraction	O
in	O
the	O
absence	O
of	O
breast	O
tissue.	O

In	O
previous	O
studies,	O
typical	O
esterase	O
(p	O
-nitrophenyl	I
acetate,	I
p	B
-nitrophenyl	I
butyrate)	I
and	O
peptidase	O
substrates	O
(amides	O
such	O
as	O
Lys-p	B
-nitroanilide)	I
were	O
tested	O
as	O
BPHL	O
substrates	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
is	O
for	O
the	O
first	O
time	O
that	O
urocanate	B
has	O
been	O
observed	O
in	O
amniotic	O
fluid	O
using	O
_1	O
H	O
NMR.	O

In	O
addition,	O
our	O
endpoint	O
is	O
potentially	O
heterogenous,	O
as	O
some	O
studies	O
have	O
suggested	O
there	O
may	O
be	O
distinct	O
molecular	O
subtypes	O
of	O
colorectal	O
cancer,	O
characterized	O
by	O
microsatellite	O
instability	O
or	O
CpG	O
island	O
methylator	B
phenotype.	O

Samples	O
were	O
prepared	O
for	O
analysis	O
by	O
the	O
addition	O
of	O
65	O
µL	O
of	O
internal	O
standard	O
containing	O
approximately	O
5	O
mmol/L	O
of	O
DSS-d	O
_6	O
[3-(trimethylsilyl)-1-propanesulfonic	O
acid-d	O
_6	O
],	O
0.2%	O

Riluzole	B
is	O
the	O
only	O
drug	O
that	O
has	O
been	O
shown	O
to	O
slow	O
the	O
course	O
of	O
ALS	O
in	O
class	O
I	O
studies,	O
by	O
some	O
attributed	O
to	O
its	O
anti-glutamatergic	B
properties	O
but	O
the	O
mechanism	O
is	O
unknown	O
.	O

The	O
_13	O
C	O
satellite	O
cross-peak	O
patterns	O
for	O
the	O
protons	O
of	O
Glu	O
(5,	O
6,	O
12,	O
20),	O
Gln	O
(9),	O
glutamyl	O
residue	O
of	O
oxidized	B
glutathione	I
(GSSG)	O
(7,	O
10,	O
13)	O
and	O
Asp	O
(16–19)	O
were	O
present	O
and	O
noted	O
by	O
vertical	O
and	O
horizontal	O
dashed	O
green	O
lines.	O

A	O
stable	O
deuterated	O
isotope	O
(D_6	O
-enzalutamide)	I
was	O
used	O
as	O
an	O
internal	O
standard.	O

Male	O
rats	O
are	O
more	O
sensitive	O
to	O
the	O
hepatocellular	O
carcinogenic	O
properties	O
of	O
furan.	B

It	O
was	O
found	O
that	O
ICP	O
did	O
not	O
tolerate	O
isopropyl	B
alcohol	I
well	O
even	O
at	O
a	O
concentration	O
as	O
low	O
as	O
2-3	O
%	O
v/v	O
and	O
isopropyl	B
alcohol	I
was	O
not	O
used	O
after	O
the	O
initial	O
trials.	O

Subject	O
characteristics	O
N/A	O
not	O
available	O
Frozen	O
saliva	O
was	O
thawed	O
and	O
dissolved	O
at	O
room	O
temperature,	O
and	O
27 μl	O
of	O
each	O
sample	O
(69	O
patients	O
with	O
oral	O
cancer	O
and	O
70	O
healthy	O
control	O
samples)	O
were	O
added	O
to	O
a	O
1.5-ml	O
Eppendorf	O
tube,	O
to	O
which	O
3 μl	O
of	O
water	O
containing	O
2 mM	O
methionine	B
sulfone	I
and	O
2 mM	O
3-aminopyrrolidine	B
as	O
internal	O
standards	O
was	O
added	O
and	O
mixed	O
well.	O

Thus,	O
it	O
plays	O
important	O
roles	O
in	O
the	O
growth	O
of	O
normal	O
and	O
cancerous	O
cells	O
and	O
many	O
studies	O
have	O
demonstrated	O
these	O
cells	O
are	O
dependent	O
on	O
glutamine	B
concentration	O
(,	O
),	O
while	O
glutamine	B
deprivation	O
on	O
cell	O
cultures	O
is	O
associated	O
with	O
malignant	O
cells	O
death	O
(,	O
).	O

Specifically,	O
S1P	O
and	O
LPA(18:2(9Z,12Z)/0:0)	B
each	O
had	O
a	O
good	O
predictability	O
of	O
disease	O
status	O
(AUC	O
>	O
0.80;	O
).	O

To	O
be	O
included	O
in	O
the	O
study,	O
subjects	O
aged	O
between	O
18	O
and	O
89	O
had	O
to	O
be	O
considered	O
healthy,	O
based	O
on	O
their	O
medical	O
history,	O
clinical	O
examination	O
(including	O
nutritional	O
status	O
and	O
gonadal/sexual	O
status),	O
routine	O
laboratory	O
tests	O
after	O
an	O
overnight	O
fast	O
(plasma	O
sodium,	O
potassium,	O
calcium,	O
phosphate,	B
creatinine,	B
glycemia,	O
total	O
blood	O
cholesterol	B
(TBC),	O
liver	O
enzymes,	O
TSH,	O
complete	O
blood	O
count,	O
albuminemia,	O
prothrombin	O
time,	O
and	O
HIV,	O
HBV	O
and	O
HCV	O
serology),	O
and	O
BMI	O
(between	O
19	O
and	O
28	O
kg/m_2	O
).	O

An	O
UPLC-MS/MS	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
serotonin	B
(5-HT),	O
dopamine	B
(DA),	O
their	O
phase	O
I	O
metabolites	O
5-HIAA,	B
DOPAC	O
and	O
HVA,	O
and	O
their	O
sulfate	B
and	O
glucuronide	B
conjugates	O
in	O
human	O
brain	O
microdialysis	O
samples	O
obtained	O
from	O
two	O
patients	O
with	O
acute	O
brain	O
injuries,	O
ventricular	O
cerebrospinal	O
fluid	O
(CSF)	O
samples	O
obtained	O
from	O
four	O
patients	O
with	O
obstructive	O
hydrocephalus,	B
and	O
a	O
lumbar	O
CSF	O
sample	O
pooled	O
mainly	O
from	O
patients	O
undergoing	O
spinal	O
anesthesia	O
in	O
preparation	O
for	O
orthopedic	O
surgery.	O

Automated	O
mass	O
spectrometry	O
deconvolution	O
and	O
identification	O
system	O
(AMDIS)	O
was	O
configured	O
to	O
build	O
a	O
retention	O
index	O
calibration	O
file	O
and	O
calculate	O
RI	B
for	O
each	O
metabolic	O
features.	O

Besides,	O
tyrosine	B
levels	O
showed	O
a	O
unique	O
association	O
with	O
diabetic	O
microangiopathy	O
in	O
comparison	O
to	O
any	O
other	O
single	O
metabolite.	O

 B,	O
we	O
observed	O
a	O
light	O
increase	O
in	O
arginine,	B
ornithine	B
and	O
citrulline	B
levels,	O
as	O
well	O
as	O
in	O
aspartate	B
in	O
the	O
tumor	O
tissue	O
compared	O
with	O
the	O
healthy	O
tissue.	O

Leucine-enkephalin	B
(Waters	O
Corporation,	O
Milford,	O
MA,	O
USA),	O
C_28	O
H_37	O
N_5	O
O_7	O
,	O
([M+H]+	O
=	O
556.2771	O
m/z)	O
was	O
used	O
as	O
lock	O
mass	O
reference	O
at	O
concentration	O
of	O
0.2	O
ng/L	O
with	O
flow	O
rate	O
of	O
10	O
μL/min.	O

In	O
TB,	O
anaerobic	O
glycolysis	O
is	O
increased	O
and	O
more	O
pyruvate	B
is	O
converted	O
into	O
lactate	B
rather	O
than	O
entering	O
into	O
the	O
TCA	O
cycle	O
pathway,	O
likely	O
as	O
a	O
result	O
of	O
lung	O
injury,	O
tissue	O
hypoxia,	O
and	O
insufficient	O
oxygen	O
supply.	O

In	O
negative	O
ESI	O
mode,	O
PG,	B
PE,	O
PI,	O
PS,	O
PA	O
and	O
GM_3	O
species	O
eluted	O
out	O
of	O
column	O
in	O
the	O
stated	O
order	O
with	O
good	O
separation.	O

In	O
the	O
pediatric	O
study	O
of	O
Mickiewicz	O
et	O
al.,	O
citrate	B
was	O
also	O
found	O
to	O
be	O
decreased.	O

Fasting	O
serum	O
total	O
cholesterol,	B
triglyceride,	B
and	O
high-density	O
lipoprotein	O
(HDL)	O
cholesterol	B
levels	O
were	O
measured	O
using	O
commercially	O
available	O
kits	O
on	O
a	O
Hitachi	O
7150	O
Autoanalyzer	O
(Hitachi	O
Ltd.,	O
Tokyo,	O
Japan).	O

As	O
a	O
result,	O
five	O
biomarkers	O
(20-Hydroxy-leukotriene	O
E4,	O
Lysopc(20:4),	B
5-methoxytryptamine,	B
Endomorphin-1,	O
Lysopc(20:3))	B
and	O
five	O
biomarkers	O
(Iso-valeraldehyde,	O
linoleic	B
acid,	I
Lysopc(18:1),	B
2-Pyrroloylglycine,	B
Dityrosine)	B
were	O
included	O
in	O
the	O
predictive	O
equation	O
of	O
NGR	O
and	O
DM,	O
respectively.	O

25(OH)D,	O
vitamin	B
D,	I
metabolomics,	O
obesity,	O

While	O
sex	O
was	O
not	O
significant	O
for	O
all	O
classes	O
at	O
age	O
75,	O
there	O
were	O
significant	O
positive	O
interactions	O
of	O
age	O
with	O
sex	O
for	O
Cer,	B
DG,	O
TG,	B
PC	O
and	O
PE	O
subclasses,	O
as	O
well	O
as	O
CE(20:X),	O
suggesting	O
the	O
negative	O
effect	O
of	O
age	O
was	O
stronger	O
in	O
males	O
(p<0.05).	O

Finally,	O
CD	O
patients	O
exhibited	O
an	O
increase	O
in	O
sugars,	O
such	O
as	O
xylose,	B
maltose,	B
galactose,	B
and	O
lactose	B
compared	O
to	O
the	O
control	O
cohort.	O

Specifically,	O
purine	B
nucleotides	O
undergo	O
dephosphorylation	O
via	O
5′-nucleotidase	O
to	O
form	O
nucleosides	O
(adenosine	O
and	O
guanosine).	O

This	O
is	O
reflected	O
in	O
the	O
high	O
levels	O
and	O
ranges	O
of	O
the	O
gut-microflora	O
produced	O
metabolites	O
examined	O
here	O
(indoxyl	O
sulfate	I
and	O
indole-3	O
acetic	B
acid,	I
IAA).	O

Etn = ethanolamine.	B

An	O
ex	O
vivo	O
model	O
for	O
the	O
study	O
of	O
tumor	O
metabolism	O
by	O
nuclear	O
magnetic	O
resonance:	O
characterization	O
of	O
the	O
phosphorus-31	B
spectrum	O
of	O
the	O
isolated	O
perfused	O
Morris	O
hepatoma	O
7777.	O

Serum	O
concentrations	O
of	O
long	O
(C16-C20)	O
and	O
very	O
long	O
(≥	O
C24)	O
chain	O
Cer's	O
as	O
well	O
as	O
of	O
their	O
synthetic	O
precursors,	O
dihydroceramides	B
(DHC's),	O
were	O
assessed	O
in	O
patients	O
with	O
HCC	O
and	O
in	O
patients	O
with	O
cirrhosis.	O

Zwitterionic	O
columns,	O
which	O
display	O
more	O
moderate	O
ion	O
exchanger	O
effects,	O
successfully	O
targeted	O
70	O
%	O
of	O
the	O
phosphates.	B

The	O
lower	O
levels	O
of	O
hippuric	B
acid	I
found	O
in	O
our	O
BC	O
urines	O
compared	O
to	O
control	O
samples	O
are	O
in	O
agreement	O
with	O
previous	O
works	O
[,].	O

Substantial	O
metabolic	O
disturbances	O
occurred	O
immediately	O
after	O
LTX	O
as	O
seen	O
in	O
the	O
time	O
course	O
of	O
the	O
esterification	O
ratio	O
of	O
all	O
sterols	O
(Fig. )	O
and	O
of	O
routine	O
parameters,	O
suitable	O
to	O
follow-up	O
LTX,	O
as	O
ALT,	O
AST,	O
bilirubin,	B
GGT,	O
glutamate	O
dehydrogenase	O
(GLDH),	O
and	O
prothrombin	O
time	O
(PT).	O

In	O
contrast	O
to	O
total	O
PSA	O
values,	O
kynurenic	B
acid	I
was	O
found	O
a	O
promising	O
biomarker	O
for	O
the	O
detection	O
of	O
prostate	O
cancer	O
particularly	O
in	O
cases	O
where	O
collection	O
of	O
urine	O
samples	O
was	O
performed	O
after	O
prostatic	O
massage.	O

Instead,	O
we	O
calculated	O
a	O
lower	O
value	O
for	O
the	O
amount	O
of	O
dissolved	O
hydrogen	B
carbonate	I
from	O
the	O
observed	O
pH	O
change	O
and	O
the	O
known	O
buffer	O
concentration	O
using	O
the	O
Henderson-Hasselbalch	O
Equation	O
(1):	O

Patients	O
with	O
low	O
albuminemia	O
had	O
increased	O
plasma	O
citrulline	B
but	O
lower	O
tryptophan	B
concentrations	O
(both	O
P	O
≤0.001)	O
(Supplemental	O
Figure	O
1A).	O

The	O
same	O
paper	O
also	O
reported	O
a	O
nonsignificant	O
decrease	O
of	O
xanthurenic	B
acid	I
in	O
the	O
IBD	O
groups	O
compared	O
to	O
the	O
control	O
group.	O

As	O
shown	O
in	O
,	O
the	O
base	O
peak	O
at	O
m/z	O
184.0733—a	O
signature	O
ion	O
of	O
phosphocholine	B
head	O
group	O
confirmed	O
the	O
identity	O
of	O
the	O
fraction	O
collected	O
in	O
the	O
mixed-mode	O
LC	O
separation	O
as	O
PC.	O

Compared	O
with	O
the	O
time	O
course	O
of	O
IP,	B
we	O
could	O
find	O
that	O
the	O
holistic	O
reaction	O
rate	O
of	O
P	O
could	O
to	O
be	O
relatively	O
higher	O
with	O
the	O
larger	O
amount	O
of	O
transformation	O
products	O
and	O
the	O
longer	O
reaction	O
time.	O

Liquid	O
chromatography	O
coupled	O
to	O
tandem	O
mass	O
spectrometry	O
was	O
applied	O
to	O
detect	O
the	O
global	O
lipidome	O
in	O
the	O
fasting	O
plasma	O
of	O
293	O
Chinese	O
individuals,	O
including	O
114	O
T2D	O
patients,	O
81	O
prediabetic	O
subjects,	O
and	O
98	O
individuals	O
with	O
normal	O
glucose	B
tolerance	O
(NGT).	O

This	O
is	O
line	O
with	O
the	O
finding	O
of	O
Meltzer	O
et	O
al	O
who	O
demonstrated	O
that	O
tamoxifen	B
and	O
NDtam	O
may	O
act	O
both	O
competitively	O
and	O
non-competitively	O
on	O
microsomal	O
mixed	O
function	O
oxidases.	O

Adding	O
insult	O
to	O
injury,	O
defects	O
in	O
butyrate	B
transport	O
across	O
the	O
epithelium	O
and	O
in	O
the	O
butyrate	B
oxidation	O
pathway	O
exist	O
during	O
inflammation	O
in	O
both	O
CD	O
(De	O
Preter	O
et	O
al.	O
)	O

MRM	O
analysis	O
of	O
eighteen	O
24	O
h	O
urine	O
sample	O
collections	O
from	O
metformin-treated	O
T2DM	O
patients	O
demonstrates	O
that	O
mean	O
IMZ	O
concentrations	O
have	O
a	O
statistically	O
significant	O
r	O
_2	O
value	O
(r	O
_2	O
=	O
0.7348;	O
p	O
<	O
0.0001)	O
with	O
metformin	B
concentrations.	O

In	O
addition	O
to	O
this	O
result,	O
the	O
HTG	O
group	O
in	O
the	O
present	O
study	O
showed	O
metabolic	O
differences	O
in	O
lysoPCs	O
and	O
fatty	O
acid	O
amides	O
but	O
not	O
in	O
amino	O
acids	O
compared	O
to	O
the	O
NTG	O
group,	O
while	O
metabolic	O
changes	O
in	O
amino	O
acids,	O
particularly	O
branched-chain	O
amino	O
acids	O
(BCAAs),	O
were	O
predominant	O
in	O
studies	O
related	O
to	O
IR,	O
impaired	O
glucose	B
tolerance,	O
and	O
T2D.	O
A	O
broad	O
range	O
of	O
amino	O
acids,	O
including	O
leucine,	B
isoleucine,	B
valine,	B
phenylalanine,	B
tyrosine,	B
alanine,	B
tryptophan,	B
and	O
homocitrulline,	B
have	O
been	O
shown	O
to	O
be	O
substantially	O
increased	O
in	O
T2D	O
patients	O
and	O
in	O
subjects	O
with	O
obesity	O
or	O
impaired	O
glucose	B
tolerance.	O

For	O
ensuring	O
accuracy	O
and	O
reproducibility,	O
leucine	B
enkephalin	I
in	O
200	O
pg/mL	O
was	O
used	O
as	O
the	O
lock-mass	O
for	O
positive	O
ESI	O
mode	O
([M+H]+	O
=	O
556.2771)	O
via	O
a	O
lock	O
spray	O
interface.	O

In	O
brief,	O
acetonitrile	B
(200	O
μl)	O
was	O
added	O
to	O
each	O
urine	O
sample	O
(200	O
μl),	O
then	O
the	O
mixture	O
was	O
vortexed	O
for	O
30	O
s	O
and	O
centrifuged	O
at	O
14,000	O
×	O
g	O
for	O
10	O
min.	O

In	O
the	O
above-mentioned	O
study,	O
it	O
was	O
shown	O
that	O
N1-acetylspermidine	B
was	O
detectable	O
24	O
and	O
72 hr	O
post	O
injury,	O
indicating	O
an	O
increased	O
SSAT	O
activity	O
and	O
disrupted	O
polyamine	B
homeostasis.	O

The	O
variability	O
in	O
creatinine	B
levels	O
agrees	O
well	O
with	O
the	O
interplay	O
between	O
liver	O
and	O
renal	O
(dis)function	O
in	O
liver	O
disease.	O

The	O
earlier	O
_1	O
H-NMR	O
study	O
of	O
15	O
males	O
and	O
17	O
females	O
reported	O
a	O
COPD-induced	O
reduction	O
in	O
BCAAs	O
(leucine	O
and	O
isoleucine).	B

Furthermore,	O
demographic	O
and	O
clinical	O
characteristics	O
(such	O
as	O
age,	O
race,	O
ethnicity,	O
education,	O
attendance	O
for	O
clinical	O
appointments,	O
duration	B
of	O
hypertension,	O
coexistent	O
comorbidities)	O
are	O
not	O
or	O
only	O
very	O
poor	O
correlates	O
of	O
adherence	O
and	O
cannot	O
provide	O
accurate	O
prediction	O
of	O
non-adherent	O
behaviour.	O

The	O
oleic	O
acid-isoleucine	O
negative	O
correlation	O
(a)	O
is	O
consistent	O
with	O
the	O
observations	O
that	O
plasma	O
oleic	B
acid	I
was	O
greater	O
in	O
HBV	O
than	O
in	O
the	O
controls	O
and	O
that	O
plasma	O
isoleucine	B
was	O
lower	O
in	O
HBV	O
than	O
in	O
the	O
controls.	O

PC	O
aa	O
C32:3;	B
38.	O

However,	O
when	O
data	O
from	O
only	O
high-ETS	O
subjects	O
is	O
correlated,	O
2-naphthol	B
correlates	O
at	O
the	O
0.05	O
level	O
with	O
Ph,	O
Pyr,	O
Chry,	O
SumMW120-180,	O
SumMW200-250	O
and	O
Sum16PAH.	O

Derivatization,	O
Estrogen,	B
Liquid	O
chromatography	O
tandem	O
mass	O
spectrometry,	O
Estrogen	B
metabolites,	O
Methylpiperazine	B

A	O
nucleoside,	O
putatively	O
identified	O
as	O
N-formyl-cytidine	B
(m/z	O
272,	O
RT	O
2.52	O
min),	O
was	O
found	O
using	O
positive	O
neutral	O
loss	O
scan	O
of	O
m/z	O
132	O
on	O
Acquity	O
UPLC-4000	O
QTrap	O
MS	O
in	O
pooled	O
urine	O
from	O
ccRCC	O
patients	O
(orange	O
line)	O
two-folds	O
higher	O
than	O
in	O
post-operative	O
controls	O
(grey	O
line)	O

Other	O
clinical	O
characteristics	O
were	O
also	O
independently	O
associated	O
with	O
24,25(OH)_2	B
D_3	O
concentration,	O
though	O
not	O
as	O
strongly	O
as	O
eGFR.	O

In	O
vivo	O
,	O
LTB4	B
is	O
rapidly	O
metabolized	O
by	O
different	O
pathways	O
in	O
an	O
attempt	O
to	O
decrease	O
the	O
inflammatory	O
effects	O
caused	O
by	O
this	O
mediator.	O

(D)	O
Bar/box	O
plot	O
showing	O
levels	O
of	O
glutamate	B
in	O
mouse	O
tumor	O
tissues	O
derived	O
from	O
adherent	O
HNSCC	O
cells	O
and	O
tumorspheres,	O
based	O
on	O
isotope	O
dilution	O
GC-MS.	O

Remarkably,	O
the	O
isomeric	O
ratio	O
of	O
GLA	O
vs.	O
ALA	O
esterified	O
in	O
triglycerides	B
was	O
three-fold	O
higher	O
than	O
the	O
ratio	O
of	O
their	O
non-esterified	O
moieties.	O

Cluster	O
one	O
contained	O
a	O
diverse	O
group	O
of	O
elevated	O
metabolites	O
including	O
several	O
predicted	O
shorter-chain	O
organic	O
molecules	O
(containing	O
11	O
to	O
21	O
carbons),	O
a	O
predicted	O
triacylgycerol,	B
and	O
a	O
putative	O
adenosine-related	O
metabolite.	O

The	O
level	O
of	O
L-octanoylcarnitine	B
at	O
3-year	O
follow-up	O
was	O
significantly	O
higher	O
in	O
overweight	O
group,	O
when	O
the	O
subjects	O
were	O
divided	O
according	O
to	O
sex	O
or	O
menopause	O
status	O
(q	O
=	O
0.002	O
in	O
male,	O
q	O
=	O
0.001	O
in	O
female;	O
q	O
=	O
0.012	O
in	O
pre-menopause,	O
q	O
=	O
0.017	O
in	O
post-menopause,	O
respectively).	O

On	O
the	O
other	O
hand,	O
in	O
several	O
cell	O
types,	O
including	O
cancer	O
cells,	O
glutamine	B
metabolism	O
via	O
glutaminase	O
is	O
up	O
regulated	O
and	O
important	O
for	O
cell	O
proliferation	O
and	O
survival,	O
which	O
makes	O
glutamine	B
a	O
conditionally	O
essentially	O
amino	O
acid.	O

Portions	O
of	O
pooled	O
plasma	O
were	O
spiked	O
with	O
_13	O
C_2	B
-oxalate,	I
1-_13	O
C-glycolate,	B
and	O
_13	O
C_2	B
-glyoxylate	I
for	O
validation	O
purposes	O
and	O
for	O
monitoring	O
accuracy	O
and	O
precision	O
during	O
the	O
analysis	O
of	O
the	O
study	O
samples.	O

Despite	O
their	O
structural	O
similarities,	O
the	O
branched‐chain	O
amino	O
acids	O
belong	O
to	O
different	O
metabolic	O
pathways,	O
with	O
leucine	B
going	O
solely	O
to	O
fats,	O
valine	B
solely	O
to	O
carbohydrates,	O
and	O
isoleucine	B
to	O
both.	O

Thus,	O
we	O
suggest	O
that	O
OH-E_2	O
rather	O
than	O
MeO-E_2	O
should	O
be	O
measured	O
directly	O
when	O
studying	O
the	O
health	O
effects	O
of	O
dioxin	B
and	O
dioxin-like	O
compound	O
exposure.	O

Angiotensin	B
2	I
levels	O
were	O
quantified	O
with	O
a	O
validated	O
commercial	O
angiotensin	B
II	I
enzyme-linked	O
immunoabsorbent	O
assay	O
(SPIBio	O
Bertin	O
Pharma,	O
Montigny	O
le	O
Bretonneux,	O
France)	O
essentially	O
as	O
described.	O

Analytical	O
grade	O
formic	B
acid,	I
chloroform,	B
MTBE,	B
and	O
MeOH	B
were	O
purchased	O
from	O
Fisher-Scientific	O
(Hampton,	O
NH).	O

CYP2D6	O
deficient	O
PM	O
patients	O
(PM/PM)	O
had	O
4.5	O
to	O
5.5	O
times	O
lower	O
(Z)‐endoxifen	B
concentrations	O
than	O
EM	O
patients	O
with	O
functional	O
CYP2D6	O
(EM/EM).	O

Total	O
cholesterol	B
increased	O
in	O
the	O
efavirenz	O
(0.50	O
mmol/L	O
[IQR	O
0.25,	O
0.81]	O
and	O
atazanavir	O
arms	O
(0.48	O
mmol/L	O

Ten	O
microliter	O
of	O
a	O
mixture	O
of	O
1	O
µg/mL	O
desmethyl-BEN	B
and	O
1	O
µg/mL	O
desmethyl-BEN-Cl_2	B
in	O
acetonitrile	B
(internal	O
standards)	O
and	O
1	O
mL	O
of	O
acetonitrile	B
were	O
added	O
to	O
200	O
µL	O
of	O
standard	O
or	O
sample.	O

One	O
HNF1A-MODY	O
had	O
impaired	O
glucose	B
tolerance	O
(IGT)	O
and	O
3	O
were	O
normoglycaemic;	B
the	O
remainder	O
had	O
diabetes.	O

NK	O
cells	O
are	O
activated	B
in	O
the	O
presence	O
of	O
LPS	B
released	O
from	O
probiotics,	O
which	O
is	O
accompanied	O
by	O
changing	O
cytokines	O
and	O
chemokines.	O

An	O
optimal	O
enzymatic	O
degradation	O
was	O
obtained	O
as	O
confirmed	O
by	O
the	O
addition	O
of	O
paracetamol	B
glucuronide	I
and/or	O
nitrocathecol	O
sulfate.	B

Quantification	O
of	O
25(OH)D_3/2,	B
3-epi-25(OH)D_3	I
,	I
1,25(OH)_2	I
D_3/2	O
and	O
24,25(OH)_2	B
D_3	O
was	O
performed	O
by	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
using	O
the	O
[M + H]_+	O
 → [(M + H)−(N(CH_3	O
)_3	O
)]_+	O
transitions	O
for	O
all	O
measured	O
vitamin	B
D	I
metabolites	O
with	O
200 ms	O
dwell	O
time	O
per	O
transition	O
(,	O
).	O

Additionally,	O
a	O
small	O
aliquot	O
of	O
each	O
experimental	O
sample	O
was	O
pooled	O
together	O
to	O
serve	O
as	O
a	O
technical	O
replicate	O
for	O
duration	B
of	O
the	O
run.	O

We	O
could	O
not	O
identify	O
significant	O
treatment-related	O
changes	O
in	O
metabolite	O
profiles	O
of	O
the	O
urine	O
samples	O
in	O
the	O
HV	B
group.	O

Taurine	B
was	O
ranked	O
#84	O
of	O
358	O
metabolites	O
by	O
PLSDA	O
analysis,	O
but	O
was	O
ranked	O
#2	O
by	O
random	O
forest	O
analysis.	O

At	O
present,	O
we	O
do	O
not	O
have	O
any	O
robust	O
explanation	O
for	O
the	O
strong	O
relationship	O
between	O
the	O
increase	O
of	O
2-aminoisobutyric	B
in	O
the	O
PMN	O
and	O
the	O
levels	O
of	O
HOMA-IR	O
or	O
BMI	O
and	O
waist	O
circumference.	O

For	O
analysis	O
of	O
tissue	O
metabolite	O
levels,	O
fresh	O
frozen	O
liver	O
tumor	O
specimens	O
were	O
pulverized	O
by	O
cryogenic	O
grinding	O
using	O
a	O
5mm	O
stainless	O
steel	O
ball	O
bearing	O
(Cryomill,	O
Retsch)	O
before	O
being	O
extracted	O
in	O
a	O
monophasic	O
mixture	O
of	O
2:5:2	O
water:methanol:chloroform	O
with	O
aminopimelic	B
acid	I
internal	O
standard.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
elevated	O
levels	O
of	O
uric	B
acid	I
in	O
serum	O
are	O
associated	O
with	O
greater	O
cancer	O
risk,	O
recurrence,	O
and	O
mortality	O
in	O
colorectal,	O
breast,	O
prostate	O
cancers_–	O
and	O
its	O
pro-inflammatory	O
properties	O
may	O
play	O
a	O
role	O
in	O
the	O
BLCA	O
pathogenesis	O
in	O
AA.	O

Monitoring	O
the	O
fortified	O
“hydrolysis	O
control	O
I”	O
in	O
each	O
run	O
yielded	O
an	O
average	O
peak	O
area	O
ratio	O
of	O
remaining	O
glucuronide	B
to	O
aglycone	B
of	O
0.37%,	O
with	O
a	O
relative	O
standard	O
deviation	O
of	O
1.5%	O
(number	O
of	O
runs	O
=	O
43).	O

A	O
1:1:1	O
extraction	O
was	O
performed,	O
with	O
500 µl	O
of	O
methanol	B
(Hypergrade	O
for	O
LC-MS,	O
Merck)	O
and	O
500 µl	O
of	O
chloroform	B
(HiPerSolv	O
Chromanorm	O
for	O
HPLC,	O
VWR	O
international),	O
both	O
ice	O
cold,	O
being	O
added	O
to	O
500 µl	O
of	O
plasma	O
in	O
a	O
1.5 ml	O
Eppendorf.	O

HC-04	O
cells	O
were	O
transfected	O
with	O
an	O
XRE-luciferase	O
reporter	O
plasmid	O
and	O
treated	O
with	O
isoflavones	B
for	O
24	O
h.	O
Both	O
GN	O
and	O
DZ	O
had	O
no	O
significant	O
effect,	O
while	O
BA	O
and	O
FN	O
significantly	O
increased	O
activity	O
to	O
5-	O
and	O
7-fold.	O

A	O
500	O
pg/mL	O
solution	O
of	O
NNAl-d_3	O
was	O
prepared	O
in	O
10%	O
methanol	B
containing	O
12	O
mM	O
HCl.	O

Path	O
“a”	O
shows	O
the	O
role	O
of	O
ROS	O
inducing	O
the	O
damage	O
to	O
the	O
endothelium	O
and	O
hypoxia	O
in	O
tissues	O
followed	O
by	O
the	O
accumulation	O
of	O
succinic	B
acid	I
in	O
mitochondria.	O

It	O
is	O
also	O
recommended	O
that	O
future	O
studies	O
confirm	O
the	O
status	O
of	O
diabetes	O
by	O
standardized	O
test	O
that	O
measure	O
blood	O
glucose	B
levels.	O

Two	O
of	O
the	O
five	O
characteristic	O
metabolites,	O
uric	B
acid	I
and	O
xanthine,	B
are	O
linked	O
metabolically	O
and	O
are	O
both	O
involved	O
in	O
the	O
purine	B
degradation	O
pathway.	O

Changes	O
in	O
choline	B
and	O
its	O
metabolites	O
during	O
lactation	O
have	O
previously	O
been	O
reported	O
in	O
human	O
and	O
porcine	B
milk	O
,	O
;	O
however,	O
there	O
has	O
not	O
been	O
a	O
systematic	O
evaluation	O
of	O
changes	O
during	O
lactation	O
in	O
choline	B
metabolites	O
in	O
milk	O
of	O
dairy	O
cows.	O

FAHFA	O
were	O
eluted	O
with	O
4	O
mL	O
ethyl	B
acetate	I
and	O
evaporated	O
under	O
a	O
nitrogen	O
stream.	O

H_2	O
O:CHCl_3	O
=2.5:1:1).	B

To	O
avoid	O
this	O
problem,	O
in	O
all	O
subsequent	O
experiments,	O
supernatants	O
were	O
used	O
directly	O
for	O
labeling	O
after	O
acetone	B
precipitation.	O

Every	O
cancer	O
has	O
their	O
own	O
characteristic	O
thiols	B
which	O
significantly	O
increased	O
or	O
decreased	O
compared	O
to	O
healthy	O
controls.	O

The	O
vitamin	B
E	I
metabolites	O
were	O
analyzed	O
by	O
mass	O
spectrometry	O
using	O
a	O
triple-quadrupole	O
Micro	O
Quattro	O
instrument	O
(MicroMass,	O
Waters,	O
UK)	O
fitted	O
with	O
an	O
electrospray	O
ionization	O
source.	O

Methylbutyryl-	B
and	O
isovaleryl-carnitine	B
were	O
not	O
separable	O
by	O
LC-HRMS,	O
and	O
are	O
therefore	O
observed	O
as	O
a	O
single	O
peak	O
that	O
acquires	O
labeling	O
from	O
both	O
_13	O
C-isoleucine	B
and	O
_13	O
C-leucine.	B

Glutamine	B
and	O
pyroglutamic	B
acid	I
were	O
omitted	O
because	O
of	O
errors	O
arising	O
from	O
glutamine	O
cyclization;	O
lactate	B
and	O
glucose	B
were	O
also	O
omitted	O
for	O
clarity	O
(see	O
for	O
data	O
for	O
all	O
30	O
metabolites).	O

Since	O
cysteine	B
was	O
converted	O
to	O
cystine	B
during	O
the	O
pre-treatment	O
procedure,	O
cysteine	B
was	O
detected	O
as	O
cystine	B
by	O
our	O
system.	O

Quantitative	O
comparisons	O
of	O
serum	O
lactate,	B
FAs,	O
glutamate,	B
and	O
triglycerides	B
among	O
SC	O
types	O
are	O
shown	O
in	O
.	O

They	O
received	O
a	O
single	O
intramuscular	O
injection	O
of	O
the	O
commercially	O
available	O
combination	O
of	O
10	O
mg	O
cyanocobalamin,	B
100	O
mg	O
pyridoxine,	B
and	O
100	O
mg	O
thiamin	B
(Neurobion;	O
Merck)	O
as	O
part	O
of	O
a	O
“before-and-after	O
treatment”	O
study	O
design.	O

The	O
MRM	O
transitions	O
for	O
the	O
three	O
metabolites	O
were	O
set	O
as	O
follows:	O
sarcosine	B
m	O
/z	O
90–44,	O
CV	O
=	O
20	O
V,	O
CE	O
=	O
8	O
V;	O
uracil	B
m	O
/z	O
113–70,	O
CV	O
=	O
40	O
V,	O
CE	O
=	O
15	O
V;	O
and	O
kynurenic	B
acid	I
m	O
/z	O

(a)	O
First	O
order	O
neighborhood	O
of	O
CKD-EPI	O
eGFR	O
values	O
based	O
on	O
serum	O
creatinine	B
(eGFR	O
).	O

Plasma	O
polyphenol	O
concentration	O
(µM)	O
quantified	O
by	O
mass	O
spectrometry	O
Data	O
represent	O
the	O
mean	O
and	O
standard	O
deviation	O
(SD)	O
at	O
the	O
beginning	O
(T0)	O
and	O
at	O
the	O
end	O
(T1)	O
of	O
dietary	O
intervention	O
with	O
olive-enriched	O
product	O
(OEP)	O
or	O
control	O
product	O
(Ctrl),	O
and	O
the	O
relative	O
p	O
value	O
after	O
factorial	O
ANOVA	O
with	O
Bonferroni’s	O
correction	O
Chlorogenic	B
acid,	I
cis	O
-piceide,	O
quercetin-3-Rha,	O
quercetin-3-glucuronide,	O
kaempferol-3-glucuronide,	B
t	O
-ferulic	O
acid,	O
ellagic	B
acid,	I
protocatechuic	B
acid,	I
cryptochlorogenic	B
acid,	I
quercetin-3-Glc + quercetin-3-gal,	O
hydroxytyrosol	B
and	O
tyrosol	B
are	O
not	O
shown,	O
since	O
the	O
levels	O
fell	O
below	O
limit	O
of	O
quantification	O

Four	O
bio-transforming	O
products	O
were	O
obtained,	O
including	O
6,7-furano-hydrocoumaric	B
acid	I
(P-1)	O
and	O
6,7-furano-hydro-	B
coumaric	I
acid	I
methyl	I
ester	I
(P-2),	O
which	O
transformed	O
from	O
P,	O
and	O
5,6-furano-hydrocoumaric	B
acid	I
(IP-1)	O
and	O
5,6-furano-hydrocoumaric	B
acid	I
methyl	I
ester	I
(IP-2),	O
which	O
were	O
transformed	O
from	O
IP.	B

Correlation	O
between	O
levels	O
of	O
sphingolipids	B
in	O
breast	O
cancer	O
tissue	O
and	O
those	O
in	O
normal	O
breast	O
tissue	O
are	O
denoted	O
by	O
R_2	O
.	O

Very	O
recently,	O
the	O
digestion	O
of	O
Alb	O
with	O
trypsin	O
using	O
pressure	O
cycling	O
was	O
shown	O
to	O
efficiently	O
recover	O
the	O
T3	O
peptide	O
A_21	O
LVLIAFAQYLLVLIAFAQYLQQCPFEDHVK_40	O
without	O
prior	O
denaturation	O
and	O
reduction	O
of	O
internal	O
disulfide	B
bonds.	O

Interestingly,	O
only	O
for	O
rs11687765	O
(valine-QTL)	O
association	O
with	O
risk	O
factors	O
reached	O
nominally	O
significant	O
P-values:	O
specifically	O
glucose	B
(P-value	O
 = 0.013),	O
HOMA,	O
insulin	O
resistance	O
(P-value	O
 = 0.049)	O
and	O
gynoid	B
fat	O
mass	O
(P-value	O
 = 0.003).	O

Urea	B
nitrogen	I
measurements	O
were	O
performed	O
on	O
hourly	O
plasma	O
samples	O
across	O
25 hours	O
using	O
the	O
ADVIA_®	O
1800	O
Chemistry	O
System	O

The	O
patients	O
had	O
significantly	O
lower	O
serum	O
enterolactone	B
glucuronide	I
levels	O
compared	O
to	O
controls	O
(median	O
3.41 nM	O
vs.	O
6.31 nM,	O
respectively;	O
P = 0.001)	O
and	O
showed	O
a	O
tendency	O
toward	O
lower	O
enterolactone	B
sulfate	I
levels	O
relative	O
to	O
controls	O
(median	O
3.41 nM	O
vs.	O
6.31 nM,	O

Dodecanamide,	B
LTB4-DMA	O
and	O
cer(d18:0/17:0)	B
showed	O
the	O
specificity	O
of	O
greater	O
than	O
0.80	O
in	O
classifying	O
NR	O
and	O
CR	O
patients.	O

In	O
some	O
studies	O
of	O
obese	O
subjects,	O
abnormal	O
plasma	O
concentrations	O
of	O
BCAAs	O
and	O
protein	O
levels	O
of	O
BCAA-catabolizing	O
enzymes	O
in	O
visceral	O
adipose	O
indicate	O
that	O
BCAAs	O
are	O
closely	O
related	O
to	O
adiposity	O
balance,	O
which	O
is	O
also	O
important	O
in	O
FD	B
patients.	O

Creatinine	B
concentrations	O
measured	O
with	O
the	O
Biocrates	O
kit	O
(74±14	O
μmol/L)	O
were	O
similar	O
to	O
those	O
obtained	O
by	O
routine	O
biochemistry	O
(75±13	O
μmol/L).	O

Phthalate	B
metabolite	O
concentrations—median	O
(95th	O
percentile)	O
in	O
µg/L—reported	O
in	O
human	O
urine	O
samples	O
for	O
children	O
and	O
adults.	O

Besides,	O
creatinine	B
levels	O
in	O
EC	O
patient	O
urine	O
samples	O
were	O
significantly	O
decreased	O
compared	O
to	O
HCs,	O
which	O
has	O
also	O
been	O
reported	O
to	O
be	O
lower	O
in	O
urine	O
samples	O
from	O
colorectal	O
cancer	O
patients[].	O

Equal	O
amounts	O
of	O
ice-cold	O
chloroform	B
(300 μl)	O
and	O
ice-cold	O
Milli-Q	O
water	O
(300 μl)	O
were	O
then	O
added	O
to	O
break	O
the	O
phases.	O

NMR	O
found	O
the	O
same	O
phenomenon	O
for	O
tyrosine,	B
valine,	B
and	O
isoleucine,	B
however,	O
not	O
for	O
methionine.	B

In	O
contrast,	O
PLTP	O
and	O
LCAT	O
activity	O
were	O
correlated	O
positively	O
with	O
triglycerides	B
and	O
inversely	O
with	O
HDL	B
cholesterol.	I

Peaks	O
marked	O
“A”	O
correspond	O
to	O
stearate	B
anion	O
at	O
m	O
/z	O
283.2.	O

Here,	O
we	O
utilize	O
an	O
LXR-response	O
element/LXRα	O
luciferase	O
assay	O
to	O
examine	O
the	O
activational	O
capacity	O
of	O
intermediates	O
in	O
the	O
acidic	O
pathway	O
of	O
bile	O
acid	O
biosynthesis	O
downstream	O
of	O
27-hydroxycholesterol.	B

Until	O
recently	O
it	O
was	O
assumed	O
that	O
the	O
existence	O
of	O
straight	O
chain	O
odd	O
number	O
fatty	O
acids	O
such	O
as	O
pentadecanoic	B
acid	I
(15:0)	O
in	O
normal	O
physiological	O
conditions	O
were	O
rare.	O

Both	O
cells	O
were	O
cultured	O
in	O
[U-_13	B
C]-glucose	I
for	O
24	O
hr	O
before	O
trichloroacetic	O
acid	O
extraction	O
and	O
HSQC	O
measurement	O
at	O
14.4	O
T.	O

The	O
LLOQ	O
for	O
MEL	O
using	O
conventional	O
LC-MS/MS	O
was	O
found	O
to	O
be	O
100	O
fmol	O
on	O
column	O
(1165	O
pg/mL,	B
100	O
μL	O
plasma,	O
23.3	O
pg	B
on	O
column),	O
and	O
the	O
ULOQ	O
was	O
10	O
pmol	O
on	O
column	O
(116500	O
pg/mL,	B
100	O
μL	O
plasma,	O
2.33	O
ng	O
on	O
column),	O
.	O

Finally,	O
isoleucine	B
and	O
oleic	B
acid	I
were	O
negatively	O
correlated	O
in	O
HCV	O
(and	O
also	O
HBV)	O
plasma.	O

Samples	O
are	O
divided	O
in	O
2	O
groups:	O
RP	B
and	O
NRP.	O

For	O
storage,	O
160	O
μL	O
of	O
ice-cold	O
methanol	B
were	O
added	O
per	O
10	O
million	O
cells	O
and	O
the	O
samples	O
frozen	O
directly	O
at	O
-80	O
°C.	O

Average	O
accuracies	O
in	O
the	O
spiked	O
samples	O
were	O
99.6%	O
for	O
25(OH)D_3	O
and	O
111%	O
for	O
1α,25(OH)_2	B
D_3	O
in	O
the	O
LLE	O
experiments	O
and	O
92.3%	O
for	O
25(OH)D_3	O
,	O
100.6%	O
for	O
25(OH)D_2	O
,	O
106%	O
for	O
1α,25(OH)_2	B
D_3	O
and	O
94.4%	O
for	O
24R	O
,25(OH)_2	O
D_3	O
in	O
the	O
SPE	O
experiments.	O

Note	O
that	O
4-hydroxy-2-decenal,	B
2-octenal	B
and	O
2-decenal	O
do	O
not	O
pass	O
the	O
correlation	O
cutoff	O
and	O
hence	O
are	O
shown	O
at	O
the	O
bottom-left	O
side.	O

The	O
membrane	O
blots	O
were	O
blocked	O
with	O
a	O
PBS/TBS	O
super-blocking	O
buffer	O
(Thermo	O
Scientific)	O
including	O
1%	O
polyvinylpyrolidone	B
(PVP)	O
and	O
2	O
mM	O
Na_3	O
VO_4	O
,	O
and	O
immunoblotted	O
with	O
selected	O
polyclonal	O
antibodies.	O

Only	O
5-MTHF	O
was	O
dissolved	O
in	O
a	O
mixture	O
of	O
10 mmol/L	O
NH4OAc	O
with	O
10 %	O
ascorbic	B
acid	I
and	O
2 %	O
DTT	O
in	O
H_2	O
O	O
to	O
prevent	O
oxidation.	O

Combined	O
with	O
the	O
loss	O
in	O
weight,	O
patients	O
in	O
the	O
RYGB	O
group	O
showed	O
significant	O
decreases	O
in	O
fasting	O
insulin	O
and	O
glucose,	B
and	O
thereby	O
HOMA-IR,	O
achieving	O
post-intervention	O
levels	O
that	O
were	O
more	O
in	O
line	O
with	O
normoglycemia.	O

In	O
human	O
studies	O
with	O
soybean-based	O
meals,	O
Allison	O
et	O
al.	O
showed	O
that	O
100	O
obese	O
people	O
exhibited	O
significantly	O
reduced	O
body	O
weight,	O
body	O
fat	O
mass,	O
total	O
cholesterol,	B
and	O
LDL	B
cholesterol	I
after	O
participation	O
in	O
a	O
randomized	O
controlled	O
trial	O
for	O
12	O
weeks.	O

Moreover,	O
impairment	O
of	O
11,12-EET	B
synthesis	O
in	O
mice	O
produced	O
by	O
disruption	O
of	O
the	O
gene-controlling	O
EET	O
synthase	O
caused	O
salt-sensitive	O
hypertension.	O

*Signals	O
of	O
phospholipids	B
at	O
the	O
surface	O
of	O
lipoproteins.	O

Phosphocholine	B
and	O
choline,	B
components	O
of	O
the	O
plasma	O
membranes,	O
are	O
often	O
regarded	O
as	O
markers	O
of	O
the	O
integrity	O
of	O
membranes.	O

Levels	O
of	O
sphingomyelin	B
(SM)	O
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue.	O

Taken	O
together,	O
our	O
findings	O
suggest	O
that	O
both	O
solutes	O
induce	O
a	O
loss	O
of	O
epithelial	O
characteristics	O
and	O
reduce	O
renal	O
glucuronide	B
formation,	O
indicating	O
changes	O
in	O
cell	O
metabolism	O
without	O
affecting	O
cell	O
viability.	O

A	O
was	O
0.1%	O
formic	B
acid	I
(FA)	O
in	O
water	O
in	O
the	O
positive	O
mode	O
or	O
0.5 mmol/L	O
NH_4	O
F	O
in	O
water	O
in	O
the	O
negative	O
mode,	O
and	O
solvent	O
B	O
was	O
0.1%	O
FA	B
in	O
ACN	O
in	O
the	O
positive	O
mode	O
or	O
100%	O
ACN	O
in	O
the	O
negative	O
mode.	O

Fifteen	O
metabolites	O
were	O
found	O
to	O
be	O
significantly	O
dysregulated	O
in	O
CAP	O
patients,	O
which	O
were	O
mainly	O
mapped	O
to	O
the	O
metabolic	O
pathways	O
of	O
sphingolipid,	B
arginine,	B
pyruvate	B
and	O
inositol	B
phosphate.	I

More	O
recently,	O
creatinine	B
was	O
found	O
to	O
be	O
decreased	O
in	O
the	O
serum	O
of	O
patients	O
with	O
HCC	O
compared	O
with	O
healthy	O
subjects.	O

The	O
serine	B
residue	O
198	O
at	O
the	O
active	O
site	O
center	O
makes	O
a	O
covalent	O
bond	O
with	O
the	O
phosphate	B
group	O
of	O
paraoxon	O
releasing	O
the	O
4-hydroxynitrobenzene	B
ring	O
structure.	O

It	O
was	O
also	O
demonstrated	O
that	O
many	O
cancer	O
cells	O
survive	O
without	O
glutamine	B
and	O
only	O
use	O
ammonia	O
as	O
a	O
nitrogen	O
source.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
control	O
and	O
UC	O
subjects	O
for	O
analyses	O
of	O
demographics	O
and	O
medical	O
histories	O
as	O
well	O
as	O
for	O
serum	O
collection	O
as	O
a	O
part	O
of	O
the	O
clinical	O
trial	O
“Effects	O
of	O
L-Arginine	B
in	O
Colitis	O
and	O
Colon	O
Cancer”,	O
identifier	O
NCT01091558	O
(clinicaltrials.gov).	O

(C)	O
Leucine	B
present	O
only	O
in	O
the	O
lyophilized	O
Panc-1	O
samples.	O

It	O
is	O
a	O
precursor	O
to	O
S-adenosylmethionine,	B
which	O
provides	O
a	O
key	O
source	O
of	O
methyl	O
groups	O
in	O
the	O
cell	O
[,	O
].	O

But,	O
enacted	O
restrictions	O
and	O
regulations	O
on	O
phthalates	O
can	O
possibly	O
decrease	O
phthalate	B
exposure	O
levels	O
from	O
many	O
products	O
in	O
the	O
general	O
population.	O

(1.07 ± 1.57	O
and	O
1.06 ± 1.31	O
vs	O
0.53 ± 0.78	O
and	O
0.61 ± 1.11)	O
for	O
Lactobacillus	B
/Enterococcus	O
spp.	O

Distributions	O
of	O
plasma	O
concentrations	O
of	O
testosterone	B
according	O
to	O
body	O
mass	O
index	O
and	O
age	O
for	O
men	O
(•)	O
and	O
women.	O

Spearman	O
rank	O
correlation	O
between	O
metabolites	O
in	O
the	O
kynurenine	B
pathway	O
and	O
selected	O
cytokines	O
Spearman’s	O
correlation	O
coefficients	O
above	O
|0.2|	O
are	O
highlighted	O
in	O
bold.	O

A	O
more	O
challenging	O
example	O
is	O
given	O
by	O
PC	B
33:1.	I

Furthermore,	O
we	O
noted	O
increased	O
levels	O
of	O
various	O
disaccharides	B
and	O
tri	O
saccharides,	B
possibly	O
resulting	O
from	O
amino	O
acid	O
catabolism	O
during	O
sepsis.	O

Thus,	O
overall,	O
12	O
unique	O
metabolites	O
were	O
identified:	O
four	O
amino	O
acids	O
(histidine,	O
leucine,	B
methionine,	B
and	O
tyrosine),	B
two	O
organic	O
acids	O
(pyroglutamic	O
acid	I
and	O
malic	O
acid),	O
carnitine	B
and	O
two	O
acylcarnitines	B
(valerylcarnitine	I
and	O
propionylcarnitine),	B
alpha-N	B
-phenylacetyl-l-glutamine,	I
thiomorpholine	B
3-carboxylate,	I
and	O
1-amino-propan-2-ol/trimethylamine	O
N	B
-oxide/2-amino-1-propanol.	I

In	O
contrast,	O
the	O
more	O
selective	O
MTBE	B
and	O
C18	O
SPE	O
methods	O
showed	O
matrix	O
effects	O
for	O
fewer	O
metabolites	O
and	O
less	O
pronounced	O
extent	O
of	O
suppression/enhancement	O
if	O
matrix	O
effects	O
were	O
present	O
(,	O
).	O

Some	O
estrogen	B
compounds	O
have	O
been	O
shown	O
to	O
not	O
only	O
decrease	O
concentrations	O
of	O
stearic	B
acid	I
but	O
also,	O
amongst	O
others,	O
increase	O
palmitic	B
acid	I
in	O
PC	O
in	O
the	O
serum.	O

For	O
GC–MS	O
metabolite	O
extraction,	O
samples	O
are	O
thawed	O
on	O
ice	O
and	O
50	O
μl	O
of	O
sample	O
used	O
for	O
extraction	O
using	O
chloroform:	B
methanol	B
procedure.	O

The	O
levels	O
of	O
uridine	B
were	O
significantly	O
higher	O
at	O
2	O
Gy	O
from	O
the	O
control	O
group	O
(P	O
=<0.001	O

Pearson’s	O
correlation	O
coefficients	O
(r	O
)	O
were	O
calculated	O
to	O
assess	O
the	O
strength	O
and	O
direction	O
of	O
linear	O
relationships	O
between	O
the	O
identified	O
metabolites,	O
and	O
clinical	O
parameters	O
included	O
WBC,	O
percentage	O
of	O
neutrophils	O
(NE%),	O
erythrocyte	O
sedimentation	O
rate	O
(ESR),	O
C-reactive	O
protein	O
(CRP),	O
procalcitonin	O
(PCT),	O
confusion,	O
urea	B
level,	O
respiratory	O
rate,	O
blood	O
pressure,	O
and	O
age > 65 years	O
(CURB-65),	O
pneumonia	O
severity	O
index	O
(PSI)	O
and	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
(APACHE	O
II)	O
scores.	O

Alterations	O
in	O
phospholipid	B
levels	O
have	O
been	O
reported	O
in	O
pancreatic	O
cancer	O
patients,	O
in	O
whom	O
LysoPC(18:2)	B
was	O
downregulated,	O
while	O
upregulation	O
of	O
this	O
metabolite	O
was	O
detected	O
in	O
the	O
HFS	O
group	O
compared	O
to	O
the	O
non-HFS	O
group.	O

For	O
analyte	O
quantitation,	O
sample	O
throughput	O
may	O
be	O
increased	O
with	O
FL,	O
BCAAs,	O
and	O
creatinine	B
analysed	O
in	O
one	O
run	O
by	O
stable	O
isotopic	O
dilution	O
analysis	O
LC-MS/MS	O
or	O
alternatively	O
by	O
_1	O
H	O
nuclear	O
magnetic	O
resonance.	O

During	O
fasting,	O
muscle	O
protein	O
is	O
catabolised	O
to	O
release	O
alanine	B
for	O
liver	O
gluconeogenesis.	O

However,	O
the	O
E-	O
and	O
D-series	O
PG	B
ISTDs	O
showed	O
temperature	O
sensitivity,	O
especially	O
PGD_2	O
-d4.	O

To	O
confirm	O
intake	O
of	O
supplements,	O
palmar	O
skin	O
carotenoid	B
levels	O
were	O
measured	O
by	O
Raman	O
spectrophotometry	O
(Pharmanex	O
Biophotonic	O
Scanner,	O
Provo,	O
UT,	O
USA).	O

For	O
the	O
analytes	O
which	O
were	O
quantified	O
together	O
(i.e.,	O
GCDCA	B
and	O
GDCA,	O
ADMA	B
and	O
SDMA,	O
and	O
TDCA	O
and	O
TCDCA),	O
only	O
one	O
ISTD	O
was	O
used.	O

The	O
data	O
for	O
the	O
current	O
analysis	O
were	O
collected	O
as	O
part	O
of	O
a	O
feasibility	O
study	O
at	O
Boston	O
University,	O
one	O
of	O
five	O
sites	O
of	O
the	O
NCI	O
Combined	O
DES	B
Cohort	O
Follow-up	O
Study.	O

Plasma	O
samples	O
were	O
obtained	O
at	O
baseline	O
from	O
all	O
study	O
participants	O
when	O
they	O
were	O
in	O
an	O
unfasted	O
state,	O
given	O
that	O
these	O
were	O
people	O
with	O
type	O
2	O
diabetes	O
at	O
risk	O
of	O
hypoglycaemic	B
episodes.	O

Moreover,	O
it	O
can	O
be	O
formed	O
during	O
bacterial	O
metabolism	O
of	O
methanethiol	B
in	O
the	O
gut	O
or	O
endogenous	O
human	O
methanethiol	B
metabolism	O
,	O
.	O

They	O
play	O
important	O
roles	O
in	O
maintenance	O
and	O
growth	O
of	O
skeletal	O
muscle,	O
are	O
used	O
as	O
an	O
energy	O
source	O
during	O
exercise,	O
and	O
can	O
serve	O
as	O
gluconeogenic	B
precursors.	O

Sera	O
has	O
been	O
recovered	O
and	O
collected	O
in	O
polypropylene	B
tubes,	O
divided	O
into	O
aliquots	O
and	O
snap	O
frozen	O
at	O
−80	O
°C.	O

The	O
present	O
analysis	O
is	O
the	O
first	O
human	O
study	O
to	O
our	O
knowledge	O
to	O
report	O
the	O
relationship	O
between	O
the	O
intestinal	O
microbiota-dependent	O
analyte	O
TMAO	B
and	O
its	O
dietary	O
precursors,	O
choline	B
and	O
betaine,	B
with	O
echocardiographic	O
indices	O
in	O
the	O
setting	O
of	O
chronic	O
systolic	O
heart	O
failure.	O

L-Palmitoylcarnitine.	B

Wilcoxon	O
matched-pairs	O
signed-rank	O
test	O
was	O
used	O
when	O
computing	O
differences	O
in	O
MADRS	O
scores,	O
plasma	O
concentrations	O
of	O
cytokines,	O
and	O
kynurenine	B
metabolites	O
in	O
patients	O
before	O
and	O
after	O
treatment	O
with	O
ECT.	O

The	O
correlations	O
of	O
cotinine	B
and	O
trans	B
-3′-hydroxycotinine	I
with	O
3-EP,	O
BUT	O
and	O
some	O
non-parent	O
PAH	O
were	O
higher	O
when	O
considering	O
the	O
non-creatinine-normalised	O
ETS	O
metabolite	O
data	O
(	O
and	O
for	O
creatinine-normalised	O
data).	O

Ultrapure	O
Water	O
(18.2	O
MΩ-cm,	B
TOC = 6	O
ppb)	O
was	O
prepared	O
with	O
a	O
Milli-Q	O
system	O
(Millipore,	O
Billerica,	O
MA,	O
USA).	O

In	O
our	O
current	O
sample	O
of	O
38	O
BD	O
patients,	O
only	O
2	O
were	O
treated	O
with	O
lithium	O
and	O
4	O
were	O
treated	O
with	O
divalproex,	B
suggesting	O
that	O
atypical	O
antipsychotics,	O
lamotrigine,	B
and	O
SSRIs,	O
the	O
most	O
commonly	O
prescribed	O
medications	O
in	O
our	O
current	O
sample,	O
may	O
not	O
exert	O
the	O
equivalent	O
hypertrophic	O
effects.	O

On	O
a	O
statistical	O
level,	O
the	O
most	O
significant	O
signal	O
observed	O
was	O
for	O
urate	B
(P=0.0002,	O
q=0.01),	O
in	O
the	O
HGD/EA	O
versus	O
BE	O
comparison,	O
and	O
for	O
creatine	B
and	O
homocysteine	B
(q<0.15)	O
in	O
the	O
BE	O
versus	O
GERD	O
comparison.	O

This	O
analysis	O
was	O
performed	O
only	O
for	O
ER(+)	B
patients	O
because	O
within	O
the	O
ER(−)	O
group	O
too	O
few	O
relapses	O
were	O
observed	O
(8	O
vs	O
3	O
respectively).	O

The	O
data	O
were	O
then	O
exported	O
to	O
the	O
Mass	O
Profiler	O
Professional	O
software	O
(Agilent)	O
for	O
peak	O
alignment,	O
followed	O
by	O
normalization	O
with	O
the	O
intensity	O
of	O
FMOC-glycine	B
and	O
baselining	O
to	O
median	O
across	O
all	O
samples.	O

cortisol,	B
CCONE:	O
corticosterone,	B
11DECOL:	O
11-deoxycortisol,	B
ADIONE:	B
17-dione,	B
TESTO:	O
testosterone,	B
17-OHIP:	O
17α-hydroxyprogesterone,	B
PROG:	O
progesterone,	B
E2:	O
estradiol,	B
E1:	O
estrone.	B

Mobile	O
phases	O
A	O
and	O
B	O
were	O
DW	O
with	O
10	O
mM	O
ammonium	B
carbonate	I
(pH	O
9.0)	O
and	O
acetonitrile,	B
respectively.	O

Although	O
the	O
significant	O
associations	O
between	O
TMAO	B
and	O
inflammatory	O
markers	O
were	O
lost	O
when	O
renal	O
function	O
was	O
accounted	O
for,	O
suggesting	O
that	O
TMAO	B
might	O
be	O
a	O
surrogate	O
marker	O
for	O
GFR,	O
we	O
cannot	O
exclude	O
that	O
TMAO	B
may	O
have	O
direct	O
proinflammatory	O
and	O
even	O
nephrotoxic	O
properties.	O

These	O
targeted	O
metabolites	O
span	O
a	O
broad	O
range	O
of	O
compound	O
classes,	O
including:	O
amino	O
acids	O
(36%	O
of	O
total	O
measured);	O
organic	O
acids	O
(30%);	O
nucleosides	O
and	O
nucleotides	O
(12%);	O
purines	B
and	O
their	O
derivatives	O
(7%);	O
amino	B
ketones	I
(4%);	O
and	O
others	O
(11%),	O
as	O
shown	O
in	O
.	O

For	O
example,	O
11,12-EpETrE	B
reduced	O
TNFɑ-induced	O
VCAM-1	O
surface	O
expression	O
in	O
HAEC.	O

For	O
glyoxylate,	B
this	O
was	O
the	O
case.	O

In	O
the	O
present	O
study,	O
endocannabinoid	B
levels	O
were	O
lower	O
in	O
CRC	O
samples	O
than	O
in	O
HC	O
samples,	O
which	O
may	O
be	O
explained	O
by	O
the	O
overexpression	O
in	O
CRC	O
of	O
lipid	O
metabolizing	O
enzyme	O
MAGL,	O
a	O
key	O
enzyme	O
in	O
endocannabinoid	B
metabolism.	O

They	O
also	O
had	O
higher	O
citrulline	B
concentrations	O
than	O
controls	O
but	O
lower	O
than	O
IBS	O
patients,	O
lower	O
concentrations	O
of	O
SDMA	O
than	O
controls	O
but	O
higher	O
than	O
IBS	O
patients,	O
and	O
higher	O
DMA	B
concentrations	O
than	O
controls	O
and	O
patients	O
with	O
inactive	O
CD.	O

[]	O
These	O
lineages	O
lack	O
sterol	O
biosynthesis	O
capacity	O
and	O
rely	O
solely	O
on	O
cholesterol	B
uptake	O
from	O
the	O
diet.	O

Only	O
the	O
use	O
of	O
ethanolamine	B
as	O
a	O
single	O
screening	O
test	O
showed	O
a	O
higher	O
accuracy	O
in	O
distinguishing	O
long-term	O
from	O
short-term	O
survivors.	O

A	O
Kaplan-Meier	O
analysis	O
showed	O
that	O
the	O
overall	O
survival	O
probabilities	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
low	O
tumor	O
ethanolamine	B
concentrations	O
compared	O
to	O
those	O
with	O
high	O
tumor	O
ethanolamine	B
concentrations	O
(Fig. ).	O

Parametric	O
and	O
nonparametric	O
tests	O
were	O
applied	O
to	O
determine	O
whether	O
tamoxifen	B
and	O
its	O
metabolite	O
concentrations	O
as	O
well	O
as	O
metabolic	O
ratio's	O
(MRs)	O
differ	O
between	O
DME	O
genotypes	O
and	O
adherence	O
behavior.	O

Similarly,	O
the	O
increased	O
levels	O
of	O
S1P	O
and	O
sphingosine	B
in	O
the	O
AERD	O
patients	O
showed	O
positive	O
correlations	O
with	O
the	O
serum	O
15-HETE	B
level,	O
while	O
the	O
levels	O
of	O
serum	O
SMs	O
were	O
negatively	O
correlated	O
with	O
the	O
serum	O
15-HETE	B
level.	O

Lipidomics	O
studies	O
of	O
exosomes	O
generated	O
from	O
prostate	O
cancer	O
3	O
(PC-3)	O
cells	O
specifically	O
identified	O
two	O
PS	O
lipids,	O
PS(18:0_18:1)	B
and	O
PS(18:0_22:6),	B
that	O
were	O
elevated	O
and	O
exclusively	O
identified	O
in	O
exosomes	O
vs.	O
the	O
parent	O
cells,	O
respectively.	O

Evaluation	O
of	O
breath	O
mass	O
spectra	O
at	O
varying	O
exhalation	O
flow	O
rates	O
and	O
using	O
spirometry	B
filters.	O

In	O
the	O
liver,	O
glycolic	B
acid	I
is	O
generated	O
from	O
ethylene	B
glycol	I
by	O
enzymes,	O
alcohol	O
dehydrogenase	O
and	O
aldehyde	O
dehydrogenase;	O
and	O
then	O
is	O
metabolized	O
to	O
oxalic	B
acid	I
by	O
enzymes,	O
glycolate	B
oxidase	O
and	O
glycolate	O
dehydrogenase.	O

Recent	O
studies	O
reported	O
that	O
the	O
change	O
in	O
lactate	B
and	O
alanine	B
can	O
act	O
as	O
an	O
important	O
parameter	O
for	O
monitoring	O
tumor	O
aggressiveness	O
in	O
prostate	O
cancer	O
and	O
prognosis	O
for	O
lung	O
cancer.	O

Summary	O
of	O
data	O
for	O
linolenic	B
acid	I
detected	O
by	O
LC–MS.	O

Finally,	O
lipid	O
fingerprinting	O
by	O
LC-MS(±)	B
was	O
the	O
only	O
analytical	O
platform	O
able	O
to	O
detect	O
glycerolipids	B
as	O
differential	O
metabolites.	O

Some	O
subjects	O
were	O
excluded	O
for	O
the	O
following	O
reasons:	O
age≥75	O
years	O
or	O
age≤18	O
years;	O
fasting	O
blood	O
glucose	B
(FBG)>7.0	O
mmol/	O

The	O
upper	O
organic	O
phase	O
was	O
collected,	O
placed	O
in	O
another	O
glass	O
tube	O
with	O
a	O
Teflon	O
lined	O
cap,	O
and	O
dried	O
under	O
nitrogen	B
gas.	I

The	O
first	O
reaction	O
is	O
the	O
conversion	O
of	O
3-phosphoglycerate	B
to	O
3-phosphohydroxypyruvate	B
by	O
phosphoglycerate	B
dehydro	I
genase	O
followed	O
by	O
further	O
conversion	O
to	O
3-phosphoserine	B
by	O
phosphoserine	O
aminotransferase	O
before	O
the	O
final	O
conversion	O
to	O
serine	B
by	O
protein	O
serine	O
phosphatase.	O

Less	O
abundant	O
flour	O
carbohydrates	O
included	O
sucrose	B
and	O
raffinose.	B

In	O
conclusion,	O
we	O
found	O
significantly	O
decreased	O
levels	O
of	O
enterolactone	B
in	O
colon	O
cancer,	O
but	O
not	O
in	O
rectal	O
cancer	O
patients.	O

To	O
further	O
elaborate	O
on	O
the	O
effects	O
of	O
α-OG	B
on	O
epigenetic	O
regulation	O
in	O
immortalized	O
normal	O
bladder	O
epithelial	O
cells,	O
we	O
measured	O
the	O
activity	O
of	O
two	O
DNA	O
methylation	O
regulators,	O
DNMT	O
and	O
TET,	O
in	O
the	O
presence	O
of	O
α-OG	B
(Fig. ).	O

We	O
suggest	O
that	O
these	O
results	O
indicate	O
that	O
the	O
kynurenine	B
pathway	O
is	O
mainly	O
important	O
in	O
SLE-related	O
fatigue.	O

However,	O
the	O
reason	O
why	O
LacCer	B
(d18:1/16:0)	I
level	O
does	O
not	O
increase	O
in	O
patients	O
with	O
recurrence	O
remains	O
to	O
be	O
elucidated.	O

DI	O
was	O
positively	O
associated	O
with	O
branched-chain	O
AAs	O
(leucine/isoleucine	O
and	O
valine;	B
r	O
=	O
0.27	O
and	O
0.29,	O
P	O
=	O
0.001),	O
neutrally	O
transported	O
AAs	O
(phenylalanine	O
and	O
methionine;	B
r	O
=	O
0.30	O
and	O
0.35,	O
P	O
<	O
0.001),	O
basic	O
AAs	O
(histidine	O
and	O
arginine;	B
r	O
=	O
0.28	O
and	O
0.23,	O
P	O
≤	O
0.007),	O
serine	B
(r	O
=	O
0.35,	O
P	O
<	O
0.001),	O
glycine	B
(r	O
=	O
0.26,	O
P	O
=	O
0.002),	O
and	O
branched-chain	O
AAs-derived	O
intermediates	O
C3,	O
C4,	O
and	O
C5	O
acylcarnitine	B
(range	O
r	O
=	O
0.18–0.19,	O
P	O
≤	O
0.04).	O

Whilst	O
succinate	B
does	O
not	O
show	O
a	O
significantly	O
increased	O
urinary	O
excretion	O
(in	O
agreement	O
with	O
our	O
previous	O
NMR	O
observations[]),	O
closely	O
related	O
metabolites,	O
namely	O
methylsuccinate	B
and	O
fumarate,	B
had	O
higher	O
urinary	O
levels	O
which	O
may	O
describe	O
a	O
selective	O
oxidation	O
of	O
aspartate,	B
tyrosine	B
and	O
phenylalanine.	B

Galactose	B
reached	O
its	O
highest	O
serum	O
levels	O
1	O
h	O
after	O
milk	O
intake	O
while	O
lactose,	B
galactitol,	B
galactonate,	B
and	O
galactono-1,5-lactone	B
reached	O
their	O
maximum	O
at	O
2	O
h.	O

These	O
two	O
compounds	O
contain	O
the	O
desired	O
proton-affine	O
imidazole	O
and	O
triazole	B
groups	O
to	O
improve	O
+	O
ESI	O
sensitivity.	O

Through	O
inactivation	O
or	O
immediate	O
metabolism	O
to	O
20-OH-LTB4,	B
this	O
could	O
explain	O
the	O
absence	O
of	O
LTB4	B
in	O
the	O
serum	O
samples	O
from	O
patients	O
studied	O
in	O
our	O
investigation.	O

The	O
local	O
1D	O
model	O
revealed	O
that	O
the	O
patients	O
with	O
an	O
eGFR	O
<	O
60	O
ml/min/1.73m_2	O
were	O
older	O
and	O
had	O
a	O
high	O
concentration	O
of	O
urinary	O
retinol	B
binding	O
protein	O
and,	O
conversely	O
for	O
individuals	O
with	O
an	O
eGFR	O

Also,	O
pioglitazone	B
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
plasma	O
adiponectin	O
concentrations.	O

This	O
might	O
indicate	O
that	O
high	O
levels	O
of	O
peripheral	O
kynurenine	B
are	O
protective	O
against	O
depressive	O
symptoms.	O

Interestingly,	O
women	O
without	O
a	O
cancer	O
diagnosis	O
(normal),	O
who	O
had	O
not	O
given	O
birth	O
within	O
the	O
past	O
five	O
years,	O
had	O
intermediate	O
levels	O
of	O
tryptophan	B
and	O
its	O
catabolites	O
in	O
between	O
the	O
levels	O
observed	O
in	O
normal	O
women	O
who	O
had	O
given	O
birth	O
within	O
the	O
past	O
five	O
years	O
and	O
PABC/non-PABC	O
patients.	O

Optionally,	O
isotopic	O
pattern	O
of	O
chlorine-35/37	B
was	O
also	O
used	O
for	O
the	O
confirmation	O
whenever	O
it	O
is	O
available.	O

The	O
VUS	O
of	O
the	O
amino	O
acid	O
concentrations	O
spanned	O
from	O
0.180	O
(arginine,	O
95 %	O
CI	O
0.106–0.270)	O
to	O
0.850	O
(glutamine,	O
95 %	O
CI	O
0.761–0.929).	O

A	O
statistically	O
significant	O
positive	O
correlation	O
between	O
plasma	O
20-HETE	B
and	O
PRA	O
was	O
observed	O
within	O
the	O
group	O
of	O
patients	O
with	O
RVD,	O
as	O
well	O
as	O
the	O
whole	O
study	O
population.	O

Within	O
each	O
metabolomic	O
set,	O
we	O
applied	O
Gene-Set	O
Analysis	O
(GSA),	O
which	O
is	O
a	O
pathway	O
analysis	O
method,	O
to	O
examine	O
whether	O
pre-defined	O
metabolic	O
pathways	O
including	O
super-	O
and	O
sub-pathways	O
were	O
related	O
to	O
retinol	B
within	O
individual	O
metabolomic	O
sets.	O

In	O
the	O
case	O
of	O
incubation	O
with	O
enzyme,	O
the	O
back	O
calculated	O
concentration	O
at	O
QC	O
1	O
was	O
outside	O
the	O
range	O
(accuracy	O
139.2 %)	O
as	O
expected,	O
because	O
the	O
endogenous	O
diosmetin	B
glucuronides	O
from	O
plasma	O
were	O
deconjugated,	O
and	O
added	O
to	O
the	O
spiked	O
concentration.	O

Four	O
compounds	O
including,	O
rigidiusculamide	B
E	O
(111),	O

Further,	O
we	O
evaluated	O
possible	O
associations	O
between	O
serum	O
SL	B
concentrations	O
and	O
severity	O
of	O
HCC	O
according	O
to	O
the	O
BCLC	O
stage.	O

	O
shows	O
that	O
factor	O
1	O
was	O
positively	O
correlated	O
with	O
total-C	O
and	O
TG	B
levels	O
in	O
all	O
three	O
groups.	O

Second,	O
the	O
absorption	O
of	O
methadone	B
across	O
mucosal	O
membranes	O
is	O
rapid,	O
as	O
demonstrated	O
previously	O
for	O
nasal	O
administration.	O

Then	O
375 μl	O
of	O
the	O
suspension	O
were	O
transferred	O
into	O
a	O
1.5-ml	O
Eppendorf	O
tube	O
containing	O
1125 μl	O
of	O
4%	O
paraformaldehyde	B
(PFA).	O

Pathway	O
analysis	O
revealed	O
networks	O
associated	O
with	O
amino	O
acid	O
metabolism,	O
glycolysis	O
and	O
gluconeogenesis,	O
fatty	O
acid	O
biosynthesis,	O
phospholipids	B
and	O
purine	B
metabolism	O
in	O
the	O
ARDS	O
BALF.	O

A	O
sepsis	O
study	O
and	O
our	O
data	O
both	O
found	O
metabolites	O
of	O
PLA2	O
to	O
be	O
associated	O
with	O
death	O
(1-arachidonoyl-GPE	O
(20:4),	I
1-arachidonoyl-GPC	B
(20:4)	I
in	O
sepsis,	O
and	O
arachidonic	B
acid	I
in	O
CM).	O

We	O
have	O
developed	O
a	O
mass	O
spectrometry-based	O
strategy	O
to	O
simultaneously	O
measure	O
191	O
metabolites	O
following	O
glucose	B
ingestion.	O

Notably,	O
capric	B
acid	I
(C10:0)	O
was	O
compromised	O
by	O
interference	O
in	O
the	O
PBRC	O
samples,	O
while	O
arachidic	B
acid	I
(C20:0)	O
was	O
observed	O
at	O
<0.05%	O
of	O
the	O
total	O
fatty	O
acid	O
profile	O
in	O
∼60%	O
of	O
the	O
subjects.	O

Since	O
Otto	O
Warburg’s	O
important	O
discovery,	O
it	O
is	O
now	O
well	O
established	O
based	O
on	O
numerous	O
reports	O
that	O
cancer	O
cells	O
show	O
increased	O
flux	O
in	O
metabolizing	O
higher	O
levels	O
of	O
glutamine	B
driven	O
at	O
least	O
in	O
part	O
due	O
to	O
higher	O
energy	O
demands	O
and	O
its	O
involvement	O
in	O
anaplerotic	O
reactions	O
such	O
as	O
conversion	O
to	O
α-ketoglutarate,	B
have	O
increased	O
lipid	O
synthesis,	O
and	O
enhanced	O
amino	O
acid	O
transport	O
compared	O
to	O
normal	O
cells.	O

Concentrating	O
on	O
the	O
direct	O
association	O
of	O
the	O
serum	O
metabolite	O
profiles	O
of	O
BC	O
and	O
the	O
histopathology	O
of	O
bladder	O
tissue,	O
a	O
composite	O
panel	O
of	O
potential	O
biomarkers	O
including	O
inosine,	B
AFMK	O
and	O
PS(O-18:0/0:0)	B
was	O
identified	O
as	O
a	O
diagnostic	O
tool,	O
which	O
could	O
precisely	O
distinguish	O
not	O
only	O
between	O
HG	O
BC	O
and	O
LG	O
BC	O
but	O
also	O
between	O
LG	O
BC	O
and	O
healthy	O
control.	O

It	O
can	O
also	O
cause	O
mitochondria-dependent	O
apoptosis	O
via	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species,	O
and	O
be	O
a	O
precursor	O
of	O
the	O
7α,	O
25-dihydroxyxcholesterol	B
which	O
is	O
the	O
most	O
potent	O
ligand	O
for	O
activation	O
and	O
migration	O
of	O
the	O
B	O
lymphocyte.	O

With	O
our	O
method,	O
peak	O
areas	O
obtained	O
in	O
spiked	O
and	O
clinical	O
samples	O
for	O
ISTD	O
11526102	O
and	O
Met	O
amino-d11	B
perfectly	O
matched,	O
with	O
an	O
overall	O
RSD	O
below	O
2%,	O
confirming	O
the	O
reliability	O
of	O
the	O
method	O
for	O
measuring	O
not	O
only	O
PBTZ169	O
but	O
also	O
six	O
known	O
metabolites	O
in	O
real	O
human	O
plasma	O
samples	O
collected	O
from	O
healthy	O
volunteers.	O

*P	O
 < 0.001	O
(Mann-Whitney	O
U	O
test)	O
(all	O
reported	O
P	O
values	O
are	O
two	O
sided)	O
No	O
differences	O
in	O
the	O
plasma	O
levels	O
of	O
tryptophan	B
or	O
any	O
of	O
the	O
other	O
kynurenine	B
metabolites	O
(kynurenine,	O
QUIN,	O
or	O
the	O
ratio	O
of	O
kynurenine/tryptophan)	B
were	O
detected	O
between	O
patients	O
with	O
MDD	O
and	O
healthy	O
volunteers	O
(Fig.	O

In	O
humans,	O
the	O
vast	O
majority	O
of	O
D-xylulose	B
is	O
metabolized	O
via	O
xylulokinase	O
[,	O
,	O
].	O

Ketoglutaric	B
acid,	I
uric	B
acid,	I
and	O
pimelic	B
acid	I
are	O
candidate	O
key	O
metabolites	O
for	O
active	O
acupoints.	O

Thus,	O
EDTA	O
and	O
heparin	B
are	O
both	O
suitable	O
for	O
blood	O
patient	O
collection	O
and	O
can	O
also	O
be	O
used	O
if	O
necessary	O
for	O
the	O
preparation	O
of	O
calibrators	O
and	O
QC	O
samples.	O

The	O
reaction	O
of	O
human	O
SA	O
with	O
HONH-PhIP	O
in	O
vitro	O
produced	O
the	O
N	O
_2	B
-cysteinesulfinyl-PhIP;	I
this	O
sulfinamide	B
linkage	O
accounted	O
for	O
greater	O
than	O
95%	O
of	O
the	O
HONH-PhIP	O
bound	O
to	O
SA.	O

Also	O
with	O
each	O
increasing	O
quartile	O
of	O
SDMA	O
[HR	O
(95%	O
CI):	O
1.63	O
(1.4-1.9)]	O
and	O
ADMA	B
[HR	O
(95%	O
CI):	O
1.46	O
(1.2-1.7)],	O
there	O
was	O
statistically	O
significant	O
increased	O
unadjusted	O
risk	O
for	O
future	O
MACE.	O

TG	B
(48:2)	I
which	O
was	O
detected	O
in	O
19/24	O
samples	O
out	O
of	O
which	O
ten	O
were	O
in	O
the	O
second	O
batch,	O
was	O
on	O
the	O
other	O
hand	O
detected	O
in	O
the	O
first	O
and	O
immediately	O
repeated	O
injections,	O
but	O
not	O
detected	O
after	O
prolonged	O
storage.	O

Although	O
the	O
genetic	O
bases	O
of	O
our	O
SCC	O
samples	O
were	O
not	O
defined,	O
our	O
results	O
agree	O
with	O
such	O
studies	O
with	O
the	O
predominance	O
of	O
aerobic	O
glycolysis,	O
fed	O
by	O
glutamine/glutamate	O
to	O
feed	O
the	O
generation	O
of	O
ATP	B
and	O
reducing	O
equivalents.	O

L	O
(126	O
mg/dL),	O
2)	O
random	O
sample	O
plasma	O
glucose	B
≥11.1	O
mmol/L	O
(200	O
mg/dL),	O
3)	O
self-report	O
of	O
a	O
physician	O
diagnosis	O
of	O
T2DM,	O
and	O
4)	O
initiation	O
of	O
glucose-lowering	O
medication	O
use,	O
retrieved	O
from	O
a	O
central	O
pharmacy	O
registry.	O

m	O
m	O
m	O
β-Apo-13-Carotenone	B
is	O
a	O
high	O
affinity	O
ligand	O
for	O
purified	O
retinoic	B
acid	I
receptors	O
and	O
fits	O
into	O
the	O
ligand	O
binding	O
site.	O

The	O
method	O
was	O
originally	O
developed	O
for	O
the	O
analysis	O
of	O
trimethylamine	B
N-oxide	I
(TMAO)	O
and	O
five	O
related	O
compounds	O
in	O
plasma	O
samples	O
(see	O
[,]),	O
but	O
was	O
adapted	O
to	O
urine	O
and	O
extended	O
to	O
28	O
analytes	O
in	O
this	O
study.	O

To	O
perform	O
a	O
direct	O
comparison	O
of	O
the	O
same	O
volume	O
we	O
used	O
5	O
mL	O
of	O
50%	O
MeOH	B
for	O
cell	O
quenching	O
followed	O
by	O
increased	O
extraction	O
volumes	O
(4	O
mL	O
CHCl_3	O
,	O
additional	O
1.5	O
mL	O
MeOH	B
and	O
1.5	O
mL	O
H_2	O
O)	O
leading	O
to	O
a	O
1:1:1,	O
v/v/v	O
ratio	O
of	O
MeOH:	B

The	O
number	O
of	O
individual	O
lipid	O
species	O
measured	O
was	O
PA,	O
20;	O
PE,	O
37;	O
PG,	B
24;	O
PI,	O
17;	O
PS,	O
23;	O
and	O
PC,	O
25.	O

In	O
our	O
ROC	O
analysis	O
differentiating	O
between	O
aMCI	O
and	O
normal	O
control,	O
the	O
area	O
under	O
the	O
curve	O
of	O
arginine	B
is	O
0.682,	O
the	O
best	O
cut-off	O
point	O
is	O
288.5	O
ng/mL,	O
at	O
which	O
the	O
sum	O
of	O
sensitivity	O
and	O
specificity	O
reaches	O
the	O
maximal	O
value,	O
with	O
a	O
sensitivity	O
of	O
80.8%	O
and	O
specificity	O
of	O
42.3%	O
for	O
aMCI	O
diagnosis;	O
the	O
area	O
under	O
the	O
curve	O
of	O
GABR	O
is	O
0.797,	O
the	O
best	O
cut-off	O
point	O
is	O
0.523,	O
at	O
which	O
the	O
sum	O
of	O
sensitivity	O
and	O
specificity	O
reaches	O
the	O
maximal	O
value,	O
with	O
a	O
sensitivity	O
of	O
84.6%	O
and	O
specificity	O
of	O
80.8%	O
for	O
aMCI	O
diagnosis.	O

Therefore,	O
our	O
finding	O
suggested	O
that	O
in	O
the	O
study	O
of	O
specific	O
PI	O
species	O
using	O
MALDI-TOF	O
MS,	O
nonpolar	O
solvent,	O
such	O
as	O
hexane,	B
is	O
more	O
suitable	O
than	O
polar	O
solvents	O
for	O
extracting	O
PI	O
from	O
a	O
complex	O
lipid	O
mixture.	O

Regarding	O
diet	O
composition,	O
recent	O
research	O
revealed	O
that	O
changes	O
in	O
macronutrient	O
intake	O
can	O
influence	O
lipid	O
and	O
fatty	O
acid	O
chain	O
in	O
acylcarnitines.	B

Although	O
the	O
estrogen-methide	O
adducts,	O
E_1	O
(E_2	B
)-9-N-Ade,	I
structurally	O
differ	O
from	O
catechol-quinone	B
adducts,	O
4-OHE_1	O
(E_2	O
)-1-N3Ade,	O
they	O
are	O
linked	O
to	O
DNA	O
backbone	O
through	O
same	O
β-N-glycoside	B
bond	O
between	O
adenine	B
(N-9)	O
and	O
deoxyribose	B
(C’-1).	O

Of	O
the	O
differentially	O
produced	O
metabolites	O
among	O
the	O
3	O
groups,	O
24	O
metabolites	O
(2-hydroxy-3-methylbutyric	O
acid,	I
3,4-dihydrxoybutyric	B
acid,	I
4-hydroxybutyric	B
acid,	I
6-aminocaproic	B
acid,	I
arabionse,	O
arabitol,	B
cellobiose,	B
cytidine	B
5′-diphosphocholine,	I
ethanolamine,	B
glyceraldehyde,	B
GCDCA-3-sulfate,	B
hydroxyprolyl-methionine,	B
hypoxanthine,	B
Ile-Thr,	B
indole-3-acetamide,	B
isoleucine,	B
lactic	B
acid,	I
myo-inositol,	B
pentanoic	B
acid,	I
threitol,	B
threoninyl-methionine,	B
trimethylamine	B
N-oxide	I
(TMAO),	O
uridine,	B
and	O
valine)	B
were	O
consistently	O
higher	O
or	O
lower.	O

Finally,	O
we	O
show	O
that	O
it	O
is	O
feasible	O
to	O
perform	O
methanol	B
extraction	O
of	O
metabolites	O
directly	O
from	O
FFPE	O
tissue	O
sections	O
preserving	O
their	O
architecture.	O

However,	O
levels	O
of	O
total	O
cholesterol	B
and	O
LDL-C	O
were	O
significantly	O
decreased	O
in	O
CE	O
patients	O
(p	O
<0.001)	O
since	O
75%	O
of	O
them	O
received	O
lipid-lowering	O
therapy.	O

Stage-independent	O
elevation	O
of	O
salivary	O
metabolite	O
markers,	O
including	O
choline	B
and	O
pipecolate,	B
were	O
also	O
reported	O
in	O
another	O
study.	O

Certain	O
processes	O
have	O
been	O
proposed	O
as	O
contributing	O
to	O
the	O
risk	O
for	O
these	O
somatic	O
diseases,	O
including	O
accelerated	O
biological	O
aging	O
[–],	O
sympathetic	O
and	O
glucocorticoid	B
dysregulation	O
[,	O
–],	O
metabolic	O
changes	O
[,	O
,	O
,	O
],	O
inflammation	O
[,	O
,	O
,	O
–]	O
and	O
others.	O

The	O
differential	O
levels	O
of	O
xanthine,	B
hypoxanthine,	B
and	O
D-mannose	B
prompted	O
us	O
to	O
examine	O
the	O
association	O
of	O
these	O
metabolites	O
with	O
PLP	O
and	O
CRC	O
risks.	O

Triterpene	B
1	O
and	O
the	O
DCM	O
leaf	O
extract	O
were	O
found	O
to	O
be	O
very	O
hydrophobic,	O
and	O
did	O
not	O
totally	O
dissolve	O
in	O
95%	O
EtOH	B
and	O
DCM.	O

IDLC;	O
total	O
cholesterol	B
in	O
intermediate	O
density	O
lipoprotein,	O
LDLC;	O
total	O
cholesterol	B
in	O
low	O
density	O
lipoprotein,	O
HDLC;	O
total	O
cholesterol	B
in	O
high	O
density	O
lipoprotein,	O
HDL2C;	O
total	O
cholesterol	B
in	O
high	O
density	O
lipoprotein	O
2,	O
HDL3C;	O
total	O
cholesterol	B
in	O
high	O
density	O
lipoprotein	O
3,	O
Est;	O
esterified	O
cholesterol,	B
Free	O
C;	O
free	O
cholesterol,	B
LDLTG,	O
triglycerides	B
in	O
low	O
density	O
lipoprotein,	O
HDL‐TG,	O
triglycerides	B
in	O
high	O
density	O
lipoprotein;	O
n‐3	O
FA,	B
Omega‐3	O
fatty	O
acids	O

A	O
similar	O
OPLS-DA	O
model	O
for	O
the	O
intake	O
of	O
whey	B
protein	O
revealed	O
similar	O
dynamic	O
changes	O
in	O
the	O
post-exercise	O
period	O
(data	O
not	O
shown).	O

As	O
mentioned	O
in	O
the	O
Introduction,	O
LDL-C	O
as	O
such	O
may	O
not	O
have	O
the	O
sensitivity	O
or	O
specificity	O
needed	O
to	O
distinguish	O
CAD	O
risk	O
within	O
all	O
the	O
subjects	O
with	O
elevated	O
LDL-C.	O
On	O
the	O
other	O
hand,	O
many	O
CAD	O
patients	O
may	O
have	O
fairly	O
normal	O
LDL-C.	O
One	O
of	O
the	O
suggested	O
markers	O
for	O
predicting	O
better	O
the	O
atherogenic	O
potential	O
of	O
LDL	O
is	O
LDL-TG	O
–	O
high	O
LDL-TGs	O
being	O
reported	O
to	O
indicate	O
cholesterol	B
ester-depleted	O
LDL,	O
elevated	O
IDL	O
and	O
dense	O
LDL.	O

500	O
μL	O
of	O
plasma	O
and	O
CSF	O
samples	O
were	O
separately	O
analyzed	O
for	O
biochemical	O
and	O
clinical	O
parameters	O
including	O
plasma	O
glucose,	B
plasma	O
insulin,	O
plasma	O
glycated	O
hemoglobin	O
A1c	O
(HbA1c),	O
CSF	O
glucose,	B
and	O
CSF	O
insulin	O
level.	O

The	O
lipid	O
changes	O
were	O
verified	O
by	O
measurement	O
of	O
the	O
common	O
disease	O
markers	O
(e.g.	O
ATP,	B
cytokine,	O
calcium)	O
using	O
conventional	O
assays.	O

In	O
particular,	O
the	O
increased	O
levels	O
of	O
acetoacetate,	B
acetone,	B
acetate	B
as	O
well	O
as	O
n-butyrate,	B
α-hydroxy-n	B
-butyrate,	I
and	O
β-hydroxybutyrate,	B
derive	O
from	O
β-oxidation	O
process.	O

Importantly,	O
lactate	B
induced	O
the	O
trapping	O
of	O
T	O
cells	O
at	O
the	O
site	O
of	O
inflammation	O
and	O
thus	O
the	O
persistence	O
of	O
pro-inflammatory	O
signaling.	O

In	O
addition,	O
multiple	O
linear	O
regressions	O
were	O
used	O
to	O
test	O
the	O
association	O
between	O
selected	O
discriminatory	O
features	O
and	O
disease	O
status	O
(DR	O
versus	O
diabetic	O
control;	O
PDR	O
versus	O
NPDR)	O
using	O
metabolite	O
intensity	O
as	O
the	O
dependent	O
variable	O
and	O
adjusting	O
for	O
potential	O
confounding	O
variables	O
including	O
age,	O
sex,	O
HbA1c,	O
and	O
diabetes	O
duration.	B

In	O
CHS,	O
the	O
mean	O
concentration	O
of	O
the	O
interfering	O
dihydroxyvitamin	B
D_3	O
metabolite(s)	O
was	O
0.73	O
±	O
0.35	O
(standard	O
deviation)	O
ng/mL,	O
while	O
the	O
mean	O
concentration	O
of	O
specific	O
24,25(OH)_2	B
D_3	O
was	O
2.77	O
±	O
1.70	O
ng/	O

After	O
overnight	O
fasting,	O
morning	O
plasma	O
samples	O
were	O
collected	O
in	O
5-mL	O
vacutainer	O
tubes	O
containing	O
the	O
chelating	O
agent	O
ethylene	B
diamine	I
tetraacetic	O
acid	O
(EDTA).	O

As	O
a	O
result,	O
at	O
a	O
25(OH)D_3	O
concentration	O
of	O
20	O
ng/mL,	O
mean	O
24,25(OH)_2	B
D_3	O
concentration	O
was	O
2.92	O
(95%	O
CI,	O
2.87–2.96),	O
2.68	O
(95%	O
CI,	O
2.64–2.72),	O
2.35	O
(95%	O
CI,	O
2.26–2.45),	O
1.92	O
(95%	O
CI,	O
1.74–2.10),	O
1.69	O
(95%	O
CI,	O
1.43–1.95),	O
1.14	O
(95%	O
CI,	O
0.62–1.66),	O
and	O
1.04	O
(95%	O
CI,1.02–1.07)	O
ng/mL	O
for	O
each	O
category,	O
respectively.	O

The	O
metabolic	O
profile	O
differences	O
at	O
first	O
24	O
hours	O
between	O
survivor/non-survivor	O
groups	O
allowed	O
the	O
selection	O
of	O
8	O
metabolites	O
(ethanol,	O
glutamine,	B
methionine,	B
arginine,	B
phenylalanine,	B
glucose,	B
hippurate	B
and	O
an	O
unknown	O
metabolite	O
located	O
at	O
1.40–1.45	O
ppm)	O
that	O
all	O
together	O
constitute	O
a	O
biosignature	O
with	O
potential	O
prognostic	O
value.	O

The	O
stable	O
isotope	O
dilution	O
HPLC-MS/MS	O
was	O
used	O
to	O
quantify	O
15	O
estrogens	O
and	O
estrogen	B
metabolites	O
that	O
circulate	O
primarily	O
as	O
sulfated	O
and/or	O
glucuronidated	O
conjugates.	O

Interestingly,	O
PC	B
(34:2),	I
PC	B
(34:1),	I
PC	B
(36:3),	I
and	O
PC	B
(36:2)	I
increased	O
in	O
both	O
tissues	O
and	O
sera	O
of	O
MF	O
patients,	O
whereas	O
SM	B
(16:0),	I
PC	B
(32:0),	I
and	O
PC	B
(38:4)	I
levels	O
increased	O
in	O
the	O
sera	O
but	O
decreased	O
in	O
the	O
tissues	O
of	O
MF	O
patients	O
compared	O
to	O
control	O
subjects.	O

NMR	O
peaks	O
in	O
the	O
range	O
δ	O
0.50-9.50	O
ppm	O
were	O
analyzed,	O
although	O
the	O
region	O
δ	O
4.50-6.40	O
ppm	O
was	O
excluded	O
to	O
remove	O
the	O
residual	O
water	O
signal	O
and	O
the	O
signal	O
from	O
urea.	B

On	O
the	O
other	O
hand,	O
all	O
the	O
fasting	O
blood	O
glucose	B
levels	O
in	O
T2DM	O
patients	O
were	O
above	O
126	O
mg/dL,	O
further	O
confirming	O
the	O
group	O
classification.	O

(G)	O
Hypotaurine	B
is	O
down-regulated	O
in	O
DOCK8-deficient	O
patients	O
compared	O
with	O
Ctrl.	O

The	O
following	O
variables	O
were	O
evaluated	O
as	O
potential	O
confounders:	O
total	O
cholesterol,	B
height,	O
body	O
mass	O
index	O
(BMI),	O
calcium	O
intake,	O
total	O
cigarettes	O
smoked	O
daily,	O
duration	B
of	O
smoking,	O
baseline	O
alcohol	O
consumption,	O
history	O
of	O
diabetes,	O
history	O
of	O
renal	O
disease,	O
fish	O
intake	O
and	O
season	O
of	O
blood	O
draw.	O

Another	O
study	O
using	O
a	O
depressive	O
animal	O
model	O
reported	O
that	O
the	O
depressive	O
behavior	O
was	O
related	O
with	O
significantly	O
changed	O
metabolites	O
in	O
the	O
tyrosine–phenylalanine	B
pathway.	O

All	O
serum	O
samples	O
were	O
analysed	O
in	O
random	O
order	O
at	O
298	O
K.	O
One-dimensional	O
spectrum	O
was	O
used	O
to	O
obtain	O
CPMG	O
spin	O
echo	O
pulse	O
sequence	O
(RD-90°-(τ-180°-τ)n-ACQ)	O
to	O
suppress	O
water	O
signal	O
with	O
a	O
relaxation	O
delay	O
of	O
5	O
s.	O

In	O
total,	O
2,089	O
molecular	O
features	O
were	O
detected	O
when	O
methanol	B
supernatants	O
were	O
analyzed	O
using	O
HILIC,	O
and	O
2,233	O
features	O
in	O
methanol-ethanol	B
supernatants.	O

Using	O
corrected	O
BMI,	O
the	O
percentage	O
of	O
the	O
BMI	O
effect	O
mediated	O
by	O
unconjugated	O
estradiol	B
was	O
19	O
for	O
the	O
Aalen	O
model	O
and	O
17	O
for	O
the	O
Cox	O
model.	O

These	O
36	O
metabolites	O
were	O
mainly	O
classified	O
into	O
several	O
major	O
categories:	O
prenol	B
lipids,	O
sterol	O
lipids,	O
fatty	O
acyls,	O
sphingolipids,	B
glycerophospholipids,	B
etc.	O

Meanwhile,	O
the	O
uric	B
acid	I
play	O
a	O
role	O
as	O
endogenous	O
secondary	O
signals	O
to	O
activate	O
the	O
trophoblast	O
inflammation	O
by	O
stimulating	O
the	O
inflammasome	O
in	O
trophoblasts.	O

Metabolic	O
syndrome,	O
Sex	O
differences,	O
Metabolomics,	O
Raine	O
study,	O
Sphingolipids,	B
Hormonal	O
contraceptives	O

With	O
WAX-S	O
tips,	O
we	O
further	O
improved	O
extraction	O
efficiency	O
to	O
42.4–81.5%	O
for	O
our	O
entire	O
11	O
cannabinoid	B
analyte	O
panel.	O

Milk	O
samples	O
were	O
analysed	O
by	O
using	O
V-PLEX	O
human	O
kits	O
[Meso	O
Scale	O
Discovery,	O
Gaithersburg,	O
MD,	O
USA],	O
and	O
the	O
results	O
were	O
expressed	O
by	O
the	O
fold	O
change	O
[IBD/HC]	O
for	O
each	O
cytokine.	O

As	O
shown	O
in	O
Table ,	O
the	O
serum	O
concentration	O
of	O
citrate,	B
but	O
not	O
of	O
any	O
other	O
metabolite,	O
was	O
significantly	O
positively	O
correlated	O
with	O
age,	O
urea	B
and	O
creatinine	B
as	O
well	O
as	O
negatively	O
correlated	O
with	O
fibrinogen,	O
and	O
HDL	B
cholesterol.	I

BMI	O
indicates	O
body	O
mass	O
index;	O
BP,	O
blood	O
pressure;	O
HDL‐C,	O
high‐density	O
lipoprotein	O
cholesterol;	B
MESA,	O
Multi‐Ethnic	O
Study	O
of	O
Atherosclerosis;	O
MET,	O
metabolic	O
equivalent;	O
N/A,	O
not	O
applicable;	O
NEO,	O
Netherlands	O
Epidemiology	O
in	O
Obesity;	O
VAT,	O
visceral	O
adipose	O
tissue.	O

The	O
second	O
group	O
consists	O
of	O
less	O
polar	O
analytes	O
(LogP ≥ 0.4)	O
which	O
demonstrate	O
good	O
recovery	O
in	O
MTBE,	B
PEP2	O
and	O
C18	O
(Group	O
II).	O

Partial	O
correlation	O
of	O
plasma	O
Phe	O
corrected	O
for	O
the	O
effect	O
of	O
BMI	O
with	O
VLDL5-free	O
cholesterol	B
(R = -0.49.1,	O
p	O
 = 0.024),	O
VLDL5-triglycerides	B
(R = -0.55,	O

Compared	O
to	O
these	O
studies,	O
we	O
evaluated	O
a	O
much	O
broader	O
population,	O
including	O
people	O
with	O
type	O
1	O
diabetes	O
and	O
normal	O
or	O
high	O
eGFR	O
(DCCT),	O
participants	O
in	O
two	O
diverse	O
community-based	O
cohorts	O
(MESA	O
and	O
CHS),	O
a	O
cohort	O
with	O
moderate-severe	B
CKD	O
not	O
requiring	O
renal	O
replacement	O
therapy	O
(SKS),	O
and	O
prevalent	O
hemodialysis	O
patients	O
(HEMO	O
Study).	O

The	O
measured	O
amino	O
acid	O
concentrations	O
were	O
corrected	O
(normalized)	O
to	O
the	O
concentration	O
of	O
creatinine	B
and	O
resulting	O
data	O
are	O
summarized	O
in	O
Supplementary	O
Material,	O
Table	O
S2.	O

Stock	O
solutions	O
of	O
the	O
IS	O
were	O
prepared	O
either	O
in	O
purified	O
and	O
deionised	O
water	O
(Milli-Q,	O
Millipore,	O
Billerica,	O
MA,	O
USA)	O
or	O
in	O
methanol	B
(J.T.Baker,	O
Deventer,	O
Holland)	O
at	O
the	O
same	O
concentration,	O
0.5 μg/μl.	O

A	O
few	O
studies	O
described	O
the	O
modulation	O
of	O
the	O
carnitine	B
system	O
by	O
anticancer	O
therapy	O
(,	O
,	O
).	O

The	O
resulting	O
powder	O
was	O
then	O
resuspended	O
in	O
50	O
mM	O
phosphate	B
buffer	O
(pH	O
7.4)	O
in	O
D_2	O
O	O
for	O
NMR	O
measurements.	O

Dithiothreitol	B
(6.5	O
mg,	O
20	O
mM)	O
was	O
added	O
to	O
the	O
solution,	O
and	O
the	O
mixture	O
was	O
incubated	O
at	O
55	O
°C	O
for	O
1	O
h.	O

These	O
results	O
suggest	O
that	O
the	O
[3-HB]/[glucose]	B
ratio	O
may	O
be	O
a	O
handy	O
criterion	O
for	O
the	O
prognostication	O
after	O
metabolic	O
surgery,	O
if	O
proven	O
in	O
a	O
larger	O
study.	O

When	O
we	O
only	O
used	O
the	O
GC/MS	O
metabolites	O
to	O
identify	O
potential	O
metabolite	O
biomarker	O
panel,	O
seven	O
metabolites	O
(24dihydroxypyrimidine,	O
aminoethanol,	B
arabitol,	B
RS23dihydroxybutanoicacid,	B
phenylalanine	B
azelaic	I
acid,	I
β-alanine)	B
were	O
included	O
into	O
the	O
potential	O
diagnostic	O
model.	O

Similarly,	O
Regalado	O
et	O
al.	O
used	O
25 mM	O
isobutylamine	B
as	O
an	O
additive	O
in	O
methanol	B
for	O
chiral	O
and	O
achiral	O
SFC	O
separations	O
of	O
a	O
variety	O
of	O
drugs	O
and	O
drug	O
metabolites	O
.	O

No	O
patient	O
had	O
a	O
cholesterol	B
level > 240 mg/dL	O
that	O
was	O
not	O
treated	O
with	O
a	O
statin	B
or	O
ezetimibe.	O

In	O
addition,	O
citric	B
acid	I
was	O
previously	O
shown	O
to	O
form	O
complexes	O
with	O
boric	O
acid	O
added	O
as	O
preservative	O
to	O
all	O
INTERMAP	O
urine	O
samples.	O

Several	O
studies	O
have	O
suggested	O
a	O
relative	O
arginine	B
deficiency	O
exists	O
in	O
subjects	O
with	O
hypertension	O
or	O
heart	O
failure	O
as	O
a	O
result	O
of	O
abnormal	O
transport	O
mechanisms	O
across	O
vascular	O
cellular	O
membranes(,,).	O

Samples	O
were	O
eluted	O
with	O
an	O
acetonitrile	B
gradient	O
containing	O
0.1%	O
formic	B
acid	I
at	O
a	O
flow	O
rate	O
of	O
0.35	O
mL/min	O
for	O
20	O
min.	O

In	O
addition,	O
an	O
increase	O
in	O
the	O
concentration	O
of	O
butyrate	B
was	O
the	O
main	O
impact	O
of	O
all	O
breads	O
on	O
the	O
overall	O
SCFA	O
production.	O

The	O
increase	O
of	O
linoleic	B
acid	I
levels	O
in	O
PCOS	O
plasma	O
may	O
be	O
accompanied	O
by	O
a	O
similar	O
change	O
in	O
the	O
follicular	O
fluid,	O
thus	O
resulting	O
in	O
blocked	O
oocyte	O
maturation	O
and	O
ovulation	O
in	O
PCOS.	O

Therefore,	O
46	O
consecutively	O
recruited	O
patients	O
underwent	O
a	O
cosyntropin	O
stimulation	O
test	O
to	O
assess	O
cortisol	B
reserve	O
10–14	O
days	O
after	O
removal	O
of	O
the	O
aldosterone-producing	O
adrenocortical	O
adenoma.	O

Some	O
of	O
the	O
concentration	O
discrepancies	O
for	O
the	O
other	O
compounds	O
may	O
be	O
explained	O
by	O
their	O
inherent	O
volatility	O
or	O
chemical	O
instability	O
(hypoxanthine,	O
methanol,	B
formic	O
acid).	O

20-Hydroxyeicosatetraenoic	B
acid,	I
eicosanoids,	B
ovarian	O
cancer,	O
Ras,	O
CYP4A/F,	O
20-HETE,	B
HRPTEC	O
cells	O

MDD,	O
major	O
depressive	O
disorder;	O
BD,	O
bipolar	O
disorder;	O
HC,	O
healthy	O
controls;	O
TRP,	O
Tryptophan;	B
KYN,	O
Kynurenine;	B
KYNA,	O
Kynurenic	B
acid;	I
QUIN,	O
Quinolinic	B
acid;	I
*P	O
<	O
0.05.	O

Besides,	O
increased	O
concentration	O
of	O
a	O
modified	O
nucleotide	O
7-methylguanosine	B
in	O
IDC	O
tissues	O
was	O
also	O
observed	O
which	O
is	O
suggestive	O
of	O
its	O
demand	O
for	O
the	O
increased	O
‘cap’	O
formation	O
for	O
rapid	O
protein	O
synthesis	O
in	O
IDC.	O

CPS1	O
mutations	O
are	O
known	O
to	O
cause	O
carbamoylphosphate	B
synthetase	O
I	O
deficiency,	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
of	O
metabolism	O
of	O
the	O
urea	B
cycle	O
which	O
causes	O
hyperammonemia.	O

Nevertheless,	O
this	O
study	O
showed	O
the	O
association	O
with	O
a	O
long-term	O
clinical	O
outcome,	O
and	O
we	O
conducted	O
various	O
analyses	O
to	O
clarify	O
the	O
relationship	O
between	O
urinary	O
myo-inositol	B
and	O
therapeutic	O
response.	O

In	O
subsequent	O
LC–PB–MS/MS	O
analysis,	O
the	O
protonated	O
PB	O
reaction	O
product	O
of	O
PE	B
16:0_18:1	I
(m/z	O
776.3,	O
[_PB	O
M+H]_+	O
)	O
was	O
selected	O
for	O
beam-type	O
CID.	O

Injecting	O
an	O
aliquot	O
of	O
a	O
methanol	B
solution	O
containing	O
62.5	O
attomoles	O
of	O
NNAL	O
hexanoate	B
(which	O
would	O
correspond	O
to	O
about	O
13	O
femtograms	O
of	O
NNAL)	O
resulted	O
in	O
a	O
peak	O
of	O
about	O
twice	O
the	O
area	O
of	O
a	O
corresponding	O
peak	O
in	O
the	O
methanol	B
blank.	O

A	O
large	O
population-based	O
case-control	O
study	O
demonstrated	O
a	O
relative	O
risk	O
reduction	O
for	O
CRC	O
development	O
for	O
statin	B
treatment	O
over	O
5	O
years.	O

Methionine;	B
35.	O

Enalapril,	O
enalaprilat	O
levels	O
in	O
plasma,	O
and	O
the	O
internal	O
standard	O
sitagliptin	B
were	O
measured	O
by	O
API	O
4000	O
LC-MS/MS.	O

From	O
each	O
patient	O
profile,	O
we	O
excluded	O
DSS	O
(internal	O
standard),	O
ibuprofen	B
and	O
salicylurate	B
(drug	O
metabolites),	O
and	O
9	O
other	O
metabolites	O
(3-hydroxybutyrate,	O
adipate,	B
benzoate,	B
ethanol,	B
galactose,	B
glycerol,	B
guanidoacetate,	B
trimethylamine,	B
urea,	B
and	O
beta-alanine)	B
that	O
were	O
considered	O
unreliably	O
measured	O
as	O
they	O
were	O
difficult	O
to	O
profile	O
due	O
to	O
both	O
noise	O
and	O
additional	O
peaks	O
that	O
can	O
lead	O
to	O
an	O
effect	O
known	O
as	O
“tenting”	O
(i.e.,	O
some	O
peaks	O
overlap	O
with	O
others,	O
forming	O
a	O
large	O
single	O
peak	O
that	O
is	O
actually	O
comprised	O
of	O
two	O
or	O
more	O
peaks).	O

The	O
ethyl	B
acetate	I
and	O
n	B
-butanol	I
extracted	O
contents	O
were	O
mixed	O
and	O
centrifuged	O
at	O
13000 rpm	O
for	O
10 min	O
before	O
injected	O
for	O
analysis.	O

An	O
additional	O
200	O
µL	O
of	O
cold	O
methanol	B
was	O
added	O
to	O
the	O
recovered	O
supernatant	O
and	O
the	O
new	O
mixture	O
was	O
centrifuged	O
at	O
14000	O
rpm	O
for	O
10	O
min.	O

The	O
ethyl	B
acetate	I
was	O
evaporated	O
to	O
dryness	O
using	O
a	O
Speedvac	O
concentrator	O
(Thermo	O
Fisher),	O
and	O
the	O
plates	O
were	O
capped	O
and	O
stored	O
in	O
a	O
-20°C	O
freezer	O
until	O
LC-MS/MS	O
analysis.	O

Nonlinear	O
correlations	O
of	O
ESR,	O
albumin,	O
transferrin,	O
HsCRP	O
and	O
fecal	O
calprotectin	O
with	O
selected	O
vitamin	B
D	I
parameters.	O
vs.:	O
versus.	O

The	O
positive	O
correlations	O
were	O
generally	O
similar	O
in	O
the	O
astrocytoma	O
spectra:	O
lactate	B
correlated	O
positively	O
with	O
alanine,	B
tCr,	O
tCho	O
and	O
tGlut;	O
tCho	O
correlated	O
positively	O
with	O
tGlut	O
and	O
with	O
lactate.	B

In	O
our	O
study,	O
glycine	B
was	O
a	O
novel	O
amino	O
acid	O
we	O
found	O
which	O
was	O
closely	O
related	O
to	O
IR	O
except	O
for	O
valine	B
and	O
leucine,	B
(Additional	O
file	O
).	O

Portions	O
of	O
800	O
MHz	O
_1	O
H	O
spectra	O
of	O
the	O
same	O
pooled	O
human	O
serum	O
highlighting	O
varied	O
levels	O
of	O
cyclization	O
of	O
glutamine	B
to	O
pyroglutamic	B
acid.	I

The	O
mobile	O
phase	O
consisted	O
of	O
5 mM	O
ammonium	B
formate:acetonitrile	O
(10:90,	O
v/v),	O
which	O
was	O
run	O
at	O
a	O
flow-rate	O
of	O
0.6 mL/min.	O

It	O
is	O
noteworthy	O
that	O
HPODEs,	O
the	O
products	O
of	O
reactive	O
oxygen	O
species	O
(ROS)-mediated	O
peroxidation	O
of	O
linoleates	B
and	O
the	O
primary	O
products	O
of	O
the	O
autoxidation	O
process,	O
are	O
considered	O
as	O
potential	O
biomarkers	O
for	O
oxidative	O
stress	O
status	O
in	O
vivo	O
_,	O
.	O

Correlated	O
features	O
matched	O
to	O
modified	O
amino	O
acids,	O
di-	O
and	O
tripeptides,	O
pentachlorocyclohexanol,	B
and	O
pentachlorodibenzodioxin.	B

Additionally,	O
levels	O
of	O
the	O
choline	B
precursor,	O
creatinine,	B
were	O
decreased	O
in	O
CRC	O
patient	O
urine	O
samples.	O

Elevated	O
amounts	O
of	O
acetylated	B
cytidine	I
have	O
been	O
described	O
in	O
numerous	O
reports,	O
dealing	O
with	O
the	O
altered	O
excretion	O
of	O
modified	O
nucleosides	O
in	O
cancer	O
diseases.	O

However,	O
there	O
are	O
several	O
standards	O
with	O
S/N	O
less	O
than	O
1500;	O
heptanoic	B
acid	I
(S/N	O
=	O
18),	O
decanoic	B
acid	I
(S/N	O
=	O
83),	O
oxalic	B
acid	I
(S/N	O
=	O
47)	O
and	O
adipic	B
acid	I
(S/N	O
=	O
87).	O

Increased	O
L-acetylcarnitine	B
levels	O
in	O
patients	O
with	O
GCA	O
are	O
associated	O
with	O
excessive	O
fatty	O
acids	O
and	O
previous	O
studies	O
have	O
revealed	O
that	O
fatty	O
acids,	O
particularly	O
unsaturated	O
fatty	O
acids,	O
are	O
a	O
major	O
source	O
of	O
energy	O
for	O
cancer	O
cells	O
(,).	O

This	O
is	O
in	O
agreement	O
with	O
a	O
study	O
conducted	O
in	O
Japanese	O
patients	O
where	O
total	O
cholesterol	B
was	O
not	O
found	O
associated	O
to	O
LVH	O
in	O
essential	O
hypertension.	O

We	O
found	O
that	O
high	O
levels	O
of	O
proline,	B
p-cresol	B
and	O
4-hydroxybenzoic	B
acid	I
revealed	O
worse	O
survival	O
rate	O
(P	O
<	O
0.01)	O
with	O
median	O
survival	O
time	O
16-mons,	O
15-mons	O
and	O
15-mons	O
respectively	O
(Figure	O
and	O
).	O

Recently,	O
studies	O
have	O
shown	O
that	O
the	O
foods	O
high	O
in	O
FODMAP	O
(Fermentable	O
oligo,	O
di,	O
monosaccharides	B
and	O
polyoles)	O
are	O
responsible	O
for	O
triggering	O
the	O
symptoms	O
of	O
IBS	O
and	O
dietary	O
intervention	O
with	O
foods	O
low	O
in	O
FODMAP	O
are	O
shown	O
to	O
reduce	O
the	O
symptoms	O
of	O
IBS	O
in	O
particular	O
abdominal	O
pain	O
and	O
flatulence.	O

As	O
evidenced	O
here	O
by	O
PRMTs	O
’	O
upregulation	O
being	O
accompanied	O
by	O
rather	O
decreased	O
systemic	O
concentrations	O
of	O
dimethylarginines	B
as	O
well	O
as	O
by	O
lack	O
of	O
direct	O
correlation	O
between	O
the	O
enzymes	O
and	O
their	O
products,	O
PRMTs	O
might	O
be	O
rather	O
loosely	O
related	O
with	O
the	O
L-arginine/NO	O
pathway.	O

We	O
also	O
found	O
that	O
total	O
lipids	O
in	O
VLDL	O
subclasses	O
were	O
positively	O
correlated	O
with	O
testosterone,	B
the	O
concentrations	O
and	O
mean	O
diameters	O
of	O
larger	O
VLDL	O
particles	O
were	O
also	O
positively	O
correlated	O
with	O
testosterone,	B
while	O
the	O
mean	O
diameter	O
of	O
LDL	O
particles	O
was	O
negatively	O
correlated.	O

It	O
is	O
possible	O
that	O
humans	O
can	O
demethylate	B
JWH-018	O
to	O
form	O
JWH-073	O
metabolites,	O
or	O
it	O
is	O
possible	O
that	O
these	O
subjects	O
may	O
have	O
had	O
a	O
previous	O
unexpected	O
exposure	O
to	O
JWH-073.	O

Third,	O
the	O
ratio	O
of	O
many	O
metabolites	O
to	O
choline	B
was	O
low	O
in	O
the	O
pre-prostatectomy	O
uEVs	O
compared	O
to	O
other	O
groups,	O
which	O
suggests	O
increased	O
choline	B
levels.	O

Other	O
compounds	O
seen	O
by	O
GC-MS	O
but	O
not	O
by	O
NMR	O
included	O
metabolites	O
that	O
were	O
generally	O
below	O
the	O
detection	O
limit	O
of	O
NMR	O
(∼2	O
µM/mM	O
creatinine)	O
such	O
as	O
indolelactic	B
acid	I
and	O
2,4-dihydroxybutanoic	B
acid.	I

Trimethoprim	O
(50	O
µm)	O
inhibited	O
anastrozole	B
metabolism	O
by	O
only	O
11.3%	O
and	O
at	O
100	O
µm	O
by	O
only	O
22%	O
(data	O
not	O
shown).	O

In	O
the	O
OD	O
group,	O
however,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
three	O
metabolites	O
(nonanoic	O
acid,	O
galactose,	B
and	O
cysteine	B
+	O
cystine)	O
when	O
compared	O
between	O
pre-	O
and	O
postoperative	O
plasma	O
samples,	O
and	O
only	O
glucose	B
significantly	O
increased	O
postoperatively.	O

(A)	O
Formation	O
rate	O
of	O
anastrozole	B
glucuronide	I
from	O
anastrozole	B
single	O
concentration	O
in	O
a	O
panel	O
of	O
purified	O
human	O
UGTs.	O

By	O
investigating	O
and	O
comparing	O
cerebral	O
metabolism	O
of	O
healthy	O
and	O
birth-asphyxiated	O
newborns,	O
low	O
values	O
of	O
the	O
ratio	O
phosphocreatine/inorganic	O
orthophosphate	B
were	O
correlated	O
with	O
poor	O
prognosis	O
for	O
survival	O
and	O
early	O
neuro	O
developmental	O
onset	O
[,	O
].	O

and	O
(19)	O
valine.	B

Further	O
purification	O
was	O
carried	O
out	O
by	O
acidification	O
to	O
pH	O
3	O
with	O
1	O
M	O
HCl	O
and	O
extraction	O
with	O
ethyl	B
acetate	I
in	O
order	O
to	O
remove	O
any	O
remaining	O
cystine	B
or	O
cysteine.	B

This	O
correction	O
revealed	O
that	O
only	O
pelargonic	B
acid	I
remained	O
to	O
be	O
significantly	O
associated	O
with	O
CAD.	O

In	O
the	O
HD	O
sheep	O
citrulline,	B
PC	B
aa	I
C36:5	I
and	O
lysoPC	O
a	O
C17:0	B
were	O
significantly	O
increased	O
and	O
valine,	B
PC	B
aa	I
C40:4,	I
SM	O
(OH)	O
C24:1,	B
threonine	B
and	O
tetradecenoylcarnitine	B
(C14:1)	I
were	O
significantly	O
decreased	O
compared	O
to	O
the	O
control	O
sheep.	O

Tyrosine	B
has	O
previously	O
been	O
reported	O
as	O
a	O
CD	O
marker	O
that	O
was	O
increased	O
in	O
faecal	O
extracts	O
from	O
CD	O
patients	O
and	O
decreased	O
in	O
the	O
plasma	O
from	O
CD	O
patients.	O

To	O
facilitate	O
quantification	O
of	O
these	O
very-long	O
chain	O
ceramides	B
in	O
clinical	O
samples	O
from	O
human	O
subjects,	O
we	O
have	O
developed	O
a	O
sensitive,	O
accurate,	O
and	O
high	O
throughput	O
assay	O
for	O
determination	O
of	O
Cer(22:0)	B
and	O
Cer(24:0)	B
in	O
human	O
plasma.	O

This	O
has	O
been	O
identified	O
by	O
comparison	O
to	O
a	O
standard	O
as	O
2-HPMA,	O
resulting	O
from	O
mercapturic	B
acid	I
formation	O
from	O
propylene	B
oxide.	I

Instead	O
of	O
the	O
complete	O
oxidation	O
of	O
glutamine	B
to	O
ATP,	B
the	O
mitochondria	O
of	O
cancer	O
cells	O
shunt	O
glutamine	B
into	O
citrate	B
for	O
the	O
production	O
of	O
NADPH	B
and	O
lipid	O
synthesis,	O
and	O
into	O
malate	B
which	O
can	O
be	O
converted	O
into	O
pyruvate	B
and	O
NADPH.	B

The	O
most	O
down-regulated	O
pathway	O
in	O
the	O
adipose	O
tissue	O
was	O
valine,	B
leucine	B
and	O
isoleucine	B
degradation	O
(p = 1.1	O

For	O
the	O
H	O
samples	O
we	O
observed	O
that,	O
metabolites	O
showing	O
lowest	O
CV	O
were	O
arachidonic	B
acid,	I
Lys,	O
heptadecanoic	B
acid,	I
butanoic	B
acid,	I
pentanedecanoic	O
acid,	O
propenoic	B
acid,	I
hexanedioic	B
acid,	I
Orn,	O
propanoic	B
acid,	I
octadecanoic	B
acid,	I
benzoic	B
acid,	I
Phe	O
among	O
others.	O

Venous	O
specimens	O
were	O
collected	O
before	O
glucose	B
loading,	O
at	O
loading,	O
and	O
30,	O
60,	O
and	O
120	O
min	O
after	O
loading	O
to	O
determine	O
the	O
serum	O
glucose	B
levels	O
and	O
responses.	O

There	O
were	O
8	O
identical	O
metabolites	O
in	O
the	O
atrial	O
appendage	O
samples	O
and	O
the	O
plasma	O
samples	O
of	O
all	O
the	O
patients	O
in	O
the	O
LC-MS	O
metabolomics	O
analysis:	O
betaine,	B
choline,	B
creatinine,	B
D-glutamic	B
acid,	I
glycerophosphocholine,	B
hypoxanthine,	B
L-valine,	B
and	O
niacinamide.	B

Elevated	O
levels	O
of	O
arginine	B
and	O
ornithine	B
were	O
observed	O
in	O
patients	O
with	O
PDR,	O
potentially	O
implicating	O
a	O
compromised	O
Mueller	O
glial	O
cell	O
metabolism	O
in	O
the	O
disruption	O
of	O
neurovascular	O
crosstalk	O
within	O
the	O
retina	O
and	O
progression	O
of	O
diabetic	O
retinopathy	O
[,	O
].	O

We	O
compared	O
the	O
plasma	O
levels	O
of	O
nervonic	B
acid	I
in	O
the	O
dMDD	O
and	O
dBD	O
patients	O
(supplementary	O
Table	O
4)	O
and	O
found	O
that	O
the	O
dMDD	O
patients	O
had	O
increased	O
plasma	O
nervonic	B
acid	I
levels	O
compared	O
with	O
those	O
in	O
the	O
dBD	O
patients	O
(d	O
=0.54,	O
P=	O
.038).	O

THS	O
was	O
significantly	O
increased	O
in	O
both	O
ACA	O
and	O
ACC	O
patients	O
compared	O
with	O
controls,	O
but	O
excretion	O
levels	O
were	O
significantly	O
higher	O
in	O
ACC	O
than	O
in	O
ACA,	O
suggesting	O
inhibition	O
or	O
lack	O
of	O
expression	O
of	O
11β-hydroxylase,	O
the	O
enzyme	O
that	O
converts	O
the	O
glucocorticoid	B
precursor	O
11-deoxycortisol	B
to	O
active	O
cortisol.	B

Peaks	O
assigned	O
as	O
glutamine,	B
glutamate,	B
and	O
palmitoylglycine,	B
as	O
well	O
as	O
polyunsaturated	O
fatty	O
acids,	O
glycerophosphoserines,	B
and	O
glycerophosphoinositols	B
were	O
observed	O
in	O
high	O
relative	O
abundances	O
in	O
gastric	O
cancer	O
tissue.	O

Since	O
HER2-positive	O
ER(+)	B
and	O
ER(−)	O
BC	O
groups	O
showed	O
distinct	O
metabolomics	O
profiles,	O
their	O
metabolic	O
responses	O
to	O
NATC	O
were	O
evaluated	O
separately.	O

The	O
decreased	O
concentration	O
of	O
other	O
compounds	O
(threonine,	O
valine,	B
arginine,	B
glutamate,	B
methanol)	B
is	O
primarily	O
associated	O
with	O
organ	O
dysfunction	O
and/or	O
higher	O
utilization	O
of	O
these	O
metabolites	O
in	O
the	O
disease	O
conditions	O
[-].	O

Vanillylmandelic	B
acid	I
is	O
a	O
major	O
metabolic	O
product	O
of	O
norepinephrine	B
which	O
is	O
involved	O
in	O
the	O
noradrenergic	O
system	O
and	O
the	O
hypothalamic-pituitary-adrenal	O
axis,	O
whose	O
elevation	O
is	O
related	O
to	O
the	O
depression	O
symptom	O
[,	O
]	O
and	O
was	O
also	O
found	O
in	O
this	O
study.	O

Recently	O
we	O
observed	O
_13	O
C-_13	O
C	O
spin-spin	O
coupling	O
in	O
_13	O
C	O
NMR	O
spectra	O
of	O
lactate	B
in	O
brain	O
tumors	O
removed	O
from	O
patients	O
who	O
were	O
infused	O
with	O
[1,2-_13	B
C]acetate	I
prior	O
to	O
the	O
surgery.	O

Score	O
and	O
loading	O
plots	O
showed	O
increased	O
levels	O
of	O
acetate,	B
lipid2	O
and	O
proline	B
betaine,	I
and	O
reduced	O
levels	O
of	O
methionine,	B
tyrosine,	B
ornithine	B
and	O
citrate	B
12	O
months	O
after	O
surgery	O
(Supplementary	O
Figure 2).	O

Levels	O
of	O
leucine,	B
isoleucine,	B
and	O
valine	B
(branched	O
chain	O
amino	O
acids,	O
BCAA)	O
are	O
higher	O
in	O
the	O
liver,	O
muscle,	O
and	O
serum	O
of	O
fasted	O
animals	O
when	O
compared	O
to	O
CPF	O
animals.	O

A	O
working	O
buffer	O
solution	O
of	O
0.2ug/mL	O
was	O
prepared	O
by	O
diluting	O
into	O
a	O
20mm	O
solution	O
of	O
potassium	B
phosphate	I
trihydrate,	O
pH	O
7.0.	O

Samples	O
were	O
eluted	O
with	O
1.5	O
mL	O
of	O
acetonitrile	B
into	O
2	O
mL	O
plastic	O
tubes.	O

Sarcosine	B
levels	O
were	O
also	O
elevated	O
in	O
invasive	O
prostate	O
cancer	O
cell	O
lines	O
relative	O
to	O
benign	O
prostate	O
epithelial	O
cells.	O

For	O
example,	O
activation	O
of	O
the	O
endocannabinoid	B
system	O
has	O
been	O
shown	O
to	O
increase	O
food	O
intake,	O
promote	O
weight	O
gain	O
,	O
,	O
and	O
can	O
also	O
contribute	O
to	O
the	O
worsening	O
of	O
a	O
cardiovascular	O
profile	O
(i.e.,	O
body	O
weight,	O
body	O
mass	O
index	O
(BMI),	O
waist	O
circumference,	O
insulin	O
and	O
adiponectin	O
levels)	O
.	O

[13,14,15,16,17,18-_13	O
C_6	I
]-E2	O

For	O
the	O
sake	O
of	O
comparison,	O
absolute	O
metabolite	O
concentrations	O
were	O
normalized	O
to	O
creatinine	B
concentrations.	O

Cannabis	B
use	O
or	O
nonuse	O
was	O
verified	O
in	O
all	O
individuals	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
(LC-MS),	O
and	O
subjects	O
were	O
excluded	O
from	O
analysis	O
if	O
their	O
self-reported	O
cannabis	B
use	O
or	O
nonuse	O
was	O
not	O
reflected	O
by	O
the	O
presence	O
or	O
lack	O
of	O
cannabis	B
metabolites	O
in	O
their	O
plasma.	O

μg/L	O
for	O
11-OH-THC,	B
CBD,	O
CBN,	O
THCAA	O
and	O
THC-gluc,	O
1–100	O
μg/L	O
for	O
CBG,	O
THCV	O
and	O
THCVCOOH	O
and	O
5–500	O
μg/L	O
for	O
THCCOOH-gluc.	O

In	O
contrast,	O
we	O
found	O
d16:1/24:0,	B
d18:1/18:0,	B
d18:1/18:1,	B
d18:1/18:2,	B
d18:1/20:0,	B
d18:1/20:1,	B
d18:1/24:1,	B
d18:1/24:2,	B
and	O
d20:1/22:3	B
SM	O
to	O
be	O
significantly	O
decreased	O
in	O
patients	O
relative	O
to	O
controls.	O

CE,	O
cholesterol	B
esters;	I
SM,	O
sphingomyelin;	B
SqCC,	O
squamous	O
cell	O
lung	O
cancer.	O

The	O
vertical	O
line	O
at	O
x=_~	O
0	O
in	O
,	O
Panel	O
I.D-F	O
shows	O
that,	O
when	O
MTBE	B
is	O
the	O
solvent,	O
PCT	O
extracts	O
a	O
series	O
of	O
high	O
abundance	O
compounds	O
from	O
fecal	O
material	O
that	O
are	O
either	O
poorly	O
or	O
not	O
extracted	O
in	O
the	O
absence	O
of	O
pressure.	O

The	O
OB/D	O
subjects	O
were	O
treated	O
with	O
metformin	B
and	O
not	O
with	O
insulin.	O

The	O
[D_4	O
]4	O
methyl	B
ester	I
was	O
finally	O
eluted	O
with	O
2	O
mL	O
of	O
100%	O
EtOAc	O
and	O
dried	O
by	O
SpeedVac.	O

Polycyclic	B
aromatic	O
hydrocarbons	B
(PAHs)	O
and	O
their	O
alkylated	O
derivatives,	O
such	O
as	O
methylnaphthalenes	B
(MeNs),	O
are	O
harmful	O
pollutants	O
ubiquitously	O
present	O
in	O
the	O
environment.	O

In	O
terms	O
of	O
body	O
measurements,	O
the	O
LMI,	O
central	O
obesity	O
and	O
BF,	O
but	O
not	O
the	O
BMI,	O
were	O
associated	O
with	O
sphingolipids;	B
ii)	O
So1P	O
was	O
significantly	O
correlated	O
with	O
the	O
progression	O
from	O
pre-DM	O
to	O
T2DM;	O
iii)	O
So1P	O
and	O
Sa	O
were	O
indicated	O
to	O
be	O
biomarkers	O
for	O
diabetic	O
patients	O
at	O
an	O
elevated	O
risk	O
for	O
cardiovascular	O
complications.	O

The	O
plasma	O
metabolic	O
signature	O
was	O
well	O
replicated	O
in	O
HepatoCells	O
medium	O
on	O
SN-38	O
exposure,	O
whereas	O
in	O
cancer	O
cell	O
medium	O
SN-38	O
induced	O
accumulation	O
of	O
pyrimidine/purine	O
nucleosides	O
and	O
nucleobases	O
while	O
having	O
no	O
impact	O
on	O
acylcarnitines	B
and	O
amino	O
acid	O
metabolites.	O

2-,	O
3-	O
and	O
4-hydroxyhippurate.	B

To	O
demonstrate	O
dilution	O
integrity,	O
five	O
replicate	O
plasma	O
samples	O
of	O
abiraterone	B
at	O
1.5*HLOQ	O
level	O
(750	O
ng/mL)	O
were	O
diluted	O
two-	O
and	O
four-fold	O
with	O
blank	O
plasma.	O

After	O
the	O
screening	O
and	O
statistical	O
analysis	O
described	O
above,	O
5	O
identical	O
metabolites	O
(creatinine,	O
D-glutamic	B
acid,	I
choline,	B
hypoxanthine,	B
and	O
niacinamide)	B
and	O
one	O
cardinal	O
pathway	O
(‘D-glutamine	O
and	O
D-glutamate	B
metabolism’)	O
had	O
been	O
filtered,	O
indicating	O
that	O
the	O
metabolite	O
D-glutamic	B
acid	I
is	O
critical	O
in	O
the	O
pathophysiological	O
mechanisms	O
of	O
AF.	B

Higher	O
levels	O
of	O
cortisol	B
were	O
inversely	O
associated	O
with	O
Trp	O
(r	O
=	O
−0.39)	O
and	O
nicotinic	B
acid	I
(r	O
=	O
−0.38).	O

Both	O
purified	O
and	O
recombinant	O
serum	O
albumin	O
exhibited	O
a	O
rate	O
of	O
appearance	O
of	O
NTB,	O
characteristic	O
of	O
the	O
enzymatic	O
hydrolysis	O
of	O
thiolactones	B
and	O
thio-esters.	B

Box-Whisker	O
plots	O
of	O
the	O
potential	O
classifiers	O
at	O
RT	O
2.68	O
min	O
(left	O
panel)	O
and	O
RT	O
12.36	O
min	O
(right	O
panel),	O
which	O
were	O
later	O
identified	O
as	O
PC	B
(34:2)	I
isomers.	I

The	O
metabolites	O
involved	O
in	O
the	O
altered	O
pathways	O
included	O
phosphatidylcholines	B
(PCs),	O
ethanolamine,	B
glucose-1-phosphate,	B
D-galactonate,	B
theophylline	B
and	O
xanthine.	B

Abbreviations,	O
Swiss-Prot	O
accession	O
number,	O
and	O
reference	O
to	O
the	O
enzyme,	O
where	O
applicable	O
(or	O
mRNA	O
transcript),	O
in	O
brain	O
are	O
as	O
follows:	O
CYP27A1	O
,	O
cytochrome	O
P450	O
27A1,	O
Q02318;	O
CYP46A1	O
,	O
cytochrome	O
P450	O
46A1,	O
Q9Y6A2;	O
CYP7B1	O
,	O
cytochrome	O
P450	O
7B1,	O
O75881;	O
CYP39A1	O
,	O
cytochrome	O
P450	O
39A1,	O
Q9NYL5;	O
HSD3B7	O
,	O
3β-hydroxysteroid	O
dehydrogenase	O
type	O
7,	O
Q9H2F3;	O
VLCS	O
,	O
very	O
long	O
chain	O
acyl-CoA	B
synthetase,	O
O35488;	O
AMACR	O
,	O
α-methylacyl-CoA	B
racemase,	O
Q9UHK6;	O
BCOX	O
,	O
branched	O
chain	O
acyl-CoA	B
oxidase,	O
Q99424;	O
DBP	B
,	O
d-bifunctional	O
protein,	O
P51659;	O
LBP	O
,	O
l-bifunctional	O
protein,	O
Q08426;	O
SCPx	O
,	O
sterol	O
carrier	O
protein	O
x	O
,	O
P22307.	O

Evaluation	O
of	O
small	O
HDL	O
lipids	O
showed	O
that	O
fractions	O
of	O
phospholipids,	B
free	O
cholesterol,	B
and	O
triglycerides	B
to	O
total	O
lipids	O
were	O
negatively	O
correlated	O
with	O
insulin	O
sensitivity,	O
while	O
fractions	O
of	O
total	O
cholesterol	B
and	O
cholesterol	B
esters	I
correlated	O
positively.	O

Blank	O
human	O
urine,	O
200	O
μL,	O
was	O
fortified	O
with	O
internal	O
standard	O
(d_3	O
-THC,	O
d_9	O
-THCCOOH,	O
d_3	B
-11-OH-THC,	I
d_3	O
-CBD,	O
d_3	O
-CBN	O
and	O
d_3	O
-THCCOOH-gluc),	O
20	O
μL	O
methanol	B
and	O
clarified	O
via	O
centrifugation	O
at	O
15,000g,	O
4°C	O
for	O
5	O
min	O
after	O
adding	O
500	O
μL	O
acetonitrile.	B

ARID1A,	O
HDAC4,	O
PKD1,	O
β-CATENIN,	B
SMARCA2,	O
and	O
PBRM1	O
were	O
suggested	O
in	O
our	O
network	O
model	O
for	O
IC	O
and	O
were	O
selected	O
for	O
further	O
validation.	O

Allantoin	B
is	O
a	O
metabolite	O
of	O
uric	B
acid	I
and	O
it	O
is	O
regularly	O
detected	O
in	O
human	O
urine.	O

Neither	O
the	O
absolute	O
difference	O
in	O
2HG	O
level	O
nor	O
the	O
percent	O
change	O
in	O
2HG	O
levels,	O
from	O
diagnosis	O
to	O
CR,	O
was	O
associated	O
with	O
survival	O
duration.	B

In	O
present	O
study,	O
increased	O
levels	O
of	O
DMA	B
and	O
TMA	O
indicated	O
the	O
existence	O
of	O
oxidative	O
stress	O
in	O
FSGS	O
patients.	O

[Google	O
Scholar]	O
FitzGerald	O
GA,	O
Oates	O
JA,	O
Hawiger	O
J,	O
Maas	O
RL,	B
Roberts	O
LJ,	O
2nd,	O
Lawson	O
JA,	O
Brash	O
AR.	O

Intrabatch	O
accuracy,	O
precision	O
and	O
recovery	O
of	O
enterolactone	B
were	O
tested	O
at	O
low,	O
medium	O
and	O
high	O
concentrations	O
and	O
the	O
relative	O
standard	O
deviation	O
did	O
not	O
exceed	O
15%.	O

For	O
hydrolysis,	O
urine	O
samples	O
(100	O
µl)	O
were	O
incubated	O
overnight	O
in	O
sodium	B
acetate	I
buffer	O
at	O
pH	O
4.9	O
in	O
the	O
presence	O
of	O
β-glucuronidase	O
(1000	O
U)	O
and	O
sulfatase	O
(45	O
U).	O

Most	O
patients	O
had	O
little	O
to	O
no	O
TPH1	O
and	O
its	O
product	O
serotonin	B
in	O
their	O
tumor	O
samples,	O
while	O
nearby	O
normal	O
tissue	O
displayed	O
TPH1-positive	O
cells	O
(E,F),	O
which	O
are	O
secretory	O
epithelial	O
cells	O
specialized	O
in	O
producing	O
serotonin	B
(;	O
;	O
),	O
named	O
enterochromaffin	B
cells	O
(ECs)	O
(Supplemental	O
Fig.	O

Given	O
that	O
alcohol	O
use	O
or	O
abuse	O
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
citrate	B
in	O
pancreatic	O
secretions,	O
it	O
is	O
notable	O
that	O
most	O
patients	O
in	O
the	O
chronic	O
pancreatitis	O
and	O
acute	O
pancreatitis	O
groups	O
reported	O
some	O
form	O
of	O
regular	O
alcohol	O
consumption.	O

The	O
highest	O
recovery	O
values	O
for	O
zearalenone	B
(89.8%)	O
and	O
for	O
α-zearalenol	B
(90.1%)	O
were	O
reported	O
for	O
four	O
extraction	O
cycles	O
with	O
a	O
combination	O
of	O
ACN/H_2	O
O	B
(84:16%	I
v/v	I
)	I
solvents	O
at	O
a	O
temperature	O
of	O
200 °C.	O

Lower	O
levels	O
of	O
glucose,	B
glycerophosphocholine,	B
LDL,	O
lipid,	O
sphingosine,	B
and	O
VLDL,	O
together	O
with	O
higher	O
levels	O
of	O
lactate,	B
and	O
certain	O
amino	O
acids	O
such	O
as	O
alanine,	B
lysine,	B
and	O
valine	B
were	O
observed	O
in	O
HCC	O
group	O
than	O
that	O
of	O
control,	O
revealing	O
high	O
consumption	O
of	O
glucose	B
in	O
HCC	O
subjects.	O

However,	O
increasing	O
the	O
LCB	O
chain	O
length	O
from	O
18	O
to	O
20	O
carbons	O
increases	O
the	O
hydrophobic	O
volume	O
and	O
the	O
transition	O
temperature	O
of	O
GG	O
species	O
leading	O
to	O
think	O
that	O
d20:1	B
LCB	O
must	O
be	O
more	O
segregated	O
and	O
more	O
efficient	O
in	O
reducing	O
membrane	O
fluidity	O
than	O
d18:1	B
LCB.	O

Because	O
lactate	B
and	O
cholesterol	B
assays	O
are	O
routine	O
laboratory	O
tests	O
it	O
would	O
be	O
valuable	O
to	O
evaluate	O
the	O
Lact/Chol	O
ratio	O
as	O
a	O
candidate	O
variable	O
in	O
future	O
predictive	O
models	O
of	O
in-hospital	O
mortality	O
risk	O
determination.	O

Phosphatidylethanolamine	B
(PE),	O
phosphatidylcholine	B
(PC),	O
and	O
LysoPC	O
are	O
the	O
intermediates	O
in	O
glycerophospholipid	B
metabolism.	O

Therefore,	O
any	O
of	O
the	O
nine	O
identified	O
urinary	O
metabolites	O
could	O
be	O
markers	O
for	O
the	O
activation	O
of	O
furan	B
to	O
protein	O
reactive	O
metabolites.	O

SF	B
content	O
at	O
time	O
of	O
use	O
was	O
202	O
μmol/g	O
powder	O
and	O
represented	O
91%	O
of	O
the	O
total	O
isothiocyanate	B
content	O
in	O
the	O
powder.	O

However,	O
the	O
sum	O
of	O
the	O
keto	O
and	O
hydroxy	B
acids	I
is	O
an	O
informative	O
aggregate	O
biomarker	O
for	O
the	O
quantitation	O
of	O
the	O
total	O
efficiency	O
of	O
the	O
NNK	O
and	O
NNAL	O
α-hydroxylation	O
pathways,	O
and	O
is	O
expected	O
to	O
be	O
used	O
in	O
future	O
large-scale	O
studies.	O

An	O
additional	O
adjustment	O
for	O
smoking,	O
BMI,	O
and	O
past	O
history	O
of	O
DM	O
attenuated	O
the	O
observed	O
associations	O
of	O
1,5‐AG	B
and	O
methionine	B
(P	O
for	O
trend	O
=	O
.06	O
and	O
.07,	O
respectively),	O
implying	O
their	O
confounding	O
effect	O
on	O
these	O
associations.	O

UPLC-ESI/MS_2	O
mass	O
chromatograms	O
of	O
adducts	O
of	O
NO_2	O
-PhIP-modified	O
SA	O
formed	O
by	O
reaction	O
of	O
the	O
carcinogen	O
with	O
human	O
SA	O
at	O
a	O
molar	O
ratio	O
of	O
3:1	O
(left	O
panel)	O
and	O
0.3:1	B
(right	I
panel);	I
the	O
SA	O
was	O
digested	O
with	O
trypsin.	O

Consistent	O
with	O
our	O
previous	O
report,	O
pyruvate,	B
an	O
important	O
intermediate	O
in	O
glycolysis,	O
was	O
also	O
detected	O
higher	O
in	O
the	O
CRC	O
patients	O
compared	O
with	O
healthy	O
controls.	O

Independent	O
variables:	O
gender	O
(reference	O
category:	O
men	O
(0)	O
vs.	O
women	O
(1));	O
age	O
(years);	O
BMI	O
(kg/m2);	O
putrescine	B
(ng/mL);	O
spermidine	B
(ng/mL);	O
and	O
spermine	B
(ng/mL).	O

The	O
metabolites	O
responsible	O
for	O
a	O
significant	O
contribution	O
to	O
the	O
separation	O
of	O
two	O
groups	O
were	O
indicated	O
in	O
the	O
corresponding	O
S-plot	O
and	O
marked	O
with	O
number	O
containing	O
glutamine,	B
N-acetyl-glycoproteins,	B
TMAO,	B
citrate,	B
phenylalanine,	B
valine,	B
isoleucine,	B
tyrosine	B
and	O
glucose.	B

The	O
labeling	O
patterns	O
in	O
glutamate	B
and	O
glutamine	B
were	O
similar	O
at	O
each	O
carbon,	O
demonstrating	O
that	O
glutamate	B
was	O
converted	O
to	O
glutamine	B
by	O
the	O
enzyme	O
glutamine	B
synthetase	O
(GS).	O

Estrone	B
(E1);	O
estradiol	B
(17	O
α/β	O
E2);	O
16-hydroxyestrone	B
(16OHE1);	O
16-hydroxyestradiol	B
(16OHE2);	O
2	O
or	O
4-methoxyestrone	B
(2	O
or	O
4-MeOE1);	O
2	O
or	O
4-methoxyestradiol	B
(2	O
or	O
4-MeOE2);	O
2,3,4–_13	B
C_3	I
-estrone	I
(_13	O
CE1);	O
2,3,4–_13	B
C_3	I
-estradiol	I
(_13	O
C_3	O
-E2);	O
2,3,4–_13	B
C_3	I
-estriol	I
(_13	O
C_3	O
-16OHE2);	O
13,14,15,16,17,18-_13	B
C_6	I
-2-methoxyestrone	I
(_13	O
C_6	O
-2MeOE1)	O
and	O
13,14,15,16,17,18-_13	B
C_6	I
-4-methoxyestradiol	I
(_13	O
C_6	O
-4MeOE2).	O

Although	O
we	O
could	O
identify	O
and	O
quantify	O
specific	O
serum	O
and	O
urine	O
amino	O
acids	O
using	O
NMR,	O
we	O
did	O
not	O
find	O
any	O
statistically	O
significant	O
difference	O
in	O
serum	O
histidine	B
levels	O
between	O
the	O
two	O
UC	O
groups	O
which	O
might	O
be	O
due	O
to	O
sampling	O
from	O
a	O
different	O
population	O
of	O
UC	O
patients	O
or	O
the	O
result	O
of	O
small	O
sample	O
size.	O

(A,B)	O
Immunohistochemical	O
expression	O
of	O
glutamine	B
synthetase	O
(GS):	O
diffuse	O
and	O
intense	O
staining	O
with	O
H-score	O
=	O
300	O

Therefore,	O
as	O
decreased	O
levels	O
of	O
inosine	B
have	O
been	O
previously	O
observed	O
in	O
adult	O
patients,	O
low	O
levels	O
of	O
inosine	B
can	O
be	O
a	O
potential	O
diagnostic	O
biomarker	O
for	O
MDD	O
in	O
children	O
and	O
adolescents.	O

Eligible	O
metastatic	O
breast	O
cancer	O
patients	O
were	O
required	O
to	O
have	O
a	O
post‐diagnosis	O
serum	O
sample,	O
and	O
were	O
unrestricted	O
with	O
regards	O
to	O
ER	O
status	O
and	O
duration	B
of	O
metastatic	O
disease.	O

Among	O
the	O
mothers,	O
age	O
range	O
42-80,	O
lower	O
melatonin	B
production	O
(as	O
measured	O
by	O
aMT6s/CR)	O
was	O
associated	O
with	O
significantly	O
higher	O
levels	O
of	O
8-oxodG	B
(p	O
<	O
0.05),	O
but	O
not	O
with	O
8-oxoGua.	O

Adenosine	B
monophosphate	I
(AMP)	O
is	O
an	O
intermediate	O
in	O
the	O
catabolism	O
of	O
ATP.	B

For	O
instance,	O
labeled	O
serine	B
and	O
glycine	B
variants	O
have	O
been	O
utilized	O
to	O
demonstrate	O
how	O
serine	B
feeds	O
one	O
carbon	O
metabolism	O
and	O
proliferation.	O

	O
10-(N	B
-Acetylcysteinyl)-9-hydroxy-9,10-dihydrophenanthrene	I
(Phe-9-hydroxy-10-NAC)	I
was	O
prepared	O
as	O
described	O
previously.	O

Metabolites	O
of	O
the	O
renin-angiotensin-aldosterone	B
system	O
were	O
not	O
included	O
in	O
the	O
classifier,	O
suggesting	O
that	O
markers	O
of	O
RAAS	O
activity	O
do	O
not	O
predict	O
the	O
response	O
to	O
RAAS	O
inhibition,	O
which	O
is	O
in	O
line	O
with	O
prior	O
studies	O
[,	O
].	O

In	O
particular	O
some	O
metabolites	O
with	O
substituents,	O
such	O
as	O
quaternary	O
ammonium	B
salt	O
(42%,	O
P	O
=	O
2.68	O
×	O
10_−6	O
;	O
FDR	O
=	O
6.13	O
×	O
10_−4	O
)	O
and	O
phosphocholine	B
(33%,	O
P	O
=	O
2.35	O
×	O
10_−5	O
;	O
FDR	O
=	O
2.69	O
×	O
10_−3	O
),	O
were	O
severely	O
affected	O
by	O
the	O
paraffin-embedding	O
procedure.	O

Since	O
the	O
participants	O
in	O
this	O
study	O
live	O
in	O
a	O
rural	O
setting	O
and	O
relatively	O
far	O
from	O
air	O
pollutants	O
such	O
as	O
naphthalene	B
(although	O
air	O
pollution	O
from	O
a	O
nearby	O
cement	O
factory	O
cannot	O
be	O
ruled	O
out),	O
we	O
suggest	O
that	O
just	O
as	O
estrogen-like	O
molecules	O
were	O
found	O
to	O
be	O
produced	O
by	O
S	O
.	O
haematobium	O
,	O
benzenoids	B
and	O
related	O
molecules	O
may	O
also	O
be	O
produced	O
by	O
the	O
parasite	O
and	O
metabolised	O
by	O
human	O
CYP,	O
leading	O
to	O
their	O
activation.	O

Specific	O
metabolic	O
changes	O
in	O
HK-2	O
cells	O
in	O
response	O
to	O
glucose.	B

Skeletal	O
muscle	O
creatine	B
is	O
converted	O
to	O
phosphocreatine,	B
which	O
is	O
a	O
source	O
of	O
high-energy	O
phosphate	B
used	O
to	O
produce	O
ATP.	B

800	O
μl	O
of	O
the	O
supernatant	O
was	O
collected	O
individually	O
from	O
each	O
sample	O
into	O
an	O
ampoule	O
bottle	O
and	O
evaporated	O
to	O
dryness	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas	I
at	O
50°C	O
for	O
approximately	O
30	O
min.	O

(A)	O
Phosphatidylcholine	B
synthesis	O
and	O
metabolism	O
pathways.	O

In	O
diabetic	O
patients,	O
ketone	B
body	O
concentration	O
is	O
high	O
and	O
their	O
detection	O
in	O
urine	O
is	O
a	O
danger	O
marker	O
which	O
suggests	O
a	O
poorly	O
controlled	O
diabetes.	O

This	O
study	O
indicated	O
that	O
protorifamycin	B
I	O
(which	O
belongs	O
to	O
phenylpropanoids	B
and	O
polyketides)	O
is	O
enriched	O
in	O
the	O
biosynthesis	O
of	O
ansamycins	B
and	O
biosynthesis	O
of	O
antibiotics.	O

a	O
is	O
the	O
_13	O
C	O
projection	O
of	O
b.	O
c,	O
d	O
sugar	O
and	O
pyrimidine	B
C5	O
region.	O

Better	O
understanding	O
of	O
the	O
mechanistic	O
underpinnings	O
of	O
metabolic	O
and	O
vascular	O
abnormalities	O
may	O
provide	O
the	O
basis	O
for	O
further	O
investigations	O
to	O
explore	O
the	O
impact	O
of	O
a	O
variety	O
of	O
treatment	O
strategies	O
aiming	O
to	O
improve	O
arginine	B
bioavailability	O
and	O
reduce	O
cardiovascular	O
risks.	O

We	O
compared	O
their	O
effects	O
with	O
the	O
action	O
of	O
itaconic	B
acid,	I
which	O
also	O
inhibits	O
SDH	O
only	O
at	O
high	O
concentrations	O
(1–10	O
mM).	O

Mobile	O
phase	O
A	O
was	O
made	O
up	O
of	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
10 mM	O
ammonium	B
acetate,	I
while	O
phase	O
B	O
was	O
acetonitrile:isopropanol	O
(5:2)	O
with	O
0.1%	O
formic	B
acid	I
and	O
10 mM	O
ammonium	B
acetate.	I

During	O
the	O
measurements,	O
the	O
subject	O
remained	O
in	O
supine	B
position	O
within	O
the	O
spectrometer.	O

Betaine,	B
also	O
glycine	B
betaine,	I
has	O
been	O
reported	O
to	O
be	O
disturbed	O
in	O
diabetes	O
and	O
it	O
is	O
regarded	O
as	O
a	O
marker	O
of	O
diabetes	O
in	O
plasma	O
and	O
urine	O
samples.	O

We	O
found	O
no	O
statistically	O
significant	O
association	O
between	O
these	O
genetic	O
variants	O
and	O
anastrozole	B
glucuronide	I
formation	O
rates	O
in	O
the	O
50	O
human	O
liver	O
microsomes	O
(supporting	O
).	O

Interestingly,	O
also	O
circulating	O
adiponectin	O
seems	O
to	O
be	O
related	O
with	O
neopterin	B
concentrations.	O

Interestingly,	O
in	O
both	O
the	O
comparisons	O
the	O
lysolipids	O
were	O
reduced	O
and	O
dipeptides	O
were	O
increased	O
in	O
the	O
high	O
SUV_max	O
CAFs,	O
suggesting	O
these	O
changes	O
are	O
characteristics	O
of	O
CAFs	O
derived	O
from	O
high	O
SUV_max	O
tumors,	O
reinforcing	O
the	O
hypothesis	O
that	O
metabolic	O
changes	O
in	O
CAFs	O
are	O
in	O
some	O
way	O
linked	O
to	O
the	O
glycolytic	B
capacity	O
of	O
the	O
tumor.	O

The	O
latter	O
is	O
detected	O
in	O
large	O
quantities	O
in	O
urine	O
in	O
cases	O
of	O
urea	B
cycle	O
disorders.	O

Therefore,	O
quantitative	O
metabolite	O
profiling	O
relative	O
to	O
creatinine	B
peak	O
area	O
may	O
yield	O
inaccurate	O
results.	O

Results	O
indicate	O
that	O
sucrose,	B
cellobiose,	B
and	O
hypoxanthine	B
can	O
be	O
signature	O
metabolites	O
highlighting	O
the	O
effect	O
of	O
active	O
acupoints	O
in	O
the	O
treatment	O
of	O
EH.	O

Those	O
with	O
liver	O
disease	O
have	O
higher	O
circulating	O
triglycerides,	B
though	O
their	O
lipoproteins	O
are	O
comparable,	O
as	O
previously	O
reported.	O

Ethanol	B
production	O
was	O
only	O
consistently	O
measured	O
in	O
control	O
patients	O
while	O
only	O
one	O
IBS	O
volunteer	O
out	O
of	O
three	O
was	O
able	O
to	O
produce	O
ethanol	B
from	O
bread	O
fermentation.	O

Relationship	O
of	O
24,25(OH)_2	B
D_3	O
with	O
25(OH)D_3	O
in	O
all	O
5	O
studies.	O

Finally,	O
we	O
determined	O
proportional	O
hazards	O
for	O
TMAO	B
considering	O
MACE	O
(n = 135,	O
51%).	O

The	O
immediate	O
product	O
of	O
the	O
PC	O
reaction	O
is	O
oxaloacetate	B
which	O
is	O
then	O
directly	O
converted	O
to	O
malate	B
and	O
citrate.	B

Moreover,	O
it	O
has	O
been	O
shown	O
that,	O
in	O
response	O
to	O
cellular	O
changes	O
of	O
glucose	B
levels,	O
glycolysis	O
and	O
gluconeogenesis	O
pathways	O
are	O
strictly	O
and	O
mutually	O
regulated.	O

At	O
a	O
cellular	O
level,	O
studies	O
on	O
min6	O
cells	O
and	O
isolated	O
mouse	O
pancreatic	O
islets	O
have	O
shown	O
an	O
increase	O
in	O
the	O
conversion	O
of	O
triacylglycerols	B
to	O
diacylglycerols	B
during	O
glucose	B
stimulation	O
(Pearson	O
et	O
al.	O
).	O

Proline	B
data	O
were	O
pooled	O
for	O
comparison	O
and	O
analyzed	O
by	O
Wilcoxon	O
rank-sum	O
test.	O

The	O
most	O
discriminant	O
metabolites	O
between	O
BC	O
and	O
control	O
samples	O
in	O
the	O
PLS-DA,	O
considering	O
a	O
variable	O
importance	O
in	O
projection	O
(VIP)	O
score	O
>	O
1	O
as	O
threshold	O
value,	O
included	O
valine,	B
alanine,	B
lysine,	B
glutamine,	B
citrate,	B
dimethylamine,	B
creatinine,	B
trimethylamine	B
N-oxide,	I
taurine,	B
sucrose,	B
creatine,	B
hippuric	B
acid,	I
histidine,	B
phenylalanine,	B
and	O
trigonelline.	B

Although	O
different	O
rankings	O
have	O
been	O
assigned	O
to	O
the	O
statins	B
in	O
terms	O
of	O
their	O
diabetogenic	O
probability,	O
most	O
studies	O
suggest	O
that	O
rosuvastatin,	B
simvastatin	B
and	O
atorvastatin	B
are	O
more	O
likely	O
to	O
cause	O
T2DM	O
than	O
pravastatin,	B
although	O
there	O
is	O
published	O
data	O
that	O
suggest	O
pravastatin	B
is	O
also	O
culpable	O
(;	O
;	O
;	O
).	O

On	O
the	O
other	O
hand,	O
S-Adenosyl-L-homocysteine	B
(SAH),	O
a	O
metabolite	O
involves	O
in	O
methionine	B
metabolism	O
and	O
methylation,	O
was	O
frequently	O
increased	O
in	O
tumor	O
relative	O
to	O
normal	O
tissues.	O

The	O
sample	O
preparation	O
protocol	O
included	O
in	O
the	O
first	O
step	O
an	O
incubation	O
of	O
a	O
mixture	O
containing	O
100 μL	O
plasma,	O
25 μL	O
glucuronidase,	O
8 mg/mL	O
(corresponding	O
to	O
an	O
activity	O
of	O
113.2	O
U);	O
25 μL	O
sulfatase,	O
50	O
units/mL;	O
10 μL	O
paracetamol-β-d-glucuronide,	B
10 μg/mL;	O
40 μL	O
p	B
-nitrocatechol	I
sulfate,	I
1 mg/mL	O
(all	O
solutions	O
prepared	O
in	O
sodium	B
acetate	I
0.2 M,	O
pH	O
4.5);	O
and	O
200 μL	O
sodium	B
acetate,	I
0.2 M	O
(pH 4.5),	O
for	O
12 h	O
at	O
37 °C,	O
with	O
constant	O
mixing	O
(Memmert).	O

Finally,	O
our	O
assay	O
was	O
tested	O
and	O
separates	O
the	O
phase	O
I	O
and	O
II	O
metabolites	O
well	O
from	O
abiraterone	B
in	O
patients	O
treated	O
with	O
this	O
drug	O
and	O
proved	O
to	O
perform	O
well	O
in	O
a	O
real-world	O
clinical	O
setting	O
The	O
metabolites	O
that	O
were	O
seen	O
on	O
the	O
same	O
mass	O
transition	O
as	O
the	O
parent	O
drug	O
are	O
assumed	O
to	O
be	O
either	O
n-oxide,	B
n-glucuronide,	O
n-sulphate,	O
o-sulphate,	O
n-oxide-o-glucuronide	B
or	O
n-oxide-o-sulphate.	B

From	O
our	O
study,	O
the	O
observed	O
progressive	O
decrease	O
in	O
the	O
concentration	O
levels	O
of	O
AA,	O
DHA,	O
DPA,	O
lysophospholipids	B
and	O
their	O
downstream	O
products	O
such	O
as	O
eicosatrienoic	B
acid	I
after	O
reperfusion	O
strongly	O
endorses	O
the	O
possible	O
part	O
that	O
PLA_2	O
plays	O
in	O
disturbed	O
phospholipid	B
homeostasis	O
during	O
the	O
transition	O
from	O
reversible	O
to	O
irreversible	O
ischemic	O
myocardial	O
injury.	O

The	O
mean	O
±	O
standard	O
deviations	O
of	O
amino	O
acid	O
and	O
acylcarnitine	B
concentrations	O
were	O
calculated	O
for	O
patients	O
with	O
lung	O
cancer	O
and	O
healthy	O
controls	O
in	O
the	O
two	O
data	O
sets.	O

Alanine,	B
an	O
isomer	O
of	O
sarcosine,	B
was	O
used	O
as	O
a	O
control	O
for	O
these	O
experiments.	O

Decreased	O
levels	O
of	O
2-oxobutyrate	B
in	O
combination	O
with	O
an	O
increase	O
in	O
2-aminobutyrate	B
might	O
favor	O
the	O
hypothesis	O
of	O
increased	O
amino	O
acid	O
catabolism	O
of	O
threonine	B
(;	O
).	O

Baseline	O
trp	O
(P=.007),	O
kyn/trp	O
ratio	O
(P≤.001),	O
and	O
hippuric	B
acid	I
(P=.002)	O
were	O
all	O
linked	O
to	O
MACE	O
on	O
univariate	O
analysis.	O

The	O
qualitative	O
analysis	O
of	O
thiols	B
in	O
cancer	O
urines	O
by	O
IL-LC-DPI-MS	O
method	O
was	O
performed	O
according	O
to	O
our	O
previous	O
work.	O

Displayed	O
are	O
six	O
individual	O
samples	O
homogenized	O
in	O
water	O
and	O
supplemented	O
with	O
the	O
same	O
volume	O
of	O
either	O
H_2	O
O	O
(brown)	O
or	O
isopropanol	B
(green)	O
(70%	O
related	O
to	O
volume)	O

Time-dependent	O
increases	O
in	O
the	O
levels	O
of	O
both	O
TMAO	B
and	O
d9-TMAO	O
were	O
also	O
observed	O
postprandially.	O

Further	O
study	O
revealed	O
others	O
mechanism	O
of	O
action	O
of	O
oleanolic	B
acid,	I
such	O
as	O
mitochondrial	O
depolarization,	O
release	O
of	O
cytochrome	O
C,	O
lysosomal	O
membrane	O
permeabilization	O
and	O
leakage	O
of	O
cathepinB.	O
MS-based	O
lipidomic	O
analysis	O
of	O
sphingolipids	B
from	O
metastatic	O
pancreatic	O
tissues	O
revealed	O
discrete	O
and	O
significant	O
changes	O
in	O
specific	O
ceramide	B
molecule	O
as	O
compared	O
to	O
either	O
pancreatic	O
cancers	O
without	O
metastases	O
or	O
non-cancerous	O
pancreatitis	O
specimens.	O

The	O
stability	O
of	O
carnitine,	B
C2,	O
C3,	O
C4	O
and	O
C5	O
for	O
24	O
h	O
at	O
37°C	O
is	O
in	O
line	O
with	O
our	O
results	O
(24°h	O
at	O
RT),	O
whereas	O
C18∶1	O
and	O
C18∶2	O
showed	O
an	O
opposing	O
trend.	O

Briefly,	O
508	O
participants	O
aged	O
older	O
than	O
18	O
years	O
who	O
were	O
primary	O
or	O
secondary	O
cardiovascular	O
prevention	O
patients	O
were	O
recruited	O
in	O
Louisville,	O
KY.	B

Fructose	B
may	O
be	O
even	O
more	O
reactive	O
in	O
AGE-mediated	O
damage	O
mechanisms	O
than	O
glucose,	B
and	O
levels	O
of	O
the	O
two	O
are	O
similar	O
in	O
AD	O
brain.	O

Although,	O
cholesterol,	B
inosine	B
and	O
threonic	B
acid	I
showed	O
changes	O
with	O
a	O
similar	O
correlation	O
structure	O
in	O
both	O
NP	O
and	O
CWP	O
and	O
arginine	B
and	O
aminomalonic	B
acid	I
showed	O
the	O
opposite	O
correlation	O
structure.	O

We	O
observed	O
higher	O
urinary	O
and	O
salivary	O
Norepinephrine	B
in	O
HIV/AIDS	O
patients,	O
which	O
reduced	O
in	O
patients	O
on	O
ART.	O

Extraction	O
of	O
lipids	O
from	O
plasma	O
or	O
serum	O
samples	O
spiked	O
with	O
6	O
lipid	O
standards	O
(2.5	O
nmol	O
of	O
monoacylglycerosphosphocholine	B
(LPC)	O
13:0,	O
diacylglycerophosphocholine	B
(PC)	O
14:0/14:0	O
and	O
19:0/19:0,	O
phosphatidylserine	B
(PS)	O
12:0/12:0,	O
diacylglycerophosphopethanolamine	B
(PE)	O
17:0/17:0,	O
and	O
diacylglycerophosphoglycerol	B
(PG)	I
15:0/15:0))	I
was	O
achieved	O
using	O
a	O
modification	O
of	O
the	O
MTBE-based	O
protocol	O
of	O
Matyash	O
et	O
al.,	O
as	O
follows:	O
Step	O
1:	O
Plasma	O
samples	O
(100	O
μL)	O
were	O
added	O
to	O
15	O
mL	O
glass	O
tubes	O
containing	O
lipid	O
standards	O
that	O
had	O
first	O
been	O
dried	O
under	O
nitrogen	O
and	O
resolubilized	O
in	O
750	O
μL	O
methanol	B
followed	O
by	O
20	O
μL	O
1M	O
formic	B
acid.	I

Dryness	O
and	O
irritation	O
symptoms,	O
as	O
opposed	O
to	O
a	O
clinical	O
diagnosis,	O
were	O
particularly	O
strongly	O
associated	O
with	O
decreased	O
androgen	O
steroid	O
metabolites,	O
with	O
all	O
reaching	O
metabolome-wide	O
significance	O
(androsterone	O
sulfate,	I

We	O
thus	O
propose	O
that	O
the	O
imbalance	O
of	O
long	O
and	O
short-chain	O
FA	B
contributes	O
to	O
the	O
pathogenesis	O
in	O
acute	O
malaria	O
infection.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
intake	O
of	O
different	O
macro-,	O
micronutrients	O
as	O
well	O
as	O
food	O
groups	O
at	O
baseline	O
in	O
patients	O
with	O
clinical	O
relapse	O
versus	O
remission	O
within	O
12	O
mo	O
of	O
follow-up,	O
except	O
for	O
poultry	O
and	O
maltose	B
intake	O
which	O
were	O
significantly	O
higher	O
in	O
patients	O
who	O
remained	O
in	O
remission	O
(Table	O
).	O

Chemicals	O
of	O
the	O
highest	O
available	O
purity	O
were	O
either	O
diluted	O
in	O
50%	O
acetonitrile	B
for	O
urine	O
samples	O
or	O
66%	O
acetonitrile	B
for	O
plasma	O
samples	O
and	O
fragmented	O
with	O
ramping	O
collision	O
energy	O
of	O
5–30	O
eV.	O
MS/MS	O
spectra	O
of	O
the	O
pure	O
chemicals	O
were	O
compared	O
to	O
the	O
biological	O
sample	O
MS/MS	O
spectra	O
for	O
the	O
masses	O
in	O
question.	O

We	O
present	O
a	O
validated	O
analytical	O
procedure	O
for	O
the	O
quantification	O
of	O
amphetamines,	B
COC,	O
opiates,	O
NIC,	O
and	O
metabolites	O
in	O
meconium,	O
employing	O
a	O
single	O
extraction	O
and	O
two	O
acquisition	O
methods.	O

Consistent	O
with	O
their	O
results,	O
the	O
higher	O
CSF	O
level	O
of	O
lactic	B
acid	I
tended	O
to	O
be	O
associated	O
with	O
a	O
shorter	O
OS	O
in	O
all	O
glioma	O
patients	O
and	O
was	O
statistically	O
associated	O
with	O
a	O
shorter	O
OS	O
in	O
malignant	O
glioma	O
alone	O
in	O
our	O
metabolomic	O
study.	O

Total	O
ketones	B
(KET),	O
3-hydroxybutyrate	B
(HBUT),	O
and	O
total	O
non-esterified	O
fatty	O
acids	O
(NEFA)	O
were	O
measured	O
on	O
a	O
Beckman	O
DxC600	O
autoanalyzer	O
(Brea,	O
CA,	O
USA)	O
using	O
reagents	O
from	O
Wako	O
(Richmond,	O
VA,	B
USA).	O

Besides	O
its	O
main	O
metabolic	O
role	O
in	O
glucose	B
homeostasis,	O
adiponectin	O
is	O
also	O
implicated	O
in	O
many	O
other	O
metabolic	O
and	O
inflammatory	O
functions,	O
including	O
for	O
instance	O
tissue	O
regeneration	O
and	O
proliferation	O
and	O
function	O
of	O
sebocytes.	O

Multiple	O
commonly	O
available	O
over-the-counter	O
antioxidant	O
compounds	O
(many	O
of	O
which	O
are	O
vitamins)	O
and	O
omega-3	B
fatty	O
acids	O
were	O
used	O
in	O
the	O
study	O
because	O
supplements	O
are	O
taken	O
in	O
real	O
life	O
as	O
'multivitamins',	O
oxidative	O
stress	O
is	O
known	O
to	O
deplete	O
multiple	O
antioxidants	O
in	O
the	O
skin,	O
and	O
multiple	O
antioxidants	O
are	O
more	O
effective	O
than	O
a	O
single	O
antioxidant	O
to	O
combat	O
oxidative	O
stress.	O

In	O
an	O
inflammatory	O
environment,	O
the	O
enzyme	O
Phospholipase	O
A2	O
catalyzes	O
the	O
esterified	O
AA	O
present	O
in	O
the	O
phospholipid	B
membrane	O
into	O
free	O
AA,	O
which	O
may	O
be	O
then	O
oxidized	O
in	O
four	O
different	O
pathways:	O
lipoxygenase	O
(LOX),	O
cyclooxygenase	O
(COX),	O
epoxygenase	O
(CYTP450)	O
and	O
isoprostane.	B

Increased	O
serum	O
level	O
of	O
malic	B
acid	I
was	O
reported	O
in	O
lung	O
cancer	O
patients	O
by	O
Hori	O
et	O
al..	O

FA	B
can	O
also	O
be	O
consumed	O
through	O
β-oxidation,	O
producing	O
key	O
substituents	O
to	O
providing	O
the	O
energy	O
needed	O
for	O
cancer	O
cell	O
survival.	O

Conversely,	O
neurons	O
exposed	O
to	O
extracellular	O
glutamate	B
showed	O
a	O
reduction	O
in	O
dendritic	O
growth	O
that	O
was	O
prevented	O
by	O
administration	O
of	O
KynA.	O
demonstrated	O
that	O
the	O
suppressive	O
effects	O
of	O
IL-1	O
on	O
human	O
hippocampal	O
progenitor	O
cells	O
in	O
vitro	O
can	O
be	O
reversed	O
by	O
treatment	O
with	O
a	O
KMO	O
inhibitor.	O

In	O
another	O
recent	O
study,	O
higher	O
intake	O
of	O
lactose,	B
alpha	O
linolenic	O
fatty	O
acid,	O
and	O
myristic	B
fatty	O
acid	O
were	O
related	O
to	O
increased	O
risk	O
of	O
relapse	O
in	O
UC	O
patients[].	O

This	O
allowed	O
the	O
subsequent	O
measurement	O
of	O
the	O
cholesterol	B
concentration	O
only	O
from	O
the	O
remaining	O
LDL	O
or	O
HDL	O
particles	O
in	O
the	O
second	O
step	O
using	O
RX	O
Series	O
CH	O
3841	O
protocol	O
to	O
measure	O
LDL	O
and	O
the	O
RX	O
Series	O
CH	O
3811	O
protocol	O
to	O
measure	O
HDL.	O

Radioactive	O
forms	O
of	O
estradiol,	B
labeled	O
with	O
tritium	O
in	O
the	O
17α,	O
2-,	O
or	O
16α-positions	B
of	O
the	O
steroid	O
ring,	O
were	O
injected	O
into	O
the	O
women;	O
and	O
the	O
rate	O
and	O
extent	O
of	O
oxidation	O
---	O
at	O
the	O
17-position,	O
which	O
converts	O
estradiol	B
to	O
estrone,	B
and	O
at	O
the	O
2-	O
and	O
16-positions,	O
which,	O
respectively,	O
estimate	O
the	O
2-hydroxylation	O
and	O
16α-hydroxylation	O
pathways	O
---	O
were	O
measured	O
in	O
serial	O
bloods.	O

Cell	O
cycle	O
transition	O
and	O
proliferation	O
were	O
measured	O
in	O
TRT-HU1	O
cells	O
treated	O
with	O
or	O
without	O
10 mM	O
of	O
α-OG.	B

Metabolite	O
pathway	O
enrichment	O
analysis	O
revealed	O
downregulation	O
of	O
the	O
phenylalanine-tyrosine-dopamine	B
axis,	O
which	O
regulates	O
natriuresis	O
and	O
blood	O
pressure,	O
due	O
to	O
enzymatic	O
downregulation	O
and	O
metabolite	O
deficiency.	O

Samples	O
were	O
incubated	O
at	O
37	O
°C	O
for	O
19	O
h.	O
After	O
hydrolysis,	O
samples	O
were	O
acidified	O
with	O
5	O
µL	O
of	O
1N	O
HCl	O
followed	O
by	O
addition	O
of	O
50	O
µL	O
saturated	O
sodium	B
chloride.	I

The	O
10–20%	O
acetone	B
in	O
DCM	O
fractions	O
from	O
the	O
chromatography	O
of	O
the	O
crude	O
leaves	O
extract	O
were	O
combined	O
and	O
rechromatographed	O
(×2)	O
in	O
petroleum	O
ether	O
to	O
afford	O
2	O
(18	O
mg).	O

Those	O
alterations	O
in	O
metabolic	O
enzyme	O
expression	O
correlated	O
with	O
metabolite	O
production	O
through	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
and	O
cysteine/methionine	O
metabolism	O
pathways.	O

It	O
has	O
been	O
suggested	O
that	O
early	O
lactate	B
clearance	O
is	O
associated	O
with	O
better	O
outcomes	O
in	O
sepsis,	O
which	O
is	O
supported	O
by	O
our	O
findings.	O

a	O
is	O
the	O
_13	O
C	O
projection	O
of	O
b.	O
c,	O
d	O
sugar	O
and	O
pyrimidine	B
C5	O
region.	O

A	O
total	O
of	O
500	O
μL	O
of	O
the	O
supernatant	O
was	O
withdrawn	O
and	O
combined	O
with	O
50	O
μL	O
of	O
the	O
internal	O
standard	O
3-(trimethylsilyl)	B
propionic	I
acid	I
(TSP,	O
Sigma-Aldrich,	O
St.	O
Louis,	O
MO,	O
USA)	O
to	O
a	O
concentration	O
of	O
1	O
mM.	O
The	O
internal	O
standard	O
and	O
buffer	O
were	O
prepared	O
with	O
D_2	O
O	O
to	O
provide	O
a	O
lock	O
for	O
the	O
NMR	O
signal.	O

A	O
recent	O
paper	O
which	O
compared	O
circulating	O
amine	O
and	O
acylcarnitines	B
levels	O
of	O
lung	O
cancer	O
patients	O
to	O
healthy	O
controls	O
reported	O
increased	O
plasma	O
arginine	B
levels	O
while	O
citrulline	B
and	O
glycine	B
were	O
decreased,	O
similar	O
to	O
what	O
we	O
observed	O
for	O
TB,	O
indicating	O
that	O
these	O
could	O
potentially	O
be	O
a	O
reflection	O
of	O
general	O
lung	O
pathology.	O

GSK3β	O
inactivation	O
might	O
result	O
in	O
decreased	O
phosphorylation	O
of	O
kinesin	O
motor	O
proteins,	O
which	O
mediate	O
the	O
translocation	O
of	O
glucose	B
transporters	O
and	O
increase	O
glucose	B
uptake.	O

As	O
a	O
pilot	O
study	O
we	O
analyzed	O
eight	O
plasma	O
samples	O
from	O
HIV-negative	O
females	O
and	O
compared	O
their	O
vitamin	B
D	I
profile	O
with	O
the	O
vitamin	B
D	I
profile	O
in	O
seven	O
plasma	O
samples	O
of	O
HIV-positive	O
females.	O

Samples	O
were	O
cooled	O
at	O
room	O
temperature,	O
precipitated	O
with	O
190	O
μ	O
L	O
acetonitrile,	B
vortexed,	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
15000g	O
and	O
4	O
°C.	O

After	O
an	O
overnight	O
fast,	O
participants	O
underwent	O
a	O
75-g	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT).	O

Albumin-catalyzed	O
metabolism	O
of	O
prostaglandin	B
D2.	I

The	O
up-regulated	O
levels	O
of	O
polyamines	B
are	O
achieved	O
through	O
increased	O
ODC	O
(ornithine	O
decarboxylase)	O
activity	O
and	O
reduced	O
polyamine	B
efflux.	O

Analogous	O
to	O
steroid	O
and	O
thyroid	O
hormones,	O
vitamin	B
D	I
and	O
its	O
hydroxylated	O
metabolites	O
circulate	O
in	O
the	O
blood	O
by	O
binding	O
to	O
a	O
transport	O
protein.	O

The	O
adjusted	O
odds	O
ratio	O
for	O
in-hospital	O
death	O
among	O
patients	O
with	O
positive	O
troponin	O
test	O
and	O
serum	O
creatinine	B
level	O
of	O
less	O
than	O
2.0	O
mg	O
per	O
deciliter	O
was	O
2.55.	O

Cyt	O
b5:	O
Cytochrome	O
b5;	B
5α-R:	I
5α	O
reductase;	O
5β-R:	B
5β	O
reductase.	O

Compared	O
with	O
the	O
control	O
group,	O
the	O
NSCLC	O
group	O
showed	O
elevated	O
levels	O
of	O
lactate,	B
alanine,	B
glutamate,	B
proline,	B
glycoprotein,	B
phenylalanine,	B
tyrosine	B
and	O
tryptophan,	B
and	O
decreased	O
levels	O
of	O
glucose,	B
taurine,	B
glutamine,	B
glycine,	B
phosphocreatine	B
and	O
threonine,	B
which	O
could	O
be	O
partially	O
or	O
completely	O
reversed	O
by	O
MWA	O
treatment.	O

m	O
Enzyme	O
kinetic	O
parameters	O
of	O
anastrozole	B
metabolite	O
formation	O
in	O
three	O
human	O
liver	O
samples	O
m	O
Representative	O
enzyme	O
kinetic	O
plots	O
for	O
the	O
formation	O
of	O
hydroxyanastrozole	B
in	O
three	O
human	O
liver	O
microsomes	O
(HL091499).	O

Using	O
a	O
modified	O
Bligh	O
and	O
Dyer	O
extraction	O
conventionally	O
used	O
to	O
analyze	O
major	O
lipid	O
families	O
in	O
biological	O
matrices,	O
recoveries	O
were	O
calculated	O
from	O
CSF	O
QC	O
samples	O
(n = 5)	O
spiked	O
with	O
22	O
non	O
endogenous	O
internal	O
standards	O
(IS)	O
representing	O
the	O
five	O
major	O
lipid	O
families	O
(fatty	O
acyls,	O
glycerophospholipids,	B
glycerolipids,	B
sphingolipids	B
and	O
sterol	O
lipids,	O
see	O
Table	O
S1	O
provided	O
as	O
supplementary	O
material).	O

Recent	O
data	O
in	O
mice,	O
show	O
that	O
maternal	O
exposure	O
during	O
pregnancy	O
to	O
environmentally	O
relevant	O
doses	O
of	O
BPA	O
(chemically	O
similar	O
to	O
DES)	O
induces	O
sex-specific,	O
dose-dependent	O
(linear	O
and	O
curvilinear),	O
and	O
brain	O
region-specific	O
changes	O
in	O
expression	O
of	O
genes	O
encoding	O
estrogen	B
receptors	O
and	O
estrogen-related	O
receptor-γ	O
in	O
juvenile	O
offspring.	O

Pearson's	O
(r)	O
and	O
Spearman's	O
(r_s	O
)	O
correlation	O
coefficients	O
between	O
the	O
kynurenine	B
pathway	O
metabolites	O
and	O
brain	O
volumes	O
within	O
the	O
BD	O
(A),	O
and	O
HC	O
(B)	O
groups.	O

The	O
ratio	O
of	O
the	O
areas	O
for	O
the	O
vitamin	B
E	I
metabolites	O
over	O
the	O
corresponding	O
internal	O
standard	O
was	O
calculated	O
for	O
each	O
metabolite.	O

The	O
effect	O
of	O
FA	B
on	O
IFNγ	O
production	O
by	O
PBMC	O
was	O
evaluated	O
in	O
vitro.	O

Although	O
the	O
_1	O
CH_2	O
and	O
_2	O
CH_2	O
peaks	O
from	O
the	O
putrescine	B
moieties	O
of	O
spermine	B
and	O
spermidine	B
were	O
not	O
distinguishable	O
from	O
each	O
other,	O
the	O
_3	O
CH_2	O
and	O
_4	O
CH_2	O
peaks	O
from	O
spermidine	B
were	O
separately	O
identifiable.	O

The	O
remaining	O
8	O
metabolites	O
(butyrylcarnitine,	O
2-hydroxybutyrate,	B
7-alpha–hydroxy–3–oxo–4–cholestenoate,	B
alpha-hydroxyisovalerate,	B
benzoate,	B
n-acetlyglycine,	B
palmitoyl	B
sphingomyelin,	I
and	O
histidine)	B
were	O
not	O
strongly	O
correlated	O
with	O
one	O
another.	O

Triacylglycerides	B
with	O
longer	O
fatty	O
acid	O
chains	O
and	O
higher	O
degree	O
of	O
unsaturation	O
were	O
found	O
at	O
higher	O
levels	O
in	O
infected	O
individuals	O
compared	O
to	O
controls.	O

The	O
mass-peak	O
area	O
of	O
the	O
137.08-m/z	O
ion	O
and	O
hypoxanthine	B
were	O
correlated	O
with	O
one	O
another	O
(Figure	O
),	O
but	O
this	O
relationship	O
did	O
not	O
reach	O
statistical	O
significance.	O

Leu:	O
leucine;	B
Lys:	O
lysine;	B
OAA:	O
oxaloacetate;	B
Orn:	O
ornithine;	B
PEP:	O
phosphoenolpyruvate;	B
PGLY:	O
phosphoglyceride;	B
Phe:	O
phenylalanine;	B
Pro:	O
proline;	B
Ser:	O
serine;	B
TAG:	O
triacylglyceride;	B
Trp:	O
tryptophan,	B
Tyr:	O
tyrosine;	B
Val:	O
valine.	B

all	O
processed	O
with	O
pure	O
MeOH	B
(i	O
.e	O
.	O

D-Glucose-1-phosphate.	B

Succinic	B
acid	I
and	O
ascorbic	B
acid	I
were	O
monitored	O
in	O
the	O
negative	O
mode,	O
while	O
carnitine	B
was	O
monitored	O
in	O
the	O
positive	O
mode.	O

Incubation	O
with	O
sofosbuvir	B
led	O
to	O
the	O
rapid	O
appearance	O
of	O
metabolite	O
X,	O
which	O
egressed	O
following	O
removal	O
of	O
the	O
drug	O
from	O
the	O
medium,	O
allowing	O
more-persistent	O
exposure	O
to	O
the	O
pharmacologically	O
active	O
triphosphate.	B

An	O
especially	O
remarkable	O
upregulation	O
of	O
DCAs	O
was	O
seen	O
in	O
the	O
comparison	O
of	O
cirrhosis	O
controls	O
vs.	O
NHC,	O
where	O
non-anedioate	O
(azelate),	O
undecanedioate	B
and	O
decanedioate	B
(sebacate)	O
showed	O
a	O
strongly	O
significant	O
respective	O
overexpression	O
of	O
54-,	O
36-	O
and	O
26-fold	O
in	O
cirrhosis	O
vs.	O
NHC.	O

In	O
the	O
present	O
study,	O
the	O
association	O
of	O
lactate	B
serum	O
levels	O
with	O
3-month	O
mortality	O
did	O
not	O
remain	O
significant	O
(p = 0.061)	O
after	O
adjusting	O
for	O
parameters	O
which	O
are	O
associated	O
with	O
mortality	O
in	O
HF	O
patients.	O

Membrane	O
glycerophospholipids	B
are	O
upregulated	O
in	O
response	O
to	O
prednisone	B
treatment.	O

Partition	O
analysis	O
of	O
the	O
relative	O
abundance	O
values	O
highlighted	O
two	O
lipids,	O
FA	B
(22:3)	I
and	O
PC	B
(39:6)	I
which	O
can	O
classify	O
samples	O
with	O
higher	O
specificity	O
(Fisher	O
test	O
with	O
p	O
-value	O
1.612e-06).	O

Frozen	O
endartery	O
tissue	O
was	O
sectioned	O
at	O
10	O
μm	O
and	O
mounted	O
on	O
a	O
slide	O
covered	O
with	O
a	O
polyethylene	B
naphthalate	O
membrane	O
(PALMZeiss	O
Microlaser	O
Technologies).	O

To	O
this,	O
750 µl	O
methyl	B
tert-butyl	I
ether	I
(MTBE)	O
was	O
added,	O
along	O
with	O
150 µl	O
of	O
internal	O
standard	O
mix,	O
containing	O
the	O
following	O
six	O
internal	O
standards:	O
1,2-di-o-octadecyl-sn-glycero-3-phosphocholine	B
(0.6 µM),	O
1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine	B
(1.2 µM),	O
C8-ceramide	B
(0.6 µM),	O
N-heptadecanoyl-D-erythro-sphingosylphosporylcholine	B
(0.6 µM),	O
undecanoic	B
acid	I
(0.6 µM),	O
and	O
trilaurin	B
(0.6 µM).	O

Six	O
subjects	O
of	O
vitamin	B
D2	I
group	O
were	O
subsequently	O
excluded	O
from	O
the	O
study,	O
five	O
subjects	O
were	O
newly	O
diagnosed	O
with	O
diabetes	O
within	O
three	O
months	O
of	O
the	O
study	O
period	O
and	O
one	O
subjects	O
had	O
hepatitis	O
C	O
viral.	O

The	O
dried	O
samples	O
were	O
diluted	O
in	O
isopropanol	B
(IPA)/MeOH/CHCl_3	O
4:2:1	O
(v/v/v)	O
containing	O
7.5 mM	O
ammonium	B
formate	I
and	O
30 μL	O
was	O
placed	O
in	O
a	O
96-well	O
twin.tec®	O
plate	O
(Eppendorf,	O
Hamburg,	O
Germany).	O

The	O
fasting	O
RaFFA	O
was	O
negatively	O
associated	O
with	O
the	O
fasting	O
concentration	O
of	O
C14:2,	B
and	O
two	O
other	O
fasting	O
AC	B
(C14:1,	I
C18:2)	I
suggesting	O
that	O
those	O
subjects	O
with	O
the	O
greatest	O
fatty	O
acid	O
turnover	O
had	O
either	O
low	O
levels	O
of	O
fatty	O
acids	O
entering	O
beta-oxidation,	O
or	O
those	O
fatty	O
acids	O
that	O
entered	O
were	O
completely	O
oxidized	O
to	O
CO_2	O
.	O

As	O
in	O
our	O
study,	O
low	O
histidine	B
concentration	O
has	O
been	O
previously	O
reported	O
in	O
RA	O
[–],	O
as	O
well	O
as	O
in	O
other	O
diseases,	O
such	O
as	O
chronic	O
kidney	O
disease	O
and	O
gallbladder	O
inflammation	O
with	O
chronic	O
cholecystitis	O
[,	O
].	O

Urea	B
showed	O
strong	O
decreases	O
in	O
UC	O
as	O
well	O
as	O
in	O
CD	O
patients,	O
which	O
is	O
in	O
contrast	O
with	O
previous	O
findings	O
of	O
urea	B
production	O
in	O
IBD	O
patients.	O

d	O
Nine	O
metabolites	O
are	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
the	O
IDH-mutation	O
in	O
gliomas	O
(1-Methyltryptophan,	O
1-Methyl-Histidine,	B
Arginine,	B
N-Acetylputrescine,	B
Succinic	B
acid	I
semialdehyde,	I
Malonate,	B
betaine	B
aldehyde,	I
Pantothenic	B
acid).	O

	O
ACN	O
(HPLC	O
grade)	O
and	O
formic	B
acid	I
(FA,	O
HPLC	O
grade)	O
were	O
purchased	O
from	O
Merck	O
(Darmstadt,	O
Germany).	O

Cysteine	B
can	O
be	O
directly	O
taken	O
off	O
sulfydryl	O
and	O
amino	B
to	O
generate	O
pyruvate,	B
which	O
can	O
form	O
acetyl-CoA	B
through	O
oxidative	O
decarboxylation,	O
and	O
then	O
be	O
further	O
converted	O
to	O
glutamate.	B

The	O
second	O
(orange)	O
node	O
in	O
each	O
set	O
represents	O
the	O
model	O
additionally	O
adjusted	O
for	O
fasting	O
plasma	O
glucose	B
level	O
and	O
waist	O
circumference,	O
and	O
the	O
third	O
(blue)	O
node	O
represents	O
the	O
model	O
additionally	O
adjusted	O
for	O
serum	O
triglyceride	B
level,	O
measured	O
by	O
standard	O
assay.	O

Standards	O
of	O
33	O
unconjugated	O
BAs,	O
27	O
conjugated	O
BAs	O
and	O
4	O
stable	O
isotope	O
labeled	O
internal	O
standards	O
summarized	O
in	O
and	O
were	O
purchased	O
from	O
Steraloids	O
(Newport,	O
RI,	B
USA),	O
TRC	O
(Toronto,	O
Canada),	O
Santa	O
Cruz	O
Biotechnology	O
(Dallas,	O
TX,	O
USA)	O
or	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

The	O
latter	O
elutes	O
at	O
2.55 min	O
and	O
the	O
transitions	O
m/z	O
198.2	O
⟶	O
m/z	O
152	O
for	O
L-DOPA	B
and	O
m/z	O
201.2	O
⟶	O
m/z	O
155	O
for	O
the	O
corresponding	O
deuterated	O
internal	O
standard	O
L-DOPA-d3	O
were	O
monitored.	O

Cytidine	B
was	O
increased	O
by	O
41%	O
(Z	O
=	O
+0.89,	O
).	O

By	O
contrast,	O
tryptophan	B
metabolites	O
downstream	O
from	O
TH	O
were	O
not	O
related	O
to	O
hemodynamic	O
indexes	O
of	O
RV-PV	O
dysfunction.	O

Specifically,	O
elevated	O
BCAA	O
levels	O
were	O
associated	O
with	O
improved	O
glucose	B
and	O
insulin	O
tolerance	O
in	O
BCATm−/−	O
mice,	O
while	O
decreases	O
in	O
BCAA	O
levels	O
are	O
associated	O
with	O
improved	O
glucose	B
and	O
insulin	O
tolerance	O
in	O
humans	O
following	O
RYGB.	O

Along	O
with	O
the	O
traditional	O
method	O
of	O
normalising	O
biomarker	O
data	O
with	O
creatinine	B
(i.e.	O
ratio	O
of	O
biomarker	O
to	O
creatinine	B
concentration),	O
we	O
tested	O
also	O
the	O
method	O
proposed	O
by	O
.	O

In	O
plasma	O
(Supporting	O
Information,	O
Figure	O
1A),	O
almost	O
all	O
glycerolipids	B
correlated	O
positively	O
with	O
visceral	O
fat	O
and	O
many	O
correlated	O
with	O
liver	O
fat.	O

Although	O
there	O
are	O
numerous	O
methods	O
that	O
have	O
been	O
reported	O
for	O
obtaining	O
isotopically	O
_13	O
C-labeled	O
derivatives	O
of	O
amino	O
acids,	O
including	O
carbamyl	O
derivatives	O
with	O
KOCN,	O
N	O
-hydroxy-methyl	O
derivatives	O
with	O
formaldehyde,	B
and	O
benzoyl	O
derivatives	O
with	O
N	B
-hydroxyscuccinamide	I
sulfonyl	I
benzoate,	I
we	O
found	O
that	O
_13	O
C-labeled	O
acetyl	O
derivatization	O
with	O
acetic	B
anhydride	I
was	O
the	O
superior	O
method	O
as	O
it	O
worked	O
well	O
at	O
room	O
temperature	O
in	O
aqueous	O
solution,	O
produced	O
high	O
yield,	O
and	O
is	O
readily	O
available	O
commercially.	O

Serum	O
levels	O
of	O
CRC-446	O
were	O
assayed	O
using	O
tandem	O
mass	O
spectrometry	O
(and	O
reported	O
as	O
cholic	B
acid	I
equivalents;	O
see	O
materials	O
and	O
methods)	O
for	O
samples	O
from	O
two	O
separate	O
cohorts	O
of	O
CRC	O
patients	O
prior	O
to	O
and	O
following	O
surgical	O
tumor	O
removal	O
as	O
well	O
as	O
matched	O
controls.	O

Another	O
metabolic	O
function	O
of	O
uridine	B
is	O
to	O
preserve	O
ATP	B
through	O
anaerobic	O
glycolysis.	O

Thus,	O
the	O
transferrin	O
molecule	O
carries	O
a	O
total	O
of	O
four	O
sialic	B
acid	I
residues.	O

Also,	O
determining	O
L-arginine	B
to	O
ADMA	B
ratio	O
has	O
been	O
advocated.	O

Analysis	O
of	O
luciferase	O
activity	O
in	O
SN4741	O
cells	O
transfected	O
with	O
an	O
LXR-responsive	O
luciferase	O
reporter	O
construct	O
(LXRE	O
)	O
and	O
LXRα,	O
as	O
indicated,	O
and	O
stimulated	O
for	O
24	O
h	O
with	O
22(R	O
)-hydroxycholesterol	I

The	O
mobile	O
phase	O
A	O
consisted	O
of	O
water/methanol	O
(1:9,	O
v/v	O
)	O
containing	O
10	O
mM	O
ammonium	B
acetate,	I
and	O
the	O
mobile	O
phase	O
B	O
consisted	O
of	O
isopropanol/methanol	O
(5:5,	O
v/v	O
)	O
containing	O
10	O
mM	O
ammonium	B
acetate.	I

The	O
distinct	O
metabolites	O
between	O
PDR	O
and	O
NDR	O
groups	O
were	O
significantly	O
enriched	O
in	O
9	O
KEGG	O
pathways	O
(P	O
 < 0.05,	O
impact	O
> 0.1),	O
namely,	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism,	O
caffeine	B
metabolism,	O
beta-alanine	B
metabolism,	O
purine	B
metabolism,	O
cysteine	B
and	O
methionine	B
metabolism,	O
sulfur	O
metabolism,	O
sphingosine	B
metabolism,	O
and	O
arginine	B
and	O
proline	B
metabolism.	O

Reduced	O
levels	O
of	O
circulating	O
LPCs	O
may	O
be	O
due	O
to	O
their	O
enhanced	O
conversion	O
by	O
extracellular	O
lysophospholipase	O
D	O
(autotaxin)	O
to	O
lysophosphatidic	B
acids	I
(LPA).	O

As	O
expected,	O
24-hour	O
tetrahydroaldosterone	B
excretion	O
was	O
significantly	O
increased	O
in	O
primary	O
aldosteronism	O
patients	O
(healthy	O
controls,	O
median	O
30	O
[interquartile	O
range	O
22–44]	O

A	O
total	O
of	O
300	O
μL	O
of	O
sodium	B
phosphate	I
buffer	O
(70	O
mmol/L	O
Na_2	O
HPO_4	O
;	O
20%	O
(v/v)	O
_2	O
H_2	O
O;	O
0.025%	O
(v/v)	O
NaN_3	O
;	O
0.8%	O
(w/v)	O
sodium	B
trimethylsilyl	I
[2,2,3,3-_2	I
H_4	I
]propionate	I
pH	O
7.4)	O
was	O
added	O
to	O
300	O
μL	O
of	O
each	O
serum	O
sample,	O
and	O
the	O
mixture	O
was	O
homogenized	O
by	O
vortexing	O
for	O
30	O
seconds.	O

This	O
indicates	O
a	O
lower	O
fractional	O
enrichment	O
in	O
glutamine,	B
and	O
the	O
pattern	O
suggests	O
that	O
_13	O
C	O
passes	O
through	O
the	O
glutamate	B
pool	O
before	O
reaching	O
glutamine,	B
rather	O
than	O
the	O
opposite.	O

The	O
relevance	O
of	O
these	O
newly	O
identified	O
markers	O
to	O
patient	O
recurrence	O
status	O
were	O
illustrated	O
in	O
Kaplan-Meier	O
plots	O
for	O
homocysteine,	B
cystathionine,	B
and	O
cysteine	B
as	O
compared	O
to	O
pre-operative	O
serum	O
PSA	O
levels,	O
and	O
time-to-recurrence.	O

Sphingolipids	B
have	O
a	O
rapid	O
turnover	O
and	O
their	O
levels	O
are	O
controlled	O
by	O
the	O
balance	O
between	O
synthesis	O
and	O
degradation	O
in	O
multiple	O
compartments.	O

Many	O
of	O
these	O
amino	O
acids,	O
particularly	O
alanine,	B
play	O
a	O
glucogenic	B
role	O
in	O
hepatic	O
glucose	B
production,	O
which	O
does	O
increase	O
during	O
exercise.	O

Abbreviation:	O
No	O
–	O
patient	O
number;	O
Gen	O
-	O
gender:	O
male/female	O
(M/F);	O
Age	O
-	O
age	O
at	O
investigation;	O
OA	O
-	O
age	O
of	O
epilepsy	O
onset;	O
HIE	O
-	O
Hipoxic-ischemic	O
encephalopathy;	O
AEDs	O
-	O
Antiepileptic	O
drugs;	O
VPA	O
–	O
Valproic	B
acid;	I
LVT	O
–	O
levetiracetam;	B
VGB	O
–	O
Vigabatrin;	O
ACTH	O
–Adrenocorticotrophic	O
hormone;	O
PB	O
–Phenobarbital;	O
CLB	O
–	O
Clobazam;	O
TPM	O
–	O
Topiramate;	B
LTG	B
-Lamotrigine;	I
CLZ	O
–	O
Clonazepam;	B
DD	O
–	O
developmental	O
delay.	O

In	O
addition,	O
a	O
detailed	O
correlation	O
of	O
ApoE	O
genotype,	O
plasma	O
levels	O
of	O
glucose	B
and	O
insulin,	O
medication,	O
liver	O
enzymes	O
and/or	O
post-prandial	O
intervals	O
may	O
help	O
to	O
follow	O
up	O
the	O
changes	O
at	O
a	O
more	O
mechanistic	O
level,	O
which	O
was,	O
however,	O
not	O
in	O
focus	O
in	O
this	O
study.	O

Kinetic	O
studies	O
for	O
anastrozole	B
metabolism	O
were	O
conducted	O
at	O
conditions	O
linear	O
for	O
duration	B
of	O
incubation	O
and	O
protein	O
concentration	O
in	O
four	O
different	O
HLM	O
preparations.	O

S-(−)equol,	O
a	O
metabolite	O
of	O
the	O
soy	O
isoflavone	B
daidzein,	I
has	O
a	O
higher	O
bioavailability	O
and	O
greater	O
affinity	O
for	O
estrogen	B
receptor-β	O
than	O
daidzein.	B

The	O
2-isopropylmalic	B
acid	I
contained	O
in	O
the	O
extraction	O
solution	O
was	O
also	O
used	O
to	O
evaluate	O
the	O
stability	O
of	O
our	O
GC/QqQMS	O
analysis	O
system.	O

In	O
the	O
current	O
study,	O
three	O
of	O
the	O
elevated	O
markers	O
in	O
the	O
CD	O
patients	O
were	O
in	O
the	O
sphingolipid	B
category.	O

(B)	O
Expansion	O
for	O
the	O
aromatic	O
region	O
showing	O
signals	O
for	O
acetaminophen	B
and	O
its	O
related	O
metabolites	O
(C)	O
Expansion	O
on	O
acetaminophen	B
region	O
at	O
δ	O
2.16.	O

The	O
metabolite	O
with	O
the	O
highest	O
importance	O
value	O
for	O
the	O
prediction	O
of	O
sex	O
from	O
urine	O
metabolite	O
profiles,	O
4-deoxythreonic	B
acid,	I
has	O
not	O
been	O
mentioned	O
in	O
literature	O
in	O
the	O
context	O
of	O
sex	O
differences	O
before.	O

All	O
the	O
statistical	O
analysis	O
was	O
performed	O
using	O
STATA	O
software	O
(IC	O
13,	O
StataCorp	O
LP,	B
TX,	O
USA).	O

From	O
each	O
sample,	O
10	O
μL	O
was	O
injected	O
onto	O
a	O
reverse-phase	O
50	O
×	O
2.1	O
mm	O
ACQUITY	O
1.7-μm	O
CSH	O
C18	O
column	O
(Waters)	O
using	O
an	O
ACQUITY	O
UPLC	O
system	O
(Waters)	O
with	O
a	O
gradient	O
mobile	O
phase	O
consisting	O
of	O
40%	O
ACN	O
solution	O
containing	O
10	O
mM	O
NH_4	O
OAC	O
and	O
0.1%	O
FA	B
(A)	O
and	O
10%	O
ACN	O
in	O
isopropanol	B
containing	O
0.1	O
%	O
FA	B
and	O
10	O
mM	O
NH_4	O
OAC	O
(B).	O

Similarly,	O
IDC	O
serum	O
showed	O
elevated	O
concentration	O
of	O
nucleotides	O
including	O
CTP	B
and	O
UTP,	O
which	O
may	O
be	O
attributed	O
to	O
their	O
release	O
from	O
damaged	O
cells.	O

For	O
metabolic	O
profiling,	O
the	O
dried	O
extracts	O
were	O
dissolved	O
in	O
400	O
µL	O
of	O
50%	O
acetonitrile	B
(in	O
water),	O
sonicated	O
and	O
centrifuged	O
to	O
pellet	O
precipitates.	O

These	O
data	O
indicate	O
that	O
it	O
is	O
essential	O
to	O
next	O
identify	O
the	O
molecular	O
targets	O
of	O
VLCDCA	B
28:4	I
to	O
understand	O
the	O
varying	O
roles	O
of	O
this	O
anti-inflammatory	O
lipid	O
in	O
different	O
forms	O
of	O
cancer.	O

To	O
optimize	O
the	O
biosensor	O
for	O
physiological	O
glucose	B
concentrations,	O
they	O
reduced	O
the	O
space	O
between	O
the	O
fluorophores	O
and	O
the	O
overall	O
flexibility	O
of	O
the	O
sensor.	O

Hepatocellular	O
carcinoma,	O
mass	O
spectrometry,	O
amino	O
acids,	O
carnitine	B

The	O
separation	O
of	O
hydrophilic	B
metabolites	O
from	O
lipids	O
by	O
MTBE	B
also	O
resulted	O
in	O
a	O
slight	O
increase	O
of	O
creatinine-d_3	B
(p=0.063)	O
with	O
1.04%	O
CV	O
versus	O
15.2%	O
when	O
no	O
separation	O
occurs.	O

Furthermore,	O
another	O
isobaric	O
deprotonated	O
[M-H]_−	O
ion	O
corresponding	O
to	O
the	O
sulfatide	B
lipid	O
species	O
(d18:2/C24:1)	O
was	O
also	O
detected	O
at	O
m/	O

Since	O
the	O
concentration	O
of	O
lactate	B
in	O
the	O
blood	O
remains	O
one	O
of	O
the	O
main	O
indicators	O
of	O
sepsis,	O
we	O
compared	O
simultaneously,	O
in	O
the	O
same	O
serum	O
samples	O
from	O
septic	O
patients,	O
the	O
concentration	O
of	O
lactic,	O
succinic	B
acids	I
and	O
Sum3.	O

For	O
the	O
LC/MS-based	O
hydrophilic	O
metabolite	O
analysis,	O
10	O
mg	O
of	O
tissue	O
was	O
mixed	O
with	O
900	O
μl	O
of	O
a	O
solvent	O
mixture	O
(MeOH:H_2	O
O:CHCl_3	O
=2.5:1:1)	B
containing	O
1	O
μM	O
2-bromohypoxanthine	B
and	O
1	O
μM	O
10-camphorsulfonic	B
acid	I
as	O
internal	O
standards,	O
and	O
then	O
the	O
solution	O
was	O
shaken	O
at	O
1,400	O
rpm	O
for	O
30	O
min	O
at	O
37°C,	O
before	O
being	O
centrifuged	O
at	O
16,000	O
g	O
for	O
3	O
min	O
at	O
4°C.	O

We	O
conclude	O
in	O
this	O
exploratory	O
study,	O
that	O
there	O
are	O
major	O
alterations	O
in	O
serum	O
and	O
urinary	O
metabolomics	O
focused	O
on	O
lipid,	O
amino-acid	B
and	O
bioenergetic	O
metabolism	O
that	O
are	O
associated	O
with	O
development	O
of	O
overt	O
HE,	O
hospitalization,	O
transplant	O
and	O
death	O
over	O
90	O
days.	O

Ammonia	O
and	O
carbon	B
dioxide	I
can	O
produce	O
urea	B
through	O
ornithine,	B
citrulline	B
and	O
arginine	B
acid	I
via	O
the	O
ornithine	B
cycle.	O

Together	O
these	O
findings	O
suggest	O
that	O
metabolomics	O
analysis	O
might	O
be	O
developed	O
for	O
defining	O
a	O
population	O
unlikely	O
to	O
benefit	O
from	O
statin	B
use	O
sufficient	O
to	O
warrant	O
risk	O
of	O
the	O
spectrum	O
of	O
side-effects.	O

Moreover,	O
all	O
control	O
subjects	O
were	O
matched	O
to	O
PCV	O
participants	O
on	O
gender,	O
age	O
and	O
serum	O
level	O
of	O
TC	O
and	O
TG.	B

Indeed,	O
LLE	O
with	O
TFA	O
highly	O
improved	O
the	O
recoveries	O
of	O
ARG	O
and	O
GABA	B
but	O
diminished	O
the	O
recoveries	O
of	O
some	O
polyamines.	B

Accurate	O
mass	O
was	O
maintained	O
by	O
introduction	O
of	O
LockSpray	O
interface	O
of	O
sulfadimethoxine	B
(311.0814	O
[M+H]	O
_+	O
or	O
309.0658	O
[M−H]_−	O
)	O
at	O
a	O
concentration	O
of	O
250	O
pg/μL	O
in	O
50%	O
aqueous	O
ACN	O
and	O
a	O
rate	O
of	O
150	O
μL/min.	O

These	O
species	O
are	O
important	O
participants	O
in	O
the	O
bacterial	O
fermentation	O
of	O
polysaccharides	B
and	O
consequently	O
the	O
production	O
of	O
SCFAs.	O

Importantly,	O
in	O
this	O
study,	O
the	O
inclusion	O
criteria	O
for	O
evaluating	O
RRM2	O
expression	O
in	O
the	O
TMA	O
were	O
that	O
the	O
patient	O
should	O
have	O
ER +	O
tumors,	O
be	O
treated	O
with	O
tamoxifen	B
in	O
an	O
adjuvant	O
setting	O
and	O
without	O
chemotherapy.	O

The	O
resulting	O
quantitative	O
metabolomic	O
data	O
showed	O
differences	O
in	O
the	O
levels	O
of	O
total	O
glutathione,	B
adenosine,	B
phosphatidylserine	B
(PtdSer),	O
and	O
sphingomyelin	B
compared	O
with	O
healthy	O
volunteers.	O

Further	O
support	O
of	O
this	O
includes	O
the	O
accumulation	O
of	O
tricarboxylic	B
acid	I
cycle	O
intermediates,	O
together	O
with	O
a	O
significant	O
elevation	O
of	O
pentose	B
sugar	O
alcohols	O
and	O
amino	B
sugars.	O

Structures	O
of	O
the	O
parent	O
compounds,	O
the	O
phosphate	B
diester	O
metabolites,	O
and	O
respective	O
internal	O
standards	O
are	O
provided	O
in	O
.	O

Urinary	O
levels	O
of	O
isoflavones	B
and	O
S-(−)equol	O
following	O
a	O
three-day	O
soy	O
challenge	O
were	O
detected	O
and	O
quantified	O
using	O
liquid	O
chromatography-multiple	O
reaction	O
ion	O
monitoring	O
mass	O
spectrometry	O
analysis.	O

These	O
450	O
spectra	O
(i.e.	O
175	O
‘P’	O
class	O
and	O
275	O
‘Cp’	O
class)	O
were	O
subsequently	O
used	O
to	O
construct	O
the	O
24	O
prediction	O
models	O
using	O
various	O
pre-processing	O
parameters	O
(see	O
validation	O
of	O
acetaminophen	B
prediction	O
models	O
later).	O

From	O
the	O
367	O
features,	O
we	O
identified	O
metabolites	O
including	O
acylcarnitines,	B
lysophospholipids,	B
phosphocholines,	B
amino	O
acids,	O
cortisol,	B
and	O
bilirubin	B
by	O
using	O
our	O
previously	O
published	O
masses	O
and	O
fragments	O
[intraassay	O
quality	O
control	O
(QC)	O
coefficient	O
of	O
variation	O
(CV),	O
25	O
±	O
3%].	O

As	O
the	O
examples	O
shown	O
in	O
,	O
glycated	O
peptides	O
gT34-35	O
(AEFAEVSKglcLVTDLTK)	O
and	O
gT37-38	O
(ADLAKglcYICENQDSISSK)	O
were	O
indentified	O
unambiguously	O
by	O
their	O
fragment	O
ions	O
in	O
MS/MS.	O
Lys-525	O
was	O
reported	O
to	O
be	O
the	O
principal	O
glycation	O
site	O
in	O
healthy	O
person,	O
along	O
with	O
a	O
few	O
lysine	B
residues	O
susceptible	O
to	O
be	O
glycated	O
[,].	O

For	O
RP	B
and	O
HILIC	O
LC-MS	O
data,	O
peak	O
finding	O
options	O
were	O
set	O
as	O
follows:	O
subtraction	O
offset,	O
10	O
scans;	O
subtraction	O
multiplication	O
factor,	O
1.3;	O
noise	O
threshold,	O
3;	O
minimum	O
spectral	O
peak	O
width,	O
1	O
amu;	O
minimum	O
retention	O
time	O
peak	O
width,	O
4	O
scans;	O
and	O
maximum	O
retention	O
time	O
width,	O
1000	O
scans.	O

Between	O
analyses,	O
columns	O
were	O
washed	O
with	O
1:1	O
CO_2	O
:methanol	B
at	O
1 mL/min	O
for	O
50 min,	O
then	O
stored	O
in	O
100%	O
CO_2	O
.	O

The	O
activities	O
of	O
5α-R/5β-R	B
were	O
increased	O
only	O
when	O
calculating	O
the	O
11-hydroxy	B
metabolites	O
of	O
androgens.	O

Cancer	O
cells	O
use	O
glutamine	B
as	O
source	O
of	O
energy	O
but	O
also	O
for	O
nucleotide	O
biosynthesis	O
or	O
the	O
synthesis	O
of	O
other	O
aminoacids.	B

Furthermore,	O
eicosanoids	B
were	O
also	O
observed	O
to	O
be	O
more	O
abundant	O
in	O
CRC	O
CTCs,	O
which	O
is	O
further	O
corroborated	O
by	O
other	O
studies	O
done	O
on	O
this	O
cancer	O
type._47	O
Glycerophospholipids	B
were	O
noticed	O
to	O
be	O
elevated	O
in	O
GC	O
CTCs,	O
which	O
also	O
concurs	O
with	O
recent	O
reports._48	O

In	O
the	O
BeMIM	O
study,	O
a	O
total	O
of	O
12	O
metabolites	O
(8	O
amino	O
acids,	O
free	O
carnitine,	B
3	O
phosphatidylcholines)	B
were	O
identified	O
to	O
show	O
significant	O
associations	O
between	O
infant	O
weight	O
or	O
BMI	O
z-score	O
change	O
from	O
1	O
to	O
4	O
months	O
of	O
age.	O

In	O
order	O
to	O
confirm	O
the	O
predicted	O
architecture	O
of	O
the	O
P.	O
falciparum	O
NAD_+	O
salvage	O
pathway,	O
we	O
grew	O
infected	O
red	O
blood	O
cells	O
(iRBCs)	O
in	O
media	O
supplemented	O
with	O
uniformly	O
labeled	O
_13	O
C-U-glucose	B
to	O
perform	O
stable	O
isotopic	O
labeling	O
studies	O
coupled	O
with	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
detection.	O

However,	O
in	O
some	O
instances,	O
namely	O
T,	O
a	O
mixture	O
of	O
both	O
syn	O
-	O
and	O
anti	O
-Girard	O
T	O
oxime	B
derivatives	O
was	O
observed	O
and	O
separated,	O
in	O
which	O
case	O
the	O
major	O
product	O
peak	O
was	O
used	O
as	O
the	O
reference	O
ion.	O

We	O
observed	O
an	O
overall	O
reduction	O
in	O
ELOVL-6	O
activity	O
in	O
response	O
to	O
the	O
high	O
fat	O
meal	O
challenge,	O
particularly	O
in	O
pro-atherogenic	O
subjects,	O
which	O
implies	O
impairment	O
of	O
elongation	O
or	O
saturation	O
of	O
palmitic	B
acid.	I

HPLC	O
grade	O
methanol	B
was	O
purchased	O
from	O
Fisher	O
Chemicals	O
(Fair	O
Lawn,	O
NJ,	O
USA).	O

Progressive	O
neurodegeneration	O
in	O
HD	O
involves	O
loss	O
of	O
both	O
grey	O
and	O
white	O
matter	O
volume	O
and	O
myelin	B
breakdown.	O

At	O
18	O
months	O
post-eradication,	O
N1,N12-Diacetylspermine	B
remained	O
unchanged	O
but	O
3-Acetamidopropanal	B
was	O
found	O
to	O
be	O
down-regulated	O
(Table	O
).	O

Inverse	O
association	O
between	O
VAT	O
and	O
urine	O
levels	O
of,	O
carnosine,	B
N-acetylaspartate	B
and	O
cinnamoylglycine	B
were	O
unique	O
to	O
women	O
as	O
well.	O

In	O
addition,	O
40%	O
(2/5)	O
of	O
the	O
unsaturated	O
fatty	O
acids	O
(bishomo-gamma-linolenic	O
acid	O
and	O
docosahexaenoic	B
acid	I
(DHA))	O
were	O
increased,	O
but	O
others	O
including	O
11,14,17-eicosatrienoic	B
acid,	I
arachidonic	B
acid,	I
and	O
eicosapentaenoic	B
acid	I
(EPA)	O
were	O
decreased.	O

Of	O
the	O
seven	O
LMIs,	O
four	O
with	O
a	O
137.0455	O
m/z	O
ion	O
at	O
RTs	O
of	O
2.04-3.14	O
min	O
were	O
upregulated	O
in	O
sera	O
from	O
OVC	O
patients;	O
those	O
LMIs	O
were	O
identified	O
as	O
hypoxanthine.	B

PCs,	O
which	O
are	O
known	O
as	O
the	O
major	O
phospholipids	B
found	O
in	O
the	O
membranes	O
of	O
mammalian	O
cells,	O
were	O
mediated	O
by	O
PLA2	O
in	O
breast	O
cancer	O
cells.	O

Metabolic	O
dysfunctions	O
in	O
several	O
molecular	O
pathways	O
implicated	O
in	O
carcinogenesis	O
such	O
as	O
ketogenesis	O
(increase	O
in	O
acetoacetate	B
and	O
decrease	O
in	O
citrate)	O
were	O
described	O
to	O
be	O
associated	O
with	O
the	O
nuclear	O
magnetic	O
resonance	O
urine	O
metabolome	O
from	O
pancreatic	O
cancer	O
patients.	O

In	O
NS,	O
aminoacids	B
doubled	O
their	O
plasma	O
concentration	O
together	O
with	O
putrescine	B
and	O
spermidine,	B
the	O
last	O
one	O
significant	O
only	O
in	O
NS	O
at	O
day	O
90.	O

Relative	O
isomer	O
ratios	O
were	O
measured	O
for	O
19	O
pairs	O
of	O
Δ9/Δ11	O
C=C	O
isomers	O
from	O
PCs/PEs	O
containing	O
C18:1.	B

EPA	O
is	O
one	O
of	O
important	O
polyunsaturated	O
FA	B
which	O
antagonistically	O
works	O
to	O
AA,	O
so	O
we	O
calculated	O
the	O
ratio	O
of	O
EPA	O
to	O
AA.	O

In	O
this	O
study,	O
multiple	O
pathway	O
metabolites	O
were	O
significantly	O
altered	O
(glycine,	O
sarcosine,	B
SAH,	O
methionine,	B
homocysteine;	B
Fig.	O

Also,	O
the	O
Child-Pugh	O
score,	O
a	O
prognostic	O
indicator	O
of	O
liver	O
diseases	O
and	O
necessity	O
of	O
liver	O
transplantation,	O
presented	O
a	O
negative	O
correlation	O
with	O
isoleucine	B
in	O
both	O
groups	O
of	O
patients.	O

These	O
increases	O
in	O
amino	O
acids	O
were	O
all	O
correlated	O
with	O
reduction	O
in	O
free	O
cholesterol,	B
and	O
were	O
all	O
highly	O
correlated	O
with	O
each	O
other.	O

This	O
pilot	O
study	O
led	O
to	O
the	O
findings	O
of	O
65	O
significantly	O
changed	O
amino	O
acids,	O
acylcarnitines,	B
and	O
some	O
of	O
their	O
ratios	O
for	O
the	O
LC,	O
LD,	O
and	O
CONT	O
groups.	O

With	O
the	O
exception	O
of	O
choline,	B
the	O
main	O
metabolic	O
changes	O
could	O
be	O
connected	O
to	O
2	O
different	O
metabolic	O
pathways:	O
tryptophan	B
metabolism	O
and	O
energy	O
metabolism.	O

Separation	O
was	O
performed	O
on	O
a	O
ACQUITY	O
UPLC™	O
BEH	O
AMIDE	B
column	O
1.7	O
μm,	O
2.1	O
mm	O
×	O
150	O
mm	O
(Waters	O
Corporation,	O
Milford,	O
MA,	O
USA)	O
suitable	O
for	O
polar	O
metabolites.	O

Hypoxanthine	B
is	O
involved	O
in	O
the	O
purine	B
metabolism	O
pathway.	O

We	O
thus	O
compared	O
metabolites	O
extracted	O
from	O
the	O
samples	O
before	O
and	O
after	O
the	O
paraffin	B
embedding	O
and	O
we	O
observed	O
a	O
global	O
depletion	O
of	O
metabolites	O
in	O
all	O
classes.	O

Serine	B
was	O
the	O
most	O
significantly	O
altered	O
amino	O
acid	O
between	O
HCC	O
patients	O
and	O
DCs	O
(P	O
=	O
7.0	O
×	O
10_−6	O
).	O

Total	O
cell	O
lysates	O
of	O
SUM149PT	O
and	O
SUM1315MO2	O
cells	O
treated	O
with	O
either	O
C75,	O
celecoxib	B
or	O
C75	O
and	O
celecoxib	B
together	O
were	O
collected	O
at	O
24	O
h	O
and	O
used	O
to	O
measure	O
p-Erk	O
and	O
p-GSK3β	O
activation	O
levels.	O

HP	B
LC-MS/MS	O
was	O
performed	O
using	O
an	O
Agilent	O
Technologies	O
1290	O
series	O
High	O
Pressure	O
Liquid	O
Chromatograph	O
interfaced	O
with	O
an	O
Agilent	O
Technologies	O
6460	O
Triple	O
Quad	O
Mass	O
Spectrometer	O
fitted	O
with	O
a	O
Jetstream	O
electrospray	O
(ESI)	O
source.	O

Protein	O
measurement	O
with	O
the	O
Folin	B
phenol	I
reagent.	O

Bowers	O
et	O
al	O
.	O
also	O
found	O
choline	B
to	O
be	O
upregulated	O
in	O
HCC	O
compared	O
to	O
HCV	O
patients,	O
but	O
this	O
was	O
attributed	O
to	O
a	O
bias	O
from	O
the	O
food	O
intake.	O

Further	O
studies	O
are	O
required	O
to	O
determine	O
whether	O
these	O
three	O
novel	O
glucuronide	B
metabolites	O
are	O
derived	O
from	O
5-HO-PhIP	B
or	O
other	O
uncharacterized	O
hydroxylated	O
PhIP	O
metabolites.	O

Most	O
antipsychotics	O
in	O
current	O
use	O
act	O
as	O
dopamine	B
and	O
serotonin	B
blockers	O
and.	O

,	O
MiniVortexer	O
(VWR),	O
Orbital	O
Mixing	O
Chilling/Heating	O
Plate	O
(Torrey	O
Pines	B
Scientific	O
Instruments),	O
speed	O
vacuum	O
concentration	O
system	O
(Labconco	O
Centrivap)	O
with	O
a	O
cold	O
trap,	O
Agilent	O
tune	O
mix	O
(Agilent,	O
cat.	O

m	O
Analysis	O
of	O
β-apo-13-carotenone	B
in	O
human	O
plasma	O
by	O
HPLC/MS.	O

The	O
samples	O
were	O
then	O
extracted	O
with	O
250	O
μL	O
methanol	B
containing	O
stable	O
isotopes	O
and	O
shaken	O
in	O
a	O
vortex.	O

N-acetyl	O
amino	O
acids	O
(N-acetyl	O
AAs),	O
alanine,	B
methylsuccinate,	B
and	O
trigonelline	B
showed	O
lower	O
concentrations	O
in	O
the	O
urine	O
of	O
several	O
different	O
IMIDs	O
compared	O
to	O
healthy	O
normal	O
controls	O
(Table ).	O

In	O
a	O
prospective	O
cohort	O
study,	O
dietary	O
oleic	B
acid	I
intake	O
was	O
inversely	O
related	O
to	O
the	O
risk	O
of	O
pancreatic	O
ductal	O
adenocarcinoma	O
(significant	O
in	O
patients	O
with	O
a	O
BMI	O
>	O
25	O
kg/m_2	O
).	O

Maintenance	O
of	O
the	O
Glu	O
pool	O
is	O
also	O
linked	O
to	O
ergothioneine,	B
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
redox	O
homeostasis	O
of	O
Mtb.	O

The	O
direct	O
association	O
of	O
BMI	O
with	O
urinary	O
pseudouridine	B
excretion	O
(P	O
=	O
2.10	O
×	O
10_−12	O
)	O
reflected	O
increased	O
whole-body	O
nucleic	O
acid	O
turnover	O
with	O
higher	O
BMI,	O
consistent	O
with	O
enhanced	O
adipose	O
tissue	O
turnover	O
associated	O
with	O
obesity.	O

It	O
is	O
possible	O
that,	O
in	O
these	O
specific	O
conditions,	O
cholesterol	B
turnover	O
might	O
be	O
increased	O
in	O
CNS	O
(due	O
to	O
neuronal	O
degradation)	O
and/or	O
that	O
the	O
rate	O
of	O
conversion	O
of	O
brain	O
cholesterol	B
to	O
24S-OH-Chol	B
might	O
be	O
higher	O
compared	O
to	O
normal.	O

The	O
plasma	O
insulin	O
levels	O
at	O
1,	O
3	O
and	O
5	O
minutes	O
after	O
the	O
glucose	B
injection	O
and	O
the	O
first-phase	O
insulin	O
response	O
(FPIR,	O
sum	O
of	O
1	O
+	O
3	O
minutes)	O
were	O
significantly	O
reduced	O
in	O
carriers	O
of	O
the	O
TCF7L2	O
risk	O
allele	O
compared	O
to	O
the	O
control	O
group,	O
whereas	O
no	O
significant	O
differences	O
in	O
the	O
second-phase	O
insulin	O
response	O
were	O
observed.	O

Pharmacokinetic	O
curve	O
of	O
a	O
patient	O
treated	O
with	O
enzalutamide	B
160	O
mg	O
once	O
daily	O
at	O
steady	O
state.	O

As	O
acetate	B
and	O
formate	B
are	O
intermediates	O
of	O
pyrimidine	B
and	O
amino	O
acid	O
degradation,	O
respectively,	O
the	O
high	O
abundance	O
of	O
these	O
metabolites	O
may	O
represent	O
a	O
deregulated	O
energy	O
metabolism	O
in	O
CSCC	O
patients.	O

Consistent	O
with	O
this	O
interpretation,	O
we	O
observe	O
statistically	O
significant	O
elevation	O
of	O
both	O
α-KB	B
and	O
cysteine	B
with	O
increasing	O
insulin	O
resistance	O
from	O
the	O
global	O
screening	O
data	O
(	O
&	O
	O
,	O
),	O
similar	O
to	O
the	O
trend	O
observed	O
with	O
α-HB.	B

This	O
study	O
examined	O
differences	O
in	O
eicosanoid	B
and	O
other	O
oxylipin	B
levels	O
in	O
human	O
colonic	O
tissue	O
from	O
individuals	O
receiving	O
aspirin	B
and/or	O
statin	B
treatment,	O
two	O
widely	O
prescribed	O
drugs	O
with	O
an	O
attributed	O
protective	O
role	O
in	O
colorectal	O
carcinogenesis.	O

Six	O
weeks	O
of	O
simvastatin	B
treatment	O
resulted	O
in	O
6.9%	O
of	O
patients	O
developing	O
hyperglycemia	O
and	O
25%	O
developing	O
changes	O
consistent	O
with	O
development	O
of	O
pre-diabetes.	O

However,	O
when	O
disease	O
duration	B
in	O
RRMS	O
exceeded	O
13	O
y,	O
the	O
number	O
of	O
significantly	O
elevated	O
VLCFA	O
species	O
(vs	O
controls)	O
increased	O
to	O
27	O
(Table ).	O

Thus,	O
creatine	B
may	O
be	O
a	O
candidate	O
biomarker	O
of	O
malignant	O
pancreatic	O
cancer.	O

FGF,	O
fibroblast	O
growth	O
factor;	O
PTH,	O
parathyroid	O
hormone;	O
24,25(OH)_2	B
D_3	I
,	I
24,25-dihydroxyvitamin	I
D_3	I
;	I
25(OH)D_3	I
,	I
25-hydroxyvitamin	I
D_3	O

The	O
water	O
phase	O
was	O
resuspended	O
in	O
D2O	O
and	O
trimethylsilyl	B
propanoic	I
acid	I
(TSP)	O
5.07	O
mM.	O
TSP	O
was	O
added	O
to	O
provide	O
an	O
internal	O
reference	O
for	O
the	O
chemical	O
shifts	O
(0	O
ppm),	O
and	O
650	O
μL	O
of	O
the	O
solution	O
was	O
transferred	O
to	O
a	O
5-mm	O
NMR	O
tube.	O

TRP	O
is	O
an	O
essential	O
amino	O
acid,	O
and	O
it	O
is	O
the	O
key	O
metabolite	O
of	O
2	O
pathways,	O
including	O
the	O
synthesis	O
of	O
the	O
neurotransmitter	O
5-hydroxytryptamine	B
(serotonin)	O
and	O
the	O
kynurenine	B
pathway	O
(KP),	O
which	O
ultimately	O
lead	O
to	O
the	O
production	O
of	O
nicotinammide	O
adenina	O
dinucleotide.	O

Only	O
the	O
association	O
of	O
alanine	B
with	O
1st-year	O
recurrent	O
wheezing	O
remained	O
significant	O
after	O
FDR	O
correction	O
at	O
0.05.	O

However,	O
long	O
chain	O
alkanes	O
such	O
as	O
pentane,	B
hexane,	B
octane	B
and	O
decane	B
were	O
identified	O
from	O
the	O
fecal	O
samples	O
but	O
none	O
of	O
these	O
appeared	O
to	O
be	O
discriminatory	O
between	O
the	O
groups.	O

A	O
previous	O
study	O
has	O
also	O
reported	O
that	O
creatine	B
augmentation	O
was	O
associated	O
with	O
an	O
improvement	O
of	O
depressive	O
symptoms	O
in	O
adolescents	O
with	O
SSRI-resistant	O
MDD.	O

The	O
present	O
analysis	O
also	O
shows	O
retinol	B
is	O
correlated	O
with	O
histidine	B
pathway	O
metabolites,	O
including	O
N-acetyl-3-methylhistidine,	B
N-acetyl-1-methylhistidine,	B
1-methylhistidine	B
and	O
3-methylhistidine.	B

Notably,	O
several	O
lines	O
of	O
evidence	O
suggest	O
that	O
rhythm	O
alterations	O
alone	O
may	O
not	O
fully	O
account	O
for	O
the	O
risk	O
of	O
stroke	O
attributed	O
to	O
AF.	B

99.99%	O
Suprapur	O
sodium	B
chloride	I
(NaCl)	O
and	O
25%	O
pure	O
hydrochloric	B
acid	I
(HCl)	O
were	O
received	O
from	O
Merck	O
(Darmstadt,	O
Germany)	O
respectively	O
AppliChem	O

It	O
has	O
been	O
reported	O
that	O
dopamine	B
influences	O
the	O
behavior	O
of	O
tumor,	O
including	O
ovarian	O
carcinoma,	O
gastric	O
cancer,	O
breast	O
cancer,	O
and	O
colon	O
cancer,	O
by	O
inhibiting	O
cell	O
proliferation.	O

Classes	O
of	O
these	O
contaminants	O
include	O
process	O
impurities	O
(e.g.,	O
silicone	O
oils	O
and	O
alkane	O
hydrocarbons)	B
present	O
in	O
blanks	O
or	O
discovered	O
after	O
manual	O
curation	O
(Supplemental	O
Table	O
S1),	O
metabolites	O
present	O
in	O
blanks,	O
and	O
unknowns	O
present	O
in	O
blanks.	O

The	O
levels	O
of	O
total,	O
free	O
and	O
esterified	O
cholesterol	B
decreased	O
by	O
43–48%,	O
and	O
the	O
levels	O
of	O
total	O
fatty	O
acids	O
and	O
specific	O
fatty	O
acids,	O
including	O
UFA,	B
18:1,	I
18:2,	O
20:4	O
and	O
22:6,	O
by	O
about	O
50%.	O

After	O
extraction,	O
the	O
samples	O
were	O
dried	O
and	O
reconstituted	O
in	O
100	O
µL	O
of	O
5%	O
MeOH,	B
0.1%	O
formic	B
acid,	I
and	O
94.9%	O
deionized	O
MilliQ	O
water	O
upon	O
analysis.	O

However,	O
there	O
was	O
no	O
study	O
reported	O
so	O
far	O
about	O
the	O
content	O
changes	O
of	O
thiol	B
in	O
urine	O
of	O
cancer.	O

The	O
yield	O
of	O
free	O
choline	B
in	O
milk	O
increased	O
during	O
the	O
initial	O
3	O
weeks	O
of	O
lactation	O
and	O
then	O
remained	O
constant	O
until	O
the	O
end	O
of	O
lactation.	O

An	O
exception	O
was	O
citric	B
acid,	I
which	O
exhibited	O
a	O
wide	O
range	O
of	O
standard	O
error,	O
as	O
shown	O
in	O
Table	O
S2.	O

The	O
parameters	O
used	O
to	O
accomplish	O
these	O
were:	O
RT	O
range	O
2.8–34.0 min;	O
m/z	O
range	O
50–250;	O
MS	O
data	O
noise	O
level	O
1.0 × 10_4	O
;	O
m/z	O
tolerance	O
0.5;	O
chromatogram	O
baseline	O
level	O
1.0 × 10_3	O
;	O
peak	O
duration	B
range	O
0.02–0.30 min.	O

While	O
early	O
metabolic	O
studies	O
demonstrated	O
the	O
synthesis	O
of	O
glutamine	B
and	O
alanine,	B
as	O
two	O
main	O
gluconeogenic	O
amino	O
acids	O
formed	O
by	O
transamination	O
of	O
α-ketoacids	B
(pyruvate	O
and	O
oxaloacetate,	B
)	O
in	O
muscle_,	O
,	O
the	O
uptake	O
pattern	O
of	O
glutamate	B
by	O
human	O
muscle	O
has	O
been	O
reported	O
only	O
by	O
Marliss	O
et	O
al.	O
using	O
enzymatic	O
assays.	O

This	O
family	O
of	O
lipids	O
consists	O
of	O
a	O
glycerol	B
backbone,	O
a	O
functional	O
head	O
group,	O
and	O
two	O
fatty	O
acids	O
of	O
varying	O
length	O
and	O
unsaturation.	O

A	O
needle	O
biopsy	O
of	O
the	O
vastus	O
lateralis	O
was	O
obtained	O
under	O
local	O
anesthesia	O
in	O
the	O
fasted	O
condition	O
immediately	O
before	O
the	O
hyperinsulinemic-euglycemic	B
clamp.	O

First,	O
we	O
compared	O
metabolites	O
found	O
in	O
the	O
supernatant	O
(n	O
=	O
132)	O
with	O
those	O
found	O
in	O
the	O
extracts	O
from	O
frozen	O
samples	O
(n	O
=	O
437),	O
as	O
described	O
in	O
to	O
identify	O
those	O
that	O
are	O
soluble	O
in	O
formalin	B
and	O
could,	O
as	O
a	O
result,	O
be	O
lost	O
in	O
the	O
analysis.	O

hUCBP	O
also	O
presented	O
higher	O
concentrations	O
of	O
eotaxin	B
and	O
fractakline	O
compared	O
to	O
the	O
culture	O
media	O
analyzed	O
(163	O
pg/ml	O
VS	O
1,24-62	O
pg/ml	O
and	O
110	O
pg/ml	O
VS	O
0	O

Bariatric	O
surgery	O
decreases	O
low-grade	O
inflammation	O
associated	O
with	O
obesity	O
and	O
improves	O
glucose	B
control.	O

High	O
resolution	O
metabolomics,	O
Lung	O
cancer,	O
LC-MS,	O
Biomarker,	O
Bisphenol	B
A,	O
Retinol,	B
L-proline	B

This	O
approach	O
could	O
also	O
prove	O
useful	O
in	O
quantifying	O
the	O
effects	O
of	O
dietary	O
intervention,	O
statins,	B
or	O
other	O
lipid-lowering	O
therapies,	O
by	O
providing	O
direct	O
real-time	O
measures	O
of	O
an	O
individual’s	O
lipid	O
metabolism	O
and	O
inflammatory	O
status.	O

Moreover,	O
besides	O
the	O
already	O
mentioned	O
higher	O
extracellular	O
concentrations	O
of	O
glutamate	B
and	O
aspartate	B
after	O
rHla-treatment,	O
glycine,	B
which	O
showed	O
the	O
steepest	O
intracellular	O
drop,	O
was	O
found	O
in	O
rapidly	O
increasing	O
concentrations	O
in	O
the	O
extracellular	O
medium	O
of	O
S9	O
as	O
well	O
as	O
of	O
16HBE14o_−	O
cells.	O

As	O
shown	O
in	O
,	O
the	O
apparent	O
formation	O
rate	O
of	O
hydroxyanastrozole	B
by	O
CYP3A4	O
and	O
CYP3A5	O
was	O
170-	O
and	O
4.6-fold	O
higher	O
in	O
those	O
preparations	O
with	O
b5	O
than	O
those	O
without	O
b5	O
(the	O
K	O
_m	O
value	O
was	O
increased	O
by	O
3.7	O
and	O
decreased	O
by	O
2.3-fold,	O
respectively).	O

Our	O
results	O
clearly	O
demonstrate	O
the	O
existence	O
of	O
a	O
new	O
mercapturic	B
acid	I
pathway	O
for	O
PAH,	O
illustrated	O
by	O
detection	O
of	O
sulfoxide	B
metabolites.	O

With	O
the	O
death	O
of	O
neurons	O
and	O
mitochondria,	O
the	O
oxidative	O
stress	O
levels	O
in	O
the	O
brain	O
may	O
increase	O
and	O
lead	O
to	O
the	O
production	O
of	O
more	O
neurotoxic	O
substances,	O
such	O
as	O
nitrotyrosine.	B

IE1,	O
pUL99,	O
and	O
β-actin	B
were	O
monitored	O
as	O
controls.	O

Seven	O
metabolites	O
exhibited	O
changes	O
in	O
concentrations	O
both	O
at	O
room	O
temperature	O
(without	O
preservative)	O
and	O
with	O
preservative	O
or	O
at	O
4 °C:	O
urobilinogen,	B
urobilin,	B
ascorbic	B
acid,	I
orotic	B
acid,	I
in	O
addition	O
to	O
isomers	O
of	O
ketoretinoic	O
acid	O
and	O
hydroxyretinoic	B
acid	I
glucuronides,	O
and	O
threonolactone	B
(Table ;	O
Figure ,	O
and	O
graphs	O
provided	O
as	O
supplementary	O
material	O
6).	O

Five	O
lipid	O
species	O
(LPC18:2,	O
LPC18:1,	B
LPC20:2,	B
LPC20:1,	B
and	O
LPC20:0)	B
met	O
this	O
criterion,	O
as	O
shown	O
in	O
.	O

One	O
conclusion	O
of	O
these	O
studies	O
is	O
that	O
diol	B
epoxide	I
stereochemistry	O
strongly	O
affects	O
conjugation.	O

dhCer,	O
dihydroceramide;	B
Cer,	B
ceramide;	B
MHC,	O
monohexosylceramide;	B
DHC,	B
dihexosylceramide;	B
THC,	O
trihexosylcermide;	O
GM3,	B
GM3	B
ganglioside;	I
SM,	O
sphingomyelin;	B
PC,	O
phosphatidylcholine;	B
PC(O),	O
alkylphosphatidylcholine;	B
PC(P),	O
alkenylphosphatidylcholine;	B
PC,	O
lysophosphatidylcholine;	B
LPC(O),	O
lysoalkylphosphatidylcholine;	B
PE,	O
phosphatidylethanolamine;	B
PE(O),	O
alkylphosphatidylethanolamine;	B
PE(P),	O
alkenylphosphatidylethanolamine;	B
LPE,	O
lysophosphatidylethanolamine;	B
PI,	O
phosphatidylinositol;	B
LPI,	O
lysophosphatidylinositol;	B
PS,	O
phosphatidylserine;	B
PG,	B
phosphatidylglycerol;	B
CE,	O
cholesterol	B
ester;	I
COH,	O
free	O
cholesterol;	B
DG,	O
diacylglycerol;	B
TG,	B
triacylglycerol.	B

The	O
spectral	O
region	O
from	O
0.5	O
to	O
3.0 ppm	O
included	O
some	O
signals,	O
such	O
as	O
leucine,	B
valine,	B
lactate,	B
citrulline,	B
acetate,	B
glutamine,	B
glutathione,	B
aspartate,	B
acetic	B
acid.	I

Leucine	B
enkephalin	I
was	O
used	O
as	O
the	O
lock	O
mass	O
(m/z	O
556.2771	O
in	O
ES+	O
mode	O
and	O
554.2615	O
in	O
ES-	O
mode)	O
at	O
a	O
concentration	O
of	O
100	O
ng/ml	O
and	O
flow	O
rate	O
of	O
0.2	O
ml/min	O
for	O
all	O
analyses.	O

Glycerol,	B
galactarate	B
and	O
butyrate	B
levels	O
were	O
increased	O
only	O
in	O
late	O
stage	O
CRCs,	O
whereas	O
the	O
opposite	O
trend	O
was	O
seen	O
for	O
carnitine.	B

Interestingly,	O
we	O
observed	O
that	O
the	O
levels	O
of	O
some	O
amino	O
acids,	O
such	O
as	O
alanine	B
(P	O
_frozen	O
=	O
7.94	O
×	O
10_−3	O
;	O
P	O
_FFPE	O
=	O
7.94	O
×	O
10_−3	O
),	O
asparagine	B
(P	O
_frozen	O
=	O
7.94	O
×	O
10_−3	O
;	O
P	O
_FFPE	O
=	O
7.94	O
×	O
10_−3	O
),	O
and	O
glutamate	B
(P	O
_frozen	O
=	O
7.94	O
×	O
10_−3	O
;	O
P	O
_FFPE	O
=	O
7.94	O
×	O
10_−3	O
),	O
were	O
significantly	O
decreased	O
in	O
androgen-independent	O
LNCaP-Abl	O
cells.	O

In	O
the	O
urine	O
again,	O
there	O
were	O
higher	O
metabolites	O
related	O
to	O
saturated	O
FAs,	O
pentoses,	O
indoles,	O
amino	O
acids,	O
purines,	B
malates,	B
disaccharides,	B
dicarboxylic	B
acids,	I
hexuronic	O
acids,	O
hexoses,	O
phenylacetate	B
and	O
citrates	O
in	O
those	O
who	O
got	O
transplanted.	O

BJ	O
cells	O
were	O
treated	O
with	O
PPARα	O
agonist	O
(Ciprofibrate) or	O
DMSO	B
as	O
a	O
control.	O

Furthermore,	O
statin	B
use	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
reduced	O
incidence	O
of	O
advanced	O
colorectal	O
adenoma,	O
suggesting	O
a	O
preventive	O
role	O
in	O
the	O
malignant	O
transformation	O
of	O
adenomatous	O
tissue	O
(,	O
).	O

Amount	O
of	O
enzyme,	O
pH,	O
temperature	O
and	O
duration	B
of	O
incubation	O
were	O
evaluated	O
for	O
optimally	O
hydrolyzing	O
glucuronides.	O

This	O
is	O
illustrated	O
in	O
which	O
shows	O
that	O
those	O
who	O
report	O
feeling	O
more	O
rested	O
when	O
they	O
awake	O
in	O
the	O
morning	O
have	O
higher	O
melatonin	B
at	O
Time	O
T1,	O
followed	O
by	O
a	O
steeper	O
decline	O
over	O
the	O
night.	O

The	O
same	O
reagent	O
was	O
used	O
for	O
estimating	O
HDL	B
cholesterol	I
levels	O
after	O
the	O
precipitation	O
of	O
low-density	O
lipoprotein	O
(LDL)	O
and	O
very	O
low-density	O
lipoprotein	O
(VLDL)	O
with	O
dextran	O
sulfate-	B
Mg_2+	I
.	O

[_2	O
H_3	O
]-NNAL	O
(1	O
ng/mL	O
final	O
concentration)	O
internal	O
standard	O
solution	O
followed	O
by	O
addition	O
of	O
200	O
µL	O
of	O
sodium	B
phosphate	I
buffer	O
(1	O
M,	O
pH	O
6.8).	O

Hippurate	B
and	O
other	O
Phe-derivative	O
compounds	O
are	O
suggested	O
as	O
urinary	O
biomarkers	O
to	O
detect	O
heat-stressed	O
dairy	O
animals	O
in	O
practice.	O

Body	O
composition,	O
asthma	O
control,	O
and	O
the	O
levels	O
of	O
IL-1β,	B
-4,	O
-13,	O
leptin	O
and	O
adiponectin	O
in	O
obese	O
asthmatics	O
were	O
significantly	O
different	O
from	O
those	O
in	O
lean	O
asthmatics.	O

Further	O
steroid	O
hormone	O
biosynthesis	O
takes	O
place	O
on	O
the	O
endoplasmic	O
reticulum,	O
except	O
for	O
the	O
final	O
steps	O
in	O
glucocorticoid	B
and	O
mineralocorticoid	O
synthesis.	O

The	O
effect	O
of	O
adding	O
a	O
second	O
MTBE	B
extraction	O
step	O
was	O
also	O
investigated	O
to	O
examine	O
if	O
this	O
will	O
further	O
improve	O
the	O
metabolite	O
recovery.	O

For	O
both,	O
H.	O
pomatia	O
and	O
bovine	O
liver	O
GUS,	O
a	O
200-mM	O
acetate	B
buffer	O
(pH	O
4.5)	O
was	O
used	O
for	O
hydrolysis,	O
and	O
for	O
E.	O
coli	O
GUS,	O
a	O
hydrolysis	O
buffer	O
of	O
75 mM	O
phosphate	B
buffer	O
(pH	O
6.8)	O
was	O
used.	O

Moreover	O
the	O
ERα	O
activation	O
induces	O
proliferation	O
by	O
ERK/mitogen-activated	O
protein	O
kinase	O
(MAPK)	O
and	O
phosphatidylinositol-3	B
kinase	O
(PI3K)/AKT	O
pathways	O
and	O
reduces	O
the	O
pro-apoptotic	O
caspase-3	O
activation.	O

The	O
synthesis	O
of	O
GPLs	O
was	O
proved	O
to	O
be	O
a	O
key	O
factor	O
in	O
cancer	O
proliferation	O
as	O
it	O
is	O
mainly	O
responsible	O
for	O
membrane	O
and	O
energy	O
production._68	O
Because	O
GPL	O
synthesis	O
requires	O
acetyl‐CoA,	B
and	O
citrate	B
is	O
an	O
acetyl‐CoA	B
donor	O
for	O
this	O
process,	O
higher	O
lipid	O
metabolism	O
can	O
be	O
associated	O
with	O
elevated	O
tricarboxylic	B
acid	I
cycle	O
activity	O
in	O
GC._69	O
,	O
_70	O
As	O
previously	O
mentioned,	O
GC	O
showed	O
overall	O
higher	O
levels	O
of	O
FAs	O
than	O
CRC.	O

Urinary	O
metabolites	O
displaying	O
the	O
largest	O
differences	O
between	O
young	O
ASD	O
and	O
control	O
children	O
belonged	O
to	O
the	O
tryptophan	B
and	O
purine	B
metabolic	O
pathways.	O

Importantly,	O
this	O
high	O
specificity	O
is	O
critical	O
in	O
limiting	O
false	O
positive	O
matches	O
when	O
extending	O
the	O
chemical	O
networking	O
to	O
unknown	O
molecules	O
for	O
classification	O
as	O
oxylipins.	B

The	O
ATBC	O
Study	O
was	O
a	O
double-blind,	O
placebo-controlled,	O
primary	O
cancer	O
prevention	O
trial	O
designed	O
to	O
test	O
the	O
influence	O
of	O
supplementation	O
with	O
α-tocopherol	B
or	O
β-carotene	B
on	O
cancer	O
incidence.	O

(A)	O
Box	O
plots	O
from	O
Urine-0h	B
(B)	O
Box	O
plots	O
from	O
Urine-24h	B
samples.	O

Increases	O
in	O
dityrosine	B
levels	O
have	O
been	O
associated	O
with	O
pathologies	O
such	O
as	O
atherosclerosis,	O
Alzheimer’s	O
Disease,	O
and	O
so	O
on.	O

Low	O
cellular	O
PC	O
levels	O
have	O
been	O
shown	O
to	O
activate	O
sterol	O
regulatory	O
element-binding	O
protein-1	O
(SREBP1),	O
a	O
transcription	O
factor	O
involved	O
in	O
glucose	B
metabolism,	O
thereby	O
contribute	O
to	O
the	O
development	O
of	O
obesity,	O
insulin	O
resistance	O
and	O
fatty	O
liver	O
disease.	O

Levels	O
of	O
choline	B
did	O
not	O
differ	O
significantly	O
between	O
CKD	O
stages	O
and	O
controls.	O

Most	O
tumors	O
have	O
the	O
ability	O
to	O
break	O
down	O
glucose	B
by	O
glycolysis	O
at	O
a	O
vastly	O
higher	O
rate	O
than	O
in	O
normal	O
tissues,	O
even	O
in	O
the	O
presence	O
of	O
high	O
oxygen,	O
the	O
phenomenon	O
known	O
as	O
Warburg	O
effect.	O

Isocitrate,	B
hippurate,	B
cysteine,	B
and	O
phenylalanine	B
overlap	O
at	O
3.96–3.99ppm	O
and	O
are	O
therefore	O
characterized	O
as	O
isocitrate/hippurate/cysteine/phenylalanine	O
in	O
this	O
manuscript.	O

At	O
each	O
sampling	O
timepoint,	O
3 ml	O
of	O
blood	O
was	O
collected	O
in	O
lithium	B
heparin	I
tubes.	O

Alanine,	B
aspartate	B
and	O
glutamate	B
metabolism.	O

Trimethylamine	B
was	O
detected	O
only	O
in	O
speed-vacuumed	O
samples	O
(E).	O

Representative	O
MRM	O
chromatograms	O
of	O
paclitaxel	O
(A),	O
docetaxel	O
(B),	O
vinblastine	B
(C),	O
vinorelbine	O
(D),	O
pemetrexed	O
(E),	O
carboplatin	B
(F),	O
etoposide	B
(G),	O
cyclophosphamide	O
(H),	O
ifosfamide	B
(I),	O
gemcitabine	O
(J),	O
irinotecan	O
(K),	O
SN-38	O
(L),	O
and	O
vindoline	B
(M,	O
IS).	O

High	O
blood	O
glucose	B
and	O
diabetes	O
are	O
amongst	O
the	O
conditions	O
causing	O
the	O
greatest	O
losses	O
in	O
years	O
of	O
healthy	O
life	O
worldwide.	O

Given	O
the	O
finding	O
of	O
an	O
oxylipin-lowering	O
effect	O
of	O
ASA	O
in	O
contrast	O
to	O
a	O
trend	O
toward	O
an	O
increase	O
of	O
oxylipins	B
in	O
colon	O
tissue	O
from	O
statin-treated	O
patients,	O
we	O
then	O
decided	O
to	O
analyze	O
the	O
subset	O
of	O
patients	O
with	O
ASA-only	O
treatment	O
versus	O
those	O
receiving	O
ASA	O
and	O
statin	B
medication.	O

The	O
surgical	O
lasers	O
were	O
connected	O
to	O
a	O
mass	O
spectrometer	O
though	O
polytetrafluoroethylene	B
tubing	O
and	O
a	O
Venturi	O
gas	O
jet	O
pump,	O
similarly	O
to	O
the	O
iKnife	O
setup.	O

RESULTS:	O
MRI	O
data	O
showed	O
excellent	O
correlation	O
with	O
the	O
concentration	O
of	O
liver	O
triglycerides,	B
other	O
hepatic	O
lipid	O
components	O
and	O
the	O
histological	O
assessment,	O
which	O
excluded	O
the	O
presence	O
of	O
non-alcoholic	O
steatohepatitis	O
(NASH).	O

Statistical	O
testing	O
for	O
interaction	O
between	O
the	O
effects	O
of	O
ASA	O
and	O
statin	B
medication	O
yielded	O
P	O
values	O
<0.05	O
for	O
the	O
metabolites,	O
PGF_2a	O
,	O
PGE_2	O
,	O
PGD_2	O
,	O
PGJ_2	O
,	O
PGE_3	O
,	O
PGD_3	B
,	I
11-HETE,	I
and	O
13-HDHA,	O
pointing	O
toward	O
the	O
possibility	O
of	O
a	O
synergistic	O
effect	O
of	O
ASA	O
and	O
statin	B
medication	O
on	O
PG	B
suppression.	O

The	O
Gleason	O
grade	O
subgroups	O
according	O
to	O
International	O
Society	O
of	O
Urological	O
Pathology	O
(ISUP)	O
category	O
with	O
corresponding	O
stage	O
based	O
on	O
RP	B
histology	O
are	O
presented	O
in	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
(A)	O
and	O
ACN	O
modified	O
with	O
0.1%	O
formic	B
acid	I
(B).	O

In	O
their	O
data,	O
elevated	O
ceramide	B
levels	O
were	O
associated	O
with	O
antiretroviral	O
therapy	O
use,	O
particularly	O
with	O
the	O
PIs	O
use.	O

The	O
levels	O
of	O
each	O
species	O
of	O
HexCer	O
(C14:0,	O
C16:0,	B
C18:1,	B
C18:0,	B
C20:0,	B
C22:0,	B
C24:1,	B
C24:0,	B
C26:1	B
and	O
C26:0)	B
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
were	O
determined.	O

The	O
melatonin	B
is	O
reported	O
to	O
increase	O
progesterone	B
level	O
and	O
expression	O
of	O
progesterone	B
receptors	O
in	O
reproductive	O
tissues.	O

cabozantinib,	B
cobimetinib,	B
dabrafenib,	O
niraparib,	O
olaparib,	O
quantification	O
method,	O
regorafenib,	O
therapeutic	O
drug	O
monitoring,	O
UPLC–MS/MS,	O
vemurafenib	O

Red	O
C	O
and	O
green	O
C	O
represent	O
_13	O
C	O
labeled	O
carbons;	O
solid	O
and	O
dashed	O
arrows	O
denote	O
single	O
and	O
multi-step	O
reactions,	O
respectively;	O
open	O
arrows	O
in	O
panel	O
A	O
delineate	O
unlabeled	O
starting	O
oxaloacetate	B
(OAA)	O
from	O
_13	O
C-labeled	O
OAA	O
after	O
one	O
turn;	O
open	O
arrow	O
in	O
panel	O
B	O
denotes	O
the	O
start	O
of	O
a	O
second	O
cycle;	O
double	O
headed	O
arrows	O
indicate	O
reversible	O
or	O
exchange	O
reactions;	O
SCS	O
denotes	O
succinyl	O
CoA	O
synthetase.	O

Fasting,	O
EDTA	O
prepared	O
plasma	O
specimens	O
collected	O
in	O
2005-2008	O
from	O
N=1500	O
participants	O
(mean	O
age	O
66.2±9.0	O
years,	O
55%	O
women)	O
of	O
the	O
community-based	O
Framingham	O
Heart	O
Study	O
Offspring	O
Cohort,	O
were	O
used	O
for	O
analyses	O
of	O
oxylipins	B
in	O
human	O
inflammation.	O

Suspension	O
culture	O
was	O
achieved	O
using	O
plates	O
coated	O
with	O
12	O
mg/mL	O
poly(2-hydroxyethyl	B
methacrylate)	I

Insulin	O
and	O
HOMA	O
plasma	O
levels	O
after	O
simvastatin	B
treatment	O
correlated	O
(p	O
<	O
0.05)	O
primarily	O
with	O
post-treatment	O
amino	O
acids	O
and	O
fatty	O
acids,	O
several	O
of	O
which	O
were	O
also	O
correlated	O
at	O
baseline.	O

Jeng	O
et	O
al[]	O
showed,	O
with	O
an	O
HPLC-based	O
study	O
in	O
Taiwanese	O
subjects,	O
that	O
the	O
nucleosides	O
adenosine,	O
cytidine	B
and	O
inosine	B
were	O
elevated	O
in	O
the	O
urine	O
of	O
patients	O
affected	O
by	O
HCC	O
and	O
if	O
joined	O
with	O
serum	O
levels	O
of	O
AFP,	O
the	O
diagnosis	O
of	O
cancer	O
was	O
reached	O
with	O
a	O
sensivity	O
of	O
80%[].	O

with	O
minor	O
modifications	O
to	O
determine	O
plasma	O
fatty	O
acids	O
as	O
methyl	B
esters.	I

We	O
also	O
investigated	O
the	O
possible	O
association	O
between	O
PPARgamma	O
Pro12Ala	O
polymorphism	O
and	O
dementia	O
or	O
24S-OH-Chol	B
levels.	O

EVs	O
from	O
both	O
sources	O
were	O
rich	O
in	O
D-Ribose	B
5-phosphate,	I
the	O
most	O
abundant	O
metabolite	O
in	O
pEVs	O
and	O
3_rd	O
most	O
abundant	O
in	O
uEVs,	O
and	O
other	O
metabolites	O
involved	O
in	O
nucleotide	O
metabolism	O
in	O
mostly	O
>	O
10	O
µM	O
to	O
mM	O
range.	O

In	O
the	O
case	O
of	O
the	O
control	O
sample	O
singled	O
out	O
as	O
outlier,	O
it	O
presented	O
very	O
intense	O
glucose	B
signals	O
that	O
overshadowed	O
the	O
rest	O
of	O
the	O
NMR	O
spectrum,	O
which	O
was	O
compatible	O
with	O
the	O
maternal	O
diagnosis	O
of	O
suboptimally	O
controlled	O
gestational	O
diabetes.	O

Cartridges	O
were	O
washed	O
with	O
1	O
mL	O
2%	O
formic	B
acid	I
and	O
1	O
mL	O
methanol	B
and	O
dried	O
under	O
vacuum	O
for	O
15	O
min.	O

lysoPC(16:0)	B
and	O
lysoPC(18:0)	B
are	O
the	O
two	O
most	O
abundant	O
lysophosphatidylcholines	B
measured	O
in	O
plasma.	O

Taurine	B
was	O
previously	O
shown	O
to	O
be	O
increased	O
in	O
serum	O
of	O
60	O
colorectal	O
cancer	O
patients	O
compared	O
to	O
60	O
apparently	O
healthy	O
individuals	O
13	O
and	O
in	O
tumor	O
tissue	O
of	O
16	O
colorectal	O
cancer	O
patients;	O
24	O
which	O
is	O
in	O
agreement	O
with	O
our	O
findings.	O

Cell	O
lines	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
the	O
_13	O
C-labeled	O
glucose	B
for	O
18	O
h.	O
shows	O
that	O
suppression	O
of	O
PC	O
decreased	O
the	O
incorporation	O
of	O
glucose	B
carbon	O
into	O
palmitate.	B

Specifically,	O
12,13-dihydroxy	B
octadecaenoic	O
acid	O
(12,13-DiHOME),	O
9,10-dihydroxy	B
octadecaenoic	O
acid	O
(9,10-DiHOME),	O
and	O
15,16-dihydroxy	B
octadecadienoic	O
acid	O
(15,16-DiHODE)	O
postprandially	O
increased	O
in	O
abundance	O
in	O
both	O
the	O
esterified	O
and	O
non-esterified	O
pools.	O

We	O
also	O
observed	O
downregulation	O
of	O
genes	O
that	O
encoded	O
enzymes	O
that	O
catalyse	O
the	O
degradation	O
of	O
phosphocholine	B
into	O
choline	B
metabolite,	O
mainly	O
from	O
the	O
phospholipase	O
D	O
(PLD)	O
family:	O
PLB1,	O
PLD1,	O
PNPLA7,	O
PLA2G12B,	O
PLA2G4C	O
(B).	O

Two	O
potential	O
C_24	O
bile	O
acids	O
were	O
identified,	O
the	O
latter	O
eluting	O
a	O
peak	O
of	O
which	O
has	O
a	O
mass	O
and	O
gave	O
MS_2	O
and	O
MS_3	O
spectra	O
compatible	O
with	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid,	I
which	O
is	O
a	O
precursor	O
of	O
chenodeoxycholic	B
acid.	I

Testosterone	B
was	O
not	O
detected	O
at	O
either	O
timepoint.	O

A	O
striking	O
observation	O
was	O
the	O
total	O
absence	O
of	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
(LCPUFAs)	O
in	O
GGs	O
of	O
the	O
retina	O
and	O
brain	O
considering	O
that	O
these	O
tissues	O
contain	O
very	O
high	O
amounts	O
of	O
LCPUFAs,	O
especially	O
docosahexaenoic	B
acid	I
(22:6	O
DHA):	O
about	O
20	O
and	O
7%	O
of	O
total	O
FAs	O
in	O
the	O
retina	O
and	O
brain	O
cerebrum,	O
respectively.	O

The	O
supernatant	O
was	O
transferred	O
to	O
glass	O
tubes,	O
evaporated	O
to	O
dryness,	O
reconstituted	O
with	O
100	O
µL	O
toluene	B
(dried	O
over	O
anhydrous	B
sodium	I
sulfate),	I
and	O
again	O
taken	O
to	O
dryness.	O

m	O
Analysis	O
of	O
β-apo-13-carotenone	B
in	O
human	O
plasma	O
by	O
HPLC/MS.	O

The	O
discovery	O
of	O
phenylacetylglutamine	B
in	O
‘PRE’	O
urine	O
might	O
be	O
partially	O
explained	O
by	O
the	O
action	O
of	O
colonic	O
microflora	O
on	O
protein-derived	O
phenylalanine	B
following	O
exposure	O
to	O
the	O
high	O
protein	O
content	O
of	O
the	O
standardized	O
evening	O
meal	O
(Clayton	O
et	O
al.	O
),	O
but	O
could	O
also	O
reflect	O
the	O
microbial	O
fermentation	O
of	O
aromatic	O
components	O
from	O
previous	O
dietary	O
phytochemical	O
intake	O
(Holmes	O
et	O
al.	O
),	O
or	O
from	O
the	O
chocolate	O
component	O
of	O
the	O
evening	O
meal	O
chocolate	O
éclair	O
(Rezzi	O
et	O
al.	O
).	O

Of	O
further	O
relevance,	O
RBC	O
possess	O
lactate	O
dehydrogenase	O
(LDH)	O
(EC	O
1.1.1.27)	O
which	O
catalyzes	O
the	O
conversion	O
of	O
α-ketobutyrate	B
to	O
2-hydroxybutyrate,	B
a	O
pathway	O
that	O
may	O
be	O
involved	O
in	O
the	O
human	O
inflammatory	O
response	O
to	O
endotoxin.	B

We	O
found	O
significantly	O
increased	O
levels	O
of	O
methionine	B
(↑	O
SP-RR)	O
and	O
the	O
methylated	B
adenine	I
residue	O
1-methyladenosine	B
(↑	O
SP-RR,	O
↑	O
SP-C)	O
in	O
SPMS	O
patients.	O

Although	O
there	O
were	O
expected	O
differences	O
in	O
medication	O
use	O
between	O
GWI	O
and	O
controls,	O
the	O
metabolomic	O
profile	O
described	O
below	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
observed	O
medication	O
uses	O
and	O
none	O
is	O
known	O
to	O
produce	O
a	O
pattern	O
of	O
increased	O
phospholipids	B
and	O
sphingolipids	B
found.	O

The	O
aim	O
was	O
to	O
study	O
the	O
effect	O
of	O
pioglitazone	B
on	O
intramyocellular	O
fat	O
metabolism.	O

In	O
addition,	O
high	O
values	O
of	O
the	O
model’s	O
goodness-of-fit	O
metrics	O
(R2Y	O
=	O
0.84,	O
Q2	O
=	O
0.44	O
and	O
R2Y	O
=	O
0.81,	O
Q2	O
=	O
0.43	O
for	O
Urine-0h	B
and	O
-24h,	O
respectively)	O
indicated	O
robustness	O
and	O
reproducibility.	O

Ice-cold	O
solvent	O
mixture	O
(900	O
µl	O
of	O
chloroform∶methanol,	B
1∶2v/v)	O
was	O
added	O
to	O
100	O
µl	O
of	O
plasma	O
sample,	O
vortexed,	O
and	O
incubated	O
on	O
ice	O
in	O
a	O
vacuum	O
chamber	O
in	O
a	O
dark	O
room	O
for	O
1	O
h	O
with	O
agitation.	O

25	O
μM	O
thymine-d_4	B
[Sigma-Aldrich,	O
St.	O
Louis,	O
MO],	O
10	O
μM	O
inosine-15N_4	B
[Cambridge	O
Isotope	O
Laboratories,	O
Tewksbury,	O
MA],	O
25	O
μM	O
phenylalanine-d_8	B
[Cambridge	O
Isotope	O
Laboratories],	O
and	O
10	O
μM	O
valine	B

Comparison	O
of	O
general	O
sequencing	O
characteristics	O
between	O
the	O
soymilk	O
and	O
control	O
groups	O
revealed	O
significant	O
differences	O
in	O
coverage	O
(P	O
 = 0.009),	O
number	O
of	O
mapped	O
fragments	O
(P	O
 = 0.012)	O
and	O
library	O
size	O
upon	O
data	O
summary	O
(P	O
 = 0.003),	O
despite	O
sample	O
randomization	O
before	O
gDNA	O
extraction	O
and	O
MethylCap-seq.	B

These	O
OzID	O
signals	O
can	O
thus	O
be	O
used	O
to	O
assign	O
the	O
structure	O
of	O
the	O
sphingomyelin	B
eluting	O
at	O
this	O
time	O
to	O
SM	B
d18:2(n	I
-4)/22:0,	I
while	O
the	O
other	O
two	O
contributors,	O
SM	B
d18:1/22:1	I
and	O
SM	B
d16:1/24:1,	I
can	O
be	O
excluded	O
from	O
consideration	O
(in	O
this	O
retention	O
time	O
slice)	O
as	O
no	O
losses	O
characteristic	O
of	O
the	O
expected	O
n	O
-7	O
or	O
n	O
-9	O
sites	O
of	O
unsaturation	O
in	O
the	O
associated	O
side	O
chains	O
were	O
observed.	O

Exposure	O
to	O
bacterial	O
pathogens	O
can	O
rapidly	O
activate	O
the	O
plasma	O
contact	O
system,	O
triggering	O
the	O
release	O
of	O
bradykinin	B
(BK)	O
and	O
its	O
metabolite	O
desArg_9	O
-bradykinin	O
(DABK)	O
to	O
induce	O
inflammation	O
and	O
innate	O
immune	O
responses.	O

(A)	O
Expansion	O
of	O
the	O
spectrum	O
where	O
the	O
betaine	B
region	O
is	O
extracted	O
for	O
lineshape	O
deconvolution.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
age,	O
sex,	O
TG,	B
and	O
HDL-C	O
between	O
healthy	O
and	O
stroke	O
groups.	O

In	O
other	O
words,	O
abnormal	O
NMDA	O
receptor	O
signaling	O
may	O
be	O
the	O
unifying	O
mechanism	O
underlying	O
the	O
glutamate	B
and	O
inflammation	O
hypotheses	O
of	O
depression	O
(;	O
;	O
).	O

3-HPMA	O
is	O
a	O
major	O
metabolite	O
of	O
acrolein	B
in	O
laboratory	O
animals.	O

Abundant	O
BCAAs	O
directly	O
inhibit	O
mitochondrial	O
respiratory	O
function,	O
leading	O
to	O
superoxide	B
accumulating	O
in	O
the	O
mitochondria	O
of	O
cardiomyocytes.	O

Merchant	O
et	O
al.	O
investigated	O
the	O
phospholipid	B
content	O
in	O
43	O
malignant	O
breast	O
tissues	O
obtained	O
from	O
patients	O
undergoing	O
surgery.	O

The	O
chloroform	B
layers	O
were	O
combined	O
for	O
analysis.	O

Afterwards,	O
the	O
metabolites	O
were	O
eluted	O
with	O
6	O
mL	O
methanol	B
containing	O
0.0004%	O
w/v	O
BHT	O
into	O
a	O
glass	O
tube	O
containing	O
10	O
μL	O
of	O
30%	O
glycerol	B
in	O
methanol.	B

In	O
the	O
past,	O
BCFA	O
and	O
valerate	B
have	O
been	O
associated	O
with	O
an	O
augmented	O
risk	O
of	O
developing	O
CRC	O
principally	O
because	O
protein	O
fermentation	O
has	O
been	O
tied	O
in	O
with	O
a	O
high	O
protein	O
intake.	O

The	O
heat	O
maps	O
demonstrate	O
(A)	O
relatively	O
decreased	O
amino	O
acids,	O
with	O
a	O
rise	O
over	O
time,	O
and	O
(B)	O
reduced	O
vitamin	O
and	O
antioxidant	O
substrates	O
(niacinamide	O
and	O
biotin)	O
and	O
increased	O
oxidative	O
catabolites	O
(propionate	O
and	O
4-pyridoxic	B
acid).	O

The	O
results	O
revealed	O
several	O
significant	O
metabolites–microbe	O
relationships,	O
including	O
strongly	O
positive	O
association	O
between	O
glycine	B
level	O
and	O
Clostridium	O
,	O
positive	O
correlation	O
of	O
homocysteine	B
with	O
Lachnospira,	O
Clostridium	O
and	O
Haemophilus	O
,	O
and	O
negative	O
association	O
of	O
homocysteine	B
with	O
Corynebacterium	O
and	O
Lachnospiraceae	O
.	O

It	O
has	O
also	O
been	O
shown	O
that,	O
before	O
neuronal	O
dysfunction	O
develops,	O
mice	O
heterozygous	O
for	O
GLUT1	O
(Slc2a1)	O
at	O
the	O
BBB	O
develop	O
cerebral	O
blood	O
flow	O
perfusion	O
deficits	O
and	O
BBB	O
breakdown	O
that	O
leads	O
to	O
vascular-mediated	O
neurodegeneration:	O
the	O
relevance	O
of	O
this	O
study	O
in	O
engineered	O
mice	O
to	O
our	O
findings	O
in	O
human	O
brain	O
is	O
uncertain,	O
given	O
that	O
these	O
authors	O
did	O
not	O
report	O
brain-glucose	B
levels.	O

Some	O
polar	O
metabolites	O
(creatine,	O
creatinine,	B
proline	B
betaine,	I
citrate,	B
glutamate,	B
carnitine,	B
acetylcarnitine)	B
were	O
quantified	O
more	O
accurately	O
by	O
DI–nESI–HRMS.	O

Interestingly,	O
oxidative	O
cleavage	O
of	O
the	O
n	O
-14	O
double	O
bond	O
in	O
the	O
sphingadiene	B
SM	I
d18:2/22:0	I
was	O
not	O
observed,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
of	O
the	O
sluggish	O
reaction	O
rate	O
of	O
the	O
allylic	B
alcohol	I
motif	O
in	O
sphingolipids.	B

In	O
general,	O
tumor	O
tissue	O
has	O
depleted	O
glucose	B
and	O
increased	O
citrate	B
and	O
succinate,	B
the	O
TCA	O
intermediates,	O
reflecting	O
high	O
TCA	O
cycle	O
activity	O
to	O
maintain	O
tumor	O
promotion[,].	O

A	O
study	O
by	O
Calejo	O
et	O
al	O
revealed	O
that	O
2-methylbutanal	B
had	O
a	O
higher	O
level	O
of	O
concentration	O
in	O
the	O
urine	O
samples	O
of	O
smokers	O
compared	O
with	O
non-smokers.	O

Urinary	O
creatinine	B
levels	O
were	O
determined	O
using	O
the	O
alkaline-picrate	B
(Jaffe)	O
reaction.	O

The	O
mean	O
metabolite-level	O
percentile	O
was	O
lowest	O
in	O
those	O
who	O
reported	O
no	O
coffee	O
consumption	O
and	O
increased	O
with	O
increasing	O
coffee	O
intake;	O
e.g.,	O
non-,	O
low,	O
and	O
high	O
coffee	O
drinkers	O
had	O
mean	O
trigonelline	B
(N	O
′-methylnicotinate)	B
levels	O
in	O
the	O
17th,	O
44th,	O
and	O
65th	O
percentiles	O
of	O
the	O
distribution,	O
respectively.	O

Supplementation,	O
however,	O
presumably	O
contributes	O
to	O
the	O
prominent	O
accumulation	O
of	O
the	O
B6	O
metabolite	O
4-pyridoxic	B
acid,	I
providing	O
an	O
example	O
of	O
the	O
unintended	O
consequences	O
of	O
drug	O
administration	O
in	O
dialysis	O
patients[].	O

This	O
solution	O
was	O
diluted	O
to	O
70%	O
ethanol	B
by	O
the	O
addition	O
of	O
0.4	O
ml	O
of	O
water,	O
ultrasonicated	O
for	O
2	O
min,	O
and	O
centrifuged	O
at	O
14,000	O
×	O
g	O
at	O
4	O
°C	O
for	O
30	O
min.	O

In	O
the	O
quetiapine	B
group,	O
1	O
patient	O
with	O
increased	O
blood	O
pressure	O
was	O
withdrawn	O
from	O
the	O
study	O
because	O
of	O
this	O
adverse	O
event.	O

This	O
is	O
in	O
line	O
with	O
past	O
literature	O
reporting	O
an	O
increase	O
in	O
decanoic	B
acid	I
42 days	O
after	O
RYGB.31	O
Decanoic	B
acid	I
is	O
a	O
medium	O
chain	O
FA	B
(MCFA).	O

A	O
standard	O
technique	O
was	O
employed	O
in	O
which	O
BALF	O
was	O
collected	O
by	O
bronchoscopy	O
in	O
which	O
150	O
ml	O
of	O
normal	O
saline	B
was	O
instilled	O
into	O
the	O
right	O
middle	O
lobe	O
or	O
lingula	O
in	O
30	O
ml	O
aliquots	O
and	O
was	O
retrieved	O
by	O
gentle	O
suctioning	O
through	O
the	O
suction	O
port	O
of	O
the	O
bronchoscope.	O

A.	O
N-acetylneuraminic	B
acid-9-phosphate;	I
B.	O
5’-methioadenosine;	B
C.	O
Uric	O
acid-3-nucleoside;	O
D.	O
Pseudouridine;	B
E.	O
L-valine;	B
F.	O
Succinic	B
acid;	I
G.	O
L-proline;	B
H.	O
β-nicotinamide	B
mononucleotide.	O

Analysis	O
of	O
the	O
OPLS-DA	O
loadings	O
reveals	O
that	O
the	O
differences	O
in	O
timepoints	O
was	O
based	O
on	O
the	O
differential	O
abundance	O
of	O
glucopyranose,	B
citric	B
acid,	I
butanoic	B
acid,	I
erythritol	B
and	O
ribitol	B
between	O
the	O
three	O
groups	O
(N =	O

To	O
confirm	O
the	O
potential	O
value	O
of	O
glutamate	B
as	O
a	O
marker	O
for	O
lung	O
inflammation,	O
a	O
PLS-LDA	O
analysis	O
was	O
performed	O
to	O
discriminate	O
between	O
patients	O
with	O
lung	O
inflammation	O
and	O
controls.	O

In	O
summary,	O
using	O
shotgun	O
lipidomics,	O
we	O
demonstrate	O
significant	O
disruptions	O
in	O
the	O
sphingolipidome	B
in	O
plasma	O
obtained	O
from	O
AD	O
patients	O
compared	O
to	O
normal	O
controls.	O

Kyn	O
can	O
be	O
further	O
metabolized	O
to	O
give	O
rise	O
to	O
kynurenic	B
acid,	I
cinnabarinic	O
acid,	O
xanthurenic	B
acid,	I
picolinic	B
acid,	I
quinolinic	B
acid,	I
and	O
NAD_+	O
(;	O
;	O
).	O

The	O
injection	O
volume	O
was	O
300 μL	O
and	O
the	O
injector	O
needle	O
was	O
washed	O
with	O
methanol	B
for	O
5 s	O
prior	O
to	O
each	O
injection.	O

FFA	O
and	O
ADIPO-IR,	O
reflecting	O
inability	O
of	O
insulin	O
to	O
suppress	O
peripheral	O
lipolysis,	O
were	O
higher	O
in	O
the	O
IGT	O
and	O
T2DM	O
groups,	O
and	O
the	O
difference	O
was	O
highly	O
significant	O
even	O
after	O
BMI	O
adjustment;	O
there	O
were	O
no	O
differences	O
in	O
total	O
cholesterol	B
or	O
LDL.	O

For	O
each	O
of	O
the	O
listed	O
pathways	O
the	O
respective	O
metabolites	O
identified	O
are	O
listed	O
below:	O
Glycine	B
and	O
serine	B
metabolism:	O
Glycine,	B
L-arginine,	B
L-methionine	B
(3/53);	O
glycerol	B
phosphate	I
shuttle:	O
Hydroquinone	B
(1/11);	O
methionine	B
metabolism:	O

180	O
µl	O
of	O
an	O
I.S.	O
consisting	O
of	O
1,2,3-tripentadecanoylglycerol	B
[TG(15:0)_3	I
],	I
1,2-diheptadecanoyl-sn	O
-glycero-3-phosphocholine	O
[PC(17:0/17:0],	O
1,2-dimyristoyl-sn	B
-glycero-3-[phospho-rac-(1-glycerol)]	I

A	O
sucrose	B
tune	O
file	O
in	O
negative/positive	O
modes	O
at	O
normal	O
LC	O
flow	O
rate	O
was	O
used.	O

To	O
investigate	O
the	O
efficiency	O
and	O
reproducibility	O
of	O
intracellular	O
metabolite	O
extraction,	O
different	O
volumes	O
and	O
ratios	O
of	O
chloroform	B
were	O
tested.	O

Furthermore,	O
an	O
experimental	O
study	O
in	O
rats	O
demonstrated	O
that	O
T4	O
administration	O
leads	O
besides	O
an	O
increased	O
rate	O
of	O
glucose	B
production	O
in	O
isolated	O
livers,	O
also	O
leads	O
to	O
an	O
increased	O
transport	O
of	O
alanine	B
in	O
hepatocytes	O
arguing	O
for	O
an	O
enhanced	O
conversion	O
of	O
alanine	B
into	O
glucose.	B

The	O
suppression	O
in	O
solvent-based	O
extractions	O
in	O
–ESI	O
RP	B
(,	O
and	O
)	O
affected	O
wider	O
range	O
of	O
analytes	O
than	O
in	O
+ESI	O
and	O
extends	O
toward	O
neutral	O
mid-hydrophobic	O
analytes	O
(cortisol	O
and	O
cortisone),	O
while	O
organic	O
acids	O
(folic,	O
pantothenic,	B
homovanillic	O
and	O
cholic)	O
remained	O
unaffected.	O

Notably,	O
after	O
LPS	B
stimulation	O
Ch25h	O
-deficient	O
macrophages	O
overproduce	O
Il1b	O
.	O

Low	O
background	O
levels	O
of	O
1,2-NPQ-Alb	B
and	O
1,4-NPQ-Alb	B
were	O
found	O
in	O
control	O
animals.	O

For	O
each	O
of	O
the	O
listed	O
pathways,	O
the	O
respective	O
metabolites	O
identified	O
are	O
listed	O
below:	O
Glycine	B
and	O
serine	B
metabolism:	O
L-arginine	B
and	O
L-methionine	B
(2/59);	O
glycerol	B
phosphate	I
shuttle:	O
Hydroquinone	B
(1/11);	O
ketone	B
body	O
metabolism:	O
Acetone	B
(1/13);	O
spermidine	B
and	O
spermine	B
biosynthesis:	O
L-methionine	B
(1/18);	O
riboflavin	B
metabolism:	O
Hydroquinone	B
(1/20);	O
betaine	B
metabolism:	O
L-methionine	B
(1/21);	O
glycerolipid	B
metabolism:	O
Hydroquinone	B
(1/25);	O
urea	B
cycle:	O
L-arginine	B
(1/29);	O
beta-alanine	B
metabolism:	O
Uracil	B
(1/34);	O
aspartate	B
metabolism:	O
L-arginine	B
(1/35);	O
methionine	B
metabolism:	O
L-methionine	B
(1/43);	O
arginine	B
and	O
proline	B
metabolism:	O
L-arginine	B
(1/53);	O
pyrimidine	B
metabolism:	O
Uracil	B
(1/59);	O
bile	O
acid	O
biosynthesis:	O
Cholic	B
acid	I
(1/65).	O

CHCl_3	O
:water	O
ext	O
+UF;	O
and	O
the	O
concentrations	O
of	O
12	O
compounds	O
were	O
different	O
between	O
MeOH	B
ppts	O
with	O
and	O
without	O
UF	O
(Table	O
S1,	O
).	O

In	O
addition,	O
the	O
association	O
of	O
the	O
mQTLs	O
with	O
the	O
metabolites	O
glycine,	B
carnitine,	B
proline,	B
pyruvate,	B
lysine	B
and	O
valine	B
did	O
not	O
change	O
after	O
adjustment	O
for	O
BMI.	O

The	O
urine,	O
plasma	O
and	O
polar	O
tissue	O
extract	O
samples	O
contained	O
mainly	O
a	O
series	O
of	O
amino	O
acids,	O
glucose	B
and	O
lipids,	O
while	O
the	O
non-polar	O
tissue	O
extract	O
samples	O
contained	O
the	O
minimum	O
metabolites,	O
dominated	O
mainly	O
by	O
triglycerides	B
(TG).	O

Serum	O
folate	B
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
high–cystathionine	B
concentration	O
group,	O
but	O
the	O
subjects	O
were	O
not	O
considered	O
deficient.	O

Binding	O
site	O
was	O
defined	O
by	O
choosing	O
arachidonic	B
acid	I
as	O
a	O
reference	O
ligand,	O
to	O
which	O
all	O
coordinates	O
were	O
computed.	O

Hierarchical	O
clustering	O
analysis	O
and	O
detailed	O
metabolite	O
level	O
measurement	O
showed	O
that	O
the	O
high	O
glucose	B
group	O
had	O
increased	O
lactate-to-pyruvate	O
ratio,	O
reduction	O
in	O
TCA	O
cycle	O
metabolites	O
and	O
anti-oxidative	O
capacity	O
(as	O
represented	O
by	O
the	O
cellular	O
glutathione	B
levels),	O
and	O
increase	O
in	O
cellular	O
methylation	O
potential	O
(as	O
represented	O
by	O
the	O
elevated	O
SAM-to-SAH	O
level).	O

FAB-M3	O
samples	O
were	O
not	O
included	O
in	O
this	O
study	O
because	O
most	O
of	O
those	O
patients	O
were	O
treated	O
by	O
more	O
effective	O
chemotherapy	O
with	O
all-trans	O
retinoic	B
acid.	I

We	O
have	O
demonstrated	O
that	O
supplementation	O
with	O
2 g	O
carnosine	B
daily	O
for	O
12	O
weeks	O
resulted	O
in	O
changes	O
in	O
plasma lipidome	O
which	O
were	O
associated	O
with	O
improved	O
insulin	O
sensitivity	O
and	O
secretion	O
as	O
well	O
as	O
serum	O
carnosinase	O
1	O
activity.	O

Three	O
metabolites,	O
alanine	B
[,	O
],	O
threonine	B
[,	O
],	O
and	O
tyrosine	B
[,	O
],	O
were	O
found	O
to	O
be	O
concordant	O
with	O
results	O
from	O
our	O
study	O
as	O
well	O
as	O
across	O
reported	O
literature.	O

A	O
constant	O
peak	O
area	O
for	O
the	O
parent	O
analyte	O
before	O
and	O
after	O
hydrolysis	O
indicated	O
hydrolysis	O
failure	O
or	O
that	O
there	O
was	O
no	O
glucuronide	B
present	O
in	O
the	O
sample.	O

p-Cresol	B
sulfate	I
alteration	O
is	O
a	O
novel	O
finding	O
and	O
may	O
indicate	O
an	O
altered	O
sulfonation	O
capacity	O
of	O
the	O
liver	O
in	O
patients	O
with	O
HCC.	O

This	O
aspect	O
further	O
supports	O
that	O
strong	O
H	O
bonding	O
between	O
bicarbonate	O
and	O
the	O
phosphate	B
choline	I
headgroup	O
in	O
the	O
PC	O
is	O
key	O
for	O
the	O
ions	O
to	O
access	O
higher	O
energy	O
of	O
activation	O
under	O
CID,	O
which	O
promotes	O
the	O
radical-directed	O
fragmentation	O
as	O
compared	O
to	O
low-energy	O
CID	O
conditions.	O

This	O
fact	O
is	O
clearly	O
seen	O
in	O
the	O
MRM	O
single-voxel	O
spectrum	O
of	O
sample	O
G	O
(,	O
middle	O
spectrum);	O
the	O
main	O
resonances	O
were	O
assigned	O
to	O
lactate,	B
alanine,	B
lipids,	O
creatine,	B
choline,	B
and	O
phosphocholine,	B
glycine	B
and	O
mannitol	B
(peaks	O
are	O
assigned	O
in	O
,	O
top	O
spectrum).	O

We	O
observed	O
that	O
circulating	O
levels	O
of	O
20-HETE	B
were	O
significantly	O
higher	O
in	O
patients	O
with	O
atheroma	O
plaque	O
than	O
in	O
healthy	O
subjects	O
(p	O
=	O
0.018).	O

A	O
sensitive	O
and	O
selective	O
ultra‐high	O
performance	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(UPLC–MS/MS)	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
seven	O
oral	O
oncolytics	O
(two	O
PARP	O
inhibitors,	O
i.e.	O
olaparib	O
and	O
niraparib,	O
and	O
five	O
tyrosine	B
kinase	O
inhibitors,	O
i.e.	O
cobimetinib,	B
cabozantinib,	B
dabrafenib,	O
vemurafenib	O
and	O
regorafenib,	O
plus	O
its	O
active	O
metabolite	O
regorafenib	O
M2)	O
in	O
EDTA	O
plasma	O
was	O
developed	O
and	O
validated.	O

As	O
expected,	O
FPG,	O
2 h	O
plasma	O
glucose	B
(2hPG)	O
and	O
fasting	O
insulin	O
(FINS)	O
in	O
T2DM-CHD	O
and	O
T2DM	O
were	O
higher	O
compared	O
to	O
the	O
controls	O
(p	O
 < 0.05),	O
particularly	O
in	O
T2DM-CHD	O
(p	O
 < 0.0001).	O

In	O
mouse	O
models,	O
exposure	O
to	O
silica	B
dust	O
leads	O
to	O
metabolomic	O
alterations	O
after	O
lung	O
inflammation.	O

Metabolite,	O
Hypoxanthine,	B
Phosphoenolpyruvate,	B
Rectal	O
neoplasms,	O
Chemoradiotherapy,	O
Low-mass	O
ions	O

Carnitine-acylcarnitine	O
translocase	O
(CACT,	O
gene	O
symbol:	O
SLC25A29)	O
plays	O
a	O
role	O
in	O
transporting	O
both	O
carnitine-FA	B
complexes	O
and	O
carnitine	B
across	O
the	O
inner	O
mitochondrial	O
membrane	O
for	O
beta-oxidation.	O

Benefit	O
from	O
the	O
addition	O
of	O
lapatinib	B
over	O
paclitaxel	O
alone	O
was	O
restricted	O
to	O
patients	O
with	O
HER2‐positive	O
disease.	O

What’s	O
more,	O
some	O
studies	O
have	O
reported	O
that	O
changed	O
concentrations	O
of	O
lysoPCs	O
are	O
associated	O
with	O
the	O
risk	O
of	O
T2DM,	O
especially	O
lysoPC(18:2),	B
which	O
was	O
significantly	O
altered	O
in	O
patients	O
with	O
impaired	O
glucose	B
tolerance	O
(IGT)	O
and	O
was	O
identified	O
as	O
an	O
IGT-specific	O
biomarker.	O

Elevated	O
level	O
of	O
alanine,	B
which	O
is	O
also	O
another	O
important	O
end	O
product	O
of	O
glycolysis/glutaminolysis,	O
was	O
found	O
in	O
HNSCC	O
and	O
metastatic	O
tissues	O
and	O
it	O
has	O
been	O
found	O
to	O
be	O
a	O
major	O
source	O
of	O
energy	O
in	O
tumor	O
proliferation	O
and	O
growth.	O

In	O
addition,	O
the	O
association	O
of	O
the	O
mQTLs	O
with	O
the	O
metabolites	O
glycine,	B
carnitine,	B
proline,	B
pyruvate,	B
lysine	B
and	O
valine	B
did	O
not	O
change	O
after	O
adjustment	O
for	O
BMI.	O

The	O
following	O
selective	O
media	O
were	O
used:	O
Plate	O
count	O
agar	O
(total	O
facultative	O
aerobes	O
and	O
anaerobes);	O
MRS	O
agar	O
(lactobacilli	O
and	O
enterococci);	O
Bifidobacterium	O
agar	O
modified	O
(bifidobacteria)	O
(Becton	O
Dickinson	O
France	O
SA,	O
Le	O
Pont	O
de	O
Claix,	O
France);	O
M17	O
(lactococci	O
and	O
streptococci);	O
Mannitol	B
salt	O
agar	O
(stafilococci);	O
Wilkins-Chalgren	O
anaerobe	O
agar	O
(total	O
anaerobes);	O
Wilkins-Chalgren	O
anaerobe	O
agar	O
plus	O
GN	O
selective	O
supplements	O
and	O
sheep	O
blood	O
defibrinated	O
(Bacteroides	O
,	O
Porphyromonas	O
and	O
Prevotella	O
);	O
Reinforced	O
Clostridial	O
Medium	O
supplemented	O
with	O
8	O
mg/L	O
novobiocin,	B
8	O
mg/L	O
colistin	O
(Clostridium	O
);	O
MacConkey	O
agar	O
No2	O
(Enterobacteria);	O
Rogosa	O
agar	O
plus	O
1.32	O
mL/L	O
of	O
glacial	B
acetic	I
acid	I
(lactobacilli);	O

Microbiota	O
of	O
donor	O
D4	O
were	O
not	O
very	O
effective	O
in	O
metabolizing	O
either	O
resveratrol	B
or	O
thunalbene	B
but	O
were	O
as	O
efficient	O
as	O
an	O
inoculum	O
of	O
donor	O
D5	O
by	O
dehydroxylating	O
piceatannol.	O

Based	O
on	O
these	O
results,	O
we	O
performed	O
a	O
multiple-regression	O
analysis	O
to	O
determine	O
independent	O
predictors	O
of	O
SBP	O
and	O
DBP.	B

ALDH7A1-depleted	O
cells	O
also	O
showed	O
an	O
increase	O
in	O
invasiveness	O
using	O
a	O
Matrigel	O
trans-well	B
invasion	O
assay	O
(Fig.	O

depicts	O
the	O
fragmentation	O
patterns	O
for	O
bile	O
acid	O
metabolites	O
3-sulfo-GCDCA,	B
TCA,	O
S-1-P	O
and	O
LysoPC	O
16:0.	O
presents	O
average	O
peak	O
intensities	O
within	O
the	O
HCC	O
and	O
cirrhosis	O
groups	O
for	O
candidate	O
metabolites	O
selected	O
in	O
this	O
study.	O

We	O
observed	O
higher	O
glycolytic	B
intermediates	O
in	O
MUC16	O
expressing	O
cells	O
in	O
comparison	O
to	O
the	O
MUC16	O
knockdown	O
cells.	O

Trauma	O
patients	O
showed	O
lower	O
nucleotide	O
synthesis	O
on	O
day	O
1:	O
adenylosuccinate	B
concentrations	O
were	O
0.08	O
(0.04–0.12)	O
relative	O
units	O
for	O
trauma	O
patients	O
vs	O
0.15	O
(0.14–0.17)	O
relative	O
units	O
for	O
healthy	O
volunteers	O
(P	O
=	O
.02)	O
and	O
cytidine	B
concentrations	O
were	O
1.44	O
(0.95–1.73)	O
relative	O
units	O
for	O
trauma	O
patients	O
vs	O
1.74(1.62–1.98)	O
relative	O
units	O
for	O
healthy	O
volunteers	O

In	O
a	O
first	O
test,	O
we	O
used	O
the	O
same	O
volume	O
of	O
1	O
mL	O
CHCl_3	O
for	O
the	O
extraction	O
step	O
(as	O
used	O
in	O
our	O
current	O
protocol)	O
and	O
observed	O
that	O
for	O
80%	O
MeOH,	B
no	O
phase	O
separation	O
occurred,	O
as	O
seen	O
in	O
Figure	O
S1.	O

Interestingly,	O
γ-glutamylglutamine	B
was	O
elevated	O
at	O
the	O
end	O
of	O
the	O
short-sleep	O
condition	O
of	O
our	O
experiment	O
and	O
addition	O
of	O
a	O
γ-glutamyl	O
group	O
to	O
amino	O
acids	O
is	O
often	O
used	O
to	O
enhance	O
the	O
transport	O
of	O
these	O
metabolites.	O

It	O
is	O
worth	O
to	O
mention	O
that	O
Wolfer	O
et	O
al.	O
have	O
reported	O
stabilities	O
of	O
long-term	O
storage	O
(−	O
80	O
°C	O
for	O
20	O
weeks),	O
undergoing	O
three	O
freeze-thaw	O
cycles,	O
for	O
43	O
oxylipins	B
generated	O
from	O
LA,	O
AA,	O
EPA,	O
and	O
DHA	O
across	O
concentration	O
levels	O
ranging	O
from	O
0.5	O
to	O
250	O
ng/mL	O
in	O
MeOH/H2O	O
(1:1)	O
and	O
found	O
no	O
significant	O
loss	O
(<	O
15%)	O
over	O
the	O
storage	O
period.	O

Transformed	O
data	O
were	O
analyzed	O
with	O
statistical	O
software	O
including	O
SIMCA-P	O
version	O
11.0	O
(Umetrics,	O
Umeå,	O
Sweden),	O
OrigionPro	O
8	O
(OriginLab	O
Corporation,	O
Northampton,	B
MA,	O
USA),	O
and	O
R	O
(The	O
R	O
Foundation	O
for	O
Statistical	O
Computing,	O
Vienna,	O
Austria).	O

Serum	O
5-HT,	O
L-DOPA	B
and	O
Trp	O
metabolite	O
levels	O
were	O
determined	O
by	O
liquid	O
chromatography-electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
(LC-ESI-MS/MS).	O

Furthermore,	O
a	O
negative	O
correlation	O
with	O
progesterone	B
levels	O
was	O
observed	O
for	O
amino	O
acids	O
and	O
for	O
acylcarnitines,	B
while	O
an	O
imbalance	O
of	O
different	O
sphingolipids	B
pathways	O
was	O
found	O
during	O
pregnancy.	O

A	O
particular	O
behavior	O
was	O
observed	O
for	O
the	O
cholesteryl	B
ester	I
internal	O
standard,	O
which	O
was	O
detected	O
at	O
10 ng.mL_−1	O
,	O
but	O
whose	O
linearity	O
range	O
started	O
at	O
100 ng.mL_−1	O
.	O

The	O
analytes	O
evaluated	O
for	O
this	O
method	O
were	O
the	O
following:	O
EMPA	O
(ethyl	O
methylphosphonic	I
acid,	I
CAS	O
1832-53-7),	O
the	O
metabolite	O
of	O
VX	O
(O	O
-ethyl	I
S	I
-(2-diisopropylaminoethyl)	I
methylphosphonothioate,	I
CAS	O
50782-69-9);	O
IMPA	O
(isopropyl	O
methylphosphonic	I
acid,	I
CAS	O
1832-54-8),	O
the	O
metabolite	O
of	O
GB	O
(isopropyl	O
methylphosphonofluoridate	I
CAS	O
107-44-8);	O
PMPA	O
(pinacolyl	O
methylphosphonic	I
acid,	I
CAS	O
616-52-4),	O
the	O
metabolite	O
of	O
GD	O
(pinacolyl	O
methylphosphonofluoridate,	I
CAS	O
96-64-0);	O
CMPA	O
(cyclohexyl	O
methylphosphonic	O
acid,	O
CAS	O
1932-60-1),	O
the	O
metabolite	O
of	O
GF	O
(cyclohexyl	O
methylphosphonofluoridate,	O
CAS	O
329-99-7);	O
MMPA	O
(2-(methyl)propyl	O
methylphosphonic	I
acid,	I
CAS	O
1604-38-2),	O
the	O
metabolite	O
of	O
VR	B
(O	I
-2-(methyl)propyl	I
S	I
-2-(diethylaminoethyl)	I
methylphosphonothioate.	I

Propylene	B
glycol	I
was	O
detected	O
in	O
CSF	O
samples	O
in	O
our	O
series.	O

For	O
analytical	O
and	O
physiological	O
normalization,	O
the	O
integrated	O
peak	O
areas	O
were	O
related	O
to	O
the	O
internal	O
standard	O
and	O
the	O
urinary	O
creatinine	B
level	O
(in	O
mg/dl):	O

The	O
microbiota-dependent	O
metabolite	O
trimethylamine-N	B
-oxide	I
(TMAO)	O
has	O
been	O
reported	O
as	O
a	O
novel	O
and	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
cardiovascular	O
and	O
metabolic	O
diseases,	O
but	O
the	O
association	O
with	O
gestational	O
diabetes	O
mellitus	O
(GDM)	O
remains	O
unclear.	O

The	O
resulting	O
crude	O
residue	O
was	O
washed	O
thrice	O
with	O
acetonitrile	B
(4	O
mL	O
each	O
time)	O
followed	O
by	O
washing	O
thrice	O
with	O
25:75	O
water/acetone	O
mixture	O
(2	O
mL	O
each	O
time)	O
to	O
yield	O
the	O
pure	O
product,	O
_15	O
N-cholamine.	B
_1	O
H	O
NMR	O
spectra	O
in	O
D_2	O
O	O
at	O
each	O
step	O
were	O
monitored	O
to	O
assess	O
the	O
purity	O
of	O
the	O
final	O
product.	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
the	O
_13	O
C-labelling	O
of	O
acylcarnitines	B
and	O
PA-based	O
OCR	O
in	O
CPT1A	O
knockdown	O
cells.	O

Initial	O
steps	O
of	O
β–oxidation	O
occur	O
in	O
the	O
cytoplasm,	O
where	O
fatty	O
acid	O
oxidation	O
is	O
catalyzed	O
through	O
acyl	O
CoA	O
ligase,	O
and	O
then	O
transported	O
into	O
the	O
mitochondria	O
via	O
an	O
acyl-carnitine	B
intermediate.	O

Additionally,	O
ox-LDL	O
correlated	O
positively	O
with	O
lysoPCs	O
containing	O
14:0,	O
16:0,	O
and	O
18:0	O
and	O
several	O
primary	O
fatty	O
acid	O
amides,	O
including	O
palmitoleamide,	B
palmitic	B
amide,	I
and	O
oleamide,	B
and	O
correlated	O
negatively	O
with	O
cis	O
-4-octenedioic	O
acid.	O

Short‐term	O
stability	O
experiment	O
in	O
treated	O
patients	O
on	O
1000	O
mg	O
once	O
daily	O
abiraterone	B
acetate.	I

Specifically,	O
enniatin	B
A1,	O
B1,	O
and,	O
also	O
enniatin	B
B	O
decreased	O
the	O
activation	O
of	O
extracellular	O
regulated	O
protein	O
kinase	O
(ERK)	O
(p44/p42).	O

5-Fluorouracil	B
(5-FU)	O
is	O
a	O
well-known	O
example	O
of	O
an	O
anti-cancer	O
drug	O
targeting	O
this	O
pathway.	O

In	O
our	O
study,	O
metabolite	O
ratios	O
normalised	O
to	O
t-creatine	B
levels	O
did	O
not	O
change	O
significantly	O
after	O
Degarelix	O
treatment	O
whereas	O
the	O
absolute	O
concentration	O
of	O
t-choline	B
was	O
significantly	O
lower.	O

Women	O
with	O
IGT	O
and	O
diabetes	O
had	O
an	O
increased	O
clinical	O
risk	O
profile	O
(higher	O
fasting	O
glucose	B
and	O
insulin	O
treatment	O
during	O
pregnancy)	O
and	O
developed	O
diabetes	O
at	O
an	O
earlier	O
gestational	O
age	O
than	O
those	O
who	O
remained	O
normoglycaemic	B
after	O
pregnancy.	O

Pearson	O
correlation	O
coefficients	O
reflect	O
moderate	O
to	O
high	O
correlation	O
among	O
the	O
metabolites	O
in	O
each	O
pattern,	O
with	O
correlation	O
coefficients	O
ranging	O
from	O
0.77	O
to	O
0.93	O
among	O
ketone	B
bodies	O
and	O
from	O
0.23	O
to	O
0.58	O
among	O
metabolites	O
in	O
the	O
second	O
pattern.	O

On	O
the	O
other	O
hand,	O
caprylic	B
acid	I
was	O
significantly	O
negatively	O
associated	O
with	O
the	O
abundance	O
of	O
Ruminococcus	O
gnavus.	O

The	O
most	O
comprehensive	O
report	O
identified	O
metabolites	O
of	O
seven	O
synthetic	O
cannabinoids:	B
JWH-018,	O
JWH-073,	O
JWH-081,	O
JWH-122,	O
JWH-210,	O
JWH-250,	O
and	O
RCS-4.	O

Those	O
included	O
BCAAs	O
(but	O
not	O
their	O
primary	O
degradation	O
products,	O
α-keto	B
acids)	O
and	O
aromatic	O
amino	O
acids,	O
gamma-glutamyl	O
amino	O
acids,	O
glutamate,	B
ω6-polyunsaturated	O
fatty	O
acids	O
or	O
palmitate	B
in	O
plasma	O
as	O
well	O
as	O
BCAA-catabolites,	O
benzoate	B
metabolites	O
and	O
cortisol	B
metabolites	O
in	O
urine.	O

The	O
alternation	O
trends	O
of	O
five	O
metabolites	O
among	O
the	O
three	O
groups	O
including	O
sphinganine,	B
p-Cresol	B
sulfate,	I
dehydroepiandrosterone	B
sulfate	I
(DHEA-S),	O
lactate	B
and	O
l-arginine	B
in	O
the	O
validation	O
cohort	O
were	O
consistent	O
with	O
those	O
in	O
the	O
discovery	O
cohort.	O

LacCer	B
synthase	O
is	O
activated	B
by	O
pro-inflammatory	O
factors	O
to	O
generate	O
LacCer,	B
which	O
in	O
turn	O
activates	O
“oxygen-sensitive”	O
signaling	O
pathways	O
that	O
affect	O
cellular	O
processes,	O
such	O
as	O
proliferation,	O
migration,	O
and	O
angiogenesis.	O

Still,	O
the	O
bioavailability	O
of	O
NO	O
is	O
determined	O
by	O
mutual	O
contrasting	O
factors	O
whereby	O
arginine	B
promotes	O
insulin	O
release	O
from	O
beta	O
cells	O
of	O
pancreas	O
and	O
insulin	O
stimulates	O
arginine	B
cellular	O
uptake	O
resulting	O
in	O
NO	O
mediated	O
vasodilation.	O

In	O
general,	O
the	O
observed	O
trend	O
of	O
alterations	O
in	O
levels	O
of	O
glucose,	B
phenylalanine,	B
lactate,	B
citrate,	B
alanine,	B
lysine,	B
leucine,	B
isoleucine,	B
tyrosine,	B
and	O
valine	B
was	O
in	O
agreement	O
with	O
the	O
observations	O
in	O
oral	O
cancer.	O

Among	O
the	O
polyamines	B
analyzed	O
in	O
serum	O
by	O
our	O
platform,	O
SPD	O
was	O
the	O
most	O
predominant	O
(152.5	O
±	O
63.7	O
nM),	O
although	O
significant	O
levels	O
of	O
other	O
polyamines,	B
such	O
as	O
PUT	O
(77.7	O
±	O
28.3	O
nM),	O
SPM	O
(25.4	O
±	O
10.0	O
nM),	O
and	O
the	O
SPD	O
acetylated	O
forms	O
N1-AcSPD	O
(76.8	O
±	O
27.4	O
nM)	O
and	O

Inclusion	O
criteria	O
were	O
age	O
18–45 years;	O
BMI	O
20–25 kg m_−2	O
,	O
normal	O
glycaemic	B
control	O
verified	O
by	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT);	O
no	O
history	O
of	O
exercise	O
on	O
a	O
regular	O
basis	O
(exercising	O
<3 d week_−1	O
)	O
and	O
VO_2max	O
 < 40	O

Isotope	O
labeled	O
ADMA	B
(2,3,3,4,4,5,5-D7-ADMA,	I
98%),	I
and	O
L-arginine:hydrochloric	O
acid	O
(D7-arginine,	O
98%)	O
were	O
purchased	O
from	O
Cambridge	O
Isotope	O
Laboratories	O
(Tewksbury,	O
MA,	O
USA).	O

To	O
add	O
to	O
the	O
requirement	O
burden,	O
the	O
major	O
amino	O
acids	O
in	O
human	O
collagen	O
1	O
alpha	O
are	O
glycine	B
(27%)	O
and	O
proline	B
(18%).	O

For	O
example,	O
a	O
recent	O
study	O
has	O
shown	O
an	O
increase	O
in	O
BMI	O
to	O
be	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
circulating	O
lysophosphatidylcholines.	B

Isotope	O
dilution	O
mass	O
spectrometry	O
was	O
used	O
to	O
quantify	O
the	O
urinary	O
excretion	O
of	O
the	O
mercapturic	O
acids	O
of	O
benzene,	B
acrolein,	B
and	O
crotonaldehyde	B
from	O
the	O
eight	O
overnight	O
12-hour	O
urine	O
samples	O
collected	O
from	O
each	O
participant	O
over	O
the	O
12-week	O
intervention	O
period.	O

The	O
urinary	O
isoflavone	B
data	O
for	O
S-(−)equol	O
were	O
expressed	O
as	O
log	O
_10	O
S-(−)equol/daidzein	O
ratio,	O
and	O
a	O
cut-off	O
at	O
−1.60	O
represented	O
a	O
separation	O
between	O
the	O
two	O
groups.	O

Since	O
oxalacetic	B
acid	I
was	O
converted	O
to	O
pyruvate	B
during	O
the	O
pre-treatment	O
procedure,	O
oxalacetic	B
acid	I
was	O
detected	O
as	O
pyruvate	B
in	O
our	O
system.	O

Comparison	O
of	O
concentrations	O
of	O
mitochondrial	O
and	O
microbial	O
metabolites	O
in	O
relation	O
to	O
lactate	B
levels	O
obtained	O
in	O
the	O
serum	O
samples	O
of	O
the	O
patients	O
with	O
late-stage	O
sepsis	O
in	O
Group	O
II	O
(n	O
=	O
22).	O

Overall,	O
all	O
lipid	O
classes	O
were	O
collected	O
into	O
these	O
fractions	O
with	O
the	O
following	O
order:	O
CE	O
and	O
TG	B
from	O
1	O
to	O
3.2	O
min;	O
Chol	O
and	O
1	O
,3	O
-DG	O
from	O
3.21	O
to	O
4.1;	O
1	O
,2	O
-DG	O
from	O
4.11	O
to	O
5.5	O
min;	O
MG	O
from	O
11	O
to	O
13.6	O
min;	O
Cer	B
from	O
13.61	O
to	O
15	O
min;	O
FAs	O
from	O
15.01	O
to	O
17	O
min;	O
PG	B
from	O
20.51	O
to	O
22	O
min;	O
PE	O
from	O
26.01	O
to	O
28	O
min;	O
PI	O
and	O
PS	O
from	O
28.01	O
to	O
30.5	O
min;	O
PC	O
from	O
30.51	O
to	O
35	O
min;	O
SM	O
from	O
35.01	O
to	O
39	O
min;	O
sn-1	O
LPC	O
from	O
39.6	O
to	O
41	O
min;	O
sn	O
-2	O
LPC	O
from	O
41.5	O
to	O
42.4	O
min.	O

It	O
is	O
known	O
that	O
omega-3	B
fatty	O
acids	O
can	O
displace	O
omega-6	B
fatty	O
acid	O
stores	O
needed	O
to	O
produce	O
TxA_2	O
,	O
in	O
cell	O
membranes	O
and	O
act	O
as	O
competitors	O
for	O
the	O
same	O
metabolic	O
pathways.	O

ADMA	B
asymmetric	I
dimethylarginine,	I
ns	O
not	O
significant	O
_a	O
Non-parametric	O
Kruskal-Wallis	O
test	O
for	O
trend	O
analysis	O
in	O
controls	O
vs.	O
patient	O
groups	O

Calibration	O
of	O
the	O
ERETIC	O
peak,	O
which	O
had	O
the	O
same	O
area	O
in	O
all	O
spectra,	O
was	O
made	O
using	O
a	O
mixture	O
of	O
9.13mM	O
of	O
citrate,	B
9.20mM	O
of	O
lactate,	B
and	O
9.10mM	O
of	O
glutamate	B
as	O
the	O
reference	O
tube.	O

Both	O
glucosepane	B
and	O
CIMT	O
correlated	O
positively	O
with	O
age.	O

In	O
patients	O
with	O
kidney	O
disease,	O
carbamylation	O
reaction	O
products	O
with	O
lysine	B
of	O
Alb	O
were	O
found.	O

Extracts	O
were	O
reconstituted	O
with	O
100	O
μL	O
of	O
mixture	O
of	O
water	O
and	O
acetonitrile	B
(97/3,	O
v/v),	O
vortex-mixed	O
for	O
10	O
seconds,	O
and	O
used	O
for	O
LC/MS/MS	O
analysis	O
immediately.	O

Selection	O
of	O
parameters	O
for	O
ASE	O
isolation	O
of	O
ZON	O
and	O
its	O
metabolite	O
Recovery	O
of	O
ZON	O
and	O
α-ZOL	B
isolated	O
from	O
animal	O
liver	O
by	O
UE	O
and	O
MIP-CDHB	O
purification	O
_a	O
RSD,	O
standard	O
deviation	O
(n	O
 = 4)	O

Incident	O
type	O
2	O
diabetes	O
was	O
determined	O
by	O
75-g	O
oral	O
glucose	B
tolerance	O
test	O
using	O
World	O
Health	O
Organization	O
criteria.	O

Concentration	O
levels/ratios	O
of	O
the	O
KP	B
metabolites	O
are	O
listed	O
in	O
.	O

A	O
significant	O
increase	O
in	O
carnitine	B
and	O
significant	O
reductions	O
in	O
creatinine	B
and	O
hippurate	B
were	O
observed	O
in	O
the	O
HCC	O
group	O
compared	O
to	O
the	O
CIR	O
group	O
(Figure	O
).	O

Our	O
results	O
about	O
PA’s	O
metabolome	O
show	O
a	O
higher	O
level	O
of	O
lactate	B
in	O
patients	O
who	O
did	O
not	O
receive	O
any	O
neoadjuvant	O
chemotherapy.	O

Of	O
these,	O
15	O
were	O
higher	O
(such	O
as	O
tartrate,	B
hydroquinone,	B
and	O
several	O
glucuronides)	O
and	O
three	O
were	O
lower	O
in	O
pre-cachectic	O
compared	O
to	O
non-cachectic	O
patients	O
(uracil,	O
acetone,	B
and	O
arginine).	B

The	O
present	O
pilot	O
study	O
is	O
an	O
attempt	O
to	O
investigate	O
whether	O
sarcosine	B
in	O
urine	O
is	O
a	O
suitable	O
alternative	O
biomarker	O
for	O
PCa	O
detection	O
and	O
progression	O
monitoring	O
[,].	O

For	O
the	O
first	O
time,	O
TMAO	B
has	O
been	O
measured	O
in	O
human	O
CSF,	O
reaching	O
quantifiable	O
levels	O
in	O
all	O
tested	O
samples.	O

The	O
high	O
pH	O
of	O
9.2	O
utilized	O
in	O
method	O
B	O
disrupts	O
attraction	O
of	O
the	O
amino	B
terminus	O
by	O
the	O
terminal	O
sulfonate	B
and	O
results	O
in	O
loss	O
of	O
retention	O
compared	O
to	O
method	O
E’s	O
neutral	O
pH.	O
Despite	O
the	O
lack	O
of	O
long-range	O
ionic	O
interactions,	O
the	O
neutral	O
amide	B
column	O
F	O
covered	O
72%	O
of	O
the	O
AA	O
library.	O

The	O
samples	O
were	O
immediately	O
transferred	O
from	O
the	O
heparin	B
syringe	O
into	O
labeled	O
aliquot	O
tube	O
and	O
centrifuged	O
at	O
4 °C	O
at	O
2000 rpm	O
for	O
20 min.	O

Change	O
in	O
isoleucine	B
(negative	O
correlation)	O
pre	O
and	O
post	O
simvastatin	B
treatment	O
correlated	O
to	O
the	O
change	O
in	O
glucose/c-peptide	O
ratio,	O
an	O
indicator	O
of	O
apparent	O
insulin	O
secretion.	O

In	O
one	O
study	O
using	O
a	O
single	O
morning	O
blood	O
sample	O
of	O
TRP	O
and	O
KYN,	O
found	O
that	O
men	O
with	O
IBS	O
had	O
higher	O
levels	O
of	O
KYN,	O
higher	O
KYN/TRP	O
ratios,	O
and	O
lower	O
kynurenate	B
(KYNA)/TRP	O
ratios	O
relative	O
to	O
a	O
control	O
group	O
of	O
men	O
without	O
IBS.	O

Through	O
interactions	O
with	O
cannabinoid,	B
vanilloid	O
and	O
peroxisome	O
proliferator-activated	O
receptors	O
(PPARs),	O
FAAs	O
regulate	O
a	O
variety	O
of	O
pathophysiological	O
functions	O
such	O
as	O
appetite,	O
lipid	O
and	O
glucose	B
metabolism,	O
vasodilation,	O
cardiac	O
function	O
and	O
inflammation.	O

Four	O
metabolites	O
(namely,	O
PC	O
diacyl	O
(aa)	O
C36:3,	B
PC	O
acyl-alkyl	O
(ae)	O
C36:3,	B
PC	B
ae	I
C38:4,	I
and	O
PC	B
ae	I
C38:5)	I
were	O
significantly	O
decreased	O
between	O
points	O
A	O
and	O
B	O
then	O
remained	O
not	O
affected—pattern	O
A	O
>	O
B	O
=	O
C;	O
a	O
similar	O
pattern	O
was	O
observed	O
in	O
the	O
case	O
of	O
24	O
and	O
3	O
metabolites	O
specific	O
to	O
CCRT	O
and	O
RT	O
groups,	O
respectively.	O

After	O
adjustment	O
for	O
unconjugated	O
estradiol,	B
these	O
hazard	O
ratios	O
changed	O
minimally;	O
however,	O
the	O
association	O
between	O
the	O
ratio	O
of	O
the	O
2-hydroxylation	O
pathway	O
to	O
the	O
16-hydroxylation	O
pathway	O
and	O
the	O
risk	O
of	O
breast	O
cancer	O
became	O
non-statistically	O
significant	O
(HR	O
=	O
0.69;	O
95%	O
CI	O
=	O
0.47	O
to	O
1.02,	O
P	O
_trend	O
=	O
.07).	O

E_2	B
-9-N-Ade	I
was	O
formed	O
by	O
peroxidase-catalyzed	O
oxidation	O
of	O
E_2	O
through	O
methide.	O

The	O
dual	O
origin	O
of	O
7DHC	O
extends	O
the	O
cholesterol	B
arm	O
all	O
the	O
way	O
from	O
8→4→3.	O

While	O
the	O
exact	O
biological	O
significance	O
of	O
the	O
noted	O
LPCs	O
and	O
amino	O
acids	O
changes,	O
and	O
how	O
these	O
might	O
be	O
related	O
to	O
longer	O
life	O
expectancy	O
and/or	O
delay	O
in	O
age-related	O
diseases,	O
are	O
not	O
clear	O
at	O
the	O
moment,	O
and	O
worth	O
further	O
investigation,	O
it	O
is	O
crucial	O
to	O
denote	O
that	O
serine	B
is	O
needed	O
for	O
the	O
metabolism	O
of	O
fats	O
and	O
fatty	O
acids,	O
muscle	O
growth,	O
and	O
to	O
maintain	O
a	O
healthy	O
immune	O
system	O
and	O
was	O
previously	O
found	O
to	O
decrease	O
in	O
plasma	O
under	O
inflammatory	O
conditions	O
,	O
while	O
phenylalanine	B
exhibits	O
anti-inflammatory	O
properties	O
and	O
it	O
is	O
often	O
used	O
to	O
treat	O
arthritis	O
and	O
Parkinson's	O
disease	O
.	O

Thus,	O
in	O
bypass	O
patient	O
samples	O
both	O
the	O
arginine:	B
ornithine	B
ratio	O
and	O
GABR	O
were	O
transiently	O
increased	O
2–4 h	O
after	O
bypass,	O
returning	O
to	O
control	O
levels	O
by	O
48 h	O
after	O
surgery	O
(Fig.	O

Calibrating	O
solutions	O
of	O
β-apo-13-carotenone	B
were	O
prepared	O
in	O
1:1	O
methyl	O
t	O
-butyl	O
ether/methanol	O
with	O
concentrations	O
based	O
on	O
an	O
extinction	O
of	O
25,300	O
at	O
368	O
nm	O
in	O
ethanol.	B

Sulfide;	B
allyl	O
methyl;	O
Hydrogen	O
azide	O
and	O
Benzeneethanamine,N-[(pentafluorophenyl)methylene]-.beta.	B

In	O
our	O
analysis,	O
both	O
cholesterol	B
and	O
TGs	O
levels	O
were	O
positively	O
associated	O
with	O
HOMA-IR.	O

The	O
majority	O
of	O
the	O
alterations	O
occurred	O
in	O
lipid-,	O
amino	B
acid-,	O
and	O
energy-related	O
metabolites.	O

The	O
MEKC-MS/MS	O
conditions	O
are	O
the	O
same	O
as	O
in	O
except	O
that	O
25	O
mM	O
poly-L,L	O
-SULA	O
and	O
25	O
kV	B
was	O
used.	O

However,	O
numerous	O
studies	O
have	O
demonstrated	O
enhanced	O
vascular	O
NO	O
responses	O
following	O
arginine	B
administration	O
(,,),	O
conditions	O
that	O
correspondingly	O
will	O
increase	O
GABR.	O

The	O
resultant	O
pellet	O
of	O
all	O
the	O
peripheral	O
blood	O
cells	O
were:	O
i)	O
for	O
direct	O
metabolomic	O
analysis,	O
washed	O
with	O
PBS	O
again	O
and	O
finally	O
stored	O
at	O
-80°C	O
after	O
adding	O
0.5	O
mL	O
of	O
ice-cold	O
methanol	B
(for	O
20	O
million	O
cells)	O
or	O
ii)	O
for	O
treatment	O
with	O
nanoparticles,	O
resuspended	O
in	O
1	O
mL	O
of	O
complete	O
RPMI	O
1640	O
medium	O
for	O
cell	O
counting	O
and	O
diluted	O
in	O
more	O
RPMI	O
1640	O
until	O
obtaining	O
a	O
solution	O
of	O
5	O
million	O
cells/mL	O

Aminoacyl‐tRNA	B
biosynthesis	O
is	O
the	O
top‐ranked	O
pathway	O
according	O
to	O
enrichment	O
criteria.	O

The	O
major	O
formation	O
of	O
creatinine	B
in	O
the	O
body,	O
however,	O
takes	O
place	O
in	O
the	O
skeletal	O
muscles.	O

The	O
residual	O
pellets	O
after	O
aqueous	O
extraction	O
were	O
sonicated	O
for	O
90	O
seconds	O
with	O
dichlorometahane	B
in	O
Methanol	B
(3:1)	I
containing	O
internal	O
standards	O
(ceramide	O
[5	O
pmole	O
µL_−1	O
]	O
and	O
LPA	O
10	O
pmol	O
µL_−1	O
)	O
in	O
glass	O
vials.	O

However,	O
in	O
the	O
ITG	O
only	O
one	O
metabolite,	O
ketoglutaric	B
acid,	I
showed	O
significant	O
change.	O

The	O
solute	O
solely	O
retained	O
in	O
one	O
patient	O
(i.e.	O
dimethylamine),	B
trigonelline	B
(due	O
to	O
lack	O
of	O
reference	O
value)	O
and	O
creatinine	B
were	O
excluded	O
from	O
this	O
analysis.	O

These	O
results	O
differ	O
from	O
those	O
of	O
Fitzgerald	O
who	O
reported	O
that	O
IBS	O
participants	O
who	O
rated	O
their	O
symptoms	O
as	O
severe	O
as	O
compared	O
to	O
HCs	O
and	O
IBS	O
with	O
less	O
severe	O
symptoms	O
had	O
higher	O
morning	O
levels	O
of	O
plasma	O
kynurenine	B
to	O
Trp	O
ratio.	O

Of	O
the	O
42	O
metabolites,	O
4	O
were	O
associated	O
with	O
changes	O
in	O
NRI	O
scores	O
(i),	O
which	O
were	O
N	B
-formyl-l-methionine,	I
phosphatidylethanolamine	B
(PE)(20:4/22:6),	I
LysoPC(16:0),	B
and	O
SM(d18:1/24:1).	B

Extensive	O
expression	O
of	O
GLUT-5,	O
a	O
fructose	B
transporter,	O
has	O
been	O
implicated	O
in	O
different	O
types	O
of	O
cancers,	O
including	O
CRC,	O
presumably	O
in	O
response	O
to	O
their	O
heightened	O
energy	O
consumption.	O

These	O
observations	O
support	O
the	O
findings	O
of	O
this	O
study,	O
that	O
lower	O
betaine	B
levels	O
may	O
be	O
a	O
good	O
predictor	O
of	O
future	O
T2DM.	O

For	O
the	O
SLC7A9	O
locus,	O
the	O
association	O
with	O
lysine/valine	B
does	O
not	O
replicate,	O
possibly	O
due	O
to	O
the	O
difficulty	O
in	O
annotating	O
lysine	B
from	O
the	O
NMR	O
spectra	O
(>	O
75%	O
missing	O
values	O
for	O
lysine).	B

Here,	O
a	O
significantly	O
decreased	O
level	O
of	O
hippuric	B
acid	I
was	O
observed	O
in	O
BC	O
subjects	O
compared	O
to	O
healthy	O
controls,	O
suggesting	O
the	O
phenylalanine	B
metabolism	O
is	O
perturbed	O
in	O
BC	O
subjects.	O

Similar	O
relationships	O
were	O
demonstrated	O
between	O
metabolic	O
factors	O
and	O
muscle	O
GM3	B
C18:0.	I

The	O
second	O
major	O
metabolic	O
pathway	O
was	O
the	O
phenylalanine	B
metabolism	O
pathway.	O

All	O
corresponding	O
metabolites	O
from	O
the	O
tyrosine	B
metabolism	O
demonstrated	O
moderate	O
to	O
strong	O
associations	O
to	O
measures	O
of	O
disease	O
severity	O
and	O
symptoms.	O

Because	O
we	O
did	O
not	O
have	O
a	O
labeled	O
internal	O
standard	O
for	O
3-epi-25(OH)D_3	B
,	O
we	O
utilized	O
25(OH)D_3	O
-	O
for	O
quantification	O
of	O
both	O
25(OH)D_3	O
and	O
3-epi-25(OH)D_3	B
.	O

With	O
these	O
studies,	O
we	O
validated	O
previous	O
findings	O
of	O
decreased	O
VLCDCA	B
28:4	I
levels	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
colorectal	O
cancer	O
and	O
pancreatic	O
cancer	O
and	O
extended	O
these	O
observations	O
to	O
detect	O
decreased	O
levels	O
of	O
VLCDCA	B
28:4	I
in	O
kidney	O
cancer	O
patients.	O

For	O
most	O
of	O
these	O
chemicals,	O
the	O
exposure	O
patterns	O
significantly	O
differ	O
not	O
only	O
between	O
children	O
and	O
adults,	O
but	O
also	O
between	O
males	O
and	O
females,	O
especially	O
with	O
higher	O
concentrations	O
of	O
parabens	O
and	O
phthalate	B
metabolites	O
in	O
female	O
and	O
children	O
subjects,	O
respectively.	O

Combined	O
with	O
the	O
t	O
-test	O
results	O
(P	O
<	O
0.05),	O
the	O
four	O
metabolites	O
were	O
as	O
follows:	O
C_4	O
sugar	O
1,	O
inositol	B
D,	O
glucose,	B
and	O
C_4	O
sugar	O
2.	O

Acylcarnitine	B
metabolites	O
including	O
hexanoylcarnitine,	B
octanoylcarnitine,	B
and	O
cis-4-decenoyl	B
carnitine	I
remained	O
notably	O
different	O
(>2-fold	O
decrease,	O
p	O
<	O
0.01),	O
and	O
several	O
sphingomyelin	B
species	O
remained	O
decreased.	O

Because	O
of	O
their	O
high	O
oxygen	O
content,	O
RBCs	O
have	O
a	O
high	O
demand	O
for	O
NADPH	B
to	O
regenerate	O
GSH	B
from	O
GSSG,	O
which	O
is	O
necessary	O
to	O
protect	O
RBCs	O
from	O
oxidative	O
damage._,	O
Further,	O
RBCs	O
lack	O
mitochondria	O
and	O
hence	O
TCA	O
cycle	O
metabolism	O
is	O
absent	O
in	O
these	O
cells.	O

In	O
the	O
process	O
of	O
cancer	O
development,	O
cancer	O
cells	O
increase	O
and	O
alter	O
the	O
metabolism	O
of	O
major	O
nutrient,	O
glucose	B
via	O
glycolysis	O
to	O
meet	O
the	O
high-energy	O
demand	O
under	O
hypoxic	O
conditions	O
[,].	O

Go	O
to:	O
The	O
overlapping	O
clinical	O
features	O
of	O
relapsing	O
remitting	O
multiple	O
sclerosis	O
(RRMS),	O
aquaporin-4	O
(AQP4)-antibody	O
(Ab)	O
neuromyelitis	O
optica	O
spectrum	O
disorder	O
(NMOSD),	O
and	O
myelin	B
oligodendrocyte	O
glycoprotein	B
(MOG)-Ab	O
disease	O
mean	O
that	O
detection	O
of	O
disease	O
specific	O
serum	O
antibodies	O
is	O
the	O
gold	O
standard	O
in	O
diagnostics.	O

Elevated	O
levels	O
of	O
cyclooxygenase	O
(COX)-derived	O
prostaglandin	B
E_2	O
(PGE_2	O
)	O
occur	O
in	O
inflamed	O
tissues.	O

In	O
this	O
study,	O
we	O
identified	O
three	O
differential	O
metabolites	O
(isobutyric	O
acid,	I
formic	B
acid	I
and	O
indoxyl	O
sulphate)	O
belonging	O
to	O
the	O
metabolic	O
byproducts	O
of	O
gut	O
microbiota.	O

Of	O
all	O
the	O
molecules	O
studied	O
related	O
to	O
platelet	O
activation	O
pathway,	O
we	O
found	O
that	O
only	O
20-HETE	B
had	O
increased	O
plasma	O
levels	O
in	O
patients	O
who	O
underwent	O
carotid	O
endarterectomy.	O

Since	O
ornithine	B
has	O
two	O
basic	O
centres,	O
it	O
runs	O
very	O
late	O
in	O
our	O
HILIC	O
method,	O
while	O
the	O
marker	O
compound	O
ran	O
much	O
earlier	O
than	O
the	O
ornithine	B
standard.	O

In	O
addition,	O
groups	O
2	O
and	O
3	O
tended	O
to	O
have	O
an	O
increased	O
urinary	O
excretion	O
of	O
other	O
gut	O
microbial	O
metabolites;	O
4-hydroxyphenylacetate	B
and	O
4-hydroxyphenylpyruvate,	B
as	O
compared	O
to	O
healthy	O
subjects.	O

To	O
examine	O
the	O
potential	O
role	O
of	O
the	O
relative	O
glutamate	B
concentration	O
as	O
a	O
single	O
diagnostic	O
marker	O
to	O
differentiate	O
between	O
lung	O
cancer	O
and	O
lung	O
inflammation,	O
we	O
constructed	O
a	O
receiver	O
operating	O
characteristic	O
(ROC)	O
curve.	O

D-dlucosaminide	O
is	O
an	O
intermediate	O
in	O
the	O
human	O
aminosugars	B
metabolism.	O

Selection	O
of	O
breast-cancer	O
patients	O
for	O
adrenalectomy	O
or	O
hypophysectomy	O
by	O
determination	O
of	O
urinary	O
17-hydroxycorticosteroids	B
and	O
aetiocholanolone.	B

L-Arginine	B
is	O
deeply	O
involved	O
with	O
the	O
metabolism	O
of	O
nitric	B
oxide	I
(NO),	O
a	O
well-studied	O
vasodilator	O
and	O
free	O
radical	O
involved	O
in	O
a	O
variety	O
of	O
lung	O
diseases	O
[,].	O

While	O
cysteine	B
was	O
depleted,	O
cystine,	B
kynurenine,	B
cytosine,	B
and	O
dCTP	O
were	O
the	O
most	O
increased	O
metabolites.	O

Higher	O
levels	O
of	O
several	O
sphingomyelins	B
(SMs),	O
lysophosphatidylcholines	B
(lysoPCs)	O
and	O
phosphatidylcholines	B
(PCs)	O
were	O
observed	O
in	O
rs7903146	O
risk	O
allele	O
carriers.	O

Eluates	O
were	O
dried	O
under	O
vacuum,	O
re-suspended	O
in	O
20 µl	O
of	O
50%	O
aqueous	O
methanol	B
containing	O
0.1%	O
formic	B
acid	I
and	O
analysed	O
immediately.	O

Reagent	O
grade	O
formic	B
acid	I
(99%	O
pure)	O
was	O
purchased	O
from	O
Acros	O
Organic	O
(Pittsburgh,	O
PA).	O

The	O
association	O
between	O
the	O
metabolites	O
and	O
BMI,	O
insulin	O
and	O
DBP	B
was	O
determined	O
using	O
a	O
linear	O
regression	O
model	O
with	O
metabolites	O
as	O
outcome	O
and	O
adjusted	O
for	O
age,	O
gender,	O
status	O
(longevity	O
family	O
member	O
or	O
control),	O
lipid	O
lowering	O
medication,	O
hypertension	O
medication	O
(fixed	O
effects)	O
and	O
household	O
(random	O
effects).	O

The	O
maximum	O
CV	O
of	O
the	O
IS-normalized	O
MF	O
calculated	O
from	O
the	O
six	O
different	O
plasma	O
samples	O
for	O
the	O
low	O
and	O
the	O
high	O
concentration	O
was,	O
respectively,	O
1.0%	O
and	O
0.9%	O
for	O
enzalutamide	B
and	O
1.0%	O
and	O
2.7%	O
for	O
N-desmethylenzalutamide,	B
fulfilling	O
the	O
acceptance	O
criteria	O
of	O
<15%.	O

At	O
the	O
end	O
of	O
each	O
intervention	O
period,	O
fasting	O
serum	O
was	O
collected	O
for	O
NMR-based	O
metabolomics	O
and	O
the	O
analysis	O
of	O
cholesterol	B
fractions.	O

It	O
should	O
be	O
noted	O
that	O
eicosanoid	B
precursors	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
phospholipids.	B

Since	O
this	O
endogenous	O
dicarboxylic	B
acid,	I
which	O
is	O
also	O
used	O
to	O
treat	O
inflammation,	O
decreased	O
when	O
subjects	O
in	O
our	O
study	O
developed	O
simvastatin-induced	O
pre-diabetes	O
and	O
apparent	O
full	O
diabetes,	O
it	O
may	O
be	O
inferred	O
that	O
this	O
statin	B
either	O
inhibits	O
azelaic	B
acid	I
production	O
or	O
accelerates	O
its	O
beta-oxidation	O
to	O
acetyl-CoA	B
and	O
malonyl-CoA;	B
alternatively,	O
the	O
reduction	O
of	O
azelaic	B
acid	I
may	O
be	O
due	O
to	O
depletion	O
in	O
response	O
to	O
elevated	O
plasma	O
glucose.	B

In	O
CKD	O
3–4	O
patients,	O
levels	O
of	O
TMAO	B
(Rho	O
=	O
-0.15;	O
p<0.0001)	O
and	O
choline	B
(Rho	O
=	O
-0.31;	O
p	O
=	O
0.023)	O
correlated	O
inversely	O
with	O
mGFR,	O
whereas	O
betaine	B
correlated	O
with	O
higher	O
mGFR	O

The	O
phase	O
2	O
Regorafenib	O
in	O
Relapsed	O
Glioblastoma	O
(REGOMA)	O
trial	O
indicated	O
a	O
survival	O
benefit	O
for	O
patients	O
with	O
first	O
recurrence	O
of	O
a	O
glioblastoma	O
when	O
treated	O
with	O
the	O
multikinase	O
inhibitor	O
regorafenib	O
(REG)	O
instead	O
of	O
lomustine.	B

Elevation	O
of	O
brain	O
glucose	B
and	O
polyol-pathway	B
intermediates	O
might	O
be	O
explained	O
by	O
impaired	O
ATP	B
supply	O
leading	O
to	O
diminished	O
glycolysis,	O
suppressing	O
these	O
ATP-requiring	O
phosphorylation	O
reactions,	O
and	O
could	O
ultimately	O
result	O
from	O
impaired	O
TCA	O
cycle	O
function.	O

A	O
third	O
and	O
final	O
phosphatidylcholine	B
challenge	O
was	O
performed	O
1	O
month	O
or	O
more	O
after	O
the	O
withdrawal	O
of	O
antibiotics	O
(and	O
subsequent	O
reacquisition	O
of	O
gut	O
flora),	O
at	O
visit	O
3.	O

Third,	O
D-ribose	B
5-phosphate	I
to	O
niacinamide	B
ratio	O
was	O
equally	O
lowered	O
in	O
pre-prostatectomy	O
samples	O
>	O
2.0-fold	O
compared	O
to	O
other	O
groups	O
separately	O
or	O
combined	O
(all	O
p	O
<	O
0.05).	O

Surprisingly,	O
IL-10	O
was	O
the	O
next	O
most	O
commonly	O
associated	O
immune	O
system	O
biomarker,	O
being	O
positively	O
associated	O
with	O
4	O
tryptophan-related	O
variables:	O
kynurenine	B
(P	O
=	O
0.0002),	O
the	O
KTR	O
(P	O
=	O
0.003),	O
3-hydroxykynurenine	B
(P	O
=	O
0.01),	O
and	O
3-hydroxyanthranilic	B
acid	I
(P	O
=	O
0.04).	O

(B)	O
Contribution	O
of	O
a	O
_1	O
H	O
NMR	O
characteristic	O
signal	O
of	O
cholesterol	B
at	O
0.68	O
ppm	O
to	O
the	O
spectrum	O
of	O
lipid	O
fraction	O
of	O
the	O
plasma	O
extract	O
(Org	O
spectrum).	O

Metabolites,	O
Quantitation,	O
Plasma,	O
Metabolomics,	O
_1	O
H	O
NMR,	O
Heteronuclear	O
correlation,	O
Isotope	O
tagging,	O
Amines,	O
Carboxylic	B
acids	I

3-phenyllactic	B
acid	I
showed	O
significant	O
differences	O
to	O
milk	O
and	O
soy	O
drink	O
intake	O
at	O
time-points	O
1,	O
2,	O
and	O
4	O
h	O
(see	O
Tables	O
S3	O
and	O
S4).	O

Overall	O
the	O
results	O
from	O
the	O
snapshot	O
of	O
metabolism	O
post-exercise	O
emphasize	O
that	O
compounds	O
of	O
anaplerotic	O
reactions	O
that	O
replenish	O
TCA	O
cycle	O
intermediates	O
(i.e.	O
aspartate	B
and	O
PEP),	O
were	O
selectively	O
reduced	O
in	O
ACE-DD	O
genotypes	O
after	O
exercise.	O

Its	O
lack	O
of	O
detection	O
in	O
GSTM1	O
competent	O
individuals	O
could	O
be	O
influenced	O
by	O
the	O
flux	O
of	O
metabolites	O
through	O
the	O
Phe-9,	B
10-epoxide	I
pathway.	O

The	O
sample	O
residues	O
were	O
then	O
treated	O
with	O
50	O
µL	O
methoxylamine	B
for	O
a	O
2	O
h	O
incubation	O
at	O
60	O
°C,	O
followed	O
by	O
rapid	O
addition	O
of	O
100	O
µL	O
N-methyl-N-(trimethylsilyl)	B
trifluoroacetamide	I
(MSTFA)	O
with	O
1%	O
trichloromethylsiloxane	O
(TCMS),	O
for	O
a	O
1	O
h	O
incubation	O
at	O
60	O
°C.	O

Among	O
them,	O
tryptophan,	B
a	O
biomarker	O
constituent,	O
showed	O
significantly	O
lower	O
level	O
even	O
after	O
multiple	O
comparison	O
correction	O
(FDR,	O
q-value = <0.001).	O

Although	O
adiponectin	O
levels	O
have	O
been	O
repeatedly	O
reported	O
to	O
be	O
lower	O
in	O
GDM	O
women	O
and	O
closely	O
associated	O
with	O
plasma	O
glucose	B
concentrations	O
of	O
OGTT,	O
the	O
area	O
under	O
the	O
receiver-operator	O
characteristic	O
(ROC)	O
curve	O
of	O
adiponectin	O
was	O
relatively	O
low	O
(–).	O

Standard	O
linear	O
models	O
(Proc	O
GLM;	O
SAS)	O
with	O
log-estrogen	O
(or	O
log-ratio)	O
as	O
the	O
dependent	O
variable	O
and	O
DES	B
status	O
as	O
the	O
independent	O
variable	O
evaluated	O
the	O
effect	O
of	O
DES	B
exposure.	O

In	O
the	O
set	O
of	O
statistically	O
significant	O
associations	O
with	O
testosterone,	B
the	O
difference	O
in	O
regression	O
coefficient	O
between	O
cases	O
and	O
controls	O
remained	O
statistically	O
significant	O
after	O
correction	O
for	O
multiple	O
comparisons	O
for	O
most	O
metabolites.	O

This	O
prioritization	O
(diversion	O
to	O
adenosine	B
production)	O
is	O
one	O
potential	O
explanation	O
for	O
the	O
differences	O
in	O
HX	O
concentrations.	O

In	O
addition,	O
the	O
dough	O
and	O
bread	O
samples	O
produced	O
using	O
the	O
sourdough	O
process	O
contained	O
higher	O
levels	O
of	O
glycerol	B
and	O
mannitol,	B
the	O
latter	O
not	O
being	O
present	O
in	O
bread	O
B	O
or	O
that	O
produced	O
using	O
the	O
CBP.	O

Compositional	O
information	O
of	O
main-	O
and	O
subclasses	O
consists	O
of	O
the	O
lipoprotein	O
content	O
concentrations	O
of	O
lipids,	O
i.e.,	O
cholesterol,	B
free	O
cholesterol,	B
phospholipids	B
and	O
triglycerides	B
and	O
apolipoproteins;	O
Apo-A1,	O
Apo-A2	O
and	O
Apo-B.	O
Model	O
performance	O
is	O
comparable	O
to	O
the	O
results	O
reported	O
in,	O
as	O
indicated	O
by	O
key	O
model	O
performance	O
parameters	O
summarized	O
in	O
Fig.	O

Increasing	O
evidence	O
points	O
towards	O
an	O
important	O
role	O
for	O
lipids	O
in	O
carcinogenesis,	O
and	O
altered	O
cellular	O
phospholipid	B
composition	O
has	O
recently	O
been	O
reported	O
across	O
a	O
variety	O
of	O
cancer	O
sub‐types	O
(Doria	O
et al.	O

For	O
each	O
replicate,	O
two	O
punch-outs	O
with	O
a	O
diameter	O
of	O
3	O
mm	O
were	O
added	O
to	O
80	O
μL	O
of	O
ice-cold	O
extraction	O
fluid	O
[8:1	O
methanol/water	O
mixture	O
(vol/vol)]	O
containing	O
1	O
μg/mL	O
[U_13	B
C]ribitol	I
(ALD-062;	O
Omicron	O
Biochemicals,	O
Inc.)	O
as	O
an	O
internal	O
standard,	O
vortexed	O
at	O
4	O
°C	O
for	O
10	O
min	O
at	O
1,400	O
rpm	O
on	O
an	O
orbital	O
shaker	O
(ThermoMixer	O
comfort,	O
Eppendorf),	O
and	O
centrifuged	O
at	O
4	O
°C	O
for	O
10	O
min	O
at	O
16,000	O
×	O
g	O
;	O
60	O
μL	O
of	O
supernatant	O
was	O
transferred	O
into	O
GC	O
glass	O
vials	O
with	O
a	O
microinsert	O
(5–250	O
μL)	O
and	O
dried	O
in	O
a	O
refrigerated	O
vacuum	O
concentrator	O
(Labconco)	O
overnight	O
at	O
−4	O
°C.	O

In	O
this	O
work,	O
poly-sodium	B
N	I
-undecenoyl-L,L	I
-leucylalaninate	I
(poly-L,L	O
-SULA)	O
was	O
employed	O
as	O
a	O
chiral	O
selector	O
after	O
screening	O
several	O
dipeptide	O
polymeric	O
chiral	O
surfactants.	O

Modification	O
of	O
arginine	B
concentration	O
may	O
be	O
related	O
to	O
the	O
altered	O
arginine/nitric	B
oxide	O
regulatory	O
pathway	O
that	O
characterize	O
glaucoma.	O

A	O
low	O
glutamate	B
concentration	O
is	O
considered	O
as	O
diagnostic	O
for	O
cancer.	O

Dein,	O
Gein,	O
and	O
equol	O
were	O
conjugated	O
by	O
UDP‐glucuronosyltransferase	O
(UGTs)‐mediated	O
glucuronidation	O
and	O
sulfotransferase	O
(SULTs)‐mediated	O
sulfonation.32,	B
33,	O
34	O
UGTs	O
and	O
SULTs	O
are	O
present	O
as	O
multiple	O
isoforms.	O

As	O
discussed	O
above,	O
1-methylnicotinamide	B
plays	O
a	O
role	O
in	O
several	O
metabolic	O
pathways	O
including	O
energy	O
production.	O

However,	O
the	O
Montoliu	O
study	O
did	O
find	O
that	O
most	O
other	O
phosphocholines	B
were	O
significantly	O
decreased	O
in	O
the	O
elderly,	O
which	O
mirrors	O
our	O
overall	O
findings.	O

In	O
the	O
present	O
study,	O
the	O
concentrations	O
of	O
palmitic	B
acid	I
were	O
20	O
times	O
lower	O
in	O
pancreatic	O
cancer	O
patients	O
than	O
healthy	O
subjects,	O
whereas	O
oleanolic	B
acid	I
levels	O
were	O
10	O
times	O
higher	O
in	O
PC	O
than	O
control	O
group.	O

Conjugated	O
bile	O
acids	O
and	O
their	O
sulfation	O
product	O
enable	O
the	O
absorption	O
of	O
lipids,	O
cholesterol	B
and	O
fat-soluble	O
vitamin	O
and	O
are	O
reported	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
detoxification	O
of	O
endogenous	O
and	O
exogenous	O
lipophilic	O
compounds	O
.	O

ADMA,	B
but	O
not	O
SDMA,	O
is	O
hydrolysed	O
by	O
dimethylarginine	O
dimethylaminohydrolase	O
(DDAH)	O
to	O
form	O
dimethylamine	B
(DMA)	O
and	O
citrulline.	B

Dehydroepiandrosterone	B
(DHEA)	O
is	O
the	O
precursor	O
of	O
androgens	O
(and	O
estrogens)	O
and	O
leads	O
via	O
enzymes	O
such	O
as	O
5α-reductase	O
to	O
epiandrosterone,	B
androsterone,	B
testosterone,	B
and	O
other	O
steroids;	O
4-androstene-3beta,17beta-diol	B
disulfate	I
1	O
and	O
2	O
also	O
are	O
known	O
as	O
androstenediols	B
and	O
are	O
intermediates	O
in	O
the	O
synthesis	O
of	O
testosterone	B
from	O
DHEA.	O

Placement	O
of	O
double	O
bonds	O
by	O
the	O
software	O
Mercury	O
ultimately	O
led	O
to	O
the	O
conclusive	O
determination	O
of	O
the	O
structure	O
as	O
(E	B
)-1,1-dimethyl-2-(5-methyl-4-oxo-4,5-dihydro-1H	I
-imidazol-2-yl)guanidine	I
(IMZ;	O
).	O

The	O
levels	O
of	O
the	O
ratios	O
of	O
depurinating	O
DNA	O
adducts	O
to	O
their	O
respective	O
estrogen	B
metabolites	O
and	O
conjugates	O
were	O
significantly	O
higher	O
in	O
high-risk	O
women	O
(p	O
<	O
0.001)	O
and	O
women	O
with	O
breast	O
cancer	O
(p	O
<	O
0.001)	O
than	O
in	O
control	O
subjects.	O

The	O
extracts	O
were	O
evaporated	O
to	O
dryness	O
using	O
a	O
Savant	O
SpeedVac	O
evaporator	O
(Thermo	O
Fisher	O
Scientific,	O
Waltham,	O
MA)	O
and	O
reconstituted	O
to	O
20	O
μL	O
with	O
acetonitrile/10	O
mM	O
ammonium	B
acetate	I
(30/70,	O
v/v).	O

According	O
to	O
the	O
manufacturers’	O
descriptions	O
of	O
the	O
columns,	O
the	O
Kinetex	O
XBC18,	O
compared	O
to	O
the	O
Hypersil,	O
contains	O
smaller	O
particles	O
of	O
silica	B
that	O
allows	O
for	O
increased	O
theoretical	O
plates,	O
and	O
the	O
silica	B
particles	O
have	O
a	O
fused	O
core	O
as	O
opposed	O
to	O
the	O
fully	O
porous	O
particles	O
in	O
the	O
Hypersil	O
column.	O

central	O
adiposity	O
gain	O
phenotype,	O
and	O
this	O
finding	O
may	O
be	O
driven	O
by	O
the	O
fructose	B
finding,	O
given	O
evidence	O
from	O
isotopic	O
tracer	O
studies	O
of	O
fructose,	B
which	O
show	O
that	O
approximately	O
one-fourth	O
of	O
ingested	O
fructose	B
is	O
converted	O
to	O
lactic	B
acid	I
within	O
hours.	O

Acylcarnitines,	B
phosphatidylcholines	B
(including	O
lysophosphatidylcholines),	B
sphingomyelins	B
and	O
hexoses	O
were	O
analyzed	O
by	O
flow	O
injection	O
analysis	O
(FIA)-MS/MS	O
measurements	O
(FIA-MS/MS).	O

Recently,	O
a	O
classical	O
antifolate	O
has	O
been	O
shown	O
to	O
possess	O
cytotoxic	O
activity	O
against	O
human	O
prostatic	O
cancer	O
cell	O
lines	O
that	O
lacked	O
hypoxanthine,	B
whereas	O
growth	O
was	O
maintained	O
in	O
tumors	O
with	O
hypoxanthine.	B

Cuhadar	O
et	O
al.	O
showed	O
stability	O
of	O
creatinine	B
and	O
glucose	B
in	O
serum	O
samples	O
for	O
up	O
to	O
ten	O
freeze-thaw	O
cycles,	O
which	O
is	O
in	O
line	O
with	O
our	O
results	O
.	O

[13C4,	O
99%],	O
d‐xylitol	O
[U‐13C5,	O
99%],	O
l‐glutamine	B
[13C5,	O
99%],	O
1,5‐AG	B
[U‐13C6,	O
98%+],	O
l‐lysine:2HCl	B
[13C6,	O
99%],	O
l‐histidine:HCl:H_2	O
O	O

Figure 	O
shows	O
the	O
relationship	O
between	O
plasma	O
concentration	O
of	O
7-oxo-DHEA	B
and	O
the	O
values	O
of	O
absolute	O
CD4+	O
T	O
cell	O
count	O
and	O
the	O
lowest	O
ever	O
CD4+	O
T	O
lymphocyte	O
count	O
(CD4+	O
T	O
cell	O
nadir).	O

Adipose	O
and	O
muscle	O
regional	O
GU	O
were	O
calculated	O
by	O
multiplying	O
tissue	O
K	O
_i	O
	O
by	O
corresponding	O
plasma	O
glucose	B
concentration	O
and	O
divided	O
by	O
lumped	O
constant.	O

Apo-A1,	O
HDL,	O
and	O
larger	O
HDL	O
subfractions’	O
contents	O
of	O
cholesterol,	B
free	O
cholesterol,	B
phospholipids,	B
and	O
apolipoprotein-A1	O
with	O
tumor	O
PgR	O
expression.	O

Serum	O
levels	O
of	O
E2,	O
estrone	B
(E1),	O
and	O
estrone	O
sulfate	O
(E1S)	O
were	O
determined	O
using	O
a	O
novel	O
and	O
highly	O
sensitive	O
radioimmunoassay	O
where	O
the	O
detection	O
limit	O
for	O
E2,	O
E1,	O
and	O
E1S	O
were	O
0.67	O
pmol/L,	O
1.14	O
pmol/L	O
and	O
0.55	O
pmol/L,	O
respectively.	O

The	O
bulk	O
powders	O
were	O
tested	O
for	O
microbial	O
contaminants	O
prior	O
to	O
release	O
by	O
Oregon	O
Freeze	O
Dry	O
and	O
again	O
upon	O
receipt	O
in	O
Baltimore	O
(IEH-JL	O
Analytical	O
Services,	O
Modesto,	O
CA	O
and	O
Eurofins	O
Strasburger	O
&	O
Siegel,	O
Hanover,	O
MD),	O
heavy	O
metals	O
(Elemental	O
Analysis,	O
Inc.,	O
Lexington,	O
KY)	O
and	O
benzene	B
(TestAmerica,	O
Pittsburgh,	O
PA).	O

Acetoacetic	B
acid	I
was	O
not	O
measured	O
in	O
this	O
study.	O

A	O
small	O
amount	O
of	O
administered	O
morphine	B
is	O
excreted	O
unchanged	O
in	O
the	O
urine	O
as	O
free	O
morphine.	B

A	O
comparison	O
of	O
retention	O
times	O
of	O
detected	O
peaks	O
with	O
the	O
literature	O
values	O
of	O
HPLC/DAD	O
analysis	O
was	O
carried	O
out	O
[,],	O
because	O
they	O
used	O
a	O
reversed-phase	O
C18	O
column	O
with	O
a	O
gradient	O
of	O
acetonitrile/water	O
containing	O
0.1	O
%	O
trifluoroacetic	B
acid,	I
which	O
is	O
comparable	O
to	O
our	O
conditions.	O

Cirrhosis;	O
HCC:	O
Hepatocellular	O
carcinoma;	O
ALT:	O
Alanine	O
transaminase;	O
ALP:	O
Alkaline	O
phosphatase;	O
Bil:	O
Bilirubin;	B
Alb:	O
Albumin;	O
AFP:	O
α-fetoprotein;	B
NA:	O
Unavailable.	O

A	O
scatter	O
plot	O
of	O
one	O
of	O
these	O
signals	O
against	O
lactose	B
concentrations	O
closely	O
mirrored	O
the	O
clustering	O
found	O
in	O
using	O
PCA.	O

The	O
calibration	O
curves	O
were	O
linear	O
over	O
the	O
concentration	O
range	O
of	O
0.25–100	O
ng/ml	O
for	O
all	O
the	O
analytes	O
in	O
plasma	O
with	O
both	O
low	O
and	O
high	O
triglyceride	B
levels.	O

To	O
our	O
interest,	O
we	O
found	O
that	O
γ-aminobutyric	B
acid	I
(GABA)	O
was	O
included	O
in	O
module	O
turquoise.	O

There	O
was	O
a	O
small,	O
but	O
significant,	O
decrease	O
in	O
HDL-cholesterol	B
between	O
T0	O
and	O
T3;	O
however,	O
HDL-cholesterol	B
levels	O
recovered	O
by	O
T6;	O
as	O
further	O
supported	O
by	O
a	O
lack	O
of	O
change	O
in	O
Apo-A1	O
levels	O
between	O
T0	O
and	O
T6.	O

Although	O
not	O
directly	O
detected	O
by	O
the	O
NMR	O
approach	O
used	O
in	O
this	O
study,	O
our	O
results	O
strongly	O
suggest	O
that	O
glycine	B
could	O
be	O
a	O
highly	O
informative	O
biomarker	O
to	O
the	O
inflammatory	O
processes	O
that	O
characterize	O
IMIDs.	O

This	O
may	O
contribute	O
to	O
the	O
higher	O
detected	O
glycerol	B
levels	O
in	O
serum	O
compared	O
with	O
WB.	O

Moreover,	O
the	O
changes	O
of	O
fatty	O
acids	O
(,	O
)	O
and	O
acylcarnitines	B
were	O
associated	O
with	O
risk	O
for	O
type	O
2	O
diabetes	O
as	O
well.	O

The	O
trace	O
653.1/300.8	O
was	O
used	O
for	O
3,7-O	B
-Digluc	I
and	O
the	O
internal	O
standard	O
of	O
this	O
method,	O
paracetamol-3-β-d-glucuronide,	B
was	O
measured	O
on	O
the	O
transition	O
328.04/151.9.	O

colorectal	O
cancer,	O
hydroxystearic	B
acid,	I
fatty	O
acid	O
esters	O
of	O
hydroxy	B
fatty	O
acids,	O
apoptosis	O

The	O
total	O
concentrations	O
of	O
glutamate+glutamine	B
or	O
aspartate+asparagine	O
were	O
calculated	O
as	O
one	O
variable.	O

Cells	O
were	O
then	O
stimulated	O
to	O
express	O
iNOS	O
with	O
LPS	B
(1 μg/ml)	O
for	O
24 h.	O
Plasma	O
was	O
then	O
removed	O
and	O
immediately	O
assays	O
nitrite	B
levels	O
as	O
a	O
marker	O
of	O
iNOS	O
activity.	O

Our	O
findings	O
unveiled	O
the	O
potential	O
of	O
tryptophan	B
as	O
a	O
new	O
marker	O
associated	O
with	O
diabetes	O
risk	O
in	O
Chinese	O
populations.	O

*	O
Participants	O
who	O
had	O
major	O
adverse	O
cardiovascular	O
events	O
also	O
had	O
higher	O
baseline	O
levels	O
of	O
TMAO,	B
as	O
compared	O
with	O
those	O
who	O
did	O
not	O
have	O
cardiovascular	O
events	O
(median,	O
5.0	O
µM	O
[interquartile	O
range,	O
3.0	O
to	O
8.8]	O
vs.	O
3.5	O
µM	O
[interquartile	O
range,	O
2.4	O
to	O
5.9];	O
P<0.001).	O

The	O
column	O
was	O
eluted	O
with	O
500	O
µL	O
methanol	B
to	O
new	O
tube,	O
dried	O
by	O
SpeedVac	O
at	O
35°C,	O
and	O
dissolved	O
in	O
200	O
µL	O
methanol,	B
resulting	O
in	O
a	O
phospholipids	B
fraction.	O

The	O
slope	O
of	O
melatonin	B
over	O
the	O
night	O
correlated	O
with	O
several	O
self-reported	O
measures,	O
with	O
better	O
sleep	O
quality	O
associated	O
with	O
a	O
steeper	O
decrease	O
in	O
melatonin.	B

Intraoperative	O
use	O
of	O
ultra	O
high	O
mass	O
resolution	O
matrix-assisted	O
laser	O
desorption/ionization	O
mass	O
spectrometry	O
imaging	O
(MALDI-MSI),	O
which	O
allows	O
localization	O
and	O
delineation	O
between	O
functional	O
PA	O
and	O
healthy	O
pituitary	O
tissue,	O
may	O
contribute	O
to	O
achievement	O
of	O
complete	O
tumor	O
resection	O
in	O
addition	O
to	O
preservation	O
of	O
pituitary	O
cell	O
lines	O
and	O
vasopressin	B
secretory	O
cells,	O
thus	O
avoiding	O
postoperative	O
diabetes	O
insipidus.	O

Third,	O
the	O
length	O
of	O
inpatients	O
duration	B
is	O
relative	O
long.	O

The	O
retention	O
time	O
for	O
both	O
proline	B
and	O
IS	O
was	O
3.6	O
min.	O

fructose-6-phosphate,	B
myo-inositol-phosphate),	B
O	B
-phosphoethanolamine,	I
and	O
the	O
amino	O
acids	O
aspartate,	O
glutamate,	B
and	O
phenylalanine,	B
which	O
were	O
all	O
affected	O
by	O
both	O
a	O
6	O
h-blood	O
incubation	O
and	O
a	O
24	O
h-serum	O
storage	O
at	O
RT.	O

Moreover,	O
the	O
main	O
difficulty	O
for	O
a	O
pathologist	O
is	O
to	O
discriminate	O
between	O
steatosis	O
and	O
steatohepatitis,	O
especially	O
before	O
the	O
inflammation	O
and	O
hepatocyte	O
degenerations	O
appeared	O
(i.e	O
.	O
ballooning	O
and	O
Mallory’s	O
hyaline	B
bodies).	O

[1,2,3,4,5,6‐D6,	O
98%],	O
and	O
uric	B
acid	I

Fused	O
silica	B
tubing	O
(0.10	O
ID×0.19	O
mm	O
OD)	O
was	O
connected	O
to	O
the	O
ion	O
source	O
housing	O
of	O
a	O
Finnigan	O
TSQ	O
Quantum	O
Discovery	O
MAX	O
operating	O
in	O
electrospray	O
ionization	O
(ESI)	O
mode	O
for	O
sample	O
introduction.	O

Thyroid	O
hormones,	O
including	O
thyroxine,	B
are	O
synthesized	O
and	O
released	O
by	O
the	O
thyroid	O
gland	O
and	O
then	O
transported	O
into	O
the	O
CNS.	O

We	O
highlight	O
that	O
none	O
of	O
the	O
markers	O
identified	O
in	O
this	O
study	O
have	O
previously	O
been	O
related	O
to	O
CRC	O
with	O
the	O
exception	O
of	O
LPC	B
(18:1).	I

The	O
combination	O
of	O
glycerol	B
and	O
proline	B
was	O
shown	O
to	O
be	O
a	O
powerful	O
predictor	O
of	O
HCC	O
recurrence	O
after	O
treatment.	O

B12,	O
vitamin	O
B-12;	O
cB12,	O
combined	O
indicator	O
of	O
vitamin	O
B-12	O
status;	O
HoloTC,	O
holotranscobalamin;	O
MMA,	O
methylmalonic	B
acid;	I
tHcy,	O
total	O
plasma	O
homocysteine.	B

In	O
WB	O
extracts,	O
the	O
levels	O
of	O
ATP	B
and	O
ADP	B
in	O
three	O
types	O
of	O
tumor	O
patients	O
were	O
comparable,	O
but	O
the	O
levels	O
of	O
AMP	B
were	O
slightly	O
elevated	O
in	O
NF	O
tumors	O
(Table _S2	O
).	O

Notably,	O
indoleacetaldehyde	B
is	O
metabolized	O
to	O
indoleacetic	B
acid	I
by	O
aldehyde	O
dehydrogenase	O
7	O
family	O
member	O
A1	O
(ALDH7A1),	O
which	O
is	O
associated	O
with	O
aggressive	O
PCa	O
[,	O
].	O

PC	B
aa	I
C34:4;	I
101.	O

For	O
two	O
groups	O
of	O
metabolites–the	O
creatine	B
and	O
choline	B
compounds–the	O
NMR	O
peaks	O
could	O
not	O
always	O
be	O
resolved.	O

et	O
al.	O
found	O
that,	O
in	O
vitro	O
,	O
lactate	B
can	O
be	O
metabolized	O
by	O
some	O
but	O
not	O
all	O
types	O
of	O
BC	O
cells.	O

As	O
a	O
greater	O
understanding	O
of	O
the	O
requirement	O
for	O
choline	B
is	O
developed	O
for	O
the	O
lactating	O
dairy	O
cow	O
there	O
may	O
be	O
value	O
in	O
predicting	O
milk	O
choline	B
output	O
based	O
on	O
easily	O
measurable	O
variables	O
on	O
farm.	O

An	O
S-plot	O
corresponding	O
to	O
every	O
OPLS-DA	O
was	O
also	O
presented	O
in	O
the	O
figure,	O
which	O
showed	O
that	O
variables	O
related	O
to	O
the	O
ppm	O
values	O
of	O
β-glucose	B
are	O
the	O
most	O
reliable	O
variables	O
for	O
discrimination	O
of	O
two	O
groups.	O

Putrescine	B
is	O
a	O
basic,	O
polycationic	O
product	O
of	O
Arg	O
degradation	O
and	O
is	O
further	O
converted	O
into	O
spermidine	B
and	O
spermine.	B

PA	B
(38:4)	I
was	O
higher	O
in	O
infected	O
compared	O
to	O
mock-infected	O
cells	O
by	O
a	O
factor	O
of	O
approximately	O
3.5,	O
and	O
PG	B
(36:2)	I
did	O
not	O
change	O
significantly	O
in	O
infected	O
cells	O
through	O
96	O
hpi	O
(Dataset	O
S1).	O

A	O
targeted	O
ultrahigh-performance	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
with	O
electrospray	O
ionization	O
(UHPLC-ESI-MS/MS)	O
method	O
has	O
been	O
developed	O
for	O
the	O
quantification	O
of	O
tryptophan	B
and	O
its	O
downstream	O
metabolites	O
from	O
the	O
kynurenine	B
and	O
serotonin	B
pathways.	O

In	O
1961,	O
the	O
toxic	O
mold	O
Aspergillus	O
flavus	O
containing	O
aflatoxin	B
B_1	O
(AFB)	O
was	O
discovered	O
to	O
be	O
responsible	O
for	O
the	O
outbreak	O
of	O
deaths	O
of	O
turkeys	O
consuming	O
contaminated	O
meal	O
in	O
Britain.	O

ARG,	O
arginase;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase,	O
NOS,	O
nitric	B
oxide	I
synthase;	O
ODC,	O
ornithine	O
decarboxylase;	O
PRMT,	O
arginine	O
N-methyltransferase;	O
CD_i,	O
inflamed	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
CD_q,	O
quiescent	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
UC_n,	O
normal	O
small	O
bowel	O
tissue	O
obtained	O
from	O
patients	O
with	O
ulcerative	O
colitis;	O
_a	O
significantly	O
different	O
from	O
CD_q;	O
_b	O
significantly	O
different	O
from	O
UC_n;	O
_c	O
significantly	O
different	O
from	O
CD_i.	O

Furthermore,	O
the	O
identities	O
of	O
the	O
analytes	O
were	O
corroborated	O
by	O
acquisition	O
of	O
full	O
scan	O
product	O
ion	O
spectra,	O
employing	O
between	O
0.5	O
and	O
5	O
pg	B
of	O
analyte	O
for	O
assay.	O

2-chloro-ATP	B

This	O
result	O
hints	O
at	O
the	O
fundamental	O
tumor	O
biology	O
underlying	O
necrosis	O
by	O
imaging	O
ceramide	B
directly	O
and	O
potential	O
downstream	O
or	O
precursor	O
species	O
sphingomyelin	B
and	O
ceramide	B
phosphates.	I

In	O
A,	O
the	O
use	O
of	O
ammonium	B
formate	I
rather	O
than	O
water	O
as	O
modifier	O
additive	O
resulted	O
in	O
baseline	O
separation	O
of	O
uridine	B
and	O
cytosine	B
on	O
the	O
BEH	O
2-EP	O
column	O
and	O
improved	O
resolution	O
on	O
the	O
Diol	B
column;	O
however,	O
when	O
the	O
BEH	O
2-EP	O
column	O
was	O
replaced	O
by	O
the	O
Diol	B
column,	O
both	O
peak	O
shape	O
(B)	O
and	O
resolution	O
improved,	O
regardless	O
of	O
which	O
additive	O
is	O
used.	O

Therefore,	O
we	O
contrasted	O
plasma	O
hormone	O
concentrations	O
with	O
clinical	O
data	O
from	O
patients,	O
with	O
remarkably	O
interesting	O
results	O
obtained	O
for	O
7-oxo-DHEA.	B

Considering	O
the	O
fact	O
that	O
isotope	O
enhanced	O
NMR	O
enables	O
access	O
to	O
additional	O
low	O
concentration	O
metabolites,_,	O
carboxyl	O
group	O
containing	O
metabolites	O
in	O
both	O
protein	O
precipitated	O
and	O
ultrafiltered	O
serum	O
were	O
tagged	O
using	O
the	O
_15	O
N-cholamine	B
smart	O
tag,	O
and	O
the	O
_1	O
H–_15	O
N	O
2D	O
HSQC	O
spectra	O
were	O
evaluated.	O

Coletta	O
et	O
al	O
.	O
reported	O
that	O
the	O
deficiency	O
in	O
endothelial	O
nitric	B
oxide	I
synthase	O
(eNOS)	O
prevented	O
the	O
ability	O
of	O
H_2	O
S	O
to	O
induce	O
angiogenesis,	O
suggesting	O
that	O
NO	O
is	O
required	O
for	O
H_2	O
S	O
to	O
have	O
its	O
vascular	O
effects.	O

It	O
has	O
to	O
be	O
noted,	O
that	O
within	O
the	O
same	O
study	O
children	O
treated	O
with	O
theophylline	B
because	O
of	O
asthma	O
showed	O
a	O
transient	O
increase	O
in	O
plasma	O
T4,	O
which	O
would	O
fit	O
to	O
the	O
disappearance	O
of	O
the	O
FT4—trigonelline	O
association	O
in	O
longitudinal	O
analyses.	O

Increasing	O
1,5‐anhydro‐d‐glucitol	B
(1,5‐AG)	I
levels	O
were	O
associated	O
with	O
a	O
decreasing	O
trend	O
in	O
pancreatic	O
cancer	O
risk	O
(OR	O
of	O
quartile	O
4	O
[Q4],	O
0.50;	O
95%	O
CI,	O
0.27‐0.93;	O
P	O
=	O
.02).	O

The	O
results	O
obtained	O
with	O
the	O
samples	O
in	O
the	O
discovery	O
set	O
revealed	O
that	O
five	O
bile	O
acids,	O
GCA,	O
GCDCA,	B
TCA,	O
TCDCA	O
and	O
GUDCA	O
were	O
significantly	O
altered	O
among	O
the	O
three	O
CP	O
grades,	O
A,	O
B,	O
and	O
C.	O

9cRA,	O
a	O
member	O
of	O
structurally	O
simple	O
lipid	O
molecules	O
derived	O
from	O
retinol,	B
was	O
demonstrated	O
to	O
have	O
the	O
best	O
discriminative	O
performance	O
for	O
this	O
phenotype.	O

The	O
expression	O
level	O
if	O
HIF-1	O
can	O
be	O
induced	O
in	O
response	O
to	O
reduced	O
oxygen	O
availability	O
and	O
other	O
stimulants	O
(such	O
as	O
nitric	B
oxide	I
(NO)	O
or	O
various	O
growth	O
factors)	O
in	O
metabolic	O
processes.	O

Indeed,	O
a	O
low	O
protein	O
diet,	O
which	O
is	O
typical	O
for	O
patients	O
with	O
chronic	O
kidney	O
disease,	O
is	O
anticipated	O
to	O
be	O
low	O
in	O
dietary	O
nutrients	O
like	O
carnitine,	B
choline,	B
and	O
phosphatidylcholine	B
that	O
can	O
generate	O
TMAO[,	O
].	O

In	O
patients	O
treated	O
with	O
riluzole	B
alone,	O
we	O
identified	O
creatinine	B
as	O
a	O
key	O
metabolite	O
associated	O
with	O
clinical	O
variables.	O

The	O
significantly	O
altered	O
pathways	O
in	O
major	O
depressive	O
disorder	O
with	O
children	O
and	O
adolescents	O
and	O
adults	O
IPA	O
ingenuity	O
pathway	O
analysis,	O
MDD	O
major	O
depressive	O
disorder	O
In	O
addition,	O
adenosine,	B
inosine,	B
and	O
hypoxanthine,	B
the	O
various	O
products	O
of	O
adenosine	B
triphosphate	I
(ATP)	O
degradation,	O
were	O
decreased,	O
indicating	O
a	O
dysfunction	O
of	O
purine	B
metabolism	O
in	O
young	O
patients	O
with	O
DN-MDD.	O

However,	O
because	O
of	O
the	O
complexity	O
of	O
protein	O
digests,	O
even	O
a	O
digest	O
of	O
a	O
single	O
protein	O
such	O
as	O
Alb	O
can	O
contain	O
many	O
isobaric	O
interferences	O
and	O
restrict	O
the	O
usage	O
of	O
the	O
TQ	O
MS	O
for	O
the	O
characterization	O
of	O
peptide-toxicant	B
adducts.	O

(G)	O
Acetate	B
was	O
present	O
in	O
both	O
groups	O
but	O
at	O
a	O
higher	O
concentration	O
in	O
SpeedVac	O
samples.	O

The	O
amounts	O
of	O
polyamine	B
metabolome	O
in	O
plasma	O
and	O
urine	O
from	O
50	O
lung,	O
50	O
liver	O
cancer	O
patients	O
and	O
heathy	O
volunteers	O
were	O
shown	O
in	O
Tables	O
S1	O
and	O
S2.	O

For	O
taurine,	B
Fig.	O

Serotonin	B
levels	O
did	O
not	O
change	O
markedly	O
across	O
the	O
night.	O

Mobile	O
phase	O
A	O
(50%	O
methanol	B
containing	O
0.5	O
mM	O
ammonium	B
formate	I
at	O
pH	O
4	O
at	O
a	O
flow	O
rate	O
of	O
200	O
μL/min)	O
was	O
used	O
from	O
0	O
to	O
15	O
min,	O
followed	O
by	O
a	O
fast-gradient	O
100%	O
mobile	O
phase	O
B	O
(95%	O
methanol	B
containing	O
0.1%	O
formic	O
acid)	O
within	O
5	O
min.	O

In	O
agreement	O
with	O
their	O
metabolic	O
fate,	O
several	O
fatty	O
acids	O
with	O
an	O
even	O
number	O
of	O
carbon	O
atoms	O
(C8:0,	O
C12:0,	B
and	O
C18:2)	B
were	O
detected	O
postprandially	O
after	O
the	O
intake	O
of	O
the	O
soy	O
drink	O
in	O
the	O
serum	O
(this	O
report)	O
but	O
not	O
in	O
urine	O
samples.	O

The	O
spectra	O
were	O
manually	O
corrected	O
for	O
phase	O
and	O
baseline	O
distortions	O
and	O
were	O
referenced	O
to	O
α-glucose	B
signal	O
(δ	O
=	O
5.225	O
ppm).	O

As	O
shown	O
in	O
,	O
these	O
included	O
cytosolic	O
malic	O
enzyme,	O
NADP-isocitrate	O
dehydrogenase,	O
ATP-citrate	O
lyase,	O
glutamate	O
dehydrogenase,	O
aspartate	O
aminotransferase	O
and	O
citrate	B
synthase.	O

BMI,	O
body	O
mass	O
index;	O
GV,	B
growth	O
velocity;	O
%FFM,	O
percentage	O
of	O
fat	O
free	O
mass	O
measured	O
by	O
bioimpedance;	O
REE,	O
resting	O
energy	O
expenditure.	O

In	O
addition,	O
xenografts	O
generated	O
using	O
MCF	O
parental	O
cells	O
(MCF-7	O
L)	O
that	O
were	O
either	O
untreated	O
(termed	O
parental)	O
or	O
treated	O
with	O
tamoxifen	B
for	O
~ 2 weeks	O
(short-term	O
treatment	O
and	O
TAM-S)	O
or	O
~ 3 months	O
(long-term	O
treatment	O
and	O
TAM-R),	O
as	O
described	O
by	O
Massarweh	O
et	O
al.	O
were	O
used.	O

This	O
study	O
was	O
performed	O
in	O
healthy	O
patients,	O
so	O
it	O
is	O
not	O
possible	O
to	O
surmise	O
whether	O
this	O
would	O
translate	O
in	O
higher	O
likelihood	O
of	O
drug-induced	O
liver	O
toxicity,	O
although	O
sulfonation	O
of	O
hepatically-metabolized	O
drugs	O
is	O
a	O
common	O
occurrence	O
and	O
it	O
is	O
possible	O
that	O
p-cresol	B
sulfate	I
is	O
a	O
surrogate	O
marker	O
of	O
liver	O
function,	O
lower	O
levels	O
reflecting	O
reduced	O
sulfonation	O
in	O
those	O
patients	O
with	O
HCC	O
and	O
worse	O
liver	O
function.	O

The	O
metabolism	O
of	O
β-alanine,	B
π-methylhistidine,	B
and	O
histidine	B
are	O
closely	O
associated	O
to	O
each	O
other	O
and	O
with	O
carnosine.	B

The	O
tGlut	O
pool	O
correlated	O
positively	O
with	O
lactate	B
in	O
all	O
tumour	O
types,	O
including	O
oligodendrogliomas,	O
whereas	O
in	O
all	O
tumour	O
types	O
there	O
was	O
a	O
negative	O
correlation	O
between	O
tGlut	O
and	O
the	O
1.3ppm	O
fatty	O
acid	O
peak.	O

If	O
urine	O
needs	O
to	O
be	O
stored	O
at	O
22	O
°C	O
for	O
48	O
h	O
or	O
in	O
high	O
temperature	O
(40	O
°C)	O
conditions	O
for	O
24–48	O
h,	O
thymol	B
is	O
an	O
effective	O
preservative.	O

MRM	O
analysis	O
of	O
92	O
metformin-treated	O
T2DM	O
human	O
urine	O
samples	O
demonstrates	O
that	O
mean	O
IMZ	O
concentrations	O
have	O
a	O
statistically	O
significant	O
r	O
_2	O
value	O
(r	O
_2	O
=	O
0.5463;	O
p	O
<	O
0.0001)	O
with	O
metformin	B
concentrations.	O

In	O
the	O
esterified	O
PUFA	O
categories,	O
there	O
was	O
significant	O
postprandial	O
reduction	O
in	O
abundance	O
of	O
several	O
n-3	O
PUFAs,	O
particularly	O
docosahexaenoic	B
acid	I
(DHA),	O
docosapentaenoic	B
acid	I
(DPA),	O
and	O
eicosapentaenoic	B
acid	I
(EPA),	O
and	O
in	O
n-6	O
PUFA,	O
dihomo-γ-linolenic	B
acid	I
(DGLA).	O

In	O
our	O
study,	O
23.4%	O
of	O
the	O
patients	O
treated	O
with	O
everolimus	O
were	O
hyperglycemic,	B
a	O
condition	O
likely	O
created	O
by	O
the	O
fasting-mimicking	O
action	O
of	O
rapalogs	O
known	O
to	O
activate	O
liver	O
gluconeogenesis	O
and	O
glycogen	B
breakdown	O
[,	O
].	O

The	O
quantification	O
was	O
performed	O
by	O
selected	O
reaction	O
monitoring	O
(SRM)	O
at	O
negative	O
mode	O
to	O
detect	O
the	O
specific	O
precursor	O
to	O
product	O
ion	O
transitions	O
m/z	O
179	O
→	O
59	O
for	O
D-mannose,	B
and	O
m	O
/z	O
185	O
→	O
92	O
for	O
IS	O
(IS	O
fragmentation	O
pattern	O
is	O
shown	O
in	O
).	O

Alb	O
adducts	O
of	O
isothiocyanates	B
found	O
in	O
vivo.	O

Relative	O
to	O
the	O
total	O
microbiome,	O
Enterobacteriaceae	O
,	O
Lactobacillus	B
and	O
Clostridium	O
XIV	O
were	O
decreased	O
in	O
the	O
UC	O
population	O
compared	O
to	O
the	O
control	O
population	O
(E:	O
UC:	O
0.714 ± 1.67,	O
C:	O
1.16 ± 2.49,	O
p=0.28;	O
L:	O
UC:	O
0.035 ± 0.043,	O
C:	O
0.042 ± 0.057,	O
p=0.72;	O
CXIV	O
,	O
UC:	O
1.16 ± 1.51,	O
C:	O
2.82 ± 5.09,	O
p=0.28).	O

Enriched	O
biology	O
perturbed	O
by	O
α-oxoglutarate.	B

Downward	O
peaks	O
indicate	O
higher	O
concentrations	O
of	O
the	O
respective	O
metabolites	O
in	O
the	O
high–cystathionine	B
concentration	O
group,	O
and	O
upward	O
peaks	O
indicate	O
higher	O
concentrations	O
of	O
respective	O
metabolites	O
in	O
the	O
low–cystathionine	B
concentration	O
group.	O

For,	O
formate;	B
G,	O
glycerol;	B
Gln,	O
glutamine;	B
Glu,	O
glutamate;	B
Gly,	O
glycine;	B
GPC,	B
glycerolphosphocholine;	B
HG,	O
homogentisate;	B
HOD,	O
the	O
residual	O
water	O
resonance;	O
IB:	O
isobutyrate;	B
Ile,	O
isoleucine;	B
IP,	B
isopropanol;	B
L,	O
lipid;	O
Lac,	O
lactate;	B
LDL,	O
low	O
density	O
lipoprotein;	O
Leu,	O
leucine;	B
Lys,	O
lysine;	B
M,	O
malonate;	B
Met,	O
methionine;	B
MG,	O
methylguanidine;	B
m-I,	O
myo	O
-inositol;	O
Mol,	O
methanol;	B
NAS,	O
N-acetyl	B
glycoprotein	I
signals;	O
OAS,	O
O-acetyl	B
glycoprotein	I
signals;	O
Phe,	O
phenylalanine;	B
Py,	O
pyruvate;	B
Sar,	O
sarcosine;	B
Thr,	O
threonine;	B
TMAO,	B
trimethylamine	B
N-oxide;	I
Tyr,	O
tyrosine;	B
Val,	O
valine;	B
VLDL,	O
very	O
low	O
density	O
lipoprotein;	O
α-Glc,	B
α-glucose;	B
β-Glc,	B
β-glucose.	B

First	O
the	O
fingertip	O
was	O
cleaned	O
and	O
sterilised	O
with	O
an	O
ethanol	B
wipe	O
and	O
a	O
small	O
superficial	O
incision	O
was	O
made	O
with	O
the	O
help	O
of	O
a	O
2.25	O
mm	O
depth	O
sterile	O
blood	O
lancet	O
(Safety	O
Lancet;	O
HemoCue®;	O

These	O
disease-specific	O
metabolites	O
include	O
phenylacetylglycine	B
in	O
UC	O
(P	O
_UC	O
 = 2.7 × 10_–7	O
),	O
tyrosine	B
in	O
RA	O
(P	O
_RA	O
 = 5.7 × 10_–4	O
),	O
and	O
3-hydroxyisovaleric	B
(P	O
_CD	O
 = 1.1	O

(4)	O
50_HIGH:	O
50%	O
MeOH	B
quenching	O
solution	O
with	O
4	O
mL	O
of	O
CHCl_3	O
for	O
extraction	O
with	O
a	O
final	O
ratio	O
of	O
1:1:1	O
(MeOH:CHCl_3	O
:H_2	O
O)	O
and	O
collection	O
of	O
6	O
mL	O
polar	O
phase	O
for	O
analysis.	O

Anastrozole	B
is	O
oxidized	O
to	O
hydroxyanastrozole	B
mainly	O
by	O
CYP3A4/5	O
and	O
glucuronidated	O
to	O
anastrozole	B
glucuronide	I
predominantly	O
by	O
UGT1A4	O
in	O
vitro	O
.	O

Both	O
cell	O
types	O
showed	O
a	O
strong	O
decline	O
in	O
the	O
intracellular	O
amounts	O
of	O
glutamine	B
and	O
glutamate	B
as	O
well	O
as	O
extracellular	O
glutamine	B
concentrations	O
upon	O
treatment	O
with	O
rHla.	O

Taurine	B
was	O
the	O
only	O
metabolite	O
affected	O
by	O
sex	O
(p = 0.004,	O
not	O
included	O
in	O
Table	O
).	O

By	O
treatment	O
analysis,	O
the	O
association	O
between	O
myoinositol	B
and	O
VFD	O
in	O
GM-CSF-treated	O
patients	O
was	O
significant	O
(P	O
=	O
0.02),	O
but	O
it	O
was	O
not	O
in	O
placebo-treated	O
patients.	O

Oxylipin	B
profiling	O
was	O
performed	O
on	O
EDTA-plasma	O
derived	O
from	O
patients	O
before	O
and	O
after	O
cardiac	O
surgery.	O

Assigned	O
metabolites:	O
1	O
branched-chain	O
amino	O
acids;	O
2	B
3-hydroxyisovalerate;	I
3	O
lactate;	B
4	B
2-hydroxyisobutyrate;	I
5	O
alanine;	B
6	O
acetate;	B
7	O
N	O
-acetyl	O
groups;	O
8	O
glutamate;	B
9	B
2-hydroxy-glutarate;	I
10	O
pyruvate;	B
11	O
citrate;	B
12	O
dimethylamine;	B
13	O
sarcosine;	B
14	O
dimethylglycine;	B
15	O
creatinine;	B
16	O
cis-aconitic	B
acid;	I
17	O
trimethylamine-N	B
-oxide;	I
18	O
methanol;	B
19	O
trans-aconitic	B
acid;	I
20	O
taurine;	B
21	O
glycine;	B
22	O
serine;	B
23	O
hippurate;	B
24	O
pseudouridine;	B
25	O
threonine;	B
26	O
dihydroxyacetone;	B
27	O
trigonelline;	B
28	O
U1;	O
29	O
fumarate;	B
30	B
2-furoylglycine;	I
31	B
4-hydroxybenzoate;	I
32	B
3-methylhistidine;	I
33	O
phenylalanine;	B
34	O
histidine;	B
35	O
hypoxanthine;	B
36	O
formate;	B
37	B
4-imidazole-acetate	I

It	O
may	O
be	O
hypothesized	O
that	O
if	O
more	O
TRP	O
was	O
shuttled	O
to	O
the	O
KYN	O
pathway,	O
then	O
less	O
would	O
be	O
available	O
for	O
conversion	O
to	O
serotonin	B
and	O
melatonin,	B
potentially	O
affecting	O
sleep	O
adversely.	O

In	O
vivo	O
,	O
D-3-hydroxybutyrylcarnitine	B
can	O
be	O
converted	O
to	O
D-3-hydroxybutyric	B
acid,	I
which	O
is	O
the	O
predominant	O
ketone	B
body	O
found	O
during	O
diabetic	O
ketoacidosis	O
[–].	O

Transmission	O
electron	O
microscopy	O
(TEM)	O
was	O
performed	O
with	O
the	O
HITACHI	O
H-7600	O
(Tokyo,	O
Japan)	O
at	O
100	O
kV	B
to	O
visualize	O
the	O
EVs	O
isolated	O
from	O
the	O
human	O
plasma	O
and	O
serum.	O

Candidate	O
genes:	O
selection	O
of	O
genes	O
based	O
on	O
variant	O
evidence	O
(genes	O
hit	O
or	O
close-by,	B
eQTL,	O
potentially	O
regulatory	O
effects,	O
or	O
missense	O
variants).	O

Then,	O
1	O
mL	O
methanol	B
(-20°C)	O
was	O
used	O
for	O
extraction,	O
following	O
addition	O
of	O
30	O
μL	O
2-chloro-L-phenylalanine	B
(0.2	O
mg/mL)	O
and	O
60	O
μL	O
heptadecanoic	B
acid	I
(0.05	O
mg/mL)	O
as	O
internal	O
standards.	O

Glutaminase	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
level	O
of	O
glutamate	B
in	O
humans	O
by	O
converting	O
glutamine	B
to	O
glutamate	B
in	O
cells.	O

Protein	O
precipitation	O
using	O
methanol	B
provided	O
well-resolved	O
_1	O
HNMR	O
spectra	O
for	O
all	O
the	O
serum	O
samples.	O

ACS	O
reagent-grade	O
formic	B
acid	I
(88%)	O
was	O
purchased	O
from	O
J.T.	O
Baker	O
(Phillipsburg,	O
NJ).	O

Using	O
reserpine	B
as	O
an	O
example,	O
the	O
parameters	O
for	O
MassWorks	O
sCLIPS	O
algorithms	O
were:	O
mass	O
tolerance,	O
5	O
ppm;	O
electron	O
state,	O
even;	O
double	O
bond	O
equivalent	O
range,	O
−3	O
to	O
50;	O
profile	O
mass	O
range,	O
−1	O
to	O
3.5	O
Da;	O
calibration	O
range,	O
−0.1	O
to	O
0.1	O

SAM	O
also	O
tightly	O
regulates	O
polyamine	B
synthesis	O
and	O
serves	O
as	O
the	O
sole	O
donor	O
of	O
an	O
aminopropyl	O
group	O
that	O
conjugates	O
with	O
putrescine	B
to	O
form	O
the	O
polyamine	B
spermidine,	I
and	O
then	O
spermine.	B

We	O
separated	O
the	O
target	O
analytes	O
on	O
a	O
pair	O
of	O
monolithic	O
RP-18	O
column	O
by	O
using	O
a	O
gradient	O
of	O
water	O
and	O
methanol,	B
including	O
ammonium	B
fluoride	I
(0.1	O
mM)	O
in	O
both	O
mobile	O
phases.	O

Recent	O
work	O
on	O
cancer	O
metabolomics	O
has	O
shown	O
that	O
glycine	B
uptake	O
is	O
associated	O
with	O
cancel	O
cell	O
proliferation	O
through	O
its	O
involvement	O
in	O
one-carbon	O
metabolism	O
(Zhang	O
et	O
al.	O
).	O

The	O
chemical	O
shifts	O
were	O
referenced	O
to	O
the	O
methyl	B
group	I
of	O
TSP	O
at	O
δ	O
0.00	O
for	O
the	O
spectra	O
of	O
urine.	O

Gut	O
bacteria	O
of	O
genus	O
Lactobacillus	B
catalyze	O
the	O
conversion	O
of	O
cholesterol	B
metabolites	O
to	O
coprostanol	B
(COPR)	O
and	O
can	O
limit	O
the	O
intestinal	O
absorption	O
of	O
cholesterol.	B

In	O
the	O
majority	O
of	O
the	O
cases,	O
a	O
collection	O
of	O
lipid	O
species	O
encompassing	O
different	O
classes,	O
such	O
as	O
fatty	O
acids	O
and	O
glycerophospholipids,	B
were	O
observed	O
as	O
the	O
discriminating	O
molecules	O
when	O
comparing	O
cancer	O
and	O
normal	O
tissues.	O

Furthermore,	O
the	O
disturbed	O
lipid	O
metabolism	O
would	O
be	O
reflected	O
by	O
changes	O
in	O
serum	O
lipid	O
metabolite	O
concentrations,	O
notably	O
levels	O
of	O
lysoPCs,	O
phosphatidylcholines	B
(PCs),	O
acylcarnitines	B
(AC),	O
and	O
sphingomyelins	B
(SM).	O

Detailed	O
analysis	O
of	O
the	O
_1	O
H	O
NMR	O
data	O
(Resource _3	O
)	O
revealed	O
the	O
presence	O
of	O
a	O
methoxy	B
group	O
(δ	O
_H	O
3.85)	O
and	O
four	O
aromatic	O
protons	O
at	O
δ	O
_H	O
7.35	O
(H-3	O
and	O
H-5)	O
and	O
7.92	O
(H-2	O
and	O
H-6).	O

OPLS-DA,	O
orthogonal	O
partial	O
squares	O
discriminant	O
analysis;	O
non-HFS,	O
non-supplemented	O
group;	O
HFS,	O
high	O
fat	O
supplement	O
group;	O
preDC,	O
day	O
before	O
discharge;	O
postDC,	O
first	O
outpatient	O
visit	O
day	O
after	O
discharge;	O
LysoPC,	O
lysophosphatidylcholine;	B
SM,	O
sphingomyelin;	B
PE,	O
phosphatidylethanolamine;	B
NRI,	O
nutritional	O
risk	O
index.	O

The	O
enhanced	O
predictive	O
ability	O
of	O
the	O
ibuprofen	B
model	O
probably	O
reflects	O
the	O
fact	O
that	O
ibuprofen	B
metabolites	O
are	O
more	O
defined	O
and	O
less	O
overlapped	O
in	O
the	O
urinary	O
spectra	O
than	O
those	O
from	O
acetaminophen.	B

Valine	B
was	O
previously	O
reported	O
to	O
have	O
a	O
significantly	O
different	O
level	O
in	O
HCC	O
vs.	O
normal	O
controls	O
in	O
analysis	O
of	O
tissues	O
by	O
LC-MS	O
and	O
serum	O
samples	O
by	O
GC-MS.	O

Subsequently,	O
a	O
volume	O
of	O
500	O
μL	O
of	O
the	O
supernatant	O
was	O
transferred	O
into	O
an	O
Eppendorf	O
vial,	O
to	O
which	O
50	O
μL	O
of	O
a	O
stock	O
solution	O
of	O
sodium	B
(3-trimethylsilyl)-2,	I
2,	I
3,	I
3-tetradeuteriopropionate	I
(TSP)	O
/D_2	O

The	O
nuclear	O
and	O
mitochondrial	O
fractions	O
were	O
removed	O
by	O
centrifugation	O
and	O
1	O
mg/ml	O
of	O
the	O
lysate	O
was	O
incubated	O
for	O
1	O
h	O
at	O
37°C	O
in	O
the	O
presence	O
of	O
100%	O
O_2	O
with	O
exogenous	O
AA	O
(40	O
μM),	O
1	O
mM	O
NADPH	B
and	O
2	O
μM	O
indomethacin	B
(to	O
prevent	O
metabolism	O
of	O
20-HETE	B
by	O
COX).	O

We	O
first	O
applied	O
this	O
chemical	O
networking	O
approach	O
to	O
m/z	O
313.2384	O
which	O
exhibited	O
two	O
identifiable	O
oxylipin	B
peaks	O
and	O
18	O
unknown	O
isobaric	O
features.	O

The	O
targeted	O
approach	O
used	O
in	O
the	O
present	O
study	O
gives	O
an	O
overview	O
of	O
four	O
main	O
metabolic	O
areas:	O
amino	O
acids	O
(and	O
biogenic	O
amines),	O
glucose	B
(sum	O
of	O
hexose	B
which	O
is	O
widely	O
represented	O
by	O
glucose	B
(90–95%)),	O
fatty	O
acids	O
(40	O
acylcarnitines)	B
and	O
lipid	O
metabolism	O
(glycerophospholipids	O
and	O
sphingolipids).	B

Zheng	O
et	O
al.	O
reported	O
that	O
higher	O
urinary	O
α-hydroxybutyrate	B
suggests	O
increased	O
oxidative	O
stress	O
in	O
BD	O
patients,	O
and	O
Andreazza	O
et	O
al.	O
reported	O
that	O
increased	O
oxidative	O
stress	O
is	O
associated	O
with	O
the	O
pathophysiology	O
of	O
BD.	O

The	O
metabolomics	O
analysis	O
of	O
serum	O
showed	O
lower	O
leucine	B
and	O
isoleucine	B
and	O
higher	O
betaine	B
and	O
N,N-dimethylglycine	B
levels	O
after	O
RB	O
than	O
WB	O
intake.	O

The	O
transformation	O
of	O
a	O
normal	O
cell	O
into	O
a	O
tumor	O
cell	O
mediates	O
through	O
diverse	O
metabolic	O
pathways	O
(e.g.,	O
glycolysis,	O
Krebs	O
cycle,	O
urea	B
cycle,	O
osmoregulation,	O
eicosanoid	B
biosynthesis,	O
lipid	O
metabolism,	O
etc.).	O

Prostaglandins.	B
13	O

There	O
is	O
a	O
definite	O
interplay	O
of	O
several	O
pathways	O
involving	O
methionine	B
and	O
cysteine;	B
glucose	B
and	O
xylitol	B
metabolism;	O
tyrosine	B
metabolism;	O
vitamin	B
B3	I
(nicotinate	O
and	O
nicotinamide)	B
metabolism;	O
and	O
the	O
pentose	B
6	O
phosphate	B
pathway.	O

After	O
controlling	O
for	O
BMI,	O
there	O
was	O
a	O
significant	O
difference	O
observed	O
for	O
C16:0	B
(p	O
=	O
0.025),	O
C18:1n9c	O
(p	O
=	O
0.018)	O
and	O
total	O
MUFA	O
(p	O
=	O
0.015)	O
between	O
males	O
and	O
females.	O

The	O
flow-rate	O
was	O
1 mL/min	O
or	O
1.2 mL/min,	O
depending	O
upon	O
whether	O
isopropanol	B
or	O
methanol	B
(respectively)	O
was	O
used	O
as	O
modifier.	O

Most	O
studies	O
examining	O
the	O
relationships	O
between	O
vitamin	B
D	I
and	O
disease	O
or	O
health	O
focus	O
on	O
the	O
main	O
25-hydroxyvitamin	B
D_3	O
(25(OH)D_3	O
)	O
metabolite,	O
thus	O
potentially	O
overlooking	O
contributions	O
and	O
dynamic	O
effects	O
of	O
other	O
vitamin	B
D	I
metabolites,	O
the	O
crucial	O
roles	O
of	O
several	O
of	O
which	O
have	O
been	O
previously	O
demonstrated.	O

The	O
different	O
GG	O
classes	O
(different	O
sugar	O
chains)	O
and	O
the	O
different	O
ceramide	B
types	O
(total	O
number	O
of	O
carbons	O
and	O
unsaturations)	O
could	O
thus	O
be	O
discriminated.	O

Our	O
results	O
demonstrated	O
significantly	O
decreased	O
levels	O
of	O
lactose	B
in	O
IBD	O
mothers’	O
breast	O
milk	O
at	O
PP3,	O
which	O
suggested	O
that	O
the	O
lower	O
lactose	B
in	O
IBD	O
milk	O
could	O
dampen	O
the	O
gut	O
health	O
of	O
neonates	O
by	O
decreasing	O
the	O
growth	O
of	O
potentially	O
beneficial	O
bacteria	O
and	O
promoting	O
potential	O
pathobionts.	O

Using	O
a	O
hierarchical	O
mixture	O
model,	O
they	O
identified	O
11	O
metabolites	O
which	O
were	O
associated	O
with	O
25(OH)D	O
levels ≥ 20 ng/ml:	O
higher	O
pyridoxate,	B
bilirubin,	B
xylose	B
and	O
cholate	B
levels,	O
as	O
well	O
as	O
lower	O
leukotrienes,	O
1,2-propanediol,	B
azelate,	B
undecanedioate,	B
sebacate,	B
inflammation-associated	O
complement	O
component	O
3	O
peptide	O
(HWESASXX)	O
and	O
piperine.	B

Hexadeuterated	O
surrogates	O
of	O
vitamin	B
D	I
metabolites	O
were	O
found	O
to	O
elute	O
~0.03	O
min	O
earlier	O
than	O
their	O
native	O
analogs	O
(see	O
).	O

The	O
cutaneous	O
melanoma	O
dataset	O
for	O
KP	B
related	O
analyses	O
in	O
melanoma	O
patients	O
was	O
comprised	O
of	O
mRNA-seq	O
data	O
(data	O
accessed	O
at	O
cBioPortal	O
for	O
Cancer	O
Genomics	O
in	O
December	O
2017,	O
http://www.cbioportal.org/).	O

The	O
coefficient	O
of	O
variation	O
for	O
alanine,	B
fatty	O
acids,	O
lactate,	B
acetoacetate,	B
ß-glucose,	B
histidine,	B
and	O
formate	B
was	O
0.2,	O
0.3,	O
0.4,	O
0.5,	O
0.4,	O
0.1,	O
and	O
0.7,	O
respectively.	O

N-acetylserotonin	B
is	O
further	O
methylated	O
by	O
N-acetylserotonin	O
O-methyltransferase	O
(ASMT)	O
to	O
generate	O
the	O
neurohormone	O
5-methyl-5-methoxy-N-tryptamine	B
or	O
melatonin.	B

Increased	O
urinary	O
carnitine	B
may,	O
therefore,	O
correspond	O
to	O
excess	O
carnitine	B
ingestion,	O
increased	O
biosynthesis,	O
or	O
poor	O
reabsorption	O
and	O
may	O
reflect	O
overproduction	O
of	O
tumor	O
carnitine	B
to	O
maintain	O
rapid	O
growth	O
and	O
fuel	O
mitochondrial	O
activity[].	O

Prostaglandin	B
(PG)E_2	O
,	O
one	O
of	O
the	O
main	O
cyclooxygenase	O
(COX)	O
products	O
suppressed	O
by	O
the	O
COX-inhibitor,	O
ASA,	O
has	O
a	O
well-established	O
pro-tumorigenic	O
role	O
in	O
CRC	O
development	O
(–)	O
and	O
oral	O
treatment	O
with	O
ASA	O
was	O
found	O
to	O
decrease	O
colonic	O
tissue	O
PGE_2	O
levels	O
in	O
individuals	O
suffering	O
from	O
CRC.	O

For	O
the	O
cross-sectional	O
analyses,	O
we	O
evaluated	O
three	O
categorically-defined	O
metabolic	O
risk	O
factors:	O
obesity	O
(BMI	O
≥30 kg/m_2	O
),	O
dysglycemia	O
(fasting	O
blood	O
glucose	B
≥100 mg/dL	O

Ribonucleotide	O
reductase	O
has	O
three	O
isoforms,	O
M1	O
(RRM1),	O
M2	O
(RRM2),	O
and	O
M2b	O
(RRM2b),	O
all	O
of	O
which	O
are	O
key	O
enzymes	O
in	O
the	O
process	O
of	O
DNA	O
replication	O
and	O
catalyzes	O
the	O
conversion	O
of	O
UDP	B
and	O
cytidine	B
diphosphate	I
(CDP)	O
to	O
their	O
respective	O
deoxygenated	O
versions	O
(dUDP/dCDP),	O
which	O
are	O
then	O
used	O
for	O
DNA	O
synthesis.	O

Side	O
effects	O
of	O
tamoxifen	B
seem	O
to	O
be	O
related	O
to	O
the	O
serum	O
levels	O
of	O
tamoxifen	B
and	O
its	O
metabolites	O
[,	O
].	O

For	O
metabolites	O
that	O
were	O
quantified	O
using	O
both	O
NMR	O
and	O
GCMS	O
platforms,	O
including	O
glutamate,	B
pyruvate,	B
lactate	B
and	O
citrate,	B
the	O
stage-wise	O
trends	O
were	O
consistent.	O

The	O
potential	O
existence	O
of	O
a	O
modest	O
functional	O
vitamin	O
B-6	O
insufficiency	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
is	O
further	O
suggested	O
by	O
the	O
trend	O
toward	O
a	O
higher	O
hydroxykynurenine:xanthurenic	O
acid	O
(XA)	O
ratio	O
(P	O
=	O
0.094),	O
a	O
functional	O
biomarker	O
of	O
vitamin	O
B-6	O
insufficiency.	O

Understanding	O
the	O
nature	O
of	O
SL	B
metabolism	O
and	O
its	O
pathological	O
effect	O
on	O
the	O
AERD	O
phenotype	O
would	O
be	O
useful	O
in	O
developing	O
novel	O
therapeutic	O
strategies	O
as	O
well	O
as	O
early	O
diagnostic	O
tools.	O

Several	O
amino	O
acids,	O
cysteine,	B
serine,	B
asparagine,	B
arginine,	B
orthinine,	O
tyrosine	B
and	O
taurine,	B
showed	O
an	O
increased	O
abundance	O
in	O
the	O
CON	O
group	O
as	O
compared	O
to	O
the	O
NP	O
group	O
and	O
only	O
valine,	B
an	O
increased	O
abundance	O
in	O
the	O
NP	O
group.	O

Next,	O
we	O
investigated	O
in	O
the	O
group	O
of	O
LMNA	O
mutation	O
carriers	O
if	O
and	O
how	O
are	O
the	O
detected	O
lipid	O
changes	O
reflected	O
in	O
cardiac	O
shape	O
and	O
volume	O
changes	O
as	O
measured	O
by	O
cine	B
MR	O
imaging.	O

Both	O
E_1	B
-9-N-Ade	I
and	O
E_2	B
-9-N-Ade	I
adducts	O
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
and	O
were	O
used	O
to	O
probe	O
estrogen	B
metabolic	O
pathway	O
in	O
vitro	O
and	O
in	O
humans.	O

Remarkably,	O
the	O
change	O
of	O
cysteine	B
is	O
specific	O
in	O
chronic	O
AD	O
patients.	O

The	O
serum	O
levels	O
of	O
these	O
cytokines	O
for	O
the	O
ER(−)	O
and	O
ER(+)	B
groups	O
are	O
summarized	O
in	O
Figure	O
S2.	O

-9,	O
cis	O
)	O
(solid	O
lines)	O
and	O
PE	B
18:1(n	I
-9,	I
trans	I
)/18:1(n	I

In	O
a	O
recent	O
study	O
using	O
an	O
alternative	O
targeted	O
metabolomics	O
platform,	O
differences	O
in	O
indoleamine	O
2,3-dioxygenase-dependent	O
tryptophan	O
metabolites,	O
tricarboxylic	B
acid	I
intermediates,	O
purine	B
metabolites,	O
and	O
arginine-nitric	B
oxide	I
metabolic	O
pathway	O
constituents	O
were	O
associated	O
with	O
right	O
ventricular–pulmonary	O
vascular	O
dysfunction.	O

Abiraterone	B
and	O
D_4	B
-abiraterone	I
were	O
for	O
at	O
least	O
stable	O
for	O
6	O
months	O
in	O
stock	O
solution.	O

It	O
also	O
involves	O
in	O
the	O
pathogenesis	O
of	O
panic	O
disorder,	O
anxiety	O
and	O
pain	O
in	O
FD.	B

Carnitine;	B
89.	O

Metabolites	O
of	O
choline	B
were	O
analyzed	O
using	O
HILIC	O
LC-MS/MS	O
based	O
on	O
methods	O
outlined	O
by	O
Zhao	O
et	O
al.	O
.	O

A	O
portion	O
of	O
the	O
_1	O
H-_15	O
N	O
HSQC	O
spectrum	O
of	O
a	O
mixture	O
of	O
standard	O
compounds	O
at	O
various	O
concentrations	O
obtained	O
after	O
tagging	O
with	O
_15	O
N-cholamine.	B

Finally,	O
1μ	B
L	I
of	O
sample	O
was	O
removed	O
with	O
a	O
glass	O
microsyringe	O
(Hamilton,	O
Bonaduz,	O
GR,	O
Switzerland)	O
and	O
manually	O
injected	O
into	O
the	O
chromatograph.	O

	O
PBMCs	O
were	O
isolated	O
from	O
peripheral	O
blood	O
(diluted	O
1.6	O
times	O
with	O
10%	O
phosphate	B
buffered	O
saline)	B
by	O
density	O
gradient	O
centrifugation	O
(800	O
×	O
g	O
for	O
25	O
min	O
at	O
room	O
temperature)	O
over	O
Isolymph	O
(specific	O
gravity	O
1.077)	O
(CT	O
Scientific	O
Supply	O
Corp.,	O
Deer	O
Park,	O
NY,	O
USA)	O
in	O
Leucosep	O
tubes	O
(Greiner	O
Bio-One,	O
Tokyo	O
Japan)	O
for	O
use	O
in	O
the	O
NK	O
cell	O
activity	O
assay.	O

Currently,	O
tris(1,3-dichloropropyl)	B
phosphate	I
(TDCIPP)	O
and	O
triphenyl	B
phosphate	I
(TPHP)	O
are	O
among	O
the	O
most	O
commonly	O
used	O
flame	O
retardants.	O

Patient	O
3	O
started	O
treatment	O
with	O
para	B
-aminosalicylic	I
acid,	I
ciprofloxacin,	B
cycloserine,	O
EMB	O
and	O
streptomycin	B
due	O
to	O
advanced	O
liver	O
disease,	O
alcoholic	O
cirrhosis	O
in	O
the	O
setting	O
of	O
hepatitis	O
C	O
infection;	O
however,	O
after	O
normalization	O
of	O
liver	O
function,	O
this	O
patient	O
was	O
switched	O
to	O
RMP,	O
Ciprofloxacin,	B
EMB	O
and	O
Streptomycin	B
until	O
the	O
treatment	O
completion.	O

Unexpectedly,	O
serum	O
levels	O
of	O
a	O
cholesterol	B
biosynthetic	O
intermediate,	O
14-desmethyl	B
lanosterol,	I
and	O
the	O
ring-structure	O
oxysterol	B
4β-hydroxycholesterol	I
also	O
correlated	O
significantly	O
(r	O
>	O
0.38)	O
with	O
plant	O
sterols.	O

The	O
bootstrapped	O
log2-fold	O
changes	O
for	O
the	O
main	O
lipid	O
classes	O
and	O
ceramides	B
involved	O
in	O
CV	O
disease	O
are	O
depicted	O
in	O
Fig.	O

Standard	O
calibration	O
curves	O
were	O
prepared	O
using	O
the	O
following	O
concentration	O
ranges:	O
5–250	O
µM	O
for	O
arginine,	B
0.05–2.5	O
µM	O
for	O
ADMA	B
and	O
SDMA,	O
1–50	O
µM	O
for	O
citrulline,	B
and	O
0.14–7.0	O
µM	O
for	O
DMA.	B

Lactate	B
still	O
correlated	O
positively	O
with	O
alanine,	B
but	O
it	O
correlated	O
negatively	O
rather	O
than	O
positively	O
with	O
tCr;	O
furthermore,	O
lactate	B
correlated	O
negatively	O
with	O
tCho	O
and	O
tGlut,	O
and	O
tGlut	O
correlated	O
positively	O
with	O
tCho	O
(	O
and	O
).	O

As	O
observed	O
in	O
IS	O
hypogonadism,	O
IR	O
hypogonadism	O
is	O
associated	O
with	O
increased	O
proline	B
and	O
lysine	B
levels.	O

All	O
analyte	O
standards	O
including	O
methylarginines	B
(listed	O
in	O
Supplementary	O
Table _1	O
)	O
were	O
obtained	O
from	O
Sigma-Aldrich	O
(Gillingham,	O
U.K.).	O

Using	O
a	O
logistic	O
regression	O
algorithm,	O
a	O
metabolite	O
panel	O
consisting	O
of	O
L-3-hydroxykynurenine,	B
1,7-dimethylguanosine,	B
and	O
tetrahydroaldosterone-3-glucuronide	B
was	O
used	O
to	O
establish	O
a	O
robust	O
model	O
for	O
distinguishing	O
between	O
RCC	O
and	O
benign	O
samples.	O

Internal	O
standard	O
Erlotinib-d6	B
was	O
acquired	O
from	O
Toronto	O
Research	O
Chemicals	O
Inc.	O
(North	O
York,	O
ON,	O
Canada).	O

Methylated	O
2-hydroxylated	O
EM	O
may	O
actually	O
inhibit	O
methylation	O
of	O
4-hydroxylated	B
catechols.	I

Only	O
a	O
very	O
minor	O
amount	O
of	O
cholesterol	B
(<1	O
ng/ml)	O
was	O
found	O
to	O
leak	O
into	O
fraction	O
SPE1-Fr-1.	B

At	O
the	O
right	O
side	O
of	O
the	O
inset	O
are	O
shown	O
the	O
structures	O
proposed	O
for	O
these	O
abundant	O
fragments,	O
including	O
the	O
fragment	O
observed	O
at	O
m/z	O
133.0659	O
that	O
results	O
from	O
loss	O
of	O
a	O
CO	O
group,	O
and	O
the	O
ion	O
at	O
m/z	O
91.0556,	O
which	O
can	O
be	O
assigned	O
as	O
the	O
result	O
from	O
cleavage	O
adjacent	O
to	O
the	O
carbon	O
located	O
in	O
the	O
α-position	O
with	O
respect	O
to	O
the	O
benzene	B
ring.	O

To	O
test	O
whether	O
these	O
polymorphisms	O
(along	O
with	O
others)	O
accounted	O
for	O
some	O
of	O
the	O
wide	O
interindividual	O
variability	O
observed	O
in	O
our	O
panel	O
of	O
human	O
liver	O
microsomes,	O
we	O
carried	O
out	O
an	O
exploratory	O
genotype-phenotype	O
association	O
analysis	O
between	O
the	O
most	O
common	O
genetic	O
variants	O
in	O
UGT1A4	O
and	O
UGT2B7	O
and	O
anastrozole	B
glucuronidation	O
formation	O
rates.	O

Among	O
the	O
24	O
metabolites	O
of	O
the	O
plasma	O
samples,	O
9	O
metabolites	O
(choline,	O
niacinamide,	B
betaine,	B
L-valine,	B
L-lactic	O
acid/TF-methoxyacetic	O
acid/glyceraldehyde,	O
creatine,	B
glycerophosphocholine,	B
creatinine,	B
and	O
3-methyl-2-oxovaleric	B
acid/2-ketohexanoic	I
acid)	O
had	O
VIP	O
values	O
above	O
3.0,	O
which	O
indicated	O
a	O
strong	O
difference	O
between	O
the	O
AF	B
and	O
non-AF	O
groups.	O

Sarcosine	B
has	O
been	O
reported	O
in	O
other	O
disease	O
conditions	O
ranging	O
from	O
HIV	O
to	O
cancer_,	O
.	O

Also,	O
no	O
deuterated	O
internal	O
standards	O
were	O
available	O
for	O
the	O
glucuronide	B
conjugates,	O
making	O
it	O
difficult	O
to	O
compensate	O
for	O
matrix	O
suppression	O
that	O
could	O
lead	O
to	O
underestimation	O
of	O
urine	O
concentrations.	O

Two	O
VOCs	O
were	O
found	O
consistently	O
and	O
significantly	O
altered	O
between	O
RCC	O
and	O
controls	O
(2‐oxopropanal	O
and,	O
according	O
to	O
identification	O
using	O
NIST14,	B
2,5,8‐trimethyl‐1,2,3,4‐tetrahydronaphthalene‐1‐ol),	I
strongly	O
suggesting	O
enhanced	O
potential	O
as	O
RCC	O
biomarkers.	O

These	O
patients	O
also	O
presented	O
with	O
normal	O
triglycerides,	B
total	O
and	O
HDL-cholesterol,	B
and	O
lipoprotein	O
phospholipids	B
in	O
whole	O
plasma.	O

At	O
50	O
and	O
100	O
μM	O
kynurenine,	B
CD8	O
T	O
cell	O
death	O
increased	O
as	O
measured	O
by	O
a	O
fixable	O
viability	O
dye,	O
while	O
CFSE	O
analysis	O
of	O
live	O
CD8	O
T	O
cells	O
indicated	O
no	O
change	O
in	O
proliferation,	O
demonstrating	O
a	O
direct	O
impact	O
of	O
kynurenine	B
specifically	O
on	O
human	O
CD8	O
T	O
cell	O
viability.	O

Changes	O
in	O
choline	B
concentration	O
were	O
evident	O
in	O
both	O
the	O
AF	B
and	O
the	O
PL.	O

However,	O
sarcosine	B
levels	O
were	O
elevated	O
only	O
in	O
tissue	O
biopsies	O
with	O
a	O
Gleason	O
pattern	O
of	O
8	O
or	O
worse	O
in	O
the	O
McDunn	O
et	O
al	O
report.	O

Exclusion	O
criteria	O
for	O
the	O
study	O
were	O
as	O
follows:	O
recent	O
glucocorticoid	B
treatment	O
(within	O
3	O
months),	O
pregnancy,	O
age	O
younger	O
than	O
18	O
or	O
older	O
than	O
40	O
years,	O
recent	O
oral	O
contraceptive	O
use	O
(within	O
3	O
months),	O
hyperprolactinemia,	O
thyroid	O
disorders,	O
and	O
frank	O
hyperglycemia.	O

Carnitine	B
(10:0),	I
a	O
medium-chain	O
acyl	O
carnitine,	O
which	O
supports	O
fatty	O
acid	O
oxidation	O
effectively,	O
was	O
also	O
decreased.	O

Plasma	O
LPC	O
species	O
after	O
4	O
h	O
infusion	O
of	O
rHDL	O
or	O
saline	B
placebo	O
rHDL,	O
reconstituted	O
HDL;	O
LPC,	O
lysophosphatidylcholine.	B

The	O
plasma	O
levels	O
of	O
valine,	B
leucine,	B
creatine,	B
citrate,	B
glycine,	B
and	O
formic	B
acid	I
were	O
unaffected	O
in	O
both	O
groups	O
before	O
and	O
after	O
surgery,	O
and	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
groups	O
of	O
patients	O
who	O
underwent	O
different	O
surgeries.	O

Creatinine	B
was	O
quantified	O
in	O
24-h	O
urine	O
specimens	O
using	O
a	O
photometric	O
assay	O
based	O
on	O
the	O
Jaffé	O
reaction	O
(DetectX_®	O
Urinary	O
Creatinine	B
Detection	O
Kit;	O
Arbor	O
Assays,	O
Ann	O
Arbor,	O
MI,	O
USA).	O

As	O
the	O
Finnish	O
patient	O
group	O
has	O
a	O
history	O
of	O
willingly	O
participating	O
in	O
research	O
of	O
their	O
disease,	O
the	O
study	O
recruitment	O
and	O
contact	O
information	O
was	O
collected	O
with	O
the	O
help	O
of	O
the	O
APECED	O
patient’s	O
association	O
(APECED	O
ja	O
Addison	O
Ry,	B
http://www.apeced.org).	O

DKD	O
was	O
associated	O
with	O
elevated	O
triglycerides,	B
lower	O
HDL	B
cholesterol	I
and	O
decreased	O
albumin	O
in	O
the	O
LIPO	O
window.	O

The	O
metabolite	O
sets	O
enrichment	O
analysis	O
demonstrated	O
that	O
aspartate	B
metabolism	O
and	O
urea	B
cycle	O
were	O
the	O
most	O
important	O
pathways	O
in	O
papillary	O
thyroid	O
cancer	O
progression.	O

Decreased	O
androgen	O
levels	O
resulted	O
in	O
significant	O
decreases	O
of	O
lactate	B
and	O
t-choline	B
concentrations	O
in	O
human	O
prostate	O
cancer	O
biopsies.	O

NRTI-triphosphates	B
(NRTI-TP)	O
compete	O
with	O
endogenous	O
2′-deoxyribonucleosides-5′-triphosphates	O
(dNTP)	O
for	O
incorporation	O
by	O
the	O
HIV-1	O
reverse	O
transcriptase	O
(RT).	O

Homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(HOMA-IR)	O
was	O
calculated	O
using	O
the	O
following	O
formula:	O
[fasting	O
glucose	B
(millimoles	O
per	O
liter)	O
*	O
fasting	O
insulin	O
(milliinternational	O
units	O
per	O
liter)/22.5].	O

The	O
same	O
procedure	O
as	O
outlined	O
above	O
for	O
MTBE	B
extraction	O
was	O
first	O
used	O
to	O
obtain	O
an	O
aqueous	O
fraction	O
and	O
a	O
lipid	O
fraction,	O
followed	O
by	O
fractionation	O
of	O
the	O
lipids	O
using	O
SPE.	O

Dimethyl	B
sulfoxide	I
(DMSO),	O
curcumin	B
(Cur),	O
hydrogen	B
peroxide	I
solution	O
(H_2	O
O_2	O
),	O
(3	O
wt	O
%	O
in	O
H_2	O
O),	O
and	O
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium	B
bromide	I
(MTT),	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

It	O
has	O
been	O
established	O
that	O
some	O
of	O
the	O
adducts	O
produced	O
by	O
pyridyloxobutylation	O
of	O
DNA	O
or	O
globin	O
release	O
4-hydroxy-1-(3-pyridyl)-1-butanone	B
(HPB).	O

The	O
HTG	O
group	O
exhibited	O
an	O
increase	O
in	O
palmitoleamide	B
and	O
palmitic	B
amide	I
and	O
a	O
decrease	O
in	O
docosanamide,	B
another	O
primary	O
fatty	O
acid	B
amide.	I

Our	O
observations	O
may	O
provide	O
additional	O
evidence	O
on	O
the	O
essential	O
role	O
of	O
this	O
pathway	O
in	O
case	O
of	O
higher	O
metabolic	O
requirements	O
for	O
glycine	B
associated	O
to	O
malnutrition,	O
higher	O
requirement	O
for	O
glutathione,	B
phase	O
II	O
metabolism	O
and/or	O
growth	O
and	O
development	O
in	O
pediatric	O
populations.	O

The	O
prospective	O
molecular	O
formulas	O
of	O
BQB-thiol	B
derivatives	O
were	O
generated	O
based	O
on	O
the	O
accurate	O
mass	O
and	O
isotope	O
patterns	O
of	O
elemental	O
composition	O
using	O
Bruker	O
Daltonics	O
Data	O
analysis	O
4.0	O
software.	O

Qualitative	O
analysis	O
and	O
quantitative	O
analysis	O
of	O
both	O
internal	O
standards	O
(ISTDs)	O
and	O
endogenous	O
metabolites	O
demonstrate	O
excellent	O
reproducibility	O
with	O
CV’s	O
below	O
15%	O
for	O
the	O
combined	O
method	O
compared	O
to	O
30%	O
using	O
the	O
methanol	B
method.	O

Both	O
methionine	B
and	O
homocysteine	B
are	O
generally	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
intestinal	O
health	O
(Townsend	O
et	O
al.,	O
).	O

We	O
thus	O
selected	O
23	O
from	O
the	O
162	O
healthy	O
controls	O
with	O
comparative	O
age,	O
BMI,	O
cholesterol,	B
triglyceride,	B
glucose	B
and	O
insulin	O
levels	O
to	O
the	O
T2D	O
group	O
(named	O
matched	O
NGT).	O

Go	O
to:	O
This	O
study	O
presents	O
a	O
selective	O
method	O
of	O
isolation	O
of	O
zearalenone	B
(ZON)	O
and	O
its	O
metabolite,	O
α-zearalenol	B
(α-ZOL),	I
in	O
neoplastically	O
changed	O
human	O
tissue	O
by	O
accelerated	O
solvent	O
and	O
ultrasonic	O
extractions	O
using	O
a	O
mixture	O
of	O
acetonitrile/water	O
(84/16%	O
v/v	O
)	O
as	O
the	O
extraction	O
solvent.	O

An	O
ACQUITY	O
UPLC®	O
system	O
(Waters	O
Corporation,	O
Milford,	O
MA)	O
including	O
binary	O
solvent	O
manager,	O
sampler	O
manager,	O
and	O
photo	O
diode	O
array	O
(PDA)	O
detector,	O
and	O
a	O
Waters	O
ACQUITY	O
UPLC™	O
BEH	O
(Ethylene	O
Bridged	O
Hybrid)	O
C_18	O
column	O
(2.1	O
mm	O
×	O
50	O
mm,	O
1.7	O
μm	O
particle	O
size)	O
were	O
used	O
for	O
online	O
LC-UV.	O

The	O
main	O
source	O
of	O
NADPH	B
is	O
the	O
pentose	B
phosphate	I
pathway	O
and	O
the	O
only	O
metabolite	O
identified	O
in	O
that	O
pathway,	O
erythrose-4-phosphate,	B
showed	O
an	O
increased	O
abundance	O
in	O
the	O
CON	O
group	O
as	O
compared	O
to	O
the	O
NP	O
group.	O

The	O
11-dehydro	B
metabolite	O
is	O
the	O
most	O
appropriate	O
analytic	O
target	O
to	O
detect	O
phasic	O
release	O
of	O
TXA2	O
in	O
the	O
human	O
circulation,	O
such	O
as	O
might	O
occur	O
in	O
human	O
syndromes	O
of	O
platelet	O
activation.	O

Interestingly,	O
a	O
higher	O
intake	O
of	O
poultry	O
and	O
maltose	B
was	O
found	O
to	O
be	O
related	O
to	O
decreased	O
risk	O
of	O
UC	O
clinical	O
relapse	O
in	O
the	O
present	O
study.	O

Data	O
regarding	O
clinical	O
parameters,	O
including	O
age,	O
sex,	O
body	O
mass	O
index,	O
blood	O
pressure,	O
smoking	O
history,	O
comorbidities,	O
and	O
renal	O
function	O
(serum	O
creatinine	B
(sCr)	O
and	O
spot	O
uPCr),	O
were	O
collected	O
at	O
the	O
time	O
of	O
kidney	O
biopsy.	O

Glycine	B
was	O
repeatedly	O
inversely	O
correlated	O
to	O
clinical	O
measures	O
of	O
diabetes,	O
a	O
possible	O
reflection	O
of	O
the	O
changing	O
metabolic	O
state	O
of	O
subjects	O
post	O
simvastatin	B
administration.	O

The	O
instrument	O
was	O
tuned	O
by	O
direct	O
infusion	O
of	O
PG	B
(17:0/17:0)	I
in	O
both	O
positive	O
and	O
negative	O
mode	O
and	O
external	O
mass	O
calibration	O
was	O
performed	O
using	O
the	O
standard	O
calibration	O
mixture	O
and	O
protocol	O
from	O
Thermo	O
Fisher	O
approximately	O
every	O
five	O
days.	O

Metabolite	O
quantifiability	O
was	O
tested	O
for	O
the	O
established	O
FIA-NMR	O
method	O
using	O
a	O
standard	O
addition	O
and	O
a	O
calibration	O
curve	O
method	O
for	O
four	O
chemically	O
different	O
compounds:	O
a	O
sugar	O
((±)-glucose),	O
an	O
aromatic	B
carboxylic	I
acid	I
(hippuric	O
acid),	O
an	O
organic	O
acid	O
(succinic	O
acid),	O
and	O
an	O
amino	O
acid	O
(alanine).	O

Gas	O
chromatography–mass	O
spectrometry;	O
HA:	B
Hyperactivation;	O
HCV:	O
Hepatitis	O
C	O
Virus;	O
HCVPR:	O
Hepatitis	O
C	O
Virus	O
protease;	O
HeLa:	O
Human	O
cervical	O
cancer	O
cell	O
line;	O
HIV:	O
Human	O
immunodeficiency	O
viruses;	O
HPLC:	O
High	O
Performance	O
Liquid	O
Chromatography;	O
IAA:	O
Indole‐3‐acetic	O
acid;	O
IARC:	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer;	O
IC_50	O
:	O
Half	O
maximal	O
inhibitory	O
concentration;	O
LC_50	O
:	O
Concentration	O
of	O
the	O
compound	O
that	O
is	O
lethal	O
for	O
50%	O
of	O
exposed	O
population;	O
LC-MS:	O

Discovery	O
in	O
the	O
AASK	O
and	O
validation	O
in	O
the	O
MESA	O
of	O
a	O
metabolite	O
model	O
eGFR	O
compared	O
with	O
using	O
estimated	O
from	O
creatinine,	B
cystatin	B
and	O
demographics	O
Equations	O
in	O
the	O
AASK	O
are	O
shown	O
in	O
.	O

The	O
2D	O
rules	O
are	O
represented	O
with	O
their	O
variable	O
conditions,	O
i.e.,	O
ranges	O
of	O
buckets	O
bins	O
for	O
the	O
buckets	O
1.28	O
(3-hydroxyisovalerate)	O
(x-axis)	O
and	O
3.16	O
(dimethylsulfone)	O
(y-axis)	O
and	O
their	O
frequency	O
over	O
the	O
100	O
models	O
(color	O
scale).	O

Notably,	O
glutathione	B
metabolism	O
is	O
the	O
consistently	O
altered	O
pathway	O
in	O
enrichment	O
and	O
pathway	O
analysis.	O

Altered	O
pathways	O
include	O
changes	O
in	O
amino	O
acid	O
metabolism,	O
biosynthesis	O
and	O
degradation	O
(glutamine,	O
lysine,	B
carnitine,	B
valine,	B
leucine/isoleucine,	O
methionine,	B
tryptophan,	B
5-hydroxytrytophan,	B
and	O
tyrosine),	B
glycolysis	O
(lactate	O
and	O
glucose),	B
ketone	B
bodies	O
synthesis	O
and	O
degradation	O
(β-hydroxybutyate),	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
(citrate)	O
and	O
fatty	O
acid	O
metabolism	O
(linoleic	O
acid,	O
linolenic	B
acid	I
and	O
myristic	B
acid).	O

Cysteine,	B
which	O
is	O
the	O
rate-limiting	O
amino	O
acid	O
for	O
glutathione	B
synthesis	O
and	O
is	O
the	O
major	O
cellular	O
antioxidant	O
in	O
mammals,	O
is	O
converted	O
into	O
hypotaurine,	B
which	O
is	O
subsequently	O
oxidized	O
to	O
taurine,	B
sulfate,	B
and	O
hydrogen	B
sulfide	I
(H_2	O
S)	O

Serum	O
total	O
cholesterol,	B
triglycerides,	B
high-density	O
lipoprotein	O
(HDL)	O
cholesterol,	B
and	O
low-density	O
lipoprotein	O
(LDL)	O
cholesterol	B
levels	O
will	O
be	O
quantified	O
by	O
commercially	O
available	O
enzymatic	O
assay	O
kits	O
(Abbott	O
Diagnostics,	O
USA).	O

Riboflavin	B
has,	O
as	O
a	O
majority	O
of	O
other	O
findings	O
herein,	O
been	O
connected	O
to	O
the	O
energy	O
metabolism	O
where	O
a	O
riboflavin	B
deficiency	O
has	O
resulted	O
in	O
a	O
mitochondrial	O
dysfunction.	O

As	O
listed	O
in	O
,	O
X	O
differentially	O
expressed	O
metabolites	O
in	O
liver	O
cirrhosis	O
and	O
hepatitis	O
condition	O
including	O
inositol,	B
2,2′-bipyridine,	B
methionine,	B
arginine,	B
stearic	B
acid,	I
palmitic	B
acid,	I
citric	B
acid,	I
2-piperidine	B
carboxylic	I
acid,	I
5-hydroxy-tryptophan,	B
and	O
tyrosine	B
were	O
obtained	O
by	O
comparison	O
among	O
healthy	O
controls,	O
benign	O
liver	O
tumor	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
HCC	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
and	O
HCC	O
without	O
liver	O
cirrhosis	O
and	O
hepatitis.	O

In	O
an	O
earlier	O
study,	O
a	O
positive	O
association	O
between	O
urinary	O
1-	B
hydroxypyrene	I
with	O
total	O
WBC	O
count	O
(serum	O
markers	O
of	O
inflammation)	O
in	O
males	O
compared	O
to	O
females	O
was	O
reported.	O

A	O
PLS-DA	O
model	O
based	O
on	O
these	O
three	O
metabolites	O
showed	O
a	O
sensitivity	O
of	O
80%,	O
specificity	O
of	O
71%	O
and	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0.83,	O
outperforming	O
the	O
clinical	O
marker	O
alpha-fetoprotein	B
(AFP).	O

For	O
the	O
HILIC	O
separation,	O
mobile	O
phase	O
“A”	O
consisted	O
in	O
50 mM	O
ammonium	B
acetate	I
mixed	O
with	O
acetonitrile	B
(95:5,	I
v	I
/v	I
),	I
while	O
eluent	O
“B”	O
was	O
composed	O
of	O
a	O
mixture	O
of	O
50 mM	O
ammonium	B
acetate:water	I
plus	O
acetonitrile	B
(95:5,	I
v	I
/v	I
).	I

Cystathionine,	B
also	O
modified	O
in	O
the	O
POAG	O
signature,	O
is	O
metabolically	O
tightly	O
connected	O
to	O
methionine	B
and	O
cysteine	B
through	O
sulfur,	O
thiols,	B
and	O
folate	B
metabolisms,	O
which	O
were	O
already	O
incriminated	O
in	O
glaucoma	O
[,].	O

It	O
did	O
show	O
a	O
positive	O
effect	O
on	O
tear	O
secretion	O
in	O
the	O
group	O
with	O
both	O
testosterone	B
cream	O
and	O
estrogen	B
gel.	O

Sulfatides	B
were	O
present	O
in	O
grade	O
III	O
oligoastrocytomas,	O
suggesting	O
an	O
astrocytoma	O
content	O
of	O
the	O
mixed	O
tumor.	O

We	O
found	O
that	O
CRC	O
patients	O
with	O
diabetes	O
had	O
increased	O
serum	O
enterolactone	B
levels.	O

Specifically,	O
p	B
-aminophenol	I
is	O
a	O
primary	O
metabolite	O
of	O
aniline	B
which	O
is	O
used	O
in	O
the	O
manufacturing	O
of	O
various	O
industrial	O
products,	O
and	O
in	O
other	O
industries,	O
e.g.	O
meat	O
production.	O

According	O
to	O
these	O
data,	O
we	O
found	O
a	O
drastic	O
increase	O
of	O
Sa	O
in	O
the	O
third	O
trimester	O
of	O
pregnancy,	O
in	O
agreement	O
with	O
a	O
possible	O
block	O
of	O
ceramides	B
de	O
novo	O
synthesis,	O
probably	O
linked	O
to	O
a	O
mechanism	O
of	O
neuroprotection.	O

The	O
cluster	O
of	O
aberrant	O
expression	O
of	O
these	O
metabolites	O
in	O
ESCC	O
indicates	O
the	O
critical	O
role	O
of	O
phospholipid	B
metabolism	O
in	O
the	O
oncogenesis	O
of	O
ESCC	O
and	O
suggests	O
its	O
potential	O
ability	O
to	O
assess	O
the	O
risk	O
of	O
ESCC	O
development	O
in	O
addition	O
to	O
currently	O
used	O
risk	O
factors.	O

The	O
changes	O
in	O
SDH	O
activity	O
by	O
the	O
influence	O
of	O
the	O
PhCAs	O
and	O
itaconic	B
acid	I
in	O
the	O
concentration	O
range	O
of	O
0.5–5.0	O
mM	O
are	O
shown	O
in	O
A.	O
Activity	O
of	O
SDH	O
was	O
measured	O
by	O
the	O
reduction	O
of	O
MTT	O
(A,B)	O
and	O
by	O
the	O
rate	O
of	O
DCPIP	O
reduction	O
(C,D).	O

Two	O
aliquots	O
were	O
treated	O
immediately	O
after	O
drawing	O
(Section	O
3.3,	O
RBC	O
lysis	O
and	O
24	O
h	O
storage	O
at	O
−20	O
°C),	O
in	O
one	O
the	O
RBC	O
were	O
washed	O
and	O
diluted	O
with	O
the	O
saline	B
solution,	O
in	O
another	O
one	O
the	O
RBC	O
were	O
washed	O
and	O
diluted	O
with	O
PBS.	O

Metabolic	O
pathway	O
analysis	O
was	O
performed	O
using	O
MetaboAnalyst	O
(version	O
4.0)	O
and	O
revealed	O
that	O
‘glycerophospholipid	B
metabolism’,	O
‘linoleic	O
acid	O
metabolism’,	O
‘fatty	O
acid	O
biosynthesis’	O
and	O
‘primary	O
bile	O
acid	O
biosynthesis’	O
were	O
significantly	O
associated	O
with	O
GCA.	O

The	O
increased	O
glucose	B
consumption	O
of	O
tumor	O
tissue	O
leads	O
to	O
a	O
decrease	O
in	O
fecal	O
glucose	B
concentration	O
in	O
parallel	O
to	O
an	O
increase	O
in	O
lactate,	B
consistent	O
with	O
increased	O
energy	O
metabolism	O
due	O
to	O
tumor	O
cell	O
activation,	O
and	O
this	O
observation	O
is	O
supported	O
by	O
an	O
elevation	O
in	O
succinate	B
and	O
glutamate	B
indicative	O
of	O
an	O
increase	O
in	O
TCA	O
cycle	O
activity.	O

Enzymatic	O
oxidation	O
of	O
AA	O
is	O
mediated	O
by	O
cyclooxygenase	O
(COX),	O
lipoxygenase	O
(LOX)	O
and	O
P450	O
epoxygenase	O
pathways	O
generating	O
eicosanoids.	B

MS/MS	O
spectra	O
of	O
PC	B
16:1/18:2	I
in	O
a	O
positive	O
ion	O
mode	O
and	O
b	O
negative	O
ion	O
mode.	O

Firstly,	O
Due	O
to	O
the	O
rapid	O
growth	O
of	O
tumor	O
cells,	O
there	O
is	O
a	O
great	O
demand	O
for	O
energy	O
and	O
more	O
glycolytic	B
production	O
of	O
ATP	B
is	O
required.	O

We	O
identified	O
63	O
metabolites	O
associated	O
with	O
serum	O
retinol	B
below	O
the	O
Bonferroni-corrected	O
P-value	O
(p < 5.3 × 10_–5	O
).	O

The	O
hydroxykynurenine:XA	O
ratio,	O
a	O
biomarker	O
of	O
vitamin	O
B-6	O
insufficiency,	O
was	O
not	O
a	O
significant	O
discriminatory	O
variable	O
between	O
the	O
cystathionine	B
groups	O
in	O
PLS-DA.	O

After	O
hematoxylin	B
and	O
eosin	B
(H&E)	O
staining,	O
slides	O
were	O
annotated	O
by	O
a	O
genitourinary	O
pathologist	O
to	O
delineate	O
areas	O
of	O
cancerous	O
and	O
normal	O
tissue.	O

By	O
contrast,	O
when	O
querying	O
only	O
the	O
subgroup	O
of	O
peaks	O
that	O
in	O
the	O
presence	O
of	O
the	O
SNPs	O
were	O
suppressed,	O
arginine	B
could	O
be	O
identified	O
with	O
a	O
matching	O
ratio	O
of	O
0.8	O
and	O
the	O
uniqueness	O
of	O
3/5	O
(one	O
of	O
the	O
broad	O
multiplets	O
of	O
a	O
CH_2	O
group	O
was	O
too	O
weak	O
to	O
observe).	O

Therefore,	O
it	O
is	O
described	O
as	O
‘cysteamine+cystamine’	B
in	O
the	O
Supporting	O
tables	O
and	O
as	O
‘cystamine’,	B
which	O
was	O
actually	O
detected	O
by	O
GC/MS	O
analysis,	O
in	O
this	O
manuscript.	O

It	O
is	O
directly	O
linked	O
to	O
the	O
TCA	O
cycle	O
via	O
the	O
malate	B
shuttle.	O

Besides	O
that,	O
choline	B
and	O
tyrosine	O
amino	O
acids	O
were	O
identified	O
as	O
important	O
for	O
the	O
discrimination	O
between	O
healthy	O
volunteers	O
and	O
osteopenia-osteoporosis	O
patients,	O
with	O
higher	O
concentrations	O
observed	O
in	O
the	O
control	O
group.	O

In	O
the	O
case	O
of	O
diabetes,	O
this	O
can	O
be	O
related	O
to	O
glucose	B
defective	O
absorption,	O
related	O
to	O
insulin	O
deficiency.	O

Interestingly,	O
the	O
degree	O
of	O
increase	O
in	O
smokers	O
for	O
alpha-tocopherol	B
and	O
pyridoxate	B
was	O
not	O
significant,	O
suggesting	O
possible	O
increased	O
conversion,	O
excretion	O
or	O
decreased	O
absorption	O
of	O
these	O
substances	O
compared	O
to	O
non-smokers.	O

The	O
dashed	O
line	O
boxes	O
indicate	O
the	O
pools	O
of	O
creatine	B
+	O
phosphocreatine	B
(tCr),	O
choline	B
+	O
phosphocholine	B
+	O
glycerophosphocholine	B
(tCho)	O
and	O
glutamate	B
+	O
glutamine	B
(tGlut).	O

Go	O
to:	O
Polychlorinated	B
dibenzo-p	I
-dioxins	I
(PCDDs,	O
dioxins),	O
polychlorinated	O
dibenzofurans	O
(PCDFs),	O
and	O
polychlorinated	O
biphenyls	O
(PCBs)	O
are	O
environmental	O
endocrine	O
disruptors	O
that	O
have	O
half-lives	O
of	O
7–10	O
years	O
in	O
the	O
human	O
body	O
and	O
have	O
toxicities	O
that	O
probably	O
include	O
carcinogenesis.	O

Ten	O
differential	O
metabolites	O
responsible	O
for	O
discriminating	O
PSD	O
subjects	O
from	O
healthy	O
control	O
(HC)	O
and	O
stroke	O
subjects	O
were	O
found,	O
and	O
five	O
of	O
these	O
metabolites	O
were	O
identified	O
as	O
potential	O
biomarkers	O
(lactate,	O
α-hydroxybutyrate,	B
phenylalanine,	B
formate,	B
and	O
arabinitol).	O

In	O
immune	O
cells	O
ADMA	B
is	O
cleaved	O
by	O
dimethylarginine-dimethylaminohydrolase-2	B
(DDAH2).	O

LC-SRM/MS	O
conditions	O
for	O
estrogen	B
NMPS	O
derivatives.	O

PC	B
ae	I
C36:3;	I
78.	O

The	O
HER2	O
gene	O
encodes	O
for	O
a	O
185‐kDa	O
tyrosine	B
kinase	O
glycoprotein	B
transmembrane	O
receptor	O
which	O
is	O
overexpressed	O
in	O
15–25%	O
of	O
breast	O
cancers.	O

Deoxycholate,	B
also	O
known	O
as	O
cholanoic	O
acid	O
(3α,12α-dihydroxy-5β-cholanate),	O
is	O
one	O
of	O
the	O
secondary	O
bile	O
acids	O
and	O
constitutes	O
a	O
significant	O
part	O
of	O
the	O
circulating	O
BA	O
pool	O
in	O
humans	O
(35%).	O

For	O
example,	O
individuals	O
who	O
reported	O
a	O
greater	O
amount	O
of	O
nocturnal	O
waking	O
had	O
significantly	O
higher	O
indole-3-acetic	B
acid	I
throughout	O
the	O
night.	O

The	O
resultant	O
17	O
metabolite	O
model	O
consisted	O
of	O
multiple	O
lipids	O
(steroids	O
in	O
particular)	O
and	O
histidine,	B
and	O
it	O
performed	O
well	O
via	O
confusion	O
matrix	O
estimates	O
for	O
the	O
differentiation	O
of	O
thrombotic	O
from	O
non-thrombotic	O
MI	O
and	O
stable	O
CAD,	O
utilizing	O
metabolite	O
abundance	O
at	O
presentation	O
alone.	O

For	O
instance,	O
17	O
metabolites	O
that	O
potentially	O
participate	O
in	O
Asp	O
metabolism,	O
ammonia	O
recycling,	O
protein	O
biosynthesis,	O
and	O
Trp	O
metabolism,	O
which	O
supports	O
the	O
environment	O
needed	O
for	O
tumorigenesis	O
(Figure	O
B),	O
were	O
only	O
quantified	O
in	O
the	O
CRC	O
group,	O
i.e.,	O
Lys,	O
heptanedioic	B
acid	I
(a	O
precursor	O
of	O
Lys),	O
norvaline,	B
and	O
several	O
amino	O
acid	O
and	O
organic	O
acid	O
derivatives	O
(Supplementary	O
Table	O
).	O

Both	O
(A)	O
myoinositol	B
and	O
(B)	O
formate	B
are	O
significantly	O
higher	O
in	O
the	O
MS-like	O
subgroup	O
compared	O
with	O
the	O
NMOSD-like	O
subgroup.	O

encoded	O
bile	O
acid-CoA	O
amino	O
acid	O
transferase	O
(BAAT)	O
to	O
form	O
tauro-	O
and	O
glycolithocholic	B
acid	I
(TLCA,	O
GLCA)	O
and	O
tauro-	O
and	O
glycodeoxycholic	B
acid	I
(TDCA	O
GDCA).	O

Associations	O
between	O
the	O
serum	O
concentrations	O
of	O
tamoxifen,	B
estrogens,	O
FSH_1	O
,	O
and	O
SHBG	O
_1	O
FSH,	O
Follicle	O
Stimulating	O
Hormone;	O
SHBG,	O
sex	O
hormone	O
binding	O
globulin;	O
4OHtam,	O
4-hydroxytamoxifen;	B
4OHNDtam,	O
4-hydroxy-N-demethyltamoxifen;	B
NDtam,	O
N-demethyltamoxifen;	B
NDDtam,	O
N-dedimethyltamoxifen;	B
tamNox,	O
tamoxifen-N-oxide;	B
r,	O
coefficient;	O
E2,	O
estradiol;	B
E1,	O
estrone;	B
E1S,	O
estrone	B
sulfate;	I
Wt/Wt	O
EM,	O
wild	O
type/wild	O
type	O
extensive	O
metabolizer	O
CYP2D6.	O

The	O
result	O
of	O
qualitative	O
profiling	O
showed	O
that	O
seven	O
metabolites,	O
i.e.	O
an	O
acetamiprid	B
metabolite,	O
N	B
-desmethyl-acetamiprid;	I
three	O
Imidacloprid	O
metabolites,	O
5-hydroxy-Imidacloprid,	B
4,5-dihydroxy-imidacloprid,	B
4,5-dehydro-Imidacloprid;	B
a	O
common	O
metabolite	O
of	O
acetamiprid	B
and	O
Imidacloprid,	O
N	B
-(6-chloronicotinoyl)-glycine;	I
and	O
two	O
clothianidin	B
metabolites,	O
N	B
-desmethyl-clothianidin,	I
N	B
-(2-(methylsulfanyl)thiazole-5-carboxyl)-glycine,	I
as	O
well	O
as	O
acetamiprid,	B
were	O
detected	O
in	O
the	O
urine	O
of	O
three	O
cases.	O

Known	O
amounts	O
of	O
the	O
isoflavone	B
β-glucosides	I
(daidzin,	I
genistin	I
and	O
glycitin)	B
and	O
the	O
aglycones,	B
daidzein,	B
genistein	B
and	O
glycitein	B
were	O
used	O
to	O
establish	O
standard	O
curves.	O

When	O
combined	O
with	O
metformin,	B
leucine	B
and	O
HMB	O
improved	O
insulin	O
sensitivity	O
by	O
activating	O
AMPK	O
and	O
SIRT1.	O

It	O
was	O
identified	O
that	O
several	O
significantly	O
abundant	O
metabolites	O
are	O
associated	O
with	O
phenylalanine,	B
tyrosine,	B
tryptophan	B
biosynthesis	O
pathways,	O
puromycin	B
biosynthesis,	O
vancomycin	B
antibiotic	O
biosynthesis,	O
amino	O
acid	O
biosynthesis,	O

LCA	O
(and	O
LCA	O
acetate	B
and	O
LCA	O
propionate)	B
can	O
also	O
activate	O
the	O
vitamin	B
D	I
receptor.	O

Culturing	O
the	O
HCT116	O
cells	O
and	O
two	O
additional	O
cell	O
lines	O
with	O
a	O
1-_13	O
C_1	B
-glucose	I
or	O
2-_13	O
C_1	B
-glucose	I
tracer	O
resulted	O
in	O
clear	O
_13	O
C	O
labeling	O
of	O
the	O
metabolite	O
ion	O
(	O
and	O
),	O
demonstrating	O
that	O
it	O
derives	O
from	O
glucose.	B

Generally,	O
the	O
species	O
that	O
elute	O
earliest	O
in	O
the	O
chromatogram	O
are	O
the	O
most	O
hydrophilic;	B
however,	O
these	O
separations	O
are	O
dictated	O
by	O
both	O
overall	O
polarity	O
and	O
FA	O
side-chain	O
length.	O

Quantitative	O
analysis	O
showed	O
that	O
the	O
levels	O
of	O
metabolites,	O
such	O
as	O
3-hydroxybutyrate,	B
acetoacetate,	B
carnitine,	B
cystine,	B
homocysteine,	B
pyruvate,	B
and	O
trimethylamine	B
N	I
-oxide	I
were	O
significantly	O
increased	O
in	O
sarcoidosis	O
patients.	O

Similar	O
observations	O
were	O
made	O
in	O
the	O
highest	O
quartile	O
of	O
citrulline	B
after	O
adjusting	O
for	O
ADMA	B
for	O
higher	O
incidence	O
of	O
MACE	O
[adjusted	O
HR(95%CI):	O
2.03(1.44-2.87),	O
p<0.001].	O

Frandsen	O
tentatively	O
identified	O
three	O
glucuronide	B
conjugates	O
of	O
5-HO-PhIP,	B
a	O
solvolysis	O
product	O
of	O
the	O
reactive	O
N	B
-acetoxy-PhIP	I
intermediate.	O

Probably	O
the	O
different	O
scheme	O
in	O
nutrition	O
explains	O
the	O
missing	O
correlation	O
between	O
liver	O
function	O
and	O
plasma	O
amino	O
acids	O
and	O
acylcarnitines.	B

The	O
metabolite	O
profiles	O
of	O
MetS	O
were	O
unique	O
for	O
both	O
genders,	O
with	O
the	O
exception	O
of	O
serine	B
and	O
creatinine,	B
which	O
were	O
lower	O
in	O
both	O
MetS_any	O
men	O
(R_2	O
 = 0.31,	O
Q_2	O
 = 0.12)	O
and	O
MetS_any	O
women	O
(R_2	O
 = 0.42,	O
Q_2	O
 = 0.30)	O
compared	O
with	O
the	O
respective	O
MetS_zero	O
groups	O
(Fig. ).	O

Triglycerides	B
were,	O
in	O
fact,	O
significantly	O
higher	O
in	O
the	O
patients	O
treated	O
with	O
AEDs	O
in	O
the	O
poly	O
therapy	O
regime	O
than	O
in	O
monotherapy	O
one.	O

All	O
modifier	O
solutions	O
were	O
prepared	O
volumetrically	O
or,	O
in	O
the	O
case	O
of	O
the	O
ammonium	B
salts,	O
by	O
addition	O
of	O
the	O
solid	O
salt	O
to	O
the	O
methanol,	B
followed	O
by	O
sonication	O
at	O
room	O
temperature	O
for	O
10 min.	O

Tricarboxylic	B
acid	I
cycle	O
(TCA	O
cycle),	O
also	O
known	O
as	O
citric	B
acid	I
cycle	O
or	O
Krebs’	O
cycle,	O
consists	O
of	O
a	O
series	O
of	O
chemical	O
reactions	O
aimed	O
at	O
generating	O
energy	O
(ATP)	O
through	O
oxidation	O
of	O
acetate	B
from	O
carbohydrates,	O
fats	O
and	O
proteins	O
into	O
carbon	B
dioxide	I
and	O
water.	O

(F)	O
Same	O
as	O
in	O
E,	O
for	O
pyrimidine	B
metabolism–associated	O
genes	O
and	O
metastasis-free	O
survival	O
across	O
686	O
ER +	O
BCa	O
tissues.	O

The	O
clear	O
separation	O
between	O
the	O
high–	O
and	O
low–cystathionine	B
concentration	O
groups	O
confirms	O
a	O
pattern	O
of	O
discriminating	O
features.	O

Fractions	O
with	O
HCTLase	O
activity	O
were	O
pooled	O
and	O
loaded	O
onto	O
a	O
2	O
mL	O
ceramic	O
hydroxyapatite	B
(HA)	O
column	O
(1	O
×	O
4	O
cm,	O
HA	B
type	O
II	O
40	O
µm,	O
BioRad,	O
Hercules,	O
CA)	O
that	O
was	O
equilibrated	O
with	O
5	O
mM	O
KPO_4	O
,	O
pH	O
6.9.	O

Mannose	B
was	O
correlated	O
only	O
with	O
threonine	B
in	O
HCV	O
plasma.	O

This	O
enzyme	O
mainly	O
associates	O
with	O
LDL	O
and	O
hydrolyses	O
the	O
fatty	O
acid	O
at	O
the	O
sn-2	O
position	O
from	O
phospholipids,	B
leading	O
to	O
a	O
LPC	O
and	O
a	O
non-esterified	O
fatty	O
acid.	O

However,	O
when	O
the	O
active	O
SLE	O
group	O
was	O
compared	O
with	O
controls,	O
the	O
tryptophan	B
levels	O
were	O
significantly	O
higher	O
in	O
controls	O
compared	O
with	O
active	O
disease	O
(SLEDAI ≥6	O
vs	O
control:	O

After	O
centrifugation	O
(1	O
000	O
g	O
,	O
3	O
min),	O
the	O
upper	O
aqueous	O
phases	O
were	O
collected	O
while	O
lower	O
organic	O
phases	O
were	O
re-extracted	O
twice	O
with	O
2	O
mL	O
CH_3	O
OH/H_2	O
O	B
(1:1,	O
v/v).	O

Adenosine	B
is	O
then	O
deaminated	O
via	O
adenosine	O
deaminase	O
and	O
hydrolyzed	O
via	O
nucleosidase	O
to	O
form	O
hypoxanthine,	B
which	O
is	O
oxidized	O
to	O
form	O
xanthine	B
and	O
then	O
uric	B
acid	I
through	O
the	O
action	O
of	O
xanthine	B
oxidase.	O

A	O
genome-wide	O
association	O
study	O
identified	O
16	O
loci	O
that	O
were	O
associated	O
with	O
levels	O
of	O
19	O
sterols	O
and	O
25-hydroxylated	O
derivatives	O
of	O
vitamin	B
D	I
(P	O
<	O
10_−7	O
).	O

After	O
addition	O
of	O
0.14	O
µg	O
ribitol	B
and	O
0.25	O
µg	O
[U-_13	B
C]-glucose	I
as	O
internal	O
standards,	O
each	O
sample	O
was	O
derivatized	O
with	O
100	O
µL	O
of	O
20	O
mg/mL	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
and	O
200	O
µL	O
of	O
N-methyl-trimethylsylil-trifluoroacetamide	B
(MSTFA),	O
following	O
the	O
protocol.	O

Indole,	B
ammonium	B
acetate,	I
t	B
-butyl	I
methyl	I
ether,	I
and	O
β-glucuronidase	O
(E.coli	O
G8295)	O
were	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO).	O

(D)	O
MIDs	O
of	O
isobutyryl-,	B
propanoyl-,	B
methylbutyryl-	B
and	O
isovaleryl-carnitine	B
in	O
extracts	O
of	O
cells	O
cultured	O
in	O
(left	O
to	O
right)	O
unlabeled	O
medium,	O
with	O
_13	O
C-isoleucine,	B
_13	O
C-leucine,	B
or	O
_13	O
C-valine.	B

Metabolic	O
networks	O
differed	O
between	O
patients	O
with	O
AP	B
and	O
those	O
without	O
after	O
ERCP;	O
however,	O
metabolomics	O
did	O
not	O
identify	O
specific	O
prognostic	O
or	O
diagnostic	O
markers	O
of	O
ERCP-induced	O
AP.	B

In	O
addition,	O
four	O
members	O
of	O
tryptophan	B
metabolism	O
were	O
affected	O
by	O
the	O
surgical	O
intervention:	O
tryptophan	B
itself	O
(0.82-fold)	O
as	O
well	O
as	O
xanthurenate	B
(0.79-fold)	O
and	O
indole-3-acetate	B
(0.80-fold)	O
were	O
diminished	O
in	O
pre-surgery	O
compared	O
to	O
post-surgery	O
patients,	O
whereas	O
3-indoxylsulfate	B
levels	O
were	O
increased	O
1.46-fold.	O

As	O
shown	O
in	O
,	O
the	O
organic	O
acid,	O
α–hydroxybutyrate	B
(α–HB)	O
was	O
the	O
top-ranked	O
metabolite	O
in	O
the	O
resulting	O
importance	O
plot,	O
which	O
ranks	O
the	O
classifiers	O
based	O
upon	O
contribution	O
of	O
each	O
to	O
the	O
separation	O
of	O
the	O
subjects	O
into	O
classes.	O

Decenedioic	B
acid	I
is	O
a	O
dicarboxylic	B
acid.	I

The	O
contributions	O
of	O
TMAO	B
in	O
the	O
development	O
of	O
these	O
chronic	O
diseases	O
have	O
brought	O
attention	O
to	O
its	O
potential	O
role	O
in	O
carcinogenesis,	O
as	O
these	O
diseases	O
are	O
all	O
cancer	O
risk	O
factors.	O

Type	O
2	O
diabetes	O
(T2D)	O
is	O
preceded	O
by	O
prolonged	O
insulin	O
resistance	O
and	O
relative	O
insulin	O
deficiency	O
incompletely	O
captured	O
by	O
glucose	B
metabolism	O
parameters,	O
HDL-c	O
and	O
triglycerides.	B

L-Lysine	B
is	O
one	O
of	O
the	O
nine	O
essential	O
amino	O
acids	O
in	O
humans.	O

One	O
calibrator	O
sample	O
containing	O
tamoxifen	B
and	O
its	O
metabolites	O
was	O
analyzed	O
with	O
each	O
batch	O
of	O
samples.	O

Analysis	O
of	O
spectral	O
data	O
by	O
PLS-DA	O
revealed	O
significant	O
separation	O
between	O
subjects	O
with	O
low	O
or	O
high	O
plasma	O
cystathionine	B
concentrations.	O

Overexpression	O
of	O
cNAMPT	O
results	O
in	O
elevation	O
of	O
the	O
NAD_+	O
levels	O
and	O
the	O
NAD(H)	O
pool	O
size.	O
compares	O
the	O
NADH	B
and	O
NAD_+	O
peaks	O
between	O
the	O
transgenic	O
mice	O
with	O
overexpression	O
of	O
cNAMPT	O
and	O
WT	O
mice.	O

It	O
was	O
found	O
that	O
1-MN,	O
creatinine	B
and	O
lactate	B
were	O
reduced	O
in	O
COPD	O
patients	O
relative	O
to	O
healthy	O
subjects.	O

Uncoupled	O
NOS	O
generates	O
superoxide	B
instead	O
of	O
nitric	B
oxide,	I
leading	O
to	O
an	O
oxidative	O
stress	O
state.	O

Stock	O
solutions	O
(1	O
mg/mL)	O
for	O
5-hydroxyindole-3-acetic	B
acid	I
(5-HIAA),	O
nicotinamide	B
adenine	I
dinucleotide	I
(NAD_+	O
),	O
citrulline,	B
dopamine,	B
picolinic	B
acid,	I
serotonin,	B
quinolinic	B
acid,	I
3-hydroxykynurenine	B
(3-HK),	O
nicotinic	B
acid,	I
kynurenine,	B
β-nicotinamide	B
mononucleotide	O
(βNM),	O
tryptophan,	B
and	O
nicotinamide	B
riboside	I
were	O
dissolved	O
in	O
100%	O
diluent-D1.	O

Among	O
significant	O
metabolites,	O
there	O
were	O
several	O
catecholamine	B
metabolites.	O

Moreover,	O
adipocyte	O
triglyceride	B
lipase	O
(ATGL)	O
was	O
down-regulated	O
in	O
NPC	O
cell	O
lines	O
relative	O
to	O
nasopharyngeal	O
epithelial	O
cell	O
lines	O
.	O

Blood	O
succinic	B
acid	I
is	O
more	O
specific	O
to	O
the	O
inflammatory	O
syndrome,	O
and	O
the	O
simultaneous	O
presence	O
of	O
microbial	O
metabolites	O
in	O
the	O
blood	O
can	O
serve	O
as	O
a	O
distinctive	O
feature	O
of	O
sepsis.	O

After	O
a	O
series	O
of	O
metabolic	O
changes,	O
the	O
resulting	O
product	O
of	O
purine	B
is	O
called	O
uric	B
acid.	I

The	O
mixtures	O
were	O
then	O
extracted	O
3	O
times	O
with	O
50 mL	O
ethyl	B
acetate.	I

The	O
plasma	O
levels	O
of	O
MDA	O
(nmol/mL)	O
and	O
of	O
F_2	B
-isoprostane	I
(pg/mL)	O
of	O
healthy	O
volunteers	O
and	O
the	O
three	O
groups	O
separated	O
by	O
the	O
staging	O
are	O
set	O
out	O
in	O
Figures	O
A,B,	O
respectively.	O

Bacterial	O
degradation	O
of	O
tryptophan	B
yields	O
in	O
ASD,	O
compared	O
to	O
controls,	O
prominently	O
larger	O
urinary	O
concentrations	O
of	O
indoxyl	B
sulfate	I
and	O
other	O
indole	B
derivatives,	O
including	O
indolyl-3-acetic	B
acid	I
and	O
especially	O
indolyl	B
lactate	I

We	O
also	O
considered	O
HOMA-IR	O
and	O
2	O
h	O
glucose	B
as	O
continuous	O
variables.	O

The	O
deuterated	O
buffer	O
contained	O
0.5	O
mM	O
sodium	B
trimethylsilylphosphate	I
(TSP)	O
to	O
provide	O
a	O
reference	O
substance	O
for	O
the	O
annotation	O
of	O
the	O
NMR	O
spectra.	O

The	O
glucuronidation	O
of	O
anastrozole	B
was	O
measured	O
in	O
pooled	O
HLMs,	O
a	O
panel	O
of	O
recombinant	O
UGTs	O
(UGT1A1,	O
1A3,	O
1A4,	O
1A6,	O
1A7,	O
1A8,	O
1A9,	O
1A10,	O
2B4,	O
2B7,	O
2B15,	O
and	O
2B17),	O
and	O
in	O
microsomes	O
from	O
53	O
individual	O
human	O
livers.	O

They	O
also	O
suggested	O
that	O
this	O
metabolite	O
is	O
derived	O
from	O
exogenous	O
origin,	O
such	O
as	O
furan	B
derivatives	O
in	O
food	O
that	O
was	O
prepared	O
by	O
strong	O
heat	O
treatment	O
again	O
pointing	O
at	O
potentially	O
varying	O
dietary	O
intakes	O
in	O
men	O
and	O
women	O
of	O
different	O
ages.	O

The	O
metabolism	O
of	O
glutamine	B
begins	O
with	O
conversion	O
of	O
glutamine	B
to	O
glutamate	B
by	O
glutaminase	O
or	O
other	O
amidases.	O

Both	O
CPMG	O
score	O
plots	O
(a)	O
and	O
LED	O
score	O
plots	O
(b)	O
show	O
plasma	O
metabolites	O
of	O
FD	B
patientsare	O
different	O
from	O
those	O
of	O
control	O
subjects().	O

The	O
positional	O
isotopomer	O
of	O
the	O
triply	O
labeled	O
malate	B
was	O
deduced	O
from	O
the	O
2-D	O
HSQC	O
analysis,	O
as	O
shown	O
in	O
Figure	O
.	O

lysoPC	O
a	O
C26:1;	B
129.	O

In	O
our	O
study,	O
the	O
salivary	O
choline	B
level	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
oral	O
and	O
pancreatic	O
cancers	O
(P	O
 = 2.30 × 10_−5	O
and	O
P	O

The	O
standard	O
reagents	O
of	O
alanine	B
(Ala),	O
glycine	B
(Gly),	O
isoleucine	B
(Ile),	O
valine	B
(Val),	O
praline	B
(Pro),	O
serine	B
(Ser),	O
threonine	B
(Thr),	O
methionine	B
(Met),	O
tyrosine	B
(Tyr),	O
tryptophan	B
(Try),	O
hippuric	B
acid,	I
ethyl	B
2-methylacetoacetate,	I
levulinic	B
acid,	I
benzylmalonic	B
acid,4-hydroxybenzoic	I
acid,	I
p-cresol	B
and	O
benzil	B
were	O
purchased	O
(J&K	O
Scientific,	O
USA).	O

The	O
optimal	O
ethanolamine	B
threshold	O
was	O
0.740 nmol/mg	O
when	O
distinguishing	O
long-term	O
from	O
short-term	O
survivors.	O

To	O
remove	O
the	O
influence	O
of	O
outlying	O
observations,	O
we	O
truncated	O
the	O
glucose	B
distribution	O
and	O
removed	O
observations	O
more	O
than	O
2	O
standard	O
deviations	O
away	O
from	O
the	O
mean	O
glucose	B
level	O
(Figure	O
S-2C).	O

The	O
mixture	O
was	O
extracted	O
with	O
200	O
µL	O
of	O
extraction	O
solvent	O
(water	O
with	O
10	O
mM	O
ammonium	B
formate,	I
pH3)	O
and	O
filtered	O
through	O
a	O
0.45	O
µm	O
member	O
filter	O
before	O
LC-MS	O
injection.	O

Polar	O
lipids	O
(acyl-carnitines	O
(acyl-Carn),	I
diacyl-phosphatidylcholines	B
(PCaa),	O
acyl-alkyl-phosphatidylcholines	B
(PCae),	O
sphingomyelines	B
(SM),	O
lyso-phosphatidylcholines	B
(LPC/LPCa),	O
alkyl-linked	B
lyso-phosphatidylcholines	I
(LPCe)),	O
non-esterified	O
fatty	O
acids	O
(NEFA)	O
and	O
amino	O
acids	O
(AA)	O
were	O
measured	O
as	O
previously	O
reported	O
[,	O
,	O
].	O

Fumarate	B
is	O
a	O
Krebs	O
cycle	O
intermediate	O
important	O
for	O
Lasso	O
analysis.	O

PET-imaging	O
studies	O
in	O
AD,	O
where	O
the	O
rate-constant	B
k_2	O
is	O
~normal,	O
argue	O
against	O
substantively-elevated	O
cytoplasmic	O
free	O
glucose	B
available	O
for	O
retrograde	O
transport	O
into	O
the	O
extracellular	O
space.	O

LC/MS-MS	O
conditions	O
were	O
an	O
electrospray	O
ionization	O
source	O
with	O
capillary	O
voltage	O
4.0	O
kV,	B
a	O
source	O
temperature	O
of	O
150°C,	O
and	O
a	O
desolvation	O
temperature	O
of	O
500°C.	O

The	O
amino	O
acids	O
were	O
separated	O
on	O
AB	O
Sciex	O
C18	O
(5	O
µm,	O
4.6	O
mm×150	O
mm)	O
column	O
by	O
binary	O
gradient	O
of	O
water	O
(mobile	O
phase	O
A)	O
and	O
methanol	B
(mobile	O
phase	O
B),	O
both	O
containing	O
0.1%	O
formic	B
acid	I
and	O
0.01%	O
heptafluorobutyric	B
acid.	I

It	O
seems	O
that	O
with	O
their	O
increase	O
in	O
circulation,	O
BCAA	O
become	O
available	O
for	O
oxidation	O
in	O
liver	O
and	O
skeletal	O
muscle,	O
leading	O
to	O
increased	O
concentration	O
of	O
the	O
acylcarnitines	B
derived	O
from	O
BCAA	O
catabolism	O
in	O
obese	O
patients	O
[,].	O

The	O
identification	O
of	O
rhamnitol	O
as	O
urinary	O
biomarker	O
of	O
apple	O
consumption	O
has	O
shown	O
how	O
overlap	O
in	O
1D	O
spectra	O
cannot	O
be	O
resolved	O
using	O
STORM	O
as	O
the	O
signals	O
overlap	O
with	O
those	O
of	O
3-hydroxyisovalerate,	B
commonly	O
found	O
in	O
urine	O
samples,	O
which	O
reduces	O
the	O
power	O
of	O
the	O
statistical	O
correlation	O
method.	O

Both	O
predictor	O
models	O
were	O
not	O
significantly	O
different,	O
the	O
CEA,	O
Glycine,	B
and	O
Tyrosine	B
model,	O
however,	O
differed	O
highly	O
significant	O
from	O
CEA	O
alone	O
(P	O
 = 0.015).	O

This	O
suggests	O
that	O
the	O
impact	O
of	O
testosterone	B
on	O
lipid	O
metabolism	O
in	O
PCOS	O
differs	O
from	O
control	O
women	O
with	O
normal	O
pre-treatment	O
androgen	O
levels.	O

This	O
is	O
of	O
interest,	O
as	O
several	O
PE	O
species,	O
such	O
as	O
PE	B
(38:6)	I
or	O
PE	B
(40:4),	I
have	O
been	O
reported	O
to	O
be	O
up-regulated	O
in	O
CRC	O
tissues	O
as	O
compared	O
to	O
normal	O
tissues.	O

A	O
fourth	O
possibility	O
is	O
suggested	O
by	O
recent	O
studies	O
on	O
the	O
interplay	O
of	O
adipose	O
tissue,	O
BCAA	O
metabolism,	O
and	O
glucose	B
homeostasis.	O

Thus,	O
the	O
activation	O
of	O
glutaminolysis	O
represents	O
an	O
adaptive	O
reaction	O
of	O
cells	O
to	O
produce	O
energy	O
as	O
a	O
consequence	O
of	O
the	O
deficiency	O
of	O
testosterone	B
but	O
only	O
when	O
insulin	O
is	O
active,	O
while	O
it	O
disappears	O
in	O
the	O
IR	O
stage.	O

A	O
small	O
increase	O
of	O
citrate	B
levels	O
was	O
found	O
in	O
Degarelix-treated	O
prostate	O
cancer	O
compared	O
to	O
untreated	O
cancer	O
samples,	O
but	O
it	O
was	O
not	O
statistically	O
significant	O
(Table ).	O

14	O
amino	O
acids,	O
hexose,	B
73	O
phospatidylcholines,	B
15	O
sphingomyelins	B
and	O
12	O
lysophosphatidylcholines.	B

Arginine	B
paradox	O
is	O
a	O
phenomenon	O
where	O
on	O
one	O
hand;	O
arginine	B
supplementation	O
improves	O
NO	O
mediated	O
vasodilation;	O
while	O
the	O
arginine	B
reserves	O
remain	O
above	O
the	O
Michelis-Menten	O
constant,	O
k_m	O
for	O
nitric	B
oxide	I
synthase.	O

Moreover,	O
our	O
results	O
on	O
allantoin	B
are	O
consistent	O
with	O
a	O
study	O
that	O
tested	O
the	O
effect	O
of	O
2-hour	O
exposure	O
to	O
0.2	O
ppm	O
ozone	O
in	O
healthy	O
volunteers	O
(n=15).	O

A	O
line-broadening	O
factor	O
of	O
1 Hz	O
was	O
applied	O
to	O
FIDs	O
before	O
FT.	B

500 µl	O
of	O
acetonitrile	B
was	O
added	O
to	O
500 µl	O
of	O
obtained	O
plasma,	O
and	O
then	O
the	O
solution	O
was	O
placed	O
into	O
the	O
ice	O
for	O
10 min,	O
then	O
it	O
was	O
mixed	O
using	O
a	O
vortex-shaker	O
during	O
30 s	O
with	O
the	O
further	O
centrifugation	O
at	O
10,000 rpm/min	O
during	O
10 min.	O

Whereas	O
no	O
differences	O
in	O
age,	O
gender,	O
traditional	O
CV	O
risk	O
factors	O
or	O
treatments	O
were	O
observed,	O
the	O
NEFA_low	O
profile	O
was	O
associated	O
with	O
higher	O
disease	O
duration,	B
RF	O
positivity	O
and	O
erosive	O
disease.	O

Five	O
bile	O
acids,	O
GCA,	O
GCDCA,	B
TCA,	O
TCDCA	O
and	O
GUDCA	O
were	O
significantly	O
altered	O
among	O
different	O
stages	O
of	O
liver	O
cirrhosis	O
(n	O
=	O
85),	O
which	O
was	O
validated	O
with	O
an	O
independent	O
cohort	O
of	O
cirrhotic	O
patients	O
(n	O
=	O
53).	O

The	O
ALS	O
patients	O
seemed	O
to	O
be	O
characterized	O
by	O
high	O
concentrations	O
of	O
pyruvate,	B
ascorbate,	B
and	O
acetone	B
whereas	O
the	O
non-ALS	O
group	O
seemed	O
to	O
be	O
weighted	O
by	O
lower	O
concentrations	O
of	O
these	O
metabolites	O
and	O
by	O
high	O
concentrations	O
of	O
formate,	B
acetate	B
and	O
β-hydroxybutyrate.	B

The	O
homogenate	O
was	O
then	O
mixed	O
with	O
160 μl	O
of	O
Milli-Q	O
water	O
and	O
400 μl	O
chloroform	B
and	O
centrifuged	O
at	O
10,000 g	O
for	O
5 min	O
at	O
4 °C.	O

Aromatic	O
spectral	O
regions	O
for	O
ibuprofen	B
metabolites	O
(δ	O
7.22	O
–	O
7.33)	O
were	O
also	O
excluded	O
due	O
to	O
potential	O
interference	O
from	O
both	O
gut	O
microbial	O
(e.g.	O
p-cresol	B
sulfate,	I
phenylacetylglutamine,	B
)	O
and	O
exogenous	O
acetaminophen	B
glucuronide	I
metabolites.	O

Recovery	O
of	O
deuterated,	O
non-endogenous	O
oxylipins;	B
the	O
recovery	O
is	O
shown	O
as	O
percentage	O
value;	O
the	O
compounds	O
are	O
arranged	O
by	O
their	O
polarity,	O
with	O
the	O
more	O
polar	O
ones	O
on	O
the	O
left	O
hand	O
side	O
In	O
summary,	O
the	O
analytical	O
oxylipin	B
platform	O
developed	O
here	O
is	O
characterized	O
by	O
high	O
sensitivity	O
reaching	O
nanomolar	O
levels,	O
linearity	O
with	O
acceptable	O
R	O
_2	O
,	O
good	O
reproducibility,	O
and	O
high	O
coverage	O
of	O
oxylipin	B
compounds.	O

In	O
RA,	O
chronic	O
inflammation	O
may	O
lead	O
to	O
endothelial	O
dysfunction,	O
an	O
early	O
indicator	O
of	O
CVD,	O
owing	O
to	O
diminished	O
nitric	B
oxide	I
(NO)	O
production.	O

The	O
ceramide	B
yielded	O
abundant	O
fragments	O
it	O
was	O
not	O
possible	O
to	O
make	O
sense	O
of	O
these.	O

All	O
metabolites,	O
except	O
for	O
tryptophan,	B
were	O
analyzed	O
using	O
positive	O
ESI	O
and	O
were	O
tuned	O
for	O
maximum	O
sensitivity	O
across	O
the	O
linear	O
range.	O

Bradykinin,	B
as	O
part	O
of	O
the	O
kinin-kallikrein	O
system,	O
is	O
released	O
from	O
high-molecular-weight	O
kininogen	O
upon	O
interaction	O
with	O
kallikrein,	O
which	O
in	O
turn	O
is	O
activated	B
by	O
factor	O
XIIa	O
in	O
the	O
course	O
of	O
activated	B
coagulation.	O

Primate	O
A15’s	O
metabolome	O
shows	O
substantial	O
elevation	O
of	O
sensitive	O
metabolites,	O
including	O
succinic	B
acid,	I
glutamic	B
acid,	I
malate,	B
and	O
glucose-1-phosphate.	B

In	O
the	O
case	O
of	O
positive	O
and	O
negative	O
ion	O
modes	O
the	O
capillary	O
voltage	O
was	O
set	O
to	O
3.2	O
kV	B
and	O
3	O
kV,	B
and	O
the	O
cone	O
voltage	O
of	O
35	O
V	O
and	O
50	O
V,	O
respectively.	O

Mean	O
changes,	O
adjusted	O
for	O
lipid-lowering	O
or	O
hyperglycemia	O
medication-use,	O
were	O
determined	O
from	O
baseline	O
to	O
follow-up	O
for	O
the	O
four	O
metabolic	O
traits:	O
0.6 ± 2.6 kg/m_2	O
for	O
BMI,	O
0.5 ± 20.4 mg/dL	O
for	O
fasting	O
glucose,	B
3.6 ± 10.7 mg/dL	O
for	O
HDL-C,	O
and	O
−0.5 ± 84.6 mg/dL	O
for	O
TAG.	O

Neutral	O
lipids	O
were	O
eluted	O
with	O
5	O
mL	O
n	O
-hexane/ethyl	O
acetate	B
(95:5,	I
by	I
vol.).	I

Acetate	B
in	O
the	O
brain	O
is	O
primarily	O
derived	O
from	O
N	B
-acetylaspartate	I

ˆ	O
ˆ	O
ˆ	O
ˆ	O
	O
}	O
}	O
e∑pi=1βˆi(Xi−X¯¯¯i)	B

In	O
our	O
series,	O
C18:1,	B
C18:1(OH)	B
and	O
C16	O
acylcarnitine	B
levels	O
increased	O
in	O
GC	O
patients	O
according	O
to	O
H.	O
pylori	O
infection	O
(a),	O
suggesting	O
a	O
positive	O
correlation	O
between	O
these	O
acylcarnitines	B
and	O
the	O
bacterium	O
presence.	O

Correlation	O
of	O
Δ	O
glucose	B
or	O
fatty	O
acids	O
(FA)	O
vs.	O
Δ	O
body	O
weight.	O

Increased	O
glutamine	B
levels	O
in	O
severe	O
IUGR	O
could	O
be	O
explained	O
by	O
the	O
inherent	O
hypercatabolic	O
status	O
of	O
this	O
condition,	O
in	O
association	O
to	O
decreased	O
glucose	B
levels	O
[,].	O

This	O
suggests	O
that	O
samples	O
E	O
and	O
F	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
high	O
glucose	B
contributions	O
due	O
to	O
disease	O
(such	O
as	O
diabetes)	O
or	O
uncontrolled	O
dietary	O
intake.	O

Ammonium	B
phosphate	I
at	O
1	O
and	O
2	O
mM	O
and	O
ammonium	B
hydrogen	I
carbonate	I
at	O
10	O
and	O
20	O
mM	O
were	O
compared.	O

Notably,	O
the	O
intra-EV	O
concentration	O
of	O
D-ribose	B
5-phosphate	I
was	O
as	O
high	O
as	O
68.8	O
mM,	O
while	O
it	O
was	O
not	O
detected	O
from	O
platelets	O
at	O
all.	O

Multiple	O
reaction	O
monitoring	O
chromatogram	O
of	O
β-apo-13-carotenone	B
in	O
blood	O
plasma	O
(top	O
)	O
and	O
a	O
standard	O
(bottom	O
)	O
as	O
analyzed	O
by	O
atmospheric	O
pressure	O
chemical	O
ionization	O
in	O
positive	O
mode	O
after	O
C30	O
HPLC.	O

The	O
majority	O
of	O
oxylipins	B
detected	O
in	O
plasma	O
are	O
assigned	O
to	O
AA	O
and	O
LA,	O
followed	O
by	O
metabolites	O
derived	O
from	O
EPA,	O
DHA,	O
DGLA,	O
and	O
ALA.	O

Both	O
primary	O
aldosteronism	O
subtypes,	O
unilateral	O
aldosterone-producing	B
adrenal	I
adenoma	O
and	O
bilateral	O
adrenal	O
hyperplasia,	O
had	O
significantly	O
higher	O
glucocorticoid	B
output	O
than	O
controls,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
2	O
disease	O
groups	O
(SI	O
Appendix	O
and	O
).	O

Creatine	B
takes	O
part	O
in	O
phosphocreatine	B
metabolism	O
which	O
in	O
turn	O
is	O
the	O
main	O
energetic	O
substrate	O
for	O
cells.	O

The	O
typical	O
total	O
ion	O
chromatograms	O
(TICs)	O
obtained	O
from	O
plasma	O
samples	O
in	O
different	O
groups	O
by	O
RRLC-(+)ESI-MS	B
are	O
shown	O
in	O
supplemental	O
Fig.	O

Bindzil_®	O
2040	O
silica	B
nanoparticles	O
(anionic	O
SNPs)	O
were	O
obtained	O
from	O
Eka	O
Chemicals.	O

Our	O
previous	O
study	O
showed	O
that	O
the	O
urine	O
level	O
of	O
IL-8	O
normalized	O
to	O
creatinine	B
could	O
be	O
a	O
possible	O
biomarker	O
with	O
the	O
capacity	O
to	O
discriminate	O
NHL	O
patients	O
from	O
normal	O
controls;	O
thus,	O
we	O
expected	O
that	O
urine	O
might	O
be	O
a	O
valuable	O
biological	O
source	O
for	O
diagnostic	O
markers	O
for	O
NHL.	O

For	O
the	O
18	O
subjects	O
of	O
the	O
intersection	O
group	O
1,	O
which	O
completed	O
the	O
marathon	O
and	O
attended	O
the	O
lab-based	O
tests,	O
this	O
concerned	O
correlations	O
between	O
the	O
time	O
to	O
complete	O
the	O
marathon	O
and	O
capillary	O
density	O
(r	O
=	O
–0.61),	O
V˙O2max	O
(r	O
=	O
–0.78),	O
BMI	O
(r	O
=	O
0.69),	O
and	O
glucose	B
concentration	O
prior	O
to	O
the	O
marathon	O
(r	O
=	O
–0.66).	O

Each	O
individual	O
saliva	O
sample	O
was	O
prepared	O
in	O
triplicate	O
and	O
labeled	O
with	O
_12	O
C-dansyl	B
chloride,	I
and	O
injected	O
three	O
times	O
for	O
LC-FTICR-MS	O
analysis.	O

The	O
differentiation	O
of	O
the	O
control	O
samples	O
arises	O
from	O
NMR	O
buckets	O
in	O
the	O
region	O
3.20-4.00	O
ppm	O
(,	O
left	O
half),	O
which	O
correspond	O
to	O
metabolites	O
like	O
α/β-glucose	B
or	O
the	O
alpha	O
and	O
beta	O
hydrogen	O
atoms	O
of	O
most	O
amino	O
acids.	O

Circulating	O
lipids	O
and	O
lipid	O
metabolism	O
are	O
integrally	O
related	O
to	O
type-2	O
diabetes	O
(T2D)	O
and	O
sphingolipids	B
specifically	O
act	O
as	O
mediators	O
of	O
fatty	O
acid-induced	O
β-cell	O
dysfunction,	O
with	O
possible	O
therapeutic	O
implications.	O

Our	O
study	O
is	O
in	O
accordance	O
with	O
other	O
studies	O
that	O
have	O
found	O
higher	O
levels	O
of	O
taurine	B
in	O
different	O
types	O
of	O
cancer,	O
probably	O
due	O
to	O
apoptosis	O
[,	O
].	O

In	O
addition,	O
patients	O
in	O
C.	O
caudatus	O
treated	O
(U)	O
group	O
will	O
be	O
advised	O
to	O
perform	O
self-monitoring	O
blood	O
glucose.	B

Individual	O
metabolite	O
levels	O
were	O
tested	O
with	O
LMM,	O
and	O
only	O
glutamate	B
remained	O
significantly	O
increased	O
after	O
6	O
months	O
after	O
correcting	O
for	O
multiple	O
tests	O
(Supplementary	O
Table 2).	O

Twelve	O
micron-thick	O
sections	O
were	O
cut	O
at	O
–20	O
°C	O
in	O
a	O
cryostat	O
and	O
thaw-mounted	O
onto	O
indium-tin-oxide	B
glass	O
slides	O
(Bruker	O
Daltonik,	O
Bremen,	O
Germany)	O
that	O
had	O
previously	O
been	O
coated	O
with	O
poly-L-lysine.	B

Advanced	O
HCC	O
can	O
be	O
complicated	O
by	O
cancer	O
cachexia	O
with	O
associated	O
sarcopenia,	O
and	O
urinary	O
creatinine	B
concentration	O
has	O
been	O
suggested	O
as	O
a	O
biomarker	O
of	O
sarcopenia[].	O

Abiraterone	B
detection	O
was	O
linear	O
in	O
the	O
range	O
2–400	O
ng/mL	O
and	O
all	O
metabolites	O
from	O
0.1–20	O

Furthermore,	O
maximum	O
velocity	O
of	O
citrate	B
synthase	O
was	O
reduced	O
in	O
cultured	O
pancreatic	O
islet	O
cells	O
cultured	O
with	O
long-chain	O
fatty	O
acids	O
or	O
high	O
dose	O
glucose,	B
which	O
may	O
play	O
a	O
role	O
for	O
glucotoxicity	O
and	O
lipotoxicity	O
in	O
β	O
-cells.	O

This	O
implies	O
that	O
trigonelline	B
may	O
be	O
useful	O
as	O
a	O
biomarker	O
for	O
coffee	O
consumption	O
(Lang	O
et	O
al.	O
)	O
even	O
though	O
small	O
amounts	O
of	O
the	O
molecule	O
may	O
also	O
be	O
produced	O
by	O
gut	O
bacteria.	O

As	O
for	O
the	O
Ibuprofen	B
model	O
(from	O
here	O
on	O
designated	O
as	O
IBU)	O
based	O
on	O
one	O
predictive	O
component	O
and	O
one	O
orthogonal	O
component,	O
the	O
model	O
statistics	O
were	O
R_2	O
X	O
=	O
0.887;	O
R_2	O
Y	O
=	O
0.924	O
and	O
Q_2	O
Y	O
=	O
0.918.	O

The	O
classes	O
of	O
lipids	O
found	O
were	O
sphingolipids,	B
glycerophospholipids	B
and	O
policetidis.	O

The	O
samples	O
further	O
underwent	O
a	O
two-step	O
derivatization	O
and	O
were	O
subjected	O
to	O
analysis	O
on	O
a	O
GC-MS	O
7890B/MS5977A	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA,	O
USA)	O
with	O
a	O
CombiPAL	O
autosampler	O
(CTC-Analytics	O
AG,	O
Zwingen,	O
Switzerland)	O
and	O
a	O
DB-5	O
ms	O
fused	O
silica	B
capillary	O
column	O
(60	O
m,	O
0.25	O
mm	O
i.d.	O

This	O
information	O
is	O
crucial	O
to	O
interpreting	O
the	O
corresponding	O
FT-ICR-MS	O
data,	O
in	O
terms	O
of	O
assigning	O
the	O
glycerolipid	B
isotopologues	O
of	O
m	O
+	O
3	O
(monoisotopic	O
mass	O
plus	O
3	O
neutrons)	O
and	O
m	O
+	O
odd	O
number	O
of	O
neutrons	O
to	O
_13	O
C	O
labeling	O
in	O
the	O
glycerol	B
backbone.	O

Bilirubin	B
was	O
also	O
upregulated	O
in	O
HCC	O
relative	O
to	O
AML	O
plasma	O
and	O
this	O
is	O
confirmed	O
by	O
clinical	O
chemistry	O
data	O
in	O
(t	O
=	O
3.24;	O
P	O
=	O
0.0024).	O

Certain	O
serine	B
proteases	O
act	O
as	O
tumor	O
suppressors	O
and	O
promote	O
angiogenesis,	O
induce	O
tumor	O
cell	O
migration,	O
and	O
enhance	O
the	O
invasive	O
potential	O
of	O
pancreatic,	O
breast,	O
and	O
lung	O
cancer	O
cells.	O

Note:	O
3	O
sulfo-GCDCA	B
and	O
GCA	O
(designated	O
by	O
*)	O
were	O
found	O
significant	O
(q	O
<	O
0.1)	O
in	O
one	O
out	O
of	O
the	O
three	O
experiments.	O

The	O
intensity	O
of	O
the	O
aromatic	O
region	O
is	O
increased	O
to	O
show	O
the	O
resonances	O
in	O
this	O
area,	O
usually	O
less	O
intense	O
than	O
those	O
observed	O
in	O
the	O
aliphatic	B
region.	O

Although	O
it	O
was	O
not	O
statistically	O
significant,	O
leucine	B
too	O
showed	O
increased	O
level	O
in	O
HCC	O
versus	O
cirrhosis,	O
consistent	O
with	O
our	O
previous	O
findings.	O

MET	O
is	O
the	O
precursor	O
for	O
homocysteine	B
and	O
cysteine,	B
which	O
plays	O
a	O
critical	O
role	O
in	O
GSH	B
synthesis.	O

In	O
this	O
study,	O
we	O
analyzed	O
3-hydroxypropylmercapturic	B
acid	I
(3-HPMA,	O
2)	O
in	O
human	O
urine.	O

Specifically,	O
there	O
were	O
significant	O
decreases	O
in	O
androsterone	B
sulfate,	I
epiandrosterone	B
sulfate,	I
4-androsten-3β,17β-diol	B
disulfate	I
2,	O
and	O
pregnendiol	O
disulfate.	B

ATP	B
levels	O
are	O
differentiating	O
in	O
the	O
muscle	O
during	O
the	O
response	O
to	O
resuscitation;	O
both	O
groups	O
of	O
animals	O
exhibit	O
a	O
decrease	O
in	O
levels	O
but	O
the	O
decrease	O
is	O
approximately	O
25	O
times	O
greater	O
in	O
FS	O
animals	O
when	O
compared	O
to	O
CPF	O
animals.	O

Age-related	O
falls	O
in	O
upper	O
cut-offs	O
between	O
22-	O
and	O
70-year	O
olds	O
for	O
other	O
steroids	O
were	O
also	O
generally	O
steeper	O
in	O
women	O
than	O
men,	O
showing	O
respective	O
falls	O
of	O
40%	O
and	O
31%	O
for	O
DHEA-SO_4	O
(,	O
panels	O
C	O
&	O
D),	O
56%	O
and	O
36%	O
for	O
androstenedione	B
(,	O
panels	O
E	O
&	O
F),	O
43%	O
and	O
42%	O
for	O
11-deoxycorticosterone	B
(,	O
panels	O
C	O
&	O
D)	O
and	O
39%	O
and	O
29%	O
for	O
cortisone	B
(,	O
panels	O
E	O
&	O
F).	O

However,	O
all	O
patients	O
in	O
this	O
study	O
had	O
received	O
chemotherapy	O
with	O
cisplatin	B
and	O
gemcitabine	O
with	O
no	O
5-FU	O
treatment,	O
hence	O
5-FU	O
cannot	O
be	O
an	O
explanation	O
for	O
the	O
increase	O
in	O
orotate	B
observed.	O

Because	O
of	O
this	O
compensatory	O
mechanism,	O
the	O
development	O
of	O
any	O
drug	O
targeting	O
the	O
folate	B
pathway	O
in	O
trypanosomatids	O
should	O
consider	O
the	O
inhibition	O
of	O
both	O
DHFR	O
and	O
PTR1	O
.	O

(G)	O
Comparison	O
of	O
the	O
ratio	O
of	O
tryptophan	B
(TRP)	O
to	O
nicotinamide	B
between	O
plasma	O
from	O
normal	O
women	O
and	O
women	O
with	O
breast	O
cancer.	O

The	O
combination	O
of	O
4-hydroxypentenoic	B
acid,	I
5-dihydrotestosterone	B
sulfate,	I
serine,	B
spermine,	B
and	O
xanthine	B
distinguished	O
OSA	O
from	O
SS	O
with	O
a	O
sensitivity	O
of	O
85%	O
and	O
specificity	O
of	O
80%.	O

In	O
parallel	O
to	O
the	O
reduction	O
of	O
leucine,	B
we	O
observed	O
an	O
increase	O
in	O
circulating	O
levels	O
of	O
2-KIC,	O
which	O
is	O
the	O
first	O
step	O
in	O
leucine	B
degradation.	O

CSF	O
in	O
70%	O
ethanol	B
(3	O
ml)	O
was	O
applied	O
to	O
the	O
cartridge	O
and	O
allowed	O
to	O
flow	O
at	O
a	O
rate	O
of	O
∼0.25	O
ml/min,	O
and	O
flow	O
was	O
aided	O
by	O
application	O
of	O
a	O
slight	O
pressure	O
from	O
a	O
Luer-lock	O
syringe.	O

Similar	O
results	O
were	O
obtained	O
when	O
growing	O
these	O
AKP	O
organoids	B
attached	O
to	O
tissue	O
culture	O
plates	O
as	O
2D	O
cultures	O
(I,J),	O
thus	O
suggesting	O
that	O
our	O
2D	O
results	O
are	O
informative	O
and	O
may	O
reflect	O
in	O
vivo	O
sensitivity	O
to	O
inhibition	O
of	O
the	O
Kyn	O
pathway.	O

Nitration	O
and	O
oxidation	O
of	O
tyrosine	B
residues	O
in	O
proteins	O
have	O
been	O
detected	O
in	O
several	O
conditions	O
of	O
oxidative	O
stress	O
that	O
involve	O
the	O
overproduction	O
of	O
NO_+	O
and	O
oxygen	O
radicals.	O

Biothiol	B
imbalances	O
in	O
biological	O
samples	O
are	O
associated	O
with	O
different	O
kinds	O
of	O
disease,	O
such	O
as	O
cardiovascular	O
disease,	O
neurodegenerative	O
disease,	O
cancer,	O
kidney	O
dysfunction,	O
and	O
diabetes	O
mellitus.	O

These	O
studies	O
demonstrate	O
that,	O
depending	O
on	O
stereochemistry	O
and	O
other	O
factors,	O
PAH	O
diol	B
epoxides	I
should	O
be	O
detoxified	O
by	O
GSTs	O
in	O
humans.	O

It	O
is,	O
thus,	O
possible	O
that	O
the	O
metabolite	O
changes	O
noted	O
from	O
intermediate	O
to	O
late	O
AMD	O
in	O
Coimbra	O
may	O
be	O
at	O
least	O
partially	O
due	O
to	O
heart	O
disease,	O
particularly	O
regarding	O
acetoacetate	B
and	O
β-hydroxybutyrate	B
levels,	O
since	O
histidine	B
variations	O
(common	O
to	O
both	O
cohorts)	O
seem	O
to	O
constitute	O
an	O
AMD-related	O
feature.	O

Thus,	O
instead	O
of	O
suggesting	O
that	O
intestinal	O
microbes	O
should	O
be	O
eradicated	O
with	O
long-term	O
use	O
of	O
antibiotics,	O
our	O
findings	O
point	O
to	O
the	O
possibility	O
that	O
plasma	O
TMAO	B
levels	O
may	O
identify	O
a	O
pathway	O
within	O
intestinal	O
microbiota	O
amenable	O
to	O
therapeutic	O
modulation.	O

13	O
[Google	O
Scholar]	O
Ruelius	O
HW,	B
Kirkman	O
SK,	O
Young	O
EM,	O
Janssen	O
FW.	B

(,	O
)	O
Myo-inositol	B
can	O
be	O
obtained	O
also	O
from	O
dietary	O
sources.	O

This	O
taurine	B
deficiency	O
may	O
be	O
associated	O
with	O
the	O
loss	O
of	O
its	O
protective	O
role	O
in	O
cells,	O
specifically	O
in	O
membrane	O
stabilization	O
as	O
well	O
as	O
antioxidation	O
and	O
detoxification	O
activities.	O

Spermine	B
and	O
spermidine	B
are	O
naturally	O
occurring	O
polyamines.	B

Increase	O
in	O
the	O
urinary	O
excretion	O
of	O
indoxyl	B
sulfate	I
predicted	O
albuminuria	O
development	O
in	O
Pima	O
Indian	O
subjects	O
with	O
T2D	O
and	O
normal	O
renal	O
function	O
at	O
baseline.	O

226.9 → m/z	O
185.9	O
for	O
BPA,	O
m/z	O
286.2 → m/z	O
245	O
for	O
retinol	B
and	O
m/z	O
116 → m/z	O
69.9	O
for	O
L-proline.	B

For	O
MS	O
analysis,	O
1	O
mM	O
model	O
mixture	O
was	O
dissolved	O
in	O
200	O
μL	O
H_2	O
O	O
of	O
which	O
10	O
μL	O
was	O
diluted	O
10-fold	O
by	O
50%/50%	O
(v/v)	O
ACN/H_2	O
O	O
solution	O
with	O
0.1%	O
formic	B
acid.	I

In	O
this	O
study,	O
a	O
low	O
serum	O
level	O
of	O
a	O
specific	O
PC,	O
PC	B
ae	I
42:1,	I
was	O
found	O
to	O
be	O
significantly	O
different	O
between	O
CHB	O
vs.	O
HBV-associated	O
cirrhosis,	O
HBV-associated	O
HCC	O
and	O
HBV-associated	O
cirrhosis	O
vs.	O
HBV-associated	O
HCC	O
meaning	O
that	O
this	O
serum	O
PC	O
level	O
may	O
prove	O
useful	O
as	O
a	O
biomarker	O
in	O
staging	O
liver	O
disease	O
progression.	O

Next,	O
800 μ	O
L	O
of	O
methanol	B
was	O
added	O
to	O
precipitate	O
protein.	O

We	O
also	O
investigated	O
the	O
potential	O
pathways	O
that	O
could	O
be	O
associated	O
with	O
increased	O
ceramide	B
expression	O
in	O
breast	O
cancer	O
tissue.	O

We	O
also	O
considered	O
the	O
possibility	O
that	O
_13	O
C-labeled	O
glutamate	B
and/or	O
glutamine	B
was	O
synthesized	O
in	O
the	O
surrounding	O
brain	O
and	O
then	O
transferred	O
to	O
the	O
tumor,	O
exaggerating	O
the	O
ability	O
of	O
the	O
tumor	O
to	O
oxidize	O
glucose	B
and	O
produce	O
these	O
intermediates.	O

Among	O
those,	O
28	O
had	O
a	O
normal	O
sonographic	O
estimation	O
of	O
fetal	O
weight	O
that	O
was	O
confirmed	O
at	O
birth	O
[Adequate-for-gestational	O
age	O
fetuses	O
(AGA)]	O
and	O
52	O
pregnancies	O
had	O
an	O
antenatal	O
diagnosis	O
of	O
fetal	O
smallness	O
[estimated	O
sonographic	O
fetal	O
weight	O
(EFW)	O
below	O
the	O
10_th	O
centile]	O
that	O
was	O
confirmed	O
at	O
birth	O
(birthweight	O
<10_th	O
centile)	O
and	O
were	O
included	O
as	O
cases.	O

A	O
primary	O
stock	O
(20	O
μg/mL	O
of	O
each	O
analyte	O
in	O
methanol)	B
purchased	O
from	O
Cerilliant	O
Corporation	O
(Round	O
Rock,	O
TX)	O
was	O
used	O
to	O
make	O
stock	O
solution	O
I	O
(4.0	O
μg/mL)	O
and	O
stock	O
solution	O
II	O
(0.2	O
μg/mL).	O

Indomethacin	B
(a	O
nonselective	O
cyclooxygenase	O
(COX)	O
inhibitor)	O
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA),	O
arachidonic	B
acid	I
and	O
NADPH	B
were	O
from	O
Cayman	O
chemicals	O
(Ann	O
Arbor,	O
MI,	O
USA),	O
and	O
EGF	O
was	O
from	O
BD	O
Biosciences	O
(San	O
Jose,	O
CA,	O
USA).	O

For	O
example,	O
the	O
KYN	O
pathway	O
is	O
upregulated	O
by	O
proinflammatory	O
activation	O
as	O
well	O
as	O
cortisol	B
(;	O
;	O
).	O

To	O
identify	O
the	O
shift	O
in	O
fatty	O
acid	O
and	O
oxylipin	B
constituents	O
differentiating	O
pro-	O
and	O
anti-atherogenic	O
TGRL,	O
a	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(PLS-DA)	O
was	O
performed.	O

It	O
can	O
be	O
noted	O
that	O
macrophages	O
are	O
localized	O
mainly	O
in	O
the	O
loci	O
of	O
lesions,	O
in	O
this	O
regard,	O
where	O
higher	O
concentrations	O
of	O
itaconic	B
acid	I
can	O
be	O
expected.	O

Vice	O
versa,	O
CYP11B2	O
was	O
associated	O
with	O
tetrahydroaldosterone	B
(P	O
<	O
0.05),	O
but	O
not	O
with	O
glucocorticoid	B
or	O
11β-hydroxyandrosterone	B
excretion.	O

In	O
the	O
PP	O
group,	O
5,	O
16,	O
and	O
9	O
patients	O
had	O
stage	O
I,	O
II,	O
and	O
III	O
disease,	O
respectively,	O
which	O
corresponded	O
to	O
4,	O
21,	O
and	O
5	O
patients	O
in	O
the	O
GP	B
group.	O

These	O
findings	O
indicate	O
that	O
this	O
generic	O
oxylipin	B
profiling	O
platform	O
can	O
be	O
applied	O
broadly	O
to	O
study	O
these	O
highly	O
bioactive	O
compounds	O
in	O
relation	O
to	O
human	O
disease.	O

QC	O
solutions	O
of	O
analytes	O
were	O
prepared	O
in	O
DNA	O
digestion	O
buffer	O
as	O
described	O
above	O
at	O
the	O
concentrations	O
400,	O
40	O
and	O
4 ng/mL	O
for	O
dTG	O
and	O
40,000,	O
4000	O
and	O
400 ng/mL	O
for	O
dA,	O
stored	O
at	O
−20 °C	O
and	O
subjected	O
to	O
between	O
1	O
and	O
3	O
freeze	O
thaw	O
cycles,	O
each	O
of	O
24 h	O
duration.	B

The	O
principal	O
findings	O
of	O
this	O
study	O
were:	O
(1)	O
12	O
(36%)	O
of	O
33	O
SLE	O
women	O
developed	O
APO;	O
(2)	O
Metabolite	O
profiling	O
of	O
mid-trimester	O
maternal	O
plasma	O
showed	O
distinctive	O
and	O
discriminatory	O
metabolic	O
physiology	O
between	O
healthy	O
pregnant	O
controls	O
and	O
SLE	O
patients;	O
(3)	O
Biomarker	O
panels	O
using	O
a	O
combination	O
of	O
two	O
biomarkers	O
(Tryptophan	O
and	O
LysoPC	O
C22:5)	B
in	O
mid-trimester	O
maternal	O
plasma	O
accurately	O
predicted	O
an	O
APO	O
among	O
pregnant	O
women	O
with	O
SLE;	O
and	O
(4)	O
The	O
metabolomic	O
biomarkers	O
were	O
closely	O
associated	O
with	O
the	O
severity	O
of	O
APO	O
in	O
patients	O
with	O
SLE	O
and	O
APO.	O

Nevertheless,	O
little	O
is	O
known	O
about	O
gut	O
microbial	O
diversity	O
and	O
blood	O
TMAO	B
levels	O
in	O
stroke	O
patients.	O

Dust	O
storms	O
also	O
contain	O
particles	O
such	O
as,	O
calcium	B
oxide	I
(CaO)	O
and	O
magnesium	B
oxide	I
(MgO),	O
and	O
oxides	B
of	O
sodium	O
and	O
potassium	O
(Na_2	O
O	O
and	O
K_2	O
O)	O
as	O
well	O
as	O
silicon	B
dioxide	I
(SiO_2	O
),	O
aluminum	B
oxide	I
(Al_2	O
O_3	O
),	O
iron	O
(Fe_2	O
O_3	O
)	O
and	O
titanium	O
(TiO_2	O
)	O
oxides	B
and	O
trace	O
elements	O
such	O
as,	O
zirconium	O
(Zr),	O
strontium	O
(Sr),	O
rubidium	O
(Rb).	O

General	O
Linear	O
Models	O
were	O
used	O
to	O
search	O
for	O
interaction	O
between	O
different	O
subject	O
characteristics	O
(e.g.	O
gender,	O
age)	O
and	O
excretion	O
of	O
creatinine	B
levels.	O

The	O
authors	O
conducted	O
two	O
tests,	O
one	O
analyzing	O
human	O
urine	O
either	O
spiked	O
or	O
not	O
with	O
32	O
metabolite	O
standards	O
and	O
another	O
comparing	O
plasma	O
of	O
rats	O
either	O
supplemented	O
or	O
not	O
with	O
vitamin	B
D.	I
Both	O
studies	O
were	O
conducted	O
using	O
NMR	O
and	O
MS	O
techniques.	O

Ethanol	B
was	O
purchased	O
from	O
Commercial	O
Alcohols,	O
Canada.	O

In	O
plasma	O
specimens,	O
another	O
metabolite	O
derived	O
from	O
phenylalanine,	B
the	O
dipeptide	O
aspartylphenylalanine,	B
also	O
changed	O
substantially	O
between	O
the	O
baseline	O
and	O
final	O
collections.	O

Albumin	O
concentration	O
and	O
total	O
choline	B
were	O
lower	O
in	O
PCOS	O
women	O
compared	O
with	O
the	O
controls.	O

Our	O
data	O
strongly	O
support	O
the	O
need	O
for	O
further	O
studies	O
to	O
determine	O
why	O
higher	O
phenylalanine	B
appears	O
to	O
be	O
a	O
consistently	O
adverse	O
signal	O
for	O
CVD	O
outcomes.	O

Pre-training	O
(after	O
warm-up)	O
and	O
post-training	O
capillary	O
blood	O
was	O
drawn	O
to	O
measure	O
lactate	B
concentrations.	O

An	O
additional	O
Blast	O
search	O
was	O
performed	O
to	O
compare	O
the	O
Atlantic	B
cod	O
protein	O
GENSCAN00000070264	O
against	O
human	O
serum	O
albumin	O
(AAA98797).	O

Thus,	O
a	O
large	O
portion	O
of	O
the	O
PhIP	O
and	O
5-HO-PhIP	B
recovered	O
from	O
N	B
-acetoxy-PhIP	I
bound	O
to	O
rat	O
or	O
human	O
SA	O
may	O
be	O
attributed	O
to	O
an	O
unstable	O
sulfenamide	B
linked	O
adduct	O
formed	O
at	O
Cys_34	O
.	O

These	O
diagnostic	O
ions	O
clearly	O
suggested	O
the	O
existence	O
of	O
Δ9	O
and	O
Δ11	O
C=C	O
locations	O
for	O
the	O
C18:1	B
chain	O
of	O
PE	B
16:0_18:1,	I
thus	O
identifying	O
the	O
C=C	O
location	O
isomers	O
as	O
PE	B
16:0_18:1(Δ9)	I
and	O
PE	B
16:0_18:1(Δ11)	I

The	O
faecal	O
_1	O
H	O
NMR	O
spectra	O
were	O
dominated	O
by	O
signals	O
arising	O
from	O
the	O
three	O
main	O
SCFA	O
namely,	O
acetate,	B
propionate,	B
and	O
butyrate	B
and	O
characterised	O
by	O
low	O
levels	O
of	O
many	O
other	O
metabolites	O
(Figure	O
).	O

Cotinine	B
is	O
the	O
primary	O
metabolite	O
coming	O
from	O
nicotine	B
that	O
is	O
very	O
stable	O
in	O
the	O
body	O
(half	O
life	O
is	O
approximately	O
18	O
h,	O
CV	O
30%)	O
and	O
can	O
be	O
measured	O
reliably	O
in	O
blood,	O
saliva	O
and	O
urine	O
for	O
monitoring	O
nicotine	B
exposure	O
in	O
people.	O

T1DM	O
was	O
composed	O
of	O
86%	O
SM,	O
10%	O
Cer,	B
and	O
4%	O
MHC	O
whereas	O
T2DM	O
accounted	O
for	O
86%	O
SM,	O
11%	O
Cer,	B
and	O
3%	O
MHC.	O

Antiretroviral	O
treatment	O
on	O
groups	O
C	O
and	O
D	O
was	O
homogeneously	O
comprised	O
of	O
an	O
association	O
of	O
fixed	O
dose	O
combination	O
of	O
zidovudine	B
and	O
3TC	O
administered	O
BID,	O
and	O
a	O
QD	O
dose	O
of	O
Efavirenz,	O
according	O
to	O
the	O
local	O
Brazilian	O
guidelines	O
at	O
that	O
time.	O

In	O
short,	O
first	O
proteins	O
were	O
precipitated	O
by	O
adding	O
800 μL	O
of	O
chilled	O
methanol	B
in	O
100 μL	O
serum	O
containing	O
20 μL	O
of	O
myristic	B
acid	I
(2 mg/mL)	O
as	O
internal	O
standard.	O

Packed	O
RBCs	O
were	O
diluted	O
10-fold	O
with	O
saline,	B
and	O
250	O
µL	O
of	O
the	O
solution	O
was	O
dispensed	O
into	O
a	O
tube	O
and	O
stored	O
at	O
−80°C	O
until	O
further	O
use.	O

Interestingly	O
glutamine	B
levels	O
are	O
rising	O
significantly	O
across	O
the	O
EBC	O
subgroups	O
then	O
falling	O
in	O
MBC	O
cohorts.	O

The	O
most	O
prominent	O
metabolic	O
alteration	O
in	O
plasma	O
of	O
cachectic	O
patients	O
was	O
the	O
decrease	O
of	O
amino	O
acids	O
and	O
derivatives	O
[especially	O
arginine,	B
tryptophan,	B
indolelactic	B
acid,	I
and	O
threonine,	B
with	O
0.4‐fold	O
change	O
(FC)	O
compared	O
with	O
non‐cachectic	O
patients],	O
along	O
with	O
the	O
reduction	O
of	O
glycerophospholipids	B
[mainly	O
lysophosphatidylcholines(O‐16:0)	B
and	O
lysophosphatidylcholines(20:3)	B

For	O
all	O
other	O
species	O
[acyl	O
carnitines	I
(AC),	O
diacylglycerides	B
(DAG),	O
TAG,	O
cholesterol	B
esters	I
(ChoE),	O
glycerophosphocholine	B
(PC),	O
glycerophosphoethanolamine	B
(PE),	O
glycerophosphoinositol	B
(PI),	O
sphingomyelin	B
(SM),	O
ceramides	B
(Cer),	O
and	O
monohexosylceramides	B
(CMH)]	O
a	O
theoretical	O
m/z	O
database	O
was	O
first	O
generated	O
for	O
all	O
possible	O
combinations	O
of	O
fatty	O
acid	O
derived	O
moieties.	O

Therefore,	O
targeting	O
glutamine	B
metabolism	O
for	O
cancer	O
treatment	O
had	O
received	O
increasing	O
attention	O
(Cervantes-Madrid	O
et	O
al.	O

Three	O
independent	O
and	O
complementary	O
analytical	O
techniques	O
for	O
metabolic	O
profiling	O
are	O
applied:	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
(HILIC–LC),	O
reversed-phase	O
liquid	O
chromatography	O
(RP–LC),	O
and	O
gas	O
chromatography	O
(GC).	O

HLP:	O
Hyperlipidemia;	O
BMI:	O
body	O
mass	O
index;	O
SBP:	O
Systolic	O
blood	O
pressure;	O
DBP:	B
Diastolic	O
blood	O
pressure;	O
TG:	B
Triglycerides;	B
TC:	O
Total	O
cholesterol.	B

A	O
head-to-head	O
comparison	O
between	O
different	O
anticoagulants	O
(i	O
.e	O
.,	O
citrate,	B
EDTA	O
and	O
heparin)	B
and	O
serum	O
was	O
performed	O
using	O
whole	O
blood	O
from	O
the	O
same	O
human	O
donor.	O

Applying	O
the	O
same	O
criteria	O
used	O
for	O
the	O
plasma	O
lipidome	O
to	O
select	O
the	O
biomarker	O
candidates,	O
five	O
lipids,	O
LPC	B
(16:1),	I
PC	B
(33:1),	I
PC	B
(35:4)B,	I
PC	B
(36:5)B	I
and	O
PC	B
(36:6),	I
discriminated	O
meloxicam-treated	O
from	O
saline-treated	O
cats.	O

The	O
most	O
intense	O
signals	O
in	O
urine	O
arose	O
from	O
glycine,	B
creatinine,	B
citrate,	B
α-ketoglutarate,	B
trimethylamine-N-oxide	B
and	O
p-hydroxyphenylacetate.	B

However,	O
few	O
studies	O
have	O
explored	O
the	O
association	O
of	O
betaine	B
with	O
incident	O
T2DM,	O
especially	O
in	O
the	O
general	O
population.	O

Validations	O
of	O
the	O
analytical	O
methods	O
on	O
urine	O
(with	O
and	O
without	O
enzymatic	O
degradation)	O
were	O
also	O
performed	O
(full	O
validation	O
for	O
glucuronides	O
determination,	O
partial	O
validation	O
for	O
diosmetin	B
quantification	O
upon	O
enzymatic	O
digestion;	O
data	O
presented	O
in	O
Table ).	O

The	O
buildup	O
of	O
TCA	O
intermediates	O
and	O
the	O
precursors	O
to	O
the	O
molecules	O
that	O
enter	O
the	O
cycle	O
(acylcarnitines	O
and	O
glutamate)	B
may	O
indicate	O
dysfunction	O
of	O
this	O
cycle,	O
or	O
at	O
least	O
the	O
inability	O
to	O
keep	O
pace	O
with	O
the	O
demands	O
of	O
the	O
most	O
active	O
cells	O
such	O
as	O
proliferating	O
pulmonary	O
vascular	O
cells.	O

The	O
[M	O
+	O
H	O
-	O
17]_+•	O
is	O
a	O
characteristic	O
fragment	O
ion	O
for	O
N	B
-hydroxy-HAAs,	I
but	O
not	O
for	O
ring-hydroxylated	O
HAAs,	O
under	O
these	O
LC-ESI/MS/MS	O
conditions	O
(,).	O

Then,	O
200	O
μL	O
of	O
phosphate	B
buffer	O
solution	O
(90	O
mM	O
NaH_2	O
PO_4	O
/Na_2	O

Miyagi	O
et	O
al.	O
also	O
reported	O
that	O
histidine	B
was	O
decreased	O
in	O
all	O
but	O
prostate	O
cancer.	O

Formic	B
acid	I
(for	O
mass	O
spectrometry)	O
and	O
ammonium	B
carbonate	I
were	O
acquired	O
from	O
Fluka	O
Analytical	O
(Sigma	O
Aldrich),	O
Steinheim,	O
Germany.	O

These	O
metabolites	O
are	O
known	O
to	O
be	O
involved	O
in	O
multiple	O
biochemical	O
processes,	O
such	O
as	O
energy	O
metabolism,	O
pentose	B
phosphate	I
pathway,	O
γ-glutamyl	O
cycle	O
and	O
futile	O
5-Oxoproline	B
cycle.	O

To	O
further	O
explore	O
the	O
potential	O
nonlinearity	O
of	O
the	O
relation	O
between	O
plasma	O
TMAO	B
and	O
odds	O
of	O
GDM,	O
a	O
restricted	O
cubic	O
spline	O
model	O
was	O
used	O
with	O
4	O
knots	O
at	O
the	O
5th,	O
35th,	O
65th,	O
and	O
95th	O
percentiles	O
of	O
plasma	O
TMAO	B
concentration	O
via	O
Stata	O
version	O
13	O
(StataCorp).	O

For	O
both	O
comparisons,	O
pathway	O
analysis	O
revealed	O
a	O
significant	O
enrichment	O
of	O
glycerophospholipid	B
metabolism,	O
as	O
well	O
as	O
of	O
purine,	B
taurine,	B
and	O
hypotaurine,	B
and	O
nitrogen	O
metabolism	O
pathways.	O

LDL-C	O
reduction	O
in	O
FR	O
subjects	O
was	O
also	O
correlated	O
with	O
post	O
simvastatin	B
treatment	O
levels	O
of	O
LCA	O
and	O
TLCA	O
(data	O
not	O
shown).	O

Overall,	O
TMAO	B
correlated	O
with	O
choline	B
(r=	O
0.40,	O
p<0.0001)	O
but	O
not	O
betaine	B
(r=0.08,	O
p=0.43),	O
and	O
choline	B
correlated	O
with	O
betaine	B
(r=	O
0.46,	O
p<0.0001).	O

In	O
contrast,	O
they	O
observed	O
higher	O
levels	O
of	O
choline	B
in	O
serum	O
samples	O
from	O
NSCLC	O
patients,	O
and	O
we	O
report	O
lower	O
levels	O
of	O
choline	B
in	O
serum	O
of	O
NSCLC	O
patients,	O
our	O
results	O
being	O
in	O
agreement	O
with	O
previous	O
results	O
obtained	O
from	O
the	O
analysis	O
of	O
tissue	O
samples	O
from	O
LC	O
tumors.	O

With	O
data	O
from	O
our	O
small	O
cohort	O
we	O
cannot	O
conclude	O
that	O
decreased	O
DDAH2	O
expression	O
is	O
monocyte	O
or	O
macrophage	O
specific,	O
as	O
PBMC	O
contain	O
not	O
just	O
blood	O
monocytes,	O
but	O
also	O
B	O
cells,	O
dendritic	O
cells,	O
and	O
activated	B
T	O
cells,	O
which	O
is	O
a	O
limitation	O
of	O
our	O
expression	O
findings.	O

Carnosine	B
is	O
a	O
dipeptide	O
of	O
histidine	B
and	O
alanine	B
that	O
is	O
present	O
at	O
high	O
concentrations	O
in	O
skeletal	O
muscle	O
and	O
brain	O
tissue.28	O

Briefly,	O
prior	O
to	O
NMR	O
spectroscopy,	O
200	O
µl	O
urine	O
supernatant	O
was	O
mixed	O
with	O
80	O
µl	O
deuteroxide	B
solution	O
containing	O
sodium	B
phosphate	I
buffer	O
(0.1	O
M;	O
pH	O
7.4)	O
and	O
sodium	B
3-trimethylsilyl-2,2,3,3-d4-propionate	I
(all	O
Sigma-Aldrich;	O
Merck	O
KGaA)	O
as	O
an	O
internal	O
standard	O
(δ=0	O
ppm),	O
then	O
sample	O
was	O
injected.	O

The	O
authors	O
also	O
showed	O
that	O
the	O
total	O
fraction	O
of	O
blood	O
lipids	O
represented	O
by	O
lysophosphatidylcholine,	B
phosphatidylethanolamine,	B
phosphatidylinositol,	B
phosphatidylcholine,	B
triacylglycerol	B
and	O
sphingomyelin	B
is	O
quickly	O
degraded	O
into	O
free	O
fatty	O
acids	O
in	O
the	O
triatomine	O
intestinal	O
tract	O
and	O
is	O
incorporated	O
into	O
epimastigotes.	O

Histamine	B
was	O
excluded	O
during	O
the	O
initial	O
data	O
clean	O
up	O
and	O
its	O
variation	O
as	O
a	O
function	O
of	O
disease	O
progression	O
could	O
not	O
be	O
assessed.	O

C-mannosyltryptophan	B
is	O
a	O
product	O
derived	O
from	O
the	O
C-glycosylation	O
of	O
the	O
aromatic	O
amino	O
acid	O
tryptophan	O
and	O
mannose.	B

Intracellular	O
sofosbuvir	B
metabolites	O
(GS-331007,	O
GS-331007	O
monophosphate,	B
GS-331007	O
diphosphate,	B
GS-331007	O
triphosphate,	B
and	O
metabolite	O
X)	O
were	O
monitored	O
in	O
TSI-negative	O
MRM	O
mode.	O

Among	O
all	O
polar	O
lipid	O
species	O
measured	O
in	O
this	O
study,	O
significant	O
decreases	O
in	O
the	O
levels	O
of	O
plasma	O
GluCer,	O
gangliosides	B
GM3	I
and	O
major	O
SM	O
species	O
were	O
observed	O
in	O
diabetic	O
monkeys	O
compared	O
to	O
normal	O
controls,	O
but	O
not	O
in	O
the	O
case	O
of	O
free	O
ceramide	B
species.	O

3-Epi-25(OH)D_3	B
was	O
obtained	O
from	O
IsoSciences.	O

(DNOP	O
-	I
(1,2	I
Benzenedicarboxylic	I
acid,	I
bis	I
(2-ethylhexyl)	I
ester).	I

Although	O
our	O
study	O
did	O
not	O
find	O
significant	O
variations	O
in	O
levels	O
of	O
these	O
oxysterols	B
in	O
patients	O
treated	O
by	O
endocrine	O
therapy	O
in	O
their	O
second	O
sampling	O
(in	O
vivo	O
),	O
we	O
admit	O
that	O
samplings	O
over	O
a	O
much	O
longer	O
period	O
and	O
evaluation	O
of	O
survival	O
of	O
patients	O
are	O
necessary	O
for	O
rigorous	O
assessment	O
of	O
the	O
utility	O
of	O
these	O
oxysterols	B
for	O
monitoring	O
of	O
resistance.	O

Of	O
note,	O
CYP3A	O
has	O
been	O
shown	O
to	O
hydroxylate	B
triazole	I
derivative	O
compounds	O
such	O
as	O
alprazolam	B
(4-hydroxylation),	I
voriconazole	B
(methyl-hydroxylation),	I
and	O
estazolam	B
(4-hydroxylation)	I

We	O
have	O
also	O
observed	O
enhanced	O
lactate	B
(p	O
<	O
0.05)	O
and	O
pyruvate	B
(p	O
<	O
0.05)	O
in	O
recurrent	O
patients.	O

A	O
key	O
finding	O
is	O
the	O
inverse	O
association	O
of	O
tyrosine	B
with	O
risk	O
of	O
microvascular	O
events,	O
independent	O
of	O
eGFR	O
and	O
urinary	O
ACR.	O

Of	O
these	O
perturbed	O
metabolic	O
pathways,	O
particular	O
importance	O
should	O
be	O
given	O
to	O
glycerophospholipid	B
metabolism.	O

Kyn	O
significantly	O
correlated	O
with	O
22	O
metabolites	O
at	O
FDR	O
<0.05,	O
dominated	O
by	O
purine	B
nucleotides	O
such	O
as	O
GDP	O
(r =	O

Studies	O
have	O
also	O
suggested	O
the	O
elevation	O
of	O
acylcarnitines	B
as	O
being	O
a	O
signature	O
for	O
inadequate	O
β-oxidation	O
in	O
macrophage	O
lipid	O
metabolism,	O
which	O
is	O
a	O
key	O
process	O
underlying	O
atherosclerosis.	O

Analogously,	O
∑qj=1∑qr=1φjr(yj,yr),	B
which	O
corresponds	O
to	O
a	O
discrete	O
pairwise	O
Markov	O
Random	O
Field,	O
describes	O
conditional	O
dependencies	O
between	O
two	O
discrete	O
variables	O
y	O
_j	O
	O
and	O
y	O
_r	O
	O
with	O
L	O
_j	O
	O
and	O
L	O
_r	O
	O
states,	O
respectively.	O

Further	O
sample	O
preparation	O
included:	O
sample	O
reduction	O
(1	O
μL	O
DTT	O
(1	O
M),	O
45	O
min	O
incubation	O
at	O
room	O
temperature),	O
alkylation	O
(5	O
μL	O
IAA	O
(1	O
M),	O
45	O
min	O
incubation	O
at	O
room	O
temperature),	O
alkylation	O
stop	O
(5	O
μL	O
DTT	O
(1	O
M),	O
45	O
min	O
incubation	O
at	O
room	O
temperature),	O
and	O
digestion	O
with	O
trypsin	O
(4.29	O
μM	O
in	O
0.01%	O
formic	B
acid,	I
Trypsin	O
Gold,	O
Promega,	O
ratio	O
1:40	O
trypsin:protein,	O
incubation	O
overnight	O
(18	O
h)	O
at	O
37	O
°C).	O

In	O
addition,	O
the	O
percentage	O
of	O
acetonitrile	B
and	O
water	O
was	O
varied	O
over	O
time.	O

Therefore,	O
it	O
will	O
be	O
important	O
to	O
determine	O
the	O
tissue	O
source(s)	O
of	O
the	O
collagen	O
breakdown	O
in	O
this	O
study	O
in	O
order	O
to	O
determine	O
whether	O
it	O
represents	O
a	O
protective	O
effect	O
of	O
limonene.	B

Acetate	B
was	O
found	O
in	O
both	O
samples	O
but	O
at	O
a	O
higher	O
concentration	O
in	O
those	O
dried	O
by	O
speed-vacuum	O
(G).	O

Biochemically,	O
these	O
groups	O
differ	O
significantly:	O
triglycerides	B
(2.8	O
versus	O
0.84	O
mmol/l),	O
cholesterol	B
(5.8	O
versus	O
4.5–4.9	O
mmol/l),	O
serum	O
creatinine	B
(116	O
versus	O
87–88	O
μmol/l)	O
and	O
24	O
h-urine	O
albumin	O
(356	O
versus	O
13–16	O
mg)	O
are	O
high,	O
whereas	O
HDL-subfractions	O
are	O
low	O
in	O
the	O
MetS	O
district.	O

To	O
obtain	O
the	O
final	O
NMR	O
sample,	O
the	O
pooled	O
filtrate	O
was	O
then	O
lyophilized	O
and	O
resuspended	O
in	O
600	O
μL	O
of	O
50	O
mM	O
sodium	B
phosphate	I
buffer	O
(pH	O
7.4)	O
in	O
D_2	O
O	O
for	O
NMR	O
measurements.	O

Second,	O
it	O
is	O
possible	O
that	O
increased	O
urea	B
cycle	O
flux	O
may	O
buffer	O
the	O
appearance	O
of	O
ammonia	O
in	O
the	O
blood	O
by	O
detoxifying	O
ammonia	O
that	O
would	O
otherwise	O
accumulate	O
as	O
a	O
by-product	O
of	O
amino	O
acid	O
catabolism.	O

	O
_1	O
H	O
NMR	O
(CDCl_3	O
)	O
δ,	O
1.00	O
(6H	O
,	O
s),	O
1.45–1.43	O
(2H	O
,	O
m),	O
1.65–1.57	O
(4H	O
,	O
m),	O
1.69	O
(3H	O
,	O
s),	O
1.85	O
(3H	O
,	O
s),	O
1.99	O
(3H	O
,	O
s),	O
2.02	O
(3H	O
,	O
s),	O
6.14	O
(3H	O
,	O
m),	O
6.19	O
(1H	O
,	O
dd,	O
J	O
=	O
13.8,	O
14.2	O
Hz),	O
6.36	O
(1H	O
,	O
d,	O
J	O
=	O
11.9	O
Hz),	O
6.68	O
(1H	O
,	O
d,	O
J	O
=	O
11.8	O
Hz),	O
6.77	O
(1H	O
,	O
dd,	O
J	O
=	O
14.2,	O
13.8	O
Hz),	O
6.92	O
(1H	O
,	O
dd,	O
J	O
=	O
13.8,	O
11.6	O
Hz),	O
7.00	O
(1H	O
,	O
d,	O
J	O
=	O
11.6	O
Hz),	O
9.42	O
(1H	O
,	O
s);	O
_13	O
C	O
NMR	O
CDCl_3	O
)	O
δ,	O
10.12,	O
12.74,	O
13.27,	O
20.24,	O
22.18,	O
25.49,	O
29.38,	O
33.53,	O
34.68,	O
40.02,	O
127.31,	O
127.63,	O
127.66,	O
130.47,	O
130.81,	O
136.31,	O
136.62,	O
137.53,	O
137.67,	O
137.89,	O
138.22,	O
141.38,	O
149.47,	O
194.38;	O
UV	O
(methanol)	O
λ_max	O
,	O
426	O
nm	O
(ϵ,	O
75,600);	O
HRMS	O
calculated	O
for	O
C_25	O
H_34	O
O	O
(M+H)	O
351.2682,	O
observed	O
351.2689.	O

Hippurate	B
(the	O
last	O
two	O
plots)	O
comprises	O
aliphatic	B
and	O
aromatic	O
resonances	O
at	O
3.97 ppm	O
and	O
7.56 ppm.	O

Since	O
extracellular	O
adenosine	B
and	O
its	O
metabolite	O
inosine,	B
can	O
both	O
permeate	O
the	O
blood–brain	O
barrier	O
[,	O
],	O
it	O
is	O
likely	O
that	O
decreased	O
plasma	O
levels	O
may	O
reflect	O
a	O
reduction	O
of	O
these	O
metabolites	O
in	O
central	O
nervous	O
system	O
(CNS).	O

Improvement	O
in	O
model	O
performance	O
that	O
was	O
introduced	O
by	O
the	O
inclusion	O
of	O
TMAO	B
levels	O
was	O
evaluated	O
with	O
the	O
use	O
of	O
net	O
reclassification	O
improvement.	O

Urine-NMR	B
metabolomics	O
has	O
potential	O
as	O
a	O
screening	O
tool	O
for	O
accurate	O
diagnosis	O
of	O
pre-invasive	O
CRN.	O

Baseline	O
characteristics	O
of	O
participants	O
ACR,	O
albumin-to-creatinine	O
ratio;	O
BP,	O
blood	O
pressure;	O
CKD,	O
chronic	O
kidney	O
disease;	O
DM,	O
diabetes	O
mellitus;	O
eGFR,	O
estimated	O
glomerular	O
filtration	O
rate;	O
HUNT,	O
Nord-Trøndelag	O
Health	O
Study;	O
SUGAR,	O
Study	O
of	O
Glucose	B
and	O
Insulin	O
in	O
Renal	O
Disease.	O

These	O
were	O
also	O
accompanied	O
by	O
a	O
significant	O
accumulation	O
of	O
lactate	B
and	O
pyruvate	B
(at	O
least	O
in	O
SCC),	O
the	O
final	O
products	O
of	O
glycolysis.	O

In	O
addition,	O
TMAO	B
has	O
been	O
studied	O
mainly	O
in	O
coronary	O
pathologies,	O
while	O
it	O
is	O
prognostic	O
value	O
in	O
other	O
arterial	O
localization,	O
such	O
as	O
PAD,	O
has	O
been	O
little	O
investigated.	O

The	O
SPE	O
bed	O
was	O
washed	O
with	O
0.6 ml	O
of	O
hexane	B
to	O
elute	O
hydrophobic	O
lipids.	O

(C,D)	O
Panels	O
show	O
the	O
concentration	O
of	O
free	O
carnitine	B
(C0),	O
acyl	B
carnitines	I
(C2,	O
C3)	O
and	O
amminoacids	O
(Leu/Ile/Pro,	O
Phe,	O
Tyr,	O
Glu,	O
Met,	O
Lys/Gln/Arg)	O
in	O
the	O
three	O
sections	O
of	O
the	O
Shirmer’s	O
paper	O
strip.	O

 > 2	O
and	O
p-value < 0.05;	O
levels	O
of	O
two	O
metabolites	O
(Ethanolamine,	O
1,3-Diaminopropane)	B
were	O
found	O
to	O
be	O
substantially	O
low.	O

Phenylalanine	B
and	O
tyrosine	B
levels	O
were	O
decreased	O
similarly	O
in	O
early	O
and	O
late	O
vasodilated	O
IUGR	O
cases.	O

Elevated	O
hexose	B
levels	O
could	O
not	O
be	O
explained	O
by	O
increased	O
glucose	B
levels,	O
as	O
neither	O
glucose	B
nor	O
HbA1c	O
were	O
significantly	O
elevated	O
after	O
6	O
months	O
in	O
chemotherapy	O
recipients.	O

feeding	O
of	O
fish	O
oil	O
in	O
mouse	O
models	O
reduced	O
concentrations	O
of	O
prostaglandin	B
E_2	O
in	O
response	O
to	O
azoxymethane,	B
whereas	O
in	O
fat-1	O
transgenic	O
mice,	O
which	O
endogenously	O
synthesize	O
n−3	O
PUFAs	O
from	O
dietary	O
n−6	O
PUFAs,	O
the	O
concentrations	O
of	O
prostaglandin	B
E_2	O
in	O
response	O
to	O
experimental	O
colitis	O
were	O
markedly	O
decreased	O
compared	O
with	O
those	O
of	O
wild-type	O
mice.	O

Similarly,	O
cholesterol,	B
Cer(d18:0/24:1)	B
(p<0.001),	O
TG(17:2/17:2/18:2)	B
(p=0.00261),	O
and	O
TG(17:2/17:2/18:0)	B
(p=0.00291)	O
were	O
detected	O
when	O
MTBE	B
was	O
used	O
but	O
were	O
not	O
observed	O
when	O
methanol	B
alone	O
was	O
used.	O

Folic	B
acid	I
is	O
known	O
to	O
be	O
one	O
of	O
the	O
feedback	O
regulatory	O
metabolites	O
of	O
the	O
FOCM	O
inhibiting	O
DHFR	O
and	O
MTHFR	O
when	O
it	O
accumulates_–	O
.	O

Analogous	O
to	O
the	O
plasma	O
samples,	O
supervised	O
PC-DA	O
was	O
carried	O
out	O
on	O
data	O
from	O
urine	O
samples	O
collected	O
during	O
the	O
run-in	O
period	O
after	O
removal	O
of	O
glucose	B
resonances	O
from	O
the	O
data.	O

Borate	O
can	O
form	O
complexes	O
with	O
alcohols	O
(ROH)	O
to	O
yield	O
neutral	O
esters	O
such	O
as	O
B(OR)_3	O
as	O
shown	O
in	O
._,	O
The	O
ion	O
[B(OH)_4	O
]_−	O
(aq)	O
also	O
readily	O
forms	O
anionic	O
1:1	O
and	O
1:2	O
complexes	O
with	O
carbohydrates	O
and	O
most	O
polyols	O
possessing	O
1,2	B
substitution_,	I
and	O
1,3	B
substitution,_,	I
and	O
molecules	O
containing	O
dicarboxylic	B
acids	I
and	O
diketones	B
may	O
also	O
form	O
complexes._,	O
These	O
complexation	O
reactions	O
are	O
readily	O
reversible	O
and	O
a	O
number	O
of	O
measurements	O
of	O
equilibrium	O
constants	O
have	O
been	O
published,	O
including	O
through	O
the	O
use	O
of	O
_11	O
B	O
NMR	O
spectroscopy.	O

Metabolic	O
pathway	O
analysis	O
also	O
suggests	O
that	O
glycine/serine/threonine/methionine	O
metabolism	O
(Supporting	O
Information	O
Figure	O
S2),	O
glutamate	B
pathway	O
(Supporting	O
Information	O
Figure	O
S3),	O
tyrosine	B
metabolism	O
(Supporting	O
Information	O
Figure	O
S4),	O
TCA	O
cycle	O
(Supporting	O
Information	O
Figure	O
S5),	O
choline	B
metabolism	O
(Supporting	O
Information	O
Figures	O
S2	O
and	O
S6),	O
and	O
bile	O
acid	O
metabolism	O
(Supporting	O
Information	O
Figure	O
S7)	O
are	O
markedly	O
altered.	O

The	O
two	O
groups	O
had	O
no	O
differences	O
in	O
sex,	O
body	O
weight,	O
or	O
total	O
cholesterol,	B
but	O
had	O
significant	O
differences	O
in	O
age,	O
glycosylated	O
hemoglobin,	O
glucose,	B
urea	B
nitrogen,	I
and	O
creatinine.	B

The	O
levels	O
of	O
13	O
amino	O
acids	O
(aspartic	O
acid,	I
glutamic	B
acid,	I
methionine,	B
phenylalanine,	B
tyrosine,	B
leucine,	B
tryptophane,	B
valine,	B
citrulline,	B
glycine,	B
ornithine,	B
glutamine	B
and	O
serine)	B
were	O
statistically	O
different	O
among	O
the	O
AL	O
children,	O
controls	O
and	O
healthy	O
children	O
group,	O
whereas	O
other	O
four	O
amino	O
acids	O
(alanine,	O
argnine,	O
histidine	B
and	O
threonine),	B
which	O
didn’t	O
show	O
any	O
statistical	O
differences,	O
were	O
not	O
enrolled	O
in	O
mathematical	O
model.	O

The	O
tandem	O
mass	O
spectra	O
of	O
Peak	O
I	O
and	O
II	O
provide	O
two	O
expected	O
product	O
ions	O
of	O
m/z	O
287	O
and	O
449	O
(iii.	O
and	O
iv.),	O
which	O
are	O
consistent	O
with	O
the	O
presence	O
of	O
sambubioside	B
glucuronides.	O

These	O
benzoate	B
metabolites	O
were	O
most	O
likely	O
produced	O
from	O
the	O
metabolism	O
of	O
BRB	O
polyphenols	O
and	O
anthocyanins	B
and	O
were	O
absorbed	O
in	O
the	O
large	O
intestine.	O

≥11.0	O
mmol/l,	O
total	O
serum	O
cholesterol	B
≥7.8	O
mmol/l,	O
serum	O
triglycerides	B
≥4.6	O
mmol/l,	O
and	O
ECG	O
abnormalities.	O

Free	O
and	O
esterified	O
cholesterol	B
were	O
separated	O
using	O
disposable	O
silica	B
columns.	O

Of	O
74	O
analysed	O
PCs,	O
only	O
delta	O
t35	O
of	O
PC	O
aa	O
C28:1,	B
PC	B
aa	I
C40:4	I
and	O
PC	B
ae	I
C40:5	I
was	O
significantly	O
higher	O
in	O
the	O
TCF7L2	O
group.	O

Phospholipids	B
(including	O
phosphorylcholine);	B
ii)	O
cholic	B
acid	I
(including	O
glycocholic	B
acid);	O
iii)	O
unsaturated	O
fatty	O
acids	O
(including	O
arachidonic	O
acid);	O
and	O
iv)	O
amino	O
acids	O
(including	O
L-acetylcarnitine;	B
).	O

Since	O
another	O
intermediate	O
of	O
the	O
citric	B
acid	I
cycle,	O
α-ketoglutaric	B
acid,	I
is	O
also	O
higher	O
in	O
women,	O
this	O
may	O
hint	O
at	O
a	O
general	O
difference	O
in	O
citric	B
acid	I
cycle	O
turnover	O
between	O
men	O
and	O
women.	O

Triglyceride	B
levels	O
did	O
not	O
change	O
significantly	O
in	O
the	O
48	O
weeks	O
following	O
treatment	O
initiation.	O

Although	O
theoretically	O
anastrozole	B
can	O
undergo	O
hydroxylation	O
in	O
the	O
aromatic	O
ring,	O
it	O
is	O
less	O
likely.	O

After	O
the	O
3-year	O
follow-up,	O
the	O
control	O
group	O
showed	O
significant	O
decreases	O
in	O
the	O
following	O
12	O
metabolites:	O
lysophosphatidylcholines	B
(lysoPCs)	O
containing	O
C14:0,	B
C16:1,	B
C16:0,	B
C17:0,	B
C18:1,	B
C18:0,	B
C20:4,	B
C20:3,	B
and	O
C22:6	B
(Suppl.	O
1),	O
PC	B
(16:0/18:1),	I
PC	B
(18:0/18:2),	I
and	O
PC	B
(18:0/20:4).	I

The	O
shipment	O
of	O
pesticides	O
in	O
Gunma	O
and	O
Japan	O
are	O
almost	O
constant	O
in	O
glyphosate,	B
imidacloprid,	O
and	O
acetemiprid	O
since	O
the	O
middle	O
of	O
1990’s,	O
but	O
has	O
been	O
increasing	O
in	O
thiamethoxam,	B
clothianidin,	B
and	O
dinotefuran	O
since	O
2001	O
here	O
after	O
neo-nicotinic	O
symptoms	O
emerged.	O

When	O
using	O
the	O
most	O
common	O
derivatization	O
agents,	O
ethoxyamine	B
hydrochloride	I
and	O
N	B
-methyl-N	I
-(trimethylsilyl)	I
trifluoroacetamide	I
(MSTFA),	O

Using	O
a	O
stronger	O
solvent	O
such	O
as	O
ethyl	B
acetate	I
would	O
decrease	O
the	O
purity	O
of	O
the	O
sample	O
and	O
the	O
yield	O
of	O
the	O
derivatization	O
reaction.	O

We	O
must	O
precise	O
that	O
for	O
those	O
metabolites	O
quantified	O
also	O
in	O
the	O
targeted	O
approach	O
(i.e.	O
acetylcarnitine,	B
tyrosine	B
and	O
histidine),	B
we	O
used	O
the	O
concentration	O
values	O
instead	O
of	O
peak	O
intensities	O
as	O
they	O
are	O
more	O
reliable.	O

Metabolomic	O
analyses	O
(carnitine	O
and	O
carnitine	B
ester	I
concentrations)	O
at	O
4	O
months	O
of	O
age	O
are	O
presented	O
as	O
medians	O
and	O
interquartile	O
ranges	O
(IQR,	O
25th	O
and	O
75th	O
percentile).	O

Phosphatidylcholine	B
is	O
used	O
to	O
synthesize	O
linoleic	B
acid	I
through	O
the	O
linoleic	B
acid	I
metabolic	O
pathway,	O
which	O
can	O
be	O
further	O
used	O
in	O
the	O
synthesis	O
of	O
arachidonic	B
acid.	I

The	O
residue	O
was	O
reconstituted	O
with	O
methanol	B
(200	O
μL	O
to	O
250	O
μL).	O

While	O
in	O
vitro	O
studies	O
have	O
indicated	O
an	O
association	O
between	O
decreases	O
in	O
arginine	B
concentrations,	O
both	O
systemic	O
and	O
locally,	O
within	O
atherosclerotic	O
plaques,	O
as	O
well	O
as	O
impairment	O
of	O
the	O
endothelial	O
NO	O
synthase-mediated	O
stress	O
responses(),	O
systemic	O
arginine	B
levels	O
have	O
not	O
been	O
correlated	O
with	O
prevalence	O
of	O
CAD().	O

Leucine	B
enkephalin	I
was	O
used	O
as	O
the	O
instrument	O
reference	O
mass	O
(m/z	O
556.	O
2771)	O
at	O
a	O
concentration	O
of	O
50	O
fmol/μL	O
with	O
a	O
flow	O
rate	O
40	O
μL/min.	O

1,2-NPQ-Alb	B
was	O
present	O
in	O
larger	O
amounts	O
than	O
1,4-NPQ-Alb.	B

Mass-spectral	O
data	O
were	O
acquired	O
in	O
positive	O
ion	O
mode	O
with	O
the	O
following	O
ESI-MS	O
parameters:	O
sheath	O
gas	O
flow	O
rate	O
setting,	O
50;	O
auxiliary	O
gas	O
flow	O
rate	O
setting,	O
10;	O
spray	O
voltage,	O
5.00	O
kV;	B
and	O
transfer	O
capillary	O
temperature,	O
250	O
°C.	O

For	O
the	O
evaluation	O
of	O
effect	O
of	O
the	O
stabilizing	O
agents	O
(Section	O
2.1),	O
the	O
LC	O
system	O
was	O
hyphenated	O
with	O
the	O
quadrupole	O
time-of-flight	O
(Q-TOF)	O
mass	O
spectrometer	O
(Agilent	O
6520	O
Accurate-Mass	B
Q-TOF	O
LC/MS)	O
equipped	O
with	O
the	O
electrospray	O
ionization	O
source	O
operated	O
in	O
a	O
positive	O
ionization	O
mode.	O

BALF	O
=	O
bronchoalveolar	O
lavage	O
fluid;	O
ARDS	O
=	O
acute	O
respiratory	O
distress	O
syndrome;	O
RP	B
=	O
reverse	O
phase;	O
HILIC	O
=	O
hydrophilic	B
interaction	O
chromatography.	O

Stabilizing	O
glucose	B
homeostasis	O
by	O
means	O
of	O
dietary	O
intake	O
of	O
complex	O
carbohydrates	O
and	O
restricting	O
exercise	O
to	O
a	O
level	O
below	O
the	O
aerobic	O
threshold	O
might	O
be	O
beneficial.	O

Aspartate	B
was	O
labeled	O
from	O
both	O
glucose	B
and	O
glutamine,	B
albeit	O
slightly	O
more	O
from	O
glutamine,	B
indicating	O
that	O
both	O
nutrients	O
contribute	O
to	O
aspartate	B
synthesis.	O

In	O
short,	O
100	O
μL	O
of	O
sera	O
or	O
calibration	O
sample,	O
10	O
µL	O
of	O
internal	O
standard	O
solution	O
in	O
water	O
(20	O
µM	O
D7-ADMA,	O
50	O
µM	O
D6-DMA,	O
and	O
100	O
µM	O
D7-arginine),	B
and	O
50	O
µL	O
of	O
borate	O
buffer	O
(	O

Subjects	O
with	O
cardiometabolic	O
diseases	O
such	O
as	O
T2DM	O
and	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(NAFLD)	O
exhibit	O
altered	O
gut	O
microbiome,	O
and	O
have	O
higher	O
levels	O
of	O
TMAO	B
and	O
lower	O
levels	O
of	O
betaine	B
compared	O
to	O
healthy	O
subjects	O
[,,,,,,,,].	O

HCAEC	O
were	O
also	O
treated	O
with	O
L-α-Phosphatidylcholine	B
(PC)	O
standard	O
(Avanti	O
Polar	O
Lipids,	O
Alabaster,	O
AL),	O
and	O
PC	O
standard	O
that	O
was	O
oxidized	O
by	O
exposure	O
to	O
room	O
air	O
for	O
48 hrs	O
as	O
previously	O
described,	O
to	O
confirm	O
the	O
effects	O
of	O
previously	O
described	O
oxidized	O
PAPC	O
in	O
our	O
model.	O

Furthermore,	O
these	O
cells	O
exhibited	O
a	O
greater	O
sensitivity	O
to	O
the	O
inhibition	O
of	O
serine	B
synthesis	O
and	O
DNA	O
methylation	O
indicating	O
a	O
role	O
for	O
activated	B
serine	I
metabolism	O
in	O
supplying	O
SAM	O
for	O
DNA	O
methylation	O
and	O
revealing	O
a	O
therapeutic	O
vulnerability	O
in	O
pancreatic	O
cancer.	O

A	O
major	O
finding	O
is	O
the	O
diminished	O
use	O
of	O
fuel	O
(glucose	O
and	O
BCAA)	O
during	O
early	O
resuscitation.	O

Our	O
previously	O
reported	O
and	O
current	O
data	O
consistently	O
show	O
that	O
activated	B
human	O
CD8_+	O
T	O
cell	O
co-incubated	O
with	O
TEX	O
bind	O
AnnexinV	O
and	O
undergo	O
apoptosis	O
(Fig.	O

Briefly,	O
100 mg	O
of	O
frozen	O
tissue	O
was	O
weighed	O
and	O
grinded	O
in	O
a	O
liquid	O
nitrogen	O
cooled	O
mortar	O
with	O
6%	O
ice-cold	O
perchloric	B
acid.	I

Box	O
plots	O
of	O
6	O
typical	O
differential	O
metabolites	O
concerning	O
5	O
metabolic	O
pathways:	O
(A)	O
fumarate,	B
(B)	O
aspartate,	B
(C)	O
tryptophan,	B
(D)	O
β	B
-hydroxybutyrate,	I
(E)	O
octenedioate,	B
(F)	O
trimethylamine	B
N	I
-oxide.	I

Moreover,	O
Kimm	O
et	O
al	O
.	O
found	O
that	O
serum	O
bilirubin	B
has	O
a	O
protective	O
function	O
against	O
stroke	O
risk,	O
and	O
a	O
low	O
serum	O
bilirubin	B
level	O
could	O
be	O
an	O
independent	O
predictor	O
of	O
stroke	O
incidence.	O

At	O
visit	O
V2	O
a	O
75	O
g	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
was	O
performed,	O
measuring	O
fasting	O
(FPG)	O
and	O
2-hour	O
venous	O
plasma	O
glucose	B
(2-h	O
PG).	O

Elevated	O
circulating	O
homocysteine	B
levels	O
are	O
an	O
independent	O
risk	O
factor	O
for	O
CVD	O
[-].	O

Indeed,	O
despite	O
identifying	O
lipofuscin	B
accumulation	O
as	O
a	O
metabolic	O
correlate	O
of	O
disease,	O
neither	O
the	O
substrate	O
of	O
TPP1,	O
nor	O
why	O
its	O
deficiency	O
causes	O
neuronal	O
cell	O
death	O
are	O
known.	O

To	O
comprehensively	O
assess	O
the	O
activity	O
of	O
β-apocarotenoids,	B
we	O
first	O
undertook	O
to	O
purify	O
or	O
synthesize	O
all	O
of	O
the	O
possible	O
eccentric	O
cleavage	O
products	O
of	O
β-carotene.	B

Acetic	B
acid,	I
formic	B
acid	I
and	O
sodium	B
hydroxide	I
were	O
obtained	O
from	O
Biosolve	O
(Valkenswaard,	O
The	O
Netherlands),	O
Acros	O
Organics	O
(Geel,	O
Belgium)	O
and	O
Merck	O
(Darmstadt,	O
Germany),	O
respectively.	O

A	O
high	O
level	O
of	O
2-hydroxybutyrate	B
was	O
previously	O
suggested	O
to	O
be	O
an	O
early	O
marker	O
for	O
impaired	O
glucose	B
regulation.	O

200	O
µl	O
of	O
sample	O
was	O
mixed	O
with	O
400	O
µl	O
of	O
0.9%	O
saline	B
solution	O
(wt/vol,	O
NaCl	O
in	O
90%	O
H_2	O
O/10%	O
D_2	O
O)	O
and	O
then	O
centrifuged	O
at	O
11,400	O
rpm	O
for	O
5	O
min	O
at	O
4°C.	O

More	O
recently,	O
data	O
from	O
a	O
small	O
sample	O
of	O
premenopausal	O
women	O
in	O
the	O
Harvard	O
Study	O
of	O
Moods	O
and	O
Cycles	O
showed	O
that	O
those	O
who	O
reported	O
prenatal	O
DES	B
exposure	O
had	O
lower	O
estradiol	B
concentrations	O
than	O
those	O
who	O
did	O
not	O
report	O
DES	B
exposure.	O

Here	O
we	O
compare	O
acetaminophen	B
and	O
ibuprofen	B
use	O
detected	O
by	O
means	O
of	O
_1	O
H	O
NMR	O
spectroscopy	O
of	O
urine	O
specimens	O
with	O
self-reported	O
analgesic	O
use	O
among	O
participants	O
in	O
the	O
INTERMAP	O
Study.	O

On	O
the	O
other	O
hand,	O
the	O
GPR	O
subset	O
provided	O
a	O
means	O
to	O
explore	O
the	O
differences	O
in	O
metabolite	O
predictors	O
of	O
the	O
highest	O
and	O
lowest	O
responses	O
to	O
drug	O
therapy,	O
although	O
the	O
results	O
may	O
be	O
applicable	O
to	O
only	O
a	O
small	O
subset	O
of	O
patients	O
who	O
take	O
simvastatin.	B

The	O
concomitant	O
drugs	O
given	O
were	O
lithium	O
(n	O
 = 1),	O
antipsychotics	O
(n	O
 = 3),	O
benzodiazepines	B
(n	O
 = 8),	O
and	O
hypnotic	O
drugs	O
(n	O
 = 12).	O

In	O
the	O
mitochondria,	O
ATP	B
is	O
produced	O
via	O
the	O
TCA	O
cycle,	O
the	O
electron	O
transport	O
chain	O
(respiratory	O
chain),	O
and	O
oxidative	O
phosphorylation.	O

More	O
pathways	O
were	O
altered	O
in	O
pre	O
and	O
post	O
comparisons	O
of	O
stretching,	O
including	O
branched-chain	O
amino	O
acid,	O
tryptophan,	B
tyrosine,	B
and	O
urea	B
cycle,	O
which	O
could	O
indicate	O
loss	O
of	O
lean	O
body	O
mass.	O

This	O
suggests	O
that	O
NF-κB	O
mediates	O
linoleic	B
acid	I
actions	O
on	O
VSMC.	O

Identities	O
of	O
amino	O
acids	O
(e.g.,	O
phenylalanine,	B
tyrosine,	B
glutamine,	B
aspartate)	O
were	O
confirmed	O
using	O
criteria	O
of	O
coelution	O
with	O
authentic	O
standards	O
and	O
ion	O
dissociation	O
(MS/MS)	O
spectra	O
,	O
,	O
,	O
.	O

PLA	O
is	O
a	O
microbiome	O
metabolite	O
of	O
phenylalanine.	B

Provided	O
it	O
is	O
especially	O
the	O
long-chain	O
acylcarnitines	B
that	O
may	O
be	O
associated	O
with	O
adverse	O
cardiometabolic	O
effects,	O
it	O
is	O
of	O
some	O
interest	O
that	O
in	O
our	O
study	O
the	O
thiazide	B
diuretic,	O
known	O
to	O
induce	O
insulin	O
resistance,	O
did	O
not	O
markedly	O
reduce	O
plasma	O
long-chain	O
acylcarnitines.	B

Both	O
tryptophan	B
and	O
kynurenine	B
were	O
significantly	O
lower	O
in	O
stage	O
3/4	O
breast	O
cancer	O
patient	O
plasma	O
than	O
in	O
plasma	O
from	O
normal	O
controls,	O
while	O
there	O
was	O
no	O
difference	O
in	O
either	O
tryptophan	B
or	O
kynurenine	B
when	O
comparing	O
stage	O
0/1	O
patients	O
versus	O
normal.	O

Lactic	B
acid	I
is	O
produced	O
by	O
lactate	O
dehydrogenase	O
(LDH)	O
and	O
is	O
usually	O
an	O
anaerobic	O
metabolic	O
product	O
that	O
occurs	O
when	O
the	O
oxygen	O
demand	O
of	O
a	O
rapidly	O
growing	O
tumor	O
exceeds	O
what	O
its	O
neovasculature	O
supplies.	O

It	O
is	O
possible	O
that	O
the	O
levels	O
of	O
glucose	B
may	O
be	O
linked	O
to	O
the	O
unique	O
behavior	O
of	O
oral	O
cancer,	O
which	O
interferes	O
with	O
the	O
ability	O
of	O
insulin	O
to	O
modulate	O
the	O
uptake	O
of	O
glucose	B
and	O
thus	O
regulates	O
consequent	O
energy	O
metabolism	O
favoring	O
the	O
accumulation	O
of	O
carbohydrates	O
and	O
the	O
process	O
of	O
ketogenesis.	O

1,5-anhydroglucitol	B
(1,5-AG),	I
the	O
1-deoxy	B
form	O
of	O
glucose	B
is	O
a	O
short-term	O
glycemic	B
marker	O
,	O
.	O

However,	O
a	O
biomarker	O
panel	O
containing	O
ten	O
metabolites	O
of	O
9cRA,	O
dehydrophytosphingosine,	B
1H-Indole-3-carboxaldehyde	B
and	O
seven	O
variants	O
of	O
LysoPCs	O
displayed	O
the	O
highest	O
AUC	O
(0.933).	O

Therefore,	O
to	O
increase	O
chemotherapy	O
sensitivity	O
in	O
cancer	O
cells,	O
combination	O
therapy	O
strategies	O
are	O
needed	O
that	O
will	O
target	O
both	O
pro-survival	O
pathways	O
and	O
simultaneously	O
inhibit	O
overproduction	O
of	O
eicosanoids	B
in	O
tumor	O
cells.	O

Thus,	O
the	O
fact	O
that	O
glutamine	B
and	O
indeed	O
glutamate	B
levels	O
are	O
lower	O
in	O
columnar	O
than	O
squamous	O
tissues	O
is	O
perhaps	O
due	O
to	O
greater	O
utilization	O
of	O
glutamine	B
.	O

Lower	O
vitamin	O
B-6	O
status	O
may	O
be	O
due	O
to	O
greater	O
B6	O
catabolism,	O
as	O
reflected	O
by	O
the	O
PAr	O
index	O
in	O
the	O
high–cystathionine	B
concentration	O
group.	O

A	O
recent	O
review	O
by	O
Bene	B
et	O
al.	O
describes	O
studies	O
that	O
report	O
decreased	O
carnitine	B
levels	O
in	O
type	O
2	O
diabetes	O
and	O
in	O
various	O
diabetic	O
complications,	O
but	O
also	O
cites	O
other	O
studies	O
in	O
which	O
no	O
relationship	O
between	O
carnitine	B
and	O
diabetic	O
complications	O
was	O
seen.	O

This	O
question	O
has	O
not	O
been	O
examined	O
but	O
other	O
α,β-unsaturated	B
aldehydes	I
have	O
been	O
detected	O
in	O
tobacco	O
smoke.	O

Individuals	O
with	O
higher	O
compared	O
with	O
lower	O
levels	O
of	O
theophylline	B
(OR	O
for	O
90th	O
compared	O
with	O
10th	O
percentiles:	O
0.44;	O
95%	O
CI:	O
0.25,	O
0.79;	O
P	O
-linear	O
trend	O
=	O
0.006),	O
caffeine	B
(OR	O
for	O
90th	O
compared	O
with	O
10th	O
percentiles:	O
0.56;	O
95%	O
CI:	O
0.35,	O
0.89;	O
P	O
-linear	O
trend	O
=	O
0.015),	O
and	O
paraxanthine	B
(OR	O
for	O
90th	O
compared	O
with	O
10th	O
percentiles:	O
0.58;	O
95%	O
CI:	O
0.36,	O
0.94;	O
P	O
-linear	O
trend	O
=	O
0.027)	O
had	O
lower	O
risk	O
of	O
colorectal	O
cancer.	O

However,	O
the	O
common	O
name	O
is	O
27-hydroxycholesterol	B
on	O
account	O
of	O
its	O
formation	O
via	O
the	O
mitochondrial	O
CYP27A1-catalyzed	O
hydroxylation	O
of	O
cholesterol,	B
and	O
this	O
will	O
be	O
the	O
name	O
used	O
here,	O
although	O
we	O
will	O
use	O
the	O
abbreviation	O
C_5	B
-3β,26-diol	I
in	O
accord	O
with	O
the	O
systematic	O
name	O
cholest-5-ene-3β,26-diol	B
recommended	O
by	O
Fahy	O
et	O
al.	O
.	O

Here	O
we	O
report	O
the	O
concentration	O
of	O
free	O
glucuronic	B
acid,	I
as	O
indicated	O
in	O
.	O

Particularly,	O
we	O
found	O
that	O
high	O
2-HG	O
was	O
related	O
to	O
serum	O
α-KG	B
level	O
and	O
poor	O
molecular	O
markers,	O
such	O
as	O
IDH1/2	O
and	O
DNMT3A	O
(Table	O
S2).	O

Taurine	B
is	O
a	O
good	O
example	O
of	O
this,	O
as	O
shown	O
in	O
Fig.	O
,	O
where	O
it	O
can	O
be	O
seen	O
that	O
one	O
pKa	O
lies	O
at	O
pH	O
1.5,	O
while	O
the	O
data	O
only	O
cover	O
the	O
pH	O
range	O
3.2–12.	O

The	O
intact	O
phase	O
II	O
metabolites,	O
5-HIAA-S,	B
DA-3-O-S,	B
DA-4-O-S,	B
5-HT-S,	B
5-HT-G,	B
and	O
HVA-O-G	O
were	O
detected	O
in	O
human	O
brain	O
or	O
CSF	O
for	O
the	O
first	O
time	O
in	O
this	O
work.	O

Briefly,	O
PCR	O
samples	O
were	O
applied	O
to	O
polyacrylamide	B
gels	O
in	O
1×	O
TAE	O
with	O
a	O
urea	B
and	O
formamide	B
denaturing	O
gradient	O
[7	O
M	O
urea	B
and	O
40 %	O
(v/v)	O
formamide	B
corresponded	O
to	O
the	O
100 %	O
gradient]	O
as	O
described	O
by	O
.	O

Serum	O
creatinine	B
was	O
measured	O
using	O
automated	O
analyzer	O
(Randof	O
Diagnostics,	O
UK,	O
Model	O
Imola).	O

TG,	B
as	O
an	O
important	O
energy	O
storage	O
form,	O
is	O
closely	O
related	O
to	O
glucose	B
homeostasis	O
and	O
its	O
dysregulation	O
is	O
associated	O
with	O
the	O
onset	O
of	O
metabolic	O
syndrome	O
such	O
as	O
diabetes,	O
obesity,	O
and	O
cardiovascular	O
diseases.	O

The	O
HMDB	O
identified	O
hypoxanthine	B
as	O
the	O
metabolite	O
corresponding	O
to	O
these	O
LMIs.	O

Identity	O
of	O
specific	O
D-series	O
resolvins	O
[resolvin	O
D1	O
(RvD1),	O
7S,	O
8R,17S-trihydroxy-4Z,	B
9E,	O
11E,	O
13Z,	O
15E,	O
19Z-docosahexaenoic	O
acid),	O
resolvin	O
D2	O
(RvD2),	O
7S,	O
16R,	O
17S-trihydroxy-4Z,	B
8E,	O
10Z,	O
12E,	O
14E,19Z-	B
docosahexaenoic	I
acid)	O
and	O
the	O
aspirin-triggered	O
RvD1	O
(AT-RvD1),	O
7S,	O
8R,17R-trihydroxy-4Z,	B
9E,	O
11E,	O
13Z,	O
15E,	O
19Z-docosahexaenoic	O
acid]	O
was	O
confirmed	O
using	O
lipid	O
mediator	O
metabololipidomics	O
analytical	O
methods,	O
as	O
described	O
by	O
Serhan	O
and	O
colleagues	O
,	O
.	O

Similarly,	O
decreases	O
were	O
noted	O
in	O
muscle	O
C18:0	B
ceramide	I
with	O
bariatric	O
surgery	O
and	O
exercise,	O
but	O
not	O
with	O
surgery	O
alone,	O
although	O
both	O
interventions	O
improved	O
insulin	O
sensitivity;	O
however,	O
this	O
may	O
have	O
been	O
related	O
to	O
higher	O
concentrations	O
of	O
C18:0	B
ceramide	I
pre‐exercise	O
27.	O

The	O
metabolites	O
that	O
were	O
found	O
to	O
be	O
the	O
strongest	O
candidates	O
for	O
biomarkers	O
were:	O
phenylalanine	B
and	O
N	O
-acetylated	O
compounds	O
in	O
serum	O
as	O
well	O
as	O
glycine	B
in	O
urine	O
(higher	O
concentration),	O
and	O
LDL	O
and	O
VLDL	O
in	O
serum	O
as	O
well	O
as	O
acetoacetate	B
in	O
urine	O
(lower	O
concentration).	O

Intake	O
of	O
total	O
choline	B
was	O
not	O
accessed	O
in	O
the	O
GCKD	O
study	O
and	O
could	O
therefore	O
not	O
be	O
used	O
for	O
confounder	O
adjustment.	O

The	O
type	O
of	O
cancer,	O
the	O
number	O
of	O
patients,	O
the	O
type	O
of	O
treatment,	O
and	O
the	O
sampling	O
hour	O
can	O
be	O
the	O
reasons	O
for	O
this	O
lack	O
of	O
consistency	O
in	O
the	O
elevation	O
of	O
cortisol.	B

Furthermore,	O
there	O
was	O
a	O
significant	O
decline	O
in	O
sphingosine‐1‐phosphate	O
phosphatase	O
1	O
activity	O
(SGPP1,	O
SYNE2	O
locus)	O
after	O
treatment,	O
particularly	O
among	O
INR,	O
when	O
evaluated	O
by	O
the	O
ratio	O
PC	O
aa	O
C28:1/PC	B
ae	I
C40:2	I
(p	O
=	O
8.4667E-7,	O
-log10(p)	O
=	O

However,	O
the	O
diagnostic	O
performance	O
of	O
analine,	B
glutamine,	B
aspartic	B
acid,	I
and	O
acetoacetate	B
combined	O
improved	O
discrimination	O
between	O
early	O
stage	O
CRC	O
patients	O
and	O
HCs	O
compared	O
to	O
any	O
single	O
metabolite	O
alone.	O

Risperidone	B
and	O
clozapine	B
were	O
the	O
most	O
frequently	O
used	O
antipsychotic	O
drugs.	O

In	O
addition,	O
L-threonic	B
acid	I
((2R	O
,3S	O
)-2,3,4-trihydroxybutanoic	O
acid)	O
is	O
also	O
an	O
oxidative	O
metabolite	O
of	O
ascorbic	B
acid	I
formed	O
via	O
dehydroascorbic	B
acid	I
(DHA)	O

This	O
metabolite	O
peak	O
depended	O
on	O
the	O
NADPH-generating	O
system,	O
duration	B
of	O
incubation	O
and	O
microsomal	O
protein	O
and	O
substrate	O
concentrations	O
(data	O
not	O
shown).	O

These	O
conversions	O
mainly	O
occur	O
in	O
the	O
liver,	O
where	O
urea	B
is	O
produced	O
and	O
released.	O

Hexanal	B
is	O
a	O
breakdown	O
product	O
of	O
lipid	O
peroxidation	O
that	O
is	O
formed	O
as	O
a	O
result	O
of	O
oxygen	O
free	O
radical	O
activity.	O

This	O
multiplet	O
demonstrates	O
complete	O
turnover	O
of	O
the	O
TCA	O
cycle	O
because	O
it	O
can	O
only	O
occur	O
if	O
both	O
acetyl-CoA	B
and	O
oxaloacetate	B
are	O
enriched	O
in	O
_13	O
C.	O

Acetonitrile	B
(ACN),	O
and	O
methanol	B
(MeOH)	O
(Lichrosolv	O
Reag.	O

More	O
precisely,	O
coelution	O
was	O
observed	O
for	O
guanosine	B
and	O
uridine	B
monophosphates,	I
and	O
all	O
detected	O
diphosphates	B
on	O
B	O
and	O
E.	O
All	O
investigated	O
columns	O
showed	O
only	O
marginal	O
selectivity	O
toward	O
isomeric	O
sugar	O
phosphates	B
such	O
as	O
fructose-,	B
glucose-	B
and	O
mannose-6-phosphate.	B

Collectively,	O
the	O
correlations	O
observed	O
between	O
metabolites	O
and	O
clinical	O
measures	O
of	O
diabetes	O
demonstrate	O
that	O
oral	O
administration	O
of	O
40	O
mg/day	O
of	O
simvastatin	B
for	O
6	O
weeks	O
increases	O
the	O
risk	O
of	O
developing	O
elevated	O
plasma	O
glucose	B
particularly	O
in	O
susceptible	O
individuals.	O

Plasma	O
carnitine	B
levels	O
in	O
study	O
subjects	O
were	O
within	O
published	O
reference	O
values	O
(31	O
to	O
61	O
nmol/mL).	O

A	O
significant	O
association	O
with	O
CAD	O
was	O
found	O
in	O
7	O
metabolites	O
(pelargonic	O
acid,	O
glucosamine:galactosamine,	O
thymine,	B
3-hydroxybutyric	B
acid,	I
creatine,	B
2-aminoisobutyric	B
acid,	I
hypoxanthine)	B
out	O
of	O
96,	O
and	O
the	O
levels	O
of	O
all	O
of	O
these	O
metabolites	O
were	O
significantly	O
lower	O
in	O
the	O
CAD	O
group	O
compared	O
with	O
the	O
non-CAD	O
group.	O

Additionally,	O
35	O
healthy	O
adults	O
composed	O
the	O
healthy	O
control	O
group	O
according	O
to	O
the	O
criteria	O
of	O
not	O
exhibiting	O
any	O
significant	O
differences	O
in	O
demographic	O
characteristics,	O
glucose	B
or	O
blood	O
pressure	O
between	O
groups.	O

The	O
slope	O
of	O
Passing	O
Bablok	O
regression	O
was	O
nearly	O
one	O
with	O
narrow	O
95%	O
confidence	O
interval	O
in	O
both	O
of	O
creatinine	B
and	O
uric	B
acid.	I

In	O
addition,	O
a	O
decrease	O
in	O
the	O
total	O
level	O
of	O
LPI	O
and	O
marginally	O
significant	O
decreases	O
in	O
major	O
PI	O
species	O
including	O
PI38:4,	B
36:2,	O
36:3,	O
34:2	O
were	O
also	O
observed	O
in	O
diabetic	O
monkeys	O
under	O
fed	O
conditions.	O

High	O
bioavailability	O
of	O
dietary	O
carnitine	B
in	O
infant	O
diets	O
and	O
a	O
balanced	O
protein	O
supply	O
are	O
important	O
to	O
ensure	O
adequate	O
carnitine	B
status,	O
as	O
the	O
endogenous	O
production	O
of	O
carnitine	B
alone	O
is	O
considered	O
insufficient	O
to	O
support	O
stable	O
plasma	O
free	O
carnitine	B
concentration	O
in	O
infancy.	O

Not	O
surprisingly,	O
several	O
lipid	O
classes	O
including	O
free	O
fatty	O
acids,	O
sphingosines,	B
diacylglycerols,	B
ceramides,	B
glycerophosphoethanolamine,	B
glycerophosphocholine,	B
sphingomyelin,	B
and	O
triacylglycerols	B
were	O
detected	O
only	O
in	O
MTBE	B
lipid	O
fraction.	O

The	O
peak	O
area	O
ratios	O
of	O
each	O
identified	O
thiol	B
from	O
the	O
cancer	O
urines	O
relative	O
to	O
healthy	O
control	O
were	O
calculated	O
by	O
the	O
forward	O
and	O
reverse	O
labeling	O
tests.	O

The	O
generation	O
of	O
kynurenine	B
and	O
other	O
tryptophan	B
metabolites	O
can	O
modulate	O
T-cell	O
immunity	O
via	O
activation	O
of	O
suppressive	O
regulatory	O
T-cells	O
and	O
activation	O
of	O
aryl	B
hydrocarbon	I
receptor,	O
thus	O
promoting	O
cancer	O
cell	O
survival.	O

The	O
relation	O
to	O
eGFR	O
and	O
creatinine	B
is	O
further	O
described	O
for	O
the	O
full	O
cohort	O
by	O
Pearson	O
correlation	O
tests	O
in	O
Table .	O

Moreover,	O
2-aminobutyrate	B
showed	O
a	O
decreasing	O
trend	O
in	O
IBD	O
compared	O
with	O
healthy	O
controls	O
at	O
PP3,	O
with	O
statistical	O
significance	O
in	O
UC	O
versus	O
healthy	O
mothers.	O

In	O
that	O
study,	O
it	O
was	O
suggested	O
that	O
oleoylethanolamide	B
was	O
produced	O
by	O
leukemic	O
cells	O
as	O
a	O
lipolytic	O
factor	O
to	O
fuel	O
their	O
growth	O
with	O
a	O
potential	O
role	O
in	O
drug	O
resistance	O
and	O
cancer	O
cachexia,	O
which	O
could	O
give	O
an	O
clue	O
to	O
the	O
physiological	O
functions	O
of	O
dodecanamide,	B
decanamide,	B
and	O
oleamide	B
in	O
this	O
study.	O

Here,	O
we	O
developed	O
a	O
comprehensive,	O
sensitive,	O
robust,	O
and	O
high-throughput	O
LC-MS/MS	O
stable-isotope	O
dilution	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
19	O
metabolites	O
related	O
to	O
polyamine	B
metabolism,	O
including	O
polyamines,	B
acetylated	O
and	O
diacetylated	B
polyamines,	I
precursors,	O
and	O
catabolites	O
from	O
liquid	O
biopsies.	O

The	O
mixture	O
was	O
heated	O
to	O
175	O
°C	O
for	O
1h	O
and	O
the	O
evolved	O
acrolein	B
was	O
led	O
into	O
a	O
10	O
mL	O
flask	O
by	O
purging	O
with	O
a	O
stream	O
of	O
N_2	O
.	O

β-oxidation	O
and	O
sphingosine‐1‐phosphate-phosphatase-1	B
activity	O
were	O
down-regulated,	O
whereas	O
acyl-alkyl-containing	O
phosphatidylcholines	O
and	O
alkylglyceronephosphate	B
synthase	O
levels	O
were	O
elevated	O
in	O
INRs.	O

The	O
apparent	O
hydroxyanastrozole	B
formation	O
rates	O
fit	O
better	O
to	O
a	O
single-site	O
Michaelis-Menten	O
equation.	O

Daidzein	B
and	O
(R	O
,	O
S	O
)‐equol	O
were	O
purchased	O
from	O
LC	O
Laboratories	O
(Woburn,	O
MA).	O

Race,	O
diabetes,	O
urine	O
albumin	O
excretion,	O
and	O
the	O
circulating	O
concentrations	O
of	O
parathyroid	O
hormone	O
and	O
fibroblast	O
growth	O
factor	O
23	O
more	O
modestly	O
modified	O
the	O
association	O
of	O
24,25(OH)_2	B
D_3	O
with	O
25(OH)D_3	O
.	O

These	O
metabolites	O
include	O
succinic	B
acid,	I
glutamic	B
acid,	I
malate,	B
arachidonic	B
acid,	I
and	O
butanoic	B
acid.	I

Aliphatic	B
region	O
of	O
the	O
spectrum	O
showing	O
connectivities	O
and	O
satellite	O
peaks	O
for	O
some	O
assigned	O
metabolites.	O

Moreover,	O
in	O
our	O
study,	O
women	O
had	O
higher	O
total	O
cholesterol	B
levels	O
than	O
men,	O
in	O
accordance	O
with	O
general	O
population	O
findings.	O

Nine	O
metabolic	O
pathways,	O
including	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism,	O
amino	O
acid	O
metabolism,	O
fatty	O
acid	O
metabolism,	O
linoleic	B
acid	I
metabolism,	O
α-linolenic	B
acid	I
metabolism,	O
and	O
arachidonic	B
acid	I
metabolism,	O
were	O
significantly	O
different	O
between	O
the	O
two	O
groups.	O

Variation	O
of	O
expression	O
of	O
histamine,	B
glutamine,	B
xanthurenic	B
acid	I
and	O
ethanolamine	B
were	O
particularly	O
significant	O
and	O
predictive.	O

This	O
process	O
would	O
be	O
mediated	O
by	O
the	O
activity	O
of	O
glycine	B
dehydrogenase	I
(decarboxylating)	I
(GLDC)	O
that	O
links	O
glycine	B
cleavage	O
with	O
the	O
charging	O
of	O
the	O
folate	B
cycle.	O

Study	O
characteristics	O
showed	O
that	O
∼80%	O
of	O
subjects	O
were	O
male	O
with	O
no	O
significant	O
sex	O
differences	O
between	O
the	O
cystathionine	B
groups,	O
which	O
reflects	O
the	O
overall	O
distribution	O
of	O
subjects’	O
sex	O
within	O
the	O
WECAC	O
study.	O

Regarding	O
the	O
branched-chain	O
amino	O
acids	O
valine	O
and	O
isoleucine,	B
their	O
urinary	O
levels	O
have	O
also	O
been	O
found	O
increased	O
in	O
human	O
colorectal	O
cancer	O
and	O
gastric	O
cancer	O
patients.	O

Compared	O
to	O
placebo,	O
insulin	O
sensitizer	O
therapy	O
increased	O
fasting	O
plasma	O
concentrations	O
of	O
phenylalanine	B
(A),	O
tyrosine	B
(B),	O
glutamic	B
acid	I
(C),	O
arginine	B
(D),	O
citrulline	B
(E),	O
aspartic	B
acid	I
(F),	O
lysine	B
(G),	O
α-aminoadipic	B
acid	I
(H),	O
and	O
ethanolamine	B
(I).	O

To	O
evaluate	O
linearity	O
of	O
standard	O
curves,	O
calibration	O
standards	O
were	O
prepared	O
at	O
concentrations	O
of	O
0.5,	O
1,	O
2,	O
5,	O
10,	O
20,	O
50,	O
100	O
and	O
200	O
pg/mL	O
of	O
each	O
estrogen	B
in	O
charcoal	O
stripped	O
human	O
serum,	O
except	O
for	O
4-OH-E2	B
and	O
2-OH-E2,	B
which	O
were	O
prepared	O
at	O
10	O
times	O
higher	O
concentration.	O

The	O
kyn/trp	O
ratio,	O
which	O
is	O
an	O
index	O
of	O
IDO1	O
or	O
TDO	O
activity,	O
has	O
been	O
found	O
to	O
be	O
elevated	O
in	O
states	O
of	O
immune	O
stimulation,	O
such	O
as	O
infection,	O
malignancy,	O
endotoxin	B
administration,	O
neurodegenerative	O
disease,	O
and	O
autoimmunity.	O

In	O
comparison,	O
the	O
background	O
levels	O
of	O
1,2-	B
and	O
1,4-BQ	B
adducts	O
in	O
commercial	O
human	O
Alb	O
(n	O
=	O
10)	O
were	O
1.6	O
and	O
8.9	O
nmol/	O

A	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(Milli-Q),	O
mobile	O
phase	O
B	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
ACN	O
and	O
mobile	O
phase	O
C	O
consisted	O
of	O
1%	O
of	O
formic	B
acid	I
in	O
ACN.	O

The	O
identified	O
ACE-I/D	O
genotype	O
dependent	O
metabolites	O
30	O
min	O
post	O
exercises	O
were	O
associated	O
with	O
the	O
metabolism	O
of	O
pyruvate	B
(PEP,	O
NADP),	O
glucose	B
and	O
amino	O
acids	O
(saccharopine,	O
L-aspartic	B
acid,	I
methylhyppuric	B
acid)	O
as	O
well	O
as	O
of	O
glutathione	B
(glutathione,	I
2-bromacetaldehyde;	I
;	I
).	I

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
infertility	O
in	O
females	O
infected	O
with	O
S.	O
haematobium	O
and	O
its	O
association	O
with	O
the	O
presence	O
of	O
schistosome-derived	O
catechol-estrogens.	B

Et_2	O
O:	O
CH_2	O
Cl_2	O
(0.5:0.5:9,	O
v/v)	O
to	O
afford	O
6	O
(13	O
mg)	O
after	O
washing	O
with	O
Et_2	O
O.	O

Metabolites	O
alteration	O
reflected	O
disorders	O
of	O
glucose	B
metabolism,	O
lipid	O
metabolism,	O
amino	O
acid	O
metabolism,	O
bile	O
acid	O
metabolism	O
as	O
well	O
as	O
intestinal	O
flora	O
metabolism	O
in	O
GDM	O
state.	O

Because	O
LysoPC	O
is	O
synthesized	O
from	O
phosphatidylcholine	B
(PC)	O
by	O
the	O
enzyme	O
phospholipase	O
A2,	O
the	O
decrement	O
of	O
LysoPC	O
indicated	O
impairment	O
of	O
these	O
enzymes	O
in	O
PC	O
re-acylation	O
or	O
de-acylation.	O

Unfortunately,	O
due	O
to	O
the	O
large	O
variations	O
of	O
oleic	B
acid	I
content	O
between	O
samples,	O
the	O
differences	O
did	O
not	O
reach	O
statistical	O
significance.	O

The	O
ability	O
of	O
extracellular	O
nucleotides	O
and	O
its	O
derivatives	O
to	O
modulate	O
diverse	O
signaling	O
responses	O
via	O
purinergic	B
receptors	O
is	O
well	O
established	O
,	O
.	O

All	O
Me-OHN	O
metabolites	O
were	O
quantified	O
with	O
_13	O
C_6	B
-2-methyl-1-naphthol	I
(2M1N)	O
as	O
the	O
internal	O
standard.	O

The	O
total	O
amount	O
of	O
each	O
class	O
of	O
phospholipid	B
in	O
human	O
serum.	O

The	O
brain	O
has	O
particularly	O
large	O
copper	O
requirements	O
compared	O
with	O
most	O
other	O
organs,	O
since	O
it	O
is	O
very	O
metabolically	O
active	O
and	O
generates	O
large	O
amounts	O
of	O
reactive	O
oxygen	O
species,	O
particularly	O
superoxide	B
anion	O
that	O
requires	O
clearance	O
by	O
SOD1	O
and	O
SOD3.	O

However,	O
one	O
metabolite	O
(arginine)	O
was	O
increased	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
compared	O
with	O
the	O
healthy	O
controls	O
in	O
the	O
two	O
data	O
sets.	O

Above	O
all,	O
the	O
exhaled	O
biomarker	O
2-methyl-1,3-butadiene,	B
better	O
known	O
as	O
isoprene,	O
represents	O
a	O
promising	O
target	O
of	O
clinical	O
diagnostics.	O

The	O
generated	O
tryptic	O
peptides	O
were	O
extracted	O
with	O
5%	O
formic	B
acid	I
(v/v):	O
acetonitrile	B
(1∶2),	I
evaporated	O
to	O
near	O
dryness	O
(CentriVap	O
vacuum	O
concentrator,	O
Labconco	O
SpeedVac,	O
Kansas	O
City,	O
MO)	O
and	O
reconstituted	O
in	O
20	O
µL	O
of	O
2%	O
acetonitrile,	B
0.1%	O
formic	B
acid.	I

The	O
majority	O
of	O
the	O
patients	O
were	O
on	O
prednisolone	B
treatment,	O
and	O
it	O
is	O
known	O
that	O
glucocorticoids	B
upregulate	O
the	O
expression	O
of	O
TDO	O
that	O
metabolises	O
tryptophan,	B
and	O
we	O
may	O
thus	O
expect	O
increased	O
kynurenine/tryptophan	O
ratio	O
due	O
to	O
treatment.	O

In	O
this	O
study,	O
a	O
significant	O
cysteine	B
increase	O
was	O
also	O
observed	O
when	O
compared	O
to	O
OD,	O
suggesting	O
that	O
the	O
active	O
glutathione	B
metabolism	O
in	O
the	O
OSCC	O
group	O
forms	O
the	O
background.	O

Previously,	O
Huang	O
et	O
al.	O
reported	O
that	O
the	O
serum	O
kynurenine/tryptophan	B
ratio	O
was	O
higher	O
in	O
colorectal	O
cancer	O
patients	O
than	O
in	O
‘non-cancer’	O
controls,	O
although	O
no	O
increased	O
level	O
of	O
kynurenine	B
was	O
observed	O
.	O

Methylamines	B
(methylamine,	I
DMA,	I
TMAO),	I
products	O
of	O
choline	B
metabolism,	O
were	O
elevated	O
in	O
gastric	O
cancer	O
tissues.	O

Predicted	O
importance	O
by	O
the	O
OPLS-DA	O
model	O
showed	O
that	O
the	O
areas	O
under	O
the	O
curve	O
(AUCs)	O
were	O
0.823	O
for	O
taurine,	B
0.783	O
for	O
alanine	B
and	O
0.842	O
for	O
3-aminoisobutyrate	B
(Fig.	O

Besides	O
measuring	O
the	O
ratio	O
of	O
lactate	B
to	O
pyruvate,	B
the	O
change	O
in	O
signal	O
can	O
be	O
measured	O
over	O
time	O
and	O
the	O
data	O
fit	O
to	O
kinetic	O
models.	O

LTB4	B
is	O
in	O
the	O
eicosanoid	B
family	O
of	O
lipids,	O
most	O
of	O
which	O
formed	O
by	O
the	O
oxidation	O
of	O
20-carbon	O
essential	O
fatty	O
acids,	O
that	O
comprise	O
prostaglandins	B
along	O
with	O
prostacyclins,	B
thromboxanes	B
and	O
endocannabinoids	B
in	O
addition	O
to	O
leukotrienes.	O

MG	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
FA	B
in	O
cancer	O
cells	O
in	O
order	O
to	O
maintain	O
an	O
FA	B
pool	O
always	O
available,	O
given	O
the	O
overexpression	O
of	O
monoacylglycerol	B
lipase	O
(MAGL)	O
as	O
reported	O
by	O
Nomura	O
et	O
al.	O

1,5-Anhydroglucitol	B
(1,5-AG)	I
increased	O
after	O
leptin	O
replacement.	O

Baseline	O
omega-3	B
fatty	O
acid	O
levels	O
were	O
not	O
associated	O
with	O
UTxB_2	O
concentration.	O

In	O
our	O
study,	O
the	O
urinary	O
F2-isoprostanes	B
returned	O
to	O
baseline	O
levels	O
by	O
24	O
hours	O
after	O
DOX	O
injection.	O

Other	O
plasma	O
metabolites	O
important	O
for	O
the	O
correct	O
classification	O
of	O
women	O
according	O
to	O
their	O
menopausal	O
status	O
include	O
creatinine,	B
serine,	B
myo	O
-inositol,	O
carnitine,	B
and	O
others.	O

The	O
analysis	O
was	O
repeated	O
for	O
a	O
subset	O
of	O
INTERMAP	O
participants	O
whose	O
urine	O
spectra	O
contained	O
evidence	O
of	O
ibuprofen	B
ingestion	O
and	O
a	O
second	O
group	O
of	O
randomly	O
sampled	O
control	O
samples.	O

Our	O
data	O
show	O
for	O
the	O
first	O
time	O
m/z	O
matches	O
for	O
two	O
Mtb	O
cell	O
wall	O
components	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
TB	O
disease,	O
the	O
verified	O
glycolipid	B
trehalose-6-mycolate	I
(a	O
component	O
of	O
the	O
mycolic	O
acid	O
layer	O
of	O
the	O
cell	O
wall)	O
and	O
PI.	O

An	O
aliquot	O
of	O
about	O
300	O
µL	O
of	O
each	O
fecal	O
sample	O
was	O
diluted	O
in	O
1	O
mL	O
of	O
PBS-EDTA	O
(phosphate	O
buffer	O
0.01	O
M,	O
pH	O
7.2,	O
0.01	O
M	O
EDTA).	O

While	O
the	O
malate	B
levels	O
fell	O
to	O
around	O
30%	O
in	O
the	O
long	O
fermentation	O
samples	O
compared	O
with	O
the	O
CBP	O
process,	O
the	O
citrate	B
levels	O
remained	O
stable	O
even	O
with	O
a	O
longer	O
fermentation	O
process	O
but	O
were	O
completely	O
absent	O
from	O
the	O
sourdough	O
product	O
spectra,	O
Succinate	B
generally	O
showed	O
an	O
opposite	O
profile,	O
increasing	O
during	O
longer	O
fermentation	O
(B)	O
but	O
decreasing	O
in	O
the	O
sourdough	O
products.	O

Nucleosides	O
and	O
nucleotides	O
(e.g.,	O
inosine	B
and	O
inosine	B
monophosphate)	I
were	O
also	O
found	O
to	O
be	O
transformed	O
into	O
purine	B
derivatives	O
(e.g.,	O
hypoxanthine).	B

In	O
all,	O
1,828	O
molecular	O
features	O
were	O
found	O
in	O
the	O
MTBE	B
extracted	O
lipid	O
fraction,	O
and	O
1,410	O
features	O
were	O
found	O
when	O
methanol	B
alone	O
was	O
used	O
in	O
conjunction	O
with	O
RPC.	O

These	O
ratios	O
are	O
not	O
always	O
reliable	O
indicators	O
of	O
progression	O
or	O
response,	O
as	O
citrate	B
levels	O
are	O
very	O
low	O
or	O
even	O
undetectable	O
by	O
NMR	O
in	O
prostate	O
cancer	O
tissue	O
samples.	O

A	O
number	O
of	O
metabolites,	O
including	O
a	O
range	O
of	O
amino	O
acids,	O
saccharides	B
(glucose,	I
maltose,	I
galactose),	I
energy	O
metabolism	O
related	O
molecules	O
(pyruvate,	O
succinate,	B
citrate,	B
lactate,	B
creatine,	B
creatinine),	O
and	O
others	O
(cholines,	O
amines	O
and	O
amides)	B
were	O
identified	O
based	O
on	O
comparison	O
with	O
the	O
Chenomx	O
metabolite	O
database,	O
as	O
well	O
as	O
2D	O
_1	O
H–_13	O
C	O
HSQC	O
and	O
_1	O
H–_1	O
H	O
TOCSY	O
NMR	O
experiments	O
(see	O
a	O
complete	O
list	O
of	O
metabolites	O
in	O
the	O
Supporting	O
Information,	O
Table	O
2S).	O

Definite	O
non-metabolite	O
contaminants	O
(equipment	O
components	O
and	O
unknowns,	O
98)	O
and	O
reagent	O
derivatives	O
(EDTA,	O
MSTFA	O
and	O
pyridine	B
derivatives,	O
5)	O
were	O
excluded	O
from	O
further	O
analysis.	O

Negative	O
ion	O
mode	O
DESI-MS	O
ion	O
images	O
of	O
glioblastoma	O
G33showing	O
the	O
distribution	O
of	O
(A)	O
m/z	O
788.8,	O
PS(36:1);	B
(B)	O
m/z	O
834.2,	O
PS(40:6);	B
(C)	O
m/z	O
885.4,	O
PI(38:4);	B
(D)	O
m/z	O
838.3,	O
PS(40:4);	B
(E)	O
m/z	O
857.3,	O
PI(36:4)	B
and	O
(F)	O
m/z	O
303.3,	O
FA(20:4).	B

The	O
glycerophospholipids	B
generally	O
showed	O
less	O
than	O
twofold	O
changes	O
in	O
response	O
to	O
infection.	O

In	O
the	O
setting	O
of	O
6.5 mM	O
ammonium	B
bicarbonate,	O
the	O
signal	O
intensity	O
was	O
recorded	O
as	O
3.49E3.	O

The	O
very	O
strong	O
correlation	O
of	O
cholesterol	B
with	O
alpha	O
and	O
gamma	O
tocopherol	B
(vitamin	O
E)	O
may	O
reflect	O
the	O
close	O
relationship	O
between	O
tocopherols	B
and	O
cholesterol	B
metabolism.	O

Among	O
these	O
findings,	O
succinate	B
was	O
the	O
common	O
alteration	O
linking	O
CE	O
stroke,	O
atrial	O
dysfunction,	O
and	O
risk	O
stratification.	O

Throughout	O
the	O
sequence	O
of	O
the	O
albumin-like	O
protein	O
of	O
Atlantic	B
cod,	O
there	O
were	O
1	O
Arg,	O
11	O
Asp,	O
4Cys,	O
7	O
Glu,	O
5His	O
and	O
8	O
Lys	O
residues,	O
comprising	O
36%	O
of	O
the	O
full	O
sequence.	O

3-me-	B

The	O
center	O
bars	O
show	O
median	O
and	O
interquartile	O
values	O
normalized	O
to	O
respective	O
creatinine	B
levels;	O
***p	O
<	O
0.001,	O
by	O
the	O
Mann-Whitney	O
U-test.	O

However,	O
arginase	O
also	O
appears	O
to	O
exert	O
its	O
effects	O
downstream	O
through	O
the	O
production	O
of	O
various	O
polyamine	B
molecules	O
(i.e.	O
putrescine,	B
spermidine,	B
spermine	B
and	O
their	O
acetylated	O
derivatives)	O
which	O
influences	O
the	O
growth	O
and	O
death	O
of	O
neural	O
cells.	O

Frozen	O
citrate	B
plasma	O
samples,	O
in	O
which	O
the	O
corresponding	O
stabilized	O
TMA	O
salt	O
was	O
formed,	O
were	O
utilized	O
to	O
perform	O
these	O
analyses.	O

Concentrations	O
of	O
E3,	O
E1,	B
16-KE2,	I
2-OHE1	I
and	O
E2	O
were	O
the	O
highest	O
among	O
all	O
groups,	O
accounting	O
for	O
approximately	O
60–70%	O
of	O
the	O
total	O
urinary	O
estrogen	B
metabolites	O
with	O
E3	O
being	O
the	O
dominant	O
estrogen	B
in	O
all	O
study	O
groups.	O

NAG	O
is	O
the	O
obligate	O
activator	O
of	O
carbamoyl	B
phosphate	I
synthetase	O
I	O
(CPS-I).	O

represents	O
the	O
metabolic	O
pathways	O
involved	O
in	O
sphingolipid	B
metabolism,	O
in	O
particular,	O
the	O
de	O
novo	O
synthesis	O
pathway,	O
sphingomyelin	B
pathway,	O
catabolic	O
pathway,	O
and	O
glucosylceramide	B
synthesis	O
pathway,	O
as	O
described	O
in	O
Panels	O
A–D,	O
respectively.	O

However,	O
it	O
is	O
noteworthy	O
that	O
this	O
study	O
also	O
reported	O
total	O
serum	O
estrogen	B
concentrations	O
in	O
postmenopausal	O
women	O
that	O
were	O
much	O
higher	O
than	O
has	O
been	O
reported	O
previously.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
offer	O
insights	O
into	O
the	O
metabolites	O
of	O
AF	B
and	O
to	O
determine	O
biomarkers	O
for	O
AF	B
diagnosis	O
or	O
prediction.	O

The	O
flow	O
from	O
the	O
PDA	O
detector	O
was	O
mixed	O
with	O
0.2 mL/min	O
makeup	O
solvent	O
(0.1%	O
v/v	O
formic	B
acid	I
in	O
methanol),	B
supplied	O
by	O
a	O
Waters	O
515	O
HPLC	O
pump,	O
and	O
the	O
ABPR	O
was	O
used	O
to	O
maintain	O
the	O
resultant	O
solvent	O
stream	O
at	O
a	O
pressure	O
of	O
2000	O
psi	O
(138 bar)	O
throughout	O
the	O
run.	O

We	O
show	O
that	O
high	O
levels	O
of	O
hexadecanedioate	B
are	O
associated	O
with	O
increased	O
risk	O
of	O
incident	O
HF	O
beyond	O
the	O
effect	O
of	O
traditional	O
risk	O
factors	O
(HR,	O
1.22;	O
P	O
=	O
3.0	O
×	O
10_−7	O
).	O

Today,	O
there	O
is	O
no	O
single	O
analytical	O
method	O
to	O
monitor	O
both	O
metabolites	O
and	O
co-factors	O
of	O
the	O
methionine	B
cycle.	O

γ-aminobutyric	B
acid	I
A	O
receptors	O
(GABA_A	O
Rs)	O
agonists	O
acutely	O
relax	O
airway	O
smooth	O
muscle	O
and	O
alleviate	O
bronchoconstriction.	O

Plasma	O
PLP	O
concentration	O
was	O
significantly	O
lower	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
(P	O
=	O
0.039).	O

Major	O
differences	O
in	O
flux	O
through	O
glycolysis	O
were	O
evident	O
from	O
incorporation	O
of	O
label	O
into	O
secreted	O
lactate,	B
which	O
accounts	O
for	O
a	O
substantial	O
fraction	O
of	O
the	O
glucose	B
carbon	O
utilized	O
by	O
the	O
cells.	O

The	O
four	O
full	O
length	O
gene	O
loci	O
corresponding	O
to	O
the	O
enzymes	O
of	O
the	O
Plasmodium	O
NAD_+	O
salvage	O
pathway	O
(pf13_0159	O
,	O
pff1410c	O
,	O
pfi1310w	O
,	O
pfc0910c	O
)	O
were	O
cloned	O
into	O
the	O
pDC2-CAM-CRT-GFP	B
plasmid	O
to	O
create	O
C-terminal	O
GFP	O
fusions	O
under	O
the	O
control	O
of	O
the	O
P.	O
falciparum	O
calmodulin	O
promoter	O
(pf14_0323	O
)	O
using	O
the	O
F	O
and	O
R	O
pDC2	O
(Table	O
S1	O
in	O
).	O

The	O
2D	O
AKP	O
cell	O
line	O
was	O
obtained	O
by	O
growing	O
organoids	B
attached	O
to	O
tissue	O
culture	O
plates	O
and	O
served	O
as	O
an	O
isogenic	O
culture	O
for	O
the	O
3D	O
experiments.	O

Compounds	O
including	O
sphingosine,	B
cholesterol,	B
glycoceramides,	B
triglycoceramides	B
were	O
found	O
in	O
the	O
neutral	O
fraction,	O
while	O
most	O
phosphocholines,	B
phosphoethanolamines	B
were	O
found	O
in	O
the	O
phospholipid	B
fraction,	O
and	O
fatty	O
acids	O
such	O
as	O
palmitoleic	B
acid,	I
heptadecylenic	O
acid,	O
hexadecanoic	B
acid,	I
3-hydroxy-eicosanoic	B
acid	I
were	O
found	O
only	O
in	O
the	O
fatty	O
acid	O
fraction.	O

Thiamine	B
or	O
vitamin	B
B1	I
has	O
an	O
important	O
role	O
in	O
cancer	O
cells	O
as	O
shown	O
by	O
investigations	O
using	O
the	O
thiamine-degrading	O
enzyme,	O
thiaminase.	O

GC	O
separation	O
of	O
volatiles	O
was	O
carried	O
out	O
on	O
a	O
DB-5 ms	O
column	O
(Agilent,	O
30 m	O
length,	O
0.25 mm	O
inner	O
diameter,	O
and	O
0.25 μm	O
film,	O
non-polar	O
phase,	O
phenyl	B
arylene	I
polymer).	O

Four	O
traditional	O
biomarkers	O
were	O
GSSG	O
(q	O
=	O
0.027)	O
and	O
GSH:GSSG	O
ratio	O
(q	O
=	O
0.039)	O
in	O
erythrocytes	O
and	O
MDA	O
(q	O
=	O
0.006)	O
and	O
IL-6	O
(q	O
=	O
0.006)	O
in	O
plasma;	O
and	O
sixteen	O
metabolites	O
were	O
amino	O
acids	O
(alanine,	O
asparagine,	B
glutamine,	B
glycine,	B
histidine,	B
lysine,	B
serine,	B
and	O
carnitine),	B
organic	O
acids	O
(citrate	O
and	O
formate),	O
purine	B
nucleotide	O
(adenine),	O
and	O
other	O
metabolites	O
(N6-acetyllysine,	O
betaine,	B
3-indoxylsulfate,	B
N	B
-phenylacetylglycine	I
(PAG),	O
and	O
phenylacetate).	B

Pre-treatment	O
metabolites	O
significantly	O
(p	O
<	O
0.05)	O
associated	O
with	O
post-treatment	O
clinical	O
measures	O
Metabolite	O
levels	O
pre-treatment	O
correlated	O
with	O
clinical	O
measurements	O
post-statin	B
treatment	O
using	O
(a)	O
univariate	O
regression	O
analysis	O
and	O
(b)	O
multiple	O
regression	O
analysis.	O

Mobile	O
phase	O
A	O
composed	O
of	O
0.1%	O
formic	B
acid	I
in	O
Milli-Q	O
water	O
and	O
mobile	O
phase	O
B	O
composed	O
of	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
(HPLC	O
grade;	O
Friendemann	O
Schmidt	O
Chemical,	O
Australia)	O

Luo	O
et al.	O
also	O
documented	O
higher	O
concentrations	O
of	O
long-chain	O
plasma	O
acylcarnitines	B
in	O
PAH	O
cases	O
versus	O
controls,	O
with	O
different	O
strengths	O
of	O
association	O
based	O
on	O
pre	O
vs.	O
post-capillary	O
PH	O
status,	O
highlighting	O
the	O
need	O
for	O
detailed	O
PH	O
phenotyping.	O

We	O
observed	O
significant	O
increase	O
in	O
glucose	B
uptake	O
(Figure	O
),	O
lactate	B
secretion	O
(Figure	O
)	O
upon	O
ectopic	O
expression	O
of	O
c-MYC	O
.	O

A	O
trend	O
toward	O
higher	O
5-	O
and	O
12-lipoxygenation	O
and	O
lower	O
15-lipoxygenation	O
products	O
and	O
18-HEPE	B
in	O
peritonitis	O
could	O
be	O
observed	O
with	O
high	O
inter-individual	O
variation,	O
while	O
for	O
SPMs	O
no	O
consistent	O
trend	O
toward	O
an	O
elevation	O
or	O
reduction	O
in	O
peritonitis	O
was	O
observed.	O

Go	O
to:	O
Clozapine	B
is	O
indicated	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
and	O
related	O
psychotic	O
disorders.	O

Patients	O
with	O
BC	O
were	O
selected	O
according	O
to	O
the	O
following	O
criteria:	O
i)	O
Female	O
sex;	O
ii)	O
patients	O
diagnosed	O
with	O
BC	O
following	O
hematoxylin	B
and	O
eosin	B
staining	O
of	O
biopsy	O
sections;	O
iii)	O
patients	O
with	O
early	O
stage	O
BC	O
(stages	O
I–II)	O
according	O
to	O
the	O
Tumor-Node-Metastasis	O
classification;	O
iv)	O
patients	O
who	O
received	O
no	O
preoperative	O
treatment,	O
including	O
adjuvant	O
chemotherapy	O
or	O
radiotherapy;	O
and	O
v)	O
patients	O
without	O
diabetes	O
or	O
other	O
simultaneous	O
diseases.	O

The	O
method	O
development	O
study	O
described	O
herein	O
indicates	O
that	O
of	O
the	O
tested	O
Waters	O
columns,	O
the	O
Torus	O
range	O
should	O
be	O
the	O
first	O
choice	O
for	O
the	O
analysis	O
of	O
any	O
class	O
of	O
polar	O
metabolite;	O
similarly,	O
the	O
use	O
of	O
either	O
ammonium	B
salts	O
or	O
water	O
as	O
modifier	O
additives	O
should	O
be	O
considered	O
when	O
analysing	O
such	O
compounds	O
using	O
SFC.	O

Multivariate	O
pattern	O
recognition	O
methods	O
were	O
applied	O
to	O
identify	O
lipidomic	O
changes	O
in	O
patients	O
with	O
AF.	B

The	O
obtained	O
serum	O
was	O
divided	O
into	O
two	O
parts:	O
one	O
part	O
was	O
used	O
for	O
the	O
measurement	O
of	O
uric	B
acid	I
(UA),	O
fasting	O
blood	O
glucose	B
(FBG),	O
total	O
cholesterol	B
(TC),	O
triglyceride	B
(TG),	O
high-	O
and	O
low-density	O
lipoprotein	O
cholesterol	B
(HDL-C,	O
LDL-C),	O
blood	O
urea	B
nitrogen	I
(BUN),	O
creatinine	B
(CRE),	O
aspartate	O
aminotransferase	O
(AST)	O
and	O
alanine	O
aminotransferase	O
(ALT)	O
concentrations	O
according	O
to	O
the	O
manufacturer’s	O
instructions	O
for	O
the	O
respective	O
commercial	O
test	O
kits.	O

Higher	O
levels	O
of	O
FFAs	O
in	O
HCV-infected	O
HCC	O
patients	O
could	O
indicate	O
a	O
more	O
activated	B
HCV	O
core	O
protein.	O

We	O
adopted	O
the	O
most	O
recent	O
AREDS2	O
definitions,	O
namely,	O
that	O
the	O
standard	O
disc	O
diameter	O
equals	O
1800	O
µm	O
(rather	O
than	O
1500	O
µm),	O
which	O
affects	O
the	O
size	O
of	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
(ETDRS)	O
grid	O
and	O
of	O
the	O
standard	O
drusen	O
circles;	O
that	O
geographic	O
atrophy	O
(GA)	O
is	O
present	O
if	O
the	O
lesion	O
has	O
a	O
diameter	O
equal	O
or	O
superior	O
than	O
433	O
µm	O
(AREDS	O
circle	O
I-2);	O
and	O
that	O
at	O
least	O
two	O
of	O
the	O
following	O
features	O
are	O
present:	O
absence	O
of	O
retinal	B
pigment	O
epithelium	O
(RPE)	O
pigment,	O
circular	O
shape,	O
or	O
sharp	O
margins	O
(thus,	O
meaning	O
that	O
the	O
involvement	O
of	O
the	O
central	O
fovea	O
is	O
not	O
a	O
requirement).	O

Abnormal	O
glycerolipid	B
degradation	O
was	O
largely	O
regulated	O
by	O
ATGL	O
and	O
HSL,	O
which	O
aroused	O
our	O
interest	O
in	O
exploring	O
their	O
expressions.	O

The	O
up-regulation	O
of	O
urinary	O
urocanic	B
acid	I
could	O
result	O
from	O
a	O
histidine	B
metabolism	O
disorder	O
in	O
tumor	O
tissue	O
and/or	O
a	O
glutamic	B
acid	I
metabolism	O
disorder.	O

Aspartate,	B
as	O
mentioned	O
earlier,	O
is	O
an	O
important	O
neurotransmitter	O
and	O
was	O
also	O
very	O
effective	O
in	O
discriminating	O
between	O
depressed	O
and	O
control	O
subjects.	O

We	O
examined	O
the	O
genes	O
within	O
the	O
pyrimidine	B
metabolic	O
pathway	O
that	O
were	O
most	O
highly	O
altered	O
in	O
basal	O
versus	O
luminal	O
BCa	O
using	O
our	O
tissue-derived	O
transcriptome	O
data	O
Both	O
uridine	O
pyrophosphorylase	O
1	O
(UPP1,	O
Supplementary	O
Figure	O
4)	O
and	O
RRM2	O
(A	O
)	O
were	O
significantly	O
(P	O
=	O
.0004)	O
elevated	O
in	O
basal-like	O
BCa	O
compared	O
to	O
luminal	O
tumors.	O

X-axis	O
indicates	O
the	O
mean	O
creatinine	B
concentrations	O
(μmol/L)	O
of	O
capillary	O
electrophoresis-mass	O
spectrometry	O
(CE-MS)	O
and	O
clinical	O
assay,	O
and	O
Y-axis	O
indicates	O
percentage	O
of	O
differences	O
between	O
these	O
two	O
methods.	O

The	O
other	O
antiepileptic	O
drugs	O
of	O
the	O
CLN2	O
disease	O
cases,	O
e.g.	O
Valproic	B
acid,	I
Clonazepam	B
and	O
Clobazam,	O
have	O
different	O
modes	O
of	O
action,	O
which	O
suggests	O
that	O
the	O
changes	O
in	O
the	O
CSF-metabolite	O
profile	O
would	O
be	O
different	O
for	O
each	O
drug.	O

The	O
identified	O
molecular	O
species	O
were	O
quantified	O
by	O
summing	O
the	O
peak	O
intensities	O
of	O
the	O
comprising	O
acyl	O
anions	O
and	O
normalized	O
against	O
the	O
acyl	O
anion	O
signals	O
of	O
the	O
pre-extraction	O
spiked	O
synthetic	O
PE	B
17:0/17:0	I
standard	O
and	O
plasma	O
volume	O
(black	O
bars),	O
as	O
described	O
by	O
Ejsing	O
and	O
colleagues.	O

In	O
chlorinated	O
water,	O
Tem	O
is	O
oxidized	O
to	O
its	O
dioxon-sulfoxide	B
(Tem-dox-SO),	O
dioxon-sulfone	B
(Tem-dox-SO_2	O
),	O
and	O
sulfoxide	B
(Tem-SO)	O
derivatives;	O
however,	O
these	O
compounds	O
are	O
not	O
commercially	O
available	O
to	O
be	O
used	O
as	O
standards	O
and	O
in	O
toxicological	O
studies.	O

Herein	O
we	O
develop	O
regression	O
models	O
to	O
predict	O
the	O
relative	O
atherogenicity	O
of	O
an	O
individual’s	O
postprandial	O
TGRL	O
based	O
on	O
the	O
oxylipins	B
present	O
in	O
these	O
lipoproteins.	O

Since	O
GSH	B
is	O
easily	O
oxidized	O
to	O
GSSG	O
during	O
extraction	O
from	O
biological	O
samples,	O
recent	O
studies	O
have	O
described	O
sample	O
preparation	O
methods	O
preventing	O
GSH	B
oxidization	O
of	O
its	O
vulnerable	O
thiol	B
group	O
with	O
the	O
use	O
of	O
derivatization	O
reagents	O
such	O
as	O
4-fluoro-7-sulfamoylbenzofurazan	B
(ABD-F)	O
or	O
N	B
-ethyl	I
maleimide	I
during	O
extraction.	O

Androstenedione	B
1,	O
testosterone	B
2,	O
E_1	B
-sulfate	I
3,	O
E_2	O
4,	O
E_1	B
5,	I
2-hydroxyestradiol	I
(2-OHE_2	O
)	O
6,	B
2-OHE_1	I
7,	I
16α-OHE_2	I
10,	I
16α-OHE_1	I
11,	I
2-methoxyestradiol	I
(2-OCH_3	O
E_2	O
)	O
12,	O
2-OCH_3	O
E_1	O
13,	O
4-OCH_3	O
E_2	O
14,	O
4-OCH_3	O
E_1	B
15,	I
2-OH-3-OCH_3	I
E_2	O
16	O
and	O
2-OH-3	B

The	O
lower	O
levels	O
of	O
vitamin	O
D-related	O
metabolites	O
seen	O
in	O
this	O
study	O
are	O
consistent	O
with	O
these	O
findings	O
and	O
suggest	O
that	O
vitamin	B
D	I
may	O
be	O
protective	O
against	O
AMD.	O

Piperine	B
has	O
a	O
range	O
of	O
physiological	O
effects,	O
including	O
antioxidant,61	O
antinflammatory,62	O
and	O
anti‐secretase63	O
activities	O
directly	O
relevant	O
to	O
AD.	O

No	O
participants	O
were	O
taking	O
an	O
oral	O
anti-inflammatory	O
steroid	O
such	O
as	O
prednisone.	B

In	O
the	O
absence	O
of	O
methoxyamine,	B
9	O
disappeared	O
and	O
a	O
new	O
metabolite	O
with	O
a	O
molecular	O
ion	O
at	O
m/z	O
345	O
increased	O
in	O
abundance.	O

For	O
example,	O
formation	O
of	O
Schiff-base	O
(aldimine)	O
linkages	O
to	O
proteins	O
is	O
the	O
first	O
step	O
in	O
a	O
reversible	O
pathway	O
leading	O
to	O
CML	B
formation,	O
reconciling	O
published	O
imaging	O
results	O
with	O
elevated	O
brain-glucose	B
levels;	O
additionally,	O
fructose	B
binds	O
to	O
proteins	O
through	O
an	O
equivalent	O
mechanism.	O

Although	O
the	O
validity	O
of	O
CYP2D6	O
as	O
a	O
predictor	O
of	O
TAM	O
outcome	O
remains	O
controversial,	O
the	O
definite	O
association	O
between	O
plasma	O
concentrations	O
of	O
endoxifen	B
and	O
CYP2D6	O
genetic	O
polymorphism	O
has	O
been	O
consistently	O
demonstrated	O
by	O
prospective	O
pharmacological	O
studies.	O

The	O
median	O
[IQR]	O
levels	O
in	O
pmol/mg	O
creatinine	B
were	O
1.104	O
[0.797,	O
1.519]	O
for	O
C/C	O
and	O
1.352	O
[0.938,	O
1.833]	O
for	O
C/A	O
or	O
A/A	O
(p=	O
0.029).	O

As	O
for	O
UPLC,	O
Agilent	O
Zorbax	O
SB-C18	O
(Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA,	O
USA)	O
was	O
firstly	O
balanced	O
with	O
mobile	O
phase	O
A	O
(0.1%	O
formic	B
acid	I
aqueous	O
solution).	O

L	O
ammonium	B
acetate,	I
10 mmol/L	O
ammonium	B
acetate/water	I
solutions	O
in	O
combination	O
with	O
either	O
methanol	B
or	O
acetonitrile.	B

In	O
the	O
cases	O
of	O
closely	O
eluted	O
peaks	O
3c	O
(11-H-9-E-LA)	O
and	O
3f	O
(9-H-12-ELA);	O
and	O
3d,	O
3e	O
(11-H-9-E-LA)	O
and	O
respective	O
3h,	O
3i	O
(11-H-12-E-LA),	O
the	O
corresponding	O
characteristic	O
ions	O
at	O
m/z	O
201,	O
193,	O
and	O
197,	O
were	O
chosen	O
as	O
MRM	O
transition	O
ions	O
for	O
11-H-9-E-LA,	B
9-H-12-E-LA,	B
and	O
11-H-12-E-LA,	B
respectively,	O
to	O
allow	O
their	O
differentiation	O
and	O
quantitation.	O

Bonnet	O
et	O
al	O
.	O
demonstrated	O
that	O
a	O
glycolytic	B
inhibitor	O
reduced	O
fibrosis	O
and	O
increased	O
survival	O
in	O
fawn-hooded	O
rats.	O

When	O
we	O
calculated	O
the	O
Kaplan-Meier	O
curves	O
(Log-Rank	O
test	O
by	O
median	O
cut-off),	O
we	O
found	O
that	O
high	O
levels	O
of	O
suberic	B
acid	I
were	O
significantly	O
associated	O
with	O
PSA	O
progression	O
(p	O
 = 0.032,	O
Log-Rank	O
test)	O
(Fig.	O

(A)	O
lipid	O
metabolisms;	O
(B)	O
glutathione	B
metabolism.	O

Similarly,	O
associations	O
of	O
age,	O
body	O
mass	O
index,	O
or	O
smoking	O
status	O
with	O
level	O
of	O
individual	O
oxysterols	B
observed	O
in	O
one	O
of	O
the	O
samplings	O
were	O
not	O
consistent	O
with	O
the	O
other	O
sampling.	O

Collection	O
a	O
was	O
positively	O
associated	O
with	O
phenol,	B
cyclopentanecarboxylic	O
acid,	O
2-pyrrolidone	B
carboxylic	I
acid,	I
fructose	B
and	O
anthracene.	B

Researchers	O
have	O
demonstrated	O
that	O
hypoxanthine	B
can	O
cause	O
endothelial	O
dysfunction	O
through	O
oxidative	O
stress-induced	O
apoptosis.	O

Olympus	O
Au560	O
automatic	O
biochemistry	O
analyzer	O
was	O
applied	O
to	O
measure	O
the	O
level	O
of	O
serum	O
alanine	B
amino	I
transferase	O
(ALT).	O

Two	O
small	O
studies	O
of	O
DES	B
and	O
hormones_,	O
were	O
conducted	O
in	O
the	O
1970s	O
with	O
inconsistent	O
results	O
and	O
using	O
hormone	O
assay	O
methods	O
far	O
inferior	O
to	O
those	O
now	O
available.	O

Ovarian	O
neoplasms,	O
Low-mass	O
ions,	O
Serum	O
metabolite,	O
Hypoxanthine,	B
Mass	O
spectrometry	O

A	O
possible	O
explanation	O
for	O
these	O
observations	O
is	O
that	O
HTK	O
use	O
leads	O
to	O
increased	O
glutamine	B
synthesis,	O
which	O
provides	O
the	O
fuel	O
necessary	O
to	O
increase	O
de	O
novo	O
pyrimidine	B
synthesis.	O

The	O
supernatant	O
was	O
collected	O
and	O
stored	O
prior	O
to	O
analysis	O
at	O
−80°C	O
after	O
dilution	O
with	O
100	O
µL	O
80%	O
methanol	B
in	O
water.	O

Therefore,	O
based	O
on	O
the	O
following	O
considerations,	O
we	O
reasoned	O
that	O
the	O
peak	O
#3	O
and	O
4	O
contains	O
a	O
20:4	O
fatty	O
acyl	O
side	O
chain	O
of	O
the	O
n-3	O
and	O
n-6	O
series,	O
respectively:	O
(i)	O
total	O
plasma	O
levels	O
of	O
C20:4n-3	B
(eicosatetraenoic	I
acid)	I
are	O
~120-fold	O
less	O
abundant	O
than	O
C20:4n-6	B
(arachidonic	O
acid)	O
in	O
healthy	O
human	O
plasma	O
and	O
(ii)	O
under	O
our	O
chromatographic	O
conditions	O
(RP),	O
lipids	O
containing	O
fatty	O
acyl	O
side	O
chain	O
of	O
n-3	O
series	O
elute	O
prior	O
to	O
their	O
n-6	O
isomer	O
counterparts.	O

We	O
prospectively	O
determined	O
plasma	O
levels	O
of	O
asymmetric	B
dimethylarginine	I
(ADMA),	O
an	O
endogenous	O
nitric	B
oxide	I
synthase	O
inhibitor,	O
and	O
global	O
arginine	B
bioavailability	O
ratio	O
[GABR=arginine/(ornithine+citrulline)]	O
by	O
tandem	O
mass	O
spectrometry	O
in	O
subjects	O
with	O
advanced	O
decompensated	O
heart	O
failure	O
in	O
the	O
intensive	O
care	O
unit	O
(“ADHF”,	O
n=68)	O
and	O
with	O
stable	O
chronic	O
heart	O
failure	O
(“CHF”,	O
n=57).	O

The	O
increase	O
of	O
5-hydroxyindoleacetic	B
acid	I
was	O
also	O
observed	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
major	O
depressed	O
patients.	O

The	O
polyamine	B
spermine	I
was	O
identified	O
in	O
the	O
Giskeodegard	O
study,	O
and	O
our	O
study	O
identified	O
spermidine,	B
a	O
related	O
polyamine.	B

Lysophosphatidylcholine	B
(LysoPC	O
16:0),	O
LysoPC	O
17:0,	O
D_31	O
_LysoPC	O
16:0	O
and	O
D_7	O
_S-1-P	O
were	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids	O
(Alabaster,	O
AL).	O

The	O
marker	O
metabolites	O
contributing	O
to	O
the	O
separation	O
of	O
the	O
two	O
groups	O
were	O
PC,	O
creatine,	B
and	O
lipid.	O

A	O
methanol/water	O
solution	O
(1:1,	O
V/V)	O
containing	O
0.1 μM	O
hexakis	O
(2,2-difluoroethoxy)	B
phosphazene	I
was	O
used	O
as	O
a	O
sheath	O
liquid	O
and	O
a	O
coaxial	O
sheath	O
liquid	O
interface	O
was	O
developed	O
to	O
realize	O
coupling	O
of	O
CE	O
with	O
TOF/MS.	O

It	O
is	O
not	O
possible	O
to	O
measure	O
the	O
N-acetyl	B
glycoprotein	I
and	O
proline	B
resonances	O
independently	O
with	O
this	O
dataset,	O
so	O
these	O
spectral	O
bins	O
are	O
labelled	O
N-acetyl	B
glycoprotein/CH_2	I
-CH	O
_2	O
-CH=	O

L-tryptophan	B
and	O
its	O
metabolites	O
serotonin	B
(5HT)	O
and	O
melatonin	B
have	O
notable	O
functions	O
in	O
regulating	O
growth	O
and	O
development	O
of	O
the	O
fetus	O
(Glover,	O
;	O
St-Pierre	O
et	O
al.,	O
;	O
Wu	O
et	O
al.,	O
)	O
and	O
are	O
involved	O
in	O
a	O
magnifique	O
number	O
of	O
physiological	O
pathways	O
and	O
adaption	O
processes	O
during	O
pregnancy	O
(Sano	O
et	O
al.,	O
).	O

We	O
observed	O
that	O
many	O
metabolites	O
(e.g.,	O
nicotinuric	B
acid,	I
hypoxanthine,	B
tiglylcarnitine,	B
1-methylhistidine)	B
were	O
the	O
basis	O
for	O
clustering	O
of	O
certain	O
indexes	O
(BMI,	O
TC,	O
TG	B
and	O
blood	O
pressure	O
before	O
eating,	O
and	O
having	O
or	O
not	O
having	O
diabetes),	O
but	O
only	O
nicotinuric	B
acid	I
clustered	O
all	O
indexes.	O

Both	O
theophylline	B
and	O
caffeine	B
are	O
substrates	O
for	O
CYP1A2.	O

In	O
the	O
case	O
of	O
positive	O
and	O
negative	O
ion	O
mode	O
the	O
capillary	O
voltage	O
was	O
set	O
to	O
3.2	O
kV	B
and	O
3	O
kV,	B
and	O
the	O
cone	O
voltage	O
of	O
35	O
V	O
and	O
50	O
V,	O
respectively.	O

The	O
optimized	O
method	O
was	O
precipitation	O
with	O
isopropanol-chloroform	B
(9:1)	I
(see	O
).	O

Inosine	B
and	O
hypoxanthine	B
are	O
the	O
products	O
of	O
adenosine	B
metabolic	O
degradation.	O

The	O
nature	O
of	O
the	O
inducible	O
factors	O
contributing	O
to	O
the	O
broccoli-enhanced	O
detoxication	O
of	O
benzene	B
is	O
not	O
resolved.	O

In	O
the	O
urine,	O
clusters	O
related	O
to	O
pentoses,	O
purines,	B
disaccharides,	B
phenylacetates,	B
sugar	O
alcohols,	O
amino	O
acids	O
(cyclic,	O
basic,	O
acidic,	O
sulfur	O
and	O
aromatic),	O
glutarates,	B
hexuronates,	O
malates,	B
hexoses,	O
sugar	O
acids,	O
citrates,	O
indoles,	O
saturated	O
FA,	B
dicarboxylates,	B
purinones	B
were	O
associated	O
with	O
hospitalizations.	O

Among	O
four	O
predicted	O
negative	O
associations,	O
caprylic	B
acid	I
did	O
indeed	O
inhibit	O
the	O
growth	O
of	O
R.	O
gnavus	O
at	O
high	O
concentrations,	O
as	O
hypothesized	O
above.	O

Strikingly,	O
all	O
differential	O
metabolites	O
except	O
dihydroceramide	B
were	O
most	O
highly	O
correlated	O
with	O
different	O
bacteria	O
between	O
cases	O
and	O
controls	O
(Supplemental	O
Table	O
3	O
in	O
the	O
Supporting	O
Information).	O

In	O
summary,	O
by	O
combining	O
the	O
association	O
of	O
gut	O
microbiota	O
phylum	O
and	O
genus	O
with	O
faecal	O
metabolites,	O
this	O
study	O
discovered	O
that	O
Firmicutes	O
and	O
their	O
associated	O
metabolites	O
L-tyrosine,	B
protorifamycin	B
I,	O
epothilone	B
A,	O
and	O
L-lysine	B
were	O
involved	O
in	O
the	O
development	O
of	O
IGR	O
and	O
T2DM	O
in	O
this	O
population.	O

We	O
have	O
developed	O
a	O
quantitative	O
method	O
to	O
simultaneously	O
assess	O
levels	O
of	O
4-oxo-2-nonen-1-ol	B
(ONO)-MA,	O
HNE-MA,	O
and	O
1,4-dihydroxy-2-nonene	B
(DHN)-MA	O
in	O
human	O
urine	O
samples	O
utilizing	O
isotope-dilution	O
mass	O
spectrometry.	O

The	O
coefficient	O
of	O
variation	O
for	O
repeated	O
measurements	O
was	O
2.6%	O
for	O
glucose	B
and	O
3.9%	O
for	O
triglycerides,	B
respectively.	O

As	O
illustrated	O
in	O
Figure ,	O
0.1%	O
formic	B
acid	I
yielded	O
greater	O
signal	O
than	O
ammonium	B
bicarbonate	O
(2.29E4	O
vs.	O
3.49E3,	O
respectively).	O

We	O
also	O
do	O
not	O
have	O
the	O
data	O
to	O
explain	O
why	O
DDAH-1	O
did	O
not	O
increase	O
further	O
along	O
with	O
elevated	O
systemic	O
ADMA	B
in	O
the	O
setting	O
of	O
HF-H.	O
However,	O
previously	O
reported	O
data	O
showing	O
improvement	O
in	O
DDAH	O
following	O
LVAD	O
support	O
provided	O
indirect	O
evidence,	O
even	O
though	O
the	O
intervention	O
is	O
not	O
directly	O
related	O
to	O
improved	O
DDAH	O
expression.	O

The	O
results	O
(B	O
)	O
showed	O
that	O
a	O
panel	O
of	O
potential	O
biomarkers	O
(decanoylcarnitine,	O
octanoylcarnitine,	B
lysoPC(18:0),	B
lysoPC(16:1),	B
lysoPC(16:0),	B
linoleic	B
acid,	I
and	O
uric	O
acid)	O
provided	O
an	O
AUC	O
of	O
0.961.	O

Receiver	O
operating	O
characteristic	O
(ROC)	O
curves	O
of	O
plasma	O
metabolic	O
biomarkers	O
(the	O
binary	O
logistic	O
regression	O
function	O
of	O
tryptophan	B
and	O
lysoPC	O
22:5)	O
and	O
sFlt-1/PlGF	O
to	O
predict	O
adverse	O
pregnancy	O
outcome	O
in	O
women	O
with	O
SLE.	O

It	O
could	O
be	O
observed	O
that	O
the	O
metabolic	O
state	O
of	O
T2DM-CHD	O
patients	O
resulted	O
in	O
the	O
decreased	O
levels	O
of	O
isopropanol,	B
glycine,	B
alanine,	B
arginine,	B
proline,	B
glutamine,	B
acetate,	B
creatine,	B
3-methylhistidine,	B
creatinine,	B
isoleucine,	B
tyrosine,	B
valine,	B
threonine	B
and	O
leucine,	B
as	O
well	O
as	O
elevated	O
levels	O
of	O
VLDL/LDL	O
and	O
glucose.	B

MS/MS	O
fragmentation	O
of	O
Unknown	O
3	O
resulted	O
in	O
a	O
fragment	O
that	O
had	O
the	O
same	O
m/z	O
as	O
N-acetylneuraminic	B
acid,	I
which	O
initially	O
was	O
found	O
to	O
differentiate	O
CLN2	O
subjects	O
from	O
normal	O
individuals	O
(Supplementary	O
Table _S3	O
).	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
prior	O
to	O
the	O
current	O
study,	O
evidence	O
relating	O
changes	O
in	O
pyrimidine	B
metabolism	O
to	O
treadmill	O
exercise	O
or	O
stretching	O
interventions	O
had	O
yet	O
to	O
be	O
reported.	O

The	O
present	O
study	O
identified	O
differences	O
between	O
subjects	O
with	O
RVD	O
and	O
those	O
with	O
either	O
EH	O
or	O
normal	O
blood	O
pressure	O
(control	O
subjects)	O
in	O
terms	O
of	O
disparities	O
between	O
the	O
2	O
groups	O
in	O
their	O
plasma	O
levels	O
and	O
urinary	O
excretion	O
of	O
EETs	O
and	O
20-HETE	B
and	O
metabolism	O
of	O
EETs	O
to	O
DHETs.	O

Their	O
etiology	O
of	O
kidney	O
disease	O
was	O
other	O
than	O
diabetic	O
kidney	O
disease	O
which	O
was	O
excluded	O
to	O
meet	O
the	O
inclusion	O
criterion	O
of	O
glycemic	B
control	O
in	O
this	O
study	O
group.	O

It	O
is	O
refered	O
that	O
decreasing	O
activity	O
or	O
suppressed	O
expression	O
of	O
succinate	O
dehydrogenase	O
may	O
be	O
one	O
of	O
the	O
mechanisms	O
for	O
energy	O
production	O
disorder	O
in	O
HF,	O
and	O
as	O
a	O
result,	O
may	O
also	O
induce	O
accumulation	O
of	O
upstream	O
intermediate	O
metabolite	O
succinate,	B
causing	O
elevation	O
of	O
succinate	B
level	O
in	O
the	O
peripheral	O
blood.	O

The	O
amount	O
of	O
phosphatidylcholine	B
was	O
relatively	O
higher	O
in	O
CSF	O
from	O
patients	O
with	O
LMC	O
(Group	O
2)	O
compared	O
with	O
patients	O
with	O
other	O
types	O
of	O
cancer	O
(groups	O
of	O
1a,	O
3,	O
and	O
4)	O
(Figure	O
).	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
monitor	O
imatinib	B
mesylate	I
therapeutically	O
in	O
the	O
Tumor	O
Biology	O
Laboratory,	O
Department	O
of	O
Hematology	O
and	O
Hemotherapy,	O
Hospital	O
das	O
Clínicas,	O
Faculdade	O
de	O
Medicina,	O
Universidade	O
de	O
São	O
Paulo	O
(USP).	O

Furthermore,	O
our	O
patients	O
were	O
treated	O
with	O
pioglitazone,	B
not	O
rosiglitazone,	B
and	O
these	O
two	O
thiazolidinediones	B
are	O
known	O
to	O
exert	O
different	O
effects	O
on	O
gene	O
expression	O
and	O
plasma	O
lipid	O
levels.	O

High	O
TMAO	B
levels	O
rendered	O
significant	O
associations	O
with	O
all	O
tested	O
models	O
(Table ).	O

In	O
conclusion,	O
these	O
experiments	O
validated	O
that	O
human	O
blood	O
cells	O
convert	O
glucose	B
into	O
erythritol	B
and,	O
based	O
on	O
the	O
positional	O
labeling	O
experiments,	O
most	O
likely	O
via	O
E4P,	O
and	O
thus	O
the	O
PPP.	O

Lab	O
2	O
precipitated	O
protein	O
in	O
the	O
urine	O
with	O
methanol	B
and	O
derivatized	O
as	O
described	O
above.	O

Caucasians	O
also	O
experienced	O
higher	O
grades	O
of	O
toxicity	O
and	O
were	O
more	O
likely	O
to	O
have	O
their	O
vincristine	B
doses	O
reduced	O
or	O
omitted	O
than	O
African	O
Americans.	O

Compound	O
dependent	O
parameters	O
for	O
D-mannose	B
and	O
IS	O
in	O
SRM	O
mode	O
for	O
LC–MS/MS	O
analysis.	O

Although	O
lipids	O
are	O
well-resolved	O
when	O
RPC	O
is	O
used	O
(compounds	O
9–12),	O
co-elution	O
of	O
hydrophilic	B
compounds	O
results	O
in	O
ion-suppression	O
(compounds	O
1–6).	O

These	O
studies	O
revealed	O
changes	O
to	O
the	O
homeostasis	O
of	O
triglycerides,	B
cholesterol,	B
phospholipids	B
and	O
long-chain	O
fatty	O
acids	O
(LCFA)	O
in	O
that	O
context.	O

Glutathione	B
is	O
the	O
most	O
abundant	O
low-molecular-weight	O
peptide	O
present	O
in	O
eukaryotic	O
cells.	O

Artesunate,	B
dihydroartemisinin,	B
and	O
halofantrine	B
could	O
also	O
be	O
found	O
sporadically	O
in	O
a	O
few	O
drug	O
shops	O
(Alba	O
S	O
et	O
al	O
.,	O
in	O
preparation).	O

The	O
capillary	O
voltage	O
was	O
2	O
kV	B
and	O
the	O
extractor	O
voltage	O
was	O
set	O
to	O
2	O
V.	O

As	O
expected,	O
patients	O
with	O
CE	O
stroke	O
were	O
more	O
likely	O
to	O
have	O
a	O
diagnosis	O
of	O
AF	B
and	O
congestive	O
heart	O
failure.	O

p	B
-Cresol-β	I
-O	I
-glucuronide	I
was	O
determined	O
to	O
be	O
a	O
level	O
2	O
metabolite	O
but	O
showed	O
a	O
very	O
high	O
correlation	O
with	O
p	O
-cresol	O
(data	O
not	O
shown).	O

On	O
the	O
basis	O
of	O
the	O
values	O
of	O
VIPs,	O
p(corr),	O
p	O
and	O
q,	O
the	O
metabolites	O
that	O
predominantly	O
contributed	O
to	O
the	O
separation	O
of	O
the	O
FSGS	O
from	O
the	O
IgAN	O
group	O
were	O
higher	O
levels	O
of	O
TMAO	B
and	O
Tau,	O
and	O
lower	O
levels	O
of	O
NMN	O
and	O
3-HB,	O
(,).	O

Acyl-amides	B
and	O
mono-acyl	B
glycerols	I
are	O
also	O
common	O
components	O
of	O
blood	O
with	O
an	O
equally	O
broad	O
spectrum	O
of	O
actions	O
.	O

The	O
collection	O
tube	O
of	O
each	O
kit	O
contains	O
2	O
mL	O
of	O
stabilizing	O
reagents	O
mainly	O
composed	O
of	O
ethanol	B
(10-30%)	O
and	O
Tris-buffer	O
(1-5%),	O
according	O
to	O
the	O
manufacturer.	O

In	O
comparing	O
all	O
BCa	O
samples	O
to	O
each	O
of	O
the	O
control	O
groups,	O
all	O
biochemicals	O
with	O
the	O
exception	O
of	O
the	O
branched-chain	O
amino	O
acids	O
(BCAA)	O
leucine,	B
isoleucine	B
and	O
valine	B
displayed	O
p≤0.05	O
statistical	O
significance	O
in	O
all	O
3	O
control	O
group	O
comparisons.	O

Firstly,	O
brain	O
tissue	O
from	O
the	O
frontal	O
and	O
occipital	O
lobes	O
of	O
AD	O
sufferers	O
has	O
significantly	O
higher	O
levels	O
of	O
purescine,	B
spermine	B
and	O
spermidine.	B

The	O
accumulation	O
of	O
tryptophan	B
catabolites,	O
such	O
as	O
kynurenine	B
and	O
QA,	O
can	O
result	O
in	O
the	O
generation	O
of	O
niacin	B
and	O
nicotinamide	B
as	O
alternative	O
substrates	O
for	O
NAD	B
synthesis	O
in	O
a	O
step	O
involving	O
quinolinate	O
phosphoribosyltransferase	O
(QPRT)	O
and	O
nicotinamide	O
phosphoribosyltransferase.	O

Initial	O
samples	O
for	O
each	O
batch	O
were	O
shimmed	O
to	O
ensure	O
half-height	O
line	O
width	O
of	O
<1.1 Hz	O
for	O
the	O
dimethyly-silapentane-sulphonate	B
peak,	O
calibrated	O
to	O
0.0 ppm.	O

MODEL	O
3:	O
Model	O
2+	O
alcohol	O
consumption,	O
waist	O
circumference,	O
apolipoprotein	O
B	O
levels,	O
triglycerides,	B
insulin	O
levels,	O
systolic	O
blood	O
pressure,	O
smoking,	O
and	O
physical	O
activity	O
index.	O

For	O
example,	O
PC38:6	B
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes.	O

Thus,	O
while	O
lysine	B
concentrations	O
could	O
be	O
determined	O
for	O
888	O
samples	O
of	O
the	O
discovery	O
cohort	O
through	O
manual	O
quantification	O
and	O
yielded	O
a	O
significant	O
genetic	O
association	O
at	O
SLC7A9	O
,	O
the	O
non-targeted	O
approach	O
did	O
not	O
capture	O
any	O
association	O
signals	O
for	O
this	O
locus.	O

Therefore,	O
identification	O
of	O
intact	O
GH	O
and	O
the	O
c13	O
ion	O
fragment,	O
corroborated	O
with	O
a	O
disruption	O
of	O
reticulin	B
fiber	O
network	O
diagnosed	O
GH-secreting	O
PA.	O

The	O
1-hour	O
changes	O
in	O
F2-isoprostane	B
levels	O
were	O
statistically	O
significant,	O
while	O
the	O
1-hour	O
change	O
in	O
allantoin	B
levels	O
was	O
borderline	O
significant.	O

In	O
this	O
study,	O
HILIC-QTOF	O
MS-based	O
serum	O
metabolomics	O
revealed	O
patients	O
with	O
WD	O
can	O
be	O
distinguished	O
from	O
healthy	O
subjects	O
based	O
on	O
metabolites	O
associated	O
with	O
aminoacyl-tRNA	B
biosynthesis,	O
the	O
TCA	O
cycle,	O
and	O
choline	B
metabolism,	O
and	O
metabolites	O
related	O
to	O
gut	O
microbiota.	O

Other	O
peaks	O
that	O
show	O
variations	O
depending	O
on	O
the	O
freezing	O
procedure	O
include	O
the	O
Hδ2	O
peak	O
of	O
His	O
(7.1–7.2	O
ppm)	O
and	O
the	O
corresponding	O
peaks	O
in	O
His	O
derivatives	O
(1-	O
or	O
3-methyl	B
histidine,	I
His	O
dipeptides),	O
but	O
also	O
creatinine	B
(4.06	O
ppm)	O
or	O
citrate	B
(2.7	O
ppm).	O

A	O
100	O
μl	O
aliquot	O
of	O
serum	O
sample	O
was	O
spiked	O
with	O
two	O
internal	O
standards	O
(10	O
μl	O
l-2-chlorophenylalanine	B
in	O
water,	O
0.3	O
mg/ml;	O
10	O
μl	O
heptadecanoic	B
acid	I
in	O
methanol,	B
1	O
mg/ml)	O
and	O
vortexed	O
for	O
10	O
s.	O

For	O
this	O
analyses,	O
flow-injection	O
with	O
LC-MS/MS	O
(1200	O
HPLC	O
Agilent,	O
Waldbronn,	O
Germany	O
coupled	O
to	O
4000QTRAP	O
Sciex,	O
Darmstadt,	O
Germany)	O
was	O
performed	O
using	O
76%	O
isopropanol,	B
19%	O
methanol	B
and	O
5%	O
water	O
as	O
mobile	O
phase.	O

Thus,	O
in	O
adults	O
with	O
type	O
2	O
diabetes,	O
smoking	O
cessation	O
may	O
be	O
better	O
achieved	O
with	O
a	O
combination	O
of	O
pharmacological	O
therapies	O
(ie,	O
varenicline	O
and	O
nicotine	B
replacement	O
together).	O

 − 0.580),	O
cortisone	B
(r_s	O
 =	O

The	O
increased	O
expression	O
of	O
NOD-like	O
receptor	O
family,	O
pyrin	B
domain-containing	O
3	O
inflammasome	O
components	O
(NLRP3)	O
and	O
apoptosis-associated	O
speck-like	O
protein	O
(ASC),	O
in	O
monocytes	O
has	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
mechanisms	O
that	O
links	O
T2DM	O
and	O
vascular	O
inflammation.	O

Based	O
on	O
the	O
KEGG	O
database,	O
we	O
conclusively	O
found	O
that	O
purine	B
metabolism	O
(cAMP),	O
tyrosine	B
metabolism	O
(tyramine),	O
and	O
histidine	B
metabolism	O
(urocanic	O
acid)	O
were	O
changed	O
by	O
the	O
pharmacological	O
effect	O
of	O
glimepiride	O
in	O
healthy	O
human	O
subjects.	O

Whereas	O
sphingomyelin	B
is	O
abundant	O
in	O
myelin-forming	O
oligodendrocytes,	O
it	O
also	O
exists	O
in	O
lipid	O
rafts	O
of	O
neuronal	O
cells,	O
which	O
influence	O
the	O
potency	O
and	O
efficacy	O
of	O
neurotransmitter	O
receptors	O
and	O
transporters.	O

S	B
-(3-methylbutanoyl)-dihydrolipoamide-E	I
appeared	O
again	O
during	O
this	O
stage,	O
which	O
suggested	O
severe	O
metabolic	O
disorders	O
of	O
BCAA	O
and	O
fatty	O
acid	O
synthesis.	O

When	O
the	O
non-targeted	O
LC-MS	O
data	O
from	O
human	O
plasma	O
was	O
searched	O
for	O
compounds	O
matching	O
the	O
accurate	O
masses	O
for	O
these	O
214	O
missing	O
chemical	O
formulas,	O
184	O
distinct	O
chromatographic	O
peaks	O
present	O
at	O
45	O
of	O
the	O
214	O
chemical	O
formulas	O
were	O
found	O
with	O
each	O
of	O
these	O
peaks	O
having	O
accurate	O
mass	O
(<	O
±2	O
ppm)	O
matching	O
to	O
a	O
theoretical	O
formula,	O
a	O
retention	O
time	O
range	O
(1.0	O
–	O
5.75	O
minutes),	O
and	O
a	O
peak	O
shape	O
(FWHM	O
<	O
0.1	O
minutes	O
and	O
tailing	O
factor	O
0.8	O
–	O
1.2)	O
consistent	O
with	O
known	O
oxylipins.	B

However,	O
this	O
predominant	O
ion	O
was	O
not	O
observed	O
in	O
4-MeO-E2	B
and	O
2-MeO-E2,	B
where	O
the	O
major	O
product	O
ions	O
arose	O
from	O
the	O
loss	O
of	O
the	O
E2	O
moiety	O
from	O
both	O
of	O
the	O
derivatives	O
(m/z	O
158.2;	O
fragment	O
b,	O
).	O

The	O
isoflavones	B
were	O
isolated	O
and	O
concentrated	O
by	O
solid-phase	O
extraction	O
(Bond	O
Elut	O
C18	O
column).	O

Each	O
100	O
μL	O
blood	O
plasma	O
sample	O
was	O
mixed	O
with	O
300	O
μL	O
methanol	B
to	O
precipitate	O
the	O
protein.	O

For	O
women	O
carrying	O
a	O
female	O
fetus,	O
E_3	O
was	O
correlated	O
with	O
E_1	O
(r	O
=	O
0.56,	O
p	O
<	O
0.01)	O
and	O
progesterone	B
(r	O
=	O
0.68,	O
p	O
<	O
0.001),	O
whereas	O
2-OH-E_2	B
was	O
associated	O
with	O
4-OH-E_2	B
(r	O
=	O
0.87,	O
p	O
<	O
0.001).	O

This	O
assay	O
is	O
highly	O
specific	O
and	O
sensitive	O
for	O
the	O
simultaneous	O
measurements	O
of	O
Clozapine	B
and	O
Norclozapine.	B

Perturbations	O
of	O
several	O
metabolic	O
pathways	O
including	O
glycolysis,	O
amino	O
acid	O
metabolism,	O
nucleotide	O
and	O
glycerophospholipid	B
metabolism	O
with	O
increased	O
fatty	O
acid	O
synthesis	O
and	O
changes	O
in	O
fatty	O
acid	O
metabolism	O
have	O
been	O
proposed	O
as	O
determinants	O
of	O
the	O
onset	O
and	O
progression	O
of	O
pancreatic	O
cancer.	O

Notably	O
there	O
was	O
a	O
much	O
higher	O
content	O
of	O
amino	O
acids,	O
GSH,	B
taurine,	B
P-choline,	B
myo-inositol,	B
adenine	B
nucleotides	O
(5'-AXP),	O
and	O
uracil	B
nucleotides	O
in	O
the	O
Rh30	O
cells.	O

We	O
considered	O
the	O
possibility	O
that	O
the	O
lactate	B
and	O
lipid	O
signals	O
had	O
been	O
inadequately	O
resolved	O
in	O
the	O
HRMAS	O
_1	O
H	O
NMR	O
spectra	O
that	O
we	O
quantified	O
(as	O
can	O
happen	O
with	O
in	O
vivo	O
MRS	O
spectra),	O
but	O
that	O
does	O
not	O
appear	O
to	O
be	O
the	O
case,	O
so	O
we	O
have	O
no	O
explanation	O
for	O
this	O
apparently	O
contradictory	O
result.	O

The	O
single	O
chemical	O
derivatization	O
added	O
a	O
dansyl	O
group	O
(1-dimethyl-amino-naphthalene-5-sulfonyl)	O
to	O
the	O
phenolic	O
hydroxyl	O
present	O
on	O
all	O
estrogens	O
and	O
estrogen	B
metabolites.	O

These	O
results	O
suggest	O
that	O
functional	O
studies	O
are	O
warranted	O
into	O
the	O
interaction	O
of	O
simvastatin	B
with	O
endogenous	O
and	O
enterobiome	O
metabolites	O
at	O
bile	O
and	O
amino	O
acid	O
transporters.	O

Normalization	O
to	O
creatinine	B
values	O
was	O
used	O
to	O
compensate	O
for	O
urine	O
concentration	O
and	O
centering	O
and	O
scaling	O
was	O
used	O
before	O
moving	O
forward.	O

As	O
has	O
been	O
noted	O
previously,	O
dietary	O
factors	O
might	O
be	O
the	O
most	O
important	O
regulators	O
of	O
circulating	O
TMAO	B
concentrations.	O

Increased	O
pro-inflammatory	O
signaling	O
through	O
ceramides	B
and	O
decreased	O
anti-inflammatory	O
signaling	O
through	O
anandamide	B
provide	O
one	O
potential	O
metabolic	O
basis	O
for	O
the	O
low-level	O
chronic	O
inflammation	O
that	O
has	O
been	O
reported	O
in	O
GWI.	O

Meconium	O
specimens	O
screening	O
negative	O
by	O
immunoassay	O
for	O
amphetamines,	B
opiates,	O
cannabinoids,	B
cocaine,	O
and	O
cotinine	B
were	O
pooled	O
and	O
mixed	O
thoroughly.	O

ANCOVA	O
that	O
controlled	O
for	O
age	O
and	O
sex	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
age	O
and	O
sex	O
on	O
the	O
nervonic	B
acid	I
levels.	O

1:	O
3-indoleacetonitrile;	O
2:	O
quinolinic	B
acid;	I
3:	O
aminophenol;	B
4:	O
3-hydroxykynurenine;	O
5:	O
p-tyrosine;	B
6:	O
m-tyrosine;	B
7:	O
serotonin;	B
8:	O
5-hydroxytryptophan;	O
9:	O
o-tyrosine;	B
10:	O
kynurenine;	B
11:	O
phenylalanine;	B
12:	O
N-formylkynurenine;	B
13:	O
hydroxyanthranillic	B
acid;	I
14:	O
tryptophan;	B
15:	O
xanthurenic	B
acid;	I
16:	O
tryptamine;	B
17:	O
kynurenic	B
acid;	I
18:	O
5-methoxytryptamine;	O
19:	O
4-chlorokynurenine;	O
20:	O
N-acetylserotonin;	B
21:	O
phenylacetylglutamine;	B
22:	O
6-hydroxymelatonin;	O
23:	O
indole-3-acetamide;	B
24:	O
anthranillic	B
acid;	I
25:	O
formyl-acetylmethoxykynurenamine;	B
26:	O
indolelactic	B
acid;	I
27:	O
melatonin;	B
28:	O
3-indoleacetic	O
acid;	O
29:	O
tryptophol;	B
30:	O
serotonin-D_4	B
;	I
31:	I
5-hydroxytryptophan-D_4	I
;	O
32:	O
kynurenine-D_4	B
;	O
33:	O
phenylalanine-D_5	B
;	O
34:	O
tryptophan-D_5	O
;	O
35:	O
xanthurenic	B
acid-D_4	O
;	O
36:	O
kynurenic	O
acid-D_5	O
;	O
37:	O
tryptamine-D_4	B
;	I
38:	I
4-chloro-kynurenine-_13	I
C_2	O
,_15	O
N;	O
39:	O
phenylacetylglutamine-D_5	B
;	I
40:	I
6-hydroxymelatonin-D_4	I
;	O
41:	O
indole-3-acetamide-D_5	B
;	O
42:	O
melatonin-D_4	O
.	O

A	O
1	O
mg/mL	O
stock	O
solution	O
of	O
neopterin-_13	O
C_5	O
was	O
prepared	O
using	O
100%	O
dimethyl	B
sulfoxide	I
(DMSO).	O

Linearity	O
of	O
the	O
calibration	O
curves	O
were	O
shown	O
by	O
the	O
high	O
r_2	O
of	O
>	O
0.998,	O
which	O
implied	O
a	O
strong	O
correlation	O
between	O
the	O
peak	O
area	O
ratio	O
and	O
concentration	O
of	O
each	O
analyte	O
in	O
their	O
linear	O
ranges	O
of	O
0.4–40.0	O
ng/mL,	O
for	O
exemestane;	O
and	O
0.2–15.0	O
ng/mL,	O
for	O
17β-dihydroexemestane	B
and	O
17β-dihydroexemestane-17-O-β-D-glucuronide.	B

In	O
contrast	O
to	O
this,	O
another	O
study	O
showed	O
that	O
a	O
seven-day	O
intermittent	O
sprint	O
training	O
on	O
a	O
bicycle	O
ergometer	O
did	O
not	O
change	O
resting	O
urinary	O
hypoxanthine	B
concentration	O
in	O
active	O
men.	O

Consequently,	O
we	O
pooled	O
the	O
data	O
for	O
these	O
two	O
groups	O
to	O
give	O
tCr	O
=	O
phosphocreatine	B
+	O
creatine,	B
and	O
tCho	O
=	O
choline	B
+	O
phosphocholine	B
+	O
glycerophosphocholine.	B

Subjects	O
with	O
elevated	O
sPAP	O
(≥50	O
mmHg)	O
demonstrated	O
higher	O
levels	O
of	O
plasma	O
ADMA	B
(1.50	O
[1.17,	O
1.82]	O
versus	O
1.19	O
[0.88,	O
1.53],	O
p=0.014)	O
and	O
lower	O
GABR	O
(0.72	O
[0.58,	O
1.08]	O
versus	O
1.04	O
[0.84,	O
1.34],	O
p=0.003)	O
compared	O
to	O
those	O
with	O
lower	O
sPAP	O
(<50mmHg).	O

On	O
the	O
other	O
hand,	O
2-ketoglutarate	B
(2-KG),	O
4-hydroxyphenylacetate,	B
fumarate,	B
lactate,	B
threonine	B
and	O
trigonellinamide	B
were	O
only	O
observed	O
to	O
change	O
in	O
the	O
unmatched	O
cohort,	O
probably	O
benefiting	O
from	O
the	O
higher	O
sample	O
numbers.	O

In	O
addition	O
to	O
glycerol,	B
fatty	O
acids	O
most	O
closely	O
matching	O
metabolomic	O
signatures	O
for	O
linoleic	B
acid,	I
and	O
stereoisomers	O
of	O
oleic	B
acid	I
were	O
also	O
higher	O
in	O
controls.	O

Effective	O
inhibition	O
by	O
low	O
dose	O
aminoglutethimide	B
of	O
peripheral	O
aromatization	O
in	O
postmenopausal	O
breast	O
cancer	O
patients.	O

PLS-DA	O
model	O
built	O
for	O
two	O
classes,	O
control	O
and	O
GDM	O
for	O
three	O
different	O
time	O
points	O
of	O
the	O
oral	O
glucose	B
tolerance	O
test	O
(oGTT)	O

Six	O
meaningful	O
metabolomics	O
factors	O
were	O
identified	O
by	O
principal	O
component	O
analysis	O
(PCA)	O
(Supplementary	O
Table _2	O
):	O
Factor	O
1	O
(ornithine,	O
glycine,	B
serine),	B
Factor	O
2	O
(BCAAs	O
leucine,	B
isoleucine,	B
valine),	B
Factor	O
3	O
(phenylalanine),	O
Factor	O
4	O
(urea,	O
creatinine),	O
Factor	O
5	O
(taurine),	O
and	O
Factor	O
6	O
(threonine).	O

Also,	O
elevated	O
L-DOPA	B
levels	O
correlated	O
with	O
AADC	O
antibodies.	O

The	O
methanol	B
solubility	O
of	O
the	O
substances	O
indicates	O
a	O
certain	O
level	O
of	O
hydrophobicity	O
and	O
that	O
they	O
may	O
penetrate	O
through	O
the	O
lipid	O
bilayer	O
into	O
the	O
eukaryotic	O
cells.	O

Vasoconstriction,	O
vascular	O
remodeling,	O
glomerulosclerosis,	O
and	O
interstitial	O
matrix	O
deposition	O
implicate	O
an	O
array	O
of	O
mediators	O
that	O
operate	O
downstream	O
from	O
Ang	B
II.	I

Lambden	O
and	O
colleagues	O
have	O
shown	O
that	O
NO	O
production	O
in	O
activated	B
mouse	O
macrophages	O
is	O
DDAH2-dependent	O
with	O
reduced	O
intracellular	O

In	O
contrast,	O
qPCR	O
revealed	O
that	O
the	O
quantity	O
of	O
lactobacilli	B
was	O
lower	O
in	O
nIBS	O
patients	O
than	O
in	O
the	O
normal	O
gut,	O
but	O
it	O
was	O
higher	O
in	O
IBS	O
patients,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
lactobacilli	B
and	O
the	O
secreted	O
organic	O
acids	O
may	O
cause	O
IBS	O
symptoms.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
3‐hydroxybutyrate	B
levels	O
are	O
high	O
during	O
the	O
first	O
week	O
post	O
bariatric	O
surgery.13	O
In	O
obesity,	O
liver	O
ketogenesis	O
is	O
reduced	O
due	O
to	O
hyperinsulinemia.28	O

The	O
gradient	O
elution	O
using	O
the	O
HILIC	O
column	O
was	O
performed	O
using	O
aqueous	O
ammonium	B
acetate	I
(200 mM,	O
eluent	O
C)	O
and	O
acetonitrile	B
containing	O
formic	B
acid	I
(0.1%,	O
v/v,	O
eluent	O
D).	O

Remarkably,	O
most	O
of	O
the	O
altered	O
concentrations	O
were	O
consistent	O
with	O
the	O
3:2	O
gene	O
dosage	O
model,	O
suggesting	O
effects	O
caused	O
by	O
the	O
presence	O
of	O
three	O
copies	O
of	O
Hsa21	O
rather	O
than	O
two:	O
DS/normal	O
ratio	O
in	O
plasma	O
was	O
1.23	O
(pyruvate),	O
1.47	O
(succinate), 1.39	O
(fumarate),	O
1.33	O
(lactate),	O
1.4	O
(formate).	O

Abbreviations:	O
CAD,	O
coronary	O
artery	O
disease;	O
PAF,	O
platelet	O
activating	O
factor;	O
HAM-D,	O
17-item	O
Hamilton	O
Depression	O
Rating	O
Scale;	O
PC,	O
phosphocholine;	B
CIHR,	O
Canadian	O
Institutes	O
of	O
Health	O
Research.	O

The	O
fact	O
that	O
we	O
can	O
only	O
sample	O
human	O
myocardial	O
tissues	O
at	O
a	O
single	O
time-point	O
has	O
limited	O
our	O
analysis	O
to	O
cross-sectional	O
comparison	O
between	O
failing	O
and	O
non-failing	O
hearts	O
regarding	O
the	O
relative	O
amounts	O
of	O
production	O
(PRMT-1)	O
and	O
degradation	O
(DDAH-1	O
and	O
DDAH-2)	O
enzymes	O
rather	O
than	O
true	O
kinetics	O
of	O
ADMA	B
at	O
the	O
level	O
of	O
the	O
myocardium.	O

[Tot-c],	O
low-density	O
lipoprotein	O
cholesterol	B
[LDL-c],	O
and	O
high-density	O
lipoprotein	O
cholesterol	B

HP	B
sample	O
resulted	O
in	O
an	O
HP-D	O
sample	O
with	O
a	O
total	O
volume	O
of	O
225	O
μL	O
in	O
a	O
proprietary	O
“low	O
ionic	O
strength”	O
pH	O
7.4	O
Tris	O
buffer.	O

Column:	O
Discovery	O
HSF5	O
(10 cm × 2.1 mm,	O
5 μm);	O
mobile	O
phase	O
gradient	O
of	O
water	O
with	O
2 %	O
acetic	B
acid	I
and	O
methanol	B
with	O
2 %	O
acetic	B
acid.	I

Ammonium	B
acetate,	I
ammonium	B
hydroxide,	I
and	O
acetic	B
acid	I
were	O
the	O
highest	O
purity	O
grade	O
available	O
from	O
Sigma-Aldrich.	O

The	O
LOQ	O
values	O
were	O
<5	O
pg/mL	O
for	O
MeIQx	O
and	O
PhIP;	O
the	O
LOQ	O
value	O
for	O
8-CH_2	O
OH-IQx	O
was	O
7	O
pg/mL;	O
the	O
LOQ	O
value	O
for	O
IQx-8-COOH	O
was	O
20	O
pg/mL;	O
and	O
the	O
LOQ	O
values	O
for	O
the	O
glucuronide	B
conjugates	O
of	O
PhIP	O
and	O
HONH-PhIP	O
ranged	O
between	O
20	O
to	O
40	O
pg/mL.	O

In	O
addition,	O
due	O
to	O
increased	O
demand	O
for	O
lipid	O
synthesis	O
in	O
malignant	O
cells,	O
spermine	B
(Spm)_,	O
and	O
phosphocholine	B
(PCho)	O
and	O
total	O
choline	B
containing	O
compounds	O
(tCho)	O
levels	O
are	O
significantly	O
higher	O
in	O
PCa	O
as	O
compared	O
to	O
normal	O
prostate.	O

In	O
the	O
case	O
of	O
NMOSD,	O
isobutyrate	B
might	O
be	O
down-regulated	O
in	O
NMOSD	O
relapse	O
compared	O
to	O
remission,	O
since	O
statistical	O
requirement	O
was	O
partially	O
satisfied	O
(p	O
-value	O
=	O
0.002,	O
FDR	O
=	O
0.064).	O

Hz	O
with	O
a	O
0.45	O
Hz	O
resolution;	O
thereafter,	O
it	O
was	O
assessed	O
by	O
calculating	O
the	O
resolution	O
of	O
the	O
anomeric	O
proton	O
of	O
sucrose	B
in	O
the	O
QC	O
sample	O
(Figure	O
A)	O
that	O
was	O
optimized	O
to	O
as	O
low	O
as	O
25%.	O

Mean	O
extraction	O
efficiencies,	O
matrix	O
effects	O
and	O
analyte	O
stability	O
at	O
room	O
temperature,	O
4	O
and	O
−20°C	O
for	O
cannabinoids	B
in	O
human	O
urine.	O

B.	O
Gene	O
expression	O
of	O
AKR	O
and	O
CBR	O
enzymes	O
in	O
human	O
adipose	O
tissue	O
biopsy	O
specimens	O
(see	O
text	O
for	O
subject	O
details),	O
by	O
rtPCR,	O
relative	O
to	O
β-actin	B
(n=4).	O

Finally,	O
protein	O
precipitation	O
with	O
CHCl_3	O
:MeOH	O
(2:1,	O
v	O
/v	O
)	O
was	O
carried	O
out	O
by	O
adding	O
167	O
µL	O
of	O
MeOH	B
and	O
333	O
µL	O
of	O
CHCl_3	O
,	O
and	O
the	O
upper	O
phase	O
was	O
transferred	O
to	O
a	O
new	O
tube.	O

The	O
aliphatic	B
region	O
at	O
0.8–4.5	O
ppm	O
in	O
all	O
spectra	O
included	O
strong	O
signals	O
from	O
water-soluble	O
metabolites,	O
such	O
as	O
lactate,	B
isobutyrate,	B
alanine,	B
glutamate,	B
glutamine,	B
acetone,	B
acetoacetate,	B
creatinine,	B
creatine,	B
cysteine,	B
dimethyl	B
sulfone,	I
malonate,	B
and	O
choline.	B

Metabolite	O
assignments	O
are	O
indicated	O
with	O
the	O
following	O
numbers:	O
1)	O
2-hydroxybutyrate,	B
2)	O
leucine,	B
3)	O
valine,	B
4)	O
ethanol,	B
5)	O
lactate,	B
6)	O
2-aminoisobutyrate,	B
7)	O
alanine,	B
8)	O
lysine,	B
9)	O
acetate,	B
10)	O
glutamate,	B
11)	O
reduced	B
glutathione	I
(GSH),	O
12)	O
oxidized	B
glutathione	I
(GSSG),	O
13)	O
pyroglutamate,	B
14)	O
pyruvate,	B
15)	O
succinate,	B
16)	O
glutamine,	B
17)	O
creatine,	B
18)	O
phosphocreatine,	B
19)	O
malonate,	B
20)	O
spermidine/spermine,	O
21)	O
phosphocholine	B
(PC),	O
22)	O
glycerophosphocholine	B
(GPC),	O
23)	O
carnitine,	B
24)	O
betaine,	B
25)	O
taurine,	B
26)	O
methanol,	B
27)	O
proline,	B
28)	O
glycine,	B
29)	O
glycerol,	B
30)	O
ascorbate,	B
31)	O
guanidino/guanido	O
acetate,	B
32)	O
6-phosphogluconate	B
33)	O
glycolate,	B
34)	O
phosphoethanolamine,	B
35)	O
ATP,	B
37)	O
AMP,	B
38)	O
NAD+,	B
39)	O
NADP+,	B
40)	O
trehalose,	B
41)	O
phosphoenolpyruvate,	B
42)	O
UDP-glucose,	B
43)	O
UDP-NAG,	O
43)	O
NADH,	B
44)	O
uracil/tryptophane,	O
45)	O
GDP,	O
46)	O
GTP,	O
47)	O
NADPH,	B
48)	O
CTP,	B
49)	O
fumarate,	B
50)	O
tyrosine,	B
51)	O
histidine/histamine,	O
52)	O
tryptophane,	B
53)	O
phenylalanine,	B
54)	O
guanosine,	B
55)	O
xanthine,	B
56)	O
guanine,	B
57)	O
hypoxanthine,	B
58)	O
CTP,	B
59)	O
CDP,	O
60)	O
ADP,	B
61)	O
formate,	B
62)	O
methionine,	B
63)	O
aspartate,	B
64)	O
malate,	B
65)	O
glucose,	B
66)	O

TMAO	B
and	O
indoxyl-sulfate	B
were	O
also	O
among	O
the	O
identified	O
metabolites	O
and	O
are	O
known	O
cardiovascular	O
markers.	O

Significant	O
metabolites	O
according	O
to	O
the	O
jack-knife	O
confidence	O
intervals	O
were:	O
oleic	B
acid	I
(lower	O
levels	O
in	O
pre-symptomatic	O
individuals	O
compared	O
with	O
controls),	O
as	O
well	O
as	O
kynurenine	B
and	O
LPC(16:0)	B
(higher	O
levels	O
in	O
pre-symptomatic	O
individuals	O
in	O
comparison	O
to	O
controls).	O

Of	O
the	O
20	O
amino	O
acids	O
quantified,	O
only	O
citrulline	B
and	O
arginine	B
had	O
significantly	O
increased	O
levels	O
in	O
HD	O
compared	O
to	O
control	O
sheep.	O

Acylcarnitines,	B
especially	O
those	O
with	O
C3	O
and	O
C5	O
acyl	O
groups,	O
are	O
derived	O
from	O
α-keto	B
acid	I
products	O
and	O
contribute	O
to	O
fatty	O
acid	O
β-oxidation	O
in	O
the	O
mitochondria	O
as	O
described	O
in	O
.	O

The	O
finding	O
that	O
the	O
melanoma	O
cell	O
lines	O
contained	O
relatively	O
high	O
levels	O
of	O
endogenous	O
estrogen	B
and	O
EMs	O
is	O
interesting.	O

The	O
evaluated	O
metabolites	O
were	O
hippurate,	B
creatinine,	B
lactate,	B
histidine,	B
and	O
alanine.	B

Microdialysis	O
catheters	O
with	O
a	O
membrane	O
length	O
of	O
10	O
mm	O
and	O
a	O
20-kDa	O
nominal	O
molecular	O
weight	O
cut-off	O
polyamide	B
membrane	O
(70	O
Brain	O
Microdialysis	O
Catheter;	O
M	O
Dialysis	O
AB,	O
Solna,	O
Sweden)	O
were	O
used.	O

In	O
addition	O
to	O
energy	O
production,	O
serine,	B
tryptophan,	B
and	O
glycine	B
supply	O
one	O
carbon	O
unit	O
for	O
synthesis	O
of	O
purines	B
and	O
pyrimidines.	B

Thus	O
oral	O
exposure	O
to	O
neonicotinoid	B
pesticides	O
may	O
exist	O
in	O
the	O
general	O
population;	O
however,	O
neonicotinoid	B
metabolites	O
in	O
human	O
body	O
fluids	O
have	O
not	O
been	O
investigated	O
comprehensively.	O

In	O
brief,	O
systolic	O
blood	O
pressure	O
measurements	O
in	O
the	O
bilateral	O
brachial,	O
dorsalis	O
pedis,	O
and	O
posterior	O
tibial	O
arteries	O
were	O
obtained	O
in	O
the	O
supine	B
position	O
using	O
a	O
hand-held	O
Doppler	O
instrument.	O

One	O
of	O
these	O
plasma	O
aliquots	O
was	O
used	O
for	O
diluted	O
plasma	O
_1	O
H	O
NMR	O
analysis	O
(250	O
µl	O
was	O
diluted	O
into	O
755	O
µl	O
final	O
mixture	O
of	O
500	O
µl	O
0,9%	B
saline	I
in	O
D_2	O
O	O
and	O
5	O
µl	O
100	O
mM	O
sodium	B
3-(trimethylsilyl)	I

Spermidine,	B
one	O
member	O
of	O
the	O
polyamine	B
metabolites,	O
is	O
required	O
for	O
mammalian	O
cell	O
growth	O
and	O
has	O
long	O
been	O
associated	O
with	O
cancer	O
progression.	O

IAA	O
at	O
uremic	O
concentrations	O
was	O
previously	O
linked	O
to	O
oxidative	O
stress	O
and	O
contribution	O
to	O
development	O
of	O
CVD	O
in	O
CKD	O
patients	O
via	O
activation	O
of	O
the	O
Aryl	B
Hydrocarbon	I
Receptor.	O

For	O
example,	O
body	O
burden	O
of	O
1,2,3,4,6,7,8-heptaCDF	B
was	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
2-OH-E_2	B
,	O
after	O
the	O
adjustment	O
for	O
other	O
congeners	O
and	O
maternal	O
age.	O

However,	O
several	O
other	O
VOCs	O
were	O
tentatively	O
identified	O
(Supplementary	O
Table	O
_2	O
)	O
and	O
were	O
also	O
able	O
to	O
discriminate	O
between	O
cancer	O
and	O
normal	O
cell	O
lines,	O
namely,	O
1,3-benzothiazole,	B
3,7-dimethyloct-7-en-1-ol	B
(22RV1	O
vs	O
PNT2,	O
PC3	O
vs	O
PNT2,	O
DU145	O
vs	O
PNT2),	O
2-methylundecanal,	B
(PC3	O
vs	O
PNT2,	O
DU145	O
vs	O
PNT2	O
and	O
LNCaP	O
vs	O
PNT2),	O
2,7-dimethyloctan-1-ol	B
(PC3	O
vs	O
PNT2),	O
2-(4-methylcyclohex-3-en-1-yl)propan-2-ol	B
(PC3	O
vs	O
PNT2),	O
decan-1-ol	B
(DU145	O
vs	O
PNT2),	O
1-methoxypropan-2-yl	B
acetate	I
(LNCaP	O
vs	O
PNT2),	O
and	O
1,4-xylene	B
(LNCaP	O
vs	O
PNT2)	O
(Table	O
).	O

Among	O
the	O
mothers,	O
aged	O
43.5	O
-	O
80.7,	O
higher	O
levels	O
of	O
nocturnal	O
melatonin	B
production,	O
as	O
measured	O
by	O
total	O
nocturnal	O
urinary	O
aMT6s/Cr,	O
were	O
associated	O
with	O
lower	O
levels	O
of	O
total	O
nocturnal	O
urinary	O
8-oxodG.	B
This	O
translates	O
into	O
lower	O
levels	O
of	O
oxidatively	O
damaged	O
guanine	B
in	O
DNA	O
because	O
nearly	O
all	O
such	O
damage	O
is	O
repaired.	O

Leucine,	B
and	O
its	O
metabolite	O
β-hydroxy-methylbutyrate	B
(HMB),	O
can	O
act	O
synergistically	O
with	O
pharmacological	O
agents	O
to	O
increase	O
their	O
potency	O
[–].	O

ALL	O
cell	O
lines	O
were	O
cultured	O
in	O
RPMI	O
1640	O
containing	O
10%	O
FBS,	O
1%	O
sodium	B
pyruvate,	I
1%	O
GlutaMax,	B
and	O
0.1%	O
gentamicin	B
(“complete	O
media”),	O
and	O
maintained	O
at	O
densities	O
between	O
0.5–2.0×106	O
cells	O
per	O
mL	O
in	O
a	O
humidified	O
incubator	O
with	O
5%	O
CO2.	O

The	O
decreased	O
level	O
of	O
glutamine	B
has	O
been	O
reported	O
previously	O
[,	O
],	O
which	O
was	O
possibly	O
due	O
to	O
its	O
consumption	O
for	O
energy	O
supply.	O

[_1	O
H	O
NMR	O
of	O
Karo	O
Light	O
indicated	O
it	O
is	O
a	O
mixture	O
of	O
mono-	O
and	O
di-saccharides	B
(glucose,	I
fructose,	I
maltose,	I
sucrose)].	I

Two	O
pairs	O
of	O
regioisomers,	O
9-HETE	B
and	O
11-HETE	B
(319	O
>	O
167),	O
7-HDHA	O
and	O
17-HDHA	B
(343	O
>	O
245)	O
were	O
nearly	O
baseline	O
separated.	O

Our	O
previous	O
findings	O
in	O
SEEDS	O
have	O
shown	O
that	O
anti-androgenic	O
phthalate	B
metabolites	O
were	O
associated	O
with	O
sperm	O
DNA	O
methylation	O
and	O
diminished	O
embryo	O
quality.	O

Likewise,	O
PA	O
were	O
characterized	O
by	O
an	O
increased	O
level	O
of	O
methionine,	B
while	O
gliomas	O
exhibited	O
low	O
levels	O
of	O
this	O
amino	O
acid	O
(Table	O
).	O

While	O
tryptophan	B
is	O
important	O
for	O
protein	O
synthesis,	O
it	O
is	O
also	O
metabolized	O
to	O
a	O
number	O
of	O
bioactive	O
compounds	O
that	O
function	O
in	O
physiological	O
processes	O
including	O
immunoregulation,	O
inflammation,_,	O
and	O
neurotransmission.	O

In	O
this	O
study,	O
15-HEPE,	B
one	O
product	O
of	O
arachidonic	B
acid,	I
is	O
increased	O
after	O
high-altitude	O
exposure,	O
which	O
may	O
contribute	O
to	O
the	O
severe	O
AMS.	O

These	O
metabolites	O
included	O
amino	O
acids	O
(valine,	O
glycine,	B
alanine,	B
leucine,	B
proline,	B
isoleucine,	B
glutamate,	B
glutamine,	B
aspartate,	B
asparagine,	B
threonine,	B
tyrosine,	B
phenylalanine,	B
ornithine,	B
creatine),	B
organic	O
acids	O
(citrate,	O
3-hydroxybutyric	B
acid,	I
lactate,	B
acetate,	B
succinate,	B
formate,	B
taurine,	B
nicotinurate),	O
nucleosides/nucleotides	O
(inosine,	O
adenine,	B
uracil,	B
uridine)	B
and	O
sugars	O
(glucose,	O
myo	O
-inositol,	O
glycogen).	B

Correlation	O
analysis	O
and	O
t	O
-test	O
furthermore	O
indicated	O
phenylalanine,	B
glucose,	B
hydroxybutyrate	B
and	O
histidine	B
as	O
significant	O
features	O
with	O
p	O
values	O
<	O
0.05	O
that	O
are	O
also	O
included	O
in	O
.	O

LOD	O
were	O
between	O
0.05	O
and	O
1.0	O
µg/l;	O
LOQ	O
were	O
between	O
0.1	O
and	O
1.0	O
µg/l.	O
Assays	O
were	O
linear	O
to	O
50	O
µg/l	O
for	O
all	O
analytes	O
except	O
100	O
µg/l	O
for	O
JWH-200	B
5-hydroxyindole,	I
JWH-398	O
N-pentanoic	B
acid	I
and	O
AM2201	O
6-hydroxyindole.	O

Such	O
studies	O
assessing	O
vitamin	B
D	I
metabolism	O
and	O
DKD	O
have	O
been	O
limited	O
by	O
cross-sectional	O
design	O
and	O
measurement	O
of	O
single	O
vitamin	B
D	I
metabolites.	O

A	O
decreased	O
level	O
of	O
L-carnitine	B
and	O
an	O
increased	O
level	O
of	O
dityrosine	B
and	O
3-dehydroxycarnitine	B
were	O
detected	O
in	O
patients	O
progressed	O
to	O
DM.	O

Ketone	B
bodies	O
elevate	O
in	O
a	O
healthy	O
fasting	O
state	O
to	O
supply	O
energy	O
in	O
times	O
of	O
low	O
glucose	B
as	O
well	O
as	O
in	O
a	O
type	O
I	O
diabetic	O
state,	O
when	O
lack	O
of	O
insulin	O
production	O
results	O
in	O
high	O
levels	O
of	O
ketone	B
bodies	O
despite	O
high	O
levels	O
of	O
plasma	O
glucose.	B

A	O
systematic	O
review	O
of	O
the	O
literature	O
was	O
conducted	O
independently	O
by	O
two	O
of	O
the	O
authors	O
via	O
PubMed,	O
Web	O
of	O
Science	O
Core	O
Collection	O
and	O
Scopus	O
databases	O
until	O
11th	O
December	O
2018,	O
using	O
following	O
keywords:	O
metabolomics	O
pituitary	O
adenoma/tumor,	O
metabolomic	O
biomarker	O
pituitary	O
adenoma/tumor,	O
metabolomic	O
analysis	O
pituitary	O
adenoma/tumor,	O
metabolomic	O
profile	O
pituitary	O
adenoma/tumor,	O
metabolites	O
pituitary	O
adenoma,	O
LC-MS	O
pituitary	O
adenoma/tumor,	O
GC-MS	O
pituitary	O
adenoma/tumor,	O
NMR	O
spectrometry	O
pituitary	O
adenoma/tumor,	O
MALDI	O
pituitary	O
adenoma/tumor,	O
deoxycholic	B
acid	I
pituitary	O
adenomas,	O
4-pyridoxic	B
acid	I
pituitary	O
adenomas,	O
phosphoethanolamine	B
pituitary	O
adenomas,	O
alanine	B
pituitary	O
adenomas,	O
N-acetyl	B
aspartate	I
pituitary	O
adenomas,	O
myo-inositol	B
pituitary	O
adenomas,	O
3-methyladipate	B
pituitary	O
adenomas,	O
glutamate	B
pituitary	O
adenomas,	O
glutamine	B
pituitary	O
adenomas,	O
taurine	B
pituitary	O
adenomas	O
.	O

Conditions	O
were	O
as	O
follows:	O
capillary	O
voltage	O
4.0	O
kV;	B
desolvation	O
gas	O
flow,10	O
L/min;	O
330°C,	O
and	O
nitrogen	B
gas.	I

p	B
-Hydroxyphenyl-acetic	I
and	O
3-(3’-hydroxyphenyl)-3-hydropropionic	B
acids	I
are	O
produced	O
by	O
gut	O
microbial	O
dehydrogenation	O
of	O
some	O
bioactive	O
compounds	O
such	O
as	O
proanthocyanidins	B
and	O
procyanidins,	B
present	O
in	O
elevated	O
quantity	O
in	O
blueberry	O
fruits.	O

[M-H]_−	O
,	O
chenodeoxycholic	B
acid	I
(3α,	O
7α-dihydroxy-5β-cholanic	B
acid)	I

Our	O
study	O
included	O
a	O
relatively	O
large	O
number	O
of	O
participants	O
(N = 264)	O
and	O
many	O
measured	O
metabolites,	O
including	O
riboflavin,	B
total	O
vitamin	B
B6	I
and	O
cotinine,	B
which	O
are	O
important	O
as	O
they	O
influence	O
tryptophan	B
catabolism.	O

As	O
the	O
primary	O
product	O
of	O
25(OH)D	O
metabolism	O
by	O
CYP24A1,	B
24,25(OH)_2	I
D	O
is	O
a	O
biomarker	O
of	O
25(OH)D	O
turnover.	O

Compared	O
to	O
patients	O
with	O
TB,	O
plasma	O
levels	O
of	O
lipids,	O
ketone	B
bodies,	O
lactate,	B
and	O
pyruvate	B
were	O
increased	O
and	O
those	O
of	O
1-methylhistidine,	B
branched-chain	O
amino	O
acids,	O
glucose,	B
nicotinate,	B
and	O
glycerophosphocholine	B
were	O
decreased	O
in	O
the	O
CAP	O
group.	O

Still,	O
our	O
findings	O
await	O
corroboration	O
using	O
research	O
that	O
incorporates	O
serial	O
collection	O
of	O
urinary	O
paracetamol	B
and	O
detailed	O
information	O
on	O
medicinal	O
and	O
environmental	O
exposures	O
in	O
the	O
context	O
of	O
couple	O
fecundity.	O

Furthermore,	O
lactate	B
at	O
1.28	O
and	O
4.05	O
p.p.m.	O
and	O
acetate	B
at	O
1.86	O
p.p.m.	O

All	O
sphingomyelin	B
species	O
were	O
significantly	O
higher	O
in	O
cancer	O
tissue	O
than	O
that	O
in	O
peri-tumor	O
or	O
normal	O
breast	O
tissue,	O
as	O
well	O
as	O
the	O
total	O
levels	O
of	O
sphingomyelin	B
determined	O
by	O
mass	O
spectrometry	O
(Figure	O
).	O

Extracts	O
of	O
the	O
pooled	O
urine	O
as	O
well	O
as	O
4:1	O
water:MeOH	O
were	O
spiked	O
at	O
three	O
levels	O
of	O
BDCPP	O
(522,	O
988	O
and	O
9931	O
pg	B
per	O
extract)	O
and	O
DPP	O
(1139,	O
2423,	O
and	O
21,245	O
pg	O
per	O
extract).	O

This	O
is	O
due	O
to	O
fetus	O
high	O
glucose	B
uptake	O
through	O
the	O
placenta.	O

Plasma	O
fasting	O
glucose	B
and	O
insulin	O
concentrations	O
were	O
measured	O
using	O
standard	O
enzymatic	O
automated	O
methods	O
and	O
HOMA-IR	O
was	O
computed.	O

These	O
are	O
the	O
first	O
data	O
known	O
to	O
have	O
assessed	O
preconception	O
urinary	O
concentrations	O
of	O
total	O
paracetamol	B
and	O
its	O
metabolite,	O
p	B
-aminophenol,	I
in	O
relation	O
to	O
TTP,	O
reflective	O
of	O
couple	O
fecundity.	O

G6PI	O
glucose	B
6-phosphate	I
isomerase;	O
K6PP	O
6-phosphofructokinase;	O
ALDOA	O
aldolase	O
A;	O
TPIS	O
triosephosphate	B
isomerase;	O
GAPDH	O
glyceraldehydes	O
3-phosphate	O
dehydrogenase;	O
PGK1	O
phosphoglycerate	B
kinase	O
1;	O
KPYM	O
pyruvate	B
kinase	O
isozymes	O
M1/M2;	O
ODPAT	O
pyruvate	O
dehydrogenase	O
E1	O
component	O
subunit	O
alpha;	O
ACLY	O
ATP-citrate	O
synthase;	O
and	O
IDHP	O
isocitrate	O
dehydrogenase	O
Levels	O
of	O
all	O
the	O
quantified	O
TCA	O
cycle	O
intermediates	O
were	O
higher	O
in	O
tumor	O
than	O
normal	O
prostate	O
tissues	O
(Fig.	O

Palmitate	B
flux	O
was	O
calculated	O
using	O
the	O
steady-state	O
equation	O
described	O
by	O
Steele	O
et	O
al.	O
and	O
Wolfe	O
et	O
al.	O

HDL/LDL	O
cholesterol	B
levels	O
were	O
selectively	O
precipitated	O
and	O
then	O
determined	O
by	O
homogenous	O
assays	O
(Dimension	O
VISTA,	O
Siemens	O
Healthcare	O
Diagnostics,	O
Eschborn,	O
Germany).	O

Carnitine	B
uptake	O
and	O
synthesis	O
are	O
regulated	O
by	O
PPAR-α	O
and	O
stimulated	O
by	O
dietary	O
energy	O
restriction.	O

These	O
duplicates	O
ions	O
were	O
attributed	O
to	O
the	O
following	O
processes:	O
(i)	O
Dimerization	O
(102	O
features):	O
this	O
occurs	O
during	O
the	O
ionization	O
process	O
with	O
ESI;	O
it	O
is	O
concentration-_,	O
and	O
instrument-_,	O
dependant	O
and	O
can	O
be	O
reduced	O
by	O
tuning	O
the	O
cone	O
voltage._,	O
Dimers	O
can	O
be	O
homodimers	O
(for	O
e.g.	O
2	O
PC)	O
or	O
heterodimers	O
(for	O
e.g.	O
steryl	B
ester	I
plus	O
cholesterol).	B

The	O
microbial	O
origin	O
of	O
9	O
phenyl	O
and	O
indole	B
uremic	O
solutes	O
was	O
confirmed	O
by	O
comparison	O
of	O
samples	O
from	O
patients	O
with	O
and	O
without	O
colons.	O

Glutamic	B
acid,	I
sorbitol,	B
pseudo-uridine,	B
and	O
threonic	B
acid	I
exhibited	O
changes	O
greater	O
than	O
2-fold	O
between	O
WD	O
and	O
healthy	O
subjects.	O

In	O
all,	O
twelve	O
fully-porous	O
columns	O
were	O
tested,	O
including	O
four	O
Acquity	O
UPC_2	O
columns	O
(BEH	O
2-EP,	O
BEH,	O
CSH	O
FP	O
and	O
HSS	O
C_18	O
SB),	O
four	O
Acquity	O
UPLC	O
columns	O
(BEH	O
Amide,	B
BEH	O
HILIC,	O
BEH	O
Phenyl	O
and	O
HSS	O
Cyano),	B
and	O
four	O
Acquity	O
UPC_2	O
Torus	O
columns	O
(2-picolylamine	O
or	O
2-PIC,	O
Diol,	B
Diethylamine	B
or	O
DEA	O
and	O
1-amino	B
anthracene	I
or	O
1-AA).	O

To	O
a	O
solution	O
of	O
Dein‐4′‐G′	O
(54.2 mg,	O
0.095 mmol)	O
in	O
95%	O
aqueous	O
ethanol,	B
60 mg	O
of	O
10%	O
Pd/C	O
was	O
added.	O

Because	O
medication	O
doses	O
were	O
significantly	O
associated	O
with	O
the	O
severity	O
of	O
symptoms	O
at	O
onset,	O
and	O
there	O
was	O
no	O
difference	O
in	O
glutamate	B
concentration	O
with	O
benzodiazepine	B
treatment	O
in	O
the	O
second	O
set,	O
it	O
is	O
difficult	O
to	O
conclude	O
that	O
medications	O
directly	O
affect	O
the	O
glutamate	B
concentration	O
in	O
peripheral	O
blood.	O

MSEA	O
revealed	O
alterations	O
in	O
steroidogenesis,	O
androstenedione	B
metabolism,	O
and	O
the	O
metabolism	O
of	O
androgens	O
and	O
estrogens	O
in	O
patients	O
who	O
were	O
overweight	O
or	O
at	O
various	O
stages	O
of	O
obesity.	O

Considering	O
SPMA,	O
metabolite	O
of	O
benzene,	B
the	O
levels	O
in	O
workers	O
were	O
about	O
an	O
order	O
of	O
magnitude	O
lower	O
than	O
the	O
biological	O
exposure	O
indices	O
(BEI)	O
(25	O
µg/g	O
creatinine)	O
proposed	O
by	O
ACGIH.	O

Of	O
the	O
six	O
polyol	O
derived	O
uremic	O
solutes	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
progression	O
to	O
ESRD,	O
myo-inositol	B
was	O
the	O
one	O
most	O
strongly	O
associated,	O
odds	O
ratio:	O
3.2	O
(95%	O
CI;	O
1.7,	O
5.9).	O

Following	O
confirmation	O
of	O
the	O
efficiency	O
of	O
the	O
nanoelectrospray	O
LC-EC-array-MS	O
platform,	O
we	O
examined	O
next	O
its	O
practical	O
utility	O
toward	O
the	O
identification	O
of	O
unknown	O
metabolites	O
of	O
the	O
pro-drug	O
sodium	B
phenylbutyrate	I
(PB)	O
in	O
patient	O
serum.	O

Statins	B
were	O
used	O
in	O
74%	O
of	O
subjects.	O

In	O
the	O
CRC	O
study,	O
SPICA	O
identified	O
6461	O
statistically	O
significant	O
ion-pairs,	O
several	O
of	O
which	O
putatively	O
mapped	O
to	O
folic	B
acid	I
biosynthesis,	O
a	O
key	O
pathway	O
in	O
colorectal	O
cancer.	O

Bay	O
region	O
and	O
fjord	O
region	O
diol	B
epoxides	I
of	O
PAH,	O
which	O
are	O
major	O
ultimate	O
carcinogens	O
of	O
compounds	O
such	O
as	O
BaP	O
and	O
benzo[c	B
]phenanthrene,	I
are	O
good	O
substrates	O
for	O
human	O
GSTA1,	O
GSTP1,	O
and	O
GSTM1	O
enzymes,	O
representing	O
cytosolic	O
GSTs	O
of	O
the	O
alpha,	O
pi,	O
and	O
mu	O
classes,	O
based	O
on	O
extensive	O
in	O
vitro	O
studies	O
(–).	O

The	O
downregulation	O
of	O
glucose,	B
AMP	B
and	O
NAD,	B
upregulation	O
of	O
formate	B
indicated	O
the	O
large	O
energy	O
requirement	O
due	O
to	O
accelerated	O
cell	O
proliferation	O
in	O
esophageal	O
cancer.	O

Little	O
has	O
been	O
known	O
about	O
circadian	O
variation	O
of	O
cortisol	B
secretion	O
in	O
patients	O
with	O
AN	O
in	O
childhood	O
and	O
adolescence.	O

 MCI	O
_b	O
Actual	O
group	O
and	O
predicted	O
group	O
are	O
completely	O
different,	O
e.g.,	O
actual	O
group = healthy,	O
predicted	O
group = AD	O
Classification	O
of	O
blinded	O
samples	O
using	O
discriminant	O
analysis	O
GCDCA	B
glycochenodeoxycholic	I
acid,	I
GDCA	O
glycodeoxycholic	B
acid,	I
GLCA	O
glycolithocholic	B
acid,	I
LCA	O
lithocholic	B
acid,	I
M	O
male,	O
F	O
female,	O
age	O
in	O
years,	O
MMSE	O
minimental	O
state	O
examination,	O
GDS	O
geriatric	O
depression	O
scale	O
Verfication	O
is	O
based	O
on	O
discriminant	O
analysis	O
as	O
given	O
in	O
Table 	O
(f0 = control,	O
f1 = MCI,	O
f2 = AD)	O
using	O
LCA	O
and	O
GDCA.	O

The	O
formation	O
of	O
S-lactoyl	B
glutathione	I
is	O
catalysed	O
by	O
glyoxalase	O
1	O
(Glo1)	O
and	O
under-expression	O
can	O
promote	O
tumour	O
growth.	O

In	O
contrast,	O
alanine	B
and	O
glutamic	B
acid	I
post-treatment	O
levels	O
were	O
high	O
in	O
patients	O
with	O
high	O
post-treatment	O
insulin	O
or	O
HOMA	O
levels;	O
however,	O
the	O
relationship	O
did	O
not	O
pass	O
multiple	O
hypothesis	O
testing.	O

Blood	O
lactate,	B
hemodynamic	O
parameters,	O
and	O
the	O
use	O
of	O
catecholamine	B
and	O
mechanical	O
ventilation	O
were	O
recorded.	O

Human	O
plasma	O
from	O
normolipidemic	O
adult	O
volunteers	O
was	O
collected	O
to	O
evaluate	O
three	O
different	O
solvent	O
extraction	O
protocols,	O
including	O
the	O
classical	O
Folch	O
method,	O
the	O
methanol/tert-butyl	O
methyl	B
ether	I
(MTBE)	O

Effect	O
of	O
disease	O
duration	B
was	O
further	O
illustrated	O
by	O
the	O
negative	O
correlation	O
observed	O
between	O
disease	O
duration	B
and	O
the	O
level	O
of	O
GTA465/403	O
in	O
RRMS	O
patients	O
(Fig. ).	O

This	O
may	O
also	O
explain	O
anabolism	O
in	O
cancer	O
cells,	O
which	O
is	O
mediated	O
by	O
the	O
rewiring	O
of	O
the	O
urea	B
cycle.	O

Correcting	O
for	O
SG	O
is	O
frequently	O
used	O
as	O
an	O
alternative	O
to	O
creatinine	B
correction,	O
because	O
urinary	O
creatinine	B
concentrations	O
may	O
vary	O
within	O
and	O
between	O
persons.	O

Other	O
small	O
molecule	O
nutrients	O
found	O
in	O
high	O
abundance	O
in	O
serum	O
include	O
amino	O
acids	O
(10	O
µM–1155	O
µM),	O
glucose,	B
glycerol,	B
lactate,	B
oxygen,	O
carbon	B
dioxide	I
(in	O
the	O
form	O
of	O
bicarbonate	O
ions)	O
and	O
several	O
waste	O
or	O
catabolic	O
byproducts	O
such	O
as	O
urea	B
and	O
creatinine.	B

The	O
inverse	O
association	O
of	O
PLTP	O
activity	O
with	O
betaine	B
remained	O
significant	O
after	O
additional	O
adjustment	O
for	O
body	O
mass	O
index	O
and	O
lipoprotein	O
variables	O
(β = −0.179,	O
p	O
 = 0.034),	O
whereas	O
its	O
association	O
with	O
LCAT	O
activity	O
lost	O
significance	O
(β = −0.056,	O
p	O
 = 0.44).	O

In	O
addition	O
to	O
secondary	O
bile	O
acids,	O
we	O
observed	O
a	O
correlation	O
between	O
response	O
to	O
simvastatin	B
and	O
higher	O
pre-treatment	O
levels	O
of	O
coprostanol	B
(COPR)	O
(,	O
,	O
and	O
).	O

The	O
class	O
of	O
serum	O
endotypes	O
included	O
proline,	B
glutamate,	B
phenylalanine	B
and	O
valine.	B

PC	O
are	O
the	O
most	O
common	O
glycerophospholipids	B
because	O
of	O
their	O
structural	O
roles	O
and	O
since	O
they	O
serve	O
as	O
a	O
precursor	O
of	O
signalling	O
molecules	O
such	O
as	O
arachidonic	B
acid,	I
diacylglycerol	B
(DG)	O
and	O
PA	O
[–].	O

The	O
higher	O
creatinine	B
concentration	O
in	O
HF	O
patients	O
may	O
be	O
secondary	O
to	O
the	O
renal	O
impairment	O
commonly	O
observed	O
in	O
HF	O
patients,	O
while	O
the	O
increase	O
in	O
the	O
amino	O
acids	O
may	O
imply	O
a	O
hypercatabolic	O
state	O
that	O
has	O
been	O
reported	O
in	O
chronic	O
HF	O
patients	O
[,	O
].	O

The	O
UC-enriched	O
[Ruminococcus]_gnavus_group	O
was	O
also	O
positively	O
correlated	O
with	O
citric	B
acid.	I

These	O
proteins	O
belong	O
to	O
functionally	O
different	O
categories	O
such	O
as	O
cytoskeleton	O
elements,	O
trafficking	O
proteins,	O
cellular	O
chaperones,	B
glycoprotein,	B
enzymes,	O
proliferation	O
and	O
cell	O
cycle	O
regulators	O
(Table	O
).	O

Our	O
results	O
may	O
shed	O
light	O
on	O
the	O
pathogenesis	O
of	O
diabetic	O
kidney	O
disease,	O
but	O
the	O
expression	O
of	O
glucose	B
metabolism-related	O
protein	O
and	O
enzyme	O
activity	O
in	O
HK-2	O
cells	O
after	O
hyperglycemia	O
condition	O
need	O
to	O
be	O
confirmed	O
by	O
further	O
studies.	O

SPE-LC-MS/MS	O
(solid	O
phase	O
extraction-LC-MS/MS)	O
was	O
applied	O
for	O
the	O
determination	O
of	O
catecholamine	B
and	O
steroid	O
levels.	O

Urinary	O
citrate	B
concentrations	O
in	O
healthy	O
controls	O
were	O
greater	O
than	O
those	O
in	O
chronic	O
pancreatitis	O
patients	O
(P=0.019,	O
validation	O
by	O
random	O
permutation).	O

Hence,	O
our	O
results	O
support	O
that	O
the	O
balance	O
among	O
stearic,	O
DHA	O
and	O
EPA	O
could	O
influence	O
the	O
IFNγ-CD4_+	B
response.	O

For	O
example,	O
in	O
this	O
study,	O
module	O
15	O
contained	O
lipids	O
from	O
various	O
subclasses	O
with	O
a	O
C22:6	B
fatty	O
acyl	O
side	O
chain;	O
this	O
module	O
was	O
strongly	O
associated	O
with	O
sex.	O

The	O
top	O
2	O
important	O
variables	O
(isopropanol	O
and	O
glycine)	B
were	O
used	O
to	O
build	O
classification	O
models,	O
the	O
AUC	O
value	O
was	O
0.983	O
and	O
95%	O
confidence	O
interval	O
(CI)	O
was	O
0.933~1.	O

Commercial	O
standards	O
for	O
225	O
oxylipins,	B
14	O
bile	O
acids,	O
8	O
sterols,	O
29	O
fatty	O
acids,	O
and	O
13	O
endocannabinoids	B
(given	O
that	O
their	O
in-source	O
fragments	O
may	O
be	O
isobaric	O
with	O
oxylipins)	B
were	O
injected	O
as	O
neat	O
solutions.	O

3,7-O	B
-Digluc	I
(C,	O
F)	O
after	O
the	O
injection	O
in	O
the	O
ion	O
mobility-MS	O
interface	O
(SelexION)	O
of	O
a	O
standard	O
mixture	O
(concentration	O
100 ng/mL)	O
or	O
a	O
urine	O
sample	O
from	O
a	O
treated	O
volunteer.	O

In	O
summary,	O
we	O
evaluated	O
the	O
association	O
between	O
15	O
estrogen	B
metabolites	O
and	O
prostate	O
cancer	O
risk	O
in	O
a	O
small	O
case-control	O
study.	O

	O
Calibration	O
series	O
and	O
QC	O
samples	O
were	O
prepared	O
by	O
pipetting	O
50	O
μL	O
of	O
diluted	O
pooled	O
SR	O
samples	O
in	O
a	O
well-plate,	O
adding	O
25	O
μL	O
of	O
the	O
multianalyte	O
mixture	O
of	O
labeled	O
internal	O
standards	O
at	O
fixed	O
concentration	O
and	O
25	O
μL	O
of	O
the	O
corresponding	O
calibrator	O
solution	O
(both	O
prepared	O
in	O
methanol),	B
and	O
making	O
up	O
the	O
total	O
volume	O
to	O
150	O
μL	O
by	O
adding	O
methanol	B
to	O
maintain	O
1:2	O
water/methanol	O
proportion.	O

We	O
also	O
observed	O
asymmetries	O
in	O
the	O
correlations	O
relating	O
to	O
ceramides	B
with	O
different	O
N-linked	O
fatty	O
acids	O
(	O
and	O
).	O

In	O
the	O
tumor	O
group,	O
PE(P-16:0/0:0)	B
exhibited	O
significant	O
relationships	O
with	O
Anaerotruncus	O
(p	O
-value	O
<	O
0.0001)	O
and	O
Intestinimonas	O
(p	O
-value	O
<	O
0.01)	O
(;	O
).	O

At	O
this	O
point	O
we	O
have	O
identified	O
3	O
glycerophosphoserines,	B
1	O
glycerophosphocholine	B
and	O
1	O
glycerophosphoinositol,	B
all	O
in	O
significantly	O
lower	O
levels	O
in	O
HCC	O
patients.	O

A	O
prospective	O
case–control	O
study	O
nested	O
within	O
the	O
Prostate,	O
Lung,	O
Colorectal,	O
and	O
Ovarian	O
Cancer	O
Screening	O
Trial	O
examining	O
associations	O
between	O
the	O
risk	O
of	O
breast	O
cancer	O
in	O
postmenopausal	O
women	O
not	O
currently	O
using	O
menopausal	O
hormone	O
therapy	O
and	O
serum	O
concentrations	O
of	O
15	O
estrogens	O
and	O
estrogen	B
metabolites,	O
in	O
unconjugated	O
and	O
conjugated	O
forms,	O
including	O
the	O
parent	O
estrogens	O
and	O
estrogen	B
metabolites	O
in	O
pathways	O
defined	O
by	O
irreversible	O
hydroxylation	O
at	O
the	O
C-2,	O
C-4,	O
or	O
C-16	O
positions	O
of	O
the	O
steroid	O
ring,	O
as	O
measured	O
by	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry.	O

Only	O
tyrosine	B
concentrations	O
were	O
positively	O
associated	O
with	O
ppBMI	O
in	O
both	O
cohorts,	O
similar	O
to	O
a	O
previous	O
report.	O

Free	O
NNAL	O
concentrations	O
ranged	O
from	O
20	O
to	O
635.8	O
pg/mL	O
(0.1	O
to	O
3.0	O
nM)	O
with	O
a	O
mean	O
of	O
151.6	O
pg/mL,	O
SEM	O
±	O
17.9	O
pg/mL	O
(0.7	O
±	O
0.1	O
nM),	O
conjugated	O
NNAL	O
concentrations	O
ranged	O
from	O
0.1	O
to	O
14.6	O
nM	O
with	O
a	O
mean	O
of	O
2.63	O
±	O
0.39	O
nM,	O
and	O
total	O
concentrations	O
ranged	O
from	O
0.2	O
nM	O
to	O
16.0	O
nM	O
with	O
a	O
mean	O
of	O
3.4	O
±	O
0.5	O
nM.	O
Urinary	O
creatinine	B
concentrations	O
for	O
the	O
60	O
subjects	O
were	O
determined	O
by	O
LC/MS	O
using	O
a	O
modification	O
of	O
a	O
previously	O
published	O
procedure	O
and	O
NNAL	O
values	O
were	O
then	O
corrected	O
for	O
urine	O
flow.	O

The	O
oxaloacetate	B
is	O
then	O
reduced	O
to	O
malate	B
catalyzed	O
by	O
cytosolic	O
malate	O
dehydrogenase.	O

To	O
test	O
this	O
hypothesis,	O
six	O
matched	O
replicate	O
samples	O
stored	O
(−80	O
°C)	O
for	O
up	O
to	O
eight	O
months	O
(short-term	O
storage)	O
or	O
for	O
3–4	O
years	O
(long-term	O
storage)	O
were	O
subjected	O
to	O
MeOH:	B

A)	O
MRM	O
profile	O
of	O
12	O
eicosanoid	B
and	O
docosanoid	B
synthetic	O
standards	O
(NPD1,	O
4-HDHA,	O
17-HDHA,	B
RVD1,	O
PGE_2	O
,	O
PGD_2	O
,	O
LTB_4	O
,	O
6-trans	O
LTB_4	O
(C1),	O
6-trans-12-epi-LTB_4	B
(C2),	O
12-HETE,	B
15-HETE,	B
5-HETE).	O

It	O
can	O
be	O
converted	O
to	O
glucose	B
for	O
more	O
energy.	O

Our	O
laboratory	O
has	O
previously	O
performed	O
a	O
series	O
of	O
pilot	O
studies	O
to	O
ensure	O
that	O
the	O
results	O
of	O
the	O
phthalate	B
analysis	O
of	O
such	O
samples	O
were	O
robust	O
and	O
likely	O
to	O
reflect	O
true	O
phthalate	B
exposure	O
at	O
time	O
of	O
collection.	O

The	O
percentage	O
change	O
is	O
defined	O
as	O
100	O
×	O
(exp(β)-1).	O

We	O
observed	O
3	O
metabolic	O
pathways	O
(phenylalanine,	O
histidine,	B
arginine	B
and	O
proline	B
metabolism)	O
to	O
be	O
significantly	O
getting	O
deregulated	O
in	O
ARD	O
subjects	O
with	O
respect	O
to	O
OW	O
(pathway	O
impact	O
threshold	O
>0.10).	O

Hydroxylation	O
seems	O
to	O
occur	O
at	O
the	O
methyl	O
site	O
(http://med.astrazeneca.co.jp/product/IF/ARI_IF.pdf),	O
but	O
the	O
possibility	O
of	O
hydroxylation	O
at	O
the	O
aromatic	O
or	O
methylene	B
sites	O
cannot	O
be	O
ruled	O
out.	O

In	O
contrast,	O
the	O
negative	O
correlations	O
of	O
lactate	B
with	O
tCho	O
and	O
tGlut	O
observed	O
in	O
E1A-Ras	O
transformed	O
cells	O
were	O
found	O
to	O
be	O
positive	O
when	O
they	O
were	O
present	O
in	O
the	O
brain	O
tumours.	O

The	O
loadings	O
of	O
PC	O
2	O
are	O
likely	O
due	O
to	O
nicotine	B
metabolites,	O
as	O
there	O
is	O
roughly	O
a	O
gradient	O
along	O
the	O
PC	O
2	O
direction	O
from	O
nonsmokers	O
to	O
smokers.	O

The	O
β-apo-13-carotenone	B
competed	O
for	O
9-cis	O
-retinoic	O
acid	O
binding	O
with	O
an	O
affinity	O
(7–8	O
nm)	O
identical	O
to	O
9-cis	O
-retinoic	O
acid	O
itself.	O

With	O
increasing	O
evidence	O
suggesting	O
that	O
ROS	O
may	O
be	O
involved	O
in	O
endometriosis	O
progression,	O
it	O
may	O
be	O
worthwhile	O
to	O
further	O
explore	O
the	O
role	O
of	O
proline	B
in	O
the	O
pathogenesis	O
of	O
the	O
disease.	O

In	O
the	O
HCC-related	O
metabolic	O
network	O
(Figure	O
),	O
eleven	O
biochemical	O
pathways,	O
including	O
energy	O
metabolism	O
like	O
glycolysis,	O
biosynthesis	O
of	O
amino	O
acids,	O
metabolisms	O
of	O
amino	O
acids,	O
pyruvate,	B
glycerolipid,	B
sphingolipid,	B
purine	B
and	O
butanoate,	B
and	O
TCA	O
cycle,	O
were	O
involved	O
in	O
pathological	O
changes	O
of	O
HCC	O
patients.	O

Varying	O
amounts	O
of	O
the	O
pooled	O
methanolic	B
extract	O
were	O
then	O
dispensed	O
into	O
new	O
microcentrifuge	O
tubes,	O
and	O
ballasted	O
with	O
7.5:1	B
MeOH/H_2	I
O	O
(v	O
/v	O
)	O
for	O
a	O
total	O
volume	O
of	O
700	O
µL.	O
The	O
limiting-dilution	O
and	O
concentration-specific	O
study	O
differed	O
in	O
the	O
volumes	O
of	O
pooled	O
methanolic	B
extract	O
used,	O
corresponding	O
to	O
different	O
plasma	O
concentrations.	O

The	O
activity	O
of	O
SDH	O
was	O
estimated	O
spectrophotometrically	O
from	O
the	O
reduction	O
of	O
the	O
electron	O
acceptor	O
methyl	B
thiazolyl	I
tetrazolium	I
(MTT)	O
or	O
dichlorophenolindophenol	B
(DCPIP).	O

Based	O
on	O
multiple	O
logistic	O
regression	O
models,	O
odds	O
of	O
recurrence	O
increased	O
5.79	O
fold	O
(95%	O
CI:	O
1.65	O
to	O
20.29,	O
p = 0.006)	O
when	O
cysteine	B
levels	O
increased	O
from	O
343	O
(lower	O
quartile,	O
henceforth	O
Q1)	O
to	O
436	O
(upper	O
quartile,	O
henceforth	O
Q3).	O

The	O
overall	O
CV2	O
procedure	O
was	O
performed	O
500	O
times,	O
and	O
only	O
those	O
m/z	O
signals	O
that	O
were	O
selected	O
in	O
at	O
least	O
80%	O
(risperidone	O
and	O
olanzapine)	B
and	O
95%	O
(quetiapine)	O
of	O
the	O
iterations	O
were	O
considered	O
relevant	O
for	O
distinguishing	O
between	O
responders	O
and	O
non-responders.	O

This	O
study	O
strengthens	O
the	O
emerging	O
link	O
between	O
fatty	O
acid	O
metabolism	O
and	O
PCa	O
progression	O
and	O
suggests	O
that	O
measuring	O
levels	O
of	O
medium-	O
and	O
long-chain	O
acylcarnitines	B
in	O
pre-operative	O
patient	O
plasma	O
may	O
provide	O
a	O
basis	O
for	O
improving	O
patient	O
stratification.	O

The	O
metabolism	O
of	O
estrone	B
sulfate	I
in	O
normal	O
males.	O

The	O
extracted	O
ion	O
chromatograms	O
of	O
representative	O
ISTDs	O
and	O
some	O
endogenous	O
metabolites	O
when	O
HILIC	O
is	O
used	O
following	O
Methanol	B
precipitation	O
(A),	O
Methanol-Ethanol	B
(1:1)	I
precipitation	O
(B),	O
MTBE	B
extraction	O
(C),	O
and	O
MTBE-SPE	O
fractionation	O
(D)	O
methods.	O

It	O
did	O
not	O
activate	O
the	O
LXRα	O
receptor,	O
but	O
interestingly	O
its	O
precursors	O
3β-hydroxycholest-5-en-26-oic	B
acid	I
and	O
3β,7α-dihydroxycholest-5-en-26-oic	B
acid	I
did	O
activate	O
LXR	O
in	O
the	O
luciferase	O
assay.	O

h	O
∥2	O
∥2	O
∥	O
∥	O
2	O
2	O
+	O
Pλ	O
Pλ	O
P	O
P	O
λ	O
λ	O
(ah)	O
(	O
ah	B
ah	I
ah	I
a	O
a	O
h	O
h	O
)	O
,	O
	O
where	O
‖·‖_2	O
is	O
the	O
Frobenius	O
norm	O
between	O
the	O
current	O
cross	O
product	O
matrix	O
(M_h	O
=	O
X_T	O
_h	O
Y_h	O
)	O
and	O
the	O
loading	O
vectors	O
(a_h	O
,	O
b_h	O
);	O
P_λ	O
(a_h	O
)	O
=	O
sign	O
(a_h	O
)	O
(a_h	B
−	I
λ)_+	I
is	O
the	O
soft-thresholding	O
function	O
that	O
approximates	O
the	O
Lasso	O
penalty	O
function.	O

The	O
Q	O
Exactive	O
mass	O
spectrometer	O
was	O
operated	O
in	O
positive	O
ion	O
mode	O
using	O
electrospray	O
ionization,	O
scanning	O
in	O
Full	O
MS	O
mode	O
(1	O
μscan)	O
from	O
100	O
to	O
1500	O
m/z	O
at	O
70,000	O
resolution,	O
with	O
4	O
kV	B
spray	O
voltage,	O
45	O
sheath	O
gas,15	O
auxiliary	O
gas.	O

HMDB	O
and	O
LIPID	O
MAPS	O
taxonomies	O
indicated	O
that	O
the	O
most	O
enriched	O
chemical	O
groups	O
of	O
candidate	O
biomarkers	O
were	O
carboxylic	B
acids,	I
amino	O
acids,	O
fatty	O
acyls,	O
fatty	O
acids	O
and	O
conjugates,	O
pyrimidines,	B
and	O
nucleosides	O
and	O
analogues.	O

We	O
found	O
that	O
lactic	B
acid	I
was	O
significantly	O
higher	O
in	O
the	O
patients	O
with	O
papillary	O
thyroid	O
carcinoma,	O
and	O
lipid	O
was	O
significantly	O
decreased.	O

Also,	O
3-hydroxybutirate	B
is	O
downregulated	O
in	O
cirrhotic	O
patients	O
(G4)	O
as	O
compared	O
to	O
G0	O
samples	O
which	O
has	O
been	O
already	O
observed	O
in	O
hepatitis	O
B	O
virus-infected	O
cirrhosis	O
and	O
alcoholic	O
cirrhosis	O
patients	O
by	O
using	O
_1	O
H	O
NMR-based	O
metabonomics.	O

Further	O
estrogen-quinone-methide-DNA	B
adduct	O
is	O
shown	O
to	O
be	O
present	O
in	O
human	O
breast	O
tissue.	O

(A)	O
Example	O
of	O
assessment	O
of	O
the	O
diagnostic	O
performance	O
through	O
ROC	O
analysis	O
obtained	O
for	O
PC3	O
vs	O
PNT2	O
at	O
pH7	O
(2-pentadecanone	O
(AUC = 1)	O
and	O
2-methylundecanal	B
(AUC = 0.84))	O
and	O
at	O
pH2	O
(4-methylheptan-2-one	O
(AUC = 0.89)	O
and	O
benzoic	B
acid	I
(AUC = 0.77).	O

There	O
were	O
no	O
significant	O
differences	O
in	O
ADMA	B
between	O
groups.	O

We	O
did	O
not	O
include	O
patients	O
taking	O
tenofovir	O
alafenamide	B
fumarate	I
in	O
the	O
darunavir/cobicistat	O
group,	O
which	O
would	O
be	O
desirable	O
for	O
a	O
better	O
analysis	O
of	O
the	O
impact	O
of	O
tenofovir	O
alafenamide	B
fumarate	I
on	O
lipid	O
disturbances.	O

In	O
our	O
study,	O
the	O
decrease	O
in	O
plasma	O
tryptophan	B
might	O
be	O
indicative	O
of	O
its	O
metabolic	O
conversion	O
into	O
serotonin,	B
which	O
could	O
enhance	O
cell	O
proliferation	O
and	O
vascular	O
remodelling	O
in	O
PAH.	O

The	O
tGlut	O
pool	O
correlated	O
positively	O
with	O
lactate	B
in	O
all	O
tumour	O
types,	O
including	O
oligodendrogliomas,	O
whereas	O
in	O
all	O
tumour	O
types	O
there	O
was	O
a	O
negative	O
correlation	O
between	O
tGlut	O
and	O
the	O
1.3ppm	O
fatty	O
acid	O
peak.	O

LDL	B
cholesterol	I
levels	O
also	O
correlated	O
positively	O
with	O
SM	O
OH-C22:1	B
(r	O
=	O
0.51).	O

This	O
is	O
now	O
considered	O
as	O
a	O
characteristic	O
feature	O
for	O
aberrant	O
choline	B
phospholipid	I
metabolisms	O
in	O
cancers.	O

In	O
addition,	O
the	O
metabolomic	O
platform	O
we	O
used	O
permitted	O
identification	O
of	O
a	O
large	O
number	O
of	O
metabolites	O
(>500)	O
and	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
biological	O
response	O
to	O
β-carotene	B
supplementation.	O

Our	O
findings	O
supported	O
the	O
identification	O
of	O
8	O
metabolites	O
that	O
were	O
discriminatory	O
between	O
CRC	O
and	O
adjacent	O
mucosa	O
in	O
previous	O
reports	O
and	O
included	O
2-aminoadipate,	B
isobar:	O
betaine	B
aldehyde,	I
N-methyldiethanolamine,	B
alpha-hydroxyisovalerate,	B
cys-gly,	B
oxidized,	O
deoxycholate,	B
7-ketodeoxycholate,	B
sorbitol,	B
and	O
asparagine	B
[,	O
,	O
].	O

(T_0	O
 = 10:30 a.m.).	B

These	O
metabolites	O
covalently	O
bind	O
to	O
estrogen	B
receptors,	O
thus	O
stimulating	O
cell	O
proliferation.	O

Using	O
this	O
approach,	O
estrone	B
(E1)	O
and	O
estradiol	B
(E2)	O
were	O
detected	O
in	O
plasma	O
(0.5 mL)	O
from	O
healthy	O
women	O
and	O
those	O
with	O
PAH	O
but	O
downstream	O
metabolites	O
16-hydroxy-E1,	B
16-hydroxy-E2,	I
2-methoxy-E1	I
and	O
4-methoxy-E1	B
were	O
only	O
detected	O
in	O
plasma	O
from	O
diseased	O
patients.	O

Reductions	O
in	O
total	O
body	O
fat	O
with	O
IER	O
were	O
less	O
than	O
those	O
previously	O
seen	O
with	O
CER:	B
–7.96	O
(SD	O
5.04)	O
vs.	O
–11.23	O
(SD	O
3.78)	O
%,	O
which	O
is	O
consistent	O
with	O
the	O
lesser	O
overall	O
energy	O
restriction	O
of	O
45 %	O
with	O
IER	O
vs.	O
60 %	O
with	O
CER	B
(Additional	O
file	O
1:	O
Table	O
S4).	O

Further	O
information	O
about	O
spectral	O
fragmentation	O
patterns	O
(MS/MS)	O
of	O
the	O
PC(18:1/20:3),	B
PC(18:1/22:5),	B
PC(18:1/22:6)	B
and	O
SM(18:1/18:2)	B
is	O
explained	O
in	O
detail	O
as	O
follows.	O

Proline	B
QC	O
samples	O
prepared	O
in	O
pooled	O
human	O
serum	O
which	O
were	O
exposed	O
for	O
three	O
cycles	O
of	O
freeze	O
(at	O
−80	O
°C)	O
and	O
thaw	O
(room	O
temperature)	O
were	O
compared	O
with	O
freshly	O
prepared	O
samples	O
at	O
the	O
same	O
concentrations.	O

Analysis	O
of	O
spectral	O
data	O
by	O
PLS-DA	O
revealed	O
significant	O
separation	O
between	O
subjects	O
with	O
low	O
or	O
high	O
plasma	O
cystathionine	B
concentrations.	O

In	O
either	O
case,	O
higher	O
levels	O
of	O
these	O
biologically	O
active	O
compounds	O
mediated	O
by	O
OEP	O
ingestion	O
warrant	O
further	O
investigation	O
in	O
acute	O
or	O
post-prandial	O
studies	O
specifically	O
targeting	O
LDL	B
cholesterol	I
oxidation	O
and	O
cognitive	O
function.	O

Previous	O
studies	O
have	O
shown	O
that	O
cigarette	O
smoke	O
directly	O
depletes	O
the	O
levels	O
of	O
circulating	O
antioxidants	O
and	O
vitamins,	O
such	O
as	O
ascorbate,	B
alpha-tocopherol,	B
beta-carotene,	B
lycopene,	B
and	O
retinol	B
[,].	O

Briefly,	O
in	O
each	O
run,	O
the	O
elastic	O
net	O
method	O
was	O
applied	O
to	O
N-1	O
of	O
the	O
samples	O
(training	O
sets)	O
and	O
the	O
model	O
obtained	O
was	O
applied	O
to	O
the	O
remaining	O
excluded	O
sample	O
(intra-validation	O
sets)	O
in	O
case	O
of	O
the	O
SATIN	B
dataset.	O

	O
depicts	O
a	O
summary	O
of	O
the	O
immunoblotting	O
and	O
immunohistochemical	O
profiling	O
of	O
enzymes	O
that	O
can	O
affect	O
anthocyanin	B
metabolism	O
in	O
human	O
oral	O
mucosa.	O

Thereby,	O
the	O
phosphatidylcholine	B
(PC)	O
internal	O
standard	O
including	O
its	O
associated	O
lyso-forms	O
(LPC),	O
ceramides	B
(Cer),	O
galactosylceramides	B
(GalCer),	O
lactosylceramides	B
(LacCer),	O
and	O
sphingomyelins	B
(SM)	O
were	O
detected	O
as	O
[M + H]_+	O
ions,	O
whereas	O
the	O
free	O
fatty	O
acids,	O
phosphatidylethanolamine	B
(PE),	O
phosphatidylinositol	B
(PI),	O
phosphatidylglycerol	B
(PG),	O
phosphatidylserine	B
(PS)	O
and	O
their	O
lyso	O
forms	O
(LPE,	O
LPI,	O
LPG	O
and	O
LPS,	B
respectively),	O
sulfatides	B
(Su)	O
and	O
monosialo-gangliosides	B
(SGL)	O
were	O
detected	O
as	O
[M − H]_−	O
ions.	O

Homonuclear	O
two-dimensional	O
(2D)	O
experiments	O
such	O
as	O
_1	O
H–_1	O
H	O
double	O
quantum	O
filtered	O
correlation	O
spectroscopy	O
(DQF-COSY)	O
and	O
_1	O
H–_1	O
H	O
total	O
correlation	O
spectroscopy	O
(TOCSY)	O
experiments	O
were	O
performed	O
for	O
both	O
ultrafiltered	O
and	O
protein	O
precipitated	O
serum	O
samples	O
using	O
methanol	B
to	O
aid	O
in	O
peak	O
assignment.	O

Hecogenin	O
at	O
5	O
µm	O
inhibited	O
anastrozole	B
glucuronidation	O
activity	O
by	O
38.4%	O
in	O
pooled	O
HLMs	O
(P	O
<	O
0.01)	O
and	O
62.2%	O
in	O
expressed	O
UGT1A4	O
(P	O
<	O
0.01).	O

The	O
mobile	O
phase	O
was	O
delivered	O
at	O
a	O
rate	O
of	O
0.5	O
mL/min	O
by	O
gradient	O
elution	O
with	O
0.1	O
%	O
aqueous	O
formic	B
acid	I
and	O
acetonitrile.	B

For	O
serum,	O
the	O
residue	O
was	O
dissolved	O
in	O
100	O
μL	O
of	O
methanol,	B
and	O
2	O
μL	O
was	O
injected	O
into	O
the	O
LC-MS/MS	O
system.	O

SM24:0	B
was	O
detectable	O
only	O
in	O
the	O
extracts	O
of	O
protocols	O
(i)–(iii).	O

Leucine	B
enkephalin	I
was	O
infused	O
via	O
the	O
reference	O
probe	O
as	O
lockspray	O
to	O
ensure	O
m/z	O
accuracy.	O

While	O
we	O
detected	O
changes	O
in	O
lactic	B
acid,	I
alanine,	B
glutamine,	B
and	O
glutamate	B
as	O
expected	O
from	O
skeletal	O
muscle	O
activity,	O
a	O
number	O
of	O
unanticipated	O
metabolites	O
were	O
also	O
determined	O
to	O
be	O
significantly	O
altered	O
including	O
Krebs	O
cycle	O
intermediates,	O
amino	O
acids	O
that	O
have	O
not	O
been	O
previously	O
implicated	O
in	O
transport,	O
and	O
a	O
few	O
oxidized	O
fatty	O
acids.	O

Heat	O
map	O
of	O
the	O
correlations	O
between	O
metabolites	O
that	O
changed	O
significantly	O
(P	O
<	O
0.05)	O
in	O
response	O
to	O
β-carotene	B
supplementation.	O

An	O
alternative	O
noninvasive	O
biomarker	O
of	O
impaired	O
renal	O
health	O
is	O
salivary	O
creatinine	B
for	O
which	O
the	O
DOR	O
value	O
for	O
the	O
same	O
classification	O
of	O
CKD	O
as	O
applied	O
herein	O
was	O
17.8,	O
cf	O
.	O

Similar	O
to	O
the	O
hopanoid	B
found	O
in	O
fecal	O
lipidome,	O
these	O
two	O
plasma	O
hopanoids	B
were	O
also	O
down-regulated	O
post-H.	O
pylori	O
eradication	O
(File	O
).	O

The	O
ionspray	O
voltage	O
and	O
source	O
temperature	O
were	O
−3.0	O
kV	B
and	O
500	O
°C,	O
respectively.	O

By	O
contrast,	O
we	O
found	O
no	O
clear	O
difference	O
for	O
3β-HSD	B
activity.	O

As	O
expected,	O
the	O
most	O
abundant	O
was	O
arachidonic	B
acid	I
(20:4n6),	O
a	O
main	O
energy	O
source	O
for	O
activated	B
immunologic	O
cells	O
that	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
cellular	O
metabolism	O
during	O
inflammation	O
[,].	O

Methadone	B
is	O
another	O
opioid	O
that	O
may	O
be	O
reported	O
as	O
false	O
negative	O
due	O
to	O
between-individual	O
differences	O
in	O
metabolism.	O

Proteins	O
were	O
precipitated	O
with	O
100 μL	O
of	O
methanol,	B
filtered	O
through	O
a	O
0.22-μm	O
hydrophilic	B
membrane	O
(Multiscreen	O
HTS™,	O
Millipore,	O
Molsheim,	O
France),	O
derivatized	O
with	O
butanolic	B
1 N	O
HCl,	O
and	O
analyzed	O
by	O
LC-tandem	O
MS	O
(Varian	O
1200	O
MS,	O
Agilent	O
Technologies,	O
Santa	O
Clara,	O
CA,	O
USA).	O

The	O
lower	O
phase	O
was	O
subjected	O
to	O
three	O
additional	O
extractions	O
each	O
including	O
3-min	O
vortex	O
and	O
5-min	O
centrifugation	O
steps	O
with:	O
(i)	O
2	O
mL	O
of	O
the	O
upper	O
phase	O
of	O
a	O
prepared	O
solution	O
of	O
MTBE/methanol/water	O
(10:3:2.5,	O
v/v/v),	O
(ii)	O
2	O
mL	O
ethyl	B
acetate	I
containing	O
saturated	O
NaCl	O
and	O
10	O
μL	O
HCl	O
10	O
M	O
and	O
(iii)	O
2	O
mL	O
ethyl	B
acetate.	I

The	O
results	O
indicated	O
that	O
in	O
ever	O
smokers	O
low	O
level	O
of	O
xanthine	B
and	O
low	O
level	O
of	O
hypoxanthine	B
showed	O
joint	O
effect	O
with	O
smoking	O
on	O
PLP	O
risk	O
(OR=12.46;	O
95%	O
CI,	O
2.04-75.95,	O
P	O
<0.01	O
and	O
OR=7.27;	O
95%	O
CI,	O
1.57-33.68,	O
P	O
=0.01	O
respectively)().	O

BRB,	O
which	O
served	O
as	O
the	O
active	O
agents	O
in	O
the	O
gel,	O
contain	O
numerous	O
compounds	O
with	O
potential	O
chemopreventive	O
activities,	O
including	O
anthocyanins,	B
ellagic,	O
ferulic,	O
and	O
p	O
-coumeric	O
acids,	O
vitamins	O
(ascorbic	O
acid,	O
α	O
and	O
β-carotene	B
and	O
folate),	O
and	O
minerals.	O

The	O
median	O
duration	B
of	O
the	O
treatment	O
in	O
DT-MDD	O
was	O
8	O
weeks	O
(range	O
4–16).	O

There	O
was	O
one	O
exception	O
for	O
this	O
internal	O
standard	O
selection	O
scheme;	O
we	O
selected	O
deuterated	O
JWH-018	O
parent	O
analyte	O
as	O
an	O
internal	O
standard	O
for	O
JWH-210	B
5-hydroxyindole	I
after	O
observing	O
poor	O
QC	O
performance	O
with	O
JWH-018	B
5-hydroxyindole-d_9	I
as	O
internal	O
standard.	O

In	O
the	O
present	O
study,	O
we	O
evaluated	O
patients	O
with	O
phosphoglucomutase	O
1	O
deficiency,	O
which	O
has	O
been	O
identified	O
previously	O
as	O
glycogenosis	B
type	O
XIV	O
(Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
database	O
number,	O
612934),	O
and	O
with	O
glycosylation	O
abnormalities	O
affecting	O
both	O
the	O
attachment	O
and	O
the	O
processing	O
of	O
N-glycans.	B

Due	O
to	O
the	O
importance	O
of	O
PCA	O
formation	O
in	O
anthocyanin	B
metabolism	O
and	O
bioactivation,	O
a	O
LC-MS/MS	O
method	O
was	O
developed	O
to	O
determine	O
residual	O
PCA	O
levels	O
in	O
post-BRB	O
rinse	O
saliva.	O

The	O
polyphenolic	O
content	O
was	O
unchanged	O
over	O
the	O
course	O
of	O
the	O
study	O
and	O
in	O
real	O
terms	O
is	O
equivalent	O
to	O
the	O
daily	O
combined	O
consumption	O
of	O
3	O
whole	O
cups	O
of	O
fresh	O
blueberries	O
(148	O
g/cup)	O
and	O
1–1/3	O
cups	O
of	O
brewed	O
green	O
tea	O
with	O
its	O
associated	O
caffeine	B
content	O
(assuming	O
8	O
fl	O
oz	O
or	O
247	O
mls	O
per	O
cup).	O

We	O
were	O
able	O
to	O
follow	O
the	O
dynamics	O
of	O
starch	O
hydrolysis	O
and	O
that	O
of	O
further	O
metabolites	O
downstream	O
of	O
glucose.	B

In	O
addition,	O
LysoPC	O
(18:2)	O
and	O
glycine	B
were	O
selected	O
and	O
validated	O
as	O
strong	O
baseline	O
predictors	O
for	O
the	O
risk	O
of	O
developing	O
IGT	O
and/or	O
T2D	O
in	O
a	O
prospective	O
analysis.	O

Another	O
example	O
of	O
the	O
EV-enriched	O
metabolites	O
were	O
ornithine	B
and	O
spermidine.	B

C	O
illustrates	O
the	O
improvement	O
in	O
separation	O
observed	O
when	O
using	O
0.5%	O
v/v	O
isobutylamine	B
(IsoButAm)	O
as	O
a	O
modifier	O
additive	O
rather	O
than	O
5%	O
water	O
(Wat).	O

The	O
pyrrolidine	B
ring	O
was	O
metabolized	O
resulting	O
in	O
an	O
oxo,	O
two	O
hydroxy,	B
and	O
one	O
dihydroxy	B
metabolite.	O

To	O
address	O
this	O
problem,	O
the	O
linear	O
gradient	O
of	O
the	O
mobile	O
phase	O
was	O
optimized	O
and	O
the	O
column	O
length	O
was	O
extended	O
from	O
50	O
to	O
100	O
mm,	O
enabling	O
the	O
chromatographic	O
separation	O
of	O
abiraterone	B
and	O
its	O
metabolites.	O

Acetonitrile,	B
HPLC	O
grade,	O
was	O
obtained	O
from	O
Merck	O
(Darmstadt,	O
Germany);	O
methanol	B
(HPLC	O
grade)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
Corporation	O
(Loughborough,	O
UK);	O
water	O
was	O
produced	O
by	O
a	O
Milli-Q	O
Ultra-pure	O
water	O
system	O
(Millipore,	O
Billerica,	O
USA);	O
formic	B
acid	I
was	O
of	O
HPLC	O
grade,	O
and	O
obtained	O
from	O
Honeywell	O
Company	O
(Morristown,	O
New	O
Jersey,	O
USA);	O
leucine	B
enkephalin	I
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Four	O
metabolites	O
were	O
found	O
to	O
be	O
elevated	O
in	O
both	O
HBV	O
and	O
HCV:	O
plasma	O
oleamide	B
(+300%,	O
+260%,	O
respectively),	O
urine	O
fucose	B
(+8%,	O
+8%,	O
respectively),	O
plasma	O
oleic	B
acid	I
(+6%,	O
+5%,	O
respectively),	O
and	O
urine	O
xylitol	B
(+11%,	O
+14%,	O
respectively).	O

The	O
combination	O
of	O
these	O
two	O
insulin	O
sensitizers	O
is	O
commonly	O
used	O
in	O
T2D.	O
Of	O
interest,	O
increase	O
in	O
insulin	O
sensitivity	O
was	O
not	O
significantly	O
correlated	O
with	O
the	O
decline	O
in	O
fasting	O
plasma	O
phenylalanine	B
or	O
tyrosine.	B

Serum	O
total	O
25OHD	O
concentration	O
was	O
the	O
only	O
vitamin	B
D	I
parameter	O
found	O
to	O
have	O
no	O
specific	O
correlation	O
with	O
any	O
of	O
the	O
inflammatory	O
markers.	O

All	O
7	O
healthy	O
young	O
adults	O
showed	O
circadian	O
variation	O
of	O
the	O
sum	O
of	O
cortisol	B
metabolites.	O

One	O
of	O
these	O
has	O
previously	O
been	O
identified	O
in	O
urine:	O
the	O
association	O
between	O
rs8056893	O
within	O
the	O
SLC7A9	O
(solute	O
carrier	O
family	O
7	O
member	O
9)	O
and	O
lysine	B
(P-value	O
 = 1.26×10_−8	O
)	O
.	O

However,	O
the	O
NIST	O
LC-MS/MS	O
method	O
quantified	O
3-epi-25(OH)D_3	B
in	O
all	O
four	O
levels	O
of	O
SRM	O
972,	O
and	O
this	O
value	O
could	O
be	O
used	O
to	O
adjust	O
or	O
correct	O
the	O
other	O
data	O
sets	O
for	O
the	O
presence	O
of	O
3-epi-25(OH)D_3	B
.	O

Previous	O
studies	O
have	O
reported	O
abnormal	O
levels	O
of	O
phospholipid	B
in	O
serum	O
[,	O
].	O

Reagent	O
grade	O
formic	O
and	O
perchloric	B
acid	I
were	O
from	O
Sigma	O
Chemicals	O
(St.	O
Louis,	O
MO,	O
USA)	O
and	O
Acros	O
Organics	O
(Morris	O
Plains,	O
NJ,	O
USA),	O
respectively.	O

Results	O
of	O
the	O
assay	O
reproducibility	O
study	O
for	O
16α-hydroxyestrone	B
(16α-OHE_1	I
).	I

We	O
bought	O
L-2-chlorophenylalanine	B
from	O
Hengbai	O
Biotechnology	O
Co	O
Ltd	O
(Shanghai,	O
China),	O
while	O
Methoxy	B
amination	O
hydrochloride	B
(chromatographic	O
grade),	O
pyridine	B
and	O
chloroform	B
(HPLC	O
grade)	O
were	O
from	O
Admas	O
(Shanghai,	O
China).	O

B.	O
Comparison	O
of	O
salivary	O
levels	O
of	O
the	O
predominant	O
BRB	O
anthocyanin	B
(cyanidin	I
3-rutinoside)	I
detected	O
over	O
time	O
following	O
rinsing	O
with	O
Rinses	O
I,	O
II	O
or	O
III	O
or	O
topical	O
intraoral	O
placement	O
of	O
a	O
10%	O
bioadhesive	O
BRB	O
gel.	O

The	O
colored	O
curves	O
represent	O
the	O
bins	O
at	O
0.83	O
ppm	O
(LDL1),	O
3.20	O
ppm	O
(choline)	O
and	O
2.30	O
ppm	O
(acetoacetate).	O

In	O
addition,	O
Ward	O
et	O
al.	O
suggested	O
that	O
20-HETE	B
plays	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
acute	O
ischaemic	O
stroke	O
and	O
subsequent	O
clinical	O
outcome.	O

Betaine	B
was	O
not	O
significantly	O
different	O
between	O
diabetic	O
and	O
non-diabetic	O
subjects,	O
despite	O
being	O
inversely	O
correlated	O
with	O
glucose	B
and	O
HbA1c.	O

Sample	O
preparation	O
was	O
conducted	O
using	O
aqueous	O
methanol	B
extraction	O
process	O
to	O
remove	O
the	O
protein	O
fraction	O
while	O
allowing	O
maximum	O
recovery	O
of	O
small	O
molecules.	O

Glu:	O
Glutamic	B
acid;	I
Met:	O
Methionine;	B
γ-Glu-Gly-Gly:	B
γ-glutamyl-glycine-glycine;	B
MLR:	O
Multiple	O
logistic	O
regression;	O
AUC:	O
Area	O
under	O
the	O
curve;	O
HCC-B:	O
Hepatitis	O
B	O
virus-related	O
HCC;	O
HCC-C:	O
Hepatitis	O
C	O
virus-related	O
HCC;	O
HCC:	O
Hepatocellular	O
carcinoma.	O

This	O
solution	O
was	O
again	O
applied	O
to	O
the	O
column	O
followed	O
by	O
a	O
wash	O
with	O
6	O
ml	O
of	O
10%	O
methanol.	B

Sodium	B
chloride	I
(NaCl)	O
was	O
from	O
VWR	O
(Leuven,	O
Belgium).	O

Intrarenal	O
dopamine	B
has	O
been	O
found	O
to	O
account	O
for	O
more	O
than	O
50%	O
of	O
the	O
kidney’s	O
salt	O
excretion	O
ability	O
and	O
is	O
therefore	O
of	O
great	O
importance	O
for	O
blood	O
pressure	O
control.	O

Ratios	O
of	O
2-pathway	O
EM	O
and	O
4-pathway	O
EM	O
to	O
16α-pathway	B
metabolites	O
significantly	O
increased	O
across	O
the	O
range	O
of	O
soy	O
intake	O
(p_trend	O
=0.01	O
for	O
each).	O

	O
Analytes,	O
neat	O
or	O
extracted	O
from	O
plasma,	O
decomposed	O
in	O
the	O
autosampler	O
after	O
reconstitution	O
in	O
acetonitrile	B
or	O
water.	O

(b)	O
The	O
carnitine	B
shuttle	O
is	O
used	O
to	O
transport	O
long	O
chain	O
FAs	O
into	O
the	O
mitochondria	O
to	O
undergo	O
β-oxidation	O
which	O
ultimately	O
leads	O
to	O
the	O
final	O
oxidation	O
product	O
(in	O
red),	O
acetyl-CoA.	B
(c)	O
Pathway	O
for	O
the	O
metabolism	O
of	O
SMs	O
(and	O
vice	O
versa)	O
to	O
S1P,	O
an	O
important	O
regulator	O
in	O
the	O
liver	O
for	O
fibrosis.	O

Since	O
these	O
metabolites	O
were	O
generally	O
present	O
in	O
high	O
concentrations	O
in	O
the	O
EVs	O
and	O
thus	O
amenable	O
to	O
measurement	O
from	O
low	O
sample	O
amounts,	O
one	O
focus	O
area	O
of	O
future	O
Pca	O
EV	O
biomarker	O
research	O
could	O
be	O
the	O
nucleic	O
acid,	O
particularly	O
the	O
purine	B
pathway,	O
metabolites.	O

Lower	O
(F1	O
downfield)	O
region	O
of	O
the	O
2D-HMBC	O
spectrum	O
of	O
the	O
metformin–methylglyoxal	B
reaction	O
product	O
in	O
DMSO-d	O
_6	O
.	O

The	O
overall	O
frequency	O
of	O
genetically	O
reduced	O
nicotine	B
metabolizers,	O
those	O
with	O
CYP2A6	O
decrease-	O
or	O
loss-of-function	O
alleles,	O
was	O
lower	O
in	O
the	O
NP	O
compared	O
to	O
the	O
SW	O
(P	O
=0.0006).	O

Furthermore,	O
leucine	B
acts	O
as	O
a	O
mTORC1	O
activator,	O
and	O
in	O
hepatic	O
cells	O
mTORC1	O
inhibits	O
the	O
CREBH-ApoA5	O
axis,	O
which	O
leads	O
to	O
blunted	O
ApoA5	O
production.	O

Recently,	O
Kim	O
et	O
al	O
.	O
reported	O
that	O
circulating	O
angiogenic	O
factors	O
measured	O
early	O
in	O
pregnancy	O
can	O
rule	O
out	O
the	O
development	O
of	O
severe	O
APO	O
among	O
patient	O
with	O
SLE	O
and/or	O
antiphospholipid	B
antibody	O
syndrome.	O

However,	O
to	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
study	O
in	O
patients	O
with	O
IBD	O
is	O
the	O
very	O
first	O
to	O
investigate	O
the	O
best	O
marker	O
of	O
vitamin	B
D	I
status	O
in	O
patients	O
with	O
chronic	O
inflammatory	O
disease,	O
and	O
an	O
important	O
first	O
step	O
to	O
further,	O
deeper	O
exploration.	O

Spectroscopic	O
biomarkers	O
with	O
correlative	O
properties	O
to	O
aggressiveness	O
include	O
choline	B
compounds	O
(CC),	O
Cit/Cre,	O
Cho/Cre,	O
(tCho	O
+	O
Cre)/Cit	O
and	O
tCho/Cre._15,22,29,32	O

For	O
a	O
key	O
to	O
the	O
identity	O
of	O
ibuprofen	B
metabolites,	O
refer	O
to	O
and	O
.	O
_1	O
H	O
and	O
_13	O
C	O
NMR	O
Chemical	O
Shifts	O
and	O
Coupling	O
Constants	O
(J/Hz)	O
for	O
Acetaminophen	B
and	O
Its	O
Metabolites	O
The	O
PCA	O
model	O
which	O
based	O
on	O
all	O
the	O
4290	O
urine	O
spectra	O
was	O
used	O
to	O
identify	O
413	O
samples	O
containing	O
acetaminophen	B
and	O
its	O
metabolites	O
with	O
the	O
remaining	O
3877	O
urine	O
spectra	O
not	O
showing	O
acetaminophen	B
metabolites.	O

In	O
this	O
process,	O
succinate	B
is	O
oxidised	O
to	O
fumarate	B
and	O
ubiquinone	B
is	O
reduced	O
to	O
ubiquinol.	B

The	O
column	O
can	O
be	O
further	O
stripped	O
with	O
an	O
additional	O
2-ml	O
aliquot	O
of	O
99.9%	O
ethanol	B
to	O
elute	O
more	O
hydrophobic	O
sterols	O
(SPE1-Fr-4).	O

The	O
synthetic	O
desamino-PhIP-K	B
adducts	O
exhibit	O
the	O
identical	O
t	O
_R	O
and	O
product	O
ion	O
spectra	O
(data	O
not	O
shown).	O

While	O
less	O
well	O
studied,	O
the	O
acyl-glycines	B
represent	O
a	O
growing	O
class	O
of	O
“orphan”	O
endogenous	O
lipids	O
which	O
are	O
candidate	O
ligands	O
for	O
a	O
variety	O
of	O
orphan	O
G-protein	O
coupled	O
receptors	O
.	O

Functional	O
differences	O
in	O
post-ERCP	O
serum	O
metabolic	O
networks	O
were	O
observed	O
immediately	O
after	O
ERCP	O
in	O
patients	O
who	O
developed	O
AP	B
compared	O
with	O
those	O
who	O
did	O
not.	O

In	O
the	O
present	O
study,	O
leukotriene	O
B_4	O
and	O
5-HETE	B
levels	O
were	O
significantly	O
lower	O
in	O
the	O
LC	O
group	O
than	O
the	O
control	O
group	O
and	O
the	O
leukocyte	O
number	O
in	O
the	O
LC	O
group	O
had	O
a	O
trend	O
toward	O
decrease	O
compared	O
to	O
the	O
control	O
group.	O

D-glutamic	B
acid	I
belongs	O
to	O
the	O
group	O
of	O
D-amino	O
acids,	O
which	O
are	O
metabolized	O
only	O
by	O
D-aspartate	B
oxidase	O
(DDO)	O
in	O
mammals	O
and	O
are	O
now	O
thought	O
to	O
be	O
naturally	O
occurring	O
physiologically	O
active	O
substances	O
and	O
biomarkers.	O

For	O
example,	O
K-RAS	O
activation	O
in	O
NSCLC	O
cells	O
was	O
metabolically	O
linked	O
with	O
the	O
decoupling	O
of	O
glycolysis	O
and	O
TCA	O
metabolism,	O
with	O
glutamine	B
supplying	O
increased	O
carbon	O
to	O
drive	O
the	O
TCA	O
cycle.	O

Thus,	O
we	O
used	O
the	O
“add-to-subtract”	O
method	O
to	O
exclude	O
glucose	B
signals	O
from	O
the	O
NMR	O
spectra:	O
(1)	O
we	O
added	O
1	O
μL	O
of	O
1M	O
D-glucose	B
in	O
PBS	O
to	O
each	O
sample	O
and	O
repeated	O
NMR	O
measurement	O
with	O
identical	O
experimental	O
parameters,	O
leading	O
to	O
a	O
total	O
of	O
302	O
spectra	O
for	O
151	O
patients	O
(151	O
original,	O
151	O
with	O
additional	O
glucose);	B
(2)	O
using	O
Topspin’s	O
multiple	O
display,	O
we	O
determined	O
the	O
corresponding	O
scaling	O
factor	O
between	O
Spectrum	O
2	O
and	O
Spectrum	O
1	O
for	O
each	O
sample	O
that	O
ensures	O
elimination	O
of	O
the	O
glucose	B
signal	O
upon	O
subtraction;	O
(3)	O
then	O
the	O
exported	O
Spectra	O
1	O
and	O
2	O
for	O
each	O
sample	O
were	O
aligned	O
using	O
“icoshift”	O
on	O
the	O
glucose	B
peaks	O
at	O
3.37–3.44 ppm	O
and	O
then	O
along	O
10	O
equal	O
segments;	O
and	O
(4)	O
for	O
each	O
sample	O

used	O
transition	O
319	O
301	O
([M-H-H_2	O
O]-)	O
as	O
a	O
surrogate	O
of	O
20-HETE.	B

Body	O
Mass	O
Index	O
(BMI),	O
use	O
of	O
NSAIDs,	O
presence	O
of	O
diabetes,	O
family	O
history	O
of	O
prostate	O
cancer	O
or	O
presence	O
of	O
BPH	O
did	O
not	O
affect	O
estrogen	B
concentrations.	O

Colorectal	O
cancers	O
(CRC)	O
are	O
associated	O
with	O
perturbations	O
in	O
cellular	O
amino	O
acids,	O
nucleotides,	O
pentose-phosphate	B
pathway	O
carbohydrates,	O
and	O
glycolytic,	B
gluconeogenic,	B
and	O
tricarboxylic	B
acid	I
intermediates.	O

As	O
early	O
as	O
in	O
the	O
mid-70s,	O
it	O
had	O
been	O
established	O
that	O
choline	O
acetyltransferase	O
activity	O
is	O
much	O
more	O
reduced	O
in	O
brain	O
tissue	O
from	O
AD	O
patients	O
than	O
in	O
age-matched	O
controls	O
–	O
an	O
observation	O
commonly	O
known	O
as	O
cholinergic	B
deficit	O
in	O
AD	O
.	O

Similar	O
to	O
TB	O
patients,	O
TB-DM	O
was	O
associated	O
with	O
low	O
levels	O
of	O
citrulline,	B
histidine,	B
ornithine	B
and	O
tryptophan,	B
among	O
others.	O

The	O
prognostic	O
metabolite	O
biomarker	O
inositol	B
cyclic	I
phosphate	I
was	O
found	O
to	O
be	O
statistically	O
significant	O
only	O
when	O
the	O
analysis	O
was	O
focused	O
on	O
the	O
undifferentiated	O
regions	O
of	O
soft	O
tissue	O
sarcoma	O
samples.	O

Human	O
lung	O
adenocarcinoma	O
A549	O
cells	O
were	O
cultured	O
in	O
RPMI	O
media	O
containing	O
10.75	O
mM	O
[U–_13	B
C]-glucose	I
(Sigma–Aldrich,	O
St.	O
Louis)	O
and	O
10%	O
dialyzed	O
fetal	O
calf	O
serum	O
as	O
previously	O
described.	O

Table 	O
summarizes	O
the	O
observed	O
changes	O
in	O
PtdEtn	O
species	O
according	O
to	O
MS	O
disease	O
state	O
and	O
duration.	B

We	O
have	O
tested	O
four	O
non-selective	O
serotonin	B
reuptake	O
inhibitors	O
(SSRIs)	O
and	O
σ1	O
receptor	O
agonists	O
with	O
reported	O
affinity	O
to	O
human	O
σ1	O
receptors,	O
fluvoxamine	B
(Luvox),	O
fluoxetine	B
(Prozac),	O
citalopram	B
(Celexa)	O
and	O
dextromethorphan	B
(DXM),	O
[,	O
]	O
for	O
growth	O
inhibition	O
against	O
N	O
.	O

Methionine	B
is	O
an	O
essential	O
amino	O
acid	O
produced	O
in	O
plants	O
only	O
from	O
TCA-cycle	O
intermediates.	O

Comparison	O
of	O
ESI	O
sensitivity	O
for	O
NNAL,	O
NNAL	O
acetate,	B
and	O
NNAL	O
hexanoate	B
with	O
different	O
HPLC	O
mobile	O
phase	O
compositions.	O

By	O
visual	O
inspection	O
of	O
such	O
a	O
modified	O
GGM	O
we	O
could	O
integrate	O
the	O
unknown	O
metabolites	O
X-11444	O
and	O
12844,	O
which	O
were	O
strongly	O
associated	O
with	O
NT-proBNP	O
in	O
both	O
fluids,	O
together	O
with	O
11-ketoetiocholanolone	B
glucuronide	I
into	O
a	O
steroid	O
metabolite	O
cascade	O
(Fig. ).	O

Based	O
on	O
the	O
cholesteryl	B
esters	I
ChoE(18:1),	I
ChoE(18:2)	B
and	O
ChoE(20:4),	B
and	O
complemented	O
by	O
PE(16:0/18:1),	B
SM(d18:1/23:0),	B
SM(42:3)	B
and	O
TG(54:1),	B
we	O
have	O
built	O
a	O
robust	O
stool	O
metabolomic	O
signature	O
with	O
an	O
AUC	O
value	O
of	O
0.821	O
(sensitivity	O
0.833	O
and	O
specificity	O
0.800).	O

Similar	O
patterns	O
were	O
also	O
detected	O
between	O
recurrent	O
and	O
non-recurrent	O
AF	B
patients.	O

This	O
finding	O
is	O
consistent	O
with	O
results	O
reported	O
by	O
,	O
which	O
suggest	O
that	O
1-hydroxypyrene	B
is	O
not	O
an	O
unequivocal	O
biomarker	O
of	O
exposure	O
to	O
atmospheric	O
PAHs	O
in	O
atmospheric	O
scenarios	O
relevant	O
to	O
the	O
general	O
population.	O

Since	O
glutamate	B
and	O
pyroglutamate	B
are	O
interconvertible	O
during	O
GC–MS	O
derivatization,	O
these	O
metabolites	O
were	O
combined.	O

Finally,	O
an	O
in	O
vitro	O
study	O
of	O
cell	O
viability	O
under	O
oxidative	O
stress	O
showed	O
that	O
cell	O
survival	O
was	O
higher	O
in	O
the	O
presence	O
of	O
reactive	O
sulfide	B
species	O
than	O
in	O
their	O
absence.	O

It	O
remains	O
to	O
be	O
elucidated	O
whether	O
the	O
apparently	O
elevated	O
H_2	O
S	O
concentrations	O
observed	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
is	O
playing	O
a	O
protective	O
or	O
detrimental	O
role.	O

Decreased	O
U-_13	O
C_6	B
-glucose	I
incorporation	O
into	O
palmitate	B
in	O
pyruvate	O
carboxylase	O
(PC)	O
knockdown	O
cell	O
lines	O
derived	O
from	O
the	O
MDA-MB-231	O
breast	O
cancer	O
cell	O
line.	O

Thus,	O
any	O
metabolite	O
biomarkers	O
discovered	O
from	O
aqueous	O
methanol	B
extracts	O
could	O
be	O
readily	O
implemented	O
into	O
the	O
current	O
clinical	O
workflow.	O

50	O
μL	O
of	O
urine	O
was	O
diluted	O
with	O
200	O
μL	O
of	O
methanol	B
and	O
centrifuged	O
at	O
13,200	O
×	O
g	O
for	O
15	O
min	O
at	O
4°C.	O

The	O
TMAO	B
assay	O
was	O
linear	O
up	O
to	O
0.25	O
ng	O
injected	O
on	O
column.	O

Of	O
note,	O
we	O
did	O
not	O
have	O
adequate	O
power	O
to	O
reject	O
the	O
null	O
hypothesis	O
for	O
indoxyl	B
sulfate,	I
hippuric	B
acid,	I
and	O
p-cresyl	B
sulfate	I
(PCS).	O

In	O
normal	O
renal	O
tubules,	O
creatinine	B
is	O
not	O
resorbed	O
but	O
cystatin	B
C	O
is	O
more	O
than	O
99%.	O

It	O
has	O
been	O
shown	O
that	O
cancer	O
increases	O
the	O
consumption	O
of	O
tryptophan	B
to	O
evade	O
immune	O
control	O
and	O
this	O
has	O
been	O
linked	O
to	O
IDO1	O
activity.	O

There	O
is	O
strong	O
inverse	O
correlation	O
between	O
urinary	O
and	O
serum	O
Neopterin	B
and	O
CD4+	O
lymphocyte	O
counts	O
in	O
HIV	O
infected	O
persons	O
.	O

We	O
conducted	O
metabolite	O
profiling	O
in	O
39	O
paired	O
(pre/post-intervention)	O
plasma	O
samples	O
from	O
early-stage	O
breast	O
cancer	O
patients	O
receiving	O
limonene	B
treatment	O
(2	O
g	O
QD)	O
before	O
surgical	O
resection	O
of	O
their	O
tumor.	O

[Google	O
Scholar]	O
Dowsett	O
M,	O
Goss	O
PE,	O
Powles	O
TJ,	O
Hutchinson	O
G,	O
Brodie	O
AM,	O
Jeffcoate	B
SL,	I
Coombes	O
RC.	O

Identification	O
of	O
lysine	B
residue	O
199	O
of	O
human	O
serum	O
albumin	O
as	O
a	O
binding	O
site	O
for	O
benzylpenicilloyl	O
groups.	O

For	O
some	O
studies,	O
the	O
Cys_34	O
of	O
SA	O
was	O
blocked	O
by	O
titration	O
of	O
the	O
thiol	B
residue	O
to	O
its	O
end	O
point	O
with	O
4-CMB,_,	O
or	O
by	O
reaction	O
with	O
a	O
5-fold	O
mol	O
excess	O
of	O
NEM	O
for	O
5	O
h	O
at	O
room	O
temperature,	O
followed	O
by	O
gel	O
filtration.	O

On-treatment	O
samples	O
display	O
higher	O
concentrations	O
of	O
acetoacetate,	B
acetone,	B
alanine,	B
cholesterol,	B
glucose,	B
glutamine,	B
glycerol,	B
glycine,	B
N	B
-acetylglycoproteins,	I
isoleucine,	B
leucine,	B
lipids,	O
LDL	O
and	O
VLDL	O
lipoproteins	O
and	O
valine,	B
and	O
lower	O
concentration	O
of	O
ethanol	B
and	O
acetate,	B
when	O
compared	O
with	O
pre-treatment	O
specimens.	O

The	O
incubation	O
of	O
morphine	B
with	O
liver	O
cytosol	O
extracts	O
resulted	O
in	O
approximately	O
equal	O
rate	O
of	O
formation	O
of	O
both	O
M3S	O
and	O
M6S.	O
In	O
conclusion,	O
sulfation	O
of	O
morphine	B
is	O
catalyzed	O
in	O
human	O
liver	O
but	O
this	O
minor	O
metabolic	O
pathway	O
probably	O
lacks	O
clinical	O
significance.	O

For	O
example,	O
recovery	O
of	O
PC(19:0/15:1)	B
(p<0.001)	O
increased	O
by	O
40%,	O
and	O
PE(20:3/18:1)	B
(p=0.012)	O
increased	O
by	O
58%.	O

Using	O
HPLC	O
with	O
UV	O
detection,	O
a	O
single	O
chromatographic	O
peak	O
that	O
was	O
unique	O
to	O
incubations	O
consisting	O
of	O
anastrozole,	B
HLMs	O
and	O
cofactors	O
was	O
noted.	O

Similar	O
trends	O
in	O
the	O
increase	O
of	O
relative	O
abundance	O
of	O
PS(40:4),	B
m/z	O
838.3	O
with	O
increase	O
of	O
the	O
oligodendroglioma	O
grade	O
are	O
observed	O
in	O
the	O
mixed	O
oligoastrocytomas,	O
likely	O
representing	O
the	O
oligodendrioglial	O
character	O
of	O
this	O
mixed	O
glioma.	O

Further,	O
they	O
raise	O
the	O
possibility	O
that	O
competition	O
between	O
simvastatin	B
and	O
bile	O
acids	O
for	O
this	O
transporter	O
may	O
influence	O
both	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
simvastatin,	B
and	O
possibly	O
risk	O
of	O
muscle	O
toxicity.	O

Yield	O
of	O
SF	B
equivalents	O
in	O
the	O
current	O
study	O
ranged	O
from	O
6.4%	O
to	O
48.9%,	O
buttressed	O
at	O
the	O
lower	O
end	O
by	O
the	O
inclusion	O
of	O
some	O
SF	B
in	O
the	O
formulation.	O

It	O
is	O
of	O
note	O
that	O
the	O
lower	O
BP	O
levels	O
and	O
detection	O
rate	O
were	O
also	O
observed	O
in	O
all	O
biomonitoring	O
surveys,	O
and	O
even	O
if	O
the	O
use	O
of	O
specific	O
paraben	B
according	O
to	O
the	O
application	O
could	O
be	O
variable	O
between	O
countries,	O
the	O
profiles	O
were	O
consistent	O
in	O
all	O
studies	O
with	O
MP	O
sharing	O
for	O
75	O
to	O
90%,	O
followed	O
by	O
PP	O
and	O
EP.	O

The	O
pathways	O
are	O
directly	O
connected	O
via	O
the	O
urea	B
cycle	O
through	O
the	O
enzyme	O
arginase	O
which	O
converts	O
L-arginine	B
to	O
urea	B
and	O
L-ornithine.	B

No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
age,	O
gender,	O
length	O
of	O
follow	O
up,	O
disease	O
duration	B
or	O
extent	O
of	O
disease	O
[proctitis/left-sided	O
colitis/extensive	O
colitis]	O
between	O
the	O
groups	O
studied	O
here.	O

For	O
GC-TOF/MS,	O
700 μL	O
of	O
MeOH	B
and	O
40 μL	O
of	O
L-2-chlorophenylalanine	B
(1 mg/mL	O
stock	O
in	O
dH_2	O
O)	O
were	O
added	O
to	O
200 μL	O
of	O
each	O
serum	O
sample,	O
and	O
the	O
samples	O
were	O
vigorously	O
vortexed	O
for	O
10 s.	O

MS-grade	O
water	O
and	O
acetonitrile	B
were	O
purchased	O
from	O
J.T.	O
Baker	O
(Center	O
Valley,	O
PA,	O
USA).	O

Conversely,	O
peroxidative	O
lipid	O
breakdown	O
products	O
such	O
as	O
the	O
dicarboxylic	B
acids	I
adipate	I
and	O
azelaic	B
acid	I
appear	O
to	O
be	O
lowered	O
in	O
lung	O
cancer	O
patients,	O
which	O
may	O
be	O
linked	O
to	O
signalling	O
functions	O
or	O
may	O
indicate	O
a	O
lowered	O
use	O
of	O
oxidative	O
pathways	O
in	O
lipid	O
metabolism	O
in	O
tumors.	O

The	O
peaks	O
in	O
the	O
chromatogram	O
are	O
PhIP	O
(t	O
_R	O
=	O
10.0),	O
5-HO-PhIP	B
(t	O
_R	O
=	O
10.2),	O
N	B
-hydroxy-N	I
-acetyl-PhIP	I
(t	O
_R	O
=	O
10.9),	O
and	O
N	B
-acetoxy-PhIP	I
(t	O
_R	O
=	O
13.7).	O

Statistical	O
analysis	O
was	O
performed	O
via	O
a	O
One-way	O
ANOVA	O
followed	O
by	O
the	O
Dunnett's	O
Multiple	O
Comparison	O
Test	O
for	O
each	O
toxin.	B

For	O
urine	O
samples,	O
metabolite	O
concentrations	O
were	O
adjusted	O
to	O
the	O
creatinine	B
concentration	O
because	O
spot	O
urine	O
measurements,	O
rather	O
than	O
24	O
h	O
urine	O
samples,	O
were	O
used	O
in	O
this	O
study.	O

e.g.	O
7-	B
oxocholesterol	I
(7-oxocholest-5-en-3β-ol,	I
C_5	I
-3β-ol-7-one).	I

The	O
concentration	O
of	O
7α,(25R)26-dihydroxycholest-4-en-3-one	B
(7α,(25R)26-diHCO,	I
0.03 ± 0.01 ng/mL,	O
cf.	O
0.02	O

In	O
the	O
TIC	O
shown	O
in	O
,	O
six	O
peaks	O
tentatively	O
identified	O
as	O
glucose	B
TMS	I
derivatives	O
in	O
these	O
three	O
samples	O
showed	O
obvious	O
signs	O
of	O
overloading	O
the	O
GC	O
column.	O

Monosodium	B
acid	I
methane	I
arsonate	O
sesquihydrate	O
was	O
obtained	O
from	O
Chem	O
Service,	O
PA,	O
USA.	O

(F)	O
Levels	O
of	O
glutamate	B
in	O
mouse	O
tumors	O
derived	O
from	O
mice	O
injected	O
with	O
UM-SCC-14A	O
cells	O
that	O
were	O
transduced	O
with	O
control	O
shRNA	O
or	O
glutaminase-shRNA	B
and	O
grown	O
under	O
adherent	O
conditions	O
(n	O
=	O
4/4	O
control	O
shRNA;	O
n	O
=	O
4/4	O
glutaminase	O
shRNA).	O

Additionally,	O
there	O
is	O
a	O
possibility	O
that	O
the	O
butanoate	B
pathway	O
through	O
aberrant	O
gut	O
microbiota	O
contributes	O
to	O
increased	O
ketone	B
body	O
production,	O
as	O
it	O
has	O
been	O
shown	O
that	O
acetate	B
is	O
normally	O
regarded	O
as	O
an	O
end	O
product	O
of	O
anaerobic	O
fermentation	O
and	O
is	O
an	O
integral	O
part	O
of	O
the	O
butyrate	B
pathway.	O

Furthermore,	O
transformed	O
Rh30	O
cells	O
were	O
much	O
more	O
active	O
in	O
de	O
novo	O
GSH	B
synthesis	O
than	O
the	O
primary	O
myocytes.	O

We	O
found	O
that	O
using	O
two	O
internal	O
standards,	O
desmethyl-BEN	B
for	O
the	O
early	O
eluting	O
compounds	O
and	O
desmethyl-BEN-Cl_2	B
for	O
later	O
eluting	O
peaks,	O
resulted	O
in	O
a	O
more	O
precise	O
and	O
reproducible	O
assay.	O

Bile	O
acid	O
metabolism	O
is	O
crucial	O
to	O
cholesterol	B
homeostasis	O
and	O
BA	O
modulate	O
metabolic	O
processes	O
through	O
G	O
protein-coupled	O
receptor	O
(TGR5)	O
and	O
nuclear	O
receptors	O
(FXR,	O
LXR	O
and	O
others).	O

The	O
most	O
important	O
conclusion	O
from	O
our	O
data	O
is	O
that	O
retinol	B
metabolism	O
dyshomeostasis	O
is	O
substantially	O
associated	O
with	O
the	O
LMCAD	O
phenotype.	O

We	O
obtained	O
serum	O
samples	O
from	O
3	O
independent	O
cohorts	O
(A,	O
B,	O
and	O
C)	O
of	O
patients	O
with	O
MS	O
(RR,	O
SP,	B
and	O
primary	O
progressive	O
[PP]),	O
as	O
well	O
as	O
age-	O
and	O
sex-matched	O
control	O
volunteers,	O
recruited	O
from	O
the	O
John	O
Radcliffe	O
Hospital,	O
Oxford,	O
UK	O
(see	O
STARD	O
flowchart	O
of	O
patient	O
recruitment,	O
exclusion,	O
and	O
methodology	O
in	O
).	O

Second,	O
although	O
FRS,	O
HbA1c,	O
and	O
diabetes	O
duration	B
was	O
matched	O
between	O
subjects	O
having	O
experienced	O
CAD	O
and	O
control	O
subjects,	O
the	O
small	O
sample	O
size	O
in	O
our	O
pilot	O
study	O
does	O
not	O
allow	O
adjustment	O
for	O
other	O
clinical	O
variables.	O

Therefore,	O
the	O
level	O
of	O
creatine	B
and	O
creatinine	B
also	O
reflect	O
the	O
disorder	O
of	O
energy	O
metabolism	O
in	O
T2DM-CHD	O
patients.	O

Kynurenines	O
combined	O
with	O
tryptophan	B
depletion	O
downregulates	O
the	O
TCR	O
zeta-chain	O
and	O
decreases	O
cytokine	O
production	O
in	O
murine	B
CD8	O
T	O
cells,	O
and	O
IDO-mediated	O
tryptophan	B
depletion	O
inhibits	O
mTOR	O
and	O
PKC-θ	O
activation	O
to	O
induce	O
murine	B
T	O
cell	O
anergy	O
and	O
autophagy.	O

Use	O
of	O
other	O
analgesics	O
was	O
similar	O
for	O
Belfast	O
and	O
Chicago	O
(for	O
the	O
first	O
clinic	O
visit,	O
40.0%	O
and	O
34.5%,	O
respectively;	O
for	O
the	O
third	O
clinic	O
visit,	O
36.4%	O
and	O
32.7%),	O
with	O
aspirin	B
being	O
the	O
most	O
commonly	O
reported	O
alternative	O
analgesic.	O

The	O
epilepsy	O
group	O
was	O
characterized	O
by	O
increased	O
levels	O
of	O
serum	O
N-acetyl-glycoproteins,	B
lactate,	B
creatine,	B
glycine	B
and	O
lipids,	O
whereas	O
the	O
levels	O
of	O
citrate	B
were	O
decreased	O
as	O
compared	O
to	O
the	O
reference	O
group.	O

Studies	O
by	O
Long	O
et	O
al	O
.	O
showed	O
that	O
the	O
activity	O
of	O
LPP1	O
is	O
closely	O
related	O
to	O
signaling	O
lipid	O
molecules,	O
such	O
as	O
DAG,	O
sphingosine-1-phosphate	B
(S1P),	O
LPA,	O
etc.	O

Citrulline	B
and	O
ornithine	B
are	O
also	O
both	O
intermediates	O
in	O
the	O
catabolism	O
of	O
amino	O
acids	O
by	O
the	O
urea	B
cycle	O
and	O
their	O
strong	O
correlation,	O
suggests	O
an	O
increased	O
flux	O
through	O
the	O
urea	B
cycle	O
and	O
amino	O
acid	O
catabolism.	O

BCAA	O
(0.93	O
–	O
1.07	O
ppm),	O
Ala	O
(1.45	O
–	O
1.51	O
ppm),	O
Ac	O
(1.91	O
–	O
1.93	O
ppm),	O
Glu	O
(2.31	O
–	O
2.40	O
ppm),	O
Gln	O
(2.42	O
–	O
2.49	O
ppm),	O
GSH	B
(2.51	O
–	O
2.61	O
ppm),	O
Asp	O
(2.62	O
–	O
2.72	O
ppm),	O
Cre	O
(3.02	O
–	O
3.07	O
ppm),	O
Tau	O
(3.39	O
–	O
3.47	O
ppm),	O
Gly	O
(3.55	O
–	O
3.57	O
ppm),	O
Phe	O
(7.30	O
–	O
7.46	O
ppm),	O
and	O
Tyr	O
(6.85	O
–	O
6.92	O
ppm)	O
were	O
used.	O

Another	O
neurotransmitter,	O
glutamate,	B
is	O
a	O
substrate	O
for	O
GABA	B
and	O
an	O
intermediate	O
in	O
the	O
glutamine	B
conversion	O
to	O
oxaloacetate	B
in	O
the	O
amino	O
acid,	O
nucleotide	O
and	O
lipid	O
synthesis.	O

It	O
is	O
also	O
of	O
note	O
that	O
although	O
the	O
addition	O
of	O
SM	B
d16:1/18:0	I
did	O
improve	O
the	O
prediction	O
of	O
future	O
diabetes	O
risk	O
for	O
a	O
relatively	O
large	O
proportion	O
of	O
the	O
population,	O
the	O
magnitude	O
of	O
change	O
of	O
the	O
predicted	O
probability	O
was	O
modest	O
and,	O
as	O
a	O
consequence,	O
may	O
not	O
have	O
a	O
large	O
effect	O
at	O
the	O
population	O
level	O
despite	O
the	O
improvement	O
in	O
prediction.	O

All	O
measured	O
phthalate	B
metabolites	O
were	O
logarithmically	O
(log_10	O
)	O
transformed	O
for	O
Pearson	O
correlation	O
analysis.	O

The	O
central	O
node	O
in	O
the	O
HCV	O
plasma	O
network	O
(b)	O
is	O
serine,	B
which	O
is	O
connected	O
directly	O
to	O
the	O
three	O
BCAAs,	O
leucine,	B
isoleucine,	B
and	O
valine	B
(positive	O
correlations),	O
and	O
also	O
to	O
myo	O
-inositol	O

For	O
a	O
representative	O
patient,	O
20.7%	O
of	O
exemestane	O
in	O
plasma	O
was	O
converted	O
into	O
17β-dihydroexemestane	B
and	O
29.0%	O
of	O
17β-dihydroexemestane	B
was	O
inactivated	O
as	O
17β-dihydroexemestane-17-O-β-D-glucuronide	B
24	O
hours	O
after	O
ingestion	O
of	O
exemestane,	O
suggesting	O
that	O
altered	O
17-dihydroexemestane	B
glucuronidation	O
may	O
play	O
an	O
important	O
role	O
in	O
determining	O
effect	O
of	O
exemestane	O
against	O
breast	O
cancer	O
cells.	O

Laboratory	O
studies	O
included	O
glucose,	B
insulin,	O
glycated	O
haemoglobin	O
(HbA1c),	O
total	O
cholesterol,	B
high-density	O
lipoprotein	O
cholesterol	B
(HDL-C),	O
low-density	O
lipoprotein	O
cholesterol	B
(LDL-C)	O
and	O
triglycerides,	B
all	O
of	O
which	O
were	O
analysed	O
using	O
a	O
conventional	O
automated	O
analyser.	O

Since	O
2010,	O
there	O
has	O
been	O
a	O
clear	O
trend	O
towards	O
the	O
development	O
and	O
application	O
of	O
multianalyte	O
methods	O
based	O
on	O
liquid	O
chromatography–electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
for	O
assessment	O
of	O
mycotoxin	B
exposure	O
made	O
possible	O
by	O
the	O
increased	O
sensitivity	O
and	O
selectivity	O
of	O
modern	O
mass	O
spectrometry	O
instrumentation	O
and	O
sophisticated	O
sample	O
cleanup	O
approaches.	O

Sensitivity	O
analysis	O
of	O
the	O
association	O
of	O
betaine	B
as	O
a	O
continuous	O
variable	O
and	O
according	O
to	O
tertiles	O
with	O
development	O
of	O
T2DM,	O
excluding	O
subjects	O
with	O
previous	O
CVD	O
history,	O
microalbuminuria,	O
eGFR	O
<	O
60	O
mL/min/1.73	O
m_2	O
,	O
and	O
use	O
of	O
lipid-lowering	O
drugs.	O

In	O
addition,	O
VLDL	O
transports	O
cholesterols,	B
oxysterols	B
and	O
triglycerides	B
from	O
the	O
liver	O
to	O
various	O
tissues,	O
and	O
rapidly	O
proliferating	O
cancer	O
cells	O
require	O
a	O
constant	O
supply	O
of	O
lipids	O
for	O
membrane	O
biogenesis,	O
protein	O
modifications	O
and	O
steroid	O
hormone	O
production.	O

The	O
structures	O
for	O
those	O
metabolites	O
that	O
could	O
be	O
annotated	O
by	O
matching	O
product	O
ions	O
to	O
literature	O
data	O
are	O
shown	O
(solid	O
boxes	O
)	O
and	O
the	O
annotation	O
of	O
a	O
AML	O
metabolite	O
based	O
on	O
spectral	O
homology	O
and	O
mass	O
differences	O
is	O
also	O
presented	O
(dashed	O
box	O
),	O
where	O
mtb	O
is	O
short	O
for	O
metabolite,	O
Glc	O
for	O
glucuronide,	B
and	O
Ox	O
for	O
oxidized.	O

Thus,	O
in	O
view	O
of	O
the	O
presently	O
documented	O
inverse	O
relationship	O
between	O
PLTP	O
and	O
betaine,	B
it	O
seems	O
warranted	O
to	O
take	O
both	O
factors	O
into	O
consideration	O
when	O
evaluating	O
the	O
extent	O
to	O
which	O
they	O
may	O
confer	O
cardiometabolic	O
risk	O
[,	O
,	O
].	O

Catalysed	O
by	O
indoleamine	O
2,3-dioxygenase	O
1	O
(IDO1)	O
and	O
tryptophan	O
2,3-dioxygenases	O
(TDO),	O
the	O
tryptophan	B
(TRP)	O
was	O
first	O
transformed	O
into	O
N-formylkynurenine	B
(NFK)	O
and	O
then	O
hydrolysed	O
into	O
kynurenine	B
(KYN)	O
by	O
kynurenine	B
formamidase.	O

Our	O
data	O
demonstrated	O
that	O
BPA	O
induced	O
cell	O
proliferation	O
in	O
vitro	O
only	O
in	O
presence	O
of	O
high	O
glucose	B
concentration.	O

Raised	O
TG	B
production	O
has	O
been	O
suggested	O
as	O
a	O
cell	O
strategy	O
to	O
decrease	O
the	O
cytotoxicity	O
generated	O
by	O
the	O
high	O
amount	O
of	O
free	O
FA	B
in	O
the	O
cytoplasm	O
[,	O
].	O

Although	O
a	O
systematic	O
study	O
on	O
the	O
stability	O
of	O
all	O
the	O
metabolites	O
measured	O
by	O
metabolomics	O
has	O
not	O
yet	O
been	O
published,	O
one	O
study	O
has	O
shown	O
that	O
polyunsaturated	O
fatty	O
acids	O
in	O
serum	O
phospholipids	B
were	O
stable	O
for	O
at	O
least	O
8–10	O
years	O
at	O
-80°C.	O

Negative	O
regulation	O
of	O
NO	O
synthesis	O
can	O
also	O
be	O
mediated	O
via	O
overproduction	O
of	O
methylated	B
arginine	I
analogues	O
such	O
as	O
MMA,	O
ADMA,	B
and	O
SDMA.	O

And	O
fumaric	B
acid,	I
uridine,	B
acetic	B
acid,	I
and	O
cytidine	B
might	O
be	O
potential	O
biomarkers	O
for	O
PDR.	O

Arginine,	B
methionine,	B
adenine,	B
uracil,	B
alanine,	B
and	O
pyruvate	B
metabolites	O
exhibit	O
conspicuous	O
peaks	O
in	O
NMR-derived	O
metabolic	O
profile,	O
thus	O
enabling	O
quantitative	O
assessment.	O

L-asparagine,	B
L-glutamine	B
and	O
L-tryptophan	B
were	O
purchased	O
separately	O
(Sigma	O
Aldrich,	O
Steinheim,	O
Germany)	O
since	O
they	O
were	O
not	O
included	O
in	O
the	O
commercial	O
standard	O
mixture.	O

It	O
has	O
been	O
reported	O
that	O
the	O
activity	O
of	O
phosphatidylcholine-specific	O
phospholipase	O
C	O
(PLC)	O
and	O
phospholipase	O
D	O
(PLD),	O
the	O
enzymes	O
responsible	O
for	O
the	O
degradation	O
of	O
phosphatidylcholine	B
was	O
higher	O
in	O
human	O
mammary	O
epithelial	O
and	O
epithelial	O
ovarian	O
carcinoma	O
cell	O
lines._,	O
	O
These	O
findings	O
suggest	O
that	O
both	O
biosynthetic	O
and	O
catabolic	O
pathways	O
of	O
the	O
phosphatidylcholine	B
cycle	O
contribute	O
to	O
the	O
accumulation	O
of	O
ChoCC	O
in	O
tumor	O
tissues.	O

Thus,	O
the	O
number	O
of	O
samples	O
for	O
8-oxodG	B
and	O
8-oxoGua	O
with	O
valid	O
data	O
is	O
lower	O
than	O
55	O
within	O
the	O
mother,	O
father,	O
and	O
oldest	O
daughter	O
groups	O
due	O
to	O
some	O
chromatographic	O
assay	O
problems.	O

In	O
the	O
cases	O
where	O
VLCDCA	B
28:4	I
was	O
not	O
detected	O
in	O
100	O
μL	O
biofluid,	O
the	O
negative	O
observations	O
were	O
further	O
validated	O
by	O
extracting	O
500	O
μL	O
biofluid.	O

The	O
intra-run	O
accuracy	O
levels	O
were	O
−3.2–0.0%RE	O
and	O
−1.0–4.1%RE	O
for	O
Cer(22:0)	B
and	O
Cer(24:0),	B
respectively.	O

We	O
observed	O
the	O
expected	O
elevations	O
in	O
plasma	O
glucose	B
(∼4	O
fold),	O
beta-hydroxybutyrate	B
(∼5	O
fold),	O
acetone	B
(∼9	O
fold),	O
and	O
acetoacetate	B
(∼40	O
fold)	O
in	O
insulin	O
deprived	O
individuals	O
compared	O
to	O
the	O
insulin	O
treated	O
state	O
and	O
non-diabetic	O
controls.	O

Uracil	B
and	O
kynurenic	B
acid	I
were	O
found	O
as	O
promising	O
biomarkers	O
in	O
urine	O
samples	O
of	O
prostate	O
cancer	O
patients,	O
when	O
urine	O
is	O
collected	O
before	O
and	O
after	O
prostatic	O
massage.	O

In	O
addition,	O
current	O
results	O
showed	O
an	O
association	O
between	O
the	O
level	O
of	O
glutamate	B
and	O
benzodiazepine	B
equivalent	O
doses.	O

The	O
distribution	O
pattern	O
of	O
the	O
three	O
main	O
fatty	O
acids	O
was	O
similar	O
but	O
did	O
not	O
fully	O
overlap	O
with	O
triglyceride	B
distribution	O
or	O
VLDL	O
deposition	O
(S.	O
Mas,	O
unpublished	O
observation).	O

Other	O
discrepancies	O
may	O
be	O
due	O
to	O
sample	O
collection/preservation	O
effects	O
(the	O
ultrafiltration	O
devices	O
we	O
used	O
contain	O
trace	O
amounts	O
of	O
glycerol)	B
or	O
possibly	O
sample	O
size	O
effects	O
(2	O
patients	O
versus	O
35	O
patients).	O

SLC7A5	O
has	O
high	O
affinity	O
for	O
large	O
neutral	O
amino	O
acids	O
such	O
as	O
phenylalanine,	B
tyrosine,	B
leucine,	B
arginine,	B
and	O
Trp	O
when	O
associated	O
with	O
SLC3A2.	O

To	O
our	O
knowledge,	O
no	O
publications	O
have	O
identified	O
upregulation	O
of	O
any	O
resolvin	O
species	O
in	O
the	O
blood	O
of	O
patients	O
with	O
non-TB	O
lung	O
diseases,	O
although	O
resolvin	B
E1	I
was	O
identified	O
in	O
the	O
sputum	O
of	O
adult	O
cystic	O
fibrosis	O
patients	O
.	O

Approximately	O
70%	O
is	O
bound	O
to	O
albumin,	O
and	O
the	O
remaining	O
30%	O
forms	O
low	O
molecular	O
weight	O
disulfides	B
predominantly	O
with	O
cysteine.	B

This	O
information	O
was	O
later	O
confirmed	O
with	O
the	O
levels	O
of	O
3-ethenylpyridine	B
(3-EP)	O
in	O
air	O
samples.	O

A	O
multilinear	B
gradient	O
was	O
formed	O
from	O
solvent	O
A	O
(see	O
above)	O
and	O
solvent	O
B	O
(methanol;	O
Merck	O
KGaA	O
Germany).	O

*This	O
amino-acid	B
group	O
consists	O
of	O
asparagine,	B
histidine,	B
serine	B
and	O
tyrosine.	B

Laboratories	O
B,	O
D	O
and	O
F	O
did	O
not	O
detect	O
one	O
or	O
more	O
of	O
the	O
polyamines	B
putrescine,	I
spermidine	B
and	O
spermine	B
as	O
reliably	O
as	O
other	O
laboratories.	O

N(alpha)-t-Butoxycarbonyl-L-leucine;	B
COM530:	O
PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z));	B
COM548:	O
PE(P-16:0/0:0);	B
COM732:	O
Val	O
Arg	O
Phe.	O

It	O
should	O
be	O
noted	O
that	O
its	O
ceramide	B
contained	O
a	O
hydroxylated	O
fatty	O
acid,	O
which	O
was	O
not	O
observed	O
among	O
the	O
ganglio-series	B
GGs.	O

It	O
should	O
be	O
noted	O
that	O
once	O
accounting	O
for	O
age,	O
the	O
group	O
effect	O
was	O
no	O
longer	O
significant	O
for	O
glutamate.	B

It	O
is	O
apparent	O
that	O
DMD	O
patients	O
are	O
not	O
metabolizing	O
creatine	B
as	O
they	O
age,	O
most	O
likely	O
due	O
to	O
loss	O
of	O
muscle	O
mass.	O

Baseline	O
plasma	O
glucose,	B
insulin	O
and	O
HOMA-IR	O
were	O
significantly	O
higher	O
in	O
the	O
RYGB	O
group.	O

The	O
supernatant	O
was	O
dried	O
completely	O
in	O
a	O
concentrator	O
for	O
1 h	O
and	O
resolved	O
in	O
30 μL	O
of	O
50 %	O
acetonitrile/0.1 %	O
trifluoroacetic	B
acid	I
(TFA)	O
on	O
a	O
vortex	O
mixer	O
for	O
30 min.	O

Increased	O
IP,	B
gut	O
microbiota	O
dysbiosis,	O
and	O
SIBO	O
have	O
been	O
associated	O
with	O
the	O
severity	O
of	O
obesity-related	O
liver	O
damage	O
[,,,].	O

spike:	O
Internal	O
standard	O
spiked	O
into	O
human	O
serum,	O
followed	O
by	O
MTBE	B
extraction	O
and	O
derivatization.	O

Changes	O
in	O
energy-restriction-associated	O
gene	O
expression	O
in	O
the	O
11	O
responding	O
IER	O
subjects	O
were	O
comparable	O
to	O
those	O
observed	O
across	O
all	O
the	O
participants	O
in	O
the	O
previous	O
60 %	O
CER	B
study	O
with	O
9/10	O
of	O
the	O
CER	B
participants	O
clustering	O
together.	O

Next,	O
the	O
22	O
oxylipins	B
identified	O
as	O
the	O
significant	O
contributors	O
to	O
the	O
PLS-DA	O
model	O
were	O
clustered	O
by	O
expression	O
pattern	O
using	O
the	O
JMP	O
13	O
Pro	O
cluster	O
variable	O
algorithm.	O

Amino	O
acid	O
changes	O
linked	O
to	O
the	O
urea	B
cycle	O
were	O
also	O
affected	O
with	O
the	O
accumulation	O
of	O
ornithine	B
and	O
arginine	B
being	O
severely	O
reduced	O
in	O
tumours	O
(Supplementary	O
Figure	O
S7).	O

Transitions	O
specific	O
to	O
metformin	B
were	O
monitored,	O
in	O
addition	O
to	O
IMZ	O
signals,	O
within	O
the	O
developed	O
MRM	O
assay.	O

Oxylipins	B
are	O
bioactive	O
mediators	O
that	O
play	O
diverse	O
roles	O
in	O
(patho)physiology.	O

The	O
mixture	O
was	O
centrifuged	O
twice	O
(16,000	O
×	O
g	O
at	O
4	O
°C	O
for	O
10	O
min),	O
and	O
then	O
the	O
supernatant	O
was	O
divided	O
into	O
two	O
parts:	O
one	O
100	O
µL	O
for	O
LC/MS	O
analysis	O
directly	O
and	O
another	O
100	O
µL	O
for	O
GC/MS	O
analysis,	O
which	O
was	O
first	O
transferred	O
to	O
a	O
glass	O
vial	O
and	O
evaporated	O
to	O
dryness	O
and	O
then	O
derivatized	O
by	O
100	O
µL	O
methoxyamine	B
(50	O
µg/mL	O
in	O
pyridine,	B
37	O
°C	O
×	O
2	O
h)	O
and	O
followed	O
by	O
100	O
µL	O
MSTFA	O
(37	O
°C	O
×	O
16	O
h).	O

In	O
particular,	O
ornithine	B
and	O
another	O
urea	B
cycle	O
intermediate,	O
citrulline,	B
increased	O
by	O
215	O
and	O
90%,	O
on	O
average,	O
respectively,	O
in	O
severe	O
psoriasis	O
patients	O
compared	O
to	O
that	O
in	O
controls	O
(Table	O
2).	O

Bacteria	O
use	O
ammonium	B
(NH4_+	O
),	O
which	O
is	O
first	O
incorporated	O
into	O
Glu	O
and	O
Gln	O
and	O
works	O
as	O
a	O
primary	O
nitrogen	O
donor,	O
as	O
the	O
key	O
molecule	O
for	O
central	O
nitrogen	O
metabolism.	O

Finally,	O
other	O
metabolites	O
found	O
to	O
be	O
increased	O
in	O
COPD	O
patients	O
are	O
pyruvate	B
and	O
α-ketoglutarate.	B

Increased	O
cysteine	B
associated	O
with	O
decreased	O
uridine	B
was	O
the	O
best	O
paired	O
combination	O
to	O
identify	O
light	O
AD	O
(MMSE>22)	O
with	O
specificity	O
and	O
sensitivity	O
above	O
75%.	O

In	O
our	O
current	O
analyses,	O
isoleucine	B
was	O
elevated	O
by	O
the	O
ε4	O
allele	O
in	O
all	O
subjects	O
in	O
2001	O
and	O
2011	O
(see	O
Figs 	O
and	O
respectively),	O
as	O
well	O
as	O
in	O
men	O
in	O
2011	O
(see	O
Supplementary	O
Fig.	O

This	O
features	O
the	O
“Warburg	O
effect”,	O
where	O
high	O
lactate	B
production	O
is	O
observed	O
even	O
in	O
the	O
presence	O
of	O
oxygen	O
and	O
a	O
low	O
level	O
of	O
aerobic	O
oxidation	O
through	O
the	O
TCA	O
cycle.	O

Following	O
the	O
enzymatic	O
hydrolysis	O
of	O
the	O
conjugated	O
androgens,	O
a	O
second	O
round	O
of	O
diethyl	B
ether	I
extraction	O
and	O
derivatization	O
was	O
conducted	O
as	O
described	O
above	O
and	O
the	O
dried	O
samples	O
stored	O
separately	O
at	O
−80	O
°C	O
until	O
analyzed	O
by	O
LC/ESI/SRM/MS.	O

In	O
total,	O
450 µL	O
of	O
urine	O
and	O
150 µL	O
of	O
phosphate	B
buffer	O
were	O
transferred	O
into	O
1.5 mL	O
centrifuge	O
tubes.	O

acyl-alkyl-phosphatidylcholine	B

Hyperlipidemia	O
was	O
diagnosed	O
according	O
to	O
the	O
levels	O
of	O
TG	B
and	O
TC.	O

In	O
contrast,	O
TMAO	B
did	O
not	O
correlate	O
with	O
any	O
methylated	B
arginine	I
metabolites,	O
and	O
only	O
modestly	O
with	O
GABR.	O

Chronic	O
fatigue	O
resulting	O
from	O
civilian	O
organophosphate	B
exposure	O
was	O
reportedly	O
more	O
similar	O
to	O
CFS	O
in	O
veterans	O
with	O
GWI	O
than	O
in	O
other	O
civilians	O
with	O
ME/CFS.	O

After	O
vortex,	O
chloroform	B
(2 ml	O
per	O
gram	O
of	O
tissue)	O
was	O
added,	O
followed	O
by	O
addition	O
of	O
50%	O
chloroform	B
(2 ml	O
per	O
gram	O
of	O
tissue).	O

Ordinarily,	O
the	O
endogenous	O
cause	O
of	O
increased	O
hypoxanthine	B
is	O
hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HGPRT)	O
deficiency,	O
which	O
leads	O
to	O
gout,	O
hyperuricemia,	O
and	O
Lesch-Nyhan	O
syndrome.	O

Bovine	O
serum	O
albumin,	O
25(OH)D_3	O
(≥98%	O
pure),	O
25(OH)D_2	O
(≥98%	O
pure),	O
and	O
phosphate-buffered	B
saline	I
were	O
obtained	O
from	O
Sigma	O
(St.	O
Louis,	O
MO).	O

It	O
contains	O
a	O
reactive	O
amino	B
group	O
and	O
a	O
reporter	O
ion.	O

At	O
0.4	O
ml/min	O
flowrate,	O
the	O
mobile	O
phase	O
ramped	O
from	O
45%	O
of	O
solvent	O
A	O
(H_2	O
O	O
+	O
0.01%	O
acetic	O
acid)	O
and	O
55%	O
of	O
solvent	O
B	O
(methanol	O
+	O
0.01%	O
acetic	O
acid)	O
to	O
15%	O
of	O
solvent	O
A	O
and	O
85%	O
of	O
solvent	O
B	O
in	O
10	O
minutes,	O
then	O
ramped	O
to	O
2%	O
of	O
solvent	O
A	O
and	O
98%	O
of	O
solvent	O
B	O
in	O
18	O
minutes,	O
and	O
then	O
stayed	O
at	O
2%	O
of	O
solvent	O
A	O
and	O
98%	O
of	O
solvent	O
B	O
until	O
25	O
minutes,	O
and	O
finally	O
changed	O
back	O
to	O
45	O
%	O
of	O
solvent	O
A	O
and	O
55%	O
of	O
solvent	O
B	O
and	O
re-equilibrated	O
until	O
30	O
minutes	O
passed.	O

The	O
heated	O
capillary	O
was	O
maintained	O
at	O
200	O
°C,	O
and	O
the	O
ESI	O
voltage	O
was	O
held	O
at	O
2.2	O
kV.	B
MS/MS	O
spectra	O
were	O
searched	O
against	O
the	O
UniProt	O
human	O
database	O
using	O
the	O
X!Tandem	O
algorithm	O
to	O
identify	O
the	O
enzyme	O
using	O
the	O
following	O
parameters:	O
no	O
enzyme	O
rules,	O
carboxamidomethylation	O
of	O
cysteine	B
(57.02	O
Da)	O
as	O
a	O
fixed	O
modification,	O
and	O
monoethyl-phosphorylation	O
(107.998	O
Da)	O
and	O
phosphorylation	O
(79.966)	O
on	O
serine,	B
threonine,	B
and	O
tyrosine	B
residues	O
as	O
a	O
variable	O
modification.	O

Decreases	O
in	O
mitochondrial	O
lipids	O
and	O
ATP	B
in	O
FTD	O
serum.	O

Similarly,	O
nervonic	B
acid	I
fell	O
3.4-fold	O
in	O
HCC	O
relative	O
to	O
LC	O
(P<0.001).	O

The	O
control	O
and	O
LPS	B
wells	O
also	O
received	O
an	O
equal	O
volume	O
of	O
ethanol.	B

Actually,	O
different	O
levels	O
of	O
glucose	B
consumption	O
reflect	O
the	O
activity	O
of	O
tumor,	O
suggesting	O
that	O
recurrence	O
or	O
metastasis	O
of	O
HCC	O
shows	O
a	O
stronger	O
vitality.	O

The	O
sodium	O
salt	O
of	O
trimethylsilylpropionic	B
acid-d_4	O
(TSP),	O
used	O
as	O
the	O
internal	O
standard,	O
was	O
from	O
Sigma-Aldrich	O
(Milwaukee,	O
WI).	O

 ,	O
see	O
Supplementary	O
Table _S6	O
),	O
especially	O
those	O
for	O
SCFA	O
(ko00650	O
butanoate,	B
ko00640	O
propanoate),	B
carbon	O
(ko01200)	O
and	O
methane	B
(ko00680)	O
metabolism.	O

To	O
be	O
noted,	O
some	O
compounds	O
such	O
as	O
3-hydroxybutyric	B
acid,	I
3-indolepropionic	B
acid,	I
4-hydroxyphenylpyruvic	B
acid,	I
5-hydroxy-L	B
-tryptophan,	I
etc.,	O
could	O
not	O
be	O
detected	O
at	O
lower	O
concentrations	O
due	O
to	O
the	O
detection	O
limit,	O
and	O
some	O
compounds	O
such	O
as	O
hydrocinnamic	B
acid,	I
L	B
-phenylalanine,	I
L	B
-glutamic	I
acid,	I
L	O
-cysteine,	O
etc.,	O
had	O
quadratic	O
regression	O
at	O
higher	O
concentrations.	O

Furthermore,	O
fingerprint	O
of	O
ganglioside	B
GM3	I
can	O
be	O
potentially	O
important	O
as	O
it	O
is	O
possible	O
that	O
changes	O
in	O
fatty	O
acyl	O
composition	O
(saturation	O
and	O
length)	O
in	O
individual	O
ganglioside	B
GM3	I
species	O
will	O
affect	O
its	O
interaction	O
with	O
insulin	O
receptor	O
in	O
membrane	O
microdomains	O
or	O
the	O
stability	O
of	O
the	O
associated	O
microdomains	O
per	O
se	O
.	O

Palmitic	B
acid	I
(16:0),	O
stearic	B
acid	I
(18:0),	O
and	O
soy-derived	O
lysophosphatidylcholine	B
(LPCsoy)	O
(Avanti	O
Polar	O
Lipids)	O
were	O
dissolved	O
in	O
100%	O
ethanol	B
and	O
filter-sterilized	O
(10	O
mM	O
stock	O
solutions).	O

There	O
is	O
also	O
evidence	O
that	O
reduced	O
sphingomyelin	B
levels	O
may	O
be	O
oncogenic	O
as	O
demonstrated	O
by	O
inhibition	O
of	O
the	O
RAS-MAPK,	O
CyclinD-CDK4/CDK6	O
and	O
PI3K-AKT	O
axes	O
through	O
the	O
activation	O
of	O
sphingomyelin	B
synthase	O
by	O
a	O
synthetic	O
fatty	O
acid.	O

Samples	O
were	O
then	O
reconstituted	O
with	O
100 μL	O
of	O
MeOH/IPA/H_2	O
O	B
65:35:5	I
(v/v/v),	O
vortexed	O
for	O
30 s	O
and	O
sonicated	O
for	O
60 s	O
before	O
injection.	O

Significant	O
metabolites	O
that	O
differentiated	O
malignant	O
and	O
benign	O
thyroid	O
lesions	O
included	O
citrate,	B
acetylcarnitine,	B
glutamine,	B
homoserine,	B
glutathione,	B
kynurenine,	B
nicotinic	B
acid,	I
hippurate,	B
tyrosine,	B
tryptophan,	B
β-alanine,	B
and	O
xanthine.	B

Chromatograms	O
obtained	O
upon	O
LC-ESI-MS/MS-SRM	O
analysis	O
of	O
products	O
formed	O
in	O
the	O
reaction	O
of	O
racemic	O
rev-BPDE	O
with	O
NAC	O
(A);	O
internal	O
standard	O
Phe-9-hydroxy-10-NAC	B
for	O
the	O
hepatocyte	O
analysis	O
(B);	O
and	O
medium	O
from	O
hepatocytes	O
incubated	O
with	O
10	O
μM	O
rev-BPDE	O
for	O
24	O
h	O
(C).	O

The	O
cartridge	O
was	O
preconditioned	O
with	O
6	O
mL	O
methanol	B
and	O
6	O
mL	O
water.	O

Phytosphingosine	B
and	O
dihydrosphingosine	B
have	O
been	O
reported	O
in	O
a	O
previous	O
metabolomic	O
study	O
to	O
be	O
down-regulated	O
in	O
HCC	O
compared	O
to	O
patients	O
with	O
cirrhosis.	O

Plasma	O
levels	O
of	O
Trp	O
and	O
its	O
metabolite	O
Kynurenine	B
(Kyn)	O
were	O
measured	O
by	O
isotope	O
dilution	O
tandem	O
mass	O
spectrometry	O
and	O
sCD14	O
was	O
assessed	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
(ELISA).	O

The	O
MS_3	O
spectra	O
correspond	O
to	O
GP-tagged	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
(c	O
)	O
and	O
a	O
trihydroxycholanoic	B
acid,	I
possibly	O
3β,x	B
,y	I
-trihydroxy-5α-cholan-24-oic	I
acid	I
(d	O
).	O

PHEMA	O
was	O
significantly	O
higher	O
in	O
workers	O
than	O
in	O
controls	O
with	O
a	O
median	O
level	O
equal	O
to	O
0.15	O
versus	O
0.07	O
µg/g	O
creatinine.	B

The	O
MALDI-MSI	O
technology	O
platform	O
provides	O
an	O
accurate	O
identification	O
of	O
endogenous	O
metabolites,	O
lipids,	O
acetylcholine	B
derivatives,	O
peptides	O
and	O
administered	O
compounds	O
(e.g.,	O
drugs	O
and	O
small	O
molecules)	O
at	O
exact	O
sampling	O
positions	O
within	O
a	O
tissue	O
section.	O

The	O
finding	O
of	O
a	O
disturbed	O
PC/lysoPC	O
metabolism	O
is	O
in	O
agreement	O
with	O
results	O
from	O
previous	O
studies	O
describing	O
that	O
altered	O
PC	O
and	O
lysoPC	O
plasma	O
profiles	O
are	O
associated	O
with	O
T2D	O
(increased	O
PC	O
aa	O
(16:0/18:2);	O
decreased	O
PC	O
aa	O
(16:0/18:0),	O
decreased	O
PC	O
aa	O
(18:0/20:4),	O
increased	O
lysoPCs	O
(C16:0,	O
C18:0,	I
C18:1,	I
C18:2,	I
C20:4)),	I
increased	O
lysoPCs	O
(C14:0,	O
C16:1,	B
C18:1,	B
C20:5,	B
C22:6),	B
impaired	O
glucose	B
tolerance	O
(decreased	O
lysoPC	O
C18:2)	B
)	O

The	O
first	O
characteristic	O
assessed	O
in	O
this	O
study	O
was	O
the	O
library	O
coverage,	O
i.e.	O
the	O
percentage	O
of	O
library	O
metabolites	O
that	O
produced	O
an	O
identifiable	O
MS	O
peak	O
after	O
separation	O
with	O
methods	O
A–G.,	O
The	O
benchmark	O
RP	B
method	O

It	O
should	O
be	O
noted	O
that	O
isocitrate	B
is	O
isobaric	O
with	O
its	O
precursor	O
metabolite,	O
citrate,	B
both	O
having	O
the	O
molecular	O
formula	O
C_6	O
H_8	O
O_7	O
.	O

Energy	O
adjusted	O
folate,	B
free-choline	O
and	O
betaine	B
intake	O
had	O
significantly	O
positive	O
correlation	O
(r	O
 = 0.519,	O

Fasting	O
plasma	O
samples	O
from	O
CKD	O
3–4	O
and	O
CKD	O
5	O
patients,	O
consecutively	O
recruited	O
into	O
two	O
observational	O
prospective	O
cohort	O
studies	O
previously	O
described	O
[,	O
,	O
],	O
at	O
Karolinska	O
University	O
Hospital,	O
Stockholm,	O
Sweden,	O
were	O
analyzed	O
for	O
TMAO,	B
choline,	B
betaine	B
and	O
systemic	O
markers	O
of	O
inflammation,	O
metabolism	O
and	O
renal	O
function.	O

Additionally,	O
seven	O
lysophosphocholines,	B
LPC(14:0),	B
LPC(16:0),	B
LPC(18:1),	B
LPC(20:2),	B
LPC(20:3),	B
LPC(20:4)	B
and	O
LPC(20:5),	B
were	O
downregulated	O
in	O
HCC	O
plasma	O
relative	O
to	O
HV	B
plasma.	O

To	O
produce	O
the	O
blueberry	O
polyphenol-soy	B
protein	O
complex,	O
44	O
L	O
of	O
blueberry	O
pomace	O
extract	O
was	O
mixed	O
with	O
176	O
L	O
of	O
water	O
(5×	O
dilution)	O
until	O
uniform	O
then	O
SPI	O
(100	O
g/L;	O
22	O
kg)	O
was	O
added	O
to	O
the	O
diluted	O
blueberry	O
pomace	O
extract	O
and	O
mixed.	O

The	O
deregulation	O
of	O
SAM-induced	O
methyltransfer	B
reactions	O
in	O
tumor	O
genesis	O
is	O
reflected	O
by	O
three	O
additional	O
feature	O
combinations	O

Alb	O
was	O
treated	O
with	O
Raney-nickel	O
to	O
release	O
1-phenylethanol	B
(1-PE)	O
and	O
2-phenylethanol	B
(2-PE),	O
representing	O
cysteine-bound	O
SO.	O

Wei	O
et	O
al	O
were	O
able	O
to	O
distinguish	O
HCC	O
from	O
HCV	O
through	O
metabolite	O
profiling	O
by	O
NMR,	O
and	O
choline	B
was	O
found	O
upregulated	O
in	O
HCC	O
patients.	O

Since	O
there	O
was	O
a	O
reciprocal	O
trend	O
in	O
VLCFA	O
and	O
GTA	O
levels	O
in	O
RRMS	O
patients	O
in	O
relation	O
to	O
disease	O
duration,	B
the	O
ratio	O
of	O
these	O
two	O
biomarkers	O
was	O
examined	O
to	O
see	O
whether	O
there	O
was	O
a	O
time-dependent	O
pattern	O
that	O
can	O
indicate	O
any	O
transitional	O
stage	O
in	O
the	O
biochemical	O
state	O
of	O
RRMS	O
patients.	O

In	O
conclusion,	O
serum	O
levels	O
of	O
2-HB,	O
3-HB,	O
tyrosine,	B
and	O
citrate	B
measured	O
at	O
admission	O
are	O
associated	O
with	O
an	O
increased	O
3-month	O
mortality	O
rate	O
in	O
AHF	O
patients	O
and	O
might	O
thus	O
be	O
of	O
prognostic	O
value	O
in	O
AHF.	O

Butyrate	B
was	O
the	O
metabolite	O
that	O
contributed	O
the	O
most	O
to	O
distinguishing	O
the	O
normal	O
subjects	O
from	O
those	O
with	O
adenoma.	O

Increases	O
in	O
acylcarnitines	B
in	O
HCC	O
patients	O
vs.	O
NHC	O
and	O
cirrhotics	O
vs.	O
NHCs	O
may	O
reflect	O
a	O
failure	O
in	O
carbamoyl	B
phosphate	I
transferase	O
I	O
(CPTI)	O
catalysed	O
unification	O
of	O
free	O
fatty	O
acid	O
with	O
carnitine	B
enabling	O
mitochondrial	O
β-oxidation	O
and	O
hence	O
may	O
explain	O
the	O
strong	O
lipid	O
signature	O
in	O
DC	O
vs.	O
NHC	O
and	O
HCC	O
vs.	O
DC.	O

Hence,	O
the	O
serum	O
levels	O
of	O
polyamines	B
and	O
acetylated	O
products	O
are	O
much	O
lower	O
than	O
those	O
for	O
related	O
amino	O
acids,	O
such	O
as	O
ARG,	O
ORN,	O
and	O
LYS	O
(nM	O
range	O
vs.	O
µM	O
for	O
amino	B
acids).	O

The	O
enzymes	O
marked	O
are:	O
1,	O
choline	B
kinase;	O
2,	O
CTP:phosphocholine	O
cytidylyltransferase	O
and	O
choline	O
phosphotransferase;	O
3,	O
phospholipase	B
Al;	I
phospholipase	O
A2,	O
and	O
lysophospholipase;	O
4,	O
GPC:choline	O
phosphodiesterase.	O

While	O
anthocyanins	B
are	O
substrates	O
for	O
sulfotransferases,	O
methylation	O
and	O
glucuronidation	O
reactions	O
represent	O
the	O
primary	O
Phase	O
II	O
metabolic	O
routes.	O

In	O
addition,	O
The	O
total	O
levels	O
of	O
PC	O
and	O
LPA	O
increased	O
while	O
the	O
total	O
levels	O
of	O
SM	O
decreased	O
in	O
HBsAg(+)	B
group	O
comparing	O
to	O
the	O
HBsAg	O
(−)	O
group	O
(Fig. ).	O

This	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
QUIN	O
is	O
not	O
the	O
final	O
product	O
of	O
the	O
KP	B
and	O
would	O
continue	O
to	O
degrade	O
to	O
NAD	B
causing	O
QUIN	O
levels	O
to	O
decrease.	O

For	O
patients	O
administered	O
Degarelix,	O
serum	O
samples	O
were	O
taken	O
immediately	O
before	O
administration	O
of	O
Degarelix	O
and	O
immediately	O
prior	O
to	O
surgery	O
for	O
measuring	O
pre-	O
and	O
post-Degarelix	O
treatment	O
testosterone	B
levels	O
respectively.	O

Reproducibility	O
measurements	O
made	O
on	O
a	O
sample	O
from	O
an	O
individual	O
with	O
pathologically	O
high	O
blood	O
lipids	O
revealed	O
that	O
inter-laboratory	O
precision	O
was	O
substantially	O
worse	O
for	O
phospholipids	B
including	O
sphingomyelins,	B
with	O
CVs	O
increasing	O
by	O
~4-fold	O
(to	O
24-26%).	O

4 × 1 μL	O
injections	O
of	O
caffeine	B
were	O
then	O
made,	O
and	O
the	O
observed	O
retention	O
time	O
stability	O
and	O
peak	O
area	O
variation	O
under	O
gradient	O
conditions	O
were	O
used	O
to	O
confirm	O
column	O
equilibration.	O

The	O
plasma	O
concentrations	O
of	O
two	O
lipid	O
subclasses,	O
triglycerides	B
and	O
monosialodihexosylganglioside	B
(GM3),	O
were	O
different	O
between	O
PD	O
and	O
control	O
participants.	O

Three-second	O
SPE-IMS-MS	O
analyses	O
of	O
a)	O
human	O
plasma	O
and	O
b)	O
urine	O
extracts	O
with	O
spiked	O
xenobiotics,	O
including	O
1	O
nM	O
of	O
tiabendazole.	B

Endocannabinoids	B
are	O
known	O
to	O
have	O
many	O
different	O
functionalities	O
in	O
the	O
gastrointestinal	O
tract,	O
specifically	O
in	O
the	O
colon,	O
and	O
they	O
have	O
been	O
reported	O
to	O
inhibit	O
CRC	O
cell	O
proliferation,	O
mainly	O
via	O
CB1	O
receptors.	O

= 0.762),	O
and	O
methionine	B
sulfoxide	I
(AUC = 0.708),	O
as	O
top	O
predictors	O
of	O
SLE.	O

Briefly,	O
two	O
15	O
minute	O
incubations	O
at	O
40	O
to	O
44°C	O
in	O
an	O
acetone/alcohol	O
solution	O
with	O
agitation	O
were	O
followed	O
by	O
a	O
15	O
minute	O
incubation	O
at	O
64	O
to	O
66°C	O
in	O
a	O
vacuum	O
in	O
a	O
mineral	O
oil	O
paraffin	B
reagent	O
and	O
finally	O
another	O
15	O
minute	O
incubation	O
at	O
64	O
to	O
66°C	O
in	O
a	O
vacuum	O
in	O
a	O
paraffin	B
reagent.	O

Cox	O
proportional	O
hazards	O
regression	O
model	O
test	O
for	O
OS	O
of	O
all	O
patients	O
LN+,	O
lymph	O
node	O
metastasis;	O
ER,	O
estrogen	B
receptor;	O
PR,	O
progesterone;	B
HER2,	O
human	O
epidermal	O
growth	O
factor	O
receptor-2;	O
Genotype-grouping,	O
three	O
groups	O
for	O
genotype	O
C/C,	O
C/T	O
and	O
T/T	O
carriers.	O

The	O
hydroxy	B
metabolite	O
described	O
by	O
Manier	O
et	O
al	O
.	O

For	O
human	O
blood	O
plasma	O
samples,	O
HILIC-LC-MS	O
was	O
performed	O
on	O
a	O
Luna	O
HILIC	O
Diol	B
HPLC	O
column	O
(150	O
×	O
3	O
mM,	O
3	O
µM	O
particle	O
size,	O
Phenomenex,	O
Torrance,	O
CA,	O
USA).	O

(LXA_4	O
),	O
resolvin	B
D1	I
(RvD1)	O
and	O
neuroprotectin	O
D1	O
(NPD1)	O
were	O
quantified.	O

Lipids	O
with	O
more	O
than	O
one	O
fatty	O
acid	O
chain	O
(phosopholipids,	O
diacyl	O
and	O
triacylglycerols),	B
had	O
their	O
identities	O
and	O
concentrations	O
determined	O
using	O
combinatorial	O
lipid	O
reconstruction	O
(CLR,	O
see	O
File	O
S1).	O

[PG(14:0/14:0],	B
1-O-Hexadecanoyl-sn	I
-glycero-3-phosphocholine	I
[lysoPC(16:0)]	I
and	O
1,2-dipalmitoyl-sn	B
-glycero-3-phospho-L-serine	I
[PS(16:0/16:0)],	I
each	O
at	O
the	O
concentration	O
of	O
5	O
µg/ml,	O
was	O
added	O
to	O
1020	O
µl	O
of	O
each	O
dilution.	O

The	O
activities	O
of	O
several	O
specific	O
hepatic	O
enzymes	O
likely	O
influence	O
EM	O
profiles;	O
for	O
example,	O
CYP1A2	O
preferentially	O
hydroxylates	B
estrogens	O
at	O
the	O
second	O
carbon,	O
while	O
CYP3A4	O
and	O
CYP3A5	O
have	O
relatively	O
higher	O
activity	O
for	O
production	O
of	O
16-hydroxylated	O
EM.	O

Ammonium	B
formate	I
(NH_4	O
HCO_2	O
)	O
was	O
purchased	O
from	O
Sigma	O
Aldrich	O
(Gillingham,	O
UK).	O

Levels	O
of	O
arginine	B
and	O
glycerate	B
(A,B)	O
were	O
significantly	O
elevated	O
after	O
long-term	O
storage.	O

It	O
is	O
of	O
interest	O
to	O
note	O
that	O
there	O
is	O
no	O
endogenous	O
3-oxocholest-4-en-26-oic	B
acid	I
in	O
CSF	O
in	O
light	O
of	O
its	O
ability	O
to	O
activate	O
the	O
DAF-12	O
orphan	O
nuclear	O
receptor	O
in	O
C.	O
elegans	O
.	O

Sodium	O
borohydride	O
(NaBH_4	O
),	O
dimethyl	B
sulfoxide,	I
trifluoracetic	B
acid,	I
acetic	B
acid,	I
acetic	B
anhydride,	I
and	O
chloroform	B
(analytical	O
grade)	O
were	O
purchased	O
from	O

Six	O
metabolites	O
were	O
analyzed	O
in	O
the	O
current	O
study:	O
α	B
-hydroxybutyrate	I

The	O
OPLS-DA	O
score	O
plots	O
clearly	O
showed	O
inter-group	O
segregation	O
of	O
samples	O
from	O
subjects	O
who	O
were	O
prednisone-naïve	O
and	O
after	O
12	O
weeks	O
of	O
prednisone	B
therapy.	O

Myoinositol	B
was	O
significantly	O
higher	O
in	O
the	O
MS-like	O
subgroup	O
compared	O
with	O
the	O
NMOSD-like	O
subgroup	O
(mean	O
[SD],	O
0.0023	O
[0.0002]	O
vs	O
0.0019	O
[0.0003]	O
AU;	O
p	O
=	O
0.041).	O

Taurine	B
and	O
hypotaurine	B
metabolism;	O
VLIB:	O
Valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis.	O

However,	O
it	O
is	O
important	O
to	O
note	O
that	O
our	O
findings	O
do	O
not	O
specifically	O
support	O
a	O
causal	O
link	O
between	O
succinate	B
and	O
CE	O
stroke	O
or	O
atrial	O
dysfunction.	O

Using	O
two	O
such	O
metabolites,	O
glutamine	B
and	O
glutamate,	B
we	O
were	O
able	O
to	O
construct	O
a	O
combined	O
pathway	O
map	O
(Fig.	O

RV	B
hypertrophy	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
RV	B
wall	O
weight	O
to	O
LV	O
wall	O
plus	O
septum	O
weight	O
(RV/[LV	O
+	O
S]	O
×	O
Fulton	O
ratio).	O

Metabolite	O
concentrations	O
were	O
determined	O
35	O
minutes	O
after	O
glucose	B
infusion	O
(t35).	O

Following	O
Bonferroni	O
correction	O
for	O
multiple	O
hypothesis	O
testing,	O
3	O
metabolites	O
were	O
significantly	O
associated	O
with	O
CE	O
stroke,	O
including	O
succinate	B
(OR	O
1.71,	O
95%	O
confidence	O
interval	O
[CI]	O
1.36–2.15,	O
p	O
=	O
1.37	O
×	O
10_−6	O
),	O
α-ketoglutarate	B
(OR	O
1.62,	O
95%	O
CI	O
1.29–2.04,	O
p	O
=	O
1.62	O
×	O
10_−5	O
),	O
and	O
malate	B
(OR	O
1.58,	O
95%	O
CI	O
1.26–1.97,	O

c	O
We	O
identified	O
5	O
metabolites	O
(Glycine/leucine,	O
Glucosamine/galactosamine,	O
Malic	B
acid,	I
3-phosphoglycerate,	B
(L)-arginino-succinate	B
and	O
Alanine)	B
significantly	O
elevated	O
in	O
the	O
CSF	O
of	O
patients	O
with	O
metastatic	O
lung	O
cancer	O
to	O
the	O
CNS	O

Interestingly,	O
supplementation	O
of	O
cell	O
culture	O
media	O
with	O
lactate	B
led	O
to	O
a	O
recovery	O
of	O
motility	O
and	O
invasiveness	O
of	O
MUC16	O
knockdown	O
cells.	O

Using	O
a	O
similar	O
instrument,	O
Cajka	O
et	O
al.	O
reported	O
only	O
118	O
glycerophospholipids	B
with	O
RSD	O
<	O
30%,	O
but	O
this	O
could	O
be	O
explained	O
by	O
the	O
short	O
15	O
min–gradient	O
as	O
their	O
focus	O
was	O
more	O
on	O
reproducibility	O
than	O
coverage.	O

From	O
each	O
individual,	O
5	O
ml	O
of	O
whole	O
blood	O
was	O
collected	O
in	O
a	O
vacutainer	O
tube	O
containing	O
Trisodium	B
citrate.	I

The	O
method	O
also	O
provided	O
wide	O
dynamic	O
ranges,	O
with	O
upper	O
linearity	O
of	O
the	O
method	O
at	O
200	O
ng/mL	O
(2-OH-NAP,	O
1-OH-NAP);	B
25	O
ng/mL	O
(2-OH-FLU);	O
20	O
ng/mL	O
(Σ2,3-OH-PHE);	O
and	O
10	O
ng/mL	O
(3-OH-FLU,	O
1-OH-PHE,	B
4-OH-PHE,	B
1-OH-PYR).	B

Four	O
hundred	O
microliters	O
of	O
ice-cold	O
75%	O
methanol	B
with	O
0.1%	O
butylated	B
hydroxytoluene	I
(BHT)	O
was	O
added	O
to	O
the	O
plasma	O
sample.	O

There	O
were	O
higher	O
concentrations	O
of	O
ascorbate	B
and	O
pyruvate	B
in	O
ALS	O
patients	O
compared	O
to	O
non	O
ALS	O
patients	O
(p = 0.003	O
and	O
p = 0.002,	O
respectively).	O

Previous	O
meconium	O
methods	O
have	O
obtained	O
comparable	O
LOQs	O
for	O
amphetamines	B
(2.5–5	O
ng/g)	O

It	O
has	O
not	O
escaped	O
our	O
attention	O
that	O
all	O
of	O
these	O
pathways	O
are	O
affected	O
by	O
statins,	B
either	O
as	O
therapeutic	O
target	O
or	O
side	O
effects,	O
suggesting	O
that	O
bile	O
acids	O
may	O
be	O
important	O
mediators	O
of	O
statin	B
activities.	O

In	O
T2DM	O
Cer	B
species,	O
C16:0	B
was	O
highest,	O
C18:0	B
was	O
second	O
highest,	O
followed	O
by	O
C24:0,	B
and	O
C24:1().	B

Stability	O
of	O
thiopurine	B
nucleotides	O
in	O
different	O
RBC	O
washing	O
and	O
dilution	O
solutions.	O

Go	O
to:	O
Hydrogen	B
sulfide	I
is	O
the	O
third	O
and	O
most	O
recently	O
discovered	O
gaseous	O
signaling	O
molecule	O
following	O
nitric	B
oxide	I
and	O
carbon	B
monoxide,	I
playing	O
important	O
roles	O
both	O
in	O
normal	O
physiological	O
conditions	O
and	O
disease	O
progression.	O

To	O
the	O
best	O
of	O
our	O
knowledge,	O
NH_4	O
F	O
has	O
not	O
been	O
used	O
as	O
an	O
eluent	O
additive	O
for	O
spironolactone,	B
7-alpha-methylthiospironolactone,	B
or	O
canrenone	B
before.	O

Moreover,	O
individual	O
assays	O
have	O
not	O
been	O
developed	O
for	O
many	O
estrogen	B
metabolites.	O

Serum	O
metabolites	O
and	O
FA	B
were	O
measured	O
using	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
and	O
improved	O
direct	O
fatty	O
acid	O
methyl	O
ester	O
synthesis	O
and	O
the	O
gas	O
chromatography/mass	O
spectrometry	O
method,	O
respectively,	O
in	O
subjects	O
who	O
completed	O
follow‐up	O
at	O
6 months	O
(n	O
 = 8).	O

α-Hydroxybutyric	B
acid	I
(α-HB),	O
β-hydroxybutyric	B
acid	I
and	O
3-methyl-2-oxo-butyric	B
acid	I
were	O
eluted	O
with	O
a	O
0.01%	O
formic	B
acid	I
in	O
water/acetonitrile-methanol	O
(1∶1)	O
gradient	O
on	O
a	O
Waters,	O
Acquity	O
BEH	O
C_18	O
column	O
(100	O
mm×2.1	O
mm,	O
1.7	O
µm)	O
at	O
a	O
mobile	O
phase	O
flow	O
rate	O
of	O
0.4	O
ml/min	O
at	O
40°C.	O

The	O
filtrate	O
was	O
desiccated	O
and	O
then	O
dissolved	O
with	O
80	O
µL	O
of	O
isopropanol	B
and	O
Milli-Q	O
(1:1,	O
v/v)	O
for	O
the	O
LC-TOFMS	O
analysis.	O

We	O
found	O
that	O
recent	O
cannabis	B
use	O
was	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
serum	O
glucose,	B
but	O
observed	O
no	O
influence	O
on	O
the	O
CSF	O
metabolite	O
profile	O
(	O
and	O
).	O

The	O
inverse	O
association	O
of	O
plasma	O
GPC	B
as	O
well	O
as	O
urinary	O
betaine	B
with	O
NT-proBNP	O
appears	O
to	O
be	O
a	O
physiologic	O
consequence	O
of	O
BNP	O
signaling	O
with	O
respect	O
to	O
its	O
role	O
in	O
diuresis.	O

(B)	O
AUCs	O
of	O
the	O
discriminant	O
metabolites	O
(citrulline,	O
0.849;	O
valine,	B
0.810;	O
arginine,	B
0.747;	O
methionine,	B
0.745;	O
glycine,	B
0.723;	O
C16-carnitine,	B
0.646).	O

For	O
example,	O
I-3-PA	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
neuronal	O
damage	O
and	O
oxidative	O
stress	O
in	O
the	O
brain	O
[,],	O
KYN	O
is	O
a	O
major	O
route	O
of	O
tryptophan	B
metabolism	O
and	O
has	O
been	O
implicated	O
in	O
pathogenesis	O
of	O
several	O
neuropsychiatric	O
diseases.	O

The	O
affected	O
metabolic	O
pathways	O
in	O
PCOS	O
patients	O
included	O
the	O
tricarboxylic	B
acid	I
(TCA),	O
glycolysis,	O
ketogenesis,	O
lipolysis,	O
proteolysis	O
and	O
urea	B
cycles.	O

Another	O
oxidative	O
stress	O
metabolite,	O
2-hydroxybutyrate,	B
was	O
also	O
strongly	O
elevated	O
in	O
HCC	O
vs.	O
cirrhosis.	O

Briefly,	O
HNSCC	O
cells	O
(UM-SCC-14A)	O
were	O
trypsinized	O
and	O
washed	O
with	O
PBS,	O
and	O
then	O
the	O
Aldefluor	B
substrate	O
was	O
added	O
to	O
1	O
×	O
10_6	O
cells/mL	O
suspended	O
in	O
Aldefluor	B
assay	O
buffer	O
and	O
incubated	O
at	O
37	O
°C	O
for	O
45	O
min.	O

Betaine	B
was	O
correlated	O
inversely	O
with	O
both	O
PLTP	O
and	O
LCAT	O
activity	O
(Table ).	O

a	O
HbA1c	O
was	O
expressed	O
in	O
National	O
Glycohemoglobin	B
Standardization	O
Program	O
(NGSP)	O
unit	O
(%);	O
it	O
would	O
be	O
82	O
±	O
26	O
in	O
T2DM	O
and	O
36	O
±	O
18	O
in	O
control	O
in	O
International	O
Federation	O
of	O
Clinical	O
Chemistry	O
(IFCC)	O
unit	O
(mmol/mol).	O

We	O
present	O
a	O
fully	O
validated	O
and	O
sensitive	O
quantitative	O
LC-MS/MS	O
method	O
for	O
simultaneously	O
measuring	O
the	O
most	O
comprehensive	O
synthetic	O
cannabinoid	B
panel	O
to-date	O
in	O
urine.	O

On	O
the	O
other	O
hand,	O
the	O
signals	O
in	O
the	O
negative	O
direction	O
indicated	O
the	O
down-regulated	O
metabolites	O
in	O
rectal	O
cancer	O
tissues,	O
including	O
myo-inositol,	B
taurine,	B
phosphocreatine,	B
creatine,	B
betaine	B
and	O
dimethylglycine.	B

The	O
experiments	O
showed	O
that	O
cysteine	B
persulfides	I
(CysSSH),	O
oxidized	O
glutathione	O
trisulfide	O
(GSSSG)	O
and	O
cystine	B
were	O
elevated	O
in	O
the	O
aqueous	O
humor,	O
and	O
CysSSH,	O
Cys,	O
and	O
cystine	B
were	O
elevated	O
in	O
the	O
vitreous.	O

Selected	O
ion	O
chromatograms	O
were	O
created	O
using	O
the	O
following:	O
malonyldaidzin	B
m/z	O
503;	O
acetyldaidzin	B
m/z	O
459;	O
daidzin	B
m/z	O
417;	O
malonylgenistin	B
m/z	O
519;	O
acetylgenistin	B
m/z	O
475;	O
and	O
genistin	O
m/z	O
433.	O

A	O
fifth	O
d-EM,	O
16-epiestriol-2,	B
4,16-d	I
_3	O
(d_3	O
-16-epiE_3	O
)	O
was	O
obtained	O
from	O
Medical	O
Isotopes,	O
Inc.	O
(Pelham,	O
NH).	O

Therefore,	O
the	O
up-regulation	O
of	O
(16:0),	O
(18:1)	O
and	O
(18:2)	O
fatty	O
acyl	B
carnitines	I
shown	O
in	O
,	O
suggest	O
transport	O
of	O
de	O
novo	O
synthetized	O
FA	B
to	O
mitochondria,	O
where	O
they	O
are	O
used	O
to	O
energy	O
production	O
via	O
β-oxidation.	O

Group	O
1—PDAC	O
patients,	O
Group	O
2—controls	O
ESI-MS/MS	O
fragmentation	O
pattern	O
typical	O
for	O
all	O
observed	O
isomers	O
of	O
polar	O
lipid	O
PC	B
(34:2)	I
found	O
in	O
this	O
study.	O

We	O
conclude	O
that	O
serum	O
levels	O
of	O
2-HB,	O
3-HB,	O
tyrosine,	B
and	O
citrate	B
are	O
associated	O
with	O
increased	O
3-month	O
mortality	O
in	O
AHF	O
patients	O
and	O
might	O
thus	O
be	O
of	O
prognostic	O
value	O
in	O
AHF.	O

Glutamine	B
pathway,	O
which	O
includes	O
glutamic	B
acid,	I
was	O
previously	O
reported	O
as	O
being	O
upregulated	O
in	O
HCC	O
vs.	O
normal.	O

We	O
found	O
that	O
C18	O
column	O
did	O
not	O
provide	O
a	O
satisfactory	O
retention	O
time	O
to	O
separate	O
proline	B
and	O
IS	O
from	O
the	O
serum	O
matrix,	O
resulting	O
significant	O
matrix	O
effect;	O
HILIC	O
and	O
NH2	O
column	O
provided	O
good	O
retention	O
times	O
for	O
separation,	O
but	O
both	O
resulted	O
broader	O
peaks	O
compared	O
to	O
cellulose	O
column.	O

This	O
work	O
presents	O
a	O
new	O
procedure	O
for	O
the	O
determination	O
of	O
isocyanate-specific	B
Alb	O
adducts.	O

In	O
this	O
regard	O
the	O
concomitant	O
reduction	O
of	O
methylhippuric	B
acid	I
is	O
of	O
interest	O
as	O
this	O
is	O
a	O
marker	O
of	O
a	O
deregulated	O
ß-oxidation	O
of	O
fatty	O
acids.	O

For	O
NMR	O
analysis,	O
dried	O
polar	O
extracts	O
were	O
then	O
resuspended	O
in	O
100	O
mM	O
sodium	B
phosphate,	I
pH	O
7,	O
with	O
0.5	O
mM	O
TSP	O
as	O
internal	O
reference	O
and	O
10%	O
D2O	O
as	O
lock	O
solvent.	O

The	O
450 μL	O
of	O
serum	O
sample	O
was	O
filled	O
in	O
5 mm	O
NMR	O
tube	O
(Wilmad	O
Glass,	O
USA)	O
and	O
a	O
sealed	O
capillary	O
tube	O
containing	O
the	O
known	O
concentration	O
of	O
0.1 mM	O
TSP	O
(Sodium	O
salt	O
of	O
3-trimethylsilyl-(2,2,3,3-d4)-propionic	B
acid)	O
dissolved	O
in	O
deuterium	O
oxide	O
(D_2	O
O)	O
was	O
inserted	O
separately	O
both	O
for	O
the	O
purpose	O
of	O
locking	O
and	O
chemical	O
shift	O
referencing.	O

Modules	O
that	O
correlated	O
the	O
most	O
with	O
age	O
contained	O
also	O
di-	O
and	O
triacylglycerols	B
(module	O
11),	O
SM	O
(module	O
5),	O
PCO-	O
(module	O
17),	O
PE	O
(module	O
18),	O
PC	O
and	O
PI	O
(modules	O
8	O
&	O
12).	O

Patients	O
with	O
large	O
active	O
tumor	O
volumes	O
and	O
high	O
glycolytic	B
burden	O
have	O
significantly	O
higher	O
plasma	O
concentrations	O
of	O
glucose,	B
glycerol,	B
NAGs,	O
threonine,	B
aspartate,	B
valine	B
on	O
one	O
hand	O
but	O
lower	O
concentrations	O
of	O
SM	O
and	O
PC	O
on	O
the	O
other	O
hand	O
(Table ).	O

In	O
nine	O
out	O
of	O
17	O
tumor	O
samples	O
examined,	O
oleic	B
acid	I
levels	O
were	O
>50%	O
lower	O
than	O
those	O
found	O
in	O
their	O
healthy	O
tissue	O
counterparts.	O

In	O
addition,	O
TMAO	B
was	O
obviously	O
positive	O
with	O
4	O
genera	O
and	O
they	O
all	O
belonged	O
to	O
Firmicutes.	O

Responsesurrogatespike	O
Responsesurrogatespike	O
Re	O
sponsesurrogatespike	O
sponsesurrogatespike	O
sponse	O
sponse	O
surrogatespike	O
surrogatespike	O
	O
	O
×	O
100	O
%	O
	O
where	O
Response_serumspike	O
is	O
the	O
peak	O
area	O
count	O
for	O
D-mannose	B
spiked	O
at	O
high	O
QC	O
sample	O
concentration	O
level	O
in	O
human	O
serum,	O
Response_serum	O
is	O
the	O
peak	O
area	O
count	O
for	O
D-mannose	B
in	O
“blank”	O
human	O
serum,	O
and	O
Response_surrogatespike	O
is	O
the	O
peak	O
area	O
count	O
for	O
D-mannose	B
spiked	O
at	O
high	O
QC	O
sample	O
concentration	O
level	O
in	O
surrogate	O
serum.	O

After	O
washing	O
with	O
10	O
mL	O
ammonium	B
acetate	I
solution	O
(0.25	O
mM,	O
pH	O
8.8)	O
and	O
4	O
mL	O
ammonium	B
acetate	I
solution	O
(0.25	B
mM,	O
pH	O
8.8)/methanol	O
(9.5:0.5,	O
v/v),	O
elution	O
was	O
carried	O
out	O
with	O
6	O
mL	O
methanol/water	O
(2:8,	O
v/v)	O
and	O
50	O
mL	O
0.2	O
M	O
formic	B
acid	I
in	O
methanol/water	O
(1:1,	O
v/v).	O

Of	O
note,	O
altered	O
FA	B
exhibited	O
diverse	O
chain	O
length	O
and	O
double	O
bound	O
location,	O
so	O
impairment	O
of	O
NEFA	O
levels	O
cannot	O
be	O
solely	O
attributed	O
to	O
their	O
chemical	O
properties.	O

Also	O
likely	O
related	O
to	O
renal	O
dysfunction	O
is	O
the	O
mild	O
accumulation	O
of	O
myo-inositol	B
in	O
the	O
blood	O
serum	O
of	O
patients	O
at	O
diagnosis	O
compared	O
to	O
treated	O
patients	O
.	O

After	O
vortexing	O
and	O
centrifugation	O
for	O
5	O
min	O
at	O
14,000	O
g	O
the	O
supernatant	O
was	O
loaded	O
on	O
the	O
SPE	O
cartridge	O
and	O
washed	O
with	O
1	O
ml	O
5%	O
(v/v)	O
methanol	B
solution.	O

(cohort	O
of	O
71	O
healthy	O
Caucasians),	O
except	O
for	O
diacylglycerols,	B
for	O
which	O
higher	O
levels	O
were	O
not	O
reported	O
in	O
males.	O

A	O
panel	O
consisting	O
of	O
six	O
urinary	O
metabolite	O
biomarkers	O
(ethanolamine,	O
azelaic	B
acid,	I
histidine,	B
threitol,	B
2,4-dihydroxypyrimidine	B
and	O
levulinic	O
acid)	O
was	O
identified.	O

The	O
most	O
prominent	O
disease	O
effects	O
on	O
metabolites	O
were	O
identified	O
for	O
cysteine	B
(increase),	O
taurine	B
(increase)	O
and	O
for	O
uridine,	B
mannose	B
and	O
several	O
unknowns	O
which	O
all	O
decreased.	O

One	O
of	O
the	O
NIST	O
LC-MS	O
methods	O
chromatographically	O
resolved	O
the	O
3-epi-25(OH)D_3	B
from	O
25(OH)D_3	O
and	O
the	O
other	O
did	O
not.	O

Ammonium	B
hydroxide	I
(NH_4	O
OH),	O
sodium	B
hydroxide	I
(NaOH),	O
potassium	B
hydroxide	I
(KOH),	O
phosphoric	B
acid	I
(H_3	O
PO_4	O
),	O
hydrochloric	B
acid	I
(HCl),	O
and	O
nitric	B
acid	I
(HNO_3	O
)	O
used	O
for	O
pH	O
adjustments	O
were	O
also	O
purchased	O
from	O
Thermo	O
Fisher	O
Scientific.	O

Consistent	O
with	O
these	O
findings,	O
a	O
previous	O
study	O
reported	O
that	O
the	O
plasma	O
level	O
of	O
linoleic	B
acid	I
in	O
MDD	O
patients	O
was	O
significantly	O
lower	O
than	O
the	O
level	O
of	O
healthy	O
subjects	O
.	O

Then	O
ketoamine	B
oxidase	O
reagent	O
was	O
added,	O
incubated,	O
and	O
absorbance	O
measured	O
again	O
at	O
546	O
nm.	O

Analysis	O
was	O
performed	O
at	O
baseline	O
(white	O
bars	O
)	O
and	O
at	O
week	O
24	O
(black	O
bars	O
)	O
in	O
Placebo	O
(a)	O
Pio	O
(b)	O
Omega-3	B
(c)	O
and	O
Pio&	O
Omega-3	B
(d)	O
subgroups.	O

Adjustment	O
was	O
considered	O
for	O
several	O
variables	O
considered	O
risk	O
factors	O
for	O
BE	O
or	O
EA—age	O
(grouped-linear:	O
20–39,	O
40–49,	O
50–59,	O
60–69,	O
70–79,	O
80+	O
years),	O
sex	O
(male/female),	O
smoking	O
history	O
(yes/no),	O
and	O
waist-to-hip-ratio	O
(WHR,	O
<0.9	O
or	O
≥0.9,	O
males;	O
<0.8	O
or	O
≥0.8,	O
females)—and	O
for	O
duration	B
of	O
specimen	O
storage	O
at	O
−80	O
°C	O
(grouped-linear:	O
0–4,	O
5–9,	O
10–14,	O
or	O
15–19	O
years).	O

The	O
individual	O
recoveries	O
were:	O
25(OH)D_3	O
,	O
74%;	O
25(OH)D_2	O
,	O
70%;	O
3-epi-25(OH)D_3	B
,	O
72%;	O
1,25(OH)_2	B
D_3	O
,	O
64%;	O
1,25(OH)_2	B
D_2	O
,	O
62%;	O
24,25(OH)_2	B
D_3	O
,	O
68%.	O

Unlike	O
free	O
cholesterol	B
that	O
is	O
a	O
predominant	O
membrane	O
component,	O
ChoEs	O
may	O
function	O
similarly	O
to	O
TGs	O
as	O
they	O
are	O
used	O
for	O
transport	O
in	O
plasma	O
or	O
as	O
inert	O
storage	O
molecules.	O

These	O
sections	O
contained	O
numerous	O
minute	O
aggregates	O
of	O
BCC	O
sparingly	B
dispersed	O
within	O
normal	O
skin.	O

150 μL	O
of	O
the	O
plasma	O
supernatant	O
was	O
then	O
diluted	O
with	O
450 μL	O
of	O
75 mM	O
sodium	B
phosphate	I
buffer	O
prepared	O
in	O
D_2	O
O	O

Briefly,	O
serum	O
samples	O
were	O
thawed	O
on	O
the	O
day	O
prior	O
to	O
analysis,	O
and	O
300	O
μL	O
of	O
each	O
sample	O
was	O
mixed	O
with	O
300	O
μL	O
of	O
phosphate	B
buffer	O
(NaHPO4,	O
0.075M,	O
pH	O
=	O
7.4).	O

24 h	O
after	O
the	O
surgery	O
(T24)	O
of	O
the	O
patients	O
(n	O
 = 5);	O
both	O
oxylipins	B
are	O
enzymatically	O
generated	O
via	O
lipoxygenase	O
(12-LOX	O
and	O
5-LOX,	O
respectively)	O
from	O
arachidonic	B
acid	I
as	O
precursor	O
PUFA;	O
dotted	O
lines	O
represent	O
the	O
limit	O
of	O
quantification	O
Another	O
5-LOX	O
generated	O
compound	O
LTB_4	O
also	O
promotes	O
the	O
chemotaxis	O
of	O
neutrophils	O
[,	O
,	O
,	O
,	O
,	O
–].	O

Therefore,	O
glycine	B
and	O
C16-carnitine	B
were	O
considered	O
to	O
be	O
potential	O
biomarkers	O
for	O
lung	O
cancer.	O

After	O
fasting	O
for	O
12	O
h,	O
all	O
subjects	O
were	O
challenged	O
with	O
the	O
equivalent	O
of	O
75	O
g	O
of	O
anhydrous	B
glucose	I
dissolved	O
in	O
250	O
mL	O
of	O
water	O
(OGTT).	O

Oxyresveratrol	B
and	O
batatasin	O
III	O
were	O
used	O
in	O
three	O
and	O
four	O
repetitions,	O
respectively.	O

Consequently,	O
the	O
authors	O
found	O
increased	O
pyruvate	B
and	O
lactate	B
levels	O
in	O
brain	O
during	O
hypoxia-ischemia.	O

The	O
significant	O
metabolites	O
in	O
the	O
PTC	O
group	O
compared	O
to	O
healthy	O
subjects	O
also	O
included	O
scyllo-	O
and	O
myo-inositol,	B
tryptophan,	B
propionate,	B
lactate,	B
homocysteine,	B
3-methyl	B
glutaric	I
acid,	I
asparagine,	B
aspartate,	B
choline,	B
and	O
acetamide.	B

Metabolites	O
that	O
are	O
important	O
for	O
correct	O
prediction	O
from	O
plasma	O
include	O
creatinine	B
detected	O
by	O
different	O
analytical	O
methods,	O
lipids	O
(mainly	O
phospholipids),	B
and	O
amino	O
acids.	O

No	O
statistically	O
significant	O
associations	O
were	O
found	O
between	O
mtDNAdel	O
and	O
urinary	O
phthalate	B
metabolite	O
or	O
isoprostane	B
concentrations.	O

These	O
changes	O
may	O
be	O
associated	O
with	O
enhanced	O
inflammation	O
and	O
pro-arrhythmic	O
conditions,	O
supporting	O
the	O
association	O
between	O
FFA	O
levels	O
and	O
the	O
risk	O
of	O
AF	B
development	O
and	O
progression.	O

These	O
fragment	O
ions	O
correspond	O
to	O
the	O
loss	O
of	O
arachidonic	B
acid	I
as	O
a	O
free	O
carboxylic	B
acid	I
from	O
the	O
sn	O
-2	O
position	O
of	O
PI	O
[M−H−R_2	O
COO]_−	O
with	O
a	O
CCS	O
of	O
236	O
Å_2	O
and	O
loss	O
of	O
AA	O
from	O
the	O
sn	O
-2	O
position	O
of	O
PA	O
[M−H−R_2	O
COO]_−	O
and	O
PS	O
[M−H−87−R_2	O
COO]_−	O
with	O
a	O
CCS	O
of	O
200	O
Å_2	O
.	O

Analyst	O
1.6.1/Lipidview	O
1.3	O
software	O
was	O
used	O
to	O
identify	O
molecular	O
species	O
and	O
to	O
determine	O
amounts	O
of	O
individual	O
lipids	O
based	O
on	O
internal	O
standard	O
concentrations	O
assuming	O
comparable	O
ionization	O
of	O
standards	O
and	O
phospholipids.	B

Unadjusted	O
Spearman’s	O
correlations	O
Significance:	O
<0.05	O
‘*’	O
Trp	O
tryptophan,	B
Kyn	O
kynurenine,	B
KTR	O
kynurenine/tryptophan	B
ratio,	O
HK	O
3-hydroxykynurenine,	B
KA	O
kynurenic	B
acid,	I
XA	O
xanthurenic	B
acid,	I
AA	O
anthranilic	B
acid,	I
HAA	O
3-hydroxyanthranilic	B
acid,	I
QA	O
quinolinic	B
acid,	I
Cot	O
cotinine	B
There	O
was	O
a	O
significant	O
inverse	O
correlation	O
between	O
age	O
and	O
tryptophan	B
in	O
this	O
material	O
as	O
a	O
whole	O
(r:	O
−0.24)	O
and	O
in	O
the	O
patient	O
group	O
(r:	O
−0.30)	O
in	O
particular.	O

Another	O
observation	O
of	O
our	O
review	O
included	O
the	O
alteration	O
of	O
myo-inositol,	B
aspartate,	B
glutamate	B
and	O
glutamine	B
in	O
gonadotropin-	O
and	O
PRL-secreting	O
PA.	O

Phenylacetylglycine	B
(PAG)	O
and	O
butyrate	B
are	O
also	O
decreased	O
in	O
AS	O
urine.	O

Relative	O
retention	O
time	O
(RRT,	O
mean)	O
was	O
to	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid.	I

In	O
addition	O
to	O
its	O
function	O
as	O
an	O
organic	O
osmolyte	O
and	O
methyl	O
donor	O
in	O
the	O
remethylation	O
step	O
of	O
the	O
methionine-homocysteine	B
cycle,	O
betaine	B
is	O
known	O
to	O
prevent	O
or	O
reduce	O
the	O
accumulation	O
of	O
fat,	O
especially	O
in	O
the	O
liver,	O
and,	O
thus,	O
is	O
called	O
a	O
lipotrope.	O

Levels	O
of	O
enzymatically	O
produced	O
24S-OHC	O
and	O
27-OHC	O
were	O
not	O
significantly	O
different	O
between	O
any	O
groups	O
irrespective	O
of	O
statin	B
intervention.	O

The	O
carbonic	B
acid	I
increase	O
corroborates	O
with	O
previous	O
report	O
where	O
higher	O
expression	O
of	O
carbonic	O
anhydrase,	O
an	O
enzyme	O
involved	O
in	O
conversion	O
of	O
carbon	B
dioxide	I
to	O
carbonic	B
acid	I
is	O
reported.	O

The	O
absolute	O
concentration	O
(ng/mL)	O
of	O
each	O
PC	O
was	O
calculated	O
based	O
on	O
the	O
peak	O
area	O
of	O
the	O
PC	O
identified	O
in	O
the	O
sample	O
and	O
the	O
peak	O
area	O
of	O
the	O
internal	O
standard	O
of	O
PC	B
(15:0/18:1)	I
corresponding	O
to	O
the	O
sample	O
(the	O
formula	O
was	O
shown	O
in	O
Figure _S1	O
).	O

COPD	O
is	O
associated	O
with	O
alterations	O
in	O
the	O
serum	O
metabolome,	O
including	O
a	O
disruption	O
in	O
the	O
histidine-histamine	B
and	O
creatine	B
metabolic	O
pathways.	O

Cinnabarinic	O
acid	O
and	O
kynurenic	B
acid	I
were	O
present	O
in	O
much	O
smaller	O
amounts	O
than	O
Kyn	O
(F).	O

For	O
the	O
analyses	O
of	O
AA,	O
amino	O
acid	O
standards	O
set	O
A,	O
L-asparagine	B
and	O
L-tryptophane	B
(Cambrigde	O
Isotope	O
Laboratories,	O
Tewksbury,	O
USA)	O
were	O
added	O
to	O
50 μL	O
of	O
the	O
supernatant.	O

Hypoxanthine	B
taken	O
up	O
by	O
tissues	O
can	O
support	O
nucleotide	O
biosynthesis	O
through	O
the	O
purine	B
salvage	O
pathway	O
(;	O
)	O
and	O
may	O
also	O
be	O
indicative	O
of	O
a	O
switch	O
from	O
catabolism	O
to	O
anabolism	O
of	O
nucleic	O
acids,	O
analogous	O
to	O
the	O
simultaneous	O
transitions	O
in	O
fat	O
and	O
protein	O
metabolism.	O

More	O
recent	O
studies	O
by	O
Guo	O
et	O
al.	O
reported	O
that	O
HETE0016,	O
a	O
selective	O
inhibitor	O
of	O
CYP4A/F	O
enzymes	O
(,	O
)	O
inhibited	O
the	O
formation	O
of	O
20-HETE	B
resulting	O
in	O
suppression	O
of	O
both	O
9L	O
gliosarcoma	O
and	O
U251	O
glioma	O
cell	O
proliferation	O
and	O
tumor	O
growth	O
(,	O
).	O

To	O
a	O
certain	O
extent,	O
our	O
results	O
hint	O
that	O
hypoxanthine	B
imbalance	O
can	O
result	O
in	O
AF.	B

This	O
led	O
to	O
the	O
identification	O
and	O
quantification	O
of	O
104	O
lipid	O
species	O
such	O
as	O
cholesterol,	B
cholesteryl	B
esters	I
(CE,	O
n = 3),	O
one	O
diacylglycerol	B
(DG),	O
triglycerides	B
(TG,	O
n = 5),	O
fatty	O
acids	O
(n = 21),	O
ceramides	B
(Cer,	O
n = 4),	O
phosphatidylcholines	B
(PC,	O
n = 18),	O
phosphatidylethanolamines	B
(PE,	O
n = 16),	O
phosphatidylinositols	B
(PI,	O
n = 14),	O
phosphatidylserines	B
(PS,	O
n = 11)	O
and	O
sphingomyelins	B
(SM,	O
n = 11).	O

Bone	O
sialoprotein	O
2,	O
named	O
according	O
to	O
its	O
high	O
sialic	B
acid	I
content,	O
is	O
expressed	O
during	O
the	O
development	O
of	O
bone	O
and	O
cementum.	O

In	O
our	O
study,	O
glycine	B
declined	O
in	O
acute	O
AD	O
patients,	O
potentially	O
indicating	O
the	O
possible	O
relation	O
between	O
endothelium	O
dysfunction	O
and	O
glycine	B
metabolism	O
disorder.	O

The	O
typical	O
positive	O
ion	O
ESI	O
conditions	O
were:	O
capillary	O
voltage,	O
+5	O
kV;	B
declustering	O
potentials	O
(DP1),	O
60	O
V;	O
DP2,	O
10	O
V;	O
focusing	O
potential,	O
250	O
V.	O
The	O
typical	O
negative	O
ion	O
ESI	O
conditions	O
were:	O
capillary	O
voltage,	O
-4.5	O
kV;	B
DP1,	O
60	O
V;	O
DP2,	O
10	O
V;	O
focusing	O
potential,	O
250	O
V.	O
Full	O
scan	O
mass	O
spectra	O
were	O
recorded	O
over	O
the	O
mass	O
range	O
of	O
m/z	O
50–2000	O
using	O
a	O
time-of	O
flight	O
(TOF)	O
analyzer	O
at	O
a	O
resolution	O
of	O
10,000	O
Full	O
Width	O
Half	O
Maximum.	O

Thus,	O
succinate	B
acts	O
as	O
an	O
inflammatory	O
signal	O
and	O
chemokine	O
for	O
migration	O
of	O
monocyte-derived	O
macrophages	O
and	O
dendritic	O
cells	O
[DCs].In	O
addition,	O
succinate	B
in	O
synergy	O
with	O
Toll-like	O
receptors	O
[TLRs]-3	O
and	O
7	O
ligands	O
enhances	O
pro-inflammatory	O
cytokine	O
production	O
by	O
DCs.	O

AUCs	O
of	O
vaccenic	B
acid	I
distinguishing	O
between	O
HCC	O
with	O
cirrhosis	O
and	O
stage	O
A	O
HCC	O
with	O
cirrhosis	O
were	O
0.798	O
and	O
0.869,	O
respectively.	O

Gas	O
chromatography–mass	O
spectrometry-based	O
serum	O
analyses	O
recently	O
identified	O
glutamic	B
acid,	I
lactic	B
acid,	I
and	O
aspartic	B
acid	I
as	O
potential	O
biomarkers	O
for	O
the	O
efficacy	O
of	O
induction	O
chemotherapy	O
in	O
OSCC.	O

Also,	O
prior	O
studies	O
show	O
that	O
their	O
abundance	O
is	O
greater	O
in	O
the	O
colonic	O
mucosa	O
of	O
cirrhotics	O
with	O
HE	O
compared	O
to	O
those	O
without	O
HE	O
and	O
lesser	O
in	O
those	O
on	O
rifaximin	O
and	O
lactulose	B
compared	O
to	O
lactulose	B
alone	O
.	O

These	O
results	O
indicate	O
that	O
tyrosine	B
metabolism	O
was	O
altered	O
in	O
response	O
to	O
glimepiride.	O

Finally,	O
in	O
order	O
to	O
extract	O
the	O
maximum	O
amount	O
of	O
information	O
from	O
our	O
data,	O
PCA	O
and	O
PLS-DA	O
were	O
also	O
performed	O
using	O
the	O
peak	O
areas	O
of	O
all	O
42	O
amines,	O
including	O
1-methylhistidine,	B
3-methylhistidine	B
and	O
glutathione	B
(Supplementary	O
Fig.	O

NS5A	O
also	O
suppresses	O
the	O
membrane	O
expression	O
of	O
the	O
SLC2A1	O
and	O
SLC2A2	O
(GLUT2)	O
transporters	O
and	O
therefore	O
glucose	B
uptake	O
into	O
liver	O
[,].	O

Estimated	O
risks	O
were	O
based	O
on	O
relative	O
hazard	O
(Cox)	O
models	O
for	O
the	O
estrogen	B
and	O
estrogen	B
metabolite	O
profile	O
of	O
each	O
control	O
subject.	O

LPC	O
profiling	O
revealed	O
statistically	O
significant	O
downregulation	O
of	O
LPC(16:0)	B
in	O
HCC	O
relative	O
to	O
AML	O
(P<0.001)	O
and	O
HV	B
(P<0.05).	O

In	O
contrast	O
to	O
alanine	B
M3,	O
which	O
is	O
predominantly	O
starch-derived,	O
protein	O
hydrolysis	O
is	O
significantly	O
contributing	O
to	O
serine	B
M3	O
and	O
glycine	B
M2	O
_13	O
C-enrichment	O
profiles	O
and	O
thus	O
represents	O
one	O
possible	O
explanation	O
for	O
the	O
less	O
pronounced	O
intervention	O
effects	O
observed	O
for	O
serine	B
M3	O
and	O
glycine	B
M2.	O

Triiodothyronine	B
(T3)	O
and	O
thyroxine	B
(T4)	O
are	O
two	O
tyrosine-based	O
thyroid	O
hormones,	O
which	O
are	O
produced	O
by	O
the	O
thyroid	O
gland	O
and	O
then	O
released	O
in	O
the	O
body.	O

While	O
tryptophan	B
catabolism	O
is	O
known	O
to	O
mediate	O
tumor	O
immune	O
evasion,	O
the	O
impact	O
of	O
IDO	O
or	O
TDO	O
activity	O
on	O
CD8	O
T	O
cells	O
was	O
thought	O
to	O
occur	O
through	O
indirect	O
suppression	O
via	O
regulatory	O
T	O
cell	O
activation.	O

Because	O
it	O
is	O
a	O
representative	O
metabolite	O
in	O
urine	O
metabolic	O
pathways,	O
Hypoxanthine	B
was	O
tested	O
first	O
to	O
determine	O
whether	O
it	O
corresponded	O
to	O
the	O
137.08	O
m/z	O
mass	O
peak	O
in	O
urine.	O

Others	O
have	O
also	O
shown	O
that	O
glutamate	B
is	O
an	O
important	O
metabolite	O
in	O
tumorigenesis,	O
including	O
HNSCC,	O
and	O
resonances	O
from	O
glutamate,	B
taurine,	B
choline,	B
lactic	B
acid,	I
and	O
lipids	O
were	O
found	O
to	O
have	O
diagnostic	O
potential	O
for	O
HNSCC;	O
however,	O
our	O
data	O
reveal	O
the	O
mechanistic	O
significance	O
of	O
glutaminolysis	O
in	O
tumorigenesis	O
and	O
its	O
regulatory	O
role	O
in	O
modulating	O
stemness.	O

Importantly,	O
the	O
studies	O
described	O
herein	O
highlight	O
the	O
discovery	O
potential	O
of	O
directed,	O
non-targeted	O
LC-MS	O
and	O
corresponding	O
computational	O
chemical	O
networking	O
approaches,	O
underscore	O
the	O
breath,	O
complexity	O
and	O
diversity	O
of	O
oxylipins	B
present	O
in	O
humans,	O
and	O
provide	O
a	O
foundation	O
for	O
new	O
insight	O
into	O
the	O
role	O
of	O
bioactive	O
lipids	O
in	O
mediating	O
human	O
health	O
and	O
disease.	O

In	O
tissue,	O
the	O
lactate	B
upregulation	O
is	O
associated	O
with	O
alanine	B
and	O
glucose	B
increasing	O
level,	O
two	O
main	O
sources	O
of	O
it.	O

Myo-inositol	B
was	O
previously	O
reported	O
to	O
be	O
low	O
within	O
spinal	O
cord	O
lesions	O
in	O
a	O
group	O
of	O
5	O
NMOSD	O
patients	O
(2	O
AQP4-Ab	O
positive	O
and	O
3	O
negative)	O
and	O
elevated	O
white	O
matter	O
myo-insoitol	O
has	O
been	O
linked	O
with	O
multiple	O
sclerosis.	O

Metabolomics	O
profiling	O
has	O
recently	O
emerged	O
as	O
a	O
powerful	O
screening	O
method	O
that	O
can	O
aid	O
in	O
the	O
prompt	B
diagnosis	O
of	O
various	O
heart	O
diseases.	O

In	O
both	O
groups	O
women	O
were	O
excluded	O
if	O
they	O
were	O
currently	O
taking	O
medications	O
for	O
GI	O
symptoms;	O
had	O
a	O
history	O
of	O
an	O
organic	O
GI	O
disease,	O
or	O
urinary	O
tract	O
and/or	O
gynecological	O
pathology;	O
were	O
currently	O
using	O
daily	O
medications,	O
eg,	O
tricyclic	B
antidepressants,	O
that	O
could	O
alter	O
serotonin	B
or	O
cortisol;	B
were	O
obese,	O
ie,	O
a	O
body	O
mass	O
index	O
(kg/m_2	O
)	O
>	O
35;	O
were	O
employed	O
during	O
the	O
late	O
evening	O
or	O
at	O
night;	O
reported	O
a	O
primary	O
sleep	O
disorder;	O
had	O
a	O
history	O
of	O
severe	O
co-morbid	O
pain	O
or	O
mental	O
health	O
conditions;	O
or	O
consumed	O
beverages	O
containing	O
≥	O
300	O
mg	O
of	O
caffeine	B
in	O
the	O
afternoon/evening,	O
or	O
drank	O
3	O
or	O
more	O
alcohol-containing	O
beverages	O
per	O
day.	O

NNK	O
is	O
rapidly	O
converted	O
into	O
NNAL	O
in	O
the	O
lung	O
and	O
then	O
activated	B
by	O
CYP2A6	O
and	O
CYP2A13	O
to	O
hydroxylated	O
reactive	O
metabolites	O
that	O
alkylate	B
DNA	O
with	O
the	O
concomitant	O
formation	O
of	O
keto	O
alcohol	O
and	O
diol	B
metabolites,	O
respectively.	O

ROC	O
curve	O
analysis	O
demonstrated	O
that	O
oleic	B
acid,	I
octanoic	O
(caprylic)	O
acid	O
and	O
glycine	B
had	O
higher	O
ability	O
than	O
AFP	O
in	O
predicting	O
HCC	O
cases	O
among	O
HCV-cirrhotic	O
patients.	O

In	O
sum,	O
allantoin	B
represents	O
a	O
convenient	O
biomarker	O
of	O
oxidative	O
stress	O
due	O
to	O
its	O
appearance	O
in	O
the	O
_1	O
H-NMR	O
spectrum	O
of	O
human	O
plasma	O
and	O
illustrates	O
how	O
insulin	O
deprivation	O
provokes	O
oxidative	O
stress,	O
possibly	O
by	O
increasing	O
the	O
rate	O
of	O
superoxide	B
production	O
as	O
a	O
consequence	O
of	O
decreased	O
mitochondrial	O
phosphorylation	O
activity.	O

Atherosclerosis	O
is	O
the	O
most	O
important	O
factor	O
and	O
link	O
in	O
the	O
mechanism	O
of	O
stroke	O
and	O
the	O
determination	O
of	O
serum	O
uric	B
acid	I
levels	O
can	O
be	O
used	O
to	O
speculate	O
the	O
risk	O
of	O
IS	O
[,,].	O

A	O
steep	O
linear	O
ramp	O
to	O
(90%	O
ACN,	O
10%	O
sodium	B
acetate	I
buffer,	O
pH	O
4.0)	O
was	O
achieved	O
in	O
1	O
min	O
to	O
serve	O
as	O
the	O
wash	O
step.	O

The	O
parallel	O
analysis	O
of	O
the	O
samples	O
with	O
SIMCA-P_+	O
and	O
Random	O
Forests	O
allows	O
for	O
the	O
ability	O
to	O
verify	O
that	O
ions,	O
which	O
are	O
identified	O
through	O
both	O
ways	O
(i.e.	O
hypoxanthine),	B
are	O
highly	O
significant,	O
as	O
depicted	O
through	O
two	O
completely	O
different	O
algorithms.	O

Thus,	O
the	O
phenomena	O
of	O
metabolic	O
inflexibility	O
mainly	O
described	O
in	O
T2D	O
and	O
other	O
insulin-resistant	O
states	O
could	O
explain	O
some	O
of	O
the	O
alterations	O
occurring	O
in	O
the	O
machinery	O
of	O
lipid	O
and	O
glucose	B
metabolism	O
,	O
.	O

Sodium	B
succinate	I
dibasic,	O
sodium	B
fumarate	I
dibasic,	O
sodium	B
4-hydroxybenzoate,	I
α-ketoglutaric	B
acid	I
sodium	I
salt,	O
4-hydroxyphenylacetic	B
acid,	I
nicotinic	B
acid	I
sodium	I
salt,	O
and	O
3-(trimethylsilyl)propionic	B
acid-d_4	O
(TSP)	O
sodium	O
salt	O
were	O
from	O
SigmaAldrich	O
(St.	O
Louis,	O
MO,	O
USA),	O
and	O
used	O
without	O
further	O
purification.	O

Phospholipids	B
are	O
complex	O
molecules	O
that	O
are	O
essential	O
for	O
intracellular	O
signaling	O
and	O
membrane	O
integrity	O
but	O
are	O
also	O
precursors	O
for	O
several	O
other	O
very	O
important	O
lipid	O
molecules	O
including	O
sphingolipids,	B
ceramides	B
and	O
glycosylphosphatidylinositol	B
anchors	O
.	O

Third,	O
a	O
sulfur	O
transferase	O
enzyme	O
(rhodanese)	O
transfers	O
a	O
sulfur	O
atom	O
to	O
sulfite	B
from	O
another	O
molecule	O
of	O
SQR-bound	O
persulfide	B
to	O
form	O
thiosulfate.	B

Additionally,	O
the	O
in	O
vitro	O
study	O
used	O
only	O
mixed	O
reactive	O
polysulfide	B
species	O
(GS(S)_n	O
SG),	O
i.e.	O
GSSSG,	O
GSSSSG,	O
and	O
GSSSSSG,	O
due	O
to	O
the	O
enormous	O
cost	O
and	O
difficulty	O
of	O
purifying	O
samples	O
of	O
each	O
reactive	O
persulfide	B
and	O
polysulfide,	B
including	O
CysSSH.	O

Study	O
participants	O
for	O
this	O
ancillary	O
metabolomics	O
study	O
were	O
selected	O
from	O
a	O
double	O
blind,	O
randomized,	O
controlled,	O
prospective	O
trial	O
of	O
high-dose	O
cholecalciferol	B
treatment	O
of	O
patients	O
with	O
pulmonary	O
TB	O
disease	O
(clinicaltrials.gov	O
identifier	O
NCT00918086)	O
.	O

In	O
the	O
second	O
model,	O
adjusting	O
for	O
sex	O
and	O
tryptophan,	B
only	O
HAA,	O
riboflavin	B
and	O
cotinine	B
remained	O
significant	O
predictors	O
of	O
ADHD/control	O
status,	O
while	O
KA	O
and	O
XA	O
were	O
no	O
longer	O
significant.	O

In	O
the	O
Nurses’	O
Health	O
Study	O
(NHS)	O
cohort	O
also,	O
adjusted	O
relative	O
risk	O
across	O
extreme	O
quartiles	O
of	O
the	O
ratio	O
became	O
inverse	O
for	O
postmenopausal	O
ER+	O
progesterone	B
receptor-positive	O
(PR+)	O
breast	O
cancer	O
(RR=0.88;	O
95%	O
CI=0.5	O
to	O
1.5).	O

The	O
hydroxylated	O
metabolite	O
eluted	O
at	O
0.99	O
min,	O
before	O
the	O
Met	O
3-OH,	O
was	O
finally	O
identified	O
as	O
the	O
trans-	B
4-OH	I
PBTZ169	O
(E/E	O
,	O
both	O
substituents	O
of	O
the	O
cyclohexyl	O
ring	O
in	O
equatorial	O
(E	O
)	O
positions)	O
by	O
co-injection	O
with	O
the	O
synthetic	O
diastereoisomeric	O
mixture	O
65:35	O
of	O
trans-E/E-	O
and	O
cis	O
-E/A-	O
4OH	O
PBTZ169.	O

For	O
deep	O
labeling,	O
cells	O
were	O
cultured	O
in	O
10	O
cm	O
tissue	O
culture	O
dishes	O
for	O
120	O
h	O
in	O
a	O
custom	O
made	O
RPMI	O
1640	O
labeled	O
medium	O
containing	O
the	O
following	O
stable	O
isotopes	O
(Cambridge	O
Isotope	O
Laboratories,	O
Inc):	O
_13	O
C_6	B
-glucose	I

Isotope	O
labeled	O
internal	O
standards	O
(L-tyrosine-_13	O
C_2	O
and	O
sodium-L-lactate-_13	B
C_3	O
)	O
were	O
purchased	O
from	O
Cambridge	O
Isotope	O
Laboratories	O
(Tewksbury,	O
MA).	O

12	O
acylcarnitines	B
and	O
the	O
sum	O
of	O
hexoses	O
are	O
fully	O
validated	O
as	O
absolutely	O
quantitative.	O

For	O
the	O
GC-qMS,	O
Agilent	O
J&W	O
DB-5MS	O
column	O
(30m	O
×	O
0.25mm	O
×	O
0.25μm	O
film	O
95%	O
dimethyl/	O
5%	O
diphenyl	B
polysiloxane)	I
+	O
10m	O
Duragard	O
Capillary	O
column	O
was	O
installed	O
and	O
calibrated.	O

Forty	O
microliters	O
of	O
a	O
phosphate	B
buffer	O
solution	O
(0.06M	O
Na_2	O
HPO_4	O
/	O
0.04	O

Formation	O
rate	O
of	O
hydroxyanastrozole	B
in	O
a	O
panel	O
of	O
characterized	O
HLMs.	O

The	O
second	O
reason	O
for	O
more	O
lactic	B
acid	I
levels,	O
that	O
it	O
may	O
be	O
due	O
to	O
poor	O
hepatic	O
function	O
a	O
consequence	O
of	O
iron	O
overload	O
in	O
these	O
patients	O
as	O
abnormal	O
concentrations	O
of	O
lactic	B
acid	I
are	O
found	O
in	O
hepatic	O
biliary	O
malignancies	O
in	O
addition	O
to	O
other	O
cancers.	O

Higher	O
amounts	O
of	O
glutamate,	B
taurine,	B
and	O
putrescine	B
in	O
milk	O
required	O
higher	O
levels	O
of	O
calibrators	O
than	O
for	O
plasma	O
in	O
LC-MS/MS	O
mode.	O

The	O
LASSO-selected	O
combination	O
of	O
aspartylphenylalanine,	B
1,3-dimethylurate,	B
and	O
phenylcarnitine	B
provided	O
a	O
correlation	O
coefficient	O
of	O
0.67	O
(p	O
=	O
1.54e_−16	O
)	O
with	O
ΔUPDRS2	O
+	O
3.	O

Xanthosine	B
is	O
associated	O
with	O
purine	B
metabolism	O
and	O
indicates	O
altered	O
purine	B
metabolism	O
that	O
is	O
further	O
supported	O
by	O
the	O
observed	O
significant	O
changes	O
in	O
xanthine,	B
which	O
is	O
also	O
associated	O
with	O
purine	B
metabolism.	O

found	O
serum	O
valine	B
decreased	O
and	O
tyrosine	B
increased	O
after	O
surgery.	O

An	O
interesting	O
observation	O
in	O
the	O
present	O
study	O
was	O
a	O
strong,	O
significant	O
positive	O
HCC	O
risk	O
association	O
for	O
the	O
exogenous	O
metabolite	O
propylene	B
glycol.	I

The	O
recovery	O
efficiencies	O
for	O
acetamiprid	B
and	O
AM-2	O
are	O
100.3	O
±	O
7.7	O
%	O
and	O
97.7	O
±	O
5.2	O
%,	O
respectively.	O

The	O
lowest	O
variations	O
were	O
obtained	O
for	O
the	O
sphingolipid	B
and	O
fatty	O
acyls	O
families	O
with	O
an	O
average	O
RSD	O
of	O
3.9	O
and	O
5.8 %,	O
respectively,	O
whereas	O
the	O
highest	O
variations	O
were	O
found	O
for	O
neutral	O
lipid	O
families	O
with	O
20.1	O
and	O
16.9 %	O
for	O
DG	O
and	O
TG	B
species,	O
respectively.	O

Calibration	O
curves	O
for	O
each	O
estrogen	B
analyte	O
were	O
constructed	O
by	O
plotting	O
peak	O
area	O
ratio	O
between	O
target	O
analyte	O
and	O
its	O
internal	O
standard	O
versus	O
the	O
amount	O
of	O
target	O
analyte.	O

Although	O
the	O
hypothesis	O
concerning	O
the	O
role	O
of	O
histamine	B
in	O
carcinogenesis	O
was	O
proposed	O
in	O
the	O
1960s,	O
the	O
mechanisms	O
by	O
which	O
histamine	B
and	O
HDC	O
are	O
involved	O
in	O
cancer	O
progression	O
remain	O
poorly	O
understood.	O

Aromatic	O
heterocyclic	B
were	O
variously	O
distributed	O
within	O
groups.	O

In	O
contrast	O
to	O
glioblastomas	O
and	O
astrocytomas,	O
tCr	O
correlated	O
positively	O
with	O
alanine	B
and	O
phosphocholine	B
with	O
glycerophosphocholine.	B

By	O
processing	O
the	O
features	O
of	O
interest	O
using	O
their	O
putative	O
metabolite	O
identity	O
utilizing	O
the	O
IPA_®	O
platform	O
(Ingenuity	O
Systems,	O
Inc),	O
a	O
number	O
of	O
canonical	O
pathways	O
in	O
serum	O
and	O
tissue	O
were	O
identified,	O
with	O
amino	B
and	O
fatty	O
acid	O
metabolism	O
ending	O
up	O
among	O
the	O
top	O
ranked	O
pathways.	O

We	O
also	O
lacked	O
data	O
on	O
sex	O
hormone	O
binding	O
globulin	O
(SHBG),	O
a	O
glycoprotein	B
that	O
binds	O
tightly	O
most	O
of	O
the	O
unconjugated	O
estradiol	B
in	O
circulation.	O

Plasma	O
levels	O
of	O
lysophosphatidylcholines	B
(LPC),	O
alkyl-acyl	B
phosphatidic	I
acid	I
34:0	I
(PeA),	I
and	O
lysophosphatidic	B
acids	I
(LPA)	O
in	O
infected	O
versus	O
negative	O
cows	O
(N = 12	O
per	O
group).	O

50 μL	O
of	O
formic	B
acid	I
solution	O
(425 mM	O
in	O
water)	O
was	O
added	O
to	O
adjust	O
the	O
final	O
pH	O
to	O
~2.5.	O

De	O
Giorgi	O
et	O
al	O
also	O
showed	O
that	O
faster	O
absorption	O
of	O
dietary	O
triglycerides	B
after	O
RYGB	O
surgery	O
may	O
be	O
responsible	O
for	O
decreased	O
postprandial	O
and	O
basal	O
triglyceride	B
concentrations	O
observed	O
in	O
these	O
patients.	O

After	O
a	O
second	O
drying	O
procedure	O
by	O
nitrogen	B
gas,	I
100	O
μL	O
of	O
mobile	O
phase	O
solution	O
was	O
added	O
into	O
each	O
well	O
to	O
redissolve	O
the	O
derivatized	O
metabolites.	O

Despite	O
having	O
57	O
targeted	O
oxylipins	B
included	O
in	O
the	O
current	O
method	O
development,	O
seven	O
of	O
them,	O
PD1,	O
RvD_3,	O
RvD_4	O
,	O
and	O
four	O
K-E-LAs	O
have	O
not	O
been	O
included	O
in	O
the	O
evaluation	O
due	O
to	O
availability	O
of	O
only	O
small	O
amounts	O
of	O
analytical	O
standards	O
for	O
spiking.	O

To	O
predict	O
the	O
presence	O
of	O
cachexia,	O
a	O
diagnostic	O
model	O
was	O
established	O
based	O
on	O
three	O
metabolites,	O
namely,	O
carnosine,	B
leucine,	B
and	O
phenyl	B
acetate,	I
with	O
high	O
accuracy	O
and	O
confirmation	O
by	O
the	O
validation	O
set	O
(94.64%	O
by	O
diagnostic	O
feature).	O

20-HETE	B
signaling	O
in	O
HRPTEC	O
cells	O
through	O
activation	O
of	O
the	O
small-GTPase	O
Ras.	O

The	O
percent	O
blood	O
glucose	B
reductions	O
of	O
1	O
at	O
25,	O
50,	O
100	O
and	O
200	O
mg/kg	O

After	O
being	O
dried	O
in	O
a	O
vacuum	O
concentrator,	O
the	O
collected	O
supernatant	O
was	O
suspended	O
in	O
40 μL	O
of	O
methoxy	B
pyridine	I
hydrochloride	I
(20 mg/mL	O
in	O
pyridine)	B
and	O
incubated	O
for	O
30 min	O
at	O
80 °C.	O

Next,	O
we	O
examined	O
inter-relationships	O
between	O
plasma	O
metabolites,	O
depression	O
scores,	O
and	O
tryptophan	B
catabolism	O
(tryptophan	O
and	O
K:T	O
ratio)	O
in	O
the	O
HIV-positive	O
test	O
and	O
validation	O
cohorts.	O

MEDFSTA,	O
statin	B
use	O
coded	O
0–9	O
(0:	O
no	O
statin;	B
1:	O
rosuvastatin;	B
2:	O
simvastatin;	B
3:	O
lovastatin;	B
4:	O
atorvastatin;	B
5:	O
pravastatin;	B
6:	O
fluvastatin;	B
7:	O
cerivastatin;	B
8:	O
unspecified;	O
and	O
9:	O
unknown).	O

Hippurate	B
and	O
other	O
Phe-derivative	O
compounds	O
are	O
produced	O
by	O
the	O
aerobic	O
and	O
anaerobic	O
degradations	O
of	O
aromatic	O
amino	O
acids	O

Indeed,	O
an	O
advantage	O
of	O
our	O
approach	O
is	O
the	O
demonstration	O
of	O
the	O
functional	O
importance	O
of	O
an	O
individual’s	O
mixture	O
of	O
oxylipins	B
and	O
their	O
potential	O
capacity	O
to	O
skew	O
the	O
inflammatory	O
response.	O

Recently,	O
a	O
6-day	O
intervention	O
designed	O
to	O
assess	O
the	O
effects	O
of	O
herbs,	O
vegetarian	O
diet,	O
mediation,	O
yoga,	O
and	O
massage	O
resulted	O
in	O
a	O
decreased	O
abundance	O
of	O
phosphatidylcholines	B
(70%	O
of	O
all	O
detected	O
metabolites),	O
with	O
the	O
remaining	O
metabolites	O
annotated	O
as	O
amino	O
acids,	O
hydroxy-sphingomyelins,	B
acylcarnitines,	B
and	O
biogenic	O
amines.	O

The	O
spectral	O
regions	O
responsible	O
for	O
discrimination	O
were	O
attributed	O
to	O
lactate	B
(δ	O
1.32	O
ppm)	O
and	O
HDL	O
(broad	O
signals	O
at	O
δ	O
0.76–0.80	O
ppm	O
and	O
δ	O
1.16–1.24	O
ppm).	O

Plasma	O
ADMA	B
and	O
OH-Kyn	O
levels	O
were	O
increased	O
in	O
patients	O
with	O
either	O
malnutrition	O
or	O
greater	O
proteinuria	O
(all	O
P	O
<0.001).	O

An	O
FDR	O
threshold	O
of	O
<0.20	O
was	O
selected	O
based	O
on	O
previously	O
published	O
metabolomics	O
studies.35,	O
36,	O
37	O
To	O
explore	O
whether	O
these	O
features	O
were	O
iatrogenic	O
metabolites	O
linked	O
to	O
AD	O
medications,	O
regression	O
models	O
were	O
constructed	O
with	O
diagnosis	O
predicting	O
each	O
m/z	O
feature,	O
adjusting	O
for	O
sex,	O
age,	O
and	O
detection	O
(yes/no)	O
for	O
three	O
AD	O
medications	O
([M + H]_+	O
for	O
memantine	O
(m/z	O
180.1748)	O
and	O
rivastigmine	B
(m/z	O
251.1753),	O

Interassay	O
imprecision	O
was	O
6.63%	O
at	O
70.2	O
nmol/L	O
for	O
25(OH)D_3	O
,	O
5.27%	O
at	O
74.5	O
nmol/L	O
for	O
25(OH)D_2	O
,	O
9.6%	O
at	O
86.3	O
pmol/L	O
for	O
1,25(OH)_2	B
D_2	O
,	O
12.2%	O
at	O
94.6	O
pmol/L	O
for	O
1,25(OH)_2	B
D_3	O
,	O
and	O
10.5%	O
at	O
7.9	O
nmol/L	O
for	O
24,25(OH)_2	B
D_3	O
.	O

There	O
is	O
a	O
clear	O
separation	O
of	O
faecal	O
metabolomics	O
profile	O
in	O
different	O
glycemic	B
stages.	O

In	O
the	O
RF	O
risk	O
score	O
algorithm,	O
bins	O
corresponding	O
to	O
phenylalanine,	B
histidine,	B
a	O
lipid	O
fraction	O
(undifferentiated),	O
methionine,	B
glutamate,	B
acetone,	B
and	O
formate	B
carried	O
the	O
most	O
weight	O
in	O
descending	O
order	O
of	O
rank.	O

Fifty	O
mg	O
of	O
PEG	B
6000	O
was	O
added	O
to	O
a	O
500	O
µL	O
portion	O
of	O
serum.	O

Positivity	O
for	O
ACPA	O
was	O
tested	O
using	O
anti-cyclic	B
citrullinated	O
peptides	O
(anti-CCP2)	O
test,	O
according	O
to	O
manufactures	O
instructions	O
(Euro	O
Diagnostica,	O
Malmö,	O
Sweden)	O
with	O
cut-off	O
set	O
at	O
25	O
AU/mL.	O
ApoA1	O
(g/L)	O
and	O
ApoB	O
(g/L)	O
were	O
analysed	O
using	O
immunoturbimetric	O
method	O
on	O
a	O
Cobas	O
8000	O
instrument	O
(Roche	O
Diagnostics	O
Scandinavia	O
AB).	O

C16-carnitine	B
was	O
revealed	O
to	O
be	O
significantly	O
different	O
between	O
the	O
patients	O
with	O
lung	O
cancer	O
and	O
the	O
healthy	O
controls	O
for	O
the	O
2017	O
data	O
set	O
under	O
multivariate	O
statistical	O
analyses,	O
and	O
for	O
the	O
2015	O
data	O
set	O
under	O
univariate	O
analyses.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
intermediates,	O
including	O
citrate,	B
aconitate,	B
α-ketoglutarate,	B
succinate,	B
fumarate,	B
and	O
malate	B
in	O
CD	O
vs.	O
control	O
and	O
UC	O
subjects.	O

A	O
mixture	O
of	O
the	O
retention	O
time	O
standards,	O
n-dodecane	B
(RI	O
1200),	O
n-pentadecane	B
(RI	O
1500),	O
n-nonadecane	B
(RI	O
1900),	O
n-docosane	B
(RI	O
2200),	O
n-octacosane	B
(RI	O
2800),	O
n-dotriacontane	B
(RI	O
3200),	O
and	O
n-hexatriacontane	B
(RI	O
3600)	O
was	O
included	O
in	O
the	O
final	O
reagent	O
volume.	O

Active	O
CD	O
can	O
be	O
distinguished	O
from	O
inactive	O
disease	O
by	O
weaker	O
ADMA	B
and	O
SDMA	O
correlation,	O
positive	O
association	O
between	O
SDMA	O
and	O
DMA,	B
and	O
by	O
ADMA	B
correlation	O
with	O
both	O
citrulline	B
and	O
arginine.	B

Diazomethane	B
in	O
ether	O
is	O
used	O
for	O
esterification	O
(methylation)	O
of	O
fatty	O
acids	O
by	O
known	O
method.	O

HMEC-1	O
cells	O
were	O
cultured	O
in	O
the	O
Roswell	O
Park	O
Memorial	O
Institute	O
(RPMI)	O
1640	O
medium	O
with	O
10%	O
fetal	O
calf	O
serum,	O
100 U/mL	O
penicillin,	B
and	O
50 μ	O
g/mL	O
streptomycin	B
(Gibco-Invitrogen,	O
CA).	O

Serum	O
cysteinsulfonic	B
acid	I
glycerophosphoinositol,	I
phosphatidylinositol	B
(40:7)	I
and	O
creatinine	B
were	O
also	O
modestly	O
elevated	O
in	O
COPD	O
smokers.	O

Multivariable	O
linear	O
regression	O
analyses	O
were	O
carried	O
out	O
to	O
discern	O
the	O
independent	O
associations	O
PLTP	O
activity	O
and	O
LCAT	O
activity	O
with	O
betaine	B
(Table ).	O

It	O
was	O
found	O
that	O
11	O
parameters,	O
including	O
amino	O
acids,	O
acylcarnitines	B
and	O
some	O
of	O
their	O
relevant	O
ratios,	O
could	O
be	O
used	O
to	O
construct	O
a	O
satisfied	O
differential	O
diagnosis	O
model.	O

[,	O
];	O
2)	O
inhibition	O
of	O
CE-activating	O
enzyme,	O
CYP1B1,	O
by	O
resveratrol	B
as	O
demonstrated	O
in	O
MCF-10F	O
cells	O
and	O
by	O
berry	O
supplementation	O
in	O
animal	O
models;	O
and	O
3)	O
phytochemicals,	O
including	O
resveratrol,	B
inducing	O
UGT	O
activity.	O

Peak	O
areas	O
of	O
metabolites	O
were	O
normalized	O
by	O
that	O
of	O
creatinine.	B

Again,	O
using	O
a	O
combination	O
of	O
exact	O
mass,	O
retention	O
time,	O
MS_2	O
and	O
MS_3	O
spectra,	O
and	O
comparison	O
with	O
authentic	O
standards,	O
the	O
C_27	O
bile	O
acids	O
3β-hydroxycholest-5-en-26-oic	O
acid	O
and	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid	I
were	O
identified.	O

It	O
also	O
seems	O
unlikely	O
that	O
the	O
positive	O
correlations	O
we	O
observed	O
with	O
glycolytic	B
products	O
were	O
due	O
to	O
phosphocreatine	B
acting	O
as	O
a	O
shuttle	O
for	O
high	O
energy	O
phosphates,	B
since	O
that	O
would	O
be	O
needed	O
in	O
a	O
cancer	O
cell	O
that	O
was	O
respiring	O
aerobically,	O
which	O
would	O
mean	O
that	O
the	O
glycolytic	B
products	O
would	O
have	O
correlated	O
negatively	O
with	O
tCr.	O

We	O
have	O
recently	O
shown	O
that	O
major	O
alterations	O
of	O
serum	O
sphingolipid	B
metabolites	O
in	O
chronic	O
liver	O
disease	O
associate	O
significantly	O
with	O
the	O
stage	O
of	O
liver	O
fibrosis	O
in	O
corresponding	O
patients.	O

For	O
example	O
PPAR-α	O
agonist	O
oleoylethanolamide	B
was	O
observed	O
to	O
be	O
significantly	O
high	O
in	O
patients	O
such	O
that	O
its	O
plasma	O
concentration	O
was	O
directionally	O
related	O
to	O
the	O
number	O
of	O
circulating	O
leukemic	O
cells.	O

These	O
results	O
indicate	O
that	O
the	O
effect	O
on	O
the	O
overall	O
appearance	O
induced	O
by	O
the	O
fiber	O
addition	O
was	O
strongest	O
for	O
glucose	B
and	O
was	O
attenuated	O
downstream	O
of	O
glucose.	B

These	O
include	O
three	O
lysophosphatidylcholines	B
and	O
five	O
phosphatidylcholines.	B

(2016)	O
showed	O
that	O
polysaccharides	B
obtained	O
from	O
endophytic	O
F.	O
oxysporum	B
stimulated	O
the	O
sprout	O
growth,	O
flavonoid	B
accumulation,	O
and	O
antioxidant	O
capacity	O
of	O
tartary	O
buckwheat.	O

Many	O
serum	O
amino	O
acids,	O
including	O
valine,	B
leucine/isoleucine,	O
tyrosine,	B
methionine,	B
tryptophan	B
and	O
5-hydroxytrytophan,	B
were	O
down-regulated	O
in	O
EAC	O
patients	O
compared	O
with	O
healthy	O
controls,	O
which	O
indicates	O
an	O
increased	O
demand	O
for	O
and	O
overutilization	O
of	O
amino	O
acids	O
in	O
the	O
tumor	O
tissue,	O
as	O
further	O
evidenced	O
by	O
other	O
reports	O
on	O
the	O
cancer	O
,	O
as	O
well	O
as	O
other	O
malignant	O
tumors	O
,	O
.	O

Fasting	O
venous	O
blood	O
was	O
collected	O
into	O
serum	O
gel,	O
EDTA	O
plasma	O
and	O
fluoride	B
oxalate	I
tubes.	O

The	O
production	O
of	O
lactate	B
is	O
also	O
impaired	O
in	O
chronic	O
liver	O
failure	O
accompanied	O
by	O
a	O
decrease	O
in	O
hepatic	O
pyruvate	O
dehydrogenase	O
activity	O
.	O

However,	O
MS/MS	O
fragmentation	O
data	O
of	O
hydroxy	B
fatty	O
acid	O
standards	O
1,	O
2	O
and	O
3	O
(Table	O
)	O
showed	O
peripheral	O
cut	O
ions	O
similar	O
to	O
those	O
produced	O
by	O
MS/MS	O
of	O
the	O
CRC	O
biomarkers,	O
and	O
consistent	O
with	O
what	O
has	O
been	O
described	O
by	O
others	O
for	O
various	O
hydroxylated	O
long-chain	O
fatty	O
acids	O
[-].	O

With	O
the	O
addition	O
of	O
galactose	B
to	O
the	O
culture	O
medium	O
of	O
fibroblasts	O
from	O
patients,	O
glycosylation	O
was	O
substantially	O
enhanced,	O
as	O
assessed	O
by	O
means	O
of	O
glycosylation	O
of	O
ICAM-1	O
and	O
Glyc-ER-GFP.	B

 ,	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
ribose‐5‐phosphate	B
levels	O
in	O
tumor	O
tissue,	O
the	O
initial	O
substrate	O
in	O
purine	B
pathway.	O

Concentrations	O
of	O
phenylcarboxylic	B
acids	I
(µM)	O
in	O
the	O
serum	O
samples	O
of	O
healthy	O
controls	O
(n	O
=	O
20)	O
and	O
patients	O
with	O
late-stage	O
sepsis	O
(n	O
=	O
22).	O

HPLC	O
conditions:	O
Luna	O
3-µm	O
silica	B
column	O
(i.d.	O

In	O
contrast,	O
2-undecenal	B
has	O
a	O
predicted	O
λ	O
_b:a	O
 = 39;	O
hence,	O
it	O
exchanges	O
partially	O
in	O
the	O
airways	O
and	O
in	O
the	O
alveoli.	O

In	O
humans,	O
SM,	O
also	O
known	O
as	O
sphingophospholipid,	B
is	O
a	O
type	O
of	O
sphingolipid	B
observed	O
in	O
the	O
cell	O
membrane;	O
it	O
represents	O
~85%	O
of	O
all	O
sphingolipids.	B

Five	O
of	O
the	O
19	O
(26%)	O
had	O
compensatory	O
hyperinsulinemia	O
(early	O
metabolic	O
dysregulation)	O
and	O
did	O
not	O
meet	O
the	O
criteria	O
for	O
either	O
prediabetes	O
or	O
MetS.	O
Characteristics	O
of	O
the	O
human	O
study	O
population	O
(n	O
 = 41)	O
_a	O
Reference	O
values	O
from	O
Quest	O
Diagnostics	O
and	O
Atherotech,	O
except	O
where	O
noted	O
_b	O
Cutoff	O
for	O
normoglycemic	B
population	O
established	O
in	O
previous	O
study	O
_c	O
Insulin	O
cutoff	O
from	O
McAuley	O
et	O
al.	O

Adv	O
Prostaglandin	B
Thromboxane	I
Leukot	O
Res.	O

β-Actin	B
was	O
utilized	O
as	O
an	O
internal	O
control.	O

As	O
only	O
two	O
men	O
had	O
cryptorchidism,	O
no	O
association	O
with	O
phthalate	B
exposure	O
was	O
apparent.	O

We	O
found	O
that	O
the	O
GLY	O
metabolite,	O
M1	O
is	O
excreted	O
in	O
the	O
urine	O
as	O
the	O
glucuronide-conjugate.	B

The	O
difference	O
between	O
the	O
β-glucuronidase	O
and	O
β-glucuronidase	O
plus	O
sulfatase	O
treatments	O
provided	O
a	O
quantitative	O
estimate	O
of	O
the	O
sulfate	B
conjugates.	O

The	O
models	O
were	O
first	O
refined	O
through	O
estimation	O
of	O
a	O
new	O
set	O
of	O
parameters,	O
including	O
the	O
significant	O
covariate	O
effects	O
previously	O
identified	O
as	O
relevant	O
(e.g.,	O
body	O
surface	O
area,	O
creatinine	B
clearance	O
as	O
calculated	O
by	O
the	O
Cockcroft	O
and	O
Gault	O
formula,	O
grade	O
of	O
transaminase	O
elevation,	O
and	O
platelet	O
count).	O

Analyzing	O
the	O
correlation	O
between	O
each	O
variable	O
and	O
the	O
first	O
LV,	O
we	O
observed	O
increased	O
levels	O
of	O
isoleucine,	B
leucine,	B
valine,	B
glutamine,	B
tyrosine,	B
and	O
glucose	B
and	O
a	O
decreased	O
level	O
of	O
3-hydroxybutyrate	B
after	O
treatment.	O

[]	O
Consistent	O
with	O
our	O
results,	O
LeWitt	O
and	O
colleagues	O
reported	O
that	O
the	O
CSF	O
concentration	O
of	O
3-hydroxykynurenine	B
was	O
increased	O
in	O
PD	O
patients.	O

For	O
NMR	O
data	O
assembly,	O
one	O
dimensional	O
_1	O
HNMR	O
spectra	O
were	O
obtained	O
on	O
a	O
Bruker	O
DRX-500	O
NMR	O
spectrometer	O
operating	O
a	O
500.13	O
MHZ	O
and	O
Carl	O
Purcell	O
Meiboom	O
Gill	O
(CPMG)	O
90-(t-180-tn-acquisiton).	B

Although	O
generally	O
not	O
native	O
to	O
mammalian	O
cell	O
lipidome,	O
glycerolphospholipids	B
containing	O
odd	O
chain	O
fatty	O
acyls	O
and	O
longer	O
chain	O
fatty	O
acyls	O
on	O
the	O
sn	O
-1	O
position	O
were	O
also	O
observed	O
and	O
passed	O
our	O
validation	O
criteria.	O

Among	O
the	O
identified	O
amino	O
acids	O
and	O
derivatives,	O
glutamate,	B
glutamine,	B
and	O
guadinoacetic	O
acid	O
showed	O
an	O
increasing	O
trend	O
in	O
breast	O
milk	O
of	O
both	O
healthy	O
and	O
IBD	O
mothers,	O
though	O
no	O
significant	O
differences	O
were	O
found.	O

_,	O
Young	O
et	O
al.	O
compared	O
different	O
methods	O
to	O
purify	O
Alb:	O
precipitation	O
with	O
ethanol	B
according	O
to	O
the	O
procedure	O
of	O
Bechtold	O
or	O
by	O
different	O
commercially	O
available	O
albumin	O
purification	O
kits.	O

Interestingly,	O
the	O
average	O
levels	O
for	O
12	O
of	O
the	O
metabolites,	O
including	O
lactic	B
acid,	I
valine,	B
leucine/isoleucine,	O
methionine,	B
tyrosine,	B
tryptophan,	B
myristic	B
acid,	I
linoleic	B
acid,	I
β-hydroxybutyrate,	B
lysine,	B
glutamine	B
and	O
citrate	B
progressively	O
changed	O
with	O
the	O
average	O
levels	O
for	O
BE	O
and	O
HGD	O
patients	O
falling	O
in	O
between	O
the	O
levels	O
for	O
healthy	O
controls	O
and	O
EAC.	O

All	O
signals	O
were	O
normalized	O
to	O
β-actin	B
obtained	O
from	O
the	O
same	O
blot,	O
and	O
expressed	O
as	O
the	O
percent	O
of	O
the	O
normal	O
medium	O
control	O
condition.	O

Isolated	O
epithelial	O
cells	O
were	O
counted	O
using	O
Coulter	O
Counter	O
model	O
ZM	O
(Beckman	O
Coulter,	O
Fullerton,	O
CA,	O
USA)	O
and	O
stored	O
in	O
1	O
ml	O
of	O
methanol	B
at	O
-20°C	O
until	O
further	O
analyses.	O

Data	O
were	O
adjusted	O
for	O
variables	O
that	O
were	O
significantly	O
different	O
between	O
the	O
low	O
NMR	O
and	O
high	O
NMR	O
groups	O
(CPD;	O
Model	O
2),	O
as	O
well	O
as	O
known	O
confounders	O
associated	O
with	O
nicotine	B
metabolism	O
(CPD,	O
race,	O
sex,	O
age,	O
and	O
BMI;	O
Model	O
3).	O

Due	O
to	O
the	O
short	O
half-life	O
of	O
the	O
artemisinin	O
component,	O
e.g.	O
45	O
min	O
for	O
dihydroartemisinin,	B
it	O
is	O
likely	O
that	O
none	O
of	O
the	O
patients	O
had	O
taken	O
a	O
co-formulated	O
ACT	O
(e.g	O
AL)	O
within	O
the	O
last	O
24	O
hours	O
.	O

The	O
serum	O
levels	O
of	O
nearly	O
all	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
metabolic	O
pathway	O
groups	O
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer,	O
but	O
none	O
of	O
the	O
associations	O
remained	O
statistically	O
significant	O
after	O
adjusting	O
for	O
serum	O
level	O
of	O
unconjugated	O
estradiol.	B

The	O
treatment	O
was	O
a	O
single	O
injection	O
of	O
10	O
mg	O
vitamin	O
B-12	O
with	O
100	O
mg	O
pyridoxine	B
and	O
100	O
mg	O
thiamin.	B

In	O
conclusion,	O
we	O
have	O
identified	O
plasma	O
metabolites	O
that	O
were	O
significantly	O
altered	O
during	O
acute	O
sleep	O
deprivation	O
(mainly	O
lipids	O
and	O
acylcarnitines,	B
serotonin,	B
tryptophan,	B
and	O
taurine),	B
all	O
increasing	O
during	O
sleep	O
deprivation.	O

For	O
the	O
GC/TOF-MS	O
measurement,	O
plasma	O
samples	O
(100	O
μl)	O
were	O
thawed	O
before	O
the	O
immediate	O
addition	O
of	O
500	O
μl	O
of	O
methanol	B
(100%)	O
to	O
stop	O
enzymatic	O
activity.	O

MyriMatch	O
was	O
configured	O
to	O
have	O
cysteines	O
to	O
contain	O
carbamidomethyl	O
(+57.021	O
Da)	O
as	O
a	O
dynamic	O
modification	O
and	O
to	O
allow	O
for	O
the	O
possibility	O
of	O
oxidation	O
(+15.996)	O
on	O
methionines,	B
and	O
deamidation	O
(−17.03	O
Da)	O
of	O
N-terminal	O
glutamines.	B

High	O
levels	O
of	O
glucose	B
were	O
found	O
in	O
the	O
plasma	O
samples	O
of	O
lung	O
cancer,	O
as	O
compared	O
to	O
controls.	O

Tuberculosis,	O
Bradykinin,	B
Antibiotics,	O
Treatment	O
response,	O
Recurrence,	O
Outcome	O

No	O
statistical	O
differences	O
(P	O
>0.05)	O
were	O
found	O
between	O
NP,	O
P	O
and	O
HC	O
for	O
presumptive	O
Lactococcus,	B
Streptococcus,	O
Staphylococcus,	O
Bacteroides	O
and	O
Enterobacteriaceae.	O

The	O
results	O
displayed	O
the	O
following	O
three	O
large	O
clusters:	O
(i)	O
sugars	O
and	O
fatty	O
acids,	O
which	O
showed	O
higher	O
abundances	O
in	O
the	O
H	O
group	O
than	O
in	O
the	O
CRC	O
group,	O
and	O
(ii)	O
amino	O
acids	O
and	O
(iii)	O
polyamines,	B
drugs	O
and	O
other	O
metabolites,	O
which	O
showed	O
higher	O
abundances	O
in	O
the	O
CRC	O
group	O
than	O
in	O
the	O
H	O
group	O
(Figure	O
A).	O

Given	O
the	O
euricoyl-sphingomyelin-25(OH)D	B
association	O
observed	O
here,	O
these	O
studies	O
warrant	O
follow-up,	O
including	O
with	O
respect	O
to	O
biological	O
mechanisms.	O

fowleri	O
from	O
making	O
cholesterol	B
de	O
novo	O
.	O

The	O
precipitate	O
was	O
resuspended	O
in	O
75%	O
isopropanol	B
(v/v),	O
and	O
samples	O
were	O
dried	O
for	O
GC/MS	O
with	O
negative	O
electrospray	O
ionization	O
(GCTOF).	O

Another	O
study	O
indicated	O
that	O
the	O
degree	O
of	O
unsaturation	O
in	O
the	O
PC	O
acyl	O
chain	O
modulates	O
the	O
movement	O
of	O
free	O
cholesterol	B
from	O
the	O
cells	O
to	O
HDL	O
[,].	O

We	O
also	O
explored	O
the	O
relationships	O
of	O
cortisol,	B
PSG	O
and	O
self-reported	O
sleep	O
indices	O
with	O
TRP	O
metabolites.	O

	O
Stock	O
solutions	O
of	O
the	O
PUFAs,	O
eicosanoids	B
and	O
docosanoids	B
were	O
prepared	O
by	O
dissolving	O
the	O
solutions	O
obtained	O
from	O
Cayman-Chemicals	O
(Estonia),	O
BioMol	O
International	O
(Kastel-Med	O
KFT,	O
Budapest,	O
H),	O
Sigma-Aldrich	O
(Budapest	O
H),	O
Larodan	O
Lipids	O
(Malmö,	O
Sweden)	O
and	O
Dr.	O
Charles	O
Serhan	O
(Harvard,	O
USA)	O
with	O
methanol	B
to	O
yield	O
a	O
final	O
concentration	O
of	O
10	O
μg/ml.	O

The	O
endocannabinoid	B
system,	O
which	O
can	O
also	O
promote	O
hyperglycemia	O
,	O
warrants	O
further	O
investigation	O
in	O
AML.	O

Taurine	B
is	O
highly	O
concentrated	O
in	O
the	O
muscles	O
and	O
involved	O
in	O
cell	O
volume	O
regulation,	O
calcium	O
homeostasis,	O
membrane	O
stabilization	O
and	O
antioxidant	O
activities,	O
all	O
important	O
with	O
respect	O
to	O
physical	O
exercise.	O

To	O
determine	O
the	O
effect	O
of	O
alpha-linolenic	B
acid	I
(18:3)	O
on	O
prostate	O
cancer	O
cell	O
growth,	O
we	O
have	O
treated	O
the	O
LNCaP	O
and	O
PC3	O
prostate	O
cancer	O
cells	O
with	O
alpha-linolenic	B
acid	I
both	O
in	O
dose	O
and	O
time	O
dependent	O
manner.	O

Additional	O
data	O
analyses	O
were	O
performed	O
in	O
R	O
(3.3.2)	O
as	O
well:	O
the	O
Student	O
t	O
-test	O
was	O
used	O
to	O
compare	O
sequencing	O
characteristics,	O
LINE-1	O
methylation,	O
and	O
global	O
DNA	O
methylation	O
between	O
groups,	O
the	O
Wilcoxon	O
rank-sum	O
test	O
for	O
the	O
comparison	O
of	O
17β-estradiol	B
concentration	O
and	O
both	O
genic-intergenic	O
and	O
promoter-genic	O
methylation	O
ratios	O
between	O
treatment	O
groups,	O
and	O
Spearman	O
correlation	O
to	O
evaluate	O
the	O
correlation	O
between	O
isoflavone	B
concentrations	O
and	O
library	O
sizes	O
resp.	O
locus-specific	O
methylation	O
degrees.	O

The	O
T1D	O
group,	O
hyperglycaemic	B
at	O
baseline,	O
showed	O
significant	O
glucose	B
depletion	O
with	O
acute	O
exercise	O
unlike	O
their	O
control	O
counterparts.	O

Consistent	O
with	O
the	O
the	O
K-M	O
survival	O
result	O
with	O
only	O
1	O
selected	O
serum	O
metabolite	O
(2,4-hexadienoic	O
acid,	I
4-methylphenyl	B
dodecanoate	I
or	O
glycerol	B
tributanoate	I
alone)	O
(Figure	O
)	O
(p	O
<0.05),	O
this	O
might	O
suggest	O
that	O
the	O
3	O
selected	O
serum	O
metabolites	O
(2,4-hexadienoic	O
acid,	I
4-methylphenyl	B
dodecanoate	I
and	O
glycerol	B
tributanoate)	I
can	O
be	O
considered	O
to	O
be	O
useful	O
prognostic	O
factors	O
for	O
GC.	O

(e.g.,	O
leucine	B
OR	O
=	O
2.94,	O
2.51‐3.44).	O

Arginine	B
was	O
important	O
to	O
maintain	O
the	O
stability	O
of	O
the	O
internal	O
environment.	O

Marchesi	O
et	O
al.	O
),	O
and	O
include	O
a	O
number	O
of	O
amino	O
acids,	O
such	O
as	O
leucine,	B
isoleucine,	B
valine,	B
lysine,	B
alanine,	B
tyrosine,	B
phenylalanine,	B
glycine,	B
glutamate,	B
and	O
aspartate,	B
and	O
the	O
microbiota-related	O
metabolites	O
including	O
butyrate,	B
propionate,	B
and	O
lactate.	B

We	O
speculate	O
that	O
either	O
of	O
following	O
mechanisms	O
could	O
be	O
responsible	O
for	O
it;	O
1)	O
massive	O
microgliosis	O
in	O
NMO	O
patients,	O
as	O
well	O
as	O
an	O
overabundance	O
of	O
the	O
CYP27	O
enzyme	O
in	O
microglia,	O
could	O
lead	O
to	O
the	O
overproduction	O
of	O
27-OHC_CSF	O
;	O
2)	O
damaged	O
astrocyte	O
in	O
NMO	O
patients	O
could	O
cause	O
altered	O
de	O
novo	O
synthesis	O
of	O
cholesterol	B
in	O
the	O
CNS,	O
which	O
in	O
turn	O
increased	O
the	O
net	O
influx	O
of	O
the	O
27-OHC	O
from	O
the	O
circulation.	O

To	O
sustain	O
a	O
pH	O
gradient	O
that	O
favors	O
the	O
simultaneous	O
release	O
of	O
lactate	B
and	O
protons	O
from	O
cancer	O
cells,	O
intracellular	O
pH	O
(pH_i	O
)	O
is	O
tightly	O
maintained	O
within	O
a	O
narrow	O
range	O
of	O
7.2–7.4_,	O
.	O

This	O
included	O
the	O
lysophospholipids	B
LPC	O
and	O
LPE,	O
as	O
well	O
as	O
some	O
glycerophospholipids	B
containing	O
a	O
polar	O
head	O
group,	O
such	O
as	O
PC,	O
PI	O
and	O
PG.	B

Thus,	O
our	O
current	O
findings	O
add	O
to	O
the	O
body	O
of	O
evidence	O
implicating	O
glutamine	B
dysregulation	O
and	O
excitotoxicity	O
in	O
AD.	O

However,	O
choline	B
and	O
glucuronic	B
acid	I
have,	O
to	O
our	O
knowledge	O
not	O
been	O
reported	O
before.	O

However,	O
a	O
recent	O
report	O
on	O
in-vitro	O
culture	O
of	O
HNSCC	O
cell	O
lines	O
shows	O
that	O
only	O
glucose	B
(not	O
glutamine)	B
is	O
the	O
dominant	O
energy	O
source	O
required	O
for	O
proliferation	O
and	O
growth,	O
therefore	O
the	O
exact	O
role	O
of	O
glutaminolysis	O
is	O
unclear	O
in	O
HNSCC.	O

The	O
dried	O
samples	O
from	O
each	O
protein	O
removal	O
method	O
were	O
mixed	O
with	O
100	O
μL	O
solution	O
of	O
phosphate	B
buffer	O
(100	O
mM)	O
in	O
D_2	O
O	O
containing	O
66.17	O
μM	O
TSP,	O
made	O
up	O
to	O
550	O
μL	O
with	O
phosphate	B
buffer	O
in	O
D_2	O
O	O
and	O
transferred	O
to	O
5	O
mm	O
NMR	O
tubes.	O

IMS	O
spectra	O
for	O
the	O
deprotonated	O
isomers	O
of	O
a)	O
fructose-6-phosphate,	B
glucose-6-phoshate,	B
and	O
glucose-1-phosphate	B
and	O
b)	O
2,6-dihydroxynaphthalene,	B
2,3-dihydroxynaphthalene	B
and	O
1,5-dihydroxynaphthalene.	B

PE	O
and	O
PI	O
species	O
were	O
identified	O
and	O
quantified	O
directly	O
from	O
lipid	O
solution	O
with	O
hexane	B
washing	O
as	O
previously	O
described	O
in	O
detail	O
,	O
).	O

7-(N	B
-Acetylcsyteinyl)-8,9,10-trihydroxy-7,8,9,10-tetrahydrobenzo[a	I
]pyrene	I
(rev-BPDE-7-NAC)	O
was	O
prepared	O
essentially	O
as	O
described	O
previously.	O

These	O
p	O
‐values	O
indicate	O
that	O
levels	O
of	O
three	O
metabolites,	O
isoleucine,	B
threonine	B
and	O
glutamine,	B
were	O
significantly	O
different	O
between	O
pCR	O
and	O
SD	O
groups	O
and	O
the	O
levels	O
of	O
two	O
metabolites,	O
threonine	B
and	O
glutamine,	B
were	O
different	O
between	O
PR	O
and	O
SD.	O

Carnitine	B
is	O
necessary	O
for	O
fatty	O
acid	O
oxidation	O
and	O
transporting	O
fatty	O
acids	O
from	O
the	O
cytosol	O
to	O
the	O
mitochondria,	O
where	O
it	O
is	O
broken	O
down	O
via	O
the	O
citric	B
acid	I
cycle	O
to	O
release	O
energy.	O

Three	O
keystone	O
faecal	O
metabolites	O
(see	O
Table )	O
were	O
related	O
to	O
HE:	O
methanol	B
(+71%)	O
and	O
threonine	B
(+38%)	O
heightened	O
the	O
risk,	O
while	O
n-butyrate	B
(−23%)	O
lowered	O
it.	O

Fraction	O
2	O
was	O
found	O
to	O
contain	O
another	O
adducted	O
peptide	O
of	O
NO_2	O
-PhIP	O
at	O
a	O
lysine	B
residue	O
(t	O
_R	O
=	O
5.7	O
min).	O

We	O
have	O
also	O
observed	O
a	O
downregulation	O
of	O
CERS4,	O
SMPD1	O
and	O
SMPD3	O
(B),	O
which	O
are	O
responsible	O
for	O
the	O
transformation	O
of	O
sphingosines	B
and	O
sphingomyelins	B
to	O
ceramides.	B

Genomic	O
deoxyribonucleic	B
acid	I
(DNA)	O
was	O
removed	O
by	O
DNase	O
treatment	O
(PureLink™	O
DNase	O
Set).	O

It	O
should	O
also	O
be	O
noted	O
that	O
glycerol-3-P	B
and	O
F6P	O
could	O
not	O
be	O
unambiguously	O
assigned	O
in	O
_1	O
H	O
and	O
_13	O
C-edited	O
experiments	O
due	O
to	O
their	O
low	O
abundance	O
and/or	O
spectral	O
crowding	O
(cf.	O
).	O

The	O
concentration	O
of	O
glutaric	B
acid	I
is	O
higher	O
in	O
younger	O
men	O
and	O
women.	O

(D)	O
TLC	O
of	O
TG	B
and	O
PE	O
in	O
FTD	O
brain	O
(N = 10)	O
compared	O
to	O
control	O
brain	O
(N = 11)	O
and	O
optical	O
density	O
measurements	O
of	O
the	O
bands.	O

Cells	O
were	O
treated	O
with	O
ATRA	O
in	O
a	O
concentration	O
range	O
of	O
0.5	O
nm	O
to	O
3	O
μm	O
in	O
the	O
absence	O
or	O
presence	O
of	O
fixed	O
concentrations	O
(1,	O
10,	O
or	O
100	O
nm)	O
of	O
β-apo-13-carotenone	B
(A	O
).	O

There	O
is	O
also	O
molecular	O
weight	O
evidence	O
for	O
the	O
presence	O
of	O
a	O
dihydroxy-3-oxocholesta-4,6-dien-26-oic	B
acid	I
(CA_4,6	O
-x	I
,y	I
-diol-3-one);	I
however,	O
the	O
MS_3	O
spectrum,	O
although	O
weak,	O
favors	O
the	O
structural	O
isomer	B
7α-hydroxy-3,x	I
-bisoxocholest-4-en-26-oic	I
acid	I
(CA_4	O
-7α-ol-3,x	I
-dione,	I
0.063	O
±	O
0.013	O
ng/ml).	O

Decreased	O
hypoxanthine	B
level	O
was	O
detected	O
in	O
the	O
urine	O
of	O
patients	O
with	O
Non-Hodgkin	O
lymphoma,	O
and	O
the	O
same	O
trend	O
of	O
reduced	O
level	O
was	O
observed	O
in	O
gastric	O
cancer	O
patients	O
compared	O
to	O
normal	O
individuals.	O

On	O
the	O
one	O
hand,	O
the	O
increased	O
bilirubin,	B
serving	O
as	O
an	O
antioxidant,	O
may	O
attenuate	O
hypoxia-induced	O
oxidative	O
stress_,	O
.	O

In	O
contrast,	O
high-resonance	O
signals	O
were	O
observed	O
in	O
this	O
part	O
of	O
the	O
_1	O
H-NMR	O
spectrum	O
after	O
acetonitrile	B
treatment.	O

Distributions	O
of	O
plasma	O
concentrations	O
of	O
corticosterone	B
(A,	O
B),	O
11-deoxycorticosterone	B
(C,	O
D),	O
cortisone	B
(E,	O
F),	O
and	O
17-hydroxyprogesterone	B
(G,	O
H)	O
according	O
to	O
age	O
for	O
males	O
(•	O
A,	O
C,	O
E	O
&	O
G)	O
and	O
females	O
(▴	O
B,	O
D,	O
F	O
&	O
H).	O

Serum	O
glucose	B
levels	O
were	O
also	O
significantly	O
increased	O
after	O
ERCP	O
(0.50	O
vs.	O
0.61 mM,	O
P	O
=0.00047,	O
).	O

In	O
order	O
to	O
associate	O
metabolites	O
at	O
baseline	O
to	O
statin	B
response	O
in	O
LDL-C	O
using	O
extreme	O
subjects’	O
data,	O
the	O
difference	O
in	O
metabolites	O
at	O
baseline	O
between	O
good	O
responders	O
and	O
poor	O
responders	O
was	O
tested	O
using	O
the	O
Wilcoxon	O
rank	O
sum	O
test.	O

(Sigma,	O
St	O
Louis,	O
MO,	O
USA))	O
(3),	O
Taxotere	O
(1),	O
CEF	O
(Cyclophosphamide	O
+	O
Epirubicin,	B
+	O
5-Fluorouracil	B
(CEF)	O
(Sigma,	O
St	O
Louis,	O
MO,	O
USA))	O

The	O
dose	O
of	O
insulin	O
was	O
adjusted	O
based	O
on	O
plasma	O
glucose	B
levels	O
every	O
30–60	O
minutes.	O

Adult	O
PKU,	O
Treatment,	O
Cholesterol,	B
Lipoprotein	O
subclasses,	O
NMR	O

Glucose	B
can	O
both	O
fuel	O
the	O
ATP	B
synthesis	O
for	O
valine	B
stimulated	O
assembly	O
of	O
new	O
mtDNA	O
as	O
well	O
as	O
provide	O
building	O
blocks	O
for	O
nucleotide	O
synthesis.	O

When	O
BCAAs	O
were	O
added	O
to	O
models	O
containing	O
metabolic	O
syndrome,	O
impaired	O
fasting	O
glucose,	B
and	O
BMI	O
(adjusted	O
for	O
age,	O
sex,	O
and	O
ethnicity),	O
aROCs	O
for	O
each	O
model	O
improved	O
(0.62–0.66,	O
0.72–0.74,	O
and	O
0.68–0.69,	O
respectively),	O
although	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
(P	O
values	O
0.10,	O
0.25,	O
and	O
0.34,	O
respectively)	O
(Supplementary	O
Figs.	O

Here,	O
a	O
remarkable	O
difference	O
is	O
the	O
clustering	O
of	O
serotonin,	B
dopamine,	B
5-HIAA,	B
N-acetyl-serotonin	B
and	O
tryptophan	B
(cluster	O
1)	O
and	O
5-methoxytryptamin,	B
melatonin	B
and	O
6-hydroxy-melatonin	B
(cluster	O
2)	O
in	O
the	O
control	O
samples	O
whereas	O
cluster	O
1	O
is	O
completely	O
dissolved	O
and	O
cluster	O
2	O
is	O
maintained	O
in	O
GDM	O
cases	O
(see	O
Figures	O
).	O

Six	O
lipid	O
classes	O
(LPC,	O
PC,	O
PS,	O
PG,	B
PE,	O
and	O
TG)	O
were	O
chosen	O
to	O
represent	O
the	O
most	O
abundant	O
lipid	O
classes,	O
including	O
a	O
balance	O
of	O
hydrophobic-hydrophilic	O
neutral	O
and	O
charged	O
lipids.	O

In	O
this	O
study,	O
glutamine	B
in	O
EC	O
tissues	O
was	O
excessively	O
consumed	O
for	O
the	O
proliferation	O
of	O
cancer	O
cells,	O
resulting	O
in	O
decreased	O
tissue	O
concentrations.	O

In	O
addition,	O
glycerophospholipids	B
are	O
essential	O
components	O
of	O
lipoproteins	O
and	O
influence	O
their	O
metabolism	O
and	O
functions_,	O
.	O

The	O
identified	O
potential	O
small	O
molecules	O
detected	O
cover	O
the	O
essential	O
metabolic	O
pathways,	O
hence	O
allowing	O
the	O
determination	O
of	O
key	O
intermediates	O
of	O
heme	B
biosynthesis	O
and	O
bilirubin	B
degradation,	O
amino	O
acid	O
metabolisms,	O
lipid	O
metabolism,	O
and	O
energy	O
metabolism	O
(tricarboxylic	O
acid	I
cycle).	O

Lactic	B
acid	I
in	O
serum	O
and	O
cancer	O
tissues	O
may	O
indicate	O
poor	O
prognosis	O
in	O
many	O
types	O
of	O
cancers	O
[–].	O

C22:6n3,	O
total	O
omega	O
3,	O
C18:3n6,	O
C15:1,	B
C20:1n9,	O
C12:0,	B
C15:0,	B
C17:0,	B
C18:0	B
and	O
total	O
omega	O
6/	O
total	O
omega	O
3	O
ratio	O
were	O
statistically	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
after	O
Bonferroni	O
correction.	O

To	O
evaluate	O
the	O
potential	O
links	O
between	O
inflammation	O
and	O
breast	O
cancer,	O
levels	O
of	O
urinary	O
prostaglandin	B
E-metabolite	O
(PGE-M),	O
a	O
stable	O
end	O
metabolite	O
of	O
PGE_2	O
,	O
were	O
quantified.	O

The	O
antitumor	O
effects	O
of	O
butyrate	B
were	O
described	O
in	O
studies	O
using	O
colorectal	O
cancer	O
cell	O
lines	O
in	O
which	O
butyrate	B
inhibits	O
growth	O
and	O
induces	O
differentiation	O
and	O
apoptosis.	O

The	O
transitions	O
301.11/286.0	O
and	O
305.11/286.0	O
were	O
used	O
to	O
monitor	O
diosmetin	B
and	O
_13	O
C,d_3	B
-diosmetin,	I
respectively,	O
while	O
the	O
paracetamol	B
resulted	O
from	O
enzymatic	O
degradation	O
and	O
d_4	B
-paracetamol	I
were	O
detected	O
on	O
the	O
transitions	O
152.02/110.1	O
and	O
156.0/114.1,	O
respectively.	O

The	O
ethyl	B
acetate	I
and	O
n	B
-butanol	I
extracted	O
contents	O
were	O
mixed	O
and	O
centrifuged	O
at	O
13000 rpm	O
for	O
10 min	O
before	O
injected	O
for	O
analysis.	O

During	O
this	O
process,	O
carnitine	B
is	O
esterified	O
to	O
form	O
acylcarnitine	B
derivatives	O
catalyzed	O
by	O
acetyl-CoA.	B

Resonances	O
arising	O
from	O
the	O
parent	O
drug	O
and	O
many	O
of	O
its	O
metabolites	O
were	O
observed	O
in	O
the	O
1D	O
NMR	O
urine	O
spectra	O
from	O
participants	O
who	O
had	O
not	O
ingested	O
any	O
drug	O
or	O
had	O
ingested	O
either	O
acetaminophen	B
(,)	O
or	O
ibuprofen	B
(,;	O
as	O
discussed	O
below).	O

The	O
most	O
pronounced	O
decreased	O
was	O
noted	O
in	O
L-PC	O
containing	O
polyunsaturated	O
and	O
very	O
long-chain	O
FA,	B
which	O
decreased	O
by	O
17%	O
and	O
18%	O
(p	O
<	O
0.01),	O
respectively	O
(C).	O

No	O
estrogen,	B
estrogen	B
metabolite,	O
or	O
metabolic	O
pathway	O
group	O
remained	O
statistically	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
after	O
adjusting	O
for	O
unconjugated	O
estradiol.	B

In	O
the	O
current	O
study,	O
intermediates	O
of	O
the	O
upper	O
and	O
lower	O
glycolytic	B
pathway	O
such	O
as	O
glucose,	B
G6P,	O
and	O
fructose	B
6-phosphate	I
(F6P)	O
and	O
metabolites	O
after	O
F6P	O
were	O
absent,	O
it	O
is	O
important	O
to	O
note	O
that	O
these	O
metabolites	O
were	O
measured	O
in	O
tissue	O
extracts	O
in	O
the	O
studies	O
reporting	O
alterations,	O
compared	O
to	O
our	O
urine-based	O
analysis.	O

Then	O
glucuronide	B
metabolites	O
from	O
plasma	O
were	O
separated	O
by	O
micro-liquid	O
chromatography	O
coupled	O
with	O
tandem	O
mass	O
spectrometry	O
on	O
a	O
HALO	O
C18	O
(50 × 0.3	O

Our	O
study	O
indicates	O
that	O
patients	O
with	O
AN	O
in	O
childhood	O
and	O
adolescence	O
after	O
recovery	O
of	O
body	O
weight	O
by	O
treatment	O
showed	O
the	O
same	O
circadian	O
variation	O
of	O
cortisol	B
secretion,	O
as	O
in	O
healthy	O
young	O
adults.	O

The	O
influence	O
of	O
confounding	O
factors	O
such	O
as	O
gender	O
and,	O
age	O
on	O
KP	B
metabolite	O
concentrations	O
was	O
compared	O
between	O
CMM	O
patients	O
and	O
healthy	O
controls	O
using	O
a	O
principal	O
component	O
analysis	O
(PCA).	O

Urine	O
samples	O
were	O
thawed,	O
and	O
900	O
µl	O
of	O
sample	O
were	O
buffered	O
with	O
100	O
µl	O
of	O
a	O
KH_2	O
PO_4	O
/KOH	O
solution	O
at	O
pH	O
7.4	O
in	O
pure	O
D_2	O
0,	O
containing	O
NaN_3	O
to	O
inhibit	O
bacterial	O
growth	O
and	O
Trimethylsilyl	B
propanoic	I
acid	I
(TSP)	O
as	O
a	O
frequency	O
and	O
concentration	O
reference.	O

Two	O
lipids	O
that	O
play	O
prominent	O
roles	O
in	O
mitochondria	O
are	O
cardiolipin	O
(CL)	O
and	O
acylcarnitine	B
(AC).	O

The	O
decrease	O
in	O
hypoxanthine,	B
slight	O
increase	O
in	O
uridine,	B
and	O
the	O
absence	O
of	O
2’-deoxyuridine	B
may	O
indicate	O
direct	O
products	O
from	O
IR	O
exposure	O
are	O
being	O
eliminated	O
and	O
cellular	O
activity	O
is	O
occurring	O
at	O
day	O
7.	O

Lipids	O
typical	O
of	O
lipoprotein	O
particle	O
membranes	O
such	O
as	O
sphingomyelins,	B
cholines,	B
and	O
free	O
cholesterol	B
were	O
positively	O
correlated	O
with	O
insulin	O
sensitivity,	O
whereas	O
triglycerides	B
were	O
negatively	O
correlated.	O

Patients	O
with	O
epilepsy	O
are	O
characterized	O
by	O
the	O
increased	O
serum	O
levels	O
of	O
NAG,	O
lactate,	B
creatine,	B
glycine	B
and	O
lipids	O
(methylene	O
group	O
at	O
1.3	O
ppm),	O
whereas	O
the	O
serum	O
levels	O
of	O
citric	B
acid	I
(at	O
2.55	O
and	O
2.7	O
ppm)	O
and	O
choline	B
are	O
decreased	O
as	O
compared	O
to	O
RG.	O

Each	O
tested	O
condition	O
is	O
presented	O
by	O
its	O
overall	O
score,	O
calculated	O
as	O
a	O
sum	O
of	O
normalized	O
intensities	O
of	O
50	O
metabolites	O
from	O
the	O
hydrophilic	B
standard	O
mixture.	O

Principal	O
components	O
analysis	O
of	O
seminal	O
plasma	O
NMR	O
spectra	O
from	O
men	O
being	O
investigated	O
for	O
prostate	O
cancer	O
(n	O
 = 151),	O
prepared	O
with	O
different	O
buffer	O
solutions	O
(Hanks	O
Balanced	O
Salt	O
Solution:	O
filled	O
square,	O
phosphate	B
buffered	O
saline:	B
empty	O
square).	O

5.5 mmol/l	O
by	O
continuous	O
infusion	O
of	O
15 %	O
glucose.	B

Model	O
2:	O
adjusted	O
for	O
hypertension	O
at	O
sampling	O
and	O
antiphospholipid	B
antibody	O
syndrome.	O

Changes	O
in	O
the	O
methionine	B
cycle	O
may	O
be	O
monitored	O
by	O
betaine–DMG	O
conversion	O
and	O
the	O
variations	O
in	O
5-MTHF	O
concentrations	O
in	O
plasma.	O

(b)	O
Myristic	B
acid	I
(C14:0)	O
and	O
(c)	O
sum	O
of	O
all	O
diacylglycerols	B
(DG)	O
liver	O
contents	O
in	O
NAFL3	O
and	O
NASH	O
patients.	O

(a)	O
A	O
typical	O
800	O
MHz	O
(cryo-probe)	O
1D	O
CPMG	O
_1	O
H	O
NMR	O
spectrum	O
of	O
a	O
pooled	O
human	O
serum	O
after	O
protein	O
precipitation	O
using	O
methanol	B
with	O
expanded	O
regions	O
(b–h)	O
and	O
annotations	O
for	O
all	O
identified	O
metabolites.	O

Compared	O
to	O
ischemic	O
period	O
(0 h),	O
there	O
were	O
marked	O
increase	O
in	O
levels	O
of	O
ascorbic	B
acid	I
and	O
oxidized	O
forms	O
of	O
ascorbate	B
and	O
glutathione	B
namely	O
dehydroascorbic	B
acid	I
and	O
GSSG,	O
following	O
reperfusion.	O

To	O
be	O
certain	O
that	O
tamoxifen	B
levels	O
were	O
in	O
steady-state	O
in	O
the	O
present	O
study	O
all	O
patients	O
included	O
were	O
treated	O
with	O
tamoxifen	B
for	O
at	O
least	O
80	O
days.	O

However,	O
at	O
6	O
months	O
postpartum	O
no	O
significant	O
difference	O
was	O
detected	O
for	O
lactose	B
between	O
the	O
groups.	O

While	O
it	O
was	O
similar	O
in	O
all	O
the	O
subgroups	O
at	O
baseline,	O
M	O
increased	O
(p	O
 = 0.04)	O
in	O
Pio&	O
Omega-3	B
subgroup	O
during	O
the	O
intervention	O
and	O
at	O
week	O
24,	O
it	O
was	O
higher	O
in	O
the	O
Pio&	O
Omega-3	B
compared	O
with	O
the	O
Omega-3	B
subgroup.	O

A	O
control	O
group	O
of	O
28	O
pregnancies	O
with	O
adequate-for-gestational	B
ages	O
(AGA)	O
fetuses	O
were	O
selected	O
among	O
low-risk	O
pregnancies	O
attending	O
third	O
trimester	O
routine	O
pregnancy	O
care	O
and	O
were	O
included	O
if	O
they	O
delivered	O
term	O
neonates	O
with	O
a	O
normal	O
birthweight	O
(between	O
20_th	O
and	O
90_th	O
centile).	O

This	O
is	O
a	O
strength	O
of	O
this	O
work,	O
further	O
strengthened	O
by	O
the	O
analysis	O
of	O
urinary	O
cotinine,	B
which	O
revealed	O
the	O
presence	O
of	O
three	O
active	O
smokers	O
and	O
an	O
overall	O
exposure	O
to	O
second-hand	O
smoke.	O

Meanwhile,	O
the	O
levels	O
of	O
arachidonic	B
acid	I
(C20:4),	O
converted	O
from	O
linoleic	B
acid	I
(C18:2),	O
did	O
not	O
show	O
any	O
statistical	O
difference	O
between	O
the	O
groups.	O

N-acetyl-lysine,	B
glutamate,	B
and	O
aspartate	B
were	O
characterized	O
based	O
on	O
their	O
acute	O
variation	O
in	O
the	O
R_BT	O
vs.	O
NR_BT	O
comparison	O
while	O
aspartate,	B
proline,	B
glutarate,	B
glycerol,	B
and	O
FFA	O
14:0	O
were	O
characterized	O
as	O
the	O
metabolites	O
highly	O
correlated	O
to	O
the	O
prediction	O
of	O
HCC	O
relapse	O
after	O
treatment.	O

The	O
same	O
aspect	O
has	O
been	O
highlighted	O
in	O
other	O
endocrine	O
tumors,	O
such	O
as	O
thyroid	O
cancer,	O
where	O
an	O
elevated	O
concentration	O
of	O
methionine,	B
glutamine,	B
glycine,	B
tyrosine	B
and	O
taurine	B
was	O
reported	O
(,	O
,	O
,	O
–).	O

Four	O
hydroxy-epoxy-octadecenoic	B
acids	I
[9-hydroxy-12,13-epoxy-octadecenoic	O
acid	I
(9-H-12-E-LA),	O
11-hydroxy-12,13-epoxy-octadecenoic	B
acid	I
(11-H-12-E-LA),	O
11-hydroxy-9,10-epoxy-octadecenoic	B
acid	I
(11-H-9-E-LA),	O
13-hydroxy-9,10-epoxy-octadecenoic	B
acid	I
(13-H-9-E-LA)]	O
and	O
three	O
keto-epoxy-octadecenoic	B
acids	I
[11-keto-12,13-epoxyoctadecenoic	O
acid	I
(11-K-12-E-LA),	O
11-keto-9,10-epoxyoctadecenoic	B
acid	I
(11-K-9-E-LA),	O
13-keto-9,10-epoxyoctadecenoic	B
acid	I
(13-K-9-E-LA)]	O
employed	O
in	O
this	O
study	O
were	O
custom-synthesized	O
by	O
Cayman	O
Chemical	O
with	O
purities	O
of	O
>	O
95%.	O

Intermediates	O
in	O
phenylalanine	B
and	O
tyrosine	B
metabolism,	O
including	O
hippuric	B
acid,	I
phenol,	B
and	O
hydroquinone,	B
were	O
produced	O
in	O
gut	O
microbiota	O
by	O
fermentation	O
of	O
dietary	O
polyphenols	O
and	O
aromatic	O
amino	O
acids.	O

Glutamic	B
acid	I
is	O
described	O
in	O
the	O
literature	O
as	O
the	O
most	O
abundant	O
fast	O
excitatory	O
neurotransmitter	O
,	O
.	O

Besides	O
the	O
IAC	O
enrichment,	O
a	O
second	O
step	O
of	O
sample	O
preparation	O
using	O
solid-phase	O
extraction	O
(SPE;	O
Oasis	O
HLB,	O
Waters)	O
was	O
conducted	O
to	O
overcome	O
issues	O
associated	O
with	O
low	O
DON	O
and	O
deepoxy-DON	B
recoveries.	O

This	O
finding	O
has	O
led	O
to	O
better	O
understanding	O
of	O
the	O
regulatory	O
mechanism	O
for	O
ROS	O
signals	O
and	O
speculation	O
that	O
DM,	O
DR	O
and	O
retinal	B
cell	O
degeneration	O
are	O
closely	O
associated	O
with	O
ROS-induced	O
hyperglycemia	O
and	O
oxidative	O
stress_,	O
_,	O
_,	O
.	O

Pathway	O
enrichment	O
analysis	O
of	O
differentially	O
expressed	O
metabolites	O
results	O
showed	O
significant	O
enrichment	O
in	O
4	O
pathways	O
following	O
treadmill	O
exercise,	O
3	O
of	O
which	O
(heparan-,	O
chondroitin-,	O
keratan-sulfate	B
degradation)	O
involved	O
connective	O
tissue	O
metabolism	O
and	O
the	O
fourth	O
involve	O
lipid	O
signaling	O
(linoleate	O
metabolism).	O

Therefore,	O
we	O
tested	O
our	O
hypothesis	O
by	O
investigating	O
SNPs	O
within	O
eleven	O
genes	O
directly	O
involved	O
in	O
the	O
synthesis	O
and	O
degradation	O
of	O
arachidonic	B
acid	I
and	O
have	O
been	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
BP	O
regulation.	O

There	O
were	O
also	O
positive	O
correlations	O
of	O
pyrraline	B
with	O
FL,	O
CML,	B
and	O
MG-H1	O
(r	O
=	O
0.43),	O
suggesting	O
significant	O
contributions	O
to	O
urinary	O
fluxes	O
of	O
these	O
analytes	O
from	O
food—.	O
In	O
subjects	O
with	O
impaired	O
metabolic	O
health,	O
surprisingly,	O
there	O
were	O
no	O
correlations	O
of	O
A1C	O
or	O
HOMA-IR	O
with	O
urinary	O
glycation	O
adducts.	O

A	O
volume	O
of	O
400	O
µL	O
ice-cold	O
methanol	B
was	O
added	O
to	O
plasma	O
sample	O
aliquots	O
containing	O
internal	O
standards,	O
then	O
the	O
mixture	O
was	O
vortexed	O
vigorously	O
for	O
30	O
sec	O
and	O
centrifuged	O
at	O
18000	O
×	O
g	O
0°C	O
for	O
15	O
min.	O

Finally,	O
various	O
amino	O
acids	O
from	O
the	O
urea	B
cycle	O
were	O
found	O
to	O
be	O
divergently	O
affected	O
during	O
TB,	O
including	O
citrulline	B
and	O
arginine	B
(Cit/Arg)	O
which	O
are	O
essential	O
for	O
nitric	B
oxide	I
(NO)	O
production	O
by	O
NO	O
synthase	O
(NOS).	O

Ceramides	B
are	O
not	O
associated	O
with	O
HIV	O
infection	O
per	O
se	O
,	O
but	O
the	O
levels	O
of	O
some	O
metabolites	O
of	O
ceramide,	B
such	O
as	O
dihexosylceramide	B
or	O
GM3,	B
have	O
been	O
found	O
to	O
be	O
decreased	O
secondarily	O
to	O
HIV	O
infection,	O
which	O
suggests	O
possible	O
dysregulation	O
of	O
the	O
enzyme	O
ceramide	O
glucosyltransferase.	O

Ceramide	B
and	O
SMs	O
were	O
quantified	O
through	O
a	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
(LC-MS/MS)	O
system	O
equipped	O
with	O
1290	O
HPLC	O
(Agilent,	O
Waldbronn,	O
Germany)	O
and	O
QTRAP	O
5500	O
(AB	O
Sciex,	O
Toronto,	O
Canada).	O

To	O
ascertain	O
that	O
α-OG	B
treatment	O
modifies	O
the	O
DNA	O
methylome	B
in	O
TRT-HU1	O
cells,	O
we	O
next	O
quantified	O
the	O
levels	O
of	O
DNA	O
methylation	O
and	O
gene	O
expression	O
of	O
the	O
targeted	O
candidate	O
genes.	O

Estradiol	B
is	O
a	O
major	O
contributor	O
to	O
the	O
production	O
of	O
ROS,	O
including	O
hydroxyl	O
radicals,	O
in	O
ovarian	O
and	O
breast	O
epithelial	O
cells,	O
which	O
are	O
the	O
primary	O
sites	O
of	O
these	O
cancers	O
[,].	O

We	O
evaluated	O
JWH-018	O
N-5-hydroxypentyl-glucuronide,	B
the	O
only	O
synthetic	O
cannabinoid	B
glucuronide	I
metabolite	O
reference	O
standard	O
commercially	O
available	O
at	O
the	O
time	O
of	O
method	O
development,	O
for	O
evaluating	O
the	O
effect	O
of	O
increasing	O
urine	O
volume	O
on	O
hydrolysis	O
efficiency,	O
as	O
we	O
did	O
not	O
have	O
fresh	O
authentic	O
specimens.	O

Furthermore,	O
our	O
metabolomics	O
analysis	O
demonstrates	O
that	O
patients	O
having	O
a	O
diabetes	O
remission	O
after	O
one	O
year	O
showed	O
larger	O
declines	O
in	O
amino	O
acids	O
levels	O
of	O
alanine,	B
proline	B
and	O
leucine	B
as	O
well	O
as	O
in	O
the	O
glycine	B
metabolite	O
sarcosine	B
and	O
the	O
glutaminic	B
acid	I
derivate	O
pyroglutamic	B
acid.	I

They	O
found	O
that	O
resonances	O
from	O
citrate,	B
glutamate,	B
and	O
taurine	B
from	O
six	O
spectral	O
sub-regions	O
when	O
analyzed	O
by	O
multivariate	O
analysis	O
could	O
discriminate	O
between	O
BPH	O
and	O
adenocarcinoma	O
and	O
gave	O
good	O
agreement	O
with	O
histopathology.	O

Three	O
metabolites,	O
taurine,	B
piperidine,	B
and	O
a	O
peak	O
at	O
120.0801 m/z	O
,	O
were	O
oral	O
cancer-specific	O
markers	O
(different	O
from	O
all	O
of	O
the	O
other	O
groups	O
at	O
P	O
 < 0.05;	O
Steel–Dwass	O
test)	O
and	O
eight	O
metabolites	O
(leucine	O
with	O
isoleucine,	B
tryptophan,	B
valine,	B
glutamic	B
acid,	I
phenylalanine,	B
glutamine,	B
and	O
aspartic	B
acid)	O
were	O
pancreatic	O
cancer-specific	O
markers.	O

Plasma	O
glucose	B
concentration	O
was	O
measured	O
with	O
a	O
hexokinase	O
assay	O
(MACS:	O
Quest	O
Diagnostics,	O
Cambridge,	O
MA;	O
FOS:	O
Abbott	O
Laboratories,	O
IL).	O

Lee	O
and	O
Hastie	O
proposed	O
to	O
describe	O
the	O
joint	O
probability	O
p(x,y;Θ)	B
as	O
a	O
pairwise	O
graphical	O
model:	O
p(x,y;Θ)	B
p(x,y;Θ)	I

Analysis	O
of	O
clinical	O
data	O
revealed	O
that	O
a	O
set	O
of	O
few	O
metabolites	O
including	O
PAI-1,	O
azotemia,	O
and	O
creatinine	B
were	O
increased	O
in	O
the	O
T2DM-C	O
group	O
and	O
potentially	O
related	O
to	O
disease	O
complications.	O

These	O
results	O
suggest	O
that,	O
in	O
healthy	O
control	O
subjects,	O
estrogen	B
metabolism	O
is	O
balanced,	O
i.e.	O
the	O
level	O
of	O
estrogen-DNA	O
adducts	O
is	O
low	O
and/or	O
the	O
levels	O
of	O
estrogen	B
metabolites	O
and	O
conjugates	O
are	O
high.	O

Genetic	O
variations	O
in	O
SULT1A2	O
and	O
2A1	O
have	O
been	O
associated	O
with	O
alteration	O
in	O
drug	O
metabolism	O
of	O
tamoxifen,	B
salbutamol,	O
as	O
well	O
as	O
androgenic	O
steroids	O
(Boulton	O
and	O
Fawcett	O
;	O
Gjerde	O
et	O
al.	O

To	O
correct	O
for	O
sodiated	O
adduct	O
formation,	O
total	O
area	O
of	O
sodiated	O
and	O
protonated	O
ions	O
was	O
used	O
in	O
calculations	O
of	O
matrix	O
effect	O
for	O
melatonin.	B

Taurochenodeoxycholate	B
(TCDCA),	O
taurocholate	B
(TCA),	O
glycohyocholate	B
(GHCA)	O
and	O
glycocholate	B
(GCA)	O
were	O
17.8-,	O
15-,	O
6.6-	O
and	O
4-fold	O
upregulated	O
in	O
DC	O
vs.	O
NHC	O
respectively.	O

All	O
estrogens	O
and	O
estrogen	B
metabolites	O
were	O
statistically	O
significantly	O
correlated	O
with	O
BMI,	O
with	O
unconjugated	O
estradiol	B
most	O
strongly	O
correlated	O
(Pearson	O
correlation	O
(r	O
)=0.45).	O

The	O
daily	O
dose	O
of	O
KBR	O
represented	O
0.9	O
g	O
of	O
total	O
phenol,	B
including	O
17.5	O
mg	O
of	O
myricetin,	B
9.6	O
mg	O
of	O
genistin,	O
7.2	O
mg	O
of	O
quercetin,	B
1.2	O
mg	O
of	O
daidzein,	B
and	O
1.2	O
mg	O
of	O
eriodictyol,	B
as	O
well	O
as	O
126	O
kcal	O
(65.5%	O
as	O
carbohydrate,	O
10.1%	O
as	O
protein,	O
and	O
5.4%	O
as	O
fat).	O

After	O
DESI-MSI,	O
the	O
tissue	O
sections	O
were	O
stained	O
(hematoxylin	O
and	O
eosin,	B
H&E)	O
and	O
blindly	O
evaluated	O
by	O
an	O
expert	O
pathologist.	O

Vitamin	B
E	I
succinate	I
(1.41	O
fold;	O
p = 1.39E-02)	O
showed	O
an	O
increase	O
and	O
3-deoxyvitamin	B
D3	O
(0.49	O
fold;	O
p = 1.86E-05)	O
showed	O
a	O
decrease	O
in	O
abundance	O
in	O
the	O
post-treatment	O
group.	O

Ten	O
lysophosphatidylcholines	B
(lysoPCs)	O
containing	O
C14:0,	B
C16:1,	B
C16:0,	B
C18:2,	B
C18:1,	B
C18:0,	B
C20:5,	B
C20:4,	B
C20:3,	B
and	O
C22:6	B
were	O
significantly	O
higher	O
in	O
prehypertensive	O
subjects	O
than	O
in	O
control	O
subjects	O
(q	O
 = 5.41E-08,	O
5.05E-14,	O
6.28E-16,	O
1.27E-0.5,	O
4.46E-10,	O
1.70E-05,	O
6.81E-05,	O
6.52E-11,	O
2.35E-09,	O
and	O
3.23E-09,	O
respectively)	O
before	O
and	O
after	O
adjusting	O
for	O
all	O
confounding	O
variables	O
including	O
Lp-PLA_2	O
activity	O
and	O
ox-LDL.	O

It	O
is	O
noticeable	O
that	O
citrate	B
makes	O
some	O
contribution	O
to	O
the	O
group	O
separation	O
in	O
the	O
model:	O
compared	O
to	O
the	O
level	O
of	O
citrate	B
in	O
the	O
remission	O
state,	O
the	O
level	O
of	O
citrate	B
seems	O
to	O
be	O
a	O
little	O
lower	O
in	O
the	O
relapse	O
state	O
while	O
the	O
statistical	O
difference	O
between	O
them	O
was	O
not	O
significant	O
(,	O
).	O

Cancer	O
initiation	O
by	O
estrogens	O
is	O
based	O
on	O
estrogen	B
metabolism	O
that	O
involves	O
a	O
disrupted	O
homeostatic	O
balance	O
between	O
activating	O
and	O
deactivating	O
pathways.	O

Interestingly,	O
for	O
ceramides,	B
differences	O
in	O
hydrophilicity	O
due	O
to	O
long-chain	O
bases	O
(LCB)	O
as	O
well	O
as	O
hydroxylated	O
and	O
non-hydroxylated	O
fatty	O
amid	O
chains	O
led	O
to	O
SFC	O
separation	O
within	O
the	O
class.	O

Amino	O
acids	O
in	O
particular	O
are	O
relatively	O
stable	O
for	O
several	O
years,	O
with	O
the	O
exception	O
of	O
their	O
keto-acids	B
(e.g.,	O
KIC),	O
which	O
we	O
have	O
not	O
included	O
in	O
the	O
present	O
analysis.	O

There	O
were	O
about	O
an	O
equal	O
number	O
of	O
results	O
reported	O
for	O
phosphopeptides	B
without	O
phosphorylation	O
modifications	O
(these	O
account	O
for	O
missing	O
line	O
numbers	O
in	O
the	O
tables).	O

_2	O
Impaired	O
glucose	B
tolerance:	O
FPG	O
≥	O
110	O
mg/dL,	O
hemoglobin	O
A1c	O
≥	O
6.5%,	O
or	O
on	O
medication.	O

Second,	O
a	O
[3,4-_13	B
C_2	I
]glucose	I
tracer	O
was	O
applied;	O
in	O
this	O
case,	O
the	O
synthesis	O
of	O
M2	O
erythritol	B
isotopologs	O
was	O
predicted.	O

Performance	O
characteristics	O
of	O
five	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry	O
(LC-MS/MS)-based	O
multibiomarker	O
methods	O
developed	O
for	O
the	O
determination	O
of	O
mycotoxins	B
and	O
relevant	O
metabolites	O
in	O
human	O
urine	O
AFB	O
_1	O
	O
aflatoxin	B
B_1	O
,	O
AFB	O
_2	O
	O
aflatoxin	B
B_2	O
,	O
AFG	O
_1	O
	O
aflatoxin	B
G_1	O
,	O
AFG	O
_2	O
aflatoxin	B
G_2	O
,	O
AFM	O
_1	O
	O
aflatoxin	B
M_1	O
,	O
CIT	O
citrinin,	B
DOM	O
de-epoxy	B
deoxynivalenol,	I
DON	O
deoxynivalenol,	B
FB	O
_1	O
	O
fumonisin	O
B_1	O
,	O
FB	O
_2	O
fumonisin	O
B_2	O
,	O
GlcA	O
glucuronide,	B
Gua	O
guanine,	B
IAC	O
immunoaffinity	O
column,	O
LOD	O
limit	O
of	O
detection,	O
NIV	O
nivalenol,	O
OTA	O
ochratoxin	B

In	O
addition	O
to	O
tissue	O
specificities	O
in	O
the	O
GG	O
class	O
pattern,	O
our	O
thorough	O
analysis	O
of	O
GGs	O
using	O
LC/MS	O
also	O
revealed	O
specificities	O
in	O
the	O
molecular	O
species,	O
i.e.	O
ceramide	B
type,	O
pattern	O
of	O
tissues	O
and	O
GG	O
classes.	O

The	O
longer	O
the	O
duration,	B
the	O
more	O
severe	O
the	O
condition	O
is.	O

Pyrimidine	B
metabolism,	O
3.	O

Solvents	O
dichloromethane	B
(CH_2	O
Cl_2	O
),	O
methanol	B
(MeOH),	O
tetrahydrofuran	B
(THF),	O
pyridine	B
(PY),	O
ethyl	B
acetate	I
(EtOAc),	O
hexane	B
(HEX)	O
and	O
acetonitrile	B
(ACN)	O
were	O
obtained	O
from	O
SINTORGAN	O
S.A.	O
(Buenos	O
Aires,	O
Argentina).	O

Subsequently,	O
multiple	O
logistic	O
regression	O
analyses	O
of	O
these	O
metabolites	O
showed	O
uric	B
acid,	I
sphinganine	B
and	O
adrenoyl	B
ethanolamide	I
were	O
potential	O
biomarkers	O
of	O
ischemic	O
stroke	O
with	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
0.941.	O

In	O
addition	O
to	O
the	O
pre-digestive	O
properties	O
of	O
food	O
fermentation,	O
the	O
bacterial	O
transformation	O
of	O
free	O
amino	O
acid	O
by	O
lactic	B
acid	I
bacteria	O
provides	O
innovative	O
solutions	O
for	O
the	O
identification	O
of	O
candidate	O
FIBs	O
for	O
food	O
fermentation.	O

Meanwhile,	O
we	O
found	O
that	O
the	O
galactose	B
metabolism	O
was	O
significantly	O
affected	O
in	O
T2DM	O
patients	O
with	O
PSD.	O

Thus,	O
the	O
development	O
of	O
a	O
common	O
metabolomics	O
platform,	O
where	O
a	O
wide	O
range	O
of	O
amino	O
acids	O
and	O
methylarginines	B
can	O
be	O
measured	O
constitutes	O
an	O
important	O
unmet	O
need.	O

Additionally,	O
in	O
primary	O
and	O
metastatic	O
cases,	O
medium-chain	O
acylcarnitines	O
were	O
positively	O
associated	O
with	O
suberic	B
acid,	I
which	O
also	O
correlated	O
with	O
the	O
risk	O
of	O
PSA	O
progression.	O

The	O
metabolites	O
with	O
the	O
highest	O
discriminating	O
potential	O
identified	O
in	O
our	O
study	O
belong	O
to	O
lysophosphatidylcholines	B
(lysoPC	O
26:0	O
and	O
lysoPC	O
26:1).	O

For	O
other	O
PCs	O
such	O
as	O
PC36:5	B
we	O
found	O
a	O
V-pattern	O
or	O
a	O
steady	O
increase	O
(PC40:7),	O
both	O
metabolites	O
have	O
been	O
shown	O
to	O
be	O
inversely	O
associated	O
with	O
coronary	O
artery	O
disease	O
and	O
mortality.	O

List	O
of	O
LC	O
retention	O
time	O
and	O
MRM	O
transitions	O
for	O
each	O
of	O
the	O
oxylipins	B
included	O
in	O
the	O
assay.	O

Sputum	O
supernatant	O
was	O
assessed	O
for	O
interleukin	O
(IL)-1β,	B
-4,	O
-5,	O
-6,	O
-13,	O
and	O
tumor	O
necrosis	O
factor	O
(TNF)-α,	O
and	O
serum	O
was	O
detected	O
for	O
leptin,	O
adiponectin	O
and	O
C-reactive	O
protein.	O

Direct	O
measurement	O
of	O
skeletal	O
muscle	O
insulin-stimulated	O
GU	O
circumvents	O
the	O
possible	O
confounding	O
to	O
M-value	O
measurement	O
by	O
endogenous	O
glucose	B
production.	O

Urine	O
creatinine	B
(u-Cr)	O
and	O
cystatin	B
C	O
(u-CysC)	O
in	O
the	O
urine	O
samples	O
of	O
TSG,	O
ASG,	O
and	O
NSG	O
were	O
analyzed	O
by	O
a	O
contract	O
research	O
organization	O
(Ikagaku	O
Co.,	O
LTD,	O
Kyoto,	O
Japan),	O
except	O
for	O
three	O
of	O
TSG	O
and	O
one	O
of	O
ASG	O
because	O
the	O
sample	O
volume	O
was	O
too	O
small.	O

In	O
individuals	O
with	O
depressed	O
25(OH)D	O
level	O
but	O
elevated	O
1α,25(OH)_2	B
D_3	O
production,	O
dietary	O
supplementation	O
with	O
vitamin	B
D	I
or	O
sun	O
exposure	O
may	O
have	O
a	O
deleterious	O
effect	O
because	O
of	O
possible	O
1α,25(OH)_2	B
D_3	O
deregulated	O
extra-renal	O
production	O
and	O
the	O
resulting	O
toxicity,	O
as	O
observed	O
for	O
example	O
in	O
some	O
lymphomas,	O
sarcoidosis	O
and	O
tuberculosis.	O

Clinicians	O
should	O
be	O
cautious	O
about	O
selecting	O
TAM	O
as	O
the	O
adjuvant	O
endocrine	O
therapy	O
in	O
female	O
Chinese	O
patients	O
below	O
40	O
years	O
of	O
age	O
and	O
carrying	O
homozygous	O
mutant	O
T/T	O
of	O
CYP2D6*10	O
(C100T)	O
genotype,	O
which	O
is	O
related	O
to	O
lower	O
endoxifen	B
level.	O

In	O
the	O
subjects	O
who	O
were	O
diagnosed	O
in	O
the	O
first	O
0‐6	O
years,	O
however,	O
low	O
1,5‐AG	B
level	O
showed	O
a	O
statistically	O
significantly	O
higher	O
risk	O
(Table	O
).	O

The	O
residue	O
was	O
reconstituted	O
in	O
50	O
μL	O
of	O
mobile	O
phase	O
B	O
(acetonitrile/methanol	O
=	O
95/5,	O
v/v)	O
and	O
25	O
μL	O
of	O
mobile	O
phase	O
A	O
(water	O
with	O
formic	B
acid,	I
pH	O
=	O
3.25),	O
and	O
centrifuged	O
at	O
13500	O
g	O
and	O
4	O
°C	O
for	O
20	O
min.	O

Fatty	O
acids	O
and	O
their	O
esters	O
(e.g.	O
octadecanoic	B
acid,	I
heptadecanoic	B
acid,	I
tetradecanoic	B
acid,	I
eicosanoic	B
acid,	I
cis	O
vaccenic	O
acid)	O
showed	O
altered	O
levels	O
in	O
breast	O
cancer	O
patients	O
in	O
our	O
study.	O

Levels	O
of	O
glucose	B
and	O
a	O
number	O
of	O
glucose-related	O
metabolites	O
(1,6-anhydro-β-D-glucose,	O
mannose,	B
lactose)	B
increase	O
in	O
the	O
urine	O
(CPF	O
increase	O
>	O
FS	O
increase).	O

Another	O
study	O
found	O
that	O
increased	O
diacyl-phosphatidylcholines	B
and	O
reduced	O
acyl-alkyl-	B
and	O
lysoPCs	O
together	O
with	O
sphingomyelins	B
were	O
associated	O
with	O
diabetes	O
in	O
a	O
European	O
population.	O

Note	O
that	O
testosterone	B
concentrations	O
are	O
presented	O
using	O
a	O
logarithmic	O
scale.	O

Hydroxycholesterols	B
(OHCs),	O
metabolites	O
of	O
CNS	O
cholesterol,	B
are	O
involved	O
in	O
diverse	O
cellular	O
responses	O
to	O
inflammation	O
and	O
demyelination,	O
and	O
may	O
also	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
NMO.	O

(D)	O
Treatment	O
with	O
2-deoxyglucose	B
(55	O
mM),	O
significantly	O
reduced	O
ECAR	O
levels	O
in	O
OE33	O
cells	O
treated	O
with	O
ACM	O
from	O
obese	O
EAC	O
patients,	O
when	O
compared	O
to	O
controls.	O

The	O
influence	O
of	O
the	O
menstrual	O
cycle	O
on	O
phosphate	B
metabolites	O
has	O
also	O
been	O
reported	O
in	O
7	O
female	O
volunteers	O
with	O
regular	O
menstrual	O
cycles	O
using	O
3D	O
_31	O
P	O
MRSI	O
at	O
four	O
time	O
points	O
during	O
the	O
menstrual	O
cycle	O
at	O
7	O
T.	O

Among	O
the	O
24	O
metabolites	O
for	O
the	O
atrial	O
appendage	O
samples,	O
8	O
metabolites	O
(hypoxanthine,	O
carnitine,	B
5-aminopentanoic	B
acid,	I
betaine,	B
L-valine,	B
creatinine,	B
choline,	B
and	O
D-glutamic	B
acid)	O
had	O
VIP	O
values	O
above	O
3.0,	O
which	O
indicated	O
a	O
strong	O
difference	O
between	O
the	O
AF	B
group	O
and	O
the	O
non-AF	O
group.	O

1	O
µm;	O
20	O
µm	O
(□)	O
m	O
m	O
m	O
m	O
To	O
identify	O
the	O
P450	O
enzymes	O
participating	O
in	O
anastrozole	O
hydroxylation,	O
10	O
µm	O
anastrozole	B
was	O
incubated	O
with	O
P450	O
isoform-specific	O
inhibitors	O
with	O
HLMs	O
and	O
cofactors.	O

The	O
mobile	O
phases	O
were	O
(A)	O
10	O
mM	O
ammonium	B
acetate	I
in	O
50:50	O
water/methanol	O
(v/v)	O
and	O
(B)	O
10	O
mM	O
ammonium	B
acetate	I
in	O
50:50	O
methanol/acetonitrile	O
(v/v).	O

Next,	O
the	O
second	O
wash	O
step	O
was	O
assessed	O
at	O
acetonitrile	B
content	O
ranging	O
from	O
93	O
–	O
83%.	O

Unequivocal	O
assignment	O
of	O
analyte	O
peaks	O
in	O
the	O
MRM	O
chromatograms	O
of	O
samples	O
to	O
the	O
investigated	O
metabolites,	O
in	O
particular	O
for	O
the	O
closely-eluting	O
dihydroxylated	B
isomers	I
1,25(OH)D_3	I
and	O
24,25(OH)_2	B
D_3	O
,	O
was	O
achieved	O
by	O
matching	O
the	O
retention	O
times	O
of	O
the	O
extracted	O
ion	O
chromatograms	O
(using	O
the	O
quantifier	O
ions)	O
with	O
those	O
of	O
the	O
isotope	O
standards	O
from	O
a	O
separate	O
calibrator	O
sample.	O

Following	O
a	O
20	O
h	O
incubation	O
at	O
37°C,	O
each	O
sample	O
was	O
extracted	O
two	O
times	O
with	O
an	O
equal	O
volume	O
of	O
t	B
-butyl	I
methyl	I
ether.	I

Differences	O
in	O
day	O
of	O
cycle	O
at	O
TP1	O
and	O
TP2	O
were	O
associated	O
with	O
modest	O
increases	O
in	O
serum	O
oestradiol	B
and	O
progesterone	B
between	O
the	O
TP1	O
and	O
TP2	O
(respective	O
Wilcoxon	O
signed	O
rank	O
test	O
(p = 0.016	O
and	O
p	O
 = 0.006)).	O

The	O
postprandial	O
GABA	B
significantly	O
increased	O
in	O
the	O
HLP	O
subjects	O
after	O
glucose	B
loading	O
(ΔGABA,	O
79.06%),	O
whereas	O
a	O
postprandially	O
low	O
level	O
of	O
γ-aminobutyric	B
acid	I
was	O
observed	O
in	O
the	O
controls	O
(ΔGABA,	O
−39.95%;	O
).	O

The	O
resulting	O
diacylglycerol	B
can	O
be	O
directly	O
acetylated	O
by	O
an	O
acyltransferase	O
to	O
form	O
a	O
triacylglycerol	B
or	O
can	O
react	O
with	O
cytidine-diphosphate-choline	B
(CDP-choline)	I
or	O
CDP-ethanolamine	B
to	O
form	O
phosphatidylcholine	B
or	O
phosphatidylethanolamine,	B
respectively.	O

Phosphatidylcholine	B
(PC)	O
is	O
abundant	O
in	O
cell	O
membranes	O
and	O
involved	O
in	O
key	O
cellular	O
signaling	O
pathways.	O

Three	O
peaks	O
identified	O
as	O
L-methionine	B
are	O
displayed	O
in	O
.	O

Glacial	B
acetic	I
acid,	I
sodium	B
acetate,	I
4-methylumbelliferyl	B
glucuronide,	I
and	O
β-glucuronidase/sulfatase	O
(Helix	O
Pomatia,	O
type	O
H-1)	O
were	O
purchased	O
from	O
Sigma–Aldrich	O
(St	O
Louis,	O
MO).	O
_13	O
C_4	B
-4-methylumbelliferone	I
was	O
obtained	O
from	O
Cambridge	O
Isotope	O
Laboratories	O
Inc.	O
(Andover,	O
MA).	O

Total	O
cholesterol	B
was	O
measured	O
on	O
a	O
Beckman	O
Coulter®	O
AU680	O
analyzer,	O
and	O
high-density	O
lipoprotein	O
cholesterol	B
(HDL-C)	O
and	O
triglycerides	B
(TG)	O
were	O
measured	O
on	O
an	O
Olympus	O
AU400	O
analyzer	O
(Beckman	O
Coulter,	O
Brea,	O
CA,	O
USA).	O

In	O
all,	O
twelve	O
fully-porous	O
columns	O
were	O
tested,	O
including	O
four	O
Acquity	O
UPC_2	O
columns	O
(BEH	O
2-EP,	O
BEH,	O
CSH	O
FP	O
and	O
HSS	O
C_18	O
SB),	O
four	O
Acquity	O
UPLC	O
columns	O
(BEH	O
Amide,	B
BEH	O
HILIC,	O
BEH	O
Phenyl	O
and	O
HSS	O
Cyano),	B
and	O
four	O
Acquity	O
UPC_2	O
Torus	O
columns	O
(2-picolylamine	O
or	O
2-PIC,	O
Diol,	B
Diethylamine	B
or	O
DEA	O
and	O
1-amino	B
anthracene	I
or	O
1-AA).	O

Further,	O
investigations	O
focused	O
on	O
the	O
evaluation	O
of	O
quantitation	O
using	O
organic	O
solvents	O
revealed	O
a	O
surprisingly	O
poor	O
performance	O
for	O
protein	O
precipitation	O
using	O
acetonitrile.	B

Although	O
glutathione	B
is	O
relatively	O
abundant	O
metabolite	O
in	O
human	O
brain	O
(~	O
2	O
mmol/kg)	O
and	O
routinely	O
observed	O
in	O
in	O
vivo	O
experiments,	O
it	O
was	O
barely	O
detected	O
in	O
our	O
experiments.	O

Persistent	O
colonisation	O
by	O
sulphate	B
reducing	O
bacteria	O
and	O
presence	O
of	O
hydrogen	B
sulphide	I
in	O
the	O
gut	O
and	O
faeces	O
have	O
been	O
shown	O
to	O
be	O
present	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
as	O
well	O
as	O
colorectal	O
cancer	O
[,	O
,	O
]	O
and	O
have	O
been	O
implicated	O
in	O
the	O
role	O
of	O
generating	O
DNA	O
damage	O
at	O
the	O
genomic	O
level.	O

The	O
numerator	O
LMIs	O
of	O
496.5022	O
m/z	O
and	O
524.5614	O
m/z	O
were	O
earlier	O
identified	O
as	O
lysophosphatidylcholine	B
(LPC)	O
16:0	O
and	O
LPC	B
18:0	I
[,].	I

On	O
the	O
other	O
hand,	O
phenylalanine	B
in	O
NF	O
tumors	O
was	O
found	O
to	O
be	O
elevated	O
in	O
both	O
serum	O
and	O
WB	O
when	O
compared	O
with	O
prolactinomas	O
but	O
it	O
met	O
the	O
statistical	O
significance	O
criteria	O
(p ≤ 0.0028)	O
only	O
in	O
the	O
serum.	O

Sarcosine	B
oxidase	O
hydrolyzes	O
sarcosine	O
to	O
glycine,	B
formaldehyde	B
and	O
peroxide.	B

Dietary	O
soy	O
isoflavones,	B
S-(−)equol	O
status,	O
postmenopausal	O
women,	O
breast	O
biopsy,	O
ductal	O
hyperplasia,	O
breast	O
cancer	O

In	O
addition,	O
higher	O
acetoacetate	B
was	O
correlated	O
with	O
lower	O
insulin	O
sensitivity	O
in	O
our	O
study.	O

Low	O
concentration	O
of	O
HDL_2	O
cholesterol	B
was	O
the	O
common,	O
albeit	O
not	O
exclusive,	O
denominator	O
for	O
all	O
complications,	O
which	O
suggests	O
that	O
HDL_2	O
has	O
a	O
protective	O
effect,	O
or	O
is	O
a	O
marker	O
of	O
a	O
favorable	O
phenotype	O
with	O
respect	O
to	O
both	O
micro-	O
and	O
macrovascular	O
complications.	O

The	O
detection	O
rate	O
of	O
DMAP	O
was	O
higher	O
in	O
the	O
high	O
UCCR	O
group	O
in	O
TSG	O
and	O
NSG,	O
but	O
the	O
trend	O
was	O
not	O
observed	O
in	O
that	O
of	O
thiamethoxam	B
in	O
TSG.	O

All	O
participants	O
were	O
asked	O
to	O
avoid	O
drinking	O
caffeine-containing	O
beverages,	O
taking	O
aspirin,	B
acetaminophen,	B
or	O
non-steroidal	O
anti-inflammatory	O
drugs	O
within	O
6	O
hours	O
of	O
their	O
usual	O
bedtime.	O

Commercially	O
available	O
androgen	O
standards	O
were	O
spiked	O
with	O
the	O
stable	O
isotope	O
internal	O
standards	O
[_13	O
C_3	O
]-T	O
(for	O
T,	O
Epi-T,	O
Δ_4	O
-AD	O
and	O
DHEA,	O
since	O
they	O
all	O
contain	O
either	O
a	O
Δ_4	O
-	O
or	O
Δ_5	O
-ene)	O
or	O
with	O
[_13	O
C_3	O
]-DHT	O
(for	O
DHT,	O
Adione	B
and	O
A,	O
since	O
they	O
are	O
5α-reduced	O
androgens).	O

Of	O
all	O
molecules	O
analysed,	O
20-HETE	B
was	O
the	O
only	O
metabolite	O
that	O
was	O
differently	O
expressed	O
in	O
plasma	O
samples.	O

The	O
LMWM	O
window	O
is	O
dominated	O
by	O
the	O
numerous	O
glucose	B
resonances	O
between	O
3.1	O
and	O
3.9	O
p.p.m.,	O
although	O
some	O
lipid	O
signals	O
still	O
remain.	O

Abbreviations:	O
CL,	O
cardiolipin;	O
FDR,	O
false	O
discovery	O
rate;	O
lyso-PC,	B
lysophosphatidylcholine;	B
nd,	O
not	O
detected;	O
PC,	O
phosphatidylcholine;	B
PS,	O
phosphatidylserine;	B
SM,	O
sphingomyelin.	B

At	O
time	O
zero,	O
a	O
prime-continuous	O
infusion	O
of	O
human	O
regular	O
insulin	O
(Novolin;	O
Novo	O
Nordisk	O
Pharmaceuticals,	O
Princeton,	O
NJ)	O
was	O
started	O
and	O
continued	O
for	O
180	O
min.	O

A	O
study	O
in	O
patients	O
with	O
diabetes	O
reported	O
that	O
erythritol	B
and	O
enrichment	O
of	O
another	O
PPP	O
biomarker	O
(ribose)	O
were	O
increased	O
in	O
patients	O
with	O
diabetic	O
retinopathy,	O
and	O
suggested	O
that	O
polyol	O
pathway	O
flux	O
may	O
yield	O
biomarkers	O
of	O
clinical	O
risk	O
in	O
diabetes.	O

No	O
correlation	O
between	O
ODC1	O
expression	O
and	O
arginine	B
was	O
found.	O

Human	O
serum	O
albumin	O
and	O
excess	O
tolmetin	B
glucuronide	I
were	O
coincubated	O
in	O
the	O
presence	O
of	O
sodium	B
cyanoborohydride	I
to	O
trap	O
imine	O
intermediates.	O

The	O
stock	O
solutions	O
of	O
Cap	O
and	O
its	O
metabolites	O
5'-DFCR,	O
5'-DFUR,	O
2'-DFUR,	O
5-FU,	O
and	O
FUH2	O
as	O
well	O
as	O
internal	O
standards	O
(IS)	O
5-ClU	O
and	O
Fdb	O
were	O
individually	O
prepared	O
in	O
methanol.	B

Epileptic	O
seizures	O
are	O
activated	B
by	O
the	O
neuroendocrine	O
system	O
secreting	O
hormones.	O

However,	O
our	O
analysis	O
refutes	O
this	O
idea,	O
showing	O
that	O
urinary	O
3-methylhistidine	B
level,	O
an	O
index	O
of	O
muscle	O
protein	O
catabolism,	O
was	O
significantly	O
reduced	O
in	O
the	O
HTK	O
group,	O
with	O
a	O
log_2	O
fold-change	O
of	O
−2.2	O
(Supplementary	O
Fig.	O

Lipid	O
molecules	O
contributing	O
to	O
the	O
highest	O
variation	O
on	O
the	O
MDS	O
plot	O
generated	O
by	O
RF	O
analysis	O
were	O
identified	O
as	O
PCs	O
(32:2,	O
32:3,	O
36:5,	O
42:6),	O
ePC	O
(32:2),	O
DG	B
(36:4),	I
and	O
TG	B
(58:7).	I

Diglyceride	B
and	O
triglyceride	B
species	O
are	O
the	O
2	O
most	O
frequently	O
incorporated	O
lipid	O
classes	O
in	O
the	O
classification	O
models,	O
including	O
the	O
diglycerides	B
16:0/16:0,	I
16:0/22:5,	O
and	O
16:0/22:6,	O
and	O
triglyceride	B
14:1/16:1/18:0.	I

We	O
have	O
shown	O
clear	O
differences	O
between	O
plasma	O
metabolite	O
concentrations	O
in	O
males,	O
and	O
HC	O
or	O
non-HC	O
females,	O
especially	O
in	O
lyso-phosphatidylcholine,	B
sphingomyelin	B
and	O
phosphatidylcholine,	B
which	O
have	O
been	O
shown	O
to	O
associate	O
with	O
obesity	O
in	O
other	O
studies.	O

In	O
plasma	O
the	O
mean	O
total	O
recovery	O
of	O
abiraterone	B
was	O
76%	O
with	O
a	O
CV	O
of	O
1%	O
and	O
for	O
the	O
internal	O
standard	O
the	O
mean	O
recovery	O
was	O
72%	O
with	O
CV%	O
of	O
1%.	O

Glutamine	B
has	O
been	O
particularly	O
studied	O
for	O
its	O
role	O
in	O
cancer	O
metabolism	O
because	O
it	O
appears	O
to	O
be	O
required	O
for	O
the	O
growth	O
of	O
many	O
types	O
of	O
tumors.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
the	O
serum	O
concentrations	O
of	O
the	O
active	O
tamoxifen	B
metabolite,	O
4OHNDtam	O
(endoxifen),	O
increase	O
with	O
age	O
during	O
steady-state	O
tamoxifen	B
treatment.	O

In	O
our	O
experience,	O
rigorous	O
quick	O
handling	O
of	O
freshly	O
drawn	O
CSF,	O
low	O
storage	O
temperature	O
and	O
the	O
careful	O
matching	O
of	O
stored	O
ALS	O
and	O
control	O
samples	O
are	O
essential	O
for	O
reliable	O
assessment	O
of	O
glutamic	B
acid	I
and	O
other	O
metabolites	O
in	O
the	O
CSF.	O

In	O
tumor	O
cells,	O
the	O
M2-PK	O
isoform	O
dominantly	O
expresses	O
and	O
contributes	O
to	O
aerobic	O
glycolysis	O
and	O
proliferation._,	O
Interaction	O
of	O
M2-PK	O
with	O
different	O
oncoproteins	O
can	O
lead	O
to	O
the	O
dimerization,	O
which	O
decreases	O
the	O
affinity	O
of	O
M2-PK	O
for	O
PEP	O
and	O
results	O
in	O
accumulation	O
of	O
phosphometabolites	B
above	O
M2-PK.	O

_,	O
It	O
acts	O
as	O
a	O
prodrug	O
that	O
is	O
activated	B
to	O
7-ethyl-10-hydroxycamptothecin	B
(SN-38)	O
by	O
carboxylesterase	O
2	O
in	O
the	O
blood	O
and	O
liver,	O
and	O
SN-38	O
is	O
subsequently	O
detoxified	O
in	O
the	O
liver	O
by	O
uridine	O
diphosphate-glucuronosyltransferase	O
1A1	O
to	O
form	O
a	O
β	O
-glucuronide	O
conjugate,	O
SN-38G.	O
SN-38	O
is	O
a	O
potent	O
inhibitor	O
of	O
DNA	O
topoisomerase	O
I,	O
an	O
essential	O
enzyme	O
that	O
controls	O
DNA	O
structural	O
changes	O
by	O
relaxing	O
DNA	O
supercoil	O
and	O
religating	O
cleaved	O
DNA	O
strands	O
during	O
DNA	O
replication	O
and	O
transcription.	O

Pyrimidine	B
degradation	O
metabolites	O
of	O
the	O
patients	O
with	O
βUP	O
deficiency.	O

Proliferating	O
tumour	O
cells	O
often	O
demand	O
for	O
nucleotides	O
for	O
the	O
rapid	O
synthesis	O
of	O
cellular	O
materials,	O
which	O
is	O
fulfilled	O
by	O
de	O
novo	O
synthesis	O
and/or	O
nucleotide	O
salvage	O
of	O
purines	B
and	O
pyrimidines.	B

The	O
present	O
study	O
did	O
not	O
replicate	O
the	O
association	O
of	O
phenylalanine	B
with	O
risk	O
of	O
ischemic	O
CVD	O
,	O
potentially	O
reflecting	O
effect	O
modification	O
by	O
an	O
environmental	O
exposure	O
such	O
as	O
dietary	O
factors	O
.	O

(C)	O
Disruption	O
of	O
histidine-histamine	B
metabolism	O
in	O
COPD.	O

Third,	O
a	O
targeted	O
and	O
quantitative	O
GC-MS	O
analysis	O
was	O
conducted	O
on	O
the	O
subset	O
of	O
metabolites	O
of	O
interest,	O
including	O
fructose,	B
leucine,	B
isoleucine,	B
valine,	B
lactic	B
acid,	I
and	O
erythritol.	B

There	O
are	O
two	O
main	O
pathways	O
of	O
alanine	B
production:	O
directly	O
from	O
protein	O
degradation,	O
and	O
via	O
the	O
transamination	O
of	O
pyruvate	B
by	O
alanine	O
aminotransferase	O
(ALT).	O

However,	O
the	O
sum	O
of	O
resolutions	O
(Σ	O
R_s	O
)	O
was	O
not	O
significantly	O
enhanced	O
by	O
any	O
additive,	O
ranging	O
from	O
a	O
median	O
value	O
of	O
4.0	O
for	O
ammonium	B
acetate	I
to	O
4.7	O
for	O
water	O
(B).	O

The	O
ion	O
m/z	O
211.146,	O
representing	O
the	O
second	O
most	O
significant	O
metabolite,	O
was	O
tentatively	O
identified	O
as	O
an	O
isomer	O
of	O
the	O
diketopiperazine	B
cyclo(leucyl-prolyl),	I
most	O
likely	O
the	O
cyclo(isoleucyl-prolyl).	O

Several	O
amino	O
acids,	O
phenylalanine,	B
threonine,	B
tyrosine,	B
lysine,	B
tryptophan,	B
asparagine	B
and	O
glycine,	B
were	O
detected	O
at	O
significantly	O
lower	O
concentration	O
in	O
the	O
urine	O
of	O
patients	O
pre-surgery	O
compared	O
to	O
post-surgical	O
timepoints	O
by	O
both	O
GC-MS	O
and	O
_1	O
H-NMR	O
analysis.	O

The	O
primary	O
transitions	O
were	O
used	O
to	O
quantify	O
the	O
allantoin	B
and	O
the	O
secondary	O
transitions	O
were	O
used	O
as	O
qualifier	O
ions.	O

Samples	O
for	O
UHPLC/HRMS	O
analysis	O
were	O
centrifuged	O
(3,000 rpm	O
for	O
5 min)	O
and	O
then	O
diluted	O
in	O
deionized	O
water	O
(dilution	O
1/5:20 μl	B
of	O
urine	O
in	O
80 μl	O
of	O
water)	O
prior	O
to	O
analysis.	O

According	O
to	O
the	O
present	O
study,	O
excessive	O
lipolysis,	O
FA	B
oxidation,	O
and	O
ketone	B
body	O
synthesis	O
all	O
seem	O
to	O
be	O
lowered	O
at	O
6 months	O
post‐RYGB,	O
and	O
these	O
changes	O
may	O
be	O
due	O
to	O
an	O
improvement	O
in	O
insulin	O
sensitivity	O
due	O
to	O
RYGB.	O

In	O
serum,	O
cysteine	B
was	O
found	O
at	O
higher	O
levels	O
in	O
GBMs,	O
while	O
lysine	B
and	O
2-oxoisocaproic	B
acid	I
showed	O
higher	O
levels	O
in	O
oligodendrogliomas.	O

The	O
identified	O
target	O
metabolites	O
were	O
found	O
to	O
encompass	O
a	O
variety	O
of	O
pathways	O
related	O
to	O
glycerophospholipid/glycerolipid-related	O
metabolism	O
(LysoPCs,	O
lysophosphatidic	B
acid	I
and	O
dehydro-phytosphingosine),	B
vitamin	O
A	O
metabolism	O
(9cRA),	O
porphyrin	O
and	O
chlorophyll	B
metabolism	O
(1H-Indole-3-carboxaldehyde).	O

After	O
this	O
mixture	O
was	O
incubated	O
in	O
the	O
dark,	O
acetonitrile	B
was	O
added,	O
and	O
then	O
the	O
sample	O
was	O
vortexed	O
and	O
sonicated	O
again.	O

Fasting	O
glucose	B
concentrations	O
were	O
enzymatically	O
measured.	O

The	O
rest	O
of	O
the	O
sample	O
was	O
used	O
to	O
extract	O
gangliosides.	B

Data	O
for	O
one	O
metabolite	O
(phenylalanine	O
at	O
7.35	O
and	O
7.41	O
ppm)	O
were	O
discarded	O
as	O
it	O
was	O
found	O
that	O
the	O
peak	O
positions	O
could	O
not	O
be	O
measured	O
accurately	O
due	O
to	O
the	O
high	O
level	O
of	O
peak	O
overlap	O
in	O
this	O
region	O
of	O
the	O
spectra.	O

(B)	O
ROC	O
curve	O
generated	O
with	O
the	O
relative	O
concentrations	O
of	O
discriminant	O
metabolites	O
(alanine,	O
aspartate	B
and	O
citrate)	O
that	O
were	O
significantly	O
different	O
between	O
HC	O
and	O
SSc	O
both	O
by	O
NMR	O
and	O
GC-MS	O
analysis.	O

The	O
simultaneous	O
analysis	O
of	O
chiral	O
amino	O
acids:	O
DL-alanine	B
(Ala),	O
DL-d4-Ala,	O
DL-arginine	B
(Arg),	O
DL-asparagine	O
(Asn),	O
DL-aspartic	B
acid	I
(Asp),	O
DL-cysteine	O
(Cys),	O
DL-glutamine	B
(Gln),	O
DL-glutamic	B
acid	I
(Glu),	O
DL-histidine	B
(His),	O
DL-isoleucine	B
(Ile),	O
DL-leucine	B
(Leu),	O
DL-lysine	B
(Lys),	O
DL-methionine	B
(Met),	O
DL-phenylalanine	B
(Phe),	O
DL-proline	B
(Pro),	O
DL-serine	B
(Ser),	O
DL-threonine	B
(Thr),	O
DL-tryptophan	B
(Trp),	O
DL-tyrosine	B
(Tyr),	O
DL-valine	B
(Val),	O
DL-citrulline	B
(Cit),	O
DL-allo	O
-Ile,	O
DL-ornithine	O
(Orn),	O
DL-allo	O
-Thr,	O
and	O
glycine	B
(Gly),	O
except	O
for	O
the	O
separation	O
between	O
D-Ile	O
and	O
D-allo	O
-Ile,	O
was	O
thus	O
achieved	O
via	O
chiral	O
tandem	O
LC-MS/MS	O
(Fig.	O

Alpha-	B
(a)	I
and	O
beta-diversity	O
(b)	O
indexes	O
after	O
16S	O
rRNA	O
metagenomic	O
analysis	O
of	O
faecal	O
samples	O
collected	O
before	O
(T0)	O
and	O
after	O
(T1)	O
dietary	O
intervention.	O

Furthermore,	O
betaine	B
was	O
additionally	O
associated	O
in	O
Health2006/08	O
and	O
barely	O
missed	O
statistical	O
significance	O
in	O
Inter	O
99	O
(FDR	O
=	O
0.06).	O

_2	O
Estimate	O
is	O
the	O
standardized	O
beta-coefficient	O
Of	O
the	O
metabolites	O
that	O
remained	O
statistically	O
significant	O
after	O
Bonferroni	O
correction,	O
the	O
majority	O
were	O
lipids	O
(n = 30	O
of	O
264	O
lipids)	O
and	O
amino	O
acids	O
(n = 20	O
of	O
157	O
amino	B
acids).	O

We	O
found	O
significantly	O
decreased	O
cis-aconitate,	B
isocitrate	B
and	O
α-ketoglutarate,	B
metabolites	O
that	O
are	O
found	O
downstream	O
of	O
the	O
metabolic	O
block,	O
while	O
other	O
TCA	O
intermediates	O
including	O
succinate,	B
malate	B
and	O
fumarate	B
were	O
not	O
dramatically	O
altered.	O

Large	O
cohort	O
studies,	O
including	O
studies	O
from	O
our	O
group,	O
have	O
highlighted	O
the	O
strong	O
potential	O
of	O
plasma	O
lipidomics	O
in	O
explaining	O
metabolic	O
disease	O
when	O
added	O
to	O
traditional	O
disease	O
markers,	O
including	O
waist	O
circumference,	O
fasting	O
glucose,	B
and	O
insulin	O
12,	O
13,	O
39.	O

While	O
D-2-HG,	O
malic	B
acid	I
and	O
succinate	B
levels	O
were	O
higher	O
in	O
IDH-mutant	O
gliomas,	O
the	O
levels	O
of	O
alanine	B
where	O
significantly	O
elevated	O
in	O
patients	O
with	O
IDH-WT	O
gliomas	O
compared	O
to	O
IDH-mutant	O
tumors	O
(Fig.	O
).	O

After	O
being	O
defrosted	O
at	O
room	O
temperature,	O
four	O
hundred	O
microliters	O
of	O
each	O
sample	O
were	O
mixed	O
with	O
50 mL	O
D_2	O
O	O
for	O
locking	O
signal	O
and	O
with	O
50 mL	O
phosphate	B
buffer	O
solution	O
(0.2 M	O
Na_2	O
HPO_4	O

Myo-inositol	B
treatment	O
ameliorated	O
the	O
decreased	O
expression	O
of	O
ZO-1	O
and	O
synaptopodin	O
in	O
an	O
in	O
vitro	O
FSGS	O
model,	O
and	O
as	O
myo-inositol	B
increased,	O
myo-inositol	O
oxygenase	O
tissue	O
expression	O
decreased	O
proportionally	O
to	O
eGFR.	O

1	O
mg/mL	O
in	O
acetonitrile)	O
and	O
purchased	O
individual	O
Me-OHN	O
stock	O
solutions	O
(50	O
μg/mL	O
in	O
isooctane)	B
were	O
used	O
to	O
prepare	O
standard	O
mixtures	O
for	O
eight	O
calibration	O
standards	O
at	O
concentrations	O
ranging	O
from	O
1–1,000	O
pg/μL,	O
except	O
for	O
1-	O
and	O
2-hydroxynaphthalene	B
(1-NAP	O
and	O
2-NAP)	O
which	O
were	O
present	O
at	O
four	O
times	O
higher	O
concentrations	O
(4–4,000	O
pg/μL).	O

Mean	O
creatinine-corrected	O
coefficients	O
of	O
variation	O
for	O
8-iso	B
-PGF_2α	I
and	O
PGE-M	O
over	O
the	O
20	O
week	O
period	O
were	O
31%	O
and	O
54%,	O
respectively,	O
while	O
the	O
corresponding	O
intra-class	O
correlation	O
coefficients	O
(ICC)	O
were	O
0.51	O
(95%	O
CI,	O
0.45,	O
0.57)	O
and	O
0.36	O
(0.30,	O
0.43),	O
respectively.	O

Previous	O
research	O
also	O
suggested	O
that	O
phenylalanine	B
was	O
a	O
large	O
neutral	O
amino	O
acid	O
that	O
could	O
affect	O
5-HT	O
synthesis_,	O
.	O

Exogenous	O
sphingomyelin	B
inhibits	O
chemokine-induced	O
cell	O
migration.	O

Low	O
(1	O
µm)	O
and	O
high	O
(20	O
µm)	O
concentrations	O
of	O
anastrozole	B
were	O
incubated	O
with	O
microsomes	O
from	O
different	O
characterized	O
human	O
livers.	O

Lipids	O
with	O
different	O
head	O
groups	O
are	O
shown	O
by	O
different	O
symbols:	O
PA	O
(◆);	O
PE	O
(■);	O
PG	B
(▲);	O
PI	O
(×);	O
PS	O
(▬▬▬);	O
and	O
PC	B
(+).	I

Details	O
of	O
the	O
method	O
for	O
the	O
Liposcale	O
for	O
lipoprotein	O
characterization	O
and	O
phosphatidylcholines	B
compounds	O
and	O
glycoprotein	B
peak	O
deconvolution	O
are	O
explained	O
in	O
the	O
supplemental	O
material.	O

We	O
synthesized	O
the	O
four	O
stereoisomeric	O
mercapturic	O
acids	O
that	O
would	O
result	O
from	O
attack	O
of	O
glutathione	B
on	O
Phe-epoxides	B
followed	O
by	O
normal	O
processing	O
of	O
the	O
conjugates.	O

These	O
features	O
include	O
multiple	O
adducts	O
of	O
arginine,	B
citrulline,	B
and	O
acylcarnitines.	B

To	O
stabilize	O
the	O
resonance	O
conditions,	O
the	O
dried	O
samples	O
were	O
dissolved	O
in	O
570 µl	O
of	O
99,9%	O
D_2	O
O.	O
Also,	O
30 µl	O
of	O
tetramethylsilane	B
(TMS)	O
were	O
added	O
for	O
the	O
calibration	O
of	O
chemical	O
shifts	O
scaling	O
and	O
the	O
determination	O
of	O
relative	O
concentrations.	O

Decreased	O
levels	O
of	O
citrate	B
and	O
increased	O
levels	O
of	O
cis-aconitate	B
during	O
RSV	O
ARI	O
compared	O
to	O
healthy	O
controls	O
may	O
indicate	O
that	O
citrate	B
is	O
depleted	O
to	O
supply	O
pro-inflammatory	O
and	O
anti-inflammatory	O
molecule	O
needs	O
of	O
immune	O
cells	O
to	O
counter	O
viral	O
replication.	O

Multivariate	O
results	O
showed	O
that	O
the	O
significant	O
association	O
between	O
TCDD	O
and	O
4-OH-E_2	B
:2-OH-E_2	I
ratio	O
(r	O
=	O
−0.111)	O
remained	O
significant	O
(and	O
also	O
the	O
association	O
between	O
1,2,3,7,8-pentaCDD	B
and	O
4-OH-E_2	B
:2-OH-E_2	I
,	O
r	O

More	O
than	O
30	O
years	O
ago,	O
Jack	O
Fishman	O
and	O
Leon	O
Bradlow	O
published	O
one	O
of	O
the	O
first	O
epidemiologic	O
studies	O
of	O
estrogen	B
metabolism	O
and	O
breast	O
cancer.	O

This	O
finding	O
is	O
supported	O
by	O
the	O
enhanced	O
_13	O
C	O
incorporation	O
into	O
citrate,	B
succinate,	B
Glu	O
(a	O
surrogate	O
marker	O
of	O
α-ketoglutarate	B
or	O
αKG)	O
and	O
Asp	O
(a	O
surrogate	O
marker	O
of	O
oxaloacetate	B
or	O
OAA)	O
in	O
tumor	O
tissues	O
(Tables	O
,	O
,	O
and	O
Fig.	O
).	O

9-HODE	B
and	O
12,13-DiHOME	B
reduced	O
VCAM-1	O
surface	O
expression,	O
whereas	O
19,	O
20-DiHDoPE	O
did	O
not	O
alter	O
VCAM-1	O
surface	O
expression	O
relative	O
to	O
TNFα.	O

Development	O
of	O
PCa	O
is	O
associated	O
with	O
the	O
metabolic	O
switch	O
from	O
a	O
high	O
level	O
of	O
citrate	B
secretion	O
to	O
citrate	B
oxidation.	O

Alb	O
adducts	O
of	O
benzene,	B
heptafluorobutyrylimidazole	B
(HBFI).	O

Although	O
much	O
less	O
common,	O
there	O
are	O
some	O
polyunsaturated	O
FAs	O
that	O
either	O
have	O
double	O
bonds	O
separated	O
by	O
more	O
than	O
one	O
methylene	B
group	O
or	O
possess	O
conjugated	O
double	O
bonds._,	O
The	O
utilization	O
of	O
the	O
40	O
Th	O
series	O
of	O
fragment	O
ions	O
can	O
discriminate	O
these	O
positional	O
isomers	O
from	O
the	O
more	O
commonly	O
occurring	O
bis-allylic	O
structures.	O

Plasma	O
IL-10,	O
tumor	O
necrosis	O
factor	O
alpha	O
(TNFα),	O
and	O
granulocyte	O
colony	O
stimulating	O
factor	O
(GCSF)	O
also	O
increased	O
following	O
3-days	O
exercise	O
(P<0.001,	O
data	O
not	O
shown),	O
with	O
no	O
significant	O
group	O
differences	O
in	O
the	O
pattern	O
of	O
change.	O

The	O
concentrations	O
of	O
HDL-C,	O
glucose	B
and	O
TG,	B
sysBP	O
and	O
WC	O
differed	O
significantly	O
between	O
males,	O
HC	O
and	O
non-HC	O
females	O
and	O
also	O
in	O
their	O
associations	O
with	O
metabolite	O
concentrations.	O

The	O
residue	O
was	O
taken	O
in	O
MeOH	B
and	O
filtrated	O
with	O
a	O
syringe	O
filter	O
Millex-LG	O
(0.20 µm,	O
PTFE	O
hydrophilic,	B
13 mm.	O

B.	O
The	O
distribution	O
of	O
insulin-mediated	O
glucose	B
disposal	O
rates,	O
expressed	O
as	O
M_FFM	O
values	O
(µmol·min_−1	O
·kg_FFM	O
_−1	O
),	O
of	O
399	O
subjects	O
selected	O
from	O
the	O
RISC	O
cohort	O
and	O
comprised	O
of	O
NGT,	O
IGT,	O
and	O
IFG	O
subjects.	O

We	O
identified	O
a	O
difference	O
in	O
the	O
levels	O
of	O
several	O
urinary	O
oxylipins	B
specific	O
to	O
young	O
women	O
(	O
and	O
).	O

NMR	O
metabolomic	O
profiling	O
of	O
fasting	O
CSF	O
samples	O
revealed	O
significantly	O
higher	O
alanine,	B
leucine,	B
tyrosine,	B
valine,	B
lactate,	B
pyruvate,	B
and	O
lower	O
histidine	B
levels.	O

In	O
PET-positive	O
patients	O
with	O
a	O
relative	O
glutamate	B
level ≤ 0.31	O
the	O
sensitivity	O
to	O
diagnose	O
cancer	O
reaches	O
100%	O
with	O
a	O
PPV	O
of	O
94%.	O

An	O
example	O
of	O
the	O
ratio	O
of	O
2	O
statistically	O
different	O
metabolites	O
between	O
normal	O
and	O
tumor	O
tissue	O
and	O
cytidine	B
5′-diphosphocholine	I
is	O
reported	O
in	O
and	O
.	O

Accordingly,	O
dietary	O
arginine	B
is	O
claimed	O
to	O
be	O
beneficial	O
in	O
animal	O
models	O
of	O
colitis.	O

Triglycerides	B
were	O
not	O
increased,	O
and	O
LDL-associated	O
lipids	O
and	O
apolipoproteins	O
were	O
decreased,	O
with	O
no	O
apparent	O
pattern	O
of	O
triglyceride	B
enrichment.	O

Ethanol	B
affected	O
the	O
CSF	O
sample	O
matrix	O
at	O
concentrations	O
above	O
~9.4 mM	O
and	O
obscured	O
a	O
significant	O
part	O
of	O
the	O
_1	O
H-NMR	O
spectrum.	O

Pinitol	B
is	O
a	O
cyclic	O
polyol	O
predominantly	O
occurring	O
in	O
the	O
Fabacea	O
plant	O
family.	O

But	O
this	O
compensation	O
is	O
not	O
sufficient	O
enough	O
by	O
body	O
because	O
decreased	O
glycerol	B
has	O
no	O
such	O
significant	O
impression	O
on	O
this	O
pathway	O
as	O
compared	O
to	O
increased	O
sucrose.	B

Lipid	O
extractions	O
were	O
performed	O
using	O
the	O
methyl-tert	B
butyl	I
ether	I
(MTBE)	O
method	O
described	O
by	O
Matyash	O
et	O
al.,	O
with	O
all	O
steps	O
performed	O
in	O
the	O
Captair	O
Pyramid	O
glove	O
box	O
(Erlab,	O
Rowley,	O
MA)	O
under	O
argon	O
gas	O
to	O
prevent	O
exposure	O
to	O
oxygen	O
and	O
subsequent	O
oxidation	O
of	O
lipids.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
a	O
previous	O
report	O
of	O
higher	O
mean	O
levels	O
of	O
Lp-PLA_2	O
and	O
8-epi	B
-PGF_2α	I
in	O
subjects	O
with	O
high	O
ox-LDL	O
than	O
those	O
in	O
subjects	O
with	O
low	O
ox-LDL	O
,	O
and	O
a	O
positive	O
association	O
between	O
plasma	O
ox-LDL	O
and	O
Lp-PLA_2	O
activity	O
in	O
metabolic	O
syndrome	O
.	O

The	O
EM	O
assay	O
is	O
being	O
optimized	O
for	O
heparin-plasma	B
samples,	O
and	O
will	O
eventually	O
be	O
extended	O
to	O
breast	O
tissue.	O

Effect	O
of	O
alkylamine	B
additives	O
on	O
chromatographic	O
performance	O
in	O
SFC	O
(UV-vis	O
data	O
only).	O

As	O
such,	O
the	O
circulating	O
levels	O
of	O
nucleobases	O
(xanthine,	O
thymine,	B
and	O
uracil)	O
on	O
irinotecan	O
exposure	O
could	O
be	O
potential	O
early	O
indicators	O
for	O
the	O
antitumor	O
effect	O
and/or	O
side	O
effects	O
(eg,	O
hematological	O
and	O
intestinal	O
toxicity)	O
in	O
patients.	O

Increased	O
circulating	O
glutamate	B
levels	O
have	O
previously	O
been	O
seen	O
in	O
cancer	O
patients;	O
however,	O
antiglutaminolysis	O
therapeutic	O
targets	O
have	O
demonstrated	O
toxic	O
side	O
effects.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
metabonomics	O
models	O
indicated	O
differences	O
between	O
the	O
groups	O
regarding	O
the	O
serum	O
levels	O
of	O
triglycerides	B
and	O
HDL.	O

Chloroform	B
and	O
methanol	B
were	O
purchased	O
from	O
Merck	O
(Merck	O
Pte.	O

Our	O
study	O
is	O
the	O
first	O
to	O
quantify	O
a	O
wide	O
range	O
of	O
eicosanoids	B
and	O
other	O
oxylipins	B
in	O
human	O
colon	O
biopsy	O
samples	O
of	O
individuals	O
under	O
aspirin	B
and	O
statin	B
treatment,	O
indicating	O
that	O
both	O
drugs	O
mainly	O
affect	O
the	O
levels	O
of	O
COX-derived	O
metabolites.	O

In	O
our	O
study,	O
spermidine	B
was	O
consistently	O
elevated	O
in	O
both	O
saliva	O
and	O
tissues.	O

Glutamine;	B
54.	O

Analytes	O
with	O
LogP	O
below	O
0.4	O
(above	O
tyrosine)	B
show	O
poor	O
recovery	O
in	O
MTBE	B
and	O
good	O
recovery	O
in	O
methods	O
suitable	O
for	O
extraction	O
of	O
polar	O
species	O
such	O
as	O
PEP2	O
and	O
methanol-based	O
solvent	O
precipitations	O
(Group	O
I).	O

In	O
this	O
study,	O
the	O
levels	O
of	O
α-linolenic	B
acid	I
(C18:3)	O
and	O
its	O
downstream	O
ω-3	B
PUFA	I
metabolites,	O
including	O
eicosapentaenoic	B
acid	I
(C20:5),	O
docosapentaenoic	B
acid	I
(C22:5),	O
and	O
docosahexaenoic	B
acid	I
(C22:6),	O
were	O
lower	O
in	O
the	O
LC	O
group	O
than	O
the	O
control	O
group;	O
however,	O
docosapentaenoic	B
acid	I
(C22:5)	O
and	O
docosahexaenoic	B
acid	I
(C22:6)	O
did	O
not	O
show	O
significant	O
differences.	O

The	O
metabolite	O
reaction	O
linking	O
hippurate	B
and	O
glycine	B
is	O
only	O
conducted	O
through	O
the	O
activity	O
of	O
the	O
gut	O
microbiota	O
Among	O
the	O
validated	O
metabolites,	O
six	O
were	O
found	O
to	O
be	O
associated	O
to	O
three	O
or	O
more	O
IMIDs	O
(Fig.	O

Hormonal	O
testing	O
performed	O
after	O
surgery	O
revealed	O
undetectable	O
FSH	O
and	O
LH	O
serum	O
levels	O
and	O
a	O
normal	O
testosterone	B
level.	O

In	O
summary,	O
the	O
results	O
presented	O
here	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
carcinogenic	O
bay	O
region	O
diol	B
epoxide	I
of	O
BaP	O
is	O
detoxified	O
by	O
GSH	B
conjugation	O
in	O
human	O
hepatocytes.	O

Some	O
of	O
the	O
previous	O
studies	O
based	O
on	O
the	O
NMR	O
or	O
GC-MS	O
analytical	O
platforms	O
identified	O
no	O
difference	O
between	O
IBD	O
(treated	O
with	O
thiopurines	B
and/or	O
with	O
other	O
drugs)	O
and	O
healthy	O
control	O
in	O
amino	O
acids	O
urinary	O
levels	O
[,].	O

Based	O
on	O
this	O
gene	O
annotation,	O
there	O
was	O
no	O
obvious	O
relation	O
to	O
the	O
associated	O
metabolite	O
ethanolamine.	B

Dysregulated	O
tyrosine	B
metabolism	O
has	O
been	O
shown	O
previously	O
to	O
be	O
associated	O
with	O
increased	O
severity	O
of	O
hepatic	O
steotosis,	O
and	O
increased	O
tyrosine	B
levels	O
were	O
associated	O
with	O
hepatocellular	O
inflammation	O
and	O
ballooning.	O

Correlations	O
between	O
cysteine	B
and	O
homocysteine	B
were	O
the	O
highest	O
among	O
all	O
pair-wise	O
correlations	O
(R_2	O
 = 0.65,	O
p<0.01),	O
and	O
cysteine	B
was	O
also	O
highly	O
correlated	O
with	O
cystathionine	B
(R_2	O
 = 0.39,	O
p<0.01,	O
).	O

It	O
is	O
known	O
that	O
glutamine	B
is	O
an	O
amino	O
acid	O
that	O
serves	O
as	O
a	O
buffer	O
to	O
the	O
biological	O
fluids	O
and	O
a	O
nitrogen	O
carrier	O
.	O

Furthermore,	O
we	O
found	O
two	O
differential	O
metabolic	O
pathways,	O
glutamate	B
metabolism	O
and	O
purine	B
metabolism	O
pathway,	O
which	O
was	O
vulnerable	O
to	O
plasma	O
treatment,	O
and	O
was	O
significantly	O
suppressed	O
by	O
plasma	O
treatment.	O

However,	O
the	O
extraction	O
recoveries	O
of	O
O	O
-DVX	O
and	O
VX	O
by	O
LLE	O
using	O
ethyl	B
acetate,	I
diethylether	B
and	O
dichloromethane	B
were	O
much	O
lower	O
compared	O
to	O
SPE	O
[,	O
].	O

Calibrators	O
were	O
prepared	O
at	O
0.5,	O
1,	O
2.5,	O
5,	O
10,	O
25,	O
50	O
and	O
100	O
μg/L	O
for	O
THC	O
and	O
THCCOOH,	O
at	O
0.5,	O
1,	O
2.5,	O
5,	O
10,	O
25	O
and	O
50	O
μg/L	O
for	O
11-OH-THC,	B
CBD,	O
CBN,	O
THCAA	O
and	O
THC-gluc,	O
at	O
1,	O
2,	O
5,	O
10,	O
20,	O
50	O
and	O
100	O
μg/L	O
for	O
CBG,	O
THCV	O
and	O
THCVCCOOH	O
and	O
at	O
5,	O
10,	O
25,	O
50,	O
100,	O
250	O
and	O
500	O
μg/L	O
for	O
THCCOOH-gluc	O
after	O
fortifying	O
20	O
μL	O
working	O
stock	O
solution	O
into	O
200	O
μL	O
blank	O
human	O
urine.	O

Another	O
notable	O
study	O
found	O
that	O
only	O
approximately	O
1	O
to	O
2%	O
of	O
the	O
rate	O
expected	O
for	O
GSH	B
conjugation	O
of	O
BPDE	O
was	O
actually	O
observed	O
in	O
cells,	O
which	O
indicated	O
the	O
importance	O
of	O
competing	O
reactions	O
of	O
BPDE.	O

Plasma	O
was	O
obtained	O
by	O
centrifugation	O
(1970g	O
(3000	O
rpm)	O
for	O
10	O
min,	O
+4°C,	O
Hettich	O
model	O
Rotanta	O
460RF	O
centrifuge;	O
Tuttligen,	O
Germany)	O
after	O
collection	O
in	O
trisodium	B
citrate	I
(3.2%)	O

The	O
isolated	O
T	O
cell	O
subsets	O
were	O
either	O
directly	O
used	O
for	O
experiments	O
(resting	O
T	O
cells)	O
or	O
activated	B
by	O
incubation	O
in	O
the	O
presence	O
of	O
anti-CD3/anti-CD28	O
antibody	O
(Ab)-coated	O
beads	O
and	O
IL-2	O
(150	O
U/mL)	O
for	O
4 h	O
or	O
overnight,	O
depending	O
on	O
the	O
experiment.	O

Sodium	B
dodecyl	I
sulfate	I
polyacrylamide	I
gel	O
electrophoresis	O
(10%	O
gel)	O
for	O
protein	O
separation	O
(50	O
μg).	O

_1	O
H	O
NMR	O
([_2	O
H_6	O
]DMSO)	O
showed	O
absence	O
of	O
methylene	B
protons,	O
δ	O
10.7	O
(2H,	O
1,	O
1′NH),	O
7.5	O
(d,	O
J	O
=	O
15.6	O

In	O
our	O
previous	O
published	O
urine	O
cannabinoid	B
method	O
using	O
supporting-liquid	O
extraction	O
(SLE),	O
extraction	O
efficiency	O
was	O
34–73%.	O

With	O
use	O
of	O
these	O
advanced	O
methods,	O
traces	O
of	O
mycotoxins	B
and	O
relevant	O
breakdown	O
and	O
conjugation	O
products	O
can	O
be	O
quantified	O
simultaneously	O
in	O
human	O
urine	O
as	O
so-called	O
biomarkers	O
and	O
can	O
be	O
used	O
to	O
precisely	O
describe	O
the	O
real	O
exposure,	O
toxicokinetics,	O
and	O
bioavailability	O
of	O
the	O
toxins	B
present.	O

The	O
accuracy	O
(i.e.	O
the	O
Pearson	O
correlation	O
between	O
true	O
and	O
estimated	O
Δglucose	B
)	O
using	O
all	O
samples	O
was	O
0.57,	O
the	O
median	O
accuracy	O
after	O
tenfold	O
cross-validation	O
was	O
0.22.	O

Ammonium	B
acetate	I
and	O
dimethyl	B
sulfoxide	I
(DMSO)	O
of	O
analytical	O
grade	O
or	O
higher	O
were	O
obtained	O
from	O
Sigma	O
Aldrich	O
Sweden	O
AB	O
(Solna,	O
Sweden).	O

High	O
glucose	B
levels	O
have	O
been	O
previously	O
noted	O
in	O
the	O
faeces,	O
colonic	O
mucosa	O
and	O
serum_,	O
of	O
patients	O
with	O
IBD	O
relative	O
to	O
controls.	O

The	O
BATMAN	O
model	O
was	O
applied	O
to	O
estimate	O
the	O
relative	O
concentrations	O
of	O
the	O
following	O
metabolites	O
in	O
the	O
400	O
MHz	O
spectra:	O
alanine,	B
arginine,	B
asparagine,	B
aspartate,	B
cysteine,	B
glutamine,	B
glutamate,	B
glycine,	B
histidine,	B
isoleucine,	B
leucine,	B
lysine,	B
methionine,	B
phenylalanine,	B
proline,	B
serine,	B
threonine,	B
tryptophan,	B
tyrosine,	B
valine,	B
α	B
-D-glucopyranose,	I
β	B
-D-glucopyranose,	I
myo-inositol,	B
acetate,	B
acetoacetate,	B
α	B
-ketoglutarate,	I
β	B
-hydroxybutyrate,	I
citrate,	B
lactate,	B
pyruvate,	B
succinate,	B
creatine,	B
and	O
creatinine.	B

Measurement	O
of	O
extracellular	O
serotonin	B
metabolic	O
intermediates	O
and	O
dopamine	B
in	O
urine	O
of	O
GDM	O
patients.	O

We	O
show	O
that	O
anastrozole	B
is	O
oxidized	O
to	O
hydroxyanastrozole	B
predominantly	O
by	O
CYP3A4.	O

The	O
increased	O
serum	O
concentration	O
of	O
1-methyladenosine	B
in	O
HCC	O
patients	O
may	O
reflect	O
the	O
hyperactive	O
nucleoside	O
modification	O
associated	O
with	O
hyper	O
methylation	O
in	O
response	O
to	O
long-term	O
inflammation	O
and	O
oxidative	O
DNA	O
damage,	O
which	O
have	O
often	O
been	O
found	O
in	O
patients	O
with	O
cancers	O
of	O
other	O
digestive	O
organs[,].	O

The	O
cholesteryl	B
linoleate	I
C(18:2)CE	I
is	O
identified	O
as	O
one	O
of	O
the	O
three	O
major	O
cholesteryl	B
esters	I
present	O
in	O
human	O
low-density	O
lipoprotein	O
(LDL),	O
and	O
the	O
oxidization	O
of	O
C(18:2)CE	B
is	O
believed	O
to	O
be	O
correlated	O
with	O
atherosclerosis.	O

Briefly,	O
HNSCC	O
cells	O
(UM-SCC-14A)	O
were	O
trypsinized	O
and	O
washed	O
with	O
PBS,	O
and	O
then	O
the	O
Aldefluor	B
substrate	O
was	O
added	O
to	O
1	O
×	O
10_6	O
cells/mL	O
suspended	O
in	O
Aldefluor	B
assay	O
buffer	O
and	O
incubated	O
at	O
37	O
°C	O
for	O
45	O
min.	O

For	O
pentadecanoic	B
acid	I
and	O
18:2	O
lysoPC,	O
their	O
amount	O
is	O
high	O
before	O
reperfusion	O
and	O
their	O
amount	O
decreases	O
considerably	O
2 h	O
post	O
reperfusion.	O

p(x,y;Θ)∝exp(12∑ps=1∑pt=1βstxsxt+∑ps=1αsxs+∑ps=1∑qj=1ρsj(yj)xs+12∑qj=1∑qr=1φrj(yr,yj)).	B

The	O
branching	O
ratio	O
is	O
the	O
ratio	O
of	O
peak	O
areas	O
of	O
two	O
mass	O
transitions	O
of	O
Cer(22:0)	B
(m/z	O
622	O
to	O
264	O
/	O
m/z	O
622	O
to	O
280)	O
or	O
Cer(24:0)	B
(m/z	O
650	O
to	O
264	O
/	O
m/z	O
650	O
to	O
280),	O
used	O
to	O
assure	O
specificity	O
of	O
the	O
detection.	O

In	O
contrast	O
to	O
the	O
data	O
of	O
Rotroff	O
et	O
al.,	O
we	O
did	O
not	O
see	O
marked	O
differences	O
in	O
plasma	O
levels	O
palmitoleic	B
and	O
arachidonic	B
acid	I
upon	O
thiazide	B
treatment.	O

In	O
addition,	O
we	O
found	O
a	O
lowered	O
ratio	O
of	O
1-methylhistamine	B
to	O
choline	B
(>	O
6.6	O
x)	O
in	O
the	O
pre-prostatectomy	O
samples	O
compared	O
to	O
all	O
the	O
other	O
groups	O
(all	O
p	O
<	O
0.01).	O

Additionally,	O
the	O
enhanced	O
level	O
of	O
α-ketoglutarate	B
suggests	O
a	O
possible	O
higher	O
demand	O
on	O
the	O
TCA	O
cycle	O
for	O
COPD	O
patients.	O

Based	O
on	O
the	O
comprehensive	O
data	O
set	O
generated	O
in	O
the	O
course	O
of	O
this	O
study,	O
we	O
conclude	O
that	O
the	O
main	O
effect	O
induced	O
by	O
the	O
intervention	O
manifests	O
in	O
glucose.	B

We	O
sought	O
to	O
establish	O
a	O
method	O
for	O
screening	O
plasma	O
levels	O
of	O
oxysterols	B
in	O
breast	O
cancer	O
patients,	O
estimate	O
their	O
individual	O
variability	O
and	O
detection	O
limits,	O
and	O
provide	O
basic	O
information	O
about	O
their	O
roles	O
in	O
tumor	O
biology.	O

Meanwhile,	O
five	O
metabolites	O
entered	O
the	O
multiple	O
regression	O
model	O
from	O
pre-DM	O
to	O
DM:	O
Iso-valeraldehyde	B
(standardized	O
[std]	O
β = −1.544,	O
p = 0.049),	O
linoleic	B
acid	I
(std	O
β = 2.194,	O
p = 0.019),	O
Lysopc(18:1)	B
(std	O
β = −4.769,	O
p = 0.013),	O
2-Pyrroloylglycine	B
(std	O
β = −2.922,	O
p = 0.044)	O
and	O
Dityrosine	B
(std	O
β = 0.285,	O
p = 0.007)	O
with	O
an	O
overall	O
correct	O
percentage	O
of	O
95.4%.	O

Regarding	O
the	O
number	O
of	O
unsaturations	O
or	O
the	O
chain	O
length,	O
ceramides	B
with	O
1	O
unsaturation	O
and	O
36	O
to	O
41	O
carbons	O
were	O
by	O
far	O
the	O
most	O
abundant	O
ones.	O

Of	O
these	O
metabolites,	O
2-Oxo-4-methylvaleric	B
acid	I
and	O
4-Aminobutanoic	B
acid	I
showed	O
the	O
largest	O
AUC	O
values	O
(AUC	O
0.687	O
(95%	O
CI:	O
0.618–0.756),	O
p	O
<	O
0.001;	O
AUC	O
0.687	O
(95%	O
CI:	O
0.618–0.756),	O
p	O
<	O
0.001;	O
respectively).	O

The	O
levels	O
of	O
FAs,	O
triglyceride	B
(TG),	O
and	O
lactate,	B
which	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
in	O
Tae-Eum	O
type,	O
were	O
confirmed	O
to	O
be	O
metabolites	O
related	O
to	O
BMI,	O
indicating	O
that	O
metabolite	O
markers	O
for	O
the	O
diagnosis	O
of	O
SC	O
could	O
be	O
associated	O
with	O
obese	O
(see	O
).	O

incubation	O
with	O
rat	O
liver	O
mitochondria	O
measured	O
by	O
MTT	O
reduction	O
(A);	O
SDH	O
activation	O
by	O
phenazine	B
methosulfate	I
(0.5	O
mM	O
PMS)	O
after	O
inhibition	O
by	O
PhLA,	O
p	O
-HPhLA,	O
p	O
-HPhAA	O
and	O
itaconic	B
acid	I
at	O
a	O
concentration	O
for	O
every	O
compound	O
of	O
5.0	O
mM	O
(B);	O
SDH	O
inhibition	O
by	O
itaconic	B
acid	I
(0.5–5.0	O
mM)	O
in	O
comparison	O
with	O
malonate	B
(5.0	O
mM)	O
measured	O
by	O
DCPIP	O
reduction	O
(C)	O
and	O
influence	O
of	O
PMS	O
and	O
succinate	B
excess	O
(5.0	O
mM)	O
on	O
the	O
DCPIP	O
reduction	O
rate	O
during	O
oxidation	O
of	O
succinate	B
(1	O
mM)	O
in	O
the	O
presence	O
of	O
5	O
mM	O
itaconic	B
acid;	I
the	O
rate	O
of	O
DCPIP	O
reduction,	O
Δ/min,	O
is	O
indicated	O
in	O
parentheses	O
(D)	O
(n	O
=	O
5,	O
P	O
=	O
0.95	O
).	O

These	O
results	O
suggest	O
that	O
metabolic	O
factors	O
of	O
the	O
KP	B
could	O
be	O
potential	O
biomarkers	O
for	O
diagnosing	O
depression	O
and	O
that	O
KYNA	O
is	O
likely	O
to	O
be	O
the	O
most	O
valuable.	O

The	O
samples	O
were	O
reconstituted	O
in	O
125	O
μL	O
of	O
10%	O
methanol	B
containing	O
12	O
mM	O
HCl	O
and	O
transferred	O
to	O
300	O
μL	O
polypropylene	B
insert	O
vials	O
for	O
analysis.	O

Metabolites	O
that	O
were	O
commonly	O
observed	O
in	O
all	O
lung	O
tissue	O
extracts	O
include	O
isoleucine	B
(Ile),	O
leucine	B
(Leu),	O
valine	B
(Val),	O
lactate,	B
alanine	B
(Ala),	O
arginine	B

A	O
high-pressure	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
system	O
was	O
used	O
for	O
the	O
determination	O
of	O
tamoxifen,	B
4OHtam,	O
4OHNDtam,	O
NDtam,	O
NDDtam	O
and	O
tamNox	O
in	O
serum	O
[,].	O

The	O
dried	O
samples	O
were	O
then	O
reconstituted	O
in	O
150	O
µL	O
of	O
40%	O
PBS/60%	O
acetonitrile	B
(ACN)	O
and	O
vortexed	O
for	O
another	O
5	O
s.	O

The	O
exact	O
blood	O
sampling	O
times	O
and	O
blood	O
glucose	B
concentrations	O
after	O
ingestion	O
of	O
[U_13	B
C]glucose	I
were	O
monitored	O
by	O
an	O
in-house	O
Android	O
application	O
and	O
glucometers	B
(Diamond	O
Mini;	O
ForaCare).	O

Metabolites	O
that	O
showed	O
a	O
higher	O
concentration	O
included	O
3-hydroxybutyrate	B
(3-HB,	O
p	O
=	O
0.002),	O
acetoacetate	B
(p	O
=	O
0.015),	O
carnitine	B
(p	O
=	O
0.019),	O
cystine	B
(p	O
=	O
0.000),	O
homocysteine	B
(p	O
=	O
0.023),	O
pyruvate	B
(p	O
=	O
0.029),	O
and	O
trimethylamine	B
N	I
-oxide	I
(TMAO,	O
p	O
=	O
0.003).	O

Abbreviations:	O
ALSPAC,	O
Avon	O
Longitudinal	O
Study	O
of	O
Parents	O
and	O
Children;	O
BMI,	O
body	O
mass	O
index;	O
DBP,	B
diastolic	O
blood	O
pressure;	O
HDL,	O
high-density	O
lipoprotein;	O
LDL,	O
low-density	O
lipoprotein;	O
SBP,	O
systolic	O
blood	O
pressure.	O

As	O
expected,	O
the	O
baseline	O
serum	O
tryptophan	B
level	O
was	O
significantly	O
higher	O
in	O
T2D,	O
compared	O
to	O
matched	O
NGT,	O
with	O
a	O
fold	O
change	O
of	O
3.06	O
and	O
a	O
p	O
value	O
lower	O
than	O
0.01	O
(	O
and	O
).	O

In	O
the	O
United	O
States,	O
acetaminophen	B
is	O
one	O
of	O
the	O
most	O
commonly	O
used	O
drugs	O
for	O
treating	O
pain,	O
with	O
29	O
billion	O
units	O
of	O
acetaminophen-containing	O
products	O
having	O
been	O
sold	O
to	O
retail	O
and	O
nonretail	O
pharmacies	O
in	O
2005.	O

Additional	O
search	O
for	O
the	O
protonated	O
form	O
of	O
L-histidine	B
revealed	O
an	O
ion	O
at	O
[M+H]_+	O
 = 156.078	O
m/z	O
and	O
retention	O
time	O
of	O
0.2864	O
min	O
(,	O
p = 0.00196).	O

Th1	O
cytokines	O
from	O
activated	B
infiltrating	O
T	O
and	O
B	O
cells	O
may	O
also	O
trigger	O
KS	O
lesion	O
formation	O
by	O
promoting	O
spindle	O
cell	O
proliferation	O
and	O
angiogenesis	O
[,	O
].	O

Compared	O
to	O
the	O
NGT	O
group,	O
the	O
T2D	O
group	O
had	O
higher	O
levels	O
of	O
tryptophan.	B

The	O
serum	O
metabolite,	O
namely	O
1-methyladenosine,	B
was	O
identified	O
as	O
the	O
characteristic	O
metabolite	O
for	O
HCC.	O

Both	O
conditions	O
are	O
associated	O
with	O
elevated	O
serum	O
cholesterol.	B

The	O
statistical	O
analysis	O
revealed	O
that	O
carnitine	B
and/or	O
acetylcarnitine	B
were	O
indeed	O
increased	O
in	O
samples	O
from	O
patients	O
with	O
active	O
disease	O
both	O
before	O
(group	O
A)	O
and	O
after	O
treatment	O
(i.e.	O
relapsed,	O
group	O
C2).	O

These	O
metabolites	O
have	O
been	O
synthesized	O
chemically	O
and	O
comprise	O
five	O
active	O
metabolites,	O
namely	O
1-OH,	O
2-OH,	O
3-OH,	O
oxo,	O
3-oxo	O
and	O
one	O
inactive	O
metabolite	O
amino.	B

Since	O
carnitine	B
and	O
its	O
short-chain	O
derivatives	O
are	O
essential	O
for	O
the	O
entry	O
of	O
fatty	O
acid	O
into	O
mitochondria	O
for	O
oxidation,	O
fatty	O
acid	O
oxidation	O
is	O
decreased	O
in	O
the	O
low-grade	O
NMIBC	O
group	O
compared	O
to	O
the	O
controls.	O

Likewise,	O
cancer-specific	O
elevations	O
of	O
hypoxanthine	B
may	O
represent	O
an	O
underlying	O
enhanced	O
capacity	O
for	O
DNA	O
synthesis	O
in	O
association	O
with	O
tumor	O
growth.	O

Patients	O
with	O
tumors	O
expressing	O
estrogen	B
receptor	O
had	O
significantly	O
higher	O
levels	O
of	O
7-ketocholesterol	B
and	O
lower	O
levels	O
of	O
27-hydroxycholesterol	B
within	O
the	O
first	O
sampling	O
than	O
those	O
without	O
expression	O
(p	O
=0.020	O
and	O
0.006,	O
respectively,	O
).	O

The	O
multivariant	O
ROC	O
curve-based	O
exploratory	O
analysis	O
revealed	O
that	O
a	O
metabolite	O
panel	O
including	O
4-ethoxymethylphenol,	B
prostaglandin	B
F2b,	O
thromboxane	B
B3,	I
hydroxybutyrylcarnitine,	B
3-hydroxyphloretin	B
and	O
N′-formylkynurenine	B
possessed	O
the	O
best	O
predictive	O
ability.	O

The	O
trend	O
in	O
peak	O
width	O
values	O
was	O
also	O
seen	O
for	O
every	O
compound	O
class,	O
with	O
both	O
Diol	B
and	O
2-PIC	O
columns	O
showing	O
significant	O
reductions	O
in	O
peak	O
width	O
for	O
all	O
classes	O
of	O
analyte.	O

In	O
addition,	O
plasma	O
jet	O
treatment	O
can	O
also	O
significantly	O
reduce	O
the	O
purine	B
metabolic	O
pathway	O
in	O
endothelial	O
cells.	O

In	O
order	O
to	O
identify	O
nonglucose	O
metabolites	O
related	O
to	O
the	O
disease	O
state,	O
PC-DA	O
was	O
repeated	O
after	O
exclusion	O
of	O
glucose	B
resonances	O
from	O
the	O
data.	O

Serum	O
creatinine	B
and	O
cysteinesulfonic	B
acid	I
showed	O
no	O
significant	O
correlation	O
with	O
any	O
of	O
the	O
lung	O
parameters.	O

To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
the	O
presence	O
of	O
p-cresyl	B
sulphate	I
in	O
plasma	O
using	O
_1	O
H-NMR	O
spectroscopy.	O

In	O
this	O
paper,	O
the	O
substances	O
responsible	O
for	O
the	O
inhibition	O
of	O
boar	O
spermatozoan	O
motility	O
in	O
the	O
extract	O
of	O
T.	O
harzianum	O
strain	O
ES39	O
were	O
identified	O
as	O
a	O
peptaibol	O
group	O
of	O
peptides,	O
based	O
on	O
the	O
molecular	O
mass	O
of	O
1,600	O
to	O
2,000	O
Da,	O
containing	O
unusual	O
amino	O
acids	O
(α-aminoisobutyric	O
acid	I
[Aib]),	O
an	O
acetylated	O
N-terminal	O
amino	O
acid,	O
and	O
C-terminal	O
amino	B
alcohol	I
residues.	O

In	O
addition,	O
findings	O
from	O
our	O
group	O
based	O
on	O
size	O
and	O
extent	O
of primary	O
prostate	O
cancer	O
cases	O
demonstrated	O
a	O
positive	O
association	O
with	O
histidine	B
metabolites	O
including	O
N-acetyl-3-methylhistidine,	B
and 1-	O
and	O
3-methylhistidine	B
in	O
T2	O
prostate	O
cancers.	O

breast	O
neoplasm,	O
carcinogenic	O
marker,	O
estrogen	B
catabolism,	O
estrogen	B
metabolism,	O
polychlorinated	O
biphenyls,	O
polychlorinated	B
dibenzodioxins,	I
polychlorinated	B
dibenzofurans	I

Other	O
major	O
findings	O
of	O
this	O
study	O
were	O
the	O
association	O
of	O
high	O
plasma	O
cystathionine	B
concentrations	O
in	O
SAP	O
with	O
higher	O
glucose,	B
TMAO,	B
choline,	B
BCAA,	O
and	O
phenylalanine	B
concentrations,	O
depressed	O
kidney	O
function,	O
incidence	O
of	O
diabetes,	O
lower	O
glutathione	B
and	O
lower	O
plasma	O
PLP	O
concentrations,	O
and	O
evidence	O
of	O
modest	O
vitamin	O
B-6	O
insufficiency.	O

S1)	O
and	O
even	O
though	O
the	O
information	O
was	O
limited,	O
the	O
fragments	O
identified	O
the	O
metabolite	O
as	O
a	O
hydroxyl	B
glucuronide	I
of	O
M31.	O

Organ-dependent	O
differences	O
were	O
prominent	O
at	O
the	O
levels	O
of	O
glycolytic	B
and	O
tricarboxylic	B
acid	I
cycle	O
intermediates	O
and	O
associated	O
energy	O
status.	O

Metabolite	O
internal	O
standards	O
were	O
purchased	O
from	O
Cambridge	O
Isotopes	O
(L-lysine-4,4,5,5-d_4	O
)	O
and	O
C/D/N	O
Isotopes	O
(creatine-methyl-d_3	O
,	O
D-leucine-d_10	B
,	O
L-tryptophan-2,3,3-d_3	B
,	O
caffeine-methyl-d_3	B
,	O
L-phenylalanine-3,3-d_2	B
,	O
and	O
D/L-carnitine-trimethyl-d_9	O
)	O

Moreover,	O
potential	O
metabolite	O
markers	O
of	O
reduced	O
sleep	O
duration	B
(chronic	O
partial	O
repeated	O
sleep	O
restriction)	O
have	O
recently	O
been	O
identified,	O
two	O
of	O
which	O
seem	O
to	O
be	O
conserved	O
between	O
rats	O
and	O
humans	O
(oxalic	O
acid	I
and	O
one	O
diacylglycerol)	B
with	O
the	O
majority	O
of	O
markers	O
of	O
restricted	O
sleep	O
in	O
both	O
species	O
being	O
lipids.	O

The	O
most	O
statistically	O
significant	O
changes	O
with	O
OSC	O
data	O
were	O
observed	O
for	O
glycine,	B
lactate,	B
threonine	B
and	O
glycerophosphocholine	B
(GPC)	O
(on	O
the	O
left	O
of	O
the	O
loading	O
plot)	O
with	O
an	O
upward	O
trend,	O
and	O
citrate	B
and	O
hippurate	B
(on	O
the	O
right	O
of	O
the	O
loading	O
plot),	O
with	O
a	O
downward	O
trend.	O

Moreover,	O
histamine	B
is	O
thought	O
to	O
be	O
involved	O
in	O
inhibition	O
of	O
the	O
local	O
immune	O
response	O
against	O
cancer	O
(Masini	O
et	O
al.	O
).	O

GSH	B
is	O
supposed	O
to	O
play	O
many	O
roles	O
in	O
regulating	O
cancer	O
development	O
and	O
growth,	O
such	O
as	O
cell	O
proliferation,	O
apoptosis,	O
and	O
resistance	O
to	O
antineoplastic	O
drugs.	O

ij	O
i	O
j	O
}	O
}	O
1+exp{β0+∑mj=1βjXij}	B
1+exp{β0+∑mj=1βjXij}	I
1	O
+	O
exp	O
{β0+∑mj=1βjXij}	O
{	O
{	O
β0+∑mj=1βjXij	B
β0	O
β0	O
β	O
β	O
β	O
	O
0	O
0	O
+	O
∑mj=1	O
∑mj=1	O
∑	O
∑	O
m	O
m	O
j=1	O
j=1	O
j	O
=	O
1	O
βjXij	O
βj	O
βj	O
β	O
β	O
β	O

who	O
demonstrated,	O
using	O
LC–MS	O
techniques,	O
that	O
urinary	O
proline	B
betaine	I
increased	O
markedly	O
after	O
drinking	O
orange	O
juice,	O
peaking	O
at	O
2 h	O
after	O
consumption.	O

Ten	O
grams	O
uniformly	O
_13	O
C	O
labeled	O
glucose	B
([U-_13	O
C]-Glc)	O
in	O
sterile	O
saline	B
solution	O
were	O
infused	O
i.v.	O

In	O
a	O
subgroup	O
of	O
patients	O
with	O
HER2‐positive	O
disease	O
treated	O
with	O
paclitaxel	O
plus	O
lapatinib,	B
metabolomic	O
profiles	O
from	O
patients	O
in	O
the	O
upper	O
and	O
lower	O
thirds	O
of	O
the	O
dataset	O
showed	O
significant	O
differences	O
for	O
time	O
to	O
progression	O
(N = 22,	O
predictive	O
accuracy =	O

In	O
this	O
metabolite	O
–	O
metabolite	O
network	O
presentation,	O
the	O
most	O
significant	O
‘hub	O
nodes’	O
or	O
metabolites	O
that	O
were	O
involved	O
in	O
the	O
flow	O
of	O
information	O
between	O
the	O
different	O
pathways	O
were	O
pyruvic	B
acid,	I
succinic	B
acid,	I
malonic	B
acid,	I
palmitic	B
acid	I
and	O
arachidonic	B
acid.	I

The	O
transitions	O
monitored	O
were:	O
508.0>135.9	O
and	O
508.0>410.2	O
for	O
ATP	B
(rt:	O
0.7	O
min),	O
428.0>135.9	O
and	O
428.0>348.1	O
for	O
ADP	B
(rt:	O
0.9	O
min),	O
330.1.>136.0,	O
330.1>119.0	O
and	O
330.1>96.9	O
for	O
cAMP	O
(rt:	O
2.7	O
min),	O
346.1>152.1,	O
346.1>135.1	O
and	O
346.1>110.0	O
for	O
cGMP	O
(rt:	O
2.5	O
min)	O
and	O
523.1>146.0	O
and	O
523.1>425.1	O
for	O
_13	O
C_10	O
_15	O
N5	O
–ATP	O
(rt:	O
0.7	O
min).	O

Therefore,	O
dietary	O
choline	B
and	O
betaine	B
intake	O
with	O
a	O
fixed	O
dose	O
may	O
alleviate	O
GC.	O

Carolyn	O
M.	O
Slupsky	O
et	O
al.,	O
however,	O
pointed	O
out	O
that	O
the	O
content	O
of	O
succinic	B
acid	I
of	O
urine	O
in	O
patients	O
with	O
ovarian	O
cancer	O
was	O
lower	O
than	O
that	O
in	O
healthy	O
people.	O

For	O
example,	O
it	O
is	O
possible	O
to	O
note	O
that	O
subject	O
AU	O
is	O
characterized	O
by	O
persistently	O
low	O
intensity	O
of	O
the	O
doublet	O
at	O
≈7.36	O
ppm	O
and	O
of	O
the	O
two	O
triplets	O
at	O
≈7.45	O
and	O
7.74	O
ppm	O
(i.e.,	O
very	O
low	O
levels	O
of	O
hippuric	B
acid	I
despite	O
the	O
absence	O
of	O
antibiotic	O
treatment),	O
whereas	O
subject	O
BI	O
presents	O
higher	O
intensity	O
of	O
the	O
multiplet	O
at	O
≈1.73	O
ppm	O
(higher	O
lysine	B
levels)	O
than	O
the	O
other	O
individuals.	O

Because	O
total	O
overnight	O
urinary	O
aMT6s/Cr	O
is	O
highly	O
correlated	O
with	O
total	O
overnight	O
melatonin	B
production,	O
the	O
relationships	O
between	O
8-oxodG,	B
8-oxoGua	O
and	O
aMT6s/Cr	O
translate	O
into	O
similar	O
relationships	O
between	O
8-oxodG,	B
8-oxoGua	O
and	O
melatonin	B
production.	O

The	O
correlation	O
between	O
the	O
ratio	O
of	O
S1P	O
to	O
ceramide	B
in	O
breast	O
cancer	O
tissue	O
and	O
nuclear	O
grade.	O

Although	O
the	O
occurrence	O
and	O
biological	O
activity	O
of	O
selected	O
β-apocarotenoids	B
in	O
mammals	O
has	O
been	O
reported	O
in	O
various	O
systems,	O
progress	O
has	O
been	O
hampered	O
because	O
many	O
of	O
the	O
compounds	O
are	O
not	O
available	O
commercially.	O

In	O
urine	O
these	O
changes	O
related	O
to	O
a	O
(gender-independent)	O
relative	O
reduction	O
of	O
hippurate	B
and	O
a	O
further	O
increase	O
of	O
aromatic	O
amino	O
acids.	O

Then	O
mobile	O
phase	O
B	O
(200	O
mM	O
sorbitol,	B
100	O
mM	O
Tris	O
and	O
50	O
mM	O
EDTA-2Na,	O
pH	O
8.5)	O
was	O
pumped	O
through	O
the	O
column	O
until	O
GA	O
was	O
completely	O
eluted.	O

A	O
higher	O
glutamate	B
concentration	O
in	O
the	O
brain	O
can	O
induce	O
excitotoxicity,	O
and	O
the	O
increase	O
of	O
Ca2+	O
concentrations	O
in	O
the	O
cell,	O
which	O
may	O
cause	O
mitochondrial	O
dysfunction	O
and	O
increase	O
oxidative	O
stress	O
and	O
neuron	O
death.	O

A	O
modification	O
of	O
our	O
well-established	O
model	O
of	O
porcine	B
hemorrhagic	O
shock	O
was	O
used	O
[,].	O

Twenty	O
five	O
overweight/obese	O
(BMI~30	O
kg/m_2	O
)	O
adults	O
with	O
impaired	O
fasting	O
glucose	B
or	O
untreated	O
diabetes	O
were	O
randomized	O
to	O
three	O
months	O
of	O
pioglitazone	B
(45	O
mg	O
per	O
day)	O
plus	O
metformin	B
(1000	O
mg	O
twice	O
per	O
day,	O
N	O
=	O
12	O
participants)	O
or	O
placebo	O
(n=13).	O

Cancer-induced	O
dysregulation	O
of	O
FA	B
metabolism	O
has	O
been	O
receiving	O
particular	O
attention	O
in	O
recent	O
years.	O

The	O
dry	O
extracts	O
were	O
then	O
reconstituted	O
in	O
100 μL	O
of	O
ACN:H_2	O
O	B
(1:1,	O
v/v),	O
sonicated	O
for	O
3 min	O
and	O
centrifuged	O
10 min	O
at	O
13000 rpm	O
and	O
4 °C	O
to	O
remove	O
insoluble	O
debris.	O

There	O
was	O
a	O
peak	O
from	O
an	O
endogenous	O
substance	O
at	O
3.6	O
min	O
when	O
monitoring	O
the	O
transition	O
for	O
rosuvastatin	B
in	O
blank	O
plasma,	O
but	O
it	O
did	O
not	O
interfere	O
with	O
the	O
quantification	O
of	O
rosuvastatin	B
which	O
elutes	O
at	O
2.9	O
min.	O

On	O
the	O
other	O
hand	O
guaiacol	B
showed	O
significant	O
increases	O
in	O
its	O
24h-iAUC	O
after	O
soy	O
drink	O
intake	O
compared	O
to	O
milk	O
intake.	O

As	O
such,	O
the	O
lipidomic	O
approach	O
used	O
for	O
the	O
present	O
study	O
may	O
complement	O
previous	O
lipidomic	O
approaches	O
by	O
identifying	O
PAFs	O
that	O
may	O
be	O
derived	O
from	O
membrane	O
phospholipids	B
such	O
as	O
PC(O	B
-36:4).	I

Plasma	O
aminograms	B
were	O
significantly	O
altered	O
in	O
patients	O
with	O
AD	O
comparing	O
with	O
CHD,	O
especially	O
in	O
acute	O
AD,	O
suggesting	O
amino	O
acid	O
profile	O
is	O
expected	O
to	O
exploit	O
a	O
novel,	O
non-invasive,	O
objective	O
diagnosis	O
for	O
AD.	O

T,	O
Epi-T,	O
Adione,	B
Δ_4	O
-AD,	O
androsterone,	B
DHEA,	O
DHEA-S	B
and	O
DHEA-G	O
were	O
from	O
Steraloids	O
(Wilton,	O
NH,	O
USA).	O

Metabolite	O
extraction	O
was	O
achieved	O
using	O
methanol,	B
chloroform	B
and	O
water	O
based	O
on	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
(Bligh	O
and	O
Dyer	O
).	O

Plasma	O
metabolite	O
analysis	O
revealed	O
biomarker	O
metabolites	O
associated	O
with	O
ICC	O
and	O
in	O
particular	O
2-hydroxyglutarate	B
(2-HG)	O
levels	O
were	O
elevated	O
in	O
both	O
samples	O
from	O
the	O
only	O
patient	O
showing	O
a	O
variant	O
allele	O
in	O
IDH1	O
.	O

Using	O
the	O
same	O
procedure,	O
another	O
five-variable	O
model	O
(AUC = 0.878,	O
95%	O
CI = 0.792–0.937,	O
probability	O
3 = exp	O
(6.176 + 1.437	O
[4-hydroxypentenoic	O
acid	I
[−2.378	O
[5-dihydrotestosterone	O
sulfate]	I
−2.415	O
[serine]	O
−0.022	O
[spermine]	O

In	O
this	O
modified	O
method,	O
cells	O
were	O
cultured	O
for	O
72	O
h	O
and	O
MCF-7	O
cells	O
were	O
plated	O
in	O
6-well	O
plates	O
in	O
RPMI	O
1640	O
media	O
without	O
phenol	B
red	O
and	O
supplemented	O
with	O
10%	O
charcoal-stripped	O
FBS,	O
1%	O
glutaMAX,	B
1%	O
AB/AM,	O
1%	O
nonessential	O
amino	O
acids,	O
and	O
insulin	O
(6	O
ng/mL)	O
at	O
3.5	O
×	O
10_5	O
cells/well.	O

Quinolinic	B
acid	I
is	O
a	O
de	O
novo	O
precursor	O
to	O
nicotinic	B
acid,	I
which	O
is	O
used	O
in	O
the	O
synthesis	O
of	O
nicotinamide	B
adenine	I
dinucleotide,	I
a	O
coenzyme	O
catalysing	O
redox	O
reactions	O
in	O
the	O
body.	O

Twelve	O
ACC	O
patients	O
had	O
combined	O
glucocorticoid	B
and	O
adrenal	O
androgen	O
excess,	O
with	O
additional	O
aldosterone	B
excess	O
in	O
two	O
of	O
them.	O

Ionization	O
was	O
achieved	O
with	O
electrospray	O
in	O
the	O
positive	O
mode,	O
and	O
polysulfide	B
derivatives	O
were	O
identified	O
and	O
quantified	O
by	O
means	O
of	O
multiple	O
reaction	O
monitoring.	O

We	O
also	O
observed	O
a	O
consistent	O
downregulation	O
of	O
dipeptides	O
pyroglutamylglycine,	B
glycylvaline,	B
alanylalanine	B
and	O
aspartyleucine	B
in	O
DC	O
vs.	O
NHC.	O

The	O
RP	B
column	O
(Phenomenex	O
Luna	O
C18(2)	O
150	O
x	O
4,6	B
mm;	I
5	O
µm	O
particle	O
size)	O
was	O
kept	O
at	O
40	O
°C.	O

A	O
tissue	O
microarray	O
with	O
adenoma	O
tissue	O
from	O
57	O
patients	O
was	O
studied	O
by	O
immunohistochemistry	O
for	O
expression	O
of	O
CYP11B1,	O
required	O
for	O
cortisol	B
and	O
11β-hydroxyandrostenedione	B
synthesis,	O
and	O
CYP11B2,	O
the	O
enzyme	O
responsible	O
for	O
aldosterone	B
synthesis,	O
followed	O
by	O
digital	O
image	O
analysis	O
for	O
quantification	O
of	O
staining	O
intensity.	O

First,	O
the	O
blood	O
samples	O
were	O
collected	O
at	O
the	O
time	O
point	O
when	O
the	O
participants	O
were	O
diagnosed,	O
a	O
single	O
measurement	O
may	O
not	O
fully	O
reflect	O
the	O
body’s	O
long-term	O
concentrations	O
of	O
choline	B
or	O
its	O
metabolite	O
TMAO.	B

Dry	O
residues	O
were	O
reconstituted	O
in	O
AcN/water	O
[50:50]	O
with	O
0.1%	O
formic	B
acid	I
followed	O
by	O
agitation	O
for	O
1 min.	O

When	O
we	O
applied	O
the	O
HbA1c	O
value	O
of	O
7.0	O
as	O
the	O
cut-off	O
value	O
for	O
the	O
glucose	B
control,	O
about	O
half	O
of	O
the	O
patients	O
(n = 10)	O
showed	O
an	O
improved	O
glycemic	B
control	O
during	O
the	O
follow-up	O
period	O
(3	O
months),	O
whereas	O
the	O
others	O
(n = 12)	O
did	O
not.	O

The	O
reverse	O
diol	B
epoxide,	I
Phe-3,4-D-1,2-E,	B
was	O
a	O
far	O
better	O
substrate	O
for	O
GSH	B
conjugation,	O
as	O
determined	O
by	O
analysis	O
of	O
Phe-3,4-D-1-NAC	B
in	O
the	O
medium,	O
than	O
was	O
the	O
bay	O
region	O
diol	B
epoxide	I
Phe-1,2-D-3,4-E,	I
for	O
which	O
only	O
minimal	O
conjugation	O
to	O
Phe-1,2-D-4-NAC	B
was	O
observed.	O

Glutamate	B
levels	O
> 0.31	O
in	O
patients	O
with	O
PET	O
negative	O
lung	O
lesions	O
is	O
likely	O
to	O
correspond	O
with	O
inflammation.	O

The	O
sample	O
(1	O
mL)	O
was	O
neutralized	O
to	O
pH	O
7	O
with	O
NH_4	O
OH	O
and	O
loaded	O
onto	O
an	O
Oasis	O
MAX	O
cartridge	O
(1	O
mL,	O
30	O
mg,	O
Waters)	O
previously	O
equilibrated	O
using	O
1	O
mL	O
MeOH,	B
and	O
1	O
mL	O
2%	O
aqueous	O
NH_4	O
OH.	O

	O
showed	O
the	O
distribution	O
and	O
median	O
levels	O
of	O
phthalate	B
metabolites	O
in	O
our	O
sample	O
of	O
the	O
general	O
Taiwanese	O
population	O
classified	O
into	O
four	O
age	O
groups.	O

Clothianidin	B
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louise,	O
MO).	O

The	O
internal	O
standard	O
solution	O
with	O
_13	O
C-labeled	O
analytes	O
was	O
prepared	O
in	O
water	O
with	O
0.2%	O
acetonitrile	B
so	O
that	O
a	O
50	O
μL	O
spike	O
would	O
result	O
in	O
approximate	O
concentrations	O
of	O
32	O
ng/mL	O
(_13	O
C-1-OH-NAP	B
and	O
_13	O
C-2-OH-NAP)	B
or	O
8	O
ng/mL	O
(other	O
_13	O
C-labeled	O
analytes).	O

Pathway	O
analyses	O
revealed	O
altered	O
lipid	O
and	O
purine	B
metabolisms	O
between	O
cancer	O
patients	O
and	O
HCs,	O
together	O
with	O
disordered	O
amino	O
acid	O
and	O
purine	B
metabolisms	O
between	O
BC	O
and	O
RCC	O
with	O
haematuria.	O

Spectra	O
in	O
(d,	O
red	O
box)	O
regions	O
of	O
cancer	O
demonstrate	O
dramatically	O
elevated	O
choline,	B
and	O
a	O
reduction	O
or	O
absence	O
of	O
citrate	B
and	O
polyamines	B
relative	O
to	O
(c,	O
green	O
box)	O
regions	O
of	O
healthy	O
peripheral	O
zone	O
tissue.	O

Therefore,	O
the	O
increased	O
levels	O
of	O
kynurenine	B
might	O
be	O
reflective	O
of	O
increased	O
IDO	O
activation	O
due	O
to	O
leptin-mediated	O
restoration	O
of	O
TNF-α	O
levels.	O

Univariate	O
and	O
multivariate	O
logistic	O
regression	O
using	O
R	O
software	O
version	O
3.3.0	O
was	O
then	O
performed	O
to	O
calculate	O
the	O
association	O
between	O
metabolite	O
to	O
Trp	O
ratio	O
and	O
KP	B
mRNA	O
expression	O
with	O
endoscopic	O
inflammation	O
and	O
histologic	O
inflammation.	O

The	O
monitored	O
amounts	O
after	O
one	O
hour	O
of	O
culture	O
rank	O
the	O
NTPs	O
as	O
follows:	O
ATP	B
(5.96	O
nmol/10_6	O
S9	O
cells;	O
7.77	O
nmol/10_6	O
16HBE14o_−	O
cells),	O
UTP	O
(1.66;	O
2.27),	O
GTP	O
(1.33;	O
1.14)	O
and	O
CTP	B
(0.65;	O
0.92).	O

It	O
also	O
exerts	O
its	O
deleterious	O
effects	O
on	O
podocytes	O
and	O
tubulointerstitial	O
cells	O
by	O
upregulating	O
AMPK	O
and	O
mTOR1	O
signaling,	O
intracellular	O
serial	O
DAG	O
and	O
PKC	O
activation,	O
induction	O
of	O
mitochondrial	O
superoxide	B
generation,	O
endoplasmic	O
reticulum	O
stress,	O
and,	O
eventually,	O
promotion	O
of	O
autophagy,	O
apoptosis,	O
and	O
cell	O
death	O
(,	O
,	O
,	O
–).	O

An	O
acute	O
injection	O
of	O
cytokines	O
led	O
to	O
a	O
rise	O
in	O
cortisol	B
levels,	O
seen	O
as	O
an	O
adaptive	O
response	O
to	O
fulfil	O
the	O
increased	O
energy	O
demand	O
of	O
inflamed	O
tissues.	O

Acylglycines	B
in	O
urine	O
have	O
been	O
reported	O
as	O
the	O
direct	O
expression	O
of	O
accumulation	O
of	O
the	O
correspondent	O
acyl-CoA	B
esters	I
in	O
the	O
mitochondrion	O
(Bonafe	O
et	O
al.	O
).	O

In	O
conclusion,	O
the	O
results	O
indicate	O
that	O
reactions	O
of	O
the	O
glutaminolytic	B
pathway	O
are	O
significantly	O
more	O
active	O
in	O
16HBE14o_−	O
cells	O
than	O
in	O
S9	O
cells	O
when	O
rHla	O
is	O
present	O
in	O
the	O
culture	O
medium	O
of	O
the	O
two	O
cell	O
types.	O

Serotonin	B
has	O
also	O
been	O
linked	O
to	O
angiogenesis	O
and	O
metastasis.	O

Between	O
sepsis	O
patients	O
and	O
controls,	O
we	O
found	O
significant	O
differences	O
in	O
the	O
serum	O
concentrations	O
of	O
the	O
following	O
eight	O
metabolites:	O
glucose	B
(median	O
concentration	O
5.63	O
mmol/l	O
vs	O
4.13	O
mmol/l,	O
p	O
<	O
0.01),	O
citrate	B
(0.08	O
mmol/	O

Sphingolipid	B
metabolites	O
in	O
healthy	O
controls	O
stratified	O
by	O
body	O
fat.	O

Although	O
ceramide	B
can	O
be	O
synthesised	O
de	O
novo,	O
it	O
is	O
rapidly	O
produced	O
from	O
sphingomyelin	B
by	O
the	O
stress-induced	O
activation	O
of	O
neutral	O
and	O
acid	O
sphingomyelinase.	O

The	O
GSH	B
conjugates	O
of	O
estrogen	B
quinones	I
are	O
further	O
converted	O
to	O
Cys	O
and	O
NAcCys	O
conjugates	O
via	O
the	O
mercapturic	B
acid	I
biosynthesis	O
pathway.	O

Lysine;	B
6.	O

HCC:	O
hepatocellular	O
carcinoma;	O
YDS:	O
Yang	O
deficiency	O
syndrome;	O
NYDS:	O
non-Yang	O
deficiency	O
syndrome;	O
PLS-DA:	O
partial	O
least	O
square	O
discriminatory	O
analysis;	O
LDL:	O
low-density	O
lipid;	O
VLDL:	O
very	O
low-density	O
lipid.	O
_	O
a	O
Chemical	O
shifts	O
were	O
reported	O
with	O
reference	O
to	O
3-trimethylsilylpropanesulfonate	B
(TPS)	O
singlet	O
resonance	O
at	O
0.000 ppm.	O

Acyl	B
carnitines	I
function	O
as	O
chaperones	B
for	O
fatty-acyl	O
Co-A	O
transport	O
into	O
the	O
mitochondrion	O
where	O
β-oxidation	O
takes	O
place.	O

Relationship	O
between	O
the	O
decrease	O
in	O
total	O
skeletal	O
muscle	O
LC-FACoA	O
(Δ	O
LC-FACoA)	O
and	O
increase	O
in	O
insulin-stimulated	O
glucose	B
disposal	O
(Δ	O
Rd)	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
after	O
pioglitazone	B
treatment	O
for	O
4	O
months.	O

In	O
contrast	O
to	O
our	O
findings,	O
Hasim	O
et	O
al.	O
reported	O
reduced	O
levels	O
of	O
lactate	B
in	O
CIN	O
and	O
cervical	O
cancer	O
as	O
compared	O
with	O
normal	O
individuals.	O

Twenty-four	O
metabolites	O
from	O
plasma	O
samples	O
and	O
24	O
metabolites	O
from	O
atrial	O
appendage	O
samples	O
were	O
screened	O
for	O
their	O
ability	O
to	O
distinguish	O
AF	B
from	O
non-AF	O
patients	O
(Supplementary	O
Tables _S1	O
and	O
_S2	O
).	O

After	O
pseudouridine	B
it	O
had	O
the	O
second	O
highest	O
fold	O
difference	O
between	O
the	O
study	O
groups.	O

In	O
the	O
present	O
study,	O
receiver–operator	O
curves	O
were	O
calculated	O
with	O
serum	O
1-methyladenosine	B
and/or	O
AFP.	O

All	O
stock	O
standard	O
solutions	O
were	O
prepared	O
in	O
MeOH	B
or	O
water	O
depending	O
on	O
the	O
solubility	O
and	O
were	O
stored	O
at	O
−80	O
°C.	O

Two	O
aliquots	O
of	O
each	O
sample	O
were	O
then	O
reconstituted	O
in	O
50 µl	O
of	O
6.5 mM	O
ammonium	B
bicarbonate	O
in	O
water	O
(pH	O
8)	O
for	O
the	O
negative	O
ion	O
analysis,	O
and	O
the	O
other	O
two	O
aliquots	O
of	O
each	O
were	O
reconstituted	O
using	O
50 µl	O
0.1%	O
formic	B
acid	I
in	O
water	O
(pH	O
~3.5)	O
for	O
the	O
positive	O
ion	O
analysis.	O

The	O
three	O
major	O
SCFAs	O
produced	O
as	O
microbial	O
metabolites,	O
acetate,	B
propionate,	B
and	O
butyrate,	B
were	O
all	O
detected	O
as	O
were	O
valeric,	O
isobutyric,	B
isovaleric,	O
caproic,	O
and	O
heptanoic	O
acids.	O

After	O
addition	O
of	O
internal	O
standard	O
(10	O
μ	O
L	O
of	O
L-2-chlorophenylalanine	B
in	O
water,	O
0.3	O
mg/mL),	O
the	O
samples	O
were	O
combined	O
with	O
400	O
μ	O
L	O
of	O
a	O
mixture	O
of	O
water,	O
methanol,	B
and	O
acetonitrile	B
(1:2:7).	I

AEDs,	O
antiepileptic	O
drugs;	O
CBZ,	O
carbamazepine;	B
LEV,	O
levetiracetam;	B
LMT,	O
lamotrigine;	B
TOP,	O
topiramate;	B
VNS,	O
vagal	O
nerve	O
stimulation;	O
FELB,	O
felbamate;	O
PB,	O
phenobarbital;	O
OXC,	O
oxcarbazepine;	B
PRI,	O
primidone;	B
type	O
of	O
seizure,	O
focal	O
or	O
generalized;	O
MRI,	O
magnetic	O
resonance	O
imaging;	O
N,	O
normal;	O
SWMG,	O
Small	O
White	O
Matter	O
Gliosis	O
.	O

The	O
correlation	O
coefficients	O
between	O
the	O
formation	O
rates	O
of	O
anastrozole	B
metabolites	O
and	O
the	O
activity	O
of	O
each	O
CYP	O
isoform	O
in	O
different	O
HLMs	O
were	O
calculated	O
(see	O
Data	O
analysis).	O

Patients	O
receiving	O
valproic	B
acid	I
and	O
lacosamide	B
were	O
excluded	O
because	O
the	O
NMR	O
resonances	O
of	O
these	O
compounds	O
affect	O
the	O
recognition	O
of	O
certain	O
metabolites	O
in	O
the	O
NMR	O
spectra	O
of	O
serum.	O

HPLC-grade	O
methanol	B
(MeOH)	O
was	O
from	O
Fisher	O
Company.	O

Altered	O
levels	O
of	O
these	O
metabolites	O
are	O
consistent	O
with	O
well-known	O
hypotheses	O
regarding	O
abnormalities	O
of	O
the	O
homocysteine	B
metabolism,	O
creatine	B
kinase-emia	O
and	O
oxidative	O
stress.	O

In	O
an	O
earlier	O
validation	O
made	O
in	O
urine,	O
a	O
linear	O
calibration	O
range	O
was	O
determined	O
to	O
500–3,500,000	O
nmol/L	O
for	O
morphine,	B
300–900,000	O
nmol/L	O
for	O
M3G,	O
and	O
300–130,000	O
nmol/L	O
for	O
M6G.	O
LLOQ	O
was	O
set	O
to	O
100	O
nmol/L	O
with	O
a	O
total	O
CV	O
of	O
7.7–14.6%	O
(n	O
=	O
14–25).	O

A	O
study	O
that	O
compared	O
prostatic	O
fluid	O
samples	O
showed	O
that	O
the	O
molar	O
ratio	O
of	O
citrate:	B
spermine	B
is	O
5:1	O
in	O
normal	O
prostatic	O
fluid,	O
but	O
a	O
relatively	O
higher	O
level	O
of	O
spermine	B
was	O
found	O
in	O
prostatic	O
fluid	O
from	O
men	O
with	O
PCa.	O

In	O
normal	O
tissues,	O
most	O
pyruvate	B
enters	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
and	O
is	O
oxidized	O
in	O
the	O
mitochondria	O
via	O
oxidative	O
phosphorylation.	O

The	O
intra-class	O
correlation	O
coefficient	O
for	O
the	O
repeated	O
measures	O
of	O
SF	B
urinary	O
metabolites	O
was	O
0.35.	O

Study	O
(n	O
=	O
5621),	O
using	O
the	O
newly	O
developed	O
proprietary	O
betaine	B
assay	O
software	O
(LabCorp,	O
Morrisville,	O
NC,	O
USA).	O

The	O
ISTDs	O
used	O
for	O
GCDCA	B
and	O
GDCA,	O
ADMA	B
and	O
SDMA,	O
and	O
TDCA	O
and	O
TCDCA	O
were	O
GDCA-d6,	O
ADMA-d7,	O
and	O
TCDCA-d9,	O
respectively.	O

This	O
shuttle	O
also	O
facilitates	O
the	O
transfer	O
of	O
NADH	B
produced	O
in	O
the	O
cytoplasm	O
to	O
the	O
mitochondrion	O
for	O
ATP	B
production	O
via	O
oxidative	O
phosphorylation.	O

The	O
serum	O
level	O
of	O
lysine	B
was	O
significantly	O
lower	O
in	O
the	O
stage	O
3–4	O
colorectal	O
cancer	O
patients	O
compared	O
with	O
the	O
healthy	O
volunteers.	O

Because	O
in	O
β-thalassemia	O
all	O
these	O
activities	O
are	O
increased	O
so	O
low	O
levels	O
of	O
hexadecane	B
can	O
be	O
co-related	O
with	O
its	O
more	O
utilization	O
and	O
less	O
availability	O
in	O
serum	O
freely.	O

Conversely,	O
high	O
myoinositol	B
levels	O
have	O
been	O
noted	O
in	O
RRMS	O
and	O
clinically	O
isolated	O
syndrome	O
compared	O
with	O
controls	O
using	O
_1	O
H	O
MRS	O
of	O
normal-appearing	O
white	O
matter,	O
indicating	O
astrocytosis	O
and	O
astrogliosis.	O

While	O
extensive	O
studies	O
have	O
been	O
performed	O
to	O
identify	O
metabolite	O
isolation	O
and	O
separation	O
methods,	O
these	O
strategies	O
introduce	O
bias	O
toward	O
lipophilic	O
or	O
water-soluble	O
metabolites	O
depending	O
on	O
whether	O
reversed-phase	O
(RP)	O
or	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
(HILIC)	O
is	O
used	O
respectively.	O

Since	O
quercetin	B
showed	O
some	O
inhibition	O
and	O
since	O
the	O
correlation	O
analysis	O
implicated	O
CYP2C8	O
in	O
anastrozole	B
metabolism,	O
trimethoprim,	O
a	O
selective	O
inhibitor	O
of	O
CYP2C8	O
was	O
used	O
as	O
additional	O
inhibitor	O
probe.	O

Higher	O
levels	O
of	O
proline,	B
p-cresol	B
and	O
4-hydroxybenzoic	B
acid	I
were	O
associated	O
with	O
poorer	O
prognosis.	O

The	O
Pearson’s	O
correlation	O
coefficients	O
r	O
for	O
UPLC–HRMS–_1	O
H	O
NMR	O
spectroscopic	O
results	O
were	O
0.99	O
for	O
creatine,	B
0.54	O
for	O
creatinine,	B
0.73	O
for	O
citrate,	B
0.88	O
for	O
hippurate,	B
and	O
0.49	O
for	O
succinate,	B
whereas	O
for	O
DI–nESI–HRMS–_1	O
H	O
NMR	O
spectroscopic	O
results	O
they	O
were	O
0.97,	O
0.54,	O
0.68,	O
0.84,	O
and	O
0.24,	O
respectively.	O

One	O
of	O
the	O
most	O
interesting	O
findings	O
of	O
the	O
current	O
study	O
was	O
the	O
intraocular	O
upregulation	O
of	O
reactive	O
persulfides	B
and	O
polysulfides,	B
including	O
CysSSH,	O
in	O
the	O
DM	O
group.	O

Finally,	O
conjugated	O
serum	O
4-MeO-E2	B
was	O
present	O
at	O
low	O
levels	O
in	O
the	O
serum	O
of	O
postmenopausal	O
women	O
but	O
was	O
below	O
the	O
LLOQ	O
in	O
older	O
men.	O

Organic	O
and	O
aqueous	O
layers	O
were	O
separated	O
by	O
centrifugation	O
at	O
1000	O
x	O
g	O
for	O
5	O
min	O
and	O
the	O
organic	O
layer	O
was	O
collected,	O
dried	O
under	O
a	O
nitrogen	O
stream	O
and	O
dissolved	O
in	O
120	O
μl	O
chloroform.	B

Interestingly,	O
the	O
pentose	B
phosphate	I
pathway	O
has	O
been	O
identified	O
in	O
both	O
sputum	O
and	O
serum	O
samples,	O
which	O
is	O
an	O
important	O
metabolic	O
pathway	O
parallel	O
to	O
glycolysis.	O

The	O
hypothesis	O
put	O
forward	O
in	O
this	O
study	O
was	O
that	O
the	O
urinary	O
concentrations	O
of	O
α-TL	B
(sulfate	I
and	O
glucuronide)	B
would	O
be	O
greater	O
in	O
patients	O
with	O
diabetes	O
compared	O
to	O
age-matched	O
controls,	O
with	O
less	O
change	O
in	O
the	O
concentrations	O
of	O
conjugated	O
α-CEHC.	B

The	O
risk	O
ratio	O
of	O
ascites	O
upon	O
recurrence	O
TE	O
was	O
2.04;	O
the	O
effect	O
of	O
ascites	O
on	O
survival	O
was	O
significantly	O
mediated	O
through	O
LysoPC(P-15:0);	B
and	O
IE	O
was	O
1.32,	O
accounting	O
for	O
39.5%	O
of	O
TE.	O

Using	O
the	O
fragment	O
peak	O
at	O
m	O
/z	O
419	O
derived	O
from	O
PC	B
16:0/18:1	I
as	O
an	O
example,	O
MS_3	O
CID	O
of	O
this	O
peak	O
produced	O
sn	O
-1	O
fatty	O
acyl	O
anions	O
at	O
m	O
/z	O
255	O
(C16:0),	O
suggesting	O
that	O
the	O
sn	O
-1	O
chain	O
is	O
preserved	O
in	O
the	O
fragment	O
(	O
and	O
possible	O
fragmentation	O
pathways	O
are	O
shown	O
in	O
Scheme	O
S1_†	O
).	O

LDL-C	O
and	O
total	O
plasma	O
cholesterol	B
were	O
significantly	O
and	O
positively	O
correlated	O
with	O
total	O
Cer(d18:1/X)	B
species,	O
as	O
well	O
as	O
total	O
SM(d18:1/X)	B
species	O
(r	O
=	O
0.45	O
and	O
0.40	O
for	O
LDL-C	O
with	O
Cer	B
and	O
SM	O
respectively,	O
p<0.001,	O
and	O
r	O
=	O
0.46	O
and	O
0.42	O
for	O
cholesterol	B
with	O
Cer	B
and	O
SM	O
respectively,	O
p<0.001).	O

The	O
average	O
duration	B
of	O
sunlight	O
during	O
the	O
study	O
is	O
around	O
3.5–5.1 h	O
of	O
sunlight	O
a	O
day	O
(Thai	O
Meteorological	O
Department,	O
2012).	O

Canonical	O
correlation	O
analysis	O
(CCorA)	O
of	O
PC	O
scores	O
vectors	O
arising	O
from	O
separate	O
PCA	O
analyses	O
of	O
(1)	O
_1	O
H	O
NMR	O
lipoprotein-associated	O
triacylglycerol	B
resonance	O
intensities	O
(terminal-CH_3	O
function	O
resonance-normalised)	O
and	O
(2)	O
clinical	O
chemistry-determined	O
total,	O
LDL-and	O
HDL-associated	O
cholesterol	B
concentrations	O
(normalised	O
to	O
total	O
TG	B
level)	O
was	O
performed	O
using	O
XLSTAT2016	O
software,	O
and	O
a	O
minimum	O
filter	O
factor	O
of	O
90%.	O

Among	O
Phe-derivatives,	O
hippurate	B
has	O
a	O
strong	O
association	O
with	O
diet	O
and	O
gastrointestinal	O
microbiota,	O
and	O
its	O
production	O
requires	O
of	O
both	O
microbial	O
and	O
mammalian	O
metabolisms.	O

This	O
also	O
explained	O
why	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism	O
are	O
abnormal	O
after	O
plasma	O
treatment.	O

A	O
mixed-mode	O
anion	O
exchange	O
solid	O
phase	O
extraction	O
(Strata-X-AW,	O
60 mg/3 mL,	O
Phenomenex	O
Inc.,	O
Torrance,	O
CA,	O
USA)	O
was	O
preconditioned	O
with	O
dichloromethane	B
(3 mL)	O
and	O
methanol	B
(3 mL)	O
sequentially.	O

In	O
peritoneal	B
effluents	O
pro-inflammatory	O
mediators	O
PGE_2	O

Up-regulation	O
of	O
prequalene	B
diphosphate,	I
an	O
intermediate	O
involved	O
in	O
cholesterol	B
biosynthesis,	O
was	O
probably	O
linked	O
to	O
the	O
increase	O
of	O
bile	O
acid	O
in	O
the	O
post-H.	O
pylori	O
eradication	O
plasma.	O

After	O
phase	O
separation,	O
the	O
lipid-containing	O
MTBE	B
phase	O
forms	O
the	O
top	O
layer,	O
whilst	O
the	O
methanol	B
and	O
water	O
forms	O
the	O
bottom	O
layer.	O

As	O
the	O
most	O
abundant	O
amino	O
acid	O
in	O
the	O
serum,	O
glutamine	B
is	O
the	O
most	O
important	O
amino	O
acid	O
gluconeogenic	O
precursor	O
for	O
adding	O
new	O
carbon	O
to	O
the	O
glucose	B
pool.	O

PAs	O
from	O
long-term	O
survivors	O
also	O
show	O
decreased	O
levels	O
of	O
threonine,	B
aspartate,	B
glycerol,	B
glutamate,	B
and	O
glutamine	B
compared	O
to	O
those	O
from	O
short-term	O
survivors.	O

Oxylipins,	B
a	O
subclass	O
of	O
lipid	O
mediators,	O
are	O
metabolites	O
of	O
various	O
polyunsaturated	O
fatty	O
acids	O
with	O
crucial	O
functions	O
in	O
regulation	O
of	O
systemic	O
inflammation.	O

Our	O
data	O
demonstrate	O
that	O
comparable	O
to	O
the	O
small	O
intestine,	O
the	O
requisite	O
hydrolytic,	B
Phase	O
II	O
and	O
efflux	O
transporting	O
enzymes	O
are	O
present	O
in	O
the	O
oral	O
cavity.	O

Stock	O
solutions	O
(1	O
mg/mL)	O
for	O
xanthurenic	B
acid,	I
3-hydroxyanthranilic	B
acid	I
(3-HAA),	O
indole-3-acetic	B
acid	I
(I-3-AA),	O
and	O
kynurenic	B
acid	I
were	O
dissolved	O
in	O
60%	O
0.1	O
M	O
sodium	B
hydroxide	I
(NaOH)	O
and	O
40%	O
diluent-D1.	O

The	O
analytes	O
were	O
extracted	O
from	O
the	O
serum	O
matrix	O
with	O
8	O
mL	O
hexane:ethyl	O
acetate	B
(50:50,	I
volume	I
fractions).	I

Among	O
all	O
statistically	O
different	O
molecules	O
found,	O
we	O
detected	O
lipid	O
species	O
belonging	O
to	O
different	O
families	O
including	O
phospholipids	B
and,	O
specifically,	O
lysophospholipids	B
(LPL).	O

However,	O
this	O
is	O
not	O
necessarily	O
the	O
case	O
with	O
(25R)26-HC	B
in	O
CSF	O
from	O
patients	O
with	O
neurodegenerative	O
diseases.	O

The	O
following	O
optimized	O
instrument	O
parameters	O
were	O
applied	O
for	O
the	O
detection	O
of	O
analyte	O
and	O
internal	O
standard:	O
N_2	O
sheath	O
gas	O
60	O
psi;	O
N_2	O
auxiliary	O
gas	O
20	O
psi;	O
capillary	O
temperature	O
300°C;	O
spray	O
voltage	O
4.5	O
kV;	B
skimmer	O
offset	O
10.0	O
V;	O
capillary	O
offset	O
35	O
V;	O
tube	O
lens	O
offset	O
122	O
V;	O
scan	O
time	O
50	O
ms;	O
and	O
Q3	O
scan	O
width	O
0.5	O
m/z	O
.	O

The	O
nominal	O
enzalutamide	B
and	O
N-desmethylenzalutamide	B
concentrations	O
of	O
15000	O
and	O
50000	O
ng/mL	O
(QCM	O
and	O
QCH)	O
were	O
within	O
the	O
calibration	O
curve	O
of	O
the	O
assay	O
used	O
in	O
Pittsburg,	O
and	O
the	O
results	O
were	O
±5.5%	O
of	O
the	O
actual	O
concentration.	O

A	O
total	O
of	O
22	O
metabolites	O
(amino	O
acids,	O
fatty	O
acids,	O
tricarboxylic	B
acid	I
cycle	O
(TCA)	O
intermediates)	O
were	O
identified	O
using	O
1H	O
NMR	O
spectroscopy	O
(see	O
for	O
the	O
chemical	O
shifts	O
and	O
peak	O
areas).	O

Surviving	O
ICU	O
patients	O
displayed	O
higher	O
levels	O
of	O
docosahexaenoic	B
acid	I
and	O
total	O
n	O
-3	O
PUFA	O
and	O
a	O
lower	O
n	O
-6/n	O
-3	O
PUFA	O
ratio	O
in	O
plasma	O
PC	O
than	O
nonsurvivors.	O

However,	O
when	O
we	O
compared	O
plasma	O
glucose	B
concentration	O
in	O
preprandial	O
conditions	O
for	O
low–cystathionine	B
compared	O
with	O
high–cystathionine	B
concentration	O
subjects,	O
we	O
observed	O
a	O
mean	O
concentration	O
of	O
5.83	O
±	O
1.76	O
mmol/L	O
compared	O
with	O
6.45	O
±	O
2.89	O
mmol/L	O
(P	O
=	O
0.529).	O

The	O
activation	O
of	O
TGR5	O
receptors	O
in	O
colonic	O
endocrine	O
cells	O
can	O
stimulate	O
GLP-1	O
secretion,	O
improving	O
glucose	B
and	O
lipid	O
homeostasis.	O

Succinylacetone	B
is	O
a	O
metabolite	O
of	O
tyrosine	B
and	O
has	O
liver	O
toxicity.	O

Dietary	O
galactose	B
may	O
be	O
converted	O
to	O
UDP-galactose	B
by	O
galactose-1-phosphate	O
uridyl-transferase	O
(GALT)	O
and	O
used	O
for	O
protein	O
glycosylation.	O

In	O
the	O
present	O
study,	O
higher	O
levels	O
of	O
phenylalanine,	B
tyrosine,	B
and	O
tryptophan	B
in	O
the	O
LC	O
group	O
in	O
comparison	O
with	O
the	O
control	O
group	O
definitely	O
showed	O
the	O
alteration	O
of	O
amino	O
acid	O
metabolism.	O

Plasma	O
samples	O
were	O
collected	O
into	O
anticoagulant	O
heparin	B
vacutainers	O
from	O
patients	O
(n = 18;	O
14	O
male	O
and	O
4	O
female;	O
66 ± 11.6	O
years)	O
before	O
cardiopulmonary	O
bypass	O
surgery	O
(pre-surgical)	O
and	O
at	O
2,	O
4,	O
8,	O
24,	O
48	O
and	O
72 h	O
post-surgery	O
at	O
Royal	O
Brompton	O
Hospital,	O
UK.	O

Sphinganine	B
is	O
a	O
major	O
component	O
of	O
sphingolipids,	B
which	O
are	O
one	O
of	O
the	O
active	O
constituents	O
of	O
the	O
mucous	O
secreted	O
by	O
the	O
alveolar	O
epithelium,	O
which	O
protects	O
the	O
lung	O
tissue	O
from	O
invading	O
pathogens.	O

Metabolites	O
associated	O
with	O
recurrent	O
stroke	O
risk	O
scores	O
(A)	O
Succinate	B
and	O
kynurenine	B
demonstrated	O
a	O
dose–response	O
relationship	O
with	O
CHADS_2	O
score	O
and	O
(B)	O
with	O
CHA_2	O
DS_2	O
-VASc	O
scores.	O

For	O
instance,	O
n-methyl-α-aminoisobutyric	B
acid	I
was	O
present	O
in	O
the	O
lyophilized	O
samples	O
but	O
undetected	O
in	O
speed-vacuum	O
dried	O
samples	O
in	O
cell	O
extracts	O
prepared	O
from	O
all	O
three	O
cell	O
lines.	O

Final	O
results	O
were	O
presented	O
after	O
adjusting	O
for	O
creatinine	B
concentrations	O
(ng/mg	O
creatinine).	O

To	O
compensate	O
for	O
these	O
changes,	O
and	O
to	O
correlate	O
LC-MS	O
data	O
to	O
the	O
LC-EC	O
peaks	O
of	O
interest,	O
an	O
offline-parallel	B
LC-EC	O
and	O
LC-MS	O
method	O
that	O
compromises	O
between	O
MS	O
and	O
EC	O
detector	O
needs	O
was	O
developed.	O

Metabolites	O
or	O
metabolite	O
ratios	O
that	O
were	O
elevated:	O
(A)	O
arginine,	B
(B)	O
glycerate,	B
(C)	O
the	O
ratio	O
of	O
aspartate	B
over	O
asparagine	B
or	O
decreased	O
(D)	O
pyruvate,	B
(E)	O
cysteine,	B
(F)	O
cystine	B
in	O
concentration	O
by	O
prolonged	O
sample	O
storage	O
at	O
−80	O
°C.	O

In	O
the	O
model	O
of	O
the	O
CRC	O
group	O
compared	O
to	O
that	O
of	O
the	O
control	O
group,	O
the	O
levels	O
of	O
isoleucine,	B
3-hydroxybutyrate,	B
lactate,	B
acetate,	B
glutamate,	B
choline,	B
glycine,	B
serine,	B
and	O
glucose	B
were	O
increased	O
in	O
the	O
CRC	O
group,	O
and	O
the	O
levels	O
of	O
lipid,	O
leucine,	B
valine,	B
alanine,	B
glutamine,	B
succinate,	B
citrate,	B
aspartate,	B
proline,	B
and	O
tyrosine	B
were	O
decreased	O
in	O
the	O
CRC	O
group	O
(Figures	O
and	O
).	O

Phospholipase	O
C	O
epsilon	O
(PLCε)	O
plays	O
an	O
important	O
role	O
as	O
an	O
oncogene.	O

For	O
each	O
category	O
of	O
a	O
covariate,	O
its	O
interaction	O
with	O
25(OH)D_3	O
was	O
reported	O
as	O
a	O
slope	O
(increment	O
in	O
24,25(OH)_2	B
D_3	O
per	O
10-ng/mL	O
increment	O
in	O
25(OH)D_3	O
)	O
and	O
an	O
intercept	O
was	O
estimated	O
for	O
25(OH)D_3	O
=	O
20	O
ng/mL,	O
a	O
clinically	O
relevant	O
concentration.	O

The	O
Dual	O
AJS	O
ESI	O
capillary	O
voltage	O
was	O
set	O
at	O
3.5	O
kV	B
and	O
nozzle	O
voltage	O
was	O
set	O
at	O
1	O
kV;	B
The	O
gas	O
temperature,	O
drying	O
gas	O
flow,	O
nebulizer	O
pressure,	O
sheath	O
gas	O
temperature	O
and	O
sheath	O
gas	O
flow	O
were	O
set	O
at	O
300°C,	O
8	O
l/min,	O
35	O
psig,	O
350°C	O
and	O
11	O
l/min,	O
respectively.	O

The	O
steroids	O
in	O
the	O
panel	O
included	O
pregnenolone,	B
progesterone,	B
11-deoxycorticosterone,	B
corticosterone,	B
aldosterone,	B
18-oxocortisol,	B
18-hydroxycortisol,	B
17-hydroxyprogesterone,	B
21-deoxycortisol,	B
11-deoxycortisol,	B
cortisol,	B
cortisone,	B
dehydroepiandrosterone	B
(DHEA),	O
dehydroepiandrosterone-sulfate	B
(DHEA-SO_4	O
),	O
androstenedione	B
and	O
testosterone.	B

Second,	O
our	O
patients	O
did	O
receive	O
exogenous	O
medications,	O
such	O
as	O
mild	O
sedatives,	O
aspirin	B
and	O
heparin,	B
with	O
the	O
procedure.	O

In	O
contrast,	O
in	O
the	O
pediatric	O
study,	O
histidine	B
levels	O
in	O
sepsis	O
were	O
increased.	O

Among	O
the	O
measured	O
polyamine-related	O
metabolites,	O
only	O
arginine,	B
ornithine,	B
and	O
putrescine	B
were	O
significantly	O
different	O
between	O
T2D	O
and	O
non-diabetic	O
subjects.	O

Other	O
molecular	O
ions	O
identified	O
in	O
normal	O
skin	O
regions	O
included	O
palmitic	B
(FA	O
16:0)	O
and	O
palmitoleic	B
(FA	I
16:1)	I
acids	I
at	O
m	O
/z	O
255.3	O
and	O
253.2	O
(SI	O
Appendix	O
,	O
Fig.	O
S3F	O
),	O
respectively;	O
glycerophosphoinositols	B
38:4,	I
PI	B
(18:0/20:4),	I
36:2,	O
PI	B
(18:2/18:0),	I
and	O
34:1,	O
PI	B
(16:1/18:0)	I
at	O
m	O
/z	O
885.6,	O
861.6,	O
and	O
835.6,	O
respectively;	O
and	O
glycerophosphoserine	B
36:1,	I
PS	B
(18:1/18:0)	I
at	O
m	O
/z	O
788.5	O
(SI	O
Appendix	O
,	O
Fig.	O

In	O
unpublished	O
studies,	O
we	O
observed	O
that	O
long-term	O
use	O
of	O
a	O
single	O
antibiotic	O
(6	O
months	O
of	O
ciprofloxacin),	B
which	O
initially	O
suppressed	O
plasma	O
TMAO	B
levels	O
in	O
a	O
rodent	O
model,	O
completely	O
lost	O
its	O
suppressive	O
effect,	O
an	O
observation	O
that	O
is	O
consistent	O
with	O
the	O
expansion	O
of	O
antibiotic-resistant	O
intestinal	O
microbiota.	O

Finally,	O
in	O
LC–MS,	O
the	O
most	O
populated	O
category	O
corresponded	O
to	O
lysophospholipids,	B
followed	O
by	O
sterol	O
lipids.	O

SPMs	O
were	O
extracted	O
from	O
plasma	O
or	O
serum	O
samples	O
and	O
effluents	O
from	O
peritoneal	B
dialysis	O
(PD)	O
using	O
solid	O
phase	O
extraction	O
(SPE)	O
(Rund	O
et	O
al.,	O
).	O

In	O
addition,	O
increased	O
cholesterol	B
levels	O
are	O
associated	O
to	O
starving	O
conditions	O
such	O
as	O
anorexia	O
nervosa	O
[,].	O

Since	O
lArg	O
and	O
hArg	O
are	O
NOS	O
substrates	O
and	O
ADMA	B
is	O
the	O
endogenous	O
NOS	O
inhibitor,	O
we	O
calculated	O
the	O
plasma	O
lArg:	O

Propionylcarnitine,	B
isobutyrylcarnitine,	B
2-methyl-butyrylcarnitine,	B
isovalerylcarnitine	B
and	O
methyl-malonylcarnitine	B
are	O
all	O
products	O
of	O
BCAA	O
catabolism	O
and	O
showed	O
an	O
accentuated	O
decrease	O
after	O
90	O
days,	O
leading	O
also	O
to	O
lower	O
ratios	O
between	O
these	O
metabolites	O
and	O
the	O
sum	O
of	O
all	O
acylcarnitines.	B

Similar	O
amounts	O
of	O
lysine-d4	B
(p=0.15)	O
and	O
15:0	O
PC	O
(p=0.62)	O
are	O
extracted	O
using	O
either	O
method,	O
with	O
lower	O
variation.	O

PAH	O
and	O
ePH	O
groups	O
had	O
higher	O
levels	O
of	O
acylcarnitines	B
at	O
rest	O
and	O
peak	O
exercise	O
compared	O
to	O
controls,	O
suggesting	O
diseased	O
groups	O
may	O
either	O
primarily	O
utilize	O
beta-oxidation	O
more	O
at	O
rest	O
and	O
exercise	O
to	O
augment	O
glycolytic	B
catabolism,	O
or	O
may	O
poorly	O
utilize	O
downstream	O
metabolites,	O
leading	O
to	O
secondary	O
build-up	O
of	O
intermediate	O
molecules	O
in	O
the	O
acylcarnitine	B
pathway.	O

When	O
medications	O
were	O
grouped	O
by	O
type,	O
the	O
number	O
of	O
subjects	O
regularly	O
taking	O
each	O
was:	O
anti-inflammatories	O
(9),	O
anti-depressants	O
(17),	O
statins	B
(3),	O
sedatives	O
(7),	O
anticonvulsants	O
(3),	O
antidiabetic	O
agents	O
(2),	O
antibiotics	O
(2)	O
and	O
beta-blockers	O
(2).	O

However,	O
serum	O
angiotensin	B
2	I
concentrations	O
were	O
not	O
increased	O
in	O
ACE-DD	O
genotypes	O
after	O
endurance	O
exercise.	O

In	O
this	O
respect	O
the	O
aligned	O
change	O
in	O
betaine	B
and	O
N,N-dimethylglycine	B
in	O
cross-sectional	O
and	O
longitudinal	O
analyses	O
are	O
of	O
particular	O
interest.	O

Women	O
with	O
PCOS	O
have	O
been	O
implicated	O
to	O
have	O
higher	O
levels	O
of	O
ALT	O
in	O
the	O
serum,	O
which	O
could	O
accelerate	O
the	O
transamination	O
of	O
pyruvate	B
to	O
alanine.	B

Other	O
studies	O
have	O
also	O
reported	O
the	O
connection	O
between	O
albuminuria	O
and	O
triglycerides	B
(;	O
;	O
),	O
but	O
the	O
exact	O
role	O
of	O
HDL	O
metabolism	O
remains	O
unclear.	O

We	O
therefore	O
excluded	O
the	O
mannitol	B
spectral	O
region	O
(from	O
3.62	O
to	O
3.90	O
ppm)	O
from	O
the	O
data	O
matrix	O
and	O
we	O
performed	O
a	O
new	O
OPLS-DA	O
analysis.	O

The	O
subsequent	O
introduction	O
of	O
a	O
two-phase	O
system	O
by	O
the	O
addition	O
of	O
water	O
and/or	O
organic	O
solvent	O
is	O
used	O
to	O
separate	O
hydrophilic	B
and	O
hydrophobic	O
metabolites.	O

For	O
serum,	O
only	O
one	O
metabolite,	O
5-hydroxylysine,	B
met	O
this	O
criterion.	O

These	O
9	O
differential	O
metabolites	O
were	O
aspartic	B
acid,	I
glycine,	B
linoleic	B
acid,	I
sorbitol,	B
myoinositol,	B
mannose,	B
6-deoxy-mannopyrannose,	B
oleic	B
acid	I
and	O
alanine.	B

The	O
results	O
demonstrated	O
that	O
‘glycerophospholipid	B
metabolism’,	O
‘linoleic	O
acid	O
metabolism’,	O
‘primary	O
bile	O
acid	O
biosynthesis’,	O
‘fatty	O
acid	O
synthesis’,	O
‘arachidonic	O
acid	O
metabolism’,	O
‘seleno	O
amino	O
acid	O
metabolism’	O
and	O
‘aminoacyl-tRNA	B
biosynthesis’	O
pathways	O
were	O
closely	O
associated	O
with	O
GCA	O
(	O
and	O
).	O

As	O
acylcarnitines	B
can	O
pass	O
through	O
mitochondrial	O
and	O
cell	O
membranes,	O
they	O
are	O
easily	O
detectable	O
in	O
human	O
blood	O
(Millington	O
and	O
Stevens	O
).	O

This	O
indicates	O
that	O
these	O
airway	O
epithelial	O
cells	O
take	O
up	O
glutamine	B
very	O
efficiently.	O

50	O
µl	O
of	O
EDTA	O
plasma	O
samples	O
were	O
spiked	O
with	O
internal	O
standard	O
solution	O
and	O
subsequently	O
subjected	O
to	O
protein	O
precipitation	O
by	O
mixing	O
with	O
250	O
µl	O
of	O
methanol.	B

Ethanolamine	B
is	O
a	O
metabolite	O
of	O
glycerophospholipid	B
metabolism.	O

Stock	O
solutions	O
of	O
each	O
analyte	O
were	O
prepared	O
separately	O
in	O
methanol	B
to	O
produce	O
a	O
concentration	O
of	O
1.0	O
mg/mL.	O
Working	O
profile	O
calibrator	O
solution	O
was	O
prepared	O
by	O
mixing	O
appropriate	O
amounts	O
of	O
individual	O
analyte	O
stock	O
solution	O
to	O
obtain	O
a	O
mixture	O
containing	O
10	O
μg/mL	O
of	O
each	O
estrogen.	B

Organic	O
phase	O
was	O
collected	O
and	O
the	O
extraction	O
steps	O
were	O
repeated	O
once	O
with	O
100	O
μl	O
MetOH,	O
300	O
μl	O
MTBE	B
and	O
100	O
μl	O
milliQ	O
H_2	O
O.	O
Lipid	O
extracts	O
were	O
dried	O
in	O
a	O
miVac	O
centrifugal	O
evaporator	O
(Genevac	O
Ltd),	O
and	O
redissolved	O
in	O
500	O
μl	O
of	O
water:acetonitrile	O
38:62.	O

Exclusion	O
criteria	O
include	O
subjects	O
with	O
kidney	O
disease,	O
liver	O
disease,	O
untreated	O
thyroid	O
dysfunction	O
and	O
ongoing	O
hormone	O
replacement	O
therapy,	O
omega-3	B
(n-3)	O
fatty	O
acid	O
(i.e.	O
fish	O
oil)	O
supplementation,	O
lipid	O
lowering	O
medications	O
(i.e.	O
statins),	O
excessive	O
or	O
prolonged	O
use	O
of	O
alcohol,	O
and	O
consumption	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
or	O
caffeinated	O
beverages	O
within	O
12	O
hrs	O
of	O
blood	O
collection.	O

Group	O
2	O
showed	O
higher	O
levels	O
of	O
mannitol	B
and	O
an	O
unassigned	O
metabolite	O
Uk3	O
when	O
compared	O
to	O
the	O
other	O
IBD	O
groups	O
and	O
healthy	O
subjects,	O
and	O
the	O
greatest	O
increase	O
in	O
4-hydroxyphenylacetate	B
when	O
compared	O
to	O
healthy	O
subjects.	O

It	O
was	O
also	O
challenging	O
to	O
compare	O
the	O
TLC/GC-FID	O
lipid	O
results	O
with	O
the	O
GC-MS	O
results	O
as	O
the	O
two	O
methods	O
only	O
identified	O
and	O
quantified	O
8	O
metabolites	O
in	O
common	O
(arachidonic	O
acid,	O
eicosanoic	B
acid,	I
linoleic	B
acid,	I
oleic	B
acid,	I
palmitelaidic	B
acid,	I
palmitic	B
acid,	I
stearic	B
acid	I
and	O
tetradecanoic	O
acid).	O

Moreover,	O
in	O
up	O
to	O
50%	O
of	O
cases,	O
including	O
2	O
cases	O
of	O
pituitary	O
apoplexy,	O
the	O
concentration	O
of	O
N-acetyl	B
aspartate	I
remained	O
unidentified.	O

All	O
chemical	O
shifts	O
were	O
referenced	O
to	O
deuterated	O
sodium	O
2,2,	O
dimethyl-silapentane-1-sulfonate	B
(DSS-d6)	O
as	O
0	O
ppm.	O

As	O
the	O
current	O
investigation	O
involved	O
targeted	O
qualitative	O
analysis	O
of	O
the	O
tissue	O
samples	O
to	O
investigate	O
metabolic	O
products	O
of	O
estrogen	B
metabolism	O
and	O
there	O
are	O
no	O
statistical	O
comparisons	O
made,	O
ten	O
samples	O
were	O
thought	O
be	O
sufficient	O
for	O
the	O
study.	O

F_2	B
-isoprostanes	I
were	O
converted	O
to	O
pentafluorobenzyl	B
esters,	I
subjected	O
to	O
thin	O
layer	O
chromatography,	O
and	O
converted	O
to	O
trimethylsilyl	B
ether	I
derivatives.	O

The	O
high	O
recovery	O
of	O
N-desmethylenzalutamide	B
is	O
likely	O
to	O
be	O
caused	O
by	O
enhancement	O
of	O
the	O
response	O
due	O
to	O
matrix	O
effect.	O

Further,	O
both	O
taurine	B
and	O
myo	O
-inositol	O
showed	O
strong	O
positive	O
correlation	O
with	O
rAFS	O
scores	O
(Supplementary	O
figure	O
3)	O
suggesting	O
their	O
role	O
in	O
disease	O
progression.	O

The	O
minor	O
peak	O
was	O
postulated	O
to	O
be	O
an	O
isomer	O
with	O
the	O
structure	O
as	O
illustrated	O
on	O
chromatogram	O
in	O
D	O
and	O
had	O
been	O
observed	O
previously	O
by	O
Pope	B
.	O

Acetonitrile	B
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(Morris	O
Plains,	O
NJ,	O
USA)	O
and	O
water	O
was	O
purchased	O
from	O
J.T.	O
Baker	O
(Phillipsburg,	O
NJ,	O
USA).	O

	O
Acylcarnitines,	B
amino	O
acids,	O
biogenic	O
amines,	O
phosphatidylcholines	B
and	O
sphingomyelins	B
were	O
determined	O
by	O
LC-MS	O
in	O
fasting	O
plasma	O
samples	O
using	O
the	O
Absolute	O
IDQ™	O
p180	O
kit	O
developed	O
by	O
Biocrates	O
AG	O
(Innsbruck,	O
Austria).	O

(a)	O
Schema	O
of	O
wheat	O
bread	O
digestion	O
(starch	O
and	O
protein	O
hydrolysis)	O
and	O
atom	O
transitions	O
for	O
metabolic	O
conversions	O
of	O
glucose	B
via	O
glycolysis	O
and	O
TCA	O
cycle;	O
(b)	O
Time-resolved	O
mass	O
isotopomer	O
(MI)	O
abundances	O
of	O
starch-derived	O
(left)	O
and	O
protein-derived	O
(right)	O
metabolites	O
and	O
metabolites	O
of	O
mixed	O
origin	O
(middle)	O
in	O
%–	O

Thus,	O
the	O
3′-hydroxycotinine	B
to	O
cotinine	B
ratio,	O
or	O
NMR,	O
serves	O
as	O
an	O
in	O
vivo	O
phenotype	O
of	O
CYP2A6	O
activity.	O

The	O
LOX	O
products	O
12-HETE	B
and	O
5-HETE	B
are	O
involved	O
in	O
chemotaxis	O
of	O
neutrophils	O
[,	O
–].	O

Elevated	O
methylmalonate	B
is	O
likely	O
associated	O
with	O
the	O
upregulation	O
of	O
the	O
TCA	O
cycle	O
and	O
the	O
degradation	O
of	O
BCAAs.	O

A	O
negative	O
relation	O
was	O
also	O
found	O
between	O
age	O
and	O
the	O
tryptophan	B
breakdown	O
index	O
KYN/TRP,	O
which	O
is	O
the	O
rate	O
of	O
tryptophan	B
conversion	O
to	O
the	O
uraemic	O
molecule	O
kynurenine	B
(R	O
 = −0.44,	O
P <	O
 0.05).	O

MassHunters	O
Quantitative	O
Analysis	O
Software	O
(version	O
B.07.00),	O
Skyline	B
Daily	O
(version	O
4.1),	O
and	O
R.	O
Data	O
from	O
the	O
diabetes	O
cohort	O
were	O
processed	O
as	O
follows:	O
(i)	O
Peaks	O
were	O
picked	O
in	O
Skyline,	B
(ii)	O
resulting	O
peak	O
areas	O
were	O
normalized	O
to	O
matching	O
internal	O
standard	O
peak	O
areas	O
in	O
R,	O
and	O
(iii)	O
the	O
resulting	O
peak	O
area	O
ratios	O
were	O
calibrated	O
to	O
concentrations	O
in	O
R	O
based	O
on	O
metabolite-specific	O
calibration	O
curves	O
run	O
during	O
the	O
analysis	O
sequence.	O

On	O
the	O
other	O
hand,	O
one	O
metabolite	O
was	O
present	O
in	O
speed-vacuumed	O
samples	O
but	O
absent	O
in	O
the	O
lyophilized	O
samples,	O
i.e.,	O
trimethylamine,	B
which	O
was	O
only	O
present	O
in	O
Panc-1	O
cell	O
extracts	O
prepared	O
by	O
SpeedVac.	O

The	O
data	O
show	O
that	O
glucose	B
had	O
no	O
effect	O
on	O
ATP	B
levels	O
in	O
response	O
to	O
radiation,	O
but	O
supplementation	O
with	O
glutamine	B
dramatically	O
enhanced	O
ATP	B
production	O
in	O
control	O
cells,	O
but	O
only	O
slightly	O
increased	O
the	O
ATP	B
levels	O
in	O
CPT1A	O
knockdown	O
cells	O
(Figure	O
C).	O

Paraben	B
and	O
BP3	O
concentrations—medians	O
(95th	O
percentile)	O
in	O
µg/L—reported	O
in	O
human	O
urine	O
samples	O
for	O
children,	O
males,	O
and	O
females.	O

Using	O
untargeted	O
CIL	O
LC-MS,	O
we	O
identified	O
multiple	O
intermediate	O
metabolites	O
that	O
participated	O
in	O
de	O
novo	O
purine	B
and	O
pyrimidine	B
biosynthesis	O
and	O
showed	O
that	O
they	O
were	O
consistently	O
increased	O
in	O
the	O
HTK	O
group.	O

No	O
effect	O
was	O
noted	O
on	O
urea	B
(P	O
0.44).	O

To	O
0.5	O
ml	O
of	O
each	O
cell	O
lysate,	O
0.5	O
ml	O
of	O
freshly	O
prepared	O
0.15	O
M	O
sodium	B
acetate	I
buffer	O
(pH	O
4.6)	O
containing	O
16	O
pg	B
of	O
each	O
SI-EM	O
and	O
2	O
mg	O
of	O
L-ascorbic	B
acid	I
was	O
added.	O

Such	O
an	O
approach	O
can	O
have	O
adverse	O
effects	O
if	O
pyroglutamic	B
acid,	I
unconnected	O
with	O
glutamine	O
cyclization,	O
is	O
already	O
present	O
in	O
the	O
sample.	O

Because	O
the	O
DSV	O
standard	O
contained	O
the	O
tryptophan	B
pathway	O
metabolite	O
kynurenine	B
(KYN),	O
this	O
previous	O
experiment	O
suggested	O
fraction	O
B09	O
should	O
contain	O
a	O
concentrated	O
amount	O
of	O
KYN.	O

The	O
mobile	O
phases	O
were	O
water	O
with	O
0.1	O
mM	O
ammonium	B
fluoride	I
(A)	O
and	O
methanol	B
with	O
0.1	O
mM	O
ammonium	B
fluoride	I
(B).	O

,	O
A	O
higher	O
amount	O
of	O
PE(20:3/18:1)	B
(p=0.094)	O
was	O
extracted	O
with	O
the	O
methanol-ethanol	B
precipitation	O
compared	O
to	O
methanol	B
only	O
precipitation.	O

High	O
level	O
of	O
palmitic,	B
myristic,	B
linolenic,	O
and	O
eicosapentaenoic	B
acids	I
enhances	O
the	O
risk	O
of	O
prostate	O
cancer	O
and	O
it	O
has	O
a	O
inverse	O
association	O
with	O
stearic	B
acid.	I

Intra-	O
and	O
interday	O
precision	O
were	O
respectively	O
less	O
than	O
5%	O
and	O
8%	O
for	O
calculated	O
24S-OH-Chol.	B

In	O
summary,	O
we	O
demonstrated	O
that	O
flatbread	O
digestion	O
and	O
catabolism	O
mainly	O
fuel	O
plasma	O
glucose,	B
while	O
for	O
its	O
downstream	O
metabolites	O
lactate,	B
alanine,	B
citrate	B
and	O
glutamate,	B
the	O
contribution	O
from	O
exogenous	O
sources	O
is	O
diluted	O
as	O
a	O
function	O
of	O
their	O
metabolic	O
distance	O
to	O
glucose.	B

From	O
left	O
to	O
right:	O
tissue	O
micrograph	O
(A	O
);	O
palmitate	B
(C16:0)	I
(B	O
);	O
palmitoleate	B
(C16:1)	I
(C	O
);	O
stearate	B
(C18:0)	I
(D	O
);	O
oleate	B
(C18:1)	I
(E	O
);	O
linoleate	B
(C18:2)	I
(F	O
);	O
image	O
overlay	O
of	O
palmiteleate	B
(red),	O
cholesterol	B
(green),	O
and	O
triglycerides	B
(blue)	O
(G	O
);	O
phosphate	B
(H	O
),	O
phosphoinositol	B
fragment	O
(I	O
),	O
triglycerides	B
(J	O
),	O
cholesterol	B
(K	O
),	O
and	O
total	O
ion	O
intensity	O
(L	O
).	O

Serum	O
creatinine	B
was	O
measured	O
by	O
enzymatic	O
methods	O
in	O
the	O
same	O
laboratory.	O

[–],	O
PC(36:0),	B
PC(36:1)	B

Asterisk	O
Specimen	O
1	O
containing	O
AMP,	B
MAMP,	O
and	O
pOHMAMP	O
was	O
diluted	O
(1:5)	O
to	O
accommodate	O
MAMP’s	O
linear	O
range	O
Two	O
analytical	O
runs	O
were	O
required	O
to	O
quantify	O
20	O
analytes	O
in	O
meconium.	O

Particularly,	O
four	O
OTUs,	O
OTU38	O
(Streptococcus	O
),	O
OTU124	O
(Veillonella	O
),	O
OTU224	O
(Streptococcus	O
)	O
and	O
OTU55	O
(Haemophilus	O
),	O
were	O
closely	O
associated	O
with	O
both	O
the	O
clinical	O
indices	O
and	O
the	O
accumulation	O
of	O
10	O
serum	O
metabolites,	O
especially	O
L-phenylalanine	B
and	O
L-tyrosine,	B
which	O
are	O
AAAs	O
that	O
play	O
a	O
pathogenic	O
role	O
in	O
liver	O
disease	O
(Morgan	O
et	O
al.,	O
;	O

5 mL	O
of	O
individual	O
stock	O
solutions	O
of	O
pyruvate,	B
lactate,	B
acetoacetate,	B
β-hydroxybutyrate,	B
succinate,	B
fumarate,	B
malate	B
and	O
α-ketoglutarate	B
at	O
a	O
concentration	O
of	O
1 mmol L_−1	O
were	O
prepared	O
in	O
H_2	O
O	O
by	O
weighing	O
of	O
pure	O
solid	O
analytical	O
standards	O
in	O
volumetric	O
flasks.	O

We	O
recruited	O
cirrhotic	O
outpatients	O
prospectively	O
from	O
GI	O
and	O
Hepatology	O
Clinics	O
at	O
Virginia	O
Commonwealth	O
University	O
and	O
McGuire	O
VA	B
Medical	O
Centers	O
after	O
informed	O
consent.	O

In	O
the	O
integrase	O
inhibitor-based	O
group,	O
the	O
use	O
of	O
tenofovir	O
alafenamide	B
fumarate	I
significantly	O
increases	O
the	O
majority	O
of	O
lipid	O
fractions,	O
when	O
compared	O
with	O
tenofovir	O
disoproxil	O
fumarate.	B

Fifteen	O
estrogens	O
and	O
estrogen	B
metabolites	O
(EM),	O
including	O
E_1	O
,	O
E_2	O
,	O
E_3	B
,	I
2-OHE_1	I
,	I
2-MeOE_1	I
,	I
2-OHE_2	I
,	I
2-MeOE_2	I
,	I
3-MeOE_1	I
,	I
4-OHE_1	I
,	I
4-MeOE_1	I
,	I
4-MeOE_2	I
,	I
16α-OHE_1	I
,	O
17-epiE_3	O
,	O
16-ketoE_2	O
,	O
and	O
16-epiE_3	O
,	O
were	O
obtained	O
from	O
Steraloids,	O
Inc.	O
(Newport,	O
RI).	O

For	O
positive	O
ion	O
mode	O
(ES+)	O
where	O
A	O
=	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
B	O
=	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid,	I
whereas	O
A	O
=	O
water	O
and	O
B	O
=	O
acetonitrile	B
for	O
negative	O
ion	O
mode	O
(ES-).	O

Third,	O
that	O
omega-3	B
fatty	O
acids	O
are	O
associated	O
with	O
migraine	O
exclusively	O
in	O
male	O
participants	O
may	O
suggest	O
distinct	O
sex-specific	O
mechanisms.	O

Given	O
this,	O
good	O
quantitation	O
of	O
17-HDoHE	B
would	O
not	O
be	O
possible	O
if	O
there	O
was	O
not	O
enough	O
LC	O
resolving	O
power.	O

The	O
cross-peak	O
of	O
C1	O
to	O
H2	O
of	O
citrate	B
(Cit-2	O
→	O
1)	O
indicates	O
the	O
presence	O
of	O
_13	O
C1,_13	O
C2-citrate,	O
which	O
is	O
also	O
a	O
product	O
of	O
the	O
Krebs	O
cycle	O
after	O
one	O
turn.	O

The	O
hydrophilic	B
moiety	O
is	O
believed	O
to	O
participate	O
in	O
determining	O
the	O
clustering	O
of	O
the	O
molecules	O
within	O
the	O
plasma	O
membrane.	O

However,	O
the	O
other	O
three	O
significantly	O
changed	O
metabolites,	O
2-hydroxycinnamic	B
acid,	I
tyrosine	B
and	O
behanic	O
acid,	O
are	O
not	O
good	O
candidates	O
because	O
of	O
their	O
relatively	O
low	O
specificity	O
(Table ).	O

Compared	O
with	O
the	O
control	O
population,	O
six	O
metabolites,	O
namely	O
leucine,	B
propylene	B
glycol,	I
citrate,	B
β-glucose,	B
acetate	B
and	O
phenylalanine,	B
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
BC.	O

Interestingly,	O
ketamine,	B
an	O
NMDA-receptor	O
antagonist,	O
has	O
also	O
been	O
reported	O
to	O
exert	O
a	O
rapid	O
antidepressant	O
effect	O
in	O
patients	O
with	O
depression	O
[–].	O

Since	O
cholesterol	B
also	O
plays	O
a	O
role	O
in	O
membrane	O
structure	O
and	O
myelination,	O
better	O
insight	O
into	O
the	O
clinical	O
significance	O
of	O
the	O
impact	O
of	O
Phe	O
on	O
lipoprotein	O
metabolism	O
is	O
desirable.	O

Therefore,	O
the	O
arachidonic	B
acid	I
content	O
in	O
patients	O
with	O
GCA	O
may	O
increase	O
to	O
allow	O
the	O
proliferation	O
of	O
tumor	O
cells.	O

Among	O
them,	O
only	O
four	O
lipid	O
species,	O
two	O
sphingomyelins	B
and	O
two	O
phosphatidylcholines,	B
were	O
combined	O
in	O
an	O
algorithm	O
that	O
differentiates	O
between	O
rapid	O
and	O
slow	O
fibrosers.	O

Inositol	B
levels	O
were	O
also	O
reduced	O
in	O
the	O
depressed	O
subjects	O
in	O
relation	O
to	O
controls,	O
a	O
finding	O
consistent	O
with	O
previous	O
studies.	O

In	O
addition,	O
logistical	O
regression	O
analysis	O
was	O
used	O
to	O
generate	O
a	O
BAV	O
diagnostic	O
model	O
that	O
incorporated	O
only	O
the	O
levels	O
of	O
GNOE	O
and	O
MG	B
(18:2),	I
with	O
the	O
following	O
expression:	O

This	O
is	O
supported	O
also	O
by	O
an	O
increased	O
unsaturation	O
in	O
the	O
NMR	O
spectra	O
for	O
the	O
TFA	O
group,	O
yet	O
the	O
FA	B
composition	O
of	O
red	O
blood	O
cell	O
phospholipids	B
did	O
not	O
show	O
any	O
overall	O
significant	O
increase	O
in	O
PUFA	O
.	O

In	O
contrast	O
to	O
a	O
reduction	O
in	O
NAAG,	B
the	O
concentration	O
of	O
its	O
downstream	O
metabolite	O
N-acetylaspartic	B
acid	I
(NAA)	O
was	O
not	O
significantly	O
changed	O
in	O
the	O
CSF,	O
whereas	O
Worgall	O
et	O
al	O
.	O

As	O
shows,	O
the	O
assignment	O
of	O
the	O
highly	O
abundant	O
phosphocholine	B
(P-choline)	I
was	O
substantiated	O
by	O
the	O
connectivity	O
between	O
its	O
two	O
methylene	B
protons	O
and	O
verified	O
by	O
comparison	O
with	O
the	O
standard	O
spectrum	O
(and	O
unpublished	O
data).	O

Boxes	O
report	O
metabolisms	O
notoriously	O
altered	O
by	O
testosterone	B
deficiency	O
(increased	O
or	O
decreased).	O

The	O
main	O
lipid	O
families	O
and	O
metabolites	O
differed	O
slightly	O
between	O
groups	O
(log2-fold	O
change;	O
P	O
-value):	O
ceramides	B
(−0.07;	O
0.49),	O
phosphatidylinositols	B
(−0.05;	O
0.63),	O
diacylglycerols	B
(0.10;	O
0.64),	O
phosphatidylethanolamines	B
(0.03;	O
0.78),	O
triacylglycerols	B
(0.27;	O
0.18)	O
and	O
lysophosphatidylethanolamines	B
(0.03;	O
0.83).	O

Number	O
of	O
metabolites	O
impacted	O
by	O
storage	O
duration.	B

The	O
targeted	O
determination	O
of	O
PUFAs	O
and	O
their	O
eicosanoid	B
metabolites	O
was	O
conducted	O
using	O
FLC-QqLIT-MS.	O

The	O
CSF	O
levels	O
of	O
creatinine,	B
ophthalmate	O
and	O
5-hydroxytryptophan	B
correlated	O
with	O
all	O
measures	O
of	O
disease	O
severity	O
and	O
DBS,	O
but	O
not	O
to	O
the	O
five	O
year	O
risk	O
of	O
onset.	O

As	O
a	O
microbiota-dependent	O
metabolite,	O
TMAO	B
was	O
first	O
identified	O
to	O
be	O
strongly	O
associated	O
with	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
a	O
large	O
independent	O
clinical	O
cohort	O
by	O
Wang	O
et	O
al.,	O
and	O
studies	O
in	O
mice	O
indicated	O
a	O
causal	O
relation.	O

The	O
cluster	O
peaks	O
of	O
sodium	B
formate	I
were	O
used	O
for	O
mass	O
calibration	O
in	O
each	O
LC	O
run.	O

Alkylamines	B
have	O
been	O
used	O
extensively	O
as	O
ion-pairing	O
agents	O
in	O
LC,	O
to	O
increase	O
retention	O
and	O
improve	O
peak	O
characteristics	O
for	O
small,	O
basic	O
analytes.	O

Despite	O
smaller	O
increases	O
of	O
BCAA	O
to	O
be	O
processed	O
in	O
CPF	O
animals,	O
levels	O
of	O
two	O
BCAA	O
catabolic	O
products	O
(3-methyl-2-oxovalerate	O
originating	O
from	O
isoleucine	B
and	O
3-hydroxyisovalerate	B
from	O
leucine)	B
increase	O
in	O
the	O
serum	O
of	O
CPF	O
animals	O
while	O
showing	O
minimal	O
change	O
or	O
a	O
decrease	O
in	O
FS	O
animals.	O

Urea	B
nitrogen	I
measurements	O
were	O
performed	O
on	O
hourly	O
plasma	O
samples	O
across	O
25 hours	O
using	O
the	O
ADVIA_®	O
1800	O
Chemistry	O
System	O

Methanol-ethanol	B
and	O
methanol	B
extractions	O
demonstrated	O
the	O
best	O
repeatability	O
versus	O
all	O
other	O
extraction	O
methods	O
independently	O
of	O
LC-MS	O
method	O
employed.	O

Oxidation	O
of	O
S	B
-[1-(5-acetylamino-5-carboxypentyl)-1H	I
-pyrrol-3-yl]methanethiol	I
generated	O
S	B
-[1-(5-acetylamino-5-carboxypentyl)-1H	I
-pyrrol-3-yl]methanethiol	I
sulfoxide.	I

A	O
volume	O
of	O
250	O
µL	O
deuterium	O
and	O
10	O
µL	O
sodium	B
trimethyl	I
[2,2,3,3-_2	I
H_4	I
]	I
propionate	I
(TSP)	O
(0.005	O
g/mL)	O
were	O
added	O
to	O
each	O
300	O
µL	O
ACM	O
sample.	O

An	O
improved	O
method	O
to	O
synthesize	O
the	O
highly	O
abundant	O
and	O
biomedically	O
important	O
urinary	O
metabolite	O
3-(3-hydroxyphenyl)-3-hydroxypropionic	B
acid	I
(HPHPA)	O
is	O
reported.	O

All	O
five	O
oxysterols	B
measured	O
in	O
this	O
study	O
were	O
higher	O
in	O
statin-naive	O
hypercholesterolaemic	B
men	O
compared	O
to	O
age-matched	O
control	O
subjects	O
at	O
baseline;	O
24S-OHC,	O
25-OHC,	O
7β-OHC	B
and	O
7-KC	O
were	O
2,	O
8,	O
1.5,	O
45	O
and	O
33	O
fold	O
higher.	O

Protonated	O
pseudomolecular	O
[M+H]	O
_+	O
ions	O
of	O
GLY	O
and	O
GP	B
appeared	O
at	O
m/z	O
494.2	O
and	O
446.2,	O
respectively.	O

Finally,	O
we	O
examined	O
DMA	B
and	O
found	O
the	O
performance	O
contribution	O
to	O
be	O
of	O
little	O
practical	O
value	O
(see	O
Fig.	O

Slightly	O
less	O
lysine-d_4	B
was	O
recovered	O
from	O
the	O
MTBE	B
aqueous	O
fraction,	O
and	O
trace	O
amounts	O
of	O
15:0	O
PC	O
was	O
detected	O
in	O
the	O
MTBE	B
aqueous	O
fraction,	O
while	O
most	O
of	O
it	O
was	O
extracted	O
into	O
the	O
lipid	O
fraction.	O

Calibration	O
curves	O
in	O
surrogate	O
serum	O
were	O
created	O
by	O
plotting	O
the	O
peak	O
area	O
ratio	O
of	O
D-mannose	B
and	O
IS	O
against	O
the	O
known	O
concentrations	O
of	O
the	O
D-mannose.	B

(A)	O
LPC	O
(C	O
18:2),	O
(B)	O
LPC	O
(C	O
18:1),	O
(C)	O
LPC	O
(C	O
18:0),	O
(D)	O
LPC	O
(C	O
20:4),	O
(E)	O
PC	O
(C	O
16:0,	O
C	B
20:5),	I
(F)	O
PC	O
(C	O
18:0,	O
C	B
20:4).	I

Blocking	O
enzymes	O
in	O
the	O
kynurenine	B
pathway	O
caused	O
preferential	O
death	O
of	O
established	O
colon	O
cancer	O
cells	O
and	O
transformed	O
colonic	O
organoids.	B

Some	O
confusion	O
may	O
arise	O
concerning	O
the	O
nomenclature	O
of	O
27-hydroxycholesterol	B
and	O
related	O
compounds.	O

Creatinine	B
and	O
creatine	B
were,	O
as	O
expected,	O
inversely	O
correlated,	O
with	O
creatinine	B
being	O
generally	O
lower	O
and	O
creatine	B
generally	O
higher	O
in	O
the	O
DMD	O
patients.	O

A	O
gradient	O
of	O
mobile	O
phase	O
comprising	O
100%	O
H_2	O
O	O
containing	O
0.1%	O
formic	B
acid	I
(Solvent	O
A),	O
100%	O
ACN	O
containing	O
0.1%	O
formic	B
acid	I
(Solvent	O
B)	O
and	O
90%	O
IPA	O
in	O
ACN	O
containing	O
0.1%	O
formic	B
acid	I
(Solvent	O
C)	O
was	O
resolved	O
for	O
13	O
minutes	O
at	O
a	O
flow	O
rate	O
of	O
0.4	O
ml/min.	O

Glycochenodeoxycholic	B
acid,	I
and	O
some	O
metabolites	O
including	O
oleamide,	B
aspartic	B
acid,	I
and	O
4-ketoglucose	B
(not	O
shown	O
in	O
)	O
were	O
consistently	O
depleted	O
at	O
each	O
of	O
the	O
four	O
stages,	O
whereas	O
glycocholic	B
acid	I
and	O
α-ketoglutaric	B
acid	I
fluctuated	O
among	O
different	O
stages.	O

Aspartame	B
sensitive	O
and	O
non-sensitive	O
participants	O
differed	O
psychologically	O
at	O
baseline	O
in	O
handling	O
feelings	O
and	O
perceived	O
stress.	O

Then,	O
200	O
μl	O
of	O
bis-(trimethylsilyl)-trifluoroacetamide	B
(BSTFA)	O
plus	O
1%	O
trimethylchlorosilane	B
(TMCS)	O
was	O
added,	O
and	O
the	O
mixture	O
was	O
again	O
vortexed	O
for	O
2	O
min	O
and	O
incubated	O
at	O
100°C	O
for	O
30min.	O

The	O
weak	O
and	O
the	O
strong	O
washes	O
were	O
95:5	O
water/acetonitrile	O
(0.2%	O
formic	O
acid)	O
(v/v)	O
and	O
100%	O
isopropanol	B
(0.5%	O
formic	O
acid),	O
respectively.	O

The	O
impact	O
of	O
pre-analytical	O
variations	O
on	O
(a)	O
taurine	B
and	O
(b)	O
O	B
-phosphoethanolamine	I
concentrations	O
in	O
EDTA	O
blood	O
and	O
plasma,	O
represented	O
by	O
boxplots;	O
In	O
(a,b),	O
stars	O
indicate	O
significant	O
differences	O
compared	O
with	O
the	O
control	O
group,	O
calculated	O
by	O
using	O
ANOVA	O
with	O
a	O
significance	O
level	O
of	O
p	O
<	O
0.05;	O
(c)	O
Legend	O
for	O
the	O
boxplots	O
in	O
(a,b).	O

Thus,	O
regarding	O
the	O
effects	O
on	O
insulin	O
sensitivity,	O
Omega-3	B
exerted	O
a	O
neutral	O
effect	O
compared	O
with	O
Placebo,	O
while	O
the	O
results	O
collectively	O
document	O
a	O
marginal	O
improvement	O
by	O
the	O
Pio&	O
Omega-3	B
intervention.	O

Total	O
ion	O
chromatograms	O
(TIC)	O
of	O
HC	O
and	O
CRC	O
samples	O
(Fig. )	O
revealed	O
a	O
clear	O
separation	O
among:	O
medium-polar	O
metabolites	O
(e.g.,	O
phospholipids,	B
lysophospholipids,	B
and	O
steroids),	O
eluted	O
between	O
minutes	O
6	O
and	O
14;	O
very	O
polar	O
metabolites	O
(e.g.,	O
some	O
amino	O
acids	O
and	O
sugars),	O
eluted	O
in	O
the	O
first	O
5 minutes	O
and	O
best	O
separated	O
using	O
a	O
HILIC	O
column;	O
and	O
non-polar	O
metabolites,	O
eluted	O
between	O
minutes	O
14	O
and	O
17.	O

Baseline	O
characteristics	O
and	O
plasma	O
sphingolipid	B
metabolite	O
levels	O
of	O
the	O
sex-	O
and	O
body	O
composition-matched	O
study	O
population.	O

Surprisingly,	O
less	O
than	O
50%	O
of	O
the	O
acetyl-CoA	B
pool	O
was	O
derived	O
from	O
blood-borne	O
glucose,	B
suggesting	O
that	O
additional	O
substrates	O
contribute	O
to	O
tumor	O
bioenergetics.	O

Lactitol	O
dehydrate	O
identified	O
here	O
is	O
a	O
hydrophilic	B
carbohydrate	O
metabolite,	O
which	O
supported	O
this	O
viewpoint.	O

Due	O
to	O
the	O
determined	O
MIDs,	O
erythritol	B
is	O
most	O
probably	O
synthesized	O
from	O
E4P,	O
an	O
intermediate	O
of	O
the	O
PPP.	O

[95%	O
CI	O
0.54,	O
0.78])	O
and	O
taurine	B
(HR	O
0.73	O
[95%	O
CI	O
0.59,	O
0.90])	O
and	O
higher	O
for	O
1	O
SD	O
increase	O
in	O
phenylalanine	B
(HR	O
1.35	O
[95%	O
CI	O
1.11,	O
1.65])	O
after	O
adjusting	O
for	O
confounders.	O

We	O
recorded	O
an	O
increase	O
in	O
glutamate	B
levels	O
in	O
RCC	O
cases	O
relative	O
to	O
controls,	O
which	O
corroborates	O
findings	O
in	O
similar	O
studies	O
[,]	O
and	O
further	O
strengthens	O
the	O
proposition	O
that	O
increased	O
glutamate	B
levels	O
may	O
indicate	O
increased	O
glutaminolysis	O
for	O
biosynthetic	O
purposes	O
in	O
RCC.	O

SM	B
C16:1;	I
10.	O

Two	O
fatty	O
acids,	O
palmitelaidic	B
acid	I
and	O
an	O
unsaturated	O
fatty	O
acid,	O
were	O
decreased,	O
while	O
tetradecanoic	B
acid	I
(12-methyl-,	O
methyl	B
ester,	I
and	O
(S	O
)-),	O
one	O
of	O
the	O
branched	O
fatty	O
acids,	O
was	O
increased.	O

R	O
_d	O
of	O
palmitate	B
(μmol/min/kg)	O
is	O
a	O
function	O
of	O
R	O
_a	O
minus	O
the	O
change	O
in	O
total	O
plasma	O
palmitate	B
between	O
two	O
time	O
points	O
(t_1	O
and	O
t_2	O
),	O
and	O
as	O
such	O
the	O
equation	O
is	O
as	O
follows:	O
Rd(palmitate)=Ra(palmitate)−pV×(C2−C1)(t2−t1)	B
Rd(palmitate)=Ra(palmitate)−pV×(C2−C1)(t2−t1)	I
Rd(palmitate)=Ra(palmitate)−pV×(C2−C1)(t2−t1)	I
Rd(palmitate)=Ra(palmitate)−pV×(C2−C1)(t2−t1)	I
Rd(palmitate)=Ra(palmitate)−pV×(C2−C1)(t2−t1)	I

As	O
a	O
general	O
trend,	O
DBP	B
showed	O
a	O
stronger	O
association	O
with	O
non-adherence	O
to	O
antihypertensive	O
medications	O
than	O
SBP	O
(,	O
).	O

Then	O
100 μL	O
of	O
pooled	O
sample	O
was	O
treated	O
with	O
100 nmol	O
of	O
tris	O
(2-carboxyethyl)	B
phosphine	I
hydrochloride	I
(TCEP,	O
10 mmol/L,	O
10 μL)	O
under	O
45 °C	O
for	O
60 min.	O

Proportionately	O
higher	O
amounts	O
of	O
butyrate	B
were	O
seen	O
in	O
stool	O
of	O
healthy	O
individuals	O
while	O
relative	O
concentrations	O
of	O
acetate	B
were	O
higher	O
in	O
stools	O
of	O
CRC	O
patients.	O

24	O
Shydroxycholesterol	B
plasma	O
levels	O
(boxplots)	O
in	O
older	O
normal	O
individuals	O
(Controls)	O
and	O
in	O
older	O
subjects	O
affected	O
by	O
vascular	O
dementia	O
(VD),	O
late	O
onset	O
Alzheimer's	O
disease	O
(LOAD)	O
or	O
cognitive	O
impairment-no	O
dementia	O
(CIND).	O

Notably,	O
we	O
observed	O
that	O
metabolites	O
from	O
the	O
purine	B
metabolic	O
pathway,	O
AMP,	B
and	O
hypoxanthine	B
were	O
associated	O
with	O
cervical	O
cancer	O
risk.	O

We	O
selected	O
4	O
amino	O
acids	O
(tyrosine,	O
threonine,	B
tryptophan	B
and	O
glycine),	B
10	O
metabolites	O
with	O
high	O
confidence	O
in	O
identification	O
(level	O
1	O
or	O
2)	O
and	O
6	O
unidentified,	O
but	O
highly	O
significant	O
species	O
(see	O
for	O
list	O
of	O
selected	O
metabolites;	O
all	O
p-adjust	O
<	O
0.10).	O

The	O
signal	O
for	O
erythritol	B
was	O
confirmed	O
in	O
a	O
targeted	O
GC-MS	O
approach	O
with	O
absolute	O
quantification	O
of	O
erythritol;	B
the	O
concentration	O
of	O
erythritol	B
was	O
14.7-fold	O
greater	O
[95%	O
confidence	O
interval	O
(CI):	O
13.27,	O
16.25]	O
in	O
incident	O
central	O
adiposity	O
gain	O
pooled	O
samples	O
compared	O
with	O
pooled	O
samples	O
of	O
participants	O
with	O
stable	O
adiposity	O
[60.8	O
(SE	O
=	O
3.1)	O
vs.	O
4.1	O
(SE	O
=	O
0.0)	O
μmol/L;	O
P	O
<	O
0.0001].	O

While	O
some	O
of	O
these	O
metabolites	O
have	O
been	O
reported	O
previously,	O
recent	O
work	O
by	O
Wang	O
et	O
al.	O
has	O
shown	O
the	O
discovery	O
of	O
down-regulation	O
of	O
GCDCA	B
and	O
its	O
fragments	O
(m/z	O
414.3)	O
in	O
serum	O
of	O
patients	O
with	O
HCC,	O
and	O
up-regulations	O
of	O
LPC	B
(16:0),	I
LPC	B
(18:0)	I
and	O
other	O
PCs,	O
supporting	O
our	O
previous	O
interpretation.	O

We	O
report	O
a	O
method	O
to	O
quantify	O
11	O
urinary	O
methyl	O
naphthols	O
(Me-OHNs),	O
metabolites	O
of	O
1-	O
and	O
2-methylnaphthalenes,	B
and	O
10	O
monohydroxy	B
PAH	O
metabolites	O
(OH-PAHs),	O
using	O
automated	O
liquid-liquid	O
extraction	O
and	O
isotope	O
dilution	O
gas	O
chromatography	O
tandem	O
mass	O
spectrometry	O
(GC-MS/MS).	O

ABCB1	O
or	O
MDR1	O
P-glycoprotein	B
are	O
involved	O
in	O
lipid	O
transport	O
which	O
is	O
their	O
main	O
function.	O

Mannose	B
plays	O
a	O
central	O
role	O
in	O
glycation	O
processes	O
of	O
lipoproteins	O
that	O
are	O
involved	O
in	O
the	O
initiation	O
and	O
development	O
of	O
atherogenesis.	O

Increased	O
concentrations	O
of	O
creatine	B
observed	O
using	O
LC/MS	O
and	O
NMR	O
were	O
consistent	O
with	O
published	O
NMR	O
data	O
(Saude	O
and	O
Sykes	O
).	O

Oxysterols	B
from	O
healthy	O
and	O
hypercholesterolaemic	B
individuals	O
spiked	O
with	O
deuterated	O
internal	O
standards	O
(1 ng	O
24-OHCd7,	O
0.25 ng	O
25-OHCd6,	O
4 ng	O
27-OHCd6,	O
0.5 ng	O
7β-OHCd7,	B
15 ng	O
7-KCd7)	O
were	O
analysed	O
as	O
previously	O
described.	O

(A)	O
Many	O
analytes	O
contained	O
in	O
the	O
library	O
can	O
be	O
resolved	O
in	O
the	O
mass	O
dimension	O
at	O
modest	O
resolving	O
power	O
(TOF	O
Rp	B
=	O
40,000),	O
with	O
only	O
incremental	O
increases	O
in	O
coverage	O
resulting	O
from	O
the	O
use	O
of	O
an	O
instrument	O
with	O
significantly	O
higher	O
resolving	O
power	O
(	O

Generally,	O
age-related	O
changes	O
were	O
indeed	O
small	O
(effect	O
sizes	O
<1),	O
healthy	O
controls	O
over	O
60	O
years	O
excreting	O
slightly	O
higher	O
levels	O
of	O
IS,	O
and	O
lower	O
levels	O
of	O
citrate,	B
cis-	B
aconitate,	I
creatine,	B
creatinine,	B
hypoxanthine	B
and	O
trigonellinamide	B
and	O
some	O
unassigned	O
resonances.	O

Specifically,	O
increases	O
in	O
cystine	B
(p<0.0012,	O
q<0.10),	O
ornithine	B
(p<0.0068,	O
q<0.26),	O
lysine	B
(p<0.0100,	O
q<0.26),	O
and	O
citrulline	B
(p<0.0160,	O
q<0.26)	O
were	O
all	O
observed	O
to	O
correlate	O
with	O
the	O
LDL-C	O
lowering	O
effects	O
of	O
simvastatin	B
with	O
significant	O
p-values	O
(<0.05),	O
but	O
high	O
q-values.	O

This	O
fragmentation	O
pattern	O
may	O
be	O
explained	O
by	O
the	O
presence	O
of	O
a	O
glucuronide	B
metabolite,	O
as	O
shown.	O

Clinical	O
evaluation	O
of	O
tumor	O
metabolism	O
is	O
an	O
established	O
practice,	O
as	O
the	O
fundamental	O
diagnostic	O
technique,	O
18F-fluorodeoxyglucose	B
positron	O
emission	O
tomography	O
(FDG-PET)	O
is	O
dependent	O
on	O
Warburg	O
metabolism	O
and	O
the	O
propensity	O
for	O
tumors	O
to	O
take	O
up	O
glucose	B
at	O
a	O
higher	O
rate	O
than	O
adjacent	O
normal	O
tissue.	O

In	O
these	O
phospholipids,	B
9-HSA	O
is	O
necessarily	O
present	O
at	O
the	O
sn-2	O
position,	O
which	O
raises	O
the	O
possibility	O
that	O
sn-2	O
may	O
constitute,	O
in	O
general	O
terms,	O
a	O
preferred	O
position	O
for	O
the	O
fatty	O
acid.	O

The	O
real-time	O
monitoring	O
of	O
lactate	B
production	O
led	O
to	O
the	O
characterization	O
of	O
a	O
novel	O
non-catalytic	O
function	O
of	O
the	O
hypoxia-induced	O
carbonic	O
anhydrase	O
IX	O
in	O
facilitating	O
the	O
rapid	O
efflux	O
of	O
lactate	B
via	O
monocarboxylate	B
transporters,	O
which	O
was	O
required	O
to	O
sustain	O
viability	O
during	O
hypoxic	O
stress.	O

For	O
instance	O
we	O
identified	O
a	O
correlation	O
between	O
the	O
fold	O
changes	O
in	O
angiotensin	B
2	I
and	O
muscle	O
capillary	O
density	O
(r	O
=	O
0.	O
65)	O
and	O
changes	O
in	O
glucose	B
(r	O
=	O
–0.846;	O
p	O
=	O
0.008)	O
after	O
one-legged	O
exercise.	O

The	O
average	O
levels	O
of	O
14,15-,	B
11,12-,	B
and	O
8,9-EETs	B
in	O
the	O
control	O
subjects	O
were	O
3.9±0.9,	O
2.0±0.9,	O
and	O
4.7±1.3	O
ng/mL,	O
respectively.	O

Our	O
results	O
show	O
a	O
higher	O
intra-individual	O
and	O
inter-individual	O
variability	O
in	O
taurine	B
urinary	O
excretion	O
relative	O
to	O
the	O
excretion	O
of	O
sulfate,	B
the	O
other	O
oxidation	O
product	O
of	O
cysteine	B
(Fig.	O
).	O

Serum	O
TMAO	B
concentrations	O
were	O
greater	O
in	O
the	O
PLC	O
group	O
than	O
the	O
control	O
group	O
(P	O
 = 0.002).	O

We	O
treated	O
50	O
μl	O
sample	O
aliquots	O
with	O
acetonitrile	B
(1:2,	O
v/v),	O
after	O
which	O
they	O
were	O
centrifuged	O
at	O
14000	O
x	O
g	O
for	O
5	O
minutes	O
at	O
4˚C	O
to	O
remove	O
proteins.	O

The	O
DSS	O
solution,	O
which	O
was	O
first	O
calibrated	O
using	O
a	O
primary	O
stoichiometric	O
standard,	O
tris(hydroxymethyl)aminomethane,	B
was	O
used	O
for	O
calibrating	O
all	O
the	O
standard	O
solutions.	O

Hypoxanthine	B
is	O
also	O
high	O
in	O
fecal	O
samples	O
in	O
a	O
chronic	O
variable	O
stress	O
rat	O
model	O
of	O
depression.	O

Urinary	O
cotinine	B
values	O
ranged	O
from	O
<LOD-395.4	O
μg/g	O
creatinine	B
with	O
a	O
geometric	O
mean	O
of	O
13.9	O
μg/g	O
creatinine.	B

Arginine	B
was	O
low	O
during	O
CM,	O
and	O
its	O
depletion	O
plays	O
an	O
important	O
role	O
in	O
the	O
vasculopathy	O
of	O
CM.	O

The	O
CV	O
of	O
the	O
IS‐normalized	O
matrix	O
effect	O
calculated	O
from	O
the	O
six	O
plasma	O
batches	O
at	O
both	O
concentrations	O
(QCL,	O
QCXL	O
for	O
cabozantinib,	B
and	O
QCH)	O
was	O
<8.2%	O
for	O
all	O
analytes.	O

For	O
example,	O
Mak	O
et	O
al.	O
reported	O
CVs	O
for	O
4-hydroxy-nonenal	B
from	O
eight	O
healthy	O
individuals	O
of	O
95.8%.	O

Previous	O
investigations	O
have	O
suggested	O
an	O
immune-modulating	O
effect	O
and	O
anti-inflammatory	O
properties	O
of	O
arginine.	B

Predicted	O
functions	O
implied	O
from	O
the	O
16S	O
rRNA	O
gene	O
sequences	O
are	O
consistent	O
with	O
findings	O
from	O
metabolomics	O
analysis	O
showing	O
depletion	O
of	O
bacteria	O
genera	O
involve	O
in	O
steroid	O
biosynthesis,	O
terpenoid	B
biosynthesis,	O
and	O
bile	O
secretion	O
in	O
tumor	O
relative	O
to	O
paired	O
normal	O
tissues.	O

Biochemical	O
analyses	O
indicated	O
that	O
patients	O
who	O
underwent	O
CE	O
had	O
significantly	O
higher	O
levels	O
of	O
fasting	O
glucose	B
and	O
HbA1c	O
(p	O
=	O
0.018	O
and	O
p	O
=	O
0.003;	O
respectively)	O
and	O
lower	O
levels	O
of	O
HDL-C	O
(p	O
=	O
0.003)	O
than	O
healthy	O
subjects.	O

The	O
dried	O
metabolic	O
extract	O
was	O
derivatized	O
with	O
30 μl	O
of	O
methoxyamine	B
(20 mg/ml)	O
for	O
1.5 h	O
at	O
37°C.	O

The	O
EM	O
profile	O
is	O
a	O
phenotypic	O
measure	O
and	O
thus	O
provides	O
a	O
direct	O
way	O
to	O
test	O
hypotheses	O
about	O
the	O
effects	O
of	O
dietary	O
and	O
lifestyle	O
factors	O
on	O
estrogen	B
metabolism	O
and	O
to	O
study	O
the	O
effects	O
of	O
estrogen	B
metabolism	O
on	O
disease	O
risk.	O

This	O
signifies	O
the	O
need	O
and	O
magnitude	O
of	O
ATP	B
production.	O

Furthermore,	O
from	O
a	O
practical	O
perspective,	O
[U-_13	B
C]glucose	I
is	O
relatively	O
inexpensive,	O
greatly	O
improving	O
the	O
affordability	O
of	O
human	O
experiments	O
involving	O
steady-state	O
infusions.	O

The	O
remaining	O
275	O
spectra,	O
5	O
spectra	O
from	O
group	O
A	O
and	O
the	O
270	O
spectra	O
from	O
group	O
B	O
not	O
containing	O
acetaminophen	B
resonances	O

About	O
3%	O
of	O
tryptophan	B
entered	O
with	O
the	O
diet	O
is	O
excreted	O
as	O
indoxyl	B
sulfate.	I

One	O
widely	O
accepted	O
pathway	O
of	O
metabolic	O
activation	O
proceeds	O
through	O
formation	O
of	O
“bay	O
region”	O
diol	B
epoxides	I
which	O
are	O
highly	O
reactive	O
with	O
DNA	O
and	O
can	O
cause	O
mutations.	O

Verification	O
of	O
metabolite	O
GDCA	O
(A1	O
and	O
A2),	O
Phe-Phe	B
(B1and	O
B2),	O
Oleyol	O
carnitine	B
(C1	O
and	O
C2),	O
and	O
3beta,	O
6beta-dihydroxy-5beta-cholan-24-oic	B
acid	I
(D1	O
and	O
D2).	O

The	O
major	O
pathway	O
for	O
the	O
intracellular	O
metabolism	O
of	O
choline	B
in	O
breast	O
cancer	O
cells	O
is	O
by	O
Gly	O
production	O
along	O
with	O
phosphatidylcholine	B
synthesis	O
[,].	O

Additional	O
CID	O
spectra	O
performed	O
in	O
the	O
negative	O
ionization	O
mode	O
enabled	O
to	O
determine	O
the	O
presence	O
of	O
the	O
fatty	O
acids	O
FA	O
16:1	O
(m/z	O
253.2172)	O
(b)	O
and	O
FA	B
16:0	I
(m/z	O
255.2327)	O
(c),	O
corresponding	O
to	O
two	O
distinct	O
PC	O
species,	O
namely	O
alkyl–acyl-PC	B
32e:1	O
and	O
alkenyl–acyl-PC32p:0	B

shows	O
the	O
typical	O
low	O
frequency	O
CPMG	O
spectra	O
of	O
plasma	O
samples	O
obtained	O
from	O
FD	B
patients	O
and	O
healthy	O
subjects.	O

Solubility	O
improvement	O
was	O
attempted	O
principally	O
by	O
replacing	O
hydrophobic	O
groups	O
with	O
more	O
hydrophilic	B
moieties.	O

Previous	O
OzID	O
experiments	O
on	O
mass-selected	O
lipids	O
have	O
shown	O
a	O
difference	O
in	O
reactivity	O
between	O
cis	O
and	O
trans	O
double	O
bond	O
geometries	O
for	O
a	O
range	O
of	O
lipid	O
classes,	O
with	O
trans	O
reacting	O
significantly	O
faster._,	O
As	O
a	O
direct	O
comparison	O
of	O
the	O
efficacy	O
of	O
OzID	O
without	O
mass	O
selection	O
towards	O
cis	O
and	O
trans	O
double	O
bonds,	O
methanolic	O
solutions	O
of	O
PE	B
18:1(n	I
-9,	I
cis	I
)/18:1(n	I

The	O
ROC	O
curve	O
for	O
a	O
two-metabolite	O
set	O
(glycine	O
and	O
PAG)	O
outperformed	O
single	O
markers	O
(glycine,	O
PAG,	B
or	O
adenine),	O
highlighting	O
that	O
this	O
set	O
is	O
a	O
promising	O
biomarker	O
that	O
possesses	O
the	O
greatest	O
discriminatory	O
power	O
to	O
predict	O
individual	O
responses	O
to	O
KBR	O
consumption	O
in	O
sedentary	O
overweight/obese	O
adults.	O

Anticoagulant	O
and	O
anti-arrhythmic	O
agents	O
were	O
more	O
frequently	O
prescribed	O
in	O
patients	O
with	O
AF	B
than	O
healthy	O
controls.	O

Persistent	O
AF	B
was	O
confirmed	O
by	O
a	O
12-lead	O
electrocardiogram	O
(ECG)	O
and	O
24	O
h	O
Holter	O
monitoring.	O

Dimethyl-glycine	B
particularly	O
correlated	O
with	O
measures	O
of	O
kidney	O
function;	O
uric	B
acid	I
(r = 0.21,	O
P-value	O
 = 2.42×10_−9	O
),	O
glomerular	O
filtration	O
rate	O
(eGFR)	O
(r = −0.14,	O
P-value	O
 = 2.53×10_−10	O
),	O
urea	B
(r = 0.18,	O
P-value	O
 = 1.20×10_−7	O
),	O
and	O
creatinine	B
(r = 0.22,	O
P-value	O
 = 1.35×10_−22	O
).	O

Analytes	O
were	O
isolated	O
from	O
the	O
serum	O
matrix	O
by	O
liquid-liquid	O
extraction	O
with	O
8	O
mL	O
hexane:ethyl	O
acetate	B
(50:50,	I
volume	I
fractions).	I

Bar	O
plots	O
of	O
four	O
characteristic	O
sphingomyelins	B
showed	O
an	O
elevated	O
level	O
in	O
plasma	O
samples	O
in	O
stage	O
I	O
caner	O
as	O
compared	O
to	O
controls	O
and	O
a	O
decreasing	O
trend	O
in	O
the	O
plasma	O
samples	O
from	O
stage	O
I	O
to	O
stage	O
IV	O
breast	O
cancer	O
patients.	O

For	O
metabolite	O
extraction,	O
frozen	O
tissue	O
samples	O
(approximately	O
50 mg)	O
were	O
plunged	O
into	O
methanol	B
(625 μl)	O
containing	O
internal	O
standards	O
and	O
20 M	O
each	O
of	O
methionine	B
sulfone,	I
D-camphor-10-sulfonic	B
acid	I
and	O
2-(n-morpholino)ethanesulfonic	B
acid	I
and	O
homogenized	O
at	O
1,500 rpm	O
for	O
15 min	O
using	O
a	O
Shake	O
Master	O
Neo	O
(BMS,	O
Tokyo,	O
Japan)	O
to	O
inactivate	O
the	O
enzymes.	O

Data	O
in	O
the	O
heatmap	O
are	O
log2	O
FC	O
values	O
for	O
individual	O
lipids	O
which	O
are	O
sorted	O
at	O
the	O
subclass	O
level	O
by	O
increasing	O
number	O
of	O
total	O
hydrocarbon	B
chain	O
length	O
and	O
then	O
the	O
total	O
of	O
double	O
bonds	O
in	O
hydrocarbon	B
chains.	O

previous	O
study	O
demonstrated	O
that	O
insulin	O
administration	O
in	O
rats	O
resulted	O
in	O
a	O
reduction	O
of	O
p-tyramine	B
and	O
an	O
increase	O
in	O
m-tyramine.	B

We	O
observed	O
increased	O
choline	B
levels	O
in	O
EC	O
tissues,	O
which	O
was	O
consistent	O
with	O
previous	O
reports[],	O
indicating	O
that	O
choline	B
could	O
be	O
a	O
viable	O
tissue	O
biomarker	O
associated	O
with	O
tumor	O
promotion.	O

The	O
optimum	O
composition	O
of	O
the	O
sheath	O
liquid	O
was	O
50%	O
(v/v	O
)	O
methanol/water	O
with	O
an	O
addition	O
of	O
5	O
mM	O
ammonium	B
acetate	I
(compromising	O
a	O
maximum	O
intensity	O
and	O
reproducibility	O
of	O
the	O
detection	O
response	O
for	O
the	O
drugs).	O

Succinate	B
was	O
still	O
an	O
independent	O
metabolite	O
after	O
adjusting	O
for	O
other	O
variables	O
significant	O
in	O
univariable	O
analysis	O
(age,	O
sex,	O
congestive	O
heart	O
failure,	O
and	O
history	O
of	O
stroke;	O
adjusted	O
OR	O
[aOR]	O
1.48,	O
95%	O
CI	O
1.11–1.97,	O
p	O
=	O
0.008).	O

The	O
cell	O
lysates	O
were	O
homogenized	O
with	O
50	O
µL	O
of	O
Millipore	O
ultrapure	O
water	O
and	O
extracted	O
with	O
200	O
µL	O
of	O
cold	O
methanol.	B

A	O
similar	O
prediction	O
power	O
between	O
C18:2	B
CE	O
and	O
SM	O
22:0	O
was	O
observed	O
in	O
the	O
validation	O
samples.	O

The	O
correlation	O
between	O
histological	O
percentages	O
of	O
triglyceride	B
accumulation	O
and	O
hepatic	O
fat	O
fraction	O
obtained	O
by	O
MRI	O
was	O
considered	O
excellent	O
(Figure	O
).	O

A	O
metabolomics	O
analysis	O
of	O
human	O
conjunctival	O
epithelial	O
cells	O
in	O
response	O
to	O
hyperosmotic	O
stress	O
found	O
that	O
levels of	O
21	O
metabolites	O
significantly	O
changed	O
under	O
hyperosmotic	O
stress;	O
glycerophosphocholine	B
increased	O
most	O
under	O
hyperosmotic	O
stress,	O
and	O
the	O
authors	O
concluded	O
that	O
this	O
metabolite	O
may	O
act	O
as	O
an	O
important	O
osmoprotectant.	O

Concentrations	O
of	O
alanine	B
and	O
proline,	B
which	O
are	O
known	O
as	O
glycogenic	O
amino	O
acids,	O
were	O
higher	O
in	O
our	O
inactive	O
groups.	O

In	O
this	O
method,	O
the	O
IL-DPI-LC-MS	O
was	O
firstly	O
applied	O
for	O
non-targeted	O
profiling	O
of	O
thiols	B
in	O
5	O
cancer	O
urines.	O

Recent	O
studies	O
suggest	O
that	O
increased	O
innate	O
immune	O
activation	O
and	O
tryptophan	B
catabolism	O
are	O
associated	O
with	O
higher	O
risk	O
of	O
depression	O
in	O
HIV	O
infection	O
and	O
other	O
chronic	O
inflammatory	O
diseases,	O
but	O
the	O
mechanisms	O
leading	O
to	O
depression	O
remain	O
poorly	O
understood.	O

Alb	O
adducts	O
were	O
found	O
in	O
F344/N	O
rats	O
exposed	O
by	O
gavage	O
to	O
0–10,000	O
μmol/kg	O
benzene.	B

That	O
being	O
said,	O
our	O
previous	O
studies	O
in	O
a	O
broad	O
population	O
of	O
cardiac	O
patients	O
also	O
demonstrated	O
prognostic	O
value	O
of	O
TMAO	B
being	O
independent	O
of	O
plasma	O
MPO	O
levels[].	O

A	O
study	O
of	O
violent	O
criminals	O
found	O
the	O
plasma	O
content	O
of	O
the	O
amino	O
acid	O
tryptophan	O
and	O
other	O
large	O
neutral	O
amino	O
acids	O
were	O
increased	O
[–];	O
however,	O
much	O
more	O
studies	O
have	O
reported	O
decreased	O
tryptophan	B
is	O
correlated	O
with	O
aggressive	O
behaviours	O

A456-4),	O
toluene	B
(Sigma–Aldrich,	O
cat.	O

Tryptophan	B
was	O
only	O
detected	O
in	O
short-term	O
storage	O
samples	O
(Table	O
S3,	O
d–f).	O

In	O
this	O
research,	O
L-tyrosine	B
in	O
stool	O
was	O
upregulated	O
in	O
T2DM	O
patients	O
compared	O
to	O
IGR	O
and	O
was	O
downregulated	O
in	O
IGR	O
compared	O
to	O
NGT.	O

In	O
an	O
in	O
vitro	O
study,	O
INF-γ	O
concentrations	O
were	O
increased	O
after	O
treatment	O
with	O
resveratrol;	B
however,	O
because	O
the	O
study	O
was	O
done	O
in	O
a	O
cell	O
culture	O
system,	O
release	O
of	O
INF-γ	O
was	O
likely	O
the	O
result	O
of	O
NK	O
cell	O
activation.	O

In	O
this	O
study,	O
in	O
comparison	O
with	O
the	O
control	O
group,	O
the	O
levels	O
of	O
palmitic	B
acid	I
(C16:0)	O
and	O
myristic	B
acid	I
(C14:0)	O
were	O
higher	O
and	O
lower	O
in	O
the	O
LC	O
group,	O
respectively.	O

Recovery	O
of	O
IS	O
1	O
(added	O
directly	O
at	O
the	O
beginning	O
of	O
sample	O
preparation)	O
was	O
determined	O
utilizing	O
1-(1-(ethylsulfonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea	B
as	O
IS	O
2	O
(added	O
after	O
sample	O
preparation	O
directly	O
before	O
measurement).	O

Here	O
we	O
replicate	O
our	O
previous	O
reports	O
of	O
reductions	O
in	O
KynA/QA	O
in	O
currently	O
depressed	O
subjects	O
with	O
MDD	O
or	O
BD	O
and	O
extend	O
the	O
finding	O
to	O
rMDD	O
subjects	O
in	O
long-term	O
remission,	O
suggesting	O
the	O
existence	O
of	O
a	O
persistent	O
abnormality	O
in	O
the	O
kynurenine	B
metabolic	O
pathway	O
in	O
MDD.	O

While	O
extensive	O
studies	O
have	O
investigated	O
the	O
detoxification	O
of	O
PAH	O
diol	B
epoxides	I
by	O
GSTs	O
in	O
various	O
in	O
vitro	O
systems	O
[–],	O
there	O
are	O
to	O
our	O
knowledge	O
only	O
two	O
reports,	O
both	O
from	O
our	O
laboratory,	O
that	O
have	O
characterized	O
human	O
urinary	O
mercapturic	O
acids	O
derived	O
from	O
PAH	O
diol	B
epoxides	I
[;].	O

This	O
may	O
explain	O
the	O
higher	O
levels	O
of	O
total	O
and	O
LDL	B
cholesterol	I
after	O
RB	O
observed	O
in	O
the	O
present	O
study	O
in	O
postmenopausal	O
women	O
with	O
slightly	O
elevated	O
circulating	O
cholesterol	B
levels.	O

LC-MS/MS	O
based	O
metabolomics	O
analysis	O
was	O
performed	O
using	O
a	O
Thermo	O
QExactive	O
orbitrap	O
mass	O
spectrometer	O
coupled	O
to	O
a	O
Thermo	O
Vanquish	B
UPLC	O
system.	O

It	O
is	O
highly	O
unlikely	O
that	O
modestly	O
higher	O
dietary	O
protein	O
intake	O
in	O
individuals	O
with	O
TB	O
disease	O
relative	O
to	O
the	O
household	O
contacts	O
accounts	O
for	O
the	O
single	O
amino	O
acid	O
(glutamate)	O
to	O
be	O
within	O
the	O
discriminating	O
metabolite	O
profile.	O

Using	O
highly	O
confident	O
EMI	O
and	O
PPI	B
data,	O
as	O
well	O
as	O
fold	O
change	O
data	O
of	O
the	O
metabolites,	O
we	O
calculated	O
RV	B
and	O
TI	O
for	O
every	O
metabolite	O
(see	O
the	O
details	O
in	O
the	O
methods	O
section).	O

Additionally,	O
the	O
abundance	O
of	O
phosphatidylinositols	B
(PI)	O
was	O
found	O
only	O
in	O
cluster	O
one,	O
which	O
are	O
also	O
hallmarks	O
of	O
viable	O
cancer	O
tissue.	O

Lactic	B
acid	I
is	O
often	O
more	O
prominent	O
in	O
the	O
highest	O
grade	O
of	O
glioma	O
in	O
MRS	O
studies.	O

Samples	O
were	O
dried	O
and	O
then	O
heated	O
to	O
allow	O
derivatization	O
with	O
pentafluoropropionic	B
anhydride	O
(PFPA,	O
Sigma	O
Aldrich,	O
Saint-Quentin	O
Fallavier,	O
France)	O
and	O
hexafluoroisopropanol	B
(HFIP,	O
Sigma	O
Aldrich).	O

Because	O
neutral	O
glycosphingolipids	B
are	O
produced	O
from	O
sphingoid	B
bases,	O
their	O
concentrations	O
are	O
also	O
decreased	O
in	O
CRC.	O

Dietary	O
omega	O
6	O
fatty	O
acids	O
that	O
include	O
arachidonic	B
acid	I
and	O
eicosatrienoic	B
acid	I
may	O
be	O
implicated	O
in	O
IBD.	O

The	O
enhancement	O
of	O
anaerobic	O
fermentation	O
of	O
malignant	O
tumor	O
cells	O
and	O
the	O
formation	O
of	O
lactic	B
acid,	I
leads	O
to	O
the	O
accumulation	O
of	O
lactic	B
acid,	I
and	O
local	O
tumor	O
acidosis.	O

Finally,	O
we	O
also	O
demonstrate,	O
for	O
the	O
first	O
time,	O
that	O
Ps	O
and	O
PsA	O
patients	O
also	O
have	O
low	O
concentrations	O
of	O
urine	O
citrate	B
compared	O
to	O
healthy	O
controls.	O

Decreased	O
1-MN	O
in	O
COPD	O
patients	O
indicates	O
impairment	O
of	O
the	O
nicotinate	B
and	O
nicotinamide	B
metabolism	O
which	O
has	O
also	O
been	O
observed	O
in	O
urine	O
samples	O
from	O
lung	O
cancer	O
.	O

In	O
addition,	O
metabolism	O
of	O
l-carnitine	B
by	O
intestinal	O
microbiota	O
has	O
been	O
recently	O
linked	O
to	O
increased	O
levels	O
of	O
inflammation	O
and	O
cardiovascular	O
risk.	O

Acrolein	B
and	O
crotonaldehyde	B
were	O
reported	O
to	O
form	O
Michael	O
adducts	O
at	O
Cys34,	O
His39,	O
Lys351,	O
and	O
Lys525,	O
and	O
acrolein	B
formed	O
a	O
Schiff	O
base	O
with	O
Lys541	O
and	O
Lys545.	O

Forty	O
quality	O
markers,	O
including	O
lysophospholipids,	B
dipeptides,	O
fatty	O
acids,	O
succinic	B
acid,	I
amino	O
acids,	O
glucose,	B
and	O
uric	B
acid	I
were	O
identified	O
by	O
G-Met	O
for	O
the	O
evaluation	O
of	O
plasma	O
sample	O
quality	O
and	O
established	O
the	O
equation	O
of	O
calculating	O
the	O
quality	O
score.	O

Substantial	O
variations	O
in	O
measures	O
of	O
estrogens	O
and	O
estrogen	B
metabolites	O
have	O
been	O
noted	O
across	O
laboratories,	O
assay	O
protocols,	O
and	O
assay	O
kit	O
manufacturing	O
lots	O
(,).	O

The	O
reference	O
standard	O
of	O
p-cresyl	B
sulphate,	I
kindly	O
provided	O
by	O
Prof.	O
R.	O
Vanholder	O
(University	O
Hospital	O
Ghent,	O
Belgium),	O
was	O
synthesized	O
as	O
a	O
potassium	O
salt	O
as	O
described	O
previously	O
.	O

We	O
calculated	O
the	O
sum	O
of	O
the	O
9	O
urinary	O
metabolites	O
measured	O
in	O
both	O
studies	O
(total	O
urinary	O
estrogens),	O
the	O
relative	O
percentages	O
for	O
the	O
3	O
metabolic	O
pathways	O
(2,4,	O
and	O
16α-OH)	B
based	O
on	O
molar	O
concentrations,	O
and	O
the	O
2/16α-OHE_1	B
ratio.	O

Plasmalogens	O
are	O
lipids	O
in	O
which	O
the	O
fatty	O
acid	O
linked	O
to	O
the	O
first	O
carbon	O
of	O
the	O
glycerol	B
backbone	O
is	O
attached	O
through	O
an	O
ether	O
or	O
vinyl-ether	B
bond	O
rather	O
than	O
an	O
ester	O
bond.	O

Freshly	O
prepared	O
α-cyano-4-hydroxycinnamic	B
acid	I
was	O
used	O
as	O
the	O
matrix	O
at	O
a	O
10-μg	O
μl_−1	O
concentration	O
in	O
50%	O
acetonitrile	B
containing	O
0.1%	O
tetrafluoroacetic	B
acid.	I

Interestingly,	O
while	O
the	O
concentration	O
of	O
asparagine	B
decreases	O
upon	O
long-term	O
storage	O
that	O
of	O
aspartate	B
increases	O
(Table	O
S1)	O
and	O
hence	O
the	O
ratio	O
of	O
aspartate	B
over	O
asparagine	B
increases	O
over	O
time	O
(C).	O

Values	O
on	O
the	O
original	O
scale	O
were	O
74.8	O
pmol/mg	O
creatinine	B
at	O
baseline	O
and	O
43.1	O
pmol/mg	O
creatinine	B
at	O
day	O
84.	O

Insulin	O
increased	O
in	O
49.7%	O
of	O
subjects	O
following	O
simvastatin	B
treatment;	O
HOMA-IR	O
and	O
HOMA-beta	O
scores	O
increased	O
in	O
49.0	O
and	O
46.0%	O
of	O
subjects,	O
respectively.	O

and	O
the	O
proton-decoupled	O
skyline	B
projections	O
(p-JRES)	O
exported	O
using	O
Agilent	O
VNMRJ	O
3.2	O
software.	O

Second	O
paracetamol	B
and	O
p	B
-aminophenol	I
measured	O
in	O
urine	O
may	O
also	O
be	O
the	O
result	O
of	O
exposure	O
to	O
other	O
ubiquitous	O
chemicals	O
in	O
the	O
environment.	O

The	O
anticipated	O
instability	O
of	O
the	O
seven-membered	O
triazepinone	B
ring	O
and	O
discord	O
with	O
other	O
similar	O
types	O
of	O
reactions	O
raised	O
our	O
concern.	O

Afterwards,	O
50	O
and	O
1	O
mL	O
of	O
acetic	B
acid	I
and	O
water,	O
respectively,	O
were	O
added	O
to	O
neutralize	O
[,,].	O

In	O
obese	O
children,	O
plasma	O
Tyr	O
concentrations	O
are	O
positively	O
associated	O
with	O
homeostasis	O
model	O
assessment	O
(HOMA),	O
which	O
might	O
be	O
explained	O
by	O
the	O
effect	O
of	O
insulin	O
on	O
Tyr	O
amino	B
transferase	O
activity.	O

More	O
importantly,	O
3	O
metabolites	O
of	O
acetoacetate,	B
acetone,	B
and	O
3-hydroxybutyrate	B
(3-HB)	O
were	O
increased	O
remarkably	O
in	O
plasma	O
of	O
GCT	O
patients.	O

Finally,	O
and	O
as	O
discussed	O
above,	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
ribose‐5‐phosphate	B
levels	O
in	O
tumor	O
tissue.	O

BMI,	O
body	O
mass	O
index;	O
CABG,	O
coronary	O
artery	O
bypass	O
grafting;	O
CHD,	O
coronary	O
heart	O
disease;	O
CI,	O
confidence	O
interval;	O
CKB,	O
China	O
Kadoorie	O
Biobank;	O
CVD,	O
cardiovascular	O
disease;	O
HDL-C,	O
high-density	O
lipoprotein	O
cholesterol;	B
IDL,	O
intermediate-density	O
lipoprotein;	O
IHD,	O
ischemic	O
heart	O
disease;	O
IS,	O
ischemic	O
stroke;	O
LDL-C,	O
low-density	O
lipoprotein	O
cholesterol;	B
MI,	O
myocardial	O
infarction;	O
NMR,	O
nuclear	O
magnetic	O
resonance;	O
PCI,	O
percutaneous	O
coronary	O
intervention;	O
RCT,	O
randomized	O
controlled	O
trial;	O
SBP,	O
systolic	O
blood	O
pressure;	O
TG,	B
triglycerides;	B
VLDL,	O
very	O
low-density	O
lipoprotein	O

A	O
similar	O
effect	O
was	O
seen	O
in	O
liver	O
cells,	O
when	O
they	O
were	O
exposed	O
to	O
DEHP,	O
resulting	O
in	O
reduced	O
insulin	O
receptor	O
concentration	O
and	O
glucose	B
oxidation.	O

All	O
of	O
the	O
participants’	O
medical	O
histories	O
were	O
obtained	O
and	O
patients	O
received	O
a	O
physical	O
examination	O
that	O
included	O
recording	O
age,	O
sex,	O
duration,	B
blood	O
pressure,	O
and	O
body	O
mass	O
index	O
(BMI).	O

Tubular	O
reuptake	O
of	O
proline	B
depends	O
on	O
a	O
low-affinity	O
system	O
shared	O
with	O
glycine	B
and	O
a	O
specific	O
system	O
with	O
high	O
affinity.	O

It	O
is	O
likely	O
that	O
the	O
background	O
metformin	B
therapy,	O
which	O
was	O
shown	O
to	O
improve	O
dyslipidemia	O
in	O
patients	O
with	O
T2D,	O
could	O
mask	O
the	O
effect	O
of	O
the	O
tested	O
interventions.	O

Peak	O
intensities	O
normalized	O
this	O
way	O
are	O
typically	O
characterized	O
by	O
feature-specific	O
variances	O
of	O
noise	O
η(ω)	B
,	O
where	O
peaks	O
of	O
low	O
intensity	O
are	O
more	O
variable	O
than	O
high-intensity	O
peaks.	O

Figure 	O
shows	O
the	O
scatterplots	O
of	O
threonine	B
versus	O
SUV_max	O
,	O
MATV_WTB	O
and	O
TLG_WTB	O
(the	O
horizontal	O
lines	O
represent	O
the	O
median	O
threonine	B
values	O
in	O
the	O
two	O
groups	O
and	O
the	O
difference	O
is	O
the	O
fold	O
change)	O
and	O
reveals	O
that,	O
although	O
the	O
correlation	O
between	O
threonine	B
and	O
the	O
PET	O
parameters	O
is	O
rather	O
weak,	O
the	O
fold	O
change	O
of	O
especially	O
MATV_WTB	O
and	O
TLG_WTB	O
allows	O
discrimination	O
between	O
the	O
groups.	O

After	O
a	O
blood	O
droplet	O
was	O
formed,	O
about	O
30	O
μL	O
of	O
blood	O
were	O
collected	O
with	O
heparinized	O
capillary	O
plastic	O
tubes	O
and	O
subjected	O
to	O
the	O
analysis	O
of	O
glucose	B
and	O
triglyceride	B
concentration	O
as	O
described	O
in	O
the	O
section	O
‘serum	O
metabolites’	O
.	O

Immunohistochemical	O
analysis	O
of	O
Glutamine	B
Synthetase	O
(GS)	O
was	O
done	O
according	O
to	O
standard	O
procedures	O
(Antibodies	O
from	O
BD	O
Transduction	O
Laboratories™,	O
dilution	O
at	O
1/400).	O

For	O
consistency	O
with	O
the	O
approach	O
of	O
developing	O
a	O
panel	O
assayed	O
by	O
mass	O
spectrometry	O
we	O
used	O
the	O
targeted	O
mass	O
spectrometry	O
assays	O
for	O
creatinine,	B
which	O
showed	O
excellent	O
agreement	O
with	O
the	O
original	O
clinical	O
chemistry	O
assays.	O

EETs	O
are	O
closely	O
involved	O
in	O
the	O
production	O
of	O
progesterone	B
[,	O
],	O
which	O
may	O
explain	O
the	O
difference	O
observed	O
between	O
young	O
and	O
elderly	O
women.	O

This	O
metabolism	O
of	O
DNR,	O
as	O
well	O
as	O
sequestration	O
of	O
other	O
chemotherapies	O
such	O
as	O
DOX	O
and	O
mitoxantrone,	B
could	O
reduce	O
the	O
concentration	O
of	O
active	O
drugs	O
in	O
adipocyte-rich	O
microenvironments,	O
such	O
as	O
adipose	O
tissue,	O
omentum,	O
and	O
bone	O
marrow.	O

OGTT,	O
and	O
higher	O
concentrations	O
of	O
triglycerides,	B

To	O
0.25 ml	O
of	O
the	O
serum	O
or	O
WB,	O
0.5 mL	O
of	O
methanol	B
and	O
0.5 mL	O
chloroform	B
(both	O
solvents	O
kept	O
at	O
4 °C)	O
were	O
added	O
in	O
the	O
ratio	O
1:2:2	O
(sample:methanol:chloroform,	O
v/v/v).	O

(C)	O
3-Methylhistidine	B
and	O
(D)	O
N-acetyl-3-methylhistidine	B
and	O
metabolites	O
of	O
the	O
urea	B
cycle,	O
(E)	O
urea	B
and	O
(F)	O
proline	B
are	O
increased	O
with	O
leptin	O
therapy.	O

In	O
our	O
laboratory,	O
diluted	O
isopropanol	B
was	O
used	O
to	O
stabilize	O
fecal	O
concentrations	O
of	O
short	O
chain	O
fatty	O
acids;	O
thus,	O
the	O
effect	O
of	O
isopropanol	B
was	O
investigated	O
for	O
DG/TG	O
concentrations.	O

These	O
enzymes	O
regulate	O
sphingomyelinase	O
to	O
increase	O
ceramide	B
biosynthesis	O
as	O
well	O
as	O
sphingomyelin	B
synthase	O
2	O
(SGMS2),	O
which	O
regulates	O
sphingomyelin	O
phosphodiesterase	O
to	O
increase	O
conversion	O
of	O
ceramide	B
to	O
sphingomyelin.	B

Oxylipins	B
are	O
oxidative	O
metabolites	O
of	O
PUFA	O
and	O
are	O
known	O
to	O
be	O
more	O
polar	O
than	O
their	O
respective	O
precursor	O
PUFA.	O

In	O
contrast,	O
12-oxoETE	B
was	O
present	O
in	O
significantly	O
lower	O
concentrations	O
in	O
the	O
patient	O
group.	O

Ziouzenkova	O
et	O
al	O
reported	O
retinal	B
as	O
a	O
distinct	O
biological	O
regulator	O
involved	O
in	O
suppressing	O
adipo-genesis,	O
diet-induced	O
obesity	O
and	O
insulin	O
resistance.	O

We	O
observed	O
a	O
25%	O
decrease	O
of	O
the	O
initial	O
body	O
weight	O
in	O
the	O
group	O
of	O
normoglycemic	B
women	O
vs	O
26.9%	O
in	O
diabetic	O
women	O
(not	O
significant).	O

The	O
number	O
of	O
samples	O
selected	O
was	O
200	O
and	O
the	O
sample	O
selection	O
was	O
made	O
based	O
on	O
the	O
presence	O
of	O
the	O
heroin	O
metabolite	O
6-acetylmorphine	B
measured	O
by	O
LC-MS/MS	O
(Andersson	O
et	O
al.	O
).	O

As	O
a	O
matter	O
of	O
fact,	O
beauvericin	B
(21)	O
and	O
bikaverin	O
(67)	O
among	O
the	O
compounds	O
isolated	O
from	O
EtOAc	O
extract	O
of	O
F.	O
oxysporum	B
,	O
endophyte	O
of	O
Cylindropuntia	O
echinocarpus	O
were	O
cytotoxic	O
against	O
a	O
panel	O
of	O
four	O
sentinel	O
cancer	O
cell	O
lines,	O
NCI-H460	O
(non-small-cell	O
lung),	O
MIA	O
Pa	O
Ca-2	O
(pancreatic),	O
MCF-7	O
(breast),	O
and	O
SF-268	O
(CNS	O
glioma).	O

The	O
relative	O
variable	O
importance	O
(VIMP)	O
ranking	O
values	O
from	O
RF	O
analysis	O
were	O
for	O
palmitic	B
acid	I
and	O
oleanolic	B
acid,	I
respectively,	O
of	O
100%	O
and	O
95.3%,	O
showing	O
a	O
clear	O
predictive	O
potential	O
and	O
a	O
substantial	O
larger	O
importance	O
of	O
the	O
two	O
metabolites	O
in	O
respect	O
to	O
all	O
others.	O

BAL	O
cell	O
counts	O
were	O
available	O
for	O
the	O
following	O
number	O
of	O
subjects:	O
eosinophils,	B
70;	O
neutrophils,	O
90;	O
lymphocytes,	O
91;	O
monocytes,	O
91;	O
and	O
macrophages,	O
91.	O

We	O
were	O
also	O
able	O
to	O
assign	O
n-6	O
vs.	O
n-3	O
C20:4	B
or	O
C22:5	B
fatty	O
acyl	O
side	O
chains	O
on	O
12	O
PC.	O

This	O
improved	O
glucose	B
hometostasis	O
by	O
3-HB	O
was	O
suggested	O
to	O
be	O
due	O
to	O
the	O
enhanced	O
hepatic	O
insulin	O
signaling,	O
as	O
evidenced	O
by	O
the	O
increased	O
phosphorylation	O
of	O
IRS2	O
and	O
AKT.	O

In	O
the	O
restricted	O
cubic	O
spline	O
model,	O
potential	O
nonlinearity	O
of	O
the	O
relation	O
between	O
plasma	O
TMAO	B
and	O
odds	O
of	O
GDM	O
was	O
found.	O

Pathway	O
analysis	O
revealed	O
alterations	O
in	O
various	O
metabolic	O
pathways	O
(e.g.,	O
glycine,	B
choline	B
and	O
methionine	B
degradation,	O
dipthamide	B
biosynthesis	O
and	O
glycolysis	O
pathways,	O
among	O
others)	O
between	O
IDH-mutant	O
and	O
IDH-wildtype	O
gliomas.	O

Untreated	O
T2DM	O
is	O
characterized	O
by	O
high	O
blood	O
glucose.	B

Normally,	O
the	O
concentration	O
of	O
creatinine	B
is	O
increased	O
in	O
males	O
when	O
compared	O
with	O
females,	O
given	O
the	O
increased	O
body	O
mass	O
index.	O

The	O
novel	O
strategy	O
proved	O
to	O
be	O
advantageous	O
in	O
the	O
case	O
of	O
low	O
abundant	O
lipid	O
classes	O
(Cer,	O
FA,	B
SPH)	O
and	O
lipids	O
with	O
low	O
ionization	O
efficiency	O
(SE,	O
ST).	O

Formic	B
acid,	I
acetamiprid,	B
N-desmethyl-acetamiprid,	B
thiacloprid,	B
and	O
thiacloprid-d_4	B
were	O
purchased	O
from	O
Fluka	O
(Seelze,	O
Germany).	O

Acyl-carnitines	B
with	O
a	O
chain	O
length	O
≥C10	O
are	O
defined	O
as	O
long-chain	O
acyl-carnitines,	B
and	O
with	O
a	O
chain	O
length	O
<C5	O
as	O
short-chain	O
acyl-carnitines.	B

A	O
shallow	O
elution	O
gradient	O
with	O
a	O
flow	O
rate	O
of	O
45	O
μL/min	O
was	O
used	O
to	O
achieve	O
separation	O
of	O
8-iso	B
-PGF_2α	I
from	O
its	O
isomers;	O
only	O
8-iso	B
-PGF_2α	I
was	O
quantified.	O

Purines	B
are	O
involved	O
in	O
energy	O
metabolism	O
at	O
an	O
intracellular	O
level,	O
but	O
also	O
have	O
extracellular	O
effects	O
through	O
the	O
activation	O
of	O
their	O
receptors	O
(such	O
as	O
P2X	O
and	O
P2Y).	O

Initial	O
MS/MS	O
fragmentation	O
suggested	O
the	O
drug	O
Levetiracetam	B
as	O
the	O
origin	O
of	O
14	O
out	O
of	O
those	O
26	O
metabolites	O
(Supplementary	O
Fig.	O

Anthropometric	O
data	O
and	O
concentration	O
of	O
sphingolipids	B
in	O
diabetic	O
patients	O
with	O
or	O
without	O
cardiovascular	O
complications.	O

Current	O
methodology	O
for	O
quantitation	O
of	O
urinary	O
cotinine	B
and	O
NNAL	O
(free	O
or	O
total)	O
is	O
based	O
almost	O
exclusively	O
on	O
tandem	O
mass	O
spectrometry.	O

However,	O
in	O
malignant	O
tissues,	O
pyruvate	B
is	O
largely	O
converted	O
to	O
lactate	B
and	O
energy	O
is	O
produced	O
anaerobically	O
through	O
the	O
Warburg	O
effect,	O
even	O
when	O
there	O
is	O
sufficient	O
oxygen	O
to	O
support	O
mitochondrial	O
function.	O

Compared	O
to	O
CA 19-9	O
alone,	O
the	O
combined	O
amino	B
acid-based	O
metabolite	O
panel	O
had	O
a	O
superior	O
selectivity	O
for	O
the	O
discrimination	O
of	O
healthy	O
controls,	O
pancreatitis,	O
and	O
pancreatic	O
carcinoma	O
patients	O
We	O
combined	O
highly	O
standardized	O
samples,	O
a	O
three-class	O
study	O
design,	O
a	O
high-throughput	O
mass-spectrometric	O
technique,	O
and	O
a	O
comprehensive	O
bioinformatic	O
framework	O
to	O
identify	O
metabolite	O
panels	O
selective	O
for	O
all	O
three	O
groups	O
in	O
a	O
single	O
approach.	O

c.	O
Plasmalogen	O
ethanolamine	B
16:0/22:6	I
levels	O
in	O
Multiple	O
Sclerosis.	O

A	O
total	O
of	O
181	O
metabolites	O
(full	O
scan)	O
were	O
consistently	O
detected	O
in	O
the	O
urine	O
samples	O
of	O
both	O
RCC	O
patients	O
and	O
healthy	O
controls,	O
and	O
it	O
was	O
possible	O
to	O
identify	O
among	O
them	O
several	O
chemical	O
classes,	O
such	O
as	O
alcohols,	O
aldehydes,	O
ketones,	B
terpenes,	B
compounds	O
containing	O
sulphur	O
and	O
furan	B
moieties,	O
steroids	O
and	O
naphthalene	B
derivatives.	O

As	O
regards	O
the	O
F_2	B
-isoprostane	I
levels,	O
there	O
were	O
no	O
statistical	O
differences	O
among	O
the	O
groups	O
evaluated	O
(Figure	O
B).	O

Comparing	O
metabolites	O
that	O
were	O
altered	O
in	O
SPMS	O
patients	O
compared	O
with	O
RRMS	O
and	O
controls,	O
19	O
metabolites	O
were	O
in	O
common:	O
1-methyladenosine,	B
3-methoxytyramine,	B
4-acetamidobutanoate,	B
5-hydroxyindoleacetate	B
(5-HIAA),	O
5-hydroxytryptophan	B
(5-HTP),	O
caffeine,	B
deoxyuridine,	B
guanosine,	B
ketoleucine,	B
kynurenate	B
(KYNA),	O
N	B
-acetylleucine,	I
N	B
-acetylphenylalanine,	I
N	B
-acetylserotonin,	I
N	O
6-(delta2-isopentenyl)-adenine,	O
O	B
-succinyl-homoserine,	I
phenylacetate,	B
pipecolate,	B
trigonelline	B
and	O
uridine.	B

This	O
is	O
in	O
contrast	O
to	O
prior	O
studies	O
investigating	O
plasma	O
responses	O
of	O
rats	O
exposed	O
to	O
acute	O
hypoxia	O
(9.5%	O
O_2	O
,	O
5–18 hrs)	O
and	O
in	O
HeLa	O
cells	O
(1%	O
O_2	O
),	O
which	O
reported	O
an	O
increase	O
in	O
isoleucine	B
levels.	O

(A)	O
Unsaturated	O
fatty	O
acids	O
(contain	O
one	O
or	O
more	O
C=C	O
double	O
bonds)	O
are	O
prone	O
to	O
lipid	O
peroxidation,	O
resulting	O
in	O
the	O
formation	O
of	O
lipid	O
aldehydes,	O
acrolein	B
(AL),	O
malondialdehyde	B
(MDA)	O
and	O
4-hydroxynonenal	B
(HNE).	O

We	O
set	O
the	O
ion	O
as	O
follows:	O
l-alanine	B
44m/z,	O
l-glycine	B
102m/z,	O
l-valine	B
144m/z,	O
l-serine	B
132m/z,	O
l-isoleucine	B
158	O
m/z,	O
l-threonine	B
101m/z,	O
l-proline	B
142m/z,	O
l-methionine	B
61m/z,	O
l-tyrosine	B
107m/z,	O
l-tryptophan	B
130m/z,	O
ethyl	B
2-methylacetoacetate	I
74m/z,	O
levulinic	B
acid	I
99m/z,	O
cresols	O
107m/z,	O
benzylmalonic	B
acid	I
131m/z,	O
4-hydroxybenzoic	B
acid	I
121m/z,	O
benzil	B
105	O
m/z,	O
hippuric	B
acid	I
134m/zandl-2-chlorophenylalanine	O
102m/z.	O

CysSSH	O
is	O
the	O
result	O
of	O
the	O
combination	O
of	O
Cys,	O
an	O
amino	O
acid,	O
with	O
extensive	O
quantities	O
of	O
sulfide.	B

Phenylacetylamine	B
levels	O
have	O
been	O
shown	O
to	O
positively	O
correlate	O
with	O
vegetable	O
intake,	O
while	O
acetate	B
is	O
a	O
metabolite	O
synthesized	O
during	O
gut	O
microbial	O
degradation	O
of	O
food.	O

This	O
mechanism	O
would	O
allow	O
kynurenine	B
to	O
exert	O
a	O
negative	O
feedback	O
loop	O
on	O
an	O
initial	O
acute	O
inflammatory	O
event	O
and	O
maintain	O
an	O
ongoing	O
balance	O
between	O
inflammation	O
and	O
immunosuppression	O
activity.	O

PC	B
ae	I
C42:4;	I
52.	O

d	O
Detail	O
showing	O
region	O
(3.15–3.25)	O
containing	O
the	O
identified	O
phosphocholine	B
and	O
glycerophosphocholine	B
signals	O
Twenty-six	O
endogenous	O
metabolites	O
were	O
identified	O
by	O
comparing	O
chemical	O
shifts	O
to	O
reference	O
libraries	O
[,	O
].	O

These	O
quinone	B
methides	O
react	O
with	O
cellular	O
DNA	O
to	O
form	O
depurinating	O
adducts.	O

Briefly,	O
ice-cold	O
methanol	B
and	O
chloroform	B
in	O
the	O
amounts	O
previously	O
outlined	O
were	O
added	O
directly	O
to	O
the	O
sample.	O

Among	O
those,	O
only	O
two	O
overlapped	O
with	O
the	O
ones	O
exhibiting	O
significant	O
changes	O
at	O
subclass	O
level	O
analysis,	O
i.e.	O
PC	B
16:0_18:1	I
and	O
PE	B
18:0_18:1.	I

The	O
–CH_2	O
–/–CH_3	O
ratio,	O
an	O
indicator	O
of	O
the	O
mean	O
length	O
of	O
the	O
aliphatic	B
lipid	O
chains,	O
was	O
significantly	O
higher	O
(P	O
 < 0.001)	O
in	O
the	O
LVH	O
group	O
than	O
in	O
the	O
hypertensive	O
group	O
without	O
LVH	O
and	O
controls.	O

These	O
include	O
L-phenyl-d5-alanine-2,3,3,-d3	B
(D-1241),	O
L-glutamic-2,3,3,4,4-d5	O
acid	O
(D-899),	O
Tyrosine-d2	B
(D-1611),	O
and	O
L-alanine-2,3,3,3-d4	B
(D-1488).	O

Although	O
plasma	O
homolanthionine	B
concentrations	O
were	O
notably	O
higher	O
than	O
lanthionine	B
concentrations	O
in	O
all	O
subjects,	O
homolanthionine	B
concentrations	O
were	O
not	O
different	O
between	O
the	O
groups	O
(P	O
=	O
0.101).	O

In	O
cluster	O
analysis,	O
we	O
found	O
that	O
glutamine	B
was	O
upregulated	O
after	O
plasma	O
treatment.	O

The	O
urine	O
models	O
for	O
these	O
groups	O
also	O
showed	O
a	O
p	O
value	O
that	O
was	O
higher	O
than	O
0.05,	O
while	O
the	O
predictive	O
potential	O
between	O
particular	O
comparisons	O
was	O
in	O
the	O
following	O
order:	O
FA	B
vs	I
HC	O
(AUC	O
test	O
set = 1) > TC	O
vs	O
HC	O
(AUC	O
test	O
set = 0.73)	O

To	O
remove	O
protein,	O
dissociate	O
small	O
molecules	O
bound	O
to	O
protein	O
or	O
trapped	O
in	O
the	O
precipitated	O
protein	O
matrix,	O
and	O
to	O
recover	O
chemically	O
diverse	O
metabolites,	O
proteins	O
were	O
precipitated	O
with	O
methanol	B
under	O
vigorous	O
shaking	O
for	O
2	O
min	O
(Glen	O
Mills	O
GenoGrinder	O
2000)	O
followed	O
by	O
centrifugation.	O

In	O
some	O
donors,	O
piceatannol	O
was	O
dehydroxylated	O
at	O
one	O
of	O
the	O
meta	O
positions	O
on	O
ring	O
A,	O
forming	O
trihydroxystilbene	B
different	O
than	O
resveratrol	B
or	O
isoresveratrol	O
(see	O
Appendix	O
A,	O
),	O
and	O
was	O
further	O
metabolized	O
to	O
3,3′,4′-trihydroxybibenzyl.	O

In	O
brief,	O
serum	O
samples	O
(10 µl)	O
diluted	O
with	O
0.15	O
M	O
NaCl	O
(10 µl)	O
and	O
spiked	O
with	O
a	O
standard	O
mixture	O
containing	O
10	O
lipid	O
species	O
were	O
extracted	O
with	O
a	O
mixture	O
of	O
chloroform	B
and	O
methanol	O
2∶1	O
(100 µl).	O

The	O
above	O
results	O
suggest	O
that	O
although	O
the	O
free	O
FAs	O
and	O
the	O
corresponding	O
fatty	O
acyls	O
in	O
phospholipids	B
may	O
contain	O
the	O
same	O
pair	O
of	O
C=C	O
location	O
isomers,	O
their	O
ratios	O
can	O
be	O
quite	O
different	O
or	O
even	O
unrelated.	O

Plasma	O
levels	O
of	O
free,	O
bioavailable	O
and	O
total	O
Testosterone	B
were	O
previously	O
reported	O
to	O
be	O
low	O
in	O
HIV	O
patients	O
,	O
and	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
serum	O
Testosterone	B
and	O
CD4+	O
cell	O
counts	O
.	O

Surprisingly,	O
both	O
Diol	B
and	O
2-PIC	O
columns,	O
with	O
narrow	O
peaks	O
and	O
higher	O
sum	O
of	O
resolution,	O
showed	O
the	O
highest	O
variation	O
in	O
median	O
caffeine	B
peak	O
area	O
(16.9	O
and	O
13.9%	O
respectively).	O

All	O
the	O
spectra	O
were	O
referenced	O
to	O
the	O
methyl	B
group	I
of	O
lactate	B
at	O
δ1.336.	O

Ethanol	B
was	O
detected	O
predominantly	O
in	O
the	O
lyophilized	O
samples	O
(A)	O
and	O
made	O
a	O
considerable	O
contribution	O
to	O
the	O
PLS-DA	O
cluster	O
separation	O
between	O
the	O
drying	O
techniques	O
as	O
it	O
had	O
the	O
four	O
highest	O
VIP	O
scored	O
buckets.	O

Bruce	O
et	O
al.	O
reported	O
methanol-ethanol	B
(1:1)	I
was	O
found	O
to	O
be	O
an	O
optimal	O
solvent	O
in	O
precipitation	O
method	O
for	O
global	O
metabolic	O
profiling	O
analysis.	O

Baseline	O
log	O
10	B
8-iso	I
-PGF_2α	I
and	O
race	O
were	O
also	O
significant	O
in	O
this	O
multivariable	O
model	O
(p	O
<	O
0.05),	O
but	O
sex	O
was	O
not	O
(p	O
>	O
0.05).	O

Ceramide	B
was	O
significantly	O
associated	O
with	O
central	O
obesity.	O

In	O
females,	O
DI	O
correlated	O
with	O
leucine/isoleucine	O
(r	O
=	O
0.30,	O
P	O
=	O
0.01),	O
valine	B
(r	O
=	O
0.27,	O
P	O
=	O
0.02),	O
phenylalanine	B
(r	O
=	O
0.29,	O
P	O
=	O
0.01),	O
alanine	B
(r	O
=	O
0.29,	O
P	O
=	O
0.01),	O
serine	B
(r	O
=	O
0.28,	O
P	O
=	O
0.02),	O
glycine	B
(r	O
=	O
0.28,	O
P	O
=	O
0.02),	O
and	O
C3	O
acylcarnitine	B
(r	O
=	O
0.27,	O
P	O
=	O
0.02).	O

These	O
enzymes	O
cleave	O
glycerophosphocholine	B
(GPC)	O
to	O
form	O
glycerol-3-phosphate	B
and	O
choline,	B
and	O
their	O
overexpression	O
has	O
been	O
described	O
in	O
cancer,	O
driving	O
tumor	O
cell	O
migration	O
and	O
metastasis.	O

In	O
contrast,	O
Sitter	O
et	O
al	O
.	O
reported	O
a	O
relative	O
decrease	O
in	O
this	O
ratio	O
from	O
grade	O
II	O
to	O
III	O
indicating	O
an	O
increase	O
in	O
choline.	B

Among	O
the	O
ceramides,	B
those	O
with	O
the	O
noncanonical	O
d16:1	B
backbone	O
had	O
more	O
strongly	O
positive	O
correlations	O
relative	O
to	O
the	O
canonical	O
d18:1	B
ceramides,	I
while	O
the	O
d18:2	B
ceramides	I
correlated	O
less	O
positively	O
or,	O
in	O
some	O
cases,	O
correlated	O
negatively	O
(;	O
;	O
;	O
and	O
).	O

The	O
centrifugation	O
procedure	O
was	O
repeated	O
followed	O
by	O
an	O
additional	O
70 %	O
perchloric	B
acid	I
(10 %	O
by	O
volume).	O

With	O
mass	O
spectrometry	O
the	O
concentrations	O
of	O
2-hydroxyglutarate	B
had	O
been	O
already	O
measured	O
and	O
compared	O
between	O
R132H	O
IDH1	O
mutation	O
tumor	O
cases	O
and	O
wild-type	O
IDH1	O
tumor	O
cases;	O
the	O
concentrations	O
of	O
2-hydroxyglutarate	B
in	O
mutation-positive	O
tumors	O
were	O
measured	O
as	O
5–35	O
μmol/g,	O
whereas	O
tumors	O
with	O
wild-type	O
IDH1	O
had	O
over	O
100-fold	O
less	O
2-hydroxyglutarate.	B

In	O
particular,	O
one	O
of	O
the	O
primary	O
products	O
resulting	O
from	O
the	O
reaction	O
of	O
MG	O
with	O
arginine	B
is	O
MG-HI,	O
a	O
hydroimidazolone	B
five-membered	O
ring.	O

Elevations	O
in	O
heme	B
metabolites	O
can	O
reflect	O
the	O
increase	O
in	O
heme	B
metabolism	O
due	O
the	O
hemolysis	O
of	O
malaria	O
infection	O
and/or	O
liver	O
injury.	O

In	O
another	O
study,	O
it	O
was	O
revealed	O
that	O
while	O
intracellular	O
concentrations	O
of	O
LTB4	B
can	O
be	O
higher	O
in	O
B-CLL	O
cells	O
relative	O
to	O
their	O
normal	O
counterpart,	O
plasma	O
concentrations	O
of	O
LTB4	B
may	O
not	O
be	O
statistically	O
different	O
between	O
patients	O
and	O
controls,	O
the	O
reason	O
being	O
that	O
LTB4	B
can	O
be	O
metabolised	O
into	O
20-OH-LTB4	B
that	O
is	O
a	O
non-circulating	O
metabolite.	O

The	O
major	O
phospholipid	B
component	O
of	O
cell	O
membranes	O
is	O
PtdCho,	O
of	O
which	O
PCho	O
is	O
the	O
breakdown	O
product	O
and	O
a	O
precursor.	O

The	O
mass	O
difference	O
between	O
the	O
precursor	O
and	O
the	O
product	O
could	O
be	O
explained	O
by	O
the	O
loss	O
of	O
the	O
ethyl	O
group	O
added	O
during	O
the	O
reaction	O
with	O
ethylhydroxylamine.	B

In	O
(B),	O
TEX	O
co-incubated	O
with	O
CD4_+	O
T	O
cells	O
also	O
induced	O
the	O
upregulation	O
of	O
inosine	B
production,	O
although	O
there	O
were	O
large	O
differences	O
among	O
cells	O
of	O
different	O
donors.	O

Importantly,	O
following	O
nephrectomy,	O
RCC	O
patients	O
exhibited	O
metabolic	O
recovery	O
as	O
indicated	O
by	O
decreases	O
in	O
creatine,	B
lactate,	B
isoleucine,	B
leucine,	B
alanine,	B
and	O
valine	B
levels	O
as	O
well	O
as	O
an	O
increase	O
in	O
choline	B
levels	O
(Figure	O
).	O

The	O
decrease	O
in	O
urea	B
and	O
ornithine	B
in	O
CD	O
patients	O
as	O
compared	O
to	O
the	O
control	O
cohort	O
may	O
indicate	O
disturbances	O
in	O
the	O
urea	B
cycle.	O

Levels	O
of	O
monohexocylceramide,	B
which	O
is	O
the	O
core	O
molecule	O
of	O
many	O
glycosphingolipids	B
involved	O
in	O
the	O
salvage	O
pathway,	O
were	O
measured	O
in	O
the	O
breast	O
cancer	O
patient	O
cohort.	O

Then,	O
15	O
µL	O
of	O
P	O
and	O
IP	B
DMSO	I
solution	O
were	O
added,	O
for	O
which	O
the	O
added	O
volumes	O
of	O
DMSO	B
were	O
no	O
more	O
than	O
0.5%	O
of	O
the	O
total	O
incubation	O
system.	O

The	O
predictive	O
performance	O
of	O
the	O
combined	O
score	O
improved	O
after	O
taking	O
tryptophan	B
into	O
account.	O

We	O
observed	O
that	O
heavy	O
cannabis	B
use	O
was	O
associated	O
with	O
significantly	O
lower	O
frequencies	O
of	O
TNF-α_+	O
B	O
cells	O
as	O
compared	O
with	O
no	O
cannabis	B
use.	O

In	O
particular,	O
the	O
KP	B
performs	O
regulatory	O
mechanisms	O
of	O
the	O
immune	O
response,	O
and	O
its	O
metabolites	O
can	O
exhibit	O
both	O
neuroprotective	O
and	O
neurotoxic	O
properties._,	O

This	O
indicates	O
that	O
DHEA	O
or	O
DHEA-S	B
shows	O
potential	O
for	O
use	O
in	O
alternative	O
therapies,	O
as	O
a	O
supplement	O
to	O
currently	O
used	O
long-term	O
antibiotic	O
treatment	O
regimens,	O
or	O
as	O
a	O
preventive	O
strategy	O
against	O
disease	O
recurrence.	O

Estrone	B
(E1),	O
17β-estradiol	B
(17βE2),	I
17α-estradiol	B
(17αE2),	I
16-hydroxyestrone	B
(16OHE1),	O
16-hydroxyestradiol	B
(16OHE2),	O
2-methoxyestrone	B
(2MeOE1),	O
4-methoxyestrone	B
(4MeOE1),	O
2-methoxyestradiol	B
(2MeOE2)	O
and	O
4-methoxyestradiol	B
(4MeOE2)	O
were	O
from	O
Steraloids,	O
Inc	O
(Newport,	O
USA).	O

Samples	O
were	O
analyzed	O
by	O
a	O
19 min	O
revered-phase	O
chromatography	O
with	O
gradient	O
elution	O
at	O
0.5 min/min	O
flow	O
rate	O
from	O
99 %	O
mobile	O
phase	O
H2O	O
(0.1 %	O
formic	O
acid)	O
to	O
99 %	O
mobile	O
acetonitrile	B
(0.1 %	O
formic	O
acid).	O

In	O
this	O
study,	O
significantly	O
increased	O
methionine	B
sulfoxide	I
was	O
found	O
in	O
uremic	O
patients	O
compared	O
to	O
the	O
controls.	O

Similarly,	O
fusaruside	O
(46),	O
and	O
a	O
known	O
metabolite	O
(2S,2ʹR,3R,3ʹE,4E,8E)-1-O-beta-D-glucopyranosyl-2-N-(2ʹ-hydroxy-3ʹ-octadecenoyl)-3-hydroxy-9-methyl-4,8-sphingadienine	B
(47)	O
both	O
showing	O
strong	O
antibacterial	O
(MIC	O
1.9–7.8μg/mL)	O
activity	O
were	O
isolated	O
from	O
a	O
chloroform-methanol	B
extract	O
of	O
Fusarium	O
sp.	B

Four	O
patients	O
(2	O
newly	O
diagnosed	O
and	O
2	O
patients	O
on	O
relapse)	O
were	O
on	O
concomitant	O
treatment	O
with	O
azathioprine	B
and	O
three	O
on	O
5-aminoasalicylates.	B

Older	O
studies	O
indicated	O
that	O
DMSO_2	O
inhibited	O
oxidant	O
production	O
in	O
activated	B
neutrophils	O
and	O
diminished	O
the	O
proliferation	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
endothelial	O
cells	O
,	O
.	O

The	O
assay	O
values	O
for	O
inter-day	O
accuracy	O
and	O
precision	O
for	O
plasma	O
with	O
high	O
triglycerides	B
ranged	O
from	O
98	O
to	O
99%	O
and	O
6	O
to	O
10%	O
for	O
SMV,	O
95	O
to	O
100%	O
and	O
7	O
to	O
10%	O
for	O
SMV-A,	O
98	O
to	O
99%	O
and	O
8	O
to	O
11%	O
for	O
ATV,	O
96	O
to	O
103%	O
and	O
8	O
to	O
12%	O
for	O
2-OH-ATV,	B
93	O
to	O
98%	O
and	O
6	O
to	O
10%	O
for	O
4-OH-ATV,	B
94	O
to	O
99%	O
and	O
7	O
to	O
11%	O
for	O
RSV.	O

There	O
were	O
positive	O
correlations	O
of	O
pyrraline	B
with	O
CML	B
(r	O
=	O
0.50)	O
and	O
MG-H1	O
(r	O
=	O
0.55),	O
suggesting	O
again	O
these	O
AGE	O
free	O
adducts	O
had	O
significant	O
contributions	O
from	O
food—.	O

There	O
were	O
1,278	O
(over	O
70%)	O
common	O
features,	O
with	O
391	O
features	O
unique	O
to	O
the	O
methanol	B
method	O
and	O
553	O
features	O
unique	O
to	O
methanol-ethanol	B
method.	O

In	O
the	O
case	O
of	O
the	O
male	O
T2DM	O
patients,	O
metabolites	O
such	O
as	O
the	O
branched	O
chain	O
amino	O
acids,	O
alanine,	B
glutamine/glutamate	O
and	O
threonine	B
(4.28	O
p.p.m.)	O
appeared	O
to	O
increase	O
with	O
RSG	O
treatment.	O

Valine,	B
leucine	B
and	O
aspartic	B
acid	I
were	O
identified	O
as	O
potential	O
BMI-sensitive	O
amino	O
acids.	O

Yij=βoj+Xi1β1j+Xi2β2j+…+Xipβpj+εij	B

215	O
[Google	O
Scholar]	O
Purkerson	O
ML,	O
Joist	O
JH,	O
Yates	O
J,	O
Valdes	O
A,	O
Morrison	O
A,	O
Klahr	O
S.	O
Inhibition	O
of	O
thromboxane	B
synthesis	O
ameliorates	O
the	O
progressive	O
kidney	O
disease	O
of	O
rats	O
with	O
subtotal	O
renal	O
ablation.	O

Intraorally,	O
anthocyanins	B
are	O
deglycosylated	O
via	O
enzymes	O
(β-glucosidase	O
and	O
lactase	O
phylorizin	O
hydrolase)	O
which	O
are	O
contained	O
in	O
oral	O
microflora,	O
saliva	O
and	O
surface	O
oral	O
epithelium.	O

The	O
same	O
was	O
true	O
for	O
the	O
assignment	O
of	O
5′ATP,	O
glycerol-3-phosphate,	B
and	O
fructose-6-phosphate	B
(F6P).	O

Reduced	O
levels	O
of	O
triglycerides	B
and	O
VLDL	O
could	O
be	O
detected	O
easily	O
in	O
the	O
NMR	O
spectra	O
of	O
the	O
low-disease-prevalence	O
group	O
and	O
may	O
explain	O
the	O
reduced	O
inflammation	O
status	O
observed	O
for	O
those	O
individuals.	O

This	O
suggests	O
that	O
the	O
association	O
between	O
factor	O
1,	O
total-C	O
and	O
TG	B
is	O
independent	O
of	O
the	O
metabolic	O
state	O
of	O
study	O
participants.	O

Greater	O
lipid	O
perturbations	O
have	O
been	O
associated	O
with	O
efavirenz	O
compared	O
with	O
other	O
modern	O
day	O
ARVs,	O
in	O
particular	O
higher	O
total	O
and	O
non-HDL	O
cholesterol	B
[–].	O

In	O
contrast	O
to	O
PCs	O
and	O
LPCs,	O
which	O
indicated	O
decreased	O
levels	O
during	O
radiotherapy	O
and	O
were	O
compensated	O
during	O
the	O
follow-up,	O
both	O
identified	O
sphingomyelines	B
showed	O
significant	O
radiation-related	O
up-regulation	O
only:	O
SM(38:3)	B
during	O
earlier	O
stage	O
of	O
the	O
treatment	O
while	O
SM(34:1)	B
during	O
later	O
stage	O
of	O
the	O
treatment	O
or	O
subsequent	O
follow-up.	O

In	O
addition	O
to	O
glucose,	B
also	O
other	O
types	O
of	O
sugars,	O
including	O
galactose,	B
were	O
significantly	O
higher	O
in	O
ADV	O
HCC.	O

We	O
identified	O
different	O
potential	O
biomarkers	O
for	O
disease	O
progression,	O
including	O
elevated	O
phosphocholine	B
and	O
reduced	O
leucine,	B
valine,	B
and	O
isoleucine	B
by	O
comparing	O
Barrett's	O
tissues	O
in	O
BO	O
and	O
EAC	O
patients.	O

In	O
brief,	O
the	O
aqueous	O
and	O
vitreous	O
humors,	O
as	O
well	O
as	O
the	O
plasma,	O
were	O
treated	O
with	O
the	O
addition	O
of	O
a	O
5	O
vol	O
excess	O
of	O
a	O
methanol	B
solution	O
containing	O
5 mM	O
monobromobimane	B
(Sigma-Aldrich,	O
St.	O
Luis,	O
MO)	O
and	O
were	O
incubated	O
at	O
37 °C	O
for	O
15 min.	O

Analysis	O
of	O
metabolic	O
profile	O
of	O
raw	O
CSF	O
and	O
their	O
lipid	O
extract	O
shows	O
decreased	O
levels	O
of	O
many	O
compounds	O
and	O
led	O
to	O
the	O
conclusion	O
that	O
MS	O
patients	O
could	O
have	O
a	O
disturbance	O
in	O
many	O
metabolic	O
pathways	O
perhaps	O
leading	O
to	O
the	O
decreased	O
level	O
of	O
acetyl-CoA	B
and/or	O
inflammation.	O

Our	O
results	O
also	O
showed	O
an	O
increasing	O
trend	O
in	O
glycine	B
levels	O
which	O
has	O
previously	O
been	O
described	O
as	O
a	O
short-term	O
effect	O
of	O
bariatric	O
surgery	O
and	O
inversely	O
related	O
to	O
type	O
2	O
diabetes	O
[,].	O

Furthermore,	O
in	O
a	O
manner	O
akin	O
to	O
human	O
type	O
2	O
diabetes	O
mellitus	O
(T2DM),	O
diabetic	O
cynomolgus	O
monkeys	O
exhibited	O
significantly	O
higher	O
plasma	O
concentrations	O
of	O
TAG	O
and	O
marginally	O
significant	O
lower	O
levels	O
of	O
HDL	B
cholesterol.	I

Since	O
TB	O
and	O
cancer	O
are	O
immunosuppressive	O
conditions,	O
strengthening	O
the	O
function	O
of	O
activated	B
T	O
cells	O
could	O
be	O
helpful	O
for	O
TB	O
and	O
cancer	O
therapy.	O

Standards	O
were	O
injected	O
in	O
10	O
μL	O
acetonitrile	B
and	O
separated	O
using	O
gradient	O
elution	O
on	O
a	O
5-cm	O
UPLC	O
BEH	O
C18	O
column	O
CID	O
spectra	O
of	O
1α,25(OH)_2	B
D_3	O
.	O

Finally,	O
serine	B
concentrations	O
were	O
reduced	O
in	O
response	O
to	O
the	O
acute	O
infusion	O
of	O
insulin,	O
while	O
it	O
was	O
increased	O
in	O
response	O
to	O
three	O
months	O
of	O
insulin	O
sensitizer	O
therapy.	O

In	O
the	O
product	O
label	O
of	O
the	O
drug,	O
hydroxyanastrozole	B
glucuronide	I
has	O
been	O
stated	O
to	O
be	O
one	O
of	O
anastrozole	B
metabolites	O
in	O
human.	O

A	O
second	O
mechanism	O
of	O
protein	O
modification	O
involves	O
the	O
covalent	O
addition	O
of	O
Hcy	O
to	O
the	O
ε-amino	B
groups	O
of	O
lysine	B
residues	O
by	O
HCTL,	O
which	O
can	O
cause	O
protein	O
misfolding,	O
aggregation,	O
loss	O
of	O
function	O
and	O
generation	O
of	O
autoimmune	O
responses	O
,	O
.	O

Pyrrole	B
had	O
the	O
largest	O
AUC	O
value	O
which	O
was	O
0.907,	O
with	O
a	O
sensitivity	O
of	O
0.933	O
and	O
a	O
specificity	O
of	O
0.867	O
at	O
the	O
best	O
cut-off	O
point.	O

These	O
increases	O
in	O
amino	O
acids	O
were	O
all	O
correlated	O
with	O
reduction	O
in	O
free	O
cholesterol,	B
and	O
were	O
all	O
highly	O
correlated	O
with	O
each	O
other.	O

Given	O
that	O
a	O
number	O
of	O
nuclear	O
receptors	O
form	O
heterodimers	O
with	O
RXR	O
and	O
that	O
ligand	O
binding	O
(either	O
agonist	O
or	O
antagonist)	O
to	O
the	O
RXR	O
leads	O
to	O
modulation	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
heterodiomers,	O
these	O
eccentric	O
cleavage	O
products	O
of	O
β-carotene	B
could	O
have	O
complex	O
global	O
effects	O
on	O
gene	O
expression.	O

Given	O
these	O
trends	O
and	O
the	O
results	O
of	O
individual	O
effects	O
analysis,	O
we	O
did	O
not	O
include	O
many	O
dietary	O
sources	O
of	O
vitamin	B
D	I
in	O
our	O
models.	O

We	O
have	O
also	O
discovered	O
a	O
positive	O
correlation	O
between	O
increased	O
dipeptide	O
abundance/increased	O
basal	O
autophagy	O
in	O
CAFs	O
and	O
the	O
tumor	O
SUV_max	O
,	O
revealing	O
a	O
possible	O
link	O
between	O
the	O
glycolytic	B
activity	O
of	O
the	O
tumor	O
and	O
autophagy.	O

A	O
relatively	O
low	O
value	O
for	O
serum	O
E2-3G	O
of	O
5.5	O
pg/mL	O
was	O
found	O
using	O
an	O
excellent	O
stable	O
isotope	O
dilution	O
assay	O
of	O
the	O
intact	O
β-glucuronide.	B

Briefly,	O
metabolites	O
were	O
derivatized	O
with	O
15	O
µL	O
of	O
2%	O
methoxyamine	B
hydrochloride	I
in	O
pyridine	B
for	O
90	O
min	O
and	O
15	O
µL	O
N-methyl-N-trimethylsilyl-trifluoroacetamide	B
(MSTFA)	O
for	O
additional	O
30	O
min	O
at	O
40	O
°C	O
under	O
continuous	O
shaking	O
using	O
a	O
Gerstel	O
MPS.	O

The	O
samples	O
were	O
then	O
eluted	O
sequentially	O
with	O
methyl	B
formate	I
and	O
methanol.	B

The	O
presence	O
of	O
some	O
amino	O
acids,	O
namely,	O
alanine	B
(Ala),	O
arginine	B
(Arg),	O
glutamine	B
(Gln),	O
Gly,	O
serine	B
(Ser),	O
tyrosine	B
(Tyr),	O
Val,	O
leucine	B
(Leu),	O
isoleucine	B
(Ile)	O
and	O
threonine	B
(Thr)	O
in	O
human	O
sperm	O
has	O
already	O
been	O
shown	O
by	O
NMR	O
spectroscopic	O
and	O
GC-MS-based	O
approaches.	O

A	O
high	O
prevalence	O
of	O
urinary	O
DMAP	O
and	O
thiamethoxam	B
detection	O
in	O
the	O
patients	O
with	O
neo-nicotinic	O
symptoms	O
at	O
ppb	O
level	O
suggests	O
two	O
major	O
possibilities.	O

Indeed,	O
we	O
observed	O
significantly	O
elevated	O
levels	O
of	O
3-hydroxybutyrate	B
and	O
acetoacetate	B
in	O
T3	O
vs	O
T2	O
comparison.	O

In	O
our	O
cohort	O
with	O
recurrent	O
malignant	O
gliomas,	O
we	O
found	O
significantly	O
elevated	O
indole,	B
indoleacrylic	B
acid,	I
and	O
anthranilic	B
acid,	I
which	O
are	O
metabolites	O
involved	O
in	O
the	O
tryptophan	B
metabolism,	O
as	O
compared	O
with	O
newly	O
diagnosed	O
patients.	O

To	O
develop	O
and	O
validate	O
a	O
better	O
extraction	O
method	O
for	O
the	O
measurement	O
of	O
16	O
estrogens	O
and	O
estrogen	B
metabolites	O
(EMs)	O
in	O
human	O
urine	O
using	O
a	O
previously	O
validated	O
LC-MS/MS	O
method	O
(Anal.	O

Arachidonic	B
Acid	I
(AA)	O
metabolism	O
via	O
cyclooxygenase	O
(COX)	O
and	O
lipoxygenase	O
(LOX)	O
pathway	O
is	O
downregulated	O
causing	O
reduction	O
of	O
pro-inflammatory	O
metabolites.	O

The	O
daily	O
rhythms	O
in	O
acylcarnitines	B
support	O
previous	O
studies	O
(,	O
)	O
(SI	O
Appendix	O
,	O
Results	O
and	O
Discussion	O
)	O
and	O
gene	O
expression	O
data,	O
with	O
key	O
transporters	O
of	O
long-chain	O
acylcarnitines	B
exhibiting	O
clear	O
oscillation	O
with	O
time	O
of	O
day	O
in	O
mice.	O

Hippuric	B
acid	I
and	O
3-hydroxyhippuric	B
acid	I
are	O
end-products	O
of	O
the	O
microbial	O
catabolism	O
of	O
numerous	O
polyphenols	O
and	O
aromatic	O
amino	O
acids.	O

Among	O
the	O
intermediates	O
in	O
the	O
TCA	O
cycle	O
(aerobic	O
respiration),	O
citrate	B
was	O
decreased	O
in	O
PTSD	O
subjects	O
in	O
the	O
Discovery	O
group	O
(p	O
=	O
0.017,	O
q	O
=	O
0.27),	O
although	O
this	O
finding	O
was	O
not	O
replicated	O
in	O
the	O
Test	O
group	O
(p	O
=	O
0.669,	O
q	O
=	O
0.62).	O

For	O
glucose	B
isotope	O
tracing	O
experiment,	O
HCT116,	O
MCF7	O
and	O
HeLa	O
cells	O
were	O
cultured	O
in	O
6-well	O
plates	O
with	O
custom	O
made	O
RPMI	O
1640	O
media	O
with	O
the	O
stabled	O
isotope	O
1-_13	O
C_1	B
-glucose	I
or	O
2-_13	O
C_1	B
-glucose	I
for	O
48	O
h.	O

(B)	O
Selectivity	O
for	O
matrix	O
interferences:	O
overlaid	O
UHPLC-MS/MS	O
profiles	O
(dotted	O
lines)	O
of	O
methanolic	B
extracts	O
from	O
ten	O
blank	O
human	O
plasma.	O

Lactate	B
is	O
one	O
of	O
the	O
most	O
known	O
biomarkers	O
in	O
tissue	O
hypoxia	O
and	O
necrosis,	O
and	O
represents	O
an	O
important	O
substrate	O
for	O
tumor	O
energy	O
metabolism	O
and	O
growth.	O

It	O
was	O
previously	O
established	O
that	O
plasma	O
ornithine	B
concentrations	O
are	O
higher	O
in	O
diabetic	O
subjects	O
,	O
and	O
this	O
is	O
a	O
marker	O
of	O
arginase	O
activity.	O

All	O
patients	O
were	O
treated	O
supportively,	O
and	O
administered	O
e.g.	O
maltose-Ringer	B
solution	O
transfusion,	O
medication	O
such	O
as	O
acetaminophen	B
for	O
pain	O
and	O
fever,	O
and	O
lactobacillus	B
for	O
abdominal	O
pain.	O

Animal	O
models	O
provided	O
evidence	O
that	O
environmental	O
toxins,	B
such	O
as	O
fungicides,	O
plasticizers,	O
dioxin,	B
hydrocarbons	B
and	O
alcohol,	O
can	O
all	O
affect	O
the	O
epigenome	O
through	O
the	O
germ	O
line.	O

_13	O
C,d_3	B
-diosmetin	I

This	O
is	O
analogous	O
to	O
common	O
genetic	O
variants	O
that	O
have	O
modest	O
effects	O
on	O
serum	O
creatinine	B
and	O
cystatin	B
C	O
levels	O
but	O
are	O
not	O
included	O
in	O
GFR	O
estimating	O
equations	O
[,	O
].	O

These	O
interrelationships	O
may	O
have	O
relevance	O
to	O
the	O
biological	O
actions	O
of	O
retinol,	B
including	O
its	O
role	O
in	O
carcinogenesis.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
observed	O
increase	O
in	O
median	O
RSD	O
from	O
35.4	O
to	O
50.9%	O
when	O
one-step	O
MTBE	B
and	O
two-step	O
MTBE	B
extractions	O
were	O
compared.	O

A	O
mobile	O
phase	O
containing	O
50 mM	O
sodium	B
acetate	I
(pH	O
6.2)	O
and	O
7 %	O
acetonitrile	B
was	O
pumped	O
through	O
the	O
reverse-phase	O
column	O
at	O
a	O
flow	O
rate	O
of	O
0.5 mL/min.	O

Applying	O
Faraday's	O
law,	O
430	O
pg	B
of	O
DA	O
was	O
calculated	O
as	O
being	O
oxidized.	O

A	O
total	O
of	O
131	O
oxylipins	B
were	O
validated.	O

However,	O
evaluating	O
the	O
total	O
list	O
of	O
metabolite	O
ion	O
masses	O
we	O
detected	O
significant	O
differences	O
exemplarily	O
shown	O
in	O
for	O
the	O
metabolite	O
ions	O
with	O
the	O
elementary	O
composition	O
of	O
C_37	O
H_66	O
O_5	O
(m/z = 613.48004	O
for	O
[C_37	O
H_66	O
O_5	O
Na]_+	O
;	O
possible	O
assignment:	O
Diacylglycerol),	B
and	O
C_41	O
H_83	O
N_2	O
O_6	O
P	O
(m/z = 731.60628,	O
[C_41	O
H_84	O
N_2	O
O_6	O
P]_+	O
possible	O
assignment:	O
Sphingomyelin).	B

The	O
acid	O
layers	O
were	O
made	O
basic	O
with	O
0.5	O
mL	O
of	O
50%	O
(w/v)	O
K_2	O
CO_3	O
and	O
then	O
extracted	O
with	O
4	O
ml	O
of	O
10%	O
ethyl	B
acetate	I
in	O
pentane	B
by	O
vortex	O
mixing,	O
centrifugation,	O
and	O
freezing	O
the	O
aqueous	O
layers.	O

More	O
importantly,	O
3	O
important	O
molecules	O
(2-hydroxy	O
valerate,	I
kynurenine	B
and	O
alanine)	B
were	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
both	O
ARD	O
and	O
TC	O
groups	O
with	O
respect	O
to	O
OW.	O

Lastly,	O
we	O
have	O
reported	O
values	O
for	O
three	O
metabolites	O
of	O
interests	O
in	O
urine	O
in	O
females	O
and	O
males	O
individuals,	O
displaying	O
no	O
gender	O
differences	O
for	O
PAG,	B
PCS,	O
2-HB	O
(,	O
).	O

Another	O
novel	O
finding	O
of	O
our	O
study	O
is	O
that	O
elevated	O
ADMA	B
and	O
diminished	O
GABR	O
were	O
associated	O
with	O
higher	O
sPAP	O
in	O
the	O
setting	O
of	O
ADHF.	O

In	O
linear	O
regression,	O
a	O
greater	O
abundance	O
of	O
the	O
PAFs	O
PC(O	B
-12:0/2:0),	I
PC(O	B
-14:1/2:0),	I
PC(O	B
-17:3/2:0),	I
and	O
PC(O	B
-18:3/2:0)	I
was	O
significantly	O
associated	O
with	O
greater	O
HAM-D	O
scores	O
in	O
CAD	O
patients,	O
while	O
the	O
PAF	O
PC(O	B
-13:0/2:0)	I
trended	O
with	O
HAM-D	O
score.	O

Detailed	O
analysis	O
of	O
the	O
metabolome	O
revealed	O
several	O
candidate	O
metabolites	O
and	O
perturbed	O
phenylalanine,	B
arginine,	B
proline	B
and	O
tryptophan	B
metabolisms	O
as	O
putative	O
biomarkers.	O

24S-OH-Chol	B
assay	O
was	O
performed	O
using	O
an	O
ultra	O
performance	O
liquid	O
cromatograph	O
(Dionex	O
Ultimate	O
3000	O
RS)	O
coupled	O
with	O
a	O
mass	O
spectrometer	O
(AB	O
SCIEX	O
Triple	O
Quadrupole	O
API	O
3000),	O
equipped	O
with	O
an	O
atmospheric	O
pressure	O
chemical	O
ionization	O
(APCI)	O
source	O
and	O
operating	O
in	O
multiple	O
reaction	O
monitoring	O
in	O
positive	O
mode.	O

In	O
conclusion,	O
we	O
showed	O
that	O
tryptophan	B
and	O
KPm	O
concentrations	O
decreased	O
after	O
a	O
bariatric	O
surgery	O
in	O
women	O
with	O
obesity,	O
and	O
our	O
results	O
suggest	O
potential	O
interactions	O
between	O
kynurenine	B
metabolite	O
production,	O
inflammation	O
and	O
glucose	B
metabolism.	O

Data	O
on	O
lipoprotein	O
particles	O
comprise	O
117	O
measures	O
describing	O
the	O
gradient	O
from	O
very-low-density	O
lipoprotein	O
(VLDL)	O
particles	O
to	O
HDL	O
particles,	O
including	O
their	O
triglycerides,	B
cholesterol,	B
free	O
cholesterol,	B
phospholipid	B
as	O
well	O
as	O
apolipoprotein	O
B	O
(ApoB),	O
A1	O
(Apo-A1)	O
and	O
A2	O
(Apo-A2)	O
content.	O

Concerning	O
our	O
studies,	O
itaconic	B
acid	I
was	O
detected	O
in	O
the	O
blood	O
of	O
septic	O
patients	O
only	O
at	O
an	O
early	O
stage	O
of	O
disease,	O
in	O
a	O
small	O
group	O
of	O
patients.	O

Amyotrophic	O
lateral	O
sclerosis,	O
a	O
condition	O
that	O
was	O
elevated	O
in	O
Gulf	O
War	O
veterans	O
in	O
the	O
early	O
years	O
after	O
the	O
conflict,	O
has	O
recently	O
been	O
found	O
to	O
have	O
some	O
metabolomic	O
abnormalities	O
that	O
overlap	O
with	O
GWI,	O
including	O
elevations	O
in	O
phosphatidylcholines	B
and	O
sphingomyelins.	B

(C)	O
External	O
prediction	O
accuracy	O
of	O
NMIBC	O
prediction	O
model	O
established	O
by	O
a	O
metabolite	O
panel	O
of	O
Dopamine	B
4-sulfate,	I
MG00/1846Z,9Z,12Z,15Z/00,	O
Aspartyl-Histidine,	B
Tyrosyl-Methionine.	B

While	O
greatly	O
expanding	O
upon	O
the	O
number	O
of	O
compounds	O
reported	O
in	O
human	O
plasma,	O
the	O
current	O
experimental	O
and	O
computational	O
approaches	O
will	O
continue	O
to	O
shed	O
even	O
more	O
insight	O
into	O
oxylipin	B
biology	O
as	O
they	O
are	O
applied	O
in	O
complementary	O
systems.	O

These	O
results	O
indicate	O
that	O
urinary	O
F2-isoprostanes	B
are	O
valid	O
biomarkers	O
and	O
allantoin	B
is	O
a	O
promising	O
biomarker	O
of	O
oxidative	O
status	O
in	O
humans.	O

In	O
addition	O
to	O
the	O
known	O
risk	O
factors	O
for	O
diabetes,	O
dyslipidemia	O
and	O
hypertension,	O
subjects	O
in	O
Cluster	O
4	O
were	O
also	O
positively	O
associated	O
with	O
the	O
levels	O
of	O
γ-glutamyltransferase	O
(γ	O
GT),	O
serum	O
glutamic-pyruvic	O
transaminase	O
(SGPT,	O
also	O
called	O
alanine	O
aminotransferase,	O
ALT)	O
and	O
uric	B
acid	I
(URATE)	O
as	O
well	O
as	O
white	O
blood	O
cell	O
count	O
(WBC).	O

Phylogenic	O
analysis	O
was	O
performed	O
on	O
the	O
Atlantic	B
cod	O
albumin-like	O
protein	O
(GENSCAN00000070264)	O
and	O
annotated	O
full-length	O
albumin/albumin-like	O
proteins	O
of	O
other	O
Teleost	O
species	O
by	O
ClustalX	O
(v.	O
2.0)	O
and	O
NJplot	O
(v.	O
2.3).	O

In	O
renal	O
adenocarcinoma	O
and	O
paraganglioma	B
cancers	O
harboring	O
loss	O
of	O
function	O
mutations	O
of	O
succinate	O
dehydrogenase,	O
PC	O
was	O
found	O
essential	O
to	O
support	O
cancer	O
proliferation	O
[,].	O

A	O
more	O
accurate	O
assessment	O
of	O
their	O
overall	O
contribution	O
to	O
the	O
metabolism	O
of	O
furan	B
will	O
require	O
the	O
use	O
of	O
internal	O
standards	O
that	O
correct	O
for	O
likely	O
differences	O
in	O
ionization	O
efficiency	O
of	O
each	O
of	O
the	O
metabolites	O
in	O
urine.	O

However,	O
using	O
ADHD-status	O
as	O
outcome	O
when	O
including	O
only	O
controls	O
and	O
patients	O
in	O
the	O
age	O
19–33	O
subgroup,	O
there	O
were	O
still	O
significantly	O
lower	O
levels	O
of	O
tryptophan	B
[OR:	O
0.71	O
(95 %	O
CI	O
0.51–0.99,	O
p:	O
0.05)]	O
and	O
HAA	O
[0.66	O
(0.47–0.91,	O
0.01)]	O
in	O
patients.	O

In	O
this	O
study,	O
we	O
further	O
showed	O
that	O
CR	O
and	O
NANA	B
can	O
be	O
measured	O
in	O
liver	O
cancer	O
tissue,	O
and	O
that	O
these	O
metabolites	O
are	O
also	O
elevated	O
in	O
ICC	O
when	O
compared	O
to	O
HCC.	O

This	O
hypothesis	O
would	O
be	O
in	O
accordance	O
with	O
the	O
use	O
of	O
glucose	B
as	O
an	O
anabolic	O
fuel.	O

Metabolomics	O
data	O
correlated	O
with	O
histopathological	O
findings,	O
including	O
haematoxylin-eosin	B
and	O
reticulin	B
staining,	O
respectively.	O

In	O
our	O
study	O
serum	O
angiotensin	B
2	I
concentrations	O
were	O
higher	O
in	O
ACE-DD	O
genotypes	O
at	O
rest	O
as	O
predicted	O
based	O
on	O
the	O
effect	O
of	O
the	O
presence	O
of	O
the	O
ACE	O
I-allele	O
on	O
the	O
expression	O
of	O
ACE	O
and	O
the	O
downstream	O
processing	O
of	O
angiotensin	B
2.	I

Chen	O
et	O
al.	O
reported	O
lower	O
levels	O
of	O
Bifidobacterium	O
sp.	B

This	O
kit,	O
in	O
combination	O
with	O
an	O
ABI	O
4000	O
Q-Trap	O
(Applied	O
Biosystems/MDS	O
Sciex)	O
mass	O
spectrometer,	O
can	O
be	O
used	O
for	O
the	O
targeted	O
identification	O
and	O
quantification	O
of	O
160	O
different	O
metabolites	O
including	O
amino	O
acids,	O
acylcarnitines,	B
glycerophospholipids,	B
and	O
sphingolipids.	B

Increased	O
monounsaturated	O
fatty	O
acids	O
(MUFAs)	O
were	O
negatively	O
and	O
the	O
ratio	O
of	O
omega	O
6-FAs	O
to	O
total	O
FAs	O
positively	O
correlated	O
with	O
insulin	O
sensitivity,	O
which	O
agrees	O
with	O
a	O
larger	O
study	O
where	O
MUFAs	O
were	O
predictors	O
of	O
worse	O
present	O
and	O
future	O
glycemia	O
and	O
omega-6	B
FAs	O
to	O
total	O
FAs	O
was	O
associated	O
with	O
better	O
glycemic	B
profiles.	O

Therefore,	O
0.1%	O
formic	B
acid	I
was	O
chosen	O
as	O
the	O
reconstitution	O
solvent.	O

A.	O
Colo357-shScr,	O
Colo357-shMUC16	O
and	O
B.	O
Capan1-shScr,	O
Capan1-shMUC16	O
cells	O
motility	O
was	O
evaluated	O
by	O
scratch	O
wound	O
healing	O
assay	O
for	O
24	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
cell	O
culture	O
media	O
supplementation	O
with	O
lactate.	B

We	O
hypothesized	O
that	O
an	O
integrated	O
assessment	O
of	O
arginine	B
with	O
its	O
catabolic	O
products	O
may	O
better	O
predict	O
cardiovascular	O
risks	O
than	O
arginine	B
levels	O
alone.	O

-(trimethylsilyl)-trifluoroacetamide	B
(BSTFA)	O
plus	O
1%	O
(v	O
/v	O
)	O
trimethylchlorosilane	B
(TMCS)	O
(REGIS	O
Technologies,	O
Morton	O
Grove,	O
IL,	O
USA)	O
for	O
2	O
hours	O
at	O
70°C	O
subsequently,	O
and	O
were	O
cooled	O
to	O
room	O
temperature	O
prior	O
to	O
GC-MS	O
analysis.	O

In	O
particular,	O
amides	B
of	O
the	O
fatty	O
acids,	O
also	O
known	O
as	O
endocannabinoids,	B
play	O
an	O
important	O
role.	O

We	O
detected	O
lower	O
methionine	B
and	O
higher	O
cysteine	B
levels	O
in	O
lung	O
cancer	O
patients	O
compared	O
to	O
controls.	O

Hematoxylin	B
and	O
eosin	B
staining	O
shows	O
the	O
tissue	O
architecture	O
was	O
retained	O
(Additional	O
file	O
).	O

For	O
the	O
top	O
10	O
compounds	O
in	O
CSF	O
samples	O
with	O
correlations	O
to	O
ΔUPDRS2	O
+	O
3,	O
the	O
strongest	O
relationship	O
was	O
an	O
inverse	O
correlation	O
with	O
benzoate	B
(−0.42,	O
p	O
=	O
0.0025).	O

Given	O
that	O
ceramide	B
is	O
one	O
of	O
the	O
components	O
of	O
the	O
cellular	O
membrane,	O
cancer	O
cells	O
with	O
a	O
high	O
proliferation	O
rate	O
would	O
be	O
expected	O
to	O
require	O
more	O
ceramide.	B

The	O
relative	O
abundances	O
of	O
Anaerotruncus	O
,	O
Intestinimonas	O
and	O
Oscillibacter	O
displayed	O
significant	O
relationships	O
with	O
both	O
steroid	O
biosynthesis	O
and	O
terpenoid	B
and	O
triterpenoid	B
biosynthesis	O
pathways.	O

In	O
contrast,	O
only	O
formic	B
acid	I
was	O
attenuated	O
by	O
10%	O
upon	O
increasing	O
the	O
methanol-to-serum	O
ratio	O
from	O
2:1	O
to	O
3:1,	O
although	O
26%	O
of	O
the	O
metabolites	O
were	O
attenuated	O
by	O
up	O
to	O
33%	O
upon	O
increasing	O
the	O
methanol-to-serum	O
ratio	O
from	O
2:1	O
to	O
4:1.	O

As	O
dA	O
is	O
always	O
present	O
in	O
processed	O
DNA	O
samples,	O
the	O
absence	O
of	O
dTG	O
in	O
negative-control	O
MOLT4	O
cells	O
and	O
in	O
patients	O
not	O
on	O
thiopurine	B
therapy	O
indicates	O
selectivity.	O

SLC16A9	O
is	O
involved	O
in	O
drug	O
transport,	O
bile	O
salt	O
and	O
organic	O
anion	O
transport	O
and	O
has	O
been	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
carnitine,	B
uric	B
acid	I
levels.	O

(C)	O
MI	O
fractions	O
from	O
isotope	O
tracing	O
experiments	O
with	O
either	O
_13	O
C_6	B
-isoleucine	I
(black),	O
_13	O
C_6	B
-leucine	I
(blue),	O
or	O
_13	O
C_5	B
-valine	I
(red)	O
for	O
48	O
h.	O

This	O
finding	O
suggests	O
a	O
particularly	O
important	O
role	O
of	O
elevated	O
tumor	O
tryptophan	B
catabolism	O
in	O
ER-negative	O
disease.	O

The	O
most	O
common	O
sample	O
preparation	O
method	O
used	O
to	O
minimize	O
matrix	O
effects	O
and	O
increase	O
sensitivity	O
in	O
oxylipin	B
profiling	O
is	O
methanol	B
precipitation	O
followed	O
by	O
SPE.	O

We	O
examined	O
tandem	O
mass	O
spectra	O
of	O
the	O
mixtures	O
of	O
18:3	O
FA	O
isomers	O
(i.e.	O
,	O
Δ_6,9,12	B
18:3,	I
γ-linolenic	B
acid	I
(GLA),	O
and	O
Δ_9,12,15	B
18:3,	I
α-linolenic	B
acid	I
(ALA)).	O

Instead	O
we	O
observed	O
positive	O
correlations	O
between	O
concentration	O
of	O
tryptophan	B
and	O
kynurenine	B
in	O
both	O
the	O
patient	O
and	O
control	O
groups,	O
indicating	O
a	O
normal	O
conversion	O
of	O
tryptophan	B
to	O
kynurenine	B
(Table ).	O

Responders	O
also	O
had	O
relatively	O
lower	O
levels	O
of	O
2-oxoglutarate	B
(2-OXO,	O
FC:	O
0.46,	O
p=0.017).	O

Methanol	B
and	O
acetonitrile	B
were	O
removed	O
by	O
Speed-Vac,	O
and	O
the	O
aqueous	O
leftover	O
was	O
dried	O
with	O
lyophilization	O
process.	O

()	O
In	O
studies	O
examining	O
other	O
markers	O
of	O
liver	O
injury,	O
positive	O
associations	O
were	O
reported	O
between	O
PFAS	O
(including	O
PFOA	O
and	O
PFHxS)	O
and	O
cytokeratin	B
18,	O
a	O
marker	O
for	O
liver	O
apoptosis,	O
but	O
inverse	O
relationships	O
were	O
reported	O
between	O
PFAS	O
and	O
serum	O
pro-inflammatory	O
cytokines	O
in	O
adults.	O

Primary	O
and	O
secondary	O
metabolites	O
of	O
di-(2-ethyl-hexyl)	B
phthalate	I
(DEHP)	O
and	O
di-iso-nonyl	B
phthalate	I
(DiNP)	O
were	O
positively	O
correlated.	O

Methadone,	B
metabolites,	O
bioavailability,	O
rectal,	O
oral,	O
intravenous,	O
human,	O
volunteers,	O
pharmacokinetics,	O
pupillometry	O

Furthermore,	O
the	O
number	O
of	O
motile	O
prostate	O
epithelial	O
cells	O
were	O
significantly	O
higher	O
upon	O
sarcosine	B
treatment	O
(t-test	O
P	O
=6.997e-06,	O
n=10)	O
compared	O
to	O
alanine-treated	O
controls.	O

L	O
phosphate	B
buffer	O
with	O
pH	O
7.4	O
and	O
10	O
mmol/	O

The	O
IMS-derived	O
data	O
was	O
also	O
mined	O
for	O
several	O
well-known	O
endogenous	O
urinary	O
metabolites	O
including	O
hippuric	B
acid,	I
pantothenic	B
acid,	I
tryptophan,	B
indoxyl	B
sulphate,	I
phenylanaline,	B
taurocholic	B
acid,	I
deoxycholic	B
acid,	I
and	O
taurolithocholic	B
acid.	I

While	O
this	O
is	O
consistent	O
with	O
studies	O
of	O
urinary	O
metabolites	O
of	O
PAH	O
such	O
as	O
1-hydroxypyrene,	B
the	O
difference	O
between	O
smokers	O
and	O
non-smokers	O
is	O
far	O
less	O
than	O
the	O
difference	O
in	O
lung	O
cancer	O
risk	O
(up	O
to	O
30	O
times	O
greater	O
in	O
smokers).	O

However,	O
no	O
correlation	O
between	O
putrescine,	B
fasting	O
glucose	B
or	O
other	O
clinical	O
parameters	O
such	O
as	O
BMI	O
or	O
HOMA-IR	O
was	O
observed.	O

This	O
is	O
in	O
sharp	O
contrast	O
to	O
HPLC-EC-array,	O
which	O
is	O
normally	O
operated	O
in	O
combination	O
with	O
normal-bore	O
(4.6-mm-i.d.)	O

Our	O
findings	O
showed	O
that	O
28	O
metabolites	O
among	O
normal,	O
CINs,	B
and	O
cervical	O
cancers	O
were	O
significantly	O
altered	O
in	O
the	O
global	O
metabolite	O
profiling	O
(discovery	O
phase).	O

Nicotinamide	B
deficiency	O
was	O
the	O
most	O
important	O
feature,	O
supported	O
by	O
its	O
identification	O
by	O
the	O
four	O
data	O
analyses	O
performed	O
in	O
this	O
study.	O

In	O
our	O
study,	O
260	O
µL	O
of	O
serum	O
and	O
260	O
µL	O
of	O
sodium	B
phosphate	I
buffer	O
(75	O
mmol/L	O
Na_2	O
HPO_4	O
in	O
80%/20%	O
H_2	O
O/D_2	O
O,	O
pH	O
7.4)	O
were	O
carefully	O
mixed	O
and	O
transferred	O
to	O
the	O
NMR	O
tubes.	O

Previous	O
studies	O
showed	O
the	O
elevation	O
of	O
lactate	B
levels	O
in	O
the	O
CSF	O
were	O
related	O
to	O
disease	O
activity	O
of	O
NMOSD	O

Gamma-glutamyl	O
transpeptidase	O
(GGTP),	O
alanine	B
(ALT/GPT)	O
and	O
aspartate	O
aminotransferases	O
(AST/SGOT)	O
activities	O
in	O
the	O
serum	O
were	O
assessed	O
according	O
to	O
International	O
Federation	O
in	O
Clinical	O
Chemistry	O
(Beckman	O
Coulter).	O

Several	O
observational	O
studies	O
have	O
identified	O
dietary	O
or	O
lifestyle	O
components	O
associated	O
with	O
levels	O
of	O
2-OHE_1	B
,	I
16α-OHE_1	I
,	O
or	O
with	O
their	O
ratio	O
(,	O
).	O

By	O
contrast	O
an	O
inverse	O
correlation	O
was	O
detected	O
between	O
3-hydroxyisovalerate	B
and	O
HOMA-IR	O
(rho	O
=	O
-061,	O
p	O
=	O
0.000324),	O
the	O
BMI	O
(rho	O
=	O
-0.59,	O
p	O
=	O
0.0003)	O
and	O
waist	O
circumference	O
(rho	O
=	O
0.67,	O
p	O
=	O
0.00004).	O

The	O
levels	O
of	O
urinary	O
glycine,	B
creatinine	B
and	O
phenylalanine	B
dropped	O
in	O
response	O
to	O
cancer	O
development.	O

The	O
most	O
abundant	O
product	O
ion	O
at	O
m/z	O
264,	O
arising	O
from	O
loss	O
of	O
fatty	O
acyl	O
chain,	O
was	O
chosen	O
to	O
set	O
up	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
transition	O
for	O
quantification	O
of	O
Cer(22:0)	B
and	O
Cer(24:0).	B

PLS-DA	O
results	O
showed	O
that	O
a	O
high	O
plasma	O
cystathionine	B
concentration	O
in	O
SAP	O
was	O
associated	O
with	O
higher	O
glucose,	B
branched-chain	O
amino	O
acids,	O
and	O
phenylalanine	B
concentrations,	O
lower	O
kidney	O
function,	O
and	O
lower	O
glutathione	B
and	O
plasma	O
PLP	O
concentrations	O
due	O
to	O
greater	O
catabolism.	O

A	O
similar	O
trend	O
was	O
observed	O
when	O
NNAL	O
values	O
were	O
expressed	O
as	O
pmol/mg	O
creatinine	B
when	O
compared	O
with	O
concentrations	O
expressed	O
as	O
nM.	O
There	O
were	O
some	O
striking	O
inter-individual	O
differences	O
in	O
the	O
ratio	O
of	O
NNAL-glucuronides/free	O
NNAL	O
using	O
either	O
concentration	O
or	O
values	O
normalized	O
for	O
creatinine	B
clearance.	O

Five	O
metabolites	O
(methionine,	O
proline,	B
ornithine,	B
pimelylcarnitine,	B
and	O
octanoylcarnitine)	B
were	O
selected	O
in	O
a	O
panel.	O

Site	O
I	O
is	O
often	O
referred	O
to	O
as	O
the	O
warfarin	O
site,	O
and	O
typically	O
large,	O
heterocyclic,	B
and	O
negatively	O
charged	O
drugs	O
bind	O
to	O
this	O
site,	O
whereas	O
small,	O
aromatic,	O
carboxylic	B
acid	I
drugs	O
such	O
as	O
diflunisal	B
and	O
ibuprofen,	B
and	O
basic	O
drugs,	O
including	O
diazepam	B
that	O
exist	O
mainly	O
in	O
the	O
un-ionized	O
form	O
at	O
neutral	O
pH	O
bind	O
with	O
high	O
affinity	O
to	O
site	O
II.	O

The	O
five	O
most	O
important	O
metabolites	O
that	O
discriminated	O
between	O
healthy	O
controls,	O
RSV	O
ARI,	O
and	O
HRV	O
ARI	O
were	O
1-methylnicotinamide,	B
creatine,	B
4-deoxythreonic	B
acid,	I
citrate,	B
2-aminobutyrate,	B
ordered	O
as	O
listed.	O

Several	O
TG	B
metabolites	O
correlated	O
inversely	O
with	O
age	O
data.	O

Trimethylamine-N	B
-oxide	I
(TMAO)	O
has	O
been	O
linked	O
to	O
increased	O
cardiovascular	O
risk.	O

Ye	O
et	O
al.	O
reported	O
that	O
metabolomics	O
profile	O
of	O
serum	O
samples	O
obtained	O
from	O
cervical	O
cancer	O
patients	O
exhibited	O
reduced	O
levels	O
of	O
most	O
essential	O
and	O
non-essential	O
amino	O
acids,	O
such	O
as	O
isoleucine,	B
valine,	B
tyrosine,	B
and	O
glycine,	B
among	O
others	O
as	O
compared	O
to	O
cervicitis	O
and	O
CIN.	O

The	O
control	O
samples	O
are	O
found	O
to	O
separate	O
along	O
PC	O
1	O
from	O
the	O
whey	B
and	O
calcium	B
caseinate	I
samples.	O

Mutations	O
of	O
genes	O
involved	O
in	O
N-glycosylation	O
may	O
affect	O
either	O
the	O
biosynthesis	O
of	O
the	O
glycan	B
precursor	O
(congenital	O
disorder	O
of	O
glycosylation	O
type	O
I	O

In	O
a	O
recent	O
study,	O
septic	O
non-survivors	O
had	O
elevated	O
levels	O
of	O
3-hydroxybutyrate	B
in	O
serum	O
compared	O
to	O
survivors.	O

The	O
rate	O
of	O
appearance	O
of	O
oxalate	B
was	O
higher	O
than	O
expected	O
in	O
the	O
healthy	O
volunteer	O
group,	O
and	O
this	O
overestimation	O
could	O
be	O
attributed	O
to	O
several	O
causes.	O

The	O
relative	O
_13	O
C	O
abundance	O
(a	O
measure	O
of	O
selective	O
enrichment)	O
of	O
these	O
two	O
carbons	O
was	O
calculated	O
by	O
normalizing	O
the	O
HSQC	O
peak	O
volume	O
to	O
the	O
total	O
succinate	B
concentration.	O

Moreover,	O
Dutta	O
RK	O
et	O
al	O
.	O
demonstrated	O
that	O
overexpression	O
of	O
MIOX	O
promotes	O
degradation	O
of	O
myo-inositol	B
and	O
decreases	O
myo-inositol	B
levels,	O
worsening	O
cisplatin-induced	O
acute	O
kidney	O
injury.	O

In	O
the	O
case	O
of	O
HBV,	O
the	O
deletion	O
mutant	O
pre-S2	O
protein	O
is	O
capable	O
of	O
activating	O
the	O
mTOR	O
signal	O
cascade,	O
which	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
SLC2A1	O
(GLUT1)	O
transporter	O
protein	O
to	O
the	O
hepatocyte	O
membrane,	O
enhanced	O
cellular	O
glucose	B
uptake,	O
and	O
aerobic	O
glycolysis	O
(‘Warburg	O
effect’).	O

Chemicals	O
and	O
reagents:	O
N-methyl-N-(trimethylsilyl)	B
trifluoroacetamide	I
(MSTFA)	O
with	O
1%	O
trimethylchlorosilane	B
(TMCS)	O
of	O
>	O
99.0%	O
purity,	O
methoxyamine	B
hydrochloride	I
(>	O
98.0%	O
purity)	O
and	O
pyridine	B
(>	O
99.8%	O
purity)	O
were	O
commercially	O
obtained	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Since	O
then,	O
TMAO	B
has	O
attracted	O
attention	O
and	O
increasing	O
studies	O
have	O
found	O
that	O
TMAO	B
is	O
associated	O
with	O
diabetes,	O
kidney	O
failure,	O
and	O
cancer.	O

The	O
EDA	O
ratio	O
was	O
calculated	O
as	O
the	O
estrogen-DNA	O
adducts	O
divided	O
by	O
estrogen	B
metabolites	O
and	O
conjugates.	O

GFR	O
was	O
the	O
dominant	O
variable	O
affecting	O
TMAO	B
(β	O
=	O
-0.41;	O
p<0.001),	O
choline	B
(β	O
=	O
-0.38;	O
p<0.001),	O
and	O
betaine	B
(β	O
=	O
0.45;	O
p<0.001)	O
levels.	O

Of	O
note,	O
tumor	O
morphology	O
consistently	O
differed	O
when	O
comparing	O
adenoma	O
tissues	O
in	O
relation	O
to	O
glucocorticoid	B
output,	O
with	O
a	O
zona	O
fasciculate–type	O
pattern	O
in	O
tissues	O
from	O
patients	O
with	O
the	O
lowest	O
glucocorticoid	B
excretion,	O
and	O
a	O
pattern	O
resembling	O
zona	O
glomerulosa	O
architecture	O
in	O
tissue	O
from	O
patients	O
with	O
the	O
highest	O
glucocorticoid	B
excretion	O
(examples	O
shown	O
in	O
).	O

As	O
is	O
already	O
mentioned	O
for	O
acetate,	B
the	O
_3	O
CH_2	O
peak	O
might	O
overlap	O
with	O
the	O
acetate	B
_2	O
CH_3	O
peak.	O

No	O
BDCPP	O
was	O
observed	O
in	O
blank	O
extractions,	O
however	O
they	O
did	O
contain	O
traces	O
of	O
DPP	O
at	O
levels	O
of	O
79	O
±	O
41	O
pg	B
mL_−1	O
.	O

α-OG,	B
a	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
intermediate,	O
reportedly	O
functions	O
to	O
suppress	O
the	O
proliferation	O
of	O
immortalized	O
normal	O
human	O
bladder	O
epithelial	O
cells.	O

Nucleophilic	O
amino	O
acids	O
of	O
SA	O
were	O
expected	O
to	O
react	O
with	O
N	B
-acetoxy-PhIP	I
or	O
the	O
proposed	O
nitrenium	O
ion	O
to	O
form	O
adducts	O
with	O
amino	O
acids	O
or	O
peptides	O
with	O
mass	O
increments	O
of	O
223	O
or	O
228	O
Da,	O
attributed	O
respectively,	O
to	O
reactive	O
PhIP	O
or	O
[_2	O
H_5	O
]-PhIP	O
species,	O
less	O
one	O
proton	O
from	O
the	O
amino	O
acid	O
residue.	O

Additionally,	O
15-65.533	O
is	O
also	O
correlated	O
with	O
several	O
other	O
known	O
metabolites,	O
including	O
Indole-3-propionic	B
acid	I
(I-3-PA),	O
Kynurenine	B
(KYN),	O
Indole-3-Acetic	B
Acid	I
and	O
Guanosine.	B

database._36	O
All	O
the	O
annotations	O
of	O
putatively	O
identified	O
lipids	O
was	O
done	O
by	O
using	O
the	O
shorthand	O
lipid	O
notation	O
system	O
suggested	O
by	O
Liebisch	O
et al,_37	O
except	O
for	O
eicosanoids	B
lipids,	O
where	O
common	O
names	O
were	O
used.	O

Interestingly,	O
our	O
study	O
found	O
decreased	O
serum	O
total	O
lipids,	O
neutral	O
lipids	O
(TAG,	O
DAG,	O
CE),	O
and	O
sphingolipids	B
(Cer,	O
SM)	O
in	O
the	O
CHB	O
without	O
NAFLD	O
group,	O
indicating	O
that	O
chronic	O
active	O
HBV	O
infection	O
may	O
be	O
inversely	O
associated	O
with	O
hyperlipidemia	O
and	O
insulin	O
resistance	O
and	O
may	O
play	O
beneficial	O
roles	O
on	O
lipid	O
profiles.	O

The	O
ATBC	O
Study	O
was	O
a	O
randomized,	O
double-blind,	O
placebo-controlled,	O
primary	O
cancer	O
prevention	O
trial;	O
participants	O
were	O
Finnish	O
male	O
smokers	O
assigned	O
to	O
1	O
of	O
4	O
intervention	O
groups:	O
1	O
)	O
α-tocopherol,	B
2	O
)	O
β-carotene,	B
3	O
)	O
both,	O
or	O
4	O
)	O
placebo.	O

(Avanti	O
Polar	O
Lipids),	O
the	O
phosphatidylethanolamines	B
with	O
PE(17∶0/17∶0)	B
(Avanti	O
Polar	O
Lipids)	O
and	O
the	O
triglycerides	B
and	O
cholesterol	B
esters	I
with	O
triglyceride	B
TG(17∶0/17∶0/17∶0)	I

The	O
concentration	O
of	O
16α-OHE_1	B
(pg	O
metabolite	O
/	O
ml	O
urine)	O
is	O
plotted	O
on	O
a	O
logarithmic	O
scale	O
on	O
the	O
y	O
axis,	O
and	O
the	O
x	O
axis	O
identifies	O
the	O
four	O
batches.	O

HTG	O
was	O
defined	O
according	O
to	O
the	O
National	O
Cholesterol	B
Education	O
Program—Adult	O
Treatment	O
Panel	O
III.	O

Xanthine	B
and	O
indole-3-lactic	B
acid	I
also	O
decreased	O
and	O
increased	O
in	O
LALI	O
and	O
HAHI,	O
respectively.	O

Based	O
on	O
the	O
data	O
obtained	O
from	O
LC/MS/MS	O
analysis,	O
one	O
metabolite	O
peak	O
that	O
was	O
consistent	O
with	O
hydroxyanastrozole	B
was	O
identified.	O

After	O
20	O
min,	O
the	O
solution	O
was	O
acidified	O
with	O
aqueous	O
HCl,	O
and	O
HMPMA	O
was	O
extracted	O
into	O
ethyl	B
acetate.	I

Several	O
facts	O
do	O
not	O
support	O
such	O
a	O
speculation:	O
cancer	O
cells	O
themselves	O
produce	O
and	O
excrete	O
large	O
amounts	O
of	O
lactate	B
in	O
their	O
stroma	O
where	O
this	O
metabolite	O
plays	O
subtle	O
and	O
complex	O
roles	O
favoring	O
tumor	O
progression	O
[,	O
];	O
Kallinowski	O
F.	O
et	O
al.	O

As	O
a	O
simple,	O
nonessential	O
amino	O
acid,	O
glycine	B
was	O
involved	O
in	O
the	O
production	O
of	O
DNA,	O
phospholipids	B
and	O
collagen	O
as	O
well	O
as	O
the	O
release	O
of	O
energy.	O

The	O
online	O
method,	O
initially	O
employed	O
in	O
ex	O
vivo	O
fresh	O
porcine	B
samples,	O
was	O
used	O
in	O
vivo	O
during	O
canine	O
oncological	O
surgery	O
and	O
enabled	O
discrimination	O
between	O
a	O
variety	O
of	O
tissue	O
types	O
and	O
diagnosis	O
in	O
combination	O
with	O
PCA.	O

The	O
main	O
elimination	O
route	O
for	O
hippurate	B
is	O
the	O
active	O
renal	O
tubular	O
secretion	O
and	O
its	O
disruption	O
results	O
in	O
its	O
accumulation	O
in	O
the	O
blood.	O

MS	O
is	O
a	O
demyelinating	O
disease	O
with	O
the	O
consequent	O
release	O
of	O
non-esterified	O
cholesterol	B
in	O
the	O
CNS.	O

Both	O
targeted	O
UPLC–HRMS	O
and	O
DI–nESI–HRMS	O
are	O
represented	O
in	O
Figure	O
S-4	O
using	O
the	O
example	O
of	O
hippurate.	B

First,	O
SQR-bound	O
persulfide	B
is	O
formed	O
at	O
a	O
cysteine	B
residue	O
of	O
SQR.	O

The	O
high	O
betaine	B
and	O
glucose	B
levels	O
were	O
not	O
directly	O
correlated	O
with	O
each	O
other	O
in	O
more	O
than	O
two	O
subjects	O
(Figure	O
S4).	O

In	O
this	O
study,	O
we	O
explore	O
the	O
potential	O
effects	O
of	O
commonly	O
available	O
oral	O
supplements	O
(containing	O
antioxidants,	O
vitamins	O
and	O
omega-3	B
fatty	O
acids)	O
on	O
the	O
metabolomes	O
of	O
smokers	O
(n	O
=	O
11)	O
compared	O
to	O
non-smokers	O
(n	O
=	O
17).	O

In	O
addition,	O
we	O
re-analysed	O
data	O
from	O
that	O
study	O
in	O
which	O
fentanyl	O
was	O
given	O
intravenously	O
alone	O
and	O
during	O
CYP3A	O
inhibition	O
by	O
ketoconazole,	B
and	O
midazolam	B
was	O
co-administered	O
orally	O
as	O
CYP3A	O
probe	O
drug.	O

Choline	B
was	O
excluded	O
based	O
on	O
dietary	O
bias	O
and	O
glycolaldehyde	B
is	O
to	O
be	O
excluded	O
based	O
on	O
robust	O
practical	O
ESI	O
considerations	O
required	O
for	O
a	O
regulated	O
clinical	O
environment.	O

Glycine	B
was	O
also	O
found	O
at	O
lower	O
concentrations	O
with	O
a	O
higher	O
number	O
of	O
MetS	O
risk	O
factors	O
in	O
both	O
genders	O
and	O
with	O
higher	O
adiposity	O
in	O
men.	O

For	O
example,	O
neopterin	B
had	O
a	O
significant	O
positive	O
association	O
with	O
the	O
KTR	O
and	O
a	O
negative	O
association	O
with	O
PLP.	O

Serum	O
samples	O
that	O
were	O
stored	O
at	O
−80°C	O
since	O
collection	O
were	O
thawed	O
at	O
4°C	O
and	O
used	O
for	O
measurement	O
of	O
estrogens	O
and	O
estrogen	B
metabolites.	O

Dopamine	B
and	O
L-DOPA	B
are	O
part	O
of	O
the	O
dopaminergic	O
pathway	O
in	O
tyrosine	B
metabolism	O
where	O
dopamine	B
is	O
produced	O
by	O
its	O
precursor	O
L-DOPA,	B
which	O
further	O
is	O
synthesized	O
from	O
tyrosine	B
and	O
phenylalanine,	B
all	O
of	O
which	O
were	O
shown	O
to	O
be	O
reduced	O
in	O
manifest	O
HD	O
patients	O
and	O
were	O
to	O
various	O
degrees	O
associated	O
with	O
disease	O
severity.	O

The	O
reference	O
substance	O
(sodium	O
3-trimethylsilyl[2,2,3,3-d_4	I
]propionate	I
(TSP)	O
40	O
mmol/l,	O
MnSO_4	O
0.6	O
mmol/	O

The	O
residue	O
was	O
reconstituted	O
with	O
50	O
µl	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
from	O
which	O
25	O
µl	O
was	O
injected	O
onto	O
the	O
LC-MS/MS	O
system	O
(see	O
above).	O

5-ASA,	O
5-aminosalicylic	B
aid;	O
C-section,	O
caesarean	O
section.	O

Rather	O
our	O
data	O
raise	O
the	O
possibility	O
of	O
a	O
persistent	O
abnormality	O
further	O
“downstream”	O
in	O
the	O
kynurenine	B
metabolic	O
pathway,	O
i.e.	O
an	O
imbalance	O
between	O
the	O
synthesis/breakdown	O
of	O
KynA	O
and	O
QA	O
in	O
the	O
periphery.	O

Because	O
betaine	B
is	O
a	O
precursor	O
of	O
methionine,	B
the	O
elevation	O
of	O
both	O
betaine	B
and	O
methionine	B
in	O
AS	O
may	O
be	O
inter-related,	O
and	O
plasma	O
NAG	O
elevation	O
may	O
also	O
suggest	O
an	O
immune	O
system	O
disorder	O
in	O
AS	O
because	O
NAG	O
can	O
acetylate	B
glycoproteins,	I
which	O
are	O
important	O
for	O
white	O
blood	O
cell	O
recognition.	O

The	O
ratio	O
of	O
these	O
three	O
oxysterols	B
in	O
CSF	O
thus	O
gives	O
an	O
indication	O
of	O
cholesterol	B
metabolism	O
in	O
brain	O
with	O
respect	O
to	O
oxysterol	B
transport	O
from	O
the	O
periphery	O
into	O
CSF.	O

This	O
set	O
of	O
QC	O
samples	O
prepared	O
in	O
pooled	O
human	O
serum	O
displayed	O
97.4%	O
average	O
proline	B
amount	O
remaining,	O
which	O
suggested	O
that	O
proline	B
in	O
human	O
serum	O
was	O
stable	O
after	O
three	O
freeze-thaw	O
cycles.	O

betaine,	B
trimethylamine	B
N-oxide	I
related	O
metabolites,	O
nuclear	O
magnetic	O
resonance	O
spectroscopy,	O
type	O
2	O

The	O
standards	O
were	O
synthesized	O
from	O
phenanthrene	B
epoxides	I
and	O
N	B
-acetylcysteine.	I

Its	O
catabolism	O
in	O
mammals	O
forms	O
2-oxobutyrate,	B
glycine	B
and	O
acetylCoA	B
.	O

All	O
40	O
study	O
participants	O
underwent	O
the	O
first	O
dietary	O
phosphatidylcholine	B
challenge	O
(visit	O
1),	O
which	O
consisted	O
of	O
the	O
ingestion	O
of	O
deuterium-labeled	B
phosphatidylcholine	I
(d9-phosphatidylcholine)	I
and	O
two	O
hard-boiled	O
eggs.	O

We	O
investigated	O
whether	O
(Z)‐endoxifen	B
concentrations	O
depended	O
on	O
either	O
factor	O
alone	O
or	O
in	O
combination.	O

The	O
release	O
of	O
tryptophan	B
from	O
its	O
binding	O
serum	O
protein	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
improvement	O
in	O
disease	O
activity	O
in	O
AS,	O
and	O
this	O
may	O
be	O
the	O
same	O
in	O
RA.	O

We	O
suggest	O
that	O
increased	O
levels	O
of	O
L-Aspartic	B
acid	I
and	O
Citrulline	B
from	O
the	O
urea	B
cycle	O
may	O
lead	O
to	O
elevated	O
levels	O
of	O
plasma	O
Fumaric	B
acid	I
in	O
HIV/AIDS	O
patients	O
and	O
those	O
on	O
ART	O
observed	O
in	O
our	O
study.	O

Exploratory	O
unsupervised	O
PCA	O
of	O
the	O
CMPG	O
spectra	O
showed	O
marked	O
differentiation	O
among	O
the	O
different	O
centers	O
of	O
collection,	O
with	O
the	O
spectral	O
region	O
of	O
lactate	B
resulting	O
in	O
the	O
most	O
relevant	O
discrimination	O
in	O
the	O
first	O
two	O
principal	O
components.	O

Among	O
ketone	B
bodies,	O
β-hydroxybutyrate	B
was	O
associated	O
with	O
MI	O
(OR	O
per	O
SD	O
increment:	O
1.35;	O
95%	O
CI:	O
1.18	O
to	O
1.54),	O
IS	O
(OR	O
per	O
SD	O
increment:	O
1.21;	O
95%	O
CI:	O
1.08	O
to	O
1.36),	O
and	O
ICH	O
(OR	O
per	O
SD	O
increment:	O
1.22;	O
95%	O
CI:	O
1.08	O
to	O
1.36),	O
and	O
acetoacetate	B
was	O
strongly	O
associated	O
with	O
IS	O
(OR	O
per	O
SD	O
increment:	O
1.44;	O
95%	O
CI:	O
1.28	O
to	O
1.61)	O
and	O
ICH	O
(OR	O
per	O
SD	O
increment:	O
1.19;	O
95%	O
CI:	O
1.08	O
to	O
1.32),	O
but	O
not	O
with	O
MI	O
(OR	O
per	O
SD	O
increment:	O
1.06;	O
95%	O
CI:	O
0.95	O
to	O
1.18).	O

The	O
selected	O
species,	O
displayed	O
in	O
,	O
show	O
similar	O
trends	O
as	O
observed	O
in	O
the	O
positive	O
ion	O
analysis	O
and	O
emphasize	O
the	O
need	O
for	O
using	O
both	O
DCM	O
and	O
MTBE	B
for	O
comprehensive	O
lipid	O
analysis.	O

The	O
steady-state	O
plasma	O
glucose	B
and	O
insulin	O
concentrations	O
during	O
the	O
180-min	O
euglycemic	B
insulin	O
clamp	O
were	O
similar	O
before	O
and	O
after	O
4	O
months	O
of	O
pioglitazone	B
monotherapy.	O

A	O
1-μl	O
extract	O
aliquot	O
of	O
the	O
extracts	O
was	O
injected	O
into	O
a	O
DB-5MS	O
capillary	O
column	O
coated	O
with	O
5%	O
diphenyl	O
cross-linked	O
95%	O
dimethylpolysiloxane	B
(30	O
m×250	O
μm,	O
0.25-μm	O
film	O
thickness;	O
Agilent	O
J&W	O
Scientific,	O
Folsom,	O
CA)	O
in	O
the	O
split	O
mode	O
(3:1).	O

The	O
mean	O
plasma	O
concentrations	O
of	O
R	O
-OH-WAR	O
are	O
ranked	O
in	O
the	O
following	O
order:	O
10-OH	O
>	O
6-OH	O
~	O
7-OH	O
~	O
4'-OH	O
~	O
8-OH	O
(Table	O
S1)	O
confirming	O
that	O
R	O
-WAR	O
is	O
metabolized	O
primarily	O
by	O
CYP3A4	O
to	O
10-OH-WAR.	B

Plots	O
for	O
total	O
estrogens	O
and	O
estrogen	B
metabolites	O
and	O
the	O
three	O
measures	O
of	O
estrogen	B
metabolism	O
are	O
presented	O
without	O
and	O
with	O
adjustment	O
for	O
unconjugated	O
estradiol.	B

Such	O
sustained	O
signaling	O
resulted	O
in	O
the	O
significant	O
upregulation	O
of	O
the	O
conversion	O
of	O
extracellular	O
ATP	B
to	O
inosine	B
(adenosine	O
metabolite)	O
by	O
Treg,	O
suggesting	O
that	O
TEX	O
signaling	O
could	O
have	O
functional	O
consequences	O
in	O
these	O
recipient	O
cells.	O

We	O
identified	O
several	O
perturbed	O
pathways,	O
including	O
fatty	O
acid	O
metabolism—particularly	O
the	O
polyunsaturated	O
fatty	O
acids	O
metabolism,	O
and	O
purine	B
metabolism—that	O
were	O
associated	O
with	O
MDD	O
in	O
these	O
young	O
patients.	O

Prehypertension-associated	O
elevations	O
in	O
lysoPCs,	O
Lp-PLA_2	O
activity,	O
ox-LDL,	O
urinary	O
8-epi-PGF_2α	B
,	O
IL-6,	O
and	O
ba-PWV	O
could	O
indicate	O
increased	O
oxidative	O
stress	O
from	O
Lp-PLA_2	O
-catalyzed	O
PC	O
hydrolysis	O
during	O
increased	O
LDL	O
oxidation,	O
thereby	O
enhancing	O
proinflammation	O
and	O
arterial	O
stiffness.	O

100	O
mg/m_2	O
IV	O
day	O
1	O
every	O
21	O
days	O
for	O
4	O
cycles);	O
(regimen	O
II):	O
TEC	O
(docetaxel	O
plus	O
doxorubicin	B
with	O
the	O
same	O
dose	O
of	O
75	O
mg/m_2	O
plus	O
cyclophosphamide	O
600	O
mg/m_2	O
every	O
21	O
days	O
for	O
6	O
cycles).	O

(D)	O
Isoleucine	B
present	O
in	O
both	O
groups	O
of	O
Panc-1	O
cell	O
extracts	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
the	O
lyophilized	O
samples.	O

Bio-Wide	O
Pore	O
C5	O
150 × 2.1 mm)	O
to	O
amide	B
(Discovery	O
RP-Amide	B
150	O

Moreover,	O
the	O
authors	O
describe	O
a	O
runtime	O
of	O
3.5	O
minute	O
on	O
HPLC	O
which	O
is	O
unlikely	O
sufficient	O
to	O
separate	O
abiraterone	B
from	O
its	O
phase	O
I	O
metabolites	O
encountered	O
in	O
humans	O
treated	O
with	O
this	O
drug().	O

Ascorbate	B
levels	O
were	O
increased	O
in	O
lung	O
SCC,	O
mostly	O
likely	O
in	O
response	O
to	O
oxidative	O
stress	O
(Supplementary	O
Figure	O
S5).	O

B.	O
It	O
not	O
only	O
involves	O
glucose	B
metabolism	O
but	O
also	O
the	O
metabolism	O
of	O
lipids,	O
amino	O
acids	O
and	O
nucleic	O
acid.	O

For	O
urobilinogen,	B
the	O
two	O
curves	O
for	O
each	O
condition	O
correspond	O
to	O
the	O
positive	O
and	O
negative	O
ionization	O
modes	O
Furthermore,	O
11	O
metabolites	O
whose	O
variations	O
related	O
to	O
bacterial	O
contamination	O
had	O
not	O
been	O
described	O
previously	O
were	O
observed	O
in	O
our	O
LC/MS	O
data	O
sets:	O
trimethylamine	B
oxide,	I
2-hydroxy-3-methylbutyric	B
acid,	I
methylguanosine,	B
methylinosine,	B
glutamine,	B
dimethylguanosine,	B
cholic	B
acid,	I
valine,	B
3-methyl-2-oxovaleric	B
acid,	I
an	O
isomer	O
of	O
aniline,	B
and	O
N-acetylcytidine	B
(Table ;	O
Figure ,	O
and	O
graphs	O
provided	O
as	O
supplementary	O
material	O
6).	O

Background:	O
Numerous	O
observational	O
studies	O
have	O
observed	O
associations	O
between	O
vitamin	B
D	I
deficiency	O
and	O
cardiometabolic	O
diseases,	O
but	O
these	O
findings	O
might	O
be	O
confounded	O
by	O
obesity.	O

Glycerol-3-phosphate	B
is	O
the	O
backbone	O
of	O
triglycerides	B
and	O
glycerophospholipids	B
and	O
is	O
also	O
involved	O
in	O
the	O
fatty	O
acid	O
oxidation	O
cycle	O
generating	O
NADH.	B

	O
Higher	O
levels	O
of	O
cortisol	B
were	O
inversely	O
associated	O
with	O
Trp	O
(r	O
=	O
−0.39)	O
and	O
nicotinic	B
acid	I
(r	O
=	O
−0.38).	O

The	O
overexpression	O
of	O
DCAs	O
in	O
DCs	O
vs.	O
NHC	O
and	O
HCC	O
vs.	O
NHC	O
may	O
be	O
related	O
to	O
the	O
impairment	O
of	O
the	O
CPT	O
shuttle	O
system	O
as	O
shown	O
by	O
the	O
build-up	O
of	O
acylcarnitines	B
in	O
DC	O
vs.	O
NHC.	O

Catechol-quinones,	B
formed	O
by	O
oxidation	O
of	O
catechols,	B
have	O
long	O
been	O
proposed	O
to	O
be	O
reactive	O
intermediates	O
that	O
are	O
responsible	O
for	O
carcinogenicity	O
of	O
estrogens	O
(	O
pathway	O
C)	O
,	O
,	O
.	O

Here,	O
reported	O
results	O
corroborate	O
the	O
accumulation	O
of	O
pyruvate	B
during	O
hypoxia-ischemia	O
and	O
show	O
the	O
evolution	O
of	O
its	O
concentration	O
profile	O
during	O
TH.	O

HER2	O
positive	O
patients	O
treated	O
with	O
paclitaxel‐lapatinib	B
(n = 22).	O

Stock	O
solutions	O
were	O
prepared	O
at	O
a	O
concentration	O
of	O
10	O
mg/mL	O
in	O
DMSO	B
(Sigma-Aldrich,	O
Stribrna	O
Skalice,	O
Czech	O
Rep)	O
and	O
kept	O
at	O
4	O
°C.	O

Such	O
negative	O
association	O
with	O
schizophrenia	O
led	O
to	O
the	O
'prostaglandin	B
deficiency'	O
hypothesis,	O
which	O
postulated	O
that	O
defective	O
enzyme	O
systems	O
converting	O
essential	O
fatty	O
acids	O
to	O
prostaglandins	B
lead	O
to	O
diminished	O
levels	O
of	O
prostaglandins,	B
which	O
as	O
a	O
consequence	O
may	O
lead	O
to	O
altered	O
monoaminergic	O
neurotransmission.	O

These	O
findings	O
suggest	O
that	O
decreased	O
expression	O
of	O
GSK3β	B
may	O
enable	O
cervical	O
cancer	O
cells	O
to	O
exhibit	O
enhanced	O
glycolytic	B
activity.	O

Many	O
metabolites	O
trended	O
towards	O
normalisation	O
in	O
PO	O
patients,	O
with	O
only	O
choline	B
remaining	O
high	O
with	O
an	O
AUC	O
of	O
0.858,	O
suggesting	O
that	O
it	O
may	O
be	O
a	O
valuable	O
potential	O
biomarker	O
for	O
neoplasm	O
progression,	O
recurrence,	O
chemoradiotherapy,	O
and	O
prognosis.	O
_1	O
H-NMR	O
spectroscopy	O
may	O
be	O
a	O
useful	O
tumour	O
detection	O
approach	O
in	O
the	O
early	O
diagnosis	O
of	O
ESCC.	O

Thus,	O
cancer	O
cells	O
enhance	O
glucose	B
uptake	O
to	O
meet	O
the	O
energy	O
requirement	O
of	O
maintaining	O
their	O
quick	O
proliferation.	O

The	O
functional	O
and	O
biological	O
limits	O
of	O
detection	O
of	O
the	O
conjugated	O
metabolites	O
were	O
determined	O
by	O
sequentially	O
diluting	O
a	O
known	O
amount	O
of	O
metabolite	O
in	O
ethanol	B
(functional	O
limit)	O
and	O
urine	O
(biological	O
limit).	O

We	O
found	O
in	O
our	O
population	O
sample	O
a	O
positive	O
correlation	O
between	O
circulating	O
valine	B
and	O
β-glucose	B
levels	O
(P	O
<0.0001).	O

Similarly,	O
Weiner	O
et	O
al	O
.	O
reported	O
lower	O
serum	O
levels	O
of	O
histidine,	B
citrulline,	B
glutamine,	B
gamma-glutamylglutamine,	B
alanine	B
and	O
threonine	B
in	O
active	O
TB	O
patients,	O
while	O
phenylalanine,	B
3-methoxytyrosine	B
and	O
aspartic	B
acid	I
were	O
elevated.	O

Moreover,	O
multivariate	O
modeling	O
identified	O
age	O
as	O
an	O
independent	O
predictor	O
of	O
parent	O
drug	O
levels	O
(i.e.,	O
tamoxifen).	B

In	O
contrast,	O
plasma	O
levels	O
of	O
uric	B
acid	I
were	O
elevated	O
in	O
pneumonia	O
cases.	O

1	O
NIST	O
standard	O
reference	O
material	O
(SRM	O
1950,	O
lithium	B
heparin	I
plasma)	O
(x3	O
replicates	O
per	O
plate).	O

Similarly,	O
the	O
reduced	O
urinary	O
excretion	O
of	O
methanol	B
and	O
urea	B
in	O
group	O
3,	O
two	O
metabolites	O
significantly	O
correlated	O
to	O
CRP	O
and	O
fecal	O
calprotectin,	O
may	O
serve	O
as	O
readout	O
for	O
monitoring	O
patients	O
that	O
recover	O
towards	O
remission	O
and	O
show	O
growth	O
improvement.	O

The	O
absolute	O
concentration	O
of	O
paracetamol-glucuronide	B
was	O
used	O
to	O
stratify	O
samples	O
in	O
the	O
PCA	O
plot:	O
the	O
direction	O
of	O
increase	O
of	O
paracetamol-glucuronide	B
was	O
found	O
to	O
match	O
the	O
direction	O
of	O
controls-patients	O
separation	O
(Fig.	O

It	O
may	O
be	O
produced	O
in	O
reasonable	O
amounts	O
in	O
the	O
colon	O
through	O
degradation	O
of	O
fiber	O
pectin	B
(which	O
is	O
contained	O
in	O
fruit,	O
vegetables,	O
jellies,	O
milk	O
products,	O
etc.)	O
and	O
taken	O
up	O
by	O
the	O
circulation.	O

As	O
listed	O
in	O
,	O
X	O
differentially	O
expressed	O
metabolites	O
in	O
liver	O
cirrhosis	O
and	O
hepatitis	O
condition	O
including	O
inositol,	B
2,2′-bipyridine,	B
methionine,	B
arginine,	B
stearic	B
acid,	I
palmitic	B
acid,	I
citric	B
acid,	I
2-piperidine	B
carboxylic	I
acid,	I
5-hydroxy-tryptophan,	B
and	O
tyrosine	B
were	O
obtained	O
by	O
comparison	O
among	O
healthy	O
controls,	O
benign	O
liver	O
tumor	O
patients	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
HCC	O
with	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
and	O
HCC	O
without	O
liver	O
cirrhosis	O
and	O
hepatitis.	O

In	O
combination	O
with	O
the	O
conventional	O
tumor	O
marker	O
CEA,	O
which	O
had	O
an	O
AUROC	O
(0.794)	O
comparable	O
to	O
the	O
recent	O
literature	O
(Wild	O
et	O
al.	O
),	O
glycine	B
and	O
tyrosine,	B
however,	O
introduced	O
a	O
surplus	O
of	O
8%,	O
suggesting	O
that—regarding	O
their	O
AUROCs	O
of	O
0.707	O
and	O
0.636	O
as	O
single	O
markers—their	O
principal	O
value	O
might	O
be	O
of	O
additive	O
nature	O
and	O
be	O
missed	O
when	O
routinely	O
available	O
CEA	O
concentrations	O
are	O
not	O
taken	O
into	O
account.	O

m	O
m	O
Retinoic	B
acid	I
receptors	O
(like	O
other	O
type	O
II	O
nuclear	O
receptors)	O
function	O
in	O
the	O
regulation	O
of	O
endogenous	O
gene	O
expression	O
by	O
binding	O
as	O
heterodimers	O
with	O
retinoid	B
X	O
receptors	O
(,	O
).	O

Moreover,	O
blood	O
profiles	O
from	O
animals	O
and	O
patients	O
with	O
VLCAD	O
deficiency	O
are	O
characterized	O
by	O
large	O
accumulations	O
of	O
long	O
chain	O
acyl	B
carnitines.	I

1,5-AG	B
is	O
currently	O
used	O
to	O
monitor	O
glycemic	B
control	O
in	O
patients	O
with	O
diabetes	O
and	O
is	O
a	O
good	O
positive	O
control	O
of	O
this	O
study	O
.	O

The	O
other	O
product	O
ion	O
in	O
the	O
spectrum	O
appeared	O
at	O
m/z	O
279	O
provides	O
the	O
information	O
about	O
one	O
of	O
the	O
acyl	O
moiety	O
of	O
the	O
PE	O
as	O
FA	B
(18:3).	I

Overlapping	O
biomarkers	O
between	O
chronic	O
pancreatitis	O
and	O
our	O
literature	O
derived	O
panel	O
included	O
lactate,	B
lysine,	B
histidine,	B
glutamine,	B
glutamate,	B
and	O
alanine,	B
which	O
were	O
found	O
elevated	O
in	O
CP	O
vs	O
NC.	O

Because	O
the	O
correlation	O
of	O
FA	B
profiles	O
to	O
the	O
clinical	O
parameters	O
of	O
each	O
AD	O
is	O
out	O
of	O
the	O
scope	O
of	O
this	O
paper,	O
the	O
clinical	O
characteristics	O
of	O
patients	O
for	O
each	O
AD	O
group	O
are	O
not	O
presented	O
here	O
but	O
will	O
be	O
examined	O
in	O
separate	O
studies.	O

Only	O
one	O
participant	O
had	O
low	O
serum	O
folate	B
(<10	O
nmol/L)	O
at	O
baseline.	O

AA,	O
anthranylic	B
acid;	I
AMI,	O
acute	O
myocardial	O
infarction;	O
B12,	O
vitamin	O
B-12,	O
cobalamin;	B
Cond.	O
1,	O
previous	O
aortocoronary	O
bypass;	O
Cond.	O
2,	O
previous	O
coronary	O
intervention;	O
Cond.	O
3,	O
previous	O
acute	O
myocardial	O
infarction;	O
Cond.	O
4,	O
previous	O
other	O
illness;	O
Cond.	O
5,	O
previous	O
coronary	O
angiographic	O
stenosis;	O
Cond.	O
6,	O
previous	O
stroke,	O
transient	O
ischemic	O
attack,	O
or	O
carotid-operated	O
stenosis;	O
Cond.	O
7,	O
known	O
atherothrombotic	O
cardiovascular	O
disease;	O
Cond.	O
8,	O
premature	O
cardiovascular	O
disease;	O
Cond.	O
9,	O
heart	O
failure;	O
Cond.	O
10,	O
previous	O
percutaneous	O
coronary	O
intervention;	O
Cond.	O

Of	O
these	O
compounds,	O
only	O
the	O
concentration	O
of	O
pyruvate	B
was	O
significantly	O
different	O
(p	O
=	O
0.01),	O
with	O
better	O
recovery	O
using	O
MeOH	B
ppt	O
+UF	O
than	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
(a–c,	O
Table	O
S2).	O

The	O
surviving	O
RGC-5	O
cells	O
were	O
measured	O
as	O
a	O
percentage	O
of	O
surviving	O
cells	O
in	O
a	O
negative	O
control,	O
which	O
comprised	O
cells	O
treated	O
with	O
PBS	O
and	O
without	O
hydrogen	B
peroxide.	I

Removal	O
of	O
the	O
glutamate	B
metabolite	O
results	O
in	O
an	O
increase	O
of	O
MCE	O
(38%)	O
and	O
a	O
decrease	O
of	O
both	O
sensitivity	O
and	O
specificity	O
(62%),	O
demonstrating	O
the	O
importance	O
of	O
glutamate	B
for	O
discrimination.	O

These	O
considerations	O
support	O
that	O
glucose	B
and	O
galactose	B
might	O
be	O
a	O
biomarker	O
for	O
OSCC.	O

4E-BP1	O
(4E-BP1;	O
Cat	O
no	O
9644)	O
and	O
phospho-4E-BP1	B
(p4E-BP1	O
Thr	O
37/46,	O
Cat	O
no	O
2855)	O
antibodies	O
were	O
obtained	O
from	O
Cell	O
Signaling.	O

The	O
metabolism	O
of	O
bilirubin	B
is	O
generated	O
by	O
the	O
combination	O
of	O
non-conjugated	O
bilirubin	B
(also	O
known	O
as	O
indirect	O
bilirubin)	O
and	O
glucuronic	B
acid.	I

Stock	O
solutions	O
were	O
prepared	O
in	O
methanol	B
(0.1 mg/mL);	O
working	O
solutions	O
were	O
obtained	O
prior	O
to	O
use	O
by	O
dilution.	O

For	O
metabolite	O
extraction,	O
high	O
purity	O
HPLC	O
(or	O
higher)	O
grade	O
solvents	O
methanol,	B
acetone,	B
isopropanol,	B
and	O
acetonitrile,	B
and	O
MQ	O
water	O
(18.2	O
M·cm,	O
<3	O
ppb	O
TOC)	O
were	O
used.	O

Interleukin	O
6	O
(IL-6),	O
IL-8,	O
tumour	O
necrosis	O
factor	O
(TNF)	O
α,	O
leptin,	O
IL-1	O
receptor	O
antagonist	O
(IL-1ra),	O
transforming	O
growth	O
factor	O
β_1	O
(TGF-β_1	O
),	O
total	O
adiponectin,	O
high-molecular-weight	O
(HMW)	O
adiponectin,	O
soluble	O
E-selectin	O
(sE-selectin)	O
and	O
soluble	O
intracellular	O
adhesion	O
molecule	O
1	O
(sICAM-1)	O
were	O
measured	O
using	O
Quantikine	O
(IL-1ra,	O
TGF-β_1	O
,	O
total	O
adiponectin,	O
HMW	O
adiponectin,	O
leptin,	O
sE-selectin,	O
sICAM-1)	O
or	O
Quantikine	O
HS	O
(IL-6,	O
IL-8,	O
TNFα)	B
ELISA	O
kits	O

The	O
depletion	O
of	O
striatal	O
dopamine	B
in	O
the	O
PD	O
brain	O
might	O
also	O
influence	O
purine	B
metabolism.	O

The	O
levels	O
of	O
phytosphingosine	B
and	O
sphinganine	B
were	O
significantly	O
increased	O
in	O
BC	O
subjects	O
relative	O
to	O
healthy	O
controls,	O
which	O
suggests	O
that	O
the	O
perturbed	O
sphingolipid	B
metabolism	O
is	O
implicated	O
in	O
BC.	O

In	O
the	O
validation	O
cohort,	O
plasma	O
concentrations	O
of	O
lactate	B
and	O
total	O
cholesterol	B
were	O
independently	O
determined	O
on	O
the	O
day	O
the	O
blood	O
was	O
drawn	O
at	O
the	O
Rangueil	O
hospital	O
Biochemistry	O
department.	O

CHCl_3	O
:water	O
ext	O
+UF	O
and	O
MeOH:CHCl_3	B
precipitations,	O
and	O
26	O
compounds	O
were	O
different	O
between	O
MeOH:	B

We	O
obtained	O
evidence	O
that	O
the	O
leading	O
GWAS	O
SNP	O
for	O
carnitine	B
(rs1171614)	O
influenced	O
the	O
expression	O
of	O
SLC16A9	O
in	O
lymphoblasts	O
(P-value	O
 = 8.91×10_−6	O
)	O
and	O
rs8056893	O
(associated	O
with	O
lysine)	B
influenced	O
the	O
expression	O
of	O
ZPF90	O
in	O
lymphoblasts	O
(P-value	O
 = 4.01×10_−6	O
)	O
and	O
SLC7A9	O
in	O
thyroid	O
cells	O
(P-value	O
 = 0.00008).	O

Moreover,	O
because	O
methionine	B
metabolism	O
mainly	O
occurs	O
in	O
hepatocytes,	O
methionine	B
metabolism	O
is	O
also	O
closely	O
related	O
to	O
liver	O
disease.	O

The	O
reduction	O
in	O
alanine	B
concentration	O
can	O
also	O
be	O
related	O
to	O
donation	O
of	O
this	O
amino	B
group	O
for	O
glutamine	B
synthesis,	O
which	O
can	O
be	O
converted	O
to	O
glutamic	B
acid	I
in	O
the	O
neurons	O
and,	O
then,	O
it	O
can	O
be	O
used	O
to	O
increase	O
the	O
levels	O
of	O
leucine.	B

From	O
these	O
variations,	O
carnitine	B
and	O
acetylcarnitine	B
were	O
observed,	O
the	O
increment	O
of	O
them	O
and	O
their	O
derivatives	O
were	O
widely	O
reported	O
in	O
various	O
tumors	O
including	O
oral,	O
hepatic,	O
and	O
pancreatic	O
cancers	O
(,	O
).	O

The	O
concentrations	O
of	O
the	O
glucuronide	B
metabolites	O
were	O
determined	O
from	O
their	O
UV	O
absorption	O
spectra	O
at	O
their	O
maxima	O
absorbance	O
in	O
CH_3	O
OH	O
(HON-PhIP-N	O
_2	O
-Glu,	O
318	O
nm;	O
HON-PhIP-N	O
3-Glu,	O
320	O
nm;	O
PhIP-N	O
_2	O
-Gl	O
305	O
nm),	O
using	O
the	O
molar	O
extinction	O
coefficient	O
for	O
PhIP	O
(315	O
nm;	O
ε	O
(M_−1	O
cm_−1	O
)	O
was	O
determined	O
as	O
22,220).	O

Increased	O
levels	O
of	O
lipid	O
oxidation	O
products	O
such	O
as	O
9-oxoODE	B
are	O
normally	O
detected	O
in	O
plasma	O
samples	O
of	O
patients	O
suffering	O
rheumatoid	O
arthritis	O
,	O
and	O
arthrosclerosis	O
.	O

Phosphate	B
buffer	O
was	O
prepared	O
as	O
a	O
4:1	O
ratio	O
of	O
KH_2	O
PO_4	O
:K_2	O
HPO_4	O
in	O
a	O
4:1	O
H_2	O
O:D_2	O
O	O
solution	O
to	O
obtain	O
a	O
final	O
concentration	O
of	O
0.5 M.	O

Another	O
ammonium	B
sulfate	I
precipitation	O
scheme	O
was	O
used	O
by	O
Wild	O
et	O
al.	O

The	O
six	O
major	O
subclasses	O
are	O
PC,	O
PS,	O
PE,	O
PI,	O
PG,	B
and	O
PA.	O

The	O
lipid	O
metabolism,	O
amino	O
acid	O
metabolism,	O
glucose	B
metabolism	O
and	O
other	O
metabolic	O
pathways	O
in	O
T2DM	O
patients	O
had	O
different	O
degrees	O
of	O
disorder	O
and	O
affect	O
each	O
other.	O

Increased	O
expression	O
of	O
α-smooth	B
muscle	O
actin	O
(αSMA)	O
is	O
one	O
commonly	O
reported	O
characteristic	O
of	O
CAFs,	O
presumably	O
reflecting	O
that	O
CAFs	O
are	O
in	O
an	O
“activated	O
state”	O
(,	O
).	O

(A)	O
Partial	O
_1	O
H	O
NMR	O
spectrum	O
of	O
a	O
CSF	O
sample	O
from	O
a	O
representative	O
drug-naïve	O
patient	O
with	O
first-onset	O
schizophrenia	O
(red)	O
and	O
a	O
matched	O
control	O
(black)	O
illustrate	O
a	O
characteristic	O
pH-dependent	O
shift	O
in	O
the	O
β-CH_2	B
and	O
γ-CH_2	B
resonances	O
of	O
glutamine.	B

Nevertheless,	O
R	B
-6-OH-WAR,	I
R	B
-10-OH-WAR,	I
S	O
-4'-OH-WAR	O
and	O
S	B
-7-OH-WAR	I
were	O
able	O
to	O
be	O
quantified	O
in	O
85%,	O
95%,	O
95%	O
and	O
98%	O
of	O
these	O
55	O
subjects,	O
respectively.	O

THP	B
loses	O
two	O
water	O
molecules	O
to	O
yield	O
the	O
5-hydroxy-pyrrole	B
(5HP),	O
which	O
is	O
known	O
to	O
tautomerize	O
to	O
5-oxo-3-pyrroline	B
and	O
5-oxo-2-pyrroline	B
in	O
a	O
ratio	O
of	O
9	O
to	O
1.	O

Conversely,	O
almost	O
all	O
detected	O
glycine-	B
and	O
taurine-conjugated	O
secondary	O
bile	O
acids	O
were	O
elevated	O
post-limonene	O
intervention	O
as	O
was	O
non-conjugated	O
deoxycholate.	B

A	O
shows	O
the	O
variation	O
in	O
peak	O
base	O
widths	O
and	O
B	O
the	O
differences	O
in	O
the	O
sum	O
of	O
resolutions	O
(across	O
water,	O
ammonium	B
formate	I
and	O
formic	O
acid-containing	O
modifiers	O
and	O
all	O
Torus	O
columns)	O
by	O
temperature.	O

The	O
malate-pyruvate	B
and	O
citrate-pyruvate	B
cycles	O
are	O
very	O
active	O
in	O
pancreatic	O
beta	O
cells	O
where	O
PC	O
protein	O
and	O
enzyme	O
activity	O
are	O
high	O
and	O
support	O
these	O
cycles	O
[,].	O

For	O
example,	O
a	O
patient	O
with	O
3-phosphoglycerate	O
dehydrogenase	O
(3-PGDH)	O
deficiency	O
presented	O
with	O
normalized	O
serine	B
due	O
to	O
serine	B
supplementation	O
(188,	O
234,	O
and	O
83	O
μmol/mL,	O
reference	O
range	O
70–194	O
μmol/mL)	O
and	O
glycine	B
(368,	O
213,	O
and	O
161	O
μmol/mL,	O
reference	O
range	O
107–343	O
μmol/mL)	O
in	O
plasma.	O

Hepatocytes	O
(approximately	O
0.12	O
mg	O
protein	O
per	O
well)	O
were	O
incubated	O
with	O
10	O
µM	O
of	O
BaP-4,5-diol,	B
BaP-7,8-diol	B
or	O
BaP-9,10-diol,	B
or	O
H_2	O
O	O
as	O
a	O
control.	O

The	O
TIC	O
of	O
4-OH-E_1	B
-1-N	I
3Ade	O
has	O
a	O
S/N	O
of	O
17	O
(	O
in	O
supplementary	O
information);	O
this	O
can	O
be	O
improved	O
by	O
reconstructing	O
the	O
TIC	O
by	O
including	O
signals	O
from	O
the	O
characteristic	O
product	O
ions	O
of	O
precursors	O
of	O
m/z	O
425	O
and	O
m/z	O
420.	O

Human	O
renal	O
proximal	O
tubule	O
epithelial	O
cells	O
(HRPTEC),	O
purchased	O
from	O
Cambrex	O
Bio	O
Science	O
Inc.	O
(Walkersville,	O
MD,	O
USA),	O
were	O
grown	O
in	O
renal	O
epithelial	O
cell	O
basal	O
medium	O
(REBM)	O
supplemented	O
with	O
0.5%	O
fetal	O
bovine	O
serum,	O
0.1%	O
mEGF,	O
0.1%	O
insulin,	O
0.1%	O
hydrocortisone,	B
0.1%	O
GA-1000,	O
0.1%	O
epinephrine,	B
0.1%	O
T3	O
and	O
0.1%	O
transferrin	O
(all	O
obtained	O
from	O
Lonza,	O
Walkersville,	O
MD,	O
USA).	O

Meanwhile,	O
serum	O
levels	O
of	O
4-OH-E_2	B
increased	O
with	O
increasing	O
concentrations	O
of	O
high-chlorinated	O
PCDFs	O
(i.e.,	O
1,2,3,4,6,7,8-hepta-CDF:	B
β	O
=	O
0.454,	O
p	O
=	O
0.03,	O
R	O
=	O
0.30).	O

The	O
only	O
difference	O
in	O
the	O
metabolites	O
identified	O
was	O
glucose,	B
which	O
had	O
a	O
lesser	O
influence	O
in	O
driving	O
the	O
models	O
derived	O
from	O
Set	O
B	O
than	O
Set	O
A.	O
This	O
difference	O
is	O
likely	O
to	O
have	O
arisen	O
from	O
variations	O
in	O
the	O
timing	O
of	O
sample	O
collection	O
in	O
the	O
clinic	O
and	O
the	O
period	O
after	O
the	O
last	O
meal.	O

Of	O
note,	O
a	O
recent	O
study	O
has	O
shown	O
significant	O
elevation	O
of	O
sphingosine-1-phosphate	B
(S1P)	O
in	O
lung	O
tissues	O
from	O
patients	O
with	O
severe	O
PAH.	O

The	O
sample	O
was	O
loaded	O
onto	O
an	O
Oasis	O
HLB	O
extraction	O
cartridge	O
(150	O
mg,	O
Waters	O
Corporation,	O
Massachusetts,	O
USA)	O
that	O
had	O
been	O
preconditioned	O
with	O
1	O
mL	O
of	O
hexane/2-propanol	O
(50:50,	O
v/v),	O
1	O
mL	O
of	O
methanol,	B
and	O
2	O
mL	O
of	O
water.	O

µM,	O
fumaric	O
Me	O
was	O
1.8	O
(1.3–2.4)	O
µM.	O
Concentrations	O
of	O
aromatic	O
microbial	O
metabolites	O
and	O
mitochondrial	O
metabolites	O
in	O
the	O
serum	O
of	O
three	O
groups	O
of	O
samples,	O
Me	O
(IQR	O
25–75%),	O
µM.	O
*	O
the	O
concentration	O
is	O
below	O
the	O
limit	O
of	O
detection	O
(LOD);	O
**	O
as	O
α-ketoglutaric	B
acid	I
was	O
determined	O
qualitatively,	O
data	O
is	O
demonstrated	O
as	O
the	O
percentage	O
of	O
presence	O
in	O
each	O
group.	O

It	O
is	O
well	O
known	O
that	O
3-hydroxybutyrate	B
levels	O
in	O
blood	O
and	O
tissues	O
may	O
increase	O
during	O
starvation	O
caused	O
by	O
end-stage	O
malignancy.	O

Before	O
their	O
analyses,	O
cells	O
were	O
trypsinized,	O
and	O
the	O
pellet	O
was	O
washed	O
thrice	O
with	O
ice-cold	O
phosphate-buffered	B
saline	I
(PBS),	O
counted	O
into	O
25	O
million	O
aliquots,	O
and	O
stored	O
at	O
− 140°C.	O

SDMA	O
is	O
a	O
stereoisomer	O
of	O
ADMA	B
which	O
does	O
not	O
directly	O
inhibit	O
nitric	B
oxide	I
synthase	O
(,	O
).	O

To	O
further	O
investigate	O
the	O
alterations	O
in	O
ECAR,	O
cells	O
were	O
treated	O
with	O
the	O
glycolytic	B
inhibitor	O
2-DG	O
and	O
the	O
ECAR	O
was	O
assessed.	O

While	O
it	O
is	O
possible	O
that	O
memantine	O
(a	O
non‐competitive	O
NMDA	O
receptor	O
antagonist)	O
might	O
influence	O
glutamine	B
levels,	O
effect	O
estimates	O
for	O
plasma	O
glutamine	B
and	O
memantine	O
predicting	O
AD	O
dementia	O
were	O
unchanged	O
in	O
models	O
containing	O
both	O
metabolites	O
simultaneously,	O
suggesting	O
these	O
metabolites	O
were	O
independently	O
related	O
to	O
AD.	O

In	O
addition,	O
we	O
noticed	O
that	O
the	O
type	O
of	O
treatment	O
[5-aminosalicylic	O
acid	I
versus	O
biologics]	O
influenced	O
the	O
milk	O
cytokines	O
and	O
metabolites	O
profile.	O

For	O
lock	O
mass	O
correction,	O
a	O
standard	O
leucine-enkephalin	B
sample	O
was	O
used,	O
which	O
should	O
generate	O
an	O
[M+H]_+	O
ion	O
with	O
a	O
theoretical	O
m/z	O
value	O
of	O
556.2771 Da	O
under	O
positive-ion	O
mode	O
and	O
an	O
[M-H]_−	O
ion	O
of	O
554.2615 Da	O
under	O
negative-ion	O
mode.	O

The	O
in	O
vitro	O
experiment	O
in	O
this	O
study,	O
which	O
showed	O
a	O
protective	O
effect	O
against	O
oxidative	O
stress	O
in	O
the	O
retinal	B
cells,	O
supports	O
this	O
hypothesis,	O
although	O
the	O
concentration	O
of	O
reactive	O
sulfide	B
species	O
in	O
the	O
experimental	O
study	O
was	O
higher	O
than	O
in	O
the	O
intraocular	O
samples.	O

Compared	O
with	O
C,	O
plasma	O
24S-OH-Chol	B
levels	O
were	O
higher	O
in	O
LOAD	O
(LSD	O
post-hoc	O
test	O
p:	O
0.01)	O
and	O
lower	O
in	O
VD	O
(LSD	O
p:	O
0.05),	O
while	O
no	O
differences	O
were	O
observed	O
as	O
regards	O
the	O
CIND	O
group	O
(model	O
ANOVA	O

Metabolism	O
of	O
these	O
essential	O
FAs	O
can	O
increase	O
the	O
levels	O
of	O
the	O
inflammation-associated	O
free	O
FA	B
arachidonate	I
(20:4n6),	I
which	O
was	O
also	O
significantly	O
higher	O
in	O
C-3N	O
subjects	O
and	O
had	O
a	O
nonsignificant	O
increased	O
trend	O
in	O
A-3N	O
subjects	O
compared	O
to	O
control	O
subjects.	O

During	O
survival	O
analysis	O
using	O
the	O
Kaplan–Meier	O
method	O
for	O
all	O
glioma	O
patients,	O
no	O
significant	O
correlation	O
was	O
discovered	O
between	O
the	O
overall	O
survival	O
(OS)	O
and	O
the	O
CSF	O
level	O
of	O
lactic	O
or	O
citric	B
acid.	I

Gangliosides	B
are	O
glycosphingolipids	B
containing	O
sialic	B
acid	I
found	O
mainly	O
in	O
the	O
plasma	O
membrane	O
and	O
having	O
functions	O
in	O
cell	O
recognition	O
and	O
signalling.	O

For	O
Coomassie	O
Blue	O
staining,	O
the	O
gel	O
was	O
fixed	O
for	O
15	O
min	O
in	O
a	O
solution	O
of	O
36%	O
(v/v)	O
methanol,	B
6%	O
(w/v)	O
trichloroacetic	O
acid	O
and	O
3.6%	O
(w/v)	O
sulfosalicylic	B
acid	I
(all	O
from	O
Sigma-Aldrich).	O

Statistical	O
analysis	O
shows	O
linolenic	B
acid	I
to	O
be	O
significantly	O
different	O
between	O
pCR	O
and	O
SD	O
groups	O
(p	O
 < 0.01).	O

Masses	O
corresponding	O
to	O
cafestol	O
and	O
kahweol,	O
the	O
well-known	O
coffee	O
diterpenoids,	B
were	O
not	O
observed	O
among	O
the	O
discriminants,	O
although	O
a	O
feature	O
at	O
[M+H]_+	O
329	O
was	O
tentatively	O
identified	O
as	O
a	O
kahweol	O
oxide	B
glucuronide.	I

All	O
patients	O
provided	O
written	O
informed	O
consent	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
local	O
research	O
ethics	O
committee	O
(Ärztekammer	O
des	B
Saarlandes,	O
ref.	O

Analysis	O
in	O
the	O
RA	O
murine	B
model	O
(K/BxN	O
transgenic	O
mouse)	O
found	O
that	O
the	O
specific	O
metabolomic	O
profile	O
(nucleic	O
acids,	O
amino	O
acids,	O
reactive	O
derivatives	O
of	O
oxygen,	O
fatty	O
acids,	O
and	O
the	O
enzymes	O
involved	O
in	O
lipolysis	O
and	O
methylation)	O
was	O
significantly	O
different	O
from	O
that	O
in	O
control	O
mice	O
(p	O
 = 0.00075),	O
and	O
evidenced	O
18	O
metabolites	O
out	O
of	O
the	O
59	O
initially	O
studied.	O

a	O
,	O
major	O
MS_2	O
fragmentation	O
routes	O
for	O
GP-tagged	O
sterols	O
and	O
bile	O
acids	O
exemplified	O
by	O
27-hydroxycholesterol.	B

This	O
is	O
supported	O
by	O
another	O
recent	O
study	O
emphasizing	O
the	O
potential	O
role	O
of	O
tryptophan	B
metabolism	O
by	O
the	O
gut	O
microbiota	O
in	O
neuroinflammation	O
and	O
MS.	O

	O
Sex,	O
age	O
and	O
body	O
composition	O
have	O
been	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
certain	O
sphingolipids,	B
including	O
So	O
and	O
Cer,	B
in	O
various	O
diseases.	O

Although	O
choline	B
is	O
considered	O
an	O
essential	O
nutrient	O
and	O
dietary	O
requirements	O
have	O
been	O
developed	O
for	O
almost	O
all	O
domestic	O
animal	O
species,	O
presently	O
there	O
is	O
no	O
requirement	O
established	O
for	O
lactating	O
dairy	O
cows	O
by	O
the	O
NRC	O
.	O

Linking	O
these	O
two	O
observations,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
an	O
up-regulation	O
of	O
DDAH-1	O
at	O
the	O
level	O
of	O
the	O
myocardium	O
may	O
provide	O
the	O
reserve	O
in	O
response	O
to	O
increased	O
systemic	O
ADMA,	B
presumably	O
to	O
maintain	O
myocardial	O
perfusion	O
at	O
the	O
local	O
level	O
in	O
the	O
setting	O
of	O
rising	O
intracardiac	O
pressures.	O

Hot	O
flashes	O
have	O
been	O
suggested	O
as	O
a	O
predictor	O
of	O
tamoxifen	B
efficacy.	O

Ethanol	B
was	O
detected	O
predominantly	O
in	O
the	O
lyophilized	O
samples	O
(A)	O
and	O
made	O
a	O
considerable	O
contribution	O
to	O
the	O
PLS-DA	O
cluster	O
separation	O
between	O
the	O
drying	O
techniques	O
as	O
it	O
had	O
the	O
four	O
highest	O
VIP	O
scored	O
buckets.	O

We	O
first	O
extracted	O
the	O
ion	O
profile	O
in	O
the	O
range	O
10.06-10.26 min	O
and	O
then	O
obtained	O
the	O
max	O
value	O
of	O
that	O
profile	O
as	O
peak	O
maxima	O
for	O
TG	B
(58:8)	I

Calibration	O
standards	O
were	O
prepared	O
by	O
10	O
times	O
dilution	O
of	O
the	O
corresponding	O
combined	O
working	O
solutions	O
with	O
blank	O
human	O
plasma	O
to	O
obtain	O
final	O
concentrations	O
in	O
the	O
range	O
of	O
25.0–2500 ng/mL	O
for	O
paclitaxel,	O
10.0–1000.0 ng/mL	O
for	O
docetaxel	O
and	O
SN-38,	O
0.1–10.0 μ	O
g/mL	O
for	O
vinorelbine	O
and	O
pemetrexed,	O
10.0–10000.0 ng/mL	O
for	O
vinblastine	B
and	O
irinotecan,	O
1.0–1000.0 ng/mL	O
for	O
cyclophosphamide	O
and	O
ifosfamide,	B
and	O
50.0–5000.0 ng/mL	O
for	O
carboplatin,	B
etoposide,	B
and	O
gemcitabine.	O

The	O
Bayesian	O
network	O
analysis	O
confirms	O
the	O
importance	O
of	O
creatine	B
and	O
creatinine,	B
although	O
it	O
does	O
not	O
select	O
the	O
testosterone	B
metabolites.	O

Chromatograms	O
of	O
SRM	O
972	O
Level	O
4	O
obtained	O
with	O
the	O
SB-CN	O
column	O
and	O
isocratic	O
elution	O
with	O
68%	O
methanol,	B
32%	O
water	O
(volume	O
fractions)	O
and	O
a	O
column	O
temperature	O
of	O
45	O
°C.	O

The	O
aqueous	O
fraction	O
of	O
the	O
extract	O
was	O
reconstituted	O
in	O
600 μL	O
of	O
D_2	O
O	O
phosphate-buffered	O
solution	O
with	O
10 μL	O
of	O
a	O
10 mM	O
3-(trimethylsilyl)-1-propanesulfonate	B
sodium	I
salt	O
(TMPS)	O
before	O
NMR	O
analysis.	O

Urine	O
samples	O
were	O
processed	O
with	O
an	O
equal	O
volume	O
of	O
50%	O
aqueous	O
acetonitrile	B
containing	O
chloropropamide	B
and	O
aminopimelic	B
acid	I
as	O
internal	O
standards	O
and	O
chromatographed	O
on	O
a	O
50	O
×	O
2.1	O
mm	O
Acquity	O
BEH	O
1.7	O
μm	O
C18	O
column	O
(reverse	O
phase	O
(RP)	O
chromatography	O
for	O
the	O
quantitation	O
of	O
CS	O
and	O
metabolite	O
561+).	O

Briefly,	O
samples	O
were	O
thawed	O
on	O
ice	O
in	O
a	O
cold	O
room	O
(4°C)	O
and	O
extracted	O
using	O
50%	O
acetonitrile	B
in	O
water	O
and	O
homogenized	O
on	O
a	O
MagNA	O
Lyser	O
to	O
generate	O
0.1	O
mg/μL	O
supernatants.	O

LC-MS_n	O
	O
analysis	O
revealed	O
that	O
the	O
derivatized	O
sterols	O
were	O
present	O
almost	O
exclusively	O
in	O
the	O
first	O
2	O
ml	O
of	O
methanol	B
eluent	O
(SPE2-Fr-1	O
and	O
SPE2-Fr-2).	B

Lastly,	O
the	O
aqueous	O
layer	O
was	O
removed	O
and	O
added	O
anhydrous	B
sodium	I
sulphate	I
to	O
eliminate	O
the	O
remaining	O
water.	O

It	O
is	O
possible	O
that	O
blood	O
pressure	O
in	O
type	O
1	O
diabetes	O
is	O
so	O
strongly	O
influenced	O
by	O
other	O
factors,	O
such	O
as	O
glycemia	O
and	O
albuminuria,	O
that	O
marginal	O
risk	O
conferred	O
by	O
insufficient	O
vitamin	B
D	I
is	O
not	O
relevant.	O

(b)	O
Plot	O
of	O
relative	O
frequency	O
versus	O
relative	O
concentrations	O
of	O
tyrosine.	B

Data	O
was	O
collected	O
over	O
a	O
mass	O
range	O
of	O
m/z	O
67-1000,	O
using	O
a	O
sheath	O
gas	O
flow	O
rate	O
of	O
40	O
units,	O
auxillary	O
gas	O
flow	O
rate	O
of	O
20	O
units,	O
sweep	O
gas	O
flow	O
rate	O
of	O
2	O
units,	O
spray	O
voltage	O
of	O
3.5	O
and	O
2.5	O
kV	B
for	O
positive	O
and	O
negative	O
ion	O
modes	O
(respectively),	O
capillary	O
inlet	O
temperature	O
of	O
275	O
°C,	O
auxillary	O
gas	O
heater	O
temperature	O
of	O
350	O
°C	O
and	O
an	O
S-lens	O
RF	O
level	O
of	O
45.	O

In	O
particular,	O
there	O
was	O
a	O
dominant	O
psoriasis-dependent	O
increase	O
in	O
the	O
majority	O
of	O
urea	B
cycle	O
intermediates	O
including	O
aspartate,	B
arginine,	B
ornithine,	B
and	O
citrulline.	B

We	O
were	O
able	O
to	O
identify	O
several	O
metabolites	O
whose	O
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
urine	O
samples	O
of	O
CT-positive	O
subjects,	O
including	O
sucrose,	B
mannitol,	B
pyruvate	B
and	O
lactate.	B

Using	O
UPLC-LTQ-Orbitrap	O
mass	O
spectrometry	O
analysis,	O
the	O
metabolomics	O
profiles	O
of	O
111	O
non-diabetic	O
and	O
non-obese	O
individuals	O
with	O
borderline-to-moderate	O
HTG	O
were	O
compared	O
with	O
those	O
of	O
111	O
age-	O
and	O
sex-matched	O
controls	O
with	O
normotriglyceridemia	O
(NTG,	O
TG	B
<150	O
mg/dL).	O

The	O
differentiated	O
metabolites	O
identified	O
in	O
the	O
CD	O
samples	O
included	O
tyrosine,	B
an	O
ornithine	B
isomer,	I
arachidonic	B
acid,	I
eicosatrienoic	B
acid,	I
docosatetraenoic	B
acid,	I
a	O
sphingomyelin,	B
a	O
ceramide,	B
and	O
dimethylsphinganine.	B

After	O
adjustment	O
for	O
age,	O
sex,	O
BMI,	O
LDL	B
cholesterol,	I
and	O
fasting	O
glucose,	B
differences	O
in	O
serum	O
lipid	O
metabolites	O
between	O
patients	O
with	O
cardiovascular	O
disease	O
(CAD)	O
and	O
control	O
subjects	O
were	O
calculated	O
using	O
general	O
linear	O
model	O
controlling	O
the	O
false	O
discovery	O
rate	O
(FDR)	O
and	O
q-value	O
<0.05	O
were	O
considered	O
to	O
be	O
statistically	O
significant.	O

These	O
methods	O
were	O
subsequently	O
used	O
to	O
evaluate	O
SRM	O
909c	O
Human	O
Serum,	O
and	O
25(OH)D_3	O
was	O
the	O
only	O
vitamin	B
D	I
metabolite	O
detected	O
in	O
this	O
material.	O

We	O
observed	O
a	O
reduction	O
in	O
glucose	B
uptake	O
in	O
MUC16	O
knockdown	O
cells.	O

For	O
example,	O
in	O
a	O
large	O
study	O
from	O
two	O
cohorts	O
we	O
recently	O
demonstrated	O
that	O
type	O
2	O
diabetes	O
is	O
significantly	O
associated	O
with	O
dihydroceramides,	B
ceramides	B
and	O
cholesterol	B
ester	I
species.	O

Method	O
precision	O
was	O
good	O
for	O
oxalate	B
and	O
glycolate	B
(coefficients	O
of	O
variation	O
[CV]	O
were	O
<6.3%	O
and	O
<4.2%	O
for	O
inter-	O
and	O
intraday	O
precision,	O
respectively)	O
and	O
acceptable	O
for	O
glyoxylate	B
(CV	O
<18.3%	O
and	O
<6.7%	O
for	O
inter-	O
and	O
intraday	O
precision,	O
respectively).	O

Albumin	O
creatinine	B
ratio	O
was	O
<30	O
mg/g	O
in	O
1092	O
(89%),	O
and	O
>30	O
mg/g	O
in	O
81	O
(11%)	O
subjects.	O

In	O
our	O
experiments,	O
α-OG	B
treatment	O
suppressed	O
TET	O
activity	O
almost	O
completely;	O
however,	O
there	O
was	O
no	O
influence	O
on	O
DNMT	O
activity	O
(Fig. ).	O

In	O
the	O
clinical	O
samples,	O
the	O
mean	O
value	O
of	O
the	O
minimum	O
glucose	B
values	O
during	O
the	O
study	O
day	O
was	O
5.4	O
mmol/L,	O
and	O
the	O
mean	O
value	O
of	O
the	O
maximum	O
glucose	B
values	O
was	O
10.4	O
mmol/	O

Epidemiological	O
studies	O
demonstrate	O
that	O
low	O
circulating	O
concentrations	O
of	O
total	O
25-hydroxyvitamin	B
D	I

Analytes	O
(fatty	O
acids,	O
fatty	O
acid–amino	O
acid	O
conjugates	O
and	O
other	O
anionic	O
species)	O
were	O
mixed	O
in	O
a	O
1:1	O
molar	O
ratio	O
with	O
DMAN	O
in	O
ethanol	B
and	O
allowed	O
to	O
dry	O
on	O
a	O
MALDI	O
metallic	O
target.	O

Males	O
had	O
significantly	O
higher	O
levels	O
of	O
PGE-M	O
than	O
females	O
(p<0.0001),	O
but	O
there	O
was	O
no	O
effect	O
of	O
gender	O
on	O
levels	O
of	O
8-iso	B
-PGF_2α	I
.	O

A	O
total	O
of	O
ten	O
urine	O
metabolites	O
were	O
found	O
to	O
be	O
significantly	O
changed	O
in	O
EC	O
patients	O
compared	O
to	O
HCs	O
(Table	O
),	O
including	O
higher	O
levels	O
of	O
acetoacetate,	B
cis-aconitate,	B
citrate	B
and	O
glutamate,	B
together	O
with	O
lower	O
amounts	O
of	O
glycine,	B
taurine,	B
creatinine,	B
ethanolamine,	B
glucose	B
and	O
hippurate.	B

Whereas	O
lactose	B
(upper	O
panels)	O
and	O
3-phenyllalctic	B
acid	I
(middle	O
panels)	O
reached	O
peak	O
values	O
in	O
serum	O
(left	O
panels)	O
in	O
the	O
2–4	O
h	O
time	O
interval,	O
pinitol	B
values	O
(lower	O
panels)	O
were	O
still	O
elevated	O
during	O
the	O
4–6	O
h	O
time	O
interval.	O

T2DM,	O
Type	O
2	O
diabetes	O
mellitus;	O
HV,	B
healthy	O
volunteer.	O

Our	O
quantitation	O
strategy	O
(example	O
of	O
one	O
metabolite,	O
citric	B
acid,	I
in	O
Figure	O
D,E)	O
was	O
implemented	O
for	O
85	O
previously	O
identified	O
metabolites	O
in	O
urine	O
(Table	O
1).	O

Both	O
the	O
independent	O
validation	O
study	O
and	O
the	O
initial	O
case-control	O
study	O
showed	O
a	O
similar	O
pattern	O
of	O
nonlinear	O
association	O
between	O
plasma	O
TMAO	B
and	O
GDM,	O
which	O
is	O
depicted	O
in	O
.	O

Since	O
this	O
study	O
identifies	O
differences	O
in	O
the	O
fatty	O
acid	O
composition	O
of	O
TGRL	O
(particularly	O
PUFA	O
and	O
PUFA-derived	O
oxylipins)	B
that	O
correlate	O
strongly	O
with	O
the	O
nature	O
of	O
an	O
inflammatory	O
response,	O
we	O
envision	O
future	O
controlled	O
dietary	O
intervention	O
studies	O
that	O
vary	O
the	O
fatty	O
acid	O
composition	O
of	O
the	O
meal	O
(e.g.	O
replacing	O
SFA	O
with	O
PUFA),	O
or	O
supplement	O
with	O
n-3	O
PUFA,	O
and	O
quantify	O
the	O
postprandial	O
response.	O

Ammonium	B
acetate,	I
formic	B
acid,	I
acetonitrile	B
and	O
ethyl	B
acetate	I
were	O
obtained	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO),	O
and	O
methanol	B
from	O
Fisher	O
Scientific	O
(Fair	O
Lawn,	O
NJ).	O

	O
Decreases	O
in	O
the	O
level	O
of	O
apolipoprotein	O
A1	O
(β	O
−0.10;	O
95%	O
confidence	O
interval	O
[CI]	O
−0.16,	O
−0.05;	O
adjusted	O
p	O
=	O
0.029)	O
and	O
free	O
cholesterol	B
to	O
total	O
lipid	O
ratio	O
present	O
in	O
small	O
high-density	O
lipoprotein	O
subspecies	O
(HDL)	O
(β	O
−0.10;	O
95%	O
CI	O
−0.15,	O
−0.05;	O
adjusted	O
p	O
=	O
0.029)	O
were	O
associated	O
with	O
migraine	O
status.	O

95%	O
CI	O
of	O
0.95−0.98),	O
the-CH	O
group	O
(δ	O
2.61,	O
r	O
=	O
0.88;	O
95%	O
CI	O
of	O
0.85−0.91),	O
and	O
the	O
methyl	B
group	I
from	O
the	O
propionic	B
acid	I
side	O
chain	O
(δ	O
1.07,	O
r	O
)	O
0.87;	O
95%	O
CI	O
of	O
0.92–0.9).	O

Importantly,	O
in	O
severe	O
NAFLD	O
there	O
were	O
significant	O
reductions	O
in	O
diglycerides	B
(DAG),	O
G-6-P,	O
fumarate,	B
NAD/NADH,	O
ATP/AMP,	O
and	O
UTP/UMP	O
(Table	O
)	O
most	O
likely	O
indicating	O
a	O
dysfunction	O
in	O
the	O
coordination	O
of	O
mitochondrial	O
fat	O
oxidation	O
and	O
glucose	B
transport	O
activity.	O

Furthermore,	O
high	O
levels	O
of	O
indoleacetic	B
acid,	I
a	O
breakdown	O
product	O
of	O
tryptophan	B
metabolism	O
directly	O
downstream	O
indoleacetaldehyde,	B
were	O
significantly	O
associated	O
with	O
PSA	O
and	O
lymph	O
node	O
progression	O
(p	O
 = 0.0081	O
and	O
p	O
 = 0.025,	O
respectively,	O
Log-Rank	O
test)	O
(Fig.	O
b	O
and	O
c).	O

Thus,	O
modulation	O
of	O
tryptophan	B
metabolism,	O
such	O
as	O
the	O
production	O
of	O
serotonin	B
can	O
be	O
used	O
as	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
CRC	O
in	O
the	O
future.	O

Three	O
sets	O
of	O
QC	O
samples	O
in	O
pooled	O
human	O
serum	O
displayed	O
97.3%,	O
98.5%,	O
and	O
96.8%	O
average	O
proline	B
amount	O
remaining	O
after	O
4,	O
8,	O
or	O
24	O
h,	O
respectively.	O

Also,	O
top	O
KEGG	O
pathway	O
analysis	O
results	O
exhibit	O
some	O
pathways	O
that	O
have	O
a	O
known	O
association	O
to	O
breast	O
and	O
other	O
cancers	O
such	O
as	O
mTOR,	O
Oxytocine,	B
MAPK,	O
AGE-RAGE	O
signaling	O
pathways.	O

Lactate	B
exerts	O
excitatory	O
effects	O
on	O
neuronal	O
activity	O
[,	O
];	O
thus,	O
increased	O
hippocampal	O
firing,	O
a	O
direct	O
action	O
of	O
lactate	B
on	O
the	O
CNS,	O
may	O
contribute	O
to	O
lactate-induced	O
panic.	O

Interestingly,	O
the	O
heterozygous	O
carrier	O
classification	O
samples	O
exhibit	O
similar	O
increases	O
in	O
the	O
triacylglycerol	B
terminal–CH_3	O
,	O
bulk	O
chain	O
(-CH_2	O
-)_n	O
,	O
and	O
vinylic	B
proton	O
spectral	O
buckets	O
as	O
the	O
NPC1	O
samples,	O
with	O
the	O
exception	O
of	O
CH_2	O
-CH	O
_2	O
-CH=	O
region	O
which	O
was	O
not	O
selected	O
as	O
a	O
discriminatory	O
variable	O
for	O
distinguishing	O
the	O
HET	O
spectra	O
(Table ).	O

It	O
should	O
be	O
noted	O
that	O
Sreekumar	O
et	O
al.	O
did	O
not	O
report	O
sarcosine	B
in	O
patient	O
serum	O
or	O
plasma	O
associated	O
with	O
metastatic	O
prostate	O
cancer.	O

The	O
best	O
studied	O
of	O
them,	O
9-hydroxystearic	B
acid	I
(9-HSA),	O
induces	O
apoptosis	O
in	O
cell	O
lines	O
by	O
acting	O
through	O
mechanisms	O
involving	O
different	O
targets.	O

The	O
strengths	O
of	O
our	O
pilot	O
study	O
include	O
the	O
use	O
of	O
multiple	O
time	O
points	O
to	O
study	O
changes	O
post‐RYGB	O
and	O
the	O
use	O
of	O
both	O
NMR‐based	O
metabolomics	O
and	O
FA	B
analysis.	O

Concentrations	O
of	O
symmetric	B
dimethylarginine	I
and	O
citrulline	B
were	O
increased	O
in	O
GC	O
(see	O
Fig.	O

The	O
experimental	O
(red)	O
spectrum	O
overlaid	O
with	O
a	O
mathematical	O
fit	O
(black)	O
from	O
a	O
composite	O
of	O
lognormal	O
(pink)	O
and	O
Lorentzian	O
(green)	O
lineshapes	O
after	O
subtraction	O
of	O
the	O
baseline	O
in	O
the	O
betaine	B
region.	O

The	O
metabolites	O
that	O
allowed	O
to	O
distinguish	O
these	O
groups	O
were:	O
N	O
-acetylated	O
compounds	O
and	O
phenylalanine	B
(up-regulated	O
in	O
serum),	O
low-density	O
lipoproteins	O
and	O
very	O
low-density	O
lipoproteins	O
(decreased	O
in	O
serum)	O
as	O
well	O
as	O
glycine	B
(increased	O
in	O
urine)	O
and	O
acetoacetate	B
(decreased	O
in	O
urine).	O

The	O
ratio	O
of	O
α-TL:α-CEHC	B
was	O
approximately	O
7	O
in	O
the	O
cohort	O
with	O
diabetes	O
compared	O
to	O
0.9	O
in	O
the	O
controls.	O

We	O
observed	O
that	O
eight	O
lipid	O
species	O
from	O
the	O
phosphatidylethanolamine	B
and	O
phosphatidylcholine	B
lipid	O
classes	O
were	O
discovered	O
and	O
validated	O
to	O
vary	O
consistently	O
across	O
the	O
three	O
time-points,	O
where	O
the	O
within-subject	O
variance	O
can	O
be	O
up	O
to	O
1.3-fold	O
higher	O
than	O
between-subject	O
variance.	O

Briefly,	O
sialic	B
acid	I
takes	O
part	O
in	O
the	O
development	O
of	O
B	O
and	O
T	O
cells	O
[,	O
]	O
and	O
plays	O
a	O
role	O
in	O
the	O
interaction	O
of	O
immune	O
cells	O
with	O
other	O
cells.	O

Coupling	O
reflects	O
adjacent	O
_13	O
C	O
nuclei	O
arising	O
from	O
the	O
metabolism	O
of	O
[U-_13	B
C]glucose.	I
_13	O
C–_13	O
C	O
coupling	O
was	O
observed	O
in	O
lactate	B
and	O
alanine,	B
as	O
expected	O
for	O
a	O
high	O
rate	O
of	O
glucose	B
metabolism	O
to	O
pyruvate	B
in	O
glycolytic	B
cells.	O
_13	O
C–_13	O
C	O
coupling	O
was	O
also	O
detected	O
in	O
glycine,	B
an	O
intermediate	O
in	O
nucleotide	O
and	O
protein	O
synthesis	O
recently	O
identified	O
as	O
an	O
important	O
fate	O
of	O
glucose	B
carbon	O
in	O
some	O
tumor	O
cells	O
[,	O
].	O

A	O
60	O
cm	O
long	O
fused	O
silica	B
capillary,	O
used	O
in	O
the	O
experiment,	O
(375	O
µm	O
O.D.,	O
with	O
50	O
µm	O
I.D)	O
was	O
obtained	O
from	O
Polymicro	O
Technologies	O
(Phoenix,	O
AZ,	O
USA).	O

Three	O
metabolites	O
were	O
identified	O
that	O
contributed	O
to	O
the	O
group	O
separation	O
in	O
both	O
studies:	O
3,4-dihydroxybutanoic	B
acid,	I
docosapentaenoic	B
acid,	I
and	O
uric	B
acid.	I

PGE-M	O
and	O
8-iso	B
-PGF_2α	I
data	I
were	O
normalized	O
by	O
dividing	O
by	O
mg	O
creatinine	B
to	O
account	O
for	O
differences	O
in	O
urine	O
concentration	O
and	O
log	O
transformed	O
because	O
of	O
right	O
skewedness.	O

Pseudouridine	B
and	O
uric	O
acid-3-nucleoside	O
concentrations	O
in	O
urine	O
of	O
patients	O
with	O
ovarian	O
cancer	O
were	O
higher	O
than	O
that	O
of	O
healthy	O
people.	O

Calibration	O
standards	O
were	O
prepared	O
by	O
spiking	O
appropriate	O
amounts	O
of	O
the	O
working	O
standard	O
solution	O
to	O
charcoal-stripped	O
human	O
serum	O
to	O
make	O
the	O
concentrations	O
of	O
0.5,	O
1,	O
2,	O
5,	O
10,	O
20,	O
50,	O
100,	O
200	O
pg/mL	O
(10	O
times	O
higher	O
concentration	O
for	O
4-OH-E2	B
and	O
2-OH-E2).	B

The	O
conversion	O
of	O
arginine	B
to	O
ornithine,	B
by	O
the	O
enzyme	O
arginase,	O
has	O
been	O
suggested	O
as	O
a	O
major	O
regulator	O
of	O
cell	O
growth.	O

After	O
ingestion	O
of	O
a	O
[U_13	B
C]glucose	I
tracer,	O
isotopically	O
enriched	O
erythritol	B
was	O
detected	O
in	O
the	O
blood	O
of	O
the	O
donor.	O

The	O
methanol,	B
2-chloro-phenylalanine,	B
methoxyamine	B
and	O
pyridine	B
were	O
obtained	O
from	O
Aladdin	O
(Shanghai,	O
China).	O

In	O
seminal	O
plasma,	O
in	O
contrast	O
to	O
sperm,	O
the	O
acylcarnitine	B
content	O
tended	O
to	O
correlate	O
positively	O
with	O
sperm	O
concentration.	O

Coproporphyrinogen	O
III,	O
protoporphyrin	B
IX,	I
hematoporphyrin,	O
and	O
harderoporphyrin	O
are	O
naturally	O
occurring	O
porphyrins,	O
intermediates	O
that	O
play	O
an	O
important	O
role	O
in	O
heme	B
biosynthesis.	O

We	O
next	O
examined	O
the	O
effect	O
of	O
blocking	O
FASN	O
and	O
COX-2	O
on	O
major	O
cell	O
survival	O
proteins	O
such	O
as	O
p-Erk	O
and	O
p-GSK3β.	B

The	O
exact	O
role	O
of	O
the	O
polyamines	B
(putrescine,	I
spermine	I
and	O
spermidine)	B
is	O
unclear,	O
although	O
they	O
are	O
involved	O
in	O
cellular	O
proliferation.	O

Metabolites	O
were	O
measured	O
during	O
cold	O
exposure	O
after	O
exercise	O
with	O
most	O
prominent	O
changes	O
seen	O
within	O
the	O
triglycerides	B
stored	O
in	O
lipoproteins.	O

To	O
each	O
well	O
internal	O
standard/protein	O
precipitation	O
solution	O
(400	O
μL)	O
was	O
added	O
except	O
that	O
isopropanol-chloroform	B
(9:1)	I
(400	O
μL)	O
was	O
used	O
for	O
a	O
blank.	O

(P	O
=	O
.004),	O
isoleucine	B
levels	O
increased	O
from	O
20.43	O
(10.92–27.41)	O
μM	O
to	O
48.72	O
(36.28–64.84)	O

In	O
accordance	O
with	O
these	O
studies,	O
we	O
observed	O
higher	O
levels	O
of	O
acylcarnitines	B
in	O
prevalent	O
type	O
2	O
diabetes	O
cases,	O
yet	O
no	O
significant	O
changes	O
in	O
incident	O
cases,	O
which	O
indicated	O
that	O
acylcarnitine-induced	O
mitochondrial	O
dysregulation	O
may	O
exacerbate	O
the	O
progression	O
of	O
type	O
2	O
diabetes	O
rather	O
than	O
serve	O
as	O
a	O
trigger.	O

(A	O
and	O
B	O
)	O
Plot	O
of	O
relative	O
intensity	O
of	O
trifluoroacetate	B
(A	O
)	O
and	O
stearate	B
(B	O
)	O
anions	O
versus	O
MAILD	O
matrices	O
(DMAN,	O
solid	O
lines;	O
DMA,	B
dashed	O
lines),	O

For	O
the	O
ATA	O
patients,	O
the	O
second	O
sampling	O
was	O
performed	O
4 hours	O
after	O
the	O
last	O
dose	O
of	O
lysine-aspirin.	B

Our	O
experimental	O
data	O
shows	O
high	O
level	O
of	O
lactic	B
acid,	I
phosphoric	B
acid	I
and	O
benzoic	B
acid	I
in	O
lung	O
cancer	O
patients,	O
as	O
compared	O
to	O
controls.	O

Lactate	B
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
the	O
progression	O
of	O
malignancy	O
through	O
the	O
formation	O
of	O
tumor	O
necrosis	O
.	O

In	O
monophasic	O
extraction,	O
ethanol	B
or	O
methanol	B
was	O
added	O
at	O
a	O
ratio	O
of	O
1:3	O
or	O
1:9	O
(plasma:solvent),	O
respectively.	O

A	O
and	O
B	O
(A:	O
99.9%	O
H_2	O
O,	O
0.1%	O
Formic	B
Acid,	I
FA;	B
B:	O
89.9%	O
acetonitrile,	B
ACN,	O
10%	O
H_2	O
O,	O
0.1%	O
FA,	B
(%	O
are	O
v/v))	O
at	O
a	O
flow	O
rate	O
of	O
10.0	O
µL/min	O
with	O
the	O
following	O
gradient	O
conditions:	O
0–5	O
min,	O
0%	O
B;	O
5–25	O
min,	O
40%	O
B;	O
25–32	O
min,	O
45%	O
B;	O
32–47	O
min,	O
45%	O
B;	O
47–49	O
min,	O
70%	O
B;	O
49–55	O
0%	O

In	O
addition,	O
and	O
importantly,	O
_15	O
N-cholamine	B
possesses	O
a	O
permanent	O
positive	O
charge,	O
which	O
enables	O
efficient	O
positive	O
mode	O
detection	O
of	O
the	O
same	O
carboxyl-containing	O
metabolites	O
by	O
MS,	O
irrespective	O
of	O
the	O
pH	O
or	O
solvent	O
conditions	O
of	O
the	O
eluting	O
media,	O
commonly	O
used	O
for	O
chromatographic	O
separation	O
before	O
detection	O
by	O
MS.	O

Inside	O
the	O
MDD	O
group,	O
the	O
plasma	O
level	O
of	O
linoleic	B
acid	I
in	O
ELS/MDD	O
patients	O
was	O
higher	O
than	O
the	O
MDD	O
patients	O
without	O
ELS.	O

2,2-dimethyl-2-silapentane-5-sulfonate-d_6	B
(DSS),	O
3-(Trimethylsilyl)propionic-2,2,3,3-d_4	O
acid	O
sodium	O
salt	O
(TSP),	O
D_2	O
O,	O
potassium	B
phosphate	I
(monobasic,	O
dibasic),	O
methanol,	B
and	O
chloroform	B
were	O
obtained	O
from	O
Sigma/Aldrich	O
(Milwaukee,	O
USA)	O
and	O
used	O
as	O
received.	O

The	O
set	O
of	O
20	O
samples	O
was	O
measured	O
9	O
times	O
across	O
the	O
study	O
populations	O
and	O
included	O
measurements	O
of	O
24,25(OH)_2	B
D_3	O
using	O
the	O
liquid-liquid	O
extraction	O
method	O
without	O
methylamine	B
in	O
the	O
chromatographic	O
method	O
and	O
the	O
method	O
with	O
methylamine.	B

The	O
duration	B
of	O
90°	O
pulses	O
was	O
automatically	O
calibrated	O
for	O
each	O
individual	O
sample	O
using	O
a	O
homonuclear	O
gated	O
nutation	O
experiment	O
on	O
the	O
locked	O
and	O
shimmed	O
samples	O
after	O
automatic	O
tuning	O
and	O
matching	O
of	O
the	O
probe	O
head.	O

However,	O
patient	O
survival	O
is	O
not	O
influenced	O
by	O
AFP,	O
total	O
bilirubin	B
(TBIL),	O
ALP	O
and	O
D-aspartic	B
acid	I
level.	O

A	O
(0.1%	O
formic	B
acid	I
in	O
water)	O
and	O
20%	O
solvent	O
B	O
(methanol).	O

The	O
ANOVA	O
analysis	O
demonstrated	O
significant	O
differences	O
between	O
the	O
three	O
patient	O
classes	O
for	O
the	O
metabolites	O
picolinic	B
acid	I
(p	O
=	O
0.009),	O
xanthurenic	B
acid	I
(p	O
=	O
0.017),	O
and	O
kynurenine	B
(p	O
=	O
0.043).	O

_,	O
A	O
secondary	O
metabolic	O
pathway	O
leads	O
to	O
the	O
production	O
of	O
the	O
neurotransmitter	O
serotonin.	B

Oxylipin	B
profiling	O
was	O
performed	O
in	O
plasma	O
of	O
each	O
participant	O
using	O
mass	O
spectrometry	O
(MS)-based	O
lipidomic	O
profiling.	O

Samples	O
for	O
amino	O
acid	O
analysis	O
underwent	O
pre-column	O
derivatisation	O
using	O
AccQ·Fluor	B
reagent	O
(Waters,	O
Milford,	O
USA).	O

Moreover,	O
the	O
MID	O
of	O
phosphatidylcholine	B
exhibited	O
two	O
distinct	O
modes	O
corresponding	O
to	O
either	O
one	O
(C_16	O
/C_18	O
)	O
or	O
two	O
(C_34	O
)	O
de	O
novo	O
synthesized	O
acyl	O
chains,	O
indicating	O
that	O
consumed	O
lipids	O
are	O
actively	O
remodeled	O
by	O
cells.	O

There	O
were	O
52	O
features	O
common	O
to	O
all	O
fractions,	O
146	O
features	O
shared	O
between	O
neutral	O
and	O
phospholipid	B
fractions,	O
26	O
features	O
shared	O
between	O
neutral	O
and	O
fatty	O
acid	O
fractions,	O
and	O
32	O
features	O
shared	O
between	O
phospholipid	B
and	O
fatty	O
acid	O
fractions.	O

a	O
3-Hydroxybutyrate;	B
b	O
Acetoacetate;	B
c	O
Carnitine;	B
d	O
Cystine;	B
e	O
Homocysteine;	B

Regarding	O
the	O
agnostic	O
approach,	O
we	O
conducted	O
the	O
PCA	O
on	O
the	O
kynurenine	B
pathway	O
metabolites	O
and	O
other	O
immune	O
markers,	O
followed	O
by	O
linear	O
regression	O
analyses	O
using	O
the	O
extracted	O
principal	O
components	O
as	O
independent	O
variables.	O

The	O
resected	O
tumors	O
were	O
then	O
sectioned	O
and	O
labeled	O
with	O
_13	O
C-glucose	B
ex	O
vivo	O
to	O
examine	O
downstream	O
metabolism.	O

The	O
AUC	O
of	O
plasma	O
glucose	B
in	O
the	O
early	O
and	O
the	O
late	O
phase	O
after	O
the	O
glucose	B
bolus	O
was	O
similar	O
in	O
rs7903146	O
risk	O
allele	O
carriers	O
and	O
controls.	O

Emericellene	B
A	O
(2),	O
obtained	O
as	O
a	O
colorless	O
amorphous	O
solid,	O
was	O
determined	O
to	O
have	O
the	O
molecular	O
formula	O
C_25	O
H_38	O
O_2	O
by	O
a	O
combination	O
of	O
HRESIMS	O
and	O
NMR	O
data	O
and	O
indicated	O
seven	O
units	O
of	O
unsaturation.	O

The	O
non-polar	O
and	O
polar	O
fractions	O
were	O
further	O
derivatized	O
with	O
O-methyl-hydroxyamine	B
hydrochloride	I
and	O
pyridine	B
to	O
convert	O
oxo-groups	O
to	O
O-methyl-oximes	B
and	O
subsequently	O
with	O
a	O
silylating	O
agent	O
before	O
analysis	O
.	O

For	O
example,	O
2-ethoxy-2-methylbutane	B
acid,	I
hexanoic	B
acid,	I
phenylmethanol,	B
2,4-dimethylheptan-1-ol,	B
benzoic	B
acid,	I
and	O
6-pentyloxan-2-one	B
were	O
significantly	O
decreased	O
in	O
the	O
extracellular	O
medium	O
of	O
high	O
metastatic	O
potential	O
cell	O
line	O
(PC3),	O
whereas	O
1-ethoxypentane	B
was	O
significantly	O
decreased	O
specifically	O
in	O
moderate	O
and	O
low	O
metastatic	O
potential	O
cell	O
line	O
(DU145	O
and	O
LNCaP,	O
respectively).	O

In	O
fact,	O
small	O
RSDs,	O
typically	O
within	O
15%,	O
were	O
found	O
for	O
all	O
Δ9/Δ11	O
isomeric	O
ratios	O
measured	O
for	O
C18:1,	B
i.e.,	O
(14 ± 4%)	O
for	O
normal	O
and	O
(15 ± 4%)	O
for	O
T2D.	O
As	O
a	O
contrast,	O
RSDs	O
of	O
43 ± 14%	O
for	O
normal	O
and	O
42 ± 12%	O
for	O
T2D	O
were	O
obtained	O
for	O
lipid	O
profiling	O
at	O
subclass	O
level.	O

Further	O
research	O
into	O
the	O
biochemical	O
role	O
of	O
N	B
-methylalanine	I
is	O
warranted	O
and	O
may	O
help	O
elucidate	O
its	O
link	O
to	O
insulin	O
levels.	O

Concentrations	O
measured	O
in	O
plasma	O
and	O
CSF	O
are	O
given	O
in	O
Online	O
Resources	O
8	O
and	O
9,	O
respectively	O
Note	O
that	O
we	O
use	O
the	O
systematic	O
nomenclature	O
where	O
addition	O
of	O
a	O
hydroxy	B
group	O
to	O
the	O
terminal	O
side	O
chain	O
of	O
cholesterol	B
leading	O
to	O
R	O
stereochemistry	O
at	O
C-25	O
gives	O
the	O
compound	O
(25R)26-hydroxycholesterol.	B

The	O
PE	O
derivatives	O
generated	O
[M+2	O
picolinic	B
acid	I
+Na]_+	O
ions	O
as	O
the	O
base	O
peaks	O
under	O
ESI	O
positive	O
conditions.	O

A	O
LC-MS/MS	O
method	O
to	O
measure	O
and	O
quantify	O
a	O
panel	O
of	O
63	O
inflammatory	O
markers	O
(eicosanoids)	O
was	O
developed	O
in	O
house.	O

In	O
HCC	O
compared	O
to	O
NTT,	O
statistical	O
models	O
showed	O
high	O
levels	O
of	O
lactate	B
and	O
phosphocholine,	B
and	O
low	O
level	O
of	O
glucose.	B

Olanzapine:	B
scatterplot	O
of	O
log‐transformed	O
capillary	O
versus	O
venous	O
plasma	O
concentrations	O
with	O
regression	O
line.	O

In	O
Rett	O
syndrome	O
patients,	O
elevated	O
total	O
cholesterol	B
was	O
detected	O
in	O
blood	O
and	O
fibroblasts	O
and	O
a	O
ketogenic	O
diet	O
was	O
found	O
to	O
ameliorate	O
some	O
neurobehavioral	O
symptoms	O
[,].	O

We	O
measured	O
the	O
effect	O
of	O
carnosine	B
supplementation	O
on	O
the	O
plasma	O
lipidome	O
in	O
non-diabetic	O
overweight	O
and	O
obese	O
adults	O
from	O
a	O
randomised	O
double-blind	O
placebo	O
controlled	O
pilot	O
trial.	O

The	O
total	O
levels	O
of	O
23	O
phospholipid	B
species	O
were	O
significantly	O
changed	O
in	O
HBsAg	O
(+)	O
group	O
comparing	O
to	O
the	O
HBsAg	O
(−)	O
group	O
(Fig.	O

We	O
did	O
detect	O
trace	O
levels	O
of	O
4′-HO-PhIP;	O
however,	O
the	O
4′-sulfate	B
conjugate	O
of	O
4′HO-PhIP	O
was	O
not	O
found	O
(data	O
not	O
shown).	O

(LDL)	O
≥3.4 mmol/l	O
(≥130 mg/dl),	O
or	O
high-density	O
lipoprotein	O
cholesterol	B
(HDL)	O
<1.04 mmol/l	O
(<40 mg/dl),	O
or	O
use	O
of	O
anti-lipidemic	O
medication.	O

This	O
finding	O
reflects	O
the	O
effects	O
of	O
leptin	O
on	O
regulation	O
of	O
serotonin	B
metabolism	O
which,	O
in	O
prior	O
studies,	O
has	O
shown	O
to	O
play	O
a	O
role	O
in	O
bone	O
mass	O
accrual,	O
appetite	O
modulation,	O
and	O
energy	O
expenditure.	O

To	O
determine	O
the	O
effect	O
of	O
reduced	O
glucose,	B
cells	O
were	O
grown	O
in	O
media	O
with	O
25	O
mM	O
or	O
5	O
mM	O
glucose.	B

The	O
receiver	O
operating	O
characteristic	O
(ROC)	O
analysis	O
of	O
23	O
phospholipid	B
species	O
(Table _S2	O
)	O
found	O
that	O
9	O
phospholipid	B
species	O
including	O
PC	B
(18:1/16:0),	I
PC	B
(16:0/18:2),	I
PC	B
(16:0/16:0),	I
PC	B
(16:1/16:0),	I
PC	B
(16:0/14:0),	I
PE	B
(22:6/18:1),	I
PE	B
(16:0/20:4),	I
PE	B
(18:2/20:4),	I
LPA	B
(16:0)	I
had	O
greater	O
diagnostic	O
power	O
with	O
an	O
area	O
under	O
the	O
ROC	O
(AUC)	O
greater	O
than	O
0.7,	O
and	O
the	O
predictive	O
power	O
of	O
PC	O
were	O
greater	O
than	O
PE	O
and	O
LPA	O
(Table ).	O

The	O
metabolome	O
from	O
frozen	O
samples	O
was	O
extracted	O
incubating	O
the	O
tissue	O
in	O
1	O
mL	O
of	O
80%	O
methanol	B
at	O
room	O
temperature	O
on	O
a	O
benchtop	O
for	O
4	O
hours.	O

The	O
sum	O
of	O
5β-tetrahydrocortisol,	B
5α-tetrahydrocortisol,	B
5β-tetrahydrocortisone	B
and	O
5α-tetrahydrocortisone	B
was	O
calculated	O
and	O
plotted	O
for	O
each	O
of	O
the	O
seven	O
healthy	O
young	O
adults.	O

Comparison	O
of	O
molecular	O
features	O
detected	O
by	O
LC-TOF	O
on	O
RPC	O
when	O
methanol	B
(MeOH)	O
or	O
methanol-ethanol	B
(MeOH-EtOH)	O
precipitation	O
methods	O
are	O
used.	O

The	O
cartridges	O
were	O
then	O
washed	O
with	O
acetic	B
acid	I
and	O
eluted	O
twice	O
with	O
acetonitrile.	B

Rett	O
syndrome,	O
sphingolipid,	B
sphinganine,	B
sphingosine,	B
MECP2	O

Furthermore,	O
Bittner	O
et	O
al.	O
extended	O
the	O
utility	O
of	O
FRET-based	O
glucose	B
sensing	O
to	O
measure	O
glycolytic	B
flux	O
by	O
establishing	O
the	O
rate	O
of	O
cytosolic	O
glucose	B
depletion.	O

The	O
sum	O
of	O
all	O
cortisol	B
metabolites	O
was	O
calculated	O
as	O
mg/g	O
creatinine.	B

Controls	O
were	O
performed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pyridoxal	B
5′-phosphate	I
and	O
α-ketoglutarate,	B
RLH	O
or	O
substrate.	O

The	O
hexane:ethyl	O
acetate	B
layer	O
was	O
removed,	O
transferred	O
to	O
a	O
50	O
mL	O
centrifuge	O
tube,	O
and	O
the	O
extraction	O
process	O
was	O
repeated	O
with	O
an	O
additional	O
8	O
mL	O
solvent.	O

Moreover,	O
glutamate,	B
an	O
immediate	O
precursor	O
for	O
glutathione,	B
plays	O
a	O
regulatory	O
role	O
in	O
its	O
synthesis,	O
removing	O
oxidants.	O

In	O
our	O
NMR	O
analyses,	O
increased	O
plasma	O
platelet	O
content	O
was	O
associated	O
with	O
higher	O
levels	O
of	O
the	O
glycolysis	O
end-product	O
pyruvate,	B
the	O
amino	O
acids	O
leucine,	O
isoleucine,	B
valine,	B
phenylalanine,	B
and	O
glutamate,	B
and	O
signals	O
from	O
N-acetylglycoproteins.	B

Altered	O
metabolites	O
mapped	O
to	O
pathways	O
involved	O
in	O
monoamine	B
metabolism,	O
mitochondrial	O
function,	O
and	O
inflammation,	O
suggesting	O
a	O
model	O
in	O
which	O
complex	O
relationships	O
between	O
monoamine	B
metabolism	O
and	O
mitochondrial	O
bioenergetics	O
contribute	O
to	O
biological	O
mechanisms	O
involved	O
in	O
depression	O
that	O
may	O
be	O
augmented	O
by	O
inflammation	O
during	O
HIV	O
infection.	O

Also,	O
RBC	O
have	O
a	O
reservoir	O
of	O
glutathione,	B
the	O
most	O
prevalent	O
anti-oxidant	O
in	O
humans	O
and	O
one	O
that	O
is	O
essential	O
for	O
the	O
protection	O
of	O
hemoglobulin	O
(,	O
).	O

EZ-Pierce	O
20μm	B
aluminum	I
foil	O
was	O
purchased	O
from	O
Thermo	O
Scientific.	O

In	O
addition,	O
the	O
levels	O
of	O
9	O
metabolites	O
(ornithine,	O
phenylalanine,	B
tyrosine,	B
aspartate	B
+	O
asparagine,	B
C3-carnitine,	B
C4-carnitine,	B
C8-carnitine,	B
C14-carnitine	B
and	O
C16-carnitine)	B
were	O
significantly	O
altered	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
only	O
in	O
the	O
2015	O
data	O
set.	O

2017	O
demonstrated	O
a	O
decrease	O
of	O
proline	B
and	O
a	O
simultaneous	O
increase	O
of	O
glutamate	B
serum	O
level	O
as	O
a	O
marker	O
of	O
acute	O
ischemic	O
stroke;	O
here,	O
we	O
demonstrated	O
an	O
increase	O
in	O
proline	B
as	O
a	O
marker	O
of	O
chronic	O
ischemic	O
stroke.	O

The	O
CSF	O
from	O
the	O
ALS	O
group	O
shows	O
differences	O
in	O
cholesterol	B
metabolite	O
concentrations	O
compared	O
to	O
controls	O
and	O
also	O
in	O
the	O
concentration	O
of	O
cholesterol	B
itself	O
(1.66 ± 0.36 μg/mL	O
cf.	O

For	O
fatty	O
acyl	O
side	O
chains,	O
abundances	O
were	O
higher	O
with	O
age	O
for	O
C22:5	B
(2),	O
C20:5	B
(2)	O
and	O
C22:4,	B
but	O
lower	O
for	O
C18:2	B
(44)	O
and	O
C20:4	B
(4).	O

When	O
we	O
started	O
the	O
delivery	O
of	O
β-pinene,	B
the	O
signal	O
of	O
the	O
protonated	O
analyte	O
raised	O
sharply	O
to	O
reach	O
a	O
plateau.	O

Antibodies	O
were	O
as	O
following:	O
anti-PLCε	O
(dilution	O
1:1000;	O
Santa	O
Cruz	O
Biotechnology);	O
anti-YAP	O
(dilution	O
1:1000;	O
CST);	O
anti-PSAT1	O
(dilution	O
1:1000;	O
Absin);	O
anti-PSPH	O
(dilution	O
1:1000;	O
Absin);	O
anti-SHMT2	O
(dilution	O
1:500;	O
Novus);	O
anti-CyclinD1	B
(dilution	O
1:500)	O
and	O
anti-PCNA	O
(dilution	O
1:500)	O
were	O
from	O
Wanlei-bio	O
(Shenyang,	O
China),	O
anti-β-actin	B
(dilution	O
1:3000),	O
and	O
anti-H3	O
(dilution	O
1:2000)	O
were	O
purchased	O
from	O
Abcam	O
(Cambridge,	O
UK).	O

Venous	O
blood	O
was	O
collected	O
in	O
polypropylene	B
tubes	O
with	O
EDTA	O
in	O
the	O
early	O
morning	O
after	O
overnight	O
fasting,	O
then	O
immediately	O
centrifuged	O
at	O
3000	O
×	O
g	O
for	O
10	O
min.	O

Samples	O
underwent	O
liquid-liquid	O
extraction	O
(LLE)	O
with	O
1.3	O
mL	O
of	O
MTBE	B
by	O
vortex-mixing	O
for	O
10	O
min,	O
followed	O
by	O
centrifugation	O
at	O
3400g	O
at	O
4	O
°C	O
for	O
15	O
min	O
(D37520	O
Osterode	O
Benchtop	O
Centrifuge,	O
Thermo	O
Electron).	O

Studies	O
in	O
humans	O
confirmed	O
these	O
findings	O
by	O
detecting	O
lower	O
blood	O
levels	O
of	O
alanine	B
and	O
glycine	B
in	O
hyperthyroidism	O
or	O
after	O
T3	O
administration	O
in	O
combination	O
with	O
an	O
increased	O
uptake	O
of	O
these	O
amino	O
acids.	O

Activation	O
of	O
Ras	O
in	O
human	O
proximal	O
tubule	O
epithelial	O
cells	O
(HRPTEC)	O
treated	O
with	O
stable	O
agonist	O
of	O
20-HETE	B
was	O
measured	O
using	O
a	O
Ras	O
pull-down	O
detection	O
kit.	O

In	O
EAC	O
tumors,	O
expression	O
of	O
the	O
glycolytic	B
marker	O
PKM2	O
was	O
significantly	O
positively	O
associated	O
with	O
obesity.	O

We	O
measured	O
lower	O
levels	O
of	O
avocadyne	O
4-acetate	B
and	O
1-acetoxy-2-hydroxy-16-heptadecen-4-one	B
in	O
the	O
urine	O
from	O
patients	O
with	O
NMIBC	O
than	O
in	O
the	O
urine	O
from	O
healthy	O
controls.	O

Our	O
findings	O
appear	O
to	O
differ	O
from	O
previous	O
investigations,	O
which	O
showed	O
increased	O
plasma	O
concentrations	O
of	O
the	O
branched	O
chain	O
amino	O
acids	O
and	O
alanine	B
in	O
insulin-resistant	O
states	O
such	O
as	O
obesity	O
[,	O
].	O

Dried	O
urine	O
extracts	O
were	O
then	O
derivatized	O
by	O
addition	O
of	O
100	O
µL	O
acetonitrile/n	O
-propyl	I
iodide	I
80/20	O
(v/v).	O

The	O
enzymes	O
driving	O
relevant	O
reactions	O
are:	O
1,	O
lactate	O
dehydrogenase;	O
2,	O
alanine	O
aminotransferase;	O
3,	O
glutamine	B
synthetase;	O
4,	O
glutaminase.	O

For	O
instance,	O
our	O
study	O
employed	O
acetonitrile,	B
whereas	O
both	O
Michopoulos	O
et	O
al	O
.	O

AP,	B
acute	O
pancreatitis;	O
ERCP,	O
endoscopic	O
retrograde	O
cholangiopancreatography.	O

Our	O
findings	O
indicated	O
that	O
patients	O
with	O
early	O
stage	O
NSCLC	O
(stage	O
IA–IIB)	O
exhibited	O
different	O
serum	O
levels	O
of	O
such	O
metabolite	O
classes	O
as	O
amino	O
acids	O
and	O
their	O
derivatives,	O
acylcarnitines,	B
and	O
organic	O
acids	O
as	O
compared	O
with	O
a	O
healthy	O
control	O
group	O
(Table ).	O

The	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
(NIST),	O
in	O
collaboration	O
with	O
the	O
National	O
Institutes	O
of	O
Health’s	O
Office	O
of	O
Dietary	O
Supplements	O
(NIH-ODS),	O
has	O
developed	O
a	O
Standard	O
Reference	O
Material	O
(SRM)	O
for	O
the	O
determination	O
of	O
25-hydroxyvitamin	B
D	I
[25(OH)D]	O
in	O
serum.	O

LPCs	O
are	O
the	O
most	O
well-characterized	O
and	O
abundant	O
LGPL	O
in	O
human	O
plasma	O
(125–143 µM	O
in	O
healthy	O
individuals)	O
,	O
and	O
circulating	O
levels	O
are	O
determined	O
by	O
their	O
generation	O
via	O
two	O
pathways	O
–	O
1)	O
transfer	O
of	O
a	O
fatty	O
acid	O
from	O
PC	O
to	O
cholesterol	B
by	O
lecithin-cholesterol	B
acyltransferase	O
(LCAT;	O
supplementary	O
Figure	O
6d),	O
and	O
2)	O
phospholipase	O
A_2	O
(PLA_2	O
)-mediated	O
hydrolysis	O
of	O
PC	O
(Supplementary	O
Figure	O
6c,	O
bottom)	O
and	O
clearance	O
via	O
transporters	O
such	O
as	O
albumin	O
and	O
alpha-1	O
acid	O
glycoprotein	O
.	O

It	O
is	O
suggested	O
that	O
ADMA	B
represents	O
one	O
major	O
source	O
for	O
urinary	O
DMA.	B

To	O
overcome	O
this	O
influence,	O
we	O
removed	O
the	O
bins	O
related	O
to	O
lactate	B
from	O
the	O
data	O
matrix.	O

Both,	O
adenosine	B
and	O
inosine	B
have	O
been	O
suggested	O
to	O
play	O
a	O
protective	O
role	O
against	O
diabetes	O
development.	O

We	O
also	O
showed	O
that	O
arachidonic	B
acid	I
is	O
involved	O
in	O
the	O
netrin	O
signaling	O
pathway	O
and	O
had	O
a	O
significant	O
association	O
with	O
HCTZ	O
BP	O
response	O
(SBP	O
adjusted-p=1×10_−4	O
,	O
DBP	B
adjusted-p=7×10_−4	O
;	O
),	O
after	O
adjustment	O
for	O
age,	O
gender	O
and	O
baseline	O
BP.	O

Groups	O
of	O
lipids,	O
important	O
to	O
evaluate	O
lipid	O
metabolism,	O
were	O
also	O
analyzed	O
by	O
summing	O
(total	O
LPCs,	O
total	O
PC	O
aa,	O
total	O
PC	B
ae,	I
total	O
SMs,	O
total	O
lipids)	O
(Table	O
B	O
in	O
).	O

However,	O
we	O
can	O
measure	O
the	O
levels	O
of	O
compounds	O
which	O
are	O
the	O
products	O
of	O
cycles	O
with	O
acetyl-CoA	B
participation	O
which	O
is	O
necessary	O
to	O
synthesize	O
FA	B
and	O
ketone	B
bodies.	O

Although	O
the	O
potential	O
role	O
of	O
the	O
metabolic	O
pathway	O
in	O
the	O
development	O
of	O
BC	O
has	O
been	O
reported	O
in	O
the	O
previous	O
urine	O
and	O
tissue	O
metabonomic	O
studies_,	O
,	O
AFMK,	O
indolelactic	B
acid	I
and	O
indoleacetic	B
acid	I
were	O
firstly	O
identified	O
as	O
the	O
diagnostic	O
serum	O
biomarkers	O
of	O
BC.	O

In	O
a	O
different	O
study,	O
elevated	O
serum	O
glucose	B
levels	O
at	O
the	O
time	O
of	O
PCa	O
diagnosis	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
recurrence	O
compared	O
with	O
patients	O
with	O
a	O
normal	O
glucose	B
level.	O

The	O
lower	O
limit	O
of	O
quantification	O
(LOQ)	O
of	O
PhIP	O
is	O
5	O
parts-per-trillion	O
(ppt),	O
and	O
the	O
LOQ	O
values	O
for	O
the	O
glucuronide	B
conjugates	O
are	O
50	O
ppt,	O
when	O
25	O
μL	O
of	O
urine	O
are	O
employed	O
for	O
assay.	O

In	O
plasma,	O
AD	O
was	O
reproducibly	O
associated	O
with	O
elevated	O
levels	O
of	O
glutamine	B
and	O
a	O
halogen‐containing	O
compound	O
and	O
reduced	O
levels	O
of	O
piperine.	B

shows	O
the	O
association	O
between	O
two	O
estrogen	B
metabolites	O
and	O
prostate	O
cancer	O
risk.	O

In	O
one	O
example,	O
chloramphenicol	B
(CAP)	O
was	O
quantified	O
by	O
spiking	O
light	O
(L;	O
unlabeled)	O
and	O
heavy	O
(H;	O
deuterium-labeled)	O
CAP;	O
into	O
human	O
plasma	O
at	O
varying	O
concentrations.	O

BMI,	O
body	O
mass	O
index;	O
DED,	O
dry	O
eye	O
disease;	O
DHEA,	O
dehydroepiandrosterone;	B
DHEA-S,	B
dehydroepiandrosterone	B
sulfate;	I
SD,	O
standard	O
deviation;	O
SQDES,	O
Short	O
Questionnaire	O
for	O
Dry	O
Eye	O
Syndrome	O

Training	O
decreased	O
total	O
lipids	O
and	O
cholesterol	B
within	O
chylomicrons	O
and	O
medium	O
VLDL	O
decreased	O
(Figure B,C).	O

The	O
first	O
examination	O
of	O
fasting	O
blood	O
glucose	B
during	O
pregnancy	O
was ≥ 5.1 mmol/L,	O
and < 7.0 mmol/L.	O
(2)	O
During	O
24–28 weeks,	O
75 g	O
glucose	B
was	O
adopted	O
for	O
2 h	O
to	O
conduct	O
Oral	O
Glucose	B
Tolerance	O
Test	O
(OGTT):	O
fasting	O
blood	O
glucose ≥ 5.1 mmol/	B

We	O
found	O
statistically	O
significantly	O
higher	O
serum	O
lactate	B
and	O
citrate	B
concentrations	O
in	O
non-survivors	O
compared	O
to	O
30-day	O
survivors.	O

Decreased	O
choline	B
concentrations	O
were	O
found	O
in	O
all	O
IUGR	O
subsets,	O
with	O
a	O
progression	O
across	O
clinical	O
severity	O
in	O
early	O
(25.7%	O
decrease),	O
vasodilated	O
late	O
(18.7%)	O
and	O
non-vasodilated	O
late	O
IUGR	O
cases	O
(9%).	O

In	O
this	O
ischemic	O
stroke	O
study,	O
citric	B
acid	I
was	O
not	O
measured,	O
but	O
two	O
additional	O
TCA	O
metabolites,	O
2-oxoglutarate	B
and	O
fumarate,	B
were	O
also	O
massively	O
increased	O
in	O
urine.	O

Feature	O
13	O
at	O
m/z	O
304.0905	O
yielded	O
one	O
hit	O
in	O
MMCD,	O
namely	O
N	B
-acetylaspartylglutamate	I
(NAAG).	O

At	O
the	O
12	O
o’clock	O
position	O
there	O
is	O
a	O
decrease	O
of	O
lipids/phospholipids	O
and	O
increase	O
of	O
lactate	B
(Lac)	O
at	O
1.33 ppm.	O

Choline	B
and	O
folic	B
acid	I
are	O
B	O
vitamins	O
that	O
are	O
essential	O
to	O
T.	O
cruzi	O
growth	O
in	O
minimal	O
medium	O
.	O

Thin	O
layer	O
chromatography	O
was	O
performed	O
with	O
plastic-backed	O
plates	O
coated	O
with	O
silica	B
gel	O
F_254	O
,	O
and	O
the	O
plates	O
were	O
visualized	O
by	O
spraying	O
with	O
vanillin/H_2	O
SO_4	O
solution,	O
followed	O
by	O
warming.	O

The	O
second	O
model	O
was	O
able	O
to	O
discriminate	O
the	O
stroke	O
subtypes	O
like	O
atherothrombotic	O
etiology	O
from	O
cardioembolic	O
and	O
lacunar	O
etiologies,	O
with	O
lysine,	B
leucine,	B
and	O
cysteine	B
plasmatic	O
concentrations	O
being	O
the	O
most	O
important	O
metabolites.	O

Furthermore,	O
urinary	O
concentrations	O
of	O
citrulline	B
(p	O
=	O
0.0205),	O
N-methylarginine	B
(p	O
=	O
0.0134),	O
methylsuccinate	B
(p	O
=	O
0.0357)	O
and	O
urea	B
(p	O
=	O
0.0159)	O
showed	O
a	O
significant	O
difference	O
with	O
increasing	O
means	O
between	O
V1	O
and	O
V3	O
while	O
no	O
significant	O
changes	O
in	O
urinary	O
metabolites	O
were	O
demonstrated	O
between	O
V1	O
and	O
V2.	O

This	O
renders	O
a	O
precise	O
integration	O
of	O
the	O
hydrogen	B
carbonate	I
band	O
difficult.	O

We	O
observed	O
significant	O
differences	O
between	O
patients	O
with	O
autism	O
and	O
controls	O
in	O
overall	O
samples	O
for	O
12	O
of	O
17	O
metabolites:	O
3	O
in	O
the	O
positive	O
mode	O
(decanoylcarnitine,	O
phytosphingosine,	B
pregnanetriol)	O
and	O
9	O
in	O
the	O
negative	O
mode	O
(DHA,	O
DPA,	O
adrenic	B
acid,	I
S1P,	O
LPA(18:2(9Z,12Z)/0:0),	B
LysoPE(0:0/16:0),	B
LysoPE(18:0/0:0),	B
UA	O
and	O
9,10-EOA).	B

These	O
claims	O
were	O
further	O
supported	O
by	O
OPLS-DA	O
analysis,	O
where	O
several	O
specific	O
metabolites	O
such	O
as	O
cadaverine,	B
Pro,	O
Ala,	O
1,4-butanedioic	B
acid,	I
urea,	B
Val,	O
Lys,	O
Leu,	O
glycerol,	B
Ile,	O
5-oxo-Pro,	B
benzenepropanoic	B
acid	I
(i.e.,	O
hydrocinnamic	B
acid),	O
Phe,	O
sedoheptulose	B
and	O
Tyr,	O
were	O
able	O
to	O
differentiate	O
CRC	O
patients	O
from	O
H	O
volunteers	O
(Figure	O
C).	O

A	O
large	O
intact	O
ATP	B
signal	O
in	O
the	O
spectrum	O
is	O
an	O
indicator	O
of	O
the	O
integrity	O
of	O
the	O
tissue	O
harvesting	O
and	O
extraction	O
method	O
as	O
shown	O
in	O
.	O

In	O
the	O
second	O
model,	O
adjusting	O
for	O
sex	O
and	O
tryptophan,	B
only	O
HAA,	O
riboflavin	B
and	O
cotinine	B
remained	O
significant	O
predictors	O
of	O
ADHD/control	O
status,	O
while	O
KA	O
and	O
XA	O
were	O
no	O
longer	O
significant.	O

Initial	O
and	O
final	O
serum	O
triglyceride	B
concentrations	O
of	O
the	O
test	O
group	O
were	O
134.7	O
±	O
13.7 mg/dL	O
and	O
123.0	O
±	O
12.8 mg/dL,	O
respectively,	O
(P	O
<	O
0.1).	O

Also,	O
the	O
subjects	O
were	O
asked	O
to	O
refrain	O
from	O
intake	O
of	O
caffeine,	B
nicotine	B
and	O
wholegrains	O
12 h	O
prior	O
to	O
the	O
blood	O
sample	O
being	O
collected	O
and	O
only	O
to	O
drink	O
water	O
in	O
the	O
last	O
2 h.	O

A	O
total	O
of	O
350 µL	O
of	O
a	O
phosphate	B
sodium	I
buffer	O
(70 mM	O
Na_2	O
HPO_4	O
;	O
20%	O
(v/v)	O
_2	O
H_2	O
O;	O
0.025%	O
(v/v)	O
NaN_3	O
;	O
0.8%	O
(w/v)	O
sodium	B
trimethylsilyl	I
[2,2,3,3-_2	I
H_4	I
]-propionate	I
(TMSP)	O
pH	O
7.4)	O
was	O
added	O
to	O
350 µL	O
of	O
each	O
serum	O
sample,	O
and	O
the	O
mixture	O
was	O
homogenized	O
by	O
vortexing	O
for	O
30 s.	O

Following	O
simvastatin	B
treatment,	O
a	O
significant	O
decrease	O
was	O
found	O
in	O
plasma	O
levels	O
of	O
cholesterol	B
(p<0.0027,	O
q<0.055),	O
alpha-tocopherol	B
(p<0.0003,	O
q<0.017),	O
and	O
gamma-tocopherol	B
(p<0.037,	O
q<0.13),	O
(vitamin	O
E),	O
and	O
lauric	B
acid	I
(p<0.0055,	O
q<0.055).	O

To	O
test	O
this	O
hypothesis,	O
we	O
conducted	O
a	O
cross-sectional	O
study	O
in	O
which	O
40	O
estrogen	B
metabolites,	O
conjugates	O
and	O
depurinating	O
DNA	O
adducts	O
were	O
analyzed	O
in	O
urine	O
samples	O
from	O
healthy	O
women,	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
based	O
on	O
Gail	O
Model	O
score	O
>1.66%,	O
and	O
women	O
with	O
breast	O
carcinoma.	O

The	O
adenosine	B
network	O
showed	O
the	O
key	O
enzymes	O
that	O
regulate	O
adenosine	B
production	O
and	O
metabolism,	O
adenosine	O
deaminase	O
(ADA;	O
EC.3.5.4.4),	O
which	O
converts	O
adenosine	B
to	O
inosine,	B
and	O
ecto-5′-nucleotidase	O
(EC3.1.3.5),	O
which	O
regulates	O
adenosine	B
production.	O

50	O
μL	O
of	O
a	O
0.24	O
M	O
(20	O
mg/mL)	O
solution	O
of	O
methoxylamine	B
hydrochloride	I
in	O
pyridine	B
was	O
added	O
to	O
each	O
vial,	O
samples	O
were	O
vortex	O
mixed,	O
and	O
left	O
to	O
react	O
for	O
17	O
h	O
at	O
room	O
temperature	O
in	O
the	O
dark.	O

Combined	O
MTBE	B
solution	O
was	O
dried	O
under	O
N_2	O
at	O
35°C,	O
and	O
then	O
dissolved	O
in	O
200	O
µL	O
methanol.	B

In	O
some	O
experiments,	O
the	O
IS	O
was	O
not	O
included,	O
in	O
which	O
case	O
relative	O
abundances	O
(%RA	O
)	O
were	O
determined	O
against	O
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid,	I
the	O
most	O
abundant	O
sterol/bile	O
acid	O
component	O
found	O
in	O
CSF,	O
by	O
applying	O
Equation	O
2.	O

Glycine	B
is	O
an	O
important	O
amino	O
acid	O
associated	O
with	O
different	O
cycles	O
in	O
colon	O
cancer	O
and	O
seen	O
to	O
increase	O
in	O
the	O
second,	O
third	O
and	O
fourth	O
stages	O
as	O
compared	O
to	O
stages	O
0	O
and	O
I.	O
High	O
glycine	B
consumption	O
was	O
seen	O
in	O
60	O
types	O
of	O
cancer	O
cells.	O

Glutamine;	B
7	O
NAc;	O
8.	O

Fast	O
metabolizers	O
may	O
not	O
have	O
any	O
parent	O
drug	O
in	O
their	O
blood	O
or	O
urine	O
within	O
just	O
a	O
day	O
or	O
so	O
after	O
the	O
last	O
dose,	O
therefore	O
it	O
is	O
imperative	O
that	O
the	O
methadone	B
metabolites	O
of	O
EDDP	O
and	O
EMDP	O
be	O
measured	O
with	O
the	O
parent	O
drug	O
before	O
non-compliance	O
is	O
concluded	O
on	O
the	O
basis	O
of	O
undetectable	O
methadone	B
concentrations.	O

Thus,	O
an	O
increase	O
in	O
Otu4	O
or	O
Otu13	O
or	O
a	O
decrease	O
in	O
Otu1	O
or	O
Otu8	O
was	O
expected	O
to	O
increase	O
threonine	B
levels,	O
as	O
observed	O
in	O
the	O
NMR	O
results	O
(Fig.	O

As	O
a	O
result,	O
it	O
is	O
reasonable	O
to	O
use	O
the	O
product	O
of	O
putrescine	B
and	O
spermidine	B
concentration	O
as	O
a	O
diagnostic	O
marker	O
to	O
characterize	O
liver	O
and	O
lung	O
cancer.	O

Several	O
other	O
baseline	O
metabolites	O
were	O
associated	O
with	O
the	O
change	O
in	O
glucose	B
to	O
c-peptide	O
level	O
and	O
monitoring	O
these	O
metabolites	O
prior	O
to	O
simvastatin	B
treatment	O
could	O
aid	O
in	O
predicting	O
the	O
potential	O
of	O
an	O
individual	O
for	O
developing	O
beta	O
cell	O
dysfunction	O
or	O
insulin	O
resistance.	O

In	O
this	O
cohort,	O
differences	O
were	O
seen	O
in	O
DMA	B
and	O
creatinine	B
levels	O
between	O
HBeAg	O
positive	O
and	O
negative	O
subjects	O
in	O
the	O
CHB	O
and	O
CIR	O
subgroups	O
respectively.	O

A	O
major	O
depletion	O
of	O
total	O
fatty	O
acids	O
and	O
cholesterol	B
was	O
observed.	O

Other	O
metabolites	O
from	O
this	O
global	O
analysis	O
that	O
significantly	O
correlated	O
to	O
insulin	O
sensitivity	O
included	O
certain	O
organic	O
acid,	O
amino	O
acid,	O
lysophospholipid,	B
acylcarnitine	B
and	O
fatty	O
acid	O
species.	O

The	O
negative	O
mode	O
UPLC-(−)	O
ESI/MS/MS	O
analysis	O
resulted	O
in	O
the	O
identification	O
and	O
quantification	O
of	O
76	O
oxylipins,	B
including	O
55	O
20-carbon	O
polyunsaturated	O
fatty	O
acid-derived	O
oxylipins	B
(	O
and	O
)	O
and	O
21	O
18-carbon	O
polyunsaturated	O
fatty-acid-derived	O
oxylipins.	B

However,	O
in	O
a	O
meta-analysis,	O
it	O
is	O
evident	O
that	O
cholesterol,	B
LDL-cholesterol	B
and	O
HDL-cholesterol	B
are	O
reduced	O
by	O
a	O
vegan	O
diet.	O

In	O
our	O
case,	O
we	O
observed	O
a	O
significant	O
higher	O
level	O
of	O
total	O
choline-containing	O
compounds	O
in	O
all	O
ovarian	O
carcinomas,	O
the	O
free	O
choline	B
being	O
more	O
pronounced	O
in	O
endometrial	O
carcinomas	O
and	O
phosphocholine/glycerophosphocholine	O
in	O
mucinous	O
and	O
serous	O
carcinomas.	O

Though	O
NAG	O
is	O
higher	O
in	O
children	O
than	O
in	O
adults,	O
the	O
N-acetyl-glycoprotein	B
(NAG)	O
signal	O
at	O
2.07	O
ppm	O
in	O
the	O
EG	O
group	O
most	O
presumably	O
reflects	O
the	O
inflammation	O
processes,	O
as	O
it	O
is	O
compared	O
to	O
that	O
for	O
the	O
RG	O
group	O
of	O
the	O
similar	O
age	O
spectrum.	O

When	O
the	O
spectrum	O
for	O
12-oxo	O
LTB4	B
and	O
one	O
of	O
these	O
unknowns	O
was	O
compared,	O
it	O
was	O
observed	O
that	O
their	O
patterns	O
were	O
highly	O
similar	O
thus	O
indicating	O
a	O
common	O
chemical	O
structure	O
(–).	O

After	O
salvage,	O
pteridine	B
precursors	O
are	O
reduced	O
to	O
their	O
respective	O
biologically	O
active	O
tetrahydro	B
forms	O
by	O
the	O
pteridine	B
reductase	O
PTR1.	O

Plots	O
of	O
the	O
ROC	O
curves	O
and	O
the	O
boxplots	O
of	O
metabolite	O
levels	O
were	O
reported	O
in	O
Figure	O
for	O
palmitic	B
acid	I
(upper	O
left	O
and	O
upper	O
right)	O
and	O
for	O
CA	O
19-9	O
(bottom	O
left	O
and	O
bottom	O
right),	O
separately.	O

These	O
concentrations	O
may	O
also	O
have	O
been	O
influenced	O
by	O
more	O
recent	O
food	O
intake	O
in	O
the	O
high–cystathionine	B
concentration	O
group	O
because	O
plasma	O
tryptophan	B
also	O
was	O
higher	O
(P	O
<	O
0.001).	O

In	O
this	O
study,	O
we	O
reported	O
urinary	O
metabolite	O
profiles	O
of	O
FSGS	O
patients	O
compared	O
to	O
those	O
of	O
MCD	O
patients	O
or	O
healthy	O
controls,	O
and	O
we	O
found	O
a	O
significant	O
difference	O
in	O
urinary	O
myo-inositol	B
levels	O
among	O
these	O
groups.	O

Semi-synthetic	O
opiates	O
are	O
produced	O
from	O
morphine	B
or	O
thebaine	O
by	O
chemically	O
modifying	O
the	O
hydroxyl	O
groups	O
or	O
other	O
parts	O
of	O
the	O
opioid	O
alkaloids.	O

The	O
reported	O
increase	O
of	O
lactic	B
acid	I
in	O
long-term	O
stability	O
studies	O
was	O
only	O
observed	O
in	O
Exp.	O

Previous	O
studies	O
demonstrated	O
that	O
high	O
plasma	O
glycine	B
levels	O
were	O
associated	O
with	O
an	O
overall	O
favorable	O
coronary	O
heart	O
disease	O
risk	O
profile.	O

Acylcarnitines,	B
especially	O
those	O
with	O
C3	O
and	O
C5	O
acyl	O
groups,	O
are	O
derived	O
from	O
α-keto	B
acid	I
products	O
and	O
contribute	O
to	O
fatty	O
acid	O
β-oxidation	O
in	O
the	O
mitochondria	O
as	O
described	O
in	O
.	O

We	O
compared	O
the	O
cognitive	O
performance,	O
MELD	O
score	O
(and	O
its	O
individual	O
components),	O
venous	O
ammonia	O
and	O
endotoxin	B
levels	O
before	O
and	O
after	O
rifaximin	O
using	O
paired	O
t-tests.	O

These	O
(and	O
potentially	O
other)	O
cross-reactivities	O
could	O
explain	O
the	O
higher	O
versus	O
lower	O
levels	O
of	O
arginine	B
recorded	O
by	O
the	O
ELISA	O
pre	O
and	O
post	O
bypass	O
respectively.	O

Similarly,	O
cell	O
growth	O
and	O
proliferation	O
need	O
amino	O
acids	O
to	O
generate	O
proteins	O
required	O
for	O
cancer	O
cell	O
synthesis[],	O
therefore	O
leading	O
to	O
decreased	O
levels	O
of	O
glycine	B
and	O
threonine	B
in	O
EC	O
pa-tients.	O

Levels	O
of	O
three	O
of	O
these	O
(octanoylcarnitine,	O
lysoPC(16:1),	B
and	O
decanoylcarnitine)	B
were	O
closely	O
correlated	O
with	O
treatment	O
effect.	O

VAT	O
was	O
further	O
positively	O
associated	O
with	O
plasma	O
levels	O
of	O
carbohydrates	O
and	O
related	O
metabolites	O
such	O
as	O
lactate,	B
pyruvate	B
and	O
the	O
sum	O
of	O
hexoses.	O

The	O
second	O
artifact	O
contains	O
a	O
cyano	B
group	O
which	O
cannot	O
be	O
introduced	O
by	O
human	O
enzymes.	O

The	O
hydrolysis	O
of	O
tryptophan	B
yields	O
indole,	B
and	O
the	O
oxidation	O
of	O
indole	B
produces	O
indoxyl.	O

Carnitine	B
is	O
used	O
both	O
for	O
the	O
removal	O
of	O
excess	O
acyl-CoA	B
from	O
mitochondria	O
as	O
well	O
as	O
for	O
fatty	O
acid	O
transport	O
into	O
mitochondria,	O
so	O
the	O
shifting	O
of	O
this	O
equilibrium	O
towards	O
acetyl-carnitine	B
could	O
possibly	O
reduce	O
the	O
availability	O
of	O
carnitine	B
for	O
CPT	O
I-dependent	O
fatty	O
acid	O
transport	O
across	O
outer	O
mitochondrial	O
membrane,	O
further	O
reducing	O
fatty	O
acid	O
oxidation.	O

Stearic	B
acid,	I
arachidonic	B
acid,	I
palmitic	B
acid,	I
myristic	B
acid,	I
etc.	O
were	O
down-regulated	O
in	O
the	O
serum	O
of	O
HCC	O
patients	O
with	O
great	O
statistical	O
significance.	O

Plasma	O
lactate	B
levels	O
were	O
not	O
significantly	O
different	O
in	O
I+	O
and	O
I−,	O
but	O
PCA	O
revealed	O
lactate	B
as	O
an	O
important	O
factor	O
that	O
contributed	O
to	O
the	O
metabolic	O
differentiation	O
of	O
I+	O
and	O
I−.	O

All	O
diacylglycerol	B
and	O
triacylglycerol	B
standards	O
were	O
dissolved	O
in	O
isooctane/isopropanol	O
(3:1 v/v)	O
with	O
a	O
concentration	O
of	O
1.0 mg/mL.	O

Glycine	B
was	O
more	O
abundant	O
in	O
plasma	O
samples	O
of	O
DLBCL	O
and	O
HL	B
cases	O
compared	O
to	O
the	O
controls.	O

Among	O
these,	O
acetic	O
and	O
valeric	O
acids	O
were	O
significantly	O
higher	O
in	O
stool	O
samples	O
from	O
CRC	O
patients	O
(p<0.0001	O
and	O
p = 0.024	O
respectively)	O
while	O
butyric	B
acid	I
was	O
significantly	O
higher	O
in	O
the	O
feces	O
of	O
healthy	O
individuals	O
(p<0.0001;	O
).	O

ii	O
,	O
LiAIH_4	O
,	O
tetrahydrofuran,	B
room	O
temperature,	O
45	O
min	O
(for	O
compound	O
2,	O
9);	O
DIBAL-H,	O
CH_2	O
Cl_2	O
,	O
room	O
temperature,	O
30	O
min	O
(for	O
compound	O
6).	O

The	O
latter	O
can	O
be	O
converted	O
to	O
α-ketoglutarate	B
to	O
increase	O
transit	O
through	O
the	O
TCA	O
cycle,	O
providing	O
sustainable	O
energy	O
required	O
for	O
rapid	O
cell	O
proliferation[].	O

Total	O
urinary	O
paracetamol,	B
its	O
metabolite	O
para-aminophenol	B
(p	I
-aminophenol),	I
and	O
a	O
summary	O
measure	O
of	O
both	O
urinary	O
biomarkers	O
were	O
quantified	O
by	O
ultra-performance	O
liquid	O
chromatography	O
coupled	O
with	O
an	O
electrospray	O
triple	O
quadrupole	O
mass	O
spectrometry	O
(UPLC-ESI-MS/MS).	O

Our	O
post-hoc	O
power	O
calculation	O
indicates	O
that	O
larger	O
studies	O
are	O
required	O
to	O
reveal	O
associations	O
between	O
AGEs	O
measured	O
using	O
LC-MS/MS-based	O
methods	O
and	O
early	O
deterioration	O
of	O
glycaemic	B
control	O
before	O
the	O
onset	O
of	O
T2D.	O

For	O
all	O
samples,	O
the	O
supernatant	O
was	O
concentrated	O
to	O
near	O
dryness	O
using	O
a	O
Centrivap	O
vacuum	O
concentrator	O
(Labconco,	O
Kansas	O
City,	O
MO,	O
USA)	O
to	O
remove	O
chloroform	B
and	O
was	O
then	O
further	O
lyophilized	O
using	O
a	O
freeze	O
dryer	O
(Labconco,	O
Kansas	O
City,	O
MO,	O
USA).	O

In	O
the	O
MAGNETIC	O
Consortium,	O
we	O
identified	O
genetic	O
variants	O
associated	O
with	O
glycine	B
and	O
phenylalanine	B
at	O
genome-wide	O
significance	O
(p	O
<	O
5	O
×	O
10_−8	O
)	O

Hypoxanthine,	B
a	O
naturally	O
occurring	O
purine	B
derivative	O
that	O
is	O
involved	O
in	O
the	O
salvage	O
pathway	O
for	O
purine	B
synthesis,	O
has	O
been	O
shown	O
to	O
stimulate	O
oxidative	O
stress	O
[,	O
],	O
and	O
elevated	O
concentrations	O
have	O
been	O
implicated	O
in	O
fear	O
in	O
dogs.	O

Among	O
these	O
factors	O
we	O
find	O
the	O
proinflammatory	O
and	O
cytotoxic	O
actions	O
of	O
high	O
glucose	B
levels	O
and	O
the	O
generation	O
of	O
advanced	O
glycation	O
end	O
products	O
of	O
proteins	O
that	O
may	O
result	O
in	O
protein	O
dysfunction	O
or	O
activation	O
of	O
the	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(,).	O

In	O
MANOVA	O
there	O
were	O
significant	O
differences	O
between	O
sensitive	O
participants	O
and	O
controls	O
on:	O
Perceived	O
stress	O
severity	O
(F(1,43)	O
=	O
6.13,	O
p	O
=	O
0.017);	O

However,	O
in	O
order	O
to	O
cover	O
the	O
extraordinary	O
cases	O
which	O
have	O
abnormal	O
higher	O
proline	B
level,	O
the	O
accuracy	O
and	O
precision	O
in	O
analysis	O
of	O
diluted	O
samples	O
were	O
evaluated:	O
accuracy	O
and	O
precision	O
for	O
5	O
times	O
dilution	O
were	O
2.50%	O
and	O
5.57%,	O
respectively;	O
for	O
10	O
times	O
were	O
1.23%	O
and	O
0.37%,	O
respectively.	O

The	O
levels	O
of	O
the	O
following	O
three	O
molecules	O
were	O
significantly	O
increased	O
in	O
gliomas	O
with	O
a	O
mutant	O
IDH	O
compared	O
with	O
that	O
observed	O
in	O
the	O
wild-type	O
IDH	O
gliomas:	O
citric	B
acid	I
(1.43-fold,	O
p	O
 = 0.0114,	O
Q =	O

Then,	O
FA	B
were	O
dissolved	O
in	O
bovine	O
serum	O
albumin	O
(10%	O
BSA,	O
Sigma)	O
at	O
the	O
final	O
ratio	O
1/10	O
(v/v)	O
in	O
William’s	O
E	O
plus	O
Glutamax™	B
medium	O
or	O
in	O
OptiMEM™	O
(Gybco,	O
Invitrogen)	O
and	O
warmed	O
again	O
at	O
55 °C	O
for	O
10 min	O
before	O
use.	O

48±3%,	O
dihydroxy	B
PUFA	O
(LTB_4	O
/a	O
5,12-diHETE)	B

The	O
precision	O
(coefficient	O
of	O
variation)	O
were	O
≤10.7%,	O
7.7%	O
and	O
9.5%	O
and	O
the	O
accuracies	O
ranged	O
from	O
88.8	O
to	O
103.1%	O
for	O
exemestane,	O
98.5	O
to	O
106.1%	O
for	O
17β-dihydroexemestane	B
and	O
92.0	O
to	O
103.2	O
for	O
17β-dihydroexemestane-17-O-β-D-glucuronide.	B

We	O
therefore	O
chose	O
to	O
synthesize	O
the	O
glucuronide	B
enzymatically	O
to	O
unequivocally	O
identify	O
this	O
phase	O
II	O
metabolite	O
of	O
p	O
-cresol	O
as	O
the	O
β	O
-O	O
-glucuronide.	O

Consistent	O
with	O
previous	O
reports,	O
CLL	O
cases	O
had	O
an	O
elevated	O
level	O
of	O
2-hydroxybutyric	B
acid,	I
a	O
by-product	O
in	O
the	O
synthesis	O
of	O
glutathione	B
from	O
cystathionine	B
under	O
oxidative	O
stress	O
condition.	O

It	O
is	O
calculated	O
as	O
follows:	O
	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm=RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
TIm	O
TIm	O
TI	O
TI	O
TI	O
m	O
m	O
=	O
RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
RVHU+NAFLDm−RVHUm∑nmi=1(RVHU+NAFLDmi−RVHUmi)	O
RVHU+NAFLDm−RVHUm	O
RVHU+NAFLDm−RVHUm	O
RVHU+NAFLDm	O
RVHU+NAFLDm	O
RV	B
RV	I
RV	I
HU+NAFLD	O
HU+NAFLD	O
H	O
U	O
+	O
N	O
A	O
F	O
L	O
D	O
m	O
m	O
−	O
RVHUm	O
RVHUm	O
RV	B
RV	I

The	O
concentrations	O
of	O
three	O
PhCAs	O
and	O
succinic	B
acid	I
are	O
shown	O
on	O
a	O
log	O
scale	O
with	O
a	O
base	O
of	O
10.	O

Among	O
them,	O
serum	O
levels	O
of	O
lysoPC(18:2),	B
urocanic	B
acid	I
and	O
indole	B
were	O
significantly	O
lower,	O
and	O
L-phenylalanine	B
levels	O
were	O
significantly	O
higher	O
in	O
AOSD	O
patients	O
compared	O
with	O
HC.	O

Nonetheless,	O
it	O
is	O
common	O
clinical	O
practice	O
to	O
relate	O
analyte	O
concentrations	O
in	O
individual	O
urine	O
samples	O
to	O
creatinine,	B
and	O
thus	O
doing	O
so	O
facilitates	O
the	O
comparison	O
of	O
our	O
findings	O
with	O
other	O
reports.	O
,	O

Following	O
validation,	O
three	O
top	O
metabolites	O
(xanthine,	O
hypoxanthine	B
and	O
D-mannose)	O
were	O
validated	O
showing	O
lower	O
levels	O
of	O
xanthine	B
and	O
hypoxanthine	B
and	O
higher	O
level	O
of	O
D-mannose	B
in	O
PLP	O
and	O
CRC	O
cases	O
compared	O
to	O
controls.	O

Tyramine	B
is	O
detectable	O
in	O
plasma,	O
serum,	O
and	O
urine,	O
and	O
the	O
measured	O
level	O
is	O
significantly	O
altered	O
in	O
certain	O
disorders	O
characterized	O
by	O
pain,	O
such	O
as	O
common	O
headaches,	O
migraines,	O
urticaria,	O
irritable	O
bowel	O
syndrome,	O
and	O
joint	O
pain.	O

A	O
,	O
Plasma	O
levels	O
of	O
Δ_9	B
-tetrahydrocannabinol	I
(THC),	O
11-hydroxy-THC	B
(11-OH-THC),	I
11-nor-carboxy-THC	B
(THC-COOH),	O
and	O
11-nor-carboxy-THC	B
glucuronide	I
(THC-COOH	O
glucuronide)	O
were	O
evaluated	O
in	O
each	O
individual.	O

Typically,	O
vitamin	B
D	I
photosynthesis	O
in	O
skin	O
is	O
thought	O
to	O
satisfy	O
most	O
human	O
dietary	O
requirements.	O

The	O
decrease	O
in	O
total	O
BCAA-derived	O
acylcarnitines	B
(BCAA_AC)	O
concentration	O
15	O
days	O
after	O
surgery	O
was	O
accentuated	O
after	O
90	O
days	O
with	O
a	O
37%	O
decrease	O
(p	O
<	O
0.05),	O
leading	O
to	O
decreased	O
ratios	O
between	O
these	O
species	O
and	O
the	O
sum	O
of	O
all	O
acylcarnitines	B
(B).	O

From	O
the	O
in	O
vitro	O
reconstitution	O
of	O
the	O
SMT	O
catalytic	O
activity,	O
among	O
thirteen	O
sterols	O
tested,	O
5	O
(zymosterol)	O
and	O
6	O
(cholesta-5,7,24-trienol)	O
were	O
equipotent	O
as	O
SMT	O
substrates	O
(set	O
at	O
100%),	O
while	O
8	O
(cholesta-7,24-dienol)	O
showed	O
67.2%	O
convertion.	O

For	O
gradients	O
of	O
indoleamine	B
2,3-dioxygenase	I
tryptophan	I
metabolites	O
across	O
the	O
pulmonary	O
circulation,	O
the	O
average	O
±	O
SD	O
percent	O
difference	O
in	O
metabolite	O
levels	O
in	O
the	O
radial	O
arterial	O
samples,	O
compared	O
with	O
the	O
pulmonary	O
arterial	O
samples,	O
is	O
indicated	O
for	O
subjects	O
with	O
pulmonary	O
vascular	O
resistance	O
(PVR)	O
≤2	O
Wood	O
units	O
(diamonds)	O
and	O
>2	O
Wood	O
units	O
(squares).	O

Together,	O
these	O
data	O
indicate	O
a	O
requirement	O
for	O
both	O
MTBE	B
and	O
DCM	O
extractions	O
for	O
studying	O
fecal	O
lipids.	O

Ultimately,	O
19	O
potential	O
diagnostic	O
biomarkers	O
were	O
identified,	O
including	O
nine	O
carnitine	B
derivatives	O
(L-carnitine	O
and	O
eight	O
acylcarnitines),	B
four	O
amino	O
acid	O
derivatives	O
(pyroglutamic	O
acid,	I
indoxyl,	O
urocanic	B
acid,	I
and	O
phenylacetylglutamine),	B
three	O
nucleosides	O
(deoxycytidine,	O
cyclic	O
adenosine	O
monophosphate	O
[cAMP],	O
and	O
cyclic	O
guanosine	O
monophosphate	O
[cGMP]),	O
two	O
purine	B
derivatives	O
(uric	O
acid	O
and	O
paraxanthine),	B
and	O
L-Fucose.	B

The	O
column	O
was	O
eluted	O
with	O
800	O
µL	O
chloroform-isopropanol	B
(2:1)	I
to	O
the	O
same	O
flow	O
through	O
tube.	O

The	O
liquid	O
phases	O
were	O
collected	O
and	O
evaporated	O
to	O
dryness	O
by	O
SpeedVac	O
and	O
then	O
redissolved	O
in	O
150	O
µL	O
pyridine.	B

Decreased	O
oxidative	O
phosphorylation	O
may	O
also	O
explain	O
the	O
reduction	O
of	O
ATP	B
levels	O
in	O
EAC	O
cells	O
incubated	O
with	O
ACM,	O
as	O
mitochondrial	O
respiration	O
is	O
the	O
most	O
efficient	O
process	O
of	O
ATP	B
generation.	O

Further	O
studies	O
are	O
needed	O
to	O
fully	O
map	O
the	O
relationship	O
between	O
serum	O
glucose	B
levels	O
and	O
PCa	O
development	O
and	O
prognosis.	O

The	O
significance	O
of	O
differences	O
in	O
the	O
concentration	O
of	O
reactive	O
polysulfide	B
species	O
in	O
the	O
aqueous	O
and	O
vitreous	O
humor	O
of	O
the	O
DM	O
and	O
control	O
eyes	O
was	O
assessed	O
with	O
the	O
Student’s	O
t-test.	O

Bars	O
represent	O
mean	O
value	O
of	O
phosphatidyl	B
ethanolamine	I
16:0/22:6	I
normalized	O
to	O
phosphatidyl	B
ethanolamine	I
16:0/18:3.	I

[N	O
-acetyl-D_3	I
]3-HPMA	O
and	O
500	O
ng	O

In	O
our	O
pilot	O
study,	O
methyl-	B
and	O
ethyl-chloroformate	B
both	O
yielded	O
satisfactory	O
derivatization	O
efficiency	O
in	O
standard	O
mixtures	O
and	O
biological	O
samples.	O

(C)	O
Palmatine.	B

ΣFA(midchainalcohols+ketones)/parentfattyacid	O
LOXFAindex=ΣFA(midchainalcohols+ketones)/parentfattyacid	O
LOXFA	O
LOXFA	O
LOX	O
LOX	O
LOX	O
LOX	O
L	O
O	O
X	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
index	O
index	O
i	O
n	O
d	O
e	O
x	O
=	O
ΣFA	O
ΣFA	O
Σ	O
Σ	O
Σ	O
Σ	O
Σ	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
(	O
midchain	O
midchain	O
m	O
i	O
d	O
c	O
h	O
a	O
i	O
n	O
alcohols	B
alcohols	I
a	O
l	O
c	O
o	O
h	O
o	O
l	O
s	O
+	O
ketones	B
ketones	I
k	O
e	O
t	O
o	O
n	O
e	O
s	O
)	O
/	O
/	O
parent	O
parent	O
p	O
a	O
r	O
e	O
n	O
t	O
fatty	O
fatty	O
f	O
a	O
t	O
t	O
y	O
acid	O
acid	O
a	O
c	O
i	O
d	O

Comparison	O
of	O
metabolites	O
from	O
methanol	B
precipitation	O
(MeOH)	O
and	O
MTBE	B
extraction	O
(MTBE)	O
on	O
RPC	O
and	O
HILIC	O
column	O
in	O
both	O
positive	O
and	O
negative	O
ionization	O
mode.	O

The	O
LLOQ	O
for	O
MEL	O
using	O
nanoflow	O
LC-MS/MS	O
was	O
determined	O
to	O
be	O
50	O
amol	O
on	O
column	O
(11.65	O
pg/mL,	B
11.65	O
fg	B
injected),	O
and	O
the	O
ULOQ	O
was	O
5.0	O
fmol	O
on	O
column	O
(1165	O
pg/mL,	B
1.17	O
pg	B
injected),	O
.	O

These	O
species	O
have	O
been	O
analyzed	O
to	O
study	O
cholesterol	B
metabolism_,	O
	O
and	O
excretion,	O
as	O
well	O
as	O
fat	O
(mal)absorption,	O
and	O
can	O
reveal	O
health/disease	O
of	O
both	O
the	O
pancreas	O
and	O
digestive	O
tract.	O

Urinary	O
level	O
of	O
furan	B
metabolite	O
in	O
urine	O
from	O
furan-treated	O
rodents	O
(nmol/mg	O
creatinine)	B

Substrates	O
and	O
enzymes	O
that	O
generate	O
ceramide	B
were	O
significantly	O
increased	O
in	O
all	O
three	O
ceramide	B
biosynthesis	O
pathways	O
in	O
cancer.	O

4-OH-E_2	B
:2-OH-E_2	I
and	O
2-OH-E_2	B
were	O
positively	O
associated	O
with	O
1,2,3,4,6,7,8-heptaCDF	B
level,	O
according	O
to	O
a	O
quadratic	O
model.	O

In	O
addition,	O
CDP-choline,	B
the	O
substrate	O
of	O
Ptdcho	O
synthesis,	O
is	O
essential	O
to	O
HPA	O
axis.	O

Go	O
to:	O
Stilbenoids	B
are	O
dietary	O
phenolics	O
with	O
notable	O
biological	O
effects	O
on	O
humans.	O

Still,	O
future	O
studies	O
controlling	O
for	O
alcohol	O
consumption	O
may	O
support	O
citrate	B
as	O
a	O
urinary	O
biomarker	O
of	O
pancreatitis.	O

The	O
volume	O
of	O
the	O
sample	O
plug	O
injected	O
corresponds	O
to	O
61 nL.	O
We	O
rinsed	O
the	O
new	O
dare	O
fused-silica	O
capillaries	O
with	O
1 M	O
sodium	B
hydroxide	I
for	O
30 min	O
at	O
930 mbar,	O
followed	O
by	O
deionized	O
water	O
for	O
20 min	O
at	O
930 mbar,	O
then	O
0.1 M	O
sodium	B
hydroxide	I
for	O
20 min	O
at	O
930 mbar,	O
and	O
followed	O
by	O
deionized	O
water	O
for	O
20 min	O
at	O
930 mbar.	O

The	O
key	O
identified	O
metabolites:	O
1,	B
2-OH-butyrate;	I
2,	B
3-OH-butyrate;	I
3,	O
Acetate;	B
4,	O
Acetoacetate;	B
5,	O
Alanine;	B
6,	O
Betaine;	B
7,	O
Carnitine;	B
8,	O
Choline;	B
9,	O
Citrate;	B
10,	O
Creatine;	B
11,	O
Cysteine;	B
12,	O
Glutamine;	B
13,	O
Glutamate;	B
14,	O
Glycine;	B
15,	O
Glycerol;	B
16,	O
Histidine;	B
17,	O
Isoleucine;	B
18,	O
Lactate;	B
19,	O
Leucine;	B
20,	O
Lipids;	O
21,	O
Methionine;	B
22,	O
Methylamine;	B
23,	O
Methanol;	B
24,	O
N-acetyl-glycoproteins;	B
25,	O
Phosphatidylcholine;	B
26,	O
Phenylalanine;	B
27,	O
Proline;	B
28,	O
Pyruvate;	B
29,	O
Trimethylamine	B
oxide;	I
30,	O
Tyrosine;	B
31,	O
Valine;	B
32,	O
Glucose.	B
_a	O
s:	O
singlet,	O
d:	O
doublet,	O
t:	O
triplet,	O
q:	O
quartet,	O
m:	O
multiplet,	O
dd:	O
doublet	O
of	O
doublet.	O

Increased	O
intake	O
of	O
purines	B
has	O
been	O
linked	O
to	O
hyperuricemia	O
and	O
gout,	O
which	O
in	O
turn	O
was	O
associated	O
with	O
increased	O
renal	O
disease	O
progression	O
in	O
animals.	O

Cx:y,	O
where	O
x	O
is	O
the	O
number	O
of	O
carbons	O
in	O
the	O
fatty	O
acid	O
side	O
chain;	O
y	O
is	O
the	O
number	O
of	O
double	O
bonds	O
in	O
the	O
fatty	O
acid	O
side	O
chain;	O
DC,	O
decarboxyl;	O
M,methyl;	O
OH,	O
hydroxyl;	O
PC,	O
phophatidylcholine;	B
SM,	O
sphingomyelin.	B

CO_2	O
H,	O
whereas	O
the	O
product	O
ion	O
spectrum	O
of	O
N	B
-hydroxy-N	I
-acetyl-PhIP	I
contains	O
a	O
base	O
peak	O
ion	O
at	O
m/z	O
241.1,	O
which	O
is	O
attributed	O
to	O
the	O
loss	O
of	O
ketene	O
(CH_2	O
CO).	O

Also,	O
the	O
hemodynamics	O
of	O
L-arginine	B
in	O
serum	O
is	O
a	O
representative	O
of	O
the	O
complex	O
interplay/crosstalk	O
between	O
its	O
synthesis	O
via	O
arginosuccinate	B
and	O
lyase	O
and	O
the	O
degradation	O
via	O
arginase,	O
that	O
is,	O
the	O
arginase	O
activity	O
being	O
altered	O
in	O
humans	O
and	O
experimental	O
models	O
of	O
hypertension.	O

The	O
main	O
clinical	O
finding	O
of	O
the	O
present	O
study	O
is	O
that	O
selected	O
metabolites	O
substantially	O
improved	O
the	O
ability	O
to	O
predict	O
type	O
2	O
diabetes,	O
beyond	O
the	O
prediction	O
achieved	O
using	O
conventional	O
risk	O
factors,	O
in	O
individuals	O
classified	O
as	O
normoglycaemic	B
based	O
on	O
fasting	O
glucose.	B

In	O
a	O
similar	O
fashion	O
to	O
other	O
mTOR	O
inhibitors,	O
the	O
result	O
of	O
everolimus	O
inhibition	O
of	O
mTOR	O
is	O
a	O
reduction	O
in	O
cell	O
proliferation,	O
angiogenesis,	O
and	O
glucose	B
uptake.	O

Thus,	O
adipocyte	O
anthracycline	B
sequestration	O
and	O
metabolism	O
may	O
contribute	O
to	O
survival	O
of	O
local	O
leukemia	O
clones	O
within	O
the	O
bone	O
marrow	O
and	O
adipocyte,	O
thus	O
increasing	O
the	O
risk	O
of	O
residual	O
disease	O
at	O
the	O
end	O
of	O
Induction	O
therapy	O
and	O
eventual	O
relapse.	O

Lysine	B
and	O
Methionine	B
synthesize	O
Carnitine,	B
which	O
augments	O
the	O
production	O
of	O
Acetoacetate	B
[34.	O

The	O
activity	O
of	O
20α-HSD,	B
as	O
measured	O
by	O
the	O
ratio	O
(α-C	B
+	I
α-CL)/(THF	I
+	I
5α-THF	I
+	I
THE),	I
was	O
elevated	O
in	O
the	O
PCOS	O
group	O
(P	O
=	O
0.01).	O

Cer	B
was	O
significantly	O
up	O
regulated	O
in	O

Comparison	O
of	O
the	O
aromatic	O
region	O
of	O
800	O
MHz,	O
cryo-probe	O
_1	O
H	O
NMR	O
spectra	O
of	O
the	O
same	O
pooled	O
human	O
serum	O
sample	O
obtained	O
by	O
suppressing	O
protein	O
signals	O
(a)	O
by	O
T_2	O
filtering	O
using	O
the	O
CPMG	O
pulse	O
sequence,	O
(b)	O
by	O
ultrafiltration	O
using	O
a	O
3	O
kDa	O
molecular	O
weight	O
cutoff	O
filter,	O
and	O
(c)	O
by	O
protein	O
precipitation	O
using	O
methanol	B
(1:2).	I

We	O
also	O
evaluated	O
the	O
associations	O
of	O
total	O
estrogens	O
and	O
estrogen	B
metabolites	O
(the	O
sum	O
of	O
all	O
estrogens	O
and	O
estrogen	B
metabolites),	O
seven	O
metabolic	O
pathway	O
groups,	O
and	O
eight	O
metabolic	O
pathway	O
ratios	O
with	O
the	O
risk	O
of	O
breast	O
cancer.	O

Effect	O
of	O
polymeric	O
dipeptide	O
surfactant	O
head	O
groups	O
on	O
the	O
simultaneous	O
enantioseparation	O
of	O
1,1’	B
=	I
O	I
-DVX	I
and	O
2,2’	B
=	I
VX.	I

Centenarians	O
displayed	O
higher	O
circulating	O
levels	O
of	O
15-hydroxy-eicosatetraenoic	B
acid	I
(15-HETE),	O
a	O
major	O
product	O
of	O
15-lipoxygenase	O
(15-LOX)	O
enzyme,	O
known	O
for	O
its	O
anti-inflammatory	O
properties	O
.	O

Elevated	O
levels	O
of	O
2-hydroxyisovalerate,	B
fructose,	B
IL-8,	O
IL-9	O
and	O
growth	O
regulated	O
oncogene	O
alpha	O
(GRO-α)	O
and	O
decreased	O
concentrations	O
of	O
TNF-β,	O
beta-nerve	O
growth	O
factor	O
(β-NGF)	O
and	O
dimethylamine	B
were	O
detected	O
in	O
septic	O
shock	O
nonsurvivors	O
compared	O
to	O
the	O
survivors.	O

Lipid	O
standards	O
BMP(14:0/14:0)	B
and	O
PG(14:0/14:0)	B
were	O
purchased	O
from	O
Avanti	O
Polar	O
Lipids,	O
Inc.,	O
and	O
analyzed	O
using	O
the	O
same	O
LC-MS	O
parameters	O
as	O
the	O
plasma	O
samples.	O

Then,	O
the	O
urine	O
was	O
spiked	O
with	O
sodium	B
acetate	I
buffer	O
(pH	O
5.5,	O
1	O
M,	O
1	O
mL)	O
containing	O
β-glucuronidase/sulfatase	O
(3000	O
unit	O

Here	O
we	O
found	O
a	O
reduction	O
in	O
the	O
putative	O
neuroprotective	O
index,	O
KynA/QA,	O
but	O
no	O
difference	O
in	O
any	O
of	O
the	O
individual	O
kynurenine	B
metabolites,	O
in	O
the	O
BD	O
group	O
versus	O
the	O
healthy	O
controls.	O

Thus,	O
although	O
we	O
identified	O
glutamine	B
and	O
histidine	B
as	O
potential	O
biomarkers	O
of	O
biological	O
interest,	O
our	O
results	O
imply	O
that	O
a	O
study	O
at	O
this	O
scale	O
does	O
not	O
yield	O
metabolomic	O
biomarkers	O
with	O
sufficient	O
predictive	O
value	O
to	O
be	O
clinically	O
useful	O
per	O
se	O
as	O
prognostic	O
biomarkers.	O

These	O
findings	O
may	O
support	O
the	O
following	O
pathologic	O
progression	O
of	O
LC:	O
initially,	O
BCAAs	O
and	O
AAAs	O
are	O
increased	O
via	O
altered	O
amino	O
acid	O
metabolism;	O
and	O
then,	O
eventual	O
degradation	O
of	O
BCAAs	O
may	O
be	O
occurred	O
by	O
carnitines,	B
which	O
oxidizes	O
BCAAs.	O

One	O
missing	O
GlycA	B
measure	O
in	O
2001	O
and	O
2007,	O
as	O
well	O
as	O
four	O
isoleucine	B
measures	O
in	O
2001	O
and	O
one	O
in	O
2007	O
were	O
mean	O
value	O
replaced.	O

The	O
procedure	O
used	O
by	O
the	O
crime	O
laboratory	O
is	O
capable	O
of	O
detecting	O
trace	O
levels	O
of	O
many	O
AAIs	O
and	O
other	O
synthetic	O
cannabinoids	B
being	O
used	O
to	O
lace	O
“K2”	O
products.	O

At	O
present,	O
oral	O
glucose	B
tolerance	O
test	O
(OGTT)	O
is	O
considered	O
as	O
the	O
gold	O
standard	O
for	O
the	O
diagnosis	O
of	O
GDM.	O

Our	O
assay	O
measures	O
plasma	O
1,25	B
(OH)_2	I
D	O
more	O
accurately	O
and	O
precisely	O
than	O
prior	O
assays,	O
but	O
substantial	O
misclassification	O
may	O
still	O
result	O
from	O
the	O
combination	O
of	O
short	O
circulating	O
half-life	O
(8–12	O
h)	O
and	O
single	O
time	O
of	O
measurement.	O

High	O
correlations	O
were	O
revealed	O
between	O
the	O
levels	O
of	O
lactic	O
and	O
succinic	B
acids	I
(r	O
=	O
0.86),	O
lactic	B
acid	I
and	O
Sum3	O
(r	O
=	O
0.83),	O
and	O
succinic	B
acid	I
and	O
Sum3	O
(r	O
=	O
0.65).	O

No	O
individual	O
estrogen,	B
estrogen	B
metabolite,	O
or	O
metabolic	O
pathway	O
group	O
remained	O
statistically	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
after	O
adjusting	O
for	O
unconjugated	O
estradiol;	B
the	O
hazard	O
ratio	O
associated	O
with	O
unconjugated	O
estradiol	B
was	O
also	O
attenuated	O
in	O
many	O
of	O
these	O
same	O
models.	O

This	O
is	O
further	O
confirmed	O
by	O
comparing	O
ISTDs	O
where	O
the	O
majority	O
of	O
testosterone-d_2	B
and	O
ceramide	B
were	O
found	O
in	O
the	O
neutral	O
fraction,	O
phospholipids	B
were	O
eluted	O
to	O
the	O
phospholipid	B
fraction,	O
while	O
fatty	O
acids	O
were	O
fractionated	O
to	O
the	O
fatty	O
acids	O
fraction.	O

To	O
this	O
end,	O
we	O
used	O
_13	O
C-labeled	O
ethyl	B
bromoacetate	I
(1-_13	O
C,	O
99%),	O
which	O
was	O
labeled	O
at	O
the	O
carbonyl	O
position.	O

This	O
discrimination	O
can	O
be	O
ascribed	O
to	O
higher	O
intensities	O
of	O
lipids	O
and	O
choline-containing	O
compounds	O
(choline,	O
phosphocholine	B
and	O
glycerophosphocholine)	B
after	O
intake	O
of	O
milk	O
proteins	O
compared	O
to	O
the	O
control.	O

We	O
collected	O
150 μ	O
L	O
of	O
serum	O
from	O
the	O
34	O
study	O
participants	O
to	O
which	O
300 μ	O
L	O
of	O
cold	O
acetonitrile	B
was	O
added	O
to	O
extract	O
soluble	O
metabolites.	O

A	O
plot	O
of	O
betaine	B
peak	O
intensity	O
levels	O
for	O
the	O
three	O
diabetic	O
subgroups	O
showed	O
that	O
the	O
HNF1A-MODY	O
subjects	O
with	O
abnormal	O
betaine	B
levels	O
were	O
all	O
female	O
(Figure	O
S5).	O

Acute	O
metabolic	O
changes	O
in	O
response	O
to	O
a	O
single	O
HIIT	O
or	O
comparable	O
sprint	O
interval	O
training	O
session	O
are	O
particularly	O
characterized	O
by	O
elevations	O
in	O
plasma	O
or	O
urinary	O
lactate	B
[,,,,],	O
confirming	O
that	O
a	O
high	O
percentage	O
of	O
the	O
energy	O
required	O
in	O
muscle	O
is	O
provided	O
by	O
the	O
anaerobic	O
energy	O
system.	O

Oxysterols	B
are	O
present	O
in	O
their	O
unconjugated	O
form	O
in	O
CSF	O
at	O
low	O
levels	O
(<1	O
ng/ml);	O
therefore,	O
to	O
further	O
maximize	O
the	O
sensitivity	O
of	O
analysis,	O
an	O
MRM-like	O
experiment	O
was	O
performed	O
in	O
the	O
LIT	O
in	O
parallel	O
to	O
the	O
acquisition	O
of	O
high	O
resolution	O
mass	O
scans	O
in	O
the	O
Orbitrap	O
(see	O
the	O
second	O
experimental	O
method	O
under	O
“Experimental	O
Procedures”).	O

Nile	O
Red	O
(151744,	O
MP	O
Biomedicals,	O
Solon,	O
OH)	O
was	O
dissolved	O
in	O
ethanol	B
for	O
staining	O
lipid	O
bodies.	O

The	O
significant	O
elevation	O
of	O
lactate	B
and	O
glucogenic	O
amino	O
acids	O
and	O
the	O
reduction	O
of	O
glucose	B
in	O
PCOS	O
plasma	O
implied	O
elevated	O
glycolysis	O
in	O
muscle	O
and	O
decreased	O
gluconeogenesis	O
in	O
liver	O
during	O
PCOS	O
pathogenesis.	O

Based	O
on	O
our	O
results,	O
we	O
speculate	O
that	O
ADV	O
patients	O
might	O
have	O
increased	O
lactate	B
utilization,	O
or	O
alternatively	O
a	O
decreased	O
glucose	B
metabolism	O
to	O
lactate,	B
considering	O
the	O
higher	O
serum	O
glucose	B
level	O
in	O
ADV	O
with	O
respect	O
to	O
EAR	O
patients.	O

In	O
particular,	O
BCAAs	O
such	O
as	O
leucine,	B
valine,	B
and	O
isoleucine	B
resulted	O
significant	O
in	O
this	O
analysis.	O

APL	O
patients	O
were	O
required	O
to	O
rinse	O
their	O
mouths	O
thoroughly	O
with	O
deionized	O
water	O
three	O
times	O
before	O
saliva	O
sampling;	O
then	O
they	O
spat	O
saliva	O
samples	O
directly	O
into	O
15-mL	O
polyethylene	B
centrifuge	O
tubes.	O

Phosphatidylinositol	B
is	O
also	O
the	O
precursor	O
for	O
a	O
wide	O
variety	O
of	O
membrane-bound	O
and	O
non-membrane-bound	O
phosphorylated	O
inositol	O
signal	O
transduction	O
molecules	O
.	O

1	O
–leucine,	B
2	O
–valine,	B
3	O
–isoleucine,	B
4	O
–threonine,	B
5	O
–alanine,	B
6	O
–lysine,	B
7	O
–methionine,	B
8	O
–glutamine,	B
9	O
–glutamate,	B
10	O
–glycine,	B
11	O
–tyrosine,	B
12	O
–phenylalanine,	B
13	O
–histidine,	B
14	O
–N,N—dimethylglycine,	B
15	O
–creatinine,	O
16	O
–creatine,	B
17	O
–choline,	B
18	O
–carnitine,	B
19	O
–dimethylamine,	B
20	O
–sarcosine,	O
21	O
–dimethylsulfone,	B
22	O
–trimethylamine	B
N-oxide	I
(TMAO),	O
23	O
–lactate,	B
24	O
–acetate,	B
25	O
–pyruvate,	O
26	O
–succinate,	B
27	O
–citrate,	O
28	O
–urocanate,	O
29	O
–fumarate,	O
30	O
–formate,	O
31	O
–acetoacetate,	B
32–2-hydroxyisovalerate,	B
33–2-hydroxybutyrate,	B
34	O
–isobutyrate,	B
35–3-hydroxybutyrate,	B
36–3-hydroxyisovalerate,	B
37	O
–proline,	B
38	O
–N-acetyl	O
groups,	O
39	O
–NAC,	O
40	O
–VLDL/LDL,	O
41	O
–acetone,	O
42	O
–methanol,	B
43	O
–glycerol,	B
44	O
–mannose,	O
45	O
–glucose,	B
46	O
–AU1,	O
47	O
–AU2,	O
48	O
–PU1,	O
49	O
–PU2.	O

Episode	O
duration,	B
course	O
of	O
disease,	O
and	O
family	O
history	O
were	O
not	O
significantly	O
different	O
across	O
the	O
depression	O
groups	O
(see	O
Table	O
).	O

4-Aminobutanoate.	B

c	O
Singlet	O
at	O
2.4	O
ppm	O
assumed,	O
but	O
not	O
verified	O
by	O
standard	O
addition,	O
to	O
be	O
succinate,	B
*p	O
value/q	O
value < 0.05.	O

First,	O
feature	O
peaks	O
were	O
purified	O
using	O
semi-preparative	O
LC,	O
collected	O
in	O
fraction	O
collector,	O
lyophilized,	O
reconstituted	O
with	O
1	O
g/L	O
ammonium	B
acetate	I
in	O
water-acetonitrile	O
(50:50,	O
v/v),	O
and	O
loaded	O
on	O
wells	O
of	O
a	O
96-well	O
plate.	O

Acetone	B
plays	O
a	O
role	O
in	O
energy	O
supply	O
to	O
vital	O
organs	O
during	O
metabolic	O
catastrophe.	O

Dicarboxylated	B
acylcarnitines	I
are	O
derivatives	O
of	O
mitochondrial	O
lipid	O
or	O
amino	O
acid	O
oxidation	O
and	O
a	O
product	O
of	O
omega-oxidation	O
by	O
microsomal	O
cytochrome	O
p450	O
enzymes	O
in	O
peroxisomes.	O

([PS	O
40:6	O
–H]-	O
)	O
and	O
888	O
([(3’-sulfo)GalCer	O
24:1	I
–H]-	I
)	O
relative	O
to	O
the	O
grey	O
and	O
white	O
matter	O
average	O
spectra,	O
and	O
therefore	O
appear	O
to	O
have	O
a	O
visually	O
distinct	O
lipid	O
profile.	O

CSF	O
sample	O
preparation	O
for	O
_1	O
H-NMR-based	O
metabolomics	O
analyses	O
should	O
therefore	O
be	O
carried	O
out	O
in	O
a	O
well-ventilated	O
atmosphere	O
with	O
laminar	O
flow,	O
and	O
use	O
of	O
ethanol	B
should	O
be	O
avoided.	O

Down-regulation	O
of	O
lactate	B
as	O
observed	O
in	O
our	O
HCC	O
samples	O
may	O
favor	O
tumor	O
growth.	O

Simvastatin	B
(40 mg/day)	O
was	O
prescribed	O
to	O
those	O
with	O
hypercholesterolaemia.	O

This	O
is	O
consistent	O
with	O
the	O
known	O
ability	O
of	O
sulforaphane	B
to	O
induce	O
phase	O
II	O
enzymes	O
such	O
as	O
glutathione-S	O
-transferases	O
involved	O
in	O
the	O
mercapturic	B
acid	I
pathway.	O

It	O
has	O
been	O
documented	O
that	O
degradation	O
of	O
triglycerides	B
within	O
VLDL	O
increases	O
during	O
moderate	O
intensity	O
exercise	O
_52	O
.	O

The	O
values	O
represent	O
the	O
unitless	O
ratio	O
of	O
serum	O
concentration	O
of	O
the	O
kynurenine	B
metabolite	O
divided	O
by	O
the	O
serum	O
concentration	O
of	O
tryptophan	B
and	O
do	O
not	O
have	O
units.	O

By	O
comparison,	O
only	O
two	O
papers	O
have	O
documented	O
baseline	O
separation	O
of	O
the	O
isoleucine	B
and	O
leucine	B
isomer	I
pair	O
[,].	O

Linear	O
regression	O
showed	O
that	O
the	O
significant	O
determinants	O
of	O
urinary	O
betaine/Cr	O
were	O
urinary	O
glucose	B
(p = 0.021)	O
and	O
type	O
of	O
diabetes	O
(p = 0.038).	O

Dose-response	B
curves	O
are	O
shown	O
for	O
(A)	O
SMT	O
inhibitors:	O
abafungin,	O
25-azacycloartenol	O
and	O
24,25-epiminolanosterol,	B
(B)	O
ERG2	O
inhibitors:	O
tamoxifen	B
and	O
AY9944,	O
(C)	O
CYP51	O
inhibitor	O
isavuconazole.	B

The	O
present	O
findings	O
also	O
argue	O
that	O
inflammation	O
and	O
oxidation	O
pathways,	O
which	O
are	O
known	O
to	O
enhance	O
protein	O
arginine	B
residue	O
post	O
translational	O
modification	O
by	O
methylation	O
and	O
subsequent	O
proteolysis,	O
may	O
indeed	O
be	O
a	O
dominant	O
mechanism	O
accounting	O
for	O
the	O
established	O
association	O
between	O
ADMA	B
and	O
both	O
prevalent	O
cardiovascular	O
disease	O
and	O
incident	O
adverse	O
events.	O

This	O
hypothesis	O
is	O
supported	O
by	O
the	O
findings	O
that	O
topically	O
applied	O
radiolabeled	O
iganidipine	B
and	O
nipradilol	O
penetrated	O
through	O
the	O
same	O
pathway	O
determined	O
by	O
an	O
autoradiographic	O
method	O
,	O
.	O

Blood	O
vinorelbine	O
and	O
its	O
active	O
metabolite,	O
4′-O	B
-deacetylvinorelbine,	I
were	O
quantified	O
using	O
liquid	O
chromatography–tandem	O
mass	O
spectrometry.	O

The	O
lipid	O
C18:2	B
CE	O
was	O
detected	O
at	O
a	O
mean	O
concentration	O
of	O
12.71	O
nmol/µl	O
in	O
22	O
SqCC	O
patients,	O
with	O
a	O
31.02%	O
downregulation	O
(P=0.0001)	O
when	O
compared	O
with	O
the	O
demographically	O
matched	O
high-risk	O
controls	O
(18.42	O
nmol/µl;	O
).	O

[Google	O
Scholar]	O
Gullino	O
PM,	O
Grantham	O
FH,	O
Courtney	O
AH,	B
Losonczy	O
I.	O
Relationship	O
between	O
oxygen	O
and	O
glucose	B
consumption	O
by	O
transplanted	O
tumors	O
in	O
vivo.	O

Many	O
other	O
studies	O
have	O
suggested	O
that	O
diabetes	O
is	O
accompanied	O
by	O
an	O
accumulation	O
of	O
glutamate	B
in	O
the	O
retina,	O
which	O
causes	O
neurotoxicity	O
and	O
the	O
development	O
of	O
DR	O
(Kowluru	O
et	O
al.	O

One	O
of	O
the	O
most	O
relevant	O
results	O
shown	O
in	O
Tables 	O
and	O
is	O
the	O
increased	O
concentration	O
of	O
cortisol	B
in	O
cachectic	O
patients,	O
found	O
with	O
two	O
different	O
methodologies.	O

These	O
preliminary	O
data	O
suggest	O
that	O
postmenopausal	O
women	O
who	O
were	O
prenatally	O
DES	B
exposed	O
may	O
have	O
relatively	O
less	O
2	O
than	O
16	O
pathway	O
estrogen	B
metabolism	O
compared	O
with	O
unexposed	O
women.	O

Alamethicin	B
from	O
Trichoderma	O
viride	O
was	O
used	O
as	O
a	O
control	O
substance	O
in	O
toxicity	O
assays,	O
and	O
it	O
was	O
obtained	O
from	O
Sigma	O
(catalog	O
no.	O

The	O
initiator	O
in	O
the	O
synthesis	O
of	O
both	O
polymers	O
was	O
2,2'-azobis(isobutynitrile)	B
(0.47 mmol).	O

Head	O
and	O
neck	O
CSC	O
(CD44_hi	O
/ALDH_hi	O
)	O
exhibited	O
higher	O
glutaminase,	O
glutamate,	B
and	O
sphere	O
levels	O
than	O
CD44_lo	O
/ALDH_lo	O
cells.	O

The	O
goal	O
of	O
this	O
study	O
was	O
therefore	O
to	O
characterize	O
the	O
oral	O
cavity's	O
anthocyanin-relevant	B
metabolic	O
enzyme	O
profile	O
and	O
to	O
evaluate	O
in	O
situ	O
anthocyanin	B
metabolism.	O

Protein	O
precipitation	O
were	O
done	O
for	O
each	O
sample	O
by	O
using	O
acetonitrile.	B

A	O
constant	O
amount	O
of	O
4-OH-E_1	B
-1-N	I
3(U-_15	O
N)Ade	O
(100	O
fmole)	O
is	O
combined	O
with	O
various	O
amount	O
of	O
4-OH-E_1	B
-1-N	I
3Ade.	O

Characteristic	O
NMR	O
spectra	O
of	O
urine	O
samples	O
obtained	O
from	O
(A)	O
benign	O
(control);	O
and	O
(B)	O
RCC	O
patients	O
0:	O
3-aminoisobutyrate,	O
1:	O
fucose,	B
2:	O
lactate,	B
3:	O
threonine,	B
4:	O
alanine,	B
5:	O
citrate,	B
6:	O
dimethylamine,	B
7:	O
creatinine,	B
8:	O
trimethylamine,	B
9:	O
methanol,	B
10:	O
3-methylxanthine,	O
11:	O
glycine	B
12:	O
gluconate.	B
13:	O
creatine,	B
14:	O
creatinine,	B
15:	O
trigonelline,	B
*—deleted	O
water	O
region,	O
16:	O
lactose,	B
17:	O
urea,	B
18:	O
Hippurate,	B
19:	O
formate,	B
20:	O
trigonelline.	B

Columns	O
were	O
dried	O
via	O
40	O
psi	O
positive	O
pressure	O
for	O
5	O
min	O
prior	O
to	O
elution	O
with	O
3	O
ml	O
2%	O
glacial	B
acetic	I
acid	I
in	O
acetonitrile	B
followed	O
by	O
3	O
ml	O
hexane:ethyl	O
acetate	B
(90:10,	O
v/v).	O

The	O
differences	O
in	O
energy	O
metabolisms	O
were	O
clearly	O
observable	O
between	O
the	O
CRC	O
tissues	O
and	O
ANIT,	O
with	O
an	O
significant	O
increase	O
in	O
glycolytic	B
capacity	O
in	O
the	O
CRC	O
tissues	O
as	O
compared	O
with	O
ANIT.	O

5-FU,	O
5-fluorouracil.	B

Pharmacogenomics,	O
Metabolomics,	O
Hydrochlorothiazide,	B
Hypertension,	O
GWAS	O

With	O
the	O
exception	O
of	O
2-OHE_1	O
(P	O
=	O
0.084)	O
and	O
2-OHE_1	O
/16α-OHE_1	B
ratio	O
(P	O
=	O
0.044),	O
exercisers	O
had	O
similar	O
levels	O
of	O
urinary	O
estrogens,	O
estrogen	B
metabolites,	O
and	O
2-OHE_1	O
/4-OHE_1	O
ratio	O
than	O
control	O
participants	O
at	O
baseline.	O

However,	O
co-treatment	O
with	O
ATRA	O
and	O
β-apo-13-carotenone	B
or	O
the	O
β-apo-14′-carotenoids	B
led	O
to	O
marked	O
inhibition	O
of	O
the	O
ATRA-induced	O
gene	O
expression	O
(B	O
).	O

The	O
units	O
of	O
measurement	O
are	O
as	O
follows:	O
aMT6s	O
-	O
ng/ml;	O
creatinine	O
-	O
mg/ml;	O
8-oxodG	B
and	O
8-oxoGua	O
-	O
nmol/litre.	O

All	O
these	O
metabolites	O
(serotonin,	O
taurine,	B
tryptophan,	B
8	O
acylcarnitines,	B
13	O
glycerophospholipids,	B
3	O
sphingolipids)	B
increased	O
during	O
the	O
sleep-deprivation	O
period.	O

Among	O
the	O
20	O
metabolites	O
with	O
adjusted	O
p	O
<	O
0.05,	O
several	O
had	O
quite	O
low	O
p-values,	O
with	O
aspartic	B
acid	I
being	O
the	O
most	O
significant,	O
followed	O
by	O
glyceraldehyde,	B
xanthine,	B
xanthosine,	B
orotate,	B
hydroxyproline/aminolevulinate	O
and	O
hippuric	B
acid.	I

Different	O
organic	O
modifiers	O
and	O
mobile	O
phase	O
additives	O
including	O
methanol,	B
acetonitrile,	B
ammonium	B
acetate,	I
and	O
trifluoroacetic	B
acid	I
were	O
also	O
investigated.	O

At	O
elevated	O
doses,	O
NAPQI	O
alkylates	B
proteins	O
via	O
a	O
Michael	O
addition	O
reaction	O
with	O
nucleophilic	O
cysteine	B
thiol	I
groups	O
and	O
induces	O
toxicity.	O

A	O
dehydrogenase	O
converts	O
dimethylglycine	B
to	O
sarcosine.	B

In	O
diabetes,	O
amino	O
acids	O
and	O
biogenic	O
amines	O
can	O
point	O
out	O
the	O
involvement	O
of	O
branched-chain	O
amino	O
acids	O
in	O
insulin	O
resistance	O
or	O
the	O
relationship	O
of	O
tryptophan	B
and	O
kynurenine	B
with	O
immune	O
/	O
inflammatory	O
processes;	O
acylcarnitines	B
can	O
help	O
to	O
assess	O
mitochondrial	O
function	O
which	O
affects	O
inflammation	O
and	O
lipid	O
accumulation	O
in	O
the	O
liver;	O
lipid	O
metabolism	O
may	O
provide	O
information	O
on	O
low	O
grade	O
inflammation,	O
as	O
lipids	O
are	O
considered	O
as	O
inflammatory	O
mediators;	O
the	O
sum	O
of	O
hexoses	O
can	O
point	O
out	O
disturbed	O
glucose	B
homeostasis.	O

Estrogen-containing	O
oral	O
contraceptives	O
are	O
well	O
established	O
to	O
increase	O
plasma	O
concentrations	O
of	O
cortisol	B
by	O
increasing	O
corticosteroid-binding	O
globulin,	O
resulting	O
in	O
increased	O
total	O
levels	O
of	O
cortisol	B
,	O
.	O

Some	O
studies	O
suggest	O
that	O
normalization	O
to	O
urinary	O
creatinine	B
may	O
be	O
inappropriate	O
at	O
times,	O
as	O
urinary	O
creatinine	B
excretion	O
rate	O
may	O
vary	O
greatly,	O
depending	O
on	O
the	O
situation.	O

This	O
finding	O
encourages	O
the	O
same	O
authors	O
to	O
continue	O
the	O
investigation	O
of	O
this	O
extract	O
which	O
led	O
to	O
the	O
identification	O
of	O
fusarithioamide	B
B	O
(50),	O
a	O
new	O
aminobenzamide	B
derivative,	O
exhibiting	O
antimicrobial	O
activity	O
towards	O
C.	O
albicans,	O
E.	O
coli,	O
B.	O
cereus	O
,	O
and	O
S.	O
aureus	O
with	O
MIC	O
of	O
1.9	O
μg/mL	O

To	O
analyze	O
PL,	O
an	O
aliquot	O
of	O
30 μL	O
of	O
the	O
supernatant	O
was	O
diluted	O
by	O
500 μL	O
methanol	B
including	O
1,2-dimyristoyl-sn-glycero-3-phosphocholine	B
and	O
1-tridecanoyl-2-hydroxy-sn-glycero-3-phosphocholine	B
(Avanti	O
Polar	O
Lipids,	O
Alabaster,	O
USA)	O
as	O
internal	O
standards.	O

L-DOPA:	B
only	O
11	O
controls.	O

Prolonged	O
fasting	O
as	O
well	O
as	O
removal	O
of	O
all	O
choline-containing	O
foods	O
from	O
the	O
diet	O
reduces	O
blood	O
choline	B
levels	O
(Wurtman	O
et	O
al.	O
).	O

Given	O
the	O
evidence	O
provided	O
here	O
for	O
GM3	B
as	O
a	O
PD	O
biomarker	O
candidate,	O
GM3	B
standards	O
for	O
future	O
studies	O
are	O
required.	O

We	O
did	O
not	O
find	O
a	O
significant	O
association	O
between	O
the	O
classes	O
of	O
acylcarnitines	B
and	O
the	O
risk	O
of	O
bone	O
progression.	O

Considering	O
that	O
Matsuta	O
et	O
al	O
.	O
did	O
not	O
find	O
a	O
hydroxy	B
metabolite	O
in	O
human	O
urine	O
leads	O
to	O
the	O
assumption	O
that	O
this	O
metabolite	O
is	O
not	O
a	O
primary	O
target	O
and	O
is	O
formed	O
only	O
in	O
very	O
small	O
amounts	O
in	O
vitro	O
,	O
which	O
might	O
explain	O
the	O
non-detection	O
via	O
automated	O
peak	O
picking.	O

We	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
combination	O
intervention	O
using	O
EPA + DHA	O
and	O
the	O
insulin-sensitizing	O
drug	O
pioglitazone	B
in	O
overweight/obese	O
T2D	O
patients	O
already	O
treated	O
with	O
metformin.	B

Next	O
we	O
considered	O
a	O
multi-metabolite	O
association	O
model,	O
in	O
which	O
m	O
=	O
3	O
metabolites	O
(hippurate,	O
alanine	B
and	O
formate)	O
are	O
assumed	O
to	O
be	O
associated	O
with	O
the	O
disease.	O

Dyslipidemia	O
was	O
defined	O
as	O
follows:	O
concentrations	O
of	O
total	O
cholesterol	B
≥5.2 mmol/	O

In	O
good	O
responders,	O
we	O
found	O
an	O
increase	O
in	O
isoleucine,	B
leucine,	B
valine,	B
alanine,	B
glutamine,	B
tyrosine,	B
and	O
glucose	B
levels	O
and	O
a	O
decrease	O
in	O
3-hydroxybutyrate	B
levels	O
after	O
six	O
months	O
of	O
treatment	O
with	O
etanercept	O
with	O
respect	O
to	O
baseline.	O

It	O
has	O
been	O
demonstrated	O
that	O
catechol-quinones,	B
especially	O
4-OHE_1	O
(E_2	O
)-Q,	O
form	O
predominantly	O
depurinating	O
DNA	O
adducts,	O
release	O
of	O
these	O
adducts	O
generates	O
abasic	O
sites,	O
which,	O
in	O
turn,	O
induce	O
mutations	O
.	O

The	O
GC/MS	O
aliquots	O
were	O
derivatized	O
for	O
1	O
h	O
at	O
60°C	O
with	O
N,	O
O-bistrimethylsilyl-trifluoroacetamide	B
in	O
a	O
solvent	O
mixture	O
of	O
acetonitrile:dichloromethane:	O
cyclohexane	O
(5:4:1),	O
containing	O
5%	O
triethylamine	B
and	O
retention	O
time	O
markers.	O

These	O
conditions	O
led	O
to	O
the	O
inhibition	O
of	O
SDH	O
by	O
all	O
compounds	O
tested,	O
which	O
was	O
not	O
observed	O
in	O
the	O
control	O
when	O
preincubation	O
was	O
carried	O
out	O
with	O
succinic	B
acid.	I

Based	O
on	O
these	O
results,	O
the	O
optimum,	O
high	O
pH	O
mobile	O
phase	O
conditions	O
for	O
HILIC/MS	O
analyses	O
using	O
aminopropyl	O
stationary	O
phase	O
were	O
comprised	O
of	O
A	O
=	O
10	O
mM	O
NH_4	O
Ac	O
and	O
10	O
mM	O
NH_4	O
OH	O
in	O
95	O
%	O
water	O
and	O
B	O
=	O
95	O
%	O
acetonitrile,	B
in	O
both	O
ESI	O
positive	O
and	O
ESI	O
negative	O
modes.	O

The	O
median	O
creatine	B
concentration	O
was	O
nearly	O
9	O
times	O
higher	O
in	O
WB	O
than	O
in	O
serum.	O

Hexadecanedioic	B
acid	I
is	O
a	O
long-chain	O
dicarboxylic	B
acid,	I
generated	O
from	O
fatty	O
acid	O
ω-oxidation	O
and	O
thereafter	O
metabolized	O
by	O
β-oxidation	O
in	O
peroxisomes.	O

For	O
OHC_CSF	O
,	O
cholesterol	B
removed	O
CSF	O
was	O
converted	O
to	O
picolinic	B
acid	I
derivatives	O
and	O
was	O
evaluated	O
as	O
blank	O
for	O
calibration.	O

A	O
comprehensive	O
understanding	O
of	O
the	O
perturbations	O
in	O
glycerophospolipid	B
metabolism	O
was	O
established	O
both	O
by	O
metabolic	O
and	O
lipid	O
approaches	O
based	O
on	O
LC-MS.	O

Comparing	O
80_HIGH	O
and	O
50_HIGH	O
conditions	O
measured	O
as	O
a	O
separate	O
batch,	O
a	O
higher	O
sum	O
of	O
area	O
was	O
found	O
using	O
50%	O
MeOH	B
as	O
quenching	O
buffer.	O

Using	O
this	O
two-pronged	O
approach,	O
we	O
discovered	O
and	O
confirmed	O
the	O
involvement	O
of	O
three	O
major	O
dysregulated	O
metabolic	O
systems	O
in	O
the	O
serum	O
of	O
PC	O
patients:	O
ultra	O
long-chain	O
fatty	O
acids,	O
numerous	O
choline-containing	O
glycerophospholipids,	O
and	O
vinyl	O
ether-containing	O
ethanolamine	B
phospholipids	I
called	O
plasmalogens.	O

Acetate	B
was	O
also	O
significantly	O
reduced	O
in	O
the	O
CSF	O
of	O
drug-naïve	O
patients	O
with	O
first-onset	O
schizophrenia.	O

Ketone	B
bodies	O
are	O
usually	O
absent	O
in	O
the	O
urine	O
of	O
healthy	O
individuals,	O
but	O
their	O
presence	O
is	O
indicative	O
of	O
fat	O
being	O
used	O
as	O
an	O
energy	O
source	O
instead	O
of	O
carbohydrates.	O

Fucose	B
is	O
a	O
hexose	B
deoxy	I
terminal	O
sugar	O
in	O
glycoconjugates	B
in	O
mammals,	O
insects	O
and	O
plants,	O
fundamental	O
sub-unit	O
of	O
fucoidan	O
(sulfated)	B
polysaccharide.	I

The	O
aim	O
was	O
to	O
investigate	O
the	O
possible	O
association	O
of	O
serum	O
levels	O
of	O
tamoxifen	B
and	O
metabolites	O
of	O
tamoxifen,	B
breast	O
cancer	O
outcomes	O
and	O
the	O
CYP2D6	O
gene.	O

Choline	B
phosphate	I
is	O
a	O
component	O
of	O
both	O
glycerophospholipids	B
and	O
sphingomyelin.	B

Furthermore,	O
for	O
the	O
52	O
serum	O
metabolites	O
tested	O
in	O
a	O
related	O
pilot	O
study	O
of	O
TIMES	O
with	O
blood	O
samples	O
obtained	O
15-min	O
apart,	O
ICCs	O
and	O
CVs	O
were	O
in	O
a	O
range	O
of	O
0.79	O
to	O
1.00	O
and	O
3–23%,	O
respectively,	O
for	O
all	O
but	O
9	O
metabolites	O
(2-Aminobutyrate	O
,	O
2-Hydroxybutyrate	B
,	O
2-Oxoglutarate	B
,	O
Acetate	B
,	O
Acetoacetate	B
,	O
Fumarate	B
,	O
Glucose	B
,	O
Methylamine	B
and	O
Oxypurinol	B
)	O
which	O
had	O
ICCs	O
below	O
0.75	O
and	O
CVs	O
above	O
25%.	O

We	O
note	O
that	O
our	O
study	O
did	O
not	O
include	O
reliable	O
recording	O
of	O
glucocorticoid	B
use,	O
because	O
this	O
is	O
a	O
natural	O
history	O
study	O
and	O
it	O
has	O
been	O
shown	O
that	O
DMD	O
patients	O
may	O
take	O
either	O
deflazacort	O
or	O
prednisone/prednisolone	O
and	O
that	O
many	O
different	O
dosing	O
regimens	O
exist.	O

After	O
injection	O
(300	O
μL),	O
the	O
sample	O
was	O
loaded	O
onto	O
an	O
Oasis	O
WAX	O
on-line	O
SPE	O
cartridge	O
with	O
0.1%	O
formic	B
acid	I
in	O
water	O
(1.5	O
mL),	O
and	O
the	O
cartridge	O
was	O
washed	O
with	O
acetonitrile/methanol/water	O
(~0.4	O
mL,	O
1/1/2,	O
v/v/v).	O

A	O
rise	O
in	O
Choline	B
levels	O
is	O
associated	O
with	O
increased	O
membrane	O
turnover,	O
demyelination	O
or	O
inflammation,	O
and	O
was	O
observed	O
in	O
demyelinating	O
diseases	O
.	O

NAD,	B
NADH,	B
AMP	B
and	O
ATP	B
changes	O
in	O
hypogonadism.	O

After	O
the	O
regions	O
of	O
δ	O
4.70–5.20	O
and	O
δ	O
3.34–3.37 ppm	O
were	O
removed	O
to	O
eliminate	O
the	O
influence	O
of	O
water	O
and	O
methanol,	B
the	O
spectra	O
were	O
segmented	O
at	O
δ	O
0.01	O
intervals	O
across	O
the	O
chemical	O
shift	O
range	O
of	O
0.5	O
to	O
9.00 ppm.	O

m	O
m	O
As	O
shown	O
in	O
,	O
significant	O
correlations	O
were	O
observed	O
between	O
anastrozole	B
glucuronide	I
formation	O
and	O
UGT1A4	O
activity,	O
as	O
measured	O
by	O
imipramine-	B

In	O
conclusion,	O
sulfation	O
of	O
morphine	B
is	O
present	O
in	O
human	O
liver	O
but	O
this	O
metabolic	O
pathway	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
in	O
vivo	O
and	O
probably	O
lacks	O
clinical	O
significance.	O

To	O
gain	O
a	O
comparable	O
number	O
of	O
model	O
variables	O
as	O
in	O
the	O
penalized	O
mlogitBMA-model	O
and	O
thereby	O
an	O
at	O
least	O
limited	O
comparability,	O
we	O
used	O
a	O
two-predictor	O
CAR	O
model	O
including	O
CA 19-9	O
and	O
aspartic	B
acid.	I

There	O
was	O
a	O
general	O
increase	O
in	O
circulating	O
essential	O
aminoacids	B
such	O
as	O
arginine,	B
tyrosine,	B
threonine	B
and	O
lysine	B
at	O
T2	O
in	O
R	O
and	O
NR,	O
but	O
only	O
lysine	B
and	O
threonine	B
rose	O
significantly	O
in	O
both	O
groups.	O

The	O
limit	O
of	O
detection	O
of	O
the	O
assay	O
was	O
50	O
pg	B
ml_−1	O
and	O
the	O
limit	O
of	O
quantification	O
was	O
100	O
pg	B
ml_−1	O
.	O

Briefly,	O
a	O
20	O
mM	O
solution	O
of	O
MAd_3	O
was	O
prepared	O
in	O
0.1	O
M	O
sodium	B
phosphate	I
buffer,	O
pH	O
8.	O

Whenever	O
there	O
is	O
a	O
balance	O
between	O
cofactors	O
and	O
substrates	O
in	O
relation	O
to	O
Nicotinamide	B
adenine	I
dinucleotide	I
phosphate	I
(NADPH),	O
NOS	O
catalyzes	O
the	O
reduction	O
of	O
O_2	O
and	O
incorporates	O
it	O
into	O
the	O
guanidine	B
group	O
of	O
L-arginine,	B
generating	O
NO.	O

LDL-cholesterol	B
was	O
reduced	O
(P	O
=	O
0.03)	O
with	O
rHDL	O
infusion,	O
but	O
there	O
was	O
no	O
change	O
in	O
apoB	O
protein	O
levels.	O

The	O
blanks	O
remained	O
as	O
such	O
through	O
addition	O
of	O
150 µl	O
chloroform	B
instead	O
of	O
internal	O
standard.	O

In	O
the	O
cohort	O
studied	O
in	O
this	O
clinical	O
trial	O
an	O
increase	O
in	O
lactate	B
levels	O
was	O
found	O
in	O
the	O
acute	O
stage	O
and	O
a	O
decreasing	O
tendency	O
with	O
time	O
was	O
observed	O
as	O
expected,	O
revealing	O
a	O
partial	O
restoring	O
of	O
aerobic	O
metabolism	O
upon	O
clinical	O
stabilization	O
as	O
a	O
consequence	O
of	O
the	O
energy	O
saving	O
mechanisms	O
triggered	O
by	O
TH.	O

Then,	O
we	O
calculated	O
and	O
compared	O
the	O
ratio	O
of	O
depurinating	O
N3Ade	O
and	O
N7Gua	O
adducts	O
to	O
the	O
sum	O
of	O
their	O
respective	O
estrogen	B
metabolites	O
and	O
conjugates	O
(see	O
footnote	O
to	O
)	O
in	O
urine	O
samples	O
from	O
the	O
two	O
groups	O
of	O
men	O
because	O
the	O
ratio	O
reflects	O
the	O
degree	O
of	O
imbalance	O
in	O
estrogen	B
metabolism	O
that	O
can	O
lead	O
to	O
cancer	O
initiation.	O

We	O
observed	O
significantly	O
increased	O
levels	O
of	O
FAs	O
(FA(14:0),	O
FA(14:1)-1,	B
FA(14:1)-2,	B
and	O
FA(18:0))	B
in	O
MSA.	O

The	O
filtrates	O
were	O
mixed	O
separately	O
with	O
a	O
100	O
μL	O
solution	O
of	O
phosphate	B
buffer	O
in	O
D_2	O
O	O
containing	O
66.17	O
μM	O
TSP.	O

Several	O
metabolites	O
important	O
for	O
this	O
prediction	O
could	O
be	O
identified	O
including	O
choline	B
in	O
plasma	O
and	O
sedoheptulose	B
in	O
urine.	O

A	O
subset	O
of	O
six	O
metabolites	O
including	O
sarcosine,	B
uracil,	B
kynurenine,	B
glycerol-3-phosphate,	B
leucine	B
and	O
proline	B
were	O
significantly	O
elevated	O
upon	O
disease	O
progression	O
from	O
benign	O
to	O
PCA	O
to	O
Mets.	O

In	O
the	O
present	O
study,	O
8	O
major	O
sphingolipid	B
metabolites,	O
namely	O
SM,	O
So,	O
Sa,	O
So1P,	O
Sa1P,	O
Cer,	B
GluCer	O
and	O
LacCer,	B
which	O
occur	O
in	O
the	O
metabolic	O
pathway	O
of	O
sphingolipids,	B
were	O
measured.	O

Additional	O
investigation	O
of	O
the	O
mediating	O
effect	O
of	O
estradiol	B
and	O
identification	O
of	O
other	O
biologic	O
pathways	O
that	O
may	O
mediate	O
the	O
BMI-breast	O
cancer	O
association	O
are	O
important	O
for	O
both	O
etiology	O
and	O
prevention.	O

Asymmetric	B
dimethylarginine	I
(ADMA),	O
which	O
was	O
enriched	O
in	O
healthy	O
controls,	O
is	O
an	O
endogenous	O
inhibitor	O
of	O
nitric	B
oxide	I
synthase	O
(NOS)	O
and	O
is	O
derived	O
from	O
methylation	O
of	O
arginine	B
residues	O
in	O
proteins.	O

For	O
data	O
acquisition,	O
scheduled	O
MRM	O
experiments	O
without	O
EPI	O
spectra	O
acquisition	O
were	O
performed	O
to	O
obtain	O
reliable	O
peak	O
areas	O
for	O
all	O
metabolite	O
aglycones,	B
as	O
well	O
as	O
JWH-018	O
hydroxypentyl	B
glucuronide.	I

Characteristic	O
voltage	O
(V_c	O
)	O
of	O
the	O
BLM	O
as	O
a	O
function	O
of	O
dilutions	O
of	O
the	O
semipurified	O
peptaibol	O
mixture	O
(eluted	O
with	O
90%	O
methanol	B
from	O
a	O
SepPak	O
C_18	O
cartridge)	O
of	O
T.	O
harzianum	O
strain	O
ES39.	O

All	O
spectra	O
were	O
manually	O
phased	O
and	O
baseline	O
referenced	O
to	O
lactate	B
resonance	O
at	O
δ1.33.	O

It	O
should	O
also	O
be	O
noted	O
that	O
no	O
labeled	O
isotopomers	O
were	O
detected	O
for	O
any	O
of	O
the	O
essential	O
amino	O
acids	O
such	O
as	O
valine,	B
leucine	B
and	O
isoleucine	B
or	O
other	O
essential	O
metabolites	O
such	O
as	O
phosphocholine	B
or	O
nicotinamide,	B
which	O
confirmed	O
the	O
absence	O
of	O
contaminating	O
microbial	O
activity.	O

Adenosine	B
may	O
prove	O
to	O
be	O
a	O
better	O
marker	O
of	O
pancreas	O
disease	O
since	O
it	O
possesses	O
known	O
anti-inflammatory	O
properties.	O

However,	O
the	O
potential	O
of	O
short-chain	O
acylcarnitines	B
(carbon	O
atoms < 10)	O
should	O
be	O
still	O
verified	O
as	O
they	O
were	O
present	O
below	O
LOQ	O
in	O
the	O
majority	O
of	O
studied	O
serum	O
samples.	O

TFA	O
and	O
anhydrous	B
citric	I
acid	I
were	O
bought	O
from	O
Acros	O
Organics.	O

Hz,	O
Cys	O
β-CH_b	B
),	O
2.22	O
(t,	O
2H,	O
J	O
=7.5	O

We	O
also	O
tested	O
the	O
effects	O
of	O
a	O
reference	O
compound,	O
alamethicin	B
(from	O
T.	O
viride	O
)	O
and	O
found	O
that	O
it	O
also	O
dissipated	O
the	O
Δψ_m	O
of	O
A549	O
cells	O
similarly	O
to	O
the	O
sperm-toxic	O
HPLC	O
fraction	O
3	O
(Table	O
).	O

Inosine	B
was	O
identified	O
as	O
the	O
most	O
effective	O
diagnostic	O
biomarker	O
for	O
DN-MDD	O
from	O
HCs,	O
with	O
an	O
AUC	O
of	O
0.999	O
(Fig. ).	O

The	O
following	O
settings	O
were	O
applied:	O
ionization	O
voltage	O
1.25 kV(+)/− 1.25 kV	B

First,	O
feature	O
peaks	O
were	O
purified	O
using	O
semi-preparative	O
LC,	O
collected	O
in	O
fraction	O
collector,	O
lyophilized,	O
reconstituted	O
with	O
1	O
g/L	O
ammonium	B
acetate	I
in	O
water-acetonitrile	O
(50:50,	O
v/v),	O
and	O
loaded	O
on	O
wells	O
of	O
a	O
96-well	O
plate.	O

Cholesterol	B
oxidase	O
converts	O
sterols	O
with	O
a	O
3β-hydroxy-5-ene	B
function	O
to	O
3-oxo-4-ene	B
analogues	O
(Scheme	O
2)	O
and	O
a	O
3β-hydroxy-5α-hydrogen	B
function	O
to	O
a	O
3-oxo	O
function.	O

In	O
order	O
to	O
analyze	O
the	O
samples	O
obtained	O
with	O
the	O
improved	O
isotope	O
infusion	O
protocol,	O
we	O
aimed	O
to	O
develop	O
and	O
validate	O
a	O
sensitive	O
and	O
accurate	O
GC–MS/MS	O
method	O
by	O
combining	O
the	O
enrichment	O
analysis	O
of	O
oxalate,	B
glyoxylate,	B
and	O
glycolate	B
into	O
one	O
single	O
analysis.	O

They	O
were	O
three	O
hydroxylated	B
sphingomyelins:	I
SM(OH)22:1,	B
SM(OH)22:2,	B
SM(OH)24:1,	B
three	O
acylcarnitines:	B
C2,	O
C16	O
and	O
C18:1	B
and	O
three	O
phosphatidylcholine	B
lipids	O
PC	B
ae	I
40:1,	I
PC	B
ae	I
42:2	I
and	O
PC	B
ae	I
42:3.	I

**	O
3-(3-Hydroxyphenyl)-3-hydroxypropionic	B
acid,	I
a	O
gut	O
microbiota	O
metabolite	O
produced	O
by	O
Clostridia	O
spp.	O

Enzyme	O
activities	O
in	O
the	O
presence	O
of	O
4-AP	O
were	O
approximately	O
equivalent	O
to	O
the	O
DMSO	B
vehicle	O
control,	O
with	O
a	O
very	O
narrow	O
range	O
of	O
increases,	O
0.89–1.2-fold,	O
across	O
concentrations	O
and	O
enzymes	O
(Figure	O
2).	O

CSF	O
AD	O
biomarker	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
in	O
a	O
Luminex	O
200	O
platform,	O
including	O
levels	O
of	O
beta‐amyloid	O
1‐42	O
(Aβ	O
42),	O
total	O
tau	O
(t‐Tau),	O
and	O
tau	O
phosphorylated	O
at	O
threonine	B
181	O
(p‐Tau_181	O
)	O

Further	O
information	O
about	O
spectral	O
fragmentation	O
patterns	O
(MS/MS)	O
of	O
the	O
PC(18:1/20:3),	B
PC(18:1/22:5),	B
PC(18:1/22:6)	B
and	O
SM(18:1/18:2)	B
is	O
explained	O
in	O
detail	O
as	O
follows.	O

Lysine	B
(C	O
_d	O
=	O
0.4211,	O
C	O
_b	O
=	O
0.0676,	O
C	O
_c	O
=	O
0.4583),	O
cystine	B
(C	O
_d	O
=	O
0.3684,	O
C	O
_b	O
=	O
0.0508,	O
C	O
_c	O
=	O
0.4231),	O
glycine	B
(C	O
_d	O
=	O
0.3684,	O
C	O
_b	O
=	O
0.0282,	O
C	O
_c	O
=	O
0.4231),	O
and	O
tryptophan	B
(C	O
_d	O
=	O
0.2632,	O
C	O
_b	O
=	O
0.0453,	O
C	O
_c	O
=	O
0.3667)	O
were	O
then	O
screened	O
as	O
hubs	O
of	O
this	O
metabolic	O
correlation	O
network.	O

All	O
patients	O
had	O
previously	O
received	O
palliative	O
gemcitabine	O
and	O
cisplatin	B
as	O
standard	O
of	O
care	O
chemotherapy	O
prior	O
to	O
blood	O
sampling.	O

Indeed,	O
a	O
high	O
4-OH-E_2	B
:2-OH-E_2	I
ratio	O
has	O
been	O
suggested	O
as	O
a	O
marker	O
for	O
breast	O
neoplasm.	O

This	O
is	O
equivalent	O
to	O
a	O
27%	O
decrease	O
in	O
mean	O
8-iso	B
-PGF_2α	I
on	O
the	O
original	O
scale	O
over	O
the	O
course	O
of	O
the	O
study.	O

Importantly,	O
4-methylnonanoic	B
acid,	I
hexanoic	B
acid	I
and	O
6-pentyloxan-2-one	B
were	O
absent	O
in	O
the	O
cellular	O
medium,	O
suggesting	O
its	O
origin	O
from	O
cellular	O
metabolism,	O
thus	O
unveiling	O
great	O
potential	O
as	O
candidate	O
biomarkers	O
to	O
be	O
further	O
validated	O
in	O
biofluids	O
from	O
PCa	O
patients.	O

Intrinsic	O
functional	O
connectivity	O
(iFC)	O
correlations	O
with	O
KP	B
levels	O
A.	O
Right	O
dACC	O
negative	O
iFC	O
with	O
the	O
right	O
precuneus	O
demonstrated	O
a	O
positive	O
correlation	O
with	O
KA	O
levels,	O
ρ	O
=	O
0.44,	O
p	O
≤	O
0.05.	O

A	O
clear	O
antioxidant	O
effect	O
was	O
observed	O
for	O
chitosan-coated	O
gold	O
nanoparticles	O
by	O
a	O
significant	O
increase	O
in	O
reduced	B
glutathione,	I
that	O
was	O
much	O
less	O
pronounced	O
for	O
gold-cerium	O
nanoparticles.	O

This	O
method	O
provides	O
simultaneous	O
quantification	O
of	O
routine	O
lipids,	O
fatty	O
acid	O
(FA)	O
composition,	O
and	O
various	O
low-molecular	O
metabolites	O
including	O
amino	O
acids,	O
ketone	B
bodies,	O
and	O
gluconeogenesis-related	O
metabolites	O
in	O
molar	O
concentration	O
units	O
and	O
lipoprotein	O
subclass	O
profiling	O
with	O
lipid	O
concentrations	O
within	O
14	O
subclasses.	O

Of	O
note,	O
the	O
difference	O
in	O
caprylic	B
acid	I
levels	O
in	O
breast	O
milk	O
of	O
UC	O
mothers	O
on	O
5-ASA,	O
compared	O
with	O
biologics,	O
was	O
significantly	O
pronounced.	O

The	O
significant	O
direct	O
association	O
between	O
BMI	O
and	O
ethanolamine	B
(P	O
=	O
2.00	O
×	O
10_−29	O
,	O
)	O
is	O
similarly	O
attenuated	O
by	O
creatinine	B
adjustment,	O
as	O
are	O
the	O
direct	O
associations	O
with	O
BMI	O
of	O
carnosine,	B
1-methylhistidine	B
(both	O
markers	O
of	O
meat	O
intake),	O
threonine,	B
alanine,	B
valine,	B
isoleucine,	B
and	O
histidine.	B

As	O
shown	O
in	O
,	O
pyruvate	O
recycling	O
produces	O
equimolar	O
mixture	O
of	O
[1,2-_13	O
C]	I
and	O
[3-_13	O
C]	O
pyruvate	B
isotopomers	O
from	O
[1,2-_13	O
C]	I
and	O
[3,4-_13	O
C]	I
OAA	O
isotopomers	O
through	O
the	O
activity	O
of	O
either	O
malic	O
enzyme	O
or	O
combined	O
activity	O
of	O
the	O
enzymes	O
phosphoenolpyruvate	O
carboxykinase	O
(PEPCK)	O
and	O
pyruvate	B
kinase	O
(PK).	O

 ,	O
samples	O
with	O
a	O
decreased	O
level	O
of	O
ethanolamine	B
had	O
a	O
high	O
probability	O
of	O
being	O
assigned	O
to	O
long-term	O
survivors.	O

Considering	O
the	O
marked	O
changes	O
of	O
plasma	O
acylcarnitines	B
induced	O
by	O
amlodipine	B
in	O
the	O
present	O
study,	O
it	O
is	O
of	O
interest	O
that	O
Menni	O
et	O
al.	O
also	O
observed	O
an	O
inverse	O
correlation	O
between	O
plasma	O
hexadecanedioate	B
and	O
carnitine	B
levels.	O

For	O
example,	O
the	O
results	O
of	O
separation	O
of	O
a	O
mixture	O
of	O
standard	O
carboxylic	B
and	O
amino	O
acids	O
performed	O
using	O
a	O
HILIC	O
column,	O
without	O
attempting	O
to	O
optimize	O
chromatography	O
conditions,	O
indicate	O
that	O
_15	O
N-cholamine	B
tagged	O
metabolites	O
can	O
be	O
separated	O
effectively.	O

The	O
metabolites	O
were	O
ChoE(18:1),	B
ChoE(18:2),	B
ChoE(20:4),	B
PE(16:0/18:1),	B
SM(d18:1/23:0),	B
SM(42:3)	B
and	O
TG(54:1)	B
and	O
the	O
model	O
was:	O

However,	O
results	O
showed	O
that	O
only	O
64	O
(62%)	O
of	O
the	O
103	O
thiols	B
could	O
be	O
calculated	O
with	O
the	O
RSDs	O
lower	O
than	O
30%	O
(data	O
not	O
shown).	O

In	O
the	O
purple	O
and	O
yellow	O
modules,	O
consisting	O
mostly	O
of	O
amino	O
acids	O
including	O
BCAAs	O
and	O
the	O
short-chain	O
acylcarnitines,	B
the	O
remitters	O
mostly	O
had	O
lower	O
baseline	O
levels	O
but	O
showed	O
an	O
upward	O
trend	O
in	O
their	O
metabolite	O
trajectories	O
from	O
baseline	O
to	O
week	O
12	O
while	O
the	O
treatment	O
failures	O
all	O
trended	O
to	O
decrease	O
to	O
lower	O
levels	O
post-therapy.	O

Elevated	O
circulating	O
homocysteine	B
has	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
head	O
and	O
neck	O
cancers,	O
colorectal	O
cancer,	O
and	O
colorectal	O
adenoma	O
recurrence	O
(–).	O

When	O
entering	O
the	O
nucleus,	O
SREBPs	O
also	O
activate	O
endogenous	O
cholesterol	B
biosynthesis.	O

Notably,	O
two	O
previous	O
metabolomics	O
studies	O
have	O
demonstrated	O
higher	O
serum	O
creatine	B
levels	O
in	O
HF	O
patients	O
[,	O
].	O

The	O
control	O
samples	O
in	O
the	O
NCNP	O
Biobank	O
were	O
collected	O
by	O
advertising	O
in	O
local	O
free	O
magazines	B
and	O
on	O
websites.	O

Here	O
the	O
effect	O
of	O
column	O
length	O
(150,	O
75	O
and	O
30 mm)	O
and	O
gradient	O
duration	B
(15,	O
7.5	O
and	O
3 min	O
respectively)	O
on	O
the	O
number	O
of	O
features	O
detected	O
when	O
untargeted	O
metabolic	O
profiling	O
of	O
human	O
urine	O
using	O
reversed-phase	O
gradient	O
ultra	O
performance	O
chromatography	O
with,	O
and	O
without,	O
ion	O
mobility	O
spectrometry,	O
has	O
been	O
examined.	O

The	O
dried	O
mixture	O
was	O
reconstituted	O
with	O
50	O
μL	O
of	O
acetonitrile—0.1%	O
formic	B
acid	I
mixture	O
(25:75,	O
v/v)	O
and	O
vortexed	O
for	O
30	O
s.	O

Ornithine	B
is	O
then	O
converted	O
back	O
to	O
arginine	B
through	O
the	O
intermediate	O
citrulline,	B
completing	O
the	O
cycle.	O

The	O
crude	O
methanolic	B
cell	O
extract	O
from	O
Trichoderma	O
harzianum	O
strain	O
ES39	O
inhibited	O
the	O
boar	O
sperm	O
cell	O
motility	O
at	O
a	O
low	O
exposure	O
concentration	O
(50%	O
effective	O
concentration,	O
1	O
to	O
5	O
μg	O
[dry	O
weight]	O
ml	O
of	O
extended	O
boar	O
semen_−1	O
).	O

(IHC,	O
Immunohistochemistry;	O
LH,	O
luteinizing	O
hormone;	O
FSH,	O
follicle	O
stimulating	O
hormone;	O
PRL,	O
prolactin;	O
NA,	O
not	O
available;	O
PRL-reference	O
range = 2–23 ng/mL;	O
*,	O
BHB	O
levels	O
measured	O
by	O
_1	O
H	O
NMR	O
spectroscopy;	O
Ψ,	O
IHC	O
was	O
positive	O
for	O
LH/FSH,	O
also	O
showed	O
scattered	O
immunoreactivity	O
for	O
PRL,	O
and	O
these	O
patient	O
also	O
showed	O
elevated	O
levels	O
of	O
PRL	O
and	O
BHB	O
similar	O
to	O
prolactinoma	O
patients;	O
#,	O
patients	O
were	O
treated	O
with	O
Cabergoline,	B

When	O
looking	O
at	O
the	O
control	O
group,	O
primate	O
C2	O
has	O
an	O
increase	O
in	O
the	O
more	O
sensitive	O
metabolites	O
(specifically	O
succinic	B
acid	I
and	O
butanoic	B
acid).	O

Additionally,	O
Lewis	O
et	O
al.	O
developed	O
a	O
reporter	O
system	O
based	O
on	O
the	O
mutant	O
IDH	O
(mtIDH1/2)	O
production	O
of	O
2-hydroxyglutarate	B
(2-HG)	O
from	O
alpha-ketoglutarate	B
(a-KG),	O
which	O
requires	O
NADPH.	B

Previous	O
reports	O
have	O
shown	O
significant	O
increases	O
in	O
levels	O
of	O
glycine,	B
benzoic	B
acid	I
and	O
butanoic	B
acid	I
in	O
CHB	O
patients	O
compared	O
with	O
the	O
control	O
groups	O
(Zhao	O
et	O
al.,	O
2013).	O

Parts	O
of	O
the	O
serine	B
and	O
the	O
methionine	B
metabolisms	O
are	O
strongly	O
connected	O
via	O
the	O
folate	B
cycle	O
into	O
the	O
so-called	O
1-carbon	O
metabolism.	O

There	O
is	O
no	O
obvious	O
trend	O
in	O
the	O
changes	O
of	O
the	O
Δ9/Δ11	O
isomers	O
and	O
neither	O
do	O
the	O
changes	O
correlate	O
with	O
relative	O
isomeric	O
composition	O
in	O
free	O
FA	B
18:1	I
(I	O
_Δ9	O
/I	O
_Δ11	O
 = 10.5 ±	O

25-HC	O
also	O
correlates	O
with	O
(25R)26-HC	B
but	O
less	O
strongly	O
than	O
24S-HC.	O

TDF/FTC,	O
tenofovir	O
disoproxil	O
fumarate/emtricitabine;	O
Mono/dual,	O
monotherapy	O
or	O
dual	O
therapy	O
(plus	O
lamivudine);	O
TAF/FTC,	O
tenofovir	O
alafenamide	B
fumarate/emtricitabine;	O
Cer,	B
ceramide.	B

We	O
were	O
interested	O
in	O
determining	O
whether	O
SNP	O
rs4149056	O
was	O
associated	O
with	O
levels	O
of	O
sterol/bile	O
acid	O
metabolites	O
whose	O
pre-treatment	O
concentrations	O
had	O
been	O
correlated	O
with	O
simvastatin	B
LDL	I
response.	O

Results	O
from	O
_1	O
H	O
NMR	O
spectroscopy	O
showed	O
significantly	O
elevated	O
glucose	B
concentrations	O
in	O
CSF	O
samples	O
from	O
drug-naïve	O
patients	O
with	O
first-onset	O
schizophrenia,	O
as	O
compared	O
to	O
the	O
demographically	O
matched	O
control	O
group,	O
with	O
a	O
relative	O
increase	O
in	O
concentration	O
of	O
6.5%	O
(p	O
=	O
0.04;	O
calculated	O
from	O
a	O
distinct	O
resonance	O
signal	O
at	O
3.68–3.72	O
ppm).	O

*Mean	O
and	O
standard	O
deviation	O
calculated	O
after	O
removing	O
cell	O
lines	O
containing	O
highest	O
and	O
lowest	O
total	O
measured	O
estrogen	B
levels.	O

The	O
general	O
increase	O
of	O
lactose	B
is	O
a	O
well-known	O
phenomenon	O
and	O
is	O
linked	O
to	O
lactation	O
and	O
the	O
prolactin	O
levels	O
in	O
blood.	O

d	O
_3	B
-Palmitic	I
acid	I
(cat.	O

Moreover	O
the	O
peak	O
corresponding	O
to	O
17-hydroxyprogesterone	B
(m/z	O
331.3 ± 0.2)	O
was	O
clearly	O
evident	O
in	O
the	O
media	O
of	O
BPA	O
treated	O
H-HepG2	O
cells.	O

Response_post-extractionspike	O
is	O
the	O
mean	O
peak	O
area	O
count	O
for	O
D-mannose	B
spiked	O
into	O
extracted	O
matrix	O
after	O
the	O
extraction	O
procedure.	O

In	O
addition	O
to	O
their	O
essential	O
role	O
in	O
building	O
muscle	O
tissue,	O
BCAA’s	O
are	O
regulators	O
of	O
key	O
cellular	O
signaling	O
pathways	O
including	O
that	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
(mTOR),	O
a	O
central	O
regulator	O
of	O
cell	O
metabolism,	O
growth	O
and	O
survival.	O

A	O
set	O
of	O
54	O
adult	O
serum	O
samples	O
was	O
collected	O
specifically	O
for	O
quantitative	O
NMR,	O
untargeted	O
GC-MS	O
and	O
targeted	O
(DFI)	O
MS/MS	O
studies,	O
and	O
a	O
second	O
set	O
of	O
3	O
samples	O
was	O
collected	O
and	O
analyzed	O
using	O
quantitative	O
lipidomics	O
assays	O
(TLC-methyl-esterification-GC-MS)	O
developed	O
by	O
Lipomics	O
Technologies	O
Inc.	O
(now	O
Tethys	O
Inc.,	O
West	O
Sacramento,	O
CA).	O

An	O
elevated	O
level	O
of	O
ornithine	B
and	O
decreased	O
level	O
of	O
arginine	B
implied	O
the	O
imbalance	O
of	O
urea	B
cycle	O
(a	O
reduced	O
level	O
of	O
citrate	B
and	O
arginine	B
has	O
been	O
reported).	O

Plasma	O
fatty	O
acids	O
were	O
quantified	O
by	O
GC-FID	O
and	O
25-hydroxyvitamin	B
D	I
and	O
homocysteine	B
by	O
LC-MS/MS.	O

Specifically,	O
lactate-to-pyruvate	O
ratio	O
was	O
25.2 ± 1.8,	O
297.0 ± 25.1,	O
and	O
464.5 ± 38.6	O
for	O
HK-2	O
cells	O
exposed	O
to	O
serum-free	O
medium,	O
glucose	B
5	O
and	O
25 mM,	O
respectively	O
(Student’s	O
t	O
test,	O
p = 0.003	O
for	O
both	O
comparisons)	O
(Fig.	O

Notably,	O
the	O
PLS	O
loadings	O
indicate	O
that	O
serum	O
hypoxanthine	B
and	O
urine	O
1-methylnicotinamide,	B
both	O
markers	O
of	O
oxidative	O
stress,	O
are	O
elevated	O
in	O
the	O
samples	O
from	O
patients	O
with	O
AP	B
(P	O
=9.4	O

¶No	O
treatment	O
implies	O
that	O
patients	O
were	O
not	O
treated	O
with	O
immunosuppressants,	O
hydroxychloroquine	B
or	O
corticosteroids.	O

We	O
generated	O
a	O
model	O
that	O
included	O
six	O
variables	O
(4-hydroxypentenoic	O
acid,	I
arabinose,	B
GCDCA-3-sulfate,	B
isoleucine,	B
serine,	B
and	O
xanthine)	B
as	O
independent	O
predictors	O
of	O
OSA	O
as	O
follows:	O
probability	O
1 = exp	O
(−0.048 + 0.987	O

Results:	O
Established	O
analytical	O
method	O
based	O
on	O
urine	O
metabolomics	O
GC-MS	O
of	O
Type	O
II	O
diabetes,	O
determine	O
the	O
urine	O
succinic	B
acid,	I
L-leucine,	B
L-isoleucine,	B
tyrosine,	B
slanine,	O
acetoace	O
acid,	O
mannose,	B
L-isoleucine,	B
L-threonine,	B
Phenylalanine,	B
fructose,	B
D-glucose,	B
palmi	O
acid,	O
oleic	B
acid	I
and	O
arachidonic	B
acid	I
were	O
significantly	O
were	O
significantly	O
changed.	O

Diosmetin	B
mean	O
PK	O
results	O
in	O
urines	O
of	O
subjects	O
treated	O
with	O
diosmin	O
Table	O
shows	O
the	O
measured	O
concentrations	O
of	O
the	O
three	O
glucuronides,	O
the	O
sum	O
of	O
all	O
glucuronide	B
determined,	O
and	O
the	O
diosmetin	B
levels	O
obtained	O
after	O
glucuronidase	O
and	O
sulfatase	O
degradation.	O

Briefly,	O
each	O
100-ml	O
serum	O
sample	O
was	O
mixed	O
with	O
350 μl	O
of	O
methanol,	B
and	O
50 μl	O
of	O
heptadecanoic	B
acid	I
(dissolved	O
in	O
methanol	B
at	O
a	O
concentration	O
of	O
1 mg	O
ml_−1	O
)	O
was	O
added	O
as	O
an	O
internal	O
standard.	O

Highly	O
active	O
glycolysis	O
and	O
an	O
impaired	O
Krebs	O
cycle	O
guarantee	O
enough	O
metabolic	O
intermediates	O
by	O
avoiding	O
thorough	O
oxidation	O
of	O
glucose.	B

The	O
kynurenine	B
pathway	O
displays	O
increases	O
in	O
xanthurenic	B
acid	I
and	O
especially	O
in	O
quinolinic	B
acid,	I
paralleled	O
by	O
a	O
considerable	O
decrease	O
in	O
kynurenic	B
acid	I
(Fig.	O

Protein	O
glycosylation,	O
an	O
enzymatic	O
process	O
by	O
which	O
saccharide	B
groups	O
are	O
added	O
to	O
the	O
maturing	O
proteins,	O
is	O
involved	O
in	O
fundamental	O
molecular	O
and	O
cell	O
biology	O
processes	O
occurring	O
in	O
cancer,	O
including	O
metastasis	O
formation.	O

The	O
ion	O
species	O
for	O
quantification	O
of	O
acetamiprid,	B
AM-2	O
and	O
fipronil	O
were	O
m	O
/z	O
=	O
222.80/126.10,	O
m	O
/z	O
=	O
209.00/126.10	O
and	O
m	O
/z	O
=	O
435.00/330.00,	O
respectively.	O

Comparison	O
of	O
the	O
concentrations	O
of	O
(a)	O
carboxylic	B
acid	I
and	O
(b)	O
amino	B
metabolites	O
in	O
the	O
NIST	O
plasma	O
obtained	O
with	O
spiking	O
(left	O
bars)	O
and	O
without	O
spiking	O
(right	O
bars)	O
with	O
the	O
standard	O
compounds.	O

In	O
total,	O
six	O
metabolites	O
(serine,	O
phenylalanine,	B
galactose,	B
palmitic	B
acid,	I
linoleic	B
acid,	I
and	O
arachidonic	O
acid)	O
were	O
identified.	O

FBS	O
(Hyclone	O
Laboratories/Thermo	O
Scientific,	O
Rockford,	O
IL)	O
and	O
1%	O
penicillin-streptomycin	B
(Hyclone	O
Laboratories).	O

Different	O
levels	O
of	O
Progesterone	B
receptor	O
status;	O
0 %,	O
20 %,	O
100 %	O
and	O
intratumoral	O
heterogeneity	O

For	O
instance,	O
treatment	O
with	O
exogenous	O
spermine	B
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
decreasing	O
body	O
weight	O
and	O
fasting	O
glucose	B
and	O
improves	O
glucose	B
tolerance	O
in	O
diet-induced	O
obese	O
mice.	O

Both	O
3-hydroxybutyric	B
acid	I
and	O
creatine	B
play	O
important	O
roles	O
in	O
energy	O
metabolism.	O

z	O
215.13	O
(α-HIBA-[_11	O
B]-3-HIBA).	I

For	O
the	O
analysis	O
of	O
GP-tagged	O
sterols	O
from	O
CSF,	O
12	O
μl	O
of	O
the	O
first	O
methanol	B
fraction	O
(1	O
ml)	O
from	O
the	O
second	O
SepPak	O
C_18	O
cartridge	O
(SPE2-Fr-1)	O
(equivalent	O
to	O
6	O
μl	O
of	O
CSF	O
assuming	O
all	O
the	O
sterols	O
elute	O
in	O
this	O
methanol	B
fraction)	O
was	O
diluted	O
with	O
8	O
μl	O
of	O
0.1%	O
formic	B
acid	I
and	O
20	O
μl	O
injected	O
onto	O
the	O
LC	O
column.	O

OPLS-DA	O
models	O
with	O
whey	B
and	O
calcium	B
caseinate	I
as	O
classes	O
made	O
to	O
investigate	O
the	O
difference	O
between	O
whey	B
and	O
calcium	B
caseinate	I
intake	O
were	O
poor,	O
and	O
they	O
were	O
unsuitable	O
for	O
interpretation	O
(Q2	O
<	O
0.5;	O
data	O
not	O
shown).	O

EETs	O
are	O
avidly	O
incorporated	O
into	O
cellular	O
phospholipids	B
and	O
“released	O
at	O
rates	O
exceeding	O
those	O
for	O
arachidonic	O
acid.”	O

One	O
important	O
advantage	O
of	O
our	O
findings,	O
is	O
that	O
circulating	O
BK	O
and	O
DABK	O
levels	O
represent	O
the	O
host's	O
response	O
to	O
pathogen–associated	O
molecular	O
patterns	O
and	O
may	O
offer	O
a	O
rational	O
route	O
forward	O
in	O
the	O
prediction	O
of	O
real-time	O
treatment	O
outcomes	O
at	O
both	O
early	O
and	O
late	O
treatment	O
stages	O
and	O
allow	O
individualization	O
of	O
treatment	O
regimens,	O
dosing,	O
and	O
treatment	O
duration.	B

Our	O
findings	O
confirm	O
a	O
previous	O
study	O
reporting	O
a	O
positive	O
association	O
of	O
HAA	O
and	O
XA	O
levels	O
to	O
concentrations	O
of	O
PLP	O
and	O
riboflavin.	B

(A)	O
1D	O
NOESY	O
spectrum	O
of	O
SP	B
collected	O
in	O
HBSS,	O
with	O
additional	O
peaks	O
due	O
to	O
exogenous	O
glucose	B
present.	O

In	O
human	O
plasma	O
and	O
tissues,	O
acetylcarnitine	B
is	O
the	O
most	O
abundant	O
naturally	O
occurring	O
derivative.	O

	O
means	O
upregulated,	O
	O
means	O
downregulated,	O
LPC	O
means	O
lysophosphocholine,	B
FA	B
means	O
fatty	O
acid,	O
AML	O
means	O
acute	O
myelogenous	O
leukemia,	O
LC	O
means	O
liver	O
cirrhosis,	O
HV	B
means	O
healthy	O
volunteers.	O

Twenty-five	O
subjects	O
were	O
fed	O
50	O
g	O
of	O
either	O
raw	O
‘Jade	O
Cross’	O
Brussels	O
sprouts	O
(high	O
glucobrassicin	B
concentration)	O
or	O
‘Blue	O
Dynasty’	O
cabbage	O
(low	O
glucobrassicin	B
concentration)	O
once	O
daily	O
for	O
three	O
days.	O

Although	O
the	O
shorter	O
products	O
of	O
the	O
eccentric	O
cleavage	O
of	O
β-carotene	B
had	O
little	O
or	O
no	O
effect	O
on	O
ATRA-induced	O
transactivation,	O
β-apo-10′-carotenoic	B
acid	I
and	O
β-apo-12′-carotenoic	B
acid	I
both	O
led	O
to	O
40–50%	O
inhibition	O
of	O
ATRA-induced	O
activation	O
of	O
all	O
three	O
RAR	O
isoforms.	O

Abbreviations:	O
U,	O
unknown;	O
3-OH-3-MBA,	B
3-hydroxy-3-methylbutyric	B
acid;	I
4-DTA,	O
4-deoxythreonic	B
acid;	I
α-KGA,	B
α-ketoglutaric	B
acid;	I
2-HPAA,	B
2-hydroxyphenylacetic	B
acid.	I

Serum	O
from	O
patients	O
with	O
epilepsy	O
were	O
characterized	O
by	O
increased	O
levels	O
of	O
3-OH-butyrate,	B
2-OH-valerate,	B
2-OH-butyrate,	B
acetoacetate,	B
acetone,	B
acetate,	B
choline,	B
alanine,	B
glutamate,	B
scyllo-inositol	B
(C < R < NR),	O
and	O
decreased	O
concentration	O
of	O
glucose,	B
lactate,	B
and	O
citrate	B
compared	O
to	O
C	O
(C > R > NR).	O

In	O
central	O
nervous	O
system	O
cholesterol	B
cannot	O
be	O
degraded	O
but	O
is	O
secreted	O
into	O
circulation	O
predominantly	O
in	O
the	O
form	O
of	O
its	O
polar	O
metabolite	O
24(S	O
)	O

In	O
vitro	O
studies	O
by	O
the	O
same	O
group	O
demonstrated	O
that	O
kynurenine	B
triggered	O
dilation	O
of	O
previously	O
constricted	O
porcine	B
arteries.	O

HC-04	O
and	O
MCF-10A	O
cells	O
were	O
obtained	O
from	O
American	O
Type	O
Culture	O
Collection	O
(ATCC,	O
Manassas,	O
VA,	B
USA).	O

Only	O
a	O
few	O
metabolites	O
that	O
were	O
decreased	O
in	O
UC	O
were	O
also	O
decreased	O
in	O
CD	O
patients	O
(i.e.,	O
citrate,	B
succinate,	B
betaine,	B
hippurate,	B
and	O
methanol)	B
as	O
compared	O
to	O
controls.	O

These	O
data,	O
associated	O
with	O
the	O
data	O
reported	O
in	O
the	O
accompanying	O
manuscript,	O
supports	O
a	O
role	O
for	O
the	O
kynurenine	B
pathway	O
in	O
the	O
pathophysiology	O
of	O
chronic	O
headache	O
disorders.	O

(D)	O
Pyrimidine	B
metabolism.	O

Abnormal	O
expression	O
of	O
carnitines	B
in	O
patients	O
with	O
malignancies	O
is	O
well	O
known.	O

In	O
our	O
study,	O
eicosanoids	B
were	O
significantly	O
overexpressed	O
in	O
HCC	O
patients	O
vs.	O
DCs	O
and	O
downregulated	O
in	O
DCs	O
vs.	O
NHC.	O

Representative	O
chromatograms	O
of	O
the	O
urine	O
extract	O
in	O
a	O
patient	O
with	O
detection	O
of	O
thiamethoxam	B
for	O
quantification	O
and	O
qualification	O
are	O
shown	O
in	O
.	O

The	O
levels	O
of	O
malate	B
and	O
citrate	B
were	O
much	O
lower	O
in	O
cell	O
line	O
PC	O
179	O
1A	O
than	O
in	O
the	O
other	O
two	O
PC	O
knockdown	O
cell	O
lines	O
shown	O
in	O
,	O
and	O
the	O
level	O
of	O
pyruvate	B
was	O
increased	O
less	O
than	O
in	O
the	O
other	O
two	O
cell	O
lines	O
in	O
this	O
cell	O
line	O
(only	O
24%	O
higher	O
than	O
in	O
the	O
control	O
cell	O
line,	O
as	O
compared	O
to	O
350%	O
higher	O
in	O
the	O
other	O
two	O
PC	O
knockdown	O
cell	O
lines).	O

Indeed,	O
the	O
capacity	O
for	O
borate	O
to	O
bind	O
to	O
vicinal	O
diols	O
has	O
been	O
widely	O
exploited	O
analytically	O
in	O
the	O
production	O
of	O
phenyl-boronate	B
sorbents	O
and	O
phases	O
that	O
can	O
be	O
used	O
to	O
extract	O
and	O
isolate	O
suitable	O
diols	O
including	O
sugars	O
and	O
drug	O
glucuronides.	O

Stars	O
in	O
boxplots	O
indicate	O
significant	O
differences	O
in	O
concentration	O
between	O
methionine	B
sulfoxide	I
in	O
serum	O
W	O
tubes	O
with	O
clotting	O
activator	O
and	O
serum	O
gel-barrier	O
tubes.	O

ACC	O
patients	O
had	O
a	O
significantly	O
higher	O
excretion	O
of	O
androgen	O
precursor	O
metabolites	O
[pregnenediol	O
(5-PD),	O
pregnenetriol	O
(5-PT),	O
DHEA,	O
16α-OH-DHEA;	B
see	O
Supplemental	O
Table	O
1]	O
and	O
also	O
of	O
metabolites	O
of	O
active	O
androgens	O
(androsterone	O
and	O
etiocholanolone;	B
A	O
and	O
Supplemental	O
Table	O
2).	O

_,	O
This	O
method	O
was	O
not	O
sensitive	O
enough,	O
especially	O
for	O
analysis	O
of	O
oxalate	B
at	O
the	O
expected	O
concentration	O
in	O
plasma	O
from	O
healthy	O
volunteers.	O

Caution	O
is	O
needed	O
in	O
patients	O
with	O
conflictive	O
results,	O
i.e.	O
PET-positive	O
patients	O
with	O
a	O
high	O
glutamate	B
concentration	O
or	O
PET-negative	O
patients	O
with	O
a	O
low	O
relative	O
glutamate	B
concentration.	O

For	O
carnosine,	B
DOPA	B
and	O
histamine	B
the	O
majority	O
of	O
values	O
across	O
laboratories	O
were	O
reported	O
as	O
missing	O
or	O
BLD	O
indicating	O
that	O
in	O
normal	O
serum/plasma	O
these	O
metabolites	O
were	O
not	O
detected	O
reliably	O
by	O
the	O
assay.	O

These	O
findings	O
indicate	O
that	O
the	O
excursions	O
in	O
Leu/Ile	O
and	O
glycerol	B
are	O
sufficient	O
to	O
capture	O
the	O
correlation	O
of	O
2-h	O
metabolite	O
changes	O
with	O
fasting	O
insulin.	O

Our	O
previous	O
study	O
observed	O
that	O
D-Mannose	B
was	O
elevated	O
in	O
late	O
stage	O
esophageal	O
cancer	O
patients,	O
consistent	O
with	O
the	O
finding	O
of	O
higher	O
levels	O
of	O
D-Mannose	B
in	O
PLP	O
and	O
CRC	O
cases	O
compared	O
to	O
controls.	O

After	O
the	O
initial	O
PCA	O
analysis	O
the	O
following	O
regions	O
corresponding	O
to	O
paracetamol	B
and	O
its	O
metabolites	O
were	O
excluded	O
from	O
the	O
analysis:	O
7.5–6.75,	O
3.95–3.8,	O
3.7–3.45,	O
2.2–2.14	O
and	O
1.84–1.88 ppm	O
according	O
to	O
(Bales	O
et	O
al.	O
).	O

Arginine	B
and	O
symmetric	B
dimethylarginine	I
decreased	O
(p	O
<	O
0.05)	O
in	O
active-CD	O
(129	O
and	O
0.437	O
µM)	O
compared	O
to	O
controls	O
(157	O
and	O
0.494	O
µM)	O
and	O
active-UC	O
(164	O
and	O
0.52	O
µM).	O

The	O
importance	O
of	O
dynamic	O
changes	O
of	O
vitamin	B
D	I
concentrations	O
and	O
intra/inter-individual	O
variability	O
after	O
administration	O
of	O
fixed	O
supplementation	O
doses	O
has	O
also	O
been	O
demonstrated	O
in	O
several	O
recent	O
studies.	O

The	O
pathway	O
analysis	O
showed	O
that	O
these	O
metabolites	O
were	O
mainly	O
involved	O
in	O
four	O
metabolic	O
pathways:	O
(p-value<0.01,	O
impact>0):	O
Taurine	B
and	O
hypotaurine	B
metabolism	O
(p=0.004,	O
impact=0.021);	O

In	O
addition,	O
Hozawa	O
et	O
al	O
.	O
found	O
that	O
uric	B
acid	I
is	O
an	O
independent	O
predictor	O
of	O
IS.	O

The	O
degree	O
of	O
contribution	O
of	O
different	O
groups	O
to	O
the	O
downfield	O
shift	O
can	O
be	O
explained	O
on	O
the	O
basis	O
of	O
the	O
corresponding	O
electronegativity,	O
as	O
a	O
sulfate	B
group	O
is	O
larger	O
than	O
a	O
glucuronyl	O
moiety.	O
_1	O
H‐NMR	O
spectra	O
of	O
equol	O
and	O
its	O
metabolites	O
(δ	O
in	O
DMSO‐d	O
_6	O
)	O
Abbreviations:	O
d,	O
doublet;	O
dd,	O
doublet	O
of	O
doublets;	O
m,	O
multilet.	O

The	O
biomarker	O
most	O
commonly	O
associated	O
with	O
tryptophan	B
metabolites	O
was	O
neopterin,	B
which	O
had	O
positive	O
associations	O
with	O
the	O
KTR,	O
kynurenine	B
(both	O
P	O
<	O
0.0001),	O
and	O
anthranilic	B
acid	I
(P	O
=	O
0.004).	O

Further,	O
we	O
examined	O
two	O
arginine-related	O
metabolites,	O
citrulline	B
and	O
ornithine,	B
as	O
absolute	O
levels	O
in	O
memory	O
clinic	O
patients	O
at	O
the	O
same	O
time,	O
and	O
calculated	O
the	O
GABR,	O
a	O
better	O
indicator	O
of	O
dysregulated	O
arginine	B
metabolism	O
than	O
concentration	O
alone.	O

Phthalate	B
metabolites	O
concentrations	O
were	O
detected	O
in	O
most	O
of	O
the	O
participants	O
with	O
a	O
range	O
of	O
83%	O
(MEHP)	O
to	O
100%	O
(MEP,	O
MBP	O
and	O
MECPP).	O

Despite	O
the	O
small	O
sample	O
size	O
analyzed,	O
our	O
results	O
indicate	O
5	O
lipids	O
that	O
drive	O
the	O
separation	O
of	O
RP	B
and	O
NRP.	O

The	O
resulting	O
supernatant	O
was	O
lyophilized	O
(LABCONCO	O
FreeZone	B
bulk	O
tray	O
dryer	O
(Kansas	O
City,	O
MO)	O
and	O
stored	O
at	O
_	O
80°C	O
until	O
NMR	O
analysis.	O

The	O
analysis,	O
by	O
mass	O
spectrometry,	O
of	O
media	O
H-HepG2	O
suggests	O
the	O
presence	O
of	O
molecules	O
belonging	O
to	O
sterols	O
family	O
activated	B
both	O
BPA	O
and	O
Sil.	O

For	O
instance,	O
in	O
a	O
fully	O
adjusted	O
multinomial	O
logistic	O
model,	O
a	O
25	O
nmol/L	O
lower	O
25-hydroxyvitamin	B
D	I
was	O
associated	O
with	O
a	O
0.8-fold	O
decrease	O
in	O
the	O
odds	O
of	O
having	O
higher	O
CAC	O
(95%	O
CI	O
0.68–0.96,	O
P	O
=	O
0.01).	O

Negatively	O
charged	O
acidic	O
metabolites,	O
such	O
as	O
lactic	B
acid,	I
citric	B
acid,	I
and	O
acetic	B
acid	I
were	O
not	O
perturbed.	O

As	O
a	O
preliminary	O
study,	O
we	O
determined	O
sulfate	B
and	O
taurine	B
concentration	O
in	O
64	O
urine	O
samples	O
collected	O
from	O
eight	O
volunteers	O
over	O
8 weeks.	O

breast	O
cancer,	O
endogenous	O
steroid	O
hormones,	O
estradiol,	B
estrogen	B
metabolites,	O
hormonal	O
carcinogenesis,	O
2-hydroxyestrone,	B
16α-hydroxyestrone	B

The	O
linoleic	B
acid	I
metabolites	O
9-HODE	B
and	O
12,13-DiHOME,	B
which	O
were	O
present	O
in	O
relatively	O
high	O
abundance	O
in	O
TGRL	O
and	O
had	O
a	O
strong	O
negative	O
influence	O
on	O
the	O
modeled	O
VCAM-1	O
expression,	O
exhibited	O
a	O
dose-dependent	O
effect	O
in	O
reducing	O
HAEC	O
VCAM-1	O
expression	O
(Fig. ).	O

The	O
levels	O
of	O
PE(16:0/16:1),	B
PE(16:0/18:3),	B
PE(16:0/18:2),	B
PE(18:0/16:0),	B
PE(17:0/18:2),	B
PE(18:0/17:1),	B
PE(17:0/18:1),	B
PE(20:5/16:0),	B
PE(18:0/18:1),	B
PE(18:1/20:4),	B
PE(18:0/20:3),	B
PC(15:0/18:1),	B
PC(16:1/20:5),	B
and	O
PC(18:0/20:1)	B
in	O
early-stage	O
NSCLC	O
were	O
significantly	O
increased	O
compared	O
with	O
HC	O
(p<0.05).	O

Analysis	O
of	O
a	O
group	O
of	O
patients	O
expressing	O
the	O
estrogen	B
receptor	O
also	O
showed	O
significantly	O
higher	O
7-ketocholesterol	B
levels	O
in	O
the	O
second	O
sampling	O
compared	O
to	O
the	O
corresponding	O
first	O
sampling	O
(n=16/17,	O
p	O
=0.022	O
by	O
the	O
Mann-Whitney	O
test).	O

Acylcarnitines,	B
Prostate	O
cancer,	O
Metabolomics,	O
Disease	O
progression,	O
Fatty	O
acid	O
metabolism	O

The	O
NMR-detectable	O
tCho	O
pool	O
correlated	O
positively	O
with	O
lactate,	B
tCr	O
and	O
tGlut,	O
and	O
negatively	O
with	O
fatty	O
acids.	O

In	O
light	O
of	O
these	O
findings	O
and	O
our	O
observation	O
that	O
the	O
ratio	O
of	O
the	O
dNTP:NTP	O
(deoxynucleotide	O
triphosphate:	I
nucleotide	O
triphosphate)	B
is	O
higher	O
in	O
TAM-R	O
in	O
vitro	O
and	O
in	O
vivo	O
samples,	O
we	O
allude	O
to	O
the	O
possibility	O
that	O
TAM	O
resistance	O
could	O
be	O
a	O
reflection	O
of	O
increased	O
RRM2	O
activity.	O

Bound	O
metabolites	O
were	O
then	O
eluted	O
into	O
an	O
Axygen	O
500μL	O
V-bottom	O
96-well	O
plate	O
by	O
addition	O
of	O
450μL	O
of	O
ethanol	B
to	O
each	O
SPE	O
plate	O
well,	O
with	O
slow	O
pull	O
through	O
(5	O
mmHg	O
vacuum)	O
after	O
120	O
second	O
equilibration.	O

These	O
metabolites	O
included	O
amino	O
acids	O
(alanine,	O
glycine),	B
carbohydrate	B
(galactose),	I
fatty	O
acids	O
(linoleic	O
acid),	O
and	O
cholesterol.	B

Similarly,	O
ketones	B
were	O
also	O
positively	O
correlated	O
with	O
several	O
amino	O
acids	O
such	O
as	O
tyrosine,	B
valine,	B
leucine,	B
and	O
phenylalanine	B
during	O
insulin	O
deprivation,	O
but	O
this	O
correlation	O
became	O
negative	O
with	O
insulin	O
treatment.	O

Creatinine;	B
98.	O

The	O
selectivity	O
of	O
the	O
method	O
was	O
established	O
by	O
the	O
analysis	O
of	O
blank	O
human	O
plasma	O
from	O
five	O
different	O
donors	O
(including	O
two	O
lipemic	O
plasma	O
samples)	O
and	O
two	O
pooled	O
regular	O
plasma	O
samples	O
(n	O
=	O
7),	O
all	O
processed	O
with	O
pure	O
MeOH.	B

-THB	O
allo-tetrahydrocorticosterone,	B
allo	O
-P2	O
allo-pregnanediol,	O
P2	O
pregnanediol,	B
P3	O
pregnanetriol,	B
Polone	B
epi-pregnanolone,	I
THS	O
tetrahydro-11-deoxycortisol,	B
PDL	O
pregnanediolone,	B
PTL	O
pregnanetriolone.	B

OGTTs	O
were	O
performed	O
after	O
a	O
12 h	O
overnight	O
fast	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
every	O
30 minutes	O
for	O
two	O
hours	O
to	O
determine	O
glucose	B
tolerance	O
status	O
(American	O
Diabetes	O
Association	O
criteria,	O
2006).	O

Yet,	O
sphingolipidomics	O
in	O
HCC	O
have	O
been	O
only	O
sparsely	O
studied	O
so	O
far	O
and	O
offered	O
limited	O
data	O
regarding	O
alterations	O
of	O
serum	O
SL	B
parameters	O
in	O
patients	O
with	O
HCC.	O

Of	O
the	O
circulating	O
factors,	O
insulin	O
and	O
FGF‐21	O
correlated	O
positively	O
and	O
adiponectin	O
inversely	O
with	O
many	O
glycerolipids,	B
but	O
FABP4	O
did	O
not	O
correlate	O
with	O
any.	O

A	O
total	O
of	O
10	O
metabolites,	O
including	O
N-acetylaspartate,	B
β-hydroxyisovalerate,	B
creatinine	B
and	O
guanosine,	B
may	O
be	O
potential	O
candidate	O
biomarkers	O
of	O
malignant	O
pancreatic	O
tissue	O
samples.	O

The	O
diluted	O
serum-	O
internal	O
standard	O
mixes	O
were	O
subsequently	O
extracted	O
through	O
solid	O
phase	O
extraction	O
cartridges	O
and	O
the	O
extracted	O
eluents	O
containing	O
the	O
tamoxifen	B
and	O
metabolites,	O
were	O
collected	O
and	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas.	I

Individuals	O
were	O
categorized	O
into	O
heavy,	O
medium,	O
or	O
occasional	O
cannabis	B
users	O
or	O
noncannabis	O
users	O
based	O
on	O
the	O
amount	O
of	O
the	O
cannabis	B
metabolite	O
11-nor-carboxy-tetrahydrocannabinol	B
(THC-COOH)	O
detected	O
in	O
plasma	O
by	O
mass	O
spectrometry.	O

In	O
a	O
prospective	O
cohort	O
study,	O
Hisamatsu	O
et	O
al[]	O
measured	O
plasma	O
levels	O
of	O
nineteen	O
amino	O
acids	O
and	O
found	O
that	O
decreased	O
histidine	B
level	O
in	O
plasma	O
free	O
amino	O
acids	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
relapse	O
in	O
UC	O
patients	O
during	O
a	O
one-year	O
follow-up.	O

The	O
lone	O
distinguishing	O
metabolite	O
detected	O
by	O
LC-MS,	O
pyroglutamic	B
acid,	I
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
74%	O
and	O
75%,	O
respectively,	O
with	O
an	O
AUROC	O
of	O
0.76.	O

Phospholipids	B
analysis	O
of	O
HBsAg	O
(−)	O
and	O
HBsAg	O
(+)	O
participants.	O

PC(28:1),	B
PC(30:2)	B
and	O
PC(38:0)	B
for	O
which	O
CLR	O
estimated	O
considerably	O
lower	O
most-probable	O
concentrations	O
than	O
Biocrates;	O
2).	O

At	O
0400,	O
the	O
signal	O
intensity	O
of	O
indole	B
at	O
0400	O
was	O
792,	O
1.5×10_3	O
and	O
4.84×10_3	O
for	O
the	O
three	O
participants,	O
implying	O
a	O
signal	O
drop	O
of	O
an	O
up	O
to	O
30-fold.	O
.	O

Although	O
caffeine	B
cannot	O
be	O
labeled	O
by	O
the	O
dansylation	O
reagent,	O
some	O
of	O
its	O
metabolites	O
are	O
labeled	O
and	O
were	O
detected	O
as	O
significantly	O
changed	O
metabolites.	O

For	O
example,	O
decreased	O
levels	O
of	O
kynurenine	B
(KYN)	O
and	O
5-Methoxyindoleacetic	B
acid	I
(5-MIAA),	O
which	O
are	O
associated	O
with	O
tryptophan	B
(TRP)	O
metabolism,	O
were	O
found	O
in	O
the	O
MDD	O
group	O
(FDR	O
q = 0.0096	O
and	O
0.016,	O
respectively).	O

Individuals	O
with	O
plasma	O
THC-COOH	O
levels	O
≥70	O
μg/L	O
were	O
classified	O
as	O
heavy	O
cannabis	B
users,	O
≤5	O
μg/L	O
as	O
occasional	O
cannabis	B
users,	O
and	O
5.1–69.9	O
μg/L	O
as	O
medium	O
cannabis	B
users.	O

For	O
benzene,	B
a	O
portion	O
(14%)	O
of	O
urine	O
samples	O
were	O
below	O
the	O
limit	O
of	O
detection	O
(i.e.,	O
<0.125	O
pmol/mL).	O

The	O
steady-state	O
plasma	O
insulin	O
concentrations	O
during	O
the	O
insulin	O
clamp	O
studies	O
were	O
similar	O
before	O
and	O
after	O
pioglitazone	B
therapy	O
(782	O
±	O
40	O
vs	O
.	O

It	O
is	O
also	O
interesting	O
to	O
note	O
a	O
stronger	O
relationship	O
between	O
_13	O
C-labeled	O
Ala	O
and	O
succinate	B
(Fig.	O
)	O
than	O
that	O
between	O
_13	O
C-labeled	O
lactate	B
and	O
succinate	B
in	O
lung	O
tumor	O
tissues.	O

On	O
the	O
other	O
hand,	O
also	O
the	O
lysine	B
degradation	O
pathway	O
was	O
among	O
the	O
metabolisms	O
which	O
maximally	O
differentiated	O
the	O
EAR	O
from	O
the	O
ADV	O
stage.	O

FDR,	O
false	O
discovery	O
rate;	O
HUNT,	O
Nord-Trøndelag	O
Health	O
Study;	O
N.s,	O
not	O
significant;	O
PLS-DA,	O
partial	O
least	O
squares	O
discriminant	O
analysis;	O
Sign.,	O
significant;	O
SUGAR,	O
Study	O
of	O
Glucose	B
and	O
Insulin	O
in	O
Renal	O
Disease;	O
VIP,	O
variable	O
importance	O
in	O
projection.	O

The	O
percentage	O
difference	O
in	O
total	O
glucocorticoid	B
excretion	O
relative	O
to	O
healthy	O
controls	O
was	O
25.0%	O
(95%	O
CI	O
14.4,	O
35.6)	O
in	O
primary	O
aldosteronism	O
and	O
only	O
3.4%	O
(95%	O
CI	O
–21.4,	O
28.1)	O
in	O
patients	O
with	O
subclinical	O
Cushing’s	O
syndrome	O
(SI	O
Appendix	O
and	O
).	O

Melatonin	B
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
of	O
all	O
cells	O
in	O
the	O
human	O
body	O
and	O
readily	O
crosses	O
the	O
blood-brain	O
barrier	O
[,,,].	O

Hydroxyproline	B
is	O
converted	O
to	O
proline,	B
then	O
to	O
P5C	O
and	O
GSA,	O
which	O
is	O
then	O
used	O
as	O
the	O
precursor	O
for	O
arginine	B
(Arg)	O
synthesis	O
from	O
ornithine	B
in	O
the	O
epithelium	O
of	O
the	O
small	O
intestine	O
under	O
conditions	O
of	O
decreased	O
calorie	O
or	O
protein	O
intake.	O

Moreover,	O
asparagine	B
is	O
a	O
precursor	O
of	O
many	O
other	O
amino	O
acids,	O
such	O
as	O
aspartate,	B
glutamine	B
and	O
glutamate,	B
which	O
can	O
be	O
used	O
to	O
supply	O
energy	O
to	O
enterocytes.	O

This	O
might	O
suggest	O
that	O
the	O
progressive	O
CSF	O
lactic	O
acidosis	O
we	O
measured	O
in	O
rabies	O
is	O
related	O
to	O
treatment	O
rather	O
than	O
rabies	O
virus	O
infection	O
itself,	O
particularly	O
given	O
the	O
lack	O
of	O
correlation	O
with	O
CSF	O
pyruvate	B
and	O
glucose	B
levels.	O

Furthermore,	O
an	O
MDS	O
plot	O
produced	O
from	O
analysis	O
of	O
dual-mapped	O
features	O
indicates	O
that	O
the	O
folate	B
biosynthesis	O
pathway	O
is	O
differentially	O
perturbed	O
when	O
compared	O
to	O
the	O
perturbation	O
of	O
the	O
two	O
lysine	B
pathways,	O
which	O
are	O
nearly	O
identical	O
(most	O
likely	O
the	O
result	O
of	O
many	O
shared	O
ion-pair	O
features).	O

The	O
separation	O
voltage	O
was	O
set	O
at	O
30	O
kV,	B
employing	O
a	O
voltage	O
ramping	O
of	O
3	O
kV/s.	B

Therefore,	O
uridine	B
can	O
act	O
as	O
an	O
alternative	O
energy	O
source	O
when	O
glucose	B
supply	O
is	O
not	O
sufficient,	O
or	O
under	O
hypoxic	O
and/or	O
ischemic	O
conditions.	O

Xevo-TQ	O
triple	O
quadruple	O
mass	O
spectrometer	O
(Waters,	O
Milford,	O
MA,	O
USA)	O
recorded	O
MS	O
and	O
MS/MS	O
spectra	O
using	O
Electro	O
Spray	O
Ionization	O
(ESI)	O
in	O
positive	O
ion	O
(PI)	O
and	O
negative	O
ion	O
(NI)	O
mode,	O
capillary	O
voltage	O
of	O
3.0	O
kV,	B
extractor	O
cone	O
voltage	O
of	O
3	O
V	O
and	O
detector	O
voltage	O
of	O
500	O
V.	O
Cone	O
gas	O
flow	O
was	O
set	O
at	O
50	O
L/h	O
and	O
desolvation	O
gas	O
flow	O
was	O
maintained	O
at	O
400	O
L/h.	O
Source	O
temperature	O
and	O
desolvation	O
temperatures	O
were	O
set	O
at	O
150	O
and	O
350°C,	O
respectively.	O

Deuterated	O
surrogates	O
of	O
vitamin	B
D	I
metabolites	O
were	O
purchased	O
from	O
Synthetica	O
(Oslo,	O
Norway)	O
and	O
Medical	O
Isotopes	O
(Pelham,	O
NH,	O
USA).	O

The	O
blank	O
controls	O
showed	O
no	O
peaks	O
co-eluting	O
with	O
abiraterone	B
and	O
D_4	B
-abiraterone.	I

After	O
adjustment	O
for	O
current	O
BMI,	O
a	O
positive	O
correlation	O
between	O
serum	O
FSH	O
level	O
and	O
maternal	O
serum	O
MiNP	O
concentration	O
(0.14,	O
p	O
 = 0.049),	O
and	O
serum	O
LH	O
levels	O
and	O
maternal	O
serum	O
∑DEHPm	O
(0.15,	O
p	O
 = 0.048)	O
was	O
noted,	O
and	O
a	O
negative	O
association	O
of	O
the	O
serum	O
LH	O
to	O
testosterone	B
ratio	O
with	O
antenatal	O
MEHP	O
concentration	O
(0.19,	O
p	O
 = 0.0137)	O

Incubation	O
of	O
estrogens	O
with	O
lactoperoxidase	O
(LPO)	O
and	O
H_2	O
O_2	O
resulted	O
in	O
formation	O
of	O
respective	O
quinone	B
methides	O
(E_1	O
(E_2	O
)-QM).	O

As	O
shown	O
in	O
A,	O
both	O
the	O
median	O
peak	O
base	O
width	O
and	O
the	O
peak	O
base	O
width	O
range	O
across	O
conditions	O
was	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
the	O
alkylamine	B
additives,	O
when	O
compared	O
to	O
results	O
obtained	O
with	O
methanol/5%	O
water	O
as	O
a	O
modifier	O
(the	O
latter	O
had	O
a	O
median	O
peak	O
base	O
width	O
of	O
7.0 s).	O

Differences	O
were	O
mostly	O
seen	O
in	O
sphingolipid	B
family	O
(SM	O
and	O
Cer,	B
but	O
not	O
CMH),	O
but	O
also	O
included	O
ChoE,	O
PC,	O
PE	O
and	O
TG	B
metabolites.	O

The	O
blank	O
controls	O
showed	O
no	O
peaks	O
co-eluting	O
with	O
enzalutamide,	B
N-desmethylenzalutamide,	B
and	O
D_6-	B
enzalutamide.	I

Box	O
plots	O
representing	O
acetate,	B
acetone,	B
ascorbate,	B
and	O
pyruvate	B
concentrations	O
in	O
the	O
ALS	O
and	O
non	O
ALS	O
groups	O
are	O
shown	O
in	O
.	O

Analytes	O
were	O
eluted	O
with	O
2	O
ml	O
75/25	O
(v/v)	O
ethyl	O
acetate/n	O
-hexane	I
with	O
1%	O
acetic	B
acid	I
in	O
glass	O
tubes	O
containing	O
6	O
μl	O
of	O
30%	O
glycerol	B
in	O
methanol.	B

In	O
our	O
studies,	O
fluorescence	O
and	O
ultraviolet	O
detection	O
were	O
used	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
urinary	O
thiols	B
and	O
isoflavones,	B
respectively.	O

Further	O
analysis	O
for	O
the	O
identification	O
of	O
phosphorylated	B
glucose	I
was	O
not	O
performed.	O

Discovered	O
in	O
serum	O
samples	O
taken	O
from	O
patients	O
of	O
Group	O
I	O
(early	O
stage	O
of	O
sepsis),	O
the	O
levels	O
of	O
succinic	B
acid	I
varied	O
widely:	O
from	O
below	O
10	O
µM	O
(in	O
36	O
samples,	O
75%)	O
to	O
medium	O
11–30	O
µM	O
(in	O
10	O
samples,	O
21%)	O
or	O
to	O
very	O
high	O
>100	O
µM	O
in	O
two	O
cases	O
(4%).	O

As	O
shown	O
in	O
,	O
19	O
metabolites	O
might	O
involve	O
in	O
the	O
progression	O
from	O
HU	O
to	O
HU+NAFLD,	O
except	O
for	O
acetoin	B
and	O
pregnenolone	B
sulfate	I
in	O
HU+NAFLD.	O

Furthermore,	O
citrulline,	B
catalyzed	O
by	O
NOS3,	O
has	O
been	O
shown	O
to	O
be	O
inversely	O
correlated	O
to	O
inflammatory	O
parameters	O
such	O
as	O
C-reactive	O
protein.	O

This	O
table	O
shows	O
total	O
number	O
of	O
putative	O
metabolites	O
(M)	O
detected	O
in	O
minimum	O
5	O
out	O
of	O
6	O
extraction	O
replicates	O
analyzed	O
using	O
RP	B
or	O
Scherzo	O
mixed-mode	O
LC-MS	O
after	O
removal	O
of	O
features	O
present	O
in	O
blank	O
extracts,	O
median	O
RSD	O
of	O
signal	O
intensity	O
across	O
all	O
putative	O
metabolite	O
features	O
detected	O
in	O
the	O
extraction	O
method	O
and	O
the	O
number	O
of	O
metabolites	O
for	O
which	O
extraction	O
method	O
was	O
highly	O
repeatable	O
with	O
RSD ≤ 30%	O
for	O
n = 6	O
independent	O
extractions	O
(M30).	O

Small	O
molecules	O
such	O
as	O
inosine	B
(decreased	O
over	O
70%	O
after	O
60	O
s	O
at	O
250	O
°C,	O
-e)	O
and	O
inosine	B
monophosphate	I
(IMP),	O
both	O
containing	O
hypoxanthine,	B
could	O
potentially	O
breakdown	O
to	O
generate	O
hypoxanthine	B
during	O
the	O
heating	O
process.	O

Carnosine	B
supplementation	O
maintained	O
trihexosylceramide	B
(0.01 ± 0.19	O
vs	O
−0.28 ± 0.34 nmol/ml,	O
p = 0.04),	O
phosphatidylcholine	B
(77 ± 167	O
vs	O
−81 ± 196 nmol/ml,	O
p = 0.01)	O
and	O
free	O
cholesterol	B
(20 ± 80	O
vs	O
−69 ± 80 nmol/ml,	O
p = 0.006)	O
levels	O
compared	O
to	O
placebo.	O

Semi-quantitative	O
analysis	O
of	O
_D,L	B
-glutamine,	I
LPC	O
16:0	O
and	O
fibrinogen	O
alpha	O
chain	O
fragment	O
using	O
peak	O
areas	O
in	O
Triple-TOF	O
mass	O
spectra.	O

The	O
rBPHL	O
failed	O
to	O
hydrolyze	O
dihydrocoumarin,	O
2-coumaranone,	B
phenyl	B
acetate	I
and	O
DL-N	B
-acetyl	I
homocysteine	I
thiolactone.	I

Chan	O
and	O
colleague	O
also	O
found	O
elevated	O
alanine	B
in	O
the	O
urine	O
of	O
gastric	O
cancer	O
patients.	O

To	O
put	O
the	O
extent	O
of	O
glucocorticoid	B
excess	O
into	O
context,	O
we	O
compared	O
glucocorticoid	B
output	O
in	O
the	O
primary	O
aldosteronism	O
patients	O
to	O
that	O
in	O
patients	O
with	O
adrenocortical	O
adenomas	O
that	O
were	O
either	O
endocrine	O
inactive	O
or	O
fulfilled	O
the	O
diagnostic	O
criteria	O
for	O
subclinical	O
and	O
clinically	O
overt	O
Cushing’s	O
syndrome	O
(,	O
SI	O
Appendix,	O
and	O
).	O

Fasting	O
blood	O
samples	O
were	O
collected	O
in	O
ethylenediaminetetraacetic	B
acid	I
(lavender	O
top)	O
tubes	O
and	O
isolated	O
plasma	O
stored	O
at	O
−80°C.	O

For	O
example,	O
DMA	B
was	O
only	O
remarkably	O
increased	O
in	O
stage	O
IV.	O

The	O
developed	O
method	O
using	O
CHCl_3	O
:MeOH	O
extraction	O
followed	O
by	O
dansyl	B
chloride	I
derivatization	O
and	O
ethyl	B
acetate	I
LLE	O
was	O
validated	O
in	O
serum	O
samples	O
by	O
determining	O
the	O
recovery,	O
accuracy,	O
limits	O
of	O
detection	O
(MDL)	O
and	O
quantification	O
(MQL),	O
linearity,	O
repeatability,	O
reproducibility,	O
and	O
matrix	O
effects.	O

Acrolein	B
did	O
not	O
induce	O
tumors	O
in	O
several	O
studies	O
in	O
mice	O
and	O
rats	O
and,	O
when	O
administered	O
by	O
inhalation	O
to	O
hamsters,	O
did	O
not	O
enhance	O
the	O
carcinogenicity	O
of	O
either	O
benzo[a	B
]pyrene	I
or	O
N	B
-nitrosodiethylamine.	I

All	O
samples	O
were	O
derivatized	O
with	O
MSTFA	O
(N-Methyl-N-trifluoroacetamide)	O
with	O
1%	O
TMCS	O
(trimethylchlorosilane)	O
and	O
the	O
resulting	O
extracts	O
were	O
separated	O
and	O
analyzed	O
using	O
an	O
Agilent	O
5890	O
Series	O
II	O
GC-MS	O
operating	O
in	O
electron	O
impact	O
(EI)	O
ionization	O
mode.	O

In	O
characterized	O
and	O
quantified	O
the	O
dG-C8	O
adducts	O
of	O
tobacco	O
smoke	O
and	O
cooked	O
meat	O
carcinogens	O
PhIP,	O
2-amino-9H	B
-pyrido[2,3-b	I
]indole	I
(AαC),	O
2-amino-3,8-dimethylimidazo[4,5-f	B
]quinoxaline	I
(MeIQx)	O
and	O
4-ABP	O
in	O
salivary	O
DNA	O
by	O
HPLC-LIT-MS_3	O
.	O

Another	O
important	O
result	O
of	O
this	O
work	O
is	O
that	O
taurine	B
and	O
O	B
-phosphoethanolamine	I
were	O
more	O
stable	O
during	O
prolonged	O
blood	O
incubation	O
when	O
EDTA	O
was	O
added	O
to	O
the	O
blood	O
samples.	O

RRMS	O
<13	O
Y:	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	O
having	O
less	O
than	O
13 years	O
of	O
disease	O
duration;	B
RRMS > =	O
13	O
Y:	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis with	O
>=	O
13 years	O
of	O
disease	O
duration;	B
SPMS:	O
Secondary	O
Progressive	O
Multiple	O
Sclerosis;	O
PPMS:	O
Primary	O
Progressive	O
Multiple	O
Sclerosis.	O

Using	O
NMR	O
spectroscopy,	O
a	O
unique	O
lipoprotein	O
profile	O
in	O
PKU	O
patients	O
can	O
be	O
demonstrated	O
which	O
mimics	O
a	O
non-atherogenic	O
profile	O
as	O
seen	O
in	O
patients	O
treated	O
by	O
statins.	B

By	O
visual	O
inspection	O
of	O
such	O
a	O
modified	O
GGM	O
we	O
could	O
integrate	O
the	O
unknown	O
metabolites	O
X-11444	O
and	O
12844,	O
which	O
were	O
strongly	O
associated	O
with	O
NT-proBNP	O
in	O
both	O
fluids,	O
together	O
with	O
11-ketoetiocholanolone	B
glucuronide	I
into	O
a	O
steroid	O
metabolite	O
cascade	O
(Fig. ).	O

Of	O
note,	O
all	O
molecules	O
showed	O
a	O
postprandial	O
increase	O
except	O
linoleic	B
acid,	I
which	O
showed	O
a	O
postprandial	O
decrease.	O

Corrected	O
p-values	O
(false	O
discovery	O
rate	O
(FDR))	O
of	O
the	O
longitudinal	O
associations	O
of	O
urine	O
metabolites	O
levels	O
(right	O
side)	O
or	O
ppm	O
(left	O
side)	O
with	O
changes	O
in	O
free	O
thyroxine	B
(FT4)	O
or	O
thyrotropin	O
(TSH)	O
in	O
Inter99.	O

Electrospray	O
ionization	O
(ESI)	O
with	O
a	O
sheath	O
gas	O
of	O
12,	O
a	O
spray	O
voltage	O
of	O
3.7	O
kV,	B
and	O
a	O
capillary	O
temperature	O
of	O
321	O
°C	O
were	O
used.	O

The	O
estimation	O
of	O
the	O
Area	O
Under	O
the	O
Curve	O
(AUC)	O
for	O
sphingosine	B
was	O
0.942	O
(0.877-1.000)	O

According	O
to	O
our	O
results,	O
serum	O
serotonin	B
levels	O
did	O
not	O
differ	O
between	O
kidney	O
function	O
groups	O
or	O
correlate	O
with	O
eGFR	O
or	O
any	O
of	O
the	O
metabolites.	O

For	O
instance,	O
although	O
lipid	O
treatment	O
was	O
most	O
common	O
in	O
the	O
MetS	O
neighborhood,	O
this	O
group	O
of	O
patients	O
still	O
had	O
the	O
highest	O
triglyceride	B
concentration.	O

A	O
(70%	O
water,	O
30%	O
acetonitrile	B
and	O
0.1%	O
acetic	O
acid)	O
and	O
B	O
(50%	O
acetonitrile,	B
50%	O
isopropanol,	B
0.02%	O
acetic	O
acid)	O
running	O
the	O
following	O
gradient:	O
1%	O
B	O
from	O
−1.00	O
to	O
0.25	O
minutes,	O
1%	O
to	O
55%	O
B	O
from	O
0.25	O
to	O
5.00	O
minutes,	O
55%	O
to	O
99%	O
B	O
from	O
5.00	O
to	O
5.50	O
minutes,	O
and	O
99%	O
B	O
from	O
5.50	O
to	O
7.00	O
minutes.	O

Overall,	O
it	O
is	O
necessary	O
to	O
pay	O
more	O
attention	O
to	O
reductions	O
in	O
hippuric	B
acid	I
in	O
developing	O
treatments	O
for	O
CKD	O
because	O
its	O
accumulation	O
can	O
directly	O
cause	O
less	O
excretion	O
of	O
other	O
acid	O
compounds	O
from	O
the	O
kidneys	O
into	O
urine.	O

(cholest-5-ene-3β,22(R	O
)-diol,	I
C_5	B
-3β,22R-diol;	I
10	O
μm)	O
a	O
known	O
LXRα	O
ligand	O
(,	O
),	O
or	O
the	O
acidic	O
compounds	O
indicated,	O
i.e.	O
3β-hydroxycholest-5-en-26-oic	B
acid,	I
CA_5	B
-3β-ol;	I
3β,7α-dihydroxycholest-5-en-26-oic	B
acid,	I
CA_5	B
-3β,7α-diol;	I
7α,12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
acid,	I
5β-BA-7α,12α-diol-3-one;	B
7α-hydroxy-3-oxocholest-4-en-26-oic	B
acid,	I
CA_4	B
-7α-ol-3-one;	I
and	O
3-oxo-5β-cholan-24-oic	B
acid,	I
5β-BA-3-one.	B

Ammonium	B
acetate	I
was	O
purchased	O
from	O
Sigma-Aldrich	O
(Poole,	O
UK).	O

Overall,	O
these	O
preliminary	O
results	O
underline	O
the	O
importance	O
of	O
the	O
specific	O
serum	O
phospholipids	B
shortage	O
with	O
the	O
GC	O
growth.	O

The	O
specific	O
representation	O
of	O
ceramides	B
43:1	I
and	O
44:2	O
in	O
the	O
optic	O
nerve	O
corresponded	O
mainly	O
to	O
the	O
presence	O
of	O
24:1,	O
25:0	O
and	O
26:1	O
FAs.	O

The	O
MS/MS	O
(m/z	O
792.5408)	O
confirmed	O
that	O
PE	B
40:5	I
is	O
present	O
and	O
predominantly	O
in	O
the	O
form	O
of	O
the	O
molecular	O
species	O
PE	B
18:0/22:5,	I
confirmed	O
by	O
the	O
detected	O
acyl	O
anions	O
(data	O
not	O
shown).	O

Because	O
AAs	O
can	O
further	O
regulate	O
β-cell	O
gene	O
expression	O
responsible	O
for	O
metabolism,	O
β-cell's	B
response	O
to	O
nutrient	O
availability	O
and	O
functional	O
integrity,	O
chronic	O
exposure,	O
in	O
an	O
otherwise	O
healthy	O
β-cell,	O
may	O
cause	O
eventual	O
deleterious	O
effects.	O

Neutral	O
loss	O
scans	O
(NLS)	O
of	O
all	O
naturally-occurring	O
aliphatic	B
chains	O
(i.e.	O
the	O
building	O
blocks	O
of	O
TAGs)	O
of	O
a	O
human	O
plasma	O
lipid	O
extract	O
were	O
used	O
to	O
determine	O
the	O
identities	O
of	O
each	O
lithiated	O
molecular	O
ion,	O
deconvolute	O
isomeric	O
species,	O
and	O
quantify	O
individual	O
TAG	O
species	O
by	O
comparisons	O
with	O
a	O
selected	O
internal	O
standard	O
(i.e.,	O
T17:1	O
TAG,	O
shown	O
in	O
NLS268).	O

These	O
results	O
suggest	O
that	O
augmented	O
tryptophan	B
catabolism,	O
a	O
marker	O
of	O
IFN	O
responses,	O
may	O
influence	O
biochemical	O
alterations	O
associated	O
with	O
depression.	O

Ala,	O
alanine;	B
Arg,	O
arginine;	B
Asn,	O
asparagine;	B
bPBS,	O
Panel	O
B	O
–	O
PBS	O
(panel	O
labelling);	O
Cho,	O
choline;	B
Cit,	O
citrate;	B
DFTMP,	O
1,1-difluoro-1-trimethylsilanyl	B
methylphosphonic	I
acid;	I
DSS,	O
4,4-dimethyl-4-silapentane-1-sulfonic	B
acid;	I
f1,	O
Chemical	O
shift;	O
Fru,	B
fructose;	B
Gln,	O
glutamine;	B
Gluc,	O
glucose;	B
Glu,	O
glutamate;	B
Ile,	O
isoleucine;	B
Lac,	O
lactate;	B
Leu,	O
leucine;	B
Lys,	O
lysine;	B
PCho,	O
phosphocholine;	B
Pyr,	O
pyruvate;	B
SP,	B
seminal	O
plasma;	O
Spe,	O
spermine;	B
Val,	O
valine.	B

The	O
levels	O
of	O
alchornoic	O
acid,	O
PI	O
(13 : 0/22 : 1),	O
15-oxo-18Z-tetracosenoic	B
acid,	I
2-oxo-docosanoic	B
acid,	I
and	O
anhydrorhodovibrin	B
were	O
decreased	O
in	O
the	O
newly	O
diagnosed	O
T2DM	O
group	O
with	O
fold	O
changes	O
of	O
9.74,	O
5.97,	O
4.07,	O
3.51,	O
and	O
3.27,	O
respectively.	O

We	O
report	O
higher	O
levels	O
of	O
quinolinic	B
acid	I
in	O
plasma	O
from	O
patients	O
with	O
SLE	O
compared	O
with	O
controls.	O

Furthermore,	O
we	O
do	O
not	O
have	O
any	O
information	O
or	O
measurements	O
regarding	O
the	O
dietary	O
habits	O
(especially	O
dietary	O
phosphatidylcholine	B
amounts	O
ingested)	O
of	O
our	O
subjects,	O
nor	O
do	O
we	O
have	O
any	O
quantification	O
of	O
intestinal	O
microbiota	O
composition,	O
intestinal	O
barrier	O
function,	O
or	O
commensal	O
versus	O
pathobiont	O
bacterial	O
growth.	O

Neonicotinoid	B
insecticides	O
are	O
widely	O
used	O
replacements	O
for	O
organophosphate	B
and	O
carbamate	B
insecticides,	O
but	O
the	O
extent	O
of	O
human	O
exposure	O
is	O
largely	O
unknown.	O

Sphingomyelin	B
has	O
also	O
been	O
reported	O
to	O
be	O
associated	O
with	O
the	O
regulation	O
of	O
neurogenesis.	O

CHPT1,	O
choline	O
phosphotransferase	O
1;	O
LCAT,	O
lecithin:	B
cholesterol	B
acyltransferase;	O
LPCAT,	O
lysophosphatidylcholine	B
acyltransferase;	O
ATGL,	O
adipose	O
triglyceride	B
lipase;	O
HSL,	O
hormone	O
sensitive	O
lipase;	O
MGL,	O
monoacylglycerol	B
lipase;	O
FFA,	O
free	O
fatty	O
acid.	O

In	O
the	O
same	O
period	O
of	O
time,	O
the	O
intracellular	O
amount	O
of	O
lactate,	B
which	O
is	O
significantly	O
higher	O
in	O
16HBE14o_−	O
cells	O
compared	O
with	O
S9	O
cells	O
decreases	O
by	O
approximately	O
54%	O
and	O
26%,	O
respectively.	O

The	O
loadings	O
and	O
explained	O
variance	O
of	O
PC	O
1	O
also	O
show	O
that	O
all	O
the	O
labs	O
are	O
identifying	O
glucose	B
and	O
other	O
sugars	O
as	O
the	O
major	O
difference	O
among	O
the	O
samples.	O

the	O
derivatization	O
efficiency	O
of	O
the	O
amino	O
acids	O
alanine	O
and	O
tryptophan	B
was	O
100%	O
and	O
30%,	O
respectively,	O
and	O
for	O
fumaric	B
acid	I
and	O
fructose	B
6-phosphate	I
it	O
was	O
60%	O
and	O
45%,	O
respectively.	O

These	O
data	O
establish	O
that	O
reduced	O
glucose	B
in	O
the	O
growth	O
medium	O
induced	O
autophagy	O
in	O
NFs.	O

Importantly,	O
no	O
difference	O
was	O
observed	O
in	O
serum	O
levels	O
of	O
PGE_2	O
and	O
15-HETE,	B
suggesting	O
CNS-specific	O
effects.	O

Phosphatidylcholine	B
(PC):	O
The	O
first	O
component	O
(F1)	O
is	O
strongly	O
correlated	O
with	O
species	O
36:3	O
(MW	O
783.7)	O
and	O
other	O
6	O
species	O
with	O
MW	O
>	O
800	O
(see	O
),	O
i.e.	O
the	O
first	O
principal	O
component	O
increases	O
with	O
increasing	O
species	O
with	O
3	O
or	O
more	O
DBs.	O

This	O
deproteinization	O
method	O
using	O
perchloric	B
acid	I
showed	O
a	O
better	O
recovery	O
rate	O
while	O
being	O
a	O
less	O
labor-intensive	O
procedure,	O
as	O
compared	O
to	O
the	O
liquid–liquid	O
extraction	O
methods	O
described	O
by	O
Lennard	O
and	O
Singleton	O
and	O
modified	O
by	O
Cuffari	O
et	O
al.	O

Conversely,	O
a	O
significantly	O
lower	O
intensity	O
of	O
a	O
characteristic	O
signal	O
of	O
cholesterol	B
relative	O
to	O
the	O
total	O
spectral	O
intensity	O
was	O
measured	O
in	O
the	O
lipid	O
fraction	O
of	O
plasma	O
from	O
the	O
30-day	O
mortality	O
group.	O

The	O
_13	O
C-labeled	O
spiking	O
solution	O
contained	O
eleven	O
_13	O
C-labeled	O
internal	O
standards	O
(_13	O
C-IS),	O
i.e.	O
10	O
labeled	O
OH-PAHs	O
and	O
_13	O
C_6	B
-2-methyl-1-naphthol	I
in	O
acetonitrile	B
(100	O
pg/μL	O
for	O
_13	O
C-labeled	O
1-	O
and	O
2-NAP,	O
25	O
pg/μL	O
for	O
the	O
remaining	O
_13	O
C-IS).	O

Down-regulated	O
metabolites	O
include	O
those	O
involved	O
in	O
bile	O
acid	O
biosynthesis	O
(specifically	O
cholesterol	B
metabolism)	O
such	O
as	O
glycochenodeoxycholic	B
acid	I
3-sulfate	I
(3-sulfo-GCDCA),	I
glycocholic	B
acid	I
(GCA),	O
glycodeoxycholic	B
acid	I
(GDCA),	O
taurocholic	B
acid	I
(TCA),	O
and	O
taurochenodeoxycholate	B
(TCDCA).	O

All	O
HIV+	O
participants	O
were	O
on	O
suppressive	O
ART	O
(HIV-1	O
RNA	O
<40	O
copies/mL)	O
for	O
a	O
mean	O
of	O
15	O
years,	O
and	O
had	O
a	O
mean	O
CD4_+	O
T	O
cell	O
count	O
of	O
603	O
cells/μL.	O
Thirty	O
percent	O
of	O
the	O
HIV+	O
group	O
were	O
current	O
smokers,	O
60%	O
reported	O
statin	B
usage,	O
40%	O
were	O
taking	O
anti-hypertensive	O
medication,	O
and	O
20%	O
were	O
taking	O
daily	O
aspirin.	B

Since	O
these	O
were	O
not	O
brain	O
tumours,	O
NAA	O
and	O
NAAG	B
were	O
omitted	O
from	O
the	O
analysis;	O
instead,	O
citrate,	B
polyamines	B
and	O
phosphocreatine	B
(PCr)	O
signals	O
were	O
simulated.	O

combined	O
with	O
staining	O
with	O
propidium	O
iodide.	B

We	O
do	O
not	O
have	O
any	O
clear	O
explanation	O
for	O
these	O
different	O
findings	O
for	O
tryptophan	B
levels.	O

Cotinine	B
is	O
divided	O
in	O
three	O
categories	O
corresponding	O
to	O
the	O
serum	O
level	O
in	O
non-smokers,	O
smokers	O
and	O
heavy	O
smokers.	O

For	O
instance,	O
a	O
recent	O
epidemiological	O
study	O
suggested	O
that	O
in	O
utero	O
exposures	O
to	O
OP	O
pesticides	O
alter	O
glucose	B
metabolism	O
at	O
birth	O
in	O
a	O
sex-dependent	O
manner,	O
suggesting	O
involvement	O
of	O
an	O
epigenetic	O
response.	O

Other	O
down-regulated	O
pathways	O
involved	O
aromatic	O
amino	O
acid	O
(phenylalanine	O
and	O
tryptophan)	O
and	O
short-chain	O
fatty	O
acid	O
(propanoate)	O
metabolism,	O
and	O
lysine	B
biosynthesis.	O

Identification	O
of	O
hydroxycholestenoic	B
and	O
hydroxyoxocholestenoic	B
acids	I
in	O
CSF.	O

Significant	O
metabolites	O
included	O
several	O
TCA	O
cycle	O
intermediates,	O
including	O
α-ketoglutarate	B
(OR	O
2.14,	O
95%	O
CI	O
1.60–2.87,	O
p	O
=	O
2.08	O
×	O
10_−8	O
),	O
aconitate	B
(OR	O
2.13,	O
95%	O
CI	O
1.52–2.99,	O
p	O
=	O
1.19	O
×	O
10_−6	O
),	O
malate	B
(OR	O
2.02,	O
95%	O
CI	O
1.53–2.66,	O
p	O
=	O
1.60	O
×	O
10_−7	O
),	O
and	O
succinate	B
(OR	O
1.86,	O
95%	O
CI	O
1.42–2.41,	O
p	O
=	O
1.22	O
×	O
10_−6	O
).	O

The	O
peak	O
numbers	O
correspond	O
to	O
the	O
following	O
analytes:	O
(1)	O
Crea,	O
(2)	O
GBB,	O
(3)	O
β-OHB,	B
(4)	O
N-MNA,	O
(4)	O
Kynu,	O
(6)	O
Leu	O
and	O
Ile,	O
(7)	O

Unlike	O
PKM1,	O
the	O
normal	O
isoform,	O
PKM2	O
can	O
be	O
inhibited,	O
which	O
blocks	O
pyruvate	B
formation	O
at	O
the	O
end	O
of	O
the	O
glycolytic	B
pathway	O
and	O
conserves	O
glycolytic	B
intermediates	O
for	O
anabolism	O
(see	O
).	O

Pathway	O
analysis	O
revealed	O
these	O
metabolites	O
are	O
involved	O
in	O
amino	O
acid	O
metabolism,	O
the	O
tricarboxylic	B
acid	I
cycle,	O
choline	B
metabolism,	O
and	O
oxidative	O
stress.	O

In	O
addition,	O
a	O
recent	O
study	O
has	O
suggested	O
that	O
hydrophilic	B
metabolites	O
may	O
provide	O
an	O
early	O
signature	O
of	O
sepsis	O
even	O
prior	O
to	O
the	O
onset	O
of	O
clinical	O
symptoms.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
mean	O
age,	O
sex,	O
BMI,	O
ALB,	O
TB,	O
BUN,	O
creatinine,	B
glucose,	B
triglyceride,	B
cholesterol	B
and	O
PLT	O
among	O
these	O
two	O
groups.	O

Amino	O
acids	O
and	O
oxidative	O
products:	O
Following	O
the	O
limonene	B
intervention,	O
statistically	O
significant	O
increases	O
in	O
glycine,	B
indolpropionate,	B
alanine,	B
3-phenylpropionate,	B
and	O
phenylacetate	B
were	O
observed	O
whereas	O
3-(4-hydroxyphenyl)lactate,	B
kynurenene,	O
gamma-glutamylisoleucine,	B
alpha-hydroxybutyrate,	B
and	O
phenylalanyltryptophan,	B
were	O
significantly	O
decreased.	O

In	O
this	O
design	O
effects	O
of	O
aspartame	B
would	O
appear	O
as	O
a	O
significant	O
interaction	O
between	O
session	O
and	O
order,	O
and	O
significant	O
effects	O
of	O
sensitivity	O
by	O
an	O
interaction	O
between	O
session,	O
order	O
and	O
type.	O

A	O
possible	O
inhibitory	O
effect	O
of	O
4-PA	O
on	O
vitamin	B
B6	I
metabolism	O
has	O
also	O
been	O
discussed.	O

High	O
performance	O
liquid	O
chromatography	O
inductively	O
coupled	O
mass	O
spectrometry	O
(HPLC-ICP-MS),	O
arsenic	O
speciation,	O
arsenic	O
metabolism	O
in	O
humans,	O
dimethylarsinous	B
glutathione	I

In	O
a	O
study	O
using	O
animal	O
models	O
and	O
human	O
lymphoma	O
tissue,	O
a	O
correlation	O
between	O
increased	O
intensities	O
of	O
various	O
glycerophosphoglycerols	B
and	O
the	O
overexpression	O
of	O
the	O
MYC	O
oncogene	O
was	O
observed	O
using	O
DESI-MSI	O
and	O
the	O
statistical	O
tool	O
significance	O
analysis	O
of	O
microarrays.	O

We	O
found	O
that	O
the	O
levels	O
of	O
phosphocholine	B
(Supplementary	O
Fig.	O

The	O
filters	O
were	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen,	O
the	O
amino	O
acids	O
in	O
the	O
sample	O
were	O
derivatized	O
with	O
5%	O
phenylisothiocyanate	B
reagent	O
(PITC),	O
and	O
the	O
filters	O
were	O
dried	O
again.	O

Plasma	O
concentrations	O
of	O
pregnenolone,	B
11-deoxycorticosterone,	B
corticosterone	B
and	O
aldosterone	B
did	O
not	O
differ	O
between	O
males	O
and	O
females,	O
whereas	O
concentrations	O
of	O
progesterone	B
were	O
higher	O
(P < 0.0001)	O
in	O
females	O
than	O
males.	O

In	O
the	O
POB	O
study,	O
the	O
relative	O
levels	O
were:	O
1	O
>	O
sulfoxide	B
3	O
>	O
sulfide	B
2.	O

Results	O
are	O
reported	O
for	O
the	O
four	O
different	O
datasets,	O
namely	O
IV	O
(intravenous),	O
oral	O
(oral),	O
rectal	O
(IV	O
)	O
(rectal	O
given	O
with	O
IV	O
methadone)	B
and	O
rectal	O
(oral	O
)	O
(rectal	O
given	O
with	O
oral	O
methadone).	B

The	O
solution	O
was	O
evaporated	O
in	O
a	O
Speed-Vac	O
and	O
either	O
subjected	O
to	O
one-dimensional	O
sodium	B
dodecyl	I
sulfate	I
polyacrylamide	I
gel	O
electrophoresis	O
(1D	O
SDS-PAGE)	O
or	O
trypsin	O
digestion	O
for	O
LC-MS/MS	O
analysis.	O

Therefore,	O
the	O
ectopic	O
fat	O
deposition	O
phenomenon	O
in	O
the	O
ligament	O
may	O
be	O
related	O
to	O
the	O
significant	O
decrease	O
in	O
choline.	B

The	O
oxidation	O
of	O
the	O
mercapturic	B
acid	I
2	O
to	O
the	O
sulfoxide	B
3	O
likely	O
results	O
from	O
an	O
enzyme-mediated	O
process	O
since	O
the	O
ratio	O
of	O
the	O
two	O
diastereomers	O
was	O
~11/1	O

All	O
16	O
monkeys	O
were	O
fasted	O
overnight	O
and	O
4	O
mL	O
of	O
blood	O
was	O
collected	O
from	O
a	O
peripheral	O
vein	O
into	O
an	O
EDTA	O
tube	O
under	O
ketamine	B
(10	O
mg/kg	O
IM	O
injection)	O
anesthesia.	O

No	O
vitamin	B
D	I
metabolite	O
was	O
associated	O
with	O
either	O
common	O
or	O
internal	O
mean	O
IMT.	O

Given	O
that	O
previous	O
studies	O
have	O
demonstrated	O
that	O
innate	O
immune	O
activation,	O
including	O
inflammatory	O
CD16_+	O
monocytes,	O
contributes	O
to	O
end-organ	O
complications	O
in	O
HIV-infected	O
individuals,	O
we	O
characterized	O
innate	O
immune	O
cell	O
frequencies	O
in	O
cannabis	B
users	O
and	O
nonusers.	O

Normalized	O
to	O
creatinine,	B
the	O
range	O
was	O
2.47	O
nmol	O
IMZ/mg	O
creatinine	B
to	O
400.04	O
nmol	O
IMZ/mg	O
creatinine.	B

Regarding	O
relative	O
concentrations	O
(in	O
mM),	O
the	O
highest	O
level	O
was	O
obtained	O
for	O
creatinine	B
followed	O
by	O
hippurate	B
in	O
the	O
BC	O
group	O
and	O
citrate	B
in	O
the	O
CTL	O
group.	O

This	O
receptor	O
has	O
the	O
same	O
affinity	O
as	O
the	O
classical	O
receptor	O
and	O
also	O
binds	O
tamoxifen.	B

For	O
both	O
BEN	O
and	O
BA,	O
we	O
observed	O
and	O
structurally	O
elucidated	O
products	O
in	O
which	O
one	O
or	O
both	O
of	O
the	O
methane	B
sulfonate	I
leaving	O
groups	O
were	O
replaced	O
by	O
either	O
a	O
chlorine	O
(from	O
plasma	O
chloride	B
ions)	O
or	O
hydroxyl	O
(from	O
plasma	O
water)	O
moiety,	O
resulting	O
in	O
a	O
total	O
of	O
12	O
analytes,	O
including	O
parent	O
compounds.	O

The	O
metabolite	O
quantification	O
results	O
of	O
OW	O
group	O
showed	O
higher	O
α,	O
β-glucose	B
at	O
5.22,	O
and	O
4.63	O
ppm	O
with	O
higher	O
level	O
lipids	O
occurring	O
at	O
0.9,	O
1.3,	O
and	O
2.0	O
ppm.	O

Furthermore,	O
the	O
behaviour	O
of	O
specific	O
VOMs	O
analysed	O
individually	O
is	O
not	O
uniform,	O
with	O
better	O
responses	O
observed	O
with	O
60 min	O
of	O
equilibration	O
for	O
(+)	B
-	I
4-carene	I
and	O
dimethylsulfide,	B
the	O
opposite	O
for	O
acetone	B
and	O
2-butanone	B
and	O
irregular	O
variations	O
for	O
toluene,	B
phenol,	B
isoprene	O
and	O
2-pentanone	B
(Supplementary	O
Fig.	O

Stable	O
isotope-labeled	O
(SIL)	O
standards	O
were	O
used	O
as	O
internal	O
standards	O
(listed	O
in	O
Table	O
1)	O
and	O
were	O
purchased	O
from	O
Toronto	O
Research	O
Chemicals	O
(Toronto,	O
Canada)	O
except	O
for	O
citrulline-D_4	B
,	O
which	O
was	O
purchased	O
from	O
Cambridge	O
Isotopes	O
(Cambridge,	O
MA,	O
U.S.A.).	O

lysoPC	O
a	O
C28:1;	B
123.	O

Amongst	O
both	O
cases	O
and	O
controls,	O
we	O
excluded	O
any	O
woman	O
with	O
a	O
history	O
of	O
pregnancy	O
in	O
the	O
prior	O
12	O
months	O
given	O
the	O
influence	O
of	O
pregnancy	O
on	O
the	O
kynurenine	B
pathway	O
and	O
the	O
fact	O
that	O
pregnant	O
women	O
were	O
excluded	O
from	O
the	O
ARKS	O
trial.	O

Here,	O
we	O
apply	O
the	O
model	O
to	O
the	O
whole	O
INTERMAP	O
_1	O
H	O
NMR	O
data	O
set	O
(9,260	O
urine	O
spectra)	O
to	O
objectively	O
assess	O
reported	O
analgesic	O
use	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
urinary	O
metabolites	O
of	O
acetaminophen	B
and	O
ibuprofen.	B

Neither	O
of	O
the	O
two	O
NHL-discriminating	O
low-mass	O
ions,	O
hypoxanthine	B
and	O
xanthine,	B
was	O
significantly	O
correlated	O
with	O
individual	O
histologic	O
types,	O
cancer	O
stage,	O
extra-nodal	O
involvement,	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
score	O
(ECOG	O
performance),	O
international	O
prognostic	O
index	O
(low,	O
low/intermediate	O
vs.	O
high/intermediate,	O
high),	O
bone	O
marrow	O
involvement	O
(absent	O
vs.	O
present),	O
first	O
response	O
to	O
chemotherapy	O
(complete	O
response,	O
partial	O
response	O
vs.	O
stable	O
disease,	O
progressive	O
disease)	O
or	O
survival	O
(data	O
not	O
shown).	O

In	O
conclusion,	O
the	O
results	O
for	O
tamoxifen	B
and	O
its	O
metabolites,	O
obtained	O
by	O
our	O
HPLC	O
fluorescent	O
method,	O
has	O
shown	O
concordance	O
with	O
results	O
obtained	O
in	O
2	O
independent	O
laboratories	O
using	O
LC-MS/MS	O
techniques.	O

Sulfonylurea-treated	O
diabetic	O
patients	O
were	O
included	O
because	O
long-term	O
sulfonylurea	B
therapy	O
is	O
not	O
known	O
to	O
have	O
any	O
direct	O
effect	O
on	O
insulin	O
sensitivity.	O

As	O
in	O
the	O
research	O
conducted	O
by	O
Oklu	O
et	O
al.,	O
Ijare	O
et	O
al.	O
also	O
identified	O
that	O
the	O
aspartate	B
and	O
glutamate	B
metabolism	O
is	O
affected	O
in	O
PRL-secreting	O
PA.	O

(a)	O
Kynurenine	B
were	O
significantly	O
lower	O
in	O
MDD	O
patients	O
than	O
in	O
control	O
subjects	O
(FDR	O
q = 0.0096).	O

The	O
chloroform/methanol	O
extraction	O
solvent,	O
which	O
is	O
commonly	O
used	O
for	O
lipid	O
extraction,	O
poorly	O
extracts	O
hydrophilic	B
metabolites.	O

For	O
quantitation	O
of	O
fatty	O
acids,	O
calibration	O
curves	O
were	O
prepared	O
with	O
heptadecanoic	B
acid	I
as	O
internal	O
standard	O
(see	O
above)	O
and	O
a	O
fatty	O
acid	O
concentration	O
range	O
of	O
0–1,000	O
μmol/	O

In	O
our	O
study,	O
we	O
determined	O
urinary	O
metabolites	O
of	O
DBP,	B
BzBP,	O
and	O
DEHP	O
as	O
those	O
phthalates	O
most	O
prevalent	O
in	O
Central	O
and	O
Eastern	O
European	O
populations.	O

Also	O
glutamine	B
can	O
be	O
a	O
precursor	O
for	O
lactate,	B
as	O
demonstrated	O
for	O
HeLa	O
cells	O
and	O
transformed	O
glioblastoma	O
cells	O
,	O
.	O

Since	O
these	O
associations	O
may	O
be	O
attributed	O
to	O
the	O
longer	O
disease	O
duration,	B
patients	O
at	O
onset	O
(n	O
=	O
18)	O
were	O
excluded	O
from	O
the	O
analysis,	O
but	O
the	O
associations	O
remain	O
significant.	O

Another	O
drug-like	O
cluster	O
was	O
annotated	O
by	O
GNPS	O
with	O
ranitidine,	B
a	O
histamine	B
H2-receptor	O
antagonist	O
(inhibiting	O
stomach	O
acid	O
production),	O
with	O
20	O
separate	O
metabolites	O
present	O
in	O
one	O
sample,	O
indicating	O
the	O
extensive	O
metabolism	O
to	O
which	O
this	O
drug	O
is	O
subject.	O

In	O
the	O
age-adjusted	O
models,	O
PC(O	B
-12:0/2:0)	I
(β=0.47,	O
R	O
_2	O
=0.24,	O
P	O
=0.02),	O
PC(O	B
-14:1/2:0)	I
(β=0.43,	O
R	O
_2	O
=0.22,	O
P	O
=0.03),	O
PC(O	B
-17:3/2:0)	I

Hypoxanthine	B
and	O
xanthine	B
concentrations	O
are	O
also	O
reduced	O
in	O
POAG	O
signature.	O

An	O
aliquot	O
(40 μL)	O
of	O
plasma	O
sample	O
was	O
a	O
mixed	O
with	O
sulfosalicylic	B
acid	I
(10 μL)	O
in	O
a	O
tube,	O
vortexed	O
for	O
30 s	O
at	O
room	O
temperature,	O
then	O
centrifuged	O
(10000 g,	O
2 min,	O
4 °C)	O
to	O
deposit	O
protein	O
following.	O

Seven	O
metabolites	O
(L-leucine,	O
glutarate	B
semialdehyde/alpha-ketoisovaleric	O
acid,	O
L-lactic	O
acid/TF-methoxyacetic	O
acid/glyceraldehyde,	O
creatinine,	B
3-methyl-2-oxovaleric	B
acid/2-ketohexanoic	I
acid,	I
a	O
methacholine-like	O
metabolite,	O
and	O
tagatose/glucose/fructose/galactose/mannose/sorbose/allose)	O
were	O
significantly	O
decreased	O
in	O
the	O
AF	B
group	O
relative	O
to	O
the	O
levels	O
in	O
the	O
non-AF	O
group,	O
whereas	O
the	O
17	O
remaining	O
metabolites	O
(choline,	O
oxidized	B
glutathione,	I
niacinamide,	B
betaine,	B
L-valine,	B
D-glutamic	B
acid,	I
gluconic	B
acid,	I
hypoxanthine,	B
creatine,	B
citrulline,	B
glycerophosphocholine,	B
malic	B
acid,	I
(S)-2-methylmalate/(R)-2-methylmalate/2-hydroxyglutarate,	B
acetylcholine/deoxycarnitine,	O
N6,N6,N6-trimethyl-L-lysine,	B
ergothioneine,	B
and	O
N-acetyl-DL-serine)	B
were	O
all	O
increased	O
(Supplementary	O
Table _S2	O
).	O

The	O
limit	O
of	O
detection	O
of	O
the	O
assay	O
was	O
50	O
pg	B
ml_−1	O
and	O
the	O
limit	O
of	O
quantification	O
was	O
100	O
pg	B
ml_−1	O
.	O

In	O
this	O
metabolomics	O
study	O
of	O
plasma,	O
as	O
compared	O
with	O
healthy	O
group,	O
the	O
PTMC	O
group	O
had	O
increased	O
glucose,	B
mannose,	B
and	O
pyruvate	B
levels,	O
and	O
an	O
increase	O
in	O
concentration	O
of	O
these	O
compounds	O
might	O
be	O
associated	O
with	O
upregulated	O
glycolysis	O
and	O
enhanced	O
amino	O
acid	O
catabolism.	O

advocate	O
creatinine	B
adjustment	O
to	O
correct	O
for	O
urine	O
dilution.	O

ΣFA	O
ΣFA	O
Σ	O
Σ	O
Σ	O
FA	B
FA	I
FA	I
(epoxides)	I
(	O
epoxides	B
epoxides	I
)	O
/	O
parent	O
fatty	O
acid	O
	O
sEHFAindex=ΣFA(diols)/ΣFA(epoxides)	B
sEHFAindex=ΣFA(diols)/ΣFA(epoxides)	I
sEHFAindex=ΣFA(diols)/ΣFA(epoxides)	I
sEHFAindex=ΣFA(diols)/ΣFA(epoxides)	I
sEHFAindex=ΣFA(diols)/ΣFA(epoxides)	I
sEHFA	O
sEHFA	O
sEH	O
sEH	O
sEH	O
sEH	O
s	O
E	O
H	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
index	O
index	O

8-iso	B
-PGF_2α	I
and	O
8-iso	O

2-aminoisobutyric	B
acid,	I
also	O
called	O
α-aminoisobutyric	B
acid,	I
is	O
a	O
non	O
proteinogenic	O
BCAA	O
which	O
results	O
as	O
the	O
end	O
product	O
of	O
pyrimidin	B
metabolism.	O

Methanol	B
supernatants	O
and	O
the	O
MTBE	B
lipid	O
fraction	O
were	O
resolved	O
using	O
RPC	O
and	O
analyzed	O
in	O
both	O
ionization	O
modes.	O

A	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(Milli-Q)	O
and	O
mobile	O
phase	O
B	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
ACN.	O

There	O
was	O
no	O
statistically	O
significant	O
association	O
between	O
baseline	O
plasma	O
lipidome	O
and	O
current	O
CD4+	O
T	O
cell	O
count	O
or	O
duration	B
of	O
known	O
HIV	O
infection	O
(data	O
not	O
shown).	O

The	O
multivariate	O
models	O
showed	O
that	O
less	O
change	O
in	O
plasmalogen	O
concentrations	O
(plasmenylcholines	O
PC	I
ae	I
C44:6,	I
PC	B
ae	I
40:2,	I
PC	B
ae	I
40:5,	I
plasmanylcholine	B
PC	I
ae	I
38:0),	I
in	O
lysoPC	O
species	O
(e.g.	O
saturated	O
lysoPC	O
C16:0,	B
C18:0),	B
and	O
in	O
fatty	O
acids	O
in	O
combination	O
with	O
larger	O
increment	O
of	O
alanine	B
were	O
associated	O
with	O
non-responsiveness	O
(Fig.	O

There	O
was	O
no	O
evidence	O
for	O
metabolic	O
scrambling	O
of	O
the	O
isotope	O
in	O
the	O
three	O
carbons,	O
which	O
suggests	O
that	O
they	O
were	O
derived	O
from	O
glucose	B
via	O
glycolysis.	O

The	O
data	O
show	O
an	O
impact	O
of	O
Phe	O
on	O
lipoprotein	O
concentration	O
in	O
plasma	O
indicating	O
a	O
negative	O
influence	O
on	O
cholesterol	B
synthesis	O
or	O
LDL	O
regulation.	O

To	O
examine	O
this,	O
we	O
described	O
relationships	O
of	O
GFR	O
(measured	O
by	O
iothalamate	O
clearance)	O
and	O
AER	O
with	O
circulating	O
vitamin	B
D	I
metabolites	O
and	O
related	O
regulatory	O
hormones	O
in	O
cross-sectional	O
analyses.	O

In	O
their	O
recent	O
meta-analysis	O
Pfister	O
et	O
al.	O
did	O
not	O
observe	O
a	O
direct	O
effect	O
of	O
serum	O
uric	B
acid	I
or	O
associated	O
genetic	O
variants	O
on	O
development	O
of	O
type	O
2	O
diabetes.	O

The	O
subjects	O
varied	O
from	O
normal	O
lipidemic	O
to	O
dyslipidemic,	O
but	O
did	O
not	O
have	O
hypertension	O
or	O
elevated	O
fasting	O
glucose,	B
and	O
thus	O
were	O
not	O
overtly	O
characterized	O
as	O
having	O
metabolic	O
syndrome	O
(Supplementary	O
Table _S1	O
).	O

HCMV	O
up-regulates	O
much	O
of	O
central	O
carbon	O
metabolism,	O
including	O
the	O
production	O
of	O
fatty	O
acids;	O
and,	O
although	O
the	O
changes	O
observed	O
for	O
total	O
cellular	O
glycerophospholipids	B
assayed	O
were	O
modest	O
(	O
and	O
Dataset	O
S1),	O
virions	O
exhibited	O
a	O
signature	O
markedly	O
distinct	O
from	O
the	O
whole	O
cell	O
(	O
and	O
Dataset	O
S2).	O

In	O
line	O
with	O
this,	O
we	O
recently	O
found	O
significantly	O
positive	O
correlation	O
between	O
IL-6	O
and	O
kynurenine	B
metabolites	O
in	O
CSF,	O
both	O
in	O
suicidal	O
attempters	O
as	O
well	O
as	O
in	O
patients	O
with	O
schizophrenia,	O
suggesting	O
an	O
intimate	O
interplay	O
between	O
this	O
cytokine	O
and	O
the	O
kynurenine	B
pathway	O
in	O
the	O
central	O
nervous	O
system.	O

One	O
study	O
found	O
five	O
salivary	O
biomarkers	O
(propionylcholine,	O
N-Acetyl-L-phenylalanine,	B
sphinganine,	B
phytosphingosine,	B
and	O
S-carboxymethyl-L-cysteine)	B
in	O
combination	O
with	O
an	O
AUC	O
value	O
of	O
0.997	O
differentiated	O
between	O
early	O
stage	O
oral	O
squamous	O
cell	O
carcinoma	O
and	O
controls,	O
while	O
we	O
found	O
a	O
panel	O
of	O
six	O
serum	O
biomarkers	O
(glucose,	O
choline,	B
glutamine,	B
glutamate,	B
valine,	B
and	O
DHT)	O
combined	O
together	O
with	O
high	O
AUC	O
values	O
of	O
0.969	O
differentiated	O
between	O
early	O
stage	O
ESCC	O
and	O
CTRL.	O

Citrate	B
inhibits	O
the	O
adenosine	B
triphosphate	I
(ATP)	O
producing	O
processes	O
of	O
glycolysis,	O
fatty	O
acid	O
beta-oxidation,	O
and	O
tricarboxylic	B
acid	I
(TCA)	O
cycle	O
as	O
well	O
as	O
stimulates	O
ATP	B
consuming	O
gluconeogenesis	O
and	O
lipid	O
synthesis.	O

In	O
PEAs,	O
a	O
pair	O
of	O
oligonucleotide-conjugatedantibodies	B
bind	O
to	O
their	O
targeted	O
protein	O
in	O
the	O
samples.	O

The	O
derivatized	O
solutions	O
were	O
dried	O
by	O
pure	O
nitrogen	B
gas	I
at	O
50°C	O
again.	O

 ,	O
3-glycerol	B
was	O
not	O
significantly	O
used	O
to	O
produce	O
TGs	O
but	O
rather	O
in	O
the	O
glycerol	B
shuttle,	O
since	O
no	O
accumulation	O
of	O
dihydroxyacetone	B
was	O
observed.	O

This	O
strategy	O
allows	O
simultaneous	O
quantification	O
of	O
186	O
metabolites	O
(40	O
amino	O
acids	O
and	O
biogenic	O
amines,	O
40	O
acylcarnitines,	B
90	O
glycerophospholipids,	B
15	O
sphingomyelins,	B
1	O
monosaccharide).	B

Compound	O
14	O
was	O
detected	O
as	O
a	O
metabolite	O
of	O
furan	B
in	O
hepatocytes.	O

A	O
larger	O
study	O
with	O
more	O
cases	O
of	O
AP	B
and	O
more	O
severe	O
disease	O
is	O
warranted.	O

We	O
anticipated	O
that	O
lactate	B
and	O
alanine	B
would	O
be	O
elevated	O
in	O
the	O
plasma	O
of	O
insulin-deprived	O
individuals,	O
consistent	O
with	O
increased	O
gluconeogenesis	O
through	O
the	O
glucose-alanine	B
and	O
Cori	O
cycles	O
as	O
previously	O
shown	O
in	O
diabetic	O
rats	O
and	O
humans	O
.	O

This	O
analysis	O
is	O
consistent	O
with	O
the	O
HBV+	O
liver	O
importing	O
glucose	B
via	O
the	O
SLC2A1	O
and	O
SLC2A2	O
transporters	O
and	O
activating	O
glycolysis	O
and	O
PPP	O
but	O
attenuating	O
the	O
TCA	O
cycle.	O

Interestingly,	O
and	O
in	O
contrast	O
to	O
previous	O
studies,	O
we	O
found	O
strong	O
associations	O
between	O
TMAO	B
and	O
inflammatory	O
biomarkers.	O

We	O
put	O
a	O
special	O
focus	O
on	O
metabolites	O
that	O
are	O
known	O
to	O
be	O
associated	O
with	O
cardiovascular	O
disease	O
and	O
CVR	O
factors	O
(including	O
diabetes)	O
such	O
as	O
amino-acids	B
(including	O
BCAA),	O
phospholipids	B
(PCs),	O
phenylalanine,	B
TMAO	B
and	O
indoxyl	B
sulfate.	I

Of	O
note,	O
the	O
BCAA	O
factor	O
identified	O
in	O
our	O
previous	O
study	O
was	O
composed	O
of	O
the	O
BCAA	O
valine	B
and	O
leucine/isoleucine,	O
the	O
aromatic	O
amino	O
acids	O
phenylalanine	O
and	O
tyrosine	B
(which	O
share	O
a	O
transporter	O
with	O
the	O
BCAA),	O
C5	O
acylcarnitine,	B
methionine,	B
and	O
alanine.	B

If	O
a	O
prospective	O
trial	O
is	O
to	O
be	O
done	O
to	O
test	O
an	O
intervention	O
that	O
may	O
attenuate	O
obesity-related	O
inflammation,	O
it	O
will	O
be	O
best	O
to	O
exclude	O
regular	O
users	O
of	O
NSAIDs	O
and	O
aspirin	B
if	O
urinary	O
PGE-M	O
is	O
to	O
be	O
used	O
as	O
a	O
biomarker.	O

First,	O
to	O
explore	O
the	O
influence	O
of	O
AXOS	O
on	O
microbiota	O
derived	O
uremic	O
retention	O
solutes,	O
we	O
focused	O
on	O
PCS,	O
PCG,	O
IS,	O
TMAO	B
and	O
PAG	B
as	O
the	O
most	O
important	O
representatives	O
of	O
this	O
group	O
of	O
solutes.	O

pentanedioic-acid-d	O
_6	O
—organic	O
acids,	O
U_13	O
C-ribitol—sugars	B
and	O
sugar	O
derivatives).	O

The	O
MQLs	O
ranged	O
from	O
0.01	O
to	O
1.40	O
nM	O
for	O
the	O
polyamines	B
and	O
from	O
2.8	O
to	O
74.0	O
nM	O
for	O
the	O
amino	O
acids.	O

LDL=low-density	O
lipoprotein;	O
VLDL=very	O
low-density	O
lipoprotein;	O
PGLYs=phosphoglycerides;	B
TAGs=triglycerides.	B

[_13	B
C_6	I
]-glucose	I
was	O
from	O
Aldrich	O
(Steinheim,	O
Germany)	O
and	O
[_2	O
H_6	O
]-salicylic	O
acid	O
was	O
from	O
Icon	O
(Summit,	O
NJ,	O
USA).	O

Both	O
impaired	O
fasting	O
glucose	B
and	O
impaired	O
glucose	B
tolerance	O
were	O
confined	O
to	O
non-diabetic	O
fasting	O
and	O
2-hour	O
concentrations.	O

Thus	O
increased	O
3αHSD	B
activity	O
might	O
be	O
characteristic	O
for	O
hyperandrogenic	O
PCOS	O
similar	O
to	O
increased	O
17α-hydroxylase/17,20	O
lyase	O
activity	O
and	O
5α	O
reductase	O
activity.	O

Polypropylene	B
tubes	O
were	O
used	O
for	O
sample	O
collection,	O
immediately	O
stored	O
at	O
− 20 °C,	O
and	O
transported	O
to	O
the	O
laboratory	O
on	O
ice.	O

Superimposed	O
in	O
color	O
are	O
the	O
fold	O
change	O
for	O
fatty	O
acids	O
and	O
oxylipins	B
identified	O
as	O
significantly	O
enriched	O
(red)	O
or	O
depleted	O
(blue)	O
postprandially	O
over	O
all	O
subjects.	O

In	O
the	O
present	O
study,	O
we	O
used	O
a	O
methanol	B
dimer	O
adduct	O
ion	O
([2MeOH + H]_+	O
,	O
m/z	O
65.059706)	O
and	O
hexakis	O
phosphazene	B
([M + H]_+	O
,	O
m/	O

It	O
has	O
not	O
escaped	O
our	O
attention	O
that	O
statin	B
effects	O
on	O
arginine	B
transport	O
function	O
may	O
contribute	O
to	O
therapeutic	O
effects	O
on	O
endothelial	O
function	O
by	O
increasing	O
NOS	O
activity.	O

Elevations	O
in	O
bile	O
acids	O
and	O
dicarboxylic	B
acids	I
were	O
highly	O
correlated	O
with	O
cirrhosis.	O

By	O
contrast,	O
a	O
decrease	O
in	O
the	O
levels	O
of	O
betaine	B
and	O
ornithine	B
was	O
observed.	O

5 × 10_6	O
monocyte-depleted	O
peripheral	O
blood	O
lymphocytes	O
(PBL)	O
were	O
washed	O
in	O
PBS,	O
resuspended	O
in	O
100 µl	O
of	O
80 %	O
methanol	B
(−80 °C).	O

Furthermore,	O
diminishment	O
of	O
lysophosphatidylcholines	B
suggests	O
that	O
subjects	O
at	O
risk	O
of	O
schizophrenia	O
may	O
be	O
more	O
susceptible	O
to	O
infections.	O

The	O
isotopes	O
_13	O
C_2	O
H_3	O
‐regorafenib,	O
_2	O
H_8	O
‐olaparib,	O
_13	O
C_6	O
‐vemurafenib,	O
_13	O
C_6	O
‐cobimetinib,	B
_13	O
C_6	O
‐niraparib,	O
_2	O
H_4	O
‐cabozantinib	B
and	O
_2	O
H_9	O
‐dabarefenib	O
used	O
as	O
internal	O
standards,	O
were	O
acquired	O
from	O
Alsachim	O
(Illkirch,	O
France).	O

Our	O
current	O
study	O
indicates	O
that	O
adenine,	B
a	O
compound	O
for	O
nucleotide	O
synthesis,	O
may	O
be	O
an	O
indicator	O
of	O
abnormal	O
cell	O
proliferation.	O

Some	O
fatty	O
acids,	O
especially	O
arachidonic	B
acid,	I
are	O
released	O
as	O
well	O
and	O
metabolized	O
into	O
several	O
molecules,	O
many	O
of	O
which	O
may	O
induce	O
cell	O
growth	O
and	O
proliferation.	O

The	O
fragmentor	O
voltage	O
was	O
set	O
at	O
120 V	O
and	O
skimmer	O
voltage	O
was	O
set	O
at	O
60 V.	O
All	O
analyses	O
were	O
acquired	O
using	O
a	O
mixture	O
of	O
10 mM	O
purine	B
(m/z	O
121.0508)	O
and	O
2 mM	O
hexakis	O
phosphazine	B
(m/z	O
922.0097)	O
as	O
internal	O
standards	O
to	O
ensure	O
mass	O
accuracy	O
and	O
reproducibility.	O

When	O
normalized	O
to	O
the	O
urine	O
creatinine	B
content	O
(measured	O
from	O
unpurified	O
urine),	O
glycine,	B
histidine,	B
proline	B
and	O
aminoisobutyric	B
acid	I
were	O
lower	O
in	O
the	O
pre-prostatectomy	O
samples	O
as	O
compared	O
to	O
the	O
combined	O
group	O
of	O
control	O
and	O
post-prostatectomy	O
samples	O
(2.5-3.2	O
x,	O
p	O
<	O
0.05).	O

REE	O
was	O
measured	O
by	O
indirect	O
calorimetry	O
(IC)	O
using	O
a	O
ventilated	O
hood	O
system	O
(Vmax	O
Encore	B
29	O
n,	O
SensorMedics	O
BV,	O
Bilthoven,	O
The	O
Netherlands).	O

	O
CHADS_2	O
and	O
CHA_2	O
DS_2	O
-Vasc	O
scores	O
were	O
used	O
to	O
categorize	O
risk	O
of	O
recurrent	O
stroke	O
in	O
patients	O
with	O
AF	B
and	O
undetermined	O
etiologies.	O

Decreased	O
DOX	O
metabolism	O
by	O
adipocytes	O
may	O
reflect	O
differing	O
enzyme	O
affinity	O
between	O
the	O
two	O
anthracyclines.	B

The	O
following	O
were	O
purchased	O
from	O
Campro	O
(Veenendaal,	O
The	O
Netherlands):	O
13C12-sucrose,	B
13C4-palmitic	B
acid	I
and	O
2H4-butanediamine.	B

We	O
used	O
this	O
procedure	O
to	O
quantify	O
the	O
levels	O
of	O
4-OH-E_1	B
-1-N	I
3Ade	O
in	O
six	O
breast-tissue	O
samples,	O
two	O
from	O
controls	O
and	O
four	O
normal	O
tissue	O
samples	O
taken	O
from	O
cancerous	O
breasts.	O

The	O
retina	O
exhibited	O
a	O
very	O
diverse	O
ganglioside	B
profile	O
and	O
shared	O
several	O
common	O
features	O
with	O
the	O
brain	O
(prominence	O
of	O
tetraosylgangliosides,	B
abundance	O
of	O
d20:1	B
long	O
chain	O
base	O
and	O
18:0	O
fatty	O
acid…).	O

However,	O
the	O
level	O
of	O
glutamate	B
was	O
no	O
significant	O
change	O
in	O
acute	O
AD	O
group,	O
so	O
the	O
down-regulation	O
of	O
histidine	B
was	O
not	O
a	O
prerequisite	O
for	O
the	O
inhibition	O
of	O
TCA.	O

We	O
observed	O
a	O
similar	O
result	O
for	O
association	O
between	O
metabolites	O
and	O
cancer	O
mortality	O
in	O
this	O
study,	O
i.e.	O
poor	O
OS	O
associated	O
with	O
the	O
increased	O
plasma	O
kynurenine.	B

	O
Lipids	O
were	O
extracted	O
as	O
previously	O
described	O
with	O
a	O
20-fold	O
scale	O
down	O
of	O
volumes;	O
10	O
μL	O
aliquots	O
of	O
plasma	O
and	O
10	O
μL	O
of	O
internal	O
lipid	O
standards	O
(Avanti	O
SPLASH	O
Lipidomix)	O
that	O
had	O
been	O
first	O
diluted	O
1:10	O
in	O
1-butanol/methanol	O
were	O
added	O
to	O
400	O
μl	O
of	O
ice-cold	O
methanol	B
followed	O
by	O
addition	O
of	O
500	O
μl	O
of	O
MTBE,	B
vortexed	O
(10	O
s),	O
then	O
sonicated	O
(1	O
h).	O

Heatmaps	O
were	O
created	O
through	O
HCA	O
to	O
provide	O
intuitive	O
visualizations	O
of	O
the	O
differences	O
in	O
the	O
patient	O
metabolites	O
between	O
the	O
AF	B
and	O
non-AF	O
groups;	O
comparisons	O
of	O
the	O
atrial	O
appendage	O
samples	O
and	O
the	O
plasma	O
samples	O
of	O
the	O
non-AF	O
group	O
and	O
the	O
AF	B
group	O
are	O
shown	O
in	O
Fig.	O

Leucine	B
Enkephalin	I
is	O
a	O
commonly	O
used	O
peptide,	O
which	O
has	O
been	O
studied	O
in	O
detail	O
and	O
is	O
commonly	O
used	O
as	O
a	O
standard	O
or	O
reference	O
compound	O
to	O
calibrate	O
mass	O
spectrometers	O
during	O
analysis.	O

Therefore,	O
we	O
evaluated	O
extraction	O
methods	O
using	O
standards	O
with	O
limited	O
but	O
systematic	O
set	O
of	O
chemical	O
properties	O
that	O
(i)	O
resembled	O
class	O
composition	O
of	O
a	O
target	O
samples	O
and	O
included	O
acids,	O
bases,	O
neutrals,	O
zwitterions,	O
lipids	O
and	O
small	O
peptides,	O
(ii)	O
were	O
systematic	O
and	O
scalable	O
in	O
terms	O
of	O
chemical	O
properties	O
(Log	O
P	O
range	O
of	O
−3.9	O
to	O
11.5,	O
MW	O
range	O
of	O
105	O
to	O
900 Da),	O
and	O
(iii)	O
amenable	O
to	O
the	O
RP	B
and	O
mixed-mode	O
LC-MS	O
analytical	O
methods	O
employed	O
in	O
the	O
study.	O

Twenty-four	O
hours	O
after	O
the	O
first	O
administration,	O
rabbits	O
were	O
anesthetized	O
by	O
an	O
intramuscular	O
injection	O
of	O
a	O
3∶1	O
mixture	O
of	O
5%	O
ketamine	B
(Ketalar	O
for	O
intramuscular	O
injection	O
500	O
mg,	O
Daiichi	O
Sankyo	O
Co.,	O
Ltd.,	O
Tokyo,	O
Japan)	O
and	O
2%	O
xylazine	B

For	O
example,	O
shows	O
high	O
levels	O
of	O
glucose	B
(m/z	O
179.0561;	O
see	O
for	O
identification)	O
and	O
low	O
levels	O
of	O
citrate	B
(m/z	O
191.0196;	O
see	O
for	O
identification)	O
in	O
cancer.	O

CYP2B6,	O
CYP2D6	O
and	O
CYP2C8	O
also	O
formed	O
hydroxyanastrozole,	B
but	O
when	O
compared	O
with	O
CYP3A4	O
and	O
3A5,	O
the	O
involvement	O
of	O
these	O
enzymes	O
was	O
very	O
low	O
(10.8-,	O
25-	O
and	O
30-fold	O
lower,	O
respectively).	O

Using	O
human	O
serum	O
_1	O
H	O
NMR	O
spectroscopic	O
profiles	O
from	O
3948	O
participants	O
from	O
the	O
Multi-Ethnic	O
Study	O
of	O
Atherosclerosis	O
(MESA),	O
we	O
have	O
performed	O
a	O
series	O
of	O
MWAS	O
for	O
serum	O
levels	O
of	O
glucose.	B

The	O
4OHtam	O
to	O
tamoxifen	B
ratio	O
was	O
positively	O
associated	O
with	O
increasing	O
CYP2C19	O
predicted	O
enzymatic	O
activity,	O
whereas	O
no	O
such	O
correlation	O
was	O
observed	O
for	O
the	O
ratio	O
of	O
4OHNDtam	O
to	O
NDtam.	O

PCOS	O
is	O
associated	O
with	O
dysregulation	O
in	O
glucocorticoid	B
degradation.	O

Ion	O
number	O
6	O
with	O
[M−H]_−	O
 = 203.0811	O
m/z	O
,	O
retention	O
time	O
of	O
1.6051	O
min	O
was	O
verified	O
to	O
be	O
L-tryptophan,	B
which	O
is	O
an	O
essential	O
amino	O
acid	O
and	O
the	O
only	O
stereoisomer	O
used	O
in	O
structural	O
or	O
enzymatic	O
proteins	O
(,	O
p = 0.006).	O

We	O
then	O
used	O
the	O
same	O
transactivation	O
assay	O
to	O
screen	O
all	O
of	O
the	O
compounds	O
for	O
their	O
potential	O
to	O
antagonize	O
the	O
ATRA-induced	O
activation	O
of	O
the	O
individual	O
RARs	O
by	O
treating	O
the	O
cells	O
with	O
maximally	O
effective	O
doses	O
of	O
ATRA	O
and	O
equimolar	O
concentrations	O
of	O
the	O
β-apocarotenoids.	B

After	O
incubating	O
the	O
solution	O
for	O
24	O
hours	O
at	O
37°C,	O
125	O
μL	O
potassium-phosphate	B
buffer,	O
25	O
μL	O
0.26	O
M	O
KOH	O
and	O
25	O
μL	O
pronase	O
E	O
solution	O
were	O
added	O
for	O
the	O
second	O
step.	O

Indeed,	O
these	O
side	O
effects	O
of	O
temsirolimus	O
correspond	O
to	O
metabolites	O
with	O
the	O
highest	O
discriminatory	O
power	O
in	O
our	O
metabolic	O
signature	O
between	O
samples	O
before	O
and	O
after	O
treatment,	O
that	O
is,	O
lipids,	O
LDL,	O
and	O
VLDL	O
lipoproteins,	O
which	O
allow	O
the	O
transport	O
of	O
cholesterol	B
and	O
endogenous	O
lipids,	O
respectively,	O
end-products	O
of	O
β-oxidation	B
(acetoacetate	I
and	O
acetone),	B
glucose,	B
and	O
glutamine.	B

The	O
use	O
of	O
ammonium	B
formate	I
and	O
water	O
also	O
resulted	O
in	O
narrower	O
peaks,	O
with	O
median	O
widths	O
of	O
19.4	O
(mean	O
of	O
25.6 s)	O
and	O
20.1 s	O
(mean	O
of	O
33.2 s)	O
respectively.	O

Similar	O
results	O
were	O
obtained	O
between	O
TLG	O
and	O
stage	O
II,	O
III	O
and	O
IV	O
except	O
for	O
β-hydroxybutyrate	B
and	O
threonine	B
in	O
stage	O
III.	O

Oxidation	O
of	O
LDL	O
produces	O
lipid	O
peroxidation	O
products	O
such	O
as	O
lipid	O
peroxides	B
that	O
in	O
turn	O
influence	O
the	O
metabolism	O
of	O
fat-soluble	O
vitamins	O
inside	O
cells.	O

The	O
lower	O
layer	O
was	O
dried	O
by	O
N_2	O
,	O
and	O
then	O
reconstituted	O
in	O
100	O
µL	O
water	O
followed	O
by	O
400	O
µL	O
methanol.	B

Homocysteine	B
levels	O
are	O
not	O
changed	O
in	O
the	O
CSF	O
of	O
AD	O
patients	O
.	O

Further	O
multiple	O
logistic	O
regression	O
analysis	O
(after	O
adjusting	O
for	O
age,	O
gender,	O
and	O
BMI)	O
revealed	O
that	O
both	O
putrescine	B
and	O
spermine	B
levels	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
T2D.	O
Association	O
between	O
putrescine	B
and	O
T2D	O
were	O
still	O
found	O
when	O
fasting	O
insulin	O
was	O
included	O
in	O
the	O
model	O
(Supplementary	O
Table	O
S1).	O

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
performance	O
of	O
a	O
newly	O
developed	O
betaine	B
assay	O
and	O
to	O
prospectively	O
explore	O
the	O
potential	O
clinical	O
associations	O
of	O
betaine	B
and	O
future	O
risk	O
of	O
T2DM	O
in	O
a	O
large	O
population-based	O
cohort.	O

Glutamate	B
is	O
the	O
metabolite	O
of	O
glutamine,	B
whereas	O
the	O
active	O
metabolism	O
of	O
glutamine	B
is	O
an	O
important	O
form	O
of	O
energy	O
metabolism	O
of	O
tumor	O
cells.	O

Coprostanol	B
(COPR)	O
did	O
not	O
correlate	O
with	O
the	O
other	O
dietary	O
sterols	O
and	O
was	O
negatively	O
correlated	O
with	O
LDL-C	O
response	O
to	O
statins,	B
while	O
β-SITO,	B
STIG	O
and	O
CAMP	O
were	O
slightly	O
positively	O
correlated	O
with	O
LDL-C	O
response.	O

Of	O
the	O
59	O
metabolites	O
analyzed	O
in	O
this	O
study,	O
five	O
were	O
found	O
to	O
differ	O
significantly	O
among	O
the	O
three	O
groups	O
by	O
Kruskal-Wallis	O
test:	O
acetone,	B
adenosine,	B
citrate,	B
ribose,	B
and	O
3-indoxylsulfate.	B

This	O
may	O
be	O
due	O
to	O
atypical	O
regulation	O
of	O
a	O
specific	O
ceramide	B
synthase	O
that	O
preferentially	O
generates	O
C16	O
ceramides,	B
likely	O
CERS6.	O

Supported	O
by	O
correlation	O
analysis,	O
this	O
pattern	O
suggests	O
a	O
metabolic	O
relationship	O
linking	O
PAG	B
and	O
tryptophan	B
to	O
changes	O
in	O
%FFM,	O
growth,	O
and	O
inflammatory	O
conditions	O
in	O
pediatric	O
patients	O
in	O
remission.	O

Diluent-D1	O
consisted	O
of	O
water	O
with	O
1	O
mg/mL	O
(0.1%)	O
citric	B
acid,	I
and	O
diluent-D2	O
consisted	O
of	O
water	O
with	O
0.1	O
mg/mL	O
(0.01%)	O
citric	B
acid.	I

Application	O
of	O
these	O
approaches	O
to	O
human	O
plasma	O
revealed	O
hundreds	O
of	O
putative	O
compounds,	O
advancing	O
upon	O
the	O
current	O
state	O
of	O
the	O
art	O
analytical	O
techniques	O
and	O
greatly	O
expanding	O
the	O
current	O
chemical	O
repertoire,	O
revealing	O
134	O
definitively	O
known,	O
362	O
putative	O
known,	O
and	O
46	O
putative	O
novel	O
oxylipins	B
observable	O
in	O
human	O
plasma.	O

Fifteen	O
estrogens	O
and	O
EMs,	O
including	O
estrone	B
(E_1	O
),	O
estradiol	B
(E_2	O
),	O
estriol	B
(E_3	O
),	O
16-epiestriol	B
(16-epiE_3	O
),	O
17-epiestriol	O
(17-epiE_3	O
),	O
16-ketoestradiol	O
(16-ketoE_2	O
),	O
16α-hydroxyestrone	B
(16α-OHE_1	I
),	I
2-methoxyestrone	B
(2-MeOE_1	O
),	O
4-methoxyestrone	B
(4-MeOE_1	O
),	O
2-hydroxyestrone-3-methyl	B
ether	I
(3-MeOE_1	O
),	O
2-methoxyestradiol	B
(2-MeOE_2	O
),	O
4-methoxyestradiol	B
(4-MeOE_2	O
),	O
2-hydroxyestrone	B
(2-OHE_1	O
),	O
4-hydroxyestrone	B
(4-OHE_1	O
),	O
and	O
2-hydroxyestradiol	B
(2-OHE_2	O
)	O
were	O
obtained	O
from	O
Steraloids,	O
Inc.	O
(Newport,	O
RI,	B
USA).	O

Median	O
duration	B
of	O
REG	O
therapy	O
was	O
45	O
days	O
(range	O
19–139).	O

It	O
is	O
worth	O
noting	O
the	O
structural	O
similarities	O
between	O
HCTL	O
and	O
VC	O
as	O
both	O
possess	O
a	O
free	O
amino	B
group	O
on	O
the	O
carbon	O
alpha	O
to	O
the	O
carbonyl	O
that	O
is	O
neutralized	O
by	O
the	O
enzyme's	O
active	O
site	O
residue	O
D123.	O

A	O
number	O
anti-oxidants	O
were	O
depleted	O
during	O
CM	O
including	O
indolepriopionate	O
a	O
neuroprotective	O
free-radical	O
scavenger	O
which	O
has	O
been	O
shown	O
to	O
provide	O
a	O
neuro	O
protective	O
effect	O
in	O
an	O
animal	O
model	O
of	O
ischemia	O
along	O
with	O
the	O
glutathione	B
precursors,	O
glutamate,	B
and	O
glycine.	B

The	O
pentose	B
phosphate	I
pathway	O
(PPP)	O
produces	O
nicotinamide	B
adenine	I
dinucleotide	I
phosphate,	I
a	O
necessary	O
cofactor	O
for	O
the	O
reduction	O
of	O
glutathione	B
disulfide	I
(marker	O
of	O
reduction	O
in	O
oxidative	O
stress).	O

The	O
compounds	O
that	O
could	O
not	O
be	O
reliably	O
detected	O
in	O
MeOH:CHCl_3	O
:water	O
ext	O
+UF	O
pooled	O
human	O
serum	O
were	O
2-hydroxybutyrate,	B
methionine,	B
and	O
tryptophan.	B

The	O
reduced	O
serum	O
levels	O
of	O
formate	B
might	O
reflect	O
an	O
increased	O
requirement	O
for	O
nucleotide	O
biosynthesis	O
in	O
an	O
inflammatory	O
condition	O
.	O

The	O
relative	O
susceptibility	O
of	O
each	O
class	O
of	O
metabolites	O
to	O
each	O
factor	O
described	O
above	O
(solubility	O
in	O
formalin,	B
the	O
covalent	O
bonding	O
to	O
cellular	O
component,	O
and	O
solubility	O
in	O
ethanol	B
and	O
xylene)	B
is	O
summarized	O
in	O
.	O

The	O
analysis	O
of	O
protein	O
expression	O
in	O
skin	O
biopsies	O
comparing	O
all	O
data	O
from	O
CMT1A	O
patients	O
to	O
the	O
controls	O
provided	O
significant	O
differences	O
in	O
mitochondrial	O
proteins	O
of	O
the	O
OXPHOS	O
system	O
which	O
included	O
representative	O
markers	O
of	O
the	O
electron	O
transport	O
chain	O
(NDUFS3	O
of	O
Complex	O
I,	O
SDH-B	O
of	O
Complex	O
II,	O
Core	O
2	O
of	O
Complex	O
III	O
and	O
COXII	O
of	O
Complex	O
IV)	O
and	O
oxidative	O
phosphorylation	O
(β-F1-ATPase	O
and	O
IF1).	B

The	O
lower	O
level	O
of	O
serum	O
choline,	B
a	O
precursor	O
of	O
membrane	O
phospholipids,	B
observed	O
in	O
the	O
group	O
of	O
patients	O
with	O
NSCLC	O
could	O
also	O
be	O
associated	O
with	O
the	O
increased	O
demand	O
of	O
this	O
metabolite	O
by	O
tumor	O
cells	O
due	O
to	O
the	O
their	O
high	O
proliferation	O
rate	O
[,	O
].	O

The	O
present	O
study	O
revealed	O
that	O
the	O
levels	O
of	O
arachidonic	B
acid	I
in	O
patients	O
with	O
GCA	O
were	O
significantly	O
increased	O
compared	O
with	O
healthy	O
subjects.	O

We	O
are	O
therefore	O
unable	O
to	O
conclude	O
regarding	O
the	O
effect	O
of	O
nutrition	O
upon	O
serum	O
levels	O
of	O
vitamin	B
B2,	I
vitamin	B
B6	I
and	O
tryptophan.	B

At	O
1 month,	O
the	O
lipid	O
classes	O
triacylglycerol	B
and	O
diacylglycerol,	B
and	O
several	O
species	O
of	O
these,	O
were	O
associated	O
with	O
a	O
decrease	O
in	O
stimulated	O
C-peptide	O
levels	O
after	O
6 months	O
(Table ).	O

The	O
concentrated	O
supernatant	O
was	O
reconstituted	O
in	O
2	O
mL	O
0.1	O
M	O
phosphate	B
buffer,	O
pH	O
6.0.	O

More	O
recently,	O
in	O
a	O
pooled	O
analysis	O
including	O
seven	O
prospective	O
studies,	O
767	O
premenopausal	O
breast	O
cancer	O
cases	O
and	O
1699	O
matched	O
controls,	O
none	O
of	O
whom	O
were	O
taking	O
exogenous	O
hormones	O
at	O
cohort	O
entry,	O
endogenous	O
estrogen	B
was	O
associated	O
with	O
increased	O
risk	O
of	O
premenopausal	O
disease,	O
though	O
not	O
as	O
strongly	O
as	O
with	O
postmenopausal	O
disease.	O

All	O
identified	O
metabolites	O
were	O
up-regulated	O
in	O
the	O
BCP	O
group,	O
except	O
for	O
one	O
metabolite;	O
pyruvic	B
acid.	I

The	O
HPLC	O
eluents	O
were	O
prepared	O
from	O
ammonium	B
acetate	I
(Sigma-Aldrich,	O
Steinheim,	O
Germany)	O
and	O
the	O
pH	O
adjustment	O
was	O
performed	O
using	O
ammonia	O
25%	O
(Carl	O
Roth,	O
Karlsruhe,	O
Germany).	O

Although	O
serum	O
cholesterol	B
and	O
total	O
fatty	O
acids	O
were	O
unaffected	O
(p	O
 = 0.738	O
and	O
0.692	O
respectively),	O
VLDL-TG	O
levels	O
were	O
lower	O
in	O
TB-DM	O
compared	O
to	O
DM	O
patients	O
(p	O
 = 6.40E_−3	O
)	O
(a),	O
which	O
is	O
consistent	O
with	O
a	O
decreased	O
amount	O
of	O
VLDL	O
particles	O
(XL	O
to	O
M)	O
(j).	O

Trimethylsilylpropionic	B
acid-d_4	O
sodium	O
salt	O
(TSP),	O
tridecanoic	B
acid,	I
chlorophenylalanine,	B
lactic	B
acid,	I
valine,	B
leucine,	B
isoleucine,	B
methionine,	B
carnitine,	B
tyrosine,	B
tryptophan,	B
myristic	B
acid,	I
margaric	B
acid,	I
linolenic	B
acid,	I
linoleic	B
acid	I
and	O
pyroglutamic	B
acid	I
were	O
purchased	O
from	O
Sigma-Aldrich	O
(analytical	O
grade,	O
St.	O
Louis,	O
MO).	O

Plasma	O
total	O
and	O
high‐density	O
lipoprotein	O
(HDL)‐cholesterol,	B
triglycerides	B
and	O
glucose	B
concentrations	O
were	O
measured	O
from	O
venous	O
blood	O
samples	O
with	O
an	O
automatized	O
enzymatic	O
assay.	O

On	O
one-way	O
ANOVA,	O
formate	B
was	O
significantly	O
different	O
across	O
the	O
3	O
subgroups	O
[F(2,38)	O
=	O
5.02;	O
p	O
=	O
0.012];	O
post	O
hoc	O
comparisons	O
using	O
the	O
Tukey	O
HSD	O
test	O
showed	O
formate	B
to	O
be	O
higher	O
in	O
the	O
MS-like	O
subgroup	O
compared	O
with	O
the	O
NMOSD-like	O
subgroup	O
(p	O
=	O
0.013),	O
as	O
indeed	O
compared	O
with	O
the	O
LBL	O
subgroup	O
(0.0027	O
[0.0006]	O
vs	O
0.0020	O
[0.0005]	O
AU;	O
p	O
=	O
0.017).	O

The	O
results	O
specifically	O
showed	O
that	O
phenylalanine	B
metabolism	O
decreased	O
and	O
tryptophan	B
metabolism	O
increased	O
in	O
the	O
samples.	O

The	O
information	O
from	O
this	O
metabolomic	O
investigation	O
might	O
also	O
have	O
a	O
place	O
in	O
a	O
meta-analysis	O
for	O
which	O
other	O
biomarker	O
candidates	O
(such	O
as	O
α-synuclein,	B
Aβ_1-42	O
,	O
or	O
fraktaline	B
measurements)	O
might	O
be	O
incorporated	O
for	O
enhancing	O
correlations	O
to	O
PD	O
progression.	O

Similar	O
analyses	O
were	O
performed	O
for	O
age,	O
sex,	O
disease	O
duration,	B
and	O
interval	O
since	O
last	O
attack	O
with	O
no	O
significant	O
differences/correlations	O
in	O
the	O
levels	O
of	O
both	O
metabolites	O
based	O
on	O
these	O
parameters	O
(data	O
not	O
shown).	O

Statins	B
lower	O
plasma	O
LDL-C	O
by	O
blocking	O
the	O
activity	O
of	O
HMG-CoA	O
reductase,	O
thereby	O
decreasing	O
the	O
synthesis	O
of	O
cholesterol	B
and	O
modifying	O
downstream	O
metabolic	O
pathways.	O

Given	O
that	O
the	O
circulating	O
levels	O
of	O
ornithine	B
(the	O
precursor	O
of	O
putrescine)	O
are	O
diminished	O
in	O
diabetic	O
individuals,	O
the	O
higher	O
putrescine	B
levels	O
cannot	O
explained	O
by	O
a	O
higher	O
availability	O
of	O
substrate.	O

The	O
internal	O
standards	O
(lithocholic	O
acid	O
sulfate	O
and	O
androsterone	B
glucuronide)	O
were	O
purchased	O
from	O
Sigma–	O

Acetamiprid	B
was	O
purchased	O
from	O
Wako	O
Pure	O
Chemical	O
Industries	O
(Osaka,	O
Japan).	O

Recently,	O
whole	O
blood	O
choline	B
(WBCHO)	O
is	O
used	O
as	O
an	O
early	O
marker	O
for	O
ACS	O
patients,	O
in	O
addition	O
to	O
predicting	O
cardiac	O
ischemia	O
in	O
patients	O
with	O
negative	O
troponin.	O

B	O
,	O
Among	O
daily	O
cannabis	B
users,	O
levels	O
of	O
THC-COOH	O
were	O
used	O
to	O
stratify	O
individuals	O
into	O
occasional,	O
moderate,	O
and	O
heavy	O
cannabis	B
use	O
groups.	O

The	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
and	O
the	O
pellet	O
re-extracted	O
with	O
1.0	O
mL	O
MTBE.	B

In	O
particular,	O
pelargonic	B
acid	I
and	O
3-hydroxybutric	B
acid	I
may	O
be	O
promising	O
surrogate	O
markers,	O
because	O
they	O
had	O
discriminatory	O
ability	O
to	O
predict	O
CAD	O
onset	O
in	O
ROC	O
analysis.	O

Metabolomics	O
data	O
showed	O
elevated	O
glutamate	B
levels,	O
although	O
routine	O
analysis	O
of	O
glutamate	B
in	O
serum	O
was	O
normal	O
in	O
most	O
of	O
our	O
patients.	O

Two	O
lipid	O
classes,	O
phosphatidylinositol	B
and	O
phosphatidylcholine,	B
increased	O
from	O
baseline	O
in	O
the	O
efavirenz	O
arm	O
while	O
in	O
the	O
atazanavir/r	O
arm	O
two	O
lipid	O
classes,	O
monohexosylceramide	B
and	O
G_M3	O
ganglioside,	B
decreased	O
in	O
concentration.	O

Not	O
surprisingly,	O
the	O
phospholipid	B
composition	O
of	O
the	O
HCMV	O
virion	O
is	O
markedly	O
different	O
from	O
that	O
of	O
viruses	O
that	O
bud	O
from	O
the	O
plasma	O
membrane,	O
including	O
HIV-1,	O
vesicular	O
stomatitis	O
virus,	O
and	O
Semliki	O
Forest	O
virus.	O

However,	O
both	O
HILIC	O
methods	O
are	O
more	O
successful	O
in	O
detecting	O
non-protected	O
AAs	O
in	O
a	O
biological	O
sample	O
than	O
the	O
standard	O
RP	B
method.	O

It	O
may	O
mediate	O
carcinogenesis	O
by	O
releasing	O
lysoPCs,	O
inducing	O
cell	O
growth	O
via	O
their	O
metabolism	O
to	O
lysophosphatidic	B
acid.	I

As	O
in	O
the	O
DSS	O
model,	O
we	O
found,	O
relative	O
to	O
the	O
control	O
cohort,	O
higher	O
levels	O
of	O
allantoin	B
and	O
tryptophan	B
in	O
UC	O
and	O
higher	O
levels	O
of	O
lactate	B
and	O
carnitine	B
in	O
UC	O
and	O
CD.	O

For	O
BDCPP,	O
recovery	O
at	O
the	O
lowest	O
spike	O
level	O
(78	O
pg	B
mL_−1	O
)	O
was	O
82	O
±	O
10%.	O

Recently,	O
integrative	O
pathway-based	O
and	O
conditional	O
Gaussian	O
Bayesian	O
network	O
analyses	O
using	O
multi-omics	O
data	O
have	O
indicated	O
that	O
an	O
altered	O
SL	B
metabolism	O
represents	O
an	O
underlying	O
feature	O
of	O
uncontrolled	O
asthma	O
and	O
a	O
therapeutic	O
response	O
to	O
albuterol.	B

Insulin	O
promotes	O
glucose	B
uptake	O
and	O
regulates	O
triglyceride	B
catabolism	O
through	O
the	O
inhibition	O
of	O
hormone-sensitive	O
lipase.	O

Phosphatidylcholines,	B
representing	O
the	O
most	O
abundant	O
glycerophospholipids	B
in	O
human	O
plasma,	O
are	O
the	O
main	O
component	O
of	O
cell	O
membranes	O
as	O
well	O
as	O
an	O
important	O
source	O
of	O
signaling	O
molecules	O
[,	O
].	O

For	O
example,	O
significantly	O
decreased	O
LDL,	O
VLDL,	O
and	O
lipid	O
concentrations	O
and	O
increased	O
acetate	B
and	O
lactate	B
concentrations	O
are	O
observed,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
of	O
both	O
rat	O
model	O
and	O
human	O
HCC	O
patients	O
[,	O
].	O

3-Deoxyvitamin	B
D3,	O
an	O
anti-inflammatory	O
metabolite,	O
was	O
reduced	O
.	O

With	O
the	O
exception	O
of	O
α-methylacyl-CoA	B
racemase	O
(necessary	O
for	O
the	O
acidic	O
pathway),	O
all	O
of	O
the	O
enzymes	O
(or	O
mRNA	O
transcripts)	O
required	O
for	O
the	O
formation	O
of	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
acid	I
are	O
present	O
in	O
brain.	O

Based	O
on	O
these	O
observations,	O
the	O
lower	O
level	O
of	O
both	O
alanine	B
and	O
glutamine,	B
found	O
in	O
the	O
serum	O
of	O
ADV	O
in	O
comparison	O
with	O
EAR	O
HCC	O
patients,	O
might	O
be	O
seen	O
as	O
a	O
consequence	O
of	O
a	O
higher	O
utilization	O
of	O
these	O
amino	O
acids	O
in	O
the	O
ADV	O
HCC	O
stage.	O

Individuals	O
who	O
developed	O
type	O
2	O
diabetes	O
did	O
not	O
differ	O
in	O
age	O
and	O
parental	O
history	O
of	O
type	O
2	O
diabetes	O
distribution	O
from	O
those	O
who	O
did	O
not	O
develop	O
type	O
2	O
diabetes,	O
but	O
diabetes	O
incidence	O
was	O
higher	O
in	O
men	O
and	O
in	O
individuals	O
who	O
had	O
significantly	O
higher	O
BMI	O
and	O
slightly	O
higher	O
glycaemic	B
trait	O
measurements	O
(fasting	O
and	O
2	O
h	O
glucose)	B
at	O
metabolomics	O
sampling.	O

As	O
shown	O
in	O
,	O
we	O
found	O
that:	O
i)	O
the	O
four	O
significantly	O
decreased	O
metabolites	O
were	O
positively	O
correlated	O
with	O
each	O
other;	O
ii)	O
the	O
six	O
significantly	O
increased	O
metabolites	O
(nicotinic	O
acid,	O
methylmalonic	B
acid,	I
L-Lactic	B
acid,	I
isobutyric	B
acid,	I
formic	B
acid	I
and	O
azelaic	O
acid)	O
were	O
positively	O
correlated	O
with	O
each	O
other;	O
and	O
iii)	O
the	O
other	O
three	O
significantly	O
increased	O
metabolites	O
were	O
positively	O
correlated	O
with	O
each	O
other.	O

Comparison	O
of	O
metabolic	O
factors	O
in	O
the	O
KP	B
among	O
three	O
groups.	O

Sixth,	O
rectal	O
contents	O
are	O
usually	O
alkaline,	B
favouring	O
uptake	O
of	O
alkaline	B
drugs	O
such	O
as	O
methadone.	B

In	O
addition,	O
this	O
thiazide	B
diuretic	O
tended	O
to	O
increase	O
the	O
urea	B
cycle	O
metabolites	O
urea	B
and	O
citrulline	B
but	O
not	O
ornithine	B
and	O
arginine.	B

In	O
hypogonadism,	O
carnosine,	B
as	O
well	O
as	O
its	O
component	O
β-alanine	B
and	O
uracil,	B
from	O
which	O
the	O
latter	O
is	O
derived	O
are	O
strongly	O
decreased	O
(Fig.	O

The	O
upper	O
organic	O
layers	O
from	O
each	O
vial	O
were	O
pooled	O
into	O
a	O
single	O
vial,	O
and	O
the	O
extraction	O
with	O
hexanes	B
was	O
repeated	O
a	O
second	O
time.	O

Urea	B
was	O
subsequently	O
omitted	O
from	O
the	O
data	O
set	O
because	O
its	O
protons	O
are	O
in	O
exchange	O
with	O
water	O
and	O
the	O
signal	O
is	O
compromised	O
by	O
water	O
suppression.	O

Acetyl-CoA	B
represents	O
a	O
major	O
entry	O
point	O
of	O
carbons	O
derived	O
from	O
the	O
oxidation	O
of	O
glucose,	B
several	O
amino	O
acids,	O
and	O
fatty	O
acids	O
into	O
the	O
TCA	O
cycle	O
and	O
is	O
also	O
a	O
the	O
precursor	O
for	O
cytosolic	O
fatty	O
acid	O
synthesis.	O

The	O
QC	O
stock	O
solution	O
was	O
diluted	O
in	O
human	O
EDTA	O
plasma	O
to	O
yield	O
QC	O
concentration	O
levels	O
of	O
5,	O
300,	O
and	O
400	O
ng/mL	O
abiraterone	B
in	O
plasma.	O

(C)	O
Hypotaurine	B
is	O
not	O
significantly	O
expressed	O
in	O
DOCK8-deficient	O
patients,	O
AUC	O
=	O
0.567	O
and	O
p	O
-value	O
of	O
0.41537.	O

We	O
sought	O
to	O
determine	O
the	O
serum	O
levels	O
of	O
5-HT,	O
tryptophan	B
(Trp)	O
metabolites	O
and	O
L-DOPA	B
in	O
37	O
Finnish	O
APECED	O
patients	O
and	O
to	O
correlate	O
their	O
abundance	O
with	O
the	O
presence	O
of	O
TPH	O
and	O
AADC	O
Aabs,	O
GI	O
dysfunction	O
and	O
depressive	O
symptoms.	O

Given	O
that	O
prior	O
work	O
by	O
one	O
of	O
the	O
authors	O
demonstrated	O
the	O
predictive	O
value	O
of	O
acylcarnitines	B
for	O
acute	O
coronary	O
syndrome	O
in	O
outpatients,	O
we	O
utilized	O
the	O
same	O
methods	O
to	O
study	O
acylcarnitines	B
in	O
the	O
current	O
subjects.	O

Resprep	O
C18	O
and	O
Strata	O
C8	O
columns	O
provided	O
efficient	O
recoveries	O
for	O
synthetic	O
cannabinoid	B
metabolites	O
(83.1–98.7%	O
recovery),	O
but	O
less	O
than	O
27.3%	O
synthetic	O
cannabinoid	B
parent	O
analyte	O
recovery	O
from	O
urine.	O

Pham	O
et	O
al.	O
demonstrated	O
monitoring	O
of	O
relative	O
compositions	O
of	O
the	O
same	O
four	O
isomers	O
of	O
PC	B
16:0_18:1	I
individually	O
from	O
MS/MS	O
experiments	O
containing	O
different	O
sequences	O
of	O
OzID	O
and	O
CID.	O

In	O
our	O
study,	O
the	O
increased	O
levels	O
of	O
long-chain	O
acylcarnitines	B
(factor	O
4,	O
)	O
seen	O
across	O
the	O
PH	O
subtypes	O
as	O
compared	O
with	O
no-PH	O
potentially	O
reflects	O
the	O
inefficiencies	O
in	O
mitochondrial	O
fuel	O
metabolism	O
previously	O
described	O
in	O
both	O
left	O
and	O
right	O
ventricular	O
failure.	O

clone	O
SP34-2),	O
anti-CD8-APC-H7	B
(clone	O
SK1),	O
anti-CD14-BV786	O
(clone	O
M5E2),	O
anti-CD16-FITC	O
(clone	O
3G8),	O
anti-CD38-PE-Cy5	B
(clone	O
HIT2),	O
anti-human	O
leukocyte	O
antigen	O
(HLA)-DR-BV711	O
(clone	O
G46-6),	O
anti-CD11c-BV650	O
(clone	O
B-ly6),	O
anti-CD123-PE-Cy7	O
(clone	O
7G3),	O
anti-IgG-PE-Cy5	O
(clone	O
G18-145);	O
(2)	O
from	O
BioLegend,	O
San	O
Diego,	O
California:	O
anti-CD4-BV605	O
(clone	O
OKT4),	O
anti-CD20-BV570	O
(clone	O
2H7),	O
anti-CD45-PerCP	O
(clone	O
HI30);	O
and	O
(3)	O
from	O
Miltenyi	O
Biotech,	O
Auburn,	O
California:	O
anti-IgA-PE-Vio770	O
(clone	O
IS11-8E10).	O

Low	O
tyrosine	B
levels	O
might	O
therefore	O
simply	O
reflect	O
impaired	O
kidney	O
function,	O
which	O
itself	O
predicts	O
future	O
microvascular	O
events.	O

A	O
significant	O
upregulation	O
of	O
oleic	B
acid	I
in	O
the	O
HFS	O
group	O
was	O
detected	O
compared	O
to	O
the	O
non-HFS	O
group	O
(Supplementary	O
Table	O
S2).	O

Passing-Bablok	O
regression	O
of	O
CE-MS	O
measurements	O
on	O
standard	O
clinical	O
laboratory	O
measurements	O
estimated	O
slope	O
0.97	O
(95%	O
confidence	O
interval:	O
0.95,	O
0.98)	O
and	O
intercept	O
-4.52	O
(-5.69,	O
-3.37)	O
for	O
creatinine,	B
and	O
slope	O
0.95	O
(0.92,	O
0.96)	O
and	O
intercept	O
-21.03	O
(-27.15,	O
-15.36)	O
for	O
uric	B
acid.	I

This	O
scenario	O
can	O
result	O
in	O
the	O
accumulation	O
and	O
release	O
of	O
citric	B
acid	I
cycle	O
intermediates	O
from	O
the	O
mitochondria	O
with	O
eventual	O
transport	O
into	O
the	O
blood	O
for	O
use	O
by	O
other	O
tissues	O
or	O
for	O
excretion	O
[–].	O

This	O
study	O
also	O
did	O
not	O
identify	O
strong	O
prognostic	O
markers	O
of	O
AP,	B
though	O
pre-ERCP	O
lipase	O
levels	O
were	O
somewhat	O
elevated	O
in	O
those	O
who	O
went	O
on	O
to	O
develop	O
AP.	B

Interestingly,	O
a	O
recent	O
study	O
has	O
shown	O
that	O
3-hydroxybutyric	B
acid	I
reduces	O
NLRP3	O
inflammasome-mediated	O
interleukin	O
(IL)-1β	B
and	O
IL-18	O
production	O
in	O
human	O
monocytes_)	O
.	O

After	O
centrifugation	O
we	O
placed	O
10 μl	O
of	O
the	O
supernatant	O
into	O
96	O
well	O
polypropylene	B
microtiter	O
plates	O
and	O
diluted	O
it	O
with	O
100 μl	O
of	O
the	O
internal	O
standard	O
solution.	O

Traditional	O
abnormal	O
clinical	O
plasma	O
lipid	O
levels	O
were	O
defined	O
in	O
this	O
study	O
as	O
abnormal	O
levels	O
of	O
at	O
least	O
2	O
of	O
the	O
4	O
lipids:	O
TG	B
≥1.10 mmol/L;	O
TC	O
≥4.403 mmol/	O

The	O
predictive	O
risk	O
algorithm	O
composed	O
of	O
the	O
C16,	O
SM(OH)22:1	B
and	O
PG-II	O
serum	O
levels	O
according	O
to	O
the	O
age	O
of	O
individuals,	O
could	O
be	O
used	O
to	O
stratify	O
FDR	O
at	O
high	O
risk	O
of	O
GC	O
development,	O
and	O
then	O
this	O
can	O
be	O
addressed	O
with	O
diagnostic	O
gastroscopy.	O

In	O
the	O
validation	O
sample,	O
there	O
were	O
168	O
glycerophospholipids	B
and	O
96	O
sphingolipids.	B

At	O
the	O
time	O
point	O
of	O
maximal	O
enrichment,	O
50%	O
of	O
the	O
total	O
glucose	B
pool,	O
35%	O
of	O
the	O
total	O
lactate	B
pool	O
and	O
25%	O
of	O
the	O
total	O
alanine	B
pool	O
was	O
food-derived.	O

Some	O
of	O
the	O
women	O
following	O
IER	O
also	O
appeared	O
to	O
have	O
had	O
increases	O
in	O
epithelial	O
cell	O
differentiation	O
(i.e.	O
increased	O
lactalbumin	O
caseins,	B
mammoglobins	O
and	O
mucins)	O
and	O
decreases	O
in	O
collagen	O
synthesis	O
(TNMD,	O
PCOLCE2,	O
TIMP4),	O
which	O
was	O
less	O
evident	O
in	O
women	O
on	O
CER	B
and	O
may	O
be	O
specific	O
to	O
IER.	O

Choline	B
metabolism	O
also	O
depends	O
on	O
the	O
gut	O
microbial	O
composition,	O
making	O
the	O
latter	O
an	O
attractive	O
target	O
for	O
early	O
prevention	O
and	O
treatment	O
of	O
T1DM.	O

To	O
further	O
understand	O
any	O
mechanistic	O
relationship	O
between	O
plasma	O
cholesterol	B
and	O
later	O
development	O
of	O
dementia,	O
others	O
have	O
investigated	O
the	O
effect	O
of	O
simvastatin	B
on	O
levels	O
of	O
the	O
toxic	O
protein	O
phospho-tau	B
in	O
the	O
cerebrospinal	O
fluid	O
of	O
cognitively	O
normal	O
adults	O
aged	O
45–60	O
years	O
and	O
a	O
positive	O
relationship	O
between	O
tau	O
and	O
plasma	O
LDL	O
was	O
observed	O
.	O

Of	O
note,	O
low	O
dopamine	B
levels	O
have	O
been	O
implicated	O
in	O
the	O
mechanisms	O
of	O
psychiatric	O
diseases	O
such	O
as	O
depression	O
[–]	O
and	O
schizophrenia[].	O

[Google	O
Scholar]	O
Ueno	O
R,	O
Narumiya	O
S,	O
Ogorochi	O
T,	O
Nakayama	O
T,	O
Ishikawa	O
Y,	O
Hayaishi	O
O.	O
Role	O
of	O
prostaglandin	B
D2	I
in	O
the	O
hypothermia	O
of	O
rats	O
caused	O
by	O
bacterial	O
lipopolysaccharide.	B

Finally,	O
multiple	O
regression	O
analysis	O
was	O
conducted	O
using	O
PROC	O
REG	O
to	O
assess	O
the	O
relationship	O
between	O
milk	O
total	O
choline	B
yield	O
and	O
animal	O
performance	O
variables	O
(i.e.	O
milk	O
yield	O
and	O
milk	O
composition)	O
during	O
lactation.	O

Current	O
guidelines	O
recommend	O
the	O
use	O
of	O
an	O
SSRI	O
(selective	O
serotonin	B
reuptake	O
inhibitor)	O
as	O
a	O
first-line	O
agent	O
where	O
treatment	O
with	O
antidepressants	O
is	O
considered	O
in	O
CKD	O
patients.	O

The	O
concentration	O
of	O
the	O
choline	B
moiety	O
in	O
milk	O
decreased	O
from	O
early	O
to	O
mid-lactation	O
before	O
rising	O
again	O
in	O
late	O
lactation;	O
however,	O
throughout	O
lactation	O
milk	O
choline	B
remained	O
below	O
the	O
levels	O
reported	O
previously	O
in	O
commercial	O
milk.	O

The	O
significant	O
increase	O
of	O
acetone	B
may	O
imply	O
that	O
the	O
elevated	O
flux	O
from	O
acetyl-CoA	B
into	O
acetoacetyl-CoA,	B
resulted	O
in	O
production	O
of	O
acetone.	B

Glucogenic	O
amino	O
acids,	O
including	O
alanine	B
and	O
glutamic	B
acid,	I
were	O
associated	O
with	O
glucose,	B
insulin	O
and	O
HOMA	O
levels;	O
glutamic	B
acid	I
also	O
correlated	O
with	O
c-peptide	O
levels.	O

The	O
previously-mentioned	O
phosphocreatine-dependent	O
uptake	O
of	O
glutamate	B
forms	O
part	O
of	O
a	O
cyclic	O
glutamate	O
and	O
glutamine	B
shuttle	O
between	O
astrocytes	O
and	O
neurons	O
in	O
the	O
normal	O
brain.	O

Apparently	O
it	O
is	O
involved	O
in	O
processes	O
of	O
endothelial	O
dysfunction,	O
increased	O
production	O
of	O
angiotensin	B
II,	I
elevated	O
levels	O
of	O
thromboxane	B
A2	I
and	O
hence	O
hypertensive	O
disorders,	O
which	O
could	O
explain	O
its	O
exclusively	O
occurrence	O
in	O
the	O
population	O
of	O
patients	O
with	O
preeclampsia	O
–.	O

In	O
a	O
population	O
with	O
impaired	O
GFR,	O
24,25	B
(OH)_2	I
D	O
concentration	O
was	O
directly	O
correlated	O
with	O
eGFR,	O
suggesting	O
that	O
low	O
24,25(OH)_2	B
D	O
concentration,	O
alone	O
or	O
relative	O
to	O
25(OH)D,	O
reflects	O
impairment	O
of	O
renal	O
vitamin	B
D	I
metabolism.	O

In	O
addition,	O
no	O
dynamic	O
differences	O
could	O
be	O
detected	O
between	O
the	O
intake	O
of	O
a	O
whey	B
protein	O
or	O
a	O
calcium	B
caseinate	I
drink	O
after	O
heavy	O
resistance	O
training.	O

Several	O
studies	O
in	O
mouse	O
models	O
and	O
humans	O
have	O
linked	O
sphingolipid	B
metabolites	O
with	O
metabolic	O
disorders	O
(,)	O
and	O
atherosclerosis	O
(,).	O

The	O
following	O
internal	O
standards	O
were	O
added	O
before	O
lipid	O
extraction:	O
10	O
nmol	O
of	O
1,2-diheptadecanoyl-sn	B
-glycero-3-phosphocholine,	I
10	O
nmol	O
of	O
1,2,3-triheptadecanoyl-sn	B
-glycerol	I
and	O
30	O
nmol	O
of	O
cholesteryl	B
tridecanoate.	I

Of	O
note,	O
the	O
association	O
of	O
LCAT	O
activity	O
with	O
betaine	B
was	O
no	O
longer	O
significant	O
after	O
adjustment	O
for	O
age,	O
sex,	O
diabetes	O
status,	O
BMI	O
and	O
lipoprotein	O
variables	O
or	O
apolipoproteins	O
(Table ,	O
models	O
1	O
and	O
2).	O

Gathering	O
the	O
results	O
of	O
unconditioned	O
media	O
(DMEM	O
and	O
Com.	O
Medium	O
)	O
and	O
comparing	O
them	O
globally	O
with	O
the	O
different	O
CM	O
it	O
is	O
possible	O
to	O
attest	O
not	O
only	O
to	O
metabolite	O
depletion	O
through	O
cell	O
metabolization	O
(as	O
the	O
glucose	B
example),	O
but	O
also	O
some	O
metabolites	O
(like	O
lactate,	B
formate	B
or	O
pyruvate)	O
that	O
were	O
present	O
in	O
higher	O
concentration,	O
reflecting	O
the	O
production	O
and	O
secretion	O
of	O
metabolites.	O

Urinary	O
levels	O
of	O
F_2	O
-IsoPs	O
and	O
its	O
major	O
urinary	O
metabolite	O
(2,3-dinor-5,6-dihydro-15-F_2t	O
-IsoP,	I
F_2	O
-IsoP-M)	O
were	O
measured	O
post-cancer	O
treatment	O
using	O
gas	O
chromatography/negative	O
ion	O
chemical	O
ionization	O
mass	O
spectrometry	O
for	O
57	O
deceased	O
breast	O
cancer	O
patients	O
(cases)	O
and	O
103	O
surviving	O
patients	O
(controls)	O
matched	O
1:2	O
on	O
age	O
at	O
diagnosis,	O
stage,	O
and	O
diagnosis	O
year.	O

The	O
deuterated	O
buffer	O
contained	O
0.5	O
mM	O
sodium	B
trimethylsilylphosphate	I
(TSP)	O
to	O
provide	O
a	O
reference	O
substance	O
for	O
the	O
annotation	O
of	O
the	O
NMR	O
spectra.	O

Our	O
metabolomic	O
data	O
further	O
implicates	O
that	O
leptin	O
replacement	O
therapy	O
has	O
a	O
significant	O
impact	O
on	O
downstream	O
pathways	O
of	O
tryptophan	B
degradation.	O

These	O
results	O
indicate	O
that	O
OPLS-DA	O
models	O
derived	O
from	O
the	O
RRLC-(±)ESI-MS	B
data	O
had	O
good	O
predictive	O
ability	O
and	O
were	O
reliable.	O

To	O
assess	O
the	O
relative	O
contribution	O
of	O
metabolites	O
from	O
anaerobic	O
and	O
aerobic	O
respiration	O
in	O
our	O
subjects,	O
we	O
defined	O
a	O
ratio	O
indicative	O
of	O
anaerobic	O
relative	O
to	O
aerobic	O
respiration,	O
and	O
calculated	O
a	O
ratio	O
from	O
the	O
relative	O
amounts	O
of	O
pyruvate,	B
lactate	B
and	O
citrate	B
in	O
each	O
subject’s	O
plasma	O
([Pyruvate	O
+	I
Lactate]/Citrate),	I
and	O
called	O
this	O
the	O
“glycolytic	B
ratio”.	O

Hemoglobin	O
A1c	O
(HbA_1c	O
),	O
glucose,	B
total	O
cholesterol,	B
urea	B
nitrogen,	I
and	O
creatinine	B
were	O
measured	O
with	O
automated	O
standardized	O
laboratory	O
techniques.	O

Furthermore,	O
levels	O
of	O
SPMA	O
were	O
comparable	O
with	O
Italian	O
reference	O
values	O
(only	O
non-smokers:	O
0.18	O
µg/g	O
creatinine,	B
95th	O
percentile)	O
and	O
US	O
reference	O
values	O
(3.03	O
µg/g	O
creatinine,	B
95th	O
percentile).	O

The	O
most	O
obvious	O
pattern	O
consisted	O
of	O
decreased	O
N-acetyl	B
aspartate	I
and	O
creatine	B
and	O
increased	O
choline-containing	O
compounds	O
levels.	O

Both	O
serum	O
and	O
WB	O
showed	O
the	O
presence	O
of	O
leucine	B
(Leu),	O
isoleucine	B
(Ile),	O
valine	B
(Val),	O
BHB,	O
lactate,	B
alanine,	B
acetate,	B
N-acetyl	O
sugars,	O
glutamate,	B
glutamine,	B
lysine/creatine,	O
glucose,	B
tyrosine,	B
histidine,	B
phenylalanine,	B
and	O
formate.	B

IV	O
(•);	O
rectal	O
(IV)	O
(▴);	O
oral	O
(▪);	O
rectal	O
(oral)	O
(▾)	O
Pharmacokinetic	O
variables	O
(mean,	O
95%	O
CI)	O
for	O
EDDP	O
after	O
IV	O
(5mg)	O
and	O
oral	O
and	O
rectal	O
(10mg)	O
administration	O
of	O
methadone	B
in	O
7human	O
subjects	O
The	O
time-course	O
(mean	O
and	O
s.d.)	O
of	O
dark-adapted	O
pupil	O
diameter	O
after	O
IV-rectal	O
and	O
oral-rectal	O
methadone	B
administration	O
for	O
the	O
first	O
24	O
h	O
is	O
shown	O
in	O
.	O

However,	O
using	O
only	O
three	O
metabolites	O
(octanoyl	O
carnitine,	I
arginine,	B
and	O
SM(C20:2))	B
along	O
with	O
NT-proBNP,	O
we	O
discovered	O
a	O
novel	O
panel	O
of	O
biomarkers	O
that	O
reliably	O
distinguishes	O
HFpEF	O
from	O
control	O
subjects.	O

Those	O
papers	O
would	O
lead	O
one	O
to	O
expect	O
a	O
positive	O
correlation	O
between	O
lipid	O
and	O
lactate	B
signals,	O
whereas	O
we	O
observed	O
a	O
negative	O
correlation.	O

Our	O
method	O
captured	O
the	O
temporal	O
relationship	O
between	O
glucose	B
and	O
intermediates	O
of	O
glycolysis.	O

The	O
recoveries	O
obtained	O
for	O
the	O
1,25-(OH)_2	B
D	O
compounds	O
using	O
LLE	O
and	O
SPE	O
were	O
similar,	O
ranging	O
from	O
71%	O
to	O
86%.	O

In	O
terms	O
of	O
inter-laboratory	O
reproducibility	O
the	O
assay	O
performed	O
very	O
well,	O
with	O
CVs	O
ranging	O
from	O
1.2%	O
(alanine)	O
to	O
12.1%	O
(lysine).	O

Alpha-ketoglutarate,	B
the	O
other	O
major	O
carbon	O
source	O
for	O
the	O
tricarboxylic	B
acid	I
(TCA)	O
cycle,	O
was	O
also	O
nearly	O
completely	O
_13	O
C,	O
indicating	O
that	O
most	O
oxidized	O
carbon	O
was	O
derived	O
from	O
the	O
medium	O
nutrients.	O

Demographic	O
information	O
on	O
acute	O
promyelocytic	O
leukemia	O
(APL)	O
patients	O
who	O
participated	O
in	O
this	O
study	O
F	O
female,	O
M	O
male	O
Ten	O
milligrams	O
of	O
As_2	O
O_3	O
(Yida	O
Pharmaceutical,	O
Harbin,	O
China)	O
dissolved	O
in	O
a	O
10-mL	O
aqueous	O
solution	O
was	O
added	O
to	O
500 mL	O
of	O
5 %	O
glucose	B
normal	O
saline	B
solution	O
for	O
intravenous	O
infusion.	O

Similarly,	O
positive	O
correlations	O
between	O
these	O
sterols	O
and	O
22R	B
-hydroxycholesterol	I
and	O
25-hydroxycholesterol	B
suggest	O
that	O
some	O
amount	O
of	O
these	O
two	O
oxysterols	B
reflects	O
formation	O
by	O
spontaneous	O
as	O
opposed	O
to	O
enzymatic	O
oxidation.	O

To	O
formally	O
assess	O
the	O
sensitivity	O
of	O
our	O
MWSL	O
estimates	O
to	O
the	O
parametric	O
form	O
of	O
the	O
response	O
variable,	O
we	O
ran	O
a	O
series	O
of	O
sensitivity	O
analyses	O
where	O
we	O
randomly	O
sampled	O
for	O
each	O
participant	O
(and	O
for	O
each	O
permutation)	O
the	O
glucose	B
levels	O
from	O
(i)	O
a	O
Gamma	O
distribution	O
fitted	O
on	O
the	O
measured	O
glucose	B
levels	O
(shape	O
=	O
15.90,	O
scale	O
=	O
6.18),	O
and	O
(ii)	O
several	O
Gaussian	O
distributions	O
(mean	O
=	O
0,	O
sd	O
=	O
1;	O
mean	O
=	O
0,	O
sd	O
=	O
10;	O
mean	O
=	O
0,	O
sd	O
=	O
100,	O
mean	O
=	O
mean(glucose),	B
sd	O
=	O
sd(glucose).	B

Changes	O
in	O
gluconeogenic	O
amino	O
acids	O
(alanine,	O
tyrosine,	B
and	O
proline)	B
and	O
UDP-GlcNAc	B
were	O
positively	O
associated	O
with	O
change	O
in	O
BMI;	O
UDP-GlcNAc	B
was	O
similarly	O
associated	O
with	O
WC	O
and	O
insulin	O
metabolism	O
(insulin	O
and	O
insulin	O
AUC).	O

N-methylalanine,	B
a	O
possible	O
pyruvate	B
precursor,	O
decreased	O
in	O
relation	O
to	O
increased	O
insulin	O
post-treatment;	O
the	O
change	O
in	O
N	B
-methylalanine	I
during	O
the	O
course	O
of	O
treatment	O
was	O
also	O
inversely	O
related	O
to	O
the	O
change	O
in	O
insulin.	O

The	O
serum	O
levels	O
of	O
glycine,	B
serine	B
and	O
threonine	B
were	O
significantly	O
changed	O
in	O
treatment-resistant	O
depression	O
.	O

Supplemental	O
Table _3	O
shows	O
the	O
associations	O
of	O
baseline	O
levels	O
of	O
individual	O
metabolites	O
and	O
relevant	O
ratios	O
with	O
T2D	O
risk	O
after	O
including	O
HDL	B
cholesterol	I
and	O
TAG	O
in	O
the	O
fully	O
adjusted	O
model.	O

The	O
second	O
locus,	O
PRODH	O
,	O
a	O
gene	O
highly	O
expressed	O
in	O
cerebral	O
cortex,	O
cerebrum	O
and	O
other	O
brain	O
tissues	O
is	O
known	O
to	O
be	O
involved	O
in	O
proline	B
metabolism,	O
but	O
also	O
in	O
central	O
nervous	O
system	O
myelination.	O

However,	O
our	O
method	O
has	O
the	O
advantage	O
of	O
quantifying	O
three	O
statins	B
simultaneously	O
with	O
their	O
active	O
metabolites.	O

One	O
of	O
them,	O
para-aminohippuric	B
acid,	I
is	O
a	O
well-established	O
diagnostic	O
marker	O
for	O
renal	O
plasma	O
flow	O
and	O
glomerular	O
filtration	O
(Reubi	O
).	O

Glycine,	B
asymmetric	B
dimethylarginine,	I
PC-O	O

Calibration	O
was	O
performed	O
as	O
follows:	O
all	O
monoacyl	O
lipids	O
except	O
cholesterol	B
esters,	I
such	O
as	O
monoacylglycerols	B
and	O
monoacyl-glycerophospholipids,	B
were	O
calibrated	O
with	O
lysophosphatidylcholine	B
PC(17∶0/0∶0)	I

_,	O
The	O
identities	O
of	O
2-HO-PhIP	B
and	O
5-HO-PhIP	B
were	O
confirmed	O
by	O
their	O
characteristic	O
product	O
ion	O
spectra._,	O
Amino	O
acid	O
adducts	O
of	O
NO_2	O
-PhIP	O
were	O
synthesized	O
by	O
the	O
reaction	O
of	O
cysteine,	B
tryptophan,	B
tyrosine	B
or	O
lysine	B
(0.1	O
μ	O
mol)	O
with	O
NO_2	O
-PhIP	O

Inclusion	O
criteria	O
were	O
40–70	O
years	O
of	O
age,	O
diagnosis	O
of	O
T2D	O
as	O
defined	O
by	O
the	O
criteria	O
of	O
the	O
American	O
Diabetes	O
Association	O
and	O
recognized	O
by	O
WHO,	O
Expert	O
Committee	O
on	O
the	O
Diagnosis	O
and	O
Classification	O
of	O
Diabetes	O
Mellitus	O
(American	O
Diabetes	O
Association,	O
2004)	O
diagnosed	O
at	O
least	O
3 months	O
preceding	O
screening	O
visit,	O
treatment	O
by	O
oral	O
metformin	B
as	O
a	O
monotherapy	O
at	O
a	O
stable	O
dose	O
(0.5–3.0 g/day)	O
for	O
at	O
least	O
1 month	O
and	O
no	O
other	O
antidiabetic	O
agent,	O
hemoglobin	O
A_1c	O

The	O
formic	B
acid	I
and	O
acetonitrile	B
were	O
purchased	O
as	O
MS-grade	O
from	O
Sigma-Aldrich.	O

SETD1B	O
is	O
a	O
component	O
of	O
the	O
methyltransferase	O
complex	O
that	O
specifically	O
methylates	B
the	O
lysine-4	B
residue	O
of	O
histone	O
H3.	O

The	O
microalbuminuric	O
pattern,	O
mainly	O
in	O
hypertension	O
and/or	O
diabetes,	O
was	O
also	O
associated	O
to	O
alterations	O
in	O
glucose	B
metabolism,	O
lipid	O
β-oxidation	O
and	O
the	O
tricarboxilic	O
acid	O
(TCA)	O
cycle	O
,	O
.	O

Serum	O
levels	O
of	O
AC	B
C18:2	I
was	O
higher	O
but	O
those	O
of	O
AC	O
C3-OH	O
and	O
SM	B
C24:1	I
were	O
lower	O
in	O
the	O
HBV-associated	O
cirrhosis	O
group	O
than	O
in	O
either	O
CHB	O
or	O
HBV-associated	O
HCC	O
groups.	O

Of	O
note,	O
phosphatidylcholines	B
(and	O
lysophosphatidylcholines)	B
represent	O
by	O
mass	O
more	O
than	O
76%	O
of	O
total	O
glycerophospholipids	B
in	O
healthy	O
volunteers.	O

Nevertheless,	O
15%	O
(v/v)	O
MeOH	B
is	O
the	O
solvent	O
of	O
choice	O
as	O
it	O
allows	O
a	O
better	O
migration	O
time	O
difference	O
between	O
positional	O
isomers	O
of	O
OH-WAR.	O

Ornithine;	B
92.	O

After	O
60 min	O
the	O
reaction	O
was	O
stopped	O
by	O
adding	O
50 µL	O
of	O
ice-cold	O
acetonitrile	B
and	O
the	O
mixture	O
was	O
subsequently	O
centrifuged	O
for	O
2 min	O
at	O
14,000 × g.	O

LC–MS	O
(Chromasolv)	O
grade	O
methanol,	B
acetonitrile	B
and	O
isopropanol	B
were	O
purchased	O
from	O
Sigma-Aldrich	O
(Poole,	O
UK);	O
water	O
was	O
obtained	O
from	O
an	O
ultra-pure	O
water	O
purification	O
system	O
(Millipore,	O
UK)	O
and	O
‘food	O
fresh’	O
liquid	O
CO_2	O
(99.8%	O
purity)	O
was	O
obtained	O
from	O
BOC	O
(UK).	O

Metabolic	O
Pathway	O
Analysis	O
also	O
showed	O
that	O
the	O
metabolism	O
of	O
glycine	B
and	O
serine	B
was	O
among	O
the	O
most	O
impacting	O
processes	O
in	O
HCC	O
progression.	O

Previous	O
lipidomics	O
analyses	O
(not	O
in	O
bvFTD)	O
showed	O
that	O
a	O
considerable	O
number	O
of	O
TG	B
and	O
DG	O
species	O
were	O
closely	O
associated	O
with	O
dyslipidemia,	O
and	O
TG	B
50:2,	I
52:2,	O
52:3,	O
and	O
52:4	O
were	O
the	O
most	O
abundant	O
species.	O

In	O
the	O
serum,	O
pyridines,	B
sugar	O
acids,	O
sugar	O
alcohols,	O
acidic	O
amino	O
acids,	O
phenylacetates,	B
disaccharides,	B
monosaccharides,	B
hexoses,	O
and	O
glutarates	B
were	O
higher	O
in	O
those	O
who	O
died	O
while	O
saturated	O
and	O
unsaturated	O
fatty	O
acids,	O
purine	O
nucleosides,	O
basic	O
and	O
sulfur	O
amino	O
acids,	O
dicarboxylic	B
acids,	I
and	O
adipates	O
were	O
lower.	O

_,	O
The	O
current	O
results	O
showed	O
that	O
the	O
creatine	B
concentration	O
in	O
patients	O
with	O
FESZ	O
increased	O
compared	O
with	O
controls	O
and	O
was	O
negatively	O
associated	O
with	O
DUP.	O

A	O
recent	O
report	O
suggests	O
that	O
all	O
phosphoglycerides,	B
namely	O
phosphatidylcholine,	B
phosphatidylethanolamine,	B
phosphatidylinositol	B
were	O
up	O
regulated	O
in	O
PCa	O
patients.	O

Glutamate	B
or	O
glutamine	B
are	O
either	O
directly	O
derived	O
from	O
protein	O
hydrolysis	O
or	O
from	O
starch	O
hydrolysis	O
and	O
subsequent	O
TCA	O
metabolism	O
of	O
glycolytic	B
acetyl-CoA.	I

The	O
extent	O
of	O
_13	O
C	O
enrichment	O
in	O
glucose	B
(as	O
[U-_13	O
C]-Glc)	O
for	O
non-cancerous	O
tissues	O
was	O
determined	O
from	O
the	O
1-D	O
_1	O
H	O
spectra	O
(cf.	O

Our	O
results	O
about	O
PA’s	O
metabolome	O
in	O
short-term	O
survivors	O
are	O
in	O
accordance	O
with	O
other	O
studies	O
that	O
found	O
a	O
higher	O
level	O
of	O
choline	B
in	O
several	O
cancers.	O

Microbiota	O
from	O
the	O
faecal	O
sample	O
of	O
donor	O
D1	O
was	O
able	O
to	O
metabolize	O
about	O
half	O
of	O
the	O
resveratrol	B
and	O
completely	O
metabolize	O
oxyresveratrol	B
and	O
piceatannol	O
within	O
48	O
h,	O
but	O
it	O
was	O
not	O
metabolizing	O
thunalbene.	B

The	O
lyso-PC	B
results	O
from	O
the	O
action	O
of	O
phospholipase	O
A2,	O
which	O
liberates	O
arachidonic	B
acid	I
from	O
PC.	O

We	O
investigated	O
whether	O
metabolic	O
changes	O
can	O
predict	O
AF	B
recurrence	O
after	O
successful	O
DCCV.	O

The	O
combined	O
analysis	O
of	O
serum	O
and	O
plasma	O
samples	O
by	O
different	O
measurement	O
techniques	O
gave	O
successful	O
discrimination	O
of	O
patients	O
and	O
controls	O
with	O
BPH,	O
and	O
provided	O
an	O
insight	O
into	O
the	O
metabolic	O
processes	O
characteristic	O
of	O
PCa,	O
with	O
data	O
suggesting	O
changes	O
in	O
fatty	O
acid	O
metabolism	O
and	O
choline	B
metabolism.	O

Plasma	O
(100	O
μl)	O
was	O
combined	O
in	O
10	O
ml	O
glass	O
tubes	O
with	O
internal	O
standard	O
solution	O
(100	O
μl)	O
composed	O
of	O
heptadecanoic	B
acid	I
(200	O
μg/ml	O
in	O
hexane	B
containing	O
0.01%	O
BHT),	O
vortex	O
mixed	O
for	O
5	O
s,	O
and	O
then	O
reduced	O
to	O
dryness	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	O
at	O
room	O
temperature.	O

A	O
highly	O
de-shielded	O
proton	O
was	O
also	O
observed	O
at	O
10.89	O
ppm	O
which	O
was	O
the	O
characteristic	O
–NH	O
proton	O
in	O
the	O
indole	B
moiety.	O

Higher	O
levels	O
of	O
glucose	B
were	O
detected	O
in	O
DMEM	O
and	O
24	O
h	O
DMEM	O
comparing	O
to	O
Com.	O

While	O
the	O
appearance	O
rate	O
of	O
glucose	B
was	O
reduced	O
by	O
20%	O
and	O
38%	O
following	O
GG2	O
and	O
GG4	O
ingestion	O
(GG2:	O
p	O
=	O
0.0866,	O
GG4:	O
p	O
=	O
0.0173),	O
this	O
effect	O
was	O
less	O
pronounced	O
for	O
lactate	B
(GG2:	O
~9%,	O
p	O
=	O
0.0867;	O
GG4:	O
~12%,	O
p	O
=	O
0.068)	O
and	O
alanine	B
(GG2:	O
~5%,	O
p	O
=	O
0.753;	O
GG4:	O
~15%,	O
p	O
=	O
0.084).	O

Despite	O
differences	O
in	O
methodology	O
(Girard	O
T	O
vs.	O
hydroxylamine	B
derivatization)	O
and	O
instrumentation,	O
the	O
percent	O
changes	O
in	O
keto-androgen	B
levels	O
following	O
drug	O
treatment	O
showed	O
good	O
concordance.	O

Deming	O
regression	O
analysis	O
of	O
betaine	B
results	O
from	O
both	O
platforms	O
produced	O
an	O
R_2	O
value	O
of	O
0.94	O
(Y	O
=	O
1.08x	O
–	O
1.89)	O
(B).	O

We	O
measured	O
the	O
ceramide	B
levels	O
in	O
breast	O
cancer	O
(n=44),	O
peri-tumor	O
(n=36),	O
and	O
normal	O
breast	O
tissues	O
(n=44)	O
(Figure	O
).	O

Disturbed	O
lysine	B
metabolism	O
has	O
been	O
previously	O
reported	O
in	O
both	O
MCI	O
and	O
AD	O
subjects,	O
but	O
we	O
found	O
it	O
to	O
be	O
only	O
disturbed	O
in	O
stable	O
MCI	O
subjects.	O

For	O
NMR	O
measurements,	O
400	O
μ	O
L	O
of	O
unfiltered	O
EDTA-plasma	O
were	O
mixed	O
with	O
200	O
μ	O
L	O
of	O
0.1 mol/L	O
phosphate	B
buffer	O
at	O
pH	O
7.4,	O
50	O
μ	O
L	O
of	O
0.75%	O
(w)	O
3-trimethylsilyl-2,2,3,3-tetradeuteropropionate	B
(TSP)	O
dissolved	O
in	O
deuterium	O
oxide,	O
and	O
10	O
μ	O
L	O
of	O
81.97 mmol/	O

Tryptophan	B
starvation	O
is	O
a	O
recognized	O
antimicrobial	O
defense	O
mechanism	O
through	O
Indoleamine	O
2,3-dioxygenase	O
(IDO)	O
and	O
mediates	O
immunoregulatory	O
effects	O
.	O

The	O
parameters	O
for	O
LTQ-FT	O
Ultra	O
MS	O
were:	O
ion	O
source	O
voltage,	O
3	O
kV;	B
nitrogen	O
sheath	O
and	O
aux	O
gas	O
flow,	O
0	O
and	O
0	O
units,	O
respectively	O
(because	O
nano-ESI	O
uses	O
low	O
volume	O
of	O
solvent	O
and	O
does	O
not	O
require	O
gas-assisted	O
de-solvation	O
and	O
ionization	O
process);	O
ion	O
transfer	O
capillary	O
temperature,	O
250	O
°C;	O
capillary	O
voltage,	O
35	O
V;	O
tube	O
lens,	O
130	O
V;	O
typical	O
ion	O
gauge	O
pressure,	O
0.60	O
×	O
10-5	O
Torr.	O

In	O
the	O
present	O
study,	O
we	O
showed	O
a	O
reduction	O
in	O
glutamine	B
levels	O
in	O
CSF	O
and	O
plasma	O
from	O
T2DM	O
patients,	O
which	O
could	O
be	O
due	O
to	O
extensive	O
oxidative	O
stress	O
in	O
T2DM.	O

Therefore,	O
KP	B
possesses	O
a	O
different	O
trajectory	O
and	O
path	O
in	O
healthy	O
individuals	O
compared	O
with	O
CMM	O
patients.	O

(E)	O
Trimethylamine	B
present	O
only	O
in	O
SpeedVac	O
dried	O
Panc-1	O
samples.	O

Together	O
with	O
the	O
concomitant	O
reduction	O
in	O
overnight	O
insulin	O
secretion	O
and	O
fasting	O
blood	O
glucose	B
concentrations	O
in	O
this	O
setting,	O
such	O
findings	O
suggest	O
a	O
metabolic	O
adaptation	O
to	O
limited	O
carbohydrate	O
availability	O
in	O
the	O
face	O
of	O
increased	O
demand	O
induced	O
by	O
extended	O
wakefulness.	O

Hypotaurine	B
is	O
finally	O
oxidized	O
to	O
the	O
final	O
product	O
taurine	B
by	O
hypotaurine	O
dehydrogenase,	O
which	O
is	O
then	O
excreted	O
out	O
of	O
the	O
body	O
or	O
used	O
within.	O

Dilutions	O
of	O
stock	O
solution	O
with	O
methanol	B
created	O
5,	O
50,	O
5,000,	O
and	O
50,000	O
ng/mL	O
working	O
solutions.	O

Fasting	O
morning	O
midstream	O
clean-catch	O
urine	O
samples	O
were	O
collected	O
at	O
three	O
visits	O
(V1:	O
gestational	O
week	O
8–20;	O
V2:	O
week	O
28±2;	O
V3∶10–16	O
weeks	O
post	O
partum),	O
and	O
routine	O
tests	O
for	O
nitrite,	B
proteinuria	O
and	O
glucosuria	O
were	O
performed	O
using	O
dipsticks.	O

(BrGMP),	O
di-	O
(BrGDP)	O
and	O
tri-phosphate	B
(BrGTP),	O
used	O
as	O
the	O
internal	O
standards	O
(IS),	O
were	O
also	O
obtained	O
from	O
Jena	O
Bioscience	O
(Jena,	O
Germany).	O

In	O
contrast,	O
knock-down	O
of	O
SARDH	O
in	O
benign	O
prostate	O
epithelial	O
cells	O
resulted	O
in	O
approximately	O
a	O
3-fold	O
increase	O
in	O
endogenous	O
sarcosine	B
levels	O
with	O
a	O
concomitant	O
>	O
3.5	O
fold	O
increase	O
in	O
invasion	O
(,	O
).	O

A	O
100,000-ng/mL	O
stock	O
solution	O
(20,000	O
ng/mL	O
for	O
BUP	O
and	O
NBUP)	O
was	O
prepared	O
in	O
methanol	B
and	O
stored	O
at	O
−20	O
°C.	O

Limit	O
of	O
quantification	O
(LoQ)	O
of	O
DG	O
and	O
TG	B
species	O
was	O
determined	O
from	O
serial	O
dilutions	O
of	O
fecal	O
samples.	O

Of	O
particular	O
interest	O
were	O
nine	O
metabolites,	O
which	O
had	O
high	O
VIP	O
scores	O
in	O
the	O
GC	O
vs	O
HE	O
OPLS	O
model	O
but	O
low	O
VIP	O
scores	O
in	O
the	O
BN	O
vs	O
HE	O
OPLS	O
model:	O
sucrose,	B
dimethylamine,	B
1-methylnicotinamide,	B
2-furoylglycine,	B
N-acetylserotonin,	B
trans-aconitate,	B
alanine,	B
formate,	B
and	O
serotonin.	B

Tamoxifen	B
and	O
its	O
metabolites	O
were	O
measured	O
by	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry.	O

Our	O
results	O
confirm	O
previous	O
studies,	O
which	O
indicated	O
higher	O
acylcarnitine	B
levels	O
in	O
CKD	O
and	O
an	O
inverse	O
association	O
with	O
eGFR,	O
which	O
was	O
suggested	O
to	O
be	O
caused	O
by	O
impaired	O
excretory	O
function	O
in	O
the	O
failing	O
kidney.	O

mL.	O
A	O
solution	O
of	O
the	O
internal	O
standard,	O
GP,	B
was	O
prepared	O
in	O
methanol	B
(1.0	O
mg/mL)	O
and	O
further	O
diluted	O
with	O
methanol:water	B
(1:1	O
v/v)	O
to	O
achieve	O
a	O
final	O
concentration	O
of	O
50	O
ng/mL	O
All	O
the	O
calibrators	O
and	O
QCs	O
were	O
aliquoted	O
and	O
stored	O
at	O
−80°C	O
along	O
with	O
clinical	O
study	O
samples.	O

Of	O
these	O
metabolites,	O
only	O
acetate	B
exhibited	O
elevated	O
levels	O
in	O
insulin-deprived	O
type	O
1	O
diabetic	O
individuals.	O

Blood	O
was	O
collected	O
in	O
ethylenediaminetetraacetic	B
acid	I
(EDTA)-containing	O
tubes,	O
centrifuged	O
and	O
isolated	O
plasma	O
immediately	O
stored	O
frozen	O
at	O
−80°C.	O

Aspartic	B
acid	I
is	O
one	O
of	O
the	O
essential	O
substances	O
of	O
the	O
in	O
vivo	O
synthesis	O
of	O
nucleotides,	O
which	O
is	O
needed	O
in	O
large	O
amounts	O
for	O
the	O
synthesis	O
of	O
nucleotides	O
to	O
promote	O
tumor	O
development	O
when	O
the	O
tumor	O
cells	O
proliferate;	O
therefore,	O
the	O
content	O
of	O
aspartic	B
acid	I
in	O
the	O
body	O
is	O
expressed	O
at	O
lower	O
level	O
than	O
normal	O
control	O
group.	O

Sodium	O
acetate	O
anhydrous	O
(>99.0%)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(Pittsburg,	O
PA,	O
USA),	O
dodecane	B
(99%),	O
ascorbic	B
acid,	I
N-methyl-N-(trimethylsilyl)-trifluoroacetamide	B
(MSTFA),	O
and	O
β-glucuronidase	O
type	O
H-1	O
with	O
sulfatase	O
activity	O
(β-glucuronidase	O
≥300,000	O
units/g,	O
sulfatase	O
≥10,000	O
units/g),	O
isolated	O
from	O
Helix	O
pomatia,	O
were	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

ARG,	O
arginase;	O
DDAH,	O
dimethylarginine	O
dimethylaminohydrolase,	O
NOS,	O
nitric	B
oxide	I
synthase;	O
ODC,	O
ornithine	O
decarboxylase;	O
PRMT,	O
arginine	O
N-methyltransferase;	O
CD_i,	O
inflamed	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
CD_q,	O
quiescent	O
tissue	O
obtained	O
from	O
patients	O
with	O
Crohn’s	O
disease;	O
UC_i,	O
inflamed	O
tissue	O
obtained	O
from	O
patients	O
with	O
ulcerative	O
colitis;	O
Normal,	O
normal	O
large	O
bowel	O
tissue	O
obtained	O
from	O
patients	O
undergoing	O
polypectomy;	O
_a	O
significantly	O
different	O
from	O
normal;	O
_b	O
significantly	O
different	O
from	O
CD_i;	O
_c	O
significantly	O
different	O
from	O
CD_q;	O
_d	O
significantly	O
different	O
from	O
UC_i.	O

1XAP	O
The	O
studies	O
reported	O
here	O
demonstrate	O
that	O
the	O
products	O
of	O
the	O
oxidative	O
eccentric	O
cleavage	O
of	O
β-carotene	B
at	O
the	O
C13–C14	O
double	O
bond	O
yields	O
products	O
that	O
are	O
antagonists	O
of	O
RARs	O
and	O
that	O
the	O
most	O
active	O
molecule	O
in	O
this	O
regard	O
is	O
β-apo-13-carotenone.	B

Moreover	O
Sil	O
activated	B
the	O
synthesis	O
of	O
vitamin	B
D3	I
metabolite	O
from	O
cholesterol	B
and	O
prevented	O
the	O
steroid	O
hormones	O
oxidation.	O

To	O
get	O
absolute	O
metabolite	O
concentrations,	O
these	O
LCModel	O
output	O
values	O
would	O
have	O
to	O
be	O
corrected	O
for	O
receiver	O
gain	O
and	O
number	O
of	O
scans	O
and	O
then	O
normalised	O
either	O
to	O
trimethylsilylpropanoic	B
acid	I
(TSP)	O
or	O
unsuppressed	O
water.	O

We	O
next	O
investigated	O
the	O
sphingomyelin	B
pathway,	O
another	O
major	O
pathway	O
of	O
ceramide	B
biosynthesis.	O

who	O
identified	O
decreases	O
in	O
histidine,	B
glutamine	B
and	O
threonine	B
in	O
early	O
and	O
late	O
lung	O
cancer	O
in	O
plasma	O
samples	O
from	O
five	O
cancers	O
(lung,	O
gastric,	O
colorectal,	O
breast	O
and	O
prostate).	O

Validating	O
this	O
response	O
score	O
in	O
another	O
independent	O
study	O
emphasized	O
the	O
importance	O
of	O
considering	O
this	O
score	O
and	O
its	O
signals	O
in	O
future	O
models	O
for	O
guiding	O
the	O
selection	O
of	O
hydrochlorothiazide	B
therapy.	O

Kidney	O
and	O
prostate	O
cancer	O
tumor	O
and	O
benign	O
biopsies	O
were	O
stained	O
with	O
hemotoxylin	B
and	O
eosin	B
and	O
prostate	O
biopsies	O
were	O
subjected	O
to	O
PIN-4	O
immunohistochemistry.	O

Our	O
results	O
showed	O
that	O
metabolites	O
associated	O
with	O
inflammation,	O
phospholipid	B
metabolism,	O
Ca_2+	O
flux,	O
and	O
cell	O
junction	O
signaling	O
pathways	O
were	O
impacted	O
in	O
CRC	O
and	O
PDAC.	O

It	O
is	O
therefore	O
expected	O
that	O
the	O
elevated	O
concentration	O
of	O
uric	B
acid	I
(or	O
called	O
hyperuricemia)	O
in	O
TNBC	O
patients	O
could	O
be	O
a	O
good	O
indicator	O
of	O
poor	O
5-year	O
survival	O
rate.	O

It	O
does	O
not	O
seem	O
feasible	O
that	O
glyphosate,	B
a	O
herbicide	O
with	O
cytotoxicity,	O
can	O
directly	O
cause	O
neo-nicotinic	O
symptoms	O
with	O
other	O
neuropsychiatry	O
symptoms	O
and	O
electrocardiographic	O
abnormality,	O
which	O
almost	O
disappeared	O
with	O
the	O
prohibition	O
of	O
specific	O
kinds	O
of	O
food.	O

The	O
increased	O
plasma	O
3-hydroxydecanoate,	B
an	O
intermediate	O
in	O
the	O
β-oxidation	O
of	O
fatty	O
acids,	O
observed	O
by	O
Dallmann	O
et	O
al.	O
during	O
40	O
h	O
of	O
continual	O
wakefulness,	O
supports	O
this	O
hypothesis.	O

Men	O
who	O
agreed	O
to	O
participate	O
provided	O
a	O
spot	O
urine	O
sample	O
in	O
a	O
sterile	O
polypropylene	B
collection	O
cup	O
on	O
the	O
same	O
day	O
of	O
semen	O
sample	O
procurement.	O

Several	O
proteins	O
such	O
as	O
tubulin,	O
thioredoxin	B
reductase,	O
AS3MT	O
with	O
a	O
high	O
cysteine	B
content	O
and	O
accessible	O
thiol	B
group	O
are	O
candidates	O
for	O
interactions	O
with	O
arsenic	O
[,].	O

The	O
increase	O
we	O
see	O
with	O
the	O
diabetic	O
samples	O
suggests	O
accumulation	O
of	O
Cer	B
and	O
therefore	O
apoptotic	O
behavior.	O

Temporal	O
response	O
to	O
an	O
oral	O
glucose	B
challenge	O
in	O
individuals	O
with	O
normal	O
glucose	B
tolerance	O
(MACS).	O

Taken	O
together,	O
a	O
decrease	O
in	O
HDL	O
and	O
an	O
increase	O
in	O
lactate	B
and	O
ketone	B
bodies	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
aerobic	O
glycolysis	O
is	O
modulated	O
towards	O
anaerobic	O
and	O
lipid	O
metabolisms.	O

A	O
comparison	O
of	O
relative	O
metabolite	O
levels	O
between	O
HCC	O
vs	O
CTR	O
and/or	O
HCC	O
vs	O
CHB	O
in	O
all	O
subjects	O
confirmed	O
that	O
carnitine	B
was	O
significantly	O
increased	O
in	O
HCC,	O
and	O
creatinine,	B
hippurate,	B
and	O
TMAO	B
were	O
significantly	O
reduced	O
in	O
HCC	O
(Figure	O
).	O

However,	O
the	O
CID	O
spectrum	O
of	O
SM(36:3)	B
did	O
not	O
reveal	O
any	O
abundant	O
ions	O
that	O
identify	O
the	O
fatty	O
acyl	O
substituents.	O

From	O
the	O
Pathway	O
Analysis,	O
porphyrin	O
and	O
chlorophyll	B
metabolism	O
was	O
found	O
to	O
be	O
the	O
major	O
perturbed	O
pathway	O
followed	O
by	O
tryptophan	B
metabolism	O
and	O
bile	O
acid	O
biosynthesis.	O

Urea	B
cycle	O
amino	O
acids	O
(factor	O
8)	O
were	O
lower	O
in	O
CpcPH	O
compared	O
to	O
postcapillary	O
PH	O
patients	O
as	O
well	O
as	O
controls.	O

Both	O
pH-regulated	O
membrane	O
Ca_2+	O
channels	O
and	O
Ca_2+	O
stores	O
have	O
been	O
implicated	O
in	O
controlling	O
HA	B
(Alasmari	O
et	O
al.	O
2013).	O

Moreover,	O
myoinositol	B
levels	O
were	O
associated	O
with	O
acute	O
physiology	O
scores	O
(APS)	O
(ρ	O
=	O
−0.53,	O
P	O
=	O
0.05,	O
q	O
=	O
0.25)	O
and	O
ventilator-free	O
days	O
(ρ	O
=	O
−0.73,	O
P	O
=	O
0.005,	O
q	O
=	O
0.01).	O

In	O
brief,	O
proteins	O
were	O
removed	O
from	O
samples	O
by	O
precipitation	O
using	O
three	O
volumes	O
of	O
acetonitrile.	B

Comparison	O
of	O
the	O
normalized	O
signal	O
intensity	O
of	O
lipids	O
in	O
urine	O
that	O
were	O
identified	O
as	O
biomarker	O
candidates	O
for	O
discriminating	O
(a)	O
meloxicam-treated	O
(M)	O
(n = 6)	O
and	O
saline-treated	O
(C)	O
cats	O
(n = 6);	O
and	O
(b)	O
baseline	O
(BM)	O
and	O
meloxicam	O
group	O
(M)	O
at	O
different	O
times	O
after	O
the	O
administration	O
of	O
saline	B
or	O
meloxicam	O
at	O
0.3 mg/kg	O
every	O
24 h	O
for	O
up	O
to	O
17	O
days	O
(times	O
2	O
to	O
5).	O

Likewise,	O
pyrimidine	B
nucleotides	O
undergo	O
similar	O
degradation	O
reactions	O
(dephosphorylation,	O
deamination,	O
and	O
cleavage	O
of	O
glycosidic	B
bonds)	O
to	O
liberate	O
pyrimidine	B
nucleobases	O
including	O
cytosine,	B
uracil,	B
and	O
thymine.	B

The	O
quantification	O
was	O
performed	O
by	O
multiple	O
reaction	O
monitoring	O
(MRM)	O
at	O
positive	O
mode	O
to	O
detect	O
the	O
specific	O
precursor	O
to	O
product	O
ion	O
transitions	O
m	O
/z	O
116	O
→	O
m	O
/z	O
70	O
for	O
proline,	B
and	O
m	O
/z	O
122	O
→	O
m	O
/z	O
75	O
for	O
IS.	O

In	O
the	O
H	O
group,	O
the	O
abundant	O
metabolites	O
were	O
mainly	O
sugars	O
(maltose,	O
fructose),	O
sugar	O
alcohols,	O
amines	O
(galactosamine)	O
and	O
a	O
large	O
set	O
of	O
organic	O
and	O
fatty	O
acids	O
(glycerol,	O
octadecanoic	B
acid,	I
hexanedioic	B
acid,	I
benezenepropanoic	O
acid,	O
linoleic	B
acid,	I
and	O
oleic	O
acid).	O

For	O
instance,	O
ecdysone,	B
a	O
steroid	O
produced	O
by	O
prothoracic	O
glands,	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
epithelial	O
cell	O
organization	O
of	O
the	O
R.	O
prolixus	O
midgut	O
and	O
the	O
dysregulation	O
of	O
the	O
neuroendocrine	O
system	O
induced	O
by	O
azadirachtin	O
(an	O
insect	O
growth	O
inhibitor	O
that	O
blocks	O
ecdysis).	O

Mitochondrial	O
aconitase	O
catalyzes	O
the	O
stereospecific	O
isomerization	O
of	O
citrate	B
to	O
isocitrate.	B

Significant	O
amounts	O
of	O
fully	O
labeled	O
(M4)	O
erythritol	B
were	O
synthesized	O
by	O
endogenous	O
activity	O
in	O
the	O
blood	O
cells	O
120	O
min	O
after	O
tracer	O
addition	O
(*P	O
=	O
0.01	O
by	O
Welch’s	O
t	O
test).	O

Subsequently,	O
50	O
µL	O
of	O
the	O
internal	O
standard	O
solution	O
(Imatinib-D8	O
solution,	O
5.0	O
µg/mL)	O
and	O
400	O
µL	O
of	O
chilled	O
methanol	B
were	O
added	O
to	O
the	O
respective	O
samples	O
and	O
stirred	O
for	O
20	O
s.	O

Undoubtedly,	O
these	O
data	O
set	O
a	O
record	O
for	O
comprehensive	O
structural	O
analysis	O
of	O
phospholipids	B
and	O
demonstrate	O
that	O
the	O
LC–PB–MS/MS	O
system	O
readily	O
meets	O
the	O
needs	O
in	O
lipidomic	O
analysis	O
in	O
terms	O
of	O
throughput,	O
sensitivity,	O
and	O
lipid	O
coverage,	O
while	O
providing	O
structural	O
analysis	O
at	O
a	O
deeper	O
level.	O

Normally,	O
10 ul	O
of	O
urine	O
are	O
dissolved	O
in	O
1 ml	O
−20 °C	O
cooled	O
acetonitrile,	B
isopropanol	B
and	O
water	O
(3:3:2 v/v)	O
mixture	O
at	O
pH	O
7.	O

However,	O
the	O
_13	O
C	O
satellite	O
pattern	O
for	O
the	O
TOCSY	O
cross-peak	O
of	O
H3	O
to	O
H2	O
of	O
Glu	O
(2.22	O
to	O
4.08	O
ppm	O
in	O
Fig.	O
)	O
shows	O
a	O
significant	O
amount	O
of	O
_13	O
C-2,3-Glu.	B

Intra-day	O
and	O
inter-day	O
precision	O
(%	O
CV)	O
and	O
accuracy	O
(%	O
deviation	O
from	O
expected)	O
of	O
quality	O
control	O
samples	O
of	O
GLY,	O
M1	O
and	O
M2	O
in	O
human	O
plasma	O
or	O
M1	O
and	O
M2	O
in	O
urine	O
CV,	O
coefficient	O
of	O
variation;	O
M1-	B
4-transhydroxy	I
glyburide;	I
M2-	B
3-cishydroxy	I
glyburide	I

The	O
total	O
run	O
time	O
was	O
10	O
min	O
and	O
the	O
mobile	O
phase	O
consisted	O
of	O
0.1%	O
formic	B
acid	I
in	O
water	O
(A)	O
and	O
0.1%	O
formic	B
acid	I
in	O
acetonitrile	B
(B).	O

Observed	O
acetylcholine	B
concentrations	O
in	O
normal	O
patients	O
reach	O
30±10	O
nM,	O
compared	O
to	O
8±4	O
nM	O
in	O
AD	O
patients.	O

Weak	O
negative	O
relationships	O
between	O
age	O
and	O
11-deoxycortisol	B
or	O
testosterone	B
were	O
only	O
apparent	O
with	O
multivariate	O
models	O
adjusting	O
for	O
age	O
and	O
body	O
mass	O
index.	O

The	O
decrease	O
of	O
ELOVL6	O
activity	O
in	O
NASH	O
was	O
consistent	O
with	O
the	O
marked	O
increase	O
in	O
LCFA	O
in	O
NASH	O
culminating	O
with	O
the	O
accumulation	O
of	O
myristic	B
acid	I
(C14:0).	O

Among	O
these,	O
10	O
amino	O
acid	O
were	O
positively	O
correlated	O
with	O
5	O
organic	O
acids,	O
such	O
as	O
L-isoleucine	B
with	O
Gamma-Aminobutyric	B
acid.	I

Testosterone	B
levels	O
were	O
significantly	O
associated	O
with	O
VLDL	O
and	O
serum	O
lipids	O
in	O
PCOS	O
cases	O
with	O
large	O
WC	O
but	O
not	O
in	O
the	O
controls.	O

This	O
is	O
also	O
compatible	O
with	O
the	O
decreased	O
creatinine	B
and	O
creatine	B
excretion	O
found	O
in	O
RCC	O
patients	O
compared	O
to	O
controls,	O
which	O
further	O
suggest	O
an	O
impaired	O
renal	O
function	O
and	O
subsequently	O
clearance	O
of	O
this	O
compounds.	O

LC-MS	O
grade	O
water	O
(H_2	O
O),	O
methanol	B
(MeOH),	O
isopropanol	B
(IPA),	O
and	O
acetonitrile	B
(ACN)	O
were	O
purchased	O
from	O
Honeywell	O
International	O
Inc.	O
(Morristown,	O
NJ,	O
USA).	O

(HbA_1c	O
),	O
total	O
cholesterol,	B
high-density	O
lipoprotein,	O
and	O
triglycerides.	B

The	O
change	O
in	O
the	O
proline	B
level	O
was	O
related	O
to	O
those	O
of	O
tryptophan	B
(r	O
=	O
0.53,	O
P	O
<	O
0.001)	O
and	O
phenylalanine	B
(r	O
=	O
0.55,	O
P	O
<	O
0.001).	O

According	O
to	O
the	O
results	O
from	O
culture-dependent	O
methods,	O
Enterococcus	O
and	O
Lactobacillus	B
were	O
found	O
at	O
the	O
highest	O
levels	O
in	O
HC.	O

,	O
For	O
instance,	O
the	O
sn	O
-purity	O
of	O
the	O
PC	B
16:0/18:1	I
sample	O
is	O
93	O
±	O
2%,	O
meaning	O
that	O
it	O
contains	O
7	O
±	O
2%	O
PC	B
18:1/16:0.	I

Mid/survivor	O
samples	O
were	O
characterized	O
by	O
lower	O
concentrations	O
of	O
isopropanol	B
and	O
pyruvate,	B
and	O
higher	O
concentrations	O
of	O
formate,	B
acetate,	B
propionate	B
and	O
glycolate.	B

The	O
combiplate	O
was	O
centrifuged	O
to	O
elute	O
the	O
methanol	B
extract	O
into	O
the	O
lower	O
receiving	O
deep-well	O
plate,	O
which	O
was	O
then	O
detached	O
from	O
the	O
upper	O
filter	O
plate.	O

L-Carnitine	B
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
USA),	O
and	O
hydrocortisone	B
was	O
purchased	O
from	O
Acros	O
Organics	O
(New	O
Jersey,	O
USA).	O

Anthropometric	O
and	O
clinical	O
parameters,	O
mean	O
(± standard	O
deviation),	O
before	O
(T0)	O
and	O
after	O
(T1)	O
dietary	O
intervention	O
with	O
olive-enriched	O
product	O
(OEP)	O
or	O
control	O
(Ctrl)	O
p	O
value	O
is	O
relative	O
to	O
one-way	O
ANOVA	O
on	O
the	O
difference	O
between	O
T0	O
and	O
T1	O
SYS	O
systolic	O
pressure,	O
DIA	O
diastolic	O
pressure,	O
WM	O
waist	O
measure,	O
HM	O
hips	O
measure,	O
BMI	O
body	O
mass	O
index,	O
TC	O
plasma	O
total	O
cholesterol,	B
HDL	O
plasma	O
high-density	O
lipoproteins,	O
LDL	O
plasma	O
low-density	O
lipoproteins,	O
TG	B
plasma	O
triglycerides,	B
Apo	O
Apolipoproteins	O
in	O
plasma,	O
Glu	O
plasma	O
glucose,	B
Ins	O
plasma	O
insulin,	O
CRP	O
plasma	O
reactive	O
C	O
protein,	O
oxLDL	O
plasma	O
oxidized	O
LDL,	O
F2	O
Isp	O
total	O
24-h	O
urine	O
Isoprostane	B
F2	O

The	O
first	O
one	O
was	O
a	O
combination	O
of	O
direct	O
injection	O
and	O
LC-MS/MS	O
assay	O
(Absolute	O
IDQ	O
p180	O
kit,	O
Biocrates	O
Life	O
Sciences	O
AG,	O
Innsbruck,	O
Austria)	O
for	O
the	O
analysis	O
of	O
amino	O
acids	O
and	O
biogenic	O
amines,	O
acylcarnitines,	B
glycerophospholipids	B
and	O
hexoses.	O

Extraction	O
was	O
done	O
by	O
adding	O
200	O
μl	O
of	O
plasma	O
to	O
1.7	O
ml	O
of	O
pre-chilled	O
(−20°C)	O
extraction	O
mixture:	O
methanol/chloroform/water	O
(2.5:1:0.5	O
(v/v/v))	O
(MCW)	O
and	O
internal	O
standard	O
was	O
spiked	O
(1	O
μmol	O
of	O
D-Sorbitol-_13	B
C_6	O
,	O
98	O
atom	O
%	O
_13	O
C,	O
Campro	O
Scientific,	O
Germany).	O

The	O
precise	O
substrates	O
and	O
pathways	O
that	O
generate	O
the	O
dicarboxylated	B
acylcarnitines	I
and	O
factors	O
that	O
foster	O
their	O
production	O
require	O
further	O
investigation.	O

A	O
number	O
of	O
studies	O
have	O
reported	O
that	O
cancer	O
patients	O
often	O
have	O
higher	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
as	O
indicated	O
by	O
increased	O
levels	O
of	O
5-hydroxymethyl-2-deoxyuridine	B
[,	O
].	O

The	O
mean	O
serum	O
concentration	O
of	O
unconjugated	O
estradiol	B
for	O
the	O
six	O
quality	O
control	O
samples	O
was	O
15.8	O
pmol/	O

Attenuation	O
of	O
GNMT	O
(,	O
)	O
in	O
DU145	O
prostate	O
cancer	O
cells	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
cell	O
invasion	O
(t-test	O
P	O
=	O
0.0073,	O
n=3)	O
with	O
a	O
concomitant	O
3-fold	O
decrease	O
in	O
the	O
intracellular	O
sarcosine	B
levels	O
compared	O
to	O
control	O
non-target	O
siRNA-transfected	O
cells.	O

Our	O
metabolomic	O
data	O
suggest	O
that	O
tyramine	B
might	O
be	O
concentrated	O
in	O
the	O
urine	O
of	O
IC	O
patients.	O

More	O
than	O
90%	O
of	O
the	O
patients	O
with	O
intermediate-risk	B
cytogenetics	O
had	O
a	O
normal	O
diploid	O
karyotype.	O

The	O
positive	O
association	O
between	O
these	O
two	O
metabolites	O
is	O
not	O
surprising	O
since	O
they	O
are	O
two	O
alternative	O
end-products	O
from	O
the	O
glycolytic	B
pathway.	O

Increased	O
levels	O
of	O
plasma	O
TMAO	B
have	O
been	O
shown	O
to	O
predict	O
future	O
major	O
adverse	O
cardiac	O
events	O
including	O
myocardial	O
infarction,	O
stroke,	O
and	O
death	O
in	O
different	O
CV	O
pathologies	O
and	O
a	O
role	O
for	O
gut	O
derived	O
metabolites	O
in	O
thrombosis	O
has	O
been	O
described	O
in	O
vivo	O
,	O
showing	O
that	O
intestinal	O
microbes	O
can	O
directly	O
modulate	O
platelet	O
hyperresponsiveness	O
and	O
clot	O
formation	O
rate	O
via	O
TMAO	B
generation.	O

The	O
overnight	O
fast	O
would	O
deplete	O
glycogen	B
stores	O
and	O
switch	O
the	O
body’s	O
main	O
fuel	O
source	O
to	O
fatty	O
acids	O
thus	O
raising	O
acylcarnitine	B
levels.	O

Altogether	O
these	O
interventions	O
attenuated	O
the	O
rate	O
of	O
ATP	B
consumption	O
and	O
enhanced	O
its	O
synthesis	O
during	O
the	O
secondary	O
energy	O
failure	O
phase	O
(5,	O
6,	O
7).	O

1 μL	O
of	O
extract	O
containing	O
choline	B
metabolites	O
was	O
injected	O
into	O
an	O
analytical	O
column,	O
BEH	O
Amide	B
(Waters,	O
USA,	O
2.1 × 100 mm,	O
1.7 μm).	O

In	O
addition,	O
absolute	O
concentrations	O
of	O
unconjugated	O
estradiol	B
were	O
highest	O
for	O
direct	O
assays,	O
lowest	O
for	O
mass	O
spectrometry	O
assays,	O
and	O
intermediate	O
for	O
indirect	O
assays,	O
suggesting	O
possible	O
cross-reactivity	O
between	O
steroids	O
in	O
the	O
direct	O
assays.	O

Urine	O
(0.1 mL)	O
was	O
added	O
with	O
0.1 mL	O
internal	O
standard	O
solution	O
(paracetamol-3-β-d-glucuronide,	O
1.5 μg/mL	O
in	O
water)	O
and	O
0.8 mL	O
water/methanol	O
(95:5,	O
v	O
/v	O
)	O
containing	O
2 %	O
acetic	B
acid,	I
mixed	O
for	O
1 min	O
(800 rpm)	O
and	O
centrifuged	O
for	O
12 min	O
at	O
4,500 rpm.	O

When	O
methanol-ethanol	B
was	O
used,	O
an	O
additional	O
453	O
(526–73)	O
features	O
were	O
found	O
compared	O
to	O
positive	O
mode.	O

In	O
the	O
present	O
study,	O
HR-MAS	O
measurements	O
also	O
showed	O
elevated	O
GSH	B
levels	O
in	O
tumor	O
and	O
LN-Met	O
tissues	O
compared	O
to	O
NAT.	O

Model	O
4:	O
smoking,	O
dyslipidemia,	O
HDL-C.	O
TMAO	B
levels	O
are	O
associated	O
to	O
CV-mortality	O
in	O
PAD.	O

Pathways	O
with	O
FDR	O
<	O
0.3	O
are	O
listed	O
below	O
Multivariate	O
regression	O
analysis	O
of	O
post-treatment	O
levels	O
resulted	O
in	O
two	O
metabolites	O
with	O
a	O
significant	O
inverse	O
relationship	O
to	O
glucose	B
post	O
simvastatin	B
treatment:	O
a	O
uridine-like	O
compound	O
(negative	O
correlation)	O
and	O
galactosyl-glycerate	B
(negative	O
correlation)	O

The	O
significant	O
increase	O
in	O
the	O
serum	O
concentration	O
of	O
phenylalanine	B
is	O
in	O
agreement	O
with	O
the	O
down-regulation	O
of	O
gene	O
modules	O
involved	O
in	O
phenylalanine	B
metabolism	O
observed	O
in	O
tissue	O
samples	O
from	O
NSCLC	O
patients,	O
and	O
could	O
reflect	O
a	O
limited	O
ability	O
of	O
lung	O
cancer	O
cells	O
to	O
process	O
this	O
amino	O
acid	O
at	O
advanced	O
stages	O
of	O
the	O
disease.	O

Using	O
_1	O
H	O
MRS	O
it	O
is	O
possible	O
to	O
detect	O
the	O
total	O
level	O
of	O
choline	B
containing	O
compounds,	O
but	O
it	O
is	O
not	O
possible	O
to	O
distinguish	O
between	O
the	O
various	O
phospholipid	B
compounds	O
like	O
PCho,	O
GPC,	B
etc.	O

Epidemiologic	O
evidence	O
also	O
supports	O
a	O
role	O
for	O
oxidative	O
metabolites,	O
particularly	O
for	O
catechol	B
estrogens	O
such	O
as	O
4-OH-E_2	B
,	O
in	O
initiation	O
of	O
breast	O
cancer.	O

A	O
total	O
of	O
61%	O
of	O
the	O
compounds	O
were	O
identified	O
in	O
all	O
three	O
body	O
fluids,	O
such	O
as	O
3-(3-hydroxyphenyl)-3-hydroxypropanoic	B
acid,	I
3-hydroxyphenylacetic	B
acid,	I
4-hydroxybenzoic	B
acid,	I
butyric	B
acid,	I
hippuric	B
acid,	I
phenylacetic	B
acid,	I
etc.	O

Six	O
of	O
these	O
study	O
participants	O
were	O
then	O
given	O
metronidazole	B
(500	O
mg	O
twice	O
daily)	O
plus	O
ciprofloxacin	B
(500	O
mg	O
once	O
daily)	O
for	O
1	O
week.	O

Another	O
900 μl	O
of	O
analytical	O
pure	O
methanol	B
was	O
added	O
again,	O
and	O
the	O
mixture	O
was	O
centrifuged	O
at	O
16172 × g	O
for	O
20 min	O
at	O
4 °C	O
for	O
outright	O
protein	O
removal.	O

Each	O
aliquot	O
was	O
supplemented	O
with	O
a	O
1	O
M	O
[U_13	B
C]glucose,	I
[6-_13	B
C_1	I
]glucose,	I
[1,2-_13	B
C_2	I
]glucose,	I
or	O
[3,4-_13	B
C_2	I
]glucose	I
(CLM-1396-1,	O
CLM-2717-PK,	O
CLM-504,	O
or	O
CLM-6750-MPT-PK;	O
Cambridge	O
Isotopes)	O
solution	O
to	O
a	O
final	O
total	O
glucose	B
(labeled	O
+	O
unlabeled)	O
concentration	O
of	O
15	O
mM.	O
The	O
volume	O
of	O
the	O
1	O
M	O
tracer	O
solution	O
added	O
to	O
the	O
blood	O
depended	O
on	O
the	O
blood	O
glucose	B
concentration	O
measured	O
before	O
and	O
was	O
adjusted	O
to	O
reach	O
a	O
final	O
concentration	O
of	O
15	O
mM	O
glucose	B
in	O
all	O
samples.	O

Only	O
trace	O
amounts	O
of	O
Cer(18:0/24:1),	B
cholesterol,	B
and	O
TG(17:2/17:2/18:0)	B
were	O
found	O
in	O
methanol-ethanol	B
samples	O
and	O
these	O
compounds	O
were	O
not	O
detected	O
when	O
only	O
methanol	B
was	O
used.	O

m_2	O
,	O
mirroring	O
the	O
positive	O
correlation	O
of	O
eGFR	O
with	O
24,25(OH)_2	B
D	O
in	O
the	O
setting	O
of	O
impaired	O
GFR	O
and	O
suggesting	O
that	O
impaired	O
25(OH)D	O
catabolism	O
may	O
be	O
an	O
early	O
sign	O
of	O
disturbed	O
renal	O
mineral	O
metabolism	O
in	O
type	O
1	O
diabetes.	O

Similarly,	O
the	O
phosphatidylinositol	B
signaling	O
system	O
was	O
upregulated	O
in	O
obesity	O
irrespective	O
of	O
insulin	O
resistance.	O

Na_2	O
HPO_4	O
,	O
1 mM	O
CaCl_2	O
,	O
1 mM	O
MgCl_2	O
and	O
25 mM	O
Hepes,	O
(pH 7.4)	O
and	O
then	O
incubated	O
with	O
either	O
2,	B
7-dichlorofluorescein	I
diacetate,	I
MitoTracker	O
Green	O
FM	O
or	O
Rhodamine	B
123	O
in	O
buffer	O
for	O
30 min	O
at	O
37°C.	O

Omega-3	B
PhL	O
Index	O
was	O
similar	O
in	O
all	O
subgroups	O
at	O
the	O
baseline,	O
while	O
at	O
week	O
24	O
it	O
was	O
not	O
affected	O
by	O
either	O
Placebo	O
or	O
Pio,	O
but	O
increased	O
to	O
a	O
similar	O
extent	O
(1.6–1.7-fold;	O
p	O
 < 0.0001	O
and	O
p	O
 = 0.0001,	O
respectively)	O
in	O
response	O
to	O
both	O
Omega-3	B
and	O
Pio&	O
Omega-3	B
(Table ).	O

In	O
2008,	O
amodiaquine,	O
SP	B
and	O
quinine	O
were	O
widely	O
available	O
in	O
the	O
private	O
sector	O
in	O
the	O
study	O
area.	O

In	O
addition	O
to	O
their	O
correlation,	O
it	O
is	O
remarkable	O
that	O
medium-chain	O
acylcarnitines	O
and	O
suberic	B
acid	I
both	O
display	O
the	O
same	O
inverse	O
association	O
with	O
tryptophan.	B

Inactive	O
CD	O
was	O
associated	O
with	O
elevated	O
citrulline	B
as	O
compared	O
to	O
controls	O
and	O
SDMA	O
as	O
compared	O
to	O
IBS	O
patients	O
as	O
well	O
as	O
with	O
DMA	B
concentrations	O
lower	O
than	O
in	O
active	O
CD,	O
UC,	O
and	O
IBS	O
and	O
higher	O
than	O
in	O
controls.	O

The	O
nomenclature	O
of	O
phospholipids	B
is	O
consistent	O
with	O
LIPID	O
MAPS	O
(http://www.lipidmaps.org/).	O

Briefly,	O
the	O
cell	O
pellet	O
was	O
extracted	O
with	O
a	O
1/1/1	O
v/v/v	O
of	O
ice-cold	O
methanol,	B
chloroform,	B
and	O
water.	O

To	O
be	O
noted,	O
some	O
compounds	O
such	O
as	O
3-hydroxybutyric	B
acid,	I
3-indolepropionic	B
acid,	I
4-hydroxyphenylpyruvic	B
acid,	I
5-hydroxy-L	B
-tryptophan,	I
etc.,	O
could	O
not	O
be	O
detected	O
at	O
lower	O
concentrations	O
due	O
to	O
the	O
detection	O
limit,	O
and	O
some	O
compounds	O
such	O
as	O
hydrocinnamic	B
acid,	I
L	B
-phenylalanine,	I
L	B
-glutamic	I
acid,	I
L	O
-cysteine,	O
etc.,	O
had	O
quadratic	O
regression	O
at	O
higher	O
concentrations.	O

Therefore,	O
the	O
value	O
of	O
sarcosine	B
as	O
a	O
prognostic	O
marker	O
for	O
PCa	O
progression	O
is	O
controversial.	O

We	O
utilized	O
dansylation	O
LC-MS	O
to	O
enable	O
relative	O
quantification	O
of	O
the	O
amine-	B
and	O
phenol-containing	O
submetabolome	O
with	O
high	O
coverage.	O

Logistic	O
regression	O
analysis	O
adjusted	O
to	O
other	O
factors	O
revealed	O
that	O
MTX	O
dose	O
and	O
duration	B
of	O
maintenance	O
showed	O
significant	O
odds	O
ratio	O
(OR)	O
of	O
1.176	O
(95%	O
CI,	O
1.022–1.354)	O
and	O
0.893	O
(0.812–0.982)	O
for	O
low	O
WBC,	O
and	O
OR	O
of	O
1.226	O
(1.032–1.457)	O
and	O
0.826	O
(0.708–0.964)	O
for	O
low	O
ANC.	O

The	O
elution	O
procedure	O
for	O
the	O
column	O
was	O
1–20%	O
B	O
over	O
0–1	O
min,	O
20–70%	O
B	O
over	O
1–3	O
min,	O
70–85%	O
B	O
over	O
3–8	O
min,	O
85–100%	O
B	O
over	O
8–9	O
min,	O
and	O
the	O
composition	O
was	O
held	O
at	O
100%	O
B	O
for	O
1	O
min,	O
where	O
A	O
=	O
water	O
with	O
0.1%	O
formic	B
acid	I
and	O
B	O
=	O
acetonitrile	B
with	O
0.1%	O
formic	B
acid	I
for	O
positive	O
mode	O
(ES+),	O
while	O
A	O
=	O
water	O
and	O
B	O
=	O
acetonitrile	B
for	O
negative	O
ion	O
mode	O
(ES−).	O

The	O
standardized	O
Luminex	O
multiplex	O
assay	O
technique	O
for	O
amyloid	O
beta	O
1-42	O
(Ab42),	O
total	O
tau	O
(t-tau)	O
and	O
tau	O
phosphorylated	O
at	O
the	O
threonine	B
181	O
position	O
(p-tau)	O
are	O
described	O
elsewhere.	O

Finally,	O
in	O
a	O
cohort	O
study,	O
allantoin	B
measured	O
in	O
urine	O
of	O
humans	O
was	O
also	O
inversely	O
associated	O
with	O
the	O
risk	O
of	O
T2D.	O
Purine	B
Catabolism	O
Pathway.	O

The	O
quantification	O
of	O
LEV	O
using	O
mass	O
spectrometry	O
however,	O
may	O
be	O
affected	O
by	O
the	O
fact	O
that	O
both	O
LEV	O
and	O
its	O
carboxylic	B
metabolite	O
share	O
the	O
same	O
product	O
ion	O
of	O
the	O
highest	O
abundance	O
(Q1/Q3	O
transitions	O
of	O
171.1>126.1	O
for	O
LEV	O
and	O
172.5>126.1	O
for	O
UCB	O
L057).	O

LC-MS	O
grade	O
water	O
(Sigma,	O
St	O
Louis,	O
MO,	O
USA)	O
and	O
LC-MS	O
grade	O
methanol	B
(Fisher	O
Scientific,	O
Pittsburgh,	O
PA,	O
USA)	O
were	O
utilized.	O

The	O
metabolites	O
that	O
significantly	O
differ	O
between	O
both	O
groups	O
might	O
point	O
to	O
disturbances	O
in	O
biochemical	O
pathways	O
including	O
(1)	O
choline	B
deficiency,	O
(2)	O
increased	O
gluconeogenesis,	O
and	O
(3)	O
glomerular	O
hyperfiltration.	O

Serum	O
creatinine	B
was	O
measured	O
using	O
an	O
enzymatic	O
assay	O
(Dimension	O
VISTA,	O
Siemens	O
Healthcare	O
Diagnostics,	O
Eschborn,	O
Germany)	O
and	O
subsequently	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
(eGFR)	O
was	O
calculated	O
using	O
the	O
CKD-EPI	O
equation.	O

Propionate	B
(short-chain	O
fatty	O
acid)	O
is	O
primarily	O
derived	O
from	O
the	O
catabolism	O
of	O
lipids	O
(fatty	O
acid	O
metabolism)	O
or	O
proteins,	O
where	O
its	O
accumulation	O
is	O
toxic	O
and	O
inhibits	O
TCA	O
cycle	O
enzymes	O
and	O
cell	O
growth.	O

Go	O
to:	O
Tamoxifen	B
is	O
the	O
most	O
widely	O
used	O
adjuvant	O
endocrine	O
therapy	O
for	O
breast	O
cancer.	O

Furthermore,	O
phenylacetate	B
was	O
more	O
often	O
detected	O
in	O
the	O
diabetes	O
group	O
in	O
this	O
study.	O

The	O
flow	O
rates	O
used	O
were	O
40	O
mL	O
min_−1	O
for	O
VOC,	O
30	O
mL	O
min_−1	O
for	O
1,3-butadiene	B
and	O
3	O
Lmin_−1	O
for	O
PAH.	O

Cleavage	O
of	O
sphingomyelin,	B
by	O
neutral	O
sphingomyelinases,	O
results	O
in	O
the	O
formation	O
of	O
both	O
choline	B
phosphate	I
and	O
ceramide	B
.	O

Given	O
sample	O
size,	O
storage	O
duration	B
and	O
confounding	O
through	O
postnatal	O
exposures,	O
further	O
studies	O
are	O
required.	O

With	O
the	O
screening	O
for	O
metabolites	O
in	O
precursor	O
ion	O
mode,	O
precursors	O
indicative	O
for	O
metabolites	O
co	O
eluting	O
with	O
abiraterone	B
were	O
not	O
found.	O

The	O
mass	O
spectra	O
and	O
the	O
possible	O
fragment	O
structures	O
were	O
then	O
performed	O
to	O
confirm	O
the	O
chemical	O
structures	O
of	O
the	O
LysoPG(20:5),	B
which	O
were	O
shown	O
in	O
and	O
Based	O
on	O
the	O
Youden	O
index	O
J	O
=	O
max	O
(sensitivity	O
+specificity-1),	O
a	O
cut-off	O
value	O
of	O
LysoPG	O
(20:5)	O
was	O
selected.	O

Metabolites	O
such	O
as	O
valine,	B
sarcosine,	B
hexanedioic	B
acid,	I
and	O
cholesterol	B
could	O
be	O
possibly	O
potential	O
biomarkers	O
and	O
need	O
to	O
be	O
validated.	O

However,	O
when	O
the	O
reaction	O
of	O
NO_2	O
-PhIP	O
with	O
SA	O
was	O
performed	O
with	O
10-fold	O
less	O
carcinogen	O
(0.3	O
mol	O
NO_2	O
-PhIP:	O
1	O
mol	O
SA),	O
targeted	O
UPLC-ESI/MS_2	O
analysis	O
revealed	O
that	O
the	O
desamino-PhIP	B
adducts	O
were	O
hardly	O
formed	O
at	O
Lys_195	O
,	O
Lys_199	O
,	O
Lys_541	O
,	O
Cys_34	O
,	O
Tyr_138	O
,	O
and	O
Tyr_401	O
,	O
and	O
desamino-PhIP	B
adduct	O
formation	O
at	O
Tyr_411	O
accounted	O
for	O
about	O
99%	O
of	O
the	O
total	O
ion	O
counts	O
of	O
SA	O
adducts.	O

Due	O
to	O
the	O
higher	O
abundance	O
of	O
iron	O
transport-related	O
bacterial	O
genes	O
in	O
the	O
peripheral	O
and	O
portal	O
blood,	O
iron	O
supplementation	O
could	O
allow	O
Proteobacteriaceae	O
members,	O
which	O
usually	O
harbour	O
genotoxins,	B
to	O
flourish.	O

Statistical	O
analysis	O
of	O
_1	O
H	O
NMR	O
spectral	O
data	O
revealed	O
that	O
signals	O
corresponding	O
to	O
venous	O
lactate	B
and	O
total	O
cholesterol	B
were	O
strongly	O
associated	O
with	O
patients’	O
death	O
within	O
30	O
days	O
following	O
admission.	O

Five	O
biogenic	O
amines	O
(creatinine,	O
taurine,	B
t4-OH-Pro,	B
SDMA	O
and	O
ADMA)	O
and	O
two	O
acylcarnitines	B
(AC	O
(0:0)	O
and	O
AC	B
(2:0))	I
were	O
quantified	O
in	O
all	O
samples	O
respectively.	O

After	O
48h	O
of	O
culture,	O
stearic	B
acid	I
promoted	O
an	O
increase	O
in	O
IFNγ	O
secretion	O
in	O
both	O
resting	O
and	O
PHA-stimulated	O
cells.	O

Several	O
biochemical	O
markers	O
were	O
measured	O
in	O
serum	O
or	O
plasma,	O
depending	O
on	O
the	O
instructions	O
and	O
have	O
been	O
reported	O
elsewhere,	O
including	O
tumour	O
necrosis	O
factor	O
α	O
(TNF-α),	O
ferritin,	O
interleukin-6	O
(IL-6),	O
insulin,	O
leptin,	O
resistin,	O
hsC-reactive	O
protein	O
(hsCRP),	O
glucose,	B
adiponectin,	O
TG,	B
non-esterified	O
fatty	O
acids	O
(NEFA)	O
and	O
total,	O
LDL	O
and	O
HDL	B
cholesterol.	I

The	O
Biocrates	O
metabolomics	O
dataset	O
contains	O
163	O
targeted	O
metabolites:	O
41	O
acylcarnitines	B

The	O
population	O
consisted	O
of	O
individuals	O
with	O
normal	O
fasting	O
glucose	B
(NFG),	O
impaired	O
fasting	O
glucose	B
(IFG),	O
or	O
type	O
2	O
diabetes	O
(T2DM).	O

The	O
role	O
of	O
choline	B
kinase	O
α	O
(Chk-α)	O
in	O
malignant	O
transformation	O
and	O
progression	O
in	O
several	O
cancers	O
has	O
been	O
well	O
described	O
in	O
the	O
literature.	O

Furthermore,	O
most	O
d18:2	B
Hex2Cers	O
did	O
not	O
retain	O
association	O
with	O
HOMA-IR	O
after	O
elastic	O
net	O
regularization,	O
suggesting	O
that	O
d18:2	B
ceramides	I
and	O
d18:2	B
SMs	O
are	O
better	O
predictors	O
of	O
the	O
relationship	O
between	O
d18:2	B
SPs	O
and	O
HOMA-IR.	O

These	O
data	O
suggested	O
that	O
2	O
is	O
a	O
bicyclic	B
sesterterpenoid	I
bearing	O
a	O
CHO	O
attached	O
to	O
a	O
tertiary	O
carbon.	O

Excess	O
activity	O
of	O
all	O
these	O
enzymes	O
in	O
concert	O
might	O
explain	O
why	O
androstanediol	B
accumulates	O
with	O
PCOS.	O

Increased	O
histidine	B
level	O
leads	O
to	O
increase	O
of	O
histamine	B
level	O
in	O
blood,	O
brain	O
and	O
possibly	O
bladder,	O
suggesting	O
the	O
possibility	O
that	O
histidine	B
may	O
have	O
many	O
other	O
possible	O
functions	O
affecting	O
human	O
bladder	O
sensory	O
system.	O

At	O
baseline,	O
the	O
overweight	O
group	O
showed	O
higher	O
BMI,	O
waist	O
circumference,	O
triglycerides,	B
FFA,	O
glucose,	B
insulin,	O
HOMA-IR,	O
and	O
hs-CRP,	O
and	O
lower	O
HDL-cholesterol	B
than	O
controls.	O

PCA	O
scores	O
plots	O
of	O
1H	O
NMR	O
data	O
from	O
controls	O
(black	O
)	O
and	O
UTI	O
patients	O
(red	O
)	O
urine	O
samples	O
at	O
baseline	O
after	O
removal	O
of	O
the	O
regions	O
corresponding	O
to	O
paracetamol	B
and	O
its	O
metabolites.	O

The	O
most	O
relevant	O
metabolites	O
that	O
differentiate	O
the	O
two	O
groups	O
of	O
patients	O
were	O
spermidine	B
and	O
tryptophan.	B

As	O
in	O
the	O
primary	O
cells,	O
lactate	B
levels	O
decreased	O
and	O
glucose	B
levels	O
increased	O
after	O
ALDH7A1-depletion	O
in	O
both	O
cell	O
lines.	O

Anhydrous	B
sodium	I
sulfate	I
(POCh,	O
Gliwice,	O
Poland)	O
was	O
the	O
drying	O
agent.	O

We	O
have	O
developed	O
a	O
label	O
free	O
untargeted	O
LC-MS-based	O
lipidomic	O
workflow	O
that	O
combines	O
the	O
following	O
characteristics:	O
(i)	O
untargeted	O
MS	O
data	O
acquisition	O
to	O
enable	O
its	O
use	O
in	O
biomarker	O
discovery,	O
(ii)	O
optimized	O
extraction	O
recovery	O
across	O
multiple	O
classes	O
of	O
polar	O
and	O
non-polar	O
lipids	O
(for	O
e.g.	O
glycerophospholipids	B
vs.	I
glycerolipids),	B
(iii)	O
chromatographic	O
resolution	O
within	O
lipid	O
isomers	O
characterized	O
by	O
fatty	O
acyl	O
side	O
chains	O
of	O
different	O
chain	O
length	O
(for	O
e.g.	O
PC(18:2_20:4)	B
and	O
PC(16:0_22:6)),	B
or	O
position	O
of	O
double	O
bonds	O
(for	O
e.g.	O
PC(18:0_20:4n-3	B
)	I
and	O
PC(18:0_20:4n-6	B
)),	I
(iv)	O
data	O
processing	O
method	O
that	O
incorporated	O
scripts	O
to	O
optimize	O
MS	O
data	O
alignment,	O
filtering	O
and	O
correction,	O
and	O
(v)	O
lipid	O
identification,	O
including	O
acyl	O
side	O
chains,	O
through	O
MS/MS.	O

Conjugated	O
bile	O
acid	O
includes	O
taurocholic	B
acid,	I
taurochenodeoxycholic	B
acid,	I
glycocholic	B
acid,	I
and	O
glycodeoxycholic	B
acid.	I

D-amino	O
acids	O
of	O
primary	O
amines	O
eluted	O
earlier	O
than	O
their	O
enantiomers,	O
whereas	O
L-amino	O
acids	O
of	O
a	O
secondary	O
amine,	O
such	O
as	O
proline,	B
eluted	O
earlier	O
than	O
its	O
enantiomers.	O

Taurine,	B
scyllo-	O
and	O
myo-inositol	B
were	O
altered	O
in	O
most	O
of	O
the	O
previous	O
metabolomic	O
studies	O
of	O
thyroid	O
carcinoma,	O
which	O
is	O
in	O
accordance	O
with	O
these	O
results	O
(,	O
-).	O

Unlike	O
for	O
the	O
two	O
standard	O
treatment	O
groups,	O
significant	O
metabolites	O
(glucose,	O
N	B
-acetylglycoproteins,	I
lipids,	O
lipoproteins	O
(LDL	O
and	O
VLDL))	O
were	O
identified	O
in	O
the	O
experimental	O
arm,	O
in	O
which	O
the	O
lipids	O
have	O
only	O
a	O
high	O
discriminatory	O
power,	O
after	O
2	O
weeks	O
of	O
therapy.	O

In	O
addition,	O
histidine,	B
an	O
essential	O
amino	O
acid	O
and	O
a	O
precursor	O
for	O
the	O
pro-inflammatory	O
histamine,	B
was	O
also	O
found	O
to	O
be	O
markedly	O
elevated	O
in	O
our	O
patients	O
with	O
recurrent	O
disease.	O

Total	O
monohexocylceramide	B
levels	O
as	O
well	O
as	O
levels	O
of	O
all	O
the	O
monohexocylceramide	B
species	O
were	O
significantly	O
higher	O
in	O
cancer	O
tissue	O
than	O
that	O
in	O
peri-tumor	O
or	O
in	O
normal	O
breast	O
tissue	O
(Figure	O
).	O

The	O
new	O
combined	O
method	O
was	O
further	O
validated	O
by	O
comparing	O
the	O
results	O
to	O
those	O
obtained	O
by	O
the	O
traditional	O
separate	O
methods	O
for	O
analysis	O
of	O
total	O
cotinine	B
and	O
total	O
NNAL	O
in	O
urine	O
samples	O
from	O
85	O
smokers.	O

ADMA,	B
asymmetric	B
dimethylarginine;	I
Cit,	O
citrulline;	B
OH-Kyn,	O
hydroxykynurenine;	B
Pro,	O
proline;	B
Trp,	O
tryptophan.	B

This	O
study	O
also	O
identified	O
increased	O
levels	O
of	O
an	O
acylcarnitine,	B
dehydroxycarnitine,	B
in	O
DR	O
patients	O
compared	O
with	O
diabetic	O
controls,	O
and	O
increased	O
plasma	O
carnitine	B
in	O
patients	O
with	O
PDR	O
compared	O
with	O
NPDR.	O

Plasma	O
samples	O
were	O
routinely	O
analysed	O
at	O
the	O
National	O
Institute	O
of	O
Health	O
using	O
a	O
standard	O
clinical	O
chemistry	O
analyzer	O
for	O
a	O
panel	O
consisting	O
of	O
32	O
standard	O
tests	O
including,	O
among	O
others,	O
total	O
cholesterol	B
and	O
total	O
triacylglycerol	B
levels.	O

Lactate	B
levels	O
were	O
disregarded	O
because	O
of	O
the	O
chance	O
of	O
glycolysis	O
occurring	O
in	O
serum	O
samples	O
during	O
the	O
experiment.	O

The	O
combination	O
of	O
these	O
approaches	O
enabled	O
the	O
detection	O
of	O
1450	O
metabolites	O
in	O
total,	O
of	O
which	O
95	O
were	O
significantly	O
altered	O
in	O
BCP,	O
including	O
amino	O
acids	O
(7),	O
organic	O
acids	O
(3),	O
sugar	O
alcohols	O
(1),	O
fatty	O
acyls	O
(15),	O
fatty	O
acylcarnitines	B
(10),	O
glycerophospholipids	B
(24)	O
and	O
glycerolipids	B
(35).	O

5	O
µm	O
section	O
was	O
cut	O
from	O
paraffin-embedded	O
tissues	O
and	O
placed	O
on	O
histology	O
slide,	O
and	O
stained	O
with	O
hematoxylin	B
and	O
eosin	B
(H&E)	O
using	O
a	O
standard	O
protocol	O
and	O
evaluated	O
by	O
a	O
pathologist.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
develop	O
and	O
validate	O
an	O
accurate,	O
rapid,	O
and	O
a	O
highly	O
sensitive	O
method	O
for	O
the	O
simultaneous	O
quantification	O
of	O
the	O
phophorylated	O
metabolites	O
of	O
NRTIs	O
such	O
as	O
abacavir	O
(ABC),	O
emtricitabine	O
[(−)-FTC],	O
tenofovir	O
disoproxil	O
fumarate	B
(TDF),	O
amdoxovir	B
(DAPD),	O
and	O
zidovudine	B
(ZDV)	O
as	O
well	O
as	O
the	O
natural	O
endogenous	O
2′-deoxyribonucleosides-5′-triphosphates	O
(dNTP).	O

2-hydroxyglutarate	B
was	O
present	O
in	O
sample	O
2,	O
as	O
displayed	O
in	O
the	O
lower	O
spectra;	O
the	O
oncometabolite	O
was	O
absent	O
in	O
sample	O
4,	O
as	O
displayed	O
in	O
the	O
upper	O
spectra.	O
_1	O
H-_1	O
H	O
COSY	O
experiments	O
could	O
further	O
identify	O
the	O
oncometabolite	O
2-hydroxyglutarate	B
even	O
when	O
other	O
metabolites	O
were	O
also	O
present,	O
as	O
is	O
shown	O
in	O
.	O

Experimentally,	O
induction	O
of	O
zinc	O
deficiency-related	O
encephalopathy	O
is	O
possible	O
with	O
oral	O
ingestion	O
of	O
histidine	B
(increasing	O
renal	O
excretion	O
of	O
zinc).	O

c	O
Saline	B
was	O
the	O
vehicle	O
for	O
isoniazid.	O

THC	O
did	O
not	O
correlate	O
with	O
other	O
cardiometabolic	O
parameters	O
and	O
carnosine	B
measurements	O
(all	O
p > 0.2).	O

Distribution	O
of	O
levels	O
of	O
oxysterols	B
in	O
patients	O
before	O
and	O
after	O
tumor	O
removal	O
with	O
all	O
outliers	O
removed	O
A,	O
25-hydroxycholesterol;	B
B,	O
27-hydroxycholesterol;	B
C,	O
7α	B
-hydroxycholesterol;	I
D,	O
7-ketocholesterol.	B

All	O
were	O
unchanged	O
after	O
the	O
placebo	O
infusion,	O
and	O
there	O
was	O
no	O
effect	O
of	O
rHDL	O
on	O
total	O
DAG	O
or	O
Cer.	B

As	O
it	O
was	O
demonstrated	O
that	O
metformin,	B
the	O
first-line	O
medication	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes,	O
could	O
inhibit	O
TDO2,	O
a	O
key	O
enzyme	O
in	O
tryptophan	B
metabolism,	O
we	O
assessed	O
the	O
potential	O
impact	O
of	O
diabetes	O
therapy	O
(except	O
insulin,	O
as	O
patients	O
on	O
insulin	O
therapy	O
were	O
excluded)	O
on	O
KPm	O
concentrations.	O

However,	O
we	O
found	O
some	O
classes	O
of	O
biochemicals	O
(including	O
several	O
purine	B
compounds)	O
that	O
were	O
predictive	O
of	O
worsening	O
parkinsonism.	O

(EAR:	O
2.0	O
μg;	O
RDA:	O
2.4	O
μg),	O
and	O
folate	B
(EAR:	O
320	O
μg;	O
RDA:	O
400	O
μg)	O
intake,	O
expressed	O
as	O
dietary	O
folate	B
equivalents.	O

Limited	O
electron	O
transport	O
through	O
the	O
ETC	O
consequently	O
decreases	O
ATP	B
production	O
and	O
leads	O
to	O
secondary	O
mitochondrial	O
respiratory	O
chain	O
dysfunction.	O

	O
Measurements	O
of	O
vitamin	B
D	I
metabolites	O
were	O
performed	O
on	O
an	O
Agilent	O
Technologies	O
(Palo	O
Alto,	O
CA,	O
USA)	O
1100	O
series	O
LC	O
coupled	O
to	O
an	O
SL	B
series	O
mass	O
spectrometric	O
detector.	O

The	O
relative	O
_13	O
C	O
abundance	O
of	O
C-2,3-succinate	B
for	O
tumor	O
tissues	O
(3.6	O
±	O
1.2)	O
was	O
significantly	O
greater	O
than	O
that	O
for	O
non-cancerous	O
tissues	O
(0.6	O
±	O
0.7)	O
with	O
a	O
p	O
value	O
of	O
<	O
0.01.	O

Moreover,	O
zeta	O
potentials	O
of	O
+	O
17	O
mV	O
(AuChi)	O
and	O
-19	O
mV	O
(AuCeO_2	O
),	O
as	O
well	O
as	O
hydrodynamic	B
sizes	O
of	O
205	O
nm	O
(AuChi)	O
and	O
133	O
nm	O
(AuCeO_2	O
),	O
that	O
are	O
optimal	O
values	O
for	O
biomedical	O
applications,	O
were	O
determined	O
by	O
DLS	O
(,	O
Fig	O
B	O
and	O
C,	O
respectively).	O

Non-esterified	O
oxysterols	B
are	O
present	O
in	O
CSF	O
at	O
pg/mL	O
levels,	O
and	O
in	O
control	O
subjects	O
25-HC	O
is	O
at	O
our	O
limit	O
of	O
quantification	O
(0.03 ng/mL)	O
and	O
was	O
not	O
found	O
to	O
change	O
in	O
any	O
of	O
the	O
patient	O
groups	O
except	O
those	O
with	O
SA/UA	O
where	O
the	O
level	O
increased	O
to	O
0.06 ±	O

T.	O
harzianum	O
strain	O
ES39	O
was	O
grown	O
on	O
2%	O
malt	O
extract	O
agar	O
plates	O
(Biokarr	O
Diagnostics,	O
Beauvais,	O
France)	O
or	O
on	O
dichloran	B
agar	O
plates	O
with	O
18%	O
glycerol	B
(DG-18	O
agar;	O

Renal	O
function	O
usually	O
improves	O
as	O
patients	O
enter	O
into	O
remission	O
and	O
may	O
deteriorate	O
at	O
relapse	O
with	O
associated	O
changes	O
in	O
beta2	O
microglobulin	O
and	O
creatinine	B
levels.	O

and	O
(D)	O
3-methyl-2-oxobutyrate	B
and	O
acylcarnitines,	B
(E)	O
acetylcarnitine,	B
and	O
(F)	O
palmitoylcarnitine	B
increased	O
with	O
metreleptin	O
treatment.	O

Both	O
TMAO	B
and	O
d9-TMAO	O
were	O
readily	O
detected	O
in	O
plasma	O
after	O
the	O
dietary	O
phosphatidylcholine	B
challenge	O
at	O
visit	O
1.	O

Taken	O
together,	O
the	O
flow	O
of	O
metabolites	O
for	O
GSH	B
pathway	O
may	O
be	O
altered,	O
positively	O
affecting	O
the	O
accumulation	O
of	O
2-hydroxybutyrate	B
and	O
pyroglutamate.	B

In	O
summary,	O
the	O
results	O
of	O
this	O
study	O
demonstrate,	O
for	O
the	O
first	O
time,	O
the	O
presence	O
in	O
human	O
urine	O
of	O
a	O
mercapturic	B
acid	I
derived	O
from	O
a	O
PAH,	O
Phe.	O

Aqueous	O
extractions	O
of	O
250 µL	O
of	O
plasma	O
were	O
performed	O
with	O
a	O
methanol/water	O
solution	O
in	O
a	O
Bravo	B
automated	O
liquid	O
handling	O
platform	O
(Agilent	O
Technologies,	O
CA).	O

Farooqui	O
et	O
al	O
reported	O
that	O
marked	O
alterations	O
in	O
neural	O
membrane	O
glycerophospholipid	B
composition	O
occurred	O
in	O
neurological	O
disorders	O
.	O

Recently,	O
in	O
an	O
untargeted	O
metabolomics	O
study	O
of	O
type	O
2	O
diabetes	O
risk	O
assessment	O
in	O
a	O
Chinese	O
population,	O
we	O
found	O
a	O
positive	O
association	O
between	O
serum	O
lysophosphatidylinositol	B
(LPI)	O
(16:1)	O
and	O
risk	O
for	O
type	O
2	O
diabetes.	O

Although	O
quality	O
of	O
treatment	O
in	O
our	O
patients	O
was	O
highly	O
variable,	O
most	O
of	O
them	O
used	O
amino	O
acid	O
supplements,	O
which	O
are	O
devoid	O
of	O
Phe	O
but	O
enriched	O
in	O
tyrosine	B
and	O
other	O
essential	O
amino	O
acids.	O

A	O
group	O
of	O
glycine	B
and	O
glycine	B
derivatives	O
was	O
significantly	O
altered	O
in	O
the	O
urine	O
of	O
PD	O
patients,	O
including	O
glycine,	B
furoylglycine,	B
tiglylglycine	B
and	O
hexanoylglycine.	B

These	O
differentially	O
abundant	O
molecules	O
represented	O
diverse	O
chemical	O
classes,	O
including	O
59	O
amino	O
acids,	O
11	O
carbohydrates,	O
10	O
cofactors	O
and	O
vitamins,	O
4	O
tricarboxylic	B
cycle	O
acid	O
(TCA)	O
cycle	O
intermediates,	O
120	O
lipids,	O
12	O
nucleotides,	O
8	O
peptides,	O
and	O
23	O
xenobiotics.	O

A	O
peak	O
at	O
375	O
m	O
/z	O
in	O
the	O
electron-impact	O
spectrum	O
indicated	O
the	O
presence	O
of	O
a	O
glucuronide	B
group	O
for	O
the	O
latter	O
compound.	O

We	O
have	O
observed	O
that	O
the	O
pretreatment	O
levels	O
of	O
bile	O
acids	O
derived	O
from	O
gut	O
bacteria	O
and	O
nutrient	O
inputs	O
are	O
correlated	O
with	O
response	O
to	O
simvastatin.	B

Genetic	O
flaws	O
in	O
the	O
propionate	B
metabolism	O
pathway	O
cause	O
faulty	O
amino	O
acid	O
and	O
fatty	O
acid	O
metabolism	O
that	O
lead	O
to	O
various	O
neurological	O
problems.	O

Indeed,	O
upregulated	O
DDAHs	O
correlated	O
with	O
both	O
products	O
of	O
ADMA	B
degradation,	O
that	O
is,	O
citrulline	B
and	O
DMA,	B
which	O
were	O
consistently	O
increased	O
at	O
the	O
systemic	O
level	O
in	O
patients	O
with	O
active	O
and	O
inactive	O
disease.	O

Among	O
these,	O
the	O
module	O
turquoise	O
was	O
positively	O
correlated	O
with	O
abdominal	O
pain,	O
duration	B
of	O
symptom,	O
abdominal	O
discomfort,	O
and	O
stool	O
form.	O

Some	O
NSAIDS	O
containing	O
the	O
carboxylic	B
acid	I
moiety	O
undergo	O
bioactivation	O
to	O
form	O
electrophilic	O
acyl-coenzyme	B
A	O
thioester	B
derivatives	O
(acyl-CoAs);	O
some	O
of	O
these	O
conjugates	O
exhibit	O
greater	O
reactivity	O
with	O
Alb	O
than	O
AGs	O
to	O
produce	O
the	O
same	O
transacylated	O
adducts.	O

However,	O
the	O
current	O
study	O
provides	O
evidence	O
for	O
the	O
concomitant	O
presence	O
of	O
glucocorticoid	B
excess	O
in	O
a	O
large	O
proportion	O
of	O
patients	O
with	O
primary	O
aldosteronism,	O
an	O
observation	O
we	O
found	O
to	O
be	O
independent	O
of	O
primary	O
aldosteronism	O
subtype	O
or	O
tumor	O
tissue	O
genotypes.	O

Cytokines	O
and	O
immunoglobulins	O
[IgA/IgG/IgE]	O
were	O
analysed	O
by	O
multiplex	O
Meso	B
Scale	O
Discovery	O

Correlation	O
values	O
between	O
the	O
N	O
-acetyl	O
δ	O
2.17	O
signal	O
and	O
signal	O
at	O
δ	O
3.89	O
derived	O
from	O
the	O
protons	O
H_5	O
`	O
on	O
the	O
glucuronide	B
ring	O
were	O
somewhat	O
weaker	O
(r	O
=	O
0.72;	O
95%	O
CI	O
of	O
0.61–0.82).	O

(a)	O
Prostate	O
section	O
processed	O
for	O
immunohistochemistry	O
using	O
PIN4	O
stain	O
where	O
red	O
indicates	O
racemase	O
and	O
brown	O
indicates	O
p63	O
and	O
basal	O
keratin.	B

Stock	O
stability	O
for	O
abiraterone,	B
its	O
metabolites	O
and	O
the	O
internal	O
standard.	O

The	O
discrimination	O
efficiency	O
and	O
accuracy	O
of	O
the	O
urinary	O
EMs	O
were	O
ascertained	O
by	O
receiver	O
operating	O
characteristic	O
curve	O
(ROC)	O
analysis	O
that	O
allowed	O
the	O
identification	O
of	O
some	O
metabolites	O
with	O
the	O
highest	O
sensitivities	O
and	O
specificities	O
to	O
discriminate	O
BC	O
patients	O
from	O
healthy	O
controls	O
(e.g.	O
creatine,	B
glycine,	B
trimethylamine	B
N-oxide,	I
and	O
serine).	B

Individuals	O
volunteering	O
were	O
classified	O
as	O
“self	O
reported	O
aspartame	B
sensitive”	O
individuals	O
if	O
they	O
reported	O
suffering	O
one	O
or	O
more	O
symptoms	O
on	O
multiple	O
occasions	O
and	O
as	O
a	O
consequence	O
were	O
actively	O
avoiding	O
consumption	O
of	O
any	O
aspartame	B
in	O
their	O
diet.	O

Lindgren	O
and	O
colleagues	O
have	O
found	O
that	O
patients	O
with	O
stroke	O
present	O
increased	O
levels	O
of	O
homocysteine	B
in	O
relation	O
to	O
acute	O
phase	O
of	O
the	O
disease	O
when	O
compared	O
to	O
control	O
group.	O

This	O
is	O
the	O
first	O
synthetic	O
cannabinoid	B
LC–MS/MS	O
assay	O
with	O
library	O
searching	O
monitoring	O
9	O
synthetic	O
cannabinoids	B
and	O
20	O
metabolites	O
in	O
urine.	O

As	O
the	O
15-HETE	B
level	O
is	O
enhanced	O
(which	O
serves	O
as	O
marker	O
for	O
the	O
LXA_4	O
pathway),	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
LXA_4	O
already	O
metabolized	O
within	O
the	O
snap	O
shot	O
time	O
and	O
that	O
LXA_4	O
levels	O
were	O
thus	O
underestimated.	O

DHA-containing	O
fatty	O
acids	O
in	O
plasma	O
phospholipids,	B
such	O
as	O
PE(18:0/22:6),	B
PE(16:0/22:6)	B
and	O
PE(18:1/22:6)	B
and	O
PC(18:0/22:6),	B
were	O
also	O
reduced	O
in	O
males	O
aged	O
over	O
75	O
years,	O
relative	O
to	O
females,	O
an	O
observation	O
also	O
reported	O
in	O
previous	O
studies	O
[,	O
].	O

In	O
postmenopausal	O
women,	O
circulating	O
androgens,	O
specifically	O
dehydroepiandrosterone	B
sulfate	I
and	O
testosterone,	B
are	O
positively	O
associated	O
with	O
circulating	O
estradiol	B
and	O
with	O
breast	O
cancer	O
risk.	O

Results:	O
Urinary	O
arginine	B
levels	O
in	O
aMCI	O
patients	O
are	O
obviously	O
lower	O
than	O
in	O
normal	O
controls	O
(q	O
<	O
0.2	O
and	O
p	O
<	O
0.05).	O

These	O
alterations	O
in	O
urinary	O
amino	O
acid	O
excretion	O
occurred	O
several	O
days	O
before	O
changes	O
in	O
urinary	O
protein	O
excretion	O
or	O
the	O
serum	O
concentrations	O
of	O
urea	B
and	O
creatinine.	B

For	O
both	O
cohorts,	O
we	O
modeled	O
the	O
transformed	O
abundance	O
of	O
each	O
feature	O
as	O
a	O
function	O
of	O
IBD	O
phenotype	O
(modeled	O
as	O
a	O
categorical	O
variable	O
with	O
“non-IBD	O
control”	O
as	O
the	O
reference	O
state),	O
with	O
age	O
as	O
a	O
continuous	O
covariate	O
in	O
both	O
cohorts,	O
and	O
four	O
medications	O
(antibiotics,	O
immunosuppressants,	O
mesalamine,	B
and	O
steroids)	O
as	O
binary	O
covariates	O
in	O
the	O
PRISM	O
cohort.	O

Molecules	O
1	O
to	O
4	O
represent	O
ethyl	B
2-methylacetoacetate,	I
levulinic	B
acid,	I
p-cresol	B
and	O
benzylmalonic	B
acid,	I
respectively.	O

Conversely,	O
significant	O
decreases	O
in	O
lysine,	B
histidine,	B
phenylalanine	B
and	O
tyrosine	B
were	O
observed	O
in	O
the	O
prognostic	O
model	O
which	O
were	O
not	O
observed	O
in	O
the	O
model	O
of	O
endoscopic	O
activity.	O

These	O
‘conjugation	O
reactions’	O
also	O
increase	O
the	O
water	O
solubility	O
of	O
a	O
drug	O
molecule	O
with	O
a	O
polar	O
moiety	O
such	O
as	O
acetate,	B
glucuronide	B
or	O
sulphate.	B

The	O
concentration	O
of	O
every	O
acylcarnitine	B
in	O
sperm	O
was	O
significantly	O
correlated	O
(P	O
<	O
0.05)	O
with	O
at	O
least	O
one	O
spermiogram	O
parameter.	O

The	O
flow-rate	O
was	O
1 mL/min	O
or	O
1.2 mL/min,	O
depending	O
upon	O
whether	O
isopropanol	B
or	O
methanol	B
(respectively)	O
was	O
used	O
as	O
modifier.	O

No	O
change	O
was	O
observed	O
in	O
serum	O
folate	B
(P	O
=	O
0.50).	O

When	O
the	O
cells	O
reached	O
approximately	O
80%	O
confluence,	O
they	O
were	O
treated	O
and	O
incubated	O
with	O
10 mM	O
of	O
α-OG	B
or	O
vehicle	O
for	O
72 h.	O

Furthermore,	O
a	O
significant	O
positive	O
arteriovenous	O
difference	O
was	O
observed	O
for	O
aspartate,	B
suggesting	O
that	O
aspartate	B
could	O
play	O
an	O
important	O
role	O
in	O
glutamate	B
supply	O
in	O
the	O
muscle	O
cells.	O

All	O
models	O
were	O
adjusted	O
for	O
age,	O
sex,	O
BMI,	O
HbA1c,	O
LDL	B
cholesterol	I
and	O
systolic	O
blood	O
pressure	O
as	O
well	O
as	O
additionally	O
for	O
coffee	O
consumption	O
in	O
a	O
second	O
model	O
(only	O
Inter99	O
and	O
cross-sectional	O
analyses).	O

Group	O
1	O
and	O
Group	O
2	O
(n = 6)	O
received	O
physiological	O
saline	B
(Otsuka	O
Normal	O
Saline,	B
Otsuka	O
Pharmaceutical	O
Factory	O
Inc.,	O
Tokushima,	O
Japan),	O
Group	O
3	O
received	O
0.1%	O
diclofenac	O
sodium	O
ophthalmic	O
solution	O
(n = 7),	O
Group	O
4	O
received	O
0.1%	O
bromfenac	O
sodium	O
hydrate	O
ophthalmic	O
solution	O
(n = 6),	O
Group	O
5	O
received	O
0.1%	O
nepafenac	O
ophthalmic	O
suspension	O
(n = 6),	O
and	O
Group	O
6	O
received	O
subcutaneous	O
indomethacin	B
as	O
a	O
positive	O
control	O
(n = 6).	O

Strong	O
suppression	O
of	O
PC	O
expression	O
(cell	O
line	O
PC	O
2096	O
4B)	O
markedly	O
decreased	O
the	O
levels	O
of	O
both	O
citrate	B
and	O
malate	B
and	O
decreased	O
the	O
incorporation	O
of	O
carbon	O
from	O
glucose	B
and	O
glutamine	B
into	O
citrate	B
and	O
malate.	B

For	O
that	O
reason,	O
the	O
working	O
solutions	O
of	O
the	O
drugs	O
were	O
prepared	O
in	O
a	O
20%	O
(v/v	O
)	O
methanolic	B
solution	O
by	O
proper	O
dilution	O
of	O
the	O
stock	O
standard	O
solutions	O
or	O
by	O
spiking	O
the	O
stock	O
standard	O
solutions	O
into	O
biological	O
samples	O
(human	O
urine).	O

We	O
observed	O
a	O
negative	O
correlation	O
between	O
alanine	B
and	O
acetone	B
levels	O
in	O
survivor	O
patients	O
with	O
low	O
ACS	O
and	O
RF	O
risk	O
scores,	O
while	O
this	O
correlation	O
disappears	O
in	O
high-risk	O
patients,	O
either	O
survived	O
or	O
deceased	O
at	O
2	O
years	O
after	O
AMI.	O

The	O
accurate	O
MS	O
and	O
MS/MS	O
spectra	O
for	O
_15	O
N-cholamine,	B
shown	O
in	O
,	O
help	O
further	O
verify	O
the	O
identity	O
and	O
purity	O
of	O
the	O
synthesized	O
smart	O
isotope	O
tag	O
(m/z=	O
104.120).	O

Our	O
goal	O
during	O
validation	O
of	O
the	O
current	O
method	O
was	O
to	O
assess	O
whether	O
more	O
β-glucuronidase	O
enzyme	O
was	O
required	O
to	O
achieve	O
similarly	O
optimal	O
hydrolysis	O
as	O
this	O
method	O
requires	O
a	O
larger	O
200	O
µL	O
urine	O
volume	O
compared	O
to	O
100	O
µL	O
urine	O
for	O
the	O
previous	O
validated	O
synthetic	O
cannabinoid	B
screening	O
method.	O

In	O
that	O
context,	O
a	O
study	O
investigating	O
the	O
inter-individual	O
variation	O
in	O
the	O
plasma	O
uptake	O
of	O
the	O
unmetabolized	O
α-tocoherol	B
has	O
shown	O
differences	O
of	O
up	O
to	O
40-fold.	O

Change	O
in	O
isoleucine	B
correlated	O
(p	O
<	O
0.05)	O
to	O
change	O
in	O
glucose	B
and	O
c-peptide	O
levels	O
while	O
change	O
in	O
ketoleucine	B
correlated	O
to	O
change	O
in	O
insulin.	O

Zhao	O
et	O
al	O
.	O
communicated	O
a	O
good	O
correlation	O
between	O
plasma	O
levels	O
of	O
C16:0	B
and	O
C24:1	B
ceramides	I
and	O
immune	O
activation	O
and	O
inflammation.	O

This	O
is	O
especially	O
evident	O
for	O
4-hydroxy-2-hexadecenal	B
(ESM	O
Fig.	O
S6).	O

A	O
stable	O
isotope	O
of	O
D-mannose	B
was	O
selected	O
as	O
the	O
IS,	O
which	O
is	O
the	O
best	O
choice	O
for	O
a	O
LC–MS/MS	O
analysis	O
because	O
it	O
can	O
effectively	O
compensate	O
for	O
variability	O
such	O
as	O
in	O
ionization	O
efficiency,	O
stability,	O
and	O
extraction	O
recovery.	O

As	O
for	O
the	O
discriminant	O
metabolites,	O
we	O
want	O
to	O
focus	O
on	O
choline	B
and	O
phosphocholine,	B
alanine	B
and	O
taurine.	B

The	O
most	O
important	O
pathways	O
altered	O
in	O
diffused	O
SSc	O
compared	O
to	O
limited	O
SSc	O
were	O
glycolysis	O
and	O
gluconeogenesis,	O
pathways	O
related	O
to	O
the	O
energetic	O
metabolism	O
and	O
glutamate-glutamine	B
metabolism.	O

In	O
a	O
study	O
using	O
AML	O
serum	O
samples,	O
all	O
the	O
common	O
identified	O
metabolites	O
showed	O
the	O
same	O
pattern	O
of	O
down-regulation	O
except	O
glucose,	B
which	O
is	O
up-regulated	O
in	O
the	O
study	O
mentioned.	O

The	O
analytic	O
method	O
for	O
determination	O
of	O
urinary	O
cotinine	B
was	O
previously	O
described	O
in	O
detail.	O

Liquid-liquid	O
extraction	O
(LLE)	O
with	O
different	O
organic	O
solvents	O
and	O
protein	O
precipitation	O
(PPT)	O
with	O
acetonitrile	B
or	O
methanol	B
were	O
evaluated	O
as	O
sample	O
pretreatment	O
techniques	O
in	O
our	O
earlier	O
studies.	O

A	O
500-ng/mL	O
(1,000	O
ng/mL	O
BUP-D_4	O
and	O
NBUP-D_3	O
)	O
working	O
internal	O
standard	O
solution	O
was	O
prepared	O
by	O
diluting	O
100	O
μg/mL	O
and	O
1.0	O
mg/mL	O
stock	O
solutions	O
in	O
methanol.	B

For	O
male,	O
the	O
differential	O
metabolites	O
were	O
mainly	O
involved	O
in	O
four	O
metabolic	O
pathways:	O
synthesis	O
and	O
degradation	O
of	O
ketone	B
bodies,	O
methane	B
metabolism,	O
phenylalanine	B
metabolism,	O
and	O
tyrosine	B
metabolism.	O

The	O
_1	O
H-NMR	O
signals	O
of	O
all	O
common	O
metabolites	O
including	O
amino-acids,	B
organic	O
acids,	O
and	O
carbohydrates	O
were	O
assigned	O
according	O
to	O
previous	O
publications.	O
.	O

These	O
data	O
led	O
to	O
the	O
identification	O
of	O
emericellene	B
E	O
as	O
(+)-emericella-3E	B
,7E	I
,22-trien-17β-al-16-oic	I
acid	I
(6).	O

Alzheimer,	O
Diagnosis,	O
Plasma,	O
Bile	O
acid,	O
Lithocholic	B
acid,	I
Biomarkers	O

The	O
levels	O
of	O
valine,	B
glutamine,	B
TMAO	B
and	O
phenylalanine	B
changed	O
significantly	O
and	O
reversed	O
to	O
normal	O
levels	O
after	O
BDT	O
treatment	O
(P	O
 < 0.01,	O
P	O
 < 0.05).	O

Mean	O
+/−	O
s.e.m.	O
of	O
sarcosine	B
levels	O
(n=3,	O
except	O
for	O
PrEC	O
cells	O
where	O
n=2).	O

Besides	O
decreased	O
tryptophan/kynurenine	O
ratio	O
that	O
has	O
been	O
associated	O
with	O
worse	O
prognosis	O
in	O
several	O
cancer	O
types	O
(,	O
),	O
KP	B
downstream	O
metabolites	O
could	O
also	O
play	O
a	O
role	O
in	O
tumoural	O
immune	O
escape.	O

This	O
involves	O
oxidation	O
and	O
thiolation	O
to	O
give	O
a	O
24-oxo-26-oyl-CoA	B
structure	O
followed	O
by	O
β-oxidation	O
to	O
the	O
C_24	O
bile	O
acid.	O

Actually	O
several	O
studies	O
suggested	O
that	O
creatinine	B
adjustment	O
could	O
induce	O
bias	O
when	O
comparing	O
different	O
populations	O
such	O
as	O
ethnical	O
groups,	O
pregnant	O
women,	O
neonatal,	O
children,	O
or	O
the	O
elderly	O
for	O
whom	O
creatinine	B
excretion	O
could	O
be	O
impacted	O
by	O
physiological	O
factor	O
not	O
directly	O
related	O
to	O
their	O
environmental	O
exposure,	O
for	O
instance,	O
renal	O
function,	O
muscle	O
mass,	O
sex,	O
ethnicity,	O
food	O
consumption,	O
and	O
age	O
[,	O
,	O
–].	O

LI	O
performed	O
the	O
IMT	O
using	O
6	O
cmH_2	O
O	O
resistance,	O
MI	O
trained	O
using	O
an	O
intensity	O
representing	O
60%	O
of	O
the	O
MIP,	B
and	O
HI	B
used	O
≈	O
85%–90%	O
of	O
the	O
MIP.	B

The	O
cross-sectional	O
study	O
population	O
included	O
259	O
subjects	O
with	O
normal	O
or	O
impaired	O
fasting	O
glucose	B
or	O
type	O
2	O
diabetes	O
in	O
whom	O
skeletal	O
muscle	O
and	O
whole-body	O
insulin	O
sensitivity	O
(M-value)	O
were	O
measured	O
during	O
euglycemic	B
hyperinsulinemic	O
clamp.	O

_1	O
H-_13	O
C	O
HSQC	O
experiments	O
were	O
performed	O
with	O
dwell	O
time	O
of	O
50.4	O
μs;	O
at	O
least	O
16	O
echo-antiecho	O
pair	O
acquisitions	O
with	O
2048	O
data	O
points	O
for	O
each	O
increment	O
in	O
t	O
_1	O
for	O
each	O
sample.	O
_1	O
H-_13	O
C	O
HMBC	O
experiment	O
for	O
disodium	B
(R	I
/S	I
)-2-hydroxyglutarate	I
reference	O
sample	O
was	O
also	O
performed	O
with	O
experimental	O
parameters	O
similar	O
to	O
HSQC.	O

Acetylcarnitine	B
and	O
shikimate	B
were	O
elevated	O
in	O
the	O
CSF	O
of	O
patients	O
with	O
IDH-WT-gliomas	O
in	O
comparison	O
to	O
control	O
CSF,	O
an	O
observation	O
that	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
that	O
analyzed	O
CSF	O
from	O
10	O
patients	O
with	O
gliomas.	O

Our	O
study	O
found	O
that	O
most	O
purine	B
catabolites,	O
including	O
1-methyladenosine,	B
decreased	O
in	O
the	O
HTK	O
group,	O
although	O
de	O
novo	O
purine	B
biosynthesis	O
was	O
upregulated.	O

At	O
0.5	O
h,	O
all	O
the	O
samples	O
tested	O
gave	O
similar	O
%	O
blood	O
glucose	B
reduction.	O

Analytical	O
standard	O
stock	O
solutions	O
for	O
LC/MS	O
were	O
prepared	O
in	O
methanol	B
(1	O
mg/mL)	O
and	O
stored	O
at	O
−80	O
°C.	O

Classification	O
of	O
patients	O
according	O
to	O
vitamin	B
D	I
status	O
and	O
inflammatory	O
activity.	O

Distribution	O
of	O
imatinib	B
serum	O
concentrations	O
observed	O
in	O
the	O
samples	O
from	O
the	O
better	O
treatment	O
response	O
subgroup	O
(n	O
=	O
223).	O

Previous	O
reports	O
have	O
revealed	O
that	O
the	O
level	O
of	O
muscle	O
ceramide	B
enriched	O
with	O
nervonic	B
acid	I
is	O
negatively	O
correlated	O
with	O
insulin	O
sensitivity,	O
but	O
the	O
authors	O
did	O
not	O
examine	O
plasma	O
lipid	O
levels.	O

(B)	O
Expression	O
levels	O
of	O
trigonelline	B
were	O
determined	O
in	O
urine	O
samples	O
of	O
IC	O
and	O
those	O
of	O
controls	O
(*FDR	O
<	O
0.05).	O

The	O
home-developed	O
software	O
(Lipid	O
Omega	O
Analyzer)	O
is	O
our	O
first	O
step	O
toward	O
this	O
direction,	O
which	O
is	O
incorporated	O
with	O
the	O
functions	O
for	O
guiding	O
PB–MS/MS	O
and	O
performing	O
multilevel	O
structural	O
analysis	O
for	O
phospholipids	B
including	O
subclass,	O
acyl/alkyl	O
chain,	O
de	O
novo	O
C=C	O
location	O
identification.	O

p	O
-value < 0.05)	O
of	O
arginine	B
than	O
NAG	O
and	O
CAG+	O
groups,	O
but	O
GC	O
and	O
PLGC	O
showed	O
comparable	O
levels.	O

According	O
to	O
Adibi	O
and	O
Gray,	O
isoleucine	B
has	O
one	O
of	O
the	O
highest	O
intestinal	O
absorption	O
rates	O
while	O
glutamate	B
has	O
one	O
of	O
the	O
lowest	O
after	O
in	O
vivo	O
perfusion	O
into	O
the	O
jejunum	O
of	O
humans	O
with	O
equimolar	O
amino	O
acid	O
mixes	O
[,].	O

The	O
O-PLS-DA	O
scores	O
plot	O
showing	O
discrimination	O
between	O
two	O
classes	O
(blue,	O
control;	O
red,	O
participants	O
who	O
had	O
taken	O
acetaminophen).	B

According	O
to	O
insect	O
models	O
,	O
the	O
chemical	O
components	O
of	O
infecting	O
microorganisms,	O
such	O
as	O
lipopolysaccharide,	B
stimulate	O
a	O
number	O
of	O
intracellular	O
transduction	O
systems,	O
including	O
those	O
responsible	O
for	O
upregulation	O
of	O
eicosanoid	B
biosynthesis	O
by	O
phospholipase	O
A_2	O
activation.	O

Adenosine,	B
levels	O
of	O
which	O
doubled	O
over	O
the	O
period	O
of	O
observation,	O
also	O
has	O
well-described	O
signaling	O
functions	O
regulating	O
both	O
vascular	O
tone	O
and	O
pre-conditioning.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Ethic	O
Committee	O
Sud-Est	O
VI	B
Clermont-Ferrand	O
(Agreement	O
number	O
AU887,	O
04/03/2011).	O

Comparisons	O
of	O
levels	O
of	O
tryptophan	B
metabolites	O
between	O
medicated	O
and	O
drug-naïve	O
patients	O
showed	O
a	O
trend	O
towards	O
lower	O
levels	O
of	O
KA	O
and	O
HAA	O
in	O
non-medicated	O
patients	O
in	O
preliminary	O
analyses.	O

The	O
MRM	O
procedures	O
used	O
(Supplemental	O
Table	O
)	O
permitted	O
determination	O
of	O
plasma	O
concentrations	O
of	O
PUFAs	O
in	O
the	O
ng/ml	O
range	O
and	O
eicosanoids	B
in	O
the	O
pg/ml	O
range	O
.	O

A	O
response	O
score	O
to	O
hydrochlorothiazide	B
was	O
created	O
using	O
the	O
three	O
replicated	O
genetic	O
signals,	O
and	O
was	O
further	O
validated	O
in	O
independent	O
participants	O
treated	O
with	O
hydrochlorothiazide.	B

Similarly,	O
Lopes	O
et	O
al	O
reported	O
significant	O
increase	O
of	O
C14,	O
C18	O
at	O
1 year	O
post‐RYGB.11	O
Significant	O
changes	O
in	O
essential	O
FA	B
or	O
omega	O
3	O
FA	B
were	O
not	O
observed	O
following	O
RYGB,	O
even	O
though	O
those	O
are	O
known	O
to	O
be	O
reduced	O
after	O
bariatric	O
surgery.11	O

A	O
strong	O
correlation	O
was	O
observed	O
between	O
plasma	O
levels	O
of	O
TMAO	B
and	O
the	O
absolute	O
urine	O
TMAO	B
level	O
(Spearman’s	O
r	O
=	O
0.58,	O
P<0.001)	O
and	O
the	O
urinary	O
ratio	O
of	O
TMAO	B
to	O
creatinine	B
(Spearman’s	O
r	O
=	O
0.91,	O
P<0.001).	O

This	O
suggests	O
that	O
serum	O
lactate	B
levels	O
may	O
identify	O
a	O
metabolic	O
classification	O
that	O
could	O
improve	O
HCC	O
diagnosis.	O

We	O
revealed	O
the	O
decreased	O
indole	B
levels	O
in	O
AOSD	O
patients,	O
which	O
was	O
similar	O
to	O
previous	O
finding	O
that	O
tryptophan	B
was	O
down-regulated	O
in	O
patients	O
with	O
ankylosing	O
spondylitis	O
compared	O
with	O
controls,	O
and	O
suggested	O
the	O
depletion	O
of	O
tryptophan	B
during	O
inflammation	O
may	O
serve	O
as	O
a	O
damping	O
effect.	O

Lactate	B
was	O
observed	O
to	O
steadily	O
increase	O
in	O
the	O
cell	O
culture	O
medium	O
of	O
S9	O
cells	O
following	O
rHla	O
treatment	O
to	O
2.5	O
mmol/	O

In	O
addition,	O
the	O
ketone	B
body	O
3-hydroxybutanoic	B
acid	I
negatively	O
correlated	O
with	O
glucose,	B
insulin	O
and	O
HOMA.	O

In	O
one	O
study,	O
levels	O
of	O
8-iso	B
-PGF_2α	I
in	O
non-smokers	O
averaged	O
0.83	O
pmol/mg	O
creatinine	B
compared	O
to	O
a	O
mean	O
of	O
0.73	O
pmol/mg	O
creatinine	B
observed	O
here	O
at	O
day	O
84.	O

In	O
addition,	O
the	O
causal	O
role	O
of	O
TMAO	B
in	O
atherosclerosis	O
development	O
has	O
been	O
further	O
studied	O
in	O
murine	B
models,	O
showing	O
accelerated	O
plaque	O
development	O
with	O
dietary	O
supplementation	O
of	O
TMAO	B
or	O
its	O
precursors	O
(e.g.:	O
choline,	B
L-carnitine).	B

Changes	O
in	O
metabolomic	O
profiles	O
were	O
closely	O
linked	O
to	O
clinical	O
progression,	O
and	O
correlated	O
with	O
glutamine	B
levels	O
in	O
Group	O
P	O
and	O
amino	O
acids,	O
lipids	O
and	O
spermidine	B
levels	O
in	O
Group	O
O.	O
Multivariate	O
models	O
accurately	O
predicted	O
disease	O
progression	O
and	O
highlighted	O
the	O
discriminant	O
role	O
of	O
sphingomyelins	B
(SM	O
C22:3,	B
SM	B
C24:1,	I
SM	O
OH	B
C22:2,	I
SM	B
C16:1).	I

The	O
Daily	O
Precipitation	O
Solution	O
(DPS)	O
containing	O
Internal	O
Standards	O
was	O
prepared	O
by	O
diluting	O
1:100	O
the	O
IS	O
mix	O
with	O
ACN,	O
with	O
0.1%	O
formic	B
acid.	I

After	O
OSC,	O
separation	O
of	O
control	O
and	O
drug-naïve	O
with	O
first-onset	O
schizophrenia	O
groups	O
in	O
the	O
PLS	O
scores	O
plots	O
(A)	O
was	O
characterized	O
by	O
similar	O
spectral	O
regions	O
as	O
previously	O
identified	O
to	O
contribute	O
to	O
the	O
separation	O
of	O
the	O
classes—i.e.,	O
glucose,	B
lactate,	B
shifts	O
in	O
glutamine	B
resonances,	O
and	O
citrate	B
(B).	O

After	O
training,	O
cold	O
exposure	O
increased	O
valine	B
and	O
albumin	O
improved	O
lipid	O
metabolism	O
by	O
decreasing	O
apo‐lipoprotein	O
B	O
(Figure C).	O

Regardless	O
of	O
which	O
DDAH	O
isoforms	O
are	O
altered,	O
the	O
ability	O
to	O
increase	O
degradation	O
of	O
ADMA	B
by	O
enhancing	O
myocardial	O
DDAH	O
expression	O
may	O
preserve	O
endothelial	O
function	O
and	O
maintain	O
hemodynamic	O
compensation	O
in	O
the	O
human	O
failing	O
heart.	O

Higher	O
levels	O
of	O
kynurenine	B
and	O
kynurenine/tryptophan	B
ratio	O
were	O
also	O
seen	O
when	O
active	O
disease	O
was	O
defined	O
by	O
SLAM.	O

The	O
decreased	O
_13	O
C	O
incorporation	O
into	O
malate	B
and	O
citrate	B
from	O
glucose	B
and	O
glutamine	B
in	O
the	O
PC	O
2096	O
4B	O
cell	O
line	O
can	O
be	O
explained	O
by	O
PC	O
knockdown	O
inhibiting	O
pyruvate	B
flux	O
through	O
the	O
citrate-pyruvate	B
and	O
the	O
malate-pyruvate	B
cycles.	O

Analysis	O
of	O
perchloric	B
acid	I
extracts	O
and	O
identification	O
of	O
1H,	O
31P	O
and	O
13C	O
resonances.	O

Variations	O
in	O
the	O
lipid	O
levels	O
in	O
oncological	O
patients	O
have	O
been	O
previously	O
associated	O
with	O
an	O
increased	O
uptake	O
of	O
cholesterol,	B
an	O
essential	O
component	O
of	O
cell	O
membranes,	O
by	O
tumor	O
cells.	O

Moreover,	O
the	O
presence	O
of	O
dimethylsulfone	B
likely	O
produced	O
by	O
the	O
gut	O
has	O
been	O
described	O
many	O
years	O
ago	O
for	O
its	O
antioxidant	O
and	O
anti-inflammatory	O
properties,	O
at	O
least	O
in	O
vitro	O
[,	O
,	O
].	O

Phospholipase	O
D	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
lysophosphatidyl	B
choline	I
(LPC)	O
to	O
generate	O
the	O
bioactive	O
lipid	O
lysophosphatidic	B
acid	I
(LPA).	O

fowleri	O
also	O
utilizes	O
cholesterol	B
obtained	O
from	O
diet	O
by	O
converting	O
it	O
into	O
7-dehydrocholesterol,	B
a	O
feature	O
typical	O
to	O
the	O
eukaryote	O
lineages	O
(e	O
.g	O
.	O

The	O
assay	O
was	O
based	O
on	O
PITC	O
(phenylisothiocyanate)-derivatization	O
in	O
the	O
presence	O
of	O
internal	O
standards	O
followed	O
by	O
FIA-MS/MS	O
(acylcarnitines,	O
lipids,	O
and	O
hexose)	O
and	O
LC/MS	O
(amino	O
acids,	O
biogenic	O
amines)	O
using	O
an	O
API4000	O
QTrap_®	O
mass	O
spectrometer	O
(Applied	O
Biosystems/MDS	O
Analytical	O
Technologies,	O
Darmstadt,	O
Germany)	O
with	O
electrospray	O
ionization.	O

UPLC-QqQ	O
data	O
were	O
collected	O
in	O
the	O
SRM	O
mode	O
on	O
QqQ	O
(Waters	O
XEVO	O
TQ)	O
operating	O
in	O
the	O
positive	O
mode	O
with	O
a	O
capillary	O
voltage	O
of	O
3	O
KV,	B
desolvation	O
gas	O
flow	O
800	O
Lhr_−1	O
,	O
and	O
desolvation	O
gas	O
temperature	O
of	O
350°C.	O

As	O
illustrated	O
in	O
,	O
in	O
the	O
metabolism	O
of	O
catechol	B
estrogens	O
there	O
are	O
activating	O
pathways	O
that	O
lead	O
to	O
the	O
formation	O
of	O
the	O
estrogen	B
quinones,	I
estrone	B
(estradiol)	O
quinones	B
[E_1	O
(E_2	O
)-Q],	O
which	O
can	O
react	O
with	O
DNA.	O

MRMs	O
were	O
as	O
follows:	O
LPA(16:0)	B
409→153	O
and	O
LPA(17:0)	B

Those	O
compounds	O
were	O
19-hydroxy-PGE_2	B
/20-hydroxy-PGE_2	I
,	I
19-hydroxy-PGF_2α	I
/20-hydroxy-PGF_2α	I
,	O
as	O
well	O
as	O
LTB_4	O
/12-epi	O
LTB_4	O
and	O
6-trans-LTB_4	B
/6-trans-12-epi	I
LTB_4	O
.	O

neutral	O
diol-HILIC	B
D	O
with	O
amide	B
F	O
(top	O
right),	O
B	O
and	O
E	O
with	O
neutral	O
F	O
(top	O
center,	O
bottom	O
left),	O
zwitterionic	O
E	O
with	O
WAX-type	O
G	O
(bottom	O
center)	O
and	O
mixed-mode	O
methods	O
C	O
and	O
D.	O

HPLC-grade	O
formic	B
acid,	I
dimethyl	B
sulfoxide	I
(DMSO),	O
and	O
ammonium	B
acetate	I
were	O
purchased	O
from	O
Tedia	O
Company	O
Inc	O
(Tedia,	O
Fairfield,	O
OH,	O
USA).	O

List	O
of	O
statistically	O
significant	O
compounds	O
identified	O
by	O
a	O
gas	O
chromatography–mass	O
spectrometry	O
(GC–MS),	O
capillary	O
electrophoresis–mass	O
spectrometry	O
(CE–MS),	O
and	O
liquid	O
chromatography–mass	O
spectrometry	O
(LC–MS)	O
with	O
regulation	O
in	O
the	O
cachexia	O
group	O
VIP,	O
variable	O
importance	O
in	O
the	O
projection;	O
FC,	O
fold	O
change;	O
LPC,	O
lysophosphatidylcholines;	B
LPE,	O
lysophosphatidylethanolamine;	B
PE:	O
phosphatidylethanolamine;	B
LPC:	O
lysophosphatidylcholine;	B
SM:	O
sphingomyelin.	B

As	O
D	O
illustrates,	O
these	O
general	O
findings	O
are	O
also	O
valid	O
in	O
the	O
case	O
of	O
individual	O
columns,	O
with	O
some	O
exceptions:	O
the	O
use	O
of	O
isopentylamine	B
as	O
an	O
additive	O
resulted	O
in	O
the	O
narrowest	O
peaks	O
for	O
the	O
BEH	O
2-EP	O
column,	O
while	O
it	O
was	O
water	O
rather	O
than	O
the	O
alkylamines	B
that	O
provided	O
the	O
greatest	O
decrease	O
in	O
peak	O
widths	O
for	O
the	O
BEH	O
Amide	B
column	O
(7.1 s	O
for	O
water	O
vs.	O
20.7	O
for	O
isopentylamine).	O

In	O
our	O
dataset	O
it	O
was	O
necessary	O
to	O
normalise	O
FIA-metabolite	O
data	O
in	O
order	O
to	O
get	O
acceptable	O
inter-laboratory	O
precision,	O
particularly	O
for	O
sphingolipids.	B

The	O
main	O
difference	O
is	O
that	O
the	O
fragment	O
ions	O
due	O
to	O
neutral	O
loss	O
of	O
fatty	O
acyl	O
as	O
ketene	O
(NLK),	O
signature	O
from	O
CID	O
of	O
formate	B
anions	O
of	O
PCs,	O
were	O
not	O
detected;	O
instead,	O
a	O
new	O
peak	O
at	O
m	O
/z	O
419	O
was	O
formed	O
at	O
relatively	O
high	O
abundance.	O

Citrate	B
was	O
measured	O
in	O
duplets	O
during	O
all	O
data	O
acquisitions	O
and	O
a	O
14.7%	O
RSD	O
in	O
the	O
raw	O
_1	O
H-NMR	O
data	O
was	O
indicative	O
of	O
an	O
analytically	O
robust	O
method	O
and	O
a	O
short-term	O
variance	O
(across	O
n	O
=	O
100	O
samples)	O
of	O
a	O
median	O
%RSD	O
of	O
5%.	O

Two	O
features	O
matched	O
ions	O
derived	O
from	O
sphingofungin	B
A,	O
a	O
natural	O
antifungal	O
produced	O
by	O
Aspergillus	O
species.	O

The	O
160	O
μL	O
supernatant	O
was	O
transferred	O
to	O
a	O
fresh	O
Eppendorf	O
tube	O
after	O
centrifugation,	O
and	O
40	O
μL	O
of	O
internal	O
standard	O
buffer	O
containing	O
250	O
mM	O
phosphate	B
buffer	O
with	O
5.0	O
mM	O
[4-dimethyl-4-silapentane-1-sulfonic	O
acid]	O
DSS	O
and	O
10%	O
D_2	O
O	O
were	O
added.	O

We	O
also	O
found	O
new	O
biochemical	O
markers	O
of	O
PCOS	O
in	O
women	O
with	O
abdominal	O
obesity,	O
including	O
albumin	O
and	O
total	O
choline.	B

Five	O
previously	O
characterized	O
metabolites	O
are	O
derived	O
from	O
the	O
reaction	O
of	O
BDA	O
with	O
cellular	O
nucleophiles	O
such	O
as	O
glutathione	B
and	O
protein.	O

Control	O
subjects	O
were	O
singleton	O
appropriate-for-gestational-age	B
(AGA)	O
fetuses	O
(birth	O
weight	O
>10_th	O
centile	O
according	O
to	O
local	O
standards)	O
that	O
were	O
matched	O
with	O
cases	O
by	O
gestational	O
age	O
at	O
delivery	O
(±	O
7	O
days)	O
and	O
gender.	O

So,	O
we	O
are	O
not	O
convinced	O
that	O
the	O
drop	O
in	O
lactate	B
levels	O
and	O
other	O
associated	O
systemic	O
metabolic	O
alterations	O
are	O
directly	O
linked	O
to	O
the	O
tumor	O
metabolism.	O

Glycerol	B
was	O
detected	O
in	O
all	O
conditions	O
but	O
was	O
not	O
analyzed	O
as	O
it	O
is	O
a	O
known	O
contaminant	O
from	O
filtration.	O

Other	O
negative	O
correlations	O
in	O
HCV	O
plasma	O
worthy	O
of	O
note	O
are	O
between	O
valine	B
and	O
cholesterol,	B
isoleucine	B
with	O
oleic	B
acid	I
(common	O
to	O
HBV	O
plasma;	O
a),	O
and	O
glycine	B
with	O
ethanolamine.	B

Tandem	O
MS/MS	O
and	O
fragmentation	O
of	O
co-eluting	O
authentic	O
reference	O
standards	O
added	O
to	O
plasma	O
was	O
used	O
to	O
verify	O
glutamate,	B
D-series	O
resolvins	O
and	O
trehalose	B
6-mycolate.	O

In	O
this	O
study,	O
some	O
of	O
potential	O
urine	O
biomarkers,	O
such	O
as	O
4-hydroxyhippuric	B
acid,	I
homocysteine,	B
and	O
tyrosine	B
showed	O
relatively	O
high	O
sensitivities	O
and	O
specificities.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
high-resolution	O
magic	O
angle	O
spinning	O
(HR-MAS)	O
1H	O
nuclear	O
magnetic	O
resonance	O
(NMR)	O
spectroscopy	O
in	O
patients	O
with	O
ductal	O
carcinoma	O
in	O
situ	O
(DCIS)	O
diagnosed	O
on	O
preoperative	O
biopsy.	O

The	O
associations	O
remained	O
significant	O
after	O
adjustment	O
for	O
age	O
and	O
sex	O
(HOMA-IR,	O
β	O
=	O
−0.058,	O
q	O
=	O
9.32e_−10	O
;	O
fasting	O
glucose,	B
β	O
=	O
−0.049,	O
q	O
=	O
3.67e_−8	O
;	O
T2D,	O
β	O
=	O
−0.050,	O
q	O
=	O
3.67e_−8	O
;	O
HOMA-B,	O
β	O
=	O
−0.035,	O
q	O
=	O
3.43e_−4	O
;	O
BMI,	O
β	O
=	O
−0.0,	O
q	O
=	O
1.42e_−7	O
;	O
WHR,	O
β	O
=	O
−0.034,	O
q	O
=	O
1.45e_−6	O
).	O

Higher	O
choline	B
(Hazard	O
ratio	O
(HR)	O
1.64	O
[95%	O
CI:	O
1.22	O
2.20],	O
p=0.001),	O
betaine	B
(HR	O
1.51	O
[1.10–2.08],	O
p=0.01),	O
and	O
TMAO	B
(HR	O
1.48	O
[1.10–1.96],	O
p=0.01)	O
predicted	O
increased	O
risk	O
for	O
5-year	O
adverse	O
clinical	O
events	O
(death/transplant).	O

These	O
resonances	O
were	O
structurally	O
identified	O
as	O
low-density	O
lipid/very	O
low-density	O
lipid	O
(LDL/VLDL)	O
(0.84 ppm,	O
0.92 ppm,	O
1.24 ppm,	O
1.28 ppm,	O
1.32 ppm),	O
isoleucine	B
(0.96 ppm),	O
lactate	B
(1.36 ppm,	O
1.40 ppm),	O
lipids	O
(2.00 ppm,	O
2.04 ppm),	O
choline	B
(3.24 ppm),	O
and	O
glucose/sugars	O
(3.28 ppm,	O
3.40 ppm,	O
3.44 ppm,	O
3.48 ppm,	O
3.72 ppm,	O
3.84 ppm,	O
3.92 ppm).	O

Analysis	O
of	O
transferrin	O
glycosylation	O
was	O
performed	O
on	O
serum	O
samples	O
with	O
the	O
use	O
of	O
isoelectric	O
focusing,_,	O
sodium	B
dodecyl	I
sulfate–polyacrylamide-gel	I
electrophoresis	O
(SDS-PAGE),	O
or	O
liquid	O
chromatography–mass	O
spectrometry	O
(,	O
and	O
the	O
).	O

The	O
enzyme	O
TPH1,	O
which	O
is	O
involved	O
in	O
the	O
production	O
of	O
serotonin,	B
was	O
down-regulated	O
in	O
∼90%	O
of	O
the	O
patient	O
samples	O
(B).	O

Surprisingly,	O
the	O
lipid	O
droplets	O
were	O
abundant	O
in	O
tumor	O
cells	O
especially	O
located	O
on	O
the	O
edge	O
of	O
the	O
typical	O
cell	O
death	O
region,	O
where	O
the	O
cells	O
are	O
found	O
with	O
homogeneous	O
cytoplasm,	O
pyknotic	O
nuclei	O
and	O
lack	O
of	O
cell	O
structures	O
under	O
hematoxylin	B
and	O
eosin	B
staining.	O

It	O
was	O
shown	O
that	O
low	O
plasma	O
cysteine	B
and	O
cystine	B
levels	O
were	O
associated	O
with	O
decreased	O
mucosal	O
synthesis	O
of	O
GSH,	B
increased	O
oxidative	O
damage,	O
and	O
presence	O
of	O
inflammation	O
in	O
UC	O
and	O
CD	O
patients[].	O

Differences	O
in	O
DHEA-S	B
between	O
patients	O
with	O
PAH	O
and	O
control	O
subjects	O
were	O
independent	O
of	O
the	O
more	O
subtle	O
effects	O
of	O
both	O
sex	O
and	O
age	O
(Figure	O
III	O
in	O
the	O
online-only	B
Data	O
Supplement),	O
and	O
lower	O
DHEA-S	B
levels	O
were	O
independently	O
associated	O
with	O
mortality.	O

'K2/SPICE'	O
products	O
are	O
commonly	O
laced	O
with	O
aminoalkylindole	B
synthetic	O
cannabinoids	B
(i.e.,	O
JWH-018	O
and	O
JWH-073)	O
and	O
are	O
touted	O
as	O
‘legal’	O
marijuana	O
substitutes.	O

Bile	O
acids	O
were	O
also	O
different	O
between	O
the	O
good	O
and	O
poor	O
responders,	O
with	O
primary	O
bile	O
acids	O
(TCA,	O
GCA,	O
TCDCA,	O
GCDCA)	O
changing	O
from	O
no	O
correlation	O
with	O
cholesterol	B
biosynthesis	O
and	O
negative	O
correlation	O
with	O
dietary	O
sterol	O
metabolites	O
in	O
good	O
responders	O
to	O
a	O
slightly	O
positive	O
correlation	O
in	O
poor	O
responders.	O

Gene	O
expression	O
of	O
ARID1A	O
was	O
significantly	O
increased	O
in	O
the	O
α-OG	B
treated	O
condition	O
(p = 0.018)	O

The	O
Phenomenex	O
Strata	O
Si-1	O
SPE	O
96-well	O
plate	O
(55	O
μM,	O
70	O
Å,	O
100	O
mg)	O
was	O
pretreated	O
with	O
1000	O
μl	O
of	O
25%	O
water	O
in	O
acetonitrile,	B
followed	O
by	O
1000	O
μl	O
of	O
acetonitrile.	B

Lastly,	O
stock	O
solutions	O
of	O
the	O
analytes	O
(50	O
μg/ml,	O
each)	O
were	O
stable	O
(94–100%)	O
up	O
to	O
one	O
month	O
when	O
stored	O
at	O
−20ºC.	O
Stability	O
of	O
SMV,	O
SMV-A,	O
ATV,	O
2-OH-ATV,	B
4-OH-ATV,	B
and	O
RSV	O
in	O
Human	O
Plasma	O
under	O
Various	O
Conditions	O
(n=6)	O
(RT=Room	O
temperature);	O
All	O
Data	O
are	O
Presented	O
as	O
Mean	O
±	O
SD	O

Of	O
these	O
compounds,	O
only	O
the	O
concentration	O
of	O
pyruvate	B
was	O
significantly	O
different	O
(p	O
=	O
0.01),	O
with	O
better	O
recovery	O
using	O
MeOH	B
ppt	O
+UF	O
than	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
(a–c,	O
Table	O
S2).	O

A	O
both	O
from	O
samples	O
B	O
and	O
samples	O
C.	O
Half	O
of	O
the	O
differentiating	O
components	O
were	O
identified	O
with	O
respect	O
to	O
their	O
lipid	O
class	O
(see	O
),	O
almost	O
all	O
of	O
them	O
being	O
phospholipids	B
containing	O
the	O
choline	B
“head”:	O
phosphatidylcholines	B
(PC;	O
10	O
compounds),	O
lysophosphatidylcholines	B
(LPC;	O
4	O
compounds)	O
and	O
sphingomyelines	B
(SM;	O
2	O
compounds).	O

When	O
comparing	O
sepsis	O
survivors	O
and	O
non-survivors,	O
we	O
found	O
a	O
significant	O
increase	O
only	O
in	O
the	O
serum	O
lactate	B
and	O
citrate	B
concentrations.	O

[Google	O
Scholar]	O
Fukushima	O
M,	O
Kato	O
T,	O
Ota	O
K,	O
Arai	O
Y,	O
Narumiya	O
S,	O
Hayaishi	O
O.	O
9-deoxy-delta	B
9-prostaglandin	I
D2,	O
a	O
prostaglandin	B
D2	I
derivative	O
with	O
potent	O
antineoplastic	O
and	O
weak	O
smooth	O
muscle-contracting	O
activities.	O

The	O
phosphoglycerides	B
degradation	O
products,	O
glycerol	B
3-phosphate,	I
glycerolphosphorylcholine	B
and	O
multiple	O
lysolipids,	O
as	O
well	O
as	O
the	O
membrane	O
sphingolipid	B
metabolites,	O
palmitoyl	B
sphingomyelin	I
and	O
stearoyl	B
sphingomyelin,	I
were	O
elevated	O
in	O
CNE2-IR	O
cells	O
(Figure	O
A-C).	O

We	O
observed	O
that	O
males	O
had	O
higher	O
ICC	O
values	O
than	O
females	O
for	O
both	O
8-iso	B
-PGF_2α	I
and	O

Through	O
the	O
potential	O
target	O
metabolic	O
pathway	O
analysis	O
with	O
MetaboAnalyst	O
3.0,	O
two	O
metabolic	O
pathways,	O
glycerophospholipid	B
metabolism	O
and	O
sphingolipid	B
metabolism,	O
were	O
found	O
to	O
be	O
associated	O
with	O
IS.	O

This	O
concept	O
is	O
best	O
highlighted	O
when	O
comparing	O
the	O
lysoPE	O
versus	O
intact	O
PE	O
lipid,	O
in	O
which	O
the	O
loss	O
of	O
a	O
FA	O
side-chain	O
(lyso)	O
decreases	O
the	O
hydrophobicity	O
of	O
the	O
molecule	O
enough	O
to	O
alter	O
its	O
extraction	O
efficiency	O
to	O
favor	O
MTBE.	B

Only	O
in	O
the	O
positive	O
ion	O
mass	O
spectra	O
of	O
Sil	O
and	O
BPA/Sil	O
was	O
presented	O
the	O
progesterone	B
(314 ± 1	O

In	O
our	O
study,	O
plasma	O
uric	B
acid	I
was	O
not	O
associated	O
with	O
future	O
risk	O
of	O
T2D,	O
but	O
correlated	O
positively	O
both	O
with	O
HOMA-IR	O
at	O
baseline	O
and	O
at	O
1-year	O
follow-up.	O

Results	O
were	O
normalized	O
relative	O
to	O
endogenous	O
β-actin	B
expression.	O

Figure 	O
shows	O
that	O
histidine	B
and	O
the	O
principal	O
degradation	O
products	O
of	O
histidine	B
were	O
distinctly	O
increased	O
after	O
the	O
use	O
of	O
HTK	O
solution,	O
indicating	O
an	O
increase	O
in	O
histidine	B
metabolism.	O

One	O
particular	O
SM,	O
SM	B
C24:1	I
was	O
lower	O
in	O
the	O
sera	O
of	O
patients	O
with	O
HBV-associated	O
cirrhosis	O
than	O
in	O
patients	O
with	O
CHB	O
and	O
HBV-associated	O
HCC	O
(,	O
;	O
).	O

FA	B
and	O
neurosteroids	O
were	O
increased	O
in	O
MSA,	O
and	O
LysoPC(16:0),	B
and	O
oxidative	O
stress	O
markers	O
were	O
changed	O
in	O
PSP.	O

Alternatively,	O
and	O
more	O
consistent	O
with	O
its	O
aforementioned	O
antibacterial	O
properties,	O
caprylic	B
acid	I
may	O
have	O
an	O
inhibitory	O
effect	O
on	O
growth	O
of	O
R.	O
gnavus	O
.	O

NAAG	B
in	O
urine	O
does	O
not	O
seem	O
to	O
previously	O
have	O
been	O
considered	O
for	O
cancer	O
detection.	O

Furthermore,	O
among	O
critically	O
ill	O
patients,	O
low	O
plasma	O
citrulline	B
levels	O
were	O
related	O
to	O
low	O
levels	O
of	O
arginine	B
and	O
glutamine	B
as	O
well	O
as	O
elevated	O
hsCRP	O
levels.	O

Another	O
interesting	O
finding	O
noted	O
in	O
veterans	O
with	O
sarcoidosis	O
was	O
with	O
pathway	O
analysis,	O
which	O
showed	O
that	O
GABA	B
synthesis	O
and	O
metabolism	O
might	O
be	O
downregulated	O
in	O
veterans	O
compared	O
to	O
civilian	O
with	O
sarcoidosis,	O
with	O
both	O
precursor	O
metabolites	O
of	O
GABA	B
(glutamate	I
or	I
glutamine)	I
and	O
breakdown	O
metabolites	O
of	O
GABA	B
(succinate	I
semialdehyde)	I
were	O
decrease	O
in	O
veterans.	O

Using	O
a	O
logistic	O
regression	O
algorithm,	O
a	O
metabolite	O
panel	O
consisting	O
of	O
N-acetyl-4-O-acetylneuraminic	B
acid,	I
4-(2-aminophenyl)-2,4-dioxobutanoic	B
acid,	I
6-keto-decanoylcarnitine,	B
3-hydroxydecanoyl	B
carnitine,	I
and	O
2-hydroxylauroylcarnitine	B
was	O
established.	O

 (2)	O
(line	O
)	O
NMR	O
samples	O
are	O
generally	O
buffered	O
to	O
neutral	O
or	O
near-neutral	O
pH	O
using	O
phosphate	B
buffer,	O
but	O
there	O
is	O
no	O
absolute	O
need	O
for	O
this,	O
and	O
some	O
studies	O
have	O
chosen	O
more	O
extreme	O
sample	O
pH	O
endpoints	O
in	O
order	O
to	O
move	O
away	O
from	O
the	O
pK	O
_a	O
values	O
of	O
highly	O
shifting	O
metabolites	O
(Beneduci	O
et	O
al.	O
;	O

The	O
effect	O
of	O
different	O
combinations	O
of	O
FA	B
on	O
IFNγ	O
production	O
was	O
examined	O
(n	O
=	O
6).	O

The	O
survival	O
curve	O
of	O
proline.	B

The	O
concentration	O
of	O
glucose	B
in	O
the	O
cell	O
culture	O
medium	O
can	O
have	O
a	O
strong	O
influence	O
on	O
the	O
concentration	O
of	O
pyruvate	B
in	O
the	O
cells.	O

To	O
confirm	O
the	O
metabolic	O
changes	O
of	O
arginine	B
and	O
cysteine	B
in	O
the	O
urine	O
of	O
aMCI	O
individuals,	O
it	O
was	O
tested	O
whether	O
the	O
arginine	B
and	O
cysteine	B
concentration	O
of	O
aMCI	O
patients	O
from	O
a	O
hospital	O
memory	O
clinic	O
were	O
different	O
from	O
those	O
of	O
control	O
subjects.	O

Autonomous	O
glucocorticoid	B
excess	O
was	O
defined	O
as	O
increased	O
urinary	O
free	O
cortisol	B
excretion.	O

(B)	O
A	O
bivariate	O
model	O
explaining	O
fasting	O
insulin	O
using	O
the	O
2-h	O
decline	O
of	O
Leu/Ile	O
and	O
glycerol.	B

Positive	O
and	O
negative	O
ion	O
MS	O
and	O
sequential	O
precursor	O
ion	O
fragmentation	O
acquisitions	O
were	O
carried	O
out	O
on	O
a	O
TripleTOF™	O
5600	O
System	O
(AB	O
SCIEX,	O
Concord,	O
ON)	O
controlled	O
with	O
Analyst®	O
TF	O
1.5.1	O
software	O
with	O
MS/MS_ALL	O
mode	O
activated	B
to	O
carry	O
out	O
series	O
of	O
product	O
ion	O
scans	O
defined	O
by	O
the	O
mass	O
range	O
and	O
Q1	O
stepped	O
masses	O
as	O
set	O
by	O
the	O
user.	O

MS/MS	O
transitions	O
evaluated	O
were	O
as	O
follows:	O
Kyn,	O
209.063–94.2;	O
Trp,	O
205.09–188.0;	O
cinnabarinic	O
acid,	O
300.99–283;	O
3-hydroxyanthranillic	O
acid,	O
153.848–136.1;	O
kynurenic	B
acid,	I
189.962–144.1;	O
melatonin,	B
233.023–174.1;	O
serotonin,	B
176.998–160;	O
xanthurenic	B
acid,	I
210.206–192.4;	O
and	O
d5-Trp,	O
210.206–192.40.	O

Our	O
HR-MAS	O
results	O
showed	O
increased	O
levels	O
of	O
glutamine,	B
glutamate,	B
aspartate	B
and	O
alanine	B
in	O
tumor	O
and	O
LN-Met	O
tissues,	O
which	O
suggest	O
that	O
in	O
addition	O
to	O
glucose,	B
HNSCC	O
cells	O
could	O
also	O
depend	O
on	O
glutaminolysis	O
for	O
carbon	O
and	O
nitrogen	O
source.	O

LOA	O
read	O
the	O
data	O
from	O
LC–MS/MS	O
in	O
negative	O
ion	O
mode	O
and	O
provides	O
lipid	O
identification	O
at	O
fatty	O
acyl	B
(alkyl)	I
chain	O
level.	O

The	O
sequence	O
of	O
the	O
recombinant	O
BPHL	O
(rBPHL)	O
and	O
hydrolytic	B
products	O
of	O
the	O
substrates	O
HCTL	O
and	O
valacyclovir	O
were	O
verified	O
by	O
MS.	O

Mediation	O
analysis	O
shows	O
further	O
that	O
LysoPC(P-15:0),	B
PC(P-34:4),	B
and	O
PC(38:6)	B
mediated	O
the	O
relationship	O
between	O
ascites	O
and	O
prognosis.	O

6-,	O
7-OH-WARs,	B
).	O

In	O
order	O
to	O
identify	O
relevant	O
metabolites,	O
MS/MS	O
fragmentation	O
analyses	O
were	O
performed	O
by	O
post-column	O
infusion	O
experiments	O
conducted	O
as	O
follows:	O
a	O
1.6	O
mM	O
solution	O
of	O
lithium	B
formate	I
dissolved	O
in	O
water-propanol	O
(1∶1)	O
was	O
infused	O
at	O
4	O
uL/min	O
using	O
a	O
Waters	O
built-in	O
syringe	O
pump.	O

From	O
this,	O
the	O
amount	O
of	O
glucose	B
consumed,	O
ΔGlc,	O
and	O
the	O
fraction	O
converted	O
to	O
lactate	B
plus	O
Ala,	O
F,	O
could	O
be	O
estimated,	O
according	O
to	O
Eq.	O

Sphingomyelins	B
are	O
structural	O
constituents	O
of	O
all	O
cell	O
membranes	O
particularly	O
abundant	O
in	O
the	O
myelin	B
membrane	O
sheaths	O
surrounding	O
axons.	O

The	O
following	O
sterols	O
and	O
bile	O
acids	O
were	O
detected	O
and	O
quantified:	O
campesterol	B
(CAMP),	O
chenodeoxycholic	B
acid	I
(CDCA),	O
cholestanol	B
(CSTN),	O
4-cholesten-7a-ol-3-one	B
(4-CHST),	O
cholesterol,	B
cholic	B
acid	I
(CA),	O
coprostanol	B
(COPR),	O
7-dehydrocholesterol	B
(7-DCH),	O
deoxycholic	B
acid	I
(DCA),	O
desmosterol	B
(DESM),	O
glycochenodeoxycholic	B
acid	I
(GCDCA),	O
glycocholic	B
acid	I
(GCA),	O
glycodeoxycholic	B
acid	I
(GDCA),	O
glycolithocholic	B
acid	I
(GLCA),	O
glycoursodeoxycholic	B
acid	I
(GUDCA),	O
7α-hydroxycholesterol	B
(7α-HC),	I
lanosterol	B
(LANO),	O
lathosterol	B
(LATH),	O
lithocholic	B
acid	I
(LCA),	O
β-sitosterol	B
(β-SITO),	I
stigmasterol	B
(STIG),	O
taurochenodeoxycholic	B
acid	I
(TCDCA),	O
taurocholic	B
acid	I
(TCA),	O
taurodeoxycholic	B
acid	I
(TDCA),	O
taurolithocholic	B
acid	I
(TLCA),	O
and	O
ursodeoxycholic	B
acid	I
(UDCA).	O

The	O
strongest	O
risk	O
factors	O
for	O
DR	O
include	O
poor	O
glycemic	B
control	O
and	O
longer	O
duration	B
of	O
diabetes.	O

To	O
test	O
whether	O
kynurenine	B
acts	O
through	O
AhR	O
to	O
affect	O
CD8	O
T	O
cell	O
viability,	O
CD8	O
T	O
cells	O
were	O
treated	O
with	O
increasing	O
doses	O
of	O
kynurenine	B
with	O
or	O
without	O
the	O
AhR	O
antagonist	O
CH-223191.	O

The	O
130.08-m/z	O
ion	O
was	O
identified	O
from	O
HMDB	O
searches	O
and	O
ESI	O
LC-MS/MS	O
analyses	O
as	O
hypoxanthine	B
(HX).	O

The	O
simultaneous	O
analysis	O
of	O
chiral	O
amino	O
acids:	O
DL-alanine	B
(Ala),	O
DL-d4-Ala,	O
DL-arginine	B
(Arg),	O
DL-asparagine	O
(Asn),	O
DL-aspartic	B
acid	I
(Asp),	O
DL-cysteine	O
(Cys),	O
DL-glutamine	B
(Gln),	O
DL-glutamic	B
acid	I
(Glu),	O
DL-histidine	B
(His),	O
DL-isoleucine	B
(Ile),	O
DL-leucine	B
(Leu),	O
DL-lysine	B
(Lys),	O
DL-methionine	B
(Met),	O
DL-phenylalanine	B
(Phe),	O
DL-proline	B
(Pro),	O
DL-serine	B
(Ser),	O
DL-threonine	B
(Thr),	O
DL-tryptophan	B
(Trp),	O
DL-tyrosine	B
(Tyr),	O
DL-valine	B
(Val),	O
DL-citrulline	B
(Cit),	O
DL-allo	O
-Ile,	O
DL-ornithine	O
(Orn),	O
DL-allo	O
-Thr,	O
and	O
glycine	B
(Gly),	O
except	O
for	O
the	O
separation	O
between	O
D-Ile	O
and	O
D-allo	O
-Ile,	O
was	O
thus	O
achieved	O
via	O
chiral	O
tandem	O
LC-MS/MS	O
(Fig.	O

Similarly,	O
cholesterol,	B
Cer(d18:0/24:1)	B
(p<0.001),	O
TG(17:2/17:2/18:2)	B
(p=0.00261),	O
and	O
TG(17:2/17:2/18:0)	B
(p=0.00291)	O
were	O
detected	O
when	O
MTBE	B
was	O
used	O
but	O
were	O
not	O
observed	O
when	O
methanol	B
alone	O
was	O
used.	O

Levels	O
of	O
serum	O
alanine	B
was	O
elevated	O
in	O
NSCLC	O
group,	O
which	O
was	O
consistent	O
with	O
previous	O
report.	O

Hydrophilic	B
extracts	O
were	O
dried	O
and	O
used	O
for	O
NMR	O
spectroscopic	O
analysis.	O

After	O
deproteinization	O
with	O
methanol	B
(1:5),	I
the	O
supernatant	O
of	O
serum	O
samples	O
was	O
dried	O
with	O
nitrogen	O
at	O
37°C,	O
dissolved	O
in	O
acetonitrile	B
and	O
water	O
(3:1)	O
and	O
centrifuged	O
at	O
10	O
000	O
×	O
g	O
for	O
15	O
min.	O

Uridine	O
5'-diphospho-glucuronosyltransferases	O
(UGTs)	O
are	O
enzymes	O
that	O
participate	O
in	O
several	O
biological	O
processes	O
involving	O
bilirubin	B
conjugation.	O

As	O
paracetamol	B
is	O
not	O
an	O
infection	O
or	O
morbidity	O
marker,	O
the	O
further	O
analysis	O
was	O
performed	O
after	O
the	O
exclusion	O
of	O
the	O
regions	O
corresponding	O
to	O
the	O
drug	O
and	O
its	O
metabolites.	O

Surprisingly	O
quinone	B
methides	O
were	O
found	O
to	O
be	O
stable	O
with	O
t_1/2	O
of	O
20.8	O
and	O
4.5	O
min	O
respectively.	O

The	O
top	O
layer	O
(hydrophilic)	O
and	O
the	O
bottom	O
layer	O
(lipophilic)	O
were	O
separated	O
and	O
transferred	O
to	O
new	O
Eppendorf	O
tubes.	O

Mitochondrial	O
damage	O
and	O
dysfunction	O
are	O
common	O
in	O
a	O
hyperglycemic	B
environment.	O

One	O
possible	O
explanation	O
for	O
the	O
different	O
results	O
obtained	O
from	O
normal	O
pooled	O
serum	O
and	O
serum	O
pooled	O
from	O
sepsis	O
patients	O
may	O
be	O
differences	O
in	O
the	O
duration	B
of	O
sample	O
storage	O
prior	O
to	O
macromolecule	O
removal.	O

In	O
some	O
other	O
studies,	O
metabolites	O
of	O
carnitine	B
metabolism,	O
which	O
are	O
responsible	O
for	O
the	O
transportation	O
of	O
fatty	O
acids	O
into	O
the	O
mitochondria,	O
have	O
been	O
found	O
to	O
be	O
increased	O
in	O
high-grade	O
tumour	O
tissues,	O
blood	O
serum	O
or	O
urine	O
[–],	O
which	O
may	O
be	O
a	O
consequence	O
of	O
improved	O
fatty	O
acid	O
β-oxidation	O
to	O
sustain	O
higher	O
rates	O
of	O
cell	O
division	O
and	O
growth.	O

One	O
characteristic	O
of	O
cancer	O
cells	O
is	O
the	O
switch	O
from	O
aerobic	O
oxygen-consuming	O
energy	O
production	O
to	O
glycolytic	B
metabolism,	O
known	O
as	O
the	O
Warburg	O
effect	O
(Warburg,	O
).	O

Regressions	O
of	O
Urinary	O
Creatinine-Adjusted	O
aMT6s,	O
Age,	O
and	O
BMI	O
on	O
8-oxodG	B
and	O
8-oxoGua	O
by	O
Mother,	O
Father,	O
and	O
Daughter	O
Regressions	O
of	O
Urinary	O
Creatinine-Adjusted	O
aMT6s,	O
Age,	O
and	O
BMI	O
on	O
8-oxodG	B
and	O
8-oxoGua	O
by	O
Mothers	O
and	O
Fathers	O
Older	O
than	O
the	O
Oldest	O
Daughter	O
The	O
primary	O
multivariate	O
analysis	O
results	O
are	O
as	O
follows:	O
1.	O
among	O
all	O
mothers,	O
there	O
was	O
a.	O
a	O
statistically	O
significant	O
(p	O
=	O
0.02)	O
decrease	O
in	O
8-oxodG	B
as	O
endogenous	O
overnight	O
urinary	O
aMT6s/Cr	O
increased	O
for	O
models	O
with	O
or	O
without	O
BMI	O
or	O
weight,	O
b.	O
a	O
marginally	O
significant	O
(p	O
<	O
0.08)	O
increase	O
in	O
8-oxodG	B
as	O
weight	O
increased	O
(data	O
not	O
shown),	O
but	O
not	O
BMI;	O
2.	O
among	O
the	O
mothers	O
older	O
than	O
the	O
oldest	O
daughter	O
(age	O
51.6),	O
a.	O
the	O
significance	O
levels	O
of	O
aMT6s/CR	O
fell	O
to	O
0.009	O
and	O
0.008	O
for	O
8-oxodG	B
with	O
BMI	O
or	O
weight	O
in	O
the	O
model,	O
respectively;	O
b.	O
BMI	O
was	O
marginally	O
positively	O
associated	O
(p	O
=	O
0.097),	O
while	O
weight	O
was	O
significantly	O
positively	O
associated	O
(p	O
=	O
0.04;	O
data	O
not	O
shown)	O
with	O
8-oxodG;	B
3.	O
among	O
all	O
fathers,	O
there	O
was	O
a.	O
a	O
marginally	O
significant	O
(p	O
=	O
0.063	O
and	O
0.065	O
with	O
BMI	O
or	O
weight	O
in	O
the	O
model,	O
respectively)	O
decrease	O
in	O
8-oxoGua	O
as	O
endogenous	O
overnight	O
urinary	O
aMT6s/Cr	O
increased;	O
4.	O
among	O
the	O
fathers	O
older	O
than	O
the	O
oldest	O
daughter	O
(age	O
51.6),	O
a.	O
the	O
inverse	O
association	O
between	O
8-oxoGua	O
and	O
aMT6s/CR	O
was	O
statistically	O
significant	O
(p	O
=	O
0.03	O
for	O
either	O
BMI	O
or	O
weight	O
in	O
the	O
model);	O
5.	O
among	O
the	O
oldest	O
daughters,	O
there	O
was	O
a.	O
a	O
marginally	O
significant	O
(p	O
<	O
0.07	O
and	O
<	O
0.08	O
for	O
BMI	O
and	O
weight,	O
respectively)	O
increase	O
in	O
8-oxoGua	O
as	O
age	O
increased.	O

Co-culturing	O
F.	O
tricinctum	O
with	O
S.	O
lividans	O
also	O
led	O
to	O
the	O
production	O
of	O
new	O
compounds	O
including	O
fusatricinones	B
A–D,	O
and	O
dihydrolateropyrone.	B

[N,	O
O-bis(trimethylsilyl)trifluoroacetamide	B
(BSTFA)	O
+	O
trimethylchlorosilane	B
(TMCS)],	O
99:1)	O
(Sigma	O
Aldrich,	O
St.	O
Louis,	O
MO,	O
USA)	O
was	O
used	O
in	O
the	O
second	O
derivatization.	O

Alternatively,	O
by	O
applying	O
an	O
ion-pairing	O
reagent	O
consisting	O
of	O
both	O
hydrophilic	B
and	O
hydrophobic	O
residues	O
in	O
a	O
single	O
molecule,	O
the	O
hydrophilic	B
metabolite	O
can	O
interact	O
with	O
the	O
hydrophobic	O
stationary	O
phase	O
of	O
the	O
RP	B
column	O
(Fig. ).	O

Diosmetin	B
mean	O
PK	O
results	O
in	O
urines	O
of	O
subjects	O
treated	O
with	O
diosmin	O

Metabolites	O
were	O
assigned	O
using	O
the	O
Chenomx	O
NMR	O
Suite	O
5.1	O
(Chenomx,	O
Inc.,	O
Edmonton,	O
Alberta,	O
Canada)	O
relative	O
to	O
4,4-dimethyl-4-silapentane-1-sulfonic	B
acid	I
(DSS)	O
as	O
an	O
internal	O
standard.	O

Those	O
39	O
differentiating	O
metabolites	O
included	O
10	O
lysophosphatidylcholines	B
(lysoPCs),	O
23	O
glycerophosphocholines	B
(PCs,	O
nine	O
PC	O
aas	O
and	O
14	O
PC	O
aes),	O
five	O
sphingomyelins	B
(SMs)	O
and	O
1	O
acylcarnitine.	B

This	O
indeed	O
is	O
a	O
reflection	O
that	O
alanine	B
biochemistry	O
is	O
an	O
integral	O
part	O
of	O
human	O
physiology	O
and	O
may	O
be	O
controlling	O
the	O
hypertension	O
through	O
aspects	O
like	O
impaired	O
insulin	O
resistance	O
or	O
imbalance	O
between	O
renal	O
transport	O
and	O
transport	O
along	O
the	O
muscle-liver	O
axis.	O

To	O
our	O
knowledge,	O
this	O
represents	O
the	O
first	O
report	O
of	O
their	O
simultaneous	O
measurement	O
in	O
HIV-TB	O
individuals	O
and	O
the	O
comparison	O
with	O
healthy	O
donors,	O
obtaining	O
statistically	O
higher	O
plasma	O
levels	O
of	O
DHEA,	O
AET	O
and	O
7-oxo-DHEA	B
in	O
patients.	O

To	O
avoid	O
any	O
potential	O
disturbances	O
of	O
the	O
test	O
system	O
caused	O
by	O
coffee	O
intake	O
it	O
was	O
finally	O
decided	O
to	O
exclude	O
all	O
models	O
that	O
used	O
trigonelline	B
as	O
a	O
feature,	O
leaving	O
a	O
total	O
of	O
33	O
and	O
60	O
candidates	O
for	O
the	O
strict	O
and	O
extended	O
setting,	O
respectively.	O

The	O
fecal	O
ratio	O
of	O
lithotomic	O
acid	O
to	O
deoxycholic	B
acid,	I
a	O
risk	O
factor	O
for	O
colon	O
cancer	O
is	O
also	O
reduced	O
in	O
rats	O
fed	O
on	O
a	O
high-fat	O
diet	O
along	O
with	O
vitamin	B
B6.	I

Therefore,	O
other	O
possible	O
by-products	O
of	O
derivatization	O
can	O
be	O
form	O
because	O
of	O
the	O
oxidation	O
of	O
secondary	O
alcohols	O
of	O
vitamin	B
D	I
metabolites	O
into	O
corresponding	O
ketones.	B

Schematic	O
showing	O
the	O
derivatization	O
reactions	O
of	O
2OH-E2	O
with	O
dansyl	B
chloride	I
(DSCl),	O
picolinoyl	B
chloride	I
(PCl)	O
or	O
picolinic	B
acid	I
(PA)	O
condensation	O
mixture,	O
pyridine-3-sulfonyl	B
chloride	I
(PSCl),	O
and	O
1-methylimidazole-2-sulfonyl	B
chloride	I
(ISCl)	O
DSCl:	O
dansyl	B
chloride;	I
PCl:	O
picolinoyl	B
chloride;	I
RT:	O
room	O
temperature;	O
PA:	O
picolinic	B
acid;	I
MNBA:	O
2-methyl-6-nitrobenzoic	B
anhydride;	O
DMAP:	O
4-dimethylaminopyridine;	B
Pyr:	O
pyridine;	B
TEA:	O
triethylamine;	B
PSCl:	O
pyridine-3-sulfonyl	B
chloride;	I
ISCl:	O
1-methylimidazole-2-sulfonyl	B
chloride.	I

Among	O
the	O
11	O
metabolites	O
detected	O
in	O
this	O
study,	O
6	O
(citrulline,	O
arginine,	B
proline,	B
N-acetylputrescine,	B
Gamma-aminobutyric	B
acid	I
and	O
homocarnosine)	O
and	O
3	O
(sarcosine,	O
N-acetylputrescine	B
and	O
4-hydroxyproline)	B
of	O
them	O
were	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
at	O
least	O
one	O
injury	O
group	O
in	O
CSF	O
and	O
serum.	O

The	O
low	O
sphingolipid	B
profile	O
in	O
CFS	O
appears	O
to	O
be	O
an	O
adaptive	O
response	O
that	O
is	O
opposite	O
to	O
the	O
increased	O
sphingolipids	B
observed	O
in	O
metabolic	O
syndrome	O
and	O
the	O
acute	O
cell	O
danger	O
response	O
(CDR)	O
and	O
ultimately	O
may	O
represent	O
a	O
fundamental	O
response	O
to	O
oppose	O
the	O
spread	O
of	O
persistent	O
viral	O
and	O
intracellular	O
bacterial	O
infections.	O

The	O
experimental	O
conditions	O
that	O
led	O
to	O
the	O
conclusion	O
that	O
triazole	B
is	O
the	O
main	O
metabolite	O
in	O
plasma	O
have	O
not	O
been	O
published	O
and	O
thus	O
are	O
difficult	O
to	O
evaluate.	O

The	O
suppression	O
of	O
intestinal	O
microbiota	O
by	O
the	O
administration	O
of	O
oral	O
broad-spectrum	O
antibiotics	O
for	O
1	O
week	O
in	O
six	O
of	O
the	O
participants	O
resulted	O
in	O
near-complete	O
suppression	O
of	O
detectable	O
TMAO	B
and	O
d9-TMAO	O
after	O
the	O
phosphatidylcholine	B
challenge	O
during	O
visit	O
2	O
in	O
both	O
plasma	O
and	O
urine.	O

Structures	O
of	O
25(OH)D_2	O
,	O
25(OH)D_3	O
,	O
and	O
3-epi-25(OH)D_3	B
are	O
shown	O
in	O
.	O

Histidine-histamine	B
metabolism	O
is	O
disrupted	O
in	O
COPD.	O

,	O
These	O
results	O
suggested	O
that	O
galactose	B
metabolism	O
had	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
depression.	O

A	O
general	O
decrease	O
in	O
short-chain	O
TG,	B
PC,	O
and	O
ePC	O
is	O
observed	O
with	O
high	O
increases	O
in	O
their	O
long-chain	O
structures	O
at	O
10	O
Gy	O
exposure.	O

Cox	O
regression	O
analysis	O
revealed	O
that	O
high	O
plasma	O
allantoin	B
levels,	O
including	O
allantoin-to-uric	O
acid	O
ratio	O
and	O
high	O
xanthine-to-hypoxanthine	O
ratio	O
were	O
inversely	O
and	O
positively	O
associated	O
with	O
T2D	O
risk,	O
respectively,	O
independently	O
of	O
classical	O
risk	O
factors.	O

There	O
was	O
a	O
highly	O
significant	O
decrease	O
in	O
subcutaneous	O
abdominal	O
adipocyte	O
size	O
with	O
four	O
to	O
five	O
weeks	O
of	O
60 %	O
CER	B
of	O
4066 μm_2	O
to	O
3593 μm_2	O

Guo	O
et	O
al	O
.	O
reported	O
the	O
up-regulation	O
of	O
fatty	O
acid	O
synthase	O
and	O
stearoyl-CoA	B
desaturase-1	O
in	O
the	O
lung	O
cancer	O
microenvironment	O
relative	O
to	O
that	O
in	O
adjacent	O
normal	O
tissues.	O

Majority	O
of	O
the	O
species	O
identified	O
are	O
in	O
the	O
class	O
of	O
TG,	B
PC,	O
SM,	O
PE,	O
and	O
LPC,	O
which	O
is	O
proportional	O
to	O
the	O
composition	O
of	O
lipid	O
library.	O

The	O
following	O
corresponding	O
stable	O
labeled	O
compounds	O
were	O
used	O
as	O
internal	O
standards:	O
α-HB-D_3	B
,	O
β-HB-D_3	B
,	I
3-methyl-2-oxobutyric	I
acid-D_7	O
,	O
palmitic	B
acid-_13	O
C_16	O
,	O
margaric	O
acid-D_3	O
,	O
oleic	O
acid-_13	O
C_18	O
,	O
stearic	O
acid-D_3	O
,	O
linoleic	B
acid-_13	O
C_18	O
,	O
linolenic	O
acid-_13	O
C_18	O
,	O
(used	O
for	O
palmitoleic	B
acid),	O
creatine-D_3	B
,	O
octanoyl	B
carnitine-D_3	I
,	O
decanoyl	B
carnitine-D_3	I
,	O
glutamic	B
acid-D_5	O
,	O
glycine-_13	B
C_2	O
-_15	O
N,	O
serine-D3,	B
threonine-_13	B
C_4	O
-_15	O
N,	O
tryptophan-D_5	O
,	O
linoleoyl-lyso-PC-D_9	B
(also	O
used	O
for	O
palmitoyl-lyso-PC	B
and	O
oleoyl-lyso-PC).	B

Briefly,	O
PCA	O
and	O
the	O
internal	O
standard	O
4-hydroxy-3-nitrobenzoic	B
acid	I
(HNBA)	O
were	O
obtained	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Increases	O
in	O
the	O
metabolites	O
hippuric	B
acid,	I
citrate,	B
and	O
lactic	B
acid	I
were	O
associated	O
with	O
infliximab	O
treatment,	O
and	O
increases	O
in	O
the	O
metabolites	O
choline,	B
phenylacetic	B
acid,	I
urea,	B
creatine,	B
and	O
methylamine	B
were	O
associated	O
with	O
etanercept	O
treatment.	O

Biomarkers,	O
lipidomic,	O
sepsis,	O
lysophosphatidylcholine,	B
sphingomyelin	B

Cine	B
MRI	O
was	O
performed	O
with	O
a	O
1.5	O
T	O
system	O
(Sonata,	O
Siemens	O
Medical	O
Solution)	O
and	O
a	O
body	O
array	O
coil.	O

Similarly,	O
the	O
reductions	O
of	O
measured	O
endocannabinoids	B
may	O
support	O
an	O
appraisal	O
of	O
cannabinoid	B
therapy.	O

In	O
particular,	O
the	O
levels	O
of	O
the	O
pharmacologically	O
active	O
triphosphate	B
metabolite	O
of	O
sofosbuvir	B
are	O
in	O
great	O
excess	O
of	O
its	O
inhibition	O
constant	O
for	O
the	O
HCV	O
NS5B	O
polymerase.	O

Food	O
components	O
including	O
trimethylamine,	B
trimethylamine	B
N-oxide,	I
lecithin	B
and	O
choline	B
have	O
been	O
found	O
to	O
increase	O
urinary	O
excretion	O
of	O
DMA	B
and	O
in	O
particular	O
after	O
the	O
consumption	O
of	O
fish	O
and	O
seafood	O
an	O
urinary	O
DMA	B
rise	O
was	O
observed	O
[,	O
].	O

However,	O
using	O
the	O
GC-MS	O
approach	O
we	O
observed	O
lower	O
levels	O
of	O
tryptophan	B
in	O
patients	O
for	O
the	O
combined	O
metabolic	O
profile	O
but	O
did	O
not	O
reach	O
significance	O
for	O
all	O
individual	O
sample	O
batches.	O

Results	O
presented	O
here	O
and	O
our	O
previously	O
published	O
work	O
indicate	O
that	O
MYC	O
drives	O
a	O
concomitant	O
increase	O
in	O
Kyn	O
and	O
AHR,	O
suggesting	O
that	O
the	O
Kyn–AHR	O
pathway	O
is	O
activated	B
in	O
MYC	O
transformed	O
cells.	O

Each	O
container	O
was	O
added	O
with	O
15 ml	O
of	O
3M	O
hydrochloridric	B
acids	I
as	O
a	O
preservative.	O

The	O
sulfhydryl	O
SH	O
of	O
Cys_34	O
reacted	O
with	O
the	O
N=O	O
bond	O
of	O
NO-PhIP	O
to	O
form	O
a	O
semimercaptal,	O
which	O
underwent	O
rearrangement	O
to	O
the	O
more	O
stable	O
sulfinamide	B
structure.	O

Sphingolipid	B
metabolism	O
is	O
decreased	O
in	O
HIV	O
patients	O
compared	O
to	O
healthy	O
controls	O
(T	O
Test	O
=	O
0.012128)	O
particularly	O
in	O
the	O
INR	O
group	O
after	O
antiretroviral	O
treatment	O
(arrow)	O
as	O
demonstrated	O
by	O
the	O
ANOVA	O
analysis	O
of	O
SGPP1	O
activity	O
(p	O
=	O
2.5266E-7,	O
-log10(p)	O

This	O
was	O
a	O
prospective	O
study	O
conducted	O
in	O
an	O
adult	O
medical	O
ICU	O
of	O
the	O
Hospital	O
Universitário	O
São	O
Francisco	O
na	O
Providência	O
de	O
Deus	O
(Bragança	O
Paulista,	O
SP,	B
Brazil).	O

A	O
more	O
recent	O
study	O
demonstrated	O
bile	O
acids	O
can	O
repress	O
hypoxia-inducible	O
factor	O
1α	B
(HIF-1α)	I
signalling	O
and	O
modulate	O
the	O
airway	O
immune	O
response,	O
which	O
may	O
have	O
a	O
significant	O
influence	O
on	O
the	O
progression	O
and	O
outcome	O
of	O
high-altitude	O
respiratory	O
disease.	O

The	O
MS_3	O
spectra	O
correspond	O
to	O
GP-tagged	O
7α-hydroxy-3-oxochol-4-en-24-oic	B
(c	O
)	O
and	O
a	O
trihydroxycholanoic	B
acid,	I
possibly	O
3β,x	B
,y	I
-trihydroxy-5α-cholan-24-oic	I
acid	I
(d	O
).	O

In	O
this	O
article,	O
we	O
perform	O
chemical	O
derivatization	O
using	O
1,1′-_13	B
C_2	I
acetic	I
anhydride	I
followed	O
by	O
1D	O
_13	O
C	O
NMR	O
or	O
inverse	O
detected	O
_1	O
H-_13	O
C	O
heteronuclear	O
single	O
quantum	O
coherence	O
(HSQC)	O
experiments	O
to	O
profile	O
amino	O
acids	O
in	O
human	O
urine	O
and	O
serum	O
with	O
high	O
resolution	O
and	O
sensitivity.	O

Suppression	O
of	O
PC	O
expression	O
should	O
lower	O
oxaloacetate,	B
resulting	O
in	O
a	O
lowered	O
level	O
of	O
aspartate.	B

In	O
plasma,	O
the	O
mean	O
recovery	O
of	O
enzalutamide	B
was	O
100%	O
with	O
a	O
CV	O
of	O
2%;	O
for	O
N-desmethylenzalutamide,	B
it	O
was	O
141%	O
with	O
a	O
CV	O
of	O
2%;	O
and	O
for	O
the	O
internal	O
standard,	O
the	O
mean	O
recovery	O
was	O
102%	O
with	O
a	O
CV	O
of	O
2%.	O

Rtx5Sil-MS	O
column	O
with	O
0.25	O
μm	O
5%	O
diphenyldimethylsiloxane	B
film.	O

Both	O
3-hydroxybutyrate	B
and	O
acetone	B
are	O
ketone	B
bodies,	O
and	O
mainly	O
synthesized	O
from	O
oxidation	O
of	O
fatty	O
acid	O
catalyzed	O
by	O
acetylcoenzyme	B
A	O
in	O
the	O
liver.	O

Reaction	O
of	O
N	B
-acetyl-L-cysteine,	I
6-amino-2-hydroxyhexanoic	B
acid	I
and	O
BDA	O
generated	O
N	B
-acetyl-S	I
-[1-(5-hydroxy-5-carboxypentyl)-1H	I
-pyrrol-3-yl]-L-cysteine.	I

Anastrozole	B
(10–1000	O
µm)	O
was	O
incubated	O
with	O
pooled	O
HLMs	O
and	O
UGT1A4	O
at	O
37°C	O
for	O
90	O
min.	O

Although	O
limited	O
evidence	O
showed	O
that	O
exposure	O
levels	O
of	O
most	O
phthalate	B
metabolites	O
significantly	O
decreased	O
after	O
enacted	O
restrictions	O
and	O
regulation,	O
DEHP	O
exposure	O
levels	O
in	O
reproductive-aged	O
Taiwanese	O
women	O
remain	O
higher	O
than	O
those	O
reported	O
from	O
other	O
countries,	O
warranting	O
further	O
investigation.	O

One	O
potential	O
explanation	O
for	O
decreased	O
brain-glucose	B
uptake	O
could	O
be	O
that	O
of	O
impaired	O
GLUT	O
activity,	O
leading	O
to	O
consequent	O
cerebral	O
‘hypometabolism’.	O

Again,	O
the	O
effect	O
is	O
strongest	O
for	O
the	O
very	O
pH-sensitive	O
metabolite	O
histidine	B
which	O
can	O
be	O
observed	O
within	O
an	O
area	O
of	O
0.54	O
ppm	O
for	O
water,	O
0.76	O
ppm	O
for	O
MeOD,	O
and	O
0.38	O
ppm	O
for	O
DMSO.	B

The	O
samples	O
were	O
dissolved	O
in	O
210	O
µL	O
of	O
hexane	B
for	O
GC-MS	O
analysis.	O

Specifically,	O
cluster	O
two	O
contained	O
several	O
PlsEtns	O
(PtdEtns	O
containing	O
a	O
vinyl-ether	B
linkage	O
at	O
the	O
SN1	O
position),	O
while	O
cluster	O
three	O
contained	O
multiple	O
phosphocholine-related	O
systems	O
including	O
PtdChos,	O
lysoPCs,	O
and	O
several	O
SMs.	O

Patients	O
lack	O
entero-endocrine	O
(EE)	O
cells	O
and	O
have	O
circulating	O
autoantibodies	O
(Aabs)	O
against	O
critical	O
enzymes	O
in	O
serotonin	B
(5-HT)	O
biosynthesis.	O

Other	O
studies	O
have	O
also	O
shown	O
glycoprotein	O
acetyls	O
to	O
associate	O
with	O
hypertension,	O
plasma	O
glucose	B
,	O
and	O
incident	O
type	O
2	O
diabetes	O
.	O

Four	O
samples	O
were	O
analyzed	O
independently	O
in	O
each	O
sample	O
group	O
(black	O
bars	O
,	O
d_6	B
1α,25(OH)_2	I
D_3	O
;	O
gray	O
bars	O
,	O
d_6	O
25(OH)D_3	O
).	O

Therefore,	O
the	O
effects	O
of	O
age,	O
sex	O
and	O
four	O
parameters	O
commonly	O
used	O
to	O
represent	O
the	O
body	O
composition,	O
i.e.	O
central	O
obesity,	O
BMI,	O
LMI	O
and	O
BF,	O
on	O
the	O
concentration	O
of	O
serum	O
sphingolipids	B
were	O
analyzed	O
in	O
112	O
healthy	O
controls	O
to	O
rule	O
out	O
any	O
potential	O
confounding	O
factors.	O

Therefore,	O
the	O
increase	O
in	O
plasma	O
α-keto	B
acids	I
suggest	O
improvement	O
in	O
mitochondrial	O
function	O
as	O
a	O
result	O
of	O
leptin	O
treatment.	O

Cholesterol	B
levels	O
are	O
largely	O
controlled	O
by	O
the	O
liver,	O
which	O
is	O
the	O
major	O
source	O
of	O
cholesterol	B
and	O
LDL	O
via	O
very	O
low-density	O
lipoprotein	O
(VLDL)	O
production,	O
and	O
also	O
the	O
major	O
site	O
of	O
LDL	O
catabolism.	O

This	O
results	O
in	O
the	O
need	O
for	O
hydrocortisone	B
replacement	O
in	O
patients	O
with	O
subclinical	O
and	O
overt	O
adrenal	O
Cushing’s	O
syndrome	O
after	O
curative	O
adrenalectomy.	O

Identification	O
of	O
monohydroxycholesterols	B
and	O
hydroxynorcholestenedione	B
in	O
CSF.	O

Hypoxanthine	B
has	O
been	O
described	O
as	O
a	O
protective	O
agent	O
against	O
hypoxic	O
injury	O
and	O
cytotoxic	O
compounds	O
in	O
normal	O
and	O
cancerous	O
cells.	O

Insulin	O
sensitivity	O
was	O
assessed	O
by	O
use	O
of	O
frequent	O
sampling	O
3-hour	O
oral	O
glucose	B
tolerance	O
tests	O
(OGTTs)	O
where	O
subjects	O
ingested	O
a	O
solution	O
of	O
75	O
g	O
glucose	B
dissolved	O
in	O
300	O
mL	O
water.	O

Lipidomics	O
profiling,	O
Malaria,	O
Plasmodium	O
falciparum	O
,	O
Triacylglycerides,	B
Lysophosphatidylcholines	B

The	O
eluates	O
were	O
evaporated	O
at	O
60 °C	O
under	O
a	O
stream	O
of	O
air	O
and	O
reconstituted	O
with	O
0.15 mL	O
methanol/water	O
(1:1,	O
v	O
/v	O
)	O
containing	O
0.1 %	O
formic	B
acid.	I

The	O
most	O
significant	O
discriminating	O
metabolites	O
(VIP	O
>1.5)	O
included	O
quinolinate,	B
malate,	B
lactate,	B
glycerol,	B
and	O
isobutyrate.	B

We	O
hypothesize	O
the	O
metabolite	O
to	O
be	O
a	O
polyamine	B
derivative,	O
but	O
further	O
investigations	O
will	O
have	O
to	O
confirm	O
the	O
exact	O
chemical	O
identity	O
of	O
the	O
metabolite.	O

The	O
concentration	O
of	O
4-hydroxyphenylacetic	B
acid	I
in	O
sepsis	O
patients	O
decreased	O
with	O
a	O
decrease	O
of	O
the	O
GCS.	O

In	O
line	O
with	O
this,	O
Moi	O
et	O
al.	O
observed	O
in	O
tumor	O
tissues	O
that	O
an	O
increase	O
of	O
coactivator	O
mRNA	O
levels	O
seems	O
to	O
be	O
an	O
early	O
response	O
to	O
tamoxifen	B
without	O
dose–response	O
relationship	O
in	O
the	O
1-	O
to	O
20-mg	O
range.	O

In	O
summary,	O
our	O
study	O
comprehensively	O
captured	O
alterations	O
in	O
the	O
human	O
metabolome	O
associated	O
with	O
different	O
glucose	B
tolerance	O
outcomes	O
of	O
pre-DM	O
in	O
a	O
longitudinal	O
cohort	O
study.	O

The	O
authors	O
concluded	O
that	O
glutamine	B
is	O
able	O
to	O
effectively	O
reduce	O
inflammation.	O

Studies	O
suggest	O
that	O
trigonelline	B
is	O
not	O
substantially	O
metabolized	O
in	O
the	O
human	O
body	O
and	O
is	O
mostly	O
excreted	O
in	O
urine	O
[,	O
].	O

Equally,	O
tumor	O
samples	O
showed	O
high	O
levels	O
of	O
antioxidants,	O
such	O
as	O
ascorbate	B
and	O
alpha/gamma‐tocopherol.	O

Pseudouridine	B
belongs	O
to	O
the	O
group	O
of	O
modified	O
nucleosides	O
that	O
are	O
regarded	O
as	O
indicators	O
of	O
whole-body	O
RNA	O
turnover.	O

We	O
also	O
found	O
that	O
levels	O
of	O
GABA	B
in	O
tumor	O
were	O
lower	O
in	O
GBM	O
compared	O
to	O
oligodendroglioma.	O

Compared	O
to	O
fecal	O
samples	O
of	O
HC,	O
NP	O
and	O
P	O
patients	O
showed	O
significantly	O
higher	O
levels	O
of	O
total	O
SCFA	O
(acetic,	O
propanoic,	O
butanoic	B
and	O
pentanoic	O
acids).	O

Notably,	O
7	O
of	O
the	O
RF-selected	O
features	O
showed	O
additional	O
significant	O
associations	O
with	O
BMI,	O
including	O
the	O
positively	O
related	O
PS	B
(38:1)	I
at	O
m/z	O
800.5850	O
(ESI+,	O
RT	O
=	O
5.20	O
min)	O
and	O
negatively	O
associated	O
LysoPC	O
(18:1)	O
at	O
m/z	O
506.3249	O
(ESI–,	O
RT	O
=	O
1.39	O
min),	O
TG	B
(62:9)	I
at	O
m/z	O
967.8174	O
(ESI+,	O
RT	O
=	O
7.97	O
min),	O
and	O
LysoPC	O
(18:2)	O
at	O
m/z	O
504.3093	O
(ESI–,	O
RT	O
=	O
1.12	O
min)	O
(Fig.	O

For	O
intracellular	O
staining,	O
T	O
cells	O
were	O
stimulated	O
for	O
4	O
hours	O
after	O
the	O
activation	O
using	O
phorbol-12-myristate-13-acetate	B
(PMA)	O
at	O
20	O
ng/mL,	O
ionomycin	B
at	O
1	O
μg/mL,	O
and	O
GolgiStop	O
(BD	O
Biosciences).	O

Imipramine	B
N	O
-glucuronidation	O
activity	O
was	O
determined	O
as	O
previously	O
reported	O
using	O
0.5	O
mm	O
imipramine.	B

With	O
respect	O
to	O
age,	O
tyramine	B
and	O
adenylsuccinic	B
acid	I
were	O
significantly	O
regulated.	O

Increased	O
circulating	O
1-methyladenosine	B
has	O
also	O
been	O
shown	O
to	O
be	O
an	O
early	O
indicator	O
of	O
oxidative	O
stress,	O
cell	O
damage,	O
and	O
mortality	O
in	O
kidney	O
disease.	O

6.	B
5,	I
10-Methylenetrahydrofolate.	I

Cells	O
were	O
either	O
treated	O
with	O
30	O
μM	O
chloroquine	B
for	O
3	O
or	O
5	O
hours	O
or	O
kept	O
in	O
normal	O
growth	O
media.	O

Baby	O
aspirin,	B
ibuprofen,	B
Tylenol	B
or	O
other	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
were	O
used	O
by	O
10	O
GWI	O
participants	O
and	O
3	O
controls	O
(p	O
<	O
0.05).	O

Polymorphisms	O
in	O
these	O
proteins	O
are	O
known	O
to	O
influence	O
simvastatin	B
pharmacokinetics	O
,	O
,	O
.	O

The	O
mobile	O
phases,	O
consisted	O
of	O
0.01%	O
formic	B
acid	I
in	O
distilled	O
water	O
(solvent	O
A),	O
and	O
0.01%	O
formic	B
acid	I
in	O
methanol	B
(solvent	O
B),	O
and	O
were	O
used	O
with	O
a	O
gradient	O
elution	O
of	O
A:B	O
=	O
50;50	O
to	O
10:90	O
(0–0.1	O
min),	O
10:90	O
to	O
5:95	O
(0.1–9.0min),	O
5:95	O
to	O
0:100	O

Abbreviations,	O
Swiss-Prot	O
accession	O
number,	O
and	O
reference	O
to	O
the	O
enzyme,	O
where	O
applicable	O
(or	O
mRNA	O
transcript),	O
in	O
brain	O
are	O
as	O
follows:	O
CYP27A1	O
,	O
cytochrome	O
P450	O
27A1,	O
Q02318;	O
CYP46A1	O
,	O
cytochrome	O
P450	O
46A1,	O
Q9Y6A2;	O
CYP7B1	O
,	O
cytochrome	O
P450	O
7B1,	O
O75881;	O
CYP39A1	O
,	O
cytochrome	O
P450	O
39A1,	O
Q9NYL5;	O
HSD3B7	O
,	O
3β-hydroxysteroid	O
dehydrogenase	O
type	O
7,	O
Q9H2F3;	O
VLCS	O
,	O
very	O
long	O
chain	O
acyl-CoA	B
synthetase,	O
O35488;	O
AMACR	O
,	O
α-methylacyl-CoA	B
racemase,	O
Q9UHK6;	O
BCOX	O
,	O
branched	O
chain	O
acyl-CoA	B
oxidase,	O
Q99424;	O
DBP	B
,	O
d-bifunctional	O
protein,	O
P51659;	O
LBP	O
,	O
l-bifunctional	O
protein,	O
Q08426;	O
SCPx	O
,	O
sterol	O
carrier	O
protein	O
x	O
,	O
P22307.	O

In	O
the	O
patient	O
group	O
with	O
highly	O
active	O
MS,	O
15-HETE	B
and	O
PGE_2	O
were	O
increased,	O
which	O
are	O
products	O
of	O
the	O
15-lipoxygenase	O
and	O
cyclooxygenase	O
pathways.	O

Controlling	O
for	O
lactate,	B
a	O
metabolite	O
associated	O
with	O
suboptimal	O
handling,	O
removed	O
much	O
of	O
the	O
bias	O
associated	O
with	O
location	O
and	O
thus	O
may	O
explain	O
the	O
cause.	O

Standard	O
stock	O
solutions	O
were	O
prepared	O
in	O
methanol	B
containing	O
the	O
18	O
compounds	O
at	O
a	O
concentration	O
of	O
10	O
ng/ml,	O
including,	O
T,	O
Prog,	O
E1,	B
2OH-3MeO-E1,	I
2MeO-E1,	I
4MeO-E1,	I
4OH-E1,	I
2OH-E1,	I
16αOH-E1,	I
E2,	B
16keto-E2,	I
2MeO-E2,	O
4MeO-E2,	O
2OH-E2,	O
4OH-E2,	O
E3,	O
16epi-E3,	O
17epi-E3.	O

(C)	O
T2DM-NC	O
vs.	O
T2DM-C.	O
(a)	O
Alanine,	B
aspartate	B
and	O
glutamate	B
metabolism;	O
(b)	O
d-glutamine	B
and	O
d-glutamate	B
metabolism;	O
(c)	O
lysine	B
degradation;	O
(d)	O
phenylalanine	B
metabolism;	O
(e)	O
aminoacyl-tRNA	B
biosynthesis;	O
(f)	O
valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis;	O
(g)	O
valine,	B
leucine	B
and	O
isoleucine	B
degradation.	O

After	O
collection	O
of	O
the	O
polar	O
phases	O
(6	O
mL),	O
proteins	O
were	O
precipitated	O
for	O
each	O
sample	O
by	O
addition	O
of	O
8	O
mL	O
100%	O
MeOH	B
to	O
avoid	O
phase	O
separation	O
followed	O
by	O
centrifugation	O
at	O
16,000×	O
g	O
speed	O
for	O
10	O
min.	O

A	O
particular	O
behavior	O
was	O
observed	O
for	O
the	O
cholesteryl	B
ester	I
internal	O
standard,	O
which	O
was	O
detected	O
at	O
10 ng.mL_−1	O
,	O
but	O
whose	O
linearity	O
range	O
started	O
at	O
100 ng.mL_−1	O
.	O

Standardized	O
biplot	O
of	O
the	O
PLS-DA	O
between	O
HNSCC-patients	O
(red	O
circles)	O
and	O
controls	O
(blue	O
triangles),	O
(#	O
-	O
1,8-cineole	O
and	O
1-propanol)	B

(A)	O
PhIP,	O
4′-HO-PhIP	O
and	O
5-HO-PhIP	B
@	O
a	O
CID	O
of	O
32	O
eV,	O
and	O
HONH-PhIP	O
and	O
1-[_2	O
H_3	O
C]-HONH-PhIP	O
@	O
a	O
CID	O
of	O
20	O
eV.	O
(B)	O
Isomeric	O
PhIP-N	O
-Gl	O
and	O
HONH-PhIP-N	O
-Gl	O
conjugates	O
and	O
1-[_2	O
H_3	O
C]-HONH-PhIP-N	O
3-Gl	O
@	O

ROS	O
in	O
turn	O
stimulates	O
glutathione	B
production	O
via	O
NRF2	O
signaling	O
and	O
subsequent	O
increased	O
expression	O
of	O
γ-glutamylcysteine	B
ligase,	O
the	O
key	O
enzyme	O
in	O
glutathione	B
production.	O

Acetonitrile	B
(HPLC	O
grade),	O
methanol	B
(HPLC	O
grade),	O
and	O
methylimidazole	B
were	O
purchased	O
from	O
Fisher/Aldrich	O
(NJ,	O
USA).	O

tryptophan,	B
tyrosine,	B
and	O
creatine	B
in	O
tissue	O
and	O
serum,	O
which	O
could	O
be	O
useful	O
in	O
screening	O
of	O
IDC	O
subjects	O
from	O
both	O
control	O
and	O
benign.	O

In	O
the	O
present	O
study,	O
a	O
distinct	O
biochemical	O
process	O
related	O
to	O
glutathione,	B
glycine	B
and	O
bile	O
acid	O
metabolism	O
distinguished	O
children	O
with	O
IBD	O
from	O
healthy	O
matched	O
controls.	O

Serum	O
TNFα	O
was	O
negatively	O
associated	O
with	O
tryptophan	B
(P	O
<	O
0.001),	O
but	O
was	O
not	O
significantly	O
associated	O
with	O
any	O
of	O
its	O
kynurenine	B
metabolites.	O

Both	O
Lyso-PCs	O
and	O
SMs	O
were	O
downregulated,	O
whereas	O
the	O
saturated	O
and	O
unsaturated	O
phosphatidylcholines	B
(PCs)	O
were	O
upregulated	O
in	O
the	O
plasma	O
and	O
erythrocytes	O
of	O
septic	O
patients.	O

Regarding	O
bile	O
acid	O
homeostasis,	O
an	O
early	O
study	O
recognized	O
that	O
fasting	O
serum	O
glycocholate	B
concentrations	O
were	O
elevated	O
in	O
most	O
patients	O
with	O
liver	O
disease,	O
but	O
especially	O
in	O
LC	O
(97.1%	O
of	O
cases)	O
and	O
HCC	O
(94.7%).	O

As	O
shown	O
in	O
Figs 	O
and	O
,	O
5-phosphoribosylamine	B
and	O
some	O
downstream	O
derivatives	O
involved	O
in	O
de	O
novo	O
purine	B
biosynthesis	O
were	O
consistently	O
increased	O
among	O
HTK	O
users,	O
whereas	O
most	O
metabolites	O
associated	O
with	O
purine-degrading	O
metabolic	O
processes	O
were	O
significantly	O
and	O
consistently	O
decreased.	O

These	O
plasma	O
metabolites	O
comprised	O
free	O
carnitine	B
(C0),	O
acetylcarnitine	B
(C2)	O
as	O
well	O
as	O
five	O
long-chain	O
acylcarnitines	B
(C14:1,	I
C16,	I
C18,	I
C18:1	I
and	O
C18:2),	B
which	O
were	O
all	O
increased	O
in	O
the	O
NDMM	O
population	O
(	O
and	O
Part	O
A	O
in	O
).	O

The	O
diagnosis	O
of	O
GDM	O
was	O
according	O
to	O
the	O
International	O
Association	O
of	O
Diabetes	O
and	O
Pregnancy	O
Study	O
Group	O
(IADPSG)	O
criteria,	O
with	O
one	O
or	O
more	O
plasma	O
glucose	B
values	O
being	O
equal	O
or	O
greater	O
than	O
the	O
following	O
plasma	O
glucose	B
values:	O
fasting,	O
5.1	O
mmol/L,	O
1	O
h,	O
10.0	O
mmol/L,	O
and	O
2	O
h,	O
8.5	O
mmol/	O

Although	O
most	O
patients	O
with	O
FESZ	O
received	O
medication,	O
altered	O
levels	O
of	O
these	O
metabolites	O
were	O
specific	O
in	O
patients	O
with	O
FESZ,	O
and	O
consistent	O
with	O
well-known	O
hypotheses	O
regarding	O
abnormalities	O
of	O
the	O
homocysteine	B
metabolism,	O
PACK	O
and	O
oxidative	O
stress.	O

Finally,	O
ursodeoxycholic	B
acid	I
(UDCA),	O
a	O
secondary	O
bile	O
acid	O
produced	O
by	O
intestinal	O
bacteria	O
was	O
approximately	O
63%	O
higher	O
in	O
healthy	O
individuals	O
compared	O
to	O
CRC.	O

Lower	O
1,5-AG	B
concentrations	O
at	O
higher	O
glucose	B
levels	O
in	O
participants	O
with	O
diabetes	O
when	O
compared	O
to	O
the	O
control	O
group	O
display	O
the	O
current	O
role	O
of	O
1,5-AG	B
as	O
a	O
marker	O
for	O
glycemic	B
control	O
in	O
patients	O
with	O
diabetes.	O

Suppression	O
of	O
PC	O
decreased	O
the	O
levels	O
of	O
total	O
citrate	B
and	O
malate	B
and	O
_13	O
C	O
incorporation	O
into	O
their	O
isotopomers	O
from	O
_13	O
C_6	O
-labeled	O
glucose	B
and	O
_13	O
C_5	O
-labeled	O
glutamine.	B

Nomenclature:	O
1,	O
lipid;	O
2,	O
branched	O
amino	O
acids;	O
3,	O
alanine;	B
4,	O
acetoacetate;	B
5,	O
creatine;	B
6,	O
tyrosine;	B
7,	O
acetate;	B
8,	O
N-acetyl	B
glycoprotein;	I
9,	O
citrate;	B
10,	O
glucose.	B

Cells	O
were	O
shipped	O
overnight	O
on	O
cold	O
preservation	O
media,	O
and,	O
upon	O
receipt,	O
media	O
were	O
replaced	O
with	O
serum-free	O
Williams'	O
E	O
media	O
(without	O
phenol	B
red)	O
and	O
supplements	O
as	O
described	O
previously.	O

_,	O
_,	O
Remarkably,	O
high	O
quality	O
product	O
ion	O
scan	O
spectra	O
were	O
acquired	O
on	O
less	O
than	O
1	O
pg	B
(<	O
5	O
fmol	O
equivalent	O
of	O
HAA)	O
for	O
PhIP,	O
MeIQx	O
(not	O
shown),	O
and	O
several	O
of	O
the	O
metabolites.	O

-hydroxycholesterol	B
pathway.	O

Compounds	O
that	O
had	O
significantly	O
higher	O
concentrations	O
in	O
subjects	O
with	O
high	O
plasma	O
cystathionine	B
concentrations	O
were	O
amino	O
acids	O
(phenylalanine,	O
cysteine,	B
proline,	B
glutamic	B
acid,	I
tyrosine,	B
isoleucine,	B
tryptophan,	B
valine,	B
leucine,	B
and	O
alanine	B
or	O
sarcosine),	O
acylcarnitines,	B
and	O
tryptophan	B
catabolism	O
metabolites	O
(kynurenine	O
and	O
kynurenic	O
acid),	O
creatinine,	B
aldopentose,	O
cysteinylglycine,	B
malate,	B
choline,	B
and	O
homovanillate.	B

Estrogen	B
receptor	O
(ER),	O
progesterone	B
receptor	O
(PR)	O
status,	O
Ki-67	O
labeling	O
index,	O
expression	O
and/or	O
HER2	O
gene	O
amplification	O
were	O
routinely	O
performed	O
following	O
international	O
recommendations	O
[–].	O

A	O
very	O
good	O
correlation	O
between	O
measured	O
diosmetin	B
and	O
glucuronide	B
metabolites	O
concentrations	O
was	O
obtained.	O

For	O
example,	O
studies	O
showed	O
that	O
caffeinated	O
coffee	O
stimulates	O
colonic	O
motor	O
activity	O
to	O
a	O
greater	O
extent	O
than	O
does	O
decaffeinated	O
coffee,	O
caffeine	B
inhibits	O
colon	O
cancer	O
cell	O
growth,	O
and	O
theophylline	B
induces	O
apoptosis	O
in	O
cancer	O
cell	O
lines.	O

A	O
consisted	O
of	O
0.1%	O
FA	B
in	O
water,	O
while	O
mobile	O
phase	O
B	O
consisted	O
of	O
0.1%	O
FA	B
in	O
methanol.	B

All	O
included	O
nucleosides/ribosylated	O
metabolites	O
were	O
isolated	O
by	O
cis-diol	B
specific	O
affinity	O
chromatography	O
and	O
measured	O
with	O
liquid	O
chromatography	O
ion	O
trap	O
mass	O
spectrometry	O
(LC-ITMS).	O

Increased	O
levels	O
of	O
polyamines	B
have	O
been	O
reported	O
in	O
the	O
plasma	O
and	O
urine	O
of	O
cancer	O
patients.	O

The	O
subjects	O
lay	O
in	O
the	O
supine	B
position	O
under	O
cooling	O
blankets	O
for	O
2 h,	O
and	O
simultaneously,	O
indirect	O
calorimetry	O
measurements	O
were	O
carried	O
out.	O

Arachidonic	B
acid	I
metabolism	O
and	O
related	O
anti-inflammatory	O
pathway	O
was	O
found	O
to	O
be	O
downregulated	O
by	O
prednisone	B
treatment	O
(	O
and	O
,	O
).	O

OH	B
(80:15:5),	I
sequentially.	O

Serum	O
S1P	O
and	O
urine	O
sphingosine	B
may	O
be	O
potential	O
biomarkers	O
for	O
the	O
AERD	O
phenotype.	O

According	O
to	O
the	O
breast	O
cancer	O
hypothesis,	O
16α-hydroxylated	O
estrogens	O
induces	O
breast	O
carcinogenesis	O
due	O
to	O
their	O
much	O
stronger	O
hormonal	O
and	O
mitogenic	O
activity	O
as	O
compared	O
to	O
the	O
catechol	B
estrogens.	O

Human	O
plasma	O
revealed	O
134	O
distinct	O
spectral	O
peaks	O
definitively	O
identified	O
as	O
known	O
oxylipins	B
by	O
precise	O
matching	O
of	O
retention	O
time,	O
accurate	O
mass,	O
and	O
tandem	O
MS	O
fragmentation	O
pattern	O
to	O
one	O
of	O
225	O
commercially	O
available	O
standards,	O
including	O
well	O
described	O
members	O
of	O
prostaglandin,	B
HETE,	O
DHET,	O
HODE	O
and	O
additional	O
families.	O

Hematoxylin	B
stain	O
was	O
performed	O
by	O
a	O
3	O
minute	O
incubation	O
in	O
hematoxylin,	B
a	O
rinse	O
in	O
deionized	O
water,	O
5	O
minute	O
incubation	O
in	O
water,	O
and	O
8	O
to	O
12	O
rapid	O
dips	O
in	O
0.3%	O
acidified	O
ethanol	O
(2,800	O
ml	O
ethanol:1,200ml	O
water:12	O
ml	O
concentrated	O
hydrochloric	O
acid)	O
to	O
de-stain	O
followed	O
by	O
2	O
×	O
1	O
minute	O
incubations	O
in	O
tap	O
water	O
and	O
a	O
2-minute	O
rinse	O
in	O
deionized	O
water.	O

Once	O
renal	O
function	O
starts	O
to	O
decrease,	O
blood	O
oxalate	B
levels	O
increase,	O
and	O
calcium-oxalate	B
crystals	O
are	O
deposited	O
throughout	O
the	O
body.	O

Totally,	O
we	O
identified	O
five	O
biomarkers	O
that	O
involved	O
in	O
different	O
metabolic	O
pathway	O
such	O
as	O
purine	B
metabolism,	O
amino	O
acid	O
metabolism	O
and	O
tyrosine	B
metabolism.	O

Creatinine	B
is	O
one	O
of	O
the	O
most	O
abundant	O
metabolites	O
in	O
urine	O
and	O
its	O
levels	O
are	O
affected	O
by	O
several	O
factors,	O
such	O
as	O
dietary	O
habit	O
and	O
muscle	O
mass.	O

To	O
test	O
this	O
hypothesis,	O
we	O
profiled	O
LPA(16:0)	B
concentrations	O
in	O
HCC	O
and	O
control	O
plasma	O
by	O
UPLC-ESI-TQMS.	O

Theophylline	B
can	O
be	O
labeled	O
by	O
the	O
dansylation	O
reagent.	O

N	B
-Acetyl-S	I
-(9,10-dihydro-9-hydroxy-10-phenanthryl)-L-cysteine	I
(PheONAC,	O
12)	O
was	O
prepared	O
by	O
the	O
reaction	O
of	O
Phe-9,10-epoxide	B
(11)	O
with	O
N	B
-acetyl-L-cysteine	I
(Sigma-Aldrich,	O
St.	O
Louis,	O
MO),	O
essentially	O
as	O
described	O
previously.	O

The	O
same	O
study	O
revealed	O
that	O
lower	O
level	O
of	O
serum	O
lathosterol	B
was	O
associated	O
with	O
a	O
decrease	O
in	O
cholesterol	B
synthesis.	O

First	O
of	O
all,	O
ω-3	B
PUFAs	I
are	O
essential	O
fatty	O
acids	O
which	O
cannot	O
be	O
synthesized	O
in	O
the	O
body	O
and	O
therefore	O
have	O
to	O
be	O
consumed	O
from	O
diet;	O
thus,	O
a	O
lack	O
of	O
ingestion	O
of	O
ω-3	B
PUFAs	I
may	O
be	O
a	O
potential	O
reason.	O

Bovine	O
paratuberculosis,	O
choline	B
glycerophospholipids,	I
sphingolipids,	B
microflora,	O
SLC11A1	O

For	O
control	O
samples,	O
the	O
pH	O
of	O
the	O
medium	O
was	O
directly	O
adjusted	O
to	O
6.5	O
with	O
0.1	O
M	O
of	O
acetic	B
acid.	I

Therefore,	O
it	O
is	O
likely	O
that	O
accumulation	O
of	O
d16:1	B
SPs	O
is	O
due	O
to	O
a	O
dysregulation	O
of	O
SPT	O
subunit	O
genes	O
as	O
a	O
result	O
of	O
increased	O
adiposity.	O

The	O
area	O
ratio	O
of	O
ion	O
abundance	O
in	O
the	O
peaks	O
of	O
interest	O
to	O
internal	O
standards	O
were	O
compared	O
with	O
standard	O
curves	O
generated	O
over	O
a	O
range	O
from	O
0.2	O
to	O
10	O
ng	O
for	O
20-HETE	B
and	O
from	O
1.0	O
to	O
10	O
ng	O
for	O
other	O
metabolites	O
in	O
order	O
to	O
quantify	O
the	O
production	O
of	O
20-HETE	B
and	O
other	O
eicosanoids.	B

This	O
finding	O
corroborates	O
the	O
inverse	O
correlation	O
we	O
found	O
(R	O
=	O
0.49	O
p	O
<	O
0.01)	O
between	O
PCS	O
and	O
the	O
meat-intake-correlated	O
metabolite	O
1-MHis.	B

Ammonium	B
hydroxide	I
(28%	O
in	O
H2O)	O
was	O
purchased	O
from	O
Sigma-Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

A	O
metabolic	O
enrichment	O
analysis	O
demonstrated	O
that	O
arginine	B
fall	O
into	O
pathways	O
affected	O
by	O
amino	O
acid	O
turnover	O
or	O
protein	O
biosynthesis,	O
cysteine	B
metabolism,	O
urea	B
metabolism,	O
as	O
well	O
as	O
arginine	B
and	O
proline	B
metabolism.	O

In	O
human	O
colorectal	O
adenocarcinomas	O
and	O
liver	O
metastasis,	O
high	O
mass	O
resolution	O
DESI-MSI	O
allowed	O
the	O
identification	O
of	O
many	O
lipids	O
with	O
increased	O
abundance	O
in	O
colorectal	O
adenocarcinoma	O
tissue,	O
including	O
glycerophosphoetanolamines,	B
glycerophosphoglycerols,	B
and	O
glycerophosphoinositols.	B

For	O
each	O
sample,	O
250 µL	O
urine	O
was	O
mixed	O
with	O
250 µL phosphate	B
-	I
buffered	I
saline (PBS)	I
(pH	O
7.4)	O
containing	O
3 mM	O
NaN_3	O
and	O
5.5 mM	O
trimethylsilyl	B
propanoic	I
acid	I
(for	O
chemical	O
shift	O
and	O
line-shape	O
calibration)	O
and	O
then	O
transferred	O
to	O
5 mm	O
NMR	O
tubes.	O

Interestingly,	O
lower	O
levels	O
of	O
cyclic	B
AMP,	I
a	O
negative	O
regulator	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(EGFR)	O
is	O
observed	O
in	O
IDC	O
serum,	O
thereby	O
possibly	O
providing	O
survival	O
advantage	O
for	O
tumours	O
and	O
promote	O
further	O
growth.	O

The	O
reverse	O
trend	O
in	O
amino	O
acid	O
expression	O
was	O
true	O
for	O
the	O
comparison	O
between	O
DCs	O
and	O
NHCs,	O
with	O
HCV-cirrhosis	O
patients	O
exhibiting	O
strongly	O
significant	O
downregulation	O
of	O
serine,	B
glycine,	B
aspartate,	B
glutamate	B
and	O
phenylalanine.	B

There	O
were	O
no	O
differences	O
in	O
age	O
(AS	O
50.5	O
±	O
16.2	O
v	O
NS	O
52.4	O
±	O
15.4),	O
weight	O
(AS	O
88.3	O
±	O
17.3	O
v	O
NS	O
83.1	O
±	O
20.3),	O
BMI	O
(AS	O
30.1	O
±	O
5.7	O
v	O
NS	O
28.9	O
±	O
5.9),	O
waist	O
(AS	O
97.0	O
±	O
2.2	O
v	O
NS	O
93.2	O
±	O
2.6),	O
or	O
hip	O
circumference	O
(AS	O
106.3	O
±	O
14.8	O
v	O
NS	O
103.2	O
±	O
17.6),	O
Baseline	O
biochemical	O
parameters	O
were	O
comparable	O
in	O
the	O
AS	O
and	O
NS	O
subjects;	O
however,	O
higher	O
triglycerides	B
(2.05	O
±	O
1.44	O
vs.	O
1.26	O
±	O
0.84mmol/L;	O
p	O
value	O
0.008)	O
and	O
lower	O
HDL-C	O
(1.16	O
±	O
0.34	O
vs.	O
1.35	O
±	O
0.54	O
mmol/L;	O
p	O
value	O
0.04)	O
were	O
observed	O
in	O
the	O
AS	O
group.	O

(D)	O
Relative	O
intensity	O
of	O
N-formylkynurenine	B
in	O
RCC,	O
benign	O
and	O
control	O
groups	O
in	O
the	O
training	O
set.	O

Thirty-eight	O
NW	O
and	O
57	O
obese	O
participants	O
were	O
classified	O
to	O
have	O
normoglycemia	O
[defined	O
as	O
a	O
glycated	O
hemoglobin	O
(HbA1c)	O
<	O
5.7%	O
(n	O
=	O
84),	O
fasting	O
glucose	B
<100	O
mg/dl	O
(n	O
=	O
95),	O
and/or	O
normal	O
glucose	B
tolerance	O
during	O
an	O
oral	O
glucose	B
tolerance	O
test	O
(n	O
=	O
9)]	O
and	O
44	O
obese	O
youth	O
to	O
have	O
dysglycemia	O
[21	O
with	O
impaired	O
fasting	O
glucose	B
(≥100	O
mg/dl),	O
six	O
with	O
impaired	O
glucose	B
tolerance	O
(≥140	O
mg/dl),	O
and	O
17	O
with	O
T2DM].	O

Acetoacetate	B
and	O
3-HIB	O
were	O
correlated	O
and	O
were	O
elevated	O
in	O
both	O
T1DM	O
and	O
T2DM	O
women,	O
whereas	O
only	O
3-HIB	O
was	O
elevated	O
in	O
the	O
IGT	O
group.	O

However,	O
in	O
rodent	O
diabetes	O
models,	O
it	O
was	O
found	O
that	O
muscle	O
hexosylceramide	B
levels	O
increased	O
in	O
a	O
T2DM	O
model	O
but	O
decreased	O
in	O
a	O
T1DM	O
model.	O

Indeed,	O
a	O
recent	O
longitudinal	O
ECT	O
study	O
shows	O
that	O
repeated	O
ECT	O
administration	O
increases	O
the	O
levels	O
of	O
KYNA,	O
shifting	O
the	O
balance	O
toward	O
the	O
neuroprotective	O
branch	O
of	O
the	O
kynurenine	B
pathway.	O

They	O
also	O
reported	O
d20:1	B
LCB	O
in	O
bovine	O
optic	O
nerve.	O

The	O
biotransformation	O
of	O
P	O
and	O
IP	B
by	O
human	O
intestinal	O
bacteria	O
was	O
performed	O
in	O
10-mL	O
incubation	O
glass	O
tubes	O
containing	O
3	O
mL	O
GAM	O
and	O
200	O
µL	O
of	O
the	O
intestinal	O
microflora	O
solution,	O
and	O
cultivated	O
for	O
12	O
h.	O

Levels	O
of	O
8-iso	B
-PGF_2α	I
and	O
PGE-M	O
were	O
analyzed	O
with	O
respect	O
to	O
amount	O
of	O
smoking,	O
gender,	O
age,	O
and	O
BMI.	O

Throughout	O
most	O
of	O
pregnancy	O
fetus	O
skin	O
is	O
transparent	O
thus	O
high	O
levels	O
of	O
urocanate	B
in	O
AF	B
in	O
T2	O
might	O
reflect	O
rapid	O
growth	O
of	O
skin	O
and	O
requirement	O
for	O
photoprotectants.	O

The	O
detection	O
limit	O
was	O
1	O
ng/mL	O
and	O
the	O
quantification	O
limit	O
5	O
ng/mL.	O
24S-OH-Chol	B
was	O
reported	O
as	O
plasma	O
levels	O
(ng/ml).	O

Patients	O
with	O
primary	O
pigmented	O
nodular	O
adrenocortical	O
disease,	O
another	O
adrenal	O
cause	O
of	O
glucocorticoid	B
excess,	O
do	O
not	O
suppress	O
after	O
dexamethasone	B
either,	O
but	O
have	O
been	O
shown	O
to	O
paradoxically	O
increase	O
glucocorticoid	B
production	O
in	O
response	O
to	O
dexamethasone.	B

The	O
effects	O
of	O
diagnosis	O
on	O
the	O
nervonic	B
acid	I
levels	O
remained	O
significant	O
(P=	O
.0016),	O
although	O
the	O
levels	O
of	O
nervonic	B
acid	I
were	O
affected	O
by	O
age	O
(P=	O
.010).	O

We	O
found	O
that	O
the	O
total	O
abundance	O
of	O
triglyceride	B
(TG)	O
increased	O
significantly	O
in	O
bvFTD,	O
whereas	O
phosphatidylserine	B
and	O
phosphatidylglycerol	B
decreased	O
significantly	O
in	O
bvFTD.	O

Trigonelline	B
was	O
the	O
7_th	O
strongest	O
discriminant	O
between	O
the	O
groups	O
in	O
our	O
study	O
(p-value = 8.68×10_−6	O
,	O
VIP = 2.57),	O
and	O
the	O
2_nd	O
most	O
intense	O
discriminant	O
in	O
urine	O
of	O
high	O
coffee	O
consumers.	O

A	O
more	O
detailed	O
investigation	O
is	O
necessary	O
to	O
further	O
characterize	O
the	O
relationship	O
between	O
carnitine	B
metabolites	O
and	O
PDR.	O

For	O
example,	O
the	O
coefficient	O
of	O
variation	O
(CV)	O
for	O
glucose	B
levels	O
for	O
a	O
2	O
h	O
OGTT	O
is	O
∼25%	O
,	O
thereby	O
leading	O
to	O
very	O
low	O
reproducibility	O
of	O
the	O
OGTT	O
test	O
for	O
diagnosing	O
IGT.	O

Whole	O
body	O
insulin-mediated	O
glucose	B
disposal	O
(Rd)	O
increased	O
significantly	O
(6.5	O
±	O
0.3	O
to	O
8.0	O
±	O
0.5	O
mg/kg	O
·	O
min;	O
P	O
<	O
0.01),	O
and	O
insulin-mediated	O
suppression	O
of	O
endogenous	O
glucose	B
production,	O
determined	O
during	O
the	O
150-	O
to	O
180-min	O
period	O
of	O
the	O
euglycemic	B
insulin	O
clamp	O
(0.20	O
±	O
0.04	O
vs	O
.	O
0.05	O
±	O
0.01	O
mg/kg	O
·	O
min,	O
P	O
<	O
0.05),	O
was	O
enhanced	O
after	O
pioglitazone	B
treatment.	O

Thus	O
our	O
results	O
indicate	O
that	O
3β-	B
hydroxycholest-5-en-26-oic,	I
3β,7α-	B
dihydroxycholest-5-en-26-oic,	I
and	O
7α,12α-dihydroxy-3-oxo-5β-cholan-24-oic	B
acids	I
are	O
specific	O
LXRα	O
ligands.	O

(D)	O
Total	O
lysophosphatidylcholines	B
concentration	O
according	O
to	O
sex.	O

[N	O
-acetyl-D_3	I
]HMPMA	O
in	O
0.1	O
mL	O
H_2	O
O	O
was	O
added	O
carefully	O
to	O
each	O
well.	O

Ongoing	O
platelet	O
metabolism	O
during	O
sample	O
processing	O
may	O
explain	O
lower	O
levels	O
of	O
citrate	B
and	O
pyruvate,	B
whereas	O
positive	O
correlations	O
with	O
glutamate	B
and	O
other	O
amino	O
acids	O
may	O
be	O
explained	O
by	O
platelet	O
transport	O
of	O
these	O
molecules.	O

Some	O
PAHs	O
are	O
found	O
more	O
likely	O
to	O
cause	O
adductations	O
as	O
they	O
present	O
a	O
more	O
adduct	O
friendly	O
structural	O
organizations	O
(i.e.	O
the	O
bay-regions	O
of	O
benzo[a	B
]pyrene)	I
or	O
they	O
have	O
higher	O
frequency	O
of	O
specific	O
reactive	O
metabolic	O
states,	O
e.g.	O
anti-diol	O
epoxide	B
metabolites	O
.	O

In	O
addition,	O
Mika	O
Hilvo	O
et	O
al	O
.	O
indicated	O
that	O
monounsaturated	O
fatty	O
acids	O
in	O
serum	O
triacylglycerols	B
were	O
associated	O
with	O
response	O
to	O
neoadjuvant	O
chemotherapy	O
in	O
breast	O
cancer	O
patients.	O

Several	O
amino	O
acids,	O
glucose,	B
organic	O
acids,	O
lipids,	O
choline	B
were	O
demonstrated	O
in	O
the	O
spectra.	O

Taken	O
together,	O
the	O
metabolic	O
pathways	O
involving	O
cysteine,	B
cysteamine,	B
and	O
taurine	B
might	O
be	O
useful	O
for	O
differentiating	O
between	O
colorectal	O
cancer	O
patients	O
and	O
healthy	O
volunteers.	O

NADPH	B
is	O
exchanged	O
for	O
NADH	B
in	O
this	O
pathway,	O
which	O
compromises	O
NADPH-dependent	O
reactions	O
such	O
as	O
glutathione	B
reductase	O
and	O
nitric	B
oxide	I
synthase.	O

Temperature	O
calibration	O
was	O
performed	O
using	O
methanol-d_4	B
(D-99.6%).	O

Prior	O
to	O
analysis,	O
800	O
µL	O
of	O
80%	O
acetonitrile	B
was	O
added	O
to	O
100	O
µL	O
of	O
plasma,	O
mixed	O
by	O
vortexing,	O
and	O
centrifuged	O
at	O
10,000	O
rpm	O
for	O
5	O
minutes	O
at	O
4°C.	O

The	O
vitamin	B
E	I
metabolites	O
were	O
detected	O
using	O
multiple-reaction	O
monitoring	O
mode	O
of	O
the	O
transitions	O
at	O
356.9>79.7	O
and	O
453.0>112.8	O
m/z	O
for	O
the	O
α-CEHC/TL	O
sulfates	B
and	O
glucuronides,	O
respectively.	O

Multiple	O
reaction	O
monitoring	O
ion	O
chromatograms	O
for	O
THCVCOOH,	O
THCCOOH-gluc,	O
THC-gluc,	O
THCCOOH,	O
THCAA	O
and	O
11-OH-THC	B
in	O
urine	O
showing	O
blank	O
urine,	O
limits	O
of	O
quantification	O
and	O
an	O
authentic	O
urine	O
specimen	O
collected	O
from	O
a	O
participant	O
20	O
h	O
after	O
a	O
vaporized	O
54	O
mg	O
THC	O
dose.	O

A	O
recent	O
study	O
also	O
reported	O
that	O
high	O
plasma	O
cystine	B
(oxidized)	O
and	O
low	O
glutathione	B
concentrations	O
were	O
strongly	O
associated	O
with	O
higher	O
mortality.	O

The	O
9000	O
×	O
g	O
supernatant	O
(300	O
uL)	O
was	O
added	O
to	O
1.5	O
mL	O
of	O
100	O
mM	O
Tris–HCl	O
buffer	O
pH	O
8.0,	O
with	O
3	O
mM	O
β-nicotinamide	B
adenine	I
dinucleotide	O
(NAD),	O
4	O
mM	O
acetaldehyde,	B
100	O
mM	O
potassium	B
chloride	I
and	O
10	O
mM	O
2-mercaptoethanol.	O

Calcium	B
formate,	I
deuterium	O
chloride,	B
and	O
sodium	B
deuteroxide	I
were	O
obtained	O
from	O
Sigma	O
Aldrich	O
(St.	O
Louis,	O
MO,	O
USA).	O

Moreover,	O
inosine	B
was	O
increased	O
significantly	O
in	O
the	O
DT-MDD	O
group	O
compared	O
with	O
HCs,	O
with	O
an	O
AUC	O
of	O
0.866	O
in	O
discriminating	O
DT-MDD	O
from	O
HCs	O
(Fig. ).	O

,4-bis[(trimethylsilyl)oxy]-	B
(,	I
).	I

Aspartame	B
(100mg,	O
equivalent	O
to	O
that	O
consumed	O
in	O
a	O
can	O
of	O
diet	O
soda	O
and	O
less	O
than	O
the	O
Acceptable	O
Daily	O
Intake	O
maximum	O
(ADI)	O
recommended	O
by	O
FDA	O
of	O
40mg/kg	O
body	O
weight/day)	O
was	O
incorporated	O
into	O
cold	O
pressed	O
cereal	O
bars	O
(Campden	O
BRI,	O
United	O
Kingdom).	O

Whether	O
or	O
not	O
elevated	O
lactate	B
and	O
alanine	B
can	O
be	O
used	O
as	O
a	O
tumor	O
marker	O
for	O
papillary	O
thyroid	O
carcinoma	O
needs	O
to	O
be	O
further	O
studied.	O

In	O
a	O
preliminary	O
small	O
study	O
using	O
the	O
same	O
NMR	O
techniques,	O
on	O
unfiltered	O
residual	O
serum	O
samples,	O
we	O
showed	O
that	O
some,	O
but	O
non	O
significant,	O
separation	O
between	O
EBC	O
and	O
healthy	O
women	O
was	O
mainly	O
due	O
to	O
lipids	O
fractions,	O
glucose,	B
alanine,	B
lactate,	B
β-hydroxy-butyrate	B
and	O
acetate	B
(Oral	O
presentation	O
in	O
ESMRMB	O
Congress,	O
Lisbon	O
2012).	O

Next,	O
we	O
examined	O
the	O
expression	O
of	O
myo-inositol	O
oxygenase	O
(MIOX),	O
which	O
is	O
primarily	O
expressed	O
in	O
the	O
kidneys	O
and	O
is	O
known	O
to	O
be	O
a	O
part	O
of	O
the	O
inositol	B
catabolism	O
pathway,	O
in	O
patients	O
with	O
FSGS	O
and	O
MCD.	O

However,	O
they	O
had	O
lower	O
glomerular	O
filtration	O
surface	O
density,	O
with	O
fewer	O
endothelial	O
fenestrations	O
after	O
adjustment	O
for	O
baseline	O
age,	O
sex,	O
duration	B
of	O
diabetes,	O
HbA1c,	O
GFR,	O
and	O
treatment	O
assignment	O
during	O
the	O
clinical	O
trial.	O

In	O
case	O
of	O
diosmetin	B
determinations	O
in	O
plasma,	O
both	O
without	O
and	O
with	O
enzymatic	O
degradation	O
of	O
the	O
conjugated	O
metabolites,	O
spiked	O
calibration	O
standards	O
(CC)	O
and	O
quality	O
control	O
(QC)	O
samples	O
were	O
prepared	O
with	O
diosmetin	B
at	O
the	O
following	O
concentrations	O
in	O
plasma:	O
0–50–100–250–750–2,000–6,000–15,000–24,000 pg/mL	O
(CC)	O
and	O
150–900–9,000–18,000 pg/mL	O
(QC	O
1,	O
2,	O
3,	O
and	O
4,	O
respectively).	O

The	O
LC-MS/MS	O
method	O
used	O
for	O
the	O
determination	O
of	O
sulfadoxine	B
(LLC = 0.5	O
ng/mL)	O
would	O
theoretically	O
make	O
it	O
possible	O
to	O
detect	O
traces	O
of	O
sulfadoxine	B
up	O
to	O
4	O
months	O
(127	O
days)	O
after	O
a	O
single	O
dose	O
of	O
25	O
mg/kg	O
of	O
sulfadoxine.	B

Carotid	O
atherosclerotic	O
plaques	O
were	O
stored	O
in	O
paraformaldehyde	B
for	O
24	O
h	O
and	O
later	O
in	O
ethanol	B
until	O
paraffin	B
embedding.	O

Since	O
the	O
levels	O
of	O
plasma	O
and	O
urinary	O
Creatinine	B
vary	O
significantly	O
among	O
HIV/AIDS	O
patients	O
and	O
those	O
on	O
ART	O
,	O
standardization	O
of	O
urine	O
samples	O
using	O
Creatinine	B
was	O
avoided.	O

We	O
further	O
observed	O
lower	O
plasma	O
levels	O
of	O
serine,	B
tryptophan	B
and	O
cysteine	B
in	O
T1DM	O
as	O
compared	O
to	O
controls.	O

Similarly,	O
a	O
reduction	O
in	O
acetyl-CoA	B
concentration	O
may	O
lower	O
ketogenesis	O
and	O
BHBA	O
levels.	O

The	O
increased	O
glutamate	B
in	O
EC	O
urine	O
observed	O
in	O
this	O
study	O
could	O
also	O
suggest	O
a	O
high	O
energy	O
demand	O
in	O
proliferating	O
cells	O
due	O
to	O
augmented	O
glutaminolysis[].	O

In	O
the	O
lower	O
panel	O
concentrations	O
are	O
normalized	O
to	O
creatinine	B
to	O
adjust	O
for	O
differences	O
in	O
urinary	O
flow.	O

s.d	O
ALT/GPT,	O
alanine	O
aminotransferases;	O
AST/SGOT,	O
aspartate	O
aminotransferases;	O
BMI,	O
body	O
mass	O
index;	O
BP,	O
blood	O
pressure;	O
f,	O
female;	O
GGTP,	O
gamma-glutamyl	O
transpeptidase;	O
GLU,	O
glucose;	B
HDL-chol,	O
HDL-cholesterol;	B
hSDS,	O
height	O
standard	O
deviation	O
score;	O
INS,	O
insulin;	O
L0,	O
non-liver	O
disease	O
patients;	O
L1,	O
liver	O
disease	O
patients;	O
L1_A	O
,	O
patients	O
L1	O
with	O
ALT+;	O
L1_AL	O
,	O
patients	O
with	O
ALT+	O
and	O
sonographic	O
liver	O
steatosis;	O
L1_L	O
,	O
patients	O
L1	O
with	O
sonographic	O
liver	O
steatosis;	O
m,	O
male;	O
NS,	O
not	O
significant;	O
T	O
chol,	O
total	O
cholesterol;	B
TG,	B
triglycerides;	B
TSH,	O
thyroid-stimulating	O
hormone;	O
WHR,	O
waist	O
to	O
hip	O
ratio.	O

As	O
anastrozole	B
glucuronidation	O
seems	O
to	O
be	O
specifically	O
catalyzed	O
by	O
UGT1A4,	O
kinetic	O
studies	O
were	O
performed	O
in	O
expressed	O
UGT1A4.	O

The	O
majority	O
of	O
fatty	O
acids	O
(93%,	O
P	O
=	O
4.74	O
×	O
10_−6	O
;	O
FDR	O
=	O
5.93	O
×	O
10_−5	O
),	O
including	O
lysophosphatidylethanolamine	B
(94%,	O
P	O
=	O
4.18	O
×	O
10_−4	O
;	O
FDR	O
=	O
4.73	O
×	O
10_−3	O
),	O
glycerolipids	B
(100%,	O
P	O
=	O
2.97	O
×	O
10_−3	O
;	O
FDR	O
=	O
2.47	O
×	O
10_−2	O
),	O
pyrimidine	B
nucleotides	O
(92%,	O
P	O
=	O
8.24	O
×	O
10_−3	O
;	O
FDR	O
=	O
5.15	O
×	O
10_−2	O
),	O
and	O
purine	B
nucleotides	O
(85%,	O
P	O
=	O
4.50	O
×	O
10_−2	O
;	O
FDR	O
=	O
1.87	O
×	O
10_−1	O
),	O
were	O
detectable	O
in	O
FFPE	O
samples,	O
whereas	O
monosaccharides	B
(23%,	O
P	O
=	O
2.11	O
×	O
10_−2	O
;	O
FDR	O
=	O
1.05	O
×	O
10_−1	O
),	O
phosphatidylcholines	B
(0%,	O
P	O
=	O
1.30	O
×	O
10_−3	O
;	O

The	O
ratios	O
between	O
metabolically	O
related	O
partners	O
(glutamate/glutamine,	O
sulfoxy	B
methionine/methionine,	O
and	O
aspartate/asparagine)	O
were	O
also	O
elevated	O
in	O
the	O
active	O
TB	O
group.	O

The	O
metabolites	O
responsible	O
for	O
the	O
separation	O
of	O
the	O
YDS-HCC	O
from	O
the	O
NYDS-HCC	O
patients	O
were	O
structurally	O
identified	O
as	O
LDL/VLDL,	O
isoleucine,	B
lactate,	B
lipids,	O
choline,	B
and	O
glucose/sugars.	O

Inadequate	O
levels	O
of	O
betaine	B
lead	O
to	O
disturbed	O
hepatic	O
protein	O
metabolism,	O
expressed	O
by	O
elevated	O
homocysteine	B
concentrations	O
and	O
decreased	O
SAM	O
concentrations	O
in	O
plasma.	O

However,	O
only	O
three	O
metabolic	O
pathways,	O
namely	O
purine	B
metabolism	O
(FDR=3.73×10_−3	O
),	O
arginine	B
and	O
proline	B
metabolism	O
(FDR=1.07×10_−2	O
)	O
and	O
pyrimidine	B
metabolism	O
(FDR=3.67×10_−2	O
)	O
were	O
shared	O
between	O
both	O
OCT-embedded	O
and	O
FFPE	O
samples.	O

Fusarithioamide	B
B	O
(50)	O
isolated	O
from	O
the	O
same	O
extract	O
was	O
strongly	O
potent	O
and	O
selective	O
towards	O
BT-549,	O
MCF-7,	O
SKOV-3,	O
and	O
HCT-116	O
cell	O
lines	O
with	O
IC_50	O
values	O
of	O
0.09,	O
0.21,	O
1.23,	O
and	O
0.59µM,	O
respectively	O
(Ibrahim	O
et	O
al.	O
2018b).	O

Furthermore,	O
it	O
has	O
been	O
shown	O
that	O
perturbations	O
on	O
sphingolipids	B
and	O
glycerophospholipids	B
altering	O
membrane	O
lipid	O
composition	O
may	O
impair	O
innate	O
immune	O
responses.	O

Acetyl-glycoproteins	B
are	O
acute-phase	O
proteins	O
that	O
can	O
act	O
as	O
inflammation	O
mediators	O
and	O
the	O
levels	O
of	O
these	O
proteins	O
increase	O
immediately	O
in	O
response	O
to	O
external	O
or	O
internal	O
challenges	O
such	O
as	O
infection,	O
inflammation,	O
and	O
stress	O
that	O
are	O
believed	O
to	O
be	O
the	O
cause	O
of	O
the	O
state.	O

For	O
initial	O
PCA,	O
buckets	O
corresponding	O
to	O
ethanol,	B
resulting	O
from	O
sample	O
preparation,	O
were	O
excluded,	O
as	O
were	O
spectra	O
that	O
were	O
outliers	O
due	O
to	O
broad	O
resonances	O
(n	O
 = 2).	O

One	O
of	O
compound	O
classes,	O
which	O
was	O
found	O
to	O
correlate	O
with	O
an	O
NSCLC	O
presence,	O
is	O
carnitine	B
and	O
its	O
acylesters.	O

Increased	O
concentration	O
of	O
3-methyladenine	B
in	O
urine	O
is	O
associated	O
with	O
increased	O
autophagy.	O

Likewise,	O
inactive	O
fusarimine,	O
a	O
novel	O
polyketide-derived	O
isoquinoline	O
alkaloid,	O
was	O
isolated	O
from	O
cultures	O
of	O
Fusarium	O
sp.	B

There	O
was	O
no	O
difference	O
in	O
the	O
activity	O
of	O
20β-HSD	B
between	O
the	O
two	O
groups,	O
as	O
measured	O
by	O
the	O
ratio	O
(β-C	B
+	I
β-CL)/(THF	I
+	I
5α-THF	I
+	I
THE).	I

Therefore,	O
the	O
m/z	O
400.3420	O
was	O
identified	O
as	O
palmitoylcarnitine	B
according	O
to	O
the	O
elemental	O
composition,	O
retention	O
time	O
and	O
fragmentation	O
information.	O

In	O
the	O
present	O
study,	O
urinary	O
DMA	B
was	O
inversely	O
associated	O
with	O
log(TSH)	O
in	O
cross-sectional	O
analyses.	O

Experimental	O
data	O
indicate	O
that	O
biosynthesis	O
of	O
histidine	B
metabolites	O
may	O
be	O
mediated	O
through	O
the	O
5-phosphoribosyl-1-pyrophosphate	B
signaling	O
pathway.	O

’s	O
0.97	O
for	O
glutamine.	B

(Lactate	O
levels	O
in	O
the	O
urine	O
rise	O
substantially	O
during	O
resuscitation	O
compared	O
to	O
the	O
shock	O
period,	O
but	O
the	O
levels	O
are	O
not	O
differentiating.)	O

Multiple	O
linear	O
regression	O
analysis	O
to	O
determine	O
the	O
effect	O
of	O
measured	O
serum	O
cytokine	O
concentrations	O
as	O
predictors	O
of	O
tryptophan	B
metabolites	O
was	O
performed	O
on	O
inverse	O
normal-rank	O
transformations	O
of	O
the	O
data,	O
adjusted	O
for	O
sex,	O
body	O
mass	O
index,	O
smoking,	O
alcohol	O
intake,	O
and	O
contraceptive	O
use	O
in	O
women.	O

Plasma	O
levels	O
of	O
carnitine	B
are	O
elevated	O
in	O
PDR	O
patients.	O

The	O
target	O
compounds	O
eluted	O
from	O
the	O
SPE	O
column	O
in	O
less	O
than	O
1	O
min	O
with	O
25%	O
acetonitrile,	B
and	O
effectively	O
refocused	O
on	O
a	O
ThermoScientific	O
Hypersyl	O
GOLD™	O
aQ	O
polar	O
encapped	O
analytical	O
column.	O

Pesticide	O
standards	O
(α-cypermethrin,	O
α-endosulfan,	B
captan,	O
chlorpyrifos,	B
deltamethrin,	O
imazalil,	O
phosalone	O
and	O
tolclofos-methyl),	O
each	O
at	O
100	O
mg·L_−1	O
in	O
methanol	B
(MeOH)	O
or	O
acetonitrile	B
(ACN),	O
were	O
purchased	O
from	O
ULTRA	O
Scientific	O
(North	O
Kingstown,	O
RI,	B
USA).	O

Of	O
the	O
other	O
oxysterols,	B
25-hydroxycholesterol	B
can	O
be	O
formed	O
enzymatically	O
by	O
a	O
cholesterol	O
25-hydroxylase	O
and	O
also	O
by	O
CYP46A1,	O
but	O
it	O
is	O
also	O
an	O
autoxidation	O
product	O
of	O
cholesterol,	B
as	O
are	O
7β-hydroxycholesterol	B
and	O
7-oxocholesterol,	B
whereas	O
6-hydroxycholesterol	B
is	O
a	O
decomposition	O
product	O
of	O
the	O
autoxidation	O
products	O
5,6-epoxycholesterol	B
(5,6-epoxycholestan-3β-ol,	I
C-3β-ol-5,6-epoxide)	I
and	O
cholestane-3β,5α,6β-triol	B
(C-3β,5α,6β-triol).	I

Vascular	O
reactivity	O
to	O
noradrenaline	B
was	O
significantly	O
increased	O
in	O
mesenteric	O
resistance	O
arteries	O
among	O
hexadecanedioate-treated	O
rats,	O
highlighting	O
a	O
possible	O
vascular	O
mechanism	O
that	O
underlies	O
hexadecanedioate	B
and	O
blood	O
pressure	O
association.	O

Each	O
plasma	O
extract	O
volume	O
was	O
ballasted	O
with	O
7.5:1	B
methanol/H_2	I
O	O
(v	O
/v	O
)	O
to	O
bring	O
the	O
total	O
volume	O
to	O
700	O
µL.	O
The	O
entire	O
limiting-dilution	O
study	O
consisted	O
of	O
10	O
batches	O
with	O
identical	O
experimental	O
design.	O
_1	B
7.5:1	I
methanol/H_2	I
O	O
(v	O
/v	O
)	O
solution	O
was	O
used	O
to	O
bring	O
the	O
total	O
volume	O
up	O
to	O
700	O
µL	O
prior	O
to	O
drying.	O

No	O
other	O
features	O
emerged	O
with	O
similar	O
strong	O
contrasts	O
and	O
other	O
PCs	O
such	O
as	O
two	O
PC(36:2)	B
isomers	I
did	O
not	O
differ	O
between	O
the	O
two	O
treatments.	O

5-Oxoproline	B
is	O
known	O
to	O
increase	O
its	O
level	O
in	O
response	O
to	O
worsened	O
kidney	O
function_,	O
.	O

During	O
insulin	O
deprivation,	O
elevated	O
allantoin	B
was	O
positively	O
correlated	O
with	O
ketones,	B
acetate,	B
creatinine,	B
and	O
lysine,	B
but	O
negatively	O
correlated	O
with	O
serine,	B
arginine,	B
glycine,	B
and	O
aspartate.	B

Lipid	O
species	O
of	O
the	O
following	O
classes	O
were	O
measured:	O
sphingosine	B
(SPH),	O
dhCer,	O
Cer,	B
HexCer,	O
Hex2Cer,	O
Hex3Cer,	O
GM3,	B
SM,	O
phosphatidylcholine	B
(PC),	O
alkylphosphatidylcholine	B
(PC‐O),	O
alkenylphosphatidylcholine	B
(plasmalogen,	O
PC‐P),	O
lysophosphatidylcholine	B
(LPC),	O
lysoalkylphosphatidylcholine	B
(LPC‐O),	O
phosphatidylethanolamine	B
(PE),	O
alkylphosphatidylethanolamine	B
(PE‐O),	O
alkenylphosphatidylethanolamine	B
(plasmalogen,	O
PE‐P),	O
lysophosphatidylethanolamine	B
(LPE),	O
phosphatidylinositol	B
(PI),	O
phosphatidylserine	B
(PS),	O
phosphatidylglycerol	B
(PG),	O
cholesterol	B
ester	I
(CE),	O
free	O
cholesterol	B
(COH),	O
DG,	O
and	O
TG.	B

-[_2	O
H_6	I
]hydroxycholesterol	I
internal	O
standard).	O

Additionally,	O
phenylalanine	B
and	O
tyrosine,	B
precursors	O
for	O
catecholamine	B
biosynthesis,	O
were	O
significantly	O
altered	O
in	O
post-surgery	O
patients.	O

Additionally,	O
as	O
illustrated	O
in	O
,	O
five	O
bile	O
acids,	O
including	O
GCA,	O
GCDCA,	B
TCA,	O
TCDCA	O
and	O
GUDCA	O
were	O
significantly	O
altered	O
among	O
the	O
three	O
CP	O
grades,	O
A,	O
B,	O
and	O
C,	O
suggesting	O
that	O
these	O
metabolites	O
could	O
be	O
potential	O
biomarkers	O
for	O
patients	O
stratification	O
at	O
different	O
pathological	O
stages	O
of	O
liver	O
cirrhosis.	O

LC-MS	O
grade	O
isopropanol	B
was	O
used	O
to	O
minimize	O
intensity	O
of	O
the	O
background	O
signal.	O

This	O
approach,	O
nevertheless,	O
has	O
gained	O
momentum,	B
as	O
evident	O
by	O
three	O
studies	O
investigating	O
endometriosis-associated	O
metabolic	O
changes	O
in	O
serum	O
and	O
urine	O
samples.	O

[–0.38	O
per	O
unit	O
SD	O
increase	O
25(OH)D,	O
P	O
-value = 1.59 × 10_−6	O
]	O
had	O
the	O
strongest	O
negative	O
associations	O
at	O
the	O
PCA	O
threshold,	O
whereas	O
palimitoyl-oleoyl-GPPG-2	B
was	O
positively	O
associated	O
with	O
serum	O
25(OH)D	O
at	O
the	O
PCA	O
threshold	O

	O
Metabolites	O
extracted	O
using	O
MTBE	B
or	O
methanol,	B
were	O
also	O
analyzed	O
in	O
negative	O
ionization	O
mode.	O

Lower	O
levels	O
of	O
tryptophan	B
[OR:	O
0.58	O
(95 %	O
CI	O
0.35–0.93,	O
p	O
value:	O
0.03)]	O
and	O
XA	O
[0.56	O
(0.22–0.91,	O
0.02)]	O
as	O
well	O
as	O
higher	O
levels	O
of	O
riboflavin	B
[2.13	O
(1.32–3.54,	O
0.003)]	O
and	O
higher	O
KTR	O
[1.65	O
(1.02–2.71,	O
0.04)]	O
were	O
significantly	O
associated	O
with	O
the	O
age	O
34–40	O
group	O
(N = 36).	O

Results:	O
A	O
majority	O
of	O
the	O
metabolites	O
associated	O
with	O
25(OH)D	O
were	O
of	O
lipid	O
origin,	O
including	O
3-carboxy-4-methyl-5-propyl-2-furanpropanoic	B
acid	I
(CMPF)	O
[beta-estimate	O
0.38	O
per	O
1	O
standard	O
deviation	O
(SD)	O
increment],	O
stearoyl-arachidonoyl-glycerophosphoethanolamine	B
(GPPE)	O
(−0.38	O
per	O
SD)	O
and	O
two	O
essential	O
fatty	O
acids:	O
eicosapentaenoate	B
(EPA;	O
0.17	O
per	O
SD)	O
and	O
docosahexaenoate	B
(DHA;	O
0.13	O
per	O
SD).	O

Numbers	O
indicate	O
the	O
following	O
metabolites:	O
1,	O
L-lactic	B
acid;	I
2,	O
L-alanine;	B
3,	O
oxalic	B
acid;	I
4,	O
L-valine;	B
5,	O
urea;	B
6,	O

These	O
data	O
suggest	O
an	O
unexpected	O
link	O
between	O
the	O
glycolytic	B
activity	O
of	O
the	O
tumor	O
(i.e.,	O
SUV_max	O
)	O
and	O
the	O
metabolic	O
profile	O
of	O
fibroblasts	O
derived	O
from	O
non-neoplastic	O
tissue	O
of	O
the	O
same	O
lobe	O
as	O
the	O
tumor.	O

For	O
RRLC-(+)ESI-MS	B
data,	O
a	O
clear	O
separation	O
was	O
observed	O
in	O
the	O
OPLS-DA	O
model	O
(A	O
),	O
indicating	O
a	O
significant	O
impact	O
of	O
CRT	O
treatment	O
on	O
global	O
metabolism.	O

Both	O
cell	O
types	O
were	O
cultured	O
in	O
RPMI	O
1640	O
with	O
L-glutamine	B
(Sigma-Aldrich)	O
supplemented	O
with	O
10%	O
heat	O
inactivated	O
dialyzed	O
fetal	O
bovine	O
serum	O
(FBS,	O
Sigma-Aldrich)	O
and	O
antibiotics	O
(penicillin	O
100	O
units/ml;	O
streptomycin	B
100	O
µg/ml,	O
Biochrom	O
AG)	O
at	O
37°C	O
with	O
5%	O
CO_2	O
in	O
a	O
humidified	O
atmosphere.	O

However,	O
there	O
was	O
no	O
evidence	O
for	O
a	O
decreased	O
level	O
of	O
lipoprotein	O
lipase	O
in	O
the	O
adipose	O
tissue	O
of	O
cancer	O
patients,	O
but	O
there	O
was	O
a	O
two‐fold	O
increase	O
in	O
the	O
relative	O
level	O
of	O
mRNA	O
for	O
hormone‐sensitive	O
lipase,	O
suggesting	O
an	O
upregulation	O
of	O
triacylglycerol	O
hydrolysis.6,	O
61	O
Also,	O
in	O
response	O
to	O
glucose	B
limitation,	O
fatty	O
acid	O
can	O
also	O
be	O
consumed	O
through	O
β‐oxidation	O
to	O
provide	O
key	O
substitute	O
energy	O
for	O
cancer	O
cell	O
survival.	O

In	O
the	O
bioanalytical	O
assay	O
that	O
we	O
developed	O
we	O
used	O
D_4	B
-abiraterone	I
as	O
an	O
internal	O
standard.	O

The	O
region	O
for	O
whole	O
blood	O
shows	O
characteristic	O
unique	O
peaks	O
for	O
NAD_+	O
,	O
NADP_+	O
,	O
NADH,	B
NADPH,	B
ATP,	B
ADP,	B
and	O
AMP.	B

Its	O
analgesic	O
activity	O
is	O
approximately	O
80-times	O
that	O
of	O
morphine.	B

The	O
acetylated	O
forms	O
of	O
GGs	O
presented	O
a	O
lower	O
number	O
of	O
ceramide	B
types	O
than	O
the	O
non-acetylated	O
forms.	O

The	O
association	O
between	O
SLC7A9	O
and	O
valine	B
has	O
previously	O
been	O
shown	O
.	O

1–5-anhydroglucitol	B
is	O
an	O
established	O
biomarker	O
for	O
short-term	O
glucose	B
control.	O

We	O
evaluated	O
the	O
role	O
of	O
adherence	O
behavior	O
and	O
pharmacogenetics	O
on	O
the	O
formation	O
rate	O
of	O
(Z)‐endoxifen.	B

Specifically,	O
C16-ceramide	B
levels	O
may	O
serve	O
as	O
a	O
novel	O
diagnostic	O
biomarker	O
for	O
the	O
identification	O
of	O
HCC	O
in	O
patients	O
with	O
liver	O
diseases.	O

Furthermore,	O
the	O
logistic	O
regression	O
analysis	O
revealed	O
the	O
independent	O
effect	O
of	O
myristic	B
acid	I
(C14:0)	O
and	O
palmitic	B
acid	I
(C16:0)	O
on	O
LC	O
progression	O
and	O
metabolic	O
pathway	O
analysis	O
showed	O
that	O
palmitic	B
acid	I
(C16:0)	O
involved	O
in	O
fatty	O
acid	O
metabolism	O
which	O
altered	O
in	O
the	O
LC	O
group.	O

The	O
levels	O
of	O
indirect	O
bilirubin	B
(IBIL),	O
gamma-glutamyl	O
transferase	O
(GGT),	O
globin	O
(GLB),	O
alkaline	O
phosphatase	O
(ALP),	O
and	O
mean	O
corpuscular	O
hemoglobin	O
(MCH),	O
mean	O
platelet	O
volume	O
(MPV),	O
platelet	O
distribution	O
width	O
(PDW)	O
were	O
increased	O
while	O
the	O
levels	O
of	O
blood	O
urea	B
nitrogen	I
(BUN),	O
hematocrit	O
(HCT),	O
hemoglobin	O
(HGB),	O
prealbumin	O
(PALB),	O
mean	O
corpuscular	O
hemoglobin	O
concentration	O
(MCHC),	O
plateletocrit	O
(PCT),	O
platelet	O
(PLT),	O
total	O
protein	O
(TP),	O
red	O
blood	O
cell	O
(RBC)	O
and	O
white	O
blood	O
cell	O
(WBC)	O
were	O
decreased	O
in	O
cirrhotic	O
patients	O
as	O
compared	O
to	O
healthy	O
controls	O
in	O
the	O
discovery	O
set.	O

To	O
detect	O
the	O
individual	O
oxylipins,	B
MRM	O
in	O
negative	O
ion	O
mode	O
was	O
performed	O
with	O
individually	O
optimized	O
fragmentor	O
voltage	O
and	O
collision	O
energies	O
(Optimizer	O
application,	O
MassHunter,	O
Agilent).	O

Extraction	O
Recovery	O
(Mean	O
±	O
SD)	O
of	O
SMV,	O
SMV-A,	O
ATV,	O
2-OH-ATV,	B
4-OH-ATV,	B
and	O
RSV	O
at	O
Three	O
Levels	O
of	O
QC	O
Samples	O
from	O
Human	O
Plasma	O
with	O
either	O
Low	O
or	O
High	O
Triglyceride	B
levels	O
Using	O
Liquid-liquid	O
Extraction	O
Method	O

It	O
was	O
shown,	O
for	O
example	O
that	O
two	O
days	O
of	O
metformin	B
therapy	O
increased	O
plasma	O
BCAA	O
in	O
insulin	O
resistant	O
adults.	O

Urinary	O
albumin	O
excretion	O
was	O
log	O
transformed	O
(logUAE)	O
and	O
associations	O
were	O
tested	O
by	O
linear	O
regression	O
models,	O
adjusted	O
by	O
age,	O
sex,	O
BMI,	O
Systolic	O
BP	O
and	O
fasting	O
glucose.	B

The	O
quantities	O
of	O
identified	O
sterols	O
and	O
bile	O
acids	O
in	O
CSF	O
were	O
determined	O
by	O
isotope	O
dilution	O
mass	O
spectrometry	O
against	O
a	O
known	O
amount	O
of	O
added	O
24(SR	O
)-[_2	O
H_6	I
]hydroxycholesterol	I
(100%	O
[_2	O
H_6	O
])	O
internal	O
standard	O
(IS).	O

Glycomodifications	B
have	O
even	O
distinguished	O
early	O
RA	O
from	O
other	O
rheumatic	O
diseases.	O

We	O
assessed	O
whether	O
cannabis	B
use	O
was	O
associated	O
with	O
alterations	O
in	O
markers	O
of	O
CD4_+	O
and	O
CD8_+	O
T-cell	O
activation,	O
a	O
hallmark	O
of	O
HIV	O
disease	O
pathogenesis	O
[,	O
].	O

Leucyl-leucine	B
is	O
a	O
product	O
of	O
incomplete	O
protein	O
breakdown,	O
and,	O
to	O
our	O
knowledge,	O
has	O
not	O
previously	O
been	O
studied	O
in	O
relation	O
to	O
carcinogenesis.	O

The	O
use	O
of	O
DBS	O
cards	O
prevented	O
our	O
ability	O
to	O
reliably	O
measure	O
some	O
critical	O
1C	O
metabolites	O
known	O
to	O
be	O
influenced	O
by	O
maternal	O
diet,	O
particularly	O
homocysteine,	B
S-adenosyl	B
methionine,	I
S-adenosyl	B
homocysteine,	I
vitamins	O
B6	O
and	O
B12,	O
and	O
riboflavin.	B

In	O
vivo	O
first-phase	O
insulin	O
secretion	O
was	O
evaluated	O
during	O
a	O
2-h	O
hyperglycemic	B
clamp	O
as	O
previously	O
described.	O

Typically,	O
flour	O
contained	O
lower	O
amounts	O
of	O
the	O
abundant	O
free	O
sugars	O
(maltose,	O
glucose	B
and	O
fructose)	O
that	O
tended	O
to	O
be	O
broken	O
down	O
in	O
the	O
dough	O
samples	O
by	O
a	O
longer	O
fermentation	O
process.	O

Using	O
predicted	O
octanol/water	O
partition	O
values,	O
metabolites	O
in	O
human	O
plasma	O
cover	O
a	O
polarity	O
range	O
from	O
-5	O
(polyamines,	O
amino	B
acids)	O
to	O
10	O
(fatty	O
acids)	O
to	O
35	O
(triacylglycerides).	O

-1-N3Ade]	O
and	O
4-hydroxyestrone(estradiol)-1-N7Guanine	O
[4-OHE_1	O
(E_2	O
)-1-N7Gua],_–	O
whereas	O
E_1	O
(E_2	B
)-2,3-Q	I
form	O
much	O
lower	O
levels	O
of	O
2-hydroxyestrone(estradiol)-6-N3Ade-nine	O
[2-OHE_1	O
(E_2	O
)-6-N3Ade]	O
(	O
and	O
).	O

These	O
studies	O
identified	O
carnitine	B
and	O
acetylcarnitine	B
as	O
novel	O
potential	O
biomarkers	O
of	O
active	O
disease	O
both	O
at	O
diagnosis	O
and	O
relapse	O
and	O
as	O
a	O
mediator	O
of	O
disease	O
associated	O
pathologies.	O

AA	O
metabolites	O
were	O
further	O
extracted	O
and	O
subjected	O
to	O
LC–MS/MS,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
to	O
detect	O
levels	O
of	O
20-HETE.	B

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
study	O
to	O
reveal	O
that	O
levels	O
of	O
sphingolipids	B
in	O
cancer	O
tissue	O
are	O
generally	O
higher	O
than	O
normal	O
breast	O
tissue	O
in	O
patients	O
with	O
breast	O
cancer.	O

Androgen	O
and	O
glucocorticoid	B
metabolites	O
were	O
measured	O
by	O
GC/MS.	O

 150 mg/dL	O
[adjusted	O
for	O
lipid-lowering	O
treatment	O
as	O
described	O
below]	O
or	O
HDL	B
cholesterol	I
[HDL-C]	O
<40 mg/dL	O
in	O
men	O
or	O
<50 mg/dL	O
in	O
women).	O

OPLS-DA	O
score	O
plots	O
based	O
on	O
the	O
data	O
from	O
RRLC-(+)ESI-MS	B
of	O
the	O
ESCC,	O
ESCC-M	O
and	O
ESCC-P	O
patients	O
and	O
controls.	O

Strengths	O
of	O
this	O
study	O
include	O
the	O
assessment	O
of	O
a	O
type	O
1	O
diabetes	O
population	O
at	O
high	O
risk	O
of	O
hypertension	O
and	O
kidney	O
disease,	O
large	O
sample	O
size,	O
use	O
of	O
novel	O
and	O
specific	O
mass	O
spectrometry	O
assays	O
for	O
three	O
complementary	O
circulating	O
vitamin	B
D	I
metabolites,	O
long	O
duration	B
of	O
follow-up,	O
use	O
of	O
detailed	O
phenotype	O
data	O
to	O
assess	O
clinically	O
important	O
outcomes	O
with	O
confidence,	O
and	O
a	O
combination	O
of	O
detailed	O
baseline	O
covariate	O
data	O
and	O
a	O
relatively	O
homogenous	O
study	O
population	O
that	O
minimizes	O
the	O
risk	O
of	O
confounding.	O

For	O
example,	O
acetone	B
has	O
a	O
high	O
charge	O
towards	O
component	O
t1	O
since	O
the	O
variable	O
axis	O
is	O
almost	O
parallel	O
to	O
the	O
corresponding	O
component	O
axis	O
t1.	O

Compared	O
with	O
healthy	O
control	O
subjects,	O
our	O
RA	O
cohort	O
showed	O
robust	O
increases	O
in	O
the	O
arginase	O
catabolic	O
product	O
l-ornithine	B
(~ 60%	O
increase)	O
and	O
diminished	O
NOS	O
catabolic	O
product	O
l-citrulline	B
(~ 18%	O
decrease),	O
with	O
a	O
significant	O
decrease	O
in	O
arginine	B
bioavailability	O
(p	O
 < 0.001).	O

Estrogen,	B
17β-estradiol,	B
breast	O
cancer,	O
endometrial	O
cancer,	O
prostate	O
cancer,	O
stable	O
isotope	O
dilution	O

6	O
+	O
7	O
+	O
12	O
+	O
13	O
+	O
16	O
through	O
28	O
	O
	O
	O
	O
Treatment	O
of	O
urine	O
with	O
glucuronidase/sulfatase	O
led	O
to	O
significant	O
increases	O
(10	O
to	O
20-fold)	O
in	O
the	O
levels	O
of	O
E_1	O
and	O
E_2	O
,	O
while	O
the	O
levels	O
of	O
estrogen	B
metabolites,	O
conjugates	O
and	O
adducts	O
changed	O
marginally	O
and	O
in	O
many	O
cases	O
decreased	O
because	O
of	O
the	O
incubation	O
for	O
8	O
hr	O
at	O
37°C.	O

From	O
,	O
there	O
appear	O
to	O
be	O
seven	O
biochemicals	O
that	O
are	O
particularly	O
important	O
in	O
differentiating	O
the	O
depressed	O
subjects	O
from	O
the	O
control	O
subjects:	O
unnamed	O
biochemical	O
X-4807,	O
azelate,	B
aspartate,	B
X-11805,	O
3-hydroxysebacate,	O
sebacate	B
and	O
aspartylphenylalanine.	B

Succinate	B
(OR	O
1.36,	O
95%	O
CI	O
1.31–1.98,	O
p	O
=	O
1.22	O
×	O
10_−6	O
),	O
α-ketoglutarate	B
(OR	O
2.14,	O
95%	O
CI	O
1.60–2.87,	O
p	O
=	O
2.08	O
×	O
10_−8	O
),	O
and	O
malate	B
(OR	O
2.02,	O
95%	O
CI	O
1.53–2.66,	O
p	O
=	O
1.60	O
×	O
10_−7	O
)	O
were	O
among	O
metabolites	O
also	O
associated	O
with	O
subclinical	O
atrial	O
dysfunction.	O

Still,	O
ornithine	B
can	O
cross	O
the	O
mitochondrial	O
membrane	O
and	O
enrich	O
the	O
cytoplasmic	O
or	O
mitochondrial	O
amino	O
acid	O
pool.	O

In	O
particular,	O
SM	O
and	O
Cer	B
mediate	O
cellular	O
responses	O
to	O
cytokines	O
and	O
oxidative	O
stress.	O

	O
Three	O
sets	O
of	O
proline	B
QC	O
samples	O
in	O
pooled	O
human	O
serum	O
were	O
freshly	O
prepared	O
and	O
left	O
on	O
the	O
bench-top	O
at	O
room	O
temperature	O
for	O
4,	O
8,	O
or	O
24	O
h,	O
respectively.	O

The	O
residue	O
was	O
subjected	O
to	O
a	O
two-step	O
derivatization	O
procedure	O
with	O
80	O
μ	O
L	O
of	O
methoxyamine	B
(15	O
mg/mL	O
in	O
pyridine)	B
for	O
90	O
min	O
at	O
30	O
°C,	O
and	O
80	O
μ	O
L	O
of	O
BSTFA	O
(1%TMCS)	O
for	O
60	O
min	O
at	O
70	O
°C.	O

We	O
found	O
male	O
urinary	O
concentrations	O
of	O
paracetamol	B
in	O
the	O
highest	O
quartile	O
(>73.5	O
ng/ml)	O
to	O
be	O
consistently	O
associated	O
with	O
a	O
longer	O
TTP	O
across	O
all	O
partner-specific	O
and	O
couple-based	O
models.	O

The	O
therapy	O
empties	O
the	O
liver	O
and	O
muscle	O
glycogen	B
stores	O
resulting	O
in	O
the	O
decrease	O
of	O
glycogenolysis	O
and	O
gluconeogenesis.	O

There	O
is	O
little	O
knowledge	O
on	O
the	O
alterations	O
in	O
systemic,	O
adipose	O
tissue	O
and	O
skeletal	O
muscle	O
metabolism	O
in	O
relation	O
to	O
insulin	O
resistance	O
in	O
normoglycemic	B
individuals	O
with	O
varying	O
degree	O
of	O
adiposity.	O

Each	O
sample	O
was	O
added	O
with	O
the	O
internal	O
standards,	O
PC(17:0/0:0),	B
PC(17:0/17:0),	B
PE	B
(17:0/17:0),	I
PG(17:0/17:0),	B
Cer(d18:1/17:0),	B
PS(17:0/17:0),	B
PA(17:0/17:0),	B
racemic	O
MG(17:0/0:0/0:0),	B
racemic	O
DG(17:0/17:0/0:0)	B
and	O
TG(17:0/17:0/17:0)	B
.	O

The	O
best	O
discriminants,	O
and	O
thus	O
potential	O
markers	O
of	O
coffee	O
consumption,	O
were	O
the	O
glucuronide	B
of	O
the	O
diterpenoid	B
atractyligenin,	O
the	O
diketopiperazine	B
cyclo(isoleucyl-prolyl),	I
and	O
the	O
alkaloid	O
trigonelline.	B

Notably,	O
decreased	O
plasma	O
concentrations	O
of	O
LPC18:1	B
and	O
LPC18:2	B
have	O
been	O
detected	O
in	O
both	O
subjects	O
with	O
metabolically	O
unhealthy	O
obesity	O
and	O
metabolically	O
healthy	O
obesity.	O

Data	O
normalized	O
to	O
the	O
specific	O
peaks	O
of	O
interest	O
allowed	O
the	O
models	O
to	O
focus	O
on	O
more	O
subtle	O
variation	O
in	O
acetaminophen	B
and	O
its	O
metabolites.	O

For	O
UPLC–HRMS,	O
three	O
metabolites,	O
expected	O
to	O
be	O
present	O
at	O
low	O
levels	O
(caffeic	O
acid,	I
nicotine,	B
and	O
daidzein),	O
were	O
less	O
precise.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
lactate	B
levels	O
or	O
lactate/pyruvate	B
ratio	O
in	O
plasma	O
specimens.	O

Glucuronic	B
acid	I
conjugates	O
of	O
bilirubin-IXalpha	B
in	O
normal	O
bile	O
compared	O
with	O
post-obstructive	O
bile.	O

It	O
could	O
be	O
that	O
low	O
levels	O
of	O
total	O
vitamin	B
B6	I
among	O
patients	O
cause	O
accumulation	O
of	O
HK	O
and	O
decreased	O
levels	O
of	O
the	O
other	O
kynurenine	B
metabolites	O
[,	O
,	O
].	O

The	O
proteins	O
were	O
separated	O
by	O
sodium	B
dodecyl	I
sulfate-polyacrylamide	I
gel	O
electrophoresis	O
(SDS-PAGE)	O
using	O
NuPAGE	O
4–12%	O

For	O
example,	O
the	O
Chinese	O
adults	O
showed	O
higher	O
MiBP	O
and	O
MnBP	O
levels	O
than	O
MEP	O
while	O
the	O
French	O
or	O
Mexican	O
women	O
[,	O
]	O
presented	O
a	O
greater	O
level	O
of	O
the	O
metabolites	O
of	O
DEHP	O
compared	O
to	O
other	O
phthalate	B
biomarkers.	O

The	O
established	O
predictive	O
model	O
was	O
composed	O
of	O
8	O
metabolites;	O
i.e.,	O
pyruvic	B
acid,	I
glycolic	B
acid,	I
tryptophan,	B
palmitoleic	B
acid,	I
fumaric	B
acid,	I
ornithine,	B
lysine,	B
and	O
3-hydroxyisovaleric	B
acid.	I

This	O
study	O
was	O
not	O
able	O
to	O
identify	O
a	O
metabolic	O
response	O
to	O
ERCP	O
that	O
was	O
independent	O
of	O
AP	B
status.	O

FFA	O
constitute	O
only	O
a	O
small	O
proportion	O
of	O
all	O
FA	B
building	O
other	O
serum	O
lipids,	O
including	O
PL	O
and	O
TG.	B

Phenanthrene	B
(Phe)	O
is	O
the	O
simplest	O
PAH	O
with	O
a	O
bay	O
region	O
and	O
an	O
excellent	O
model	O
for	O
the	O
study	O
of	O
PAH	O
metabolism.	O

It	O
is	O
normally	O
found	O
in	O
urine,	O
and	O
an	O
increased	O
level	O
of	O
hippurate	B
indicates	O
disorder	O
of	O
the	O
gut	O
microbiota.	O

Altogether,	O
the	O
network	O
of	O
urinary	O
molecules	O
participating	O
in	O
groups	O
separation	O
was	O
characterized	O
by	O
lower	O
levels	O
of	O
xylitol	B
(p	O
<	O
0.05)	O
and	O
phenyl	B
acetic	I
acid	I
(p	O
<	O
0.05)	O
in	O
obese	O
vs.	O
normal	O
weight	O
individuals.	O

Although	O
the	O
possible	O
role	O
of	O
linoleamide	B
and	O
palmitic	B
amide	I
in	O
HAPE	O
could	O
not	O
be	O
directly	O
elucidated,	O
the	O
physiological	O
functions	O
of	O
the	O
other	O
FAM	O
such	O
as	O
endocannabinoid	B
anandamide	I
could	O
give	O
an	O
indirect	O
clue	O
to	O
them.	O

This	O
is	O
consistent	O
with	O
a	O
previous	O
GC-MS	O
study	O
showing	O
that	O
several	O
amino	O
acids	O
branched-chain	O
amino	O
acids	O
(BCAAs),	O
valine,	B
leucine,	B
and	O
isoleucine	B
have	O
been	O
reported	O
to	O
have	O
connections	O
with	O
HCC	O
and	O
were	O
also	O
downregulated	O
in	O
liver	O
cirrhosis	O
patients.	O

The	O
association	O
of	O
smoking	O
and	O
TxA_2	O
generation,	O
in	O
the	O
absence	O
of	O
platelet	O
COX-1	O
activity,	O
among	O
aspirin	B
treated	O
patients	O
warrants	O
further	O
study.	O

Krebs	O
cycle	O
intermediates	O
are	O
imported	O
from	O
urine	O
by	O
the	O
sodium-dicarboxylate	B
symporter	O
NaDC-3	O
transporter	O
which	O
is	O
mostly	O
located	O
in	O
the	O
proximal	O
tubular	O
cells	O
in	O
the	O
kidney	O
.	O

3	O
d	O
running	O
(e.g.,	O
hippurate,	B
4-hydroxyhippurate,	B
4-methylcatechol	B
sulfate,	I
1.8-,	O
1.9-,	O
2.5-fold,	O
respectively,	O
P<0.05),	O
an	O
effect	O
which	O
persisted	O
for	O
14-h	O
post-exercise.	O

Given	O
the	O
postulated	O
role	O
of	O
choline	B
in	O
tumor	O
progression,	O
as	O
indicated	O
by	O
elevated	O
in vivo	O
levels,	O
reliable	O
quantification	O
of	O
choline-based	O
metabolites	O
in	O
SP	B
is	O
desired.	O

Each	O
compound	O
was	O
dissolved	O
in	O
10	O
mM	O
ammonium	B
formate,	I
pH	O
2.8,	O
and	O
directly	O
infused	O
into	O
the	O
ion	O
source.	O

In	O
recent	O
years,	O
many	O
studies	O
have	O
reported	O
associations	O
between	O
TMAO	B
and	O
chronic	O
diseases.	O

Indeed,	O
the	O
predicted	O
fragments	O
supporting	O
the	O
identify	O
of	O
PE	B
40:5	I
and	O
PC	B
37:5	I
and	O
PC-O	O
38:5	O
were	O
detected	O
in	O
corresponding	O
MS/MS	O
data	O
in	O
the	O
negative	O
ion	O
mode	O
derived	O
from	O
the	O
MS/MS_ALL	O
analysis.	O

Therefore,	O
the	O
lower	O
malic	O
enzyme	O
level	O
was	O
probably	O
a	O
down-regulatory	O
response	O
of	O
the	O
cell	O
to	O
a	O
lower	O
level	O
of	O
the	O
substrate	O
malate	B
for	O
reasons	O
that	O
are	O
not	O
exactly	O
clear.	O

The	O
solvent	O
from	O
the	O
sample	O
eluate	O
was	O
removed	O
using	O
a	O
rotary	O
evaporator	O
and	O
the	O
residuum	O
was	O
dissolved	O
again	O
in	O
0.5	O
mL	O
ammonium	B
formate	I
solution	O
(5	O
mM,	O
pH	O
5).	O

Additional	O
adjustment	O
for	O
potential	O
confounders	O
attenuated	O
the	O
observed	O
associations	O
of	O
1,5‐AG	B
and	O
methionine	B
(P	O
for	O
trend	O
=	O
.06	O
and	O
.07,	O
respectively).	O

It	O
is	O
known	O
that	O
glutamine,	B
as	O
a	O
precursor	O
of	O
glutathione,	B
plays	O
a	O
crucial	O
role	O
in	O
the	O
prevention	O
of	O
oxidative	O
damage	O
in	O
the	O
human	O
body	O
and	O
thus	O
also	O
has	O
a	O
positive	O
influence	O
on	O
the	O
maintenance	O
of	O
the	O
gastrointestinal	O
barrier	O
and	O
the	O
endothelial	O
function	O
of	O
the	O
blood	O
vessels.	O

Ala:	O
alanine;	B
Arg:	O
arginine;	B
Asp:	O
aspartate;	B
Glu:	O
glutamine;	B
Phe:	O
phenylalanine;	B
Pro:	O
proline.	B

However,	O
significant	O
ion	O
suppression	O
was	O
identified	O
when	O
the	O
method	O
was	O
applied	O
to	O
plasma;	O
signals	O
were	O
typical	O
suppressed	O
to	O
by	O
56–71%,	O
even	O
following	O
the	O
2%	O
FA	B
wash.	O

The	O
aliquots	O
dissolved	O
in	O
acidic	O
conditions	O
were	O
eluted	O
through	O
a	O
C18	O
column	O
(Waters	O
UPLC	O
BEH	O
C18-2.1	O
×	O
100	O
mm,	O
1.7	O
µM)	O
using	O
gradient	O
elution	O
of	O
water,	O
methanol,	B
and	O
0.1%	O
formic	B
acid.	I

Conclusion:	O
These	O
data	O
suggest	O
that	O
metabolic	O
perturbations	O
consistent	O
with	O
higher	O
CVD	O
risk	O
exist	O
in	O
SAP	O
patients	O
with	O
elevated	O
plasma	O
cystathionine	B
concentrations.	O

In	O
we	O
present	O
multivariable-adjusted	O
estrogen	B
measures	O
by	O
quintiled	O
measures	O
of	O
diversity	O
of	O
the	O
fecal	O
microbiome.	O

For	O
reversed	O
phase	O
(RPLC)-MS	O
analysis,	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
clean	O
vial	O
and	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas.	I

A	O
total	O
flow	O
rate	O
of	O
1.0	O
mL/min	O
delivered	O
at	O
0.9	O
mL/min	O
A	O
(0.1	O
M	O
ammonium	B
acetate)	I
and	O
0.1	O
mL/min	O
B	O
(75%	O
ACN/0.1	O
M	O
ammonium	B
acetate).	I

A	O
similar	O
graded	O
increase	O
in	O
risk	O
was	O
observed	O
when	O
levels	O
of	O
TMAO	B
were	O
analyzed	O
as	O
a	O
continuous	O
variable	O
in	O
increments	O
of	O
1	O
SD	O
(unadjusted	O
hazard	O
ratio,	O
1.40	O
[95%	O
CI,	O
1.29	O
to	O
1.51;	O
P<0.001];	O
adjusted	O
hazard	O
ratio,	O
1.30	O
[95%	O
CI,	O
1.20	O
to	O
1.41;	O
P<0.001]).	O

A	O
3-oxo-4-ene	B
functionality	O
was	O
generated	O
by	O
oxidation	O
of	O
the	O
native	O
3β-hydroxy-5-ene	B
function	O
by	O
cholesterol	B
oxidase	O
prior	O
to	O
treatment	O
with	O
GP	B
reagent.	O

Elevated	O
hypoxanthine	B
levels	O
might	O
reflect	O
an	O
early	O
stage	O
of	O
this	O
mechanism.	O

Sphingolipid	B
measurements	O
were	O
performed	O
according	O
to	O
a	O
previously	O
published	O
protocol.	O

In	O
conclusion,	O
our	O
study	O
lends	O
initial	O
support	O
to	O
the	O
existence	O
of	O
metabolic	O
alterations	O
in	O
early	O
pancreatic	O
cancer	O
development,	O
highlighting	O
glutamine	B
and	O
histidine	B
as	O
metabolites	O
of	O
interest,	O
but	O
also	O
underscores	O
the	O
challenges	O
to	O
find	O
robust,	O
prognostic	O
biomarkers	O
for	O
rare	O
disorders.	O

The	O
extent	O
of	O
biotinylation	O
was	O
estimated	O
by	O
UV-absorption	O
maxima	O
at	O
280/354	O
nm	O
in	O
Du	O
640	O
Spectrophotometer	O
(Beckman	O
Instrument	O
Inc.,	O
CA),	O
and	O
the	O
stoichiometry	O
between	O
protein	O
and	O
biotin	B
was	O
calculated	O
using	O
the	O
program	O
calculator	O
provided	O
by	O
the	O
manufacturer.	O

For	O
sofosbuvir,	B
mostly	O
submicromolar	O
levels	O
of	O
metabolite	O
X	O
were	O
detected	O
(median,	O
0.16	O
μM	O
[minimum,	O
0.007	O
μM;	O
maximum,	O
5.08	O
μM]).	O

To	O
extract	O
phospholipids,	B
2	O
×	O
10_6	O
cells	O
were	O
washed	O
twice	O
with	O
ice-cold	O
PBS,	O
scraped	O
into	O
800	O
μL	O
of	O
ice-cold	O
0.1	O
N	O
HCl:CH_3	O
OH	B
(1:1),	I
and	O
transferred	O
into	O
a	O
cold	O
microfuge	O
tube.	O

The	O
changes	O
in	O
the	O
metabolic	O
profile	O
start	O
with	O
the	O
increased	O
signals	O
due	O
to	O
lipids	O
(0.9	O
and	O
1.3 ppm)	O
and	O
phospholipids	B
(3.2 ppm).	O

Among	O
four	O
predicted	O
positive	O
associations,	O
taurine	B
and	O
docosapentaenoic	B
acid	I
were	O
confirmed	O
to	O
enhance	O
growth,	O
while	O
phytosphingosine	B
exhibited	O
a	O
paradoxical	O
inhibitory	O
effect.	O

Model	O
1:	O
Insulin=Testosterone+WC;	B
Model	O
2:	O
HOMA	O
IR=Testosterone+WC;	B
Beta	O
values	O
for	O
insulin	O
and	O
HOMA	O
IR	O
levels	O
are	O
mutually	O
adjusted_a	O
and	O
by	O
unit	O
increase	O
in	O
exposure	O
level.	O

Although	O
the	O
mechanisms	O
responsible	O
for	O
the	O
formation	O
of	O
the	O
eccentric	O
cleavage	O
products	O
of	O
β-carotene	B
in	O
mammals	O
are	O
not	O
fully	O
known,	O
it	O
is	O
clear	O
that	O
some	O
of	O
the	O
long	O
chain	O
β-apocarotenals	B
(e.g.	O
8′,	O
10′,	O
12′,	O
14′)	O
are	O
found	O
in	O
the	O
plasma	O
of	O
humans	O
and	O
experimental	O
animals	O
and	O
that	O
these	O
are	O
increased	O
under	O
conditions	O
of	O
oxidative	O
stress	O
and	O
high	O
dietary	O
doses	O
of	O
β-carotene.	B

Interestingly,	O
in	O
another	O
study	O
evaluating	O
serum	O
_1	O
H-NMR	O
metabolomic	O
profile	O
of	O
EBC	O
and	O
responses	O
to	O
chemotherapy,	O
the	O
combination	O
of	O
lactate,	B
alanine	B
and	O
glucose	B
levels	O
were	O
significant	O
in	O
multivariate	O
analysis	O
to	O
predict	O
tumor	O
response.	O

After	O
the	O
extracts	O
were	O
completely	O
dried	O
by	O
speed	O
vacuum	O
concentrator	O
or	O
by	O
freeze-drying,	O
20	O
µL	O
of	O
40	O
mg/mL	O
methoxylamine	B
hydrochloride	I
in	O
pyridine	B
was	O
added,	O
and	O
samples	O
were	O
agitated	O
at	O
30	O
°C	O
for	O
30	O
min.	O

Urinary	O
cotinine	B
levels	O
declined	O
and	O
then	O
reached	O
a	O
plateau,	O
presumably	O
due	O
to	O
use	O
of	O
transdermal	O
nicotine.	B

Therefore,	O
the	O
metabolites	O
identified	O
from	O
untargeted	O
approach	O
and	O
used	O
for	O
these	O
analyses	O
were:	O
acetylcarnitine,	B
pyruvic	B
acid,	I
lactic	B
acid,	I
stearic	B
acid,	I
kynuramine,	B
citric	B
acid,	I
myristic	B
acid,	I
palmitoleic	B
acid,	I
palmitic	B
acid,	I
oleic	B
acid,	I
tyrosine,	B
histidine.	B

Homogenized	O
tumor	O
samples	O
were	O
collected	O
and	O
cold	O
80%	O
methanol	B
was	O
added	O
to	O
these	O
samples	O
maintaining	O
similar	O
proportion	O
of	O
80%	O
methanol	B
to	O
the	O
tumor	O
weights.	O

Endogenous	O
PC	O
can	O
produce	O
arachidonic	B
acid	I
(AA)	O
and	O
lysophosphatidylcholine	B
(LPC)	O
through	O
deacylation	O
promoted	O
by	O
the	O
cytosolic	O
phospholipase	O
A_2	O
(cPLA_2	O
).	O

PCA,	O
PLS-DA	O
and	O
univariate	O
statistics	O
were	O
applied	O
and	O
found	O
substantial	O
differences	O
between	O
the	O
time	O
points,	O
dominated	O
by	O
a	O
steady	O
increase	O
of	O
urinary	O
lactose	B
concentrations,	O
and	O
an	O
increase	O
during	O
pregnancy	O
and	O
subsequent	O
dramatic	O
reduction	O
of	O
several	O
unidentified	O
NMR	O
signals	O
between	O
0.5	O
and	O
1.1	O
ppm.	O

Previous	O
studies	O
performed	O
in	O
patients	O
with	O
CKD	O
stages	O
3–5	O
showed	O
that	O
reducing	O
kidney	O
function	O
was	O
associated	O
with	O
increasing	O
plasma	O
concentrations	O
of	O
citrulline	B
(,,).	O

It	O
also	O
acts	O
as	O
biochemical	O
precursor	O
for	O
the	O
synthesis	O
of	O
niacin	B
cofactor,	O
through	O
pathways	O
of	O
kynurenine	B
(Kyn)	O
and	O
for	O
the	O
synthesis	O
of	O
melatonin	B
from	O
serotonin	B
(Set)	O
via	O
the	O
methoxyindoles	B
pathway	O
(Figure	O
).	O

Thus,	O
HDC	O
constitutes	O
a	O
key	O
regulator	O
of	O
histamine	B
concentration.	O

Although	O
an	O
effective	O
HBV	O
vaccine	B
has	O
been	O
developed,	O
it	O
has	O
not	O
been	O
made	O
available	O
to	O
everyone	O
and	O
there	O
are	O
many	O
HBV	O
carriers	O
who	O
are	O
still	O
at	O
increased	O
risk	O
of	O
developing	O
cirrhosis.	O

Strong	O
correlations	O
(red/orange	O
data	O
points)	O
between	O
this	O
resonance	O
and	O
many	O
related	O
ibuprofen	B
resonances	O
can	O
be	O
observed.	O

AP	B
was	O
defined	O
as	O
abdominal	O
pain	O
with	O
elevation	O
of	O
amylase	O
and	O
lipase	O
three	O
times	O
normal.	O

Patient	O
demographics	O
for	O
plasma	O
VLCDCA	B
28:4	I
measurements.	O

However,	O
in	O
other	O
cohort	O
studies,	O
a	O
slight	O
decrease	O
in	O
arginine	B
was	O
detected	O
in	O
CSF	O
of	O
AD	O
patients	O
(Fonteh	O
et	O
al.,	O
;	O

Somewhat	O
surprisingly,	O
the	O
metabolism	O
of	O
valine,	B
leucine,	B
and	O
isoleucine	B
was	O
significantly	O
associated	O
with	O
migraine,	O
and	O
not	O
in	O
line	O
with	O
the	O
findings	O
from	O
the	O
single-metabolite	O
analyses.	O

MG,	O
diacylglycerol	B
15:0–18:1(d7)	I
DG,	O
triacylglycerol	B
15:0–18:1(d7)-15:0	I
TG,	I
sphingomyelin	B
18:1(d9)	I

M1	O
and	O
M2	O
fully	O
retain	O
the	O
same	O
metabolic	O
properties	O
as	O
human	O
insulin	O
(HI),	O
but	O
in	O
contrast	O
to	O
glargine,	O
they	O
do	O
not	O
differ	O
from	O
HI	B
in	O
affinity	O
for	O
IGF-1	O
receptor	O
(IGF-1R)	O
and	O
mitogenesis.	O

Although	O
our	O
data	O
provide	O
evidence	O
of	O
an	O
association	O
between	O
higher	O
plasma	O
TMAO	B
concentrations	O
and	O
GDM,	O
the	O
involvement	O
of	O
TMAO	B
in	O
any	O
causal	O
or	O
compensatory	O
pathway	O
has	O
not	O
been	O
proven.	O

1:	O
Lipids	O
LDL	O
CH_3	O
-(CH_2	O
)_n	O
-;	O
2:	O
Lipids	O
VLDL	O
CH_3	O
-(CH_2	O
)_n	O
-;	O
3:	O
Leucine;	B
4:	O
Isoleucine;	B
5:	O
Valine;	B
6:	O
3-Methyl-2-oxovalerate;	O
7:	O
Isobutyrate;	B
8:	O
3-Hydroxybutyrate;	O
9:	O
Lipids	O
LDL	O
CH_3	O
-(CH_2	O
)_n	O
-;	O
10:	O
Lipids	O
VLDL	O
CH_3	O
-(CH_2	O
)_n	O
-;	O
11:	O
Lactate;	B
12:	O
Threonine;	B
13:	O
Alanine;	B
14:	O
Lipids	O
VLDL	O
CH_2	O
-CH_2	O
-C=O;	O
15:	O
Lysine;	B
16:	O
Acetate;	B
17:	O
Lipids	O
-CH_2	O
-CH=CH-;	O
18:	O
N-acetylated	O
compounds;	O
19:	O
Glutamine;	B
20:	O
Lipids	O
-CH_2	O
-C=O;	O
21:	O
Acetone;	B
22:	O
Acetoacetate;	B
23:	O
Pyruvate;	B
24:	O
Citrate;	B
25:	O
Dimethylamine;	B
26:	O
Lipids	O
=CH-CH_2	O
-CH=;	O
27:	O
Trimethylamine;	B
28:	O
Creatine;	B
29:	O
Creatinine;	B
30:	O
Dimethyl	B
sulfone;	I
31:	O
Choline;	B
32:	O
Phosphocholine;	B
33:	O
Glycerophosphocholine;	B
34:	O
α	O
and	O
β-Glucose;	B
35:	O
Methanol;	B
36:	O
Glycine;	B
37:	O
β-Glucose;	B
38:	O
α-Glucose;	B
39:	O
Lipids	O
-CH=CH-;	O
40:	O
Urea;	B
41:	O
Tyrosine;	B
42:	O
1-Methylhistidine;	O
43:	O
Phenylalanine;	B
44:	O
Formate.	B

The	O
temperatures	O
of	O
injection,	O
interface,	O
and	O
ion	O
source	O
were	O
adjusted	O
at	O
230°C,	O
290°C,	O
and	O
220°C,	O
respectively,	O
with	O
an	O
electron	O
energy	O
of	O
70	O
eV	O
and	O
a	O
trap	O
current	O
of	O
70	O
µA.	O
The	O
GC	O
oven	O
temperature	O
was	O
first	O
held	O
at	O
70°C	O
for	O
5	O
min	O
solvent	O
delay	O
and	O
then	O
ramped	O
at	O
5°C/min	O
to	O
a	O
final	O
temperature	O
of	O
310°C,	O
and	O
this	O
was	O
followed	O
by	O
a	O
1	O
min	O
isocratic,	O
cool-down	B
to	O
70°C,	O
and	O
an	O
additional	O
5	O
min	O
delay.	O

Stock	O
solutions	O
were	O
made	O
using	O
commercially	O
available	O
standards	O
for	O
T,	O
DHT,	O
Epi-T,	O
Δ_4	O
-AD,	O
Adione,	B
A	O
and	O
DHEA	O
in	O
ethanol	B
for	O
calibration	O
curves	O
and	O
quality	O
control	O
standards.	O

Effect	O
sizes	O
were	O
small	O
but	O
directionally	O
concordant	O
with	O
those	O
seen	O
for	O
current	O
and	O
longer-term	O
MVPA	O
measures	O
in	O
relation	O
to	O
cholesterol	B
in	O
VLDL	O
and	O
LDL	O
particles	O
and	O
triglycerides	B
across	O
all	O
particle	O
types,	O
while	O
SBP	O
and	O
DBP	B
appeared	O
to	O
flip	O
their	O
direction	O
of	O
effect.	O

The	O
expression	O
profiles	O
of	O
non-responders	O
in	O
the	O
IER	O
study	O
appeared	O
similar	O
to	O
the	O
non-dieting	O
controls	O
in	O
the	O
earlier	O
CER	B
study	O
(Fig. )	O
and	O
was	O
confirmed	O
by	O
gene	O
set	O
enrichment	O
analysis	O
(adjusted	O
p	O
 = 0.027).	O

Whereas,	O
the	O
serum	O
concentrations	O
of	O
several	O
PCs,	O
LysoPC(C18:2),	B
LysoPC(C20:4),	B
some	O
sphingomyelins,	B
acetate,	B
acetoacetate,	B
2-hydroxybutyrate,	B
and	O
3-hydroxybutyrate	B
were	O
found	O
to	O
be	O
lower	O
in	O
HFrEF	O
patients	O
than	O
non-HF	O
controls	O
(,	O
).	O

Patients	O
with	O
inactive	O
UC	O
had	O
significantly	O
higher	O
citrulline	B
than	O
controls	O
and	O
patients	O
with	O
active	O
disease	O
and	O
higher	O
DMA	B
than	O
controls.	O

However,	O
this	O
or	O
any	O
other	O
N-dealkylated	O
metabolites	O
of	O
anastrozole	B
[e.g.	O
3,5-Bis-(2-methylpropiononitrile)-benzoic	B
acid]	O
could	O
not	O
be	O
detected	O
in	O
our	O
in	O
vitro	O
studies.	O

Erythronic	B
acid	I
was	O
found	O
decreased	O
while	O
butanedioic	B
acid	I
was	O
found	O
increased	O
in	O
MDD.	O

BCAA	O
are	O
essential	O
amino	O
acids	O
derived	O
from	O
the	O
diet	O
that	O
play	O
an	O
important	O
role	O
in	O
the	O
synthesis	O
of	O
peptides,	O
sterols,	O
ketones,	B
and	O
glucose.	B

The	O
methanol,	B
2‐chloro‐phenylalanine,	B
methoxyamine	B
and	O
pyridine	B
were	O
purchased	O
from	O
Aladdin	O
(Shanghai,	O
China).	O

More	O
consistently,	O
ε4	O
allele	O
associated	O
with	O
low	O
cholesterol	B
of	O
large-	O
and	O
medium-sized	O
HDL-particles.	O

These	O
include	O
the	O
glucose	B
transporter	O
GLUT1,	O
hexokinase	O
1,2	B
(HK	I
1,2),	I
phosphoglycerate	B
mutase	O
1	O
(PGAM1),	O
pyruvate	B
kinase	O
M2	O
(PKM2),	O
phosphofructo-2-kinase/fructose-2,6-bisphosphatase	O
3	O
(PFKFB3),	O
isocitrate	O
dehydrogenase	O
2	O
(IDH2),	O
succinate	O
dehydrogenase	O
(SDH),	O
and	O
fumarate	B
hydratase	O
(FH).	O

The	O
analytical	O
method	O
employed	O
methylates	B
free	O
fatty	O
acids	O
and	O
transesterifies	O

So,	O
further	O
study	O
should	O
focus	O
on	O
the	O
identification	O
of	O
thiols	B
and	O
provide	O
an	O
insight	O
into	O
the	O
better	O
use	O
of	O
urinary	O
thiols	B
as	O
biomarkers	O
for	O
cancers.	O

When	O
E_1	O
(E_2	B
)-3,4-Q	I
react	O
with	O
DNA,	O
they	O
form	O
predominantly	O
the	O
depurinating	O
adducts	O
4-hydroxyestrone(estradiol)-1-N3Ade	O

In	O
contrast,	O
the	O
change	O
in	O
triglycerides	B
did	O
not	O
alter	O
the	O
inflammatory	O
upregulation	O
of	O
ICAM-1	O
expression	O
across	O
subjects,	O
which	O
tended	O
to	O
be	O
less	O
variable	O
(Fig.	O

We	O
have	O
previously	O
shown	O
that	O
dysregulation	O
in	O
glycolytic	B
and	O
tricarboxylic	B
acid	I
cycle	O
intermediates	O
can	O
distinguish	O
benign	O
lesions	O
from	O
RCC	O
in	O
a	O
stage-specific	O
manner.	O

Regarding	O
creatinine,	B
relative	O
concentrations	O
obtained,	O
and	O
their	O
respective	O
differences	O
between	O
groups	O
under	O
study,	O
this	O
metabolite	O
might	O
be	O
considered	O
a	O
potential	O
artefact	O
given	O
that	O
creatinine	B
values	O
may	O
be	O
altered,	O
as	O
the	O
generation	O
of	O
creatinine	B
may	O
not	O
be	O
simply	O
a	O
product	O
of	O
muscle	O
mass	O
but	O
influenced	O
by	O
muscle	O
function,	O
muscle	O
composition,	O
activity,	O
diet,	O
and	O
health	O
status.	O

Next,	O
10	O
μL	O
of	O
2‐isopropylmalic	B
acid	I
(0.5	O
mg/mL)	O
was	O
added	O
as	O
an	O
internal	O
standard.	O

Assay	O
(Life	O
Technologies)	O
and	O
normalized	O
to	O
a	O
concentration	O
of	O
50	O
pg/μL.	O
Illumina	O
sequencing	O
libraries	O
were	O
prepared	O
from	O
100–250	O
pg	B
of	O
DNA	O
using	O
the	O
Nextera	O
XT	O
DNA	O
Library	O
Preparation	O
kit	O
(Illumina)	O
according	O
to	O
the	O
manufacturer’s	O
recommended	O
protocol,	O
with	O
reaction	O
volumes	O
scaled	O
accordingly.	O

Pentanoic	B
acid,	I
11-eicosenoic	B
acid,	I
pentaenoate	B
showed	O
increased	O
while	O
UDP	B
showed	O
decreased	O
abundance	O
in	O
both	O
tissue	O
and	O
serum	O
samples	O
of	O
IDC	O
when	O
compared	O
to	O
control.	O

It	O
was	O
positively	O
correlated	O
with	O
lactate	B
concentration	O
in	O
glioblastomas,	O
astrocytomas	O
and	O
meningiomas	O
while	O
in	O
oligodendrogliomas	O
these	O
metabolites	O
showed	O
a	O
moderate	O
correlation	O
that	O
lay	O
just	O
outside	O
statistical	O
significance	O
(p	O
=	O
0.07).	O

Those	O
57	O
metabolites	O
used	O
in	O
this	O
study	O
can	O
be	O
categorized	O
into	O
six	O
classes,	O
that	O
is,	O
12	O
are	O
unique	O
for	O
acetamiprid	B
(AM-1–12),	O
11	O
are	O
unique	O
for	O
imidacloprid	O
(IM-1–11),	O
13	O
are	O
unique	O
for	O
clothianidin	B
(CM-1–13),	O
10	O
are	O
common	O
for	O
chloropyridinyl	B
neonicotinoid	I
(CPM-1–10),	O
one	O
is	O
common	O
for	O
imidacloprid	O
and	O
clothianidin	B
(ICM-1),	O
and	O
10	O
are	O
common	O
for	O
clothianidin	B
and	O
thiamethoxam	B
(CTM-1–10)	O
(,	O
).	O

Significant	O
differences	O
in	O
six-month	O
changes	O
between	O
RYGB	O
and	O
WLM	O
therefore	O
mostly	O
reflect	O
changes	O
for	O
RYGB	O
(with	O
WLM	O
mostly	O
unchanged)	O
and	O
since	O
weight	O
loss	O
was	O
equivalent	O
between	O
groups,	O
suggest	O
an	O
association	O
with	O
glycemic	B
improvement.	O

FA	B
dimers	O
had	O
particularly	O
strong	O
ion	O
signals	O
at	O
m	O
/z	O
537.4	O
(oleic	O
acid	O
+	O
palmitic	B
acid)	O
and	O
at	O
m	O
/z	O
563.5	O
(oleic	O
acid	O
+	O
oleic	O
acid),	O
but	O
not	O
at	O
m	O
/z	O
585.5	O
(oleic	O
acid	O
+	O
arachidonic	O
acid)	O
in	O
normal	O
skin.	O

The	O
study	O
overall	O
showed	O
a	O
good	O
correlation	O
between	O
venous	O
and	O
capillary	O
drug	O
concentrations	O
but	O
also	O
showed	O
a	O
time‐dependent	O
difference,	O
in	O
particular	O
for	O
paliperidone	B
and	O
olanzapine.	B

PC	B
(34:2),	I
PC	B
(34:1),	I
PC	B
(36:3),	I
and	O
PC	B
(36:2)	I
levels	O
were	O
increased	O
in	O
both	O
tissues	O
and	O
sera	O
from	O
MF	O
patients,	O
whereas	O
SM	B
(16:0),	I
PC	B
(32:0),	I
and	O
PC	B
(38:4)	I
levels	O
were	O
increased	O
in	O
MF	O
sera	O
but	O
were	O
decreased	O
in	O
MF	O
tissues.	O

Uni	O
and	O
multivariate	O
analyses	O
of	O
metabolites	O
identified	O
in	O
urine	O
by	O
_1	O
H	O
NMR	O
revealed	O
11	O
deregulated	O
molecules	O
in	O
ARD	O
subjects	O
and	O
involved	O
in	O
phenylalanine,	B
histidine,	B
arginine	B
and	O
proline	B
metabolism.	O

Larger	O
extended	O
upward	O
variances	O
in	O
females	O
than	O
males,	O
despite	O
opposite	O
or	O
no	O
significant	O
overall	O
differences	O
in	O
plasma	O
concentrations,	O
were	O
observed	O
for	O
cortisol	B
and	O
aldosterone	B
indicating	O
respective	O
9%	O
and	O
49%	O
higher	O
97.5	O
percentiles	O
for	O
these	O
steroids	O
in	O
women	O
than	O
men.	O

Boxplots	O
of	O
myoinositol	B
and	O
formate	B
in	O
patients	O
with	O
RRMS	O
and	O
Ab-NMOSD	O
are	O
constructed	O
from	O
the	O
same	O
data	O
used	O
to	O
generate	O
the	O
AUC	O
graphs	O
in	O
.	O

ciPTEC	O
were	O
seeded	O
at	O
40%	O
confluence	O
in	O
12-well	O
plates	O
and	O
allowed	O
to	O
adhere	O
over	O
night	O
at	O
33°C	O
followed	O
by	O
maturation	O
for	O
7	O
days	O
at	O
37°C,	O
before	O
being	O
treated	O
for	O
48	O
h	O
with	O
clinically	O
relevant	O
uremic	O
toxin	B
concentrations.	O

2.5	O
mL	O
of	O
MTBE	B
was	O
added	O
to	O
the	O
dried	O
residue	O
followed	O
by	O
vortexing	O
vigorously	O
for	O
10	O
sec,	O
then	O
625	O
µL	O
of	O
water	O
was	O
added	O
to	O
the	O
mixture	O
and	O
vortexed	O
vigorously	O
for	O
30	O
sec.	O

ROC	O
curves	O
based	O
on	O
D-glutamic	B
acid	I
were	O
drawn	O
to	O
explicitly	O
determine	O
which	O
metabolites	O
can	O
definitely	O
diagnose	O
AF	B
in	O
patients.	O

G-6-P,	O
glucose-6-phosphate;	B
Ala,	O
alanine;	B
Trp,	O
tryptophan;	B
Ser,	O
serine;	B
Ile,	O
isoleucine;	B
Leu,	O
leucine;	B
Val,	O
valine;	B
His,	O
histidine;	B
Arg,	O
arginine;	B
Pro,	O
proline;	B
Glu,	O
glutamic	B
acid;	I
Gln,	O
glutamine;	B
Lys,	O
lysine;	B
Met,	O
methionine;	B
Thr,	O
threonine;	B
Asp,	O
aspartic	B
acid;	I
Asn,	O
asparagine;	B
Phe,	O
phenylalanine;	B
Tyr,	O
tyrosine;	B
and	O
Gly,	O
glycine.	B

It	O
was,	O
therefore,	O
not	O
surprising	O
to	O
find	O
a	O
significant	O
negative	O
correlation	O
between	O
tissue	O
and	O
serum	O
levels	O
of	O
alanine,	B
lysine,	B
phenylalanine	B
and	O
leucine	B
(Fig. ).	O

Lysophosphatidylcholine	B
(20:0)	I
and	O
lysophosphatidylcholine	B
(18:2)	I
were	O
purchased	O
from	O
Larodan	O
AB	O
(Malmo,	O
Sweden).	O

Nonpolar	O
organic	O
solvents	O
in	O
which	O
lipids	O
are	O
soluble	O
like	O
chloroform,	B
methyl-tert	B
-butyl	I
ether,	I
and	O
heptane,	B
are	O
typically	O
used	O
to	O
extract	O
lipids	O
from	O
the	O
aqueous	O
phase.	O

This	O
method	O
can	O
be	O
used	O
to	O
identify	O
and	O
quantify	O
distinct	O
lipid	O
classes	O
including	O
neutral	O
lipids,	O
such	O
as	O
cholesterol	B
esters	I
(CEs),	O
free	O
fatty	O
acids	O
(FFAs),	O
triacylglycerols	B
(TGs)	O
and	O
diacylglycerols	B
(DGs)	O
as	O
well	O
as	O
phospholipids	B
such	O
as	O
lysophosphatidylcholines	B
(LysoPCs),	O
phosphatidylcholines	B
(PCs)	O
and	O
phosphatidyl-ethanolamines	B
(PEs).	O

Urinary	O
sarcosine	B
and	O
cysteine	B
levels	O
were	O
significantly	O
higher	O
(p = 0.03	O
and	O
p = 0.007	O
respectively)	O
in	O
the	O
recurrent	O
group.	O

[M + H]_+	O
of	O
PC34:1.	B

Differentially	O
abundant	O
metabolites	O
identified	O
by	O
NMR	O
in	O
EA	O
tissue	O
relative	O
to	O
normal	O
tissue	O
have	O
included	O
phosphocholine,	B
glutamate,	B
myo-inositol,	B
adenosine-containing	O
compounds,	O
uracil,	B
and	O
inosine.	B

However,	O
many	O
other	O
TG,	B
and	O
other	O
plasma	O
lipids,	O
were	O
only	O
different	O
when	O
comparing	O
the	O
OIR	O
and	O
Lean	O
groups.	O

()	O
employed	O
a	O
QIT	O
to	O
screen	O
for	O
DNA	O
adducts	O
formed	O
with	O
another	O
major	O
α	O
,β	O
-unsaturated	O
aldehyde,	O
trans	B
-4-hydoxy-2-nonenal	I
(HNE),	O
which	O
forms	O
4	O
isomeric	O
cyclic	O
1,N	O
_2	O
adducts	O
with	O
dG.	O
The	O
HNE-dG	O
adducts	O
were	O
identified	O
in	O
hippocampus/parahippocampal	O
gyrus	O
(HPG)	O
and	O
inferior	O
parietal	O
lobule	O
(IPL)	O
regions	O
of	O
postmortem	O
brains	O
by	O
HPLC-QIT-MS_2	O
.	O

When	O
we	O
investigated	O
the	O
contribution	O
of	O
the	O
single	O
molecules,	O
we	O
found	O
an	O
inverse	O
association	O
between	O
acetylcarnitine	B
(C2)	O
and	O
risk	O
of	O
PSA	O
progression	O
(p	O
 = 0.016,	O
global	O
Log-Rank	O
p	O
 = 0.05	O
with	O
multivariate	O
Cox	O
regression	O
analysis	O
for	O
the	O
panel	O
of	O
acylcarnitine	B
associated	O
with	O
risk	O
of	O
PSA	O
progression	O
tested	O
for	O
proportional	O
hazard	O
assumption,	O
median	O
cut-off)	O
(Fig.	O

The	O
chromatographic	O
separation	O
of	O
abiraterone	B
with	O
its	O
multiple	O
metabolites	O
was	O
addressed	O
by	O
using	O
a	O
longer	O
analytical	O
column	O
and	O
adjusting	O
the	O
gradient.	O

Several	O
bile	O
acids,	O
cholic	B
acid,	I
glycocholic	B
acid,	I
deoxycholic	B
acid	I
and	O
glycochenodeoxycholic	B
acid,	I
altered	O
differently	O
in	O
concentration	O
in	O
the	O
HCC	O
patients	O
with	O
or	O
without	O
liver	O
cirrhosis	O
and	O
hepatitis,	O
which	O
hold	O
the	O
potential	O
as	O
markers	O
for	O
the	O
stratification	O
of	O
HCC	O
subjects	O
with	O
and	O
without	O
cirrhosis	O
and	O
hepatitis.	O

Additionally,	O
35%	O
of	O
all	O
Cer,	B
42%	O
of	O
LPCs,	O
20%	O
of	O
PCs,	O
25%	O
of	O
diacylglycerophosphoglycerols	B
(PGs),	O
and	O
50%	O
of	O
diacylglycerophosphoserines	B
(PSs)	O
showed	O
greater	O
than	O
4.5	O
FC,	O
indicating	O
that	O
these	O
lipid	O
classes	O
are	O
strongly	O
influenced	O
by	O
the	O
progress	O
of	O
and/or	O
recovery	O
from	O
EVD.	O

The	O
residue	O
was	O
first	O
reconstituted	O
in	O
80	O
μL	O
of	O
methoxyamine	B
(15	O
mg/mL	O
in	O
pyridine),	B
vortexed	O
for	O
30	O
seconds,	O
and	O
kept	O
at	O
37°C	O
for	O
90	O
minutes.	O

Multiple	O
sclerosis	O
(MuS)	O
is	O
an	O
autoimmune	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
characterized	O
by	O
neuroinflammation,	O
neurodegeneration,	O
and	O
degradation	O
of	O
the	O
myelin	B
sheath.	O

Glutamate	B
has	O
been	O
implicated	O
as	O
a	O
biomarker	O
of	O
PCa	O
aggressiveness,	O
suggesting	O
that	O
modulation	O
of	O
the	O
pathways	O
and	O
the	O
metabolome	O
could	O
modulate	O
tumor	O
behavior	O
(,	O
).	O

_3	O
Diabetes	O
category:	O
Impaired	O
fasting	O
glucose,	B
100≤	O
fasting	O
glucose	B
<126mg/dL;	O
Diabetes,	O
fasting	O
glucose	B
≥126mg/dL.	O
_4	O
Tested	O
by	O
one-way	O
analysis	O
of	O
variance	O
(ANOVA)	O
with	O
bonferroni’s	O
multiple	O
comparisons	O
test	O
(p<0.05).	O

The	O
specific	O
change	O
trends	O
that	O
higher	O
levels	O
of	O
glutamine,	B
N-acetyl-glycoproteins,	B
TMAO,	B
citrate,	B
tyrosine	B
and	O
phenylalanine	B
and	O
lower	O
levels	O
of	O
valine,	B
isoleucine,	B
and	O
glucose	B
were	O
revealed	O
in	O
.	O

It	O
is	O
perhaps	O
not	O
that	O
straightforward	O
to	O
link	O
the	O
metabolites	O
to	O
a	O
specific	O
pathway	O
as	O
a	O
recent	O
study	O
already	O
demonstrated	O
that	O
many	O
of	O
the	O
acylglycines	B
and	O
tryptophan	B
metabolites	O
in	O
mammalian	O
blood	O
have	O
shown	O
a	O
relation	O
to	O
gut	O
“microbiome”	O
(Wikoff	O
et	O
al.	O
)	O
which	O
could	O
explain	O
a	O
presence	O
in	O
urine	O
by	O
regular	O
excretion.	O

We	O
calculated	O
hazard	O
ratios	O
(HRs)	O
approximating	O
risk	O
in	O
highest	O
vs	O
lowest	O
deciles	O
of	O
individual	O
estrogens	O
and	O
estrogen	B
metabolites,	O
estrogens	O
and	O
estrogen	B
metabolites	O
grouped	O
by	O
metabolic	O
pathways,	O
and	O
metabolic	O
pathway	O
ratios	O
using	O
multivariable	O
Cox	O
proportional	O
hazards	O
models.	O

In	O
pooled	O
healthy	O
baboon	O
WB,	O
41	O
compounds	O
were	O
detected	O
and	O
quantified	O
after	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF	O
(n	O
=	O
10),	O
and	O
39	O
compounds	O
after	O
blood	O
was	O
MeOH:	B

The	O
mobile	O
phase	O
consisted	O
of	O
water	O
containing	O
1%	O
acetic	B
acid	I
(eluent	O
A)	O
and	O
acetonitrile	B
(eluent	O
B)	O
at	O
a	O
constant	O
flow	O
rate	O
set	O
at	O
450	O
µl/min.	O

In	O
our	O
study,	O
however,	O
the	O
correlation	O
between	O
logged	O
cotinine	B
and	O
logged	O
trans	B
-3′-hydroxycotinine	I
with	O
logged	O
creatinine	B
is	O
very	O
low	O
(N	O
=86;	O
R_Cot	O
=0.06;	O
R_T3HCot	O
=0.26;	O
p	O
>	O
0.10)	O
suggesting	O
that	O
Thompson’s	O
method	O
is	O
not	O
valid	O
in	O
the	O
case	O
of	O
non-smoker	O
subjects.	O

Among	O
these	O
metabolites,	O
the	O
high	O
level	O
of	O
C8-ceramide,	B
palmitoylcarnitine,	B
hypoxanthine,	B
linoleamide,	B
palmitic	B
amide,	I
methionine,	B
sphingosine	B
and	O
inosine,	B
and	O
the	O
low	O
level	O
of	O
isoleucine,	B
valine,	B
glutamine,	B
lysoPC(18:2),	B
lysoPC(20:3)	B
and	O
lysoPC(22:5)	B
were	O
observed	O
in	O
HAPE	O
subjects	O
relative	O
to	O
healthy	O
controls.	O

Compared	O
with	O
ANIT,	O
we	O
further	O
observed	O
higher	O
levels	O
of	O
cysteine	B
and	O
GSH	B
in	O
CRC	O
tumors,	O
which	O
has	O
also	O
been	O
observed	O
in	O
human	O
esophageal	O
cancer.	O

High	O
serum	O
enterolactone	B
concentrations	O
were	O
associated	O
with	O
low	O
tumor	O
grade,	O
high	O
serum	O
creatinine	B
levels,	O
and	O
concomitant	O
diabetes.	O

In	O
HIV/AIDS	O
patients	O
we	O
observed	O
increased	O
plasma	O
levels	O
of	O
Methylmalonic	B
acid	I
(MMA),	O
a	O
dicarboxylic	B
acid	I
that	O
forms	O
methylmalonyl-CoA,	B
which	O
is	O
converted	O
into	O
succinyl-CoA	B
in	O
a	O
vitamin	O
B12-dependent	O
process,	O
and	O
enters	O
the	O
Krebs	O
cycle.	O

In	O
the	O
human	O
free	O
choline	B
can	O
be	O
taken	O
up	O
from	O
circulation	O
(via	O
active	O
transport)	O
by	O
the	O
mammary	O
epithelium	O
across	O
a	O
steep	O
concentration	O
gradient	O
,	O
,	O
and	O
recently	O
Ilcol	O
found	O
a	O
positive	O
correlation	O
between	O
serum	O
free	O
choline	B
and	O
milk	O
free	O
choline	B
concentrations	O
(r = 0.74,	O
p<0.01).	O

A	O
was	O
5%	O
methanol	B
in	O
0.1%	O
aqueous	O
formic	B
acid,	I
and	O
mobile	O
phase	O
B	O
was	O
100%	O
methanol.	B

Alanine	B
is	O
a	O
glycogenic	O
(glycogen-producing)	O
amino	O
acid	O
that	O
can	O
be	O
converted	O
to	O
pyruvate	B
and	O
tricarboxylic	B
acid	I
cycle	O
intermediates,	O
and	O
then	O
to	O
glucose	B
by	O
gluconeogenesis,	O
functioning	O
as	O
an	O
energy	O
source	O
to	O
meet	O
the	O
huge	O
demand	O
of	O
energy	O
consumed	O
in	O
various	O
metabolic	O
activities	O
in	O
tumor	O
cells.	O

For	O
example,	O
altered	O
TMAO	B
concentrations	O
could	O
simply	O
be	O
an	O
indicator	O
of	O
changes	O
in	O
gut	O
microbiota	O
composition.	O

For	O
example,	O
when	O
N1,	O
N12-diacetylspermine,	B
lactic	B
acid	I
and	O
citrulline	B
were	O
used	O
as	O
a	O
panel	O
of	O
biomarkers,	O
the	O
AUC	O
value	O
was	O
increased	O
to	O
0.957.	O

PGF2α	B
was	O
also	O
elevated,	O
in	O
patients	O
with	O
low	O
BM	O
or	O
peripheral	O
blasts	O
and	O
with	O
a	O
favorable	O
prognostic	O
risk.	O

The	O
assay	O
lower	O
limit	O
of	O
quantitation	O
(LLOQ)	O
was	O
1	O
pg/mL	O
for	O
each	O
estrogen	B
and	O
estrogen	B
metabolite	O
with	O
intra-and	O
inter-batch	O
coefficients	O
of	O
variation	O
<15%	O
and	O
assay	O
accuracy	O
between	O
85–115%	O
of	O
known	O
targeted	O
values	O
at	O
LLOQ.	O

These	O
cells	O
are	O
pivotal	O
to	O
the	O
transport	O
and	O
tissue	O
exchange	O
of	O
amino	O
acids	O
and	O
are	O
a	O
reservoir	O
of	O
anti-oxidants	O
like	O
glutathione	B
and	O
a	O
number	O
of	O
enzymes	O
such	O
as	O
LDH.	O

The	O
majority	O
of	O
samples	O
displayed	O
prominent	O
signals	O
of	O
triacylglycerol	B
(TG)	O
and	O
diacylglycerol	B
(DG)	O
species	O
that	O
could	O
be	O
verified	O
by	O
MS2	O
spectra.	O

Family	O
history	O
of	O
prostate	O
cancer=defined	O
as	O
having	O
any	O
blood	O
relative	O
diagnosed	O
with	O
prostate	O
cancer	O
P_H	O
:	O
comparison	O
between	O
cases	O
and	O
healthy	O
controls	O
P_B	O
:	O
comparison	O
between	O
cases	O
and	O
biopsy	O
controls	O
P_H/B	O
:	O
comparison	O
between	O
healthy	O
and	O
biopsy	O
controls	O
Results	O
showed	O
that	O
in	O
all	O
groups,	O
the	O
ranking	O
of	O
the	O
estrogen	B
metabolites	O
based	O
on	O
median	O
concentration	O
in	O
urine	O
was	O
similar.	O

Taurine,	B
which	O
is	O
a	O
sulfuric	O
amino	O
acid,	O
can	O
be	O
synthesized	O
by	O
the	O
human	O
body	O
from	O
cysteine.	B

His	O
testosterone	B
level	O
was	O
within	O
the	O
normal	O
range,	O
with	O
undetectable	O
FSH	O
and	O
LH.	O

However,	O
in	O
high-grade	O
gliomas	O
alone,	O
the	O
CSF	O
citric	O
and	O
isocitric	B
acid	I
levels	O
were	O
significantly	O
higher	O
in	O
gliomas	O
with	O
gadolinium	O
enhancement	O
than	O
in	O
those	O
without	O
gadolinium	O
enhancement	O
(citric	O
acid:	O
p	O
 = 0.019,	O
isocitric	B
acid:	I
p	O
 = 0.019).	O

Mobile	O
phases	O
A	O
and	O
B	O
involved	O
10	O
mM	O
ammonium	B
acetate	I
in	O
an	O
acetonitrile:water	O
(4:6,	O
v/v)	O
solution	O
and	O
10	O
mM	O
ammonium	B
acetate	I
in	O
an	O
acetonitrile:isopropanol	O
(1:9,	O
v/v)	O
solution,	O
respectively.	O

The	O
29	O
metabolites	O
that	O
exhibited	O
Bonferroni-corrected	O
significant	O
inter-group	O
differences	O
were	O
subjected	O
to	O
a	O
stepwise	O
variable	O
selection	O
method,	O
and	O
8	O
metabolites	O
(pyruvic	O
acid-meto-TMS,	O
glycolic	B
acid-2TMS,	O
tryptophan-3TMS(/SI),	O
palmitoleic	B
acid-TMS,	O
fumaric	O
acid-2TMS(/SI),	O
ornithine-4TMS(/SI),	B
lysine-4TMS,	B
and	O
3-hydroxyisovaleric	B
acid-2TMS)	O
were	O
selected	O
as	O
variables	O
for	O
the	O
multiple	O
logistic	O
regression	O
model.	O

MS2	O
does	O
not	O
distinguish	O
the	O
sn1	O
and	O
sn2	O
acyl	O
positions	O
of	O
glycerolipids,	B
nor	O
the	O
position	O
of	O
unsaturations	O
in	O
acyl	O
chains	O
and	O
acyl	O
branching.	O

We	O
showed	O
that	O
the	O
free	O
radical-dependent	O
oxysterols	B
(7-KC,	O
7β-OHC	B
and	O
25-OHC)	O
were	O
circulating	O
in	O
people	O
with	O
asymptomatic	O
hypercholesterolaemia	O
at	O
up	O
to	O
45	O
times	O
the	O
concentrations	O
that	O
could	O
be	O
observed	O
in	O
men	O
with	O
normal	O
plasma	O
cholesterol	B
and	O
that	O
the	O
significance	O
of	O
the	O
effect	O
was	O
maintained	O
either	O
before	O
or	O
after	O
correction	O
for	O
differences	O
in	O
plasma	O
cholesterol	B
concentration.	O

To	O
recover	O
the	O
mutated	O
plasmid,	O
the	O
native	O
template	O
was	O
digested	O
with	O
DpnI	O
(New	O
England	O
Biolabs)	O
and	O
then	O
transformed	O
into	O
E.	O
coli	O
strain	O
DH5α.	B

Sarcosine	B
treatment	O
however	O
did	O
not	O
affect	O
the	O
ability	O
of	O
these	O
cells	O
to	O
progress	O
through	O
the	O
different	O
stages	O
of	O
cell	O
cycle	O
or	O
impair	O
cell	O
proliferation.	O

We	O
established	O
novel	O
analytical	O
approaches,	O
which	O
are	O
based	O
on	O
a	O
simple	O
gradient	O
elution,	O
to	O
quantify	O
polar	O
lipids	O
in	O
plasma	O
including	O
(i)	O
glycerophospholipids	B
(phosphatidylcholine,	I
PC;	I
phosphatidylethanolamine,	I
PE;	I
phosphatidylinositol,	I
PI;	I
phosphatidylglycerol,	I
PG;	I
phosphatidylserine,	I
PS;	I
phosphatidic	I
acid,	I
PA);	I
(ii)	O
sphingolipids	B
(sphingomyelin,	I
SM;	I
ceramide,	I
Cer;	I
Glucocyl-ceramide,	I
GluCer;	I
ganglioside	I
mannoside	I
3,	I
GM3).	I

In	O
addition,	O
several	O
clinical	O
studies	O
have	O
demonstrated	O
associations	O
between	O
low	O
plasma	O
glutamine	B
levels	O
and	O
unfavorable	O
outcome	O
in	O
critically	O
ill	O
patients.	O

It	O
is	O
clearly	O
shown	O
that	O
levels	O
of	O
some	O
metabolites	O
(e.g.	O
creatinine	B
at	O
m/z	O
114.06)	O
and	O
the	O
unknown	O
compound	O
at	O
m/z	O
=	O
312)	O
are	O
not	O
substantially	O
different	O
between	O
DMD	O
and	O
healthy	O
volunteers	O
at	O
young	O
ages,	O
then	O
their	O
levels	O
substantially	O
diverge	O
at	O
around	O
15	O
years	O
of	O
age.	O

Kynurenine	B
was	O
the	O
top	O
predictor	O
of	O
NAC	O
effect	O
in	O
SLE	O
(AUC = 0.851).	O

Four	O
of	O
these	O
16	O
metabolites	O
(methionine,	O
5-hydroxymethyl-2′-deoxyuridine,	B
N2,N2-dimethylguanosine	B
and	O
uric	O
acid)	O
that	O
showed	O
the	O
lowest	O
p	O
-values	O
were	O
used	O
to	O
develop	O
and	O
internally	O
validate	O
a	O
classification	O
model	O
using	O
partial	O
least	O
squares	O
discriminant	O
analysis.	O

Metabonomic	O
analysis	O
using	O
1H	O
Magic	O
Angle	O
Spinning	O
Nuclear	O
Magnetic	O
Resonsance 	O
(MAS-NMR)	O
spectroscopy,	O
demonstrated	O
increased	O
abundance	O
of	O
taurine,	B
isoglutamine,	B
choline,	B
lactate,	B
phenylalanine	B
and	O
tyrosine	B
and	O
decreased	O
levels	O
of	O
lipids	O
and	O
triglycerides	B
in	O
tumour	O
relative	O
to	O
adjacent	O
healthy	O
tissue.	O

Aberrant	O
glutaminolysis	O
has	O
been	O
described	O
as	O
a	O
hallmark	O
of	O
cancer,	O
as	O
many	O
cancer	O
cells	O
undergo	O
metabolic	O
reprogramming	O
that	O
makes	O
them	O
highly	O
glutamine	B
dependent	O
for	O
their	O
survival	O
and	O
proliferation	O
[,	O
].	O

Thus,	O
a	O
sample	O
collection/storage	O
protocol	O
should	O
be	O
implemented	O
that	O
limits	O
the	O
PAP	O
reaction	O
to	O
2–3%	O
progression,	O
such	O
as	O
our	O
recommendation	O
that	O
ejaculate	O
samples	O
be	O
collected	O
in	O
a	O
sterile	O
urine	O
jar	O
containing	O
5mM	O
tartrate	B
in	O
20 mL	O
PBS	O
solution	O
cooled	O
to	O
4°C.	O

All	O
calculations	O
included	O
normalization	O
for	O
creatinine	B
levels	O
to	O
account	O
for	O
variation	O
in	O
urine	O
concentration	O
between	O
individuals.	O

Our	O
findings	O
point	O
toward	O
several	O
amino	B
acid–based	O
dysregulations	O
in	O
central	O
metabolic	O
pathways	O
compared	O
with	O
age-	O
and	O
sex-matched	O
controls,	O
which	O
can	O
both	O
initiate	O
and	O
aggravate	O
nephrosclerosis	O
pathology.	O

For	O
each	O
sample,	O
5	O
μ	O
L	O
of	O
diethylaminobenzaldehyde	B
(DEAB),	O
a	O
specific	O
ALDH	O
inhibitor,	O
was	O
added	O
to	O
0.5	O
mL	O
of	O
Aldefluor-stained	O
cells	O
as	O
a	O
negative	O
control.	O

Phosphatidylcholine	B
promotes	O
apoptosis	O
in	O
the	O
human	O
gastric	O
cancer	O
cell	O
line	O
BGC823,	O
downregulates	O
the	O
expression	O
of	O
ATP	B
binding	O
cassette	O
subfamily	O
F	O
member	O
2	O
and	O
reduces	O
the	O
number	O
of	O
cancer	O
stem	O
cells	O
(,).	O

The	O
supernatant	O
was	O
transferred	O
to	O
an	O
Eppendorf	O
vial,	O
and	O
acetonitrile	B
was	O
removed	O
by	O
using	O
a	O
gentle	O
flow	O
of	O
nitrogen.	O

Eleven	O
phthalate	B
metabolites	O
including	O
mono-ethylhexyl	B
phthalate	I
(MEHP),	O
mono-(2-ethyl-5-oxo-hexyl)	B
phthalate	I
(MEOHP),	O
mono-(2-ethyl-5-hydroxyhexyl)	B
phthalate	I
(MEHHP),	O
mono-(2-ethyl-5-carboxypentyl)	B
phthalate	I
(MECPP),	O
mono-(2-carboxymethylhexyl)	B
phthalate	I
(MCMHP),	O
mono-n	B
-butyl	I
phthalate	I
(MnBP),	O
mono-iso-butyl	B
phthalate	I
(MiBP),	O
mono-ethyl	B
phthalate	I
(MEP),	O
mono-iso-nonyl	B
phthalate	I
(MiNP),	O
mono-benzyl	B
phthalate	I
(MBzP)	O
and	O
mono-methyl	B
phthalate	I
(MMP)	O
representing	O
exposure	O
to	O
seven	O
commonly	O
used	O
phthalates	O
(DEHP,	O
DnBP,	O
DiBP,	O
DEP,	O
di-iso-nonyl	B
phthalate	I
(DiNP),	O
benzyl	O
butyl	O
phthalates	O
(BBzP)	O
and	O
dimethyl	B
phthalate	I
(DMP)	O
were	O
measured	O
in	O
each	O
urine	O
sample.	O

They	O
observed	O
that	O
a	O
few	O
lipids	O
like	O
LysoPC	O
(16:0),	O
LPA	B
(16:0/0:0)	I
and	O
LPA	B
(0:0/16:0)	I
were	O
aberrantly	O
expressed	O
in	O
CTCL	O
plasma	O
in	O
positive	O
and	O
negative	O
modes.	O

Hence,	O
therapy-related	O
changes	O
in	O
serum	O
levels	O
of	O
phospholipids	B
(and	O
albumin)	O
were	O
not	O
associated	O
directly	O
with	O
a	O
treatment-related	O
drop	O
in	O
the	O
patient’s	O
body	O
mass.	O

Despite	O
this	O
caveat,	O
considerable	O
progress	O
has	O
been	O
achieved	O
in	O
the	O
direct	O
quantification	O
of	O
mycotoxin	B
conjugates	O
without	O
the	O
need	O
for	O
enzymatic	O
hydrolysis.	O

Anastrozole	B
was	O
dissolved	O
and	O
serially	O
diluted	O
in	O
methanol	B
to	O
the	O
required	O
concentration.	O

Ascorbic	B
acid,	I
which	O
is	O
an	O
antioxidant,	O
protects	O
cells	O
against	O
oxidative	O
stress	O
induced	O
by	O
ROS,	O
so	O
increased	O
levels	O
of	O
ascorbic	B
acid	I
might	O
have	O
antioxidant	O
effects	O
in	O
CRC	O
tissue.	O

The	O
failure	O
of	O
urinary	O
excretion	O
of	O
CML	B
and	O
MG-H1	O
to	O
emerge	O
as	O
diagnostic	O
features	O
for	O
diagnosis	O
of	O
early	O
decline	O
in	O
metabolic	O
and	O
vascular	O
health	O
may	O
be	O
due	O
to	O
a	O
large	O
and	O
variable	O
contribution	O
to	O
urinary	O
excretion	O
of	O
these	O
analytes	O
from	O
digested	O
food,	O
compared	O
to	O
increases	O
of	O
endogenous	O
formation.	O

On	O
the	O
other	O
hand,	O
formic	B
acid	I
was	O
present	O
in	O
both	O
samples	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
those	O
dried	O
by	O
speed-vacuum	O
(B).	O

It	O
has	O
been	O
observed	O
in	O
a	O
previous	O
study_,	O
that	O
major	O
contributors	O
to	O
the	O
ion	O
complexity	O
of	O
DNA	O
hydrolysate	B
samples	O
are	O
impurities	O
present	O
in	O
the	O
hydrolysis	O
enzymes	O
and	O
plasticizers	O
found	O
in	O
plastic	O
devices	O
used	O
in	O
sample	O
preparation	O
such	O
as	O
solid-phase	O
extraction	O
cartridges	O
and	O
molecular	O
weight	O
filters.	O

The	O
improvements	O
in	O
dyslipidemia	O
associated	O
with	O
gastric	O
bypass	O
were	O
previously	O
demonstrated	O
by	O
increases	O
in	O
HDL-cholesterol	B
and	O
reductions	O
in	O
total	O
cholesterol,	B
LDL-cholesterol,	B
and	O
triglycerides	B
,	O
.	O

A	O
structure	O
of	O
a	O
co-crystal	O
of	O
the	O
bacterial	O
NMNAT	O
and	O
one	O
of	O
the	O
most	O
effective	O
inhibitors,	O
compound	O
1a-a,	O
suggested	O
that	O
this	O
compound	O
and	O
those	O
closely	O
related	O
to	O
it,	O
bind	O
to	O
the	O
enzyme	O
in	O
its	O
apo	O
form	O
and	O
interact	O
with	O
both	O
the	O
NaMN	O
binding	O
pocket	O
and	O
the	O
ATP	B
binding	O
site	O
.	O

Based	O
on	O
their	O
similarity	O
of	O
structures	O
and	O
retention	O
times,	O
_13	O
C_6	O
-E_2	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
E_2	O
;	O
_13	O
C_6	O
-E_1	O
for	O
E_1	O
;	O
d_3	O
-E_3	O
for	O
E_3	O
,	O
16-ketoE_2	O
,	O
and	O
16α-OHE_1	B
;	O
d_3	O
-16-epiE_3	O
for	O
16-epiE_3	O
and	O
17-epiE_3	O
;	O

Trp	O
metabolites	O
not	O
identified	O
by	O
this	O
procedure	O
included	O
3-hydroxyanthranilic	B
acid,	I
quinolinic	B
acid,	I
5-hydroxyl-indole-3-acetic	B
acid,	I
3-indole-sulfate,	B
5-hydroxy-tryptophan,	B
xanthurenic	B
acid,	I
and	O
3-hydroxykynurenine.	B

Charcoal-stripped	O
human	O
urine	O
(Golden	O
West	O
Biologicals,	O
Temecula,	O
CA)	O
that	O
contained	O
0.1%	O
(w/v)	O
L-ascorbic	B
acid	I
and	O
had	O
no	O
detectable	O
level	O
of	O
any	O
EM	O
was	O
used	O
for	O
preparation	O
of	O
calibration	O
standards	O
and	O
quality	O
control	O
samples.	O

The	O
univariate	O
tests	O
demonstrated	O
that	O
11	O
metabolites	O
were	O
perturbed,	O
of	O
which	O
L-DOPA,	B
xanthine,	B
ophthalmate,	O
creatinine,	B
tyrosine,	B
5-hyproxytryptophan,	B
adenosine	B
and	O
phenylalanine	B
remained	O
significant	O
after	O
correcting	O
for	O
multiple	O
comparisons.	O

Lactate	B
is	O
a	O
marker	O
for	O
hypoxia,	O
as	O
it	O
provides	O
an	O
alternative	O
pathway	O
for	O
energy	O
production	O
in	O
the	O
absence	O
of	O
oxygen.	O

Changes	O
in	O
choline	B
metabolism	O
have	O
also	O
been	O
related	O
with	O
HCC	O
previously.	O

At	O
baseline	O
(RT),	O
there	O
was	O
a	O
correlation	O
between	O
BAT	O
GU	O
and	O
plasma	O
lactate	B
(Figure E),	O
while	O
during	O
cold,	O
there	O
was	O
a	O
positive	O
association	O
between	O
the	O
cold‐stimulated	O
BAT	O
GU	O
and	O
whole	O
body	O
energy	O
expenditure	O
before	O
(r	O
 = 0.86,	O

ROS	O
formation	O
begins	O
with	O
unpaired	O
electrons	O
escaping	O
from	O
the	O
electron	O
transport	O
chain	O
and	O
combining	O
with	O
molecular	B
oxygen,	I
resulting	O
in	O
formation	O
of	O
superoxide.	B

Creatine	B
is	O
phosphorylated	O
in	O
mitochondria	O
by	O
ATP	B
derived	O
from	O
oxidative	O
phosphorylation	O
and	O
the	O
phosphocreatine,	B
subsequently	O
exported	O
outside	O
mitochondria,	O
used	O
by	O
the	O
cytosolic	O
creatine	B
kinase	O
to	O
resupply	O
ATP	B
for	O
muscle	O
activity.	O

Ideally	O
methadone	B
screening	O
assay	O
should	O
measure	O
the	O
parent	O
drug,	O
EDDP	O
and	O
the	O
minor	O
metabolite,	O
EMDP.	O

There	O
were	O
a	O
larger	O
number	O
of	O
significant	O
correlations	O
between	O
the	O
genes	O
responsible	O
for	O
de	O
novo	O
synthesis,	O
desaturation,	O
elongation,	O
and	O
β-oxidation	O
of	O
various	O
serum	O
fatty	O
acids,	O
glycerolipids,	B
and	O
long	O
chain	O
ACs.	O

More	O
than	O
60	O
neutral	O
lipids,	O
including	O
ChE,	O
DG,	O
and	O
TG,	B
were	O
detected	O
in	O
our	O
lipidomics	O
platform	O
(data	O
not	O
shown).	O

Cotinine,	B
[_13	O
CD_3	O
]cotinine,	O
NNAL,	O
and	O
[_13	O
C_6	O
]NNAL	O
(Figure	O
)	O
were	O
procured	O
from	O
Toronto	O
Research	O
Chemicals	O
(Ontario,	O
Canada).	O

To	O
gain	O
further	O
insight	O
into	O
mutations,	O
copy-number	O
alterations,	O
and	O
expression	O
profiles	O
of	O
KP	B
enzymes,	O
we	O
examined	O
the	O
TCGA	O
database	O
(data	O
available	O
at	O
cBioportal.org).	O

There	O
was	O
a	O
strong	O
positive	O
association	O
between	O
C18:0	B
and	O
hsCRP,	O
IL-6	O
and	O
adiponectin.	O

The	O
presence	O
of	O
phosphate	B
ion	O
correlates	O
with	O
the	O
presence	O
of	O
biological	O
tissue	O
and	O
is	O
comparable	O
with	O
the	O
optical	O
image	O
in	O
.	O

Among	O
them,	O
three	O
metabolites	O
clearly	O
stood	O
out,	O
the	O
proline	B
metabolites	O
PHP	O
(plasma	O
and	O
urine)	O
and	O
glycylproline	B
(urine)	O
as	O
well	O
as	O
the	O
unknown	O
metabolite	O
X-18927	O
(urine)	O
(	O
and	O
).	O

Finally,	O
the	O
plate	O
was	O
washed	O
with	O
0.7	O
mL	O
of	O
30%	O
MeOH	B
in	O
2%	O
aqueous	O
formic	B
acid	I
and	O
the	O
eluants	O
were	O
collected	O
in	O
the	O
square	O
2	O
mL	O
96-well	O
plates.	O

Increased	O
levels	O
of	O
taurine	B
have	O
been	O
reported	O
in	O
the	O
rat	O
brain	O
cortex	O
following	O
paradoxical	O
sleep	O
deprivation	O
and	O
have	O
been	O
shown	O
to	O
be	O
a	O
activator	O
of	O
extrasynaptic	O
GABA(A)	O
receptors	O
in	O
the	O
mouse	O
ventrobasal	O
thalamus,	O
an	O
area	O
involved	O
in	O
regulating	O
the	O
transitions	O
between	O
sleep	O
and	O
wakefulness.	O

Dilutions	O
in	O
methanol	B
produced	O
1,000,	O
4,000	O
(for	O
BUP	O
and	O
NBUP),	B
and	O
10,000	O
ng/mL	O
solutions.	O

Using	O
reserpine	B
as	O
an	O
example,	O
the	O
parameters	O
for	O
MassWorks	O
sCLIPS	O
algorithms	O
were:	O
mass	O
tolerance,	O
5	O
ppm;	O
electron	O
state,	O
even;	O
double	O
bond	O
equivalent	O
range,	O
−3	O
to	O
50;	O
profile	O
mass	O
range,	O
−1	O
to	O
3.5	O
Da;	O
calibration	O
range,	O
−0.1	O
to	O
0.1	O

For	O
example,	O
GC-MS	O
does	O
not	O
identify	O
organic	O
diphosphates	B
or	O
metabolites	O
larger	O
than	O
trisaccharides.	B

Melatonin	B
and	O
5-Hydroxytryptophan	B
involved	O
in	O
melatonin	B
biosynthesis	O
were	O
down-regulated	O
following	O
H.	O
pylori	O
eradication.	O

After	O
1	O
h,	O
30	O
μL	O
of	O
heptane	B
(containing	O
0.5	O
μg	O
of	O
methyl	O
stearate)	O
was	O
added.	O

*indicates	O
a	O
partially	O
identified	O
compound:	O
pentonic	O
acid	O
is	O
an	O
aldonic	O
acid	O
with	O
five	O
carbons	O
and	O
hexaric	B
acid	I
is	O
an	O
aldonic	O
acid	O
with	O
six	O
carbons.	O

Similarly,	O
the	O
splitting	O
patterns	O
of	O
the	O
2′-	O
to	O
4′carbons	O
of	O
the	O
nucleotide	O
ribose	B
were	O
triplets	O
while	O
that	O
of	O
the	O
1′	O
carbon	O
was	O
a	O
doublet,	O
which	O
is	O
consistent	O
with	O
uniform	O
labeling	O
of	O
the	O
nucleotide	O
riboses	O
via	O
the	O
pentose	B
phosphate	I
pathway	O
(PPP).	O

Nicotine	B
administration	O
induced	O
increases	O
in	O
proteinuria	O
and	O
glomerular	O
injury	O
score	O
in	O
rats	O
with	O
5/6	O
nephrectomies,	O
which	O
were	O
prevented	O
by	O
co-administration	O
of	O
an	O
α7-nAChR	O
selective	O
antagonist,	O
methyllicaconitine.	B

Numerous	O
disorders	O
have	O
been	O
described	O
that	O
lead	O
to	O
disturbances	O
in	O
energy	O
production	O
and	O
intermediary	O
metabolism,	O
which	O
are	O
characterized	O
by	O
the	O
abnormal	O
levels	O
of	O
acylcarnitines	B
(–).	O

Another	O
interesting	O
metabolite	O
group	O
that	O
has	O
been	O
significantly	O
impacted	O
by	O
long-term	O
storage	O
is	O
lipid	O
hydroperoxides,	B
which	O
have	O
been	O
increased	O
over	O
time	O
by	O
lipid	O
oxidation	O
and	O
auto-oxidation	O
processes.	O

CPT	O
catalyzes	O
the	O
transfer	O
of	O
the	O
acyl	O
group	O
of	O
a	O
FA	B
to	O
carnitine	B
to	O
allow	O
its	O
movement	O
from	O
the	O
cytosol	O
to	O
mitochondria	O
for	O
oxidation.	O

Interestingly,	O
in	O
patients	O
with	O
no	O
or	O
very	O
moderate	O
NAFLD,	O
the	O
levels	O
of	O
triglycerides	B
and	O
oleic	B
acid	I
were	O
low	O
and	O
there	O
were	O
increased	O
hepatic	O
levels	O
of	O
polyunsaturated	O
fatty	O
acids	O
(PUFA)ω-3	O
fatty	O
acyls,	O
docosahexanoic	B
22:6	I
(n-3)	O
(DHA),	O
arachidonic	O
20:4	O
(n-6)	O
(ARA)	O
+	O
eicosapentaenoic	B
20:5	I
(n-3)	O
(EPA),	O
and	O
the	O
ratio	O
between	O
poly-	O
and	O
mono-unsaturated	O
fatty	O
acids	O
(PUFA/MUFA).	O

The	O
hourly	O
plasma	O
concentrations	O
of	O
urea	B
nitrogen	I
in	O
the	O
control	O
and	O
HD	O
sheep	O
are	O
presented	O
in	O
.	O

The	O
liver	O
was	O
rapidly	O
removed	O
and	O
homogenized	O
in	O
an	O
ice-cold	O
isolation	O
buffer	O
containing	O
300	O
mM	O
sucrose,	B
1	O
mM	O
EGTA,	O
and	O
10	O
mM	O
HEPES–Tris	O
(pH	O
7.4).	O

There	O
are	O
several	O
potential	O
factors	O
that	O
are	O
likely	O
to	O
explain	O
elevated	O
plasma	O
lactate	B
in	O
response	O
to	O
insulin	O
deprivation.	O

Subjects	O
were	O
in	O
a	O
rested,	O
fasting	O
state	O
and	O
blood	O
was	O
taken	O
from	O
the	O
antecubital	O
vein	O
and	O
collected	O
in	O
10 ml	O
BD	O
ethylenediamine-tetra-acetic	B
acid	I
(EDTA)	O
blood	O
tubes	O
(Southern	O
Syringe	O
Services	O
LTD).	O

Before	O
this	O
study	O
was	O
carried	O
out	O
it	O
was	O
not	O
known	O
how	O
important	O
the	O
sulfation	O
pathway	O
was	O
in	O
morphine	B
metabolism	O
in	O
humans.	O

Ultra	O
performance	O
liquid	O
chromatography	O
(UPLC)-grade	O
acetonitrile,	B
isopropanol,	B
methanol,	B
ethyl-acetate,	B
and	O
water	O
were	O
purchased	O
from	O
Biosolve	O
(the	O
Netherlands).	O

Solvent	O
2	O
:	O
A,	O
0.1%	O
formic	B
acid,	I
5 mM	O
methylamine	B
in	O
H_2	O
O,	O
and	O
B,	O
0.1%	O
formic	B
acid	I
in	O
methanol.	B

For	O
untargeted	O
analysis,	O
the	O
_1	O
H	O
NMR	O
spectra	O
were	O
digitized	O
(after	O
the	O
removal	O
of	O
water,	O
urea,	B
and	O
TSP	O
regions)	O
to	O
a	O
resolution	O
of	O
0.001	O
ppm,	O
aligned,	O
normalized	O
by	O
PQN,	O
and	O
mean-centered.	O

Subjects	O
with	O
higher	O
cystathionine	B
concentrations	O
also	O
were	O
more	O
likely	O
to	O
have	O
mildly	O
reduced	O
kidney	O
function,	O
as	O
indicated	O
by	O
their	O
lower	O
eGFR	O

When	O
features	O
found	O
in	O
the	O
methanol	B
pellet	O
fraction	O
were	O
compared	O
to	O
MTBE	B
only	O
lipids	O
without	O
SPE,	O
790	O
(565	O
+	O
225)	O
out	O
of	O
918	O
(86%)	O
features	O
were	O
common.	O

The	O
increased	O
oxidative	O
stress	O
in	O
cancer	O
cells	O
could	O
likely	O
to	O
cause	O
the	O
elevated	O
expression	O
of	O
antioxidant	O
enzymes	O
such	O
as	O
glutathione	B
peroxidase,	O
glutathione	B
reductase	O
and	O
glutathione-S-transferase.	O

Before	O
that,	O
we	O
tested	O
different	O
proportions	O
and	O
combinations	O
of	O
organic	O
solvents,	O
for	O
example,	O
ethyl	B
acetate,	I
isopropanol,	B
dichloromethane,	B
trichloromethane,	B
methyl	B
tertiary-butyl	I
ether,	I
and	O
cyclohexane.	B

Lipids	O
were	O
extracted	O
from	O
tissue	O
samples	O
and	O
sphingolipids	B
were	O
quantified	O
by	O
liquid	O
chromatography,	O
electrospray	O
ionization-tandem	O
mass	O
spectrometry	O
(LC-ESIMS/MS,	O
4000	O
QTRAP,	O
ABI)	O
as	O
described	O
previously	O
at	O
Virginia	O
Commonwealth	O
University	O
Lipidomics	O
Core	O
[,	O
].	O

Comparing	O
cachectic	O
and	O
non-cachectic	O
patients,	O
eight	O
metabolites	O
had	O
differing	O
mean	O
levels,	O
with	O
four	O
being	O
lower	O
in	O
cachectic	O
patients	O
(2.3.-butanediol,	O
2.3.-	B
dihydroxybutyrate,	I
acetone,	B
and	O
arginine)	B
and	O
four	O
being	O
higher	O
(sugar	O
15.798	O
min,	O
4-hydroxyphenylacetate,	B
glucuronide	B
28.543	O
min,	O
and	O
3-methylxanthine)	B
compared	O
to	O
patients	O
without	O
cachexia.	O

Carnosine,	B
a	O
safe	O
and	O
cheap	O
over-the-counter	O
food	O
supplement,	O
may	O
therefore	O
be	O
an	O
effective	O
strategy	O
to	O
prevent	O
or	O
delay	O
the	O
development	O
of	O
insulin	O
resistance	O
and	O
T2DM	O
through	O
improving	O
the	O
plasma	O
lipid	O
profile	O
&	O
metabolism.	O

Regeneration	O
of	O
tetrahydrobiopterin	B
from	O
dihydrobiopterin	B
is	O
reduced	O
in	O
CKD	O
leading	O
to	O
reduced	O
tetrahydrobiopterin-dihydrobiopterin	B
ratios,	O
which	O
probably	O
are	O
the	O
best	O
functional	O
measures	O
of	O
the	O
tetrahydrobiopterin.	B

Hensley	O
et	O
al.	O
assessed	O
the	O
metabolic	O
profile	O
of	O
lung	O
tumors	O
from	O
nine	O
NSCLC	O
patients	O
who	O
received	O
_13	O
C-glucose	B
infusions	O
prior	O
to	O
tumor	O
resection	O
and	O
showed	O
substantial	O
intratumoral	O
heterogeneity	O
in	O
glucose	B
metabolism,	O
with	O
concurrent	O
glycolysis	O
and	O
glucose	B
oxidation.	O

Briefly,	O
lipoxygenases	O
are	O
dioxygenases	O
that	O
catalyze	O
the	O
addition	O
of	O
oxygen	O
to	O
unsaturated	O
fatty	O
acids,	O
which	O
contain	O
a	O
cis	B
,cis	I
-1,4-pentadiene	I
system.	O

The	O
ion	O
source	O
voltage	O
was	O
5	O
kV.	B
Nitrogen	O
sheath	O
and	O
aux	O
gas	O
flow	O
was	O
60	O
and	O
20	O
units	O
respectively.	O

The	O
implementation	O
of	O
preventive	O
therapies	O
on	O
high	O
risk	O
individuals	O
is	O
possible	O
considering	O
tryptophan	B
level,	O
along	O
with	O
other	O
metabolites	O
and/or	O
clinical	O
markers	O
associated	O
with	O
T2D	O
risk.	O

Accordingly,	O
in	O
clinical	O
settings,	O
oxidized	O
derivates	O
of	O
LA,	O
such	O
as	O
9-	O
and	O
13-HODE,	B
are	O
correlated	O
with	O
NASH.	O

Creatinine	B
is	O
a	O
breakdown	O
product	O
of	O
creatine	B
phosphate	I
in	O
muscle	O
and	O
is	O
eliminated	O
from	O
the	O
body	O
by	O
glomerular	O
filtration	O
and	O
partial	O
tubular	O
excretion.	O

In	O
this	O
project	O
the	O
arithmetic	O
mean	O
urinary	O
cotinine	B
level	O
is	O
3.33±6.39	O
μg/L	O
and	O
the	O
geometric	O
mean	O
and	O
standard	O
deviation	O
is	O
0.88	O
(5.28)μg/L,	O
which	O
shows	O
that	O
our	O
non-smoking	O
subjects	O
are	O
towards	O
the	O
lower	O
end	O
of	O
the	O
range	O
of	O
ETS	O
exposure.	O

This	O
is	O
consistent	O
with	O
the	O
transformations	O
of	O
glucose	B
into	O
Asp	O
or	O
Glu	O
via	O
glycolysis,	O
anaplerotic	O
pyruvate	O
carboxylation	O
(PC),	O
and	O
the	O
Krebs	O
cycle.	O

Mobile	O
phase	O
B	O
was	O
acetonitrile.	B

The	O
mobile	O
phase:	O
a	O
phase	O
was	O
0.1%	O
formic	B
acid	I
aqueous,	O
and	O
B	O
phase	O
was	O
0.1%	O
formic	B
acid	I
acetonitrile	I
separately,	O
gradient	O
elution	O
was	O
used	O
for	O
the	O
sample,	O
and	O
the	O
gradient	O
was	O
set	O
as	O
shown.	O

The	O
levels	O
of	O
citrulline	B
and	O
ornithine,	B
two	O
non-proteinogenic	O
amino	O
acids	O
that	O
participate	O
in	O
hepatic	O
urea	B
synthesis,	O
decreased	O
by	O
35	O
and	O
29%,	O
respectively	O
during	O
the	O
2-h	O
test.	O

In	O
addition,	O
antibiotic	O
compounds	O
such	O
as	O
lateropyrone,	O
enniatins	B
B,	O
B1	O
and	O
A1,	O
and	O
fusaristatin	B
A,	O
were	O
also	O
upregulated	O
(Moussa	O
et	O
al.	O
2019).	O

CHCl_3	O
:water	O
ext	O
+UF	O
than	O
in	O
the	O
MeOH	B
precipitation	O
conditions	O
(citrate	O
median,	O
IQR:	O
MeOH:CHCl_3	B
:water	O
ext	O
+UF:	O
73.3,	O
25.5	O
μM;	O
MeOH	B
ppt	O
+UF:	O
26.9,	O
11.4	O
μM;	O
MeOH	B
ppt	O
only:	O
29.5,	O
8.1	O
μM)	O
(Table	O
S1).	O

+∑ps=1∑qj=1ρsj(yj)xs+12∑qj=1∑qr=1φrj(yr,yj)).	B

Sphingolipid	B
metabolites	O
in	O
healthy	O
controls	O
stratified	O
by	O
the	O
absence/presence	O
of	O
central	O
obesity.	O

Most	O
interestingly,	O
both	O
cardiac	O
infarction	O
and	O
cardiac	O
arrhythmia	O
were	O
positively	O
associated	O
with	O
an	O
NMR	O
bucket	O
at	O
3.275 ppm,	O
which	O
could	O
be	O
identified	O
as	O
trimethylamine-N-oxide	B
(TMAO)	O
and	O
minor	O
signals	O
from	O
D-glucose	B
and	O
betaine.	B

Serum	O
sterol	O
and	O
vitamin	B
D	I
levels	O
in	O
3,230	O
subjects	O
The	O
vitamin	B
D	I
derivatives	O
and	O
sterols	O
routinely	O
detected	O
in	O
the	O
study	O
population	O
are	O
listed	O
together	O
with	O
their	O
mean	O
and	O
median	O
concentrations	O
and	O
ranges.	O

5′-phosphate	B
(PLP)	O
with	O
LC–tandem	O
mass	O
spectrometry	O
methodologies.	O

Four	O
potential	O
biomarkers	O
(glucose,	O
glutamate,	B
pyruvate,	B
and	O
valine)	B
with	O
an	O
AUC	O
value	O
of	O
0.985	O
for	O
distinguishing	O
the	O
two	O
groups,	O
were	O
further	O
selected	O
for	O
the	O
biomarker	O
panel.	O

y]	O
and	O
sphingomyelin-derivatives	O
[SM(OH)x:y];	O
and	O
92	O
glycerophospholipids	B
[PC	O
and	O
lysoPC].	O

The	O
novel	O
glucuronide	B
metabolite	O
was	O
identified	O
based	O
on	O
the	O
presence	O
of	O
peaks	O
m	O
/z	O
291	O
and	O
m	O
/z	O
328	O
in	O
the	O
product	O
ion	O
spectra,	O
see	O
Electronic	O
Supplementary	O
Material	O
(ESM)	O

The	O
strongest	O
association	O
with	O
progression	O
to	O
ESRD	O
was	O
for	O
pseudouridine,	B
odds	O
ratio	O
7.8	O
(95%	O
CI;	O
3.1,	O
19).	O

Vitamin	B
E	I
succinate,	I
which	O
has	O
anti-inflammatory	O
properties,	O
was	O
increased	O
.	O

	O
Pre-treatment	O
and	O
serial	O
on-treatment	O
sera	O
were	O
available	O
for	O
121	O
patients	O
participating	O
in	O
the	O
French	O
clinical	O
trial	O
TORAVA,	O
in	O
which	O
171	O
randomised	O
patients	O
with	O
mRCC	O
received	O
a	O
bevacizumab	O
and	O
temsirolimus	O
combination	O
(experimental	O
arm	O
A)	O
or	O
a	O
standard	O
treatment:	O
either	O
sunitinib	B
(B)	O
or	O
interferon-α+bevacizumab	O
(C).	O

CPTI,	O
carnitine	B
palmitoyltransferase-1;	I
CPTII,	O
carnitine	B
palmitoyltransferase-2.	I

Specimens	O
were	O
reconstituted	O
in	O
150	O
µL	O
mobile	O
phase	O
consisting	O
of	O
50%	O
A	O
(0.01%	O
formic	B
acid	I
in	O
water)	O
and	O
50%	O
B	O
(0.01%	O
formic	B
acid	I
in	O
50:50	O
methanol:acetonitrile).	O

Another	O
example	O
can	O
be	O
shifted	O
balance	O
of	O
valine,	B
where	O
decreased	O
level	O
in	O
blood	O
serum	O
is	O
observed	O
and	O
increased	O
in	O
tissue	O
extract.	O

Levels	O
of	O
pyruvate	B
and	O
lactate	B
were	O
elevated	O
in	O
the	O
sera	O
of	O
TB	O
patients,	O
consistent	O
with	O
increased	O
anaerobic	O
glycolysis.	O

These	O
findings	O
might	O
be	O
a	O
general	O
feature	O
of	O
(severe)	O
inflammatory	O
conditions,	O
as	O
a	O
previous	O
study	O
observed	O
decreased	O
levels	O
of	O
urea	B
cycle	O
intermediates	O
in	O
subjects	O
with	O
sepsis	O
and	O
trauma.	O

Heavy	O
cannabis	B
users	O
had	O
decreased	O
frequencies	O
of	O
intermediate	O
and	O
nonclassical	O
monocyte	O
subsets,	O
as	O
well	O
as	O
decreased	O
frequencies	O
of	O
interleukin	O
23–	O
and	O
tumor	O
necrosis	O
factor-α–producing	O
antigen-presenting	O
cells.	O

Significant	O
alterations	O
in	O
the	O
carnitine-acylcarnitine	B
and	O
tryptophan	B
metabolic	O
pathways	O
were	O
detected	O
in	O
urine	O
specimens	O
from	O
BCA	O
patients	O
compared	O
to	O
those	O
of	O
healthy	O
controls.	O

The	O
majority	O
of	O
the	O
sarcosine	B
produced	O
in	O
the	O
body	O
is	O
made	O
in	O
the	O
liver	O
as	O
a	O
downstream	O
product	O
of	O
SAM	O
and	O
homocysteine.	B

PCa	O
patients	O
had	O
increased	O
serum	O
levels	O
of	O
glucose	B
compared	O
with	O
BPH	O
controls.	O

It	O
is	O
possible	O
that	O
these	O
beneficial	O
outcomes	O
in	O
HIV/SIV	O
infection	O
are	O
due	O
to	O
the	O
immunomodulatory	O
capabilities	O
of	O
cannabis,	B
including	O
decreasing	O
cellular	O
proliferation	O
and	O
reducing	O
cytokine	O
production.	O

Taken	O
together,	O
the	O
common	O
metabolic	O
disturbances	O
we	O
identified	O
in	O
either	O
benign	O
or	O
malignant	O
SPNs	O
represent	O
the	O
self-defense	O
mechanisms	O
or	O
anti-oxidative,	O
anti-inflammatory	O
pathways	O
that	O
are	O
damaged	O
or	O
activated	B
during	O
the	O
course	O
of	O
a	O
variety	O
of	O
diseases.	O

Methanol	B
and	O
DMSO	B
show	O
a	O
good	O
reproducibility	O
with	O
relative	O
standard	O
deviations	O
below	O
7%	O
for	O
methanol	B
and	O
around	O
10%	O
for	O
DMSO	B
for	O
all	O
metabolites.	O

Major	O
Cer	B
species	O
were	O
identified	O
and	O
quantified	O
in	O
human	O
cadaver	O
corneas	O
from	O
Healthy,	O
T1DM,	O
and	O
T2DM	O
donors.	O

At	O
her	O
inclusion	O
during	O
the	O
first	O
trimester	O
of	O
the	O
pregnancy	O
(4_th	O
to	O
15_th	O
week),	O
each	O
woman	O
had	O
to	O
return	O
a	O
first	O
morning	O
void	O
urine	O
sample	O
that	O
she	O
collected	O
and	O
transferred	O
into	O
two	O
vials	O
containing	O
nitric	B
acid	I
to	O
avoid	O
bacterial	O
degradation.	O

Analogously,	O
branched-chain	O
amino	O
acids,	O
isoleucine	B
and	O
valine,	B
as	O
well	O
as	O
ethanol,	B
resulted	O
significantly	O
lower	O
in	O
the	O
group	O
of	O
GR	O
as	O
compared	O
to	O
the	O
PR	O
patients.	O

mPREF	O
biopsies	O
were	O
then	O
removed	O
from	O
aqueous	O
methanol	B
and	O
transferred	O
to	O
formalin	B
until	O
processed.	O

None	O
of	O
the	O
rated	O
symptoms	O
differed	O
between	O
aspartame	B
and	O
control	O
bars,	O
or	O
between	O
sensitive	O
and	O
control	O
participants.	O

We	O
then	O
calculated	O
the	O
hazard	O
ratio	O
for	O
unconjugated	O
estradiol	B
and	O
one	O
additional	O
estrogen	B
or	O
estrogen	B
metabolism	O
measure	O
as	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯1	O
X¯¯¯	O
X¯¯¯	O
X¯¯¯	O
X	O
X	O
	O
¯¯¯	O
¯¯¯	O
¯¯¯	O
¯	O
¯	O
¯	O
	O
1	O
1	O
	O
where	O
X	O
_2	O
corresponds	O
to	O
the	O
log	O
of	O
the	O
other	O
measure.	O

Acylase-1	O
(20 mg;	O
grade	O
I	O
from	O
porcine	B
kidney,	O
≥2,000 units/mg	O
protein,	O
Sigma-Aldrich,	O
Cat	O
no.	O
A3010)	O
was	O
added,	O
and	O
the	O
reaction	O
mixture	O
was	O
incubated	O
at	O
25°C	O
for	O
2.5	O
days.	O

Uridine	B
in	O
both	O
positive	O
and	O
negative	O
ion	O
modes,	O
phenethylamine,	B
and	O
pyridine-2,3-dicarboxylate	B
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
low–cystathionine	B
concentration	O
group	O
(P	O
<	O
0.0002).	O

Bipolar	O
disorder,	O
inflammation,	O
kynurenine,	B
quinolinic	B
acid,	I
magnetic	O
resonance	O
imaging,	O
hippocampus	O

The	O
exosomes	O
were	O
extracted	O
with	O
50%	O
MeOH,	B
and	O
freeze	O
–	O
thaw	O
cycles	O
were	O
carried	O
out	O
to	O
assist	O
the	O
releasing	O
of	O
metabolites	O
from	O
exosomes	O
during	O
extraction.	O

Some	O
subjects	O
were	O
treated	O
with	O
more	O
than	O
1	O
of	O
the	O
studied	O
antipsychotics	O
such	O
that	O
plasma	O
concentration	O
data	O
were	O
included	O
in	O
the	O
analyses	O
from	O
patients	O
in	O
the	O
risperidone	B
(n	O
=	O
21),	O
paliperidone	B
(n	O
=	O
22),	O
quetiapine	B
(n	O
=	O
40),	O
olanzapine	B
(n	O
=	O
73),	O
and	O
aripiprazole	B
(n	O
=	O
25)	O
groups.	O

Therefore,	O
each	O
H-E-LAs	O
and	O
K-ELAs	O
can	O
theoretically	O
have	O
eight	O
or	O
four	O
structural	O
isomers,	O
respectively,	O
although	O
based	O
on	O
our	O
predictions,	O
there	O
would	O
be	O
expected	O
to	O
be	O
only	O
four	O
isomers	O
of	O
hydroxy-epoxides	B
and	O
two	O
for	O
each	O
keto	O
epoxide	B
[,	O
].	O

Notable	O
exceptions	O
were	O
asparagine,	B
which	O
showed	O
significantly	O
lower	O
levels	O
in	O
dough	O
and	O
bread	O
B	O
but	O
whose	O
levels	O
were	O
unchanged	O
in	O
the	O
sourdough	O
samples	O
and	O
threonine	B
whose	O
levels	O
were	O
decreased	O
with	O
a	O
longer	O
fermentation	O
process	O
and	O
which	O
disappeared	O
completely	O
in	O
the	O
sourdough	O
products.	O

Similarly,	O
plasma	O
from	O
patients	O
with	O
CSCC	O
had	O
higher	O
levels	O
of	O
acetate	B
and	O
formate,	B
together	O
with	O
lower	O
levels	O
of	O
creatine,	B
lactate,	B
isoleucine,	B
leucine,	B
valine,	B
alanine,	B
glutamine,	B
histidine	B
and	O
tyrosine.	B

Interestingly,	O
we	O
found	O
that	O
the	O
fatty	O
acids,	O
tri	O
and	O
diglycerides	B
are	O
altered	O
in	O
PCa	O
patient’s	O
serum	O
along	O
with	O
phospholipds.	B

Lactate	B
was	O
also	O
absent	O
in	O
DMEM	O
but	O
it	O
could	O
be	O
detected	O
in	O
24	O
h	O
DMEM.	O

This	O
phenomenon	O
has	O
already	O
been	O
described	O
for	O
polyamines	B
in	O
biological	O
matrices	O
by	O
Häkkinen	O
et	O
al..	O

The	O
TDO2	O
inhibitor	O
680C91	O
(Sigma-Aldrich)	O
or	O
the	O
AhR	O
antagonist	O
CH-223191	O
(TOCRIS	O
Bioscience)	O
prepared	O
in	O
dimethyl	B
sulfoxide	I
(DMSO)	O
were	O
used.	O

Moreover,	O
in	O
two	O
of	O
the	O
six	O
samples,	O
we	O
observed	O
a	O
drop	O
of	O
TG	B
concentrations.	O

A	O
densitometric	O
analysis	O
of	O
the	O
GG-bound	O
sialic	B
acid	I
detected	O
on	O
the	O
plates	O
was	O
performed,	O
using	O
a	O
CCD	O
camera	O
(Chemidoc_™	O
MP	O
System	O
from	O
Biorad,	O
USA).	O

These	O
data	O
provide	O
evidence	O
for	O
aberrant	O
one-carbon	O
metabolism	O
and	O
increased	O
homocysteine-methionine	B
conversion	O
in	O
lung	O
cancer	O
patients.	O

Specifically,	O
plasma	O
level	O
of	O
THC-COOH	O
at	O
≥70	O
µg/L	O
was	O
associated	O
with	O
heavy	O
cannabis	B
consumption,	O
and	O
plasma	O
concentrations	O
of	O
≤5	O
µg/L	O
were	O
correlated	O
with	O
occasional	O
cannabis	B
use.	O

Interestingly,	O
we	O
observed	O
lower	O
urinary	O
urea	B
levels	O
among	O
late-stage	O
patients.	O

The	O
MGM	O
correctly	O
identifies	O
NMR	O
buckets	O
corresponding	O
to	O
D-glucose	B
signals,	O
namely	O
3.785 ppm,	O
3.865 ppm,	O
3.875 ppm,	O
and	O
3.765 ppm,	O
in	O
the	O
first-order	O
neighborhood	O
of	O
elevated	O
blood	O
sugar,	O
Fig.	O

A-C.	O
Classifier	O
androstanediol.	B

In	O
the	O
current	O
study,	O
we	O
identified	O
only	O
1	O
GM3	B
species	O
(d18:1/16:0).	O

Despite	O
many	O
decades	O
of	O
research	O
into	O
the	O
metabolic	O
pathways	O
involved	O
in	O
oxalate	B
synthesis,	O
uncertainties	O
still	O
remain	O
regarding	O
the	O
metabolic	O
alterations	O
of	O
the	O
various	O
PH	O
subtypes.	O

Unlike	O
previous	O
metabonomic	O
studies	O
including	O
our	O
own	O
NMR	O
study,	O
the	O
current	O
study	O
introduced	O
a	O
three	O
-	O
step	O
strategy	O
to	O
identify	O
potential	O
biomarkers	O
of	O
FD.	B

Our	O
team	O
previously	O
reported	O
that	O
L-tryptophan	B
metabolism,	O
including	O
L-tryptophan,	B
3-indolepropionic	B
acid,	I
kynurenine,	B
and	O
5-hydroxyindoleacetaldehyde,	B
was	O
disturbed	O
in	O
EOC	O
patients.	O

The	O
LCB	O
were	O
identified	O
and	O
the	O
associated	O
FA	B
was	O
then	O
deduced	O
based	O
on	O
the	O
exact	O
mass	O
of	O
the	O
molecule.	O

Our	O
method	O
is	O
robust	O
down	O
to	O
a	O
LLOQ	O
of	O
0.2	O
pg	B
on	O
column	O
for	O
T	O
(0.5	O
ng/dL	O
in	O
sample)	O
and	O
1	O
pg	B
on	O
column	O
for	O
DHT	O
(2.5	O
ng/dL	O
in	O
sample)	O
.	O

Two	O
FAAs,	O
that	O
are	O
considered	O
to	O
act	O
as	O
endocannabinoids,	B
displayed	O
an	O
unquantifiable	O
increase	O
in	O
AML	O
plasma,	O
since	O
they	O
were	O
undetectable	O
in	O
control	O
plasmas	O
(Supplemental	O
Table	O
2).	O

Individual	O
ratios	O
of	O
depurinating	O
estrogen-DNA	O
adducts	O
to	O
estrogen	B
metabolites	O
and	O
conjugates	O
in	O
urine	O
of	O
healthy	O
control	O
men	O
and	O
men	O
with	O
non-Hodgkin	O
lymphoma	O
(NHL).	O

Cer,	B
ceramide.	B

Most	O
serum	O
sterols	O
are	O
associated	O
with	O
circulating	O
lipoprotein	O
particles	O
(LDL,	O
very	O
low-density	O
lipoprotein,	O
HDL)	O
leading	O
to	O
strong	O
correlations	O
between	O
these	O
lipids	O
and	O
cholesterol	B
and	O
triglyceride	B
levels	O
(,	O
,	O
).	O

Even	O
after	O
prolonged	O
infusion,	O
enrichment	O
of	O
glutamate	B
carbons	O
3	O
and	O
4	O
was	O
readily	O
detected	O
in	O
normal	O
brain	O
but	O
not	O
in	O
the	O
tumor.	O

In	O
contrast,	O
the	O
microbes	O
that	O
were	O
enriched	O
in	O
stroke	O
and	O
TIA	O
patients	O
were	O
mainly	O
opportunistic	O
pathogens,	O
such	O
as	O
Enterobacter	O
,	O
Megasphaera	O
,	O
and	O
Desulfovibrio	B
.2,	O
3	O

The	O
unique	O
elemental	O
composition	O
of	O
m/z	O
407.1527	O
was	O
assigned	O
as	O
C_15	O
H_28	O
O_11	O
Na	O
using	O
Mass	O
Works_TM	O
based	O
on	O
LC-MS	O
data	O
acquired	O
using	O
HPLC-LTQ	O
FT	B
Ultra	O
MS	O
at	O
100,000	O
resolution.	O

The	O
conversion	O
of	O
phosphatidylserine	B
to	O
phosphatidylethanolamine	B
is	O
catalyzed	O
by	O
phosphatidylserine	O
decarboxylase	O
(EC4.1.1.65).	O

LC–PB–MS/MS	O
was	O
successful	O
in	O
analyzing	O
unsaturated	O
free	O
FAs,	O
PG,	B
and	O
PI	O
in	O
negative	O
ion	O
mode.	O

Another	O
possibility	O
relates	O
to	O
CYP3A4	O
mediation	O
of	O
testosterone	B
metabolism	O
through	O
its	O
conversion	O
to	O
2β-,	O
6β	O
or	O
15β-hydroxytestosterone	B
metabolites	O
and	O
away	O
from	O
the	O
more	O
potent	O
dihydrotestosterone	B
(DHT)	O
believed	O
to	O
play	O
a	O
role	O
in	O
prostate	O
cancer	O
aetiology.	O

However,	O
if	O
the	O
non-oxidative	O
branch	O
of	O
the	O
PPP	O
were	O
significant	O
with	O
the	O
use	O
of	O
non	O
_13	O
C	O
sources,	O
different	O
labeling	O
patterns	O
in	O
the	O
ribose	B
moieties	O
would	O
have	O
been	O
observed.	O

There	O
were	O
no	O
significant	O
differences	O
for	O
specific	O
heart	O
conditions	O
or	O
current	O
heart	O
medications	O
between	O
the	O
subjects	O
according	O
to	O
cystathionine	B
group.	O

Given	O
the	O
evidence	O
for	O
variable	O
dephosphorylation	O
in	O
the	O
clinical	O
samples,	O
in	O
vitro	O
studies	O
were	O
initiated	O
to	O
allow	O
for	O
a	O
quantitative	O
understanding	O
of	O
the	O
relative	O
distribution	O
of	O
the	O
individual	O
metabolites	O
and	O
levels	O
of	O
the	O
pharmacologically	O
active	O
triphosphate	B
metabolites.	O

To	O
test	O
this	O
expectation,	O
an	O
amino	O
acid	O
standard	O
mixture	O
(aa-mixture)	O
was	O
labeled	O
with	O
_12	O
C-dansyl	B
chloride	I
and	O
the	O
UV	O
absorbance	O
of	O
the	O
labeled	O
aa-mixture,	O
with	O
various	O
dilutions,	O
was	O
analyzed	O
using	O
the	O
fast	O
step-gradient	O
LC-UV	O
method	O
described	O
in	O
the	O
Experimental	O
Section	O
and	O
.	O

The	O
transitions	O
monitored	O
were:	O
337.2>207.1	O
and	O
337.2>319.3	O
for	O
14(15)-DiHET	O
(rt:	O
5.4	O
min),	O
337.2>167.0	O
and	O
337.2>319.3	O
for	O
11(12)-DiHET	O
(rt:	O
5.7	O
min),	O
319.2>275.3,	O
319.2>301.3	O
and	O
319.2>289.2	O
for	O
20-HETE	B
(rt:	O
6.6	O
min),	O
319.2>219.2,	O
319.2>301.3	O
and	O
319.2>175.0	O
for	O
15-HETE	B
(rt:	O
7.6	O
min),	O
319.2>179.2,	O
319.2>301.3	O
and	O
319.2>257.2	O
for	O
12-HETE	B
(rt:	O
8.2	O
min),	O
303.2>259.2,	O
303.2>205.1	O
and	O
303.2>58.7	O
for	O
AA	O
(rt:	O
15.1	O
min)	O
and	O
311.3>267.3	O
for	O
AA-d8	O
(rt:	O
14.9	O
min).	O

B_4	O
(d_4	O
-LTB_4	O
),	O
d_5	B
-lipoxin	I
A_4	O

Inborn	O
errors	O
of	O
purine	B
metabolism	O
are	O
associated	O
with	O
behavioral	O
abnormalities	O
including	O
autistic	O
features.	O

An	O
elevated	O
TMAO	B
level	O
predicted	O
an	O
increased	O
risk	O
of	O
major	O
adverse	O
cardiovascular	O
events	O
after	O
adjustment	O
for	O
traditional	O
risk	O
factors	O
(P<0.001),	O
as	O
well	O
as	O
in	O
lower-risk	O
subgroups.	O

Increased	O
urine	O
concentrations	O
of	O
N1,	O
N12-diacetylspermine	B
occurs	O
in	O
many	O
types	O
of	O
cancers	O
(e.g.,	O
breast	O
cancer	O
[,	O
],	O
colorectal	O
cancer,	O
non-small	O
cell	O
lung	O
cancer,	O
bladder	O
cancer,	O
metastatic	O
and	O
primary	O
brain	O
tumors	O
including	O
grade	O
3	O
and	O
4	O
gliomas	O
and	O
primary	O
CNS	O
lymphoma,	O
hepatocellular	O
carcinoma,	O
and	O
leukemia).	O

After	O
30,	O
60	O
and	O
120	O
min,	O
the	O
concentration	O
of	O
glucose	B
in	O
the	O
cell	O
culture	O
medium	O
of	O
rHla-treated	O
S9	O
cells	O
decreased	O
by	O
1.4	O
mmol/l,	O
1.8	O
mmol/l	O
and	O
2.8	O
mmol/l,	O
respectively.	O

However,	O
we	O
found	O
urinary	O
sarcosine	B
to	O
be	O
significantly	O
elevated	O
at	O
the	O
time	O
of	O
surgery	O
in	O
patients	O
who	O
developed	O
biochemical	O
recurrence,	O
as	O
originally	O
reported	O
for	O
patients	O
with	O
frank	O
prostate	O
metastatic	O
lesions	O
.	O

In	O
our	O
study,	O
the	O
changes	O
in	O
valine	B
and	O
isoleucine	B
levels	O
were	O
different	O
from	O
those	O
in	O
leucine	B
levels.	O

Normalized	O
fold	O
activation	O
relative	O
to	O
vehicle-treated	O
cells	O
is	O
shown	O
for	O
all-trans	O
-retinoic	O
acid	O
(far	O
left	O
bar	O
in	O
each	O
histogram)	O
or	O
the	O
β-apocarotenoids	B
resulting	O
from	O
cleavage	O
at	O
the	O
“a”,	O
“b”,	O
“c”,	O
or	O
“d”	O
sites	O
from	O
top	O
to	O
bottom	O
,	O
respectively.	O

In	O
conclusion,	O
our	O
proof‐of‐concept	O
study	O
suggests	O
that	O
the	O
dual	O
monitoring	O
of	O
tamoxifen	B
plasma	O
levels	O
as	O
surrogate	O
marker	O
for	O
adherence	O
and	O
(Z)‐endoxifen	B
formation	O
as	O
surrogate	O
marker	O
for	O
clinical	O
response	O
could	O
be	O
a	O
strategy	O
to	O
improve	O
patients'	O
chances	O
to	O
avoid	O
recurrence	O
and	O
premature	O
death	O
in	O
the	O
future.	O

This	O
is	O
illustrated	O
in	O
,	O
where	O
among	O
those	O
with	O
more	O
days	O
with	O
loose	O
stools	O
serotonin	B
increases	O
over	O
the	O
night,	O
while	O
among	O
those	O
with	O
fewer	O
days	O
of	O
loose	O
stools	O
it	O
is	O
stable	O
over	O
the	O
night.	O

Recently,	O
2	O
signaling	O
pathways	O
associated	O
with	O
neutral	O
sphingomyelinase-2,	B
an	O
enzyme	O
that	O
hydrolyzes	O
SM	O
to	O
ceramide,	B
and	O
the	O
EGF	O
receptor	O
(EGFR),	O
respectively,	O
have	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
processes	O
associated	O
with	O
cigarette	O
smoke	O
exposure	O
in	O
the	O
lung	O
airways;	O
EGFR	O
was	O
also	O
revealed	O
to	O
be	O
co-localized	O
in	O
the	O
plasma	O
membrane	O
in	O
ceramide-enriched	O
regions	O
(,).	O

Besides	O
the	O
high	O
levels	O
of	O
12-HETE	B
and	O
5-HETE,	B
increases	O
in	O
the	O
analogous	O
EPA	O
metabolites	O
12-HEPE	B
and	O
5-HEPE	B
were	O
observed	O
(Fig.	O

Thus,	O
lower	O
3‐hydroxybutyrate	B
levels	O
are	O
observed	O
in	O
persons	O
with	O
obesity	O
than	O
in	O
individuals	O
with	O
normal	O
weight.29	O
However,	O
urinary	O
3‐hydroxybutyrate	B
levels	O
are	O
higher	O
in	O
pre‐operative	O
patients	O
with	O
obesity	O
than	O
in	O
healthy	O
controls,13	O
since	O
there	O
is	O
increased	O
lipolysis	O
in	O
the	O
adipose	O
tissue	O
with	O
increased	O
β‐oxidation	O
and	O
ketogenesis	O
in	O
the	O
liver	O
due	O
to	O
the	O
low	O
calorie	O
preoperative	O
diet.30	O
It	O
is	O
likely	O
that	O
the	O
increase	O
in	O
ketones	B
during	O
the	O
early	O
post‐surgery	O
period	O
is	O
due	O
to	O
both	O
surgical	O
stress	O
and	O
caloric	O
restriction	O
since	O
Laferrere	O
et	O
al	O
observed	O
that	O
plasma	O
3‐hydroxybutyrate	B
similarly	O
increased	O
following	O
~10‐kg	O
weight	O
loss	O
after	O
RYGB	O
(~1 month	O
post‐surgery)	O
and	O
caloric	O
restriction	O
(~2 months	O
post‐intervention).14	O
Interestingly,	O
an	O
early	O
increase	O
of	O
3‐hydrobutyrate	B
is	O
observed	O
with	O
better	O
glycemic	B
control	O
post‐surgery	O
and	O
the	O
3‐hydroxybutyrate/glucose	B
concentration	O
ratio	O
has	O
been	O
proposed	O
as	O
an	O
indicator	O
of	O
metabolic	O
improvement	O
post‐surgery.7	O

Elution	O
of	O
pemetrexed,	O
carboplatin,	B
and	O
gemcitabine	O
needed	O
high	O
percentage	O
(at	O
least	O
80%)	O
of	O
organic	O
solvent	O
in	O
the	O
mobile	O
phase;	O
however,	O
high	O
proportion	O
of	O
organic	O
solvent	O
(85%)	O
caused	O
that	O
the	O
analytes	O
could	O
not	O
be	O
totally	O
separated	O
from	O
the	O
endogenous	O
interfering	O
materials	O
on	O
the	O
SB-C_18	O
and	O
C_8	O
column.	O

In	O
our	O
current	O
study,	O
the	O
GPC	B
concentration	O
was	O
lower	O
in	O
the	O
DCIS	O
accompanying	O
invasive	O
carcinoma	O
group	O
than	O
in	O
the	O
pure	O
DCIS	O
group,	O
however,	O
the	O
difference	O
did	O
not	O
reach	O
statistical	O
significance.	O

As	O
a	O
control,	O
acetonitrile	B
0.1	O
%	O
in	O
medium	O
was	O
used.	O

Glycerophospholipids	B
are	O
differentiated	O
with	O
respect	O
to	O
the	O
presence	O
of	O
ester	O
(a)	O
and	O
ether	O
(e)	O
bonds	O
in	O
the	O
glycerol	B
moiety,	O
where	O
two	O
letters	O
(aa	O
=	O
diacyl,	O
ae	B
=	O
acyl-alkyl)	O
denote	O
that	O
two	O
glycerol	B
positions	O
are	O
bound	O
to	O
a	O
fatty	O
acid	O
residue,	O
while	O
a	O
single	O
letter	O
(a	O
=	O
acyl)	O
indicates	O
the	O
presence	O
of	O
a	O
single	O
fatty	O
acid	O
residue.	O

These	O
three	O
observation	O
frequencies	O
were	O
used	O
in	O
an	O
attempt	O
to	O
maximize	O
the	O
visualization	O
of	O
effects	O
due	O
to	O
any	O
differences	O
in	O
exchange	O
rates	O
between	O
the	O
metabolite	O
and	O
the	O
borate.	O
_1	O
H	O
NMR	O
spectra	O
of	O
a	O
standard	O
solution	O
containing:	O
(A–C)	O
citrate,	B
(D–F)	O
citrate/borate	B
complex,	O
(G–I)	O
mannitol,	B
(J–L)	O
mannitol/borate	B
complex.	O

who	O
observed	O
58–68%	O
overlap	O
between	O
the	O
two	O
methods	O
and	O
ability	O
to	O
detect	O
600	O
additional	O
features	O
when	O
comparing	O
SPE	O
to	O
methanol	B
precipitation.	O

Reported	O
data	O
suggests	O
that	O
Arachidonic	B
Acid,	I
and	O
linoleic	B
acid	I
(LA),	O
an	O
omega-6	B
polyunsaturated	O
FA	B
stimulates	O
prostate	O
cancer	O
cell	O
growth	O
in	O
vitro	O
[,].	O

Thus,	O
EDTA	O
and	O
heparin	B
are	O
both	O
suitable	O
for	O
blood	O
patient	O
collection	O
and	O
can	O
also	O
be	O
used	O
if	O
necessary	O
for	O
the	O
preparation	O
of	O
calibrators	O
and	O
QC	O
samples.	O

Likewise,	O
total	O
cholesteryl	B
ester	I
concentrations,	O
as	O
opposed	O
to	O
individual	O
cholesterol	B
esters,	I
also	O
showed	O
generally	O
good	O
agreement	O
with	O
cholesterol	B
measurements	O
reported	O
in	O
the	O
literature.	O

The	O
relevance	O
of	O
this	O
analysis	O
is	O
exemplified	O
by	O
the	O
pathway	O
linked	O
to	O
adenosine	B
in	O
which	O
ADA	O
encodes	O
adenosine	O
deaminase	O
(EC.3.5.4.4),	O
the	O
enzyme	O
that	O
catalyzes	O
the	O
irreversible	O
deamination	O
of	O
adenosine	B
to	O
inosine	B
and	O
regulates	O
intra-	O
and	O
extracellular	O
concentrations	O
of	O
adenosine.	B

Eleven	O
serum	O
metabolites,	O
that	O
is,	O
betaine	B
(P	O
=	O
0.026),	O
benzoic	B
acid	I
(P	O
=	O
0.024),	O
pyroglutamic	B
acid	I
(P	O
=	O
0.021),	O
pipecolic	B
acid	I
(P	O
=	O
0.042),	O
N	B
-phenylacetamide	I

On	O
the	O
other	O
hand,	O
L-tryptophan	B
and	O
adenosine-5′-diphosphate	B
(ADP)	O
in	O
Panels	O
D	O
and	O
E	O
are	O
significantly	O
downregulated	O
in	O
pneumonia	O
samples.	O

During	O
the	O
3	O
days	O
prior	O
to	O
the	O
study,	O
subjects	O
who	O
were	O
taking	O
multiple	O
daily	O
insulin	O
injections	O
were	O
instructed	O
to	O
use	O
ultra	O
rapid-acting	O
insulin	O
before	O
meals	O
and	O
bedtime	O
based	O
on	O
blood	O
glucose	B
concentrations.	O

They	O
found	O
that	O
those	O
cells	O
exhibiting	O
persistent	O
acidification	O
die,	O
whereas	O
cells	O
that	O
can	O
recover	O
a	O
more	O
alkaline	B
pH_i	O
due	O
to	O
a	O
shift	O
towards	O
mitochondrial	O
oxidation	O
survive,	O
revealing	O
that	O
metabolic	O
flexibility	O
contributes	O
to	O
cancer	O
cell	O
persistence	O
in	O
response	O
to	O
prolonged	O
exposure	O
to	O
anti-cancer	O
therapies.	O

Sphingolipid	B
metabolites,	O
such	O
as	O
sphingomyelin,	B
GM3,	B
ceramides	B
and	O
the	O
precursor	O
and	O
metabolites	O
of	O
ceramide,	B
dihydroceramide,	B
monohexosylceramide,	B
dihexosylceramide	B
and	O
trihexosylceramide,	B
were	O
overall	O
associated	O
with	O
a	O
lower	O
C-peptide	O
level	O
after	O
3,	O
6	O
and	O
12 months	O
(Table ),	O
although	O
not	O
reaching	O
significance	O
after	O
correction	O
for	O
multiple	O
testing.	O

In	O
the	O
healthy	O
controls,	O
the	O
levels	O
of	O
ten	O
metabolites	O
(methionine,	O
aminobutyric	B
acid,	I
niacinamide,	B
4-hydroxy-l-proline,	B
valine,	B
γ-aminobutyric	B
acid	I
(GABA),	O
glutamic	B
acid,	I
asparagine,	B
tyrosine	B
and	O
allantoin)	O
decreased,	O
and	O
the	O
concentrations	O
of	O
four	O
amino	O
acids	O
(serine,	O
taurine,	B
cysteine	B
and	O
creatine)	B
increased	O
significantly	O
after	O
the	O
OGTT	O
(A,B).	O

For	O
RP	B
and	O
HILIC	O
LC-MS	O
data,	O
peak	O
finding	O
options	O
were	O
set	O
as	O
follows:	O
subtraction	O
offset,	O
10	O
scans;	O
subtraction	O
multiplication	O
factor,	O
1.3;	O
noise	O
threshold,	O
3;	O
minimum	O
spectral	O
peak	O
width,	O
1	O
amu;	O
minimum	O
retention	O
time	O
peak	O
width,	O
4	O
scans;	O
and	O
maximum	O
retention	O
time	O
width,	O
1000	O
scans.	O

This	O
work	O
aimed	O
at	O
shedding	O
light	O
into	O
the	O
evolution	O
of	O
several	O
key	O
metabolites	O
related	O
to	O
energy	O
metabolism,	O
including	O
lactate,	B
together	O
with	O
pyruvate,	B
the	O
ketone	B
bodies	O
acetoacetate	B
and	O
β-hydroxybutyrate	B
as	O
well	O
as	O
several	O
Krebs	O
cycle	O
intermediates,	O
in	O
newborns	O
with	O
HIE	O
receiving	O
TH	O
during	O
the	O
first	O
72 hours	O
of	O
life	O
(see	O
Fig.	O

Our	O
results	O
share	O
some	O
characteristic	O
metabolites	O
with	O
some	O
similar	O
studies	O
[,	O
,	O
],	O
including	O
acetate,	B
ethanol,	B
glucose,	B
etc	O
.	O

Eight	O
metabolites	O
were	O
found	O
to	O
both	O
differentiate	O
OB	O
from	O
OB/D	O
subjects	O
consistently	O
at	O
all	O
time	O
points	O
and	O
change	O
over	O
time	O
(T0	O
vs.	O
other	O
two	O
time	O
points	O
T3,	O
T6):	O
lycopene,	B
asparagine,	B
lysophosphatidylcholine	B
(C18:2),	I
p-Cresol	B
sulfate,	I
lactate,	B
nervonic	B
acid	I
(C24:cis1),	O
glucose,	B
and	O
mannose.	B

In	O
contrast,	O
metabolic	O
specificities	O
were	O
displayed	O
in	O
boxes	O
on	O
horizontal	O
and	O
vertical	O
axis:	O
(i)	O
in	O
HCC-Cirrhosis:	O
a	O
high	O
level	O
of	O
β-HB	B
(signals	O
at	O
1.18	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5	O
and	O
signals	O
at	O
1.19–1.20	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45)	O
(A),	O
Tyr	O
(signals	O
at	O
3.94–3.95	O
ppm	O
and	O
6.88–6.91	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5	O
;	O
signals	O
at	O
7.17–7.18	O
ppm,	O
with	O
p	O
(corr)	O
=	O
0.45),	O
Phe	O
(signal	O
7.34–7.37	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5;	O
signal	O
7.40–7.44	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45)	O
and	O
His	O
(signal	O
7.07–7.09	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5);	O
signal	O
7.91	O
ppm	O
with	O
p	O
(corr)	O
=	O
0.45)	O
(B);	O
(ii)	O
in	O
HCC-NAFLD:	O
high	O
level	O
of	O
Glutamate	B
(Glu)	O
and	O
Gln	O
(signals	O
at	O
2.11–2.17	O
ppm	O
and	O
2.45	O
ppm	O
with	O
p	O
(corr)	O
>	O
0.5)	O
(C).	O

*p	O
 < 0.05,	O
**p	O
 < 0.01,	O
***p	O
 < 0.001	O
against	O
hypogonadal	O
men	O
In	O
IR	O
male	O
hypogonadism,	O
more	O
acetyl-CoA	B
is	O
transformed	O
into	O
cholesterol,	B
which	O
increases	O
up	O
to	O
243 mg/dL	O
(Table 	O
and	O
Fig.	O

The	O
signal	O
attributed	O
to	O
methyl	B
group	I
of	O
lactate	B
(δ	O
1.33	O
ppm)	O
was	O
used	O
as	O
chemical	O
shift	O
reference.	O

Cloud	O
plots	O
showing	O
dysregulated	O
metabolite	O
features	O
(represented	O
by	O
“bubbles”)	O
in	O
a	O
bacterial	O
response	O
to	O
nitric	B
oxide	I
treatment	O
analyzed	O
by	O
HILIC/MS	O
and	O
RPLC/MS.	O

AA,	O
an	O
essential	O
polyunsaturated	O
fatty	O
acid	O
with	O
signaling	O
functions	O
and	O
the	O
precursor	O
of	O
prostaglandins	B
and	O
leukotrienes,	O
is	O
proposed	O
to	O
be	O
stored	O
in	O
its	O
esterified	O
form	O
in	O
lipid	O
bodies	O
[–].	O

Given	O
the	O
experimental	O
setting	O
of	O
our	O
study,	O
the	O
diet	O
itself	O
is	O
an	O
unlikely	O
factor	O
behind	O
the	O
observed	O
diminishment	O
of	O
odd-chain	O
triglycerides	B
in	O
the	O
DCM	O
groups.	O

Among	O
the	O
20	O
identified	O
plasma	O
metabolites,	O
the	O
normalized	O
peak	O
intensities	O
of	O
3	O
amino	O
acids	O
(leucine,	O
phenylalanine,	B
and	O
tryptophan)	O
were	O
significantly	O
higher	O
in	O
prehypertensive	O
subjects	O
than	O
in	O
control	O
subjects;	O
however,	O
these	O
differences	O
disappeared	O
after	O
adjusting	O
for	O
BMI,	O
WHR,	O
smoking,	O
alcohol	O
consumption,	O
serum	O
lipid	O
profiles,	O
glucose,	B
and	O
insulin.	O

LC-MS/MS	O
analysis	O
of	O
methoxyestrone	B
metabolites	O
(2-MeOE_1	O
,	O
4-MeOE_1	O
)	O
in	O
MCF-10A	O
and	O
MCF-7	O
cells	O
and	O
CYP1A1	O
and	O
CYP1B1	O
expression	O
levels	O
in	O
MCF-7	O
cells.	O

In	O
the	O
mitochondria,	O
saturated	O
acyl-CoA	B
is	O
degraded	O
by	O
oxidation	O
at	O
the	O
β-carbon.	B

They	O
include	O
ornithine,	B
hippuric	B
acid,	I
choline,	B
pseudouridine,	B
glucuronic	B
acid,	I
phenylalanine,	B
potassium	O
in	O
plasma	O
and	O
glutaric	B
acid,	I
creatinine,	B
N-acetylaspartic	B
acid,	I
2,5-furandicarboxylic	B
acid,	I
sedoheptulose,	B
and	O
several	O
unknown	O
metabolites	O
in	O
urine	O
(	O
and	O
).	O

The	O
serotonin	B
pathway	O
sees	O
tryptophan	B
being	O
converted	O
into	O
5-hydroxytryptophan	B
(5-HTP)	O
by	O
tryptophan	O
hydroxylase	O
and	O
onwards	O
to	O
5-hydroxytryptamine	B
(5-HT)	O
or	O
serotonin	B
by	O
5-HTP	O
decarboxylase.	O

Metabolite	O
tyramine,	B
at	O
RT	O
4.33	O
min,	O
is	O
clearly	O
detected	O
in	O
the	O
MS	O
chromatogram;	O
however,	O
its	O
signal	O
is	O
suppressed	O
in	O
the	O
EC-array	O
due	O
to	O
a	O
matrix	O
peak	O
at	O
4.5	O
min.	O

Fasting	O
blood	O
samples	O
were	O
taken	O
from	O
the	O
cubital	O
vein	O
of	O
participants	O
in	O
the	O
supine	B
position	O
between	O
7.00	O
and	O
13.00 h.	O

Right:	O
900	O
MHz	O
raster	O
multiplet	O
for	O
glutamine.	B

The	O
anti-proliferative	O
effect	O
of	O
methoxyestrogens	B
has	O
not	O
yet	O
been	O
demonstrated	O
in	O
relation	O
to	O
the	O
prostate	O
but	O
it	O
was	O
shown	O
that	O
in	O
breast	O
cancer	O
cells	O
the	O
effect	O
can	O
occur	O
independently	O
of	O
ERα	O
and	O
ERβ.	O

It	O
is	O
interesting	O
that	O
the	O
ratio	O
of	O
LCA	O
(lithocholic	O
acid)/DCA	O
(deoxycholic	O
acid)	O
may	O
be	O
an	O
important	O
factor	O
to	O
distinguish	O
tendency	O
to	O
colon	O
cancer.	O

Considering	O
other	O
changes	O
in	O
amino	O
acid	O
metabolism,	O
important	O
changes	O
occurred	O
in	O
tryptophan	B
catabolism	O
(Supplementary	O
Figure	O
S6).	O

In	O
addition,	O
medical	O
records	O
for	O
trauma	O
patients	O
were	O
reviewed	O
to	O
obtain	O
hospital-based	O
plasma	O
glucose	B
levels	O
acquired	O
within	O
4	O
hours	O
of	O
venous	O
blood	O
sampling	O
for	O
this	O
study.	O

Succinate,	B
malic	B
acid	I
and	O
lactic	B
acid	I
were	O
particularly	O
elevated	O
in	O
IDH-mutant	O
gliomas	O
(Fig.	O
).	O

The	O
combination	O
of	O
evaluated	O
levels	O
of	O
both	O
glucose	B
and	O
lactate	B
in	O
serum	O
may	O
be	O
a	O
sign	O
of	O
pyruvate-dehydrogenase	O
pathway	O
and	O
liver	O
function	O
that	O
is	O
associated	O
with	O
blood	O
lipid	O
impairment	O
in	O
the	O
obese.	O

Based	O
on	O
our	O
results,	O
plasma	O
glutamine	B
and	O
glutamic	B
acid	I
were	O
selected	O
as	O
biomarker	O
candidates	O
for	O
distinguishing	O
DR	O
cases.	O

Favorable	O
performance	O
parameters	O
of	O
the	O
IEC-ESI-MS/MS	O
method	O
(LLOQs	O
1–10	O
nmol/L,	O
accuracy	O
95–105%,	O
intra-day	O
and	O
inter-day	O
precision	O
<	O
10%,	O
selectivity	O
demonstrated	O
via	O
no	O
sample	O
matrix	O
interferences)	O
and	O
acceptable	O
stability	O
(peak	O
area	O
fluctuations	O
<	O
15%)	O
of	O
clinical	O
samples	O
under	O
the	O
proposed	O
sample	O
preparation	O
conditions	O
{(i)	O
EDTA	O
anticoagulant	O
tube	O
for	O
the	O
blood	O
collection;	O
(ii)	O
4	O
°C	O
and	O
4	O
h	O
between	O
the	O
sample	O
collection	O
and	O
RBC	O
isolation;	O
(iii)	O
phosphate-buffered	B
saline	I
for	O
RBC	O
washing	O
and	O
re-suspendation;	O

N	O
‐Methyl‐N	B
‐(trimethylsilyl)	I
trifluoroacetamide	I
(MSTFA)	O
was	O
acquired	O
from	O
GL	O
Sciences	O
Inc.	O
(Tokyo,	O
Japan).	O

Subsequent	O
interpretation	O
of	O
the	O
peaks	O
with	O
distinctive	O
_1	O
H	O
NMR	O
signatures	O
showed	O
that	O
RSG	O
treatment	O
appears	O
to	O
induce	O
a	O
decrease	O
in	O
hippurate	B
and	O
a	O
further	O
increase	O
in	O
aromatic	O
amino	O
acids	O

Here,	O
we	O
found	O
that	O
methionine	B
had	O
significants	O
association	O
with	O
EDSS,	O
disease	O
duration,	B
and	O
the	O
size	O
of	O
spinal	O
cord	O
and	O
third	O
ventricle,	O
but	O
no	O
association	O
with	O
ageing.	O

Glutathione	B
transferases	O
(GSTs)	O
may	O
prevent	O
pathologies	O
by	O
catalysing	O
the	O
formation	O
of	O
glutathione	B
conjugates	O
of	O
o-quinones.	B

For	O
HILIC,	O
in	O
both	O
ESI	O
positive	O
and	O
negative	O
modes,	O
the	O
final	O
mobile	O
phase	O
was	O
composed	O
of	O
A	O
=	O
10	O
mM	O
ammonium	B
acetate	I
and	O
10	O
mM	O
ammonium	B
hydroxide	I
in	O
95%	O
water	O
and	O
B	O
=	O
95%	O
acetonitrile.	B

In	O
both	O
serum	O
and	O
urine	O
samples,	O
we	O
observed	O
that	O
the	O
use	O
of	O
internal	O
standards	O
is	O
essential	O
for	O
the	O
analysis	O
of	O
polyamines.	B

4-Hydroxyproline	B
is	O
a	O
specific	O
amino	O
acid	O
in	O
collagen	O
protein	O
that	O
plays	O
a	O
key	O
role	O
in	O
collagen	O
stability	O
and	O
reflects	O
the	O
collagen	O
content	O
or	O
fibrosis	O
stage.	O

A	O
bioavailability	O
study	O
(two	O
periods,	O
two	O
sequences,	O
cross-over,	O
block-randomized,	O
single-dose	O
design),	O
approved	O
by	O
the	O
regulatory	O
authorities	O
and	O
Ethical	O
Committee,	O
was	O
performed	O
in	O
accordance	O
with	O
good	O
clinical	O
practice	O
norms	O
on	O
12	O
healthy	O
volunteers	O
treated	O
orally	O
with	O
diosmin	O
(450 mg);	O
subjects	O
received	O
a	O
diet	O
poor	O
in	O
flavonoids	B
during	O
study	O
period	O
(3 days	O
before	O
drug	O
administration	O
and	O
2 days	O
after).	O

The	O
connection	O
between	O
acylcarnitine,	B
vitamin	O
B-12	O
status,	O
and	O
nerve	O
function	O
was	O
confirmed	O
in	O
the	O
correlation	O
analyses.	O

Endogenous	O
adenosine	B
nucleotide	O
concentrations	O
in	O
human	O
liver	O
sections.	O

However,	O
only	O
1	O
VOC,	O
4-heptanone,	B
was	O
able	O
to	O
distinguish	O
B-NHL	O
from	O
benign	O
lymphatic	O
disease.	O

This	O
method	O
was	O
successfully	O
applied	O
for	O
the	O
quantification	O
of	O
D-mannose	B
in	O
the	O
serum	O
samples	O
of	O
320	O
esophageal	O
cancer	O
patients	O
and	O
323	O
healthy	O
volunteers.	O

In	O
contrast	O
to	O
the	O
amino	O
acids	O
mentioned	O
above,	O
aspartate	B
was	O
significantly	O
increased	O
upon	O
longer	O
storage.	O

TG	B
also	O
had	O
the	O
highest	O
number	O
of	O
lipid	O
species	O
with	O
1,115	O
species	O
identified	O
(Table	O
).	O

However,	O
in	O
a	O
study	O
including	O
ten	O
healthy	O
white	O
women	O
of	O
age	O
20–40	O
years	O
with	O
regular	O
endogenous	O
menstrual	O
cycles	O
between	O
24–34	O
days,	O
the	O
range	O
of	O
24-hour	O
urinary	O
excretion	O
of	O
androgens	O
and	O
glucocorticoids	B
was	O
in	O
a	O
similar	O
range	O
as	O
measured	O
in	O
our	O
study	O
and	O
no	O
differences	O
were	O
found	O
between	O
menstrual,	O
follicular	O
and	O
luteal	O
phase	O
of	O
the	O
menstrual	O
cycle	O
for	O
the	O
urinary	O
excretion	O
of	O
androgens	O
and	O
of	O
the	O
five	O
glucocorticoids	B
cortisol,	I
cortisone,	B
TH-cortisol,	O
allo-TH-cortisol	O
and	O
TH-cortisone.	B

The	O
most	O
widely	O
used	O
protocol	O
for	O
global	O
metabolomics	O
of	O
plasma	O
is	O
solvent	O
precipitation	O
using	O
cold	O
methanol	B
or	O
methanol/ethanol	B
(1/1,	O
v/v)	O
with	O
a	O
plasma-to-solvent	O
ratio	O
of	O
1	O
to	O
3	O
or	O
4_,	O
_,	O
_,	O
.	O

While	O
urinary	O
adenosine	B
concentrations	O
may	O
vary	O
with	O
changes	O
in	O
extracellular	O
adenosine,	B
variation	O
in	O
urinary	O
adenosine	B
concentration	O
is	O
known	O
to	O
be	O
low	O
in	O
humans,	O
and	O
is	O
unaffected	O
by	O
sodium	O
content	O
or	O
changes	O
in	O
fluid	O
homeostasis.	O

Vitamin	O
E-related	O
metabolites	O
(A)	O
alpha-tocopherol,	B
(B)	O
gamma-arboxyethylhydrochroman,	B
and	O
(C)	O
gamma-CEHC	B
glucuronide	I
are	O
elevated	O
after	O
leptin	O
treatment.	O

The	O
clinical	O
variables	O
assessed	O
were	O
age,	O
antihypertensive	O
medication,	O
BMI,	O
duration	B
of	O
diabetes,	O
glycated	O
hemoglobin	O
(HbA1c),	O
insulin	O
day	O
dose,	O
sex,	O
smoking,	O
systolic	O
blood	O
pressure,	O
total	O
cholesterol,	B
and	O
total	O
triglycerides.	B

Azelaic	B
acid	I
is	O
a	O
dicarboxylic	B
acid	I
known	O
to	O
have	O
T2DM	O
therapeutic	O
properties	O
and	O
was	O
inversely	O
correlated	O
to	O
diabetes	O
risk	O
in	O
our	O
study;	O
the	O
reduction	O
of	O
azelaic	B
acid	I
may	O
possibly	O
be	O
due	O
to	O
simvastatin-induced	O
decarboxylation.	O

Among	O
multiple	O
metabolites	O
detected,	O
2-hydroxybutyric	B
acid	I
(2-HBA)	O
declined	O
most	O
significantly	O
after	O
six	O
months	O
in	O
comparing	O
patients	O
that	O
underwent	O
RYGB	O
versus	O
those	O
in	O
WLM	O
(P	O
<	O
0.001),	O
corresponding	O
with	O
declines	O
in	O
HOMA-IR	O
(P	O
=	O
0.025).	O

While	O
metabolites	O
may	O
be	O
detectable	O
in	O
paraffin	B
embedded	O
tissue,	O
the	O
assay	O
of	O
metabolites	O
retrieved	O
from	O
paraffin	B
should	O
be	O
carefully	O
considered.	O

Although	O
the	O
concentrations	O
of	O
some	O
amino	O
acids	O
were	O
primarily	O
affected	O
by	O
co-variables	O
such	O
as	O
fasting	O
status,	O
many	O
other	O
amino	O
acids,	O
such	O
as	O
phenylalanine,	B
threonine,	B
tyrosine,	B
lysine,	B
tryptophan,	B
asparagine	B
and	O
glycine	B
for	O
example,	O
were	O
excreted	O
at	O
lower	O
concentrations	O
in	O
pre-surgery	O
CRC	O
patients’	O
urine.	O

One	O
is	O
a	O
TG	B
species	O
(CalcMz = 824.77)	O
with	O
16	O
carbons	O
in	O
each	O
of	O
the	O
three	O
fatty	O
acid	O
chains,	O
and	O
the	O
other	O
is	O
a	O
DG	O
species	O
(CalcMz = 696.65)	O
with	O
18	O
and	O
22	O
carbons	O
in	O
each	O
of	O
the	O
two	O
fatty	O
acid	O
chains.	O

358	O
metabolites	O
from	O
46	O
biochemical	O
pathways	O
were	O
measured	O
by	O
hydrophilic	B
interaction	O
liquid	O
chromatography	O
and	O
tandem	O
mass	O
spectrometry.	O

Cholesterol	B
is	O
metabolised	O
in	O
the	O
CNS	O
in	O
astrocytes	O
through	O
cytochrome	O
P450	O
(CYP)	O
27A1	O
catalysed	O
oxidation	O
to	O
(25R)26-HC	B
and	O
subsequently	O
to	O
3β-HCA	B
and	O
then	O
on	O
to	O
3β,7α-diHCA	B
and	O
7αH,3O-CA	B
by	O
the	O
consecutive	O
action	O
of	O
CYP7B1	O
and	O
hydroxysteroid	O
dehydrogenase	O
(HSD)	O
3B7	O
enzymes	O
(Fig.	O
).	O

d	O
The	O
use	O
of	O
WB	O
eliminates	O
many	O
of	O
the	O
pre-analytical	O
processing	O
problems	O
of	O
serum,	O
and	O
captures	O
the	O
red	O
blood	O
cell	O
metabolome,	O
including	O
the	O
energy	O
molecules	O
ATP,	B
ADP,	B
and	O
AMP	B
[,].	O

On	O
the	O
contrary,	O
the	O
product	O
ion	O
spectrum	O
of	O
PTAD-derivatized	O
1,25-(OH)_2	B
D_3	O
exhibits	O
only	O
one	O
major	O
fragment	O
ion	O
at	O
m	O
/z	O

Monounsaturated	O
(oleic	O
acid,	O
C18:1)	B
and	O
saturated	O
fats	O
(stearic	O
acid,	O
C18:0)	B
had	O
less	O
satiety	O
effects	O
than	O
polyunsaturated	O
fats	O
(linolenic	O
acid,	O
C18:2).	B

The	O
genes	O
that	O
mapped	O
to	O
this	O
pathway	O
encode	O
the	O
cytosolic	O
and	O
mitochondrial	O
components	O
of	O
the	O
pathway	O
and	O
included	O
both	O
genes	O
common	O
to	O
the	O
degradation	O
of	O
all	O
BCAAs,	O
namely	O
isoleucine,	B
leucine	B
and	O
valine	B
(BCAT1,	O
BCKDHB	O
)	O
and	O
those	O
specific	O
for	O
the	O
degradation	O
of	O
leucine	B
(MCC2,	O
AUH	O
),	O
isoleucine	B
(PCCA,	O
PCCB	O
)	O
and	O
valine	B
(HIBADH,	O
ALDH6A1	O
).	O

To	O
identify	O
sterols	O
that	O
naturally	O
possess	O
a	O
3-oxo	O
function	O
from	O
those	O
oxidized	O
to	O
contain	O
one,	O
CSF	O
samples	O
were	O
analyzed	O
in	O
parallel	O
in	O
the	O
presence	O
(Scheme	O
1,	O
route	O
B	O
)	O
and	O
absence	O
(Scheme	O
1,	O
route	O
A	O
)	O
of	O
cholesterol	B
oxidase.	O

Pyruvate	O
carboxylation	O
is	O
an	O
important	O
anaplerotic	O
reaction	O
that	O
replenishes	O
citric	B
acid	I
cycle	O
intermediates	O
when	O
they	O
intermediates	O
are	O
removed	O
from	O
mitochondria	O
by	O
their	O
export	O
to	O
the	O
cytosol	O
(cataplerosis).	O

The	O
ROC	O
analysis	O
demonstrated	O
once	O
again	O
tryptophan	B
was	O
a	O
good	O
discriminator	O
between	O
T2D	O
and	O
NGT,	O
regardless	O
of	O
all	O
(AUC	O
=	O
0.88)	O
or	O
matched	O
(AUC	O

Quantified	O
amino	O
acids	O
and	O
acylcarnitine	B
in	O
serum	O
samples	O
in	O
the	O
2017	O
data	O
set.	O

Also,	O
glucose	B
is	O
metabolized	O
in	O
the	O
human	O
body	O
and	O
filtered	O
in	O
the	O
glomeruli	O
(about	O
180g/day),	O
it	O
would	O
be	O
detrimental	O
to	O
the	O
human	O
system	O
to	O
lose	O
such	O
enormous	O
amount	O
of	O
glucose,	B
so	O
it	O
is	O
reabsorbed	O
in	O
the	O
proximal	O
tubule	O
and	O
this	O
may	O
explain	O
the	O
absence	O
of	O
glucose	B
and	O
other	O
glycolytic	B
intermediates	O
in	O
our	O
urine	O
samples.	O

Collision	O
induced	O
dissociation	O
(CID)	O
product	O
ion	O
spectra	O
of	O
representative	O
SPMs	O
comprising	O
(A)	O
ARA	O
derived	O
lipoxin	B
5(S	O
),6(R	O
),15(S	O
)	O

However,	O
Bonferroni	O
correction	O
indicated	O
that	O
only	O
the	O
levels	O
of	O
C22:6n3,	O
total	O
omega	O
3,	O
C18:3n6,	O
C15:1,	B
C20:1n9,	O
C12:0,	B
C15:0,	B
C17:0,	B
C18:0	B
and	O
total	O
omega	O
6/	O
total	O
omega	O
3	O
ratio	O
were	O
statistically	O
significantly	O
different.	O

This	O
suggests	O
that	O
linoleic	B
acid	I
intake	O
trended	O
inversely	O
with	O
fasting	O
insulin	O
in	O
the	O
schizophrenia	O
cohort.	O

These	O
observations	O
motivate	O
a	O
need	O
for	O
further	O
investigation	O
to	O
establish	O
a	O
causative	O
role	O
for	O
enrichment	O
in	O
individual	O
oxylipins	B
within	O
TGRL	O
in	O
modulating	O
ER	O
stress	O
responses	O
that	O
promote	O
endothelial	O
inflammation.	O

The	O
lipid	O
profile	O
of	O
PCOS	O
women	O
with	O
abdominal	O
obesity	O
was	O
highly	O
associated	O
with	O
testosterone	B
(;	O
).	O

Hippuric	B
acid	I
is	O
a	O
conjugate	O
of	O
glycine	B
with	O
benzoic	B
acid	I
and	O
is	O
excreted	O
in	O
the	O
urine.	O

We	O
also	O
observed	O
an	O
association	O
between	O
the	O
CARS	O
score	O
and	O
decanoylcarnitine	B
(r	O
=	O
−0.2564,	O
p	O
=	O
0.07)	O
and	O
pregnanetriol	B
(r	O
=	O
−0.3240,	O
p	O
=	O
0.020)	O
and	O
between	O
the	O
ABC	O
score	O
and	O
pregnanetriol	B
(r	O
=	O
0.2697,	O
p	O
=	O
0.06),	O
DHA	O
(r	O
=	O
−0.2611,	O
p	O
=	O
0.06),	O
DPA	O
(r	O
=	O
−0.3175,	O
p	O
=	O
0.023)	O
and	O
S1P	O
(r	O
=	O
0.2746,	O
p	O
=	O
0.05;	O
).	O

Endogenous	O
(unlabeled)	O
TMAO	B
and	O
choline	B
and	O
betaine	B
were	O
present	O
in	O
fasting	O
plasma	O
samples	O
at	O
baseline.	O

In	O
the	O
present	O
study,	O
apoE	O
polymorphism	O
associated	O
consistently	O
and	O
as	O
expected	O
over	O
the	O
followed	O
years	O
with	O
plasma	O
concentrations	O
of	O
basic	O
lipids	O
i.e.,	O
total	O
cholesterol,	B
LDL-C	O
and	O
apoB	O
(as	O
widely	O
reported	O
in	O
literature,	O
including	O
the	O
previous	O
YFS	O
follow-up).	O

P-cresol	B
has	O
been	O
noted	O
to	O
be	O
toxic	O
in	O
high	O
doses,	O
especially	O
in	O
the	O
context	O
of	O
renal	O
impairment,	O
and	O
is	O
associated	O
with	O
the	O
microbiome.	O

Additionally,	O
integrating	O
genomics	O
and	O
metabolomics	O
data	O
revealed	O
three	O
polymorphisms	O
(rs2727563	O
PRKAG2	O
,	O
rs12604940	O
DCC	O
,	O
and	O
rs13262930	O
EPHX2)	O
along	O
with	O
arachidonic	B
acid,	I
converging	O
in	O
the	O
netrin	O
signaling	O
pathway	O
(p=1×10_−5	O
),	O
as	O
potential	O
markers	O
significantly	O
influencing	O
HCTZ	O
BP	O
response.	O

This	O
change,	O
coupled	O
with	O
the	O
above-mentioned	O
enrichments	O
for	O
LCFAs	O
and	O
cholesterols,	B
is	O
consistent	O
with	O
previously	O
suggested	O
perturbations	O
of	O
fatty	O
acid	O
metabolism	O
in	O
IBD.	O

This	O
modified	O
procedure	O
facilitated	O
the	O
aspiration	O
of	O
the	O
supernatant	O
from	O
above	O
the	O
pellet	O
containing	O
the	O
labeled	O
25(OH)D.	O
The	O
WHNRC	O
participates	O
in	O
the	O
DEQAS	O
Vitamin	B
D	I
External	O
Quality	O
Assessment	O
Scheme	O
(http://www.deqas.org/)	O
and	O
calibration	O
standards	O
from	O
DEQAS	O
analyzed	O
during	O
this	O
period	O
were	O
all	O
within	O
acceptable	O
limits.	O

Bradykinin	B
plays	O
a	O
particularly	O
important	O
role	O
in	O
various	O
classifications	O
of	O
angioedema,	O
but	O
also	O
in	O
other	O
inflammatory	O
processes	O
such	O
as	O
allergic	O
rhinitis.	O

One	O
mL	O
of	O
the	O
human	O
urine	O
containing	O
1	O
ng/mL	O
of	O
fipronil	O
as	O
I.S.	O
was	O
loaded	O
in	O
a	O
pre-conditioned	O
SPE	O
cartridge	O
(Oasis	O
WAX	O
Plus,	O
225	O
mg,	O
60	O
μm,	O
Waters),	O
washed	O
with	O
2	O
ml	O
of	O
0.1	O
M	O
NaOH,	O
50	O
mM	O
sodium	B
phosphate	I
buffer	O
(pH	O
=	O
7.4)	O
and	O
water,	O
and	O
extracted	O
with	O
2	O
mL	O
of	O
acetonitrile.	B

Pathway	O
analysis	O
carried	O
out	O
by	O
IPA	O
software	O
revealed	O
that	O
three	O
metabolic	O
pathways	O
including	O
glycerophospholipid	B
metabolism,	O
Lipoate	B
Biosynthesis	O
and	O
Incorporation	O
II,	O
and	O
Melatonin	B
Degradation	O
II	O
were	O
found	O
to	O
contribute	O
in	O
the	O
process	O
from	O
pre-DM	O
to	O
NGR	O
(Fig. ).	O

Cholesterol,	B
LDL,	O
grip	O
strength,	O
lysoPCs	O
(16:0,	O
17:0,	O
18:0,	O
18:1	O
(11Z),	O
18:3(9Z,	O
12Z,	O
15Z),	O
P-18:1	B
(9Z),	I
20:1	O
(11Z),	O
(20:3	O
(8Z,	O
11Z,	I
14Z)),	I
glycerophosphocholine,	B
ornithine,	B
glucuronic	B
acid,	I
glycerophosphoserine	B
and	O
taurocholic	B
acid	I
were	O
sensitive	O
markers	O
in	O
the	O
assessment	O
of	O
nutritional	O
status.	O

Phenanthrene-4,5-dicarboylate	B
and	O
m-coumaric	B
acid	I
have	O
roles	O
in	O
aromatic	O
compound	O
degradation.	O

By	O
contrast,	O
methane	B
metabolism	O
and	O
pyruvate	B
metabolism	O
were	O
over-represented	O
in	O
IBS-C	O
patients	O
(Fig.	O

Free	O
anti-TB	O
drug	O
treatment	O
was	O
provided	O
to	O
all	O
patients,	O
which	O
consisted	O
of	O
a	O
standard	O
regimen	O
of	O
isoniazid,	O
rifampin,	O
pyrazinamide,	B
and	O
ethambutol	O
(2HRZE/4H3R3)	O
according	O
to	O
the	O
Indonesian	O
national	O
TB	O
program	O
guideline.	O

Visual	O
comparison	O
of	O
the	O
spectra	O
in	O
suggests	O
apparent	O
decreases	O
in	O
acetate,	B
p	O
-cresol	O
sulfate	B
(p-	O
CS),	O
trimethylamine	B
N	I
-oxide	I
(TMAO),	O
hippurate,	B
indoxyl	B
sulfate	I
(IS)	O
and	O
trigonelline,	B
in	O
RCC	O
samples.	O

In	O
contrast,	O
p-aminobenzoic	B
acid,	I
biotin	B
and	O
pyridoxine	B
were	O
not	O
essential	O
to	O
T.	O
cruzi	O
.	O

Briefly,	O
thawed	O
plasma	O
samples	O
were	O
centrifuged	O
at	O
3,200	O
×	O
g	O
for	O
5	O
minutes	O
and	O
80	O
µl	O
of	O
plasma	O
was	O
added	O
to	O
vials	O
containing	O
80	O
µl	O
of	O
a	O
methanolic	B
solution	O
of	O
a	O
mixture	O
of	O
internal	O
standards	O
(400	O
pg	B
of	O
the	O
deuterated	O
version	O
of	O
each	O
oxysterol)	B
or	O
blank	O
(methanol	O
without	O
oxysterols).	B

For	O
example,	O
the	O
Pearson	O
correlation	O
coefficients	O
between	O
the	O
serum	O
concentration	O
of	O
unconjugated	O
estradiol	B
and	O
serum	O
concentrations	O
of	O
total	O
estrogens	O
and	O
estrogen	B
metabolites,	O
parent	O
estrogens,	O
and	O
the	O
2-,	O
4-,	O
and	O
16-hydroxylation	O
pathways	O
were	O
0.66,	O
0.66,	O
0.65,	O
0.58,	O
and	O
0.66,	O
respectively.	O

CKD	O
patients	O
had	O
higher	O
TMAO	B
levels	O
than	O
controls	O
and	O
the	O
levels	O
rose	O
with	O
decreasing	O
renal	O
function.	O

After	O
analysing	O
the	O
relationships	O
between	O
the	O
identified	O
metabolites	O
with	O
clinical	O
parameters,	O
and	O
calculating	O
the	O
diagnostic	O
efficacy	O
of	O
these	O
metabolites	O
using	O
ROC,	O
we	O
concluded	O
that	O
three	O
metabolites—sphinganine,	O
lactate	B
and	O
DHEA-S,	B
related	O
to	O
the	O
severity	O
of	O
CAP—might	O
represent	O
a	O
panel	O
of	O
potential	O
small	O
molecule	O
biomarkers	O
for	O
assessing	O
CAP	O
severity.	O

In	O
the	O
endometrioid	O
carcinoma	O
cases	O
and	O
in	O
the	O
normal	O
ovarian	O
tissues,	O
we	O
did	O
not	O
observe	O
either	O
N-acetyl-aspartate	B
or	O
N-acetyl-lysine.	B

All	O
NMR	O
spectra	O
were	O
referenced	O
with	O
respect	O
to	O
the	O
formic	B
acid	I
signal	O
at	O
8.463 ppm.	O

Scatter	O
plot	O
of	O
concentrations	O
(relative	O
to	O
creatinine	B
concentration;	O
log	O
axes)	O
of	O
lactose	B
and	O
an	O
unidentified	O
substance	O
with	O
an	O
NMR	O
signal	O
at	O
0.62	O
ppm.	O

However,	O
we	O
also	O
identified	O
differences	O
in	O
the	O
levels	O
of	O
hippuric	B
acid	I
among	O
urines	O
collected	O
from	O
controls	O
and	O
patients	O
with	O
primary	O
and	O
recurrent	O
tumors,	O
suggesting	O
differences	O
in	O
the	O
metabolism	O
of	O
these	O
types	O
of	O
tumors.	O

The	O
resulting	O
sample	O
solution	O
was	O
divided	O
into	O
three	O
parts:	O
First,	O
one	O
aliquot	O
was	O
assessed	O
using	O
acidic	O
positive	O
ion-optimized	O
conditions	O
for	O
hydrophilic	B
compounds.	O

Each	O
subject	O
was	O
sampled	O
for	O
a	O
group	O
of	O
14	O
VOCs	O
and	O
1,3-butadiene	B
(separately)	O
for	O
a	O
total	O
of	O
five	O
consecutive	O
24-h	O
periods	O
using	O
one	O
personal	O
sampler	O
pump	O
(SKC	O
model	O
PCXR8),	O
connected	O
to	O
two	O
different	O
sorbent	O
tubes	O
(one	O
for	O
14	O
VOCs	O
and	O
the	O
other	O
for	O
1,3-butadiene),	B
and	O
during	O
one	O
concurrent	O
day	O
an	O
additional	O
pump	O
sampled	O
PAH	O
on	O
47-mm	O
quartz	O
filters.	O

There	O
were	O
45	O
metabolites	O
whose	O
levels	O
were	O
significantly	O
changed	O
between	O
pretreatment	O
and	O
within-	O
or	O
post-treatment	O
serum	O
samples,	O
including	O
38	O
phospholipids.	B

Arginine	B
metabolism	O
has	O
an	O
important	O
role	O
in	O
the	O
remodeling	O
of	O
the	O
extracellular	O
matrix	O
and	O
the	O
production	O
of	O
polyamines,	B
creatine	B
and	O
nitric	B
oxide	I
(Rath	O
et al	O
.,	O
2014).	O

Estrogen	B
metabolites	O
in	O
maternal	O
serum	O
were	O
analyzed	O
by	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry.	O

In	O
this	O
study,	O
CRC	O
samples	O
revealed	O
alterations	O
in	O
lipid	O
species	O
involved	O
in	O
endocannabinoid,	B
sphingolipid,	B
and	O
glycerophospholipid	B
metabolisms.	O

The	O
higher	O
plasma	O
alanine	B
in	O
NR	O
may	O
be	O
a	O
sign	O
of	O
lower	O
hepatic	O
capacity	O
for	O
conversion	O
of	O
alanine	B
to	O
glucose.	B

Only	O
Stearic	B
acid	I
is	O
significantly	O
increased	O
in	O
BDTT	O
patient.	O

None	O
of	O
the	O
previously	O
reported	O
analytical	O
methods	O
provide	O
adequate	O
sensitivity	O
for	O
the	O
expected	O
sub-nanogram/mL	O
maternal	O
and	O
umbilical	O
cord	O
plasma	O
concentrations	O
of	O
glyburide	B
during	O
pregnancy.	O

These	O
results	O
suggest	O
that	O
accumulation	O
of	O
N-formylkynurenine	B
in	O
RCC	O
patients'	O
urine	O
may	O
be	O
used	O
as	O
a	O
potential	O
biomarker	O
for	O
RCC	O
diagnosis.	O

In	O
line	O
with	O
these	O
findings,	O
serum	O
creatine	B
and	O
creatinine	B
levels	O
are	O
also	O
significantly	O
reduced	O
in	O
fibrosis	O
patients.	O

Phosphatidylethanolamine	B
(PE)	O
is	O
class	O
of	O
phospholipids	B
found	O
in	O
biological	O
membranes;	O
it	O
can	O
be	O
found	O
in	O
all	O
living	O
organism.	O

This	O
association	O
accounted	O
for	O
31%	O
of	O
the	O
observed	O
variance	O
in	O
interindividual	O
24S	B
-hydroxycholesterol	I
levels.	O

Our	O
results	O
show	O
that	O
the	O
major	O
changes	O
in	O
glycerophosphocholine	B
species	O
between	O
septic	O
and	O
healthy	O
patients	O
were	O
in	O
monoacyl	O
(lyso-PC)	O
and	O
diacylglycerophosphocholine	B
(PC)	O
as	O
indicated	O
by	O
the	O
PLS-DA	O
analysis	O
of	O
the	O
ESI-MS	O
lipid	O
profile	O
data.	O

Sodium	B
phenyl	I
butyrate,	I
Huntington	O
disease,	O
LCECA,	O
metabolites,	O
parallel	O
LC-EC-array/LC-MS,	O
tandem	O
mass	O
spectrometry	O

Because	O
most	O
cancers	O
use	O
glucose	B
and	O
glutamine	B
as	O
the	O
two	O
main	O
carbon	O
sources	O
for	O
both	O
energy	O
production	O
and	O
biosynthesis,	O
we	O
used	O
uniformly	O
labeled	O
_13	O
C_6	B
-glucose	I
or	O
_13	O
C_5	B
-glutamine	I
and	O
LC-MS	O
or	O
GC-MS	O
to	O
track	O
the	O
fluxes	O
of	O
these	O
two	O
substrates	O
into	O
the	O
synthesis	O
of	O
various	O
metabolites.	O

Metabolites	O
with	O
only	O
one	O
isomeric	O
state	O
appear	O
as	O
“Metabolite_1_1”,	O
such	O
as	O
“Acetic_acid_1_1”,	O
whereas	O
metabolites	O
with	O
more	O
than	O
one	O
isomeric	O
state	O
and/or	O
spin	O
system	O
appear	O
as	O
“Metabolite	O
Name_n	O
_m	O
”	O
where	O
n	O
=1,2,3,	O
…	O
are	O
different	O
isomers	O
of	O
the	O
same	O
metabolite	O
(e.g.,	O
Glucose_1_1,	O
Glucose_2_1	O
for	O
α-glucose	B
and	O
β-glucose,	B
respectively)	O
and	O
m	O
=1,2,3,	O
…	O
are	O
different	O
spin	O
systems	O
of	O
the	O
metabolite	O
(e.g.,	O
L-Carnitine_1_1,	O
L-Carnitine_1_2).	O

The	O
multibiomarker	O
methods	O
presented	O
have	O
been	O
applied	O
in	O
several	O
pilot	O
studies	O
to	O
prove	O
their	O
applicability	O
and	O
to	O
estimate	O
mycotoxin	B
exposure	O
in	O
the	O
populations/individuals	O
tested.	O

In	O
that	O
study,	O
reactions	O
of	O
metabolites	O
with	O
cholamine	B
were	O
made	O
in	O
organic	O
solution	O
in	O
contrast	O
to	O
the	O
aqueous	O
media	O
used	O
here.	O

Changes	O
in	O
lactosylceramide	B
correlated	O
positively	O
with	O
△	O
decanoylcarnitine	B
and	O
negatively	O
with	O
△	O
L-valine,	B
△	O
lysoPCs	O
(14:0,	O
16:0,	O
18:2,	O
18:0,	O
20:3,	O
and	O
22:6),	O
and	O
△	O
PC	B
(18:0/20:4)	I
(r	O
=	O
0.266,	O
P	O
=	O
0.004).	O

The	O
supernatant	O
from	O
protein	O
precipitation	O
was	O
transferred	O
into	O
2-mL	O
plastic	O
tubes	O
(Fisher	O
Scientific)	O
containing	O
400	O
μL	O
0.4	O
M	O
K_2	O
HPO_4	O
and	O
mixed	O
using	O
a	O
Vortex	O
mixer	O
for	O
30	O
s	O
followed	O
by	O
the	O
addition	O
of	O
500	O
μL	O
methyl	B
t	I
-butyl	I
ether	I
(MTBE).	O

The	O
increased	O
demand	O
of	O
lipid	O
oxidation	O
in	O
tumour	O
cells	O
has	O
been	O
previously	O
reported	O
as	O
a	O
reason	O
to	O
avoid	O
carnitine	B
supplementation	O
during	O
anticancer	O
therapy	O
,	O
.	O

A	O
model	O
mixture	O
was	O
prepared	O
by	O
dissolving	O
the	O
following	O
26	O
metabolites:	O
lysine,	B
isoleucine,	B
histidine,	B
alanine,	B
glutamine,	B
ornithine,	B
carnitine,	B
shikimate,	B
arginine,	B
glutamate,	B
fructose,	B
ribose,	B
galactose,	B
glucose,	B
lactose,	B
sucrose,	B
inosine,	B
threonine,	B
valine,	B
leucine,	B
proline,	B
cysteine,	B
methionine,	B
adenosine,	B
serine,	B
and	O
citrulline.	B

Structures	O
of	O
the	O
phosphatidylethanolamine	B
standards	O
(a)	O
PE	B
18:1(n	I
-9,	I
cis	I
)/18:1(n	I

Compared	O
to	O
Placebo,	O
metabolic	O
flexibility	O
was	O
improved	O
by	O
all	O
interventions	O
in	O
the	O
following	O
order	O
of	O
effect:	O
Pio < Omega-3 < Pio&	B
Omega-3	I
(see	O
the	O
PRCF	O
curve	O
shifts	O
in	O
the	O
legend	O
to	O
Fig.	O

Gut	O
microbiota	O
composition	O
and	O
abundance	O
were	O
altered	O
in	O
different	O
glycemic	B
stages.	O

β-Actin	B
was	O
used	O
as	O
a	O
control	O
to	O
confirm	O
equal	O
loading	O
of	O
protein.	O

Hippurate	B
(the	O
last	O
two	O
plots)	O
comprises	O
aliphatic	B
and	O
aromatic	O
resonances	O
at	O
3.97 ppm	O
and	O
7.56 ppm.	O

Interestingly,	O
we	O
find	O
that	O
TB	O
leads	O
to	O
increased	O
plasma	O
levels	O
of	O
β-hydroxybutyrate,	B
a	O
ketone	B
body	O
which	O
has	O
been	O
implicated	O
in	O
Mtb	O
-induced	O
intracellular	O
lipid	O
droplet	O
formation.	O

We	O
hypothesized	O
that	O
lower	O
plasma	O
concentrations	O
of	O
25(OH)D,	O
1,25(OH)_2	B
D,	O
and	O
24,25(OH)_2	B
D—representing	O
interrelated	O
deficiencies	O
in	O
vitamin	B
D	I
intake,	O
activation,	O
and	O
catabolism,	O
respectively—would	O
each	O
be	O
associated	O
with	O
increased	O
risks	O
of	O
microalbuminuria,	O
impaired	O
GFR,	O
and	O
hypertension	O
over	O
long-term	O
follow-up.	O

Twenty	O
portions	O
of	O
serum	O
(350	O
μ	O
L	O
each)	O
were	O
mixed	O
with	O
methanol	B
in	O
a	O
1:2	O
ratio	O
(v/v),	O
vortexed	O
and	O
incubated	O
at	O
−20	O
°C	O
for	O
20	O
min.	O

Uric	B
acid	I
is	O
considered	O
an	O
antioxidant,	O
and	O
previous	O
studies	O
have	O
indicated	O
that	O
low	O
serum	O
uric	B
acid	I
levels	O
are	O
correlated	O
with	O
the	O
risk	O
of	O
disease	O
and	O
progression	O
in	O
PSP.	O

Furthermore,	O
two	O
potential	O
biomarkers,	O
xylose	B
and	O
C_4	O
sugar	O
2,	O
were	O
discovered	O
in	O
the	O
two	O
syndromes	O
using	O
K-OPLS/SPA	O
and	O
t	O
-test.	O

In	O
all	O
plots,	O
individuals	O
are	O
classified	O
as	O
noncannabis	O
users	O
or	O
cannabis	B
users	O
stratified	O
by	O
moderate	O
or	O
heavy	O
cannabis	B
use	O
as	O
determined	O
by	O
plasma	O
quantities	O
of	O
11-nor-carboxy-tetrahydrocannabinol.	B

The	O
method	O
is	O
specific	O
for	O
compounds	O
that	O
will	O
undergo	O
LC-ECA	O
oxidation	O
or	O
reduction,	O
and	O
includes	O
multiple	O
compounds	O
from	O
the	O
tyrosine,	B
tryptophan,	B
sulfur	O
amino	O
acid	O
and	O
purine	B
pathways,	O
as	O
well	O
as	O
markers	O
of	O
oxidative	O
stress	O
and	O
protection	O
(see	O
Additional	O
file	O
:	O
Table	O
S1).	O

Adjusted	O
for	O
age	O
(years),	O
sex,	O
total	O
calorie	O
intake	O
(Kcal/day),	O
total	O
physical	O
activity	O
(MET-minutes/week),	O
smoking	O
(cigarettes/day)	O
and	O
alcohol	O
consumption	O
(g/day)	O
†Metabolites	O
were	O
ln-transformed	O
‡	O
p	O
-values	O
were	O
Bonferroni	O
corrected	O
at	O
0.05/104	O
metabolites = 4.8 × 10_−4	O
Abbreviations:	O
SE	O
standard	O
error,	O
Ala	O
alanine,	B
Asn	O
asparagine,	B
Glu	O
glutamic	B
acid,	I
Ile	O
isoleucine,	B
Leu	O
leucine,	B
Pro	O
proline,	B
Ser	O
serine,	B
Tyr	O
tyrosine,	B
Val	O
valine,	B
LPCa	O
acyl-lysophosphatidylcholine,	B
LPCe	O
alkyllysophosphatidylcholine,	B
PCaa	O
diacyl-phosphatidylcholine,	B
PCae	O

Sphingolipids	B
are	O
integral	O
structural	O
constituents	O
of	O
lipid	O
membranes	O
and	O
are	O
involved	O
in	O
cell	O
signaling	O
and	O
apoptosis	O
[,],	O
with	O
SMs	O
being	O
the	O
most	O
prevalent	O
SLs	O
in	O
human	O
plasma	O
that	O
can	O
be	O
derived	O
from	O
Cers	O
via	O
SMS,	O
releasing	O
a	O
DAG	O
in	O
the	O
process	O
[,]	O
(Supplementary	O
Figure	O
6a).	O

In	O
the	O
unadjusted	O
model,	O
the	O
percentage	O
of	O
isoleucine	B
(p	O
=	O
0.003)	O
was	O
significantly	O
higher	O
in	O
males	O
vs	O
.	O
females.	O

In	O
a	O
previous	O
study,	O
no	O
albumin-like	O
proteins	O
of	O
the	O
Atlantic	B
cod	O
plasma	O
proteome	O
were	O
identified	O
among	O
the	O
characterized	O
high	O
abundant	O
proteins	O
(HAPs)	O
of	O
the	O
Atlantic	B
cod	O
plasma	O
proteome	O
.	O

metabolomics,	O
epilepsy,	O
drug-resistant	O
epilepsy,	O
biomarkers,	O
ketone	B
bodies	O

We	O
presume	O
that	O
the	O
EC	O
cells	O
take	O
in	O
just	O
enough	O
FFAs	O
to	O
promote	O
the	O
release	O
of	O
fatty	O
glyceride.	B

,	O
C	O
=	O
fasting	O
plasma	O
palmitate	B
concentration	O
at	O
time	O
1	O
and	O
time	O
2,	O
E	O
=	O
tracer	O
(labeled	O
palmitate)	B
to	O
tracee	O
(endogenous	O
palmitate)	B
ratio	O
(TTR)	O
at	O
time	O
1	O
and	O
time	O
2,	O
and	O
t	O
=	O
time.	O

LPC,	O
Lysophosphatidylcholines;	B
PC,	O
Phosphatidylcholines;	B
PC-O	O
,	O
1-O-alkyl-2-acylglycerophosphocholines;	B
SM,	O
Sphingomyelines;	B
SM-OH	O
,	O
Hydroxy-Sphingomyelin.	B

The	O
levels	O
of	O
hypoxanthine	B
slightly	O
increased	O
at	O
2	O
Gy,	O
but	O
were	O
lower	O
than	O
controls	O
at	O
4	O
Gy	O
(P	O
=0.026	O

On	O
the	O
other	O
hand,	O
23	O
lipids	O
exhibited	O
a	O
significant	O
increase	O
in	O
NAFL	O
and/or	O
NASH,	O
including	O
6	O
fatty	O
acids,	O
2	O
cholesteryl	B
esters,	I
1	O
diglyceride,	B
5	O
triglycerides	B
and	O
9	O
phospholipids.	B

The	O
effect	O
of	O
percent	O
methanol	B
on	O
simultaneous	O
enantioseparation	O
of	O
O	O
-DVX	O
and	O
VX	O
is	O
summarized	O
in	O
a	O
series	O
of	O
electropherograms	O
shown	O
in	O
.	O

PA	B
(32:0)	I
was	O
elevated	O
to	O
the	O
greatest	O
extent	O
within	O
infected	O
cells.	O

Hexadecanoic	B
acid.	I

The	O
strong	O
decrease	O
of	O
glycerol	B
and	O
increase	O
of	O
VLDL	O
cholesterol	B
after	O
SLM	O
did,	O
however,	O
not	O
affect	O
the	O
magnitude	O
and	O
direction	O
of	O
the	O
association	O
with	O
BMI.	O

Cancer	O
and	O
polyps	O
are	O
often	O
accompanied	O
by	O
low	O
expression	O
levels	O
of	O
xanthine	B
and	O
hypoxanthine	B
likely	O
due	O
to	O
increased	O
DNA	O
synthesis	O
(adenine	O
utilization)	O
in	O
the	O
hyper-proliferative	O
tissues.	O

Reduced	O
lactate	B
levels	O
in	O
Degarelix-treated	O
prostate	O
cancer	O
might	O
be	O
an	O
indication	O
of	O
lower	O
glycolysis	O
(Table ;	O
Fig.	O

Notably,	O
the	O
association	O
of	O
eGFR	O
and	O
creatinine	B
with	O
component	O
2	O
were	O
independent	O
of	O
hypertension	O
(eGFR,	O
β	O
=	O
0.056,	O
q	O
=	O
5.14e_−9	O
;	O
creatinine,	B
β	O
=	O
0.051,	O
q	O
=	O
6.42e_−8	O
).	O

While	O
the	O
metabolite	O
correlations	O
in	O
CSF	O
are	O
dominated	O
by	O
the	O
“acidic	O
pathway”	O
of	O
bile	O
acid	O
biosynthesis,	O
the	O
correlations	O
in	O
plasma	O
are	O
reflective	O
of	O
both	O
the	O
“acidic	O
pathway”	O
and	O
of	O
the	O
“neutral	O
pathway”	O
starting	O
with	O
7α-HC	B
followed	O
by	O
7α-hydroxycholest-4-en-3-one	B
(7α-HCO,	I
Fig.	I
)	I
which	O
are	O
strongly	O
correlated	O
(Online	O
Resource	O
11,	O
see	O
Online	O
Resource	O
7	O
for	O
P	O
values	O
for	O
the	O
significance	O
of	O
correlation).	O

Furthermore,	O
while	O
the	O
evaluated	O
alkylamines	B
dramatically	O
improve	O
separation	O
on	O
all	O
columns	O
(except	O
BEH	O
Amide),	B
smaller	O
branched-chain	O
alkyl	O
groups	O
appear	O
to	O
be	O
preferable	O
to	O
larger	O
ones.	O

To	O
determine	O
whether	O
this	O
mechanism	O
was	O
relevant	O
to	O
PAH,	O
we	O
measured	O
plasma	O
angiogenin	O
in	O
a	O
representative	O
subset	O
of	O
age-	O
and	O
sex-matched	O
healthy	O
control	O
subjects	O
and	O
patients	O
with	O
PAH	O
from	O
the	O
discovery	O
analysis	O
(Table	O
V	O
in	O
the	O
online-only	B
Data	O
Supplement).	O

Forty-five	O
of	O
distinguishing	O
metabolites	O
were	O
identified	O
and	O
12	O
of	O
them,	O
including	O
glucose,	B
formate,	B
AMP,	B
NAD,	B
creatine,	B
creatinine,	B
DMG,	B
DMA,	B
TMA,	O
short-chain	O
fatty	O
acids,	O
acetate	B
and	O
GABA,	B
were	O
significantly	O
changed	O
along	O
with	O
the	O
progression	O
of	O
esophageal	O
cancer.	O

The	O
increased	O
levels	O
of	O
alanine,	B
lactate,	B
and	O
pyruvate	B
in	O
intermediates	O
of	O
glycolysis	O
and	O
TCA	O
cycle	O
suggest	O
high	O
consumption	O
of	O
glucose	B
by	O
HCC	O
in	O
response	O
to	O
the	O
stimulated	O
aerobic	O
glycolysis	O
or	O
the	O
Warburg	O
effect	O
with	O
conversion	O
through	O
pyruvate	B
to	O
alanine	B
and	O
lactate	B
[,	O
].	O

Compared	O
with	O
healthy	O
controls,	O
NSCLC	O
patients	O
showed	O
significantly	O
elevated	O
serum	O
levels	O
of	O
lactate,	B
alanine,	B
glutamate,	B
proline,	B
glycoprotein,	B
phenylalanine,	B
tyrosine	B
and	O
tryptophan,	B
and	O
markedly	O
decreased	O
serum	O
levels	O
of	O
glucose,	B
taurine,	B
glutamine,	B
glycine,	B
phosphocreatine	B
and	O
threonine	B
(p	O
 < 0.05).	O

It	O
is	O
a	O
central	O
intermediate	O
in	O
purine	B
degradation	O
and	O
biosynthesis.	O

ADMA	B
ratio	O
correlated	O
with	O
the	O
severity	O
of	O
sepsis	O
as	O
measured	O
by	O
the	O
SOFA	O
score	O
we	O
performed	O
Spearman’s	O
rank	O
correlation	O
analysis.	O

Blood	O
plasma	O
of	O
subjects	O
belonging	O
to	O
the	O
low	O
disease	O
prevalence	O
cluster	O
exhibited	O
lowered	O
levels	O
of	O
the	O
GlycA	B
inflammation	O
marker,	O
very	O
low-density	O
lipoprotein	O
and	O
low-density	O
lipoprotein	O
cholesterol,	B
triglycerides,	B
valine	B
and	O
leucine	B
compared	O
to	O
controls.	O

Another	O
amino	O
acid,	O
proline	B
was	O
also	O
found	O
to	O
have	O
significant	O
lower	O
levels	O
in	O
tissue,	O
but	O
showed	O
positive	O
correlation	O
with	O
serum	O
level	O
of	O
Stage	O
II	O
endometriosis.	O

In	O
our	O
study,	O
increased	O
cholic	B
acid	I
level	O
was	O
observed	O
in	O
T2DM	O
patients,	O
similarly	O
with	O
that	O
in	O
the	O
urine	O
of	O
streptozotocin-induced	O
diabetic	O
rats	O
[,	O
].	O

Worgall	O
et	O
al	O
.	O
demonstrated	O
the	O
association	O
of	O
impaired	O
SL	B
synthesis	O
with	O
airway	O
hyperreacitivity	O
by	O
using	O
de	O
novo	O
SPT	O
inhibitor	O
and	O
an	O
SPT	O
knockout	O
mouse	O
model.	O

In	O
the	O
phenylalanine,	B
tyrosine	B
and	O
tryptophan	B
biosynthesis	O
pathway,	O
4-hydroxyphenylpyruvic	B
acid	I
was	O
significantly	O
down-regulated	O
(Fig.	O
c).	O

Adenine,	B
Uracil,	B
Thymine,	B
Hypoxanthine,	B
Hypotaurine,	B
β-Alanine,	B
Taurine,	B
Tryptophan,	B
Glutamine,	B
Glutamic	B
acid,	I
and	O
Putrescine	B
are	O
the	O
results	O
of	O
GC/MS	O
analysis.	O

revealed	O
ROC	O
curves	O
for	O
the	O
first	O
principal	O
component	O
from	O
the	O
PLS-DA	O
model	O
and	O
6	O
discriminate	O
metabolites	O
(glycine,	O
valine,	B
methionine,	B
citrulline,	B
arginine	B
and	O
C16-carnitine).	B

2-Chloropyrimidine-5-carboxylic	B
acid	I
98%	O
was	O
obtained	O
from	O
Ark	O
Pharm,	O
Inc.	O
(Libertyville,	O
IL,	O
USA).	O

Interestingly,	O
these	O
metabolites	O
included	O
glucose,	B
formate,	B
AMP,	B
NAD,	B
creatine,	B
creatinine,	B
DMG,	B
DMA,	B
trimethylamine	B
(TMA),	O
short-chain	O
fatty	O
acids,	O
acetate	B
and	O
GABA,	B
which	O
are	O
mainly	O
involved	O
in	O
energy,	O
fatty	O
acids	O
and	O
choline	B
metabolic	O
pathways.	O

l	O
l	O
Uric	B
acid	I
is	O
synthesized	O
by	O
the	O
enzyme	O
xanthine	B
oxidase;	O
xanthine	B
and	O
hypoxanthine	B
serve	O
as	O
substrates.	O

Twenty	O
metabolites	O
were	O
also	O
selected	O
for	O
the	O
MNG	O
group	O
compared	O
to	O
normal	O
subjects	O
including	O
carnitine,	B
tryptophan,	B
glutathione,	B
citrate,	B
hypotaurine,	B
glutaric	B
acid,	I
propionate,	B
O-acetylcarnitine,	B
methionine,	B
succinate,	B
citrulline,	B
acetate,	B
glutamine,	B
myo-inositol,	B
acetone,	B
alanine,	B
scyllo-inositol,	B
isoleucine,	B
valine,	B
and	O
lactate,	B
which	O
were	O
all	O
increased	O
in	O
MNG	O
serum	O
samples.	O

A	O
volume	O
of	O
200 μ	O
L	O
serum	O
was	O
mixed	O
with	O
400 μ	O
L	O
of	O
saline	B
solution	O
containing	O
10%	O
D_2	O
O.	O
Samples	O
were	O
centrifuged	O
at	O
13,000 rpm	O
for	O
15 min	O
at	O
10°C	O
and	O
then	O
550 μ	O
L	O
supernatants	O
were	O
transferred	O
into	O
5 mm	O
NMR	O
tubes	O
for	O
NMR	O
analysis.	O

The	O
concentrations	O
of	O
circulating	O
tryptophan	B
were	O
influenced	O
by	O
several	O
amino	O
acids	O
(notably	O
leucine,	B
valine,	B
isoleucine,	B
tyrosine,	B
phenylalanine	B
and	O
methionine)	B
as	O
they	O
share	O
the	O
same	O
trans-membrane	B
protein.	O

This	O
derivatization	O
converted	O
the	O
α-ketone	B
to	O
an	O
O	B
-methyl	I
oxime	I
and	O
resulted	O
in	O
the	O
shift	O
of	O
the	O
molecular	O
ion	O
by	O
29	O
Da	O
to	O
m/z	O
402.	O

Consistent	O
with	O
its	O
implicated	O
role	O
in	O
advanced	O
liver	O
disease,	O
we	O
observed	O
significantly	O
elevated	O
levels	O
of	O
haeme	O
catabolites	O
bilirubin	B
and	O
elevations	O
in	O
biliverdin	B
and	O
urobilinogen	B
in	O
DC	O
vs.	O
NHC	O
and	O
HCC	O
vs.	O
NHC.	O

The	O
Leu	O
carbon	O
skeleton	O
is	O
converted	O
to	O
α	B
-ketoisocaproate,	I
which,	O
like	O
glutamine,	B
is	O
released	O
into	O
the	O
extracellular	O
medium.	O

The	O
decreased	O
levels	O
of	O
adenosine	B
and	O
inosine	B
suggest	O
that	O
the	O
perturbance	O
of	O
these	O
physiological	O
processes	O
may	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
child	O
and	O
adolescent	O
depression.	O

The	O
normal	O
reference	O
interval	O
for	O
betaine	B
was	O
confirmed	O
in	O
two	O
populations,	O
a	O
cohort	O
of	O
apparently	O
healthy	O
volunteers	O
and	O
the	O
full	O
set	O
of	O
PREVEND	O
cohort	O
participants.	O

Sarcosine,	B
an	O
N-methyl	O
derivative	O
of	O
the	O
amino	O
acid	O
glycine,	O
was	O
identified	O
as	O
a	O
differential	O
metabolite	O
that	O
was	O
highly	O
elevated	O
during	O
prostate	O
cancer	O
progression	O
to	O
metastasis	O
and	O
can	O
be	O
detected	O
non-invasively	O
in	O
urine.	O

Plasma	O
glucose	B
was	O
maintained	O
at	O
euglycemia	O
(~5	O
mmol/L)	O
by	O
a	O
primed	O
and	O
then	O
continuous	O
insulin	O
infusion	O
at	O
40	O
mU/body	O
surface	O
area	O
m_2	O
/min	O
and	O
20%	O
glucose	B
infusion	O
based	O
on	O
plasma	O
glucose	B
measurements	O
taken	O
every	O
5	O
to	O
10	O
minutes.	O

Finally,	O
we	O
reported	O
novel	O
associations	O
between	O
the	O
plasma	O
metabolite	O
TMAO	B
and	O
cardiac	O
arrhythmia	O
as	O
well	O
as	O
infarction	O
in	O
adult	O
CKD	O
stage	O
3	O
patients.	O

The	O
mean	O
level	O
of	O
trans,	O
anti	O
-BaPT	O
(0.71	O
±	O
0.64	O
fmol/mg	O
creatinine,	B
n	O
=	O
30)	O
in	O
the	O
urine	O
of	O
smokers	O
was	O
significantly	O
higher	O
(P	O
=	O
0.0018)	O
than	O
that	O
in	O
non-smokers	O
(0.34	O
±	O
0.20	O
fmol/mg	O
creatinine,	B
n	O
=	O
30).	O

(A,	O
B)	O
Levels	O
of	O
total	O
sphingomyelin	B
(SM)	O
(A)	O
and	O
each	O
sphingomyelin	B
species	O
(C14:0,	O
C16:0,	B
C18:1,	B
C18:0,	B
C20:0,	B
C22:0,	B
C24:1,	B
C24:0,	B
C26:1	B
and	O
C26:0)	B
(B)	O
in	O
cancer	O
tissue	O
(Cancer	O
or	O
C),	O
peri-tumor	O
tissue	O
(Peri	O
or	O
P)	O
and	O
normal	O
tissue	O
(Normal	O
or	O
N)	O
were	O
determined	O
by	O
mass	O
spectrometry.	O

Plasma	O
samples	O
were	O
thawed	O
gradually,	O
and	O
165	O
μl	O
from	O
each	O
sample	O
was	O
mixed	O
with	O
250	O
μl	O
of	O
ethanol	B
solution	I
(80%	O
ethanol,	B
19.9%	O
H_2	O
O,	O
and	O
0.1%	O
formic	O
acid)	O
to	O
precipitate	O
out	O
proteins.	O

T1,	B
20:00	I
and	O
21:20	O
(awake);	O
T2,	O
22:40	O
and	O
24:00	O
(transition	O
from	O
wake	O
to	O
sleep);	O
T3,	O
01:20	O
and	O
02:40	O
(early	O
sleep);	O
T4,	O
04:00	O
and	O
05:20	O
(mid	O
to	O
late	O
sleep).	O

We	O
investigated	O
the	O
salvage	O
pathway,	O
one	O
of	O
the	O
three	O
major	O
pathways	O
of	O
ceramide	B
biosynthesis,	O
as	O
a	O
source	O
of	O
ceramide	B
in	O
human	O
breast	O
cancer	O
tissues	O
(Figure	O
).	O

Acylcarnitines	B
(AC)	O
present	O
in	O
DBS	O
methanolic	B
extracts	O
were	O
quantified	O
using	O
LC-MS/MS,	O
following	O
the	O
method	O
of	O
Giesbertz	O
et	O
al..	O

We	O
interpret	O
this	O
observation	O
as	O
to	O
reflect	O
the	O
role	O
of	O
the	O
aerobic	O
oxidation	O
of	O
glucose	B
for	O
performance	O
in	O
the	O
exhaustive	O
type	O
of	O
exercise.	O

Two	O
pathways	O
are	O
used	O
in	O
mammalian	O
cells	O
to	O
synthesize	O
cholesterol.	B

Other	O
than	O
generation	O
of	O
ceramide	B
in	O
tissues,	O
several	O
lines	O
of	O
evidence	O
suggest	O
the	O
liver	O
is	O
a	O
major	O
source	O
of	O
ceramides	B
circulating	O
on	O
LDL	O
and	O
taken	O
up	O
by	O
skeletal	O
muscle	O
in	O
a	O
LDL	O
receptor‐independent	O
manner	O
31.	O

Enhanced	O
NO	O
production	O
observed	O
in	O
response	O
to	O
elevations	O
in	O
extracellular	O
arginine,	B
despite	O
high	O
intracellular	O
arginine	B
concentrations,	O
is	O
often	O
referred	O
to	O
as	O
the	O
“arginine	B
paradox”(,).	O

Quon	O
et	O
al.	O
have	O
by	O
repeated	O
MRS	O
in	O
glioma	O
patients	O
undergoing	O
surgery	O
and	O
radiotherapy	O
demonstrated	O
that	O
changes	O
in	O
choline	B
could	O
provide	O
prognostic	O
information.	O

Although	O
the	O
supplements	O
recommended	O
in	O
this	O
study	O
did	O
not	O
contain	O
carnitine	B
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
patients	O
were	O
taking	O
carnitine	B
on	O
their	O
own.	O

In	O
the	O
healthy	O
control	O
group,	O
the	O
TC	O
was	O
negatively	O
associated	O
with	O
changes	O
in	O
valine	B
and	O
isoleucine	B
between	O
0	O
and	O
120	O
min	O
(p	O
<	O
0.05),	O
and	O
TG	B
was	O
positively	O
related	O
to	O
changes	O
in	O
valine,	B
serine	B
and	O
creatine.	B

For	O
estrogens	O
determination	O
by	O
LC-MS/MS	O
analysis,	O
200	O
µL	O
from	O
each	O
serum	O
sample,	O
calibrators,	O
and	O
QCs,	O
after	O
adding	O
20	O
µL	O
of	O
internal	O
standard	O
mix	O
(2H4-E1	O
and	O
2H4-E2)	O
at	O
500	O
pg/mL,	O
was	O
treated	O
with	O
methyl	B
tert-butyl	I
ether	I
(1	O
mL),	O
vortex-mixed	O
for	O
30	O
s,	O
and	O
centrifuged	O
at	O
16,400	O
rpm	O
for	O
20	O
min	O
at	O
4	O
°C.	O

p	O
 < 0.001)	O
and	O
GABR	O
(0.36 ± 0.16	O
vs.	O
0.73 ± 0.24,	O
p	O
 < 0.001),	O
elevated	O
levels	O
of	O
ADMA	B
(0.76 ± 0.12	O
vs.	O
0.62 ± 0.12 μmol/L,	O
p	O
 < 0.001),	O
SDMA	O
(0.54 ± 0.14	O
vs.	O
0.47 ± 0.13 μmol/L,	O
p	O
 < 0.001),	O
and	O
ArgMI	O
(6.51 ± 1.86	O
vs.	O
5.54 ± 1.51,	O
p	O
 < 0.001).	O

Carboxy-terminal	B
FGF-23	O
was	O
measured	O
by	O
ELISA	O
(Immutopics)	O
for	O
CHS.	O

Methanol/chloroform-extracted	O
serum	O
samples	O
were	O
mixed	O
(1:12,	O
v/v)	O
with	O
an	O
α-cyano-4-hydroxycinnamic	B
acid	I
solution	O
in	O
50%	O
acetonitrile/0.1%	O
TFA.	O

The	O
most	O
significant	O
pathways	O
associated	O
with	O
MPO	O
gains	O
suggested	O
by	O
the	O
metabolites	O
for	O
all	O
three	O
levels	O
of	O
evidence	O
were:	O
aminoacyl-tRNA	B
biosynthesis	O
(b,	O
c,	O
d,	O
h,	O
i);	O
alanine,	B
aspartate	B
and	O
glutamate	B
metabolism	O
(b,	O
c,	O
g);	O
glycine,	B
serine	B
and	O
threonine	B
metabolism	O
(d,	O
g,	O
j),	O
arginine	B
and	O
proline	B
metabolism	O
(c,	O
e,	O
j);	O
valine,	B
leucine	B
and	O
isoleucine	B
biosynthesis	O
(d,	O
g);	O
taurine	B
and	O
hypotaurine	B
metabolism	O
(b,	O
g);	O
nitrogen	O
metabolism	O
(f,	O
i),	O
glyoxylate	B
and	O
dicarboxylate	B
metabolism	O
(g,	O
k),	O
phenylalanine	B
metabolism	O
(g,	O
h);	O
glycerolipid	B
metabolism	O
(a);	O
phenylalanine,	B
tyrosine	B
and	O
tryptophan	B
biosynthesis	O
(i);	O
purine	B
metabolism	O
(f),	O
pyruvate	B
metabolism/glycolysis	O
or	O
gluconeogenesis/nicotinate	O
and	O
nicotinamide	B
metabolism/citrate	O
cycle	O
(g).	O

BDA-N	O
_α	B
-acetyllysine,	I
N	B
-acetylcysteine-BDA-lysine	I
and	O
its	O
sulfoxide	B
were	O
detected	O
in	O
most	O
human	O
urine	O
samples	O
from	O
three	O
different	O
groups.	O

Twenty	O
midlife,	O
cardiovascular	O
symptom-free	O
male	O
adults	O
(40–60	O
years	O
old,	O
mean	O
age	O
46.9	O
years)	O
were	O
recruited	O
from	O
general	O
medical	O
practices	O
in	O
the	O
Birmingham	O
area	O
with	O
(total	O
cholesterol	B
> 6.5 mM	O
measured;	O
n = 10)	O
and	O
without	O
(n	O

Its	O
well-known	O
role	O
in	O
circadian	O
rhythmicity	O
makes	O
it	O
an	O
ideal	O
candidate	O
to	O
explain	O
the	O
frequent	O
occurrence,	O
especially	O
at	O
the	O
onset	O
of	O
ASD	O
and	O
during	O
early	O
infancy,	O
of	O
sleep	O
disorders	O
highly	O
responsive	O
to	O
melatonin	B
as	O
a	O
pharmacological	O
therapy.	O

For	O
serum,	O
the	O
pathways	O
that	O
are	O
important	O
in	O
both	O
enrichment	O
and	O
topological	O
analysis	O
are	O
phenylalanine	B
metabolism	O
and	O
arginine	B
and	O
proline	B
metabolism.	O

The	O
positive	O
correlation	O
between	O
tGlut	O
and	O
lactate	B
might	O
be	O
connected	O
with	O
the	O
positive	O
correlation	O
between	O
lactate	B
and	O
alanine	B
that	O
was	O
discussed	O
in	O
the	O
previous	O
section.	O

In	O
addition,	O
the	O
rate	O
of	O
metacyclogenesis	O
induction	O
by	O
the	O
total	O
lipid	O
fraction	O
was	O
shown	O
to	O
be	O
about	O
half	O
of	O
that	O
obtained	O
by	O
a	O
total	O
intestinal	O
extract	O
and	O
similar	O
to	O
that	O
of	O
free	O
fatty	O
acids	O
or	O
oleic	B
acid	I
alone	O
(used	O
as	O
a	O
representative	O
of	O
the	O
free	O
fatty	O
acid	O
fraction).	O

In	O
our	O
data	O
of	O
colorectal	O
polyp,	O
the	O
level	O
of	O
lactate	B
was	O
increased	O
and	O
the	O
level	O
of	O
acetate	B
was	O
decreased.	O

_a	O
Serum	O
creatinine;	B
EGJ:	O
esophagogastric	O
junction;	O
CT:	O
computer	O
tomography;	O
ALT:	O
alanine	O
transaminase;	O
SD:	O
standard	O
deviation;	O
P	O
_1	O
:	O
P	O
value	O
of	O
the	O
EC	O
patients	O
supplying	O
serum	O
compared	O
with	O
the	O
healthy	O
control;	O
P	O
_2	O
:	O
P	O
value	O
of	O
the	O
EC	O
patients	O
supplying	O
tissue	O
compared	O
with	O
the	O
healthy	O
control.	O

By	O
contrast,	O
sarcosine	B
was	O
undetectable	O
in	O
adjacent	O
non-neoplastic	O
tissues	O
from	O
patients	O
with	O
metastatic	O
disease.	O

The	O
main	O
outcome	O
measures	O
were	O
acute	O
effects	O
of	O
aspartame	B
measured	O
using	O
repeated	O
ratings	O
of	O
14	O
symptoms,	O
biochemistry	O
and	O
metabonomics.	O

We	O
performed	O
an	O
in-depth	O
analysis	O
of	O
gangliosides	B
of	O
the	O
human	O
retina,	O
especially	O
using	O
powerful	O
LC/MS	O
methods.	O

β-apo-14′-carotenal,	B
β-apo-14′-carotenoic	B
acid,	I
and	O
β-apo-13-carotenone),	B
with	O
the	O
greatest	O
inhibitory	O
activity	O
being	O
displayed	O
by	O
β-apo-13-carotenone.	B

D-glutamic	B
acid	I
might	O
activate	O
transporter-associated	O
Cl_−	O
conductance	O
and	O
has	O
been	O
reported	O
to	O
regulate	O
neuronal	O
transmission.	O

We	O
first	O
examined	O
the	O
far	O
methyl	O
region	O
of	O
the	O
spectra,	O
which	O
contains	O
signals	O
from	O
lipoproteins	O
and	O
triglycerides.	B

This	O
strategy	O
resulted	O
in	O
an	O
approximate	O
20-fold	O
decrease	O
in	O
the	O
cotinine	B
signal,	O
diminishing	O
problems	O
associated	O
with	O
the	O
large	O
difference	O
in	O
concentrations	O
of	O
total	O
cotinine	B
and	O
total	O
NNAL	O
in	O
each	O
urine	O
sample.	O

Principal	O
component	O
analysis	O
(PCA)	O
separated	O
the	O
three	O
conditions,	O
and	O
corroborates	O
lower	O
variance	O
in	O
MeOH	B
ppt	O
+UF	O
samples	O
(Figure	O
S3).	O

When	O
comparing	O
the	O
concentration	O
of	O
serum	O
choline	B
metabolites	O
in	O
infants	O
fed	O
either	O
breast	O
milk	O
or	O
bovine-based	O
infant	O
formula,	O
Ilcol	O
et	O
al.	O
reported	O
around	O
2-fold	O
greater	O
serum	O
Cho	O
levels	O
in	O
breast	O
milk	O
fed	O
infants,	O
with	O
these	O
levels	O
positively	O
correlated	O
with	O
the	O
concentrations	O
of	O
water-soluble	O
choline	B
metabolites	O
(i.e.	O
Cho,	O
PCho	O
and	O
GPCho)	O
in	O
breast	O
milk.	O

We	O
aimed	O
to	O
find	O
an	O
index	O
that	O
would	O
be	O
easy	O
to	O
determine	O
based	O
on	O
the	O
venous	O
cholesterol	B
and	O
lactate	B
concentration.	O

Instead,	O
relative	O
mRNA	O
expression	O
levels	O
of	O
inflammatory	O
cytokines,	O
such	O
as	O
IL-1β	B
and	O
TNF-α,	O
which	O
revealed	O
that	O
the	O
expression	O
of	O
IL-1β	B
and	O
TNF-α	O
was	O
significantly	O
upregulated	O
in	O
AF	B
patients	O
relative	O
to	O
controls.	O

GPC	B
is	O
a	O
derivative	O
of	O
the	O
membrane	O
metabolite	O
choline	B
and	O
one	O
of	O
the	O
major	O
forms	O
of	O
choline	B
storage	O
in	O
the	O
cytosol.	O

Both	O
12,13-DiHOME	B
and	O
12,13-EpOME	B
are	O
PPAR-γ	O
ligands	O
with	O
potentially	O
wide-ranging	O
effects.	O

Interestingly,	O
omega-9	B
and	O
saturated	O
fatty	O
acids	O
were	O
also	O
positively	O
correlated	O
with	O
testosterone.	B

Thyroxine	B
showed	O
particular	O
promise	O
as	O
it	O
was	O
associated	O
to	O
all	O
measures	O
including	O
the	O
five	O
year	O
risk	O
of	O
onset	O
in	O
premanifest	O
HD	O
subjects.	O

DMAP	O
and	O
thiamethoxam	B
were	O
detected	O
in	O
all	O
three	O
age	O
groups,	O
i.e.	O
under	O
15,	O
15–49,	O
over	O
50	O
years	O
old,	O
of	O
TSG.	O

The	O
results	O
indicated	O
a	O
lower	O
level	O
of	O
aspartate,	B
alanine,	B
choline,	B
glutamate,	B
and	O
glutarate	B
in	O
SSc	O
patients	O
compared	O
with	O
healthy	O
controls.	O

Lactate	B
and	O
lipids	O
were	O
important	O
discriminators	O
of	O
inflammatory	O
burden	O
in	O
early	O
arthritis,	O
what	O
is	O
in	O
agreement	O
with	O
our	O
findings	O
showing	O
that	O
inflammation	O
related	O
changes	O
in	O
metabolite	O
and	O
especially	O
lipid	O
metabolism	O
can	O
be	O
detected	O
already	O
at	O
the	O
early	O
stages	O
of	O
the	O
disease.	O

This	O
could	O
be	O
due	O
to	O
the	O
increase	O
of	O
plasma	O
cortisol	B
levels	O
and	O
impaired	O
serotonin	B
uptake.	O

Considering	O
the	O
small	O
size	O
and	O
aliphatic	B
structure	O
of	O
polyamines,	B
dansyl	B
chloride	I
was	O
used	O
as	O
a	O
derivative	O
agent	O
to	O
increase	O
their	O
retention	O
and	O
ionization.	O

The	O
mentioned	O
functions	O
of	O
sphingolipids	B
are	O
executed	O
primarily	O
within	O
the	O
cells,	O
whereas	O
our	O
data	O
is	O
from	O
lipids	O
in	O
circulation.	O

LysoPCs	O
represent	O
5–20%	O
of	O
the	O
total	O
plasma	O
phospholipids,	B
and	O
are	O
formed	O
by	O
the	O
action	O
of	O
lecithin	B
cholesterol	I
acyltransferase	O
(LCAT)	O
in	O
plasma	O
.	O

ADMA	B
may	O
contribute	O
to	O
vascular	O
dysfunction	O
through	O
competitively	O
inhibiting	O
the	O
oxidation	O
of	O
arginine	B
to	O
citrulline,	B
thereby	O
hindering	O
nitric	B
oxide	I
production.	O

Fasting	O
levels	O
of	O
total	O
cholesterol	B
and	O
triglyceride	B
were	O
measured	O
using	O
commercially	O
available	O
kits	O
and	O
a	O
Hitachi	O
7150	O
Autoanalyzer	O
(Hitachi	O
Ltd.,	O
Tokyo,	O
Japan).	O

Specifically,	O
a	O
combination	O
profile	O
of	O
LysoPC	O
18.2,	O
L-Proline,	B
Hexadecanoic	B
acid,	I
Octadecanoic	B
acid,	I
Phenylalanine	B
and	O
LysoPC	O
16:1	O
showed	O
close	O
correlation	O
for	O
eight	O
weight-losing	O
samples	O
(≥5%	O
weight	O
loss)	O
and	O
nine	O
weight-stable	O
samples	O
(<5%weight	O
loss)	O
between	O
predicted	O
and	O
actual	O
weight	O
change	O
(r	O
=	O
0.976,	O
p	O
=	O
0.0014).	O

Thus,	O
emericellene	B
C	O
was	O
identified	O
as	O
(+)-17-hydroxy-emericella-3E	B
,7E	I
,12Z	I
,22-tetraen-16-oic	I
acid	I
(4).	O

These	O
amino	O
acids	O
are	O
used	O
in	O
the	O
liver	O
to	O
produce	O
glucose	B
by	O
gluconeogenesis.	O

The	O
amino	O
acid	O
tryptophan	O
was	O
increased	O
in	O
the	O
GCS = 14	O
points	O
to	O
12	O
points	O
group,	O
and	O
2	O
TCA	O
cycle	O
intermediates	O
(malic	O
acid	O
and	O
oxalic	B
acid)	O
were	O
similarly	O
increased.	O

In	O
female	O
BD	O
subjects,	O
we	O
observed	O
increased	O
levels	O
of	O
α-hydroxybutyrate	B
as	O
well	O
as	O
decreased	O
levels	O
of	O
N-methylnicotinamide,	B
acetone,	B
and	O
oxalacetate.	B

Oximation	O
(90 min	O
at	O
40°C)	O
was	O
performed	O
after	O
adding	O
20 μl	O
of	O
a	O
56 mg/ml	O
ethoxyamine	B
hydrochloride	I
solution	O
in	O
pyridine	B
and	O
20 μl	O
of	O
pyridine	B
to	O
the	O
extracts.	O

A	O
reduction	O
in	O
proline	B
and	O
lysine	B
levels	O
is	O
also	O
observed,	O
which	O
might	O
be	O
a	O
resulted	O
by	O
high	O
rates	O
of	O
catabolism,	O
and	O
leading	O
to	O
an	O
upregulated	O
production	O
of	O
glutamate.	B

However,	O
phosphatidylcholine	B
(PC)	O
and	O
sphingomyelin	B
(SM)	O
were	O
detectable	O
only	O
by	O
protocols	O
(i)–(iv),	O
whereas	O
phosphatidylserine	B
(PS)	O
was	O
detectable	O
only	O
by	O
protocols	O
(iii)–(vi),	O
and	O
phosphatidylethanolamine	B
(PE)	O
was	O
detectable	O
only	O
by	O
protocols	O
(v)–(vi).	O

Histamine	B
can	O
induce	O
cell	O
proliferation	O
and	O
differentiation,	O
and	O
regulates	O
both	O
gastrointestinal	O
function	O
and	O
the	O
immune	O
response.	O

N-acetyl-1-methylhistidine	B
is	O
presumably	O
derived,	O
like	O
1-methylhistidine,	B
from	O
dietary	O
anserine	B
which	O
is	O
formed	O
from	O
carnosine	B
in	O
many	O
animals	O
but	O
not	O
in	O
humans[–].	O

Sofosbuvir	B
and	O
ribavirin	B
exert	O
their	O
anti-hepatitis	O
C	O
virus	O
(anti-HCV)	O
activity	O
following	O
metabolic	O
activation	O
in	O
the	O
liver.	O

AFB-dibromo	B
(in	O
vitro)	O
or	O
AFB-epoxide	B
(in	O
vivo)	O
react	O
first	O
with	O
water	O
to	O
yield	O
the	O
same	O
intermediate,	O
the	O
AFB-diol.	O

Unknown1	O
(mass	O
863.40	O
Da	O
at	O
8.8	O
min	O
retention	O
time),	O
creatinine	B
and	O
2-methylhippurate	B
showed	O
the	O
most	O
significant	O
correlation	O
with	O
mFBP	O
(r	O
=	O
0.77,	O
P	O
<3.0	O
x	O
e-23	O
;	O
r	O
=	O
0.47,	O
P<1.3	O
x	O
e-7	O
;	O
and	O
r	O
=	O
0.47,	O
P<2.5	O
x	O
e-7	O
,	O
respectively).	O

A	O
comprehensive	O
study	O
showed	O
that	O
Lys190,	O
Lys199,	O
Lys351,	O
Lys432,	O
Lys541,	O
and	O
Lys545	O
(Table	O
S1,	O
Supporting	O
Information)	O
were	O
the	O
major	O
sites	O
of	O
reaction	O
of	O
AX	O
with	O
Alb	O
ex	O
vivo	O
in	O
plasma._,	O
Interestingly,	O
the	O
sites	O
of	O
Lys	O
adduction	O
can	O
vary	O
widely	O
between	O
subjects	O
treated	O
with	O
the	O
structurally	O
related	O
β-lactam	B
antibiotic	O
benzylpenicillin	B
and	O
was	O
found	O
to	O
form	O
multiple	O
adducts	O
in	O
vivo	O
with	O
Alb	O
in	O
human	O
subjects	O
at	O
Lys190,	O
Lys195,	O
Lys432,	O
and	O
Lys541.	O

HPLC-UV-diode	O
array	O
analyses	O
revealed	O
that	O
the	O
ratios	O
of	O
the	O
β-glucoside	B
conjugates	O
were	O
1:10:5	O
(for	O
malonyl	B
β-glucosides,	I
acetyl	B
β-glucosides	I
and	O
β-glucosides,	B
respectively)	O
for	O
daidzein	B
and	O
1:10:3	O
for	O
genistein.	B

Serum	O
creatinine	B
concentration	O
was	O
assessed	O
with	O
a	O
modified	O
Jaffe	O
test	O
(Krea	O
Flex;	O
Dade	O
Behring),	O
and	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
was	O
calculated	O
using	O
the	O
CKD-EPI	O
equation.	O

Huang,	O
et	O
al.	O
performed	O
a	O
liquid	O
chromatography	O
(LC)	O
mass	O
spectrometry-based	O
metabolomics	O
analysis	O
and	O
showed	O
that	O
the	O
level	O
of	O
urinary	O
carnitine	B
C9:1	I
was	O
significantly	O
decreased	O
in	O
patients	O
with	O
BCA,	O
particularly	O
in	O
those	O
with	O
early	O
BCA.	O

In	O
this	O
study,	O
a	O
comparison	O
between	O
the	O
plasma	O
of	O
OSCC	O
and	O
OD	O
revealed	O
decreasing	O
glucose	B
levels	O
in	O
OSCC,	O
suggesting	O
that	O
active	O
energy	O
metabolism	O
using	O
glucose	B
is	O
performed	O
because	O
of	O
the	O
cell	O
proliferation	O
in	O
cancer	O
cells.	O

The	O
BCAAs	O
leucine,	B
isoleucine,	B
and	O
valine	B
as	O
well	O
as	O
their	O
gamma-glutamyl-derivates	B
are	O
all	O
increased	O
in	O
the	O
diabetes	O
group,	O
indicating	O
an	O
impaired	O
short-term	O
metabolic	O
control	O
,	O
i.e.	O
peripheral	O
tissues	O
such	O
as	O
skeletal	O
muscle	O
may	O
have	O
lost	O
their	O
ability	O
to	O
react	O
to	O
the	O
presence	O
of	O
energy	O
sources	O
by	O
selective	O
uptake	O
mechanisms.	O

There	O
was	O
evidence	O
for	O
three	O
other	O
glucuronide	B
conjugates	O
of	O
hydroxylated	O
PhIP	O
metabolites	O
[M+H]_+	O
at	O
m/z	O
417.1,	O
(t	O
_R	O
13.3–14.5	O
min),	O
when	O
the	O
transition	O
[M+H]_+	O
→	O
[M+H	O
–194]_+	O
(417.1→	O
223.1),	O
due	O
to	O
loss	O
of	O
glucuronide	B
and	O
H_2	O
O.	O

The	O
potential	O
association	O
of	O
carnitine	B
metabolism	O
to	O
development	O
and	O
treatment	O
of	O
hypertension	O
appears	O
to	O
be	O
complex.	O

NHP	O
serum	O
contained	O
high	O
levels	O
of	O
34	O
and	O
36	O
C	O
DG	O
species,	O
of	O
which	O
DG	B
(36:3)	I
was	O
present	O
in	O
the	O
highest	O
abundance.	O

Two	O
enzymes	O
i.e.	O
β-glucosidase	O
and	O
lactase	O
phlorizin	O
hydrolase	O
(LPH)	O
are	O
responsible	O
for	O
deglycosylation	O
of	O
anthocyanins,	B
resulting	O
in	O
formation	O
of	O
the	O
aglycone,	B
cyanidin.	B

In	O
addition,	O
seven	O
compounds	O
had	O
concentrations	O
somewhat	O
higher	O
than	O
previously	O
reported	O
values	O
(L-asparagine,	O
glycerol,	B
glycine,	B
L-histidine,	B
hypoxanthine,	B
methanol	B
and	O
propylene	B
glycol),	I
while	O
two	O
compounds	O
had	O
concentrations	O
lower	O
than	O
previously	O
reported	O
(L-cystine	O
and	O
formic	O
acid).	O

Collagen	O
turnover	O
is	O
also	O
associated	O
with	O
changes	O
in	O
aminosugars,	B
which	O
are	O
involved	O
in	O
protein	O
glycosylation	O
reactions.	O

Similar	O
to	O
the	O
preparation	O
of	O
the	O
calibration	O
samples,	O
either	O
0.1	O
ml	O
5mol/l	O
HCl,	O
5	O
mol/l	O
NaOH	O
or	O
ultra-pure	O
water	O
was	O
also	O
added	O
into	O
control	O
samples	O
depending	O
on	O
the	O
required	O
final	O
pH.	O
Blank	O
samples	O
were	O
prepared	O
by	O
adding	O
10	O
ml	O
ultra-pure	O
water	O
into	O
20	O
ml	O
GC	O
vials	O
(previously	O
added	O
with	O
3	O
g	O
sodium	B
chloride	I
and	O
either	O
0.1	O
ml	O
l	O
5	O
mol/l	O
HCl,	O
5	O
mol/l	O
NaOH	O
or	O
ultra-pure	O
water.	O

The	O
more	O
efficient	O
clearance	O
of	O
guanidine	B
in	O
HFD	O
than	O
in	O
HD	O
in	O
the	O
present	O
study	O
may	O
account	O
for	O
the	O
better	O
clinical	O
treatment	O
effects	O
of	O
HFD	O
because	O
it	O
led	O
to	O
patients	O
having	O
a	O
better	O
quality	O
of	O
life	O
with	O
fewer	O
complications	O
than	O
HD.	O

We	O
added	O
the	O
metals	O
(as	O
chloride	B
salts)	O
to	O
the	O
ion-exchange-resin-treated	O
urine	O
sample,	O
to	O
final	O
concentrations	O
ranging	O
from	O
0.01 mM	O
to	O
1 M.	O

Negative	O
prognosis	O
patients	O
presented	O
higher	O
values	O
of	O
ethanol,	B
glucose,	B
hippurate	B
and	O
an	O
unknown	O
compound,	O
but	O
lower	O
levels	O
of	O
methionine,	B
glutamine,	B
arginine	B
and	O
phenylalanine.	B

>	O
0.7),	O
phosphocholine	B
(PC),	O
phosphoethanolamine	B
(PE),	O
glutamine	B
(Gln)	O
(p	O
(corr)	O
>	O
0.5)	O
and	O
low	O
level	O
of	O
glucose	B
(Glc)	O
and	O
monounsaturated	O
fatty	O
acids	O
(MUFA)	O

The	O
highest	O
AUC	O
value,	O
which	O
is	O
an	O
indicator	O
of	O
the	O
highest	O
discriminating	O
potential,	O
was	O
determined	O
for	O
lysoPC	O
a	O
C26:0.	B

Tryptophan	B
metabolism	O
and	O
the	O
observed	O
changes	O
in	O
the	O
kynurenine	B
and	O
serotonin	B
pathways.	O

An	O
increase	O
in	O
urinary	O
1-methyladenosine	B
was	O
also	O
reported	O
to	O
be	O
a	O
sensitive	O
biomarker	O
of	O
cellular	O
hypoxia.	O

Exact	O
mass	O
measurement	O
using	O
electrospray	O
ionization	O
mass	O
spectrometry	O
(ESI-TOFMS)	O
in	O
the	O
simultaneous	O
negative	O
and	O
positive	O
mode	O
resulted	O
in	O
the	O
identification	O
of	O
different	O
phospholipids	B
in	O
the	O
methanol	B
fractions	O
from	O
human	O
urine.	O

Higher	O
benzoate	B
in	O
urine	O
of	O
ARD	O
indicates	O
poor	O
detoxification	O
via	O
phase	O
II	O
glycine	B
conjugation.	O

ADMA/SDMA	O
levels	O
were	O
inversely	O
related	O
to	O
changes	O
in	O
2-hour	O
glucose,	B
a	O
finding	O
previously	O
supported.	O

= 0.26)	O
and	O
significantly,	O
at	O
the	O
methylene	B
singlet	O
at	O
4.06 ppm	O
(P	O
 = 0.03).	O

The	O
known	O
pentose	B
acids	I
of	O
biological	O
origin	O
are	O
arabinonate	B
and	O
ribonate,	B
which	O
derive	O
from	O
the	O
pentose	B
sugars	O
arabinose	B
and	O
ribose,	B
respectively;	O
and	O
xylonate	B
and	O
lyxonate,	B
which	O
derive	O
from	O
the	O
hexose	B
acid	I
gulonate.	I

The	O
tested	O
SFC	O
columns	O
included	O
both	O
the	O
recently	O
introduced	O
ACQUITY	O
UPC_2	O
Torus	O
columns,	O
designed	O
for	O
improved	O
robustness	O
and	O
stability	O
in	O
mixed	O
CO_2	B
-methanol	I
mobile	O
phases	O
,	O
,	O
and	O
the	O
older	O
ACQUITY	O
UPC_2	O
range.	O

In	O
IS	O
hypogonadism	O
subjects,	O
most	O
amino	O
acids	O
did	O
not	O
undergo	O
strong	O
alterations	O
(Supplementary	O
Figure 1),	O
except	O
glutamine	B
and	O
glutamate	B
as	O
a	O
consequence	O
of	O
the	O
upregulated	O
malate	B
shuttle	O
(Fig. ).	O

500	O
MHz	O
_1	O
H-NMR	O
spectrum	O
of	O
plasma	O
from	O
CKD	O
patient	O
following	O
(A)	O
ultrafiltration,	O
(B)	O
acetonitrile	B
precipitation	O
or	O
(C)	O
PCA	O
extraction.	O

Owing	O
to	O
the	O
great	O
difference	O
of	O
physicochemical	O
property	O
between	O
Cap	O
and	O
its	O
metabolites,	O
liquid-liquid	O
extraction	O
by	O
ethyl	B
acetate	I
and	O
isopropanol	B
(19 : 1,	O
vol : vol)	O
was	O
chosen	O
as	O
the	O
extraction	O
solvent	O
which	O
gave	O
optimal	O
extraction	O
recovery	O
and	O
matrix	O
effect	O
in	O
pretreatment	O
procedure.	O

A	O
Hamilton	O
Starlet	O
(Reno,	O
NV)	O
robotic	O
liquid	O
handler	O
was	O
used	O
to	O
process	O
samples	O
including	O
mixing	O
steps	O
(aspirate-dispense).	O

